<SEC-DOCUMENT>0000310158-22-000034.txt : 20221103
<SEC-HEADER>0000310158-22-000034.hdr.sgml : 20221103
<ACCEPTANCE-DATETIME>20221103162844
ACCESSION NUMBER:		0000310158-22-000034
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		87
CONFORMED PERIOD OF REPORT:	20220930
FILED AS OF DATE:		20221103
DATE AS OF CHANGE:		20221103

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Merck & Co., Inc.
		CENTRAL INDEX KEY:			0000310158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				221918501
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-06571
		FILM NUMBER:		221358479

	BUSINESS ADDRESS:	
		STREET 1:		2000 GALLOPING HILL ROAD
		CITY:			KENILWORTH
		STATE:			NJ
		ZIP:			07033
		BUSINESS PHONE:		908-740-4000

	MAIL ADDRESS:	
		STREET 1:		2000 GALLOPING HILL ROAD
		CITY:			KENILWORTH
		STATE:			NJ
		ZIP:			07033

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Merck & Co. Inc.
		DATE OF NAME CHANGE:	20091103

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SCHERING PLOUGH CORP
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>mrk-20220930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:18be82ff-6aae-4643-b5c5-ea6de452de6c,g:778f8bae-d5d9-4bda-a4ad-ec173f2835d1,d:6b4e4280ad2344a5bc7fdcaa77e417f0--><html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:mrk="http://www.merck.com/20220930" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns="http://www.w3.org/1999/xhtml" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>mrk-20220930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80L2ZyYWc6NWU3MWY0Yjg4MWJmNDA1NzkyZTk3ODc1YTkxNDU5NzcvdGFibGU6NTMwODk3ODI2MTUzNDA1MzkxMzc3ZGFmYjhjMjE2OTgvdGFibGVyYW5nZTo1MzA4OTc4MjYxNTM0MDUzOTEzNzdkYWZiOGMyMTY5OF8zLTEtMS0xLTk0NDE0_ecc8260c-b71f-4c56-8c7f-34ea4ea18108">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80L2ZyYWc6NWU3MWY0Yjg4MWJmNDA1NzkyZTk3ODc1YTkxNDU5NzcvdGFibGU6NTMwODk3ODI2MTUzNDA1MzkxMzc3ZGFmYjhjMjE2OTgvdGFibGVyYW5nZTo1MzA4OTc4MjYxNTM0MDUzOTEzNzdkYWZiOGMyMTY5OF80LTEtMS0xLTk0NDE0_81c2931f-4b09-421e-843f-a2e18d03b188">2022</ix:nonNumeric><ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80L2ZyYWc6NWU3MWY0Yjg4MWJmNDA1NzkyZTk3ODc1YTkxNDU5NzcvdGFibGU6NTMwODk3ODI2MTUzNDA1MzkxMzc3ZGFmYjhjMjE2OTgvdGFibGVyYW5nZTo1MzA4OTc4MjYxNTM0MDUzOTEzNzdkYWZiOGMyMTY5OF81LTEtMS0xLTk0NDE0_1fc3e71f-6ba0-43de-b92f-0a3cfb92061a">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80L2ZyYWc6NWU3MWY0Yjg4MWJmNDA1NzkyZTk3ODc1YTkxNDU5NzcvdGFibGU6NTMwODk3ODI2MTUzNDA1MzkxMzc3ZGFmYjhjMjE2OTgvdGFibGVyYW5nZTo1MzA4OTc4MjYxNTM0MDUzOTEzNzdkYWZiOGMyMTY5OF82LTEtMS0xLTk0NDE0_f2dfa510-cdbd-46b6-9cee-d5ec4db4eb6a">0000310158</ix:nonNumeric><ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80L2ZyYWc6NWU3MWY0Yjg4MWJmNDA1NzkyZTk3ODc1YTkxNDU5NzcvdGFibGU6NTMwODk3ODI2MTUzNDA1MzkxMzc3ZGFmYjhjMjE2OTgvdGFibGVyYW5nZTo1MzA4OTc4MjYxNTM0MDUzOTEzNzdkYWZiOGMyMTY5OF83LTEtMS0xLTk0NDE0_a9164299-306f-42d1-a5e2-4fbf82fd6df5">12/31</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i11700d15290f425cb74a002a0cd2a29e_D20210602-20210602" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNy9mcmFnOjFlOTcwNGY2ZThhYjRiOGZhNzVmZjkyNGNjMTllNjdjL3RleHRyZWdpb246MWU5NzA0ZjZlOGFiNGI4ZmE3NWZmOTI0Y2MxOWU2N2NfMjc_ce3969f9-8ade-43ef-be7f-ce7c58774a5d">0.1</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i6533dbb8649144648ffc4f4c1244c7c9_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNy9mcmFnOjFlOTcwNGY2ZThhYjRiOGZhNzVmZjkyNGNjMTllNjdjL3RleHRyZWdpb246MWU5NzA0ZjZlOGFiNGI4ZmE3NWZmOTI0Y2MxOWU2N2NfMTky_3bc21732-98e4-459d-9b41-8b93143cb8e6">0</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i26b4f40fba294c2ab11871350926ecda_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNy9mcmFnOjFlOTcwNGY2ZThhYjRiOGZhNzVmZjkyNGNjMTllNjdjL3RleHRyZWdpb246MWU5NzA0ZjZlOGFiNGI4ZmE3NWZmOTI0Y2MxOWU2N2NfMTk1_ec1da32d-feec-4e1e-b9b7-39754c320fc2">0</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i6533dbb8649144648ffc4f4c1244c7c9_D20210701-20210930" decimals="-6" name="us-gaap:RelatedPartiesAmountInCostOfSales" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNy9mcmFnOjFlOTcwNGY2ZThhYjRiOGZhNzVmZjkyNGNjMTllNjdjL3RleHRyZWdpb246MWU5NzA0ZjZlOGFiNGI4ZmE3NWZmOTI0Y2MxOWU2N2NfMTk4_18b17651-2424-4945-9705-217c5851688a">0</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i26b4f40fba294c2ab11871350926ecda_D20210101-20210930" decimals="-6" name="us-gaap:RelatedPartiesAmountInCostOfSales" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNy9mcmFnOjFlOTcwNGY2ZThhYjRiOGZhNzVmZjkyNGNjMTllNjdjL3RleHRyZWdpb246MWU5NzA0ZjZlOGFiNGI4ZmE3NWZmOTI0Y2MxOWU2N2NfMjAx_e3851a61-43c4-40c7-aaaf-610be71b16c4">0</ix:nonFraction><ix:nonNumeric contextRef="i53f76af88d63418dba6b1ea3a71d7ecb_I20211231" name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNC0xLTEtMS0xMDUwNTY_4beacbd1-84ea-489f-8ac6-b09392c17877">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrent</ix:nonNumeric><ix:nonNumeric contextRef="ic7eb7aa0cad44ae481279be50ead5cf3_I20220930" name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNC0xLTEtMS0xMDUwNTY_4c50954f-2f04-4bb2-9e7e-854b1813a13f">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i92c41baff7714a72894f9c962e96d0a8_I20220930" name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNS0xLTEtMS05NDQxNA_2a5d2377-4bbd-47ad-9925-404ca9a51736">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i97bb92e54ef74a8db32f912747efe346_I20211231" name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNS0xLTEtMS05NDQxNA_c6df00f3-bff8-4562-abe7-498764d34146">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i92c868d7e8f9475893857146e49ffbb1_I20220930" name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNi0xLTEtMS05NDQxNA_6baf831a-4ac8-4464-8eb1-254345d36853">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i8f6e2cbf96bd4896863dbb8f79fdf2b1_I20211231" name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNi0xLTEtMS05NDQxNA_95f68aac-d3b4-4319-9f3d-70e85b1424c4">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i338b3ccaae68438b96b0f370fd0bb963_I20211231" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNy0xLTEtMS05NDQxNA_6a9babb4-e747-4df0-a56c-3595290d8927">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="ic2398c81940b40eabe737fa14c821b96_I20220930" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNy0xLTEtMS05NDQxNA_ae73e90d-8b40-4bfe-b1e5-b0c0132d4407">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="ifa0ad26fa2f64d7ca0cf4d95ae5c7567_I20220930" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfOC0xLTEtMS05NDQxNA_3d168174-838c-4aa7-834d-0305c0dea6db">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ib67ea4886b8c40868d422b24ac9e580d_I20211231" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfOC0xLTEtMS05NDQxNA_8a78e2f6-5d79-40d5-8cfd-da850ad40e02">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i7382fed477fc47e3acfc51cf0827f22a_I20220930" name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTEtMS0xLTEtMTA1MTE3_0942da13-4366-4941-8d73-f86fd1003d65">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrent</ix:nonNumeric><ix:nonNumeric contextRef="ieba4d46f4e9b4513aa30046a1640a2d1_I20211231" name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTEtMS0xLTEtMTA1MTE3_ed1a83b6-f315-4484-ba3e-ac3634db5ded">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i7382fed477fc47e3acfc51cf0827f22a_I20220930" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTItMS0xLTEtMTA1MTE5_35d04908-60bc-47a5-b559-4d800d70da91">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="ieba4d46f4e9b4513aa30046a1640a2d1_I20211231" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTItMS0xLTEtMTA1MTE5_f4049782-8c11-4ab1-9f60-0268bac9cd63">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" name="us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTMtMC0xLTEtOTQ0MTQ_415ec0c9-4bba-4fb9-aa01-b4c7b84244a9">http://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpense</ix:nonNumeric><ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTMtMC0xLTEtOTQ0MTQ_a2ea2169-dd57-478e-b872-7cc7be5bf76a">http://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpense</ix:nonNumeric><ix:nonNumeric contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" name="us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTMtMC0xLTEtOTQ0MTQ_c6f59e51-c8a0-4c45-930c-4ef2ed96eb20">http://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpense</ix:nonNumeric><ix:nonNumeric contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" name="us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTMtMC0xLTEtOTQ0MTQ_ff915512-cf0d-456d-a25d-7aab715fc26c">http://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpense</ix:nonNumeric><ix:nonNumeric contextRef="i6f0b5b41d05242aba7c807e0dd337a4d_D20221219-20221219" name="mrk:LossContingencyTrialPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81NS9mcmFnOjNiNDE0ZjBmNjBmMDQwMzliNDRkNjY1ODhlODBiYTcyL3RleHRyZWdpb246M2I0MTRmMGY2MGYwNDAzOWI0NGQ2NjU4OGU4MGJhNzJfMTY0OTI2NzQ4NjEyNg_dc252ca0-1f84-47f5-aa4a-e30b0bbfb328">P1D</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="mrk-20220930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0e20af91c5143088498043650185a6c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7000ad694c3b4ad882a0d1dfafbd3864_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mrk:A0.500Notesdue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f2be8ca05e84092be3101ab17e36630_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mrk:A1.875Notesdue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4c29ff612c740d08bbaa6fdd4e76510_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mrk:A2.500Notesdue2034Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i143bd665f1bf44a2a2623915d83f6b2b_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mrk:A1.375Notesdue2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3f74b51a5dc4dc6b59e6013885b63ab_I20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9490e02538244c88fb94e67f0f84467_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b76c3e2ce274f17b07c82ae1459e9f9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48930a09b1404293820fbeb015eb6729_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i602313dd11d54187bb2dce59c76d9f21_I20210602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mrk:OrganonCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7ff920b80fa44a2bb7838de95556452_I20210602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16de1f9b952c486594ae6f32e5927154_D20210602-20210602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrk:TransitionServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-02</xbrli:startDate><xbrli:endDate>2021-06-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab8a608181a042f2beef71b113878321_D20210602-20210602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrk:TransitionServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-02</xbrli:startDate><xbrli:endDate>2021-06-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06897842e70e4eeda8309f8e1ee91277_D20210602-20210602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrk:ManufacturingAndSupplyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-02</xbrli:startDate><xbrli:endDate>2021-06-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47ff0bcc16874008b1f561555e4a69e4_D20210602-20210602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrk:ManufacturingAndSupplyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-02</xbrli:startDate><xbrli:endDate>2021-06-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54368f9911b347738909e680bf95d53e_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrganonCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic18b206b366941b3bc21e6598f14fb5a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrganonCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13d3cfa7934c4d6088d6cd23cfa71865_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrganonCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32aa48e818164158ab6157217075e834_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrganonCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11700d15290f425cb74a002a0cd2a29e_D20210602-20210602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrganonCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-02</xbrli:startDate><xbrli:endDate>2021-06-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i6533dbb8649144648ffc4f4c1244c7c9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrganonCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26b4f40fba294c2ab11871350926ecda_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrganonCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bca04a61d0b44f38244083585df424c_D20221001-20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8c7d497ea31438baaf4030a8d162610_D20220801-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrnaTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75ee5a60ce374caea61b986d91c7b118_D20220801-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:DevelopmentMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrnaTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cce51215fdf4e1f8b49f6ac5e538125_D20220801-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrnaTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d770d493ee2465aad2e7a4f35310a08_D20220801-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrnaTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie81fe052a58c4ac79c6c1914541dbb46_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:OrnaTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc75b85439f349c791c677badeda87e6_D20220701-20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrionCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib486ae5e04ba46c792826e98b7405eb9_D20220701-20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifca4efa458684a00b6c8c8e3b1f41518_D20220701-20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:DevelopmentMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4a01db11db64f5285ad73bae142f347_D20220701-20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0e7fb5afd034fe49f7ea947b722c5af_D20220701-20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bc205e805cf4d5f9d260e0bc1e150de_D20220501-20220531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i039f123196e246019e2836c6f6bb9e91_D20220501-20220531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:DevelopmentMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddd9e1044d91482a92ae2a06341f0748_D20220501-20220531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:FirstCommercialSaleMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d354163674a44d68678d3dc0bf63d9a_D20220501-20220531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i043e841d659649cfaea941c020c82892_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:PandionTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idacd23b3b6ae489b89729f7dc49d6220_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:PandionTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcccabd6edb749bf9c5977174f86658e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:PandionTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie491bc3ce3bf4fcab2d52425ea46de0a_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:ArtivaBiotherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="research_program"><xbrli:measure>mrk:research_program</xbrli:measure></xbrli:unit><xbrli:unit id="collaboration_target"><xbrli:measure>mrk:collaboration_target</xbrli:measure></xbrli:unit><xbrli:context id="ic3a1ed78727c4d759751ea2f43de095d_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:ArtivaBiotherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:DevelopmentMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4629f08bbd144fe582e499da3dad8b06_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:ArtivaBiotherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bce0692a5b4447e9a52850be6e554f4_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:ArtivaBiotherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6dcf6134f32d478dbe1941c9aea8779c_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:ArtivaBiotherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2347cdd094484cb5b876055e05600443_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:ArtivaBiotherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie42db3b5c5b74f21afa507c6dc74632e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:COVID19Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21912ec93da743c79ae9ba5d3f089bd9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8f4acef9645432a86030dbdecb44682_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaefdc2743e3b4f459d997a63fcf5409f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3afa0051e006445592494b5f1781aead_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bf3affc3e9f436d8fceb9cc9572407c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1907a491b1ab4494bcb5711a999a46d8_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia10ed00bf75d4fe2a88f22919b63e42d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if40bc016be9844ffacc5e3a61649fd8f_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05a4a8f891ea43e9b071e6f036172468_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d0093add0344d4bb0ff3793ac7752e2_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba2c1ce6973c439cb0304ebd132fa0fd_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30533c21f6874363adc26d834802514f_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueKoselugoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a6d8edecf524875b4d7cadcf837faa0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueKoselugoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e730ddeb7ba4b2ba74c9e90f63cce43_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueKoselugoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4589c546fa744a2c966fbe3b84783265_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueKoselugoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia817e4175b9a4610b08f54e5e830ee23_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bbde3b507d74bd89695b20384edb9a3_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if25ae27f28a94974802d948c498415fd_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i398ea6779f6a4327a6a7e64c91583bf4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i039199e857634ca4ba7aafc3dbc79228_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5897251afffb44088ec89b19d1bdc84a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9da90caa29d94f0a8da61f2d1f19ae81_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1589a04249264c3daa20424018a01187_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5050d3fe45a40b8a7b4a69b944c22a9_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i587510372b604b139812c4dd9779e273_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb2de2469e144d4893a6dcc97d4e3c99_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ed206b7f8a24c26b903ee925c1c1961_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ee4ac5f1b264ca69d35cbb50d96ea05_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i138101fbf41c4f9dafc07d2a4e620fca_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i613c1d9fab0f431fade5cfdf29823c97_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccffbf6b9b604242a9e75a41475ad0f0_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id481255ba6384775831f82ad3ae7549e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id55d4ae3b325406e91eef2de4b2e7b99_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia80cb9af76954141b50f85baffdadb69_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbdca7f63bbb466b9c0edf3825db2b0e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b48257a883b4a79aca85a1019943388_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf53d38799a3490799f7eac25c464fe4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib322c590099749b29efd1012a6436a56_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d3c8bd139d14d1c9571445aad6c4723_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieab0ff535a8a4357924a2ea4759b4813_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie403795b3c984fa5adccd65ae3284b98_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i144701b5635f49b6a87e388b5a112a0c_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa0c7c07509a49b2bba97e430289c5a0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8782c7cfeac4f45be3816e9c23d40e2_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i981c732452864a0a89b0bdd4ea1ca966_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e9c637f23f8498097ccb65785974c6e_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9a88c5549694dec907e06fa69cae667_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7893a61b773e42eaa4750e61ccc3e264_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42218d013fb34f1f8c1048bf798e322e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic860b4ba2f6b47eb8e120d99349e2f88_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife92a3473bc4415aaff470cb4cf0a01c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a3be947f65b41ad82a9e53d652dd2b0_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide4d6dda5b9e4f48ac02ead988fe068f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie590418643204f47816759f2195d86d2_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i366906fcc328447985b2dd9207bbfdb0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb33f80f44364328b49c32741943ae6f_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67dfa7f3e534416abfb0f9c1ea1869c5_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ae012bcf60c4cd692cca1d41ea9a0e7_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7be328837202423290bff8758c427630_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ac2724c045a44b1815128ce8f6b20f4_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i683cd7e98cb547bfb87dc770c0d74e58_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf806d58f30c4be4bca6c3be1abe66c9_D20220101-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if15ad2dc23594b05a094920b78cb9281_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbf925ccbf934ad1bbd6105bd116f495_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VerquvoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia903414baf944a4c85e8b48c1ec54218_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if192c98d9a7e4b0c881c0a5da15bd44c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i061a8128f7d54a66b9329be138104804_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if960063333f14939a78490bbd9873025_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35d4d64303ab483e97f9f6829d296385_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba08ab1ba316433da1eb64e967da1f14_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81c4bab0b60647bba82d1e4ad7faa825_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c06ca35260641c481956f20cb681bb1_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i519e6b6f4af34d2e9581f65447c1311f_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VerquvoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ddb0dd7fa034178a6eb152be9603780_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VerquvoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9999b3f45ca41a4a2542f94612afb3d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VerquvoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i212e8f35bf4a468cb7a86750d3383cf4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VerquvoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90dd98ecefa24e27863c524456240e09_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i186331a72ef04ac9b7b6241c63ffaf24_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedf5c07624db4e01a7cf689fdcff82a5_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27f892355464487d8539768fc6061eb5_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib78cfd0dce084d31981552de8a046a04_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30d1694e33a8460db578cfe950cf06d2_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56264076164d4059af8de0e8936319cc_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9f07ed930f14354adbe45102b20b9c4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bdc458f37d94074bbb7340625918b7c_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i323143b5b858466db34d0d2c5c944f28_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia91b5a3c675c4ef88e4f8f57394a5380_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5053a9df2c864fa090b207df72bef585_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3525e1187e8a48de986cf4be04ae95f4_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7be680bb4e346ee9310c38a476bb72e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58b09de6ba674b5b96551d497a48a9b5_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0771df2198d740108535caf3238d43d7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="market"><xbrli:measure>mrk:market</xbrli:measure></xbrli:unit><xbrli:unit id="course"><xbrli:measure>mrk:course</xbrli:measure></xbrli:unit><xbrli:context id="i3723cbf2e9d946a999ed600588ab4dcf_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if65526f98e4a40e2b1e489150cc1a2ab_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccbbed27ee8c445fa7d6d65e80591a7a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fdf0be182b9481c8354305d8e3858bf_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd2d41565b6f42a997d55a3d36cb68d1_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5885bf545144e9fbc3756e4e3d7b93a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb36d80fe9584e529d590578a9d319d2_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3627424b141f4c858a9b7d5990d0cd74_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibccd6eb894bd4564a6c0a0c44c562587_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9f5d07a2f4c4a9f82674c37fd6d528a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17a18d3e962d4cd9b3dd760b10d9798b_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i434e35353dae4fc0b4b54dc274539d65_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib23b0153d3f34c168976ed88f8d51ecf_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c3f6bda0cc24696bb0a6048cab3d8ad_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e9026c7a16e448aa12d13cee7a70f46_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida58e25739ea40aab501d63f8e5ca681_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39554fdd833642dcb810f17c8dc0e061_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i425575da0166424ea1fd3084934e226f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27570eaa57364d34ba707b5178e9750a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82096e190c7a476a960b881f6f4ec492_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a2d8c4a46554ddebb3ddc81810f3b42_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6730c99096144e189cec49f74ada9510_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6ab39f8789a4b6fa4f623fa5d27795c_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueReblozylMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0715d2eaae6e4be98aee0bd0d1931927_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueReblozylMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f62c15a0dd94e4a890739e8dafcc0e8_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6564f481b634b6fa99cd7e8116cf98f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i607e39f2759d4b5691b37d2c9b39dcc7_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ec10c038b504097b605bfddb4195539_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fb3a552dc224a94b2299fd6c6cf8889_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic03376b1c2a3499d90e8c3ebcf2e8843_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67cab3cf205f49af9b2cbd5c33f66aaa_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i940e1b01bd364068818c54a265d128b1_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72dc17aba95d4c5dbc3a2194bd16fbbd_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec1e587d8b0d40bdb598eb257221971d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70303f64175d4dc4b0012ac52b4f5e26_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3578096e6ff448caa0f52989e5f64761_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ad3e04cc3e3418cb4a53a75ae5c3e2c_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8849203e046e46cbad3f2f952d1f4e26_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c93d3a120f84e38a20a1a70937efcd7_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaece706c71314f32b319a33cc075cdd3_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i310bfcc0be584465a56866ddaad54dde_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i521c621370414b959a6f7126a06cd3db_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45b5fd4276104c17a8bc518c8e4ee367_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id015ab72aa4f4666af512c49587ba178_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie78da687a4494c7fb93cf5f0da80fd52_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92d26b2795bd42e49f6d1a0b2f14a67e_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie67e7f4f21244b38ac40aac5e3a31725_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica35ec1eb9ea4c119a570c9e6bd607d1_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bf969645ea14edeb5fb224b37851e85_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cf8194e2b5745f0bb10f0b19e79ef0d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idae084acd38849fea32bf72eca48cb01_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7e6f52cb1c84ad79bc614920f692b13_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fedc08d43254caca03ecd529c042551_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bc054b6f538473eadeef1645e9b4c4b_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9362212891c34b43a1bd670fb2f4062f_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a992f86ee914509b7bdf62709a6811d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5aff9663fce2448c99f02618375e2e64_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b0c1dffc5964f349f9a75222d0c1430_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0106fbddb424e3aa3b3ba43ca616389_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8d2797912764a54a9b0c8b56a5cb401_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba55b4c871c84cf8aff0cc19a6430038_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a2cfacf23e041649e6e810a01b78367_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6578e5480804aaabbdd710e9e7d4dec_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5f3b77e795a4cecb84d959b27d815f5_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53cc7f522cf94a9ba8b27371253d34fd_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37502c19e33b478ba485f3769f7edde9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dbf94fcba07458c9985b487a4e8e11a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i897e9c4831fe4162b3092f6346596330_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b3871ab9cbd41ffabab932a2f1a7a00_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic248a691eef3457980491b2190cd4476_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2181ab62a29c4f39995a887b7394ab97_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icae4aa9b209147aa9d9bf757f4c8c2e5_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0582722a90814a31816b9004352bfa16_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia278f201fcb0483ea8de813bd868a23b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie582a185448546fc8001d7759a7730db_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36d4bd762ee74c8b99495575010c996f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6ccd75209b14ac48e453f8ae771b430_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90654f8e2de64d88a4d14ff9c355cff7_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae11b50969c44470b085b71a202c369b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fef4e3614274432a2cb07854dd86e09_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14b940f93da941d89457a0cb5087dc05_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f0e3061236541d88cb6730bdf73a36c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fe0bb2d87cc463ba0afd98a1d4f6c49_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fde48e69dd3472e9819a95aa4746a43_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0f98d96c0344d749893dc7317abd393_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f83f5cfdae84508a28c38bc5dc977cb_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i727f0dd97e804d1cab3731ca3b4c50cb_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98e34a5cb81241399b51495bac59245a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e4b050ead3647479f62f1237a1c63c5_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i309f819f3951487382595bf493061e13_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i874c7a8482d9491690e6210b479df219_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5db3736668d14dc8ad614ba24ea70f21_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12cf63265e33426a9ac172ae9d1f6ad3_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5216105f6e064bba87cac0aa0ae94efd_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i955e203846ca40e1adf9d2507ef80695_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4afc7e4c5b9a43a7af38307f4daa99e9_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie766e05eb57f41bea33a66d0f8d1fa6c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb61cb5684ff4b9c828cf20066ed6299_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb5b904f4f0748a6aa9b86108608f108_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86d01d6cbe2846bab4a8e80b2c1c31d2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3f2085cbdba410eb279bbb464b3ec8e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6edbfe83866410d981411c92bc94739_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic795a5720c194aaaa03944a5d453e5e9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a52aaf7232745dbbf9787cba14d23ca_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if340c59c3f4d4832acc93316ac66cbcf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87df032ae149438c8311b443f96f3fa1_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79ed206618d34ac9b28a27e2dc6fb6b3_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f9135826ed64fa09549e1defcc31184_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2de9fcd183e42f8bd39ac5db830d924_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c8be2269d6c4eb4bc6e4bcb3ddcfc30_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie27e3a1d731a4e8aab46753956e07c5d_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ae35cdeb80c488d9810adba90ad5a22_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5ffef0aa5134d30a7bc87c2f1471202_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f49cd47d7c34c2db675a1a70530cbc8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieab5e8f43e5e4ecb92c95a699771341a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01953d66b4ed43759d677deacf2426b3_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6c315ba79954d888131d6d2b08f5b46_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ac58f37e82a4b95ab6c2445433ee541_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f5e74c553ad4cea9c9915ab749a9781_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e5bf65d147a4bdc965896b6d99c4860_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e5ed55b09f84d5498e328aa1b4f5417_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i772590a293ba478db2f7600cf2cb3eb4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i099e48fafeba46d08da6b31e799e3b7f_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03e7ee1c569b46239abaca544705e805_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia780135900c240e5b9abf1b31ee64f6e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92c75e458aed405ab0daac044db42401_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e0dd76b1ff5456f8f9ea13bb5b3d393_I20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="interest_rate_swap"><xbrli:measure>mrk:interest_rate_swap</xbrli:measure></xbrli:unit><xbrli:context id="if00c71a39ce54be38bef228f86d7f5bf_I20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mrk:A2.35NotesDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3f2b646e97448bb985e896a02467668_I20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.35NotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea3f69b723254e88a143cf7acb00abe9_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i486ffaa742a0496f9d919416396e1c12_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mrk:A2.40NotesDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c212ea75a92431aa81258fd9e8294ba_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mrk:A2.40NotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e5951a5bcea4965af6bb7344a6a099d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.40NotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdb46049abd240818d8639edc52d2396_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:LongTermDebtCurrentMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc438baf83774566bb16844255c68486_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:LongTermDebtCurrentMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53f76af88d63418dba6b1ea3a71d7ecb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7eb7aa0cad44ae481279be50ead5cf3_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45b3ae0db3cf41c3acafc444ed25c107_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:DeferredIncomeTaxesAndOtherAssetsCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if41d8f4f2079476e813d82c9d789e8fc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:DeferredIncomeTaxesAndOtherAssetsCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92c41baff7714a72894f9c962e96d0a8_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:DeferredIncomeTaxesAndOtherAssetsCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97bb92e54ef74a8db32f912747efe346_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:DeferredIncomeTaxesAndOtherAssetsCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92c868d7e8f9475893857146e49ffbb1_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:DeferredIncomeTaxesAndOtherAssetsNoncurrentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f6e2cbf96bd4896863dbb8f79fdf2b1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:DeferredIncomeTaxesAndOtherAssetsNoncurrentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i338b3ccaae68438b96b0f370fd0bb963_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2398c81940b40eabe737fa14c821b96_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa0ad26fa2f64d7ca0cf4d95ae5c7567_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib67ea4886b8c40868d422b24ac9e580d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf409d1f24c84ee6b661d53c0d63d271_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15d7e32d159245d8962254b1ac043b09_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7382fed477fc47e3acfc51cf0827f22a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieba4d46f4e9b4513aa30046a1640a2d1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8bb1afef334464cafe180cee4605e3b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:DeferredIncomeTaxesAndOtherAssetsCurrentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6964796fa04f4808aa3493a670881eca_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:DeferredIncomeTaxesAndOtherAssetsCurrentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f8b8b04c81b4fb99373775effba54e1_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id74f2287203447e1b810c5fa36a1ed55_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cdb1dee02174c02a0606014cbbae99e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54c9fc9da50e4192912b25f5131e50fc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic44487f92a5448159923c27c8d731670_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4d2e0c5ba4449618b901ef68baa6ea0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic76064667e0a419bb6d0e5c3426be249_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia325483b4883403c90d79d1be19c51da_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2090286591394c9fa952301d7aa1370f_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4bbf795a5864635b793460597f6ab25_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe3cb650f6ab4c9b92198643023e4afa_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i408273e5bb4c48509f2537d97a208c52_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a250ba5d2eb4f398ca0d688c55ce97b_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4884545f3a04d2592a0a6552ec37a9e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3adbbede1e4c4a219df434d3b02b9d73_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24ff49aba1234e2089a06728556f905e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8487d36b908947f3b19f1402064fea62_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7aadf0e5ed8498e968fa72fc5dd2235_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id156cdfb0da54388a5c8bd98db65a8b3_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1673663dc72f4e86a51bc9229008f01d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i047a084a24b645f68be7cd35a8fc04a6_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeFutureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0264f6f727c4a4b966ea14b2e2a52ac_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeFutureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1f6dbfb4c7146b99019ed98f23895de_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeFutureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e75809733d64f339d96ee9714ec260e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeFutureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4720a53a91d5435188a1da01bfe210fa_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d9a78619aff46ea84120beb595fcb13_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffb605e60b334d25829964639aa3cf58_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9df8f1a7ad004c23af8f2239cda6077b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id736b7b8bba944b58bf0232a18e5113e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bfa097e481a425fb4b73f31bdcecc30_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8ea7018241f4bbe9b73f4cb4ecc1d8c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a1c00996a864ae7bc40a0fbc771bd76_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i010c9478893544c28a5d7f544dc8e662_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i099b739b13c44281a0c6d085f13b276d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9e54f6ced9e4ef1b0e99ea06c1e9ef7_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3580944146354ced840addc5a64825b3_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i734d905417484b12868c71bc4c409e5a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic41821eed5a14d76af729b6ab39c2ea7_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51e48c4224c04c2a8bdb9693ed998b0f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba9a552130db4292b0e26dabff225e15_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d25405b868b4e26aefbe7888fc41f43_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1426949b23ca4b71afa632f63d710aad_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d7092dc98a44dff9517d3c284f1849b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie37c5d029c6648c8a2ed03a8d89af9b2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1509e49abe14db0828288f4c189b466_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac3cf219c1b341109243396f0c18a2ba_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icaf187dd1d10491f92cbfb112d50b31f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5dfb72ba12644a297b93978abb2da49_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24b11ce36fae442893c46a0e7203cdfa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37c6e32ba0824ee38f745770cec9a2d3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7c90958615d4c819c1023d563e55db5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3eec1411691a43719325ad418681ac13_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7584c66c93fc49e79ea35b57c4e39390_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7fc87b646454715bebf1e86eed2c3f4_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1317ac689e934a98bcc9a08673feae09_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd40f186b450434689326d7a01e529ba_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i805bffc3fe574f44bdab78a3217cffd8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ad98dd1519d4e5ba2a6d482e01bb026_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e5b8eb982b3417191aa735376241712_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23d23f5244de4df5a78fbcc38021abc9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5cc583b3ac545afb27d7011fbd7878e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7b005680367482db7f6c5526d8a8330_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5806d7d6752145c89d6aed6b12c0de58_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03d038eb8e67488896fcaf65d65f5a4c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88cb48af3d36483bb4a106b4973f8a8b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9b5923422814e839a9eace38e185dc2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53252463645d40a49cf3666fc9496c89_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95e44cbbb3c8441db74551146976a2b5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib55137ada6674e97b937072f652336fc_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia34cec2011844b3abbbecd5c96aa140b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9d82f620e50424d92c3ec570c9584c7_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96a1014d1ffc460ea40f01ffc40ca637_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4a852e542ad490499c3bbfa84c21253_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0249004b56d4566adef1bedb1ae2649_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7d1ba12651d49ca9605e8d70b0465db_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62dc854b928b49a1945ab2a202ed9435_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7bca4ee680b4b53bd3c893bfc03df3a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if02abc99fb924ec7b0925ad5b953f9a0_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7eedae5d638b46e08efb6239577ce6a7_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30c84521440546809e99309ada3e6429_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66af9dda5d5a4116ac1581f86efa6274_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec03db9221fc48e3aae39a8b07057d6b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c3110d2fc4241989477e58acec0f4b3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4589bd6805f421980e686f3847f3f2a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a48ff5c326b4d30a9df72d6f4e2cc4e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f242540e8e74ae39f0f26f08bedea4b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia57d77b66d2f4f38a0d399ea6f3efb81_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2e22773379b440b9fd05bd8ebbb205a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a773b58a7504fb78494693a086bafcb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05efb95673774e31aaf4d68427669b60_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b85ae7b23754291aed374cfe63220b4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77e75274a39649d087e97960c6fdb1da_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f4e74eaf7314a6f9b6f0534ffb3fad5_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06b468d5994c457b9893c14bd393221a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if123e3f18ada47ea9d007bf17e6267a0_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d2873d5334e4202befee01684ddbb00_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e6b581a6b0347088dff9d709ad77eec_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i891d6272e42a4cb2afb1b6651756ea76_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf235de4a0b04bebbe52a604c0a5aec9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78a40cfbe8af4bbaa128d619556eef8d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b8fe718d6fd40a2bb40eac7eb3ec7a5_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i891529025c4d453c984c2df2e720aabc_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c660dcc9c53431ea4f8bf9732b7f414_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16903db8243d43c6a0558e66c138694a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4220f301677a4e66966080b9f99d020c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc979a929d5b473dac3eb798c69af53e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3256ceaea4e54171a07f3e8e012df401_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if57cd225864c49d1b3170aa0a6cc6eac_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief790689a028402aa25ab7e36ca0ef81_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if556bca6c6704fee88ef4a1501269201_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f6c358374a442b8908f3ddffb11dba7_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">mrk:SanofiPasteurMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia921450fc1e646fdb798d9bdb31e85e7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a678e64e2774577a007e2d6f57ae9e6_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoryNotExpectedtobeSoldWithinOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b4bff14a1a9425cb5bf3661e7e1e54d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoryNotExpectedtobeSoldWithinOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i816e17e24e684044addf68e60f3d7cdd_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoriesProducedinPreparationforProductLaunchesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i871e3e80b793441c8f0be12b7c62ca4b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoriesProducedinPreparationforProductLaunchesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b998b01dd7b4aedbe8d12d9cd13b5db_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06851cb5c98f4da69ac686f6c2411879_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NemtabrutinibMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c885d79a0554b91bbfa7bc3397951e7_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NemtabrutinibMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3ff202f9b6d48749d7758af33b9b823_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FosamaxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="case"><xbrli:measure>mrk:case</xbrli:measure></xbrli:unit><xbrli:context id="i367d0d796d80424da91051e66c46b38a_D20140301-20140331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FosamaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:FederalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mrk:FemurFractureLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-03-01</xbrli:startDate><xbrli:endDate>2014-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if701c2dad3a448b8baf48efce7ff3da8_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mrk:CasesCompanyAgreedToTollStatuteOfLimitationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="claim"><xbrli:measure>mrk:claim</xbrli:measure></xbrli:unit><xbrli:context id="i23dfb067c82241afa5f99f21bef689a1_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3433b64365a54af2b3af67c46a542197_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie980ee86472c42588cfeec3bc06a4e83_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CO</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5268335c17cf4ff1ba48ee77aa8846cb_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:ZetiaantitrustlitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5302423c142d450a83f2d69d472c5fd6_D20220630-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:ZetiaantitrustlitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-30</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f0b5b41d05242aba7c807e0dd337a4d_D20221219-20221219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">us-gaap:PatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-19</xbrli:startDate><xbrli:endDate>2022-12-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d703348a1634fdbb823234f6176f03a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">us-gaap:PatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i251ca90ae959435d934e00a6b5636367_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">us-gaap:PatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied8204c596b34fe69666b537c6dd68ed_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">us-gaap:PatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaAndJanumetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i623b3d56da7f44d9a270d2a0c4de1efe_D20230109-20230109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:PatentInfringementLawsuitAgainstZydusWorldwideDMCCZydusPharmaceuticalsUSAIncAndCadilaHealthcareLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-09</xbrli:startDate><xbrli:endDate>2023-01-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e7203ee8afa4167bcbca2845a05174c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">mrk:LegalDefenseCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab20286c913c43ab9d138d102915562b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">mrk:LegalDefenseCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7dee7788157d45e1a5392aebf32b5f84_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i769035208b1b48838e202af7a6565d8e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9efdb7d75087494cbe98cd19e691e3fa_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7e47c5bf82f40adb471e36675ba4ee6_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaab9e1dfa7444fc3bae3cc093d6fe99b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id23a801131ac4b8c945a76709e53ab57_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3afe38f10fec457498b49dc2c46ff07d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff86b236dd274c4686ba706b239b2836_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ecbfa0ca4994647873a7f5f0bd59cdd_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8928a318d22448f497a03f892bcee237_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4df4b3c64fe4fa28360813d66561107_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c45ff5f83594356b2993ac3c0f1c8c0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie32bbd59665e48c4ab1a7a2fb3b32c83_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8d08e2935f04a3892dc8bf49cba95aa_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieeb453ea070a4057ad9c6dd3435f8906_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99c020a806d84d1cb9f8c8d97329cf8c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3750629558d54ed8b2491825206bbff1_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bec43526f964113b92ba5a981053063_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fc33f512e4c4f3dbfc4ffd56fbaacfb_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i163092cff85f4f96832f89ece004f615_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45e71d3b257b4deaa9068f76e93341ed_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9864609863b94d00aa7ba3ced3bea441_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a2cf1e51feb4bf9bf40f48b1eb15164_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia75bfa90c3194a5d875d56f842b27bff_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d5f781c87ab40f58ea21a9500d8154a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if014c4b837bd4c0d8e2b84afeadf9c75_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2a2791bc9db4ced8a0f57eebcf50852_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9706bcf110ad4f7e9558da712a96dfba_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c57e5ba569c45d99424f3d170f677b8_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib76e902784e74151b5da455c02992dd8_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3d50d8ac75f45d487c729ce8817f47e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01a43e0ab33146bcad94c2c546eac8bf_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fb137c2da28404fade360f5042d137a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0803cc4f2c64fa7a8e0196a811eaf28_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6aaba1fa4024e1cae697b7460337046_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia63f0e081f0a42f198e5d12dcd18cba3_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8266a2de763495e917e7346aae13f81_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46979b5fbfcf4bcfbe34ca9f2816df20_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb58c93066b54a02965539a527ce9165_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93d7029f006b4d91a535c2e9905f5a89_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf444f353af04455b87e388e584fc395_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc4cef6237e84b5f977c6f638148d150_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfb7a35d7d0e432f9e66dd2215b3116e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43d9233de62a46b78fb5fdd056a05478_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac51e60463f94de2b9a560820ae84413_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a2bd52c5dca47a292248a21f88ae298_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib23f7298a6c6404c9b917d37bd3494f3_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58a9ea166bd8462bb92f1bde0e0c38ed_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54fbdd4b47aa41a69dfd52ac2443383f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf1f3c1c1c05447abdc62cc369de9b5f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54f6686da6db4e38aeb2e4b266dc881f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2b77295046047d1b7a851bf3bc457b3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb6e56eb418d416f86418139727649f6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69b491e8b3b84d76b979f1d2543f1bec_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd52fe4f8612434abba6e97f4c0f64e5_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i398ce1837bda4dd2867a24cf3db019b2_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac4516ad133342f381e01ac656921924_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65949c6818b4456e8bda505693b348eb_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i320809a777744dfdb73841889368aa2c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09a399429407463c94fb6f4a770e06ca_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia48fc689e3e9494a8b708e96f1579dd7_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37b081294e5b4b8e9e5a11799924a2f4_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i129ad2aa2cbf44d79bda671ff94c6b3a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f56c3589dcf455e940e768c35266f9a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f795846dbf2495a9b51d25b57687dbd_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i113e99a5148f4c19a209d84850a178e7_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49a0549eef484d24b04fa8fcdb43efe2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcb20618db4549fa96838e2cc81877ae_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3dcb6bbb4364846bb3cb11e71d7614c_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if26b7f13a9ad441d8310410aad545b78_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cf6fed6709947cdb2d2ccc2ee3bea72_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38abb5b6d35e4640ae278494162794cb_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i355d324b4b084fcd9897163416bb017d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5747fab0a16f42f8b7a20235e05fc43d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib62f00b41eb24b118fee32484d16e6ed_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76c87fa1c62a44db871fbb8b83163687_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52a4807b00fd4898baafe70f646f2a51_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia164fd181a4240bb9f3e9e496fc60bb0_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04361801595c41ef86be85e444162b27_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i998f48f9bf1e4663850834c5e23fe862_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79db0e250e4c4f81b2bbcc5c8fefea2d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fbc79b742df422b8eb80da9c3923e51_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i871670fc66504079bbcb712e2def07e3_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0ae37c4002d4f7c8945b238b450a3ff_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0de005cbf7c64be2bbb15d3ad2747c39_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf6a11570b2f4b75989bbe9a432b4263_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4376d5e08b3472d9cdbcc59389ab13f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i940d159cf6fc4de7a976d223e5df88bd_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i820aa0a4094e46508f3d90c1102a977b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3d89e2baf3b40f3b69759154662da14_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc4cbcf7fafb47afaea1141b1ace9b8c_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b887851ae3f40518c8ab99172a256c1_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f45167f24e645d2ad668c47635fc09b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b4bb3ccba1a4790beb19a0ca2cd4721_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0df51b82a6bf4ed3a20acde326a2a355_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i754a465cfe674a28bad93eaa56b395ec_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2877989be5ba41eda5048c75789f5d0b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdc463d6e9e74476b4efb5e0ad43ff93_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46dd5b7c9aab4334a81feabf9ee87525_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a93811c7004483b89e5b2b7d7a47e27_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5aab13ae412a418dad03dcc21e39fa7f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01ae4d028c1e4ad69e3c0718f2a9cad7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e2ba0ae31ae4ff3b092f4b0364ad5e6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic491ffcc027b4b0ab4d63e1874c095cb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62ef644e97384716bfc5c3610ba4245e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1f9224028414e8f866988517a90edcb_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie83ec1e38c7b4f8bbfdc941221d33647_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>mrk:segment</xbrli:measure></xbrli:unit><xbrli:context id="iea72657d01094ffca27df83746971588_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51f8f155c2a64e689c87b4aa3495476e_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie356d6063dec4577b2f6d9d0462d8e7e_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4afb690c9224cf998243be692e833e4_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecae6fa25eb342d9927a9e48d4dba455_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie61d00b2a6bd4ecb9cf24db30e5da1a9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if011579e71f84295ac8c9b109ec9a4ac_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide55c02ef5074706a5aa037e6c934afd_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95106ae9af4848e58d3a94156cc2bedc_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i770403621f9447659861ff7d3c027d04_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5065fd92c2c5486cb1c8595222c14bcc_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia40b9cd0df2a4a739c315a7e10c645be_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i906fb9f369f24ad5bc7c94038e03d844_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i143fc202262a44e4b14db40020296c68_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i556dfb6e8e81410c9a188d168e0cdfbe_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2efc45c7c6e54f1e8772b6a7d931aa76_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f250204e97849f4b2597c9ccfb28c6e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80d8c27dc4c4418ba9ec00bdfd449ac8_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d2992b75ac049a8adc9368ebd3b710c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib17fdc41fa4b4440bdb187fc784528ce_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ef1b7a971cb4cf0aa1e17dbdc38ff87_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if88c3613f4d7400abeaaf7edc177e242_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5b535ea1a074ab0990a6830301b99c8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id41d2a02c14f46749037b85143f80400_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i032733796fec487a9ec5363a6de6bb37_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7bb2d455a324d85b663449ae922babb_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3725ce6128304af89af87fd977d6dc98_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc093a125435445ba1dc79fbc34e64e1_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e380088b1224143bea2f6722190f293_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c913add24e44a0f9348623b21235818_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58100a918de34961bf23cb6d60b59996_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57645af2264341fb887ea206a381c869_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if31c285904b6492897698f18cb4e6080_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fa27317ec3f442fbd94cf33b21e1eb2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id51eb40c9a094ab9a113fb3a71d38030_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie892b4d7a041422abdd832f50a0f95cc_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib48d2e82b97541f38e95af0a653ab27b_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueReblozylMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1eddcb43b5d249a2af4318c0c246a2fc_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueReblozylMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25082e66e59a4337a66ed93fb65581c8_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueReblozylMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia27a4765f6f24c37a3b517d089f2ecde_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueReblozylMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ae58919bbbb482997e5aa8e96123089_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueReblozylMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4269d8f661374131bbab73264dcada9f_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueReblozylMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04dbdc20bf3942789452bbdc6a5e24da_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueReblozylMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ae38dadcae24a6686971665f448c5b0_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueReblozylMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i793c1193aa2f4af6bcef7074919dee8e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueReblozylMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67bb7f002f384902b0a86cfd9129bfc2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueReblozylMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7bba4c38acc4bc0bb07a1951b9d31dd_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d5c095574c748718095a6fbabbd214c_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e3866f93c3d42e8b58a917f29364c00_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa2f870185b742c0a08a8329ad6e8053_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4008d740f8e74af8a6058243d2c4bffb_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90271b2f98e64375a768383e3ac49db9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c0492792ca04bd3b53c001091f93a58_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5efa6e77fc3b43c197b420bd2930d959_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia765dfa77c1847ddb5439dfe5e593cc2_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id754ab9092f541f1bb0c46f84d571073_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ea41eae43e44e758d73f10739ebef8f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d98ee5588f64bb89006d5f3b1ef89ef_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93650c21d0cb4dce8f66684f468b7f9d_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i541aec5947cc4f8794cf3d8f132542a0_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63937b576d734bdd874c9b62aff67ca0_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic105ebb39d4f45fdb7e76b65b2f7c268_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0270857a4ce04adc87d535004968cca2_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20ab8f4749914720b66e1986e30f2490_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d316c927f914028b471fa7baa8efe76_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if90d628440614f1a8b82d9012cf44d19_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff0b49e0a2214244b08be408fb0071a8_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie667b194da5b43139fa7eb334e923aea_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if75e90d893fe4d2daef008b05cd61801_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3221816ac6554c0ea0725b82fcbe8866_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8664e2a8ba934ef993c8af9df045661c_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice6230b5dd6b4590816f68ea0611bc32_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47949af4a1384b7cb8b878121f95341a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica0fb5867c7f4a1d81c9b8e00f1299c2_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02f6c72e13d24ad5b8a9242d1bef0091_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81969b509926485a8a666277757c512b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e2ff6b002b74a17a257416545ef6e96_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib71b6b89fc16436fbbf1fa07b6363b8a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9222172d1bf54d24871e696a611f9678_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a245b712a5e48669e48a3980e039452_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49e1542b3ba3448aa3d564e26fc2446a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13729599ed214b168aa63442d6acd6de_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffcb1d041de24e8a98b15f54038962b9_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57a185fc411c4db19484a70301bf7c8e_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i585b71b55aa241f0a689cb6373aa1fa2_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i225b62c9d0a94897ac8731640188187b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08bd174e76dc49ca8a3aa6f8f34dba50_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43dfc854ee5a409bac203fb32dd6d61d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa04548d03764d5bb771484866fddd91_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i443086dbe08048deaf609109e2104c35_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2dc12fb55f1f4323a0b4d26b08dcc080_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddeb3ed477674caaa13204bb072a80e2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5ba933b43ec40cbb59d3def6165f9fe_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7eecf1f67c2446fca9b82fda9e4a3949_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f6536581b11466c97256e257fb58583_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idee3f0ae73e249cd86d1e98f97ccfaca_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48b01fe75e9e4b59aaff1fce21ed2c4c_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46c35e3833b04258a27da6cf08e2b9c8_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icaf0413c2916445aa22a3cb92baf44d4_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8285527fce2495eaf46116e50f1d995_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47293d92044b48e99da891220e8b196c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3002e359e24742fbbcf884cc6e683e05_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d13aaae18a24197815774e133bc1254_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib67c4ec99f724cbd9c5c4fb76245033c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb6d9b7fab874ffe8c1b46f7744ebb79_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97fe20ab999940b48ca93613926a0d93_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e45830a855742509ff087274006e575_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i296fff24993d4fcd957a26fcdc376978_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4dd006ef18ba4a51a0b449e2d732ad40_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i685056aa30374b748c91c804e8696590_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i265d220c8c194add815250d378abc902_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8a9bf2b9f8d40f5891228af7ee73a36_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81070fb665a64fc9a92e648528dced5c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idec7bac0c49d4b1db34ff840907bd798_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if971fc9feaff4a3c9a5eb10f74e1957b_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if294e1aa3b5d46f8b28217723b28ef92_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a7dcef569de4308a78959562aefdfa5_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e0a807fffc84f018f4b4464b1bf9072_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1687a5207479439f8e16e57fa7ac046e_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbcc716f1b8a4294a8ac7755d58d7e4a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60ba948e10b04bf89e609fd126195611_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65e784f938b34793a6b9a65d6d6cc86e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01d05ced165944a29e318440a8eca779_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9538df57cac43428fedf093f6e753f1_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4649f1b3f8614c1fb6696040dc8e573c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac88839387e24360951822241927d01c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccc7aacfa4b9410a985e8faec1f16f9e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i182af2613ed348cf9d6dc2f9be178a66_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id57f4527272f411e8eec3fcf5da09481_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifacfb5ed95734fe7b4fc8bba627a8845_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd682219d26f42589766951ab88e1c3e_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86d0c8eba6b548b2980070d44447b21d_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieafdddb927484d7aa5ac090781377625_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie32bcc064d0f4de8ba4e1e7150a0afe2_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f5e562de1574da48919247a881ec58c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98f319f069c14e75848d9f78788ecfd8_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i461a9aeec04e4fd48e331e0d1ae98fcd_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26820a66f9dc4af881c3df742b2e0a5a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7115d8a391344fec99e5f60ebfc980dc_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieab69433fba045ac8b7a8451cd492815_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c1221038a2149c9b97c80c8f611679c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36a64ebf107e4f91a169bc853c046233_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71f41596ea7a4b3e8416589c8c7a8138_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ad0235b784c4439a674f0deccf68980_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib964e6bb433d42f49dd769839ac28238_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1001be10a5d043f397906bd36d10ee6a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id51b949ade4f41899e4a18fbbbd2a1ff_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdb4e966b7da4d629f6fe2c428ed1ef1_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c824b0655ff4c1fb993fba481533fb9_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8e89580305548a490f0bbe9f637440e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37ba015ecbcd405abc7b38785b7dcfd2_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cf6dc7c6c1c4858bf616a299a8c6420_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81ea1f35405a45cebb4edeb8610e28c5_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01c00548f8444dec89b6744b02a85fa3_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd81b81346ae4eca826a989395f148a0_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f785e58506544309ceddc1407668851_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07bb128b4a6049b9a45a4721c32a8c32_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85318a4d743d44788fda10cd96301c42_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf4fe0a8e4d04a23976ea2fabe3f04e3_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i098c29dbbb064deea26d4c4f34218264_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4a66566cbcd44aa9f077d342fdead01_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie28efd140c154386aad5f6975c8566b1_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5585d223173d42a68c6f66af1f246d09_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fef72442c5244cfb5a176eb81962df1_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie99454bc8d07443483aa94820869b584_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf5e6b24740e4c4fb42a6d01883937d7_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcf29d14a518483185f8a99cefa1fa46_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19565b312a7b438cbc10861858b1d449_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icff15fd8bd1a4d6bb79c3beaf3519324_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7d439da126f4be48f56a1860640621b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2a2dc400d82406cb2a4f1761521e529_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i819facc7b2e14484a4cb6e0c2a7f93df_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fe58d8dc5984f3cbd65658d904a9481_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied9c00ac4d8941b4a017cbbccf4329cf_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29dea2ed4a654c42952ab41ac972c731_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i099da3aa99d1482b90ff756d321bd102_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f2ab84f59744e4aa1b796e01ba81c31_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i312d000608614fe586d2aedc23ea4dc0_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ea07e7b467b4e8ba73b1f10c45b4e02_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b9ab232d5ee4970b968974b33aa9605_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46397225389c4799b9e0002cbf9db54c_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38f7b98bc0114fcfac64f5b19a7f97b5_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie43d1efcc1f2463a9e6ceb872a750592_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08ddddbcb59e45afa01649b4a5c0df02_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6441c5f89ab7428dbb9ce2a77c7d178c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2859c498f1484388a0c92b4ee1831d83_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if28586c5985c4caeb1cdebafd9ae7432_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a21006f6f464cf49d94de523666ae32_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bfa337eca3546e49132dfadd33405e8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64edd776e6f848789f0bcc6abe69aed9_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idba160b3c84d4ded8e2ad24897f18196_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife2e7a726c45443f849fea10fc2e4265_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9b27b189bfb40db8b98e551a462b6d6_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7ba48e565be4304b70078ffe4498c8c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b9d23875fe444829c441808824a5a21_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2fc16b785504c63ae17c7cdb9c1c0b0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65ebba197f3740bdb38b629ffcf72ad5_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3da352c9af7146f4810e485c59906a57_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i097267c7483c4f3baaa83fa953994d7b_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id92b88c5c7c54cd897660ab28b07a038_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebc064d77e2e4de99ab716e87a9baf1b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7010efc10b11415da35666aae647506f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6d0e90eb56c49078c2cd876e4644e59_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ea29fb65ae64c838799c4c459626dfb_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifeca289c0b3048be95fdcdfd0d64787f_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib14fcc9488ae4e079debc5ad6830716e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i704a839b6eba4ee4be94748f20064afe_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a3a4ecb829e4aa78305ce022676ad3a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9dc2db957bf417fa3ce1024b7aa3b58_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie752e3ceb65d4068848193b5489d1ca3_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8121dcf41149486dbe2439280ef18566_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1535a34aeb8e4f90b2765beaa325bd11_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4bc4cefe1a64728bdc75ff662c4916e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03f405d0ec044a3ebbf4e986c0cf3fb0_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id39b9efc953f44ddb788ea54e6fcb237_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17605919063e4da08e1c137da9bd3927_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64942fccdbcb49f7bde01d647d805b92_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d4ef7a87b2d430ab843f888c43c62b3_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i367dd154acc944f59b4091bdf4c3f88e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifafb1bde68d54e8e8d59fc667e7ad4db_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic98aa56795ec4ca9818d28b0c15c1e2c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d8f2e37a7fd434e9e575af158e4ebe9_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf83422a855b450a895434e02b798a86_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba5e8751427840c2bb6a518bf2c47c4f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica014ad63af547c985fc0232bff3d28d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic864a76a6f394f3c8b7bcf2a3d9f5b0f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i143277cfa467423cb7fd3d1598c01536_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fe74c4805104d82a48ee99f39bcc191_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida94e955b46346cca755a98f10e0cbd8_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1db5110e8cf94c3b870dd8e4773cc5f5_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33c340fce6894f5cadf9174aacc50b85_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i541eb2cfc8a1420f8d0c271d8d5b58a0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife50c78eda8146feada734d5de383031_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i715add2286974690806d8b1238a739dd_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88c57ba1eaf34b319e49c2126ff89f7a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44361401a04e43f58bdac9768e7239c0_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f94cdf096df4338a0b6aad26feb4378_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4a89e0cf61f4161b7a76d02b5e911b6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0219c877aef4d4d9bb018be638aca5a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i141c5ef857bb4d94935c24ab8fdae687_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied8cbea9f58646b5a29e12373656d30a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7192b6bdb8d54ccd902726f77a8a569d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cdb131b17ab470c9b46b991b14cadba_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie20a9ffe89114cf3b00ba22b79b96752_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01b61b9f737f4bfeb5d1e650b58a2ff0_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i820113b59fbd45409278436c72703385_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17a30514b5f04fcaa8af426469cdf39a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib31766a1f9ca49ed944d511b368436c8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i462cdaa6b90e45118710c4ae51e35e3a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f7a6b941763460e99621c2796d825ab_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb68c7470877490d9ceaade2f13e2c2e_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i671e7da6a18b400fbf6ead97234042fc_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5651cfaf52164a8ab6636928219a061e_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c45c8df98804459883ad5bff7805922_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i080623730f624bba8919833c19347c19_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf02f0982f4a409b968d6265bca89fa6_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd09a4e622c048fa8abcdbbf99ea24f5_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f4560eb1ee848ef935cf4f82c3c219b_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28b8b17a1b1c4ca4a2c3921c1d59b492_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29caa9c297504c4895226b55191e48e9_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6f8d0cdf8b34365ad1b5066369bb0c6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39f38d6401dc4807878d88582b25ad7a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a5b415115604e5eb5904c3c92e949f3_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75c73a0ad09046059e2cacc3ca286709_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30253a8fdb944b15bcfad5941879e748_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i477c1387bccc4478a6df52168a873e5e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6e598d60eca4ef790eea98e2e3cf9fb_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide9c58e91b6e49748dcf2aabec8cefe5_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifaba7e93e3174a09b5fe7fadb95cf5a8_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id72e0113997c414097828708b9146825_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31af4a0627894e13a9092294ef53779d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82914b6cb0b04d3b8dfa0c36fcb1e3e1_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i875eaced42e244509d41e272f4b64999_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13f4e544586d4c689babc9b7bb643038_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a567b0578254433ab2843507871f589_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i803f3b4be6844c91ad48b04634b3d57a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bcc18bbe90e47da9b7fffcfbe9b7c7f_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34c4ac2cb8084a4192568712dceb7c7b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48743be2360640e9b25e34524209acf5_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6df70951a3345f5bef560a3d668c977_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04b63cc78f284d3cb3291a6b392e691a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida55387137da4467910d468e15316ed5_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie22a90598b6444e593ecca7b8a7971cf_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c97559608224dfe87e9d5af61432405_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6bbe8c6cf234e73a1885c86ba3a53a6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d352f2ba8364c5eaa02ddd326723d7e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifee9f2e555d6447ca4a77928972c53a3_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29d4d29ca30c43db9f653c0173a02a88_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i907dc799123d4d8a8d59145f2fe460ff_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71b8800d43dc425ba37b1e7fbaf13774_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib88e6348738c43e789677fefc86824f0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2842b6655db442f9b1d51ae4beb1bfbf_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4d05b65c7b54139b25ac70c4ab19df3_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i553b3f72bfd042dabe4870ebbc230630_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56d699e134f741c0a256a5bbbd4a83fe_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if81ecb7810414c37ac52874e47f9559c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3d729fce8a044979a61be3f06e6bf4a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i039289771e0a4a92a82f0e23c7b58113_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c94024cf7444cc986c90074aa354bdb_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacc83a958e43414884a750ac18d8715c_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie795535b2e254799b2ec04408e04506f_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7abdbd57cda413bb900bc952b307246_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie81d29f45ec7442a847822087f81a983_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaeb741d79fae4f8c9612915e80120b77_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91f6e6feded64f13ad8e45634369dff0_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if25cccf1ea4a4ce9b81f781649b78865_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i242133cf5e834e02a75bc0fb1d5dbaa2_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0a3898f0f3e4eda824b64c14e338702_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08274445c04f4069980cb990559bb715_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ffb95f5c9c046ba9c390129a0e69d65_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb00fde3c5fe4302aff44ebc212aecc1_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if513f7a17c0e49989ccf849ee4dc9331_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i638069bb860a415daddfd8838b2cdd19_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f7703ad94b54db9a9215c0db5b0cd62_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i783f44f8b2654fc4af2d919e37ce22a7_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66a5cfc38a70434b9ceec5c2285168aa_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1310ca8214184c8b9d2a080cfe0da7c0_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1abf9ffbfb5d44aeb0a9463ac4398eab_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71b867c3c4ec478abe984d94d0169df7_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i823ae7ab9f7e4d099e7876b9b19ae298_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i095b912afc3343538d71712bd5e5af82_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f8a3bf7c42c44aea99cef1412e8dbb0_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic22e7e95653e4fb0a95e61763a3569b2_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id51e37617d5248369c24578f16a1cf14_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44564486e4b54deba76702deafc0f64b_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1e17bbb1a904f4f9887423378bb5af6_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07782e31373f44de9555f3b81cdd9628_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd79168d00974ebc85c149dd99401528_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if91a5aa8a47941858c207f93c372c557_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50377394250b4f6eb2cdd388e247c98e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4485c1a08fb843e2a1746a8633829398_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8da429c5485f4cb78dbd9c99fc97e840_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i241616d8d1cc4bd1a17072d1fe359907_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3168b97c7cfe40dd968aff24fac21714_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic827d96e5107479f8a50ac1552243075_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f280f0335f34739a091905a7605c8fb_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie50dbb604c9b4e1a89e5a02734c3435e_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7e482e96daf4d1aba90f65b4d004d1c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0984754f7dc14a15ae031293bbf02033_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb3bab98f9034f8381e05152809cb5ba_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia409b352549644d08a3f0a4940dba700_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d9ec8e3f10a4277a866ec3be3d50f2e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11db00c425ed4fb0885192fe0be29cc9_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i839b44dbb9c245789d8af1b83cda8eb5_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0efc28dad4a44fa5966707fcb540b4b1_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1aea48b047e34184a2746ed722f8d736_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9588db6b282c4b73afec4971984508f9_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i097a676b323a42889c16acb4a376e3c0_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic40e96203c084d60902d25625a1bc564_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6427cb6f43ec40cfa361720f0ac45cd2_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43885c95db8a44fe80b17b1fef791c59_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38960dddb9404fe98542807220cd75b8_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8993fa041a484e879c4a6485620bebd7_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ee7156a4b614122a54d9522c59d5c78_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i641cb943aa714600b89da7ddd3df0d89_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia71e4576e6394e3780b1fb370ab8eca7_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8df911dbd564fbf849019ee57246892_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b5cb0fe57d04ef598a24dd039eef72c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54a7afab074f405e8ef80dabdfecdf0e_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31118e3777414395bca00605e465fac7_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c738afeb7f541e7a7cee2e74587d6e2_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic630a421623e412e899316999b1d84a3_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i947ae1e75b3d491087466d3c41d239a4_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7874341a97d4c089a290cd4c52ca3ef_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3a9a7407ef94ca0a066f8f1b41ac915_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie74c0c26e4194d0ca851b4f339b64aff_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if24d9980d69a415285bcfb8af2e4760a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie52d61f419f94c0cafc9a9d7cc18a763_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0eaeb3befcf640f7b164ca0a1c2686aa_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d6fe701a40b465cacd7765161ea4559_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic37bfb89cb3640ad8e236e59f73d6359_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8fd87789a924ef1962a3681f884ed11_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie736eb61ba964832abed00a756bb99fe_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bf14f8f5d2747e58b18f20cc5051555_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30e83259e5b648859b1c791fc219f795_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i769a6f6f373c4424a78daa11151e8693_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifae6a5b5be2d4e27b57c8cb59e7b736d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4d49c3f485c4a969fc279eae65aea0c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic976522683894b2f851b9eb9a9e99339_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6158ef12bd24d40b494575847b10455_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c9b56c797144ae883e07ceee9eb81ad_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i748adeb1c1b74b4a80ea71f1622e0a83_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58abc744b88c49d996c9335dc7e4e26a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2cdaaadd890437ea5827bcebf07e28c_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b6ac35939974a6680f67f6f5cb6cfbd_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifecb5cf258f942c68db448dc19d76074_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7452b2558944b89aa0c78702511531b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie95d0a9de94f48bc9a2edc6e093ccd9d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46b3dbdcc4454d4ab3079f2407d0e808_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i997e727369cc4c879b4f65634d5c9167_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied57d33df852404ea42cbb9249fb4ff7_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dd1ed9c80f84232aa613ebfc30fce1b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f54658358b74dd2a2602a4b93e49d03_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7a6672a05e34d6090ab13ec171a3c16_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dbe9922fd544a0e817961eb18397dfb_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i998bc7df80cd421c86a31d55b20b2f00_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1501c38c01f24f46ab98fa0918a29aea_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i461edb12a6e0421a95ce0ac6c93adbca_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie95f6e7a4c9a45b98ee10519480bcc57_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i609ee3a20dca4ef2a07a72f3aa7bd472_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5dcd8e73f06541bf90ce68a9090f463c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ddf8513030e4e22ab98fead59aa24a8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide9fd53158404da68f8ed38707c6e730_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5c146f01bfc4a0fb436eac2074cdf40_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9eb6d9a053c248a8abc9535a66f119f6_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95e954dfb89d4490bc7f62728171c3c7_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic896ad83efec4ff7a7a62329387853a7_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e4b569901524a64b1ef34cb1524a967_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fce1d67949c48ccb03f9e12c3e52dae_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i050b473f8c3f4780be91b8883989770d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icab0d5373a6143ba8a8971886fd366eb_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94657ee062ab4c07a5644722ec7e5f4d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i011ff8ae410c45ee9363ef7b31f62ff6_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ccfec64c8df4db89a86df0ec6e79d66_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bf58675420348dea4421700f6d61b1d_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22eef57a3e534bce9a842560378654e4_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fe1b46c7e9040539c417e8044482c9a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0820e5db91674b1b9eb3859fb1471846_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e743f7eaf994261a54320837d8cdc38_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic25e83ccb0774f9f8d3a60252008d95d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c91091b09d34c3eb1b8f917bf6a6e92_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b5a7c79bc084682a64cd091d3a8258c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97fa5da6b3924d8d99c2fbceb69c59d9_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccf7a7e39a1444609739fe18036ae1a6_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22490ec2cbf04c3994fd5195617c0cd1_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d7cf65513ab4159b2feb11639c2f8b8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69959f4306b342dbbb1318e7d3cf276a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59506b8e5aae42f880005525de216ce0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1091a13b711442e0848bc698d9a73a45_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9e3336b01ef433aa8801b345dea8c4d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i6b4e4280ad2344a5bc7fdcaa77e417f0_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:219.75pt"><tr><td style="width:1.0pt"></td><td style="width:217.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGV4dHJlZ2lvbjpmNjU1OWQ4NzkzMzA0OTQ5YWZiMjYwY2RlNTk2MTU2NV8xODk3_13118461-31b2-4299-9ca0-7f2395d4f07d">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:219.75pt"><tr><td style="width:1.0pt"></td><td style="width:217.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9pt"><span style="color:#333333;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGFibGU6MmU2NmY1MjQzOGZiNGJkODg1NWExOTBjN2Y5ZTNjMmQvdGFibGVyYW5nZToyZTY2ZjUyNDM4ZmI0YmQ4ODU1YTE5MGM3ZjllM2MyZF8wLTAtMS0xLTk0NDE0_38557a66-9fbe-406a-80a6-627684a224bb">&#9746;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="padding-left:180pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGV4dHJlZ2lvbjpmNjU1OWQ4NzkzMzA0OTQ5YWZiMjYwY2RlNTk2MTU2NV8xNDA_f46a70dc-1ded-480e-b2a1-e9ddb219bcc6">September 30, 2022</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGFibGU6YjFiOTYxNWI4Yjk3NDg0ODliOTA3ODZlNzFhZjkyMTAvdGFibGVyYW5nZTpiMWI5NjE1YjhiOTc0ODQ4OWI5MDc4NmU3MWFmOTIxMF8wLTAtMS0xLTk0NDE0_892da2ca-49cb-4e25-8322-2034cca0c9b5">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:180pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For the transition period from ______ to ______</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File No.&#160;<ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGV4dHJlZ2lvbjpmNjU1OWQ4NzkzMzA0OTQ5YWZiMjYwY2RlNTk2MTU2NV8xODkw_247dfb0b-7f67-4bb6-816f-ebf25ee179b2">1-6571</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGV4dHJlZ2lvbjpmNjU1OWQ4NzkzMzA0OTQ5YWZiMjYwY2RlNTk2MTU2NV8xODkx_97068807-b3c2-4936-8614-7e0b5d3e48a5">Merck&#160;&amp; Co., Inc.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.545%"><tr><td style="width:1.0%"></td><td style="width:41.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGFibGU6ZmM1N2EzNmIzZjY4NDlhNWIyYTg0YjEyY2E5NTdlNTUvdGFibGVyYW5nZTpmYzU3YTM2YjNmNjg0OWE1YjJhODRiMTJjYTk1N2U1NV8wLTAtMS0xLTk0NDE0_486a57cc-51b7-4e36-bab2-9cefc73011af">New Jersey</ix:nonNumeric></span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGFibGU6ZmM1N2EzNmIzZjY4NDlhNWIyYTg0YjEyY2E5NTdlNTUvdGFibGVyYW5nZTpmYzU3YTM2YjNmNjg0OWE1YjJhODRiMTJjYTk1N2U1NV8wLTEtMS0xLTk0NDE0_5240791a-4165-49dc-b452-8acfdcec3fa4">22-1918501</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation)</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGFibGU6ZmM1N2EzNmIzZjY4NDlhNWIyYTg0YjEyY2E5NTdlNTUvdGFibGVyYW5nZTpmYzU3YTM2YjNmNjg0OWE1YjJhODRiMTJjYTk1N2U1NV8zLTAtMS0xLTk0NDE0_532a32a2-74da-4649-a946-8330d94ecfc6">126 East Lincoln Avenue</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGFibGU6ZmM1N2EzNmIzZjY4NDlhNWIyYTg0YjEyY2E5NTdlNTUvdGFibGVyYW5nZTpmYzU3YTM2YjNmNjg0OWE1YjJhODRiMTJjYTk1N2U1NV80LTAtMS0xLTk0NDE0_1164c88f-1265-40b5-b2fc-f2aad993b6bb">Rahway</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGFibGU6ZmM1N2EzNmIzZjY4NDlhNWIyYTg0YjEyY2E5NTdlNTUvdGFibGVyYW5nZTpmYzU3YTM2YjNmNjg0OWE1YjJhODRiMTJjYTk1N2U1NV80LTEtMS0xLTk0NDE0_8b776d7b-31d9-4745-8781-da0d9b7863b5">New Jersey</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGFibGU6ZmM1N2EzNmIzZjY4NDlhNWIyYTg0YjEyY2E5NTdlNTUvdGFibGVyYW5nZTpmYzU3YTM2YjNmNjg0OWE1YjJhODRiMTJjYTk1N2U1NV80LTItMS0xLTk0NDE0_a3bd47a4-beeb-4d2b-85ea-609d47df7055">07065</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Address of principal executive offices) (zip code)</span></td></tr></table></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGV4dHJlZ2lvbjpmNjU1OWQ4NzkzMzA0OTQ5YWZiMjYwY2RlNTk2MTU2NV8xODky_025829a9-da23-4e6d-967c-804ce049d6de">(908)</ix:nonNumeric>&#160;<ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGV4dHJlZ2lvbjpmNjU1OWQ4NzkzMzA0OTQ5YWZiMjYwY2RlNTk2MTU2NV8xODkz_8305c08c-facd-4625-9b68-f458033a52cc">740-4000</ix:nonNumeric> </span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"><tr><td style="width:1.0%"></td><td style="width:20.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.011%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Not Applicable</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Former name, former address and former fiscal year, if changed since last report.)</span></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.557%"><tr><td style="width:1.0%"></td><td style="width:35.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.394%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities Registered pursuant to Section&#160;12(b) of the Act:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id0e20af91c5143088498043650185a6c_D20220101-20220930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGFibGU6ZWNjOGNhOTBiZjk4NGNkNGE4OTFhNTM2Y2M5MjFiYTUvdGFibGVyYW5nZTplY2M4Y2E5MGJmOTg0Y2Q0YTg5MWE1MzZjYzkyMWJhNV8yLTAtMS0xLTk0NDE0_4f5b5464-b067-458a-a678-937f2d412e27">Common Stock ($0.50&#160;par value)</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id0e20af91c5143088498043650185a6c_D20220101-20220930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGFibGU6ZWNjOGNhOTBiZjk4NGNkNGE4OTFhNTM2Y2M5MjFiYTUvdGFibGVyYW5nZTplY2M4Y2E5MGJmOTg0Y2Q0YTg5MWE1MzZjYzkyMWJhNV8yLTEtMS0xLTk0NDE0_363d23ca-ab16-42ea-a2d7-fa9fb0ba281f">MRK</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id0e20af91c5143088498043650185a6c_D20220101-20220930" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGFibGU6ZWNjOGNhOTBiZjk4NGNkNGE4OTFhNTM2Y2M5MjFiYTUvdGFibGVyYW5nZTplY2M4Y2E5MGJmOTg0Y2Q0YTg5MWE1MzZjYzkyMWJhNV8yLTItMS0xLTk0NDE0_be5e0b2b-61f5-4427-95e4-81008d49d450">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7000ad694c3b4ad882a0d1dfafbd3864_D20220101-20220930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGFibGU6ZWNjOGNhOTBiZjk4NGNkNGE4OTFhNTM2Y2M5MjFiYTUvdGFibGVyYW5nZTplY2M4Y2E5MGJmOTg0Y2Q0YTg5MWE1MzZjYzkyMWJhNV8zLTAtMS0xLTk0NDE0_7186ea8e-4fe7-4b1c-ab93-4c6dcfc8a777">0.500% Notes due 2024</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7000ad694c3b4ad882a0d1dfafbd3864_D20220101-20220930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGFibGU6ZWNjOGNhOTBiZjk4NGNkNGE4OTFhNTM2Y2M5MjFiYTUvdGFibGVyYW5nZTplY2M4Y2E5MGJmOTg0Y2Q0YTg5MWE1MzZjYzkyMWJhNV8zLTEtMS0xLTk0NDE0_3562408a-b201-4298-b53a-f9793ae3452d">MRK 24</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7000ad694c3b4ad882a0d1dfafbd3864_D20220101-20220930" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGFibGU6ZWNjOGNhOTBiZjk4NGNkNGE4OTFhNTM2Y2M5MjFiYTUvdGFibGVyYW5nZTplY2M4Y2E5MGJmOTg0Y2Q0YTg5MWE1MzZjYzkyMWJhNV8zLTItMS0xLTk0NDE0_f0b5a440-5673-44da-817f-d731abb40d0c">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5f2be8ca05e84092be3101ab17e36630_D20220101-20220930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGFibGU6ZWNjOGNhOTBiZjk4NGNkNGE4OTFhNTM2Y2M5MjFiYTUvdGFibGVyYW5nZTplY2M4Y2E5MGJmOTg0Y2Q0YTg5MWE1MzZjYzkyMWJhNV80LTAtMS0xLTk0NDE0_afbcfdd8-908f-488e-857d-e71642e62b64">1.875% Notes due 2026</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5f2be8ca05e84092be3101ab17e36630_D20220101-20220930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGFibGU6ZWNjOGNhOTBiZjk4NGNkNGE4OTFhNTM2Y2M5MjFiYTUvdGFibGVyYW5nZTplY2M4Y2E5MGJmOTg0Y2Q0YTg5MWE1MzZjYzkyMWJhNV80LTEtMS0xLTk0NDE0_0a7acd41-a56a-4635-a18f-9e4d5147bfce">MRK/26</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5f2be8ca05e84092be3101ab17e36630_D20220101-20220930" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGFibGU6ZWNjOGNhOTBiZjk4NGNkNGE4OTFhNTM2Y2M5MjFiYTUvdGFibGVyYW5nZTplY2M4Y2E5MGJmOTg0Y2Q0YTg5MWE1MzZjYzkyMWJhNV80LTItMS0xLTk0NDE0_fbe2a2ed-6b6b-463f-a4b7-5628535d410a">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id4c29ff612c740d08bbaa6fdd4e76510_D20220101-20220930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGFibGU6ZWNjOGNhOTBiZjk4NGNkNGE4OTFhNTM2Y2M5MjFiYTUvdGFibGVyYW5nZTplY2M4Y2E5MGJmOTg0Y2Q0YTg5MWE1MzZjYzkyMWJhNV81LTAtMS0xLTk0NDE0_c27c6419-e78f-49b1-9070-8d546792ad83">2.500% Notes due 2034</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id4c29ff612c740d08bbaa6fdd4e76510_D20220101-20220930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGFibGU6ZWNjOGNhOTBiZjk4NGNkNGE4OTFhNTM2Y2M5MjFiYTUvdGFibGVyYW5nZTplY2M4Y2E5MGJmOTg0Y2Q0YTg5MWE1MzZjYzkyMWJhNV81LTEtMS0xLTk0NDE0_1899a022-49a0-4beb-8a78-36798e5c402f">MRK/34</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id4c29ff612c740d08bbaa6fdd4e76510_D20220101-20220930" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGFibGU6ZWNjOGNhOTBiZjk4NGNkNGE4OTFhNTM2Y2M5MjFiYTUvdGFibGVyYW5nZTplY2M4Y2E5MGJmOTg0Y2Q0YTg5MWE1MzZjYzkyMWJhNV81LTItMS0xLTk0NDE0_5a9a1d82-a0ae-4ecb-aa85-6d4f50245777">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i143bd665f1bf44a2a2623915d83f6b2b_D20220101-20220930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGFibGU6ZWNjOGNhOTBiZjk4NGNkNGE4OTFhNTM2Y2M5MjFiYTUvdGFibGVyYW5nZTplY2M4Y2E5MGJmOTg0Y2Q0YTg5MWE1MzZjYzkyMWJhNV82LTAtMS0xLTk0NDE0_7711d788-16bd-47f8-aaff-7e08516e3c70">1.375% Notes due 2036</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i143bd665f1bf44a2a2623915d83f6b2b_D20220101-20220930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGFibGU6ZWNjOGNhOTBiZjk4NGNkNGE4OTFhNTM2Y2M5MjFiYTUvdGFibGVyYW5nZTplY2M4Y2E5MGJmOTg0Y2Q0YTg5MWE1MzZjYzkyMWJhNV82LTEtMS0xLTk0NDE0_f3c0f58c-bc9d-426e-b14a-d54b2cc5181c">MRK 36A</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i143bd665f1bf44a2a2623915d83f6b2b_D20220101-20220930" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGFibGU6ZWNjOGNhOTBiZjk4NGNkNGE4OTFhNTM2Y2M5MjFiYTUvdGFibGVyYW5nZTplY2M4Y2E5MGJmOTg0Y2Q0YTg5MWE1MzZjYzkyMWJhNV82LTItMS0xLTk0NDE0_59c9f8bf-526b-4ef9-99da-de6591d9c425">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;<ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGV4dHJlZ2lvbjpmNjU1OWQ4NzkzMzA0OTQ5YWZiMjYwY2RlNTk2MTU2NV8xODk0_ccf12b35-0944-4344-aeb5-02a3f6458909">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#9744;</span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required&#160;to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;<ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGV4dHJlZ2lvbjpmNjU1OWQ4NzkzMzA0OTQ5YWZiMjYwY2RlNTk2MTU2NV8xODk1_25fa19a8-81cd-4d89-8b3f-b4461b1a7c38">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#9744;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. (Check one):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.988%"><tr><td style="width:1.0%"></td><td style="width:17.814%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.639%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.879%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.268%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGFibGU6NWUzYjA4MGQ1ZjA0NGQyZGExNjJjN2U4NDM5ZTRmMjcvdGFibGVyYW5nZTo1ZTNiMDgwZDVmMDQ0ZDJkYTE2MmM3ZTg0MzllNGYyN18wLTAtMS0xLTk0NDE0_b3e17b2e-7d26-41b5-9329-c45e5ec078f6">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#9744;</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#9744; </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGFibGU6NWUzYjA4MGQ1ZjA0NGQyZGExNjJjN2U4NDM5ZTRmMjcvdGFibGVyYW5nZTo1ZTNiMDgwZDVmMDQ0ZDJkYTE2MmM3ZTg0MzllNGYyN18yLTMtMS0xLTk0NDE0_5f47d8d4-d254-4214-9848-300f6b2ffbaf">&#9744;</ix:nonNumeric></span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGFibGU6NWUzYjA4MGQ1ZjA0NGQyZGExNjJjN2U4NDM5ZTRmMjcvdGFibGVyYW5nZTo1ZTNiMDgwZDVmMDQ0ZDJkYTE2MmM3ZTg0MzllNGYyN180LTMtMS0xLTk0NDE0_a9970143-df18-43e9-8d8d-89fc0f204bc4">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  &#9744;</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;Yes&#160;&#9744;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGV4dHJlZ2lvbjpmNjU1OWQ4NzkzMzA0OTQ5YWZiMjYwY2RlNTk2MTU2NV8xODk2_4eef1dfe-406d-4c8c-b801-d2c6f381e26e">&#9746;</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The number of shares of common stock outstanding as of the close of business on October&#160;31, 2022: <ix:nonFraction unitRef="shares" contextRef="if3f74b51a5dc4dc6b59e6013885b63ab_I20221031" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGV4dHJlZ2lvbjpmNjU1OWQ4NzkzMzA0OTQ5YWZiMjYwY2RlNTk2MTU2NV8xODg3_fa744165-ce60-41d0-a095-6cc007f83571">2,535,395,974</ix:nonFraction></span></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i6b4e4280ad2344a5bc7fdcaa77e417f0_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"><tr><td style="width:1.0%"></td><td style="width:13.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.475%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page No.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i6b4e4280ad2344a5bc7fdcaa77e417f0_10">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6b4e4280ad2344a5bc7fdcaa77e417f0_10">3</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6b4e4280ad2344a5bc7fdcaa77e417f0_13">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6b4e4280ad2344a5bc7fdcaa77e417f0_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6b4e4280ad2344a5bc7fdcaa77e417f0_16">Condensed Consolidated Statement of Income</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6b4e4280ad2344a5bc7fdcaa77e417f0_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6b4e4280ad2344a5bc7fdcaa77e417f0_19">Condensed Consolidated Statement of Comprehensive Income</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6b4e4280ad2344a5bc7fdcaa77e417f0_19">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6b4e4280ad2344a5bc7fdcaa77e417f0_22">Condensed Consolidated Balance Sheet</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6b4e4280ad2344a5bc7fdcaa77e417f0_22">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6b4e4280ad2344a5bc7fdcaa77e417f0_25">Condensed Consolidated Statement of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6b4e4280ad2344a5bc7fdcaa77e417f0_25">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6b4e4280ad2344a5bc7fdcaa77e417f0_31">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6b4e4280ad2344a5bc7fdcaa77e417f0_31">6</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6b4e4280ad2344a5bc7fdcaa77e417f0_79">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6b4e4280ad2344a5bc7fdcaa77e417f0_79">33</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6b4e4280ad2344a5bc7fdcaa77e417f0_112">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6b4e4280ad2344a5bc7fdcaa77e417f0_112">50</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6b4e4280ad2344a5bc7fdcaa77e417f0_115">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6b4e4280ad2344a5bc7fdcaa77e417f0_115">51</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6b4e4280ad2344a5bc7fdcaa77e417f0_118">Cautionary Factors That May Affect Future Results</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6b4e4280ad2344a5bc7fdcaa77e417f0_118">51</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART II</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i6b4e4280ad2344a5bc7fdcaa77e417f0_121">OTHER INFORMATION </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6b4e4280ad2344a5bc7fdcaa77e417f0_121">51</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6b4e4280ad2344a5bc7fdcaa77e417f0_124">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6b4e4280ad2344a5bc7fdcaa77e417f0_124">51</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A.</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6b4e4280ad2344a5bc7fdcaa77e417f0_127">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6b4e4280ad2344a5bc7fdcaa77e417f0_127">51</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6b4e4280ad2344a5bc7fdcaa77e417f0_130">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6b4e4280ad2344a5bc7fdcaa77e417f0_130">52</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6b4e4280ad2344a5bc7fdcaa77e417f0_133">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6b4e4280ad2344a5bc7fdcaa77e417f0_133">52</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6b4e4280ad2344a5bc7fdcaa77e417f0_136">Signatures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6b4e4280ad2344a5bc7fdcaa77e417f0_136">53</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i6b4e4280ad2344a5bc7fdcaa77e417f0_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Part I - Financial Information</span></div><div id="i6b4e4280ad2344a5bc7fdcaa77e417f0_13"></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Item&#160;1. Financial Statements</span></div><div id="i6b4e4280ad2344a5bc7fdcaa77e417f0_16"></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MERCK&#160;&amp; CO., INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENT OF INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited, $ in millions except per share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMi0xLTEtMS05NDQxNA_6f1eac12-5c2c-41fd-ac77-39963b7135eb">14,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMi0zLTEtMS05NDQxNA_7c9e15ac-9811-439e-84e6-e6b6358bcdd1">13,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMi01LTEtMS05NDQxNA_93be19a2-92d3-44b5-b71c-13e4fcfbeb64">45,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMi03LTEtMS05NDQxNA_0d5bd26d-2afc-4501-b448-9026aedf7176">35,183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs, Expenses and Other</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfNC0xLTEtMS05NDQxNA_f7417167-1e04-41d3-8912-48071813d73b">3,934</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfNC0zLTEtMS05NDQxNA_706351fc-53a1-411d-8335-5b2f3aa0aee1">3,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfNC01LTEtMS05NDQxNA_11424b05-f72f-4356-8588-40cd3ffdf6a8">13,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfNC03LTEtMS05NDQxNA_25ab2b96-912e-406c-86a8-32eefb7f0c57">9,752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfNS0xLTEtMS05NDQxNA_5947444d-0abc-4cca-b183-ebeb69b88811">2,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfNS0zLTEtMS05NDQxNA_9899ecf5-36f2-46b6-ace4-e215a5e15d79">2,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfNS01LTEtMS05NDQxNA_c49d0b51-f73a-4d71-b0db-15f2c24a625a">7,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfNS03LTEtMS05NDQxNA_7c594f2b-3e6f-45c5-b8e0-4faa1eec1e8a">6,804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfNi0xLTEtMS05NDQxNA_e8682ad2-3cfb-4df8-8c83-ff7a319c92a2">4,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfNi0zLTEtMS05NDQxNA_445d6066-9e7a-46f6-9d86-ce5b36e00a17">2,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfNi01LTEtMS05NDQxNA_52232775-dd1c-4a95-904f-4a3d85cf175f">9,773</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfNi03LTEtMS05NDQxNA_551fc86a-d45a-42bb-8d83-b7a885f85813">9,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfNy0xLTEtMS05NDQxNA_3b467474-7449-4e07-88ab-41c1e8d35d0f">94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfNy0zLTEtMS05NDQxNA_c3cfaddb-c615-406a-ba26-8d0a3180b811">107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfNy01LTEtMS05NDQxNA_2f329723-52c9-4fde-8599-95400497c1ae">288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfNy03LTEtMS05NDQxNA_6cfc9cbf-634a-43bc-b5af-38d64c7e1e47">487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfOC0xLTEtMS05NDQxNA_98a35210-07de-4355-b4b4-18c86704965a">429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfOC0zLTEtMS05NDQxNA_8362a6f4-b404-4ce2-8bf4-7d60a2a82159">450</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfOC01LTEtMS05NDQxNA_929c0cda-d181-4452-ac66-b60ec2a3bdd6">1,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfOC03LTEtMS05NDQxNA_676d5b83-5c23-4cf8-ac8a-80374ad66dd3">1,007</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" name="mrk:CostsExpensesAndOther" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfOS0xLTEtMS05NDQxNA_3356f8ac-2fa1-45a7-a1e4-012f038de813">11,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" name="mrk:CostsExpensesAndOther" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfOS0zLTEtMS05NDQxNA_8164411f-7dd9-4bbe-b36a-7b97202bf13b">7,888</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="mrk:CostsExpensesAndOther" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfOS01LTEtMS05NDQxNA_895773cd-5396-4ce2-9ab7-c98f4cdc9ed2">32,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="mrk:CostsExpensesAndOther" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfOS03LTEtMS05NDQxNA_15de6d62-c5e7-4816-b45e-6ed651f48e80">25,213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Continuing Operations Before Taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTAtMS0xLTEtOTQ0MTQ_93aac89d-1ae8-4936-8994-890787581275">3,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTAtMy0xLTEtOTQ0MTQ_ccb8c8d0-9930-4c49-93a8-6221f343eeba">5,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTAtNS0xLTEtOTQ0MTQ_dcabfccf-bc0f-4cfa-86df-04d0d653bbf9">12,931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTAtNy0xLTEtOTQ0MTQ_27a78b47-68d9-4b62-beab-b167d1a2940a">9,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes on Income from Continuing Operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTEtMS0xLTEtOTQ0MTQ_4a3e459c-1d78-4aef-bde5-17b47f871429">330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTEtMy0xLTEtOTQ0MTQ_cc7b145f-94fe-4959-b271-36cee1ca4dcd">695</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTEtNS0xLTEtOTQ0MTQ_e8a7122c-197b-4890-a721-a79a536b3b2e">1,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTEtNy0xLTEtOTQ0MTQ_4452e434-e435-44aa-bc59-c4df8f544263">1,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income from Continuing Operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTItMS0xLTEtOTQ0MTQ_90becf3a-b86c-4df5-9d94-4392645edff4">3,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTItMy0xLTEtOTQ0MTQ_c043ca3f-92d7-4d01-aa9b-b7d3da25b04b">4,571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTItNS0xLTEtOTQ0MTQ_58b890b4-aa82-40e9-a3af-04aad8bc691b">11,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTItNy0xLTEtOTQ0MTQ_c1b7ea98-a513-4f40-8d52-7e7fef16b379">8,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net Income Attributable to Noncontrolling Interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTMtMS0xLTEtOTQ0MTQ_53c9f10a-e01d-4843-8fd6-5f185d9ea2f2">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTMtMy0xLTEtOTQ0MTQ_112acf93-19e2-45a1-a5e2-22e128597abd">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTMtNS0xLTEtOTQ0MTQ_9df0039f-e542-4c25-8922-de321eb20b7c">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTMtNy0xLTEtOTQ0MTQ_d6b7e219-1fda-4ee5-9751-c7ddea0d122e">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income from Continuing Operations Attributable to Merck&#160;&amp; Co., Inc.</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTQtMS0xLTEtOTQ0MTQ_3ca4fb79-2e29-4af2-a284-adf416c3b9f8">3,248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTQtMy0xLTEtOTQ0MTQ_5812de08-569d-469a-af9e-d851870321b3">4,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTQtNS0xLTEtOTQ0MTQ_7cdcc5ce-d4ba-4741-ac11-20906dab718c">11,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTQtNy0xLTEtOTQ0MTQ_091c3483-969e-4f7c-b615-0cb0e9de901e">8,525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTUtMS0xLTEtOTQ0MTQ_67b64335-4261-4169-a8ea-27702368cc44">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTUtMy0xLTEtOTQ0MTQ_7773b34f-6432-49d2-abe6-1c03d5e56861">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTUtNS0xLTEtOTQ0MTQ_c4d81f46-a89c-4457-886a-20adec386e0f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTUtNy0xLTEtOTQ0MTQ_429fa82d-8885-4e45-8d43-2e19ea30525d">766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income Attributable to Merck &amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTYtMS0xLTEtOTQ0MTQ_f37d7260-ed4c-448f-88a2-3153a34b4e6d">3,248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTYtMy0xLTEtOTQ0MTQ_20551ccc-e7f7-4be6-8e28-b954ff1340c5">4,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTYtNS0xLTEtOTQ0MTQ_7d874c72-8553-405a-a5d7-562195f53654">11,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTYtNy0xLTEtOTQ0MTQ_f91f3ff0-e0af-4bd8-8b6d-d179f866d588">9,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic Earnings per Common Share Attributable to Merck &amp; Co., Inc. Common Shareholders:</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Continuing Operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTgtMS0xLTEtOTQ0MTQ_bf5c0d36-73a0-4506-9f3f-08c22af2bba2">1.28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTgtMy0xLTEtOTQ0MTQ_237b80b7-03d4-4c9d-b340-ae5908132a86">1.81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTgtNS0xLTEtOTQ0MTQ_caaddab5-d9cd-49e9-887f-c505090a9c69">4.55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTgtNy0xLTEtOTQ0MTQ_9ee0e920-2f1c-4fe9-af03-e1075e60c747">3.37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Discontinued Operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTktMS0xLTEtOTQ0MTQ_1dcbad67-4f2a-43e8-9972-45b281a08e55">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTktMy0xLTEtOTQ0MTQ_971f30c8-4660-403f-ab31-27d9a6e520e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTktNS0xLTEtOTQ0MTQ_33d5ddba-eb32-42d3-a77d-4c08fe830753">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTktNy0xLTEtOTQ0MTQ_adb031cb-8d6a-401e-ab11-b0cfcae0c0ed">0.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMjAtMS0xLTEtOTQ0MTQ_c960d90a-4255-45c4-871e-18d013d7d0c3">1.28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMjAtMy0xLTEtOTQ0MTQ_76bddf48-670e-4651-8b91-41300e0273eb">1.81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMjAtNS0xLTEtOTQ0MTQ_199865b8-762c-47ec-b476-7c28c4de9c9a">4.55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMjAtNy0xLTEtOTQ0MTQ_300e090e-7275-408f-88f9-9bfa9c2ec253">3.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per Common Share Assuming Dilution Attributable to Merck &amp; Co., Inc. Common Shareholders:</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Continuing Operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMjItMS0xLTEtOTQ0MTQ_aec9e309-f8db-4fda-8a0a-f0da178b7b42">1.28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMjItMy0xLTEtOTQ0MTQ_48d4c42d-eeb6-4c04-926b-ab329aadb069">1.80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMjItNS0xLTEtOTQ0MTQ_cdd7dbdf-b68a-41e2-906f-03f06ad2c6d6">4.53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMjItNy0xLTEtOTQ0MTQ_ab226745-1aaf-49d6-8b49-edbff717f9c0">3.36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Discontinued Operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMjMtMS0xLTEtOTQ0MTQ_12cbe9ce-8252-4cdc-83de-121a03c05b97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMjMtMy0xLTEtOTQ0MTQ_6f7dba63-a4cb-47cb-b980-74f97aed8f4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMjMtNS0xLTEtOTQ0MTQ_ac74df35-3419-4b05-a793-10879ef6b1e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMjMtNy0xLTEtOTQ0MTQ_05f3fd1a-bfab-4612-8cc1-a6d0c03eb363">0.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMjQtMS0xLTEtOTQ0MTQ_3187c599-8fa4-485e-a559-69ae5d36e8d9">1.28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMjQtMy0xLTEtOTQ0MTQ_067bedc9-ce1f-404e-b7eb-d6418b2d2179">1.80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMjQtNS0xLTEtOTQ0MTQ_183fce9f-e95b-4195-b50a-05a70fcf86f9">4.53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMjQtNy0xLTEtOTQ0MTQ_1459728d-2197-4ed1-aaac-d1605cb4e5a4">3.66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i6b4e4280ad2344a5bc7fdcaa77e417f0_19"></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MERCK&#160;&amp; CO., INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited, $ in millions)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.700%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income Attributable to Merck&#160;&amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xOS9mcmFnOjI1M2U1Mzc0MjMyYTRiZDZiZGNlMjM1N2ZmN2EyMzMxL3RhYmxlOjcyNzkwNTY5ODMwNTQ5MTU5MTgxYTFkMjdmNzEwYWU0L3RhYmxlcmFuZ2U6NzI3OTA1Njk4MzA1NDkxNTkxODFhMWQyN2Y3MTBhZTRfMi0xLTEtMS05NDQxNA_f6ce972c-1072-4318-989f-f3be8a726f69">3,248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xOS9mcmFnOjI1M2U1Mzc0MjMyYTRiZDZiZGNlMjM1N2ZmN2EyMzMxL3RhYmxlOjcyNzkwNTY5ODMwNTQ5MTU5MTgxYTFkMjdmNzEwYWU0L3RhYmxlcmFuZ2U6NzI3OTA1Njk4MzA1NDkxNTkxODFhMWQyN2Y3MTBhZTRfMi0zLTEtMS05NDQxNA_23650903-1550-4bf9-a53e-7186b6c2410f">4,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xOS9mcmFnOjI1M2U1Mzc0MjMyYTRiZDZiZGNlMjM1N2ZmN2EyMzMxL3RhYmxlOjcyNzkwNTY5ODMwNTQ5MTU5MTgxYTFkMjdmNzEwYWU0L3RhYmxlcmFuZ2U6NzI3OTA1Njk4MzA1NDkxNTkxODFhMWQyN2Y3MTBhZTRfMi01LTEtMS05NDQxNA_2941608e-e12f-41ba-b71a-adb7bb7cddde">11,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xOS9mcmFnOjI1M2U1Mzc0MjMyYTRiZDZiZGNlMjM1N2ZmN2EyMzMxL3RhYmxlOjcyNzkwNTY5ODMwNTQ5MTU5MTgxYTFkMjdmNzEwYWU0L3RhYmxlcmFuZ2U6NzI3OTA1Njk4MzA1NDkxNTkxODFhMWQyN2Y3MTBhZTRfMi03LTEtMS05NDQxNA_7b5a420a-4e8f-473f-befe-905fd73a678a">9,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Comprehensive (Loss) Income Net of Taxes:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain on derivatives, net of reclassifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xOS9mcmFnOjI1M2U1Mzc0MjMyYTRiZDZiZGNlMjM1N2ZmN2EyMzMxL3RhYmxlOjcyNzkwNTY5ODMwNTQ5MTU5MTgxYTFkMjdmNzEwYWU0L3RhYmxlcmFuZ2U6NzI3OTA1Njk4MzA1NDkxNTkxODFhMWQyN2Y3MTBhZTRfNC0xLTEtMS05NDQxNA_c61569b9-9814-481b-883a-dcbf79f11187">338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xOS9mcmFnOjI1M2U1Mzc0MjMyYTRiZDZiZGNlMjM1N2ZmN2EyMzMxL3RhYmxlOjcyNzkwNTY5ODMwNTQ5MTU5MTgxYTFkMjdmNzEwYWU0L3RhYmxlcmFuZ2U6NzI3OTA1Njk4MzA1NDkxNTkxODFhMWQyN2Y3MTBhZTRfNC0zLTEtMS05NDQxNA_53377e23-3f2e-490c-b98d-3fa1c3a128fe">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xOS9mcmFnOjI1M2U1Mzc0MjMyYTRiZDZiZGNlMjM1N2ZmN2EyMzMxL3RhYmxlOjcyNzkwNTY5ODMwNTQ5MTU5MTgxYTFkMjdmNzEwYWU0L3RhYmxlcmFuZ2U6NzI3OTA1Njk4MzA1NDkxNTkxODFhMWQyN2Y3MTBhZTRfNC01LTEtMS05NDQxNA_b7b9a8b2-2057-499e-b99c-5b49a5931fce">584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xOS9mcmFnOjI1M2U1Mzc0MjMyYTRiZDZiZGNlMjM1N2ZmN2EyMzMxL3RhYmxlOjcyNzkwNTY5ODMwNTQ5MTU5MTgxYTFkMjdmNzEwYWU0L3RhYmxlcmFuZ2U6NzI3OTA1Njk4MzA1NDkxNTkxODFhMWQyN2Y3MTBhZTRfNC03LTEtMS05NDQxNA_46683567-061f-43f5-ab08-6c5a4d05789f">324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit plan net (loss) gain and prior service (cost) credit, net of amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xOS9mcmFnOjI1M2U1Mzc0MjMyYTRiZDZiZGNlMjM1N2ZmN2EyMzMxL3RhYmxlOjcyNzkwNTY5ODMwNTQ5MTU5MTgxYTFkMjdmNzEwYWU0L3RhYmxlcmFuZ2U6NzI3OTA1Njk4MzA1NDkxNTkxODFhMWQyN2Y3MTBhZTRfNS0xLTEtMS05NDQxNA_dc8868fc-8c94-49d9-90f6-b01d79f91337">186</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xOS9mcmFnOjI1M2U1Mzc0MjMyYTRiZDZiZGNlMjM1N2ZmN2EyMzMxL3RhYmxlOjcyNzkwNTY5ODMwNTQ5MTU5MTgxYTFkMjdmNzEwYWU0L3RhYmxlcmFuZ2U6NzI3OTA1Njk4MzA1NDkxNTkxODFhMWQyN2Y3MTBhZTRfNS0zLTEtMS05NDQxNA_b72a35f1-67a3-4a3d-980c-c13422b81165">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xOS9mcmFnOjI1M2U1Mzc0MjMyYTRiZDZiZGNlMjM1N2ZmN2EyMzMxL3RhYmxlOjcyNzkwNTY5ODMwNTQ5MTU5MTgxYTFkMjdmNzEwYWU0L3RhYmxlcmFuZ2U6NzI3OTA1Njk4MzA1NDkxNTkxODFhMWQyN2Y3MTBhZTRfNS01LTEtMS05NDQxNA_59ac5fe0-41ef-4599-8ec8-1439fdf08324">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xOS9mcmFnOjI1M2U1Mzc0MjMyYTRiZDZiZGNlMjM1N2ZmN2EyMzMxL3RhYmxlOjcyNzkwNTY5ODMwNTQ5MTU5MTgxYTFkMjdmNzEwYWU0L3RhYmxlcmFuZ2U6NzI3OTA1Njk4MzA1NDkxNTkxODFhMWQyN2Y3MTBhZTRfNS03LTEtMS05NDQxNA_b99ad749-969b-41a3-ae55-6b2be5758a55">1,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative translation adjustment</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xOS9mcmFnOjI1M2U1Mzc0MjMyYTRiZDZiZGNlMjM1N2ZmN2EyMzMxL3RhYmxlOjcyNzkwNTY5ODMwNTQ5MTU5MTgxYTFkMjdmNzEwYWU0L3RhYmxlcmFuZ2U6NzI3OTA1Njk4MzA1NDkxNTkxODFhMWQyN2Y3MTBhZTRfNi0xLTEtMS05NDQxNA_215101c7-ee57-4b67-8d9b-a14845afcdc2">568</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xOS9mcmFnOjI1M2U1Mzc0MjMyYTRiZDZiZGNlMjM1N2ZmN2EyMzMxL3RhYmxlOjcyNzkwNTY5ODMwNTQ5MTU5MTgxYTFkMjdmNzEwYWU0L3RhYmxlcmFuZ2U6NzI3OTA1Njk4MzA1NDkxNTkxODFhMWQyN2Y3MTBhZTRfNi0zLTEtMS05NDQxNA_bdd08fed-30e2-42bd-80c7-91d85b2cebce">84</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xOS9mcmFnOjI1M2U1Mzc0MjMyYTRiZDZiZGNlMjM1N2ZmN2EyMzMxL3RhYmxlOjcyNzkwNTY5ODMwNTQ5MTU5MTgxYTFkMjdmNzEwYWU0L3RhYmxlcmFuZ2U6NzI3OTA1Njk4MzA1NDkxNTkxODFhMWQyN2Y3MTBhZTRfNi01LTEtMS05NDQxNA_a5c2482c-6f26-4b0e-acef-13030823b80f">990</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xOS9mcmFnOjI1M2U1Mzc0MjMyYTRiZDZiZGNlMjM1N2ZmN2EyMzMxL3RhYmxlOjcyNzkwNTY5ODMwNTQ5MTU5MTgxYTFkMjdmNzEwYWU0L3RhYmxlcmFuZ2U6NzI3OTA1Njk4MzA1NDkxNTkxODFhMWQyN2Y3MTBhZTRfNi03LTEtMS05NDQxNA_5166aa5d-085a-4d3a-a1f0-71298e70a03f">251</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xOS9mcmFnOjI1M2U1Mzc0MjMyYTRiZDZiZGNlMjM1N2ZmN2EyMzMxL3RhYmxlOjcyNzkwNTY5ODMwNTQ5MTU5MTgxYTFkMjdmNzEwYWU0L3RhYmxlcmFuZ2U6NzI3OTA1Njk4MzA1NDkxNTkxODFhMWQyN2Y3MTBhZTRfNy0xLTEtMS05NDQxNA_ecc7e171-50f9-4ea8-a6c1-f45040b84323">416</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xOS9mcmFnOjI1M2U1Mzc0MjMyYTRiZDZiZGNlMjM1N2ZmN2EyMzMxL3RhYmxlOjcyNzkwNTY5ODMwNTQ5MTU5MTgxYTFkMjdmNzEwYWU0L3RhYmxlcmFuZ2U6NzI3OTA1Njk4MzA1NDkxNTkxODFhMWQyN2Y3MTBhZTRfNy0zLTEtMS05NDQxNA_aeb6184f-6920-4dee-aa1a-9d80de5b37cc">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xOS9mcmFnOjI1M2U1Mzc0MjMyYTRiZDZiZGNlMjM1N2ZmN2EyMzMxL3RhYmxlOjcyNzkwNTY5ODMwNTQ5MTU5MTgxYTFkMjdmNzEwYWU0L3RhYmxlcmFuZ2U6NzI3OTA1Njk4MzA1NDkxNTkxODFhMWQyN2Y3MTBhZTRfNy01LTEtMS05NDQxNA_f72a47c5-76d2-4263-82d9-4b052712e6b6">314</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xOS9mcmFnOjI1M2U1Mzc0MjMyYTRiZDZiZGNlMjM1N2ZmN2EyMzMxL3RhYmxlOjcyNzkwNTY5ODMwNTQ5MTU5MTgxYTFkMjdmNzEwYWU0L3RhYmxlcmFuZ2U6NzI3OTA1Njk4MzA1NDkxNTkxODFhMWQyN2Y3MTBhZTRfNy03LTEtMS05NDQxNA_ef44f324-3bf9-4fb8-ab4f-5b5e6f735430">1,595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive Income Attributable to Merck&#160;&amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xOS9mcmFnOjI1M2U1Mzc0MjMyYTRiZDZiZGNlMjM1N2ZmN2EyMzMxL3RhYmxlOjcyNzkwNTY5ODMwNTQ5MTU5MTgxYTFkMjdmNzEwYWU0L3RhYmxlcmFuZ2U6NzI3OTA1Njk4MzA1NDkxNTkxODFhMWQyN2Y3MTBhZTRfOC0xLTEtMS05NDQxNA_eb581d19-09f7-42d0-ba7c-e5c50be97127">2,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xOS9mcmFnOjI1M2U1Mzc0MjMyYTRiZDZiZGNlMjM1N2ZmN2EyMzMxL3RhYmxlOjcyNzkwNTY5ODMwNTQ5MTU5MTgxYTFkMjdmNzEwYWU0L3RhYmxlcmFuZ2U6NzI3OTA1Njk4MzA1NDkxNTkxODFhMWQyN2Y3MTBhZTRfOC0zLTEtMS05NDQxNA_21427ea0-ba0f-4bde-98af-50c9b6e5b26f">4,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xOS9mcmFnOjI1M2U1Mzc0MjMyYTRiZDZiZGNlMjM1N2ZmN2EyMzMxL3RhYmxlOjcyNzkwNTY5ODMwNTQ5MTU5MTgxYTFkMjdmNzEwYWU0L3RhYmxlcmFuZ2U6NzI3OTA1Njk4MzA1NDkxNTkxODFhMWQyN2Y3MTBhZTRfOC01LTEtMS05NDQxNA_40035125-0da8-4bdc-ac12-7cad1398467b">11,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xOS9mcmFnOjI1M2U1Mzc0MjMyYTRiZDZiZGNlMjM1N2ZmN2EyMzMxL3RhYmxlOjcyNzkwNTY5ODMwNTQ5MTU5MTgxYTFkMjdmNzEwYWU0L3RhYmxlcmFuZ2U6NzI3OTA1Njk4MzA1NDkxNTkxODFhMWQyN2Y3MTBhZTRfOC03LTEtMS05NDQxNA_ce9cdafc-02fd-45b6-aacd-5df110e9ad47">10,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 3 -</span></div></div></div><div id="i6b4e4280ad2344a5bc7fdcaa77e417f0_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MERCK&#160;&amp; CO., INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEET</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited, $ in millions except per share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.867%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMy0xLTEtMS05NDQxNA_fe816bb7-30c8-4e0d-a48b-6aba101923db">11,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMy0zLTEtMS05NDQxNA_337b864f-94d2-4ad7-b45d-f5ba6a4b664e">8,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:ShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfNC0xLTEtMS05NDQxNA_874874e9-cea3-432c-af85-6e76adda437c">103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:ShortTermInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfNC0zLTEtMS05NDQxNA_05bdbaef-c967-4596-977d-b238535f97c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable (net of allowance for doubtful accounts of $<ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfNS0wLTEtMS05NDQxNC90ZXh0cmVnaW9uOjdiZmE4NjUwZTljZDQ5YWE4YTJlZmZmZWI0NzFjMDEwXzY3_77ef4f52-6c47-4ca8-bca8-0b5d5d361c51">77</ix:nonFraction> in 2022</span></div><div style="padding-left:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;and $<ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfNS0wLTEtMS05NDQxNC90ZXh0cmVnaW9uOjdiZmE4NjUwZTljZDQ5YWE4YTJlZmZmZWI0NzFjMDEwXzgx_d03efed6-02aa-468b-ae76-ed1826f1c629">62</ix:nonFraction> in 2021) </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfNS0xLTEtMS05NDQxNA_780f56c5-8f28-44f5-aeae-430f7420a030">9,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfNS0zLTEtMS05NDQxNA_b1262537-8ed0-44a2-9b29-7991ac4c1948">9,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories (excludes inventories of $<ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfNi0wLTEtMS05NDQxNC90ZXh0cmVnaW9uOjE5NDhjMzk0MmFlNDQ0NTBhYmQyOWYwMjhhMTJlYWU5XzQy_68bee09b-def8-4884-92ea-38a3167a6267">2,641</ix:nonFraction> in 2022 and $<ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfNi0wLTEtMS05NDQxNC90ZXh0cmVnaW9uOjE5NDhjMzk0MmFlNDQ0NTBhYmQyOWYwMjhhMTJlYWU5XzU1_46c1e742-8ab4-4004-8f69-00f3ee17b4fe">2,194</ix:nonFraction> in 2021</span></div><div style="padding-left:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">classified in Other assets - see Note&#160;7)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfNi0xLTEtMS05NDQxNA_14c0139b-f125-45db-9d77-e8a59c763218">5,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfNi0zLTEtMS05NDQxNA_0d264b47-4b78-4a1d-bf77-6d210993393b">5,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:DeferredIncomeTaxesAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfNy0xLTEtMS05NDQxNA_bc38e30b-1ecc-484e-9a1d-00fbef431128">7,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxesAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfNy0zLTEtMS05NDQxNA_e1fce653-b54b-4440-a55b-3d30438755fb">6,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfOC0xLTEtMS05NDQxNA_f68a753f-a025-4363-b3a0-ccf52d39f2bb">33,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfOC0zLTEtMS05NDQxNA_fbbd7d75-2ef8-4b4d-bbcb-677610ae68ee">30,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfOS0xLTEtMS05NDQxNA_5ca599f7-2900-42bb-a014-5e527dc44eb4">984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfOS0zLTEtMS05NDQxNA_e63d356b-f134-4950-96b3-3d2e968da9fe">370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, Plant and Equipment, at cost, net of accumulated depreciation of $<ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMTAtMC0xLTEtOTQ0MTQvdGV4dHJlZ2lvbjo1OTk1ZmY4YzA5Yjg0YTg5YmI0ZDMwNDlmMDkwYmRlMV83OQ_d7bb6a10-c690-48ea-91ec-b1735c28729f">17,921</ix:nonFraction></span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">in 2022 and $<ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMTAtMC0xLTEtOTQ0MTQvdGV4dHJlZ2lvbjo1OTk1ZmY4YzA5Yjg0YTg5YmI0ZDMwNDlmMDkwYmRlMV85Mg_3b929f44-365a-41d1-81eb-fc90be394852">18,192</ix:nonFraction> in 2021</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMTAtMS0xLTEtOTQ0MTQ_e210a328-661a-4232-99e2-3c974c8d699f">20,424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMTAtMy0xLTEtOTQ0MTQ_90df69bb-92fd-4ede-a6f3-2a5a94bf1670">19,279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMTEtMS0xLTEtOTQ0MTQ_17badbdf-2f36-4aef-9c3a-b8cb7d3aa7de">21,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMTEtMy0xLTEtOTQ0MTQ_ecf91b08-78ea-4cfc-a14a-4759a0684fc1">21,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Intangibles, Net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMTItMS0xLTEtOTQ0MTQ_f1edd0ca-9b5f-4bc0-9bdf-40048757905e">21,368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMTItMy0xLTEtOTQ0MTQ_6dfaa11d-f749-4299-a98a-1a2b11fb53d6">22,933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMTMtMS0xLTEtOTQ0MTQ_9a5237f2-dbb4-49cb-9be7-4b0380ee6e1c">9,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMTMtMy0xLTEtOTQ0MTQ_bb142150-834d-4ba3-83bd-6078a4daa62a">11,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMTQtMS0xLTEtOTQ0MTQ_b32a4da7-289b-4b55-aaa9-f39df5149a27">107,081</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMTQtMy0xLTEtOTQ0MTQ_782d8e5e-dc00-490a-b914-8f86f87ec606">105,694</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loans payable and current portion of long-term debt</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMTctMS0xLTEtOTQ0MTQ_ce01946f-d8d4-436c-afcc-943a2e6ddc49">1,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMTctMy0xLTEtOTQ0MTQ_37963b77-6d33-48b6-b19c-d29c1c892209">2,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMTgtMS0xLTEtOTQ0MTQ_5187f488-fbe6-4bb4-baa7-2fca92a1bb20">3,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMTgtMy0xLTEtOTQ0MTQ_24cfd80c-9a1c-4982-9f0a-b03dd1390590">4,609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMTktMS0xLTEtOTQ0MTQ_106ee3f1-22f0-4133-b162-fc40a0a75171">14,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMTktMy0xLTEtOTQ0MTQ_4a39e243-9c2d-401f-b425-b20cb8693a61">13,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMjAtMS0xLTEtOTQ0MTQ_ae9a8b1c-f59d-41b0-8f59-17354f9c66ad">1,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMjAtMy0xLTEtOTQ0MTQ_438c29b0-7dd2-424c-a8ef-5d4464b1d660">1,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:DividendsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMjEtMS0xLTEtOTQ0MTQ_85c9c705-fe37-4e77-bf82-246748dc0042">1,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:DividendsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMjEtMy0xLTEtOTQ0MTQ_3ba47ea0-1cc4-49f4-b81e-fb1de8e8d95f">1,768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMjItMS0xLTEtOTQ0MTQ_91a13c65-e519-4df4-9aa2-022b9f35c555">22,998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMjItMy0xLTEtOTQ0MTQ_89999e93-ecc9-4554-b7e1-62b3ab0a61b9">23,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-Term Debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMjMtMS0xLTEtOTQ0MTQ_fedeae10-7b48-41f4-97c6-f43012e6a868">28,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMjMtMy0xLTEtOTQ0MTQ_2e8f42c4-0457-476e-a4d8-6135873187d3">30,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred Income Taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMjQtMS0xLTEtOTQ0MTQ_1d85af4a-7863-4263-9604-8e1e10ebfbe7">2,417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMjQtMy0xLTEtOTQ0MTQ_91bb3c37-cc1a-407b-b8ae-e68ca3096a87">3,441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMjUtMS0xLTEtOTQ0MTQ_83f96891-6912-470e-9b2e-123d1b9903d7">8,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMjUtMy0xLTEtOTQ0MTQ_0a37a1b6-70e3-41b2-8d81-ebbdb59e320c">9,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck&#160;&amp; Co., Inc. Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMjctMC0xLTEtOTQ0MTQvdGV4dHJlZ2lvbjpmMGRkMzMwNTliYzE0ZmMyOGE4MjA3MWZmYWUxNjViMl8xOQ_8756d8ec-bf52-4045-bf60-9fcb3bdfa775"><ix:nonFraction unitRef="usdPerShare" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMjctMC0xLTEtOTQ0MTQvdGV4dHJlZ2lvbjpmMGRkMzMwNTliYzE0ZmMyOGE4MjA3MWZmYWUxNjViMl8xOQ_912be4aa-2245-4234-b81d-36be69babd5d">0.50</ix:nonFraction></ix:nonFraction> par value</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Authorized - <ix:nonFraction unitRef="shares" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMjctMC0xLTEtOTQ0MTQvdGV4dHJlZ2lvbjpmMGRkMzMwNTliYzE0ZmMyOGE4MjA3MWZmYWUxNjViMl80NQ_40997d64-4f8f-4f90-be19-fa68385871b6"><ix:nonFraction unitRef="shares" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMjctMC0xLTEtOTQ0MTQvdGV4dHJlZ2lvbjpmMGRkMzMwNTliYzE0ZmMyOGE4MjA3MWZmYWUxNjViMl80NQ_f884c983-a783-4afe-b85f-c56efb33da64">6,500,000,000</ix:nonFraction></ix:nonFraction> shares</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued - <ix:nonFraction unitRef="shares" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMjctMC0xLTEtOTQ0MTQvdGV4dHJlZ2lvbjpmMGRkMzMwNTliYzE0ZmMyOGE4MjA3MWZmYWUxNjViMl82NA_21931a48-a39f-40f5-894b-47b76e4139cc"><ix:nonFraction unitRef="shares" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMjctMC0xLTEtOTQ0MTQvdGV4dHJlZ2lvbjpmMGRkMzMwNTliYzE0ZmMyOGE4MjA3MWZmYWUxNjViMl82NA_f2ce5382-e4e0-4a12-b2e2-e78e53985c38">3,577,103,522</ix:nonFraction></ix:nonFraction> shares in 2022 and 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMjctMS0xLTEtOTQ0MTQ_049bbac7-5f52-4cf4-8523-d9dd65c91a29">1,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMjctMy0xLTEtOTQ0MTQ_e73a8b07-205a-4e9c-a786-cba069937085">1,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other paid-in capital</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMjgtMS0xLTEtOTQ0MTQ_e80ec825-ea7c-44e7-9717-48a1098bb4fc">44,243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMjgtMy0xLTEtOTQ0MTQ_a3ca1387-e083-4316-a116-a601e3c20bab">44,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMjktMS0xLTEtOTQ0MTQ_5bb480bf-15ad-4598-b66d-80c1dfa0580c">59,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMjktMy0xLTEtOTQ0MTQ_a9ed350f-523f-4b18-a2f0-b12a6e8ae274">53,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMzAtMS0xLTEtOTQ0MTQ_95804bc9-db42-402a-b452-a6303e7072a0">4,743</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMzAtMy0xLTEtOTQ0MTQ_a1a0c539-0113-4c09-a320-2c381e62cad8">4,429</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:StockholdersEquityBeforeTreasuryStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMzEtMS0xLTEtOTQ0MTQ_67eba5d3-ce84-4244-8bac-07a1bafcda7f">101,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:StockholdersEquityBeforeTreasuryStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMzEtMy0xLTEtOTQ0MTQ_757fbf64-d8eb-4a17-9fa8-ed62fbdc7c27">95,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less treasury stock, at cost:</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMzItMC0xLTEtOTQ0MTQvdGV4dHJlZ2lvbjo5MjVlZWI1ZDE1ZjQ0Mzg3YWU3NWQ5NGU3YjQxZWUzZV8zNQ_5b3ae06e-e1b0-4a10-a5f5-f9b8c365eaff">1,043,697,097</ix:nonFraction> shares in 2022 and <ix:nonFraction unitRef="shares" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMzItMC0xLTEtOTQ0MTQvdGV4dHJlZ2lvbjo5MjVlZWI1ZDE1ZjQ0Mzg3YWU3NWQ5NGU3YjQxZWUzZV81NQ_95d1e336-7cf0-4176-b439-4a414dac4766">1,049,499,023</ix:nonFraction> shares in 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMzItMS0xLTEtOTQ0MTQ_7ff95959-1e04-45a0-9826-36ff54d16293">56,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMzItMy0xLTEtOTQ0MTQ_66a0b57d-3a7f-457e-bcec-6576bee5daa3">57,109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Merck&#160;&amp; Co., Inc. stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMzMtMS0xLTEtOTQ0MTQ_7646b2c9-355e-45c8-ba03-a4cb3b7743e7">44,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMzMtMy0xLTEtOTQ0MTQ_7bee0107-162f-4627-af39-5ffdc06be234">38,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling Interests</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMzQtMS0xLTEtOTQ0MTQ_533dd312-d391-4144-9d8f-a0b4bd3badd6">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMzQtMy0xLTEtOTQ0MTQ_4bded0de-9d68-4e09-8d8d-baf960d0a3e1">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMzUtMS0xLTEtOTQ0MTQ_7c9fa102-9f24-4cff-bf09-d5cca77e2db6">44,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMzUtMy0xLTEtOTQ0MTQ_4f7d693e-49c7-4c2c-b372-3fd5501bfca2">38,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMzYtMS0xLTEtOTQ0MTQ_89f66c13-5d47-4c67-97ba-e9c614170d56">107,081</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMzYtMy0xLTEtOTQ0MTQ_abfef1da-11a4-4125-a112-be534c772a4d">105,694</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of this condensed consolidated financial statement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 4 -</span></div></div></div><div id="i6b4e4280ad2344a5bc7fdcaa77e417f0_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MERCK&#160;&amp; CO., INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited, $ in millions)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.575%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Operating Activities of Continuing Operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income from continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMy0xLTEtMS05NDQxNA_a9656176-0b12-4494-bd9e-074a7793092c">11,508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMy0zLTEtMS05NDQxNA_09b457fe-e2a6-4fe0-85d5-bca09d5ea82f">8,534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income from continuing operations to net cash provided by operating activities of continuing operations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfNS0xLTEtMS05NDQxNA_7c7a490b-e934-4e58-b8f4-acf184d217d0">1,623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfNS0zLTEtMS05NDQxNA_04eecbc1-5976-467e-adb6-e7a212ae9533">1,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfNi0xLTEtMS05NDQxNA_a449bc7d-05de-4e7f-97d0-e9b409df2e17">1,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfNi0zLTEtMS05NDQxNA_3fe9b10e-739d-4678-ab29-921e1ff194ce">1,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset impairment charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfNy0xLTEtMS05NDQxNA_726ef460-ccbd-440c-ae7f-7e7f364cd53d">910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfNy0zLTEtMS05NDQxNA_6f4913a4-f5c4-40c3-a7b6-ffd10168a82c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss (income) from investments in equity securities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfOC0xLTEtMS05NDQxNA_3d4b918c-0138-4883-995b-12af34761b52">1,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfOC0zLTEtMS05NDQxNA_01aaea91-dc4b-4ccb-9bdb-cf10d7912332">1,535</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charge for the acquisition of Pandion Therapeutics, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfOS0xLTEtMS05NDQxNA_4b7450c8-62bc-4700-8c59-74d1a016275b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfOS0zLTEtMS05NDQxNA_6a22f692-2b97-43ae-b97e-f284d94fe733">1,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMTAtMS0xLTEtOTQ0MTQ_699c7491-34eb-4232-b11e-8a5fc4b693e1">1,261</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMTAtMy0xLTEtOTQ0MTQ_643e7565-6112-4f5b-90ab-af41287ccf1b">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMTEtMS0xLTEtOTQ0MTQ_aa64cdd6-9bfa-40af-8cd4-7d146301ecfe">396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMTEtMy0xLTEtOTQ0MTQ_a4786b19-f00c-4e40-a7d9-898a06186da6">360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMTItMS0xLTEtOTQ0MTQ_a7a3fef9-8954-4963-9435-217b0c9e11fa">1,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMTItMy0xLTEtOTQ0MTQ_7b978b1c-36ef-402a-a836-985978443422">499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net changes in assets and liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:IncreaseDecreaseInOperatingCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMTMtMS0xLTEtOTQ0MTQ_c9859a3c-29c6-4a90-8437-3ef1b04b33a0">2,435</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:IncreaseDecreaseInOperatingCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMTMtMy0xLTEtOTQ0MTQ_99a57ef0-43db-4547-a21e-8de2458d761c">3,794</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Cash Provided by Operating Activities of Continuing Operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMTQtMS0xLTEtOTQ0MTQ_6fe41570-65f2-41ec-b5e8-026ea361dd51">14,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMTQtMy0xLTEtOTQ0MTQ_aaee9313-787f-4760-8aa3-36442ca2b23c">8,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Investing Activities of Continuing Operations</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMTYtMS0xLTEtOTQ0MTQ_4e22f3db-6302-4d62-9f5d-a31c5af3bfde">3,239</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMTYtMy0xLTEtOTQ0MTQ_2778bc18-6063-4a6e-ab0c-6a6badb2be5b">3,240</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of securities and other investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMTctMS0xLTEtOTQ0MTQ_94aae18d-2242-4eb6-b51c-ffb05ceb618b">710</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMTctMy0xLTEtOTQ0MTQ_d408d7ac-91ab-4326-8e4c-bbc5232d67e8">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales of securities and other investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMTgtMS0xLTEtOTQ0MTQ_3503ff3e-f0de-4c7a-8355-518da8bbea2b">709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMTgtMy0xLTEtOTQ0MTQ_e8503b5a-3d3c-494a-b0f7-f05447d0a9b5">497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of Pandion Therapeutics, Inc., net of cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMTktMS0xLTEtOTQ0MTQ_095693c0-fd67-44f0-ac99-c114ad5ee086">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMTktMy0xLTEtOTQ0MTQ_f1b7c489-1388-495a-9baf-e3ae1c0ccd4e">1,554</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other acquisitions, net of cash acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMjAtMS0xLTEtOTQ0MTQ_529767f3-bc15-43fd-a666-67bd7d3f73e9">121</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMjAtMy0xLTEtOTQ0MTQ_738ae9d3-1d3d-41d0-80a7-c282b4008c2b">89</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMjEtMS0xLTEtOTQ0MTQ_01920ee1-14cd-4a94-8432-64610ddf687e">149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMjEtMy0xLTEtOTQ0MTQ_67325e8a-be0c-4fb5-840e-1b5bdd1a96ee">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Cash Used in Investing Activities of Continuing Operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMjItMS0xLTEtOTQ0MTQ_c0e9f939-8fe6-4b65-8954-726465eae313">3,212</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMjItMy0xLTEtOTQ0MTQ_32b6125f-71b8-48ee-83b3-8042747a1a26">4,372</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Financing Activities of Continuing Operations</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in short-term borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMjQtMS0xLTEtOTQ0MTQ_1db70ac0-44a4-4e7f-ada7-5cc1672fb1e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMjQtMy0xLTEtOTQ0MTQ_e775c648-3010-44aa-9ea9-82d94a49c86a">3,983</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments on debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMjUtMS0xLTEtOTQ0MTQ_8fabce80-c1ec-4b06-9222-577cc33ab7a3">2,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMjUtMy0xLTEtOTQ0MTQ_8d2e98b7-766a-4fb6-ab4c-250bd89ae8b8">1,153</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution from Organon &amp; Co.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="mrk:DisposalGroupInclDiscontinuedOperationsDistributionReceived" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMjYtMS0xLTEtOTQ0MTQ_ef39a6d8-568c-4ea3-8b8b-c1d947eca874">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="mrk:DisposalGroupInclDiscontinuedOperationsDistributionReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMjYtMy0xLTEtOTQ0MTQ_f3189d82-303e-4825-9053-a523c8b5b9b4">9,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of treasury stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMjctMS0xLTEtOTQ0MTQ_53e7bf3a-4678-42a5-9d5b-f7e8dd21938a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMjctMy0xLTEtOTQ0MTQ_cea12228-4576-4ce2-a0ef-5f0d5120ec17">822</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends paid to stockholders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMjgtMS0xLTEtOTQ0MTQ_c1917464-5c90-47ad-8e63-eb2b8254a3b3">5,262</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMjgtMy0xLTEtOTQ0MTQ_0a2b0735-3c8e-4d50-a139-21ea1a0f28e8">4,967</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMjktMS0xLTEtOTQ0MTQ_28ad0636-f069-4cc2-8163-548fe600d2b0">119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMjktMy0xLTEtOTQ0MTQ_32d7792e-961d-4d0d-8a05-7abde4c7a03c">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMzAtMS0xLTEtOTQ0MTQ_780fd8ea-b594-4d7b-aed7-e75993b24350">172</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMzAtMy0xLTEtOTQ0MTQ_7c6d3500-ce2f-4441-a527-8ec74f11ec08">253</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Cash Used in Financing Activities of Continuing Operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMzEtMS0xLTEtOTQ0MTQ_becc37ce-da32-4555-9f30-8b01b108eb94">7,565</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMzEtMy0xLTEtOTQ0MTQ_a0e9c8e5-865e-41b7-8891-912cb794a67a">2,110</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Discontinued Operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMzMtMS0xLTEtOTQ0MTQ_d2b6a683-ca51-4b8b-962c-7443c7472db3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMzMtMy0xLTEtOTQ0MTQ_4107c568-9dd9-4153-8f1a-07996492fa00">1,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMzQtMS0xLTEtOTQ0MTQ_23e9a99d-9dcb-43b5-bbe5-03cd5b8372ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMzQtMy0xLTEtOTQ0MTQ_6c5d06ae-7ba3-4fa1-b8be-639869693a14">134</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMzUtMS0xLTEtOTQ0MTQ_945c4114-e12d-4836-90fc-c2cce32f55aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMzUtMy0xLTEtOTQ0MTQ_5845881a-9355-442a-8896-19fe7c58ccb3">504</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Cash Flows Provided by Discontinued Operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:NetCashProvidedByUsedInDiscontinuedOperations" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMzYtMS0xLTEtOTQ0MTQ_ed033934-7fd2-4909-b2a1-ef5d0b7c0575">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:NetCashProvidedByUsedInDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMzYtMy0xLTEtOTQ0MTQ_fb071b66-433f-468c-b4f9-56b35449858d">413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMzctMS0xLTEtOTQ0MTQ_46a9f020-87ba-4017-8c3c-1f0b37f26b46">776</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMzctMy0xLTEtOTQ0MTQ_42e07120-dcfa-4841-85d4-f09ab2f7856e">65</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Increase in Cash, Cash Equivalents and Restricted Cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMzgtMS0xLTEtOTQ0MTQ_4d702447-a934-4aaf-b1c6-5b2a6e8b8e06">3,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMzgtMy0xLTEtOTQ0MTQ_e265f53c-118d-48dc-8b1d-bc2dc6d9a2f7">1,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMzktMC0xLTEtOTQ0MTQvdGV4dHJlZ2lvbjphZGViOGJmZjBiMGY0MWY2YmUzM2Q3NGRiZWViMTVlNl85OA_d18da6a6-512a-4eed-ad39-3681b8fe78ee">71</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i6b76c3e2ce274f17b07c82ae1459e9f9_I20201231" decimals="-6" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMzktMC0xLTEtOTQ0MTQvdGV4dHJlZ2lvbjphZGViOGJmZjBiMGY0MWY2YmUzM2Q3NGRiZWViMTVlNl8xMDU_92e422dc-8b8b-4c75-b316-858b94398684">103</ix:nonFraction> at January 1, 2022 and 2021, respectively, included in Other current assets)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMzktMS0xLTEtOTQ0MTQ_ba743f91-114e-416e-ba6d-bdbd8be8f540">8,167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b76c3e2ce274f17b07c82ae1459e9f9_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMzktMy0xLTEtOTQ0MTQ_491551c1-30a6-4d10-9bd0-d8d017962418">8,153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $<ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfNDAtMC0xLTEtOTQ0MTQvdGV4dHJlZ2lvbjpjYWMzZDZhMDU2MzY0N2U1YTVjY2E4ZTdkZTkzNWM0ZV85Mw_3ab52448-5c83-4f88-9bde-f3e7d31e427f">134</ix:nonFraction> </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and $<ix:nonFraction unitRef="usd" contextRef="i48930a09b1404293820fbeb015eb6729_I20210930" decimals="-6" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfNDAtMC0xLTEtOTQ0MTQvdGV4dHJlZ2lvbjpjYWMzZDZhMDU2MzY0N2U1YTVjY2E4ZTdkZTkzNWM0ZV8xMDE_07560286-8648-4e0a-81fd-572359cfa837">30</ix:nonFraction> at September&#160;30, 2022 and 2021, respectively, included in Other current assets)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfNDAtMS0xLTEtOTQ0MTQ_2217932c-21ba-45f3-b026-2e3e835ab8dc">11,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48930a09b1404293820fbeb015eb6729_I20210930" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfNDAtMy0xLTEtOTQ0MTQ_9a8cc49c-496a-497f-bf6a-f2c0561b3ffb">10,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of this condensed consolidated financial statement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 5 -</span></div></div></div><div id="i6b4e4280ad2344a5bc7fdcaa77e417f0_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span></div></div><div><span><br/></span></div><div id="i6b4e4280ad2344a5bc7fdcaa77e417f0_31"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.    <ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zMS9mcmFnOmYyNTNiNGIyZTJkYzRjZjRiZjAyOTg3NWZjZmJhZjNjL3RleHRyZWdpb246ZjI1M2I0YjJlMmRjNGNmNGJmMDI5ODc1ZmNmYmFmM2NfNjE2Ng_bcba8da3-4176-426a-baff-8dc72132f1e8" continuedAt="id34dbcfca55e4c29ab0da48dd4257989" escape="true"><ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zMS9mcmFnOmYyNTNiNGIyZTJkYzRjZjRiZjAyOTg3NWZjZmJhZjNjL3RleHRyZWdpb246ZjI1M2I0YjJlMmRjNGNmNGJmMDI5ODc1ZmNmYmFmM2NfNjE4MQ_92aa83c9-ecfd-4f88-81c2-1f7fb1706993" continuedAt="idfa7fc06adba46d1be670b1e07f560ab" escape="true">Basis of Presentation</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="id34dbcfca55e4c29ab0da48dd4257989" continuedAt="i5bd4cfc614134a18853d5b2b0e69d6ba"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="idfa7fc06adba46d1be670b1e07f560ab" continuedAt="ie5cd6380058043b6a10a9bcf302bb582">The accompanying unaudited condensed consolidated financial statements of Merck&#160;&amp; Co., Inc. (Merck or the Company) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the United States (U.S.) (GAAP) for complete consolidated financial statements are not included herein. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Merck&#8217;s Form 10-K filed on February&#160;25, 2022. </ix:continuation></span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie5cd6380058043b6a10a9bcf302bb582">The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company&#8217;s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature.</ix:continuation> </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Spin-Off of Organon &amp; Co.</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 2, 2021, Merck completed the spin-off of products from its women&#8217;s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon &amp; Co. (Organon) through a distribution of Organon&#8217;s publicly traded stock to Company shareholders. The distribution is expected to qualify and has been treated as tax-free to the Company and its shareholders for U.S. federal income tax purposes. The established brands included in the transaction consisted of dermatology, non-opioid pain management, respiratory, select cardiovascular products, as well as the rest of Merck&#8217;s diversified brands franchise. Merck&#8217;s existing research pipeline programs continue to be owned and developed within Merck as planned. The historical results of the businesses that were contributed to Organon in the spin-off have been reflected as discontinued operations in the Company&#8217;s consolidated financial statements through the date of the spin-off (see Note&#160;2).</span></div><ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zMS9mcmFnOmYyNTNiNGIyZTJkYzRjZjRiZjAyOTg3NWZjZmJhZjNjL3RleHRyZWdpb246ZjI1M2I0YjJlMmRjNGNmNGJmMDI5ODc1ZmNmYmFmM2NfNjE4NQ_badf433e-26e3-4e0d-baf4-ffd5b18c5cd4" continuedAt="i996e3f9cc98340ecbb5d4b90423911b0" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Financial Accounting Standards Board (FASB) issued amended guidance on the accounting for convertible instruments and contracts in an entity&#8217;s own equity. The guidance removes the separation model for convertible debt instruments and preferred stock, amends requirements for conversion options to be classified in equity as well as amends diluted earnings per share (EPS) calculations for certain convertible debt instruments. The Company adopted the new guidance on January 1, 2022 using a modified retrospective approach. There was no impact to the Company&#8217;s consolidated financial statements upon adoption.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the FASB issued new guidance to increase the transparency of transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. The guidance requires annual disclosures of such transactions to include the nature of the transactions and the significant terms and conditions, the accounting treatment and the impact to a company&#8217;s financial statements. The Company adopted the new guidance on January 1, 2022 on a prospective basis. There was no material impact to the Company&#8217;s consolidated financial statements upon adoption.</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting and subsequently issued clarifying amendments. The guidance provides optional expedients and exceptions for accounting for contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (LIBOR) or another reference rate expected to be discontinued because of reference rate reform. The Company adopted the optional guidance on July 1, 2022 on a prospective basis. There was no material impact to the Company&#8217;s consolidated financial statements upon adoption. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Standards Not Yet Adopted</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued amended guidance that requires acquiring entities to recognize and measure contract assets and liabilities in a business combination in accordance with existing revenue recognition guidance. The amended guidance is effective for interim and annual periods in 2023 and is to be applied prospectively. Early adoption is permitted on a retrospective basis to the beginning of the fiscal year of adoption. The adoption of this guidance will not have an impact on the Company&#8217;s consolidated financial statements for prior acquisitions; however, the impact in future periods will be dependent upon the contract assets and contract liabilities acquired in future business combinations.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5bd4cfc614134a18853d5b2b0e69d6ba"><ix:continuation id="i996e3f9cc98340ecbb5d4b90423911b0">In June 2022, the FASB issued guidance related to the fair value measurement of an equity security subject to contractual restrictions that prohibit the sale of the equity security. The new guidance also introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. The amended guidance is effective for interim and annual periods in 2024 and is to be applied prospectively. Early adoption is permitted for both interim and annual periods. The Company is currently evaluating the impact of adoption on its consolidated financial statements.</ix:continuation></ix:continuation> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 6 -</span></div></div></div><div id="i6b4e4280ad2344a5bc7fdcaa77e417f0_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span></div></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.     <ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RleHRyZWdpb246MDdlMjdjMTQwZDFhNGI3NTkyNTc2OTFmMGJkOTVmMjNfNDg5OQ_11f28c54-e64c-4cdc-b145-8acdcd22940e" continuedAt="i6aa7fd5dd7de4fcca315466a004c9d8d" escape="true">Spin-Off of Organon &amp; Co. </ix:nonNumeric></span></div><ix:continuation id="i6aa7fd5dd7de4fcca315466a004c9d8d" continuedAt="i8f53fb302bd54165924e1b958186cb15"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 2, 2021, Merck completed the spin-off of Organon through a distribution of Organon&#8217;s publicly traded stock to Company shareholders. In connection with the spin-off, each Merck shareholder received one tenth of a share of Organon&#8217;s common stock for each share of Merck common stock held by such shareholder. The distribution is expected to qualify and has been treated as tax free to Merck and its shareholders for U.S. federal income tax purposes. Indebtedness of $<ix:nonFraction unitRef="usd" contextRef="i602313dd11d54187bb2dce59c76d9f21_I20210602" decimals="-8" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RleHRyZWdpb246MDdlMjdjMTQwZDFhNGI3NTkyNTc2OTFmMGJkOTVmMjNfNDgx_924b9d01-5687-49d4-a2ee-61a82a5e303a">9.5</ix:nonFraction>&#160;billion principal amount, consisting of term loans and senior notes, was issued in 2021 in connection with the spin-off and assumed by Organon. Merck is no longer the obligor of any Organon debt or financing arrangements. Cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="ic7ff920b80fa44a2bb7838de95556452_I20210602" decimals="-8" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RleHRyZWdpb246MDdlMjdjMTQwZDFhNGI3NTkyNTc2OTFmMGJkOTVmMjNfNzE1_acf09f46-aeda-4f27-8b19-a86aefa942b7">9.0</ix:nonFraction>&#160;billion were distributed by Organon to Merck in connection with the spin-off. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in connection with the spin-off, Merck and Organon entered into a separation and distribution agreement and also entered into various other agreements to effect the spin-off and provide a framework for the relationship between Merck and Organon after the spin-off, including a transition services agreement (TSA), manufacturing and supply agreements (MSAs), trademark license agreements, intellectual property license agreements, an employee matters agreement, a tax matters agreement and certain other commercial agreements. Under the TSA, Merck is providing Organon various services and, similarly, Organon is providing Merck various services. The provision of services under the TSA generally will terminate within <ix:nonNumeric contextRef="i16de1f9b952c486594ae6f32e5927154_D20210602-20210602" name="us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RleHRyZWdpb246MDdlMjdjMTQwZDFhNGI3NTkyNTc2OTFmMGJkOTVmMjNfMTUxMg_575dcb40-1298-4301-90a0-2d14bc5c9813">25</ix:nonNumeric> months following the spin-off; however, the provision of certain services has been extended to <ix:nonNumeric contextRef="iab8a608181a042f2beef71b113878321_D20210602-20210602" name="us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RleHRyZWdpb246MDdlMjdjMTQwZDFhNGI3NTkyNTc2OTFmMGJkOTVmMjNfMTYwMw_3dfa4512-251f-462d-afc3-2c94041f6e39">31</ix:nonNumeric> months. Merck and Organon also entered into a series of interim operating agreements pursuant to which in various jurisdictions where Merck held licenses, permits and other rights in connection with marketing, import and/or distribution of Organon products prior to the separation, Merck is continuing to market, import and distribute such products until such time as the relevant licenses and permits are transferred to Organon. Under such interim operating agreements and in accordance with the separation and distribution agreement, Merck is continuing operations in the affected markets on behalf of Organon, with Organon receiving all of the economic benefits and burdens of such activities. Additionally, Merck and Organon entered into a number of MSAs pursuant to which Merck is (a) manufacturing and supplying certain active pharmaceutical ingredients for Organon, (b) manufacturing and supplying certain formulated pharmaceutical products for Organon, and (c) packaging and labeling certain finished pharmaceutical products for Organon. Similarly, Organon and Merck entered into a number of MSAs pursuant to which Organon is (a) manufacturing and supplying certain formulated pharmaceutical products for Merck, and (b) packaging and labeling certain finished pharmaceutical products for Merck. The terms of the MSAs range in initial duration from <ix:nonNumeric contextRef="i06897842e70e4eeda8309f8e1ee91277_D20210602-20210602" name="us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RleHRyZWdpb246MDdlMjdjMTQwZDFhNGI3NTkyNTc2OTFmMGJkOTVmMjNfMjk1NQ_907319df-19f3-44e5-8f62-2a0ee224dfae">four years</ix:nonNumeric> to <ix:nonNumeric contextRef="i47ff0bcc16874008b1f561555e4a69e4_D20210602-20210602" name="us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RleHRyZWdpb246MDdlMjdjMTQwZDFhNGI3NTkyNTc2OTFmMGJkOTVmMjNfMjk2MQ_8e476f6a-e4ef-4635-a3d8-35e4c17abc93">ten years</ix:nonNumeric>. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts included in the condensed consolidated statement of income for the above MSAs include sales of $<ix:nonFraction unitRef="usd" contextRef="i54368f9911b347738909e680bf95d53e_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RleHRyZWdpb246MDdlMjdjMTQwZDFhNGI3NTkyNTc2OTFmMGJkOTVmMjNfMzA2OQ_fa1f1321-4f06-41c0-986e-4a8b4ce8607a">100</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ic18b206b366941b3bc21e6598f14fb5a_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RleHRyZWdpb246MDdlMjdjMTQwZDFhNGI3NTkyNTc2OTFmMGJkOTVmMjNfMzA3Ng_9b7f6ce8-83fb-44a1-993f-1d93f6fc65c9">293</ix:nonFraction>&#160;million and related cost of sales of $<ix:nonFraction unitRef="usd" contextRef="i54368f9911b347738909e680bf95d53e_D20220701-20220930" decimals="-6" name="us-gaap:RelatedPartiesAmountInCostOfSales" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RleHRyZWdpb246MDdlMjdjMTQwZDFhNGI3NTkyNTc2OTFmMGJkOTVmMjNfMzEwOA_a811f2ec-790c-4c2a-ac6d-2084cebe387d">104</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ic18b206b366941b3bc21e6598f14fb5a_D20220101-20220930" decimals="-6" name="us-gaap:RelatedPartiesAmountInCostOfSales" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RleHRyZWdpb246MDdlMjdjMTQwZDFhNGI3NTkyNTc2OTFmMGJkOTVmMjNfMzExNQ_e5f7dba0-241c-46da-82ae-b854278deb92">312</ix:nonFraction>&#160;million for the three and nine months ended September&#160;30, 2022, respectively. The amounts included in the condensed consolidated statement of income for the MSAs in the same periods of 2021 were immaterial. Amounts included in the condensed consolidated statement of income for the TSAs were immaterial for the three and nine months ended September&#160;30, 2022 and September&#160;30, 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts due from Organon under all of the above agreements were $<ix:nonFraction unitRef="usd" contextRef="i13d3cfa7934c4d6088d6cd23cfa71865_I20220930" decimals="-6" name="us-gaap:DueFromRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RleHRyZWdpb246MDdlMjdjMTQwZDFhNGI3NTkyNTc2OTFmMGJkOTVmMjNfMzQ5OQ_80bc9041-88cd-48d1-a7d6-1dd209e6e685">567</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i32aa48e818164158ab6157217075e834_I20211231" decimals="-6" name="us-gaap:DueFromRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RleHRyZWdpb246MDdlMjdjMTQwZDFhNGI3NTkyNTc2OTFmMGJkOTVmMjNfMzUwNg_4ac5b8f6-e3d7-4250-a176-8cccc57367ce">964</ix:nonFraction>&#160;million at September&#160;30, 2022 and December&#160;31, 2021, respectively, and are reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amounts due to Organon under these agreements were $<ix:nonFraction unitRef="usd" contextRef="i13d3cfa7934c4d6088d6cd23cfa71865_I20220930" decimals="-6" name="us-gaap:DueToRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RleHRyZWdpb246MDdlMjdjMTQwZDFhNGI3NTkyNTc2OTFmMGJkOTVmMjNfMzY1MA_336a9560-31c6-4277-9ebf-376352fef485">333</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i32aa48e818164158ab6157217075e834_I20211231" decimals="-6" name="us-gaap:DueToRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RleHRyZWdpb246MDdlMjdjMTQwZDFhNGI3NTkyNTc2OTFmMGJkOTVmMjNfMzY1Nw_3941b87b-d24b-4fef-bd64-953d9e5bd352">400</ix:nonFraction>&#160;million at September&#160;30, 2022 and December&#160;31, 2021, respectively, and are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of the women&#8217;s health, biosimilars and established brands businesses (previously included in the Pharmaceutical segment) that were contributed to Organon in the spin-off, as well as interest expense related to the debt issuance in 2021, have been reflected as discontinued operations in the Company&#8217;s condensed consolidated statement of income as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for periods prior to the spin-off on June 2, 2021. Merck incurred separation costs of $<ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RleHRyZWdpb246MDdlMjdjMTQwZDFhNGI3NTkyNTc2OTFmMGJkOTVmMjNfNDMxNw_e6ab1d55-40f2-4edd-a456-e71b9452b7d5">556</ix:nonFraction>&#160;million for the nine months ended September&#160;30, 2021 related to the spin-off of Organon, which are also included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. These costs primarily relate to professional fees for separation activities within finance, tax, legal and information technology functions, as well as investment banking fees. </span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 7 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span></div></div><ix:continuation id="i8f53fb302bd54165924e1b958186cb15"><ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RleHRyZWdpb246MDdlMjdjMTQwZDFhNGI3NTkyNTc2OTFmMGJkOTVmMjNfNDkwMA_1b5b2611-42e1-47de-a70a-63440718e2c6" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RhYmxlOmQ3MWEzODE3NjkwZTRiMTI5NjFhZjc3YmE4NDA4NjkxL3RhYmxlcmFuZ2U6ZDcxYTM4MTc2OTBlNGIxMjk2MWFmNzdiYTg0MDg2OTFfMi0zLTEtMS05NDQxNA_15604e95-57bc-4554-a5f8-1013e22e9981">2,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs, Expenses and Other</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RhYmxlOmQ3MWEzODE3NjkwZTRiMTI5NjFhZjc3YmE4NDA4NjkxL3RhYmxlcmFuZ2U6ZDcxYTM4MTc2OTBlNGIxMjk2MWFmNzdiYTg0MDg2OTFfNC0zLTEtMS05NDQxNA_f3cb1a0a-d76b-4ace-9d5b-f12e21276576">789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RhYmxlOmQ3MWEzODE3NjkwZTRiMTI5NjFhZjc3YmE4NDA4NjkxL3RhYmxlcmFuZ2U6ZDcxYTM4MTc2OTBlNGIxMjk2MWFmNzdiYTg0MDg2OTFfNS0zLTEtMS05NDQxNA_ce2d6051-bcd9-4976-b2fe-267ede42281c">877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="mrk:DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RhYmxlOmQ3MWEzODE3NjkwZTRiMTI5NjFhZjc3YmE4NDA4NjkxL3RhYmxlcmFuZ2U6ZDcxYTM4MTc2OTBlNGIxMjk2MWFmNzdiYTg0MDg2OTFfNi0zLTEtMS05NDQxNA_991d5365-c2af-4f72-acf9-8373e36907a9">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="mrk:DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RhYmxlOmQ3MWEzODE3NjkwZTRiMTI5NjFhZjc3YmE4NDA4NjkxL3RhYmxlcmFuZ2U6ZDcxYTM4MTc2OTBlNGIxMjk2MWFmNzdiYTg0MDg2OTFfNy0zLTEtMS05NDQxNA_9eee0f0b-be74-46d4-ad27-3191d9898c3d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="mrk:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RhYmxlOmQ3MWEzODE3NjkwZTRiMTI5NjFhZjc3YmE4NDA4NjkxL3RhYmxlcmFuZ2U6ZDcxYTM4MTc2OTBlNGIxMjk2MWFmNzdiYTg0MDg2OTFfOC0zLTEtMS05NDQxNA_58d95f50-44e6-41db-b52b-3f3ae756cf59">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RhYmxlOmQ3MWEzODE3NjkwZTRiMTI5NjFhZjc3YmE4NDA4NjkxL3RhYmxlcmFuZ2U6ZDcxYTM4MTc2OTBlNGIxMjk2MWFmNzdiYTg0MDg2OTFfOS0zLTEtMS05NDQxNA_d97fbf2e-df70-4fa2-be3f-a5de605728a5">1,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations before taxes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RhYmxlOmQ3MWEzODE3NjkwZTRiMTI5NjFhZjc3YmE4NDA4NjkxL3RhYmxlcmFuZ2U6ZDcxYTM4MTc2OTBlNGIxMjk2MWFmNzdiYTg0MDg2OTFfMTAtMy0xLTEtOTQ0MTQ_21097342-72f6-42a1-b550-ac1516bcddae">757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RhYmxlOmQ3MWEzODE3NjkwZTRiMTI5NjFhZjc3YmE4NDA4NjkxL3RhYmxlcmFuZ2U6ZDcxYTM4MTc2OTBlNGIxMjk2MWFmNzdiYTg0MDg2OTFfMTEtMy0xLTEtOTQ0MTQ_032d4a45-5f84-48aa-bba5-2716ff761428">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, net of taxes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RhYmxlOmQ3MWEzODE3NjkwZTRiMTI5NjFhZjc3YmE4NDA4NjkxL3RhYmxlcmFuZ2U6ZDcxYTM4MTc2OTBlNGIxMjk2MWFmNzdiYTg0MDg2OTFfMTItMy0xLTEtOTQ0MTQ_7cab9a5a-c469-4664-97fa-6ce99d33f5ca">769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Income of discontinued operations attributable to noncontrolling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RhYmxlOmQ3MWEzODE3NjkwZTRiMTI5NjFhZjc3YmE4NDA4NjkxL3RhYmxlcmFuZ2U6ZDcxYTM4MTc2OTBlNGIxMjk2MWFmNzdiYTg0MDg2OTFfMTMtMy0xLTEtOTQ0MTQ_0f03aa91-ee36-4b81-9472-219f867a25ff">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RhYmxlOmQ3MWEzODE3NjkwZTRiMTI5NjFhZjc3YmE4NDA4NjkxL3RhYmxlcmFuZ2U6ZDcxYTM4MTc2OTBlNGIxMjk2MWFmNzdiYTg0MDg2OTFfMTQtMy0xLTEtOTQ0MTQ_938bd17a-675e-4aeb-8353-84bb4d64e666">766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Reflects amounts through the June 2, 2021 spin-off date.</span></div></ix:nonNumeric></ix:continuation><div id="i6b4e4280ad2344a5bc7fdcaa77e417f0_40"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="mrk:AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfNzg1MQ_628c0e60-06fb-46ac-ae5b-6ee3d9991820" continuedAt="i6678b14270c64ad2b472e16b3b0b022b" escape="true">Acquisitions, Research Collaborations and License Agreements</ix:nonNumeric></span></div><ix:continuation id="i6678b14270c64ad2b472e16b3b0b022b" continuedAt="i993bd247d4d148698b74acb02e0d74c2"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to pursue acquisitions and the establishment of external alliances such as research collaborations and licensing agreements to complement its internal research capabilities. These arrangements often include upfront payments, as well as expense reimbursements or payments to the third party, and milestone, royalty or profit share arrangements, contingent upon the occurrence of certain future events linked to the success of the asset in development. The Company also reviews its marketed products and pipeline to examine candidates which may provide more value through out-licensing and, as part of its portfolio assessment process, may also divest certain assets. Pro forma financial information for acquired businesses is not presented if the historical financial results of the acquired entity are not significant when compared with the Company&#8217;s financial results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Transactions</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, Merck and Royalty Pharma plc (Royalty Pharma) entered into a funding arrangement under which Royalty Pharma paid Merck $<ix:nonFraction unitRef="usd" contextRef="i9bca04a61d0b44f38244083585df424c_D20221001-20221031" decimals="-6" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfMTA5OTUxMTY0ODM4Mw_833c9f24-b2c1-466b-be3f-af96813eb4ee">50</ix:nonFraction>&#160;million to co-fund Merck&#8217;s development costs for a Phase 2b trial of MK-8189, an investigational oral Phosphodiesterase 10A (PDE10A) inhibitor, which is being evaluated for the treatment of schizophrenia. Under the agreement, Royalty Pharma has no rights to MK-8189 and has no decision-making authority over the program. If Merck elects to advance MK-8189 into a Phase 3 study, Royalty Pharma has the option to provide additional funding of <ix:nonFraction unitRef="number" contextRef="i9bca04a61d0b44f38244083585df424c_D20221001-20221031" decimals="2" name="mrk:ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfMTA5OTUxMTY1MjE0OA_60b0971a-2463-472d-94c5-1a2d90526e13">50</ix:nonFraction>% of the development costs up to $<ix:nonFraction unitRef="usd" contextRef="i9bca04a61d0b44f38244083585df424c_D20221001-20221031" decimals="-6" name="mrk:ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfMTA5OTUxMTY1MDkxNw_c50cf5ab-d1d0-41a7-9193-8e516c691dc3">375</ix:nonFraction>&#160;million for the Phase 3 trial. If such additional funding is provided, Royalty Pharma becomes eligible to receive future regulatory milestone payments contingent upon certain marketing approvals, as well as royalties. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, Merck exercised its option to jointly develop and commercialize personalized cancer vaccine mRNA-4157/V940 pursuant to the terms of an existing collaboration and license agreement with Moderna, Inc. (Moderna), which resulted in a $<ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" name="mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfNTQ5NzU1ODQ3MTQy_17adfb19-194c-4ef2-a709-605128a2280a"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfNTQ5NzU1ODQ3MTQy_7386307e-9b87-4bcb-a79e-f0d991066522">250</ix:nonFraction></ix:nonFraction>&#160;million charge in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in the third quarter and first nine months of 2022. The payment to Moderna was made in the fourth quarter of 2022. mRNA-4157/V940 is currently being evaluated in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pembrolizumab), Merck&#8217;s anti-PD-1 therapy, as adjuvant treatment for patients with high-risk melanoma in a Phase 2 clinical trial being conducted by Moderna. Under the 2016 agreement, as amended in 2018, Merck and Moderna will collaborate on development and commercialization and will share costs and any profits equally under this worldwide collaboration. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, Merck and Orna Therapeutics (Orna), a biotechnology company pioneering a new investigational class of engineered circular RNA (oRNA) therapies, entered into a collaboration agreement to discover, develop, and commercialize multiple programs, including vaccines and therapeutics in the areas of infectious disease and oncology. Under the terms of the agreement, Merck made an upfront payment to Orna of $<ix:nonFraction unitRef="usd" contextRef="ie8c7d497ea31438baaf4030a8d162610_D20220801-20220831" decimals="-6" name="mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfMTA5OTUxMTY0Nzc4Nw_7866b727-3e8f-45ee-8d91-9883d88693be">150</ix:nonFraction>&#160;million, which was recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in the third quarter and first nine months of 2022. In addition, Orna is eligible to receive future contingent development-related payments aggregating up to $<ix:nonFraction unitRef="usd" contextRef="i75ee5a60ce374caea61b986d91c7b118_D20220801-20220831" decimals="-6" name="mrk:ContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfMTA5OTUxMTY0NjgzMQ_ff2bc861-b0f8-4556-948b-a620b613bd59">440</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i7cce51215fdf4e1f8b49f6ac5e538125_D20220801-20220831" decimals="-6" name="mrk:ContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfMTA5OTUxMTY0Njg1Mg_cca02bfe-209d-4292-9ad9-af813e0b9c92">675</ix:nonFraction> million in regulatory milestones, and $<ix:nonFraction unitRef="usd" contextRef="i1d770d493ee2465aad2e7a4f35310a08_D20220801-20220831" decimals="-8" name="mrk:ContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfMTA5OTUxMTY0Njg3Ng_27d427e5-4f07-4668-a677-814a81705cc8">2.4</ix:nonFraction> billion in sales milestones associated with the progress of the multiple vaccine and therapeutic programs, as well as royalties </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 8 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i993bd247d4d148698b74acb02e0d74c2" continuedAt="i30540eb9465448ca85585b6575793e73"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ranging from a high-single-digit rate to a low-double-digit rate on any approved products derived from the collaboration. Merck also invested $<ix:nonFraction unitRef="usd" contextRef="ie81fe052a58c4ac79c6c1914541dbb46_D20221001-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfMTA5OTUxMTY0NjkyNA_fda591fd-b32c-4893-9fd0-fa757d6765ab">100</ix:nonFraction>&#160;million in Orna&#8217;s Series B preferred shares in the fourth quarter of 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, Merck and Orion Corporation (Orion) announced a global co-development and co-commercialization agreement for Orion&#8217;s investigational candidate ODM-208 (MK-5684) and other drugs targeting cytochrome P450 11A1 (CYP11A1), an enzyme important in steroid production. ODM-208 is an oral, non-steroidal inhibitor of CYP11A1 currently being evaluated in a Phase 2 clinical trial for the treatment of patients with metastatic castration-resistant prostate cancer. Merck made an upfront payment to Orion of $<ix:nonFraction unitRef="usd" contextRef="ifc75b85439f349c791c677badeda87e6_D20220701-20220731" decimals="-6" name="mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfMTQxNQ_3afbfac0-d699-4ed8-841d-6a00f5ab3bc5">290</ix:nonFraction>&#160;million, which was recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in the third quarter and first nine months of 2022. Orion is responsible for the manufacture of clinical and commercial supply of ODM-208. In addition, the contract provides both parties with an option to convert the initial co-development and co-commercialization agreement into a global exclusive license to Merck. If the option is exercised, Merck would assume full responsibility for all past development and commercialization expenses associated with the program since inception of the agreement, as well as all future development and commercialization expenses. In addition, Orion would be eligible to receive milestone payments associated with progress in the development and commercialization of ODM-208 as well as tiered double-digit royalties on sales if the product is approved. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in July 2022, Merck and Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (Kelun-Biotech) closed a license and collaboration agreement in which Merck gained exclusive worldwide rights for the development, manufacture and commercialization of an investigational antibody drug conjugate (ADC) (MK-1200) for the treatment of solid tumors. Under the terms of the agreement, Merck and Kelun-Biotech will collaborate on the early clinical development of the investigational ADC. Merck made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ib486ae5e04ba46c792826e98b7405eb9_D20220701-20220731" decimals="-6" name="mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfMjc2OQ_1f48c80b-2b2e-493a-9f1f-cb72d7e033a8">35</ix:nonFraction>&#160;million, which was recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in the third quarter and first nine months of 2022. Kelun-Biotech is also eligible to receive future contingent milestone payments aggregating up to $<ix:nonFraction unitRef="usd" contextRef="ifca4efa458684a00b6c8c8e3b1f41518_D20220701-20220731" decimals="-6" name="mrk:ContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfMjk2MA_9166ffda-5456-405d-979a-231d36c04e02">82</ix:nonFraction>&#160;million in developmental milestones, $<ix:nonFraction unitRef="usd" contextRef="ia4a01db11db64f5285ad73bae142f347_D20220701-20220731" decimals="-6" name="mrk:ContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfMjk5Mg_cbd5117b-ddaa-4c97-8e8e-e87db72a1422">334</ix:nonFraction>&#160;million in regulatory milestones, and $<ix:nonFraction unitRef="usd" contextRef="ic0e7fb5afd034fe49f7ea947b722c5af_D20220701-20220731" decimals="-6" name="mrk:ContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfMzAyNQ_32dd15c6-b81a-4806-ac26-5873da2d928f">485</ix:nonFraction>&#160;million in sales-based milestones. The agreement also provides for Merck to pay tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, in connection with an existing arrangement, Merck exercised its option to obtain an exclusive license outside of China for the development, manufacture and commercialization of Kelun-Biotech&#8217;s trophoblast antigen 2 (TROP2)-targeting ADC programs, including its lead compound, SKB-264 (MK-2870). SKB-264 is currently being evaluated in Phase 2 trials for non-small-cell lung cancer and advanced solid tumors. Under the terms of the agreement, Merck and Kelun-Biotech will collaborate on certain early clinical development plans, including evaluating the potential of SKB-264 as a monotherapy and in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for advanced solid tumors. Upon option exercise, Merck made a payment of $<ix:nonFraction unitRef="usd" contextRef="i0bc205e805cf4d5f9d260e0bc1e150de_D20220501-20220531" decimals="-6" name="mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfMzkyOA_5f043ae6-677e-4b05-bc02-a070079831c0">30</ix:nonFraction>&#160;million, which was recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in the first nine months of 2022, and agreed to make additional payments of $<ix:nonFraction unitRef="usd" contextRef="i0bc205e805cf4d5f9d260e0bc1e150de_D20220501-20220531" decimals="-6" name="mrk:MilestonePaymentsToBeMadeToACollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfNDA2MQ_7507a655-9087-4ef1-a894-016f21ae2735">30</ix:nonFraction>&#160;million upon completion of specified project activities and $<ix:nonFraction unitRef="usd" contextRef="i0bc205e805cf4d5f9d260e0bc1e150de_D20220501-20220531" decimals="-6" name="mrk:MilestonePaymentToBeMadeToACollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfNDExNg_8f59e70f-211d-43df-8afb-40a19c2a3197">25</ix:nonFraction>&#160;million upon technology transfer. Merck also agreed to make quarterly payments in 2022 and 2023 aggregating up to $<ix:nonFraction unitRef="usd" contextRef="i0bc205e805cf4d5f9d260e0bc1e150de_D20220501-20220531" decimals="-6" name="mrk:ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfNDIxOQ_f7bfd318-ad84-4c00-8d85-1b02d6c5a910">101</ix:nonFraction>&#160;million to fund Kelun-Biotech&#8217;s ongoing research and development activities. In addition, Kelun-Biotech is eligible to receive future contingent milestone payments (which includes all program compounds) aggregating up to $<ix:nonFraction unitRef="usd" contextRef="i039f123196e246019e2836c6f6bb9e91_D20220501-20220531" decimals="-6" name="mrk:ContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfNDQzNQ_1b6072bc-4358-441f-9abd-b02fee90537b">90</ix:nonFraction>&#160;million in developmental milestones, $<ix:nonFraction unitRef="usd" contextRef="iddd9e1044d91482a92ae2a06341f0748_D20220501-20220531" decimals="-6" name="mrk:ContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfNDQ2Nw_51f9a7c4-3201-4baf-975c-b1a7e58e7725">290</ix:nonFraction>&#160;million in first commercial sale milestones, and $<ix:nonFraction unitRef="usd" contextRef="i4d354163674a44d68678d3dc0bf63d9a_D20220501-20220531" decimals="-6" name="mrk:ContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfNDUxMQ_a2f83e90-4724-49b1-b7ef-2a6bbe0bc2e0">780</ix:nonFraction>&#160;million in sales-based milestones. The agreement also provides for Merck to pay tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Transactions</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, Merck acquired Pandion Therapeutics, Inc. (Pandion), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases. Pandion is advancing a pipeline of precision immune modulators targeting critical immune control nodes. Total consideration paid of $<ix:nonFraction unitRef="usd" contextRef="i043e841d659649cfaea941c020c82892_D20210401-20210430" decimals="-8" name="us-gaap:AssetAcquisitionConsiderationTransferred" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfNTAzOA_5b186f78-fb70-42eb-b24a-080a82f6c4f4">1.9</ix:nonFraction> billion included $<ix:nonFraction unitRef="usd" contextRef="i043e841d659649cfaea941c020c82892_D20210401-20210430" decimals="-6" name="us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfNTA1MA_c5760d8a-81d7-4662-9bcc-51e6bc66b4b9">147</ix:nonFraction>&#160;million of costs primarily comprised of share-based compensation payments to settle equity awards. The transaction was accounted for as an acquisition of an asset. Merck recorded net assets of $<ix:nonFraction unitRef="usd" contextRef="idacd23b3b6ae489b89729f7dc49d6220_I20210430" decimals="-6" name="mrk:AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfNTI1MA_14f00d22-ed5d-4bf7-9630-a2c6a83a2416">156</ix:nonFraction> million (primarily cash) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses of $<ix:nonFraction unitRef="usd" contextRef="idcccabd6edb749bf9c5977174f86658e_D20210101-20210930" decimals="-8" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfNTMxMQ_b80692b8-3db0-44d0-93cd-1174c24ab11d">1.7</ix:nonFraction> billion in the first nine months of 2021 related to the transaction. There are no future contingent payments associated with the acquisition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, Merck entered into an exclusive license and research collaboration agreement with Artiva Biotherapeutics, Inc. (Artiva) to discover, develop and manufacture CAR-NK cells that target certain solid tumors using Artiva&#8217;s proprietary platform. Merck and Artiva agreed to engage in up to <ix:nonFraction unitRef="research_program" contextRef="ie491bc3ce3bf4fcab2d52425ea46de0a_D20210101-20210131" decimals="0" name="mrk:CollaborativeArrangementNumberOfResearchPrograms" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfMTY0OTI2NzQ3NzgyNA_dcfe3321-8c42-4fee-9eaa-8cf725290fca">three</ix:nonFraction> different research programs, each covering a collaboration target. Merck has sole responsibility for all development and commercialization activities (including regulatory filing and approval). Under the terms of the agreement, Merck made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ie491bc3ce3bf4fcab2d52425ea46de0a_D20210101-20210131" decimals="-6" name="mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfNjAzMg_52dd084e-05ff-407b-9a7e-f9f4779636a4">30</ix:nonFraction>&#160;million, which was included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in the first nine months of 2021, for license and other rights for the first two collaboration targets and agreed to make another upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ie491bc3ce3bf4fcab2d52425ea46de0a_D20210101-20210131" decimals="-6" name="mrk:UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfNjIzOQ_51239237-f1ac-496a-89da-bee29e2baebb">15</ix:nonFraction>&#160;million for license and other rights for the third collaboration target when it is selected by Merck and accepted by Artiva. In addition, Artiva is eligible to receive future contingent milestone payments (which span all <ix:nonFraction unitRef="collaboration_target" contextRef="ie491bc3ce3bf4fcab2d52425ea46de0a_D20210101-20210131" decimals="0" name="mrk:CollaborativeArrangementNumberOfCollaborationTargets" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfMTY0OTI2NzQ3NzgxNA_b055e88f-49c3-41a4-8ab4-97db1714b9ba">three</ix:nonFraction> collaboration targets), aggregating up to $<ix:nonFraction unitRef="usd" contextRef="ic3a1ed78727c4d759751ea2f43de095d_D20210101-20210131" decimals="-5" name="mrk:ContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfNjUwNA_c0cbb74c-aa35-4410-b4f0-de9d722ca489">217.5</ix:nonFraction>&#160;million in developmental milestones, $<ix:nonFraction unitRef="usd" contextRef="i4629f08bbd144fe582e499da3dad8b06_D20210101-20210131" decimals="-6" name="mrk:ContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfNjUzNg_b831f6cd-e4f8-4c5f-b611-acd84938f493">570</ix:nonFraction>&#160;million in regulatory milestones, and $<ix:nonFraction unitRef="usd" contextRef="i7bce0692a5b4447e9a52850be6e554f4_D20210101-20210131" decimals="-7" name="mrk:ContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfNjU2OQ_b41f3edf-96ae-4c93-8623-8fcacf5c49cc">1.05</ix:nonFraction>&#160;billion in sales-based milestones. The agreement also provides for Merck to pay tiered royalties ranging from <ix:nonFraction unitRef="number" contextRef="i6dcf6134f32d478dbe1941c9aea8779c_D20210101-20210131" decimals="2" name="mrk:RoyaltyRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfNjY3NA_c881b7cf-8fe5-4dfe-a360-61ad7198ce41">7</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i2347cdd094484cb5b876055e05600443_D20210101-20210131" decimals="2" name="mrk:RoyaltyRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfNjY4MA_4b828a81-12a9-47f3-bb3c-c8c2b13371b8">14</ix:nonFraction>% on future sales.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 9 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><ix:continuation id="i30540eb9465448ca85585b6575793e73"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of Merck&#8217;s 2020 acquisition of OncoImmune, Merck obtained MK-7110, a therapeutic candidate that was being evaluated for the treatment of patients hospitalized with COVID-19. In 2021, Merck received feedback from the U.S. Food and Drug Administration (FDA) that additional data would be needed to support a potential Emergency Use Authorization application and therefore the Company did not expect MK-7110 would become available until the first half of 2022. Given this timeline and the technical, clinical and regulatory uncertainties, the availability of a number of medicines for patients hospitalized with COVID-19, and the need to concentrate Merck&#8217;s resources on accelerating the development and manufacture of the most viable therapeutics and vaccines, Merck decided to discontinue development of MK-7110 for the treatment of COVID-19. Due to the discontinuation, the Company recorded charges of $<ix:nonFraction unitRef="usd" contextRef="ie42db3b5c5b74f21afa507c6dc74632e_D20210101-20210930" decimals="-6" name="mrk:ChargesRelatedToProgramDiscontinuation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfNzYxNw_e5d668ab-345e-4a87-96a3-4f61893516d6">207</ix:nonFraction>&#160;million in the first nine months of 2021, which are reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and relate to fixed assets and materials written off, as well as the recognition of liabilities for purchase commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></ix:continuation></div><div id="i6b4e4280ad2344a5bc7fdcaa77e417f0_43"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfMTE3NTU_41272532-f8a1-4197-b1ed-45f38cda2a9c" continuedAt="iff04da69bd7c4e11a5d93a4d0b76d9dd" escape="true">Collaborative Arrangements</ix:nonNumeric></span></div><ix:continuation id="iff04da69bd7c4e11a5d93a4d0b76d9dd" continuedAt="ib1d891ced4cb4700ba81f6480d3c6c87"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. Both parties in these arrangements are active participants and exposed to significant risks and rewards dependent on the commercial success of the activities of the collaboration. Merck&#8217;s more significant collaborative arrangements are discussed below. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AstraZeneca</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, Merck and AstraZeneca PLC (AstraZeneca) entered into a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca&#8217;s Lynparza (olaparib) for multiple cancer types. Independently, Merck and AstraZeneca will develop and commercialize Lynparza in combinations with their respective PD-1 and PD-L1 medicines, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Imfinzi. The companies are also jointly developing and commercializing AstraZeneca&#8217;s Koselugo (selumetinib) for multiple indications. Under the terms of the agreement, AstraZeneca and Merck will share the development and commercialization costs for Lynparza and Koselugo&#160;monotherapy and non-PD-L1/PD-1 combination therapy opportunities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Profits from Lynparza and Koselugo&#160;product sales generated through monotherapies or combination therapies are shared equally. AstraZeneca is the principal on Lynparza and Koselugo sales transactions. Merck records its share of Lynparza and Koselugo product sales, net of cost of sales and commercialization costs, as alliance revenue and its share of development costs associated with the collaboration as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses. Reimbursements received from AstraZeneca for research and development expenses are recognized as reductions to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the agreement, Merck made an upfront payment to AstraZeneca and also made payments over a multi-year period for certain license options. In addition, the agreement provides for contingent payments from Merck to AstraZeneca related to the successful achievement of sales-based and regulatory milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2022, Merck determined it was probable that sales of Lynparza in the future would trigger a $<ix:nonFraction unitRef="usd" contextRef="i21912ec93da743c79ae9ba5d3f089bd9_D20220101-20220331" decimals="-6" name="mrk:ProbableContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfMjE3Mw_85096ebb-9fc8-4933-bc84-733637243a7a">600</ix:nonFraction>&#160;million sales-based milestone payment from Merck to AstraZeneca. Accordingly, Merck recorded a $<ix:nonFraction unitRef="usd" contextRef="ic8f4acef9645432a86030dbdecb44682_I20220331" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfMjI2Mw_de2dcef3-7d0d-40ce-bd93-52626b071d5a">600</ix:nonFraction>&#160;million liability and a corresponding increase to the intangible asset related to Lynparza. Merck also recognized $<ix:nonFraction unitRef="usd" contextRef="iaefdc2743e3b4f459d997a63fcf5409f_D20220101-20220331" decimals="-6" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfMjM3Mg_06e2ce8c-ea91-41a1-98ce-c30fbde803d7">250</ix:nonFraction>&#160;million of cumulative amortization catch-up expense related to the recognition of this milestone in the first quarter of 2022. In the first nine months of 2022, Merck made a sales-based milestone payment to AstraZeneca (which had been previously accrued for) of $<ix:nonFraction unitRef="usd" contextRef="i3afa0051e006445592494b5f1781aead_D20220101-20220930" decimals="-6" name="mrk:MilestonePaymentsSalesBased" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfMjYyNw_955e36a7-b28d-45bc-81ec-e0bc60328e21">400</ix:nonFraction>&#160;million. As of September&#160;30, 2022, sales-based milestone payments accrued but not yet paid totaled $<ix:nonFraction unitRef="usd" contextRef="i4bf3affc3e9f436d8fceb9cc9572407c_I20220930" decimals="-6" name="mrk:MilestonePaymentsAccruedSalesBased" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfMjcwNQ_6977d33f-3371-4d0f-8445-e44b8cc135e2">600</ix:nonFraction>&#160;million. Potential future sales-based milestone payments of $<ix:nonFraction unitRef="usd" contextRef="i1907a491b1ab4494bcb5711a999a46d8_I20220930" decimals="-8" name="mrk:PotentialFutureMilestonePaymentsSalesBased" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfMjc2MA_4e8948dd-dc38-48b0-b8eb-32ff7041632e">2.1</ix:nonFraction> billion have not yet been accrued as they are not deemed by the Company to be probable at this time. In the first nine months of 2022, Lynparza received regulatory approvals triggering capitalized milestone payments of $<ix:nonFraction unitRef="usd" contextRef="i3afa0051e006445592494b5f1781aead_D20220101-20220930" decimals="-6" name="mrk:MilestonePaymentsMadetoCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfMjk3NA_2ef9d228-ad24-4feb-be82-8a07b5bcc1bd">250</ix:nonFraction>&#160;million from Merck to AstraZeneca. Potential future regulatory milestone payments of $<ix:nonFraction unitRef="usd" contextRef="i1907a491b1ab4494bcb5711a999a46d8_I20220930" decimals="-8" name="mrk:PotentialFutureMilestonePaymentsRegulatory" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfMzA1NA_e6ab3e85-c0e0-4bac-8f0f-abbc39f85f8d">1.2</ix:nonFraction> billion remain under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible asset balance related to Lynparza (which includes capitalized sales-based and regulatory milestone payments) was $<ix:nonFraction unitRef="usd" contextRef="ia10ed00bf75d4fe2a88f22919b63e42d_I20220930" decimals="-8" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfMzIxMw_abb862df-ece8-4687-8b2c-e243f97bf6a2">1.5</ix:nonFraction> billion at September&#160;30, 2022 and is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amount is being amortized over its estimated useful life through 2028 as supported by projected future cash flows, subject to impairment testing.</span></div></ix:continuation><div style="margin-top:6pt;text-indent:45pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 10 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="ib1d891ced4cb4700ba81f6480d3c6c87" continuedAt="id5452304903a4d229dc2b0b43e2399ef"><ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfMTE3NjI_c61eabb4-b365-4e24-a69c-9b70813ae48a" continuedAt="if46b8f9a62224f5f9f4b2612f24222e1" escape="true"><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:63.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.535%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.123%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.713%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if40bc016be9844ffacc5e3a61649fd8f_D20220701-20220930" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfMi0xLTEtMS05NDQxNA_dcf142c4-a181-4b4a-b082-4ae6b3fa8a15">284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05a4a8f891ea43e9b071e6f036172468_D20210701-20210930" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfMi0zLTEtMS05NDQxNA_5628a980-8a88-4a84-812a-a66f156f06fa">246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d0093add0344d4bb0ff3793ac7752e2_D20220101-20220930" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfMi01LTEtMS05NDQxNA_b3778277-dd99-4102-b64a-c52c232d819c">825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2c1ce6973c439cb0304ebd132fa0fd_D20210101-20210930" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfMi03LTEtMS05NDQxNA_b7e6fb29-b167-42af-a232-3d0fe426f398">721</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Koselugo</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30533c21f6874363adc26d834802514f_D20220701-20220930" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfMy0xLTEtMS05NDQxNA_85c10d10-7c01-4732-804e-176037015090">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a6d8edecf524875b4d7cadcf837faa0_D20210701-20210930" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfMy0zLTEtMS05NDQxNA_4b803af9-90ed-43dd-8f32-92cccab4f107">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e730ddeb7ba4b2ba74c9e90f63cce43_D20220101-20220930" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfMy01LTEtMS05NDQxNA_14bbe4f9-5f5b-4b9c-a0fc-18eb959720de">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4589c546fa744a2c966fbe3b84783265_D20210101-20210930" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfMy03LTEtMS05NDQxNA_fac063a3-0b89-4aeb-9c0f-93a8e6f12b68">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total alliance revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia817e4175b9a4610b08f54e5e830ee23_D20220701-20220930" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfNC0xLTEtMS05NDQxNA_6a83224a-b5e5-476c-a6aa-cb831d9cb8cb">294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bbde3b507d74bd89695b20384edb9a3_D20210701-20210930" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfNC0zLTEtMS05NDQxNA_3b52d313-6a91-420c-9205-4984fc9ae7dc">252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if25ae27f28a94974802d948c498415fd_D20220101-20220930" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfNC01LTEtMS05NDQxNA_04980c34-6d0a-4536-812e-c732454f007c">868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i398ea6779f6a4327a6a7e64c91583bf4_D20210101-20210930" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfNC03LTEtMS05NDQxNA_a8c683e6-50b8-427e-a04b-15ef39378084">741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i039199e857634ca4ba7aafc3dbc79228_D20220701-20220930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfNi0xLTEtMS05NDQxNA_dd7a7e8b-d879-41aa-bee7-3d907f87c4e1">64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5897251afffb44088ec89b19d1bdc84a_D20210701-20210930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfNi0zLTEtMS05NDQxNA_80be44dc-5041-4be2-9496-1766c2dc0356">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da90caa29d94f0a8da61f2d1f19ae81_D20220101-20220930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfNi01LTEtMS05NDQxNA_aaba9502-df1f-4a3e-b017-579a0fbf7667">425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1589a04249264c3daa20424018a01187_D20210101-20210930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfNi03LTEtMS05NDQxNA_f2448ccb-aa2e-4694-9e31-4a030a81d05c">125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5050d3fe45a40b8a7b4a69b944c22a9_D20220701-20220930" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfNy0xLTEtMS05NDQxNA_c2da9ea0-bf07-46e3-96f1-0e93f6435d6b">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i587510372b604b139812c4dd9779e273_D20210701-20210930" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfNy0zLTEtMS05NDQxNA_7cadfaad-8b33-4185-aba5-62ea36183c8a">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb2de2469e144d4893a6dcc97d4e3c99_D20220101-20220930" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfNy01LTEtMS05NDQxNA_30b36ff8-75c3-4f49-9611-b9b2423cc54a">135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ed206b7f8a24c26b903ee925c1c1961_D20210101-20210930" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfNy03LTEtMS05NDQxNA_9e012967-af13-4aa5-9a75-1e9fd1e59403">127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ee4ac5f1b264ca69d35cbb50d96ea05_D20220701-20220930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfOC0xLTEtMS05NDQxNA_82dde18b-be21-4e88-bd63-af629ff46048">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i138101fbf41c4f9dafc07d2a4e620fca_D20210701-20210930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfOC0zLTEtMS05NDQxNA_1456bfc3-a022-47dd-94fa-adcbd6abc4f1">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i613c1d9fab0f431fade5cfdf29823c97_D20220101-20220930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfOC01LTEtMS05NDQxNA_a983f925-6992-49ee-90a0-32583682f71d">79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccffbf6b9b604242a9e75a41475ad0f0_D20210101-20210930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfOC03LTEtMS05NDQxNA_4e4d46cf-4941-49a3-8fd5-29ef8b54be8c">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from AstraZeneca included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id481255ba6384775831f82ad3ae7549e_I20220930" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfMTEtNS0xLTEtOTQ0MTQ_05b1d746-585e-429d-86e2-8c97eb550028">290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55d4ae3b325406e91eef2de4b2e7b99_I20211231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfMTEtNy0xLTEtOTQ0MTQ_040f408f-73c9-45af-9c7d-4fa7725e9021">271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Trade accounts payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80cb9af76954141b50f85baffdadb69_I20220930" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfMTItNS0xLTEtOTQ0MTQ_2671b1ef-3d26-4cc4-ad5f-b46de55bdf42">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbdca7f63bbb466b9c0edf3825db2b0e_I20211231" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfMTItNy0xLTEtOTQ0MTQ_4e001997-7c8c-4666-a138-ffff6a333ed7">415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b48257a883b4a79aca85a1019943388_I20220930" decimals="-6" name="us-gaap:LiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfMTMtNS0xLTEtOTQ0MTQ_ad6acfcc-97b6-48b2-b037-9af6e0342b3e">600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf53d38799a3490799f7eac25c464fe4_I20211231" decimals="-6" name="us-gaap:LiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfMTMtNy0xLTEtOTQ0MTQ_efaa794c-090e-4e72-8aa7-dba9913fa66f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments. Amount in the first nine months of 2022 includes $<ix:nonFraction unitRef="usd" contextRef="i9da90caa29d94f0a8da61f2d1f19ae81_D20220101-20220930" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfMzYwNg_dc66ee21-f929-41fc-96b8-b08af4df2a4c">250</ix:nonFraction>&#160;million of cumulative amortization catch-up expense as noted above.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued milestone payments.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Eisai</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, Merck and Eisai Co., Ltd. (Eisai) announced a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima (lenvatinib), an orally available tyrosine kinase inhibitor discovered by Eisai. Under the agreement, Merck and Eisai will develop and commercialize Lenvima jointly, both as monotherapy and in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Eisai records Lenvima product sales globally (Eisai is the principal on Lenvima sales transactions) and Merck and Eisai share applicable profits equally. Merck records its share of Lenvima product sales, net of cost of sales and commercialization costs, as alliance revenue. Expenses incurred during co-development are shared by the two companies in accordance with the collaboration agreement and reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expenses. Certain expenses incurred solely by Merck or Eisai are not shareable under the collaboration agreement, including costs incurred in excess of agreed upon caps and costs related to certain combination studies of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Lenvima.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the agreement, Merck made an upfront payment to Eisai and also made payments over a multi-year period for certain option rights (of which the final $<ix:nonFraction unitRef="usd" contextRef="ib322c590099749b29efd1012a6436a56_D20210301-20210331" decimals="-6" name="mrk:Licenseoptionpaymentrelatedtocollaborativearrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfNDkxOA_a423e885-c303-4e64-b7b2-3f4e81c432d6">125</ix:nonFraction> million option payment was made in March 2021). In addition, the agreement provides for contingent payments from Merck to Eisai related to the successful achievement of sales-based and regulatory milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first nine months of 2022, Merck made sales-based milestone payments to Eisai (which had been previously accrued for) aggregating $<ix:nonFraction unitRef="usd" contextRef="i8d3c8bd139d14d1c9571445aad6c4723_D20220101-20220930" decimals="-6" name="mrk:MilestonePaymentsSalesBased" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfNTI1Ng_87b5c2a5-c142-41cc-8bc0-ca3a382737b4">600</ix:nonFraction> million. Potential future sales-based milestone payments of $<ix:nonFraction unitRef="usd" contextRef="ieab0ff535a8a4357924a2ea4759b4813_I20220930" decimals="-8" name="mrk:PotentialFutureMilestonePaymentsSalesBased" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfNTMxMQ_b9fa220a-f8ad-4435-9143-7f95cb60d693">2.6</ix:nonFraction> billion have not yet been accrued as they are not deemed by the Company to be probable at this time. In the first nine months of 2022, Lenvima received regulatory approvals triggering capitalized milestone payments of $<ix:nonFraction unitRef="usd" contextRef="i8d3c8bd139d14d1c9571445aad6c4723_D20220101-20220930" decimals="-6" name="mrk:MilestonePaymentsMadetoCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfNTUyNA_251a1499-95b0-4b2c-bb70-8d5b7107f2c5">50</ix:nonFraction>&#160;million from Merck to Eisai. There are no regulatory milestone payments remaining under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible asset balance related to Lenvima (which includes capitalized sales-based and regulatory milestone payments) was $<ix:nonFraction unitRef="usd" contextRef="ie403795b3c984fa5adccd65ae3284b98_I20220930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfNTg4NQ_fc674bde-1a67-4e98-b324-a94a8d36c455">867</ix:nonFraction> million at September&#160;30, 2022 and is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amount is being amortized over its estimated useful life through 2026 as supported by projected future cash flows, subject to impairment testing.</span></div></ix:continuation><div style="margin-top:6pt;text-indent:45pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 11 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="id5452304903a4d229dc2b0b43e2399ef" continuedAt="ida0a1383dfec4cadb0623dce6b3e8a72"><ix:continuation id="if46b8f9a62224f5f9f4b2612f24222e1" continuedAt="i0ab0c36b36d944b7a52fc15c4c274c7b"><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.678%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i144701b5635f49b6a87e388b5a112a0c_D20220701-20220930" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjlhODYxNDk5NGE5ZjQzOTI5YTY3ZmQ1NjAzMmU0ZGE5L3RhYmxlcmFuZ2U6OWE4NjE0OTk0YTlmNDM5MjlhNjdmZDU2MDMyZTRkYTlfMi0xLTEtMS05NDQxNA_06883aba-0062-4809-afbb-91be12df0fa8">202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa0c7c07509a49b2bba97e430289c5a0_D20210701-20210930" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjlhODYxNDk5NGE5ZjQzOTI5YTY3ZmQ1NjAzMmU0ZGE5L3RhYmxlcmFuZ2U6OWE4NjE0OTk0YTlmNDM5MjlhNjdmZDU2MDMyZTRkYTlfMi0zLTEtMS05NDQxNA_dde316ac-71db-48bf-b510-f2475bf03fb9">188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8782c7cfeac4f45be3816e9c23d40e2_D20220101-20220930" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjlhODYxNDk5NGE5ZjQzOTI5YTY3ZmQ1NjAzMmU0ZGE5L3RhYmxlcmFuZ2U6OWE4NjE0OTk0YTlmNDM5MjlhNjdmZDU2MDMyZTRkYTlfMi01LTEtMS05NDQxNA_b58d7f64-a2e6-402d-990f-c01e4af13d38">660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i981c732452864a0a89b0bdd4ea1ca966_D20210101-20210930" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjlhODYxNDk5NGE5ZjQzOTI5YTY3ZmQ1NjAzMmU0ZGE5L3RhYmxlcmFuZ2U6OWE4NjE0OTk0YTlmNDM5MjlhNjdmZDU2MDMyZTRkYTlfMi03LTEtMS05NDQxNA_76b169d5-e158-4a5c-a646-0f0e8e04d7ba">498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e9c637f23f8498097ccb65785974c6e_D20220701-20220930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjlhODYxNDk5NGE5ZjQzOTI5YTY3ZmQ1NjAzMmU0ZGE5L3RhYmxlcmFuZ2U6OWE4NjE0OTk0YTlmNDM5MjlhNjdmZDU2MDMyZTRkYTlfNC0xLTEtMS05NDQxNA_b32f5b65-824b-4625-b12d-4a30430e3a5a">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9a88c5549694dec907e06fa69cae667_D20210701-20210930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjlhODYxNDk5NGE5ZjQzOTI5YTY3ZmQ1NjAzMmU0ZGE5L3RhYmxlcmFuZ2U6OWE4NjE0OTk0YTlmNDM5MjlhNjdmZDU2MDMyZTRkYTlfNC0zLTEtMS05NDQxNA_8cc185bd-96e6-495e-b9da-f610b3bbcd4b">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7893a61b773e42eaa4750e61ccc3e264_D20220101-20220930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjlhODYxNDk5NGE5ZjQzOTI5YTY3ZmQ1NjAzMmU0ZGE5L3RhYmxlcmFuZ2U6OWE4NjE0OTk0YTlmNDM5MjlhNjdmZDU2MDMyZTRkYTlfNC01LTEtMS05NDQxNA_f0d0aa5a-4e09-4081-a3d4-5c659720bbc3">159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42218d013fb34f1f8c1048bf798e322e_D20210101-20210930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjlhODYxNDk5NGE5ZjQzOTI5YTY3ZmQ1NjAzMmU0ZGE5L3RhYmxlcmFuZ2U6OWE4NjE0OTk0YTlmNDM5MjlhNjdmZDU2MDMyZTRkYTlfNC03LTEtMS05NDQxNA_ab5ed1f0-1edd-492a-ab22-ebd161eaee5b">143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic860b4ba2f6b47eb8e120d99349e2f88_D20220701-20220930" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjlhODYxNDk5NGE5ZjQzOTI5YTY3ZmQ1NjAzMmU0ZGE5L3RhYmxlcmFuZ2U6OWE4NjE0OTk0YTlmNDM5MjlhNjdmZDU2MDMyZTRkYTlfNS0xLTEtMS05NDQxNA_f0fe3e1f-eff0-42cb-8a86-8657d07fdff4">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife92a3473bc4415aaff470cb4cf0a01c_D20210701-20210930" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjlhODYxNDk5NGE5ZjQzOTI5YTY3ZmQ1NjAzMmU0ZGE5L3RhYmxlcmFuZ2U6OWE4NjE0OTk0YTlmNDM5MjlhNjdmZDU2MDMyZTRkYTlfNS0zLTEtMS05NDQxNA_13971ecb-ab92-4a47-855d-4d3496060031">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a3be947f65b41ad82a9e53d652dd2b0_D20220101-20220930" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjlhODYxNDk5NGE5ZjQzOTI5YTY3ZmQ1NjAzMmU0ZGE5L3RhYmxlcmFuZ2U6OWE4NjE0OTk0YTlmNDM5MjlhNjdmZDU2MDMyZTRkYTlfNS01LTEtMS05NDQxNA_ffcb2617-3fbb-4426-81f6-97ccdfffedba">115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4d6dda5b9e4f48ac02ead988fe068f_D20210101-20210930" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjlhODYxNDk5NGE5ZjQzOTI5YTY3ZmQ1NjAzMmU0ZGE5L3RhYmxlcmFuZ2U6OWE4NjE0OTk0YTlmNDM5MjlhNjdmZDU2MDMyZTRkYTlfNS03LTEtMS05NDQxNA_75860e94-57c1-4c79-a23f-ea0d6b3914b0">88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie590418643204f47816759f2195d86d2_D20220701-20220930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjlhODYxNDk5NGE5ZjQzOTI5YTY3ZmQ1NjAzMmU0ZGE5L3RhYmxlcmFuZ2U6OWE4NjE0OTk0YTlmNDM5MjlhNjdmZDU2MDMyZTRkYTlfNi0xLTEtMS05NDQxNA_b0cc3447-75f0-4f94-ae4a-41bc22fa183b">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i366906fcc328447985b2dd9207bbfdb0_D20210701-20210930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjlhODYxNDk5NGE5ZjQzOTI5YTY3ZmQ1NjAzMmU0ZGE5L3RhYmxlcmFuZ2U6OWE4NjE0OTk0YTlmNDM5MjlhNjdmZDU2MDMyZTRkYTlfNi0zLTEtMS05NDQxNA_3fdcdc3b-2eb4-49d8-a33d-2c8b50824779">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb33f80f44364328b49c32741943ae6f_D20220101-20220930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjlhODYxNDk5NGE5ZjQzOTI5YTY3ZmQ1NjAzMmU0ZGE5L3RhYmxlcmFuZ2U6OWE4NjE0OTk0YTlmNDM5MjlhNjdmZDU2MDMyZTRkYTlfNi01LTEtMS05NDQxNA_36dc4ddc-f8f7-45d1-81ff-f6d66d9d25bc">128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67dfa7f3e534416abfb0f9c1ea1869c5_D20210101-20210930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjlhODYxNDk5NGE5ZjQzOTI5YTY3ZmQ1NjAzMmU0ZGE5L3RhYmxlcmFuZ2U6OWE4NjE0OTk0YTlmNDM5MjlhNjdmZDU2MDMyZTRkYTlfNi03LTEtMS05NDQxNA_7142ffa9-5b3a-417c-99e9-86906034d574">165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from Eisai included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ae012bcf60c4cd692cca1d41ea9a0e7_I20220930" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjlhODYxNDk5NGE5ZjQzOTI5YTY3ZmQ1NjAzMmU0ZGE5L3RhYmxlcmFuZ2U6OWE4NjE0OTk0YTlmNDM5MjlhNjdmZDU2MDMyZTRkYTlfOS01LTEtMS05NDQxNA_3c2f2659-5739-4906-8767-af9480ea530d">202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7be328837202423290bff8758c427630_I20211231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjlhODYxNDk5NGE5ZjQzOTI5YTY3ZmQ1NjAzMmU0ZGE5L3RhYmxlcmFuZ2U6OWE4NjE0OTk0YTlmNDM5MjlhNjdmZDU2MDMyZTRkYTlfOS03LTEtMS05NDQxNA_7cd9658a-f5c2-46fc-a9ae-922273cb9e59">200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Eisai included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ac2724c045a44b1815128ce8f6b20f4_I20220930" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjlhODYxNDk5NGE5ZjQzOTI5YTY3ZmQ1NjAzMmU0ZGE5L3RhYmxlcmFuZ2U6OWE4NjE0OTk0YTlmNDM5MjlhNjdmZDU2MDMyZTRkYTlfMTAtNS0xLTEtOTQ0MTQ_aff3b9c7-b5bb-4643-b934-3eca40968b44">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i683cd7e98cb547bfb87dc770c0d74e58_I20211231" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjlhODYxNDk5NGE5ZjQzOTI5YTY3ZmQ1NjAzMmU0ZGE5L3RhYmxlcmFuZ2U6OWE4NjE0OTk0YTlmNDM5MjlhNjdmZDU2MDMyZTRkYTlfMTAtNy0xLTEtOTQ0MTQ_385778d5-cf44-4ef1-a0b8-988a84319d8e">625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments.</span></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Amount as of December 31, 2021 includes accrued milestone payments.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bayer AG</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators including Bayer&#8217;s Adempas (riociguat). The two companies have implemented a joint development and commercialization strategy. The collaboration also includes development of Bayer&#8217;s Verquvo (vericiguat), which was approved in the U.S. in January 2021, in Japan in June 2021 and in the EU in July 2021. Under the agreement, Bayer commercializes Adempas in the Americas, while Merck commercializes in the rest of the world. For Verquvo, Merck commercializes in the U.S. and Bayer commercializes in the rest of the world. Both companies share in development costs and profits on sales. Merck records sales of Adempas and Verquvo in its marketing territories, as well as alliance revenue. Alliance revenue represents Merck&#8217;s share of profits from sales of Adempas and Verquvo in Bayer&#8217;s marketing territories, which are product sales net of cost of sales and commercialization costs. Cost of sales includes Bayer&#8217;s share of profits from sales in Merck&#8217;s marketing territories. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the agreement provided for contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones. In January 2022, Merck made the final $<ix:nonFraction unitRef="usd" contextRef="iaf806d58f30c4be4bca6c3be1abe66c9_D20220101-20220131" decimals="-6" name="mrk:MilestonePaymentsSalesBased" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfNzYwNw_59a107f5-1aae-463e-98cb-7b16edd38ea3">400</ix:nonFraction> million sales-based milestone payment under this collaboration to Bayer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible asset balances related to Adempas (which includes the acquired intangible asset balance, as well as capitalized sales-based milestone payments attributed to Adempas) and Verquvo (which reflects the portion of the final sales-based milestone payment that was attributed to Verquvo) were $<ix:nonFraction unitRef="usd" contextRef="if15ad2dc23594b05a094920b78cb9281_I20220930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfNzk3Ng_45c85203-d967-4622-bc25-05b7ef935507">597</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifbf925ccbf934ad1bbd6105bd116f495_I20220930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfNzk4Mw_2594e6f3-cf67-4ae4-bf4d-e91d13009a73">53</ix:nonFraction> million, respectively, at September&#160;30, 2022 and are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The assets are being amortized over their estimated useful lives (through 2027 for Adempas and through 2031 for Verquvo) as supported by projected future cash flows, subject to impairment testing. </span></div><ix:continuation id="i0ab0c36b36d944b7a52fc15c4c274c7b" continuedAt="i40a949dc351e460a917a759bbd5deeeb"><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.947%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Adempas/Verquvo</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia903414baf944a4c85e8b48c1ec54218_D20220701-20220930" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfMi0xLTEtMS05NDQxNA_f8a9d9eb-cc71-4977-98fc-35d2ae4afa32">88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if192c98d9a7e4b0c881c0a5da15bd44c_D20210701-20210930" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfMi0zLTEtMS05NDQxNA_83299deb-26db-430d-868e-4ca53bd331ae">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i061a8128f7d54a66b9329be138104804_D20220101-20220930" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfMi01LTEtMS05NDQxNA_32e19cce-db0e-4757-9954-4f84d8e2c60f">258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if960063333f14939a78490bbd9873025_D20210101-20210930" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfMi03LTEtMS05NDQxNA_d32cc261-4064-481b-a880-b4669c625bf3">248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales of Adempas recorded by Merck</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35d4d64303ab483e97f9f6829d296385_D20220701-20220930" decimals="-6" name="mrk:CollaborativeArrangementSalesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfMy0xLTEtMS05NDQxNA_762ae048-8259-4f59-ad01-db8247396a12">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba08ab1ba316433da1eb64e967da1f14_D20210701-20210930" decimals="-6" name="mrk:CollaborativeArrangementSalesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfMy0zLTEtMS05NDQxNA_f6c340d0-7d2e-4c88-9a58-7c6cfcbf9277">59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81c4bab0b60647bba82d1e4ad7faa825_D20220101-20220930" decimals="-6" name="mrk:CollaborativeArrangementSalesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfMy01LTEtMS05NDQxNA_725e1f90-2e68-4342-97dc-1f91611d7f0e">181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c06ca35260641c481956f20cb681bb1_D20210101-20210930" decimals="-6" name="mrk:CollaborativeArrangementSalesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfMy03LTEtMS05NDQxNA_94e7eab8-6a09-4991-9eeb-6acb3ca48c9d">188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales of Verquvo recorded by Merck</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i519e6b6f4af34d2e9581f65447c1311f_D20220701-20220930" decimals="-6" name="mrk:CollaborativeArrangementSalesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfNC0xLTEtMS05NDQxNA_0f327e0c-40be-407d-9dac-6373e9e96f05">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ddb0dd7fa034178a6eb152be9603780_D20210701-20210930" decimals="-6" name="mrk:CollaborativeArrangementSalesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfNC0zLTEtMS05NDQxNA_a651ecda-adc3-4dbb-a132-471fc3befbfe">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9999b3f45ca41a4a2542f94612afb3d_D20220101-20220930" decimals="-6" name="mrk:CollaborativeArrangementSalesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfNC01LTEtMS05NDQxNA_1c317170-811e-415c-8d9c-f5d230aa0e74">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i212e8f35bf4a468cb7a86750d3383cf4_D20210101-20210930" decimals="-6" name="mrk:CollaborativeArrangementSalesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfNC03LTEtMS05NDQxNA_9bd17d7b-2e07-4e28-a120-eda7b03df9b6">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia903414baf944a4c85e8b48c1ec54218_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfNS0xLTEtMS05NDQxNA_dc582f3a-6b01-49eb-a512-8bc9829b1680">151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if192c98d9a7e4b0c881c0a5da15bd44c_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfNS0zLTEtMS05NDQxNA_e15bfc6e-a75e-40dd-bcf0-4499bd0105db">161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i061a8128f7d54a66b9329be138104804_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfNS01LTEtMS05NDQxNA_97018b61-fca1-4bc3-823c-261b633e35c8">454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if960063333f14939a78490bbd9873025_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfNS03LTEtMS05NDQxNA_ff2eacd6-1b0d-46e6-a03d-70a48ee3b8da">439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90dd98ecefa24e27863c524456240e09_D20220701-20220930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfNy0xLTEtMS05NDQxNA_fa948360-6465-4ee2-9ea2-3b163281971f">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i186331a72ef04ac9b7b6241c63ffaf24_D20210701-20210930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfNy0zLTEtMS05NDQxNA_11c78758-c656-48da-9f07-8e0c11147bc5">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedf5c07624db4e01a7cf689fdcff82a5_D20220101-20220930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfNy01LTEtMS05NDQxNA_71896952-53ed-4a62-87aa-897d64939e1d">158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27f892355464487d8539768fc6061eb5_D20210101-20210930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfNy03LTEtMS05NDQxNA_1a641f99-8f7b-49ad-913f-1791cdc30aa6">328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib78cfd0dce084d31981552de8a046a04_D20220701-20220930" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfOC0xLTEtMS05NDQxNA_99cf64d4-fd0e-44de-924c-52478e20012b">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30d1694e33a8460db578cfe950cf06d2_D20210701-20210930" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfOC0zLTEtMS05NDQxNA_75737937-6521-44cb-937f-e2b614cde264">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56264076164d4059af8de0e8936319cc_D20220101-20220930" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfOC01LTEtMS05NDQxNA_e92fbf0b-1d31-4be8-be0d-9e05c3d77212">107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9f07ed930f14354adbe45102b20b9c4_D20210101-20210930" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfOC03LTEtMS05NDQxNA_aa0bfc6b-2055-4235-bdc9-77448ece9930">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bdc458f37d94074bbb7340625918b7c_D20220701-20220930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfOS0xLTEtMS05NDQxNA_e7a8fc82-8472-4386-910c-873ba73c6a65">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i323143b5b858466db34d0d2c5c944f28_D20210701-20210930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfOS0zLTEtMS05NDQxNA_ba149d1c-cbe9-4fbc-92bf-b3646a3531f4">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia91b5a3c675c4ef88e4f8f57394a5380_D20220101-20220930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfOS01LTEtMS05NDQxNA_c03b514a-94db-4ff6-909c-8d2b3155c50b">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5053a9df2c864fa090b207df72bef585_D20210101-20210930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfOS03LTEtMS05NDQxNA_1a3bece2-c892-4d29-87e5-df1b1b06d81c">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from Bayer included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3525e1187e8a48de986cf4be04ae95f4_I20220930" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfMTEtNS0xLTEtOTQ0MTQ_045387b3-0a60-44f3-9cd4-1f0fe2035aea">144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7be680bb4e346ee9310c38a476bb72e_I20211231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfMTEtNy0xLTEtOTQ0MTQ_124f97cb-c76a-4103-91df-727a6e17ed9e">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Bayer included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b09de6ba674b5b96551d497a48a9b5_I20220930" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfMTItNS0xLTEtOTQ0MTQ_c095d008-1524-493e-ba30-438425c0762d">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0771df2198d740108535caf3238d43d7_I20211231" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfMTItNy0xLTEtOTQ0MTQ_29b50e56-0d61-46f0-b4c1-8c7164d83a5b">472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Includes amortization of intangible assets. Amount in the first nine months of 2021 includes $<ix:nonFraction unitRef="usd" contextRef="i27f892355464487d8539768fc6061eb5_D20210101-20210930" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfODQyNQ_09777f70-7056-4339-ae38-9b70b0f59930">153</ix:nonFraction>&#160;million of cumulative amortization catch-up expense. In addition, cost of sales includes Bayer&#8217;s share of profits from sales in Merck&#8217;s marketing territories.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Amount as of December 31, 2021 includes accrued milestone payment.</span></div></ix:continuation></ix:continuation><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 12 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="ida0a1383dfec4cadb0623dce6b3e8a72"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ridgeback Biotherapeutics LP</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, Merck and Ridgeback Biotherapeutics LP (Ridgeback), a closely held biotechnology company, entered into a collaboration agreement to develop </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (molnupiravir), an orally available antiviral candidate in clinical development for the treatment of patients with COVID-19. Merck gained exclusive worldwide rights to develop and commercialize </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and related molecules. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Ridgeback received an upfront payment and is eligible to receive future contingent payments dependent upon the achievement of certain developmental and regulatory approval milestones. The agreement also provides for Merck to reimburse Ridgeback for a portion of certain third-party contingent milestone payments and royalties on net sales, which is part of the profit sharing calculation. Merck is the principal on sales transactions, recognizing sales and related costs, with profit sharing amounts recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Profits from the collaboration are split equally between the partners. Reimbursements from Ridgeback for its share of research and development costs (deducted from Ridgeback&#8217;s share of profits) are reflected as decreases to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has received multiple authorizations or approvals worldwide and Merck has entered into advance purchase and supply agreements for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in more than <ix:nonFraction unitRef="market" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-1" name="mrk:SupplyCommitmentMinimumNumberOfMarkets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfMTAwNDU_d0ab995b-3936-48b6-a2e2-780dca4b45d8">40</ix:nonFraction> markets. As of September&#160;30, 2022, the Company has <ix:nonFraction unitRef="course" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-5" name="mrk:SupplyCommitmentRemainingMinimumCoursesCommitted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfMTAwODM_6f7c26df-8102-4f6a-92bc-5a8aa30437d8">0.8</ix:nonFraction> million remaining courses to be supplied under these agreements.</span></div><ix:continuation id="i40a949dc351e460a917a759bbd5deeeb"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.947%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> sales</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3723cbf2e9d946a999ed600588ab4dcf_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjVlODRiZGE1OWI5ODQ4NmViNGYyMmU4MDIzMTZiN2UxL3RhYmxlcmFuZ2U6NWU4NGJkYTU5Yjk4NDg2ZWI0ZjIyZTgwMjMxNmI3ZTFfMi0xLTEtMS05NDQxNA_6be0eda9-33c8-4d41-afa1-d3ca3df23b48">436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65526f98e4a40e2b1e489150cc1a2ab_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjVlODRiZGE1OWI5ODQ4NmViNGYyMmU4MDIzMTZiN2UxL3RhYmxlcmFuZ2U6NWU4NGJkYTU5Yjk4NDg2ZWI0ZjIyZTgwMjMxNmI3ZTFfMi0zLTEtMS05NDQxNA_ef4f363c-731c-4541-bcd2-bdfb58ede5c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccbbed27ee8c445fa7d6d65e80591a7a_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjVlODRiZGE1OWI5ODQ4NmViNGYyMmU4MDIzMTZiN2UxL3RhYmxlcmFuZ2U6NWU4NGJkYTU5Yjk4NDg2ZWI0ZjIyZTgwMjMxNmI3ZTFfMi01LTEtMS05NDQxNA_d5192687-b0bd-4c1c-9dec-c896852321dc">4,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fdf0be182b9481c8354305d8e3858bf_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjVlODRiZGE1OWI5ODQ4NmViNGYyMmU4MDIzMTZiN2UxL3RhYmxlcmFuZ2U6NWU4NGJkYTU5Yjk4NDg2ZWI0ZjIyZTgwMjMxNmI3ZTFfMi03LTEtMS05NDQxNA_326e50d6-9033-4191-9484-25afc3f66bf5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd2d41565b6f42a997d55a3d36cb68d1_D20220701-20220930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjVlODRiZGE1OWI5ODQ4NmViNGYyMmU4MDIzMTZiN2UxL3RhYmxlcmFuZ2U6NWU4NGJkYTU5Yjk4NDg2ZWI0ZjIyZTgwMjMxNmI3ZTFfNC0xLTEtMS05NDQxNA_a2940711-e109-402d-a116-a7e91700c4b7">234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5885bf545144e9fbc3756e4e3d7b93a_D20210701-20210930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjVlODRiZGE1OWI5ODQ4NmViNGYyMmU4MDIzMTZiN2UxL3RhYmxlcmFuZ2U6NWU4NGJkYTU5Yjk4NDg2ZWI0ZjIyZTgwMjMxNmI3ZTFfNC0zLTEtMS05NDQxNA_ccadfa11-6dc9-4df5-a253-5e90aac85678">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb36d80fe9584e529d590578a9d319d2_D20220101-20220930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjVlODRiZGE1OWI5ODQ4NmViNGYyMmU4MDIzMTZiN2UxL3RhYmxlcmFuZ2U6NWU4NGJkYTU5Yjk4NDg2ZWI0ZjIyZTgwMjMxNmI3ZTFfNC01LTEtMS05NDQxNA_255a11bb-d768-4c46-9087-5ccc6218b701">2,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3627424b141f4c858a9b7d5990d0cd74_D20210101-20210930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjVlODRiZGE1OWI5ODQ4NmViNGYyMmU4MDIzMTZiN2UxL3RhYmxlcmFuZ2U6NWU4NGJkYTU5Yjk4NDg2ZWI0ZjIyZTgwMjMxNmI3ZTFfNC03LTEtMS05NDQxNA_e2bdb00b-9905-4d1a-b67c-5e36f296b3dd">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibccd6eb894bd4564a6c0a0c44c562587_D20220701-20220930" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjVlODRiZGE1OWI5ODQ4NmViNGYyMmU4MDIzMTZiN2UxL3RhYmxlcmFuZ2U6NWU4NGJkYTU5Yjk4NDg2ZWI0ZjIyZTgwMjMxNmI3ZTFfNS0xLTEtMS05NDQxNA_61af584e-7baf-404f-a020-d5fc1d6f8992">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9f5d07a2f4c4a9f82674c37fd6d528a_D20210701-20210930" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjVlODRiZGE1OWI5ODQ4NmViNGYyMmU4MDIzMTZiN2UxL3RhYmxlcmFuZ2U6NWU4NGJkYTU5Yjk4NDg2ZWI0ZjIyZTgwMjMxNmI3ZTFfNS0zLTEtMS05NDQxNA_c480e443-36a6-42b3-876e-5770567cb426">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17a18d3e962d4cd9b3dd760b10d9798b_D20220101-20220930" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjVlODRiZGE1OWI5ODQ4NmViNGYyMmU4MDIzMTZiN2UxL3RhYmxlcmFuZ2U6NWU4NGJkYTU5Yjk4NDg2ZWI0ZjIyZTgwMjMxNmI3ZTFfNS01LTEtMS05NDQxNA_c7f2c76e-263c-4518-83ea-f593151d6345">105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i434e35353dae4fc0b4b54dc274539d65_D20210101-20210930" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjVlODRiZGE1OWI5ODQ4NmViNGYyMmU4MDIzMTZiN2UxL3RhYmxlcmFuZ2U6NWU4NGJkYTU5Yjk4NDg2ZWI0ZjIyZTgwMjMxNmI3ZTFfNS03LTEtMS05NDQxNA_1d2dc433-1f59-474a-8c88-46ae0fea89d7">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23b0153d3f34c168976ed88f8d51ecf_D20220701-20220930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjVlODRiZGE1OWI5ODQ4NmViNGYyMmU4MDIzMTZiN2UxL3RhYmxlcmFuZ2U6NWU4NGJkYTU5Yjk4NDg2ZWI0ZjIyZTgwMjMxNmI3ZTFfNi0xLTEtMS05NDQxNA_c16f6eb8-3a94-4fef-a5e0-a0c48d005d90">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c3f6bda0cc24696bb0a6048cab3d8ad_D20210701-20210930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjVlODRiZGE1OWI5ODQ4NmViNGYyMmU4MDIzMTZiN2UxL3RhYmxlcmFuZ2U6NWU4NGJkYTU5Yjk4NDg2ZWI0ZjIyZTgwMjMxNmI3ZTFfNi0zLTEtMS05NDQxNA_f2b65935-67b6-49c7-a7a2-b1830c6f7520">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e9026c7a16e448aa12d13cee7a70f46_D20220101-20220930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjVlODRiZGE1OWI5ODQ4NmViNGYyMmU4MDIzMTZiN2UxL3RhYmxlcmFuZ2U6NWU4NGJkYTU5Yjk4NDg2ZWI0ZjIyZTgwMjMxNmI3ZTFfNi01LTEtMS05NDQxNA_c2246a78-7112-4b1f-b3bd-bef964446003">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida58e25739ea40aab501d63f8e5ca681_D20210101-20210930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjVlODRiZGE1OWI5ODQ4NmViNGYyMmU4MDIzMTZiN2UxL3RhYmxlcmFuZ2U6NWU4NGJkYTU5Yjk4NDg2ZWI0ZjIyZTgwMjMxNmI3ZTFfNi03LTEtMS05NDQxNA_fdd9fa06-0ef5-44af-9994-1419312285a6">167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Ridgeback included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39554fdd833642dcb810f17c8dc0e061_I20220930" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjVlODRiZGE1OWI5ODQ4NmViNGYyMmU4MDIzMTZiN2UxL3RhYmxlcmFuZ2U6NWU4NGJkYTU5Yjk4NDg2ZWI0ZjIyZTgwMjMxNmI3ZTFfOS01LTEtMS05NDQxNA_804a4537-2f8d-49be-af58-0cc95d70b2ca">193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i425575da0166424ea1fd3084934e226f_I20211231" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjVlODRiZGE1OWI5ODQ4NmViNGYyMmU4MDIzMTZiN2UxL3RhYmxlcmFuZ2U6NWU4NGJkYTU5Yjk4NDg2ZWI0ZjIyZTgwMjMxNmI3ZTFfOS03LTEtMS05NDQxNA_81fec732-543d-4e42-8a54-5489df606a90">283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Includes royalty expense and amortization of capitalized milestone payments.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Includes accrued royalty and milestone payments.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bristol Myers Squibb</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reblozyl (luspatercept-aamt) is a first-in-class erythroid maturation recombinant fusion protein obtained as part of Merck&#8217;s November 2021 acquisition of Acceleron Pharma Inc. that is being developed and commercialized through a global collaboration with Bristol Myers Squibb (BMS). Reblozyl is approved in the U.S., Europe, Canada and Australia for the treatment of anemia in certain rare blood disorders and is also being evaluated for additional indications for hematology therapies. BMS is the principal on sales transactions for Reblozyl; however, Merck co-promotes Reblozyl (and will co-promote all future products approved under this collaboration) in North America, which is reimbursed by BMS. Merck receives a <ix:nonFraction unitRef="number" contextRef="i27570eaa57364d34ba707b5178e9750a_D20220101-20220930" decimals="2" name="mrk:RoyaltyRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfMTExMDU_e4b5ce3a-e0b0-4a21-8203-39a7b5979742">20</ix:nonFraction>% sales royalty from BMS which could increase to a maximum of <ix:nonFraction unitRef="number" contextRef="i82096e190c7a476a960b881f6f4ec492_D20220101-20220930" decimals="2" name="mrk:RoyaltyRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfMTExNjg_93fcfb28-7c25-4b38-892a-f836c3481870">24</ix:nonFraction>% based on sales levels. This royalty will be reduced by <ix:nonFraction unitRef="number" contextRef="i9a2d8c4a46554ddebb3ddc81810f3b42_D20220101-20220930" decimals="2" name="mrk:RoyaltyRateDeductionPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfMTEyMjY_a646eccf-4a06-488e-8469-5ff07a3940b7">50</ix:nonFraction>% upon the earlier of patent expiry or generic entry on an indication-by-indication basis in each market. Additionally, Merck is eligible to receive future contingent sales-based milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="i6730c99096144e189cec49f74ada9510_D20220101-20220930" decimals="-6" name="mrk:ContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfMTE0MzQ_7ecd27ec-8cd5-44bb-9bb3-94504d012c6b">80</ix:nonFraction>&#160;million. Merck recorded alliance revenue of $<ix:nonFraction unitRef="usd" contextRef="ie6ab39f8789a4b6fa4f623fa5d27795c_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfMTE0NzM_c37c8f2a-8804-45f2-b9d6-19be54b5986e">39</ix:nonFraction> million (consisting of royalties) within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the third quarter of 2022 related to this collaboration. Merck recorded alliance revenue of $<ix:nonFraction unitRef="usd" contextRef="i0715d2eaae6e4be98aee0bd0d1931927_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfMTA5OTUxMTYzOTg5NQ_895aa20d-816c-4c81-8ea2-5a39b8c48348">124</ix:nonFraction> million in the first nine months of 2022, which includes royalties of $<ix:nonFraction unitRef="usd" contextRef="i9a2d8c4a46554ddebb3ddc81810f3b42_D20220101-20220930" decimals="-6" name="us-gaap:RoyaltyIncomeNonoperating" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfMTE2NzA_e59a0130-32dd-4908-8326-c59751a01d76">104</ix:nonFraction>&#160;million, as well as the receipt of a regulatory approval milestone payment of $<ix:nonFraction unitRef="usd" contextRef="i6f62c15a0dd94e4a890739e8dafcc0e8_D20220101-20220930" decimals="-6" name="mrk:ContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfMTE3NDM_dc583625-9323-43c6-8042-94557a2d366c">20</ix:nonFraction>&#160;million.</span></div></ix:continuation><div id="i6b4e4280ad2344a5bc7fdcaa77e417f0_46"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RleHRyZWdpb246M2E2NDYyY2Y1Y2U5NDVkNGFkN2RmODRlZTllNGNkMDVfMzMzMg_2800087c-4481-41ff-9c45-9c1124c42320" continuedAt="i5dcfb91793514b56b183e50081075f41" escape="true">Restructuring</ix:nonNumeric></span></div><ix:continuation id="i5dcfb91793514b56b183e50081075f41" continuedAt="i47028f419d1d48d2bf741e6747ff2184"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, Merck&#160;approved a global restructuring program (Restructuring Program) as part of a worldwide initiative focused on further optimizing the Company&#8217;s manufacturing and supply network, as well as reducing its global real estate footprint.&#160;This program is a continuation of the Company&#8217;s plant rationalization and builds on prior restructuring programs. The actions currently contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $<ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-8" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RleHRyZWdpb246M2E2NDYyY2Y1Y2U5NDVkNGFkN2RmODRlZTllNGNkMDVfNjE5_53638959-f9cb-41d1-aabb-3ab31a01a121">3.5</ix:nonFraction> billion. The Company estimates that approximately <ix:nonFraction unitRef="number" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="2" name="mrk:EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RleHRyZWdpb246M2E2NDYyY2Y1Y2U5NDVkNGFkN2RmODRlZTllNGNkMDVfNjY0_a5b20b26-73b6-49c4-a04c-6201f5fba7e0">70</ix:nonFraction>% of the cumulative pretax costs will result in cash outlays, primarily related to employee separation expense and facility shut-down costs. Approximately <ix:nonFraction unitRef="number" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="2" name="mrk:EstimateOfCumulativePreTaxCostsThatWillBeNoncash" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RleHRyZWdpb246M2E2NDYyY2Y1Y2U5NDVkNGFkN2RmODRlZTllNGNkMDVfODIw_dadfd7ab-113d-4ee9-b8b3-2a4d5f5e25d9">30</ix:nonFraction>% of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded total pretax costs of $<ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RleHRyZWdpb246M2E2NDYyY2Y1Y2U5NDVkNGFkN2RmODRlZTllNGNkMDVfMTAwNw_ec921359-6b46-4b42-bc9f-59760a0099a9">175</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RleHRyZWdpb246M2E2NDYyY2Y1Y2U5NDVkNGFkN2RmODRlZTllNGNkMDVfMTAxNA_2b513efe-5379-4a53-99ed-34ea2080efca">168</ix:nonFraction> million in the third quarter of 2022 and 2021, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RleHRyZWdpb246M2E2NDYyY2Y1Y2U5NDVkNGFkN2RmODRlZTllNGNkMDVfMTA2Nw_5ca7e339-3743-4c30-8feb-097203757283">559</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RleHRyZWdpb246M2E2NDYyY2Y1Y2U5NDVkNGFkN2RmODRlZTllNGNkMDVfMTA3NA_0d24fe8c-5c23-438b-9802-5a9cc3a3aebf">630</ix:nonFraction> million for the first nine months of 2022 and 2021, respectively, related to </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 13 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i47028f419d1d48d2bf741e6747ff2184" continuedAt="iec4cb9622a0949b594280bc465856786"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">restructuring program activities. Since inception of the Restructuring Program through September&#160;30, 2022, Merck has recorded total pretax accumulated costs of approximately $<ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-8" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RleHRyZWdpb246M2E2NDYyY2Y1Y2U5NDVkNGFkN2RmODRlZTllNGNkMDVfMTMwMg_89fc3c3b-907b-49ef-8fc9-884b848ce0c0">3.2</ix:nonFraction> billion. For the full year of 2022, the Company expects to record charges of approximately $<ix:nonFraction unitRef="usd" contextRef="id6564f481b634b6fa99cd7e8116cf98f_I20221231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RleHRyZWdpb246M2E2NDYyY2Y1Y2U5NDVkNGFkN2RmODRlZTllNGNkMDVfMTM4Ng_0651fc56-49f2-4864-b244-1b12f07d1705">600</ix:nonFraction> million related to the Restructuring Program. For segment reporting, restructuring charges are unallocated expenses.</span></div><ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RleHRyZWdpb246M2E2NDYyY2Y1Y2U5NDVkNGFkN2RmODRlZTllNGNkMDVfMzMyOQ_5aa97547-f98d-42fe-9c8e-1ab0404ac53d" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the charges related to restructuring program activities by type of cost:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i607e39f2759d4b5691b37d2c9b39dcc7_D20220701-20220930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfMi0xLTEtMS05NDQxNA_0e5f7d56-78dc-4a47-a76d-b413a936551a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ec10c038b504097b605bfddb4195539_D20220701-20220930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfMi0zLTEtMS05NDQxNA_de5d9f9a-3486-4fed-99d9-958da1a8a812">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fb3a552dc224a94b2299fd6c6cf8889_D20220701-20220930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfMi01LTEtMS05NDQxNA_a16c9184-5598-4d03-b1e1-4f3d138c2a9d">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic03376b1c2a3499d90e8c3ebcf2e8843_D20220701-20220930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfMi03LTEtMS05NDQxNA_75c42477-a4b1-4b81-9131-19393619ac46">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67cab3cf205f49af9b2cbd5c33f66aaa_D20220101-20220930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfMi05LTEtMS05NDQxNA_c92dda0c-e77b-4456-8e0a-01325ec3eee1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940e1b01bd364068818c54a265d128b1_D20220101-20220930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfMi0xMS0xLTEtOTQ0MTQ_9682c58a-69ec-47a7-9dad-4bc94b5c5f3a">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72dc17aba95d4c5dbc3a2194bd16fbbd_D20220101-20220930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfMi0xMy0xLTEtOTQ0MTQ_325cd004-f4bf-4d29-8aa6-6fcd9e67b346">116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec1e587d8b0d40bdb598eb257221971d_D20220101-20220930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfMi0xNS0xLTEtOTQ0MTQ_fb1bacfd-9d7a-4b9e-8222-3ac91c3847fe">167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70303f64175d4dc4b0012ac52b4f5e26_D20220701-20220930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfMy0xLTEtMS05NDQxNA_55d34c45-61c6-4aa3-aae4-ace9d0dc93af">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3578096e6ff448caa0f52989e5f64761_D20220701-20220930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfMy0zLTEtMS05NDQxNA_a650dd46-87a8-4490-8229-66f40d4a58bb">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ad3e04cc3e3418cb4a53a75ae5c3e2c_D20220701-20220930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfMy01LTEtMS05NDQxNA_f70f8df3-98d2-4c8f-8a47-ba554365f501">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8849203e046e46cbad3f2f952d1f4e26_D20220701-20220930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfMy03LTEtMS05NDQxNA_2aa48ef8-2f78-43d1-9314-dd6a9524f3d8">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c93d3a120f84e38a20a1a70937efcd7_D20220101-20220930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfMy05LTEtMS05NDQxNA_eb81f5a7-38e5-4c97-ad50-4b5feb18613c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaece706c71314f32b319a33cc075cdd3_D20220101-20220930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfMy0xMS0xLTEtOTQ0MTQ_e9532c1f-16e3-4bd3-9352-f091d41445fc">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i310bfcc0be584465a56866ddaad54dde_D20220101-20220930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfMy0xMy0xLTEtOTQ0MTQ_b704bd89-7c5c-4d85-bd1c-99d8da4f4252">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i521c621370414b959a6f7126a06cd3db_D20220101-20220930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfMy0xNS0xLTEtOTQ0MTQ_b136df86-bb6c-4cb9-9b82-0a72ca4e5a5e">74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45b5fd4276104c17a8bc518c8e4ee367_D20220701-20220930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfNC0xLTEtMS05NDQxNA_ea83645a-5806-4d4e-9fc9-486e40076cef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id015ab72aa4f4666af512c49587ba178_D20220701-20220930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfNC0zLTEtMS05NDQxNA_d2cecbe9-3983-43a3-a323-87789c35e82e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie78da687a4494c7fb93cf5f0da80fd52_D20220701-20220930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfNC01LTEtMS05NDQxNA_1918f6f7-8055-4a50-8bb6-4c58f1fed3d2">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92d26b2795bd42e49f6d1a0b2f14a67e_D20220701-20220930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfNC03LTEtMS05NDQxNA_ee136006-e202-43cc-a6f1-bd25d0c2bb1f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie67e7f4f21244b38ac40aac5e3a31725_D20220101-20220930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfNC05LTEtMS05NDQxNA_65cacadb-72ea-4ff1-867f-8c42da186959">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica35ec1eb9ea4c119a570c9e6bd607d1_D20220101-20220930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfNC0xMS0xLTEtOTQ0MTQ_70c99c0c-e350-4659-ab28-528fcf9934e6">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bf969645ea14edeb5fb224b37851e85_D20220101-20220930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfNC0xMy0xLTEtOTQ0MTQ_7419fd6e-5d12-4429-ab33-b918bedb1334">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf8194e2b5745f0bb10f0b19e79ef0d_D20220101-20220930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfNC0xNS0xLTEtOTQ0MTQ_03826c76-5b85-4fac-8ea8-103c019d11df">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idae084acd38849fea32bf72eca48cb01_D20220701-20220930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfNS0xLTEtMS05NDQxNA_e2aa5a6c-dd3a-4851-a280-76b7629ae1e6">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7e6f52cb1c84ad79bc614920f692b13_D20220701-20220930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfNS0zLTEtMS05NDQxNA_cf660b35-6565-4eae-bc10-6789ad585d1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fedc08d43254caca03ecd529c042551_D20220701-20220930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfNS01LTEtMS05NDQxNA_2c1bcbdc-868f-432f-b1d3-efc6bd400153">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bc054b6f538473eadeef1645e9b4c4b_D20220701-20220930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfNS03LTEtMS05NDQxNA_2239d380-8699-40b6-a616-f725fd471849">94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9362212891c34b43a1bd670fb2f4062f_D20220101-20220930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfNS05LTEtMS05NDQxNA_e3c5c2e1-7813-4b02-bf86-a5849966c3a8">197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a992f86ee914509b7bdf62709a6811d_D20220101-20220930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfNS0xMS0xLTEtOTQ0MTQ_091d4a78-7413-4dbf-b7a0-79b3e9635d07">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aff9663fce2448c99f02618375e2e64_D20220101-20220930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfNS0xMy0xLTEtOTQ0MTQ_1b11114e-23dd-4eab-bf86-6704891f213d">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b0c1dffc5964f349f9a75222d0c1430_D20220101-20220930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfNS0xNS0xLTEtOTQ0MTQ_347b5eff-2346-4384-a7cc-fb57d23212d5">288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0106fbddb424e3aa3b3ba43ca616389_D20220701-20220930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfNi0xLTEtMS05NDQxNA_2dfd952c-9ee2-47a9-9f60-573395e56f4d">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8d2797912764a54a9b0c8b56a5cb401_D20220701-20220930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfNi0zLTEtMS05NDQxNA_0f2f5802-b8d7-46d3-94e9-232f29eaec87">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba55b4c871c84cf8aff0cc19a6430038_D20220701-20220930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfNi01LTEtMS05NDQxNA_500943ff-f7d0-4c86-bb3c-fbf8062e83b2">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfNi03LTEtMS05NDQxNA_87391279-e3c4-432b-becc-ae0fb25b8ead">175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2cfacf23e041649e6e810a01b78367_D20220101-20220930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfNi05LTEtMS05NDQxNA_897e5874-d923-425a-98ff-4b104adfa025">197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6578e5480804aaabbdd710e9e7d4dec_D20220101-20220930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfNi0xMS0xLTEtOTQ0MTQ_eefb34bf-adfd-4544-9995-5a2dbcfb9eb3">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f3b77e795a4cecb84d959b27d815f5_D20220101-20220930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfNi0xMy0xLTEtOTQ0MTQ_f8adf823-c61b-4612-b117-0d7d44e71b67">265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfNi0xNS0xLTEtOTQ0MTQ_abc85dac-7ca0-4c11-a5ea-c126b03baba9">559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53cc7f522cf94a9ba8b27371253d34fd_D20210701-20210930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfMi0xLTEtMS05NDQxNA_6733d648-7326-4d2d-87a1-89f322340862">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37502c19e33b478ba485f3769f7edde9_D20210701-20210930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfMi0zLTEtMS05NDQxNA_2136448e-4648-4a29-9fc5-486f564be167">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbf94fcba07458c9985b487a4e8e11a_D20210701-20210930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfMi01LTEtMS05NDQxNA_f456f2a1-ae3b-4ad5-aa57-9681660709da">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i897e9c4831fe4162b3092f6346596330_D20210701-20210930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfMi03LTEtMS05NDQxNA_4c3d19e0-91eb-47d0-93d9-1940d13c47c9">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b3871ab9cbd41ffabab932a2f1a7a00_D20210101-20210930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfMi05LTEtMS05NDQxNA_5d90b6a2-2278-436a-a944-91348309230e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic248a691eef3457980491b2190cd4476_D20210101-20210930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfMi0xMS0xLTEtOTQ0MTQ_49b82507-58c4-480c-afa4-a1ed1484a40a">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2181ab62a29c4f39995a887b7394ab97_D20210101-20210930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfMi0xMy0xLTEtOTQ0MTQ_21d7d1b9-6b49-40ce-a337-3d9c85672c1a">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icae4aa9b209147aa9d9bf757f4c8c2e5_D20210101-20210930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfMi0xNS0xLTEtOTQ0MTQ_c6b60479-d66d-4932-893d-815c502efcdf">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0582722a90814a31816b9004352bfa16_D20210701-20210930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfMy0xLTEtMS05NDQxNA_4b822805-7033-41f6-b2f7-d3eca2fb4d05">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia278f201fcb0483ea8de813bd868a23b_D20210701-20210930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfMy0zLTEtMS05NDQxNA_01e3e47d-aa9e-48d1-870f-89dff53c19a3">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie582a185448546fc8001d7759a7730db_D20210701-20210930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfMy01LTEtMS05NDQxNA_a5e2664c-a332-4feb-addf-f2dec0eea7f6">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36d4bd762ee74c8b99495575010c996f_D20210701-20210930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfMy03LTEtMS05NDQxNA_e58d5916-b4ed-4850-9cd9-517fe0921b64">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ccd75209b14ac48e453f8ae771b430_D20210101-20210930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfMy05LTEtMS05NDQxNA_d513db36-afb0-49f5-921a-143d04932887">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90654f8e2de64d88a4d14ff9c355cff7_D20210101-20210930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfMy0xMS0xLTEtOTQ0MTQ_a4bb2b91-3b64-4afb-9435-f8a7548dc7e6">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae11b50969c44470b085b71a202c369b_D20210101-20210930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfMy0xMy0xLTEtOTQ0MTQ_0225aa40-3ca4-4376-b4af-b08cb921cf96">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fef4e3614274432a2cb07854dd86e09_D20210101-20210930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfMy0xNS0xLTEtOTQ0MTQ_9297bf80-8be5-4ed4-8687-fde016251272">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14b940f93da941d89457a0cb5087dc05_D20210701-20210930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfNC0xLTEtMS05NDQxNA_937cee3a-7c89-4fb1-bd29-f9ade0088032">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f0e3061236541d88cb6730bdf73a36c_D20210701-20210930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfNC0zLTEtMS05NDQxNA_3de9135c-e43b-4696-b145-09ca5413ed2f">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fe0bb2d87cc463ba0afd98a1d4f6c49_D20210701-20210930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfNC01LTEtMS05NDQxNA_b8d46664-4a7b-4c56-acc1-d361dcb0dc41">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fde48e69dd3472e9819a95aa4746a43_D20210701-20210930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfNC03LTEtMS05NDQxNA_614ba670-bd56-49bd-9c67-e4403ef4be30">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0f98d96c0344d749893dc7317abd393_D20210101-20210930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfNC05LTEtMS05NDQxNA_93c42c55-1f50-44a4-b9c3-8c19684f2b69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f83f5cfdae84508a28c38bc5dc977cb_D20210101-20210930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfNC0xMS0xLTEtOTQ0MTQ_f4e07aa4-a776-40ad-bbd2-9c4048d0f076">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727f0dd97e804d1cab3731ca3b4c50cb_D20210101-20210930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfNC0xMy0xLTEtOTQ0MTQ_eeb526ac-4af3-4e0b-9216-10f41a8595ae">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98e34a5cb81241399b51495bac59245a_D20210101-20210930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfNC0xNS0xLTEtOTQ0MTQ_5e6f7c5b-60e1-4099-9732-257fc2c50e01">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4b050ead3647479f62f1237a1c63c5_D20210701-20210930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfNS0xLTEtMS05NDQxNA_2c4fc7af-34d4-48f7-b1d9-8d984d240cec">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i309f819f3951487382595bf493061e13_D20210701-20210930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfNS0zLTEtMS05NDQxNA_d0af2e42-0fb1-4a28-b11f-383de46b972b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i874c7a8482d9491690e6210b479df219_D20210701-20210930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfNS01LTEtMS05NDQxNA_82cc48f0-e1f6-4acd-9311-6116838c0675">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5db3736668d14dc8ad614ba24ea70f21_D20210701-20210930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfNS03LTEtMS05NDQxNA_10b17197-937b-4ece-85cb-a3017025b7c4">107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12cf63265e33426a9ac172ae9d1f6ad3_D20210101-20210930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfNS05LTEtMS05NDQxNA_fa8de0bd-354f-4685-9d03-cd6577f26ffa">310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5216105f6e064bba87cac0aa0ae94efd_D20210101-20210930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfNS0xMS0xLTEtOTQ0MTQ_a1c1e174-ad1e-4580-8ce3-c25d1a3c0425">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i955e203846ca40e1adf9d2507ef80695_D20210101-20210930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfNS0xMy0xLTEtOTQ0MTQ_13a3c154-2caa-41e9-8e80-4de53e5afd03">177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4afc7e4c5b9a43a7af38307f4daa99e9_D20210101-20210930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfNS0xNS0xLTEtOTQ0MTQ_1836f5e8-2375-469e-83ad-48a09b65ab29">487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie766e05eb57f41bea33a66d0f8d1fa6c_D20210701-20210930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfNi0xLTEtMS05NDQxNA_96ba594c-88f8-4acd-8f06-50e252863c36">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb61cb5684ff4b9c828cf20066ed6299_D20210701-20210930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfNi0zLTEtMS05NDQxNA_4df006f7-8d3a-4b2a-bf35-24f48b4325e3">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5b904f4f0748a6aa9b86108608f108_D20210701-20210930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfNi01LTEtMS05NDQxNA_b2415017-663c-4daa-a33c-2c3e1cd99297">129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfNi03LTEtMS05NDQxNA_788775fb-0434-45d0-a38a-8990b033d996">168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86d01d6cbe2846bab4a8e80b2c1c31d2_D20210101-20210930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfNi05LTEtMS05NDQxNA_94453f26-d505-4f19-9c06-f672feda9a62">310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3f2085cbdba410eb279bbb464b3ec8e_D20210101-20210930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfNi0xMS0xLTEtOTQ0MTQ_b8d0658f-8e7d-4208-b326-97fc04c1a9e2">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6edbfe83866410d981411c92bc94739_D20210101-20210930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfNi0xMy0xLTEtOTQ0MTQ_a424a81f-dacf-4b79-839b-481cb04b14b0">260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfNi0xNS0xLTEtOTQ0MTQ_ba32d3eb-624b-40e3-81c5-9e9860f9fe7e">630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separation costs are associated with actual headcount reductions, as well as those headcount reductions which were probable and could be reasonably estimated. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated depreciation costs primarily relate to manufacturing, research and administrative facilities and equipment to be sold or closed as part of the program. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. All the sites have and will continue to operate up through the respective closure dates and, since future undiscounted cash flows are sufficient to recover the respective book values, Merck is recording accelerated depreciation over the revised useful life of the site assets. Anticipated site closure dates, particularly related to manufacturing locations, have been and may continue to be adjusted to reflect changes resulting from regulatory or other factors.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other activity in 2022 and 2021 includes asset abandonment, facility shut-down and other related costs, as well as pretax gains and losses resulting from the sales of facilities and related assets. Additionally, other activity includes certain employee-related costs associated with pension and other postretirement benefit plans (see Note&#160;11) and share-based compensation.</span></div><ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RleHRyZWdpb246M2E2NDYyY2Y1Y2U5NDVkNGFkN2RmODRlZTllNGNkMDVfMzM0NQ_be03bdad-3589-4407-9f52-52a7ed7a779a" continuedAt="ia867918eac854daebb5a76d50efa6da3" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the charges and spending relating to restructuring program activities for the nine months ended September&#160;30, 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserves January&#160;1, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic795a5720c194aaaa03944a5d453e5e9_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOmIzN2ZjNDAyNjYyZjQxNzc4MGYzYmI3YmMwYjk2MTUyL3RhYmxlcmFuZ2U6YjM3ZmM0MDI2NjJmNDE3NzgwZjNiYjdiYzBiOTYxNTJfMS0xLTEtMS05NDQxNA_33388dfd-72fc-4a4a-a5d7-35e3a10f2434">596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52aaf7232745dbbf9787cba14d23ca_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOmIzN2ZjNDAyNjYyZjQxNzc4MGYzYmI3YmMwYjk2MTUyL3RhYmxlcmFuZ2U6YjM3ZmM0MDI2NjJmNDE3NzgwZjNiYjdiYzBiOTYxNTJfMS0zLTEtMS05NDQxNA_6774eec8-ecfb-43e6-ac1f-b1d0b7664f47">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if340c59c3f4d4832acc93316ac66cbcf_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOmIzN2ZjNDAyNjYyZjQxNzc4MGYzYmI3YmMwYjk2MTUyL3RhYmxlcmFuZ2U6YjM3ZmM0MDI2NjJmNDE3NzgwZjNiYjdiYzBiOTYxNTJfMS01LTEtMS05NDQxNA_daeaca82-3be3-461f-be64-db7e80064288">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOmIzN2ZjNDAyNjYyZjQxNzc4MGYzYmI3YmMwYjk2MTUyL3RhYmxlcmFuZ2U6YjM3ZmM0MDI2NjJmNDE3NzgwZjNiYjdiYzBiOTYxNTJfMS03LTEtMS05NDQxNA_66765bc0-8c27-4bc4-ab5b-c09ba37dde1d">637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2cfacf23e041649e6e810a01b78367_D20220101-20220930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOmIzN2ZjNDAyNjYyZjQxNzc4MGYzYmI3YmMwYjk2MTUyL3RhYmxlcmFuZ2U6YjM3ZmM0MDI2NjJmNDE3NzgwZjNiYjdiYzBiOTYxNTJfMi0xLTEtMS05NDQxNA_b20b423c-dba8-473e-9203-bf0fb197fbee">197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6578e5480804aaabbdd710e9e7d4dec_D20220101-20220930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOmIzN2ZjNDAyNjYyZjQxNzc4MGYzYmI3YmMwYjk2MTUyL3RhYmxlcmFuZ2U6YjM3ZmM0MDI2NjJmNDE3NzgwZjNiYjdiYzBiOTYxNTJfMi0zLTEtMS05NDQxNA_595c76e1-5007-47f8-b084-5089e06a41a8">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f3b77e795a4cecb84d959b27d815f5_D20220101-20220930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOmIzN2ZjNDAyNjYyZjQxNzc4MGYzYmI3YmMwYjk2MTUyL3RhYmxlcmFuZ2U6YjM3ZmM0MDI2NjJmNDE3NzgwZjNiYjdiYzBiOTYxNTJfMi01LTEtMS05NDQxNA_51884691-b797-4245-8784-b85c0119b855">265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOmIzN2ZjNDAyNjYyZjQxNzc4MGYzYmI3YmMwYjk2MTUyL3RhYmxlcmFuZ2U6YjM3ZmM0MDI2NjJmNDE3NzgwZjNiYjdiYzBiOTYxNTJfMi03LTEtMS05NDQxNA_2053f498-a51f-441c-8cf8-3afb4495af5f">559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Payments) receipts, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a2cfacf23e041649e6e810a01b78367_D20220101-20220930" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOmIzN2ZjNDAyNjYyZjQxNzc4MGYzYmI3YmMwYjk2MTUyL3RhYmxlcmFuZ2U6YjM3ZmM0MDI2NjJmNDE3NzgwZjNiYjdiYzBiOTYxNTJfMy0xLTEtMS05NDQxNA_93cdf7fa-eb1d-4c61-8686-0ef06855cf46">303</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6578e5480804aaabbdd710e9e7d4dec_D20220101-20220930" decimals="-6" name="us-gaap:PaymentsForRestructuring" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOmIzN2ZjNDAyNjYyZjQxNzc4MGYzYmI3YmMwYjk2MTUyL3RhYmxlcmFuZ2U6YjM3ZmM0MDI2NjJmNDE3NzgwZjNiYjdiYzBiOTYxNTJfMy0zLTEtMS05NDQxNA_7a7cd64a-eb55-41d2-b09d-60cd744f39de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5f3b77e795a4cecb84d959b27d815f5_D20220101-20220930" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOmIzN2ZjNDAyNjYyZjQxNzc4MGYzYmI3YmMwYjk2MTUyL3RhYmxlcmFuZ2U6YjM3ZmM0MDI2NjJmNDE3NzgwZjNiYjdiYzBiOTYxNTJfMy01LTEtMS05NDQxNA_a7261165-34fe-4df8-9b6b-a31f2cb39371">458</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOmIzN2ZjNDAyNjYyZjQxNzc4MGYzYmI3YmMwYjk2MTUyL3RhYmxlcmFuZ2U6YjM3ZmM0MDI2NjJmNDE3NzgwZjNiYjdiYzBiOTYxNTJfMy03LTEtMS05NDQxNA_6d54b55a-018c-4f49-8bcf-4e1036ee4e16">761</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2cfacf23e041649e6e810a01b78367_D20220101-20220930" decimals="-6" name="mrk:RestructuringReserveIncreaseDecreaseNoncashActivity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOmIzN2ZjNDAyNjYyZjQxNzc4MGYzYmI3YmMwYjk2MTUyL3RhYmxlcmFuZ2U6YjM3ZmM0MDI2NjJmNDE3NzgwZjNiYjdiYzBiOTYxNTJfNC0xLTEtMS05NDQxNA_d72cb9d2-c9b2-45ed-b1c7-5cab531b30dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6578e5480804aaabbdd710e9e7d4dec_D20220101-20220930" decimals="-6" sign="-" name="mrk:RestructuringReserveIncreaseDecreaseNoncashActivity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOmIzN2ZjNDAyNjYyZjQxNzc4MGYzYmI3YmMwYjk2MTUyL3RhYmxlcmFuZ2U6YjM3ZmM0MDI2NjJmNDE3NzgwZjNiYjdiYzBiOTYxNTJfNC0zLTEtMS05NDQxNA_b04933d0-0d75-4ae9-bfa9-b68ca6152435">97</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f3b77e795a4cecb84d959b27d815f5_D20220101-20220930" decimals="-6" name="mrk:RestructuringReserveIncreaseDecreaseNoncashActivity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOmIzN2ZjNDAyNjYyZjQxNzc4MGYzYmI3YmMwYjk2MTUyL3RhYmxlcmFuZ2U6YjM3ZmM0MDI2NjJmNDE3NzgwZjNiYjdiYzBiOTYxNTJfNC01LTEtMS05NDQxNA_cceb9168-0f63-41d9-9611-0759b6ef58e9">183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="mrk:RestructuringReserveIncreaseDecreaseNoncashActivity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOmIzN2ZjNDAyNjYyZjQxNzc4MGYzYmI3YmMwYjk2MTUyL3RhYmxlcmFuZ2U6YjM3ZmM0MDI2NjJmNDE3NzgwZjNiYjdiYzBiOTYxNTJfNC03LTEtMS05NDQxNA_17a4a322-6dc4-4df0-a96d-f58c040a9087">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserves September&#160;30, 2022 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87df032ae149438c8311b443f96f3fa1_I20220930" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOmIzN2ZjNDAyNjYyZjQxNzc4MGYzYmI3YmMwYjk2MTUyL3RhYmxlcmFuZ2U6YjM3ZmM0MDI2NjJmNDE3NzgwZjNiYjdiYzBiOTYxNTJfNS0xLTEtMS05NDQxNA_3d76b89c-7e39-4a4c-8781-8d21f2ea45f2">490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79ed206618d34ac9b28a27e2dc6fb6b3_I20220930" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOmIzN2ZjNDAyNjYyZjQxNzc4MGYzYmI3YmMwYjk2MTUyL3RhYmxlcmFuZ2U6YjM3ZmM0MDI2NjJmNDE3NzgwZjNiYjdiYzBiOTYxNTJfNS0zLTEtMS05NDQxNA_1fd9e5ae-4f61-4c66-9367-f7764c449262">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f9135826ed64fa09549e1defcc31184_I20220930" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOmIzN2ZjNDAyNjYyZjQxNzc4MGYzYmI3YmMwYjk2MTUyL3RhYmxlcmFuZ2U6YjM3ZmM0MDI2NjJmNDE3NzgwZjNiYjdiYzBiOTYxNTJfNS01LTEtMS05NDQxNA_11e046ca-05ba-4423-a892-5be2946ec769">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOmIzN2ZjNDAyNjYyZjQxNzc4MGYzYmI3YmMwYjk2MTUyL3RhYmxlcmFuZ2U6YjM3ZmM0MDI2NjJmNDE3NzgwZjNiYjdiYzBiOTYxNTJfNS03LTEtMS05NDQxNA_ad03e150-472c-42cd-be61-d0e5e9c7e5cc">521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"><ix:continuation id="iec4cb9622a0949b594280bc465856786" continuedAt="i839fb9edb6b0475e95c6966bdf9d8617"><ix:continuation id="ia867918eac854daebb5a76d50efa6da3" continuedAt="i95fe762949174f75803d7f96ec6e8c62">(1)</ix:continuation></ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:continuation id="i839fb9edb6b0475e95c6966bdf9d8617"><ix:continuation id="i95fe762949174f75803d7f96ec6e8c62">The remaining cash outlays are expected to be substantially completed by the end of 2023.</ix:continuation></ix:continuation> </span></div><div id="i6b4e4280ad2344a5bc7fdcaa77e417f0_49"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTkyODY_f146ccb7-9846-4ac2-989e-406560a70948" continuedAt="i8e2f99c949ed45249d840906a0e11047" escape="true">Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="i8e2f99c949ed45249d840906a0e11047" continuedAt="ifce6784406df4462a0ed6989f2a33325"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derivative Instruments and Hedging Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages the impact of foreign exchange rate movements and interest rate movements on its earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 14 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="ifce6784406df4462a0ed6989f2a33325" continuedAt="i4ffce416b8ae4c63b1b8ed70aef3d38f"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of the Company&#8217;s revenues and earnings in foreign affiliates is exposed to changes in foreign exchange rates. The objectives of and accounting related to the Company&#8217;s foreign currency risk management program, as well as its interest rate risk management activities are discussed below.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Risk Management</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has established revenue hedging, balance sheet risk management and net investment hedging programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by changes in foreign exchange rates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The objective of the revenue hedging program is to reduce the variability caused by changes in foreign exchange rates that would affect the U.S. dollar value of future cash flows derived from foreign currency denominated sales, primarily the euro, Japanese yen and Chinese renminbi. To achieve this objective, the Company will hedge a portion of its forecasted foreign currency denominated third-party and intercompany distributor entity sales (forecasted sales) that are expected to occur over its planning cycle, typically no more than <ix:nonNumeric contextRef="ic2de9fcd183e42f8bd39ac5db830d924_D20220101-20220930" name="us-gaap:DerivativeAverageRemainingMaturity1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTQ2Ng_532b0cb7-fcc2-403a-bacf-2cf0ad230237">two years</ix:nonNumeric> into the future. The Company will layer in hedges over time, increasing the portion of forecasted sales hedged as it gets closer to the expected date of the forecasted sales. The portion of forecasted sales hedged is based on assessments of cost-benefit profiles that consider natural offsetting exposures, revenue and exchange rate volatilities and correlations, and the cost of hedging instruments. The Company manages its anticipated transaction exposure principally with purchased local currency put options, forward contracts and purchased collar options. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the Condensed Consolidated Balance Sheet. Changes in the fair value of derivative contracts are recorded each period in either current earnings or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (OCI), depending on whether the derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash flow hedges, the unrealized gains or losses on these contracts are recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated Other Comprehensive Loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCL)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and reclassified into </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> when the hedged anticipated revenue is recognized. For those derivatives which are not designated as cash flow hedges, but serve as economic hedges of forecasted sales, unrealized gains or losses are recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> each period. The cash&#160;flows from both designated and non-designated contracts are reported as operating activities&#160;in the Condensed Consolidated Statement of&#160;Cash Flows. The Company does not enter into derivatives for trading or speculative purposes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages operating activities and net asset positions at each local subsidiary in order to mitigate the effects of exchange on monetary assets and liabilities. The Company also uses a balance sheet risk management program to mitigate the exposure of net monetary assets that are denominated in a currency other than a subsidiary&#8217;s functional currency from the effects of volatility in foreign exchange. In these instances, Merck principally utilizes forward exchange contracts to offset the effects of exchange on exposures denominated in developed country currencies, primarily the euro, Japanese yen, British pound, Canadian dollar and Swiss franc. For exposures in developing country currencies, including the Chinese renminbi, the Company will enter into forward contracts to offset the effects of exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the exchange rate and the cost of the hedging instrument. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The forward contracts are not designated as hedges and are marked to market through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than <ix:nonNumeric contextRef="i9c8be2269d6c4eb4bc6e4bcb3ddcfc30_D20220101-20220930" name="us-gaap:DerivativeAverageRemainingMaturity1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfNTA2Mg_a9ab8636-8132-4f2c-b120-0c1751e0ea00">one year</ix:nonNumeric>.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also uses forward exchange contracts to hedge a portion of its net investment in foreign operations against movements in exchange rates. The forward contracts are designated as hedges of the net investment in a foreign operation. The unrealized gains or losses on these contracts are recorded in foreign currency translation adjustment within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and remain in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> until either the sale or complete or substantially complete liquidation of the subsidiary. The Company excludes certain portions of the change in fair value of its derivative instruments from the assessment of hedge effectiveness (excluded components). Changes in fair value of the excluded components are recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company recognizes in earnings the initial value of the excluded components on a straight-line basis over the life of the derivative instrument, rather than using the mark-to-market approach. The cash flows from these contracts are reported as investing activities in the Condensed Consolidated Statement of Cash Flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange risk is also managed through the use of foreign currency debt. The Company&#8217;s senior unsecured euro-denominated notes have been designated as, and are effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in foreign currency translation adjustment within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 15 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i4ffce416b8ae4c63b1b8ed70aef3d38f" continuedAt="i38af86ba7e8a4988aae9167012b7475c"><ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTkyMjM_5976179b-17a7-411a-afdd-604dfdea1fd3" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effects of the Company&#8217;s net investment hedges on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the Consolidated Statement of Income are shown below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.366%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> for Amounts Excluded from Effectiveness Testing</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Relationships</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie27e3a1d731a4e8aab46753956e07c5d_D20220701-20220930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjlmNTRmZGZhZjlhYjQ3MTdiOGQ3MTFmNjY2OGJhOTkwL3RhYmxlcmFuZ2U6OWY1NGZkZmFmOWFiNDcxN2I4ZDcxMWY2NjY4YmE5OTBfNC0xLTEtMS05NDQxNA_ffc5f871-d3c3-4cb7-8978-945687274431">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ae35cdeb80c488d9810adba90ad5a22_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjlmNTRmZGZhZjlhYjQ3MTdiOGQ3MTFmNjY2OGJhOTkwL3RhYmxlcmFuZ2U6OWY1NGZkZmFmOWFiNDcxN2I4ZDcxMWY2NjY4YmE5OTBfNC0zLTEtMS05NDQxNA_4af7685a-f285-4b0c-80e4-e25b4d9f14d5">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5ffef0aa5134d30a7bc87c2f1471202_D20220101-20220930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjlmNTRmZGZhZjlhYjQ3MTdiOGQ3MTFmNjY2OGJhOTkwL3RhYmxlcmFuZ2U6OWY1NGZkZmFmOWFiNDcxN2I4ZDcxMWY2NjY4YmE5OTBfNC01LTEtMS05NDQxNA_eda0085f-b303-475d-bec0-d9fdb0539fd6">47</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f49cd47d7c34c2db675a1a70530cbc8_D20210101-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjlmNTRmZGZhZjlhYjQ3MTdiOGQ3MTFmNjY2OGJhOTkwL3RhYmxlcmFuZ2U6OWY1NGZkZmFmOWFiNDcxN2I4ZDcxMWY2NjY4YmE5OTBfNC03LTEtMS05NDQxNA_c07059e3-65c4-428a-b6fe-3ca95aa36ae2">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieab5e8f43e5e4ecb92c95a699771341a_D20220701-20220930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjlmNTRmZGZhZjlhYjQ3MTdiOGQ3MTFmNjY2OGJhOTkwL3RhYmxlcmFuZ2U6OWY1NGZkZmFmOWFiNDcxN2I4ZDcxMWY2NjY4YmE5OTBfNC05LTEtMS05NDQxNA_6d2eca35-8cd8-442d-9f7f-843e96fd7cab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i01953d66b4ed43759d677deacf2426b3_D20210701-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjlmNTRmZGZhZjlhYjQ3MTdiOGQ3MTFmNjY2OGJhOTkwL3RhYmxlcmFuZ2U6OWY1NGZkZmFmOWFiNDcxN2I4ZDcxMWY2NjY4YmE5OTBfNC0xMS0xLTEtOTQ0MTQ_d4735afb-e3af-4693-bcbb-9d1839e00a7b">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6c315ba79954d888131d6d2b08f5b46_D20220101-20220930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjlmNTRmZGZhZjlhYjQ3MTdiOGQ3MTFmNjY2OGJhOTkwL3RhYmxlcmFuZ2U6OWY1NGZkZmFmOWFiNDcxN2I4ZDcxMWY2NjY4YmE5OTBfNC0xMy0xLTEtOTQ0MTQ_9869162a-950d-43c5-9e04-cc2960e0aa19">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ac58f37e82a4b95ab6c2445433ee541_D20210101-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjlmNTRmZGZhZjlhYjQ3MTdiOGQ3MTFmNjY2OGJhOTkwL3RhYmxlcmFuZ2U6OWY1NGZkZmFmOWFiNDcxN2I4ZDcxMWY2NjY4YmE5OTBfNC0xNS0xLTEtOTQ0MTQ_f266deeb-1fcf-44a3-ae47-fe25df5dbd3c">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro-denominated notes</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f5e74c553ad4cea9c9915ab749a9781_D20220701-20220930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjlmNTRmZGZhZjlhYjQ3MTdiOGQ3MTFmNjY2OGJhOTkwL3RhYmxlcmFuZ2U6OWY1NGZkZmFmOWFiNDcxN2I4ZDcxMWY2NjY4YmE5OTBfNS0xLTEtMS05NDQxNA_f75ed8d8-6e52-4ba8-8e81-3d729e1e2ae0">250</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e5bf65d147a4bdc965896b6d99c4860_D20210701-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjlmNTRmZGZhZjlhYjQ3MTdiOGQ3MTFmNjY2OGJhOTkwL3RhYmxlcmFuZ2U6OWY1NGZkZmFmOWFiNDcxN2I4ZDcxMWY2NjY4YmE5OTBfNS0zLTEtMS05NDQxNA_e7f90261-a7be-44dc-b164-3d7905ed8093">77</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e5ed55b09f84d5498e328aa1b4f5417_D20220101-20220930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjlmNTRmZGZhZjlhYjQ3MTdiOGQ3MTFmNjY2OGJhOTkwL3RhYmxlcmFuZ2U6OWY1NGZkZmFmOWFiNDcxN2I4ZDcxMWY2NjY4YmE5OTBfNS01LTEtMS05NDQxNA_86440834-ad0b-4fcd-9995-387d1562d3d7">431</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i772590a293ba478db2f7600cf2cb3eb4_D20210101-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjlmNTRmZGZhZjlhYjQ3MTdiOGQ3MTFmNjY2OGJhOTkwL3RhYmxlcmFuZ2U6OWY1NGZkZmFmOWFiNDcxN2I4ZDcxMWY2NjY4YmE5OTBfNS03LTEtMS05NDQxNA_6aa360e3-db45-4eae-b949-da670c3f96bb">199</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i099e48fafeba46d08da6b31e799e3b7f_D20220701-20220930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjlmNTRmZGZhZjlhYjQ3MTdiOGQ3MTFmNjY2OGJhOTkwL3RhYmxlcmFuZ2U6OWY1NGZkZmFmOWFiNDcxN2I4ZDcxMWY2NjY4YmE5OTBfNS05LTEtMS05NDQxNA_c5c133ed-2b79-431f-92db-6eb4e3865da6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03e7ee1c569b46239abaca544705e805_D20210701-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjlmNTRmZGZhZjlhYjQ3MTdiOGQ3MTFmNjY2OGJhOTkwL3RhYmxlcmFuZ2U6OWY1NGZkZmFmOWFiNDcxN2I4ZDcxMWY2NjY4YmE5OTBfNS0xMS0xLTEtOTQ0MTQ_97f5c252-be9c-4ab4-b711-73f99184cd21">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia780135900c240e5b9abf1b31ee64f6e_D20220101-20220930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjlmNTRmZGZhZjlhYjQ3MTdiOGQ3MTFmNjY2OGJhOTkwL3RhYmxlcmFuZ2U6OWY1NGZkZmFmOWFiNDcxN2I4ZDcxMWY2NjY4YmE5OTBfNS0xMy0xLTEtOTQ0MTQ_87d0990e-e430-47e8-ae45-1b79cc87c5cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92c75e458aed405ab0daac044db42401_D20210101-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjlmNTRmZGZhZjlhYjQ3MTdiOGQ3MTFmNjY2OGJhOTkwL3RhYmxlcmFuZ2U6OWY1NGZkZmFmOWFiNDcxN2I4ZDcxMWY2NjY4YmE5OTBfNS0xNS0xLTEtOTQ0MTQ_ed78ecae-5f4b-47a7-9342-9f0baf3fb0f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> No amounts were reclassified from AOCL into income related to the sale of a subsidiary.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk Management</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes and to reduce its overall cost of borrowing. The Company does not use leveraged swaps and, in general, does not leverage any of its investment activities that would put principal at risk. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022,&#160;<ix:nonFraction unitRef="interest_rate_swap" contextRef="i0e0dd76b1ff5456f8f9ea13bb5b3d393_I20220228" decimals="INF" name="us-gaap:NumberOfInterestRateDerivativesHeld" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfNzEzNw_0bf4ef41-f82e-45bd-a5a8-8dca7252c8df">five</ix:nonFraction>&#160;interest rate swap contracts with a total notional amount of&#160;$<ix:nonFraction unitRef="usd" contextRef="if00c71a39ce54be38bef228f86d7f5bf_I20220228" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfNzE5Mg_b6319fe0-d7fd-481a-ae1b-3ae658920aa3">1.25</ix:nonFraction> billion matured. These swaps effectively converted the Company&#8217;s&#160;$<ix:nonFraction unitRef="usd" contextRef="if3f2b646e97448bb985e896a02467668_I20220228" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfNzI1Mg_b1a77ea3-65a4-478f-a3ea-d3dc12c5cca8">1.25</ix:nonFraction> billion,&#160;<ix:nonFraction unitRef="number" contextRef="if3f2b646e97448bb985e896a02467668_I20220228" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfNzI1Ng_a9e3f1a1-f59e-4a8d-b5ed-1cc2e27d1dc6">2.35</ix:nonFraction>%&#160;fixed-rate notes due 2022 to variable rate debt.&#160;In September 2022, <ix:nonFraction unitRef="interest_rate_swap" contextRef="iea3f69b723254e88a143cf7acb00abe9_I20220930" decimals="INF" name="us-gaap:NumberOfInterestRateDerivativesHeld" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfNzM0Mg_487d42a0-003a-4da0-b4b3-b11b6d682110">four</ix:nonFraction> interest rate swap contracts with a total notional amount of $<ix:nonFraction unitRef="usd" contextRef="i486ffaa742a0496f9d919416396e1c12_I20220930" decimals="INF" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfNTQ5NzU1ODMzNTc4_a24061df-5476-40c9-a41e-ed508aa99b6b">1.0</ix:nonFraction>&#160;billion matured. These swaps effectively converted the Company&#8217;s $<ix:nonFraction unitRef="usd" contextRef="i6c212ea75a92431aa81258fd9e8294ba_I20220930" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfNTQ5NzU1ODMzNTky_a49a1879-f7bc-4253-8b65-d4ccb1968b64">1.0</ix:nonFraction>&#160;billion, <ix:nonFraction unitRef="number" contextRef="i2e5951a5bcea4965af6bb7344a6a099d_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfNTQ5NzU1ODMzNjA2_533b7209-843d-4028-b183-6cd4ecfed284">2.40</ix:nonFraction>% fixed rate notes due 2022 to variable rate debt. The interest rate swap contracts were designated hedges of the fair value changes in the notes attributable to changes in the benchmark LIBOR swap rate. The fair value changes in the notes attributable to changes in the LIBOR swap rate were recorded in interest expense along with the offsetting fair value changes in the swap contracts. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows. The Company is not currently a party to any interest rate swaps.</span></div><ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTkyMTk_c84e2bef-d4e1-443d-b7a6-91fb4f58a1ca" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the location of amounts recorded in the Condensed Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.338%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.040%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Amount of Hedged Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Line Item in which Hedged Item is Included</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loans payable and current portion of long-term debt</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdb46049abd240818d8639edc52d2396_I20220930" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedge" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmMzODRkN2JkYjY1YjQ0ZGNiZDVkMjQyZDM2MzNhNDE0L3RhYmxlcmFuZ2U6YzM4NGQ3YmRiNjViNDRkY2JkNWQyNDJkMzYzM2E0MTRfMy0xLTEtMS05NDQxNA_b82486df-cbe5-4935-8b12-83757533031d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc438baf83774566bb16844255c68486_I20211231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedge" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmMzODRkN2JkYjY1YjQ0ZGNiZDVkMjQyZDM2MzNhNDE0L3RhYmxlcmFuZ2U6YzM4NGQ3YmRiNjViNDRkY2JkNWQyNDJkMzYzM2E0MTRfMy0zLTEtMS05NDQxNA_761e3059-ec26-41c8-96f5-ede50a13e3fa">2,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdb46049abd240818d8639edc52d2396_I20220930" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmMzODRkN2JkYjY1YjQ0ZGNiZDVkMjQyZDM2MzNhNDE0L3RhYmxlcmFuZ2U6YzM4NGQ3YmRiNjViNDRkY2JkNWQyNDJkMzYzM2E0MTRfMy01LTEtMS05NDQxNA_89c7e23e-0969-4d67-8817-042324b67d01">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc438baf83774566bb16844255c68486_I20211231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmMzODRkN2JkYjY1YjQ0ZGNiZDVkMjQyZDM2MzNhNDE0L3RhYmxlcmFuZ2U6YzM4NGQ3YmRiNjViNDRkY2JkNWQyNDJkMzYzM2E0MTRfMy03LTEtMS05NDQxNA_d8ead55c-c505-4810-a84e-88dc3563e8e3">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTkyMjU_80436299-1f7e-4694-8e23-3031062eacfd" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.241%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair&#160;Value&#160;of&#160;Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.&#160;Dollar<br/>Notional</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair&#160;Value&#160;of&#160;Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.&#160;Dollar<br/>Notional</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Designated as Hedging Instruments</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNC0xLTEtMS0xMDUwNTY_4beacbd1-84ea-489f-8ac6-b09392c17877"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNC0xLTEtMS0xMDUwNTY_4c50954f-2f04-4bb2-9e7e-854b1813a13f">Other current assets</span></span></span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7eb7aa0cad44ae481279be50ead5cf3_I20220930" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNC0yLTEtMS05NDQxNA_268490c5-e313-4361-b8d6-a2cb153978cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45b3ae0db3cf41c3acafc444ed25c107_I20220930" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNC02LTEtMS05NDQxNA_8c7e87fb-347e-427c-bb08-3d9cb9bcc214">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53f76af88d63418dba6b1ea3a71d7ecb_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNC04LTEtMS05NDQxNA_28611bd7-4881-401c-8c34-6b22db6bfb51">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if41d8f4f2079476e813d82c9d789e8fc_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNC0xMi0xLTEtOTQ0MTQ_38edebdf-a030-4445-95b3-cb27e2fb4925">2,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNS0xLTEtMS05NDQxNA_2a5d2377-4bbd-47ad-9925-404ca9a51736"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNS0xLTEtMS05NDQxNA_c6df00f3-bff8-4562-abe7-498764d34146">Other current assets</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92c41baff7714a72894f9c962e96d0a8_I20220930" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNS0yLTEtMS05NDQxNA_7572e690-f69e-415e-ba7a-babc3f1166fe">826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92c41baff7714a72894f9c962e96d0a8_I20220930" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNS02LTEtMS05NDQxNA_c650a149-96ce-44d2-99ce-ea0d8a5adf8b">7,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97bb92e54ef74a8db32f912747efe346_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNS04LTEtMS05NDQxNA_8aaaed19-bf0f-4b65-abbf-eeab15b8d723">271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97bb92e54ef74a8db32f912747efe346_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNS0xMi0xLTEtOTQ0MTQ_9beb4d52-bdba-48d2-87da-7a99e3f93a44">6,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNi0xLTEtMS05NDQxNA_6baf831a-4ac8-4464-8eb1-254345d36853"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNi0xLTEtMS05NDQxNA_95f68aac-d3b4-4319-9f3d-70e85b1424c4">Other Assets</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92c868d7e8f9475893857146e49ffbb1_I20220930" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNi0yLTEtMS05NDQxNA_e808b6f1-93ad-4a77-b3d1-5e5ab8b2ee1a">85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92c868d7e8f9475893857146e49ffbb1_I20220930" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNi02LTEtMS05NDQxNA_ae85dbc8-dfa3-4984-bd44-41ebd6f92dcb">1,408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f6e2cbf96bd4896863dbb8f79fdf2b1_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNi04LTEtMS05NDQxNA_4759f3dd-135b-4f9e-939b-de0e67f344bf">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f6e2cbf96bd4896863dbb8f79fdf2b1_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNi0xMi0xLTEtOTQ0MTQ_e525fdfa-a963-4a00-8037-26cfcce42c46">1,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNy0xLTEtMS05NDQxNA_6a9babb4-e747-4df0-a56c-3595290d8927"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNy0xLTEtMS05NDQxNA_ae73e90d-8b40-4bfe-b1e5-b0c0132d4407">Accrued and other current liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2398c81940b40eabe737fa14c821b96_I20220930" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNy00LTEtMS05NDQxNA_0248917f-8b6f-4b6e-a38f-1ab1606b1b57">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2398c81940b40eabe737fa14c821b96_I20220930" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNy02LTEtMS05NDQxNA_5b93829b-dadb-42cd-9cc7-2510f7735c24">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i338b3ccaae68438b96b0f370fd0bb963_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNy0xMC0xLTEtOTQ0MTQ_aa89d3da-a4ad-4932-9cc4-30820844c0b1">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i338b3ccaae68438b96b0f370fd0bb963_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNy0xMi0xLTEtOTQ0MTQ_a8e70c8f-6ba5-4779-b998-1aa5a77d80d7">1,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfOC0xLTEtMS05NDQxNA_3d168174-838c-4aa7-834d-0305c0dea6db"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfOC0xLTEtMS05NDQxNA_8a78e2f6-5d79-40d5-8cfd-da850ad40e02">Other Noncurrent Liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa0ad26fa2f64d7ca0cf4d95ae5c7567_I20220930" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfOC00LTEtMS05NDQxNA_8977ac65-37e5-4207-8906-1ab7d4b7870f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa0ad26fa2f64d7ca0cf4d95ae5c7567_I20220930" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfOC02LTEtMS05NDQxNA_eaf38c10-3075-43cf-9961-70c407bd4d70">93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib67ea4886b8c40868d422b24ac9e580d_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfOC0xMC0xLTEtOTQ0MTQ_d314dd5b-fd21-43e0-8224-1ce4959ca409">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib67ea4886b8c40868d422b24ac9e580d_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfOC0xMi0xLTEtOTQ0MTQ_89221e33-d77e-455c-afe0-dda1f9346a48">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf409d1f24c84ee6b661d53c0d63d271_I20220930" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfOS0yLTEtMS05NDQxNA_8594e1f6-a023-4152-bc75-1477dc581e26">911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf409d1f24c84ee6b661d53c0d63d271_I20220930" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfOS00LTEtMS05NDQxNA_e0ac6a42-50e7-407f-9010-5e8b451d5420">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf409d1f24c84ee6b661d53c0d63d271_I20220930" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfOS02LTEtMS05NDQxNA_a09762cb-efc6-44da-aca8-09478449e388">8,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d7e32d159245d8962254b1ac043b09_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfOS04LTEtMS05NDQxNA_bb5d7b19-3dae-46c4-8ba8-12dfe75644f4">328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d7e32d159245d8962254b1ac043b09_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfOS0xMC0xLTEtOTQ0MTQ_441b8d17-37dd-4dc4-9fe3-c2946c1e73ca">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d7e32d159245d8962254b1ac043b09_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfOS0xMi0xLTEtOTQ0MTQ_9e2d5f6a-9c38-449c-bd35-8df0682f20cd">12,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTEtMS0xLTEtMTA1MTE3_0942da13-4366-4941-8d73-f86fd1003d65"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTEtMS0xLTEtMTA1MTE3_ed1a83b6-f315-4484-ba3e-ac3634db5ded">Other current assets</span></span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7382fed477fc47e3acfc51cf0827f22a_I20220930" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTEtMi0xLTEtOTQ0MTQ_3d65d989-a2e1-4391-b3d2-9a8218a11a81">597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8bb1afef334464cafe180cee4605e3b_I20220930" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTEtNi0xLTEtOTQ0MTQ_bf55d6f3-ae64-44f4-9a2f-c8182c58f011">9,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieba4d46f4e9b4513aa30046a1640a2d1_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTEtOC0xLTEtOTQ0MTQ_95354b91-1ef3-4b41-91de-c2763d3f58f1">221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6964796fa04f4808aa3493a670881eca_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTEtMTItMS0xLTk0NDE0_0207734c-52ca-4007-a6b1-c9a082196757">10,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTItMS0xLTEtMTA1MTE5_35d04908-60bc-47a5-b559-4d800d70da91"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTItMS0xLTEtMTA1MTE5_f4049782-8c11-4ab1-9f60-0268bac9cd63">Accrued and other current liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7382fed477fc47e3acfc51cf0827f22a_I20220930" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTItNC0xLTEtOTQ0MTQ_edc24b3d-1e8a-416d-bdac-0a30b4110064">240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8b8b04c81b4fb99373775effba54e1_I20220930" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTItNi0xLTEtOTQ0MTQ_71f50cbe-5d3b-40c9-8526-15e6023984a9">7,715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieba4d46f4e9b4513aa30046a1640a2d1_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTItMTAtMS0xLTk0NDE0_392da74b-efc9-43bb-977c-6e1030f25627">96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id74f2287203447e1b810c5fa36a1ed55_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTItMTItMS0xLTk0NDE0_db0efdbc-5cda-4015-973b-a613783cf129">10,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cdb1dee02174c02a0606014cbbae99e_I20220930" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTMtMi0xLTEtOTQ0MTQ_12d7b2b8-1bd3-4a26-ab88-42639f2ef19c">597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cdb1dee02174c02a0606014cbbae99e_I20220930" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTMtNC0xLTEtOTQ0MTQ_20765a6a-b034-445b-97ae-1deffef95890">240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cdb1dee02174c02a0606014cbbae99e_I20220930" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTMtNi0xLTEtOTQ0MTQ_d344c14d-24b8-4dad-9cac-34ad36a83833">17,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c9fc9da50e4192912b25f5131e50fc_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTMtOC0xLTEtOTQ0MTQ_7a0a208a-e49a-4361-af0b-6491283d5d07">221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c9fc9da50e4192912b25f5131e50fc_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTMtMTAtMS0xLTk0NDE0_1982b2d8-a6bf-4e66-a4bc-1b9e7ad92ed9">96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c9fc9da50e4192912b25f5131e50fc_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTMtMTItMS0xLTk0NDE0_52ef7029-42ef-4fdd-a9b5-7169278dd96b">20,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTQtMi0xLTEtOTQ0MTQ_c3d219e2-3750-4aa9-9073-9f9aea636bb7">1,508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTQtNC0xLTEtOTQ0MTQ_b09780e2-d345-4433-8616-bf768c2fd050">242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTQtNi0xLTEtOTQ0MTQ_bacdb8d7-10c0-4a5c-afda-74916b648c26">26,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTQtOC0xLTEtOTQ0MTQ_ad74e337-d21f-45eb-a116-aa1c49c636a0">549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTQtMTAtMS0xLTk0NDE0_faafa25c-8cf9-4573-8d94-8a69ac6e34c2">121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTQtMTItMS0xLTk0NDE0_f6c10b3a-99e3-4f85-b35e-20634231987b">32,958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, the Company records its derivatives on a gross basis in the Condensed Consolidated Balance Sheet. The Company has master netting agreements with several of its financial institution counterparties (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentrations of Credit Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below). <ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="mrk:OffsettingAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTkyNDM_0fd15bb1-ddc1-4ca3-a1ff-c2bbf8d77e8b" continuedAt="ic6ab3a5b808245389543bdcb080889ce" escape="true">The following table provides information on the Company&#8217;s derivative positions subject to these master </ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 16 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i38af86ba7e8a4988aae9167012b7475c" continuedAt="i5a66118343ac4588bd64618b974e561f"><ix:continuation id="ic6ab3a5b808245389543bdcb080889ce"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:64.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross amounts recognized in the condensed consolidated balance sheet</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjY3NTU2ODVjN2IzYjQwNDBhMzVlZmQ4YzY1NmJlYTVjL3RhYmxlcmFuZ2U6Njc1NTY4NWM3YjNiNDA0MGEzNWVmZDhjNjU2YmVhNWNfMi0xLTEtMS05NDQxNA_c6b96c6f-cccc-421b-a3b8-fb94ed592beb">1,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjY3NTU2ODVjN2IzYjQwNDBhMzVlZmQ4YzY1NmJlYTVjL3RhYmxlcmFuZ2U6Njc1NTY4NWM3YjNiNDA0MGEzNWVmZDhjNjU2YmVhNWNfMi0zLTEtMS05NDQxNA_9f6f0534-018f-4642-bee0-7b33fd7e934a">242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjY3NTU2ODVjN2IzYjQwNDBhMzVlZmQ4YzY1NmJlYTVjL3RhYmxlcmFuZ2U6Njc1NTY4NWM3YjNiNDA0MGEzNWVmZDhjNjU2YmVhNWNfMi01LTEtMS05NDQxNA_dd634436-357f-40f2-a431-93a87a6c9b98">549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjY3NTU2ODVjN2IzYjQwNDBhMzVlZmQ4YzY1NmJlYTVjL3RhYmxlcmFuZ2U6Njc1NTY4NWM3YjNiNDA0MGEzNWVmZDhjNjU2YmVhNWNfMi03LTEtMS05NDQxNA_d0ce3bbe-6ce5-455d-9c26-115c026ba317">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjY3NTU2ODVjN2IzYjQwNDBhMzVlZmQ4YzY1NmJlYTVjL3RhYmxlcmFuZ2U6Njc1NTY4NWM3YjNiNDA0MGEzNWVmZDhjNjU2YmVhNWNfMy0xLTEtMS05NDQxNA_d5336f2c-1660-4838-abed-44322989e7a2">217</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjY3NTU2ODVjN2IzYjQwNDBhMzVlZmQ4YzY1NmJlYTVjL3RhYmxlcmFuZ2U6Njc1NTY4NWM3YjNiNDA0MGEzNWVmZDhjNjU2YmVhNWNfMy0zLTEtMS05NDQxNA_a9ee8e5d-f1e1-44e2-9b62-26ea1825201c">217</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjY3NTU2ODVjN2IzYjQwNDBhMzVlZmQ4YzY1NmJlYTVjL3RhYmxlcmFuZ2U6Njc1NTY4NWM3YjNiNDA0MGEzNWVmZDhjNjU2YmVhNWNfMy01LTEtMS05NDQxNA_efb61867-55ea-42cf-aecc-8f803a466917">110</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjY3NTU2ODVjN2IzYjQwNDBhMzVlZmQ4YzY1NmJlYTVjL3RhYmxlcmFuZ2U6Njc1NTY4NWM3YjNiNDA0MGEzNWVmZDhjNjU2YmVhNWNfMy03LTEtMS05NDQxNA_12edb302-a417-4abf-a044-5a2facafab02">110</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash collateral received</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:DerivativeCollateralObligationToReturnCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjY3NTU2ODVjN2IzYjQwNDBhMzVlZmQ4YzY1NmJlYTVjL3RhYmxlcmFuZ2U6Njc1NTY4NWM3YjNiNDA0MGEzNWVmZDhjNjU2YmVhNWNfNC0xLTEtMS05NDQxNA_84b4130d-1358-49bd-932c-2693aeaf98fe">794</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:DerivativeCollateralRightToReclaimCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjY3NTU2ODVjN2IzYjQwNDBhMzVlZmQ4YzY1NmJlYTVjL3RhYmxlcmFuZ2U6Njc1NTY4NWM3YjNiNDA0MGEzNWVmZDhjNjU2YmVhNWNfNC0zLTEtMS05NDQxNA_283b303c-205c-4db6-9b86-ced7c2042664">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:DerivativeCollateralObligationToReturnCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjY3NTU2ODVjN2IzYjQwNDBhMzVlZmQ4YzY1NmJlYTVjL3RhYmxlcmFuZ2U6Njc1NTY4NWM3YjNiNDA0MGEzNWVmZDhjNjU2YmVhNWNfNC01LTEtMS05NDQxNA_368dc513-772b-43d1-a5e3-9a74090b052f">164</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:DerivativeCollateralRightToReclaimCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjY3NTU2ODVjN2IzYjQwNDBhMzVlZmQ4YzY1NmJlYTVjL3RhYmxlcmFuZ2U6Njc1NTY4NWM3YjNiNDA0MGEzNWVmZDhjNjU2YmVhNWNfNC03LTEtMS05NDQxNA_fdaa5103-7dbd-4557-88fd-29740e599a81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net amounts</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjY3NTU2ODVjN2IzYjQwNDBhMzVlZmQ4YzY1NmJlYTVjL3RhYmxlcmFuZ2U6Njc1NTY4NWM3YjNiNDA0MGEzNWVmZDhjNjU2YmVhNWNfNS0xLTEtMS05NDQxNA_fc588340-1da6-44b6-858c-d96f6ab1e52b">497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjY3NTU2ODVjN2IzYjQwNDBhMzVlZmQ4YzY1NmJlYTVjL3RhYmxlcmFuZ2U6Njc1NTY4NWM3YjNiNDA0MGEzNWVmZDhjNjU2YmVhNWNfNS0zLTEtMS05NDQxNA_56eafd3c-c104-4c4d-a30d-ca917df84c6d">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjY3NTU2ODVjN2IzYjQwNDBhMzVlZmQ4YzY1NmJlYTVjL3RhYmxlcmFuZ2U6Njc1NTY4NWM3YjNiNDA0MGEzNWVmZDhjNjU2YmVhNWNfNS01LTEtMS05NDQxNA_defb3505-8f62-44d5-8ea7-dc0716d28bca">275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjY3NTU2ODVjN2IzYjQwNDBhMzVlZmQ4YzY1NmJlYTVjL3RhYmxlcmFuZ2U6Njc1NTY4NWM3YjNiNDA0MGEzNWVmZDhjNjU2YmVhNWNfNS03LTEtMS05NDQxNA_d88ff3ba-b3a0-4522-963f-20ef471fd4b0">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTkyNjQ_814d54ec-1376-43bf-9474-dc77eb95d183" escape="true"><div style="margin-top:4pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides information regarding the location and amount of pretax gains and losses of derivatives designated in fair value or cash flow hedging relationships:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.907%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Financial Statement Line Items in which Effects of Fair Value or Cash Flow Hedges are Recorded</span></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other (income) expense, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other (income) expense, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMy0xLTEtMS05NDQxNA_6f1eac12-5c2c-41fd-ac77-39963b7135eb">14,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMy0zLTEtMS05NDQxNA_7c9e15ac-9811-439e-84e6-e6b6358bcdd1">13,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMy01LTEtMS05NDQxNA_98a35210-07de-4355-b4b4-18c86704965a">429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMy03LTEtMS05NDQxNA_8362a6f4-b404-4ce2-8bf4-7d60a2a82159">450</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMy05LTEtMS05NDQxNA_80b80e71-f490-4500-a64d-b908330b5506">416</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMy0xMS0xLTEtOTQ0MTQ_fa0fef12-42e9-4908-87b8-16701e1aedbf">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMy0xMy0xLTEtOTQ0MTQ_93be19a2-92d3-44b5-b71c-13e4fcfbeb64">45,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMy0xNS0xLTEtOTQ0MTQ_0d5bd26d-2afc-4501-b448-9026aedf7176">35,183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMy0xNy0xLTEtOTQ0MTQ_929c0cda-d181-4452-ac66-b60ec2a3bdd6">1,576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMy0xOS0xLTEtOTQ0MTQ_676d5b83-5c23-4cf8-ac8a-80374ad66dd3">1,007</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMy0yMS0xLTEtOTQ0MTQ_f72a47c5-76d2-4263-82d9-4b052712e6b6">314</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMy0yMy0xLTEtOTQ0MTQ_ef44f324-3bf9-4fb8-ab4f-5b5e6f735430">1,595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(Gain) loss on fair value hedging relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Hedged items</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic44487f92a5448159923c27c8d731670_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfNi01LTEtMS05NDQxNA_1456f5eb-e50b-4618-ab5b-71fc083d0405">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4d2e0c5ba4449618b901ef68baa6ea0_D20210701-20210930" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfNi03LTEtMS05NDQxNA_3cb71ea2-1b8f-48a9-a5de-1e59447699e7">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic76064667e0a419bb6d0e5c3426be249_D20220101-20220930" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfNi0xNy0xLTEtOTQ0MTQ_37f9f92b-4e51-43de-ae52-a4926be283c5">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia325483b4883403c90d79d1be19c51da_D20210101-20210930" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfNi0xOS0xLTEtOTQ0MTQ_ee792f9d-92cc-4c74-8f78-62a4e7bbc29c">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic44487f92a5448159923c27c8d731670_D20220701-20220930" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfNy01LTEtMS05NDQxNA_eac7b6bd-ec70-4de7-a8d7-cc1b83d47b1d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4d2e0c5ba4449618b901ef68baa6ea0_D20210701-20210930" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfNy03LTEtMS05NDQxNA_39c0d6c4-e3e6-4a09-b92d-68d6737d99b5">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic76064667e0a419bb6d0e5c3426be249_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfNy0xNy0xLTEtOTQ0MTQ_4027d05b-05e2-4aa5-a7da-a20c5f1a2106">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia325483b4883403c90d79d1be19c51da_D20210101-20210930" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfNy0xOS0xLTEtOTQ0MTQ_1ab4e228-ea85-4cd4-8ae3-17a8b5d16ed0">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Impact of cash flow hedging relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of gain recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie27e3a1d731a4e8aab46753956e07c5d_D20220701-20220930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTAtOS0xLTEtOTQ0MTQ_bc29177c-2788-4101-8640-5826f5d99e31">682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ae35cdeb80c488d9810adba90ad5a22_D20210701-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTAtMTEtMS0xLTk0NDE0_04647d35-f750-475c-9aee-1b1a87054577">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5ffef0aa5134d30a7bc87c2f1471202_D20220101-20220930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTAtMjEtMS0xLTk0NDE0_c0e512f2-575d-4288-a2d6-2003ba58490b">1,233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f49cd47d7c34c2db675a1a70530cbc8_D20210101-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTAtMjMtMS0xLTk0NDE0_f494d756-ddc9-458d-884c-1808093bc0f3">193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Increase (decrease) in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> as a result of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">AOCL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> reclassifications</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2090286591394c9fa952301d7aa1370f_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTEtMS0xLTEtOTQ0MTQ_6553e07e-a8f8-4e3c-8ca0-de9b00cb5b51">253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4bbf795a5864635b793460597f6ab25_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTEtMy0xLTEtOTQ0MTQ_33162687-9fac-4a53-9859-127ec7546804">36</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie27e3a1d731a4e8aab46753956e07c5d_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTEtOS0xLTEtOTQ0MTQ_b94fd6b8-7362-4195-8e23-84b2850dce43">253</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ae35cdeb80c488d9810adba90ad5a22_D20210701-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTEtMTEtMS0xLTk0NDE0_721dd2be-91ef-4204-babf-dcc2a634bb59">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe3cb650f6ab4c9b92198643023e4afa_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTEtMTMtMS0xLTk0NDE0_b03b1681-e82a-4725-ac15-b486d2e85405">491</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i408273e5bb4c48509f2537d97a208c52_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTEtMTUtMS0xLTk0NDE0_8b9906b5-c668-44fc-a880-444a52025f17">219</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5ffef0aa5134d30a7bc87c2f1471202_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTEtMjEtMS0xLTk0NDE0_7b13a4d6-df32-483a-9699-50b72a720ae7">491</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f49cd47d7c34c2db675a1a70530cbc8_D20210101-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTEtMjMtMS0xLTk0NDE0_6b906737-3a8f-488f-8cfa-126ed06e758b">219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTMtMC0xLTEtOTQ0MTQ_415ec0c9-4bba-4fb9-aa01-b4c7b84244a9"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTMtMC0xLTEtOTQ0MTQ_a2ea2169-dd57-478e-b872-7cc7be5bf76a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTMtMC0xLTEtOTQ0MTQ_c6f59e51-c8a0-4c45-930c-4ef2ed96eb20"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTMtMC0xLTEtOTQ0MTQ_ff915512-cf0d-456d-a25d-7aab715fc26c"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of gain recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></span></span></span></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a250ba5d2eb4f398ca0d688c55ce97b_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTMtNS0xLTEtOTQ0MTQ_279d8d1e-9009-45b3-833c-55edf17d9e0f">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4884545f3a04d2592a0a6552ec37a9e_D20210701-20210930" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTMtNy0xLTEtOTQ0MTQ_ac82776b-3fa1-4610-9c23-7042dc534afb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3adbbede1e4c4a219df434d3b02b9d73_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTMtMTctMS0xLTk0NDE0_244cee6d-22a7-4470-95a2-e6c1a31cb614">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24ff49aba1234e2089a06728556f905e_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTMtMTktMS0xLTk0NDE0_5ef1ea0a-0fe6-4e64-9a72-215bca64b5ae">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of loss recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a250ba5d2eb4f398ca0d688c55ce97b_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTQtOS0xLTEtOTQ0MTQ_117144f1-c241-4cfc-b436-ec90004127c8">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4884545f3a04d2592a0a6552ec37a9e_D20210701-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTQtMTEtMS0xLTk0NDE0_37fab61f-70aa-4a6e-9f0b-35bfc74a8b1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3adbbede1e4c4a219df434d3b02b9d73_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTQtMjEtMS0xLTk0NDE0_520eac66-2f39-4e91-859a-aee4a64cd19b">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24ff49aba1234e2089a06728556f905e_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTQtMjMtMS0xLTk0NDE0_e8e4022d-31f1-48ac-988f-95ababb758d7">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Interest expense is a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTkyODI_bd94eed6-43de-478c-9e6a-8d34d4373790" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Derivative Pretax (Gain) Loss Recognized in Income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Income Statement Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8487d36b908947f3b19f1402064fea62_D20220701-20220930" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjBjOWI4NmU4M2Q0YjQ4ZGQ4M2M1ODFhMTFmNWVmMThjL3RhYmxlcmFuZ2U6MGM5Yjg2ZTgzZDRiNDhkZDgzYzU4MWExMWY1ZWYxOGNfNC0zLTEtMS05NDQxNA_31334573-ba68-49f0-90de-a99b225a85c6">41</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7aadf0e5ed8498e968fa72fc5dd2235_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjBjOWI4NmU4M2Q0YjQ4ZGQ4M2M1ODFhMTFmNWVmMThjL3RhYmxlcmFuZ2U6MGM5Yjg2ZTgzZDRiNDhkZDgzYzU4MWExMWY1ZWYxOGNfNC01LTEtMS05NDQxNA_64adb809-983f-4375-b799-1939fd93f119">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id156cdfb0da54388a5c8bd98db65a8b3_D20220101-20220930" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjBjOWI4NmU4M2Q0YjQ4ZGQ4M2M1ODFhMTFmNWVmMThjL3RhYmxlcmFuZ2U6MGM5Yjg2ZTgzZDRiNDhkZDgzYzU4MWExMWY1ZWYxOGNfNC03LTEtMS05NDQxNA_b249c7f2-1fa2-409e-9f62-31b047e7ff79">77</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1673663dc72f4e86a51bc9229008f01d_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjBjOWI4NmU4M2Q0YjQ4ZGQ4M2M1ODFhMTFmNWVmMThjL3RhYmxlcmFuZ2U6MGM5Yjg2ZTgzZDRiNDhkZDgzYzU4MWExMWY1ZWYxOGNfNC05LTEtMS05NDQxNA_cd42d019-7a09-4ecd-bcf4-153d006f7d23">234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i047a084a24b645f68be7cd35a8fc04a6_D20220701-20220930" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjBjOWI4NmU4M2Q0YjQ4ZGQ4M2M1ODFhMTFmNWVmMThjL3RhYmxlcmFuZ2U6MGM5Yjg2ZTgzZDRiNDhkZDgzYzU4MWExMWY1ZWYxOGNfNS0zLTEtMS05NDQxNA_69c95b74-b1da-42a0-9528-558c34e4e29b">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0264f6f727c4a4b966ea14b2e2a52ac_D20210701-20210930" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjBjOWI4NmU4M2Q0YjQ4ZGQ4M2M1ODFhMTFmNWVmMThjL3RhYmxlcmFuZ2U6MGM5Yjg2ZTgzZDRiNDhkZDgzYzU4MWExMWY1ZWYxOGNfNS01LTEtMS05NDQxNA_1fb0af6b-37d4-427c-b217-57f47b5d41e3">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1f6dbfb4c7146b99019ed98f23895de_D20220101-20220930" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjBjOWI4NmU4M2Q0YjQ4ZGQ4M2M1ODFhMTFmNWVmMThjL3RhYmxlcmFuZ2U6MGM5Yjg2ZTgzZDRiNDhkZDgzYzU4MWExMWY1ZWYxOGNfNS03LTEtMS05NDQxNA_a81308cf-9abc-45c5-a690-7b7a4d049601">42</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e75809733d64f339d96ee9714ec260e_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjBjOWI4NmU4M2Q0YjQ4ZGQ4M2M1ODFhMTFmNWVmMThjL3RhYmxlcmFuZ2U6MGM5Yjg2ZTgzZDRiNDhkZDgzYzU4MWExMWY1ZWYxOGNfNS05LTEtMS05NDQxNA_88c9db8b-92c5-4b0d-a8b0-e673b23676f2">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates. Amount in the first nine months of 2021 includes a loss on forward exchange contracts entered into in conjunction with the spin-off of Organon.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> These derivative contracts serve as economic hedges of forecasted transactions.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2022, the Company estimates $<ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfOTg5NQ_d14be63d-ae54-4535-a4fc-f68f56f4a534">864</ix:nonFraction> million of pretax net unrealized gains on derivatives maturing within the next 12 months that hedge foreign currency denominated sales over that same period will be reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amount ultimately reclassified to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity.</span></div></ix:continuation><div style="margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 17 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i5a66118343ac4588bd64618b974e561f" continuedAt="i5fd55cd8061c4e6dbf5186bacc4e6c03"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments in Debt and Equity Securities</span></div><ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTkyMjE_0c1464b4-327f-4262-8267-da356daf355e" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information on investments in debt and equity securities is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.659%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross&#160;Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross&#160;Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4720a53a91d5435188a1da01bfe210fa_I20220930" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNC0xLTEtMS05NDQxNA_c3534b15-128a-4adc-ac35-74c0929d2165">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4720a53a91d5435188a1da01bfe210fa_I20220930" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNC0zLTEtMS05NDQxNA_041ea68e-0f19-4f44-aae0-95f6ea59e2ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4720a53a91d5435188a1da01bfe210fa_I20220930" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNC01LTEtMS05NDQxNA_460588f4-4ec4-492d-aa5a-9f7ac7842e6e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4720a53a91d5435188a1da01bfe210fa_I20220930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNC03LTEtMS05NDQxNA_2dbbef94-e981-445f-9219-a3fab5d6035b">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d9a78619aff46ea84120beb595fcb13_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNC05LTEtMS05NDQxNA_efbd1242-ed11-4e11-a59c-b3ecb1c7c802">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d9a78619aff46ea84120beb595fcb13_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNC0xMS0xLTEtOTQ0MTQ_3dbe39c7-a9f6-400f-80f0-6ef2cfce409e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d9a78619aff46ea84120beb595fcb13_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNC0xMy0xLTEtOTQ0MTQ_a962f30a-a040-48c4-b544-8b67764be73a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d9a78619aff46ea84120beb595fcb13_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNC0xNS0xLTEtOTQ0MTQ_34edc051-234f-4266-be2e-3358abd4cead">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffb605e60b334d25829964639aa3cf58_I20220930" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNS0xLTEtMS0xMDU3MjA_a7cbe398-2b41-4781-a10d-3705a098ed65">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffb605e60b334d25829964639aa3cf58_I20220930" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNS0zLTEtMS0xMDU3MjA_c07d43d3-a0c1-496b-b725-d1f9103cdd47">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffb605e60b334d25829964639aa3cf58_I20220930" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNS01LTEtMS0xMDU3MjA_8eb999f0-b22a-42d7-ae35-86c130edf9a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffb605e60b334d25829964639aa3cf58_I20220930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNS03LTEtMS0xMDU3MjA_e321f960-3f8a-4a76-981e-e21bf07141b4">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df8f1a7ad004c23af8f2239cda6077b_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNS05LTEtMS0xMDU3MjA_da563196-6570-4266-ad1d-99813ed04005">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df8f1a7ad004c23af8f2239cda6077b_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNS0xMS0xLTEtMTA1NzIw_9c0892b3-e6c3-4903-a2bd-7f23679043eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df8f1a7ad004c23af8f2239cda6077b_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNS0xMy0xLTEtMTA1NzIw_f6a69593-ee2c-430b-b50a-1392adf46155">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df8f1a7ad004c23af8f2239cda6077b_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNS0xNS0xLTEtMTA1NzIw_f0995756-cd3e-4024-a8d8-9b4b36f8aa80">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id736b7b8bba944b58bf0232a18e5113e_I20220930" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNS0xLTEtMS05NDQxNA_48400644-3466-40f7-b209-4c983034a6b9">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id736b7b8bba944b58bf0232a18e5113e_I20220930" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNS0zLTEtMS05NDQxNA_95b494e4-b7e6-4e96-9d8d-1fe007f68bdc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id736b7b8bba944b58bf0232a18e5113e_I20220930" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNS01LTEtMS05NDQxNA_afb1ded8-d790-4a06-b183-9da56a7f9386">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id736b7b8bba944b58bf0232a18e5113e_I20220930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNS03LTEtMS05NDQxNA_6ea7d612-10c4-49fd-9a74-067cee218f17">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bfa097e481a425fb4b73f31bdcecc30_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNS05LTEtMS05NDQxNA_065e694a-e761-4ec7-b2a0-42b56b267976">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bfa097e481a425fb4b73f31bdcecc30_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNS0xMS0xLTEtOTQ0MTQ_09e6698e-a701-40f3-b8ef-fef546c273dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bfa097e481a425fb4b73f31bdcecc30_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNS0xMy0xLTEtOTQ0MTQ_3ad38b35-d25c-4409-9f38-b012bc8b215c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bfa097e481a425fb4b73f31bdcecc30_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNS0xNS0xLTEtOTQ0MTQ_a9832f52-1bdb-4e41-9b66-0de6ccc5e843">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8ea7018241f4bbe9b73f4cb4ecc1d8c_I20220930" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNi0xLTEtMS05NDQxNA_a6d5b18b-8165-4564-93bb-5e3715cecb6a">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8ea7018241f4bbe9b73f4cb4ecc1d8c_I20220930" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNi0zLTEtMS05NDQxNA_b16b2f7e-89db-4e2a-b77f-b39ca40a7560">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8ea7018241f4bbe9b73f4cb4ecc1d8c_I20220930" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNi01LTEtMS05NDQxNA_876e569f-b969-4d5b-ba4f-938894db37b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8ea7018241f4bbe9b73f4cb4ecc1d8c_I20220930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNi03LTEtMS05NDQxNA_d50fa134-cbdb-47cb-bdf2-dabc8190e7dd">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a1c00996a864ae7bc40a0fbc771bd76_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNi05LTEtMS05NDQxNA_e248bb7e-3e93-445e-b4d6-5d4611b6ac9e">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a1c00996a864ae7bc40a0fbc771bd76_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNi0xMS0xLTEtOTQ0MTQ_2c7fb09e-0661-47d6-8dc1-344e4c39a745">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a1c00996a864ae7bc40a0fbc771bd76_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNi0xMy0xLTEtOTQ0MTQ_70149f3d-8af9-4845-9041-d49dade26c32">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a1c00996a864ae7bc40a0fbc771bd76_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNi0xNS0xLTEtOTQ0MTQ_82d1dc2e-0c26-49db-86b6-ea0ed8d48890">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNy0xLTEtMS05NDQxNA_69fd3d09-ad55-4b7e-b378-612456b39b96">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNy0zLTEtMS05NDQxNA_13e3162b-d16c-472b-b877-8e49990726c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNy01LTEtMS05NDQxNA_83d9c11c-1578-41c4-8e68-b2d3a4148e54">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNy03LTEtMS05NDQxNA_ce4cb1ca-68a9-4a19-82d4-dd6fefff89e2">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNy05LTEtMS05NDQxNA_bc852421-cbca-4040-919f-8ca289716fe2">86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNy0xMS0xLTEtOTQ0MTQ_c3099606-1f0d-453c-9edb-f9d7306fced6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNy0xMy0xLTEtOTQ0MTQ_5f8f4b2f-bcc4-4f55-8c64-ba36682bf786">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNy0xNS0xLTEtOTQ0MTQ_1a7997cb-0769-40de-b052-7afbde890c89">86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfOC03LTEtMS05NDQxNA_fe7425eb-39a9-4f59-891c-b54a01d749a1">1,334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfOC0xNS0xLTEtOTQ0MTQ_733faedc-b801-4f82-bd0c-7cdd0176a904">1,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt and publicly traded equity securities</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="mrk:DebtSecuritiesandEquitySecuritiesFVNI" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfOS03LTEtMS05NDQxNA_8971e2f1-8f28-4ce4-b581-b2c9bbde021e">1,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="mrk:DebtSecuritiesandEquitySecuritiesFVNI" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfOS0xNS0xLTEtOTQ0MTQ_70c71f78-0abe-4175-8add-c987fc321bd7">1,733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Unrealized net losses of $<ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTA0MjI_fcb5dbe0-ad7e-40b2-97d1-1a36b19a7285">221</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTA0Mjk_ed420029-2385-408a-a210-4622ffaa02d9">415</ix:nonFraction> million were recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> in the third quarter and first nine months of 2022, respectively, on equity securities still held at September&#160;30, 2022. Unrealized net (gains) losses of $(<ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTA2MDA_ced0df1c-e2d2-4777-b84d-7cc87ceab5b7">90</ix:nonFraction>) million and $<ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTA2MDc_59b67774-071f-4dde-b0dd-02eb2a3995ed">109</ix:nonFraction>&#160;million were recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> in the third quarter and first nine months of 2021, respectively, on equity securities still held at September&#160;30, 2021.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2022 and September&#160;30, 2021, the Company also had $<ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTA3ODg_6978b2f8-fd61-4bd3-9b1f-714a8bd5b8b2">705</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i48930a09b1404293820fbeb015eb6729_I20210930" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTA3OTU_0c17702a-deb9-4c1d-8a42-7c1a184c6906">578</ix:nonFraction> million, respectively, of equity investments without readily determinable fair values included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company records unrealized gains on these equity investments based on favorable observable price changes from transactions involving similar investments of the same investee and records unrealized losses based on unfavorable observable price changes, which are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. During the first nine months</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company recorded unrealized gains of $<ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTEyODM_0a8c9754-57d9-4122-893d-32f73d95a1c5">21</ix:nonFraction> million and unrealized net losses of $<ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTEzMTU_a059a9d0-5bdd-4ae0-8675-2d2fdc2314f3">12</ix:nonFraction>&#160;million related to certain of these equity investments still held at September&#160;30, 2022. During the first nine months</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company recorded unrealized gains of $<ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTE0NTg_ecf0e497-b3b8-4de4-8a3d-7124e590ba96">104</ix:nonFraction>&#160;million and unrealized losses of $<ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTE0ODY_6e97b954-68bf-4d4c-8ed5-1f765d4e9342">1</ix:nonFraction>&#160;million related to certain of these investments still held at September&#160;30, 2021. Cumulative unrealized gains and cumulative unrealized losses based on observable price changes for investments in equity investments without readily determinable fair values still held at September&#160;30, 2022 were $<ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTE3NDM_349d6d40-9d15-4f76-b9a9-9eed02b04195">255</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTE3NTA_3ad83157-998a-41c4-a77a-5461d75f2b2d">19</ix:nonFraction> million, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2022 and September&#160;30, 2021, the Company also had $<ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTE4MDQ_68acee95-2d76-4c0e-bfab-49c054ade4de">655</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i48930a09b1404293820fbeb015eb6729_I20210930" decimals="-8" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTE4MTE_4994c71a-e45b-450d-9e68-d3daa60bacc0">1.2</ix:nonFraction>&#160;billion, respectively, recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for equity securities held through ownership interests in investment funds. Losses (gains) recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> relating to these investment funds were $<ix:nonFraction unitRef="usd" contextRef="i010c9478893544c28a5d7f544dc8e662_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTIwMjU_dbe71c33-901c-48c5-874f-e73b42761c87">141</ix:nonFraction>&#160;million and $(<ix:nonFraction unitRef="usd" contextRef="i099b739b13c44281a0c6d085f13b276d_D20210701-20210930" decimals="-6" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTIwMzI_1bcb4535-1e6a-4486-a7b7-66a514ad5395">391</ix:nonFraction>)&#160;million for the third quarter of 2022 and 2021, respectively, and were $<ix:nonFraction unitRef="usd" contextRef="if9e54f6ced9e4ef1b0e99ea06c1e9ef7_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTIwOTU_169771a9-f26a-4b78-bd61-5b0cf36f4191">952</ix:nonFraction>&#160;million and $(<ix:nonFraction unitRef="usd" contextRef="i3580944146354ced840addc5a64825b3_D20210101-20210930" decimals="-6" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTIxMDI_aba125ac-b6d6-4523-808e-473808ee4f80">893</ix:nonFraction>)&#160;million for the first nine months of 2022 and 2021, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level&#160;1 having the highest priority and Level 3 having the lowest: </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Quoted prices (unadjusted) in active markets for identical assets or liabilities; </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Unobservable inputs that are supported by little or no market activity. Level 3 assets or liabilities are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as assets or liabilities for which the determination of fair value requires significant judgment or estimation. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.</span></div></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 18 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i5fd55cd8061c4e6dbf5186bacc4e6c03" continuedAt="i4195abd069df4b8eb633622909d10741"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTkyNjA_d9054666-6e0d-4476-95d6-6dee9622d3f4" escape="true"><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities measured at fair value on a recurring basis are summarized below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.654%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i734d905417484b12868c71bc4c409e5a_I20220930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfNS0xLTEtMS05NDQxNA_a6df7511-479d-454d-a305-1a5e66f2add2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic41821eed5a14d76af729b6ab39c2ea7_I20220930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfNS0zLTEtMS05NDQxNA_c2e1a492-073c-4501-95dc-7d77d9395e6e">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51e48c4224c04c2a8bdb9693ed998b0f_I20220930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfNS01LTEtMS05NDQxNA_f82fba55-b5d5-4970-be7c-3303f73234d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba9a552130db4292b0e26dabff225e15_I20220930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfNS03LTEtMS05NDQxNA_b810b08d-08a7-4237-85f3-ca02610130ae">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d25405b868b4e26aefbe7888fc41f43_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfNS05LTEtMS05NDQxNA_88d26e59-8928-4ad1-82bb-943745092638">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1426949b23ca4b71afa632f63d710aad_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfNS0xMS0xLTEtOTQ0MTQ_49ca1a5b-e1ba-4938-aaa9-7e4588454573">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d7092dc98a44dff9517d3c284f1849b_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfNS0xMy0xLTEtOTQ0MTQ_fa6929e7-42b7-48b8-96be-75fb121e9b3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie37c5d029c6648c8a2ed03a8d89af9b2_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfNS0xNS0xLTEtOTQ0MTQ_81c64365-3b94-4459-bf17-73eac2d50808">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1509e49abe14db0828288f4c189b466_I20220930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfNi0xLTEtMS05NDQxNA_06fed069-9edf-4700-becb-e49d1f401367">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac3cf219c1b341109243396f0c18a2ba_I20220930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfNi0zLTEtMS05NDQxNA_3afabf92-0250-4d84-bc5d-8bb307c552bf">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icaf187dd1d10491f92cbfb112d50b31f_I20220930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfNi01LTEtMS05NDQxNA_0a5b0e8b-6347-4978-a4f9-f59761b42b38">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5dfb72ba12644a297b93978abb2da49_I20220930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfNi03LTEtMS05NDQxNA_158cd9a9-6fdd-482d-bad0-75f812b09981">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24b11ce36fae442893c46a0e7203cdfa_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfNi05LTEtMS05NDQxNA_b3fb9b1a-8634-4a8f-815b-95b084638f28">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37c6e32ba0824ee38f745770cec9a2d3_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfNi0xMS0xLTEtOTQ0MTQ_e33bbb1c-7dd3-4e58-ab3e-5c9ab4873772">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7c90958615d4c819c1023d563e55db5_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfNi0xMy0xLTEtOTQ0MTQ_52c661df-af00-411f-bf7a-594e5ccb76f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3eec1411691a43719325ad418681ac13_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfNi0xNS0xLTEtOTQ0MTQ_8d2f718f-edc2-40b0-9825-5a42fbfd0480">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7584c66c93fc49e79ea35b57c4e39390_I20220930" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfNy0xLTEtMS05NDQxNA_77ba06ef-ef39-421d-822e-937661c286d6">1,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7fc87b646454715bebf1e86eed2c3f4_I20220930" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfNy0zLTEtMS05NDQxNA_087fc90f-e84e-4403-a6b4-4073c12fe7ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1317ac689e934a98bcc9a08673feae09_I20220930" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfNy01LTEtMS05NDQxNA_1fdd11a0-b960-4fef-97ba-a39924f288c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd40f186b450434689326d7a01e529ba_I20220930" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfNy03LTEtMS05NDQxNA_b037a75f-06ea-4a87-88fd-bb7543e7e849">1,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i805bffc3fe574f44bdab78a3217cffd8_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfNy05LTEtMS05NDQxNA_c82c7a04-01e3-4eeb-bb41-32050368121f">368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ad98dd1519d4e5ba2a6d482e01bb026_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfNy0xMS0xLTEtOTQ0MTQ_f9bc2637-d7d5-4434-ba4f-870b449541cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e5b8eb982b3417191aa735376241712_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfNy0xMy0xLTEtOTQ0MTQ_d97a2a1d-faf4-47ae-bed8-42c6adc84ce5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d23f5244de4df5a78fbcc38021abc9_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfNy0xNS0xLTEtOTQ0MTQ_5cde5302-8ad1-4b68-a26e-2be581908010">368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5cc583b3ac545afb27d7011fbd7878e_I20220930" decimals="-6" name="us-gaap:TradingSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfOC0xLTEtMS05NDQxNA_6db504b9-4010-46d2-a783-e04c9e80bfbd">1,081</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7b005680367482db7f6c5526d8a8330_I20220930" decimals="-6" name="us-gaap:TradingSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfOC0zLTEtMS05NDQxNA_5891350d-17e1-4e68-b9cf-96f969f605e9">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5806d7d6752145c89d6aed6b12c0de58_I20220930" decimals="-6" name="us-gaap:TradingSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfOC01LTEtMS05NDQxNA_9f95aca8-fc25-4d34-95d8-40f71914c8ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d038eb8e67488896fcaf65d65f5a4c_I20220930" decimals="-6" name="us-gaap:TradingSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfOC03LTEtMS05NDQxNA_e2349a0e-4040-435c-9570-6bf044bbf74c">1,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88cb48af3d36483bb4a106b4973f8a8b_I20211231" decimals="-6" name="us-gaap:TradingSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfOC05LTEtMS05NDQxNA_27499acf-550f-4391-84c2-5dca21412bd2">368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9b5923422814e839a9eace38e185dc2_I20211231" decimals="-6" name="us-gaap:TradingSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfOC0xMS0xLTEtOTQ0MTQ_e41ab672-f568-45ad-8d65-03fd740e6d06">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53252463645d40a49cf3666fc9496c89_I20211231" decimals="-6" name="us-gaap:TradingSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfOC0xMy0xLTEtOTQ0MTQ_d2195e16-f9a9-4792-8e15-48da99fc0431">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95e44cbbb3c8441db74551146976a2b5_I20211231" decimals="-6" name="us-gaap:TradingSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfOC0xNS0xLTEtOTQ0MTQ_d42f9612-ca60-4587-9698-04e9cbbf2b2e">370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib55137ada6674e97b937072f652336fc_I20220930" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTAtMS0xLTEtOTQ0MTQ_4d24ce9d-6792-4a22-aac3-d970ce7b5239">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia34cec2011844b3abbbecd5c96aa140b_I20220930" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTAtMy0xLTEtOTQ0MTQ_c585ae2c-2684-4cf0-9f5a-4bd7b4c529e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9d82f620e50424d92c3ec570c9584c7_I20220930" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTAtNS0xLTEtOTQ0MTQ_1f61379f-0c74-4d8b-a144-63aa18be8725">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96a1014d1ffc460ea40f01ffc40ca637_I20220930" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTAtNy0xLTEtOTQ0MTQ_a6770a60-2196-4f71-9080-ebf523f8ef39">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a852e542ad490499c3bbfa84c21253_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTAtOS0xLTEtOTQ0MTQ_3671d444-2222-4da4-a804-54022a5dd09b">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0249004b56d4566adef1bedb1ae2649_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTAtMTEtMS0xLTk0NDE0_15630d0f-718e-45d3-b2a8-335f76823caf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7d1ba12651d49ca9605e8d70b0465db_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTAtMTMtMS0xLTk0NDE0_c5176db1-c798-4da8-b561-d1043fd6b426">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62dc854b928b49a1945ab2a202ed9435_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTAtMTUtMS0xLTk0NDE0_3f2c7387-44ef-44b0-9684-fb44e6f77d4d">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7bca4ee680b4b53bd3c893bfc03df3a_I20220930" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTEtMS0xLTEtOTQ0MTQ_82f35496-0d06-4ffa-85c7-8a8a85ab2801">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if02abc99fb924ec7b0925ad5b953f9a0_I20220930" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTEtMy0xLTEtOTQ0MTQ_0cc2fb2d-d557-4ca3-8018-5dcf9516bfd4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eedae5d638b46e08efb6239577ce6a7_I20220930" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTEtNS0xLTEtOTQ0MTQ_770e6bd8-55c0-4064-894f-b4330cf9250d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30c84521440546809e99309ada3e6429_I20220930" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTEtNy0xLTEtOTQ0MTQ_4ae584cf-b912-46c2-ad06-4aba89d2aaab">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66af9dda5d5a4116ac1581f86efa6274_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTEtOS0xLTEtOTQ0MTQ_3a178a6b-78cb-49a0-98b1-cfc47a6854d2">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec03db9221fc48e3aae39a8b07057d6b_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTEtMTEtMS0xLTk0NDE0_e5e5ad3a-6ca5-4929-bc6b-1508e5a4f1c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c3110d2fc4241989477e58acec0f4b3_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTEtMTMtMS0xLTk0NDE0_7840442d-99e6-4da9-a543-e811767100d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4589bd6805f421980e686f3847f3f2a_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTEtMTUtMS0xLTk0NDE0_86069fc5-727b-493f-b6dd-b20f323e65a2">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7584c66c93fc49e79ea35b57c4e39390_I20220930" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTItMS0xLTEtOTQ0MTQ_f91b682a-b4ba-4125-a883-b6d481fbd915">253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7fc87b646454715bebf1e86eed2c3f4_I20220930" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTItMy0xLTEtOTQ0MTQ_30a761d2-021d-4689-9084-dbe3a398c810">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1317ac689e934a98bcc9a08673feae09_I20220930" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTItNS0xLTEtOTQ0MTQ_ad9d08c5-c746-46a2-abee-38334d9f1ed1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd40f186b450434689326d7a01e529ba_I20220930" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTItNy0xLTEtOTQ0MTQ_f7d81f58-d107-4486-808c-bf025b817950">253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i805bffc3fe574f44bdab78a3217cffd8_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTItOS0xLTEtOTQ0MTQ_ec429086-c062-408f-86a4-26d37ea1efcf">1,279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ad98dd1519d4e5ba2a6d482e01bb026_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTItMTEtMS0xLTk0NDE0_ec5101a0-684d-41a6-869d-6f709b9cb23d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e5b8eb982b3417191aa735376241712_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTItMTMtMS0xLTk0NDE0_6e3d7ca9-8c2a-413c-ba48-58f230b0b493">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d23f5244de4df5a78fbcc38021abc9_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTItMTUtMS0xLTk0NDE0_7415717b-ad23-4f34-a222-1af5389c34cb">1,279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5cc583b3ac545afb27d7011fbd7878e_I20220930" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTMtMS0xLTEtOTQ0MTQ_374ac586-3734-442d-a353-a73486895792">323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7b005680367482db7f6c5526d8a8330_I20220930" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTMtMy0xLTEtOTQ0MTQ_d512a7c1-0804-4d2a-9443-342b3d893169">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5806d7d6752145c89d6aed6b12c0de58_I20220930" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTMtNS0xLTEtOTQ0MTQ_af0f31d1-0238-4765-baa0-97c818e1e716">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d038eb8e67488896fcaf65d65f5a4c_I20220930" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTMtNy0xLTEtOTQ0MTQ_13b0b3a0-78d8-481d-b14c-fa4775c87025">323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88cb48af3d36483bb4a106b4973f8a8b_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTMtOS0xLTEtOTQ0MTQ_33fc0cbd-a640-46ab-ad93-f647a3b7caf5">1,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9b5923422814e839a9eace38e185dc2_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTMtMTEtMS0xLTk0NDE0_773d4b9c-28e7-4fbb-85cd-94cf62b4257b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53252463645d40a49cf3666fc9496c89_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTMtMTMtMS0xLTk0NDE0_0421b263-efbd-48c4-9a26-a579fb87d8d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95e44cbbb3c8441db74551146976a2b5_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTMtMTUtMS0xLTk0NDE0_d26b2c54-4394-4ef1-88a6-1250b882bb1a">1,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivative assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a48ff5c326b4d30a9df72d6f4e2cc4e_I20220930" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTUtMS0xLTEtOTQ0MTQ_43af1133-c7b5-4103-8c14-1d5d8e6979fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f242540e8e74ae39f0f26f08bedea4b_I20220930" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTUtMy0xLTEtOTQ0MTQ_b1a656da-d2a5-4883-8993-19afe37bf0bf">945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia57d77b66d2f4f38a0d399ea6f3efb81_I20220930" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTUtNS0xLTEtOTQ0MTQ_f4b1da32-f1e8-46a8-9de6-a6bb26ed1315">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2e22773379b440b9fd05bd8ebbb205a_I20220930" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTUtNy0xLTEtOTQ0MTQ_5d32682d-9a5c-4305-b9f3-71f21234f017">945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a773b58a7504fb78494693a086bafcb_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTUtOS0xLTEtOTQ0MTQ_f691d700-77f4-44cb-a607-0e7880af2983">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05efb95673774e31aaf4d68427669b60_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTUtMTEtMS0xLTk0NDE0_ff2db091-51a0-44c4-a603-c7fd7569d0ff">351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b85ae7b23754291aed374cfe63220b4_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTUtMTMtMS0xLTk0NDE0_80665c19-ba6c-476b-baad-25884533c776">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77e75274a39649d087e97960c6fdb1da_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTUtMTUtMS0xLTk0NDE0_9cfc2cab-b204-4221-b924-6e6decc129f9">351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased currency options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f4e74eaf7314a6f9b6f0534ffb3fad5_I20220930" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTYtMS0xLTEtOTQ0MTQ_261df952-851c-4a79-95cc-d97a2c7d96ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b468d5994c457b9893c14bd393221a_I20220930" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTYtMy0xLTEtOTQ0MTQ_b9200c3e-206c-48a4-a03d-d380e10e617a">563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if123e3f18ada47ea9d007bf17e6267a0_I20220930" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTYtNS0xLTEtOTQ0MTQ_d92f6917-fd81-41c3-ab3a-2291f09cc493">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d2873d5334e4202befee01684ddbb00_I20220930" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTYtNy0xLTEtOTQ0MTQ_3d97eb8d-060f-4a09-894d-4708579e6f30">563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e6b581a6b0347088dff9d709ad77eec_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTYtOS0xLTEtOTQ0MTQ_d126a65a-bdd1-4a8c-b828-3a1dacfadbf2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i891d6272e42a4cb2afb1b6651756ea76_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTYtMTEtMS0xLTk0NDE0_b7b71b8a-3c1a-4a65-b710-82d2bc131ed7">184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf235de4a0b04bebbe52a604c0a5aec9_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTYtMTMtMS0xLTk0NDE0_6a5d030e-1b42-47cd-aed3-4b4780f9c38a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a40cfbe8af4bbaa128d619556eef8d_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTYtMTUtMS0xLTk0NDE0_d0054cc2-b4fe-4d5e-893a-f9ae3afc61fd">184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b8fe718d6fd40a2bb40eac7eb3ec7a5_I20220930" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTctMS0xLTEtOTQ0MTQ_f628c17a-21d8-457f-811d-9866e93dbc6d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i891529025c4d453c984c2df2e720aabc_I20220930" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTctMy0xLTEtOTQ0MTQ_c91fb8f8-3e27-4ba5-9f1e-6f48cbebb866">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c660dcc9c53431ea4f8bf9732b7f414_I20220930" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTctNS0xLTEtOTQ0MTQ_13793bd0-962e-415b-b389-55ec117e75bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16903db8243d43c6a0558e66c138694a_I20220930" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTctNy0xLTEtOTQ0MTQ_49e71e04-b32a-4a89-82ca-2ebfb588da94">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4220f301677a4e66966080b9f99d020c_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTctOS0xLTEtOTQ0MTQ_3f867772-605f-4f20-b26f-2c8e37a8eeee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc979a929d5b473dac3eb798c69af53e_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTctMTEtMS0xLTk0NDE0_1b6e21e7-fe64-4c4e-86e2-e72838ab7834">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3256ceaea4e54171a07f3e8e012df401_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTctMTMtMS0xLTk0NDE0_9d321dc8-63ee-49bd-9d7d-8c1de1343478">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57cd225864c49d1b3170aa0a6cc6eac_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTctMTUtMS0xLTk0NDE0_8ee15369-eff6-4560-a0b3-098020100a3e">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5cc583b3ac545afb27d7011fbd7878e_I20220930" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTgtMS0xLTEtOTQ0MTQ_d6e3e1df-959e-4864-942b-e8a538405ce9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7b005680367482db7f6c5526d8a8330_I20220930" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTgtMy0xLTEtOTQ0MTQ_34cef064-4d28-4a25-a42a-220fb14c3a8c">1,508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5806d7d6752145c89d6aed6b12c0de58_I20220930" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTgtNS0xLTEtOTQ0MTQ_bc9636b4-a834-4226-9937-da1b28a522f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d038eb8e67488896fcaf65d65f5a4c_I20220930" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTgtNy0xLTEtOTQ0MTQ_806d5580-ed82-4907-b561-b1c517439a57">1,508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88cb48af3d36483bb4a106b4973f8a8b_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTgtOS0xLTEtOTQ0MTQ_81ddf86a-d0f7-441c-aed7-c58a791158d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9b5923422814e839a9eace38e185dc2_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTgtMTEtMS0xLTk0NDE0_bb107b96-73e1-485f-90ec-45e9cfd15504">549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53252463645d40a49cf3666fc9496c89_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTgtMTMtMS0xLTk0NDE0_0b755268-c64f-476d-aae3-0623c398ec60">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95e44cbbb3c8441db74551146976a2b5_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTgtMTUtMS0xLTk0NDE0_fb80da29-8dcf-41ae-a912-32129de679a9">549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5cc583b3ac545afb27d7011fbd7878e_I20220930" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTktMS0xLTEtOTQ0MTQ_43c35596-cde7-4f87-a920-606e11c509c4">1,404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7b005680367482db7f6c5526d8a8330_I20220930" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTktMy0xLTEtOTQ0MTQ_ec702633-41de-4e91-9bf4-bb9b4f13454a">1,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5806d7d6752145c89d6aed6b12c0de58_I20220930" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTktNS0xLTEtOTQ0MTQ_e22c9d7d-fb1e-4c47-966f-8f77d9b30f9d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d038eb8e67488896fcaf65d65f5a4c_I20220930" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTktNy0xLTEtOTQ0MTQ_99aa03bc-6697-4246-a595-fd2ec857de9e">2,918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88cb48af3d36483bb4a106b4973f8a8b_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTktOS0xLTEtOTQ0MTQ_a8a312a0-ce51-461d-942d-437e233abd5d">1,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9b5923422814e839a9eace38e185dc2_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTktMTEtMS0xLTk0NDE0_1874e57e-7ed9-4404-93a1-216e32a0fca3">551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53252463645d40a49cf3666fc9496c89_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTktMTMtMS0xLTk0NDE0_5c1e8ac1-fd6a-4935-921e-ebc992063ceb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95e44cbbb3c8441db74551146976a2b5_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTktMTUtMS0xLTk0NDE0_f1f3e64c-e2c8-4866-9fbe-539fd99389c9">2,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5cc583b3ac545afb27d7011fbd7878e_I20220930" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjItMS0xLTEtOTQ0MTQ_1e6a7b3a-3052-466e-9395-af6ce9c27af5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7b005680367482db7f6c5526d8a8330_I20220930" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjItMy0xLTEtOTQ0MTQ_4dd4eea3-a9d0-4c91-96f1-3f56afc2d7c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5806d7d6752145c89d6aed6b12c0de58_I20220930" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjItNS0xLTEtOTQ0MTQ_d8e68af6-0484-4070-8fdd-815f3b574d4b">499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d038eb8e67488896fcaf65d65f5a4c_I20220930" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjItNy0xLTEtOTQ0MTQ_e78de016-17e5-472e-8e79-5fc4ee3c61b1">499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88cb48af3d36483bb4a106b4973f8a8b_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjItOS0xLTEtOTQ0MTQ_5c5eddf8-5c71-4c96-938d-0444226bb04c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9b5923422814e839a9eace38e185dc2_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjItMTEtMS0xLTk0NDE0_91e51720-45d6-4588-a9bb-613e6ec7444c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53252463645d40a49cf3666fc9496c89_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjItMTMtMS0xLTk0NDE0_119ba0ce-5269-4fce-b480-d528cdb8dfbb">777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95e44cbbb3c8441db74551146976a2b5_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjItMTUtMS0xLTk0NDE0_75e216ae-cae2-4feb-b80e-fa61dbf3fd9c">777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivative liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a48ff5c326b4d30a9df72d6f4e2cc4e_I20220930" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjQtMS0xLTEtOTQ0MTQ_327ecd6a-3a2d-4982-b705-dabd46f337b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f242540e8e74ae39f0f26f08bedea4b_I20220930" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjQtMy0xLTEtOTQ0MTQ_c441ca73-6fb7-4047-8e99-98c0a9d8682c">242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia57d77b66d2f4f38a0d399ea6f3efb81_I20220930" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjQtNS0xLTEtOTQ0MTQ_53d6fc4d-1153-44a6-a23f-3887ac3b0711">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2e22773379b440b9fd05bd8ebbb205a_I20220930" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjQtNy0xLTEtOTQ0MTQ_aa506155-0fcb-4152-b94a-741e34440d14">242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a773b58a7504fb78494693a086bafcb_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjQtOS0xLTEtOTQ0MTQ_1e7c84cd-093d-4368-ad8c-488700701dee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05efb95673774e31aaf4d68427669b60_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjQtMTEtMS0xLTk0NDE0_ec8065be-f753-4090-83a9-4c3ed493096a">120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b85ae7b23754291aed374cfe63220b4_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjQtMTMtMS0xLTk0NDE0_062d3516-1633-47c0-bfb2-356da0ad968a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77e75274a39649d087e97960c6fdb1da_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjQtMTUtMS0xLTk0NDE0_8f8dd627-fc70-49be-a5de-301a0669b454">120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Written currency options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f4e74eaf7314a6f9b6f0534ffb3fad5_I20220930" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjUtMS0xLTEtOTQ0MTQ_95e9c726-2873-46a2-bc06-9f332e627c42">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b468d5994c457b9893c14bd393221a_I20220930" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjUtMy0xLTEtOTQ0MTQ_f32248b1-f4ad-4f01-a3b0-87595175ec4d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if123e3f18ada47ea9d007bf17e6267a0_I20220930" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjUtNS0xLTEtOTQ0MTQ_7eb35128-16ac-46dc-ae68-6c65fc676e21">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d2873d5334e4202befee01684ddbb00_I20220930" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjUtNy0xLTEtOTQ0MTQ_50786daf-ef47-4688-ad4e-ad2e06044516">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e6b581a6b0347088dff9d709ad77eec_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjUtOS0xLTEtOTQ0MTQ_af0cbf7e-c468-4751-80b2-7967fd02b683">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i891d6272e42a4cb2afb1b6651756ea76_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjUtMTEtMS0xLTk0NDE0_526710ea-d2a9-4d7b-a428-f1744b1bcb06">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf235de4a0b04bebbe52a604c0a5aec9_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjUtMTMtMS0xLTk0NDE0_8cfb0b1e-5117-43c1-80c0-4ce83227b0ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a40cfbe8af4bbaa128d619556eef8d_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjUtMTUtMS0xLTk0NDE0_c3e906c8-828b-4a22-9549-b1346ce5c28c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5cc583b3ac545afb27d7011fbd7878e_I20220930" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjYtMS0xLTEtOTQ0MTQ_dedc2665-25fb-4b98-9ba1-5335b3dacf32">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7b005680367482db7f6c5526d8a8330_I20220930" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjYtMy0xLTEtOTQ0MTQ_15e6d9d7-d147-4ed8-9a35-311e1a181af6">242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5806d7d6752145c89d6aed6b12c0de58_I20220930" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjYtNS0xLTEtOTQ0MTQ_e6b07422-0859-48ee-9170-69afc01ce43f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d038eb8e67488896fcaf65d65f5a4c_I20220930" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjYtNy0xLTEtOTQ0MTQ_35d50d1f-0039-415e-8867-33170ddeff6b">242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88cb48af3d36483bb4a106b4973f8a8b_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjYtOS0xLTEtOTQ0MTQ_660525b7-6711-4d47-8afd-ecd5ed56d45c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9b5923422814e839a9eace38e185dc2_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjYtMTEtMS0xLTk0NDE0_4bda484b-f8d4-44f4-8f21-bc7b1e83f8f6">121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53252463645d40a49cf3666fc9496c89_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjYtMTMtMS0xLTk0NDE0_d5b39aa0-8710-456b-ba68-f1540f3396e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95e44cbbb3c8441db74551146976a2b5_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjYtMTUtMS0xLTk0NDE0_fe17c222-ed44-4981-9069-8a0f3f4f95c5">121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5cc583b3ac545afb27d7011fbd7878e_I20220930" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjctMS0xLTEtOTQ0MTQ_dbe6e8e0-2f5e-4a7a-b497-42c104c2f9db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7b005680367482db7f6c5526d8a8330_I20220930" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjctMy0xLTEtOTQ0MTQ_51828f7b-5a5d-4f5e-a16a-d65d8c6c9050">242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5806d7d6752145c89d6aed6b12c0de58_I20220930" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjctNS0xLTEtOTQ0MTQ_b5aa8dad-86af-4b72-85c1-79e66aef60d1">499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d038eb8e67488896fcaf65d65f5a4c_I20220930" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjctNy0xLTEtOTQ0MTQ_6b345452-01fe-45c2-8429-17e35eca10bc">741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88cb48af3d36483bb4a106b4973f8a8b_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjctOS0xLTEtOTQ0MTQ_d44ec871-79d0-42d9-9189-ae0e8d0bdd38">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9b5923422814e839a9eace38e185dc2_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjctMTEtMS0xLTk0NDE0_6633cb31-b46c-4f7b-a59b-d74f1ee8419f">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53252463645d40a49cf3666fc9496c89_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjctMTMtMS0xLTk0NDE0_96037f7b-5f52-4994-8351-e96ba1016cd9">777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95e44cbbb3c8441db74551146976a2b5_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjctMTUtMS0xLTk0NDE0_7b66c4db-a060-4cee-974a-e955ea782988">898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt"> Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company&#8217;s own credit risk, the effects of which were not significant.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022 and December&#160;31, 2021, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included $<ix:nonFraction unitRef="usd" contextRef="ief790689a028402aa25ab7e36ca0ef81_I20220930" decimals="-8" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTQzMDE_5b61e7a9-e94f-46df-a99c-7615b32795b2">10.0</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="if556bca6c6704fee88ef4a1501269201_I20211231" decimals="-8" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTQzMDg_68202e59-36ca-40de-9981-70cb202a00e3">6.8</ix:nonFraction> billion of cash equivalents, respectively (which would be considered Level 2 in the fair value hierarchy). </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration</span></div><ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTkyMzk_38d9973a-fc5b-44b1-a62f-3c3ba80e3981" escape="true"><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information about the changes in the fair value of liabilities for contingent consideration associated with business combinations is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:80.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.846%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJhNWNlODY4OWU2OTRiOThiN2Y1ZGUxMTUwMGQwMDMyL3RhYmxlcmFuZ2U6YmE1Y2U4Njg5ZTY5NGI5OGI3ZjVkZTExNTAwZDAwMzJfMS0xLTEtMS05NDQxNA_12ca51fb-5f43-4cb5-8ffb-c4c83402fc99">777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b76c3e2ce274f17b07c82ae1459e9f9_I20201231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJhNWNlODY4OWU2OTRiOThiN2Y1ZGUxMTUwMGQwMDMyL3RhYmxlcmFuZ2U6YmE1Y2U4Njg5ZTY5NGI5OGI3ZjVkZTExNTAwZDAwMzJfMS0zLTEtMS05NDQxNA_3e388d22-8429-42d9-bf6e-7eb3d852ec1b">841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJhNWNlODY4OWU2OTRiOThiN2Y1ZGUxMTUwMGQwMDMyL3RhYmxlcmFuZ2U6YmE1Y2U4Njg5ZTY5NGI5OGI3ZjVkZTExNTAwZDAwMzJfMi0xLTEtMS05NDQxNA_c531e231-6a2d-4198-8d91-64de581cf067">156</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJhNWNlODY4OWU2OTRiOThiN2Y1ZGUxMTUwMGQwMDMyL3RhYmxlcmFuZ2U6YmE1Y2U4Njg5ZTY5NGI5OGI3ZjVkZTExNTAwZDAwMzJfMi0zLTEtMS05NDQxNA_14844ce1-cb82-440c-9ecf-9b2fd4771cce">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJhNWNlODY4OWU2OTRiOThiN2Y1ZGUxMTUwMGQwMDMyL3RhYmxlcmFuZ2U6YmE1Y2U4Njg5ZTY5NGI5OGI3ZjVkZTExNTAwZDAwMzJfMy0xLTEtMS05NDQxNA_62d17b36-9bbf-4777-89d9-58108b266a34">119</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJhNWNlODY4OWU2OTRiOThiN2Y1ZGUxMTUwMGQwMDMyL3RhYmxlcmFuZ2U6YmE1Y2U4Njg5ZTY5NGI5OGI3ZjVkZTExNTAwZDAwMzJfMy0zLTEtMS05NDQxNA_ffa47c61-6d08-45f0-a494-f978670a6de2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="mrk:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJhNWNlODY4OWU2OTRiOThiN2Y1ZGUxMTUwMGQwMDMyL3RhYmxlcmFuZ2U6YmE1Y2U4Njg5ZTY5NGI5OGI3ZjVkZTExNTAwZDAwMzJfNC0xLTEtMS05NDQxNA_760639be-4315-4683-bb1e-9a8aa1ae4693">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="mrk:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJhNWNlODY4OWU2OTRiOThiN2Y1ZGUxMTUwMGQwMDMyL3RhYmxlcmFuZ2U6YmE1Y2U4Njg5ZTY5NGI5OGI3ZjVkZTExNTAwZDAwMzJfNC0zLTEtMS05NDQxNA_d7a55987-17d0-4a99-b40b-6b38d1dd8afc">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value September 30 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJhNWNlODY4OWU2OTRiOThiN2Y1ZGUxMTUwMGQwMDMyL3RhYmxlcmFuZ2U6YmE1Y2U4Njg5ZTY5NGI5OGI3ZjVkZTExNTAwZDAwMzJfNS0xLTEtMS05NDQxNA_dcfe808a-7b94-45a9-a54d-bed8be5a88d1">499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48930a09b1404293820fbeb015eb6729_I20210930" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJhNWNlODY4OWU2OTRiOThiN2Y1ZGUxMTUwMGQwMDMyL3RhYmxlcmFuZ2U6YmE1Y2U4Njg5ZTY5NGI5OGI3ZjVkZTExNTAwZDAwMzJfNS0zLTEtMS05NDQxNA_07fc6bbc-825d-4485-b660-901621e6c075">902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">  Recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cost of sales, Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> expenses, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">. Includes cumulative translation adjustments.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">At September&#160;30, 2022, $<ix:nonFraction unitRef="usd" contextRef="i8f6c358374a442b8908f3ddffb11dba7_I20220930" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTQ3NTE_274dda3f-22e7-4054-acb8-55b44851de53">358</ix:nonFraction> million of the liabilities relate to the 2016 termination of the Sanofi Pasteur MSD joint venture. As part of the termination, Merck recorded a liability for contingent future royalty payments of <ix:nonFraction unitRef="number" contextRef="i8f6c358374a442b8908f3ddffb11dba7_I20220930" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTQ5NDI_602be6cf-1436-42c3-bc11-79e22a0964b2">11.5</ix:nonFraction>% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate to present value the cash flows. Balance at September&#160;30, 2022 includes $<ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTU0NDI_2a20f9d9-14db-4db3-bd4b-1547089e3107">139</ix:nonFraction> million recorded as a current liability for amounts expected to be paid within the next 12 months.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The payments of contingent consideration in 2022 relate to the Sanofi Pasteur MSD liabilities described above.</span></div></ix:continuation><div style="margin-top:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 19 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i4195abd069df4b8eb633622909d10741" continuedAt="i8c2c889cfb3a45a29fb4e324a71aec15"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Fair Value Measurements</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the Company&#8217;s financial instruments, such as cash and cash equivalents, receivables and payables, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of loans payable and long-term debt (including current portion) at September&#160;30, 2022, was $<ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-8" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTYwMDA_6870bd9f-8691-47c6-84a1-4b0971a8fdc3">25.9</ix:nonFraction> billion compared with a carrying value of $<ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-8" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTYwMzc_7a0bf3ca-b1e9-4c3a-b96b-5263067b81a2">30.4</ix:nonFraction> billion and at December&#160;31, 2021, was $<ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-8" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTYwNTU_a9655b08-3b77-42ef-93ad-52f6feef5c5c">35.7</ix:nonFraction> billion compared with a carrying value of $<ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-8" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTYwOTI_b23135e8-6c67-4b89-80f9-b80ad5b4e292">33.1</ix:nonFraction> billion. Fair value was estimated using recent observable market prices and would be considered Level 2 in the fair value hierarchy. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, the Company monitors concentrations of credit risk associated with corporate and government issuers of securities and financial institutions with which it conducts business. Credit exposure limits are established to limit a concentration with any single issuer or institution. Cash and investments are placed in instruments that meet high credit quality standards as specified in the Company&#8217;s investment policy guidelines. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company&#8217;s accounts receivable arise from product sales in the U.S., Europe and China and are primarily due from drug wholesalers and retailers, hospitals and government agencies.&#160;The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company also continues to monitor global economic conditions, including the volatility associated with international sovereign economies, and associated impacts on the financial markets and its business. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored $<ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-8" name="us-gaap:AccountsReceivableSale" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTc0ODM_295c3301-3b47-4a77-8f40-92869b34b7af">2.3</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ia921450fc1e646fdb798d9bdb31e85e7_D20210101-20211231" decimals="-8" name="us-gaap:AccountsReceivableSale" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTc0OTA_bdb5edae-4863-40d5-9440-0225de28c549">2.8</ix:nonFraction> billion of accounts receivable as of September&#160;30, 2022 and December&#160;31, 2021, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Condensed Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions. As of September&#160;30, 2022 and December&#160;31, 2021, the Company had collected $<ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTgwMjI_fe0516b2-cf46-4c7a-a2df-de6b15ec6e49">55</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTgwMjk_6e1c9b88-a79b-448b-a9fb-523f32e26daf">62</ix:nonFraction>&#160;million, respectively, on behalf of the financial institutions, which is reflected as restricted cash in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the related obligation to remit the cash within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company remitted the cash to the financial institutions in October 2022 and January 2022, respectively. The net cash flows related to these collections are reported as financing activities in the Condensed Consolidated Statement of Cash Flows. The cost of factoring such accounts receivable was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de minimis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><ix:continuation id="i8c2c889cfb3a45a29fb4e324a71aec15" continuedAt="i69784177f1a343b697907c1755b1222c"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements. The master agreements with several of the Company&#8217;s financial institution counterparties also include credit support annexes. These annexes contain provisions that require collateral to be exchanged depending on the value of the derivative assets and liabilities, the Company&#8217;s credit rating, and the credit rating of the counterparty. Cash collateral received by the Company from various counterparties was $<ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:DerivativeCollateralObligationToReturnCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTkwNzc_ff076615-7dd9-4322-8472-9f960095011a">794</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:DerivativeCollateralObligationToReturnCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTkwODQ_8a4916a6-2d68-4013-91c0-9a62f5830d13">164</ix:nonFraction>&#160;million at September&#160;30, 2022 and December&#160;31, 2021, respectively. The obligation to return such collateral is recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i69784177f1a343b697907c1755b1222c">.</ix:continuation> </span></div><div id="i6b4e4280ad2344a5bc7fdcaa77e417f0_52"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81Mi9mcmFnOjcyMjUyYjhjOTBmNzQ4MzFiNDQyZTBhYjhiZTViZWNlL3RleHRyZWdpb246NzIyNTJiOGM5MGY3NDgzMWI0NDJlMGFiOGJlNWJlY2VfNDA2_cb7d7576-90ce-42d7-8dad-9e02202e33bd" continuedAt="i6638f1e0e6814840acf47243f3757813" escape="true">Inventories</ix:nonNumeric></span></div><ix:continuation id="i6638f1e0e6814840acf47243f3757813"><ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81Mi9mcmFnOjcyMjUyYjhjOTBmNzQ4MzFiNDQyZTBhYjhiZTViZWNlL3RleHRyZWdpb246NzIyNTJiOGM5MGY3NDgzMWI0NDJlMGFiOGJlNWJlY2VfNDI0_0cb2f779-e2d7-4324-a725-2c5065a674b2" escape="true"><div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81Mi9mcmFnOjcyMjUyYjhjOTBmNzQ4MzFiNDQyZTBhYjhiZTViZWNlL3RhYmxlOjJkMWU3ZDgwMmY0MDQ1NTE5MTZiZjk5NjYxYzBjYzIyL3RhYmxlcmFuZ2U6MmQxZTdkODAyZjQwNDU1MTkxNmJmOTk2NjFjMGNjMjJfMS0xLTEtMS05NDQxNA_7e80f696-e7e1-4372-8c63-11d7a0441c18">1,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81Mi9mcmFnOjcyMjUyYjhjOTBmNzQ4MzFiNDQyZTBhYjhiZTViZWNlL3RhYmxlOjJkMWU3ZDgwMmY0MDQ1NTE5MTZiZjk5NjYxYzBjYzIyL3RhYmxlcmFuZ2U6MmQxZTdkODAyZjQwNDU1MTkxNmJmOTk2NjFjMGNjMjJfMS0zLTEtMS05NDQxNA_9b072ee5-9930-4316-84b6-54ec79d60445">1,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:InventoryWorkInProcessAndRawMaterials" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81Mi9mcmFnOjcyMjUyYjhjOTBmNzQ4MzFiNDQyZTBhYjhiZTViZWNlL3RhYmxlOjJkMWU3ZDgwMmY0MDQ1NTE5MTZiZjk5NjYxYzBjYzIyL3RhYmxlcmFuZ2U6MmQxZTdkODAyZjQwNDU1MTkxNmJmOTk2NjFjMGNjMjJfMi0xLTEtMS05NDQxNA_a3d56c3d-8e44-4a1e-9e60-79736f10f6a0">6,532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:InventoryWorkInProcessAndRawMaterials" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81Mi9mcmFnOjcyMjUyYjhjOTBmNzQ4MzFiNDQyZTBhYjhiZTViZWNlL3RhYmxlOjJkMWU3ZDgwMmY0MDQ1NTE5MTZiZjk5NjYxYzBjYzIyL3RhYmxlcmFuZ2U6MmQxZTdkODAyZjQwNDU1MTkxNmJmOTk2NjFjMGNjMjJfMi0zLTEtMS05NDQxNA_cfdd7184-a7c0-4c14-b697-7d392739b8ed">6,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:OtherInventorySupplies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81Mi9mcmFnOjcyMjUyYjhjOTBmNzQ4MzFiNDQyZTBhYjhiZTViZWNlL3RhYmxlOjJkMWU3ZDgwMmY0MDQ1NTE5MTZiZjk5NjYxYzBjYzIyL3RhYmxlcmFuZ2U6MmQxZTdkODAyZjQwNDU1MTkxNmJmOTk2NjFjMGNjMjJfMy0xLTEtMS05NDQxNA_ab665606-0b85-4339-bb2f-141e967a6947">227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:OtherInventorySupplies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81Mi9mcmFnOjcyMjUyYjhjOTBmNzQ4MzFiNDQyZTBhYjhiZTViZWNlL3RhYmxlOjJkMWU3ZDgwMmY0MDQ1NTE5MTZiZjk5NjYxYzBjYzIyL3RhYmxlcmFuZ2U6MmQxZTdkODAyZjQwNDU1MTkxNmJmOTk2NjFjMGNjMjJfMy0zLTEtMS05NDQxNA_21ca209a-8e55-4e43-94be-ae144070e745">196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total (approximates current cost)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81Mi9mcmFnOjcyMjUyYjhjOTBmNzQ4MzFiNDQyZTBhYjhiZTViZWNlL3RhYmxlOjJkMWU3ZDgwMmY0MDQ1NTE5MTZiZjk5NjYxYzBjYzIyL3RhYmxlcmFuZ2U6MmQxZTdkODAyZjQwNDU1MTkxNmJmOTk2NjFjMGNjMjJfNC0xLTEtMS05NDQxNA_4aad6675-a4e7-403f-8607-3962eea74fb5">8,442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81Mi9mcmFnOjcyMjUyYjhjOTBmNzQ4MzFiNDQyZTBhYjhiZTViZWNlL3RhYmxlOjJkMWU3ZDgwMmY0MDQ1NTE5MTZiZjk5NjYxYzBjYzIyL3RhYmxlcmFuZ2U6MmQxZTdkODAyZjQwNDU1MTkxNmJmOTk2NjFjMGNjMjJfNC0zLTEtMS05NDQxNA_868c0dec-0065-4cdc-b1a5-a8f34c9dd9dd">8,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease to LIFO cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:InventoryLIFOReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81Mi9mcmFnOjcyMjUyYjhjOTBmNzQ4MzFiNDQyZTBhYjhiZTViZWNlL3RhYmxlOjJkMWU3ZDgwMmY0MDQ1NTE5MTZiZjk5NjYxYzBjYzIyL3RhYmxlcmFuZ2U6MmQxZTdkODAyZjQwNDU1MTkxNmJmOTk2NjFjMGNjMjJfNS0xLTEtMS05NDQxNA_a07cdd76-fdb6-4566-8825-be0f33e59a39">187</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:InventoryLIFOReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81Mi9mcmFnOjcyMjUyYjhjOTBmNzQ4MzFiNDQyZTBhYjhiZTViZWNlL3RhYmxlOjJkMWU3ZDgwMmY0MDQ1NTE5MTZiZjk5NjYxYzBjYzIyL3RhYmxlcmFuZ2U6MmQxZTdkODAyZjQwNDU1MTkxNmJmOTk2NjFjMGNjMjJfNS0zLTEtMS05NDQxNA_bd54e327-1b46-43c3-857c-3a7efc2921ae">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="mrk:InventoryNetAndInventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81Mi9mcmFnOjcyMjUyYjhjOTBmNzQ4MzFiNDQyZTBhYjhiZTViZWNlL3RhYmxlOjJkMWU3ZDgwMmY0MDQ1NTE5MTZiZjk5NjYxYzBjYzIyL3RhYmxlcmFuZ2U6MmQxZTdkODAyZjQwNDU1MTkxNmJmOTk2NjFjMGNjMjJfNi0xLTEtMS05NDQxNA_079e69c0-c80d-4e45-81c6-4f3b8722e644">8,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="mrk:InventoryNetAndInventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81Mi9mcmFnOjcyMjUyYjhjOTBmNzQ4MzFiNDQyZTBhYjhiZTViZWNlL3RhYmxlOjJkMWU3ZDgwMmY0MDQ1NTE5MTZiZjk5NjYxYzBjYzIyL3RhYmxlcmFuZ2U6MmQxZTdkODAyZjQwNDU1MTkxNmJmOTk2NjFjMGNjMjJfNi0zLTEtMS05NDQxNA_d4cabe87-2fbd-4271-9b92-62284e3f397f">8,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81Mi9mcmFnOjcyMjUyYjhjOTBmNzQ4MzFiNDQyZTBhYjhiZTViZWNlL3RhYmxlOjJkMWU3ZDgwMmY0MDQ1NTE5MTZiZjk5NjYxYzBjYzIyL3RhYmxlcmFuZ2U6MmQxZTdkODAyZjQwNDU1MTkxNmJmOTk2NjFjMGNjMjJfOC0xLTEtMS05NDQxNA_d21b7409-6559-4d16-94b0-2128ce08cd08">5,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81Mi9mcmFnOjcyMjUyYjhjOTBmNzQ4MzFiNDQyZTBhYjhiZTViZWNlL3RhYmxlOjJkMWU3ZDgwMmY0MDQ1NTE5MTZiZjk5NjYxYzBjYzIyL3RhYmxlcmFuZ2U6MmQxZTdkODAyZjQwNDU1MTkxNmJmOTk2NjFjMGNjMjJfOC0zLTEtMS05NDQxNA_53759065-484d-4a37-ab6e-2545fb81655d">5,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81Mi9mcmFnOjcyMjUyYjhjOTBmNzQ4MzFiNDQyZTBhYjhiZTViZWNlL3RhYmxlOjJkMWU3ZDgwMmY0MDQ1NTE5MTZiZjk5NjYxYzBjYzIyL3RhYmxlcmFuZ2U6MmQxZTdkODAyZjQwNDU1MTkxNmJmOTk2NjFjMGNjMjJfOS0xLTEtMS05NDQxNA_e467bf93-71f6-4569-be74-e22a467af6f5">2,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81Mi9mcmFnOjcyMjUyYjhjOTBmNzQ4MzFiNDQyZTBhYjhiZTViZWNlL3RhYmxlOjJkMWU3ZDgwMmY0MDQ1NTE5MTZiZjk5NjYxYzBjYzIyL3RhYmxlcmFuZ2U6MmQxZTdkODAyZjQwNDU1MTkxNmJmOTk2NjFjMGNjMjJfOS0zLTEtMS05NDQxNA_22c93b26-fb26-4bd5-8395-f0c58a9ddf72">2,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are comprised almost entirely of raw materials and work in process inventories. At September&#160;30, 2022 and December&#160;31, 2021, these amounts included $<ix:nonFraction unitRef="usd" contextRef="i5a678e64e2774577a007e2d6f57ae9e6_I20220930" decimals="-8" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81Mi9mcmFnOjcyMjUyYjhjOTBmNzQ4MzFiNDQyZTBhYjhiZTViZWNlL3RleHRyZWdpb246NzIyNTJiOGM5MGY3NDgzMWI0NDJlMGFiOGJlNWJlY2VfMTky_4bae9858-7dc4-4194-a96f-720b8724044c">2.2</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i9b4bff14a1a9425cb5bf3661e7e1e54d_I20211231" decimals="-8" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81Mi9mcmFnOjcyMjUyYjhjOTBmNzQ4MzFiNDQyZTBhYjhiZTViZWNlL3RleHRyZWdpb246NzIyNTJiOGM5MGY3NDgzMWI0NDJlMGFiOGJlNWJlY2VfMTk5_c6059b97-f460-41bf-b98b-1966d58421c0">1.9</ix:nonFraction> billion, respectively, of inventories not expected to be sold within one year. In addition, these amounts included $<ix:nonFraction unitRef="usd" contextRef="i816e17e24e684044addf68e60f3d7cdd_I20220930" decimals="-6" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81Mi9mcmFnOjcyMjUyYjhjOTBmNzQ4MzFiNDQyZTBhYjhiZTViZWNlL3RleHRyZWdpb246NzIyNTJiOGM5MGY3NDgzMWI0NDJlMGFiOGJlNWJlY2VfMzA5_2f014cd3-1583-4797-98dd-0ccc4e287477">417</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i871e3e80b793441c8f0be12b7c62ca4b_I20211231" decimals="-6" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81Mi9mcmFnOjcyMjUyYjhjOTBmNzQ4MzFiNDQyZTBhYjhiZTViZWNlL3RleHRyZWdpb246NzIyNTJiOGM5MGY3NDgzMWI0NDJlMGFiOGJlNWJlY2VfMzE2_dcce17af-802f-4e07-871b-299dad04ff56">256</ix:nonFraction> million at September&#160;30, 2022 and December&#160;31, 2021, respectively, of inventories produced in preparation for product launches.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 20 -</span></div></div></div><div id="i6b4e4280ad2344a5bc7fdcaa77e417f0_1313"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.     <ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xMzEzL2ZyYWc6MzU4ODJlZTI1NTkxNDkwNGEyOWFjOTEzNDZjYzVjMDEvdGV4dHJlZ2lvbjozNTg4MmVlMjU1OTE0OTA0YTI5YWM5MTM0NmNjNWMwMV81NDk3NTU4MTcyMDc_d54935b3-0865-48c7-81c2-093d90b772ae" continuedAt="i44ea13c461814fd5bbb7d2c740f1ccd2" escape="true">Other Intangibles</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><ix:continuation id="i44ea13c461814fd5bbb7d2c740f1ccd2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2022, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i0b998b01dd7b4aedbe8d12d9cd13b5db_D20220701-20220930" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xMzEzL2ZyYWc6MzU4ODJlZTI1NTkxNDkwNGEyOWFjOTEzNDZjYzVjMDEvdGV4dHJlZ2lvbjozNTg4MmVlMjU1OTE0OTA0YTI5YWM5MTM0NmNjNWMwMV81NDk3NTU4MTcyMzI_0f6007c1-784f-4ed1-89f6-1c86809a6062">887</ix:nonFraction> million of impairment charges within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses related to intangible assets obtained in connection with the 2020 acquisition of ArQule, Inc. Of this amount, $<ix:nonFraction unitRef="usd" contextRef="i06851cb5c98f4da69ac686f6c2411879_D20220701-20220930" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xMzEzL2ZyYWc6MzU4ODJlZTI1NTkxNDkwNGEyOWFjOTEzNDZjYzVjMDEvdGV4dHJlZ2lvbjozNTg4MmVlMjU1OTE0OTA0YTI5YWM5MTM0NmNjNWMwMV81NDk3NTU4MTcyMjc_aac7a104-93d2-4945-983f-0d073d8f7a30">807</ix:nonFraction> million represents an in-process research and development (IPR&amp;D) impairment charge related to nemtabrutinib (MK-1026), a novel, oral BTK inhibitor currently being evaluated for the treatment of B-cell malignancies. Following discussions with regulatory authorities in the third quarter, the development period for nemtabrutinib was extended, which constituted a triggering event that required the evaluation of the nemtabrutinib intangible asset for impairment. The Company estimated the current fair value of nemtabrutinib utilizing an income approach which calculates the present value of projected future cash flows. The market participant assumptions used to derive the forecasted cash flows were updated to reflect a delay in the anticipated launch date for nemtabrutinib, which resulted in lower cumulative revenue forecasts and a reduction in the estimated fair value. The revised estimated fair value of nemtabrutinib when compared with its related carrying value resulted in the IPR&amp;D impairment charge noted above. The remaining IPR&amp;D intangible asset related to nemtabrutinib is $<ix:nonFraction unitRef="usd" contextRef="i1c885d79a0554b91bbfa7bc3397951e7_I20220930" decimals="-8" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xMzEzL2ZyYWc6MzU4ODJlZTI1NTkxNDkwNGEyOWFjOTEzNDZjYzVjMDEvdGV4dHJlZ2lvbjozNTg4MmVlMjU1OTE0OTA0YTI5YWM5MTM0NmNjNWMwMV81NDk3NTU4MTcyMDQ_24524a57-11d7-4f6c-822a-0c147ac52df9">1.2</ix:nonFraction> billion. If the assumptions used to estimate the fair value of nemtabrutinib prove to be incorrect and the development of nemtabrutinib does not progress as anticipated thereby adversely affecting projected future cash flows, the Company may record an additional impairment charge in the future and such charge could be material.</span></ix:continuation></div><div id="i6b4e4280ad2344a5bc7fdcaa77e417f0_55"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81NS9mcmFnOjNiNDE0ZjBmNjBmMDQwMzliNDRkNjY1ODhlODBiYTcyL3RleHRyZWdpb246M2I0MTRmMGY2MGYwNDAzOWI0NGQ2NjU4OGU4MGJhNzJfMjU1Njg_f904b421-1958-42df-8632-d6c1b82639ba" continuedAt="ib40411e1174f45b791df9b82f7a7b72d" escape="true">Contingencies</ix:nonNumeric></span></div><ix:continuation id="ib40411e1174f45b791df9b82f7a7b72d" continuedAt="i6f3677e8ccae400c85586eae9b01ee2c"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property, and commercial litigation, as well as certain additional matters including governmental and environmental matters. In the opinion of the Company, it is unlikely that the resolution of these matters will be material to the Company&#8217;s financial condition, results of operations or cash flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the nature of the litigation discussed below and the complexities involved in these matters, the Company is unable to reasonably estimate a possible loss or range of possible loss for such matters until the Company knows, among other factors, (i)&#160;what claims, if any, will survive dispositive motion practice, (ii)&#160;the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii)&#160;how the discovery process will affect the litigation, (iv)&#160;the settlement posture of the other parties to the litigation and (v)&#160;any other factors that may have a material effect on the litigation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. For product liability claims, a portion of the overall accrual is actuarially determined and considers such factors as past experience, number of claims reported and estimates of claims incurred but not yet reported. Individually significant contingent losses are accrued when probable and reasonably estimable. <ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="us-gaap:LegalCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81NS9mcmFnOjNiNDE0ZjBmNjBmMDQwMzliNDRkNjY1ODhlODBiYTcyL3RleHRyZWdpb246M2I0MTRmMGY2MGYwNDAzOWI0NGQ2NjU4OGU4MGJhNzJfMjU1NzM_512f0a15-2ec3-4351-9d34-84d931a1136f" escape="true">Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such decisions are made. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability Litigation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fosamax</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, Merck is a defendant in product liability lawsuits in the U.S. involving Fosamax (alendronate sodium) (Fosamax Litigation). As of September&#160;30, 2022, approximately <ix:nonFraction unitRef="case" contextRef="ib3ff202f9b6d48749d7758af33b9b823_I20220930" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81NS9mcmFnOjNiNDE0ZjBmNjBmMDQwMzliNDRkNjY1ODhlODBiYTcyL3RleHRyZWdpb246M2I0MTRmMGY2MGYwNDAzOWI0NGQ2NjU4OGU4MGJhNzJfMjQzNg_77592c90-a843-4e15-82c6-b0165fe10e96">3,450</ix:nonFraction> cases are pending against Merck in either a federal multidistrict litigation (Femur Fracture MDL) or state court. Plaintiffs in the vast majority of these cases generally allege that they sustained femur fractures and/or other bone injuries (Femur Fractures) in association with the use of Fosamax.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2014, the Femur Fracture MDL court dismissed with prejudice approximately <ix:nonFraction unitRef="case" contextRef="i367d0d796d80424da91051e66c46b38a_D20140301-20140331" decimals="0" name="us-gaap:LossContingencyClaimsDismissedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81NS9mcmFnOjNiNDE0ZjBmNjBmMDQwMzliNDRkNjY1ODhlODBiYTcyL3RleHRyZWdpb246M2I0MTRmMGY2MGYwNDAzOWI0NGQ2NjU4OGU4MGJhNzJfMjgyMQ_33320ec5-e992-47f5-addb-2c68ee59107b">650</ix:nonFraction> cases on preemption grounds. Plaintiffs in approximately <ix:nonFraction unitRef="case" contextRef="i367d0d796d80424da91051e66c46b38a_D20140301-20140331" decimals="0" name="mrk:LossContingencyClaimsonAppealNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81NS9mcmFnOjNiNDE0ZjBmNjBmMDQwMzliNDRkNjY1ODhlODBiYTcyL3RleHRyZWdpb246M2I0MTRmMGY2MGYwNDAzOWI0NGQ2NjU4OGU4MGJhNzJfMjg4MQ_63bc3c7e-eda7-4c35-9b0e-5b129ab30c2b">515</ix:nonFraction> of those cases appealed that decision to the U.S. Court of Appeals for the Third Circuit (Third Circuit). In March 2017, the Third Circuit issued a decision reversing the Femur Fracture MDL court&#8217;s preemption ruling and remanding the appealed cases back to the Femur Fracture MDL court. In May 2019, the U.S. Supreme Court decided that the Third Circuit had incorrectly concluded that the issue of preemption should be resolved by a jury, and accordingly vacated the judgment of the Third Circuit and remanded the proceedings back to the Third Circuit to address the issue in a manner consistent with the Supreme Court&#8217;s opinion. In November 2019, the Third Circuit remanded the cases back to the District Court in order to allow that court to determine in the first instance whether the plaintiffs&#8217; state law claims are preempted by federal law under the standards described by the Supreme Court in its opinion. On March 23, 2022, the District Court granted Merck&#8217;s motion and ruled that plaintiffs&#8217; failure to warn claims are preempted as a matter of law to the extent they </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 21 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i6f3677e8ccae400c85586eae9b01ee2c" continuedAt="ic27132a028c646a990cd94943448b264"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assert that Merck should have added a warning or precaution regarding atypical femur fractures prior to September 2010. Plaintiffs have indicated that they do not intend to move forward with any other claims at this point and intend to appeal the District Court&#8217;s preemption ruling to the Third Circuit.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discovery is presently stayed in the Femur Fracture MDL. As part of the spin-off of Organon, Organon is required to indemnify Merck for all liabilities relating to, arising from, or resulting from the Fosamax Litigation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia/Janumet</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, Merck is a defendant in product liability lawsuits in the U.S. involving </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (sitagliptin) and/or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (sitagliptin and metformin HCl). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most claims were filed in multidistrict litigation before the U.S. District Court for the Southern District of California (MDL). In March 2021, the MDL court issued an omnibus order granting defendants&#8217; summary judgment motions based on preemption and failure to establish general causation, as well as granting defendants&#8217; motions to exclude plaintiffs&#8217; expert witnesses. The plaintiffs appealed that order. Since that time, more than half of these claims have been dismissed with prejudice as to Merck, and in October 2021, the U.S. Court of Appeals for the Ninth Circuit dismissed the appeal as to Merck and two of its codefendants. The MDL court&#8217;s judgment is now final and no longer appealable with respect to remaining claims.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside of the MDL, the majority of claims were filed in coordinated proceedings before the Superior Court of California, County of Los Angeles (California State Court). On April 6, 2021, the court in California issued an omnibus order granting defendants&#8217; summary judgment motions and also granting defendants&#8217; motions to exclude plaintiffs&#8217; expert witnesses. On May 31, 2022, the court entered judgment in favor of Merck as to all of the claims pending against Merck in that jurisdiction.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the claims noted above, the Company has agreed to toll the statute of limitations for approximately <ix:nonFraction unitRef="claim" contextRef="if701c2dad3a448b8baf48efce7ff3da8_I20220930" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81NS9mcmFnOjNiNDE0ZjBmNjBmMDQwMzliNDRkNjY1ODhlODBiYTcyL3RleHRyZWdpb246M2I0MTRmMGY2MGYwNDAzOWI0NGQ2NjU4OGU4MGJhNzJfNzI2MA_b65ec96e-8330-4b38-8c65-5c1da52af88b">50</ix:nonFraction> additional claims. The Company intends to continue defending against any remaining lawsuits.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil/Gardasil 9</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck is a defendant in product liability lawsuits in the U.S. involving </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 9 (Human Papillomavirus 9-valent Vaccine, Recombinant). As of September&#160;30, 2022, approximately <ix:nonFraction unitRef="case" contextRef="i23dfb067c82241afa5f99f21bef689a1_I20220930" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81NS9mcmFnOjNiNDE0ZjBmNjBmMDQwMzliNDRkNjY1ODhlODBiYTcyL3RleHRyZWdpb246M2I0MTRmMGY2MGYwNDAzOWI0NGQ2NjU4OGU4MGJhNzJfNTQ5NzU1ODQzODk4_bb9d0318-86e1-4dd5-a25e-5cc70ba5d89f">65</ix:nonFraction> cases were filed and pending against Merck in either federal or state court. In these actions, plaintiffs allege, among other things, that they suffered various personal injuries after vaccination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 9, with postural orthostatic tachycardia syndrome as a predominate alleged injury. In August 2022, the Judicial Panel on Multidistrict Litigation ordered that </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil/Gardasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 9 product liability cases pending in federal courts nationwide be transferred to Judge Robert J. Conrad in the Western District of North Carolina for coordinated pre-trial proceedings. There are fewer than <ix:nonFraction unitRef="case" contextRef="i3433b64365a54af2b3af67c46a542197_I20220930" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81NS9mcmFnOjNiNDE0ZjBmNjBmMDQwMzliNDRkNjY1ODhlODBiYTcyL3RleHRyZWdpb246M2I0MTRmMGY2MGYwNDAzOWI0NGQ2NjU4OGU4MGJhNzJfNTQ5NzU1ODQzODk0_2c0e6c49-0753-4084-ac60-a15df8a4c756">15</ix:nonFraction> product liability cases pending outside the U.S., including <ix:nonFraction unitRef="case" contextRef="ie980ee86472c42588cfeec3bc06a4e83_I20220930" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81NS9mcmFnOjNiNDE0ZjBmNjBmMDQwMzliNDRkNjY1ODhlODBiYTcyL3RleHRyZWdpb246M2I0MTRmMGY2MGYwNDAzOWI0NGQ2NjU4OGU4MGJhNzJfMTY0OTI2NzQ4NjE0OQ_49dd8454-efdc-4fa7-aef2-131daa87f968">one</ix:nonFraction> purported class action in Colombia.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governmental Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, from time to time, the Company&#8217;s subsidiaries in China receive inquiries regarding their operations from various Chinese governmental agencies. Some of these inquiries may be related to matters involving other multinational pharmaceutical companies, as well as Chinese entities doing business with such companies. The Company&#8217;s policy is to cooperate with these authorities and to provide responses as appropriate.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, from time to time, the Company receives inquiries and is the subject of preliminary investigation activities from competition and other governmental authorities in markets outside the U.S. These authorities may include regulators, administrative authorities, and law enforcement and other similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials, inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings. Should those proceedings be determined adversely to the Company, monetary fines and/or remedial undertakings may be required.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercial and Other Litigation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zetia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antitrust Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, Merck, MSD, Schering Corporation, Schering-Plough Corporation, and MSP Singapore Company LLC (collectively, the Merck Defendants) are defendants in a number of lawsuits filed in 2018 on behalf of direct and indirect purchasers of Zetia (ezetimibe) alleging violations of federal and state antitrust laws, as well as other state statutory and common law causes of action. The cases were consolidated in a federal multidistrict litigation (the Zetia MDL) before Judge Rebecca Beach Smith in the Eastern District of Virginia.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 22 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="ic27132a028c646a990cd94943448b264" continuedAt="i93c9edc6b24a4a9e84c2e1b2cf1c676d"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, the direct purchaser plaintiffs and the indirect purchaser plaintiffs filed motions for class certification. In August 2020, the district court granted in part the direct purchasers&#8217; motion for class certification and certified a class of <ix:nonFraction unitRef="claim" contextRef="i5268335c17cf4ff1ba48ee77aa8846cb_I20200831" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81NS9mcmFnOjNiNDE0ZjBmNjBmMDQwMzliNDRkNjY1ODhlODBiYTcyL3RleHRyZWdpb246M2I0MTRmMGY2MGYwNDAzOWI0NGQ2NjU4OGU4MGJhNzJfOTQ3Mw_b939c661-a4a0-4bbe-a880-5ad2d8df9536">35</ix:nonFraction> direct purchasers. In August 2021, the Fourth Circuit vacated the district court&#8217;s class certification order and remanded for further proceedings consistent with the court&#8217;s ruling. In September 2021, the direct purchaser plaintiffs filed a renewed motion for class certification. On January 25, 2022, the magistrate judge recommended that the district court deny the motion for class certification. On February 8, 2022, the direct purchaser plaintiffs filed objections to the recommendation. On April 13, 2022, the district court denied the direct purchaser plaintiffs&#8217; renewed motion for class certification. In August 2021, the district court granted certification of a class of indirect purchasers.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020 and 2021, United Healthcare Services, Inc., Humana Inc., Centene Corporation and others, and Kaiser Foundation Health Plan, Inc. (collectively, the Insurer Plaintiffs), each filed a lawsuit in a jurisdiction outside of the Eastern District of Virginia against the Merck Defendants and others, making similar allegations as those made in the Zetia MDL, as well as additional allegations about Vytorin. These cases have been transferred to the Eastern District of Virginia to proceed with the Zetia MDL.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 9, 2022, the Insurer Plaintiffs filed amended complaints. On March 2, 2022, the Merck Defendants, jointly with other defendants, moved to dismiss certain aspects of the Insurer Plaintiffs&#8217; complaints, including any claims for Vytorin damages. That motion to dismiss the Vytorin-related claims is still pending.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, the direct purchaser plaintiffs moved for an order setting a deadline for direct purchasers of Zetia not currently parties to the case to file cases against defendants in order for those cases to be coordinated for trial with the existing direct purchaser plaintiffs and other MDL plaintiff groups. The court granted that motion, setting a deadline of June 30, 2022 for unnamed direct purchasers to file claims. On June 30, 2022, <ix:nonFraction unitRef="claim" contextRef="i5302423c142d450a83f2d69d472c5fd6_D20220630-20220630" decimals="0" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81NS9mcmFnOjNiNDE0ZjBmNjBmMDQwMzliNDRkNjY1ODhlODBiYTcyL3RleHRyZWdpb246M2I0MTRmMGY2MGYwNDAzOWI0NGQ2NjU4OGU4MGJhNzJfMTEzODk_841dc8a8-d5bf-4294-95a4-a8088b1cd7f4">23</ix:nonFraction> new entities, many related, brought new complaints against defendants or otherwise sought to intervene. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 2, 2022, the Magistrate Judge issued a Report and Recommendation denying the Merck Defendants&#8217; and Glenmark Defendants&#8217; motions for summary judgment. Defendants have objected to the Report and Recommendation, and are awaiting a final decision from Judge Smith. The court has scheduled trial for all plaintiffs other than the Insurer Plaintiffs for April 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">340B Program Litigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck has filed a complaint in the U.S. District Court for the District of Columbia to challenge the letter Merck received from the Health Resources and Services Administration (HRSA) in May 2022 regarding Merck&#8217;s 340B Program integrity initiative. HRSA&#8217;s letter to Merck asserts that Merck is in violation of the 340B statute. HRSA further claims that continued failure to provide the 340B price to covered entities using contract pharmacies may result in civil monetary penalties for each instance of alleged overcharging, in addition to repayment for any instance of overcharging. The letter is very similar to letters HRSA has sent to other manufacturers, which letters have been held to be unlawful by multiple federal courts. Merck disagrees with HRSA&#8217;s assertion. Merck remains committed to the 340B Program and to providing 340B discounts to eligible covered entities. Merck&#8217;s 340B Program integrity initiative is consistent with the requirements of the 340B statute and is intended to ensure the integrity and sustainability of the 340B statute by reducing prohibited duplicate discounts and diversion and putting patients back at the center of the program. Merck continues to offer all of the Company&#8217;s covered outpatient drugs to all 340B covered entities for purchase at or below the 340B ceiling price. On September 13, 2022, the court stayed the case pending the D.C. Circuit&#8217;s ruling in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Novartis Pharmaceuticals Corp. v. Johnson and United Therapeutics Corp. v. Johnson</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent Litigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, generic manufacturers of pharmaceutical products file abbreviated New Drug Applications (NDAs) with the FDA seeking to market generic forms of the Company&#8217;s products prior to the expiration of relevant patents owned by the Company. To protect its patent rights, the Company may file patent infringement lawsuits against such generic companies. Similar lawsuits defending the Company&#8217;s patent rights may exist in other countries. The Company intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. As with any litigation, there can be no assurance of the outcomes, which, if adverse, could result in significantly shortened periods of exclusivity for these products and, with respect to products acquired through acquisitions accounted for as business combinations, potentially significant intangible asset impairment charges.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, between January and November 2020, the Company received multiple Paragraph IV Certification Letters under the Hatch-Waxman Act notifying the Company that generic drug companies have filed applications to the FDA seeking pre-patent expiry approval to sell generic versions of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (sugammadex) Injection.&#160;In March, April and December 2020, the Company filed patent infringement lawsuits in the U.S. District Courts for the District of New Jersey and the Northern District of West Virginia against those generic companies.&#160;All actions in the District of New Jersey have been consolidated. These lawsuits, which assert one or more patents covering sugammadex and methods of using sugammadex, automatically stay FDA approval of the generic applications until June 2023 or until adverse court decisions, if </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 23 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i93c9edc6b24a4a9e84c2e1b2cf1c676d" continuedAt="i4e5f326076824e9c8c6744903964d10d"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any, whichever may occur earlier. The West Virginia case was jointly dismissed with prejudice on August 8, 2022 in favor of proceeding in New Jersey. The remaining defendants in the New Jersey action have stipulated to infringement of the asserted claims and have stated they are withdrawing all remaining claims and defenses other than a defense seeking to shorten the patent term extension of the sugammadex patent to December 2022. In light of this, the U.S. District Court for the District of New Jersey cancelled the scheduled trial and scheduled a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81NS9mcmFnOjNiNDE0ZjBmNjBmMDQwMzliNDRkNjY1ODhlODBiYTcyL3RleHRyZWdpb246M2I0MTRmMGY2MGYwNDAzOWI0NGQ2NjU4OGU4MGJhNzJfMTY0OTI2NzQ4NjEyNg_dc252ca0-1f84-47f5-aa4a-e30b0bbfb328">one</span>-day trial on December 19, 2022 on this remaining patent term extension calculation defense.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has settled with <ix:nonFraction unitRef="case" contextRef="i5d703348a1634fdbb823234f6176f03a_D20220101-20220930" decimals="INF" name="us-gaap:LossContingencyClaimsSettledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81NS9mcmFnOjNiNDE0ZjBmNjBmMDQwMzliNDRkNjY1ODhlODBiYTcyL3RleHRyZWdpb246M2I0MTRmMGY2MGYwNDAzOWI0NGQ2NjU4OGU4MGJhNzJfMTc4NTI_710dce89-11bb-4f76-b72a-f6b89b3f4dd8">five</ix:nonFraction> generic companies providing that these generic companies can bring their generic versions of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the market in January 2026 (which may be delayed by any applicable pediatric exclusivity) or earlier under certain circumstances. The Company has agreed to stay the lawsuit filed against <ix:nonFraction unitRef="case" contextRef="i251ca90ae959435d934e00a6b5636367_I20220930" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81NS9mcmFnOjNiNDE0ZjBmNjBmMDQwMzliNDRkNjY1ODhlODBiYTcyL3RleHRyZWdpb246M2I0MTRmMGY2MGYwNDAzOWI0NGQ2NjU4OGU4MGJhNzJfMTgxNDY_e9f97edf-cab1-4688-9248-4bf2922c92f0">two</ix:nonFraction> generic companies, which in exchange agreed to be bound by a judgment on the merits of the consolidated action in the District of New Jersey. One of the generic companies in the consolidated action requested dismissal of the action against it and the Company did not oppose this request, which was subsequently granted by the court. The Company does not expect this company to bring its generic version of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the market before January 2026 or later, depending on any applicable pediatric exclusivity, unless the Company receives an adverse court decision.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia, Janumet, Janumet XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; As previously disclosed, the FDA has granted pediatric exclusivity with respect to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (sitagliptin and metformin HCl extended-release), which provides a further six months of exclusivity in the U.S. beyond the expiration of all patents listed in the FDA&#8217;s Orange Book. Adding this exclusivity to the term of the key patent protection extends exclusivity on these products to January 2023. However, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contain sitagliptin phosphate monohydrate and the Company has another patent covering certain phosphate salt and polymorphic forms of sitagliptin that expires in May 2027, including pediatric exclusivity (2027 salt/polymorph patent). In 2019, Par Pharmaceutical filed suit against the Company in the U.S. District Court for the District of New Jersey, seeking a declaratory judgment of invalidity of the 2027 salt/polymorph patent. In response, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Par Pharmaceutical and additional companies that also indicated an intent to market generic versions of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> following expiration of key patent protection, but prior to the expiration of the 2027 salt/polymorph patent, and a later granted patent owned by the Company covering the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> formulation where its term plus the pediatric exclusivity ends in 2029. The Company also filed a patent infringement lawsuit against Mylan in the Northern District of West Virginia. The Judicial Panel on Multidistrict Litigation entered an order transferring the Company&#8217;s lawsuit against Mylan to the U.S. District Court for the District of Delaware for coordinated and consolidated pretrial proceedings with the other cases pending in that district.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the beginning of the scheduled October 2021 trial in the U.S. District Court for the District of Delaware on invalidity issues, the Company settled with all defendants scheduled to participate in that trial. In the Company&#8217;s case against Mylan, a bench trial was held in December 2021 in the U.S. District Court for the Northern District of West Virginia, and the closing arguments were held on April 13, 2022. On September 21, 2022, the District Court for the Northern District of West Virginia issued a decision in the Company&#8217;s favor, upholding all asserted patent claims. Mylan (now Viatris) has appealed to the U.S. Court of Appeals for the Federal Circuit.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In total, the Company has settled with <ix:nonFraction unitRef="case" contextRef="ied8204c596b34fe69666b537c6dd68ed_D20220101-20220930" decimals="INF" name="us-gaap:LossContingencyClaimsSettledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81NS9mcmFnOjNiNDE0ZjBmNjBmMDQwMzliNDRkNjY1ODhlODBiYTcyL3RleHRyZWdpb246M2I0MTRmMGY2MGYwNDAzOWI0NGQ2NjU4OGU4MGJhNzJfMjEyNjM_b313607b-2e23-48b9-a194-6442262f165e">22</ix:nonFraction> generic companies providing that these generic companies can bring their generic versions of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the market in May 2026 or earlier under certain circumstances, and their generic versions of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the market in July 2026 or earlier under certain circumstances.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in 2019, Mylan filed a petition for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review (IPR) at the U.S. Patent and Trademark Office (USPTO) seeking invalidity of some, but not all, of the claims of the 2027 salt/polymorph patent. The USPTO instituted IPR proceedings in May 2020, finding a reasonable likelihood that the challenged claims are not valid. A trial was held in February 2021 and a final decision was rendered in May 2021, holding that all of the challenged claims were not invalid. Mylan appealed the USPTO&#8217;s decision to the U.S. Court of Appeals for the Federal Circuit, and a hearing was held on August 2, 2022. On September 29, 2022, the Court of Appeals for the Federal Circuit ruled in the Company&#8217;s favor, upholding the USPTO&#8217;s decision.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc., and Cadila Healthcare Ltd. (collectively, Zydus). In that lawsuit, the Company alleged infringement of the 2027 salt/polymorph patent based on the filing of Zydus&#8217;s application seeking approval of its sitagliptin tablets. While the U.S. District Court for the District of Delaware originally set a <ix:nonNumeric contextRef="i623b3d56da7f44d9a270d2a0c4de1efe_D20230109-20230109" name="mrk:LossContingencyRecoveryFromThirdPartyBenchTrialPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81NS9mcmFnOjNiNDE0ZjBmNjBmMDQwMzliNDRkNjY1ODhlODBiYTcyL3RleHRyZWdpb246M2I0MTRmMGY2MGYwNDAzOWI0NGQ2NjU4OGU4MGJhNzJfMTY0OTI2NzQ4NjE3MQ_fbc8a1d9-ac8d-4f64-a8d8-7f92380ec80a">three-day</ix:nonNumeric> bench trial in this matter beginning on October 31, 2022, the trial date has been moved to January 9, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generic companies have sought revocation of the Supplementary Protection Certificate (SPC) for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in a number of European countries. In February 2022, a Finnish court referred certain questions to the Court of Justice of the European Union that could determine the validity of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SPCs in Europe. In June 2021, a German court decided that the SPC for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is invalid, which decision the Company has appealed. The validity of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SPC was upheld in the Czech Republic in March 2022 in a first instance decision, which has been appealed. In June 2022, a Romanian court decided </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 24 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i4e5f326076824e9c8c6744903964d10d"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that the SPC for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was invalid in a first instance decision. In August 2022, the validity of the SPC for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was upheld in Sweden in a first instance decision, which decision has been appealed. MSD has filed injunction actions against generic companies in Belgium, Finland, France, Greece, Ireland and Portugal. In September 2022, the following decisions were issued: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex-parte</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> preliminary injunctions were granted in Finland; a preliminary injunction was granted in France, and the validity of the SPC and the associated patent were held to be </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">prima facie</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> valid in these proceedings; and a temporary restraining order was granted in Greece. In October 2022, requests for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex parte</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> preliminary injunctions were refused in Portugal.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Litigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are various other pending legal proceedings involving the Company, principally product liability and intellectual property lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of the Company, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to the Company&#8217;s financial condition, results of operations or cash flows either individually or in the aggregate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Defense Reserves</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by the Company; the development of the Company&#8217;s legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against the Company; the costs and outcomes of completed trials and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The amount of legal defense reserves as of September&#160;30, 2022 and December&#160;31, 2021 of approximately $<ix:nonFraction unitRef="usd" contextRef="i5e7203ee8afa4167bcbca2845a05174c_I20220930" decimals="-6" name="us-gaap:LitigationReserve" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81NS9mcmFnOjNiNDE0ZjBmNjBmMDQwMzliNDRkNjY1ODhlODBiYTcyL3RleHRyZWdpb246M2I0MTRmMGY2MGYwNDAzOWI0NGQ2NjU4OGU4MGJhNzJfMjQ5NDI_1b470a5a-1edb-4dfb-b3e6-ed4a31e86521"><ix:nonFraction unitRef="usd" contextRef="iab20286c913c43ab9d138d102915562b_I20211231" decimals="-6" name="us-gaap:LitigationReserve" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81NS9mcmFnOjNiNDE0ZjBmNjBmMDQwMzliNDRkNjY1ODhlODBiYTcyL3RleHRyZWdpb246M2I0MTRmMGY2MGYwNDAzOWI0NGQ2NjU4OGU4MGJhNzJfMjQ5NDI_43e5c687-7d9d-4758-b55c-52351d7aec0c">230</ix:nonFraction></ix:nonFraction> million represents the Company&#8217;s best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by the Company. The Company will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.</span></div></ix:continuation><div id="i6b4e4280ad2344a5bc7fdcaa77e417f0_58"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RleHRyZWdpb246OGRkYzBmNDFhMjY1NDVmZGEyZTcwYmJiMTA5M2RhYmRfMzI_dc0b5d29-ca1d-4400-9b0b-aca9ab3688d7" continuedAt="ic906c20dd47c4fb3ae41747eec0fdb9a" escape="true">Equity</ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="ic906c20dd47c4fb3ae41747eec0fdb9a" continuedAt="i7445a80ba41b4f4fba8779235be6d066"><ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="us-gaap:ScheduleOfStockholdersEquityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RleHRyZWdpb246OGRkYzBmNDFhMjY1NDVmZGEyZTcwYmJiMTA5M2RhYmRfMzM_f6b46002-20a7-416d-9475-b7c88df56a41" continuedAt="id7f2d1fb353042d18a25e8ce85a3d922" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:29.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.795%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-<br/>controlling<br/>Interests</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ and shares in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Par&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at July 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7dee7788157d45e1a5392aebf32b5f84_I20210630" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMy0xLTEtMS05NDQxNA_64cb7ebf-b956-459c-ab4f-272d598710b8">3,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dee7788157d45e1a5392aebf32b5f84_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMy0yLTEtMS05NDQxNA_6cbcb773-b056-4377-bb21-eb8ff0cc6758">1,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i769035208b1b48838e202af7a6565d8e_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMy0zLTEtMS05NDQxNA_993c98b9-7f97-437c-a6f0-6fe78de4d409">44,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9efdb7d75087494cbe98cd19e691e3fa_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMy00LTEtMS05NDQxNA_98c8725c-5204-48f2-a164-ac7d904ef54e">48,777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7e47c5bf82f40adb471e36675ba4ee6_I20210630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMy01LTEtMS05NDQxNA_1c123418-a297-49de-bad7-93e1666a028b">4,628</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaab9e1dfa7444fc3bae3cc093d6fe99b_I20210630" decimals="-3" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMy02LTEtMS05NDQxNA_306e08d2-2eb8-4c3e-99a8-5a88992b3098">1,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaab9e1dfa7444fc3bae3cc093d6fe99b_I20210630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMy03LTEtMS05NDQxNA_fd5fa5ea-8435-4b43-bf64-44982b08be4a">56,682</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23a801131ac4b8c945a76709e53ab57_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMy04LTEtMS05NDQxNA_f0969ec4-c269-4e18-9bbd-799e65d4fffe">94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3afe38f10fec457498b49dc2c46ff07d_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMy05LTEtMS05NDQxNA_207c161b-0eea-4204-bd70-43c8aa26d6ff">33,388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck&#160;&amp; Co., Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff86b236dd274c4686ba706b239b2836_D20210701-20210930" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfNC00LTEtMS05NDQxNA_935cd3d8-56bd-4883-9492-5d9176a67030">4,567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfNC05LTEtMS05NDQxNA_00bb8028-b325-4fc1-a42e-094c978b07d0">4,567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecbfa0ca4994647873a7f5f0bd59cdd_D20210701-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfNS01LTEtMS05NDQxNA_e59ed4da-bc76-4047-b871-358dbbab68e3">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfNS05LTEtMS05NDQxNA_6bb62076-8744-496f-a813-9676be94106f">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($<ix:nonFraction unitRef="usdPerShare" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfNi0wLTEtMS05NDQxNC90ZXh0cmVnaW9uOjYwM2U1YzJjZWViZjQ4NjNhYmEwOGU0NDBhNWI4OTMwXzQ1_f4937f2e-e680-46e0-802d-48abaa2891f0">0.65</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff86b236dd274c4686ba706b239b2836_D20210701-20210930" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfNi00LTEtMS05NDQxNA_20813833-cc57-4aa2-81c5-90c4de680434">1,653</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfNi05LTEtMS05NDQxNA_7c06da24-b0b6-4772-81b3-988a6f7691ff">1,653</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock shares purchased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8928a318d22448f497a03f892bcee237_D20210701-20210930" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfNy02LTEtMS05NDQxNA_3956fbda-33b0-45a5-86fb-243b1531b2f4">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8928a318d22448f497a03f892bcee237_D20210701-20210930" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfNy03LTEtMS05NDQxNA_8ac8acfd-ef04-449c-8703-f38dfa1a305a">583</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfNy05LTEtMS05NDQxNA_3101acc4-ea16-440e-b465-83fcf8644179">583</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4df4b3c64fe4fa28360813d66561107_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfOS0zLTEtMS05NDQxNA_ffd24c37-3971-48f1-8e71-2043bb6ea067">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8928a318d22448f497a03f892bcee237_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfOS03LTEtMS05NDQxNA_712869c8-6591-4722-a435-80947f5261f4">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfOS05LTEtMS05NDQxNA_eb76f829-5d7c-4004-8238-50376932b22f">131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c45ff5f83594356b2993ac3c0f1c8c0_D20210701-20210930" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTAtOC0xLTEtOTQ0MTQ_43e09d7b-84d9-4395-9999-98ed1f3aef3f">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTAtOS0xLTEtOTQ0MTQ_63212a31-4671-4627-8611-85b55434a18e">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c45ff5f83594356b2993ac3c0f1c8c0_D20210701-20210930" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTAtOC0xLTEtOTc2MTg_a45417d6-fb83-44ae-b7db-cf8d862ce12d">29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTAtOS0xLTEtOTc2MTg_58de95be-106c-4040-b035-733fc2b018d7">29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie32bbd59665e48c4ab1a7a2fb3b32c83_I20210930" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTEtMS0xLTEtOTQ0MTQ_22a8068b-1af8-435c-a1d5-fc3bb47f10c3">3,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie32bbd59665e48c4ab1a7a2fb3b32c83_I20210930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTEtMi0xLTEtOTQ0MTQ_d50fb371-31b7-4a8e-ab6f-fa440c1169b5">1,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d08e2935f04a3892dc8bf49cba95aa_I20210930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTEtMy0xLTEtOTQ0MTQ_5a83d7da-9206-4cf4-97bf-604c7c347152">44,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieeb453ea070a4057ad9c6dd3435f8906_I20210930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTEtNC0xLTEtOTQ0MTQ_4b8084da-750a-4dd8-b233-69330bc47047">51,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99c020a806d84d1cb9f8c8d97329cf8c_I20210930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTEtNS0xLTEtOTQ0MTQ_b866b508-abef-4da0-8b76-dd655411ce81">4,590</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3750629558d54ed8b2491825206bbff1_I20210930" decimals="-3" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTEtNi0xLTEtOTQ0MTQ_6bbbf776-f778-4999-ac3c-320ace91a4c7">1,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3750629558d54ed8b2491825206bbff1_I20210930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTEtNy0xLTEtOTQ0MTQ_544fea57-8620-4efb-b10e-047a237197e6">57,244</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bec43526f964113b92ba5a981053063_I20210930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTEtOC0xLTEtOTQ0MTQ_9b1d0e38-97fe-4b2e-92ec-72372dd5689e">69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48930a09b1404293820fbeb015eb6729_I20210930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTEtOS0xLTEtOTQ0MTQ_f517c25e-2d89-47b4-b996-2588587f3749">35,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at July 1, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6fc33f512e4c4f3dbfc4ffd56fbaacfb_I20220630" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTItMS0xLTEtOTQ0MTQ_4634bc75-ebae-4f08-9a2f-3c4f9db01ade">3,577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fc33f512e4c4f3dbfc4ffd56fbaacfb_I20220630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTItMi0xLTEtOTQ0MTQ_a3de8d53-4e78-42bb-a3dc-0103e925834f">1,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i163092cff85f4f96832f89ece004f615_I20220630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTItMy0xLTEtOTQ0MTQ_4a713922-f129-4147-8172-53eac9444a84">44,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45e71d3b257b4deaa9068f76e93341ed_I20220630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTItNC0xLTEtOTQ0MTQ_da0b9ca0-503a-442f-bcf5-3fbbc667ea3b">58,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9864609863b94d00aa7ba3ced3bea441_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTItNS0xLTEtOTQ0MTQ_b8918473-eabe-4d06-9545-0516ab77ce5a">4,327</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6a2cf1e51feb4bf9bf40f48b1eb15164_I20220630" decimals="-3" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTItNi0xLTEtOTQ0MTQ_c7332946-f758-4f18-ba62-990d0eac4387">1,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a2cf1e51feb4bf9bf40f48b1eb15164_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTItNy0xLTEtOTQ0MTQ_c7c83b29-3a35-46ac-a0d2-3af4284f82d3">56,770</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia75bfa90c3194a5d875d56f842b27bff_I20220630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTItOC0xLTEtOTQ0MTQ_16687ab0-4553-4ef4-9868-7f334c9aaeaa">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d5f781c87ab40f58ea21a9500d8154a_I20220630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTItOS0xLTEtOTQ0MTQ_09c0a655-c44d-4dda-9646-7867a2607e6d">43,318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck&#160;&amp; Co., Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if014c4b837bd4c0d8e2b84afeadf9c75_D20220701-20220930" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTMtNC0xLTEtOTQ0MTQ_54dfe33f-4aa2-4064-8f22-6a21ede5691a">3,248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTMtOS0xLTEtOTQ0MTQ_1a5d239b-8cbb-4687-99a9-7ce53e261129">3,248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2a2791bc9db4ced8a0f57eebcf50852_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTQtNS0xLTEtOTQ0MTQ_b3a0079e-76ae-44bd-9b8e-a35ac4e8cf0d">416</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTQtOS0xLTEtOTQ0MTQ_78589d84-f26a-421d-9e43-19ba9828bbba">416</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($<ix:nonFraction unitRef="usdPerShare" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTUtMC0xLTEtOTQ0MTQvdGV4dHJlZ2lvbjoyYzQxYThhNzE3NzA0Nzc3OTA2MmU4N2ZkYzlmODQ4Ml80NQ_d000e483-56f7-4a63-b43e-b2af0c488eec">0.69</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if014c4b837bd4c0d8e2b84afeadf9c75_D20220701-20220930" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTUtNC0xLTEtOTQ0MTQ_c33b732a-5c06-4291-926c-12fa07cd7e5c">1,757</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTUtOS0xLTEtOTQ0MTQ_ea96325a-4cf0-4b8d-9a19-378197a935a8">1,757</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9706bcf110ad4f7e9558da712a96dfba_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTYtMy0xLTEtOTQ0MTQ_d45054b2-6877-4eb0-b87f-a7449ba41dab">128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c57e5ba569c45d99424f3d170f677b8_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTYtNy0xLTEtOTQ0MTQ_2b04d0a5-b044-4b56-b737-0866363999de">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTYtOS0xLTEtOTQ0MTQ_8eb3149b-eb0f-41d8-8a48-124be35d9235">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib76e902784e74151b5da455c02992dd8_D20220701-20220930" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTctOC0xLTEtOTQ0MTQ_90085d68-36aa-4eea-be9d-0833ba0af4b8">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTctOS0xLTEtOTQ0MTQ_59f70184-5b3c-4bfd-8017-e8141359694b">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib76e902784e74151b5da455c02992dd8_D20220701-20220930" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTgtOC0xLTEtMTA1NDM0_7ad073cd-df25-4367-b1b6-4c49b88406f8">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTgtOS0xLTEtMTA1NDM0_6a8fd511-aea8-4917-9c84-1007a8785701">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if3d50d8ac75f45d487c729ce8817f47e_I20220930" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTgtMS0xLTEtOTQ0MTQ_5c6169f5-f203-4320-b3f3-d102c5321716">3,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3d50d8ac75f45d487c729ce8817f47e_I20220930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTgtMi0xLTEtOTQ0MTQ_a70dbea4-8a9c-4f8f-b646-8f86396d4402">1,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01a43e0ab33146bcad94c2c546eac8bf_I20220930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTgtMy0xLTEtOTQ0MTQ_086bf1d5-77ac-416b-9a91-2ebcc030cc92">44,243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fb137c2da28404fade360f5042d137a_I20220930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTgtNC0xLTEtOTQ0MTQ_f6f9fcb0-4812-4919-a50c-cda1bbb3f32e">59,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0803cc4f2c64fa7a8e0196a811eaf28_I20220930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTgtNS0xLTEtOTQ0MTQ_f9b978ba-2098-4659-8bd8-05da9a2b4fc2">4,743</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia6aaba1fa4024e1cae697b7460337046_I20220930" decimals="-3" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTgtNi0xLTEtOTQ0MTQ_03ad54b7-3d40-4934-8d1d-2f2405d14fe5">1,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6aaba1fa4024e1cae697b7460337046_I20220930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTgtNy0xLTEtOTQ0MTQ_684c33f7-b97f-4d63-8af6-5112088818f6">56,758</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63f0e081f0a42f198e5d12dcd18cba3_I20220930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTgtOC0xLTEtOTQ0MTQ_7329a9fa-27ac-446e-b832-88350499a6d7">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTgtOS0xLTEtOTQ0MTQ_dded5457-ec65-451d-8181-ae220e96d621">44,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 25 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><div><ix:continuation id="i7445a80ba41b4f4fba8779235be6d066"><ix:continuation id="id7f2d1fb353042d18a25e8ce85a3d922"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.747%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.775%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-<br/>controlling<br/>Interests</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ and shares in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Par&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January&#160;1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie8266a2de763495e917e7346aae13f81_I20201231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMy0xLTEtMS05NDQxNA_ece24c35-bf41-4e10-af5b-92fdf5323866">3,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8266a2de763495e917e7346aae13f81_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMy0yLTEtMS05NDQxNA_3ef8a692-16f1-4fca-95f8-a349d47384fb">1,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46979b5fbfcf4bcfbe34ca9f2816df20_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMy0zLTEtMS05NDQxNA_d8505f3d-c15c-4015-a4cd-0297cd40fbbf">39,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb58c93066b54a02965539a527ce9165_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMy00LTEtMS05NDQxNA_d03bcfa3-e650-44de-8652-6b6b6ee5680a">47,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93d7029f006b4d91a535c2e9905f5a89_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMy01LTEtMS05NDQxNA_e18eb790-a4ef-4a83-982f-d00cb85c9927">6,634</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibf444f353af04455b87e388e584fc395_I20201231" decimals="-3" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMy02LTEtMS05NDQxNA_57732c9e-d49e-4043-9dca-f639d0a10d93">1,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf444f353af04455b87e388e584fc395_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMy03LTEtMS05NDQxNA_4743bd07-11f0-492c-a84b-9d9006703647">56,787</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc4cef6237e84b5f977c6f638148d150_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMy04LTEtMS05NDQxNA_ce443f96-ffb6-4c4c-b46f-e55910d05ad7">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b76c3e2ce274f17b07c82ae1459e9f9_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMy05LTEtMS05NDQxNA_9c63082e-973a-442c-8259-94c5f89cf079">25,404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck&#160;&amp; Co., Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfb7a35d7d0e432f9e66dd2215b3116e_D20210101-20210930" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfNC00LTEtMS05NDQxNA_827372d1-360f-4377-89f0-51021862e3f8">9,291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfNC05LTEtMS05NDQxNA_e8e2709d-5286-46bd-b5f2-6024bfcd2809">9,291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43d9233de62a46b78fb5fdd056a05478_D20210101-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfNS01LTEtMS05NDQxNA_25c415c5-f360-4fd1-a918-e7fa71ba390e">1,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfNS05LTEtMS05NDQxNA_57f25084-cdbc-4cc7-a21d-05e24db44834">1,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($<ix:nonFraction unitRef="usdPerShare" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfNi0wLTEtMS05NDQxNC90ZXh0cmVnaW9uOjdhYWVjNTI1NzczZjRjY2FiZjQ1NmJjZTY1OWM4YzM1XzQ1_abaab81d-6f92-4dd7-936d-627d0767878d">1.95</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idfb7a35d7d0e432f9e66dd2215b3116e_D20210101-20210930" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfNi00LTEtMS05NDQxNA_72a2a40f-c669-4840-ab35-48ad3d215586">4,962</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfNi05LTEtMS05NDQxNA_a4e9ce11-504f-46d9-9acb-461b1aed1656">4,962</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock shares purchased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iac51e60463f94de2b9a560820ae84413_D20210101-20210930" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfNy02LTEtMS05NDQxNA_98e114ef-7764-4051-900c-56a800782a24">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac51e60463f94de2b9a560820ae84413_D20210101-20210930" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfNy03LTEtMS05NDQxNA_1bb62bc2-f45e-49f0-9f2d-79af83cf0510">822</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfNy05LTEtMS05NDQxNA_cf13cefa-fb18-4c60-a257-1cd6d822dd12">822</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spin-off of Organon &amp; Co.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a2bd52c5dca47a292248a21f88ae298_D20210101-20210930" decimals="-6" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfOC0zLTEtMS05NDQxNA_5732fda2-ec7b-484c-8dac-bc88d888017e">4,643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43d9233de62a46b78fb5fdd056a05478_D20210101-20210930" decimals="-6" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfOC01LTEtMS05NDQxNA_525af297-2d98-46ab-bea0-c3ff60a987ef">449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib23f7298a6c6404c9b917d37bd3494f3_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfOC04LTEtMS05NDQxNA_3964beae-4c3f-4434-b99c-7cdfba6e7aeb">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfOC05LTEtMS05NDQxNA_3e81aef1-182a-47dc-97b8-e9188f636322">5,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a2bd52c5dca47a292248a21f88ae298_D20210101-20210930" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfOS0zLTEtMS05NDQxNA_c053aa3d-4de4-4465-a1f9-19f68dd09be4">82</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iac51e60463f94de2b9a560820ae84413_D20210101-20210930" decimals="-6" name="us-gaap:StockholdersEquityOtherShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfOS02LTEtMS05NDQxNA_15ed690c-1a4d-4ea8-9c61-a7a75dd4dc79">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac51e60463f94de2b9a560820ae84413_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfOS03LTEtMS05NDQxNA_b6363215-e046-451f-bf6e-eda60543c007">365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfOS05LTEtMS05NDQxNA_835e7024-bb4e-4bca-8080-396c670026c1">283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23f7298a6c6404c9b917d37bd3494f3_D20210101-20210930" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTAtOC0xLTEtOTQ0MTQ_884eaec3-b853-498c-a35e-23d05dfa660f">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTAtOS0xLTEtOTQ0MTQ_aa3b9244-fbbb-4b92-ae23-859cc190feff">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib23f7298a6c6404c9b917d37bd3494f3_D20210101-20210930" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTEtOC0xLTEtOTc5MDI_3fb1e46b-5d73-471b-af76-9c8029b8768b">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTEtOS0xLTEtOTc5MTI_464178c4-d341-479c-944d-4db2bba1b95f">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie32bbd59665e48c4ab1a7a2fb3b32c83_I20210930" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTEtMS0xLTEtOTQ0MTQ_2845172d-aaf1-4a2b-9337-31960dc1bf3e">3,577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie32bbd59665e48c4ab1a7a2fb3b32c83_I20210930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTEtMi0xLTEtOTQ0MTQ_87a4f501-28c5-4d75-9830-42ee166d1545">1,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d08e2935f04a3892dc8bf49cba95aa_I20210930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTEtMy0xLTEtOTQ0MTQ_4052df59-8ba1-4b71-a45c-e718a93ff4a2">44,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieeb453ea070a4057ad9c6dd3435f8906_I20210930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTEtNC0xLTEtOTQ0MTQ_c4694d9f-86e4-4612-988d-10446901692d">51,691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99c020a806d84d1cb9f8c8d97329cf8c_I20210930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTEtNS0xLTEtOTQ0MTQ_755db335-8572-4558-a20f-db3d0c2d6b78">4,590</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3750629558d54ed8b2491825206bbff1_I20210930" decimals="-3" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTEtNi0xLTEtOTQ0MTQ_f1dd91a2-26a9-436e-875c-23fab4ca3ff6">1,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3750629558d54ed8b2491825206bbff1_I20210930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTEtNy0xLTEtOTQ0MTQ_45bdf8bf-c6c6-4635-9036-9e6f88c4448c">57,244</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bec43526f964113b92ba5a981053063_I20210930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTEtOC0xLTEtOTQ0MTQ_99edf337-542f-46e6-9f6a-5e11127169a9">69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48930a09b1404293820fbeb015eb6729_I20210930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTEtOS0xLTEtOTQ0MTQ_8c32535a-2581-4935-b062-05411c0f701b">35,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January&#160;1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i58a9ea166bd8462bb92f1bde0e0c38ed_I20211231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTItMS0xLTEtOTQ0MTQ_50a65c00-23ff-4d83-ac31-5c2ae3cbcc07">3,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58a9ea166bd8462bb92f1bde0e0c38ed_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTItMi0xLTEtOTQ0MTQ_e9a4c8c2-094a-46b8-9954-5da0f4b3c03a">1,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54fbdd4b47aa41a69dfd52ac2443383f_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTItMy0xLTEtOTQ0MTQ_5fb54794-7ce3-4ea3-83f5-59e64d0a2ad0">44,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf1f3c1c1c05447abdc62cc369de9b5f_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTItNC0xLTEtOTQ0MTQ_81309222-3b6b-44f1-b5ac-3bf64a350c2c">53,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54f6686da6db4e38aeb2e4b266dc881f_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTItNS0xLTEtOTQ0MTQ_c26beb8c-5bbb-4ed4-92dc-8409c16733f6">4,429</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id2b77295046047d1b7a851bf3bc457b3_I20211231" decimals="-3" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTItNi0xLTEtOTQ0MTQ_cede6346-a99e-4e31-b5be-7d5f5ce34c68">1,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2b77295046047d1b7a851bf3bc457b3_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTItNy0xLTEtOTQ0MTQ_cf7b990f-9930-40a0-87bf-4b69fe70bcb1">57,109</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb6e56eb418d416f86418139727649f6_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTItOC0xLTEtOTQ0MTQ_8df27c0e-e0fb-49ee-8e4b-168a20515900">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTItOS0xLTEtOTQ0MTQ_f9fefd90-0b0c-4037-a026-02e10e6df889">38,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck&#160;&amp; Co., Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69b491e8b3b84d76b979f1d2543f1bec_D20220101-20220930" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTMtNC0xLTEtOTQ0MTQ_68d04d04-8efc-40bf-9946-425e2143f9dc">11,502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTMtOS0xLTEtOTQ0MTQ_2ceddacb-32a9-452f-8cbf-59f7d490b468">11,502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd52fe4f8612434abba6e97f4c0f64e5_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTQtNS0xLTEtOTQ0MTQ_cb820084-0fac-4620-a415-59a328088967">314</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTQtOS0xLTEtOTQ0MTQ_15da704b-693b-4169-ab73-7874704a32c5">314</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($<ix:nonFraction unitRef="usdPerShare" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTUtMC0xLTEtOTQ0MTQvdGV4dHJlZ2lvbjpjMTIyODUzMDU1ZGY0OWUwOGNkZjUwMWM5ZDgyOTJmMV80NQ_b5ad7427-749a-493d-accb-319ab602b6c6">2.07</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69b491e8b3b84d76b979f1d2543f1bec_D20220101-20220930" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTUtNC0xLTEtOTQ0MTQ_410485d1-fce8-4e39-928f-390db62864ff">5,270</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTUtOS0xLTEtOTQ0MTQ_ee51f1d6-2c3c-496a-84e6-e59b1c01fafe">5,270</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i398ce1837bda4dd2867a24cf3db019b2_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTctMy0xLTEtOTQ0MTQ_23a59ddb-1cb0-4030-91cd-4d6883ad777e">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iac4516ad133342f381e01ac656921924_D20220101-20220930" decimals="-6" name="us-gaap:StockholdersEquityOtherShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTctNi0xLTEtOTQ0MTQ_250dc3c6-1c27-46d5-9c84-f38f2139fc06">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac4516ad133342f381e01ac656921924_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTctNy0xLTEtOTQ0MTQ_7b435ce7-d26a-4c6a-8b28-c672f9587009">351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTctOS0xLTEtOTQ0MTQ_af2af770-19da-44f8-8672-c68d3eca9bd3">356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65949c6818b4456e8bda505693b348eb_D20220101-20220930" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTgtOC0xLTEtOTQ0MTQ_457ff5dc-787a-4b6e-997a-042898e3f91b">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTgtOS0xLTEtOTQ0MTQ_7a200c6e-e72c-4ecf-9e18-48308114cad6">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65949c6818b4456e8bda505693b348eb_D20220101-20220930" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTktOC0xLTEtOTQ0MTQ_e55ee3d8-9560-4b94-9240-f3ff442b15a7">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTktOS0xLTEtOTQ0MTQ_89861775-2830-44d4-a633-e615a57ab6cb">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if3d50d8ac75f45d487c729ce8817f47e_I20220930" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMjAtMS0xLTEtOTQ0MTQ_37608e41-4a51-4188-bf73-0429a76e3561">3,577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3d50d8ac75f45d487c729ce8817f47e_I20220930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMjAtMi0xLTEtOTQ0MTQ_f0f111fb-9813-4fcb-8e6b-6bc28f7378ce">1,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01a43e0ab33146bcad94c2c546eac8bf_I20220930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMjAtMy0xLTEtOTQ0MTQ_c85342ac-86b0-4ffe-a42f-476ae0a813c0">44,243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fb137c2da28404fade360f5042d137a_I20220930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMjAtNC0xLTEtOTQ0MTQ_65328f76-191a-4c59-98c6-9a243b9a04a0">59,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0803cc4f2c64fa7a8e0196a811eaf28_I20220930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMjAtNS0xLTEtOTQ0MTQ_6c24c916-6fae-411b-a08f-34685e870138">4,743</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia6aaba1fa4024e1cae697b7460337046_I20220930" decimals="-3" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMjAtNi0xLTEtOTQ0MTQ_9adfa049-f322-4b7a-bc4d-8c91480dc60e">1,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6aaba1fa4024e1cae697b7460337046_I20220930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMjAtNy0xLTEtOTQ0MTQ_83d1211b-c189-4193-aa33-29e61988c3f7">56,758</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63f0e081f0a42f198e5d12dcd18cba3_I20220930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMjAtOC0xLTEtOTQ0MTQ_b7263505-df6c-4508-b3a9-d1dc57829552">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMjAtOS0xLTEtOTQ0MTQ_5dcd6f53-6298-408a-b709-d9800eb66a9e">44,524</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div id="i6b4e4280ad2344a5bc7fdcaa77e417f0_61"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;Pension and Other Postretirement Benefit Plans</span></div><ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RleHRyZWdpb246MjRmZDBlZmNhYWM2NDIxMTg2Mzg3NTJkNzhiNzZkZWVfMjIzNA_95e59c73-c528-458a-a46e-75069d3ed68c" continuedAt="i221435f5a9d84f52a9d14ff95ff6e06e" escape="true"><ix:nonNumeric contextRef="i320809a777744dfdb73841889368aa2c_D20220101-20220930" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RleHRyZWdpb246MjRmZDBlZmNhYWM2NDIxMTg2Mzg3NTJkNzhiNzZkZWVfMjIyOA_46693c5f-ee68-4db3-bad3-bc36995b4483" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has defined benefit pension plans covering eligible employees in the U.S. and in certain of its international subsidiaries. The net periodic benefit cost of such plans (including certain costs reported as part of discontinued operations in the first nine months of 2021) consisted of the following components:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.096%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09a399429407463c94fb6f4a770e06ca_D20220701-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfMy0xLTEtMS05NDQxNA_e028775b-d79b-4fa3-b847-a6d74b67bfb7">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia48fc689e3e9494a8b708e96f1579dd7_D20220701-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfMy0zLTEtMS05NDQxNA_1e922a99-5ef7-4506-aa9a-97fb9b638228">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37b081294e5b4b8e9e5a11799924a2f4_D20210701-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfMy01LTEtMS05NDQxNA_93d3cec8-7912-4018-a22d-ab11627771cb">104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129ad2aa2cbf44d79bda671ff94c6b3a_D20210701-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfMy03LTEtMS05NDQxNA_26f329c9-53f3-4355-bf45-1911d80e4fbb">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f56c3589dcf455e940e768c35266f9a_D20220101-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfMy05LTEtMS05NDQxNA_5218432c-191d-42cf-82ed-28e9c371fa98">289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f795846dbf2495a9b51d25b57687dbd_D20220101-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfMy0xMS0xLTEtOTQ0MTQ_853cb53b-c9c5-4caf-a7dd-e39de40ddce2">213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113e99a5148f4c19a209d84850a178e7_D20210101-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfMy0xMy0xLTEtOTQ0MTQ_ba92644e-3c47-4b18-b66d-ab1565f55324">302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49a0549eef484d24b04fa8fcdb43efe2_D20210101-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfMy0xNS0xLTEtOTQ0MTQ_23d20afb-0430-4f61-bf21-56b5cc4dd4ce">254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09a399429407463c94fb6f4a770e06ca_D20220701-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNC0xLTEtMS05NDQxNA_2760b5f8-eac9-4938-a139-93c3b3ff21fb">123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia48fc689e3e9494a8b708e96f1579dd7_D20220701-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNC0zLTEtMS05NDQxNA_5e83ab7d-3ea6-4f7e-9593-3fece5019c77">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37b081294e5b4b8e9e5a11799924a2f4_D20210701-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNC01LTEtMS05NDQxNA_2822a217-c7ad-4f92-b96a-58e8479637f3">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129ad2aa2cbf44d79bda671ff94c6b3a_D20210701-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNC03LTEtMS05NDQxNA_48349d79-fa42-474c-92a1-02c4113a530f">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f56c3589dcf455e940e768c35266f9a_D20220101-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNC05LTEtMS05NDQxNA_f322edf9-ba17-4c67-a59f-c56b0323ffc6">330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f795846dbf2495a9b51d25b57687dbd_D20220101-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNC0xMS0xLTEtOTQ0MTQ_f41fd58f-55db-4fb7-b258-06565c816a77">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113e99a5148f4c19a209d84850a178e7_D20210101-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNC0xMy0xLTEtOTQ0MTQ_7dd257d1-1586-4aa9-bf66-c82c5b6e9391">305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49a0549eef484d24b04fa8fcdb43efe2_D20210101-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNC0xNS0xLTEtOTQ0MTQ_b64cd2d1-0d08-4965-bb85-bf9318f04551">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i09a399429407463c94fb6f4a770e06ca_D20220701-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNS0xLTEtMS05NDQxNA_6bf01b6c-7e53-46db-ab7d-6b365d68a69a">182</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia48fc689e3e9494a8b708e96f1579dd7_D20220701-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNS0zLTEtMS05NDQxNA_1b91a374-2c0b-488b-bddb-74a97131794b">93</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37b081294e5b4b8e9e5a11799924a2f4_D20210701-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNS01LTEtMS05NDQxNA_c16fe4dd-489f-479b-9659-e1043cbe83e7">188</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i129ad2aa2cbf44d79bda671ff94c6b3a_D20210701-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNS03LTEtMS05NDQxNA_7ae9c7d6-5cda-4084-84c5-d4c7c58451a1">105</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f56c3589dcf455e940e768c35266f9a_D20220101-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNS05LTEtMS05NDQxNA_f24ac7a1-b261-42bd-bfcc-4c8aec94ca4b">576</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f795846dbf2495a9b51d25b57687dbd_D20220101-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNS0xMS0xLTEtOTQ0MTQ_e99164fa-5e44-4b78-8dd3-0238965e6c23">292</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i113e99a5148f4c19a209d84850a178e7_D20210101-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNS0xMy0xLTEtOTQ0MTQ_c9e349a3-e4bd-4a33-bdc9-a01cb0d1b009">568</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49a0549eef484d24b04fa8fcdb43efe2_D20210101-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNS0xNS0xLTEtOTQ0MTQ_609456b7-f1c9-494d-b67a-ccf15109bbb9">313</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of unrecognized prior service credit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i09a399429407463c94fb6f4a770e06ca_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNi0xLTEtMS05NDQxNA_f02a11cb-6e8b-4b77-b35f-c408e378bb30">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia48fc689e3e9494a8b708e96f1579dd7_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNi0zLTEtMS05NDQxNA_1967749b-9ec9-4865-9f49-1c912f66f723">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37b081294e5b4b8e9e5a11799924a2f4_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNi01LTEtMS05NDQxNA_ac93615b-ff91-4db9-9995-585917e936ad">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i129ad2aa2cbf44d79bda671ff94c6b3a_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNi03LTEtMS05NDQxNA_0f26add7-9145-47d5-9a8e-f44e4f9e8971">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f56c3589dcf455e940e768c35266f9a_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNi05LTEtMS05NDQxNA_b9a9e1f3-2ef3-4a72-9b4c-2201874be3c5">24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f795846dbf2495a9b51d25b57687dbd_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNi0xMS0xLTEtOTQ0MTQ_e7c20c15-c139-4115-ab92-171f2e58fdf4">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i113e99a5148f4c19a209d84850a178e7_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNi0xMy0xLTEtOTQ0MTQ_157a50ec-2dda-41f2-9299-034acd37da81">29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49a0549eef484d24b04fa8fcdb43efe2_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNi0xNS0xLTEtOTQ0MTQ_9841aaaf-1317-4471-8f8d-af957bf5aa6b">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09a399429407463c94fb6f4a770e06ca_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNy0xLTEtMS05NDQxNA_a3d8d25e-7a26-41ca-aa89-2260a9e8eb9a">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia48fc689e3e9494a8b708e96f1579dd7_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNy0zLTEtMS05NDQxNA_202031b9-c6cb-42dd-b414-fbea6b81621c">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37b081294e5b4b8e9e5a11799924a2f4_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNy01LTEtMS05NDQxNA_fefa716e-6826-4f64-a248-ba70c914334c">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129ad2aa2cbf44d79bda671ff94c6b3a_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNy03LTEtMS05NDQxNA_fa63113d-cbb4-4189-bbfe-e86f9d39913e">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f56c3589dcf455e940e768c35266f9a_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNy05LTEtMS05NDQxNA_96bdb878-233d-4a54-94c2-7c280233cdc2">122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f795846dbf2495a9b51d25b57687dbd_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNy0xMS0xLTEtOTQ0MTQ_f7ee1735-0fc7-4141-ab15-a803db990db6">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113e99a5148f4c19a209d84850a178e7_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNy0xMy0xLTEtOTQ0MTQ_0fe1c20f-4c8e-4989-adf2-821a9db60ba3">218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49a0549eef484d24b04fa8fcdb43efe2_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNy0xNS0xLTEtOTQ0MTQ_52892b7a-2d73-4ce3-a50d-b21283c3958c">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09a399429407463c94fb6f4a770e06ca_D20220701-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfOC0xLTEtMS05NDQxNA_7b2a52e9-0f6b-49e7-988a-4197681b9742">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia48fc689e3e9494a8b708e96f1579dd7_D20220701-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfOC0zLTEtMS05NDQxNA_cf4ba818-b8ba-4b8e-b2da-c14a1a282496">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37b081294e5b4b8e9e5a11799924a2f4_D20210701-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfOC01LTEtMS05NDQxNA_363da7c5-1825-460b-8aa2-aa8b0cd71533">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129ad2aa2cbf44d79bda671ff94c6b3a_D20210701-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfOC03LTEtMS05NDQxNA_8b1e977a-89af-4049-9459-d782da1c72d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f56c3589dcf455e940e768c35266f9a_D20220101-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfOC05LTEtMS05NDQxNA_bfa27aca-c4a0-4bd3-b9ad-359558dcc827">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f795846dbf2495a9b51d25b57687dbd_D20220101-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfOC0xMS0xLTEtOTQ0MTQ_3cc233c5-749d-44c4-b71d-5543ec7e205c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113e99a5148f4c19a209d84850a178e7_D20210101-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfOC0xMy0xLTEtOTQ0MTQ_76043064-7d46-4517-aff7-ae1e4f2cb180">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49a0549eef484d24b04fa8fcdb43efe2_D20210101-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfOC0xNS0xLTEtOTQ0MTQ_d002f1b1-8db1-42e6-a68e-4b6834c6788b">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09a399429407463c94fb6f4a770e06ca_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfOS0xLTEtMS05NDQxNA_0c9a76e6-035a-4a1d-b331-69c9154aee1f">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia48fc689e3e9494a8b708e96f1579dd7_D20220701-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfOS0zLTEtMS05NDQxNA_b681b5ca-7cf4-482a-a2f7-d2d53a52c3e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37b081294e5b4b8e9e5a11799924a2f4_D20210701-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfOS01LTEtMS05NDQxNA_36ae592e-d72b-4f7f-9480-0416006c371f">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129ad2aa2cbf44d79bda671ff94c6b3a_D20210701-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfOS03LTEtMS05NDQxNA_8cc6f6b1-2788-4540-94aa-22a1b8b919ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f56c3589dcf455e940e768c35266f9a_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfOS05LTEtMS05NDQxNA_92d57b3c-82ad-4b3c-96a1-7b6fb7f30134">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f795846dbf2495a9b51d25b57687dbd_D20220101-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfOS0xMS0xLTEtOTQ0MTQ_60802cb1-016c-43ad-953b-7b59e71f4dc9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113e99a5148f4c19a209d84850a178e7_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfOS0xMy0xLTEtOTQ0MTQ_f89a99bd-7c7e-4414-80c8-39fd967f74e3">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49a0549eef484d24b04fa8fcdb43efe2_D20210101-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfOS0xNS0xLTEtOTQ0MTQ_8cdadfe6-586a-4ea0-b56f-b5c4c1933c5d">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09a399429407463c94fb6f4a770e06ca_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfMTAtMS0xLTEtOTQ0MTQ_80755380-5482-4910-9106-d80a2ebce42e">79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia48fc689e3e9494a8b708e96f1579dd7_D20220701-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfMTAtMy0xLTEtOTQ0MTQ_ac99177f-f834-4836-9049-da3c8ef39195">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37b081294e5b4b8e9e5a11799924a2f4_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfMTAtNS0xLTEtOTQ0MTQ_6ce874ff-cd9b-41a9-93a6-702b383865f4">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129ad2aa2cbf44d79bda671ff94c6b3a_D20210701-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfMTAtNy0xLTEtOTQ0MTQ_a4777e14-0cb9-4f9f-b913-dcefe31b0856">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f56c3589dcf455e940e768c35266f9a_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfMTAtOS0xLTEtOTQ0MTQ_a76a0455-2688-4c07-9c83-ac2afbbf0670">180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f795846dbf2495a9b51d25b57687dbd_D20220101-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfMTAtMTEtMS0xLTk0NDE0_ba802a36-c8cd-445b-b1bb-5f7cd405369b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113e99a5148f4c19a209d84850a178e7_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfMTAtMTMtMS0xLTk0NDE0_f9720efc-e335-4c7b-9204-6d7160ddded6">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49a0549eef484d24b04fa8fcdb43efe2_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfMTAtMTUtMS0xLTk0NDE0_6f007c8d-fc12-4a9b-9582-440031cda650">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09a399429407463c94fb6f4a770e06ca_D20220701-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfMTEtMS0xLTEtOTQ0MTQ_c3ba1cae-7aac-40b6-9567-c9606ce0765d">117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia48fc689e3e9494a8b708e96f1579dd7_D20220701-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfMTEtMy0xLTEtOTQ0MTQ_a5c34211-ce3f-4e4c-acee-96138d0517aa">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37b081294e5b4b8e9e5a11799924a2f4_D20210701-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfMTEtNS0xLTEtOTQ0MTQ_8f07d36f-3a51-40bf-a77b-25aedf019566">224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129ad2aa2cbf44d79bda671ff94c6b3a_D20210701-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfMTEtNy0xLTEtOTQ0MTQ_3aba6686-049c-461c-8b1e-d7c6f6afa5a0">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f56c3589dcf455e940e768c35266f9a_D20220101-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfMTEtOS0xLTEtOTQ0MTQ_8124d608-0e3a-4f9a-a1ba-30e45ea34e5b">334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f795846dbf2495a9b51d25b57687dbd_D20220101-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfMTEtMTEtMS0xLTk0NDE0_bae17095-5d63-48d5-88a3-365ece9b80dc">95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113e99a5148f4c19a209d84850a178e7_D20210101-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfMTEtMTMtMS0xLTk0NDE0_d6baa7b1-62d8-4407-b2bf-bad7a1279292">436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49a0549eef484d24b04fa8fcdb43efe2_D20210101-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfMTEtMTUtMS0xLTk0NDE0_4a894dbc-7bfb-49c8-a766-b7eb7ba0d5da">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 26 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i221435f5a9d84f52a9d14ff95ff6e06e"><ix:nonNumeric contextRef="ifcb20618db4549fa96838e2cc81877ae_D20220101-20220930" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RleHRyZWdpb246MjRmZDBlZmNhYWM2NDIxMTg2Mzg3NTJkNzhiNzZkZWVfMjIyNw_9d65a98d-218b-41be-abbd-f412a4ff3b75" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides medical benefits, principally to its eligible U.S. retirees and similar benefits to their dependents, through its other postretirement benefit plans. The net credit of such plans consisted of the following components:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.947%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3dcb6bbb4364846bb3cb11e71d7614c_D20220701-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfMi0xLTEtMS05NDQxNA_e23bb35d-fce6-4283-b075-707e5ac80887">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if26b7f13a9ad441d8310410aad545b78_D20210701-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfMi0zLTEtMS05NDQxNA_a0095ad0-5654-4ffd-9839-036a67bbfff0">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcb20618db4549fa96838e2cc81877ae_D20220101-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfMi01LTEtMS05NDQxNA_20bb1756-aad1-4836-bd3d-9203df861e3a">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cf6fed6709947cdb2d2ccc2ee3bea72_D20210101-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfMi03LTEtMS05NDQxNA_e887a38d-63d5-4953-a21c-8b32a1212bd5">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3dcb6bbb4364846bb3cb11e71d7614c_D20220701-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfMy0xLTEtMS05NDQxNA_22fb173e-cb3f-42cd-86f9-511be295ce4b">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if26b7f13a9ad441d8310410aad545b78_D20210701-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfMy0zLTEtMS05NDQxNA_8a6318f6-c350-4a08-b214-b3724dff7f86">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcb20618db4549fa96838e2cc81877ae_D20220101-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfMy01LTEtMS05NDQxNA_fdc07ff0-3fd2-46fc-91df-0ea4d151d83f">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cf6fed6709947cdb2d2ccc2ee3bea72_D20210101-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfMy03LTEtMS05NDQxNA_1da4749b-5df6-4ebe-9048-149494d24fff">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3dcb6bbb4364846bb3cb11e71d7614c_D20220701-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfNC0xLTEtMS05NDQxNA_57897539-8c88-4ec6-bfbb-d7d8c419bbf5">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if26b7f13a9ad441d8310410aad545b78_D20210701-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfNC0zLTEtMS05NDQxNA_4e83b9b3-74ce-4d8d-b6d9-e31ebf35411c">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifcb20618db4549fa96838e2cc81877ae_D20220101-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfNC01LTEtMS05NDQxNA_4e458d61-4a20-432a-a73f-9ab0a653d44f">64</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cf6fed6709947cdb2d2ccc2ee3bea72_D20210101-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfNC03LTEtMS05NDQxNA_7f17b075-a817-45c4-bfd5-e97c45764b62">59</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of unrecognized prior service credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3dcb6bbb4364846bb3cb11e71d7614c_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfNS0xLTEtMS05NDQxNA_96c21875-2384-456c-b5f4-e12bb97188c9">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if26b7f13a9ad441d8310410aad545b78_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfNS0zLTEtMS05NDQxNA_680c79db-e70b-4225-a6c7-5f909506f9a0">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifcb20618db4549fa96838e2cc81877ae_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfNS01LTEtMS05NDQxNA_313ebb09-968c-464c-ac3a-b81fd75ef0a9">42</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cf6fed6709947cdb2d2ccc2ee3bea72_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfNS03LTEtMS05NDQxNA_f8421418-3c67-4ceb-a978-1f8b82a6532e">48</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3dcb6bbb4364846bb3cb11e71d7614c_D20220701-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfNi0xLTEtMS05NDQxNA_a04ffb59-8040-49a3-bbd1-a56f6c55e205">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if26b7f13a9ad441d8310410aad545b78_D20210701-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfNi0zLTEtMS05NDQxNA_994bff74-6f05-454e-b921-04fafaf9dee5">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifcb20618db4549fa96838e2cc81877ae_D20220101-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfNi01LTEtMS05NDQxNA_56edeb94-d62c-4f3c-87ed-343bb6459807">32</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cf6fed6709947cdb2d2ccc2ee3bea72_D20210101-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfNi03LTEtMS05NDQxNA_5dc3c548-1c95-4fa6-9280-affb0286fa8f">30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3dcb6bbb4364846bb3cb11e71d7614c_D20220701-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfNy0xLTEtMS05NDQxNA_207fc446-18c6-479b-9a37-16f971c879c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if26b7f13a9ad441d8310410aad545b78_D20210701-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfNy0zLTEtMS05NDQxNA_a0ac3248-de31-4feb-a82f-482879e5f8f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcb20618db4549fa96838e2cc81877ae_D20220101-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfNy01LTEtMS05NDQxNA_de914cf0-8624-4baa-9935-52cc056ee3a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cf6fed6709947cdb2d2ccc2ee3bea72_D20210101-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfNy03LTEtMS05NDQxNA_bc92fb1b-7d0d-4a83-8f98-1bea2cac1fe2">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3dcb6bbb4364846bb3cb11e71d7614c_D20220701-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfOC0xLTEtMS05NDQxNA_55a70fde-3601-412e-831c-dbcce8f87ac2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if26b7f13a9ad441d8310410aad545b78_D20210701-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfOC0zLTEtMS05NDQxNA_d944352d-8915-4bfc-9004-c7f3bd3916d2">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifcb20618db4549fa96838e2cc81877ae_D20220101-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfOC01LTEtMS05NDQxNA_71b6f431-1db9-4695-8f64-2037e6c70167">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cf6fed6709947cdb2d2ccc2ee3bea72_D20210101-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfOC03LTEtMS05NDQxNA_57489a80-6aea-47a2-b0f9-51393e00098f">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3dcb6bbb4364846bb3cb11e71d7614c_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfOS0xLTEtMS05NDQxNA_0f578dd5-f0e2-4662-977e-8f6f9a067401">24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if26b7f13a9ad441d8310410aad545b78_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfOS0zLTEtMS05NDQxNA_e5edfe7d-4b7b-4666-9ce3-ab8a5b4abae2">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifcb20618db4549fa96838e2cc81877ae_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfOS01LTEtMS05NDQxNA_ce83228d-8757-4bf9-8c88-6ac4b2149645">69</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cf6fed6709947cdb2d2ccc2ee3bea72_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfOS03LTEtMS05NDQxNA_e079aad5-6509-40f1-a386-7882159540c7">58</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net periodic benefit cost (credit) for pension and other postretirement benefit plans in the first nine months of 2021 includes expenses for curtailments, settlements and termination benefits provided to certain employees in connection with the spin-off of Organon.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with restructuring actions (see Note&#160;5), termination charges were recorded on pension plans related to expanded eligibility for certain employees e</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iting Merck. Also, in connection with these restructuring activities, curtailments and settlements were recorded on certain pension plans. In addition, lump sum payments to U.S. pension plan participants triggered partial settlement charges in the third quarter and first nine months of 2022 and 2021. These partial settlements triggered remeasurements of some of the Company&#8217;s U.S. pension plans. The third quarter 2022 remeasurement, which was calculated using discount rates and asset values as of September 30, 2022, resulted in a net increase of $<ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RleHRyZWdpb246MjRmZDBlZmNhYWM2NDIxMTg2Mzg3NTJkNzhiNzZkZWVfMTU1OQ_8435fb50-fab4-4e9d-a38a-d34077cc0e8b">296</ix:nonFraction>&#160;million to net pension liabilities and also resulted in a related adjustment to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Remeasurements during the first nine months of 2022 have resulted in a net increase of $<ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RleHRyZWdpb246MjRmZDBlZmNhYWM2NDIxMTg2Mzg3NTJkNzhiNzZkZWVfNTQ5NzU1ODE3MjIx_b94f92b6-18bb-4dfa-a686-c37c2152573a">131</ix:nonFraction>&#160;million to net pension liabilities with related adjustments to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCL.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net periodic benefit cost (credit) other than the service cost component are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (see Note&#160;12), with the exception of certain amounts for termination benefits, curtailments and settlements, which are recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> if the event giving rise to the termination benefits, curtailment or settlement is related to restructuring actions or in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> if related to the spin-off of Organon (each as noted above).</span></div></ix:continuation><div id="i6b4e4280ad2344a5bc7fdcaa77e417f0_64"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RleHRyZWdpb246YTBjYTUyNjlkMWVhNGY1YzkxYWFkMTIxN2ViOTA4YmVfNjc5_e821adbc-7330-4dfb-bbeb-fe667241c49a" continuedAt="i3063217ea69d4a06abc56ccc3e8c33c7" escape="true">Other (Income) Expense, Net</ix:nonNumeric></span></div><ix:continuation id="i3063217ea69d4a06abc56ccc3e8c33c7"><ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RleHRyZWdpb246YTBjYTUyNjlkMWVhNGY1YzkxYWFkMTIxN2ViOTA4YmVfNjg5_c5491800-908f-44ec-8ff6-4fe2ab34d0c4" continuedAt="i6424bfd26e4949dabe1202aa81b7f65d" escape="true"><div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (income) expense, net, consisted of:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfMi0xLTEtMS05NDQxNA_8bbee8e8-73b1-441f-b541-88baed42fb41">40</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfMi0zLTEtMS05NDQxNA_d1674cd7-58e1-40f7-a1b2-f641423e0174">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfMi01LTEtMS05NDQxNA_b55f9dfe-f7bb-4085-b246-f2240148d1d0">62</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfMi03LTEtMS05NDQxNA_7587bae7-5d77-481d-8d2d-80fd15ad9886">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfMy0xLTEtMS05NDQxNA_35430208-9210-4edd-8f7d-e5cf4e636325">244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfMy0zLTEtMS05NDQxNA_8dd6b1cc-f393-46cf-a21d-dcaa643bb730">196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfMy01LTEtMS05NDQxNA_cb4082c1-39d6-4fd5-a348-19ae70deb767">727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfMy03LTEtMS05NDQxNA_3db23abf-5139-4e71-8d12-d09fcc4d3a85">597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfNC0xLTEtMS05NDQxNA_3f4a5835-5066-4f23-abba-2b01005a207d">96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfNC0zLTEtMS05NDQxNA_e7876461-2a41-4e93-b326-0950d00ef807">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfNC01LTEtMS05NDQxNA_a956b2dc-628a-4600-b7da-c7b2ecae9926">220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfNC03LTEtMS05NDQxNA_e04ffb67-61bc-4abf-99e5-9a0898ceca1f">202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss (income) from investments in equity securities, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfNS0xLTEtMS05NDQxNA_965201a2-0fdf-46a2-ba00-3b4dfa55fcf1">371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfNS0zLTEtMS05NDQxNA_8ceaf6da-f2f6-4908-b3b1-9bd147e08f81">683</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfNS01LTEtMS05NDQxNA_699ddf86-569e-48d6-8b8f-a4a412aa906c">1,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfNS03LTEtMS05NDQxNA_5537c502-7851-4147-9e35-504781b8973c">1,535</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic defined benefit plan (credit) cost other than service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfNi0xLTEtMS05NDQxNA_ab741f0c-b747-46e7-a068-b1f97bd7c0d0">60</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfNi0zLTEtMS05NDQxNA_0195cc26-362e-4831-90b6-ea5edae7b4ab">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfNi01LTEtMS05NDQxNA_09914e82-2d75-44e8-9f48-ff0b8edf9011">208</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfNi03LTEtMS05NDQxNA_f7d95d40-8f58-4df8-8c6d-40e3f7b7fbbc">159</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" name="mrk:OtherNonoperatingIncomeExpenseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfNy0xLTEtMS05NDQxNA_c2dee8d9-d7b2-4473-b4f2-68ae9d61d8aa">182</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" name="mrk:OtherNonoperatingIncomeExpenseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfNy0zLTEtMS05NDQxNA_82c9afec-d52f-4fc3-a7fb-dd00249ec344">42</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="mrk:OtherNonoperatingIncomeExpenseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfNy01LTEtMS05NDQxNA_eebf23d4-5ed8-40df-95a0-6a54be1266db">462</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="mrk:OtherNonoperatingIncomeExpenseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfNy03LTEtMS05NDQxNA_0dfa6716-59c3-4f33-9cef-721e628acb8b">85</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfOC0xLTEtMS05NDQxNA_e193fbb0-aff0-410c-9d95-c37cb94ff474">429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfOC0zLTEtMS05NDQxNA_2252623b-301e-4740-a60a-7a80af0c63ba">450</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfOC01LTEtMS05NDQxNA_3a7fa95a-e7a8-4437-abc7-129b020c5f30">1,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfOC03LTEtMS05NDQxNA_8c1b2ea9-9688-478f-8086-2ec33d2346c0">1,007</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"><ix:continuation id="i6424bfd26e4949dabe1202aa81b7f65d" continuedAt="ic6d79e93d7e043c0ae7e08bca50bd356">(1)&#160;&#160;&#160;&#160;</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="ic6d79e93d7e043c0ae7e08bca50bd356">Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag.</ix:continuation> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest paid for the nine months ended September&#160;30, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:InterestPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RleHRyZWdpb246YTBjYTUyNjlkMWVhNGY1YzkxYWFkMTIxN2ViOTA4YmVfNjU2_71ca59fd-30d8-4402-840e-554d194cc4eb">660</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:InterestPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RleHRyZWdpb246YTBjYTUyNjlkMWVhNGY1YzkxYWFkMTIxN2ViOTA4YmVfNjYz_e882fbf1-7ae1-4921-92ee-81489241e62c">570</ix:nonFraction> million, respectively.</span></div></ix:continuation><div id="i6b4e4280ad2344a5bc7fdcaa77e417f0_67"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 27 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82Ny9mcmFnOjMxYjJmMmVhYmVmNTQyMjdhOWU5OTYzYzEwM2RhYzgyL3RleHRyZWdpb246MzFiMmYyZWFiZWY1NDIyN2E5ZTk5NjNjMTAzZGFjODJfMTU1OQ_2b64ff65-6757-4bd4-a671-0ea4877c6fd0" continuedAt="i9c82bf2d4ab04650abaddba16a89fe87" escape="true">Taxes on Income</ix:nonNumeric></span></div><ix:continuation id="i9c82bf2d4ab04650abaddba16a89fe87"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective income tax rates from continuing operations were <ix:nonFraction unitRef="number" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82Ny9mcmFnOjMxYjJmMmVhYmVmNTQyMjdhOWU5OTYzYzEwM2RhYzgyL3RleHRyZWdpb246MzFiMmYyZWFiZWY1NDIyN2E5ZTk5NjNjMTAzZGFjODJfNzU_01f88c04-8169-4c71-a76d-702a367ad247">9.2</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82Ny9mcmFnOjMxYjJmMmVhYmVmNTQyMjdhOWU5OTYzYzEwM2RhYzgyL3RleHRyZWdpb246MzFiMmYyZWFiZWY1NDIyN2E5ZTk5NjNjMTAzZGFjODJfODI_50512536-9941-49f3-834f-37b00ef27800">13.2</ix:nonFraction>% for the third quarter of 2022 and 2021, respectively, and <ix:nonFraction unitRef="number" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82Ny9mcmFnOjMxYjJmMmVhYmVmNTQyMjdhOWU5OTYzYzEwM2RhYzgyL3RleHRyZWdpb246MzFiMmYyZWFiZWY1NDIyN2E5ZTk5NjNjMTAzZGFjODJfMTM2_e4334660-b6da-473a-98ff-b3e101cdbb49">11.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82Ny9mcmFnOjMxYjJmMmVhYmVmNTQyMjdhOWU5OTYzYzEwM2RhYzgyL3RleHRyZWdpb246MzFiMmYyZWFiZWY1NDIyN2E5ZTk5NjNjMTAzZGFjODJfMTQz_f8af046c-5d22-4d99-85b4-23ebfe051c77">14.4</ix:nonFraction>% for the first nine months of 2022 and 2021, respectively. The effective income tax rates from continuing operations reflect the beneficial impact of foreign earnings. The effective income tax rates from continuing operations in the third quarter and first nine months of 2022 also include the favorable impact of net unrealized losses from investments in equity securities and intangible asset impairment charges, which were taxed at the U.S. tax rate. The effective income tax rate from continuing operations in the first nine months of 2021 reflects the unfavorable effect of a charge for the acquisition of Pandion for which <ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="0" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82Ny9mcmFnOjMxYjJmMmVhYmVmNTQyMjdhOWU5OTYzYzEwM2RhYzgyL3RleHRyZWdpb246MzFiMmYyZWFiZWY1NDIyN2E5ZTk5NjNjMTAzZGFjODJfNTE3_4c37ab6d-36c8-4f99-a858-1250380ece6f"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="0" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82Ny9mcmFnOjMxYjJmMmVhYmVmNTQyMjdhOWU5OTYzYzEwM2RhYzgyL3RleHRyZWdpb246MzFiMmYyZWFiZWY1NDIyN2E5ZTk5NjNjMTAzZGFjODJfNTE3_aa43912b-533f-42e7-85b6-26a7ce0e7a5f">no</ix:nonFraction></ix:nonFraction> tax benefit was recognized, as well as a net tax benefit of $<ix:nonFraction unitRef="usd" contextRef="i38abb5b6d35e4640ae278494162794cb_D20210101-20210930" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82Ny9mcmFnOjMxYjJmMmVhYmVmNTQyMjdhOWU5OTYzYzEwM2RhYzgyL3RleHRyZWdpb246MzFiMmYyZWFiZWY1NDIyN2E5ZTk5NjNjMTAzZGFjODJfNjcy_8eb31327-52dc-46da-bc95-59af8ce5030e">207</ix:nonFraction>&#160;million related to the settlement of certain federal income tax matters as discussed below. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2021, the Internal Revenue Service (IRS) concluded its examinations of Merck&#8217;s 2015-2016 U.S. federal income tax returns. As a result, the Company was required to make a payment of $<ix:nonFraction unitRef="usd" contextRef="i355d324b4b084fcd9897163416bb017d_D20210101-20210331" decimals="-6" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82Ny9mcmFnOjMxYjJmMmVhYmVmNTQyMjdhOWU5OTYzYzEwM2RhYzgyL3RleHRyZWdpb246MzFiMmYyZWFiZWY1NDIyN2E5ZTk5NjNjMTAzZGFjODJfOTY1_7c82e5e7-b8e2-416b-9a42-a64e1d74fd04">190</ix:nonFraction>&#160;million (of which $<ix:nonFraction unitRef="usd" contextRef="i5747fab0a16f42f8b7a20235e05fc43d_D20210101-20210331" decimals="-6" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82Ny9mcmFnOjMxYjJmMmVhYmVmNTQyMjdhOWU5OTYzYzEwM2RhYzgyL3RleHRyZWdpb246MzFiMmYyZWFiZWY1NDIyN2E5ZTk5NjNjMTAzZGFjODJfOTc4_f04849a5-2833-4a08-82f6-3a7d2bbe4946">172</ix:nonFraction>&#160;million related to continuing operations and $<ix:nonFraction unitRef="usd" contextRef="ib62f00b41eb24b118fee32484d16e6ed_D20210101-20210331" decimals="-6" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82Ny9mcmFnOjMxYjJmMmVhYmVmNTQyMjdhOWU5OTYzYzEwM2RhYzgyL3RleHRyZWdpb246MzFiMmYyZWFiZWY1NDIyN2E5ZTk5NjNjMTAzZGFjODJfMTAxOA_20b300c1-a57b-4642-ae0e-9fdfeb55b26c">18</ix:nonFraction>&#160;million related to discontinued operations). The Company&#8217;s reserves for unrecognized tax benefits for the years under examination exceeded the adjustments relating to this examination period and therefore the Company recorded a $<ix:nonFraction unitRef="usd" contextRef="i76c87fa1c62a44db871fbb8b83163687_D20210101-20210930" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82Ny9mcmFnOjMxYjJmMmVhYmVmNTQyMjdhOWU5OTYzYzEwM2RhYzgyL3RleHRyZWdpb246MzFiMmYyZWFiZWY1NDIyN2E5ZTk5NjNjMTAzZGFjODJfMTI0MQ_8ffb8aaa-6d96-49bb-bce4-5c6a7e4413db">236</ix:nonFraction>&#160;million net tax benefit in the first nine months of 2021 (of which $<ix:nonFraction unitRef="usd" contextRef="i38abb5b6d35e4640ae278494162794cb_D20210101-20210930" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82Ny9mcmFnOjMxYjJmMmVhYmVmNTQyMjdhOWU5OTYzYzEwM2RhYzgyL3RleHRyZWdpb246MzFiMmYyZWFiZWY1NDIyN2E5ZTk5NjNjMTAzZGFjODJfMTMwMQ_8eb31327-52dc-46da-bc95-59af8ce5030e">207</ix:nonFraction>&#160;million related to continuing operations and $<ix:nonFraction unitRef="usd" contextRef="i52a4807b00fd4898baafe70f646f2a51_D20210101-20210930" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82Ny9mcmFnOjMxYjJmMmVhYmVmNTQyMjdhOWU5OTYzYzEwM2RhYzgyL3RleHRyZWdpb246MzFiMmYyZWFiZWY1NDIyN2E5ZTk5NjNjMTAzZGFjODJfMTM0MQ_d571b384-c603-457b-8dc6-e942568fa0a3">29</ix:nonFraction>&#160;million related to discontinued operations). This net benefit reflects reductions in reserves for unrecognized tax benefits and other related liabilities for tax positions relating to the years that were under examination.</span></div></ix:continuation><div id="i6b4e4280ad2344a5bc7fdcaa77e417f0_70"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RleHRyZWdpb246NGFhODQyNmI1YzE2NDk1YWE0MWE5MWY4MTUzNzcyZWRfNDUz_a2f27cab-95b0-41ab-a322-ac38bd714e02" continuedAt="id7e6f9bce868497b87af69595d90b2d5" escape="true">Earnings Per Share</ix:nonNumeric></span></div><ix:continuation id="id7e6f9bce868497b87af69595d90b2d5" continuedAt="i7a713b1094944220880abbf7836313ff"><ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RleHRyZWdpb246NGFhODQyNmI1YzE2NDk1YWE0MWE5MWY4MTUzNzcyZWRfNDYw_e15e72ea-eb9a-45c2-ba24-913b6b95eb73" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculations of earnings per share are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.677%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ and shares in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income from Continuing Operations Attributable to Merck&#160;&amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMi0xLTEtMS05NDQxNA_3f2505fd-6e8f-4373-a3ad-5bfd3bfb31a3">3,248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMi0zLTEtMS05NDQxNA_fea73ef0-8701-419c-9f43-21f745ce79d0">4,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMi01LTEtMS05NDQxNA_0236d342-2b66-420b-a945-c3c873913a25">11,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMi03LTEtMS05NDQxNA_649901eb-0139-4f06-bc46-90dbd8748102">8,525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMy0xLTEtMS05NDQxNA_5ac82b44-7fa0-45f8-ad3f-aa6ffe7e010a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMy0zLTEtMS05NDQxNA_cd1c2db2-1958-494e-a447-8808cb1ecf54">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMy01LTEtMS05NDQxNA_dc73a092-2044-4c0d-abc3-0b8a413befc8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMy03LTEtMS05NDQxNA_6d44aa4a-f521-4de4-b637-aee6df038345">766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income Attributable to Merck&#160;&amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfNC0xLTEtMS05NDQxNA_3c516582-1dcb-4ee6-8196-27995f766d90"><ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfNC0xLTEtMS05NDQxNA_5a455bc8-6389-46d5-82b7-7d3d64dbd252">3,248</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfNC0zLTEtMS05NDQxNA_219cf3f1-118c-4f60-8758-422cbf0a8454"><ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfNC0zLTEtMS05NDQxNA_55ac1b45-4ce1-4f44-82e0-617c3a2ae9f9">4,567</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfNC01LTEtMS05NDQxNA_ebb04da4-054f-42fd-a62c-db45d9212215"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfNC01LTEtMS05NDQxNA_f70ba8f4-1387-4bc1-8177-af028b3c8981">11,502</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfNC03LTEtMS05NDQxNA_3d25d310-a789-49a9-a7b9-73f3691767b0"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfNC03LTEtMS05NDQxNA_84a0351b-2979-483c-b609-5103abd6ca39">9,291</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfNS0xLTEtMS05NDQxNA_6ca42779-bd08-47c3-a3bb-db2bbeba553e">2,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfNS0zLTEtMS05NDQxNA_e4a30f04-ac4b-441d-a1c0-55d0f178be6c">2,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfNS01LTEtMS05NDQxNA_1673320c-daa4-40b9-a84c-ddcaf42be7db">2,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfNS03LTEtMS05NDQxNA_2602e0a5-2a29-458e-b319-a000f41241f5">2,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares issuable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfNi0xLTEtMS05NDQxNA_60f97169-fc8e-4a6b-9312-691847704790">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfNi0zLTEtMS05NDQxNA_0c608936-1f97-461b-b7a4-d3f436876921">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfNi01LTEtMS05NDQxNA_c365e45b-aed5-43eb-856f-b4c7eb6d2c12">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfNi03LTEtMS05NDQxNA_8fb73287-c62d-46da-8150-56325f146d5d">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average common shares outstanding assuming dilution </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfNy0xLTEtMS05NDQxNA_5b43792a-42e5-400b-9ba7-558b9e03fc4b">2,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfNy0zLTEtMS05NDQxNA_4ec103aa-f7f3-4857-8c90-7b2d1ecf0bdd">2,536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfNy01LTEtMS05NDQxNA_9324611f-44b2-4099-a105-1d7bf83fe625">2,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfNy03LTEtMS05NDQxNA_ae0bd9d8-b7cc-431c-af30-9323ff52bf88">2,539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic Earnings per Common Share Attributable to Merck &amp; Co., Inc. Common Shareholders:</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Continuing Operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfOS0xLTEtMS05NDQxNA_9a4f2acf-5229-480c-ba5a-0263348fd2b2">1.28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfOS0zLTEtMS05NDQxNA_2e5615bb-7449-4a3e-a0a9-f071d7c14ec1">1.81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfOS01LTEtMS05NDQxNA_94cf5496-c99f-4246-9b7e-d67586733aa9">4.55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfOS03LTEtMS05NDQxNA_087ce0b5-6158-49f0-9904-35ced729e690">3.37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Discontinued Operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMTAtMS0xLTEtOTQ0MTQ_6eec1e00-bc47-40e9-aed7-a837d967fcd2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMTAtMy0xLTEtOTQ0MTQ_bde97e50-c559-449e-b47a-5f49153dbad6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMTAtNS0xLTEtOTQ0MTQ_a668527d-967a-44df-8f43-dfdaca0687c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMTAtNy0xLTEtOTQ0MTQ_9fd03cd7-1b53-45c2-8bf2-d9d2a5232e15">0.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMTEtMS0xLTEtOTQ0MTQ_2ec81bed-e7d5-4b07-8470-65e3b3efcd9c">1.28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMTEtMy0xLTEtOTQ0MTQ_15fa60cb-9d78-4973-8fa3-44c8d82a93a1">1.81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMTEtNS0xLTEtOTQ0MTQ_60dfdb0f-2cbf-4562-9a42-951481ebacb8">4.55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMTEtNy0xLTEtOTQ0MTQ_887df273-c91b-4bd1-823c-736c47431313">3.67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per Common Share Assuming Dilution Attributable to Merck &amp; Co., Inc. Common Shareholders:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Continuing Operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMTMtMS0xLTEtOTQ0MTQ_d7dd3c06-6980-4d4f-bc71-559890f43b72">1.28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMTMtMy0xLTEtOTQ0MTQ_dccb4172-0650-4e99-a590-966561db0835">1.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMTMtNS0xLTEtOTQ0MTQ_7b95200f-6ae3-4a26-b40d-4a84a5ef0a2e">4.53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMTMtNy0xLTEtOTQ0MTQ_e7a94198-bdea-4e23-a456-bc82f3e7ca69">3.36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Discontinued Operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMTQtMS0xLTEtOTQ0MTQ_9ad16bfe-ef12-4cca-8aff-1c2fc4134fd2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMTQtMy0xLTEtOTQ0MTQ_e66db743-c155-451b-9b6e-f5cd5794840f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMTQtNS0xLTEtOTQ0MTQ_44ee97ea-c809-4248-96b1-5bfe27d13ecb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMTQtNy0xLTEtOTQ0MTQ_f6f42b46-cc84-4c49-b5ce-6d0598095e4b">0.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMTUtMS0xLTEtOTQ0MTQ_e7850f85-ebfa-4c65-a172-52e5e3ee997b">1.28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMTUtMy0xLTEtOTQ0MTQ_8ea49180-3a10-4ecf-b0c5-6472ce2fdfaf">1.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMTUtNS0xLTEtOTQ0MTQ_cb692d6a-e3df-432d-89c0-76126a9f0a83">4.53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMTUtNy0xLTEtOTQ0MTQ_0044e863-5788-4148-9bf8-86e21c1817ff">3.66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt">Issuable primarily under share-based compensation plans.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7a713b1094944220880abbf7836313ff">For the third quarter of 2022 and 2021, <ix:nonFraction unitRef="shares" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RleHRyZWdpb246NGFhODQyNmI1YzE2NDk1YWE0MWE5MWY4MTUzNzcyZWRfMTYx_452ce140-e4d0-4935-b723-1caba5c67069">2</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RleHRyZWdpb246NGFhODQyNmI1YzE2NDk1YWE0MWE5MWY4MTUzNzcyZWRfMTY4_adaf6588-dde2-46e3-9e19-14d38e4354f5">8</ix:nonFraction> million, respectively, and for the first nine months of 2022 and 2021, <ix:nonFraction unitRef="shares" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RleHRyZWdpb246NGFhODQyNmI1YzE2NDk1YWE0MWE5MWY4MTUzNzcyZWRfMjMy_c91d4303-e3e5-4211-a3d9-c7dbbbada964">5</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RleHRyZWdpb246NGFhODQyNmI1YzE2NDk1YWE0MWE5MWY4MTUzNzcyZWRfMjM5_a4925bc2-a245-46fc-a761-15841fe80e54">10</ix:nonFraction> million, respectively, of common shares issuable under share-based compensation plans were excluded from the computation of earnings per common share assuming dilution because the effect would have been antidilutive.</ix:continuation> </span></div><div id="i6b4e4280ad2344a5bc7fdcaa77e417f0_73"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 28 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RleHRyZWdpb246YTlkZWZkY2FiOGEwNDhjYzg1ODMzMzgyNDg1YjUwYWFfMzM4_964363be-a13a-489e-9098-e0fb2f36b531" continuedAt="i61d002e5edcb44fc86529242981dbcc5" escape="true">Other Comprehensive Income (Loss)</ix:nonNumeric></span></div><ix:continuation id="i61d002e5edcb44fc86529242981dbcc5"><ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RleHRyZWdpb246YTlkZWZkY2FiOGEwNDhjYzg1ODMzMzgyNDg1YjUwYWFfMzQ2_2601487c-5444-4f12-b4b1-b674491bf96a" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in each component of other comprehensive income (loss) are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.870%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee<br/>Benefit<br/>Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign Currency<br/>Translation<br/>Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance July 1, 2021, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia164fd181a4240bb9f3e9e496fc60bb0_I20210630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMi0xLTEtMS05NDQxNA_d506c6c1-d33d-4ffb-ad80-be66113a3812">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04361801595c41ef86be85e444162b27_I20210630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMi0zLTEtMS05NDQxNA_989040b1-70d7-4411-87fe-e5dabba0b925">3,028</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i998f48f9bf1e4663850834c5e23fe862_I20210630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMi01LTEtMS05NDQxNA_f913cc8c-c440-4af5-935b-489a8f465f85">1,574</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7e47c5bf82f40adb471e36675ba4ee6_I20210630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMi03LTEtMS05NDQxNA_b9f1bc5b-6dc0-4286-b549-aeae93f4ff8c">4,628</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79db0e250e4c4f81b2bbcc5c8fefea2d_D20210701-20210930" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMy0xLTEtMS05NDQxNA_b2cb3b9f-2559-41fb-a9a1-df21185c8011">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2fbc79b742df422b8eb80da9c3923e51_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMy0zLTEtMS05NDQxNA_f443fb83-c7d0-46a5-b987-9200ea5fc77f">24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i871670fc66504079bbcb712e2def07e3_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMy01LTEtMS05NDQxNA_b63bf210-7002-45ea-9006-1b01657cfb5c">96</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMy03LTEtMS05NDQxNA_c37b1391-02ad-41f1-84eb-91eaa923ccb4">48</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i79db0e250e4c4f81b2bbcc5c8fefea2d_D20210701-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfNC0xLTEtMS05NDQxNA_209395ca-cac6-43d3-8da4-60cd6273250e">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fbc79b742df422b8eb80da9c3923e51_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfNC0zLTEtMS05NDQxNA_e2ddb5de-8e5d-47a2-82b7-ddb249beeb37">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i871670fc66504079bbcb712e2def07e3_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfNC01LTEtMS05NDQxNA_52872b14-b79a-46ca-88e5-42e076f5eaa6">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfNC03LTEtMS05NDQxNA_3f64fddf-5b68-4302-9103-87c685314aa1">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79db0e250e4c4f81b2bbcc5c8fefea2d_D20210701-20210930" decimals="-6" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfNS0xLTEtMS05NDQxNA_eddeaa96-732f-4402-87bc-9e1369fefcc4">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2fbc79b742df422b8eb80da9c3923e51_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfNS0zLTEtMS05NDQxNA_c75d0dea-6cbc-48d3-afdf-1b14672a9008">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i871670fc66504079bbcb712e2def07e3_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfNS01LTEtMS05NDQxNA_9b965fe3-4116-4e25-ae75-ad959a0d8b38">84</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfNS03LTEtMS05NDQxNA_d329940a-74fd-49b0-91ed-638d2d636708">36</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79db0e250e4c4f81b2bbcc5c8fefea2d_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfNi0xLTEtMS05NDQxNA_1a1f1139-92dd-44fa-8b0a-db42b01cbfe6">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fbc79b742df422b8eb80da9c3923e51_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfNi0zLTEtMS05NDQxNA_9e654d49-1c09-4a18-9936-6b8268442f8e">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i871670fc66504079bbcb712e2def07e3_D20210701-20210930" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfNi01LTEtMS05NDQxNA_ce31a905-111a-45c1-bb5a-746b323a155d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfNi03LTEtMS05NDQxNA_88893410-75d7-4b34-999d-0d7dd075ad6c">104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i79db0e250e4c4f81b2bbcc5c8fefea2d_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfNy0xLTEtMS05NDQxNA_35ab004b-58fd-4841-8249-3fd316918e45">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2fbc79b742df422b8eb80da9c3923e51_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfNy0zLTEtMS05NDQxNA_9e07bad7-b6de-41b1-9793-8b34b233597c">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i871670fc66504079bbcb712e2def07e3_D20210701-20210930" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfNy01LTEtMS05NDQxNA_b4dbbaf7-1d95-4823-abb6-952775f6df9b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfNy03LTEtMS05NDQxNA_020dab1c-d7f4-4152-83ac-3ee8eb0657aa">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79db0e250e4c4f81b2bbcc5c8fefea2d_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfOC0xLTEtMS05NDQxNA_98da9d40-d179-4846-af44-67ba76af4e52">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fbc79b742df422b8eb80da9c3923e51_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfOC0zLTEtMS05NDQxNA_b8ba3346-a330-4639-a771-706b6649e677">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i871670fc66504079bbcb712e2def07e3_D20210701-20210930" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfOC01LTEtMS05NDQxNA_0b679184-399f-4469-90fe-e45143bbe97f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfOC03LTEtMS05NDQxNA_790e25de-a771-4525-be23-2d8c9428cc4c">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79db0e250e4c4f81b2bbcc5c8fefea2d_D20210701-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfOS0xLTEtMS05NDQxNA_f90f0dbe-6a54-423b-bf5a-dd35f16f8d7e">84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fbc79b742df422b8eb80da9c3923e51_D20210701-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfOS0zLTEtMS05NDQxNA_47f86251-57ed-465e-931c-21b85fd9a23c">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i871670fc66504079bbcb712e2def07e3_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfOS01LTEtMS05NDQxNA_d9582a81-b93b-46cb-94dc-390f0d089c9c">84</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfOS03LTEtMS05NDQxNA_be9f0d7a-3d04-4afb-ae47-3913a0bd7475">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance September 30, 2021, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0ae37c4002d4f7c8945b238b450a3ff_I20210930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTEtMS0xLTEtOTQ0MTQ_e7f0a931-349b-471a-9ace-9534a6d6e969">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0de005cbf7c64be2bbb15d3ad2747c39_I20210930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTEtMy0xLTEtOTQ0MTQ_230f2500-c120-434d-81b5-c609bfbbee7f">2,990</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf6a11570b2f4b75989bbe9a432b4263_I20210930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTEtNS0xLTEtOTQ0MTQ_32a92e4b-1891-48ca-9097-2fa267fae228">1,658</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99c020a806d84d1cb9f8c8d97329cf8c_I20210930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTEtNy0xLTEtOTQ0MTQ_f446f676-a21c-4fab-a10e-4ac3ae51d3bc">4,590</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance July 1, 2022, net of taxes</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4376d5e08b3472d9cdbcc59389ab13f_I20220630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTItMS0xLTEtOTQ0MTQ_74fe5953-2638-4356-bdc6-df4b666b0b43">390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i940d159cf6fc4de7a976d223e5df88bd_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTItMy0xLTEtOTQ0MTQ_4ad0aef5-5eda-41dc-98c2-72a405409c08">2,465</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i820aa0a4094e46508f3d90c1102a977b_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTItNS0xLTEtOTQ0MTQ_a29d7aa4-05c7-474f-b51b-a30fa5d5016f">2,252</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9864609863b94d00aa7ba3ced3bea441_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTItNy0xLTEtOTQ0MTQ_e66d4cb3-71a7-43a2-92fa-b7184786e6b9">4,327</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3d89e2baf3b40f3b69759154662da14_D20220701-20220930" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTMtMS0xLTEtOTQ0MTQ_e2f192fb-c270-453b-9415-9cfc59314811">682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc4cbcf7fafb47afaea1141b1ace9b8c_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTMtMy0xLTEtOTQ0MTQ_797e27db-f772-4a0d-9983-1f6e09483524">294</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b887851ae3f40518c8ab99172a256c1_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTMtNS0xLTEtOTQ0MTQ_43390bbd-bcae-465f-b07b-b4a364b717de">618</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTMtNy0xLTEtOTQ0MTQ_6e9c59a4-15c1-4de2-b8a9-374bd73b4772">230</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3d89e2baf3b40f3b69759154662da14_D20220701-20220930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTQtMS0xLTEtOTQ0MTQ_8535b243-c115-4411-8cfc-a19c4269e1d0">143</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc4cbcf7fafb47afaea1141b1ace9b8c_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTQtMy0xLTEtOTQ0MTQ_5f999ce9-bd59-4968-81f0-f38d2589779d">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b887851ae3f40518c8ab99172a256c1_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTQtNS0xLTEtOTQ0MTQ_8ea4b44c-f793-4c74-b386-666708fb632a">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTQtNy0xLTEtOTQ0MTQ_30d9b197-c283-4e44-8fd8-c64b2d39d92d">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3d89e2baf3b40f3b69759154662da14_D20220701-20220930" decimals="-6" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTUtMS0xLTEtOTQ0MTQ_55109df5-6dcb-4d3a-908e-b125befeed77">539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc4cbcf7fafb47afaea1141b1ace9b8c_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTUtMy0xLTEtOTQ0MTQ_1384d9a3-5e71-4541-9074-80b8b30198ec">232</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b887851ae3f40518c8ab99172a256c1_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTUtNS0xLTEtOTQ0MTQ_811f7b46-6dc1-4b78-87c1-7e04800ad7d0">568</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTUtNy0xLTEtOTQ0MTQ_af8017e8-204a-40fd-b208-47ec9a592015">261</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3d89e2baf3b40f3b69759154662da14_D20220701-20220930" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTYtMS0xLTEtOTQ0MTQ_12c833ca-606a-4487-bf83-8ee6da34af88">254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc4cbcf7fafb47afaea1141b1ace9b8c_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTYtMy0xLTEtOTQ0MTQ_c8426025-274e-4957-a396-3afc5d01fc9a">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b887851ae3f40518c8ab99172a256c1_D20220701-20220930" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTYtNS0xLTEtOTQ0MTQ_862f7f64-fe28-4dfa-8942-803bbe1bec7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTYtNy0xLTEtOTQ0MTQ_5490f4da-a8c6-4d6c-98c4-627ce61da96d">177</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3d89e2baf3b40f3b69759154662da14_D20220701-20220930" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTctMS0xLTEtOTQ0MTQ_e2da8d8f-f02d-46c1-9c5c-5560815ea7ad">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc4cbcf7fafb47afaea1141b1ace9b8c_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTctMy0xLTEtOTQ0MTQ_21990bde-9e59-448a-94e3-03b2703da8d5">31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b887851ae3f40518c8ab99172a256c1_D20220701-20220930" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTctNS0xLTEtOTQ0MTQ_662228da-2e31-4bcc-a366-ef16990f3673">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTctNy0xLTEtOTQ0MTQ_650c77d0-79af-436d-8293-7116a0736638">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3d89e2baf3b40f3b69759154662da14_D20220701-20220930" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTgtMS0xLTEtOTQ0MTQ_ab831fae-53cd-4fa0-8c3a-cc42cadddf1b">201</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc4cbcf7fafb47afaea1141b1ace9b8c_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTgtMy0xLTEtOTQ0MTQ_5afdcbd9-b0a0-4da4-954d-6de459b94b3b">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b887851ae3f40518c8ab99172a256c1_D20220701-20220930" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTgtNS0xLTEtOTQ0MTQ_a3c1a9fa-750e-457f-a216-f631a6d09fc6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTgtNy0xLTEtOTQ0MTQ_f103f269-243e-4bf0-a45a-716c3d7d17c5">155</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3d89e2baf3b40f3b69759154662da14_D20220701-20220930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTktMS0xLTEtOTQ0MTQ_b863c34c-72a2-4ad5-b009-9aa51e762ed8">338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc4cbcf7fafb47afaea1141b1ace9b8c_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTktMy0xLTEtOTQ0MTQ_1b5b9690-f56b-4f8d-bbc9-76ebed038380">186</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b887851ae3f40518c8ab99172a256c1_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTktNS0xLTEtOTQ0MTQ_9344766c-1d91-4890-8495-2f5e25b5c765">568</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTktNy0xLTEtOTQ0MTQ_4f087568-1ebb-4d72-8943-79bfd490d995">416</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance September 30, 2022, net of taxes</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f45167f24e645d2ad668c47635fc09b_I20220930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMjAtMS0xLTEtOTQ0MTQ_301684b8-945e-4280-b8fc-17a0f6090795">728</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b4bb3ccba1a4790beb19a0ca2cd4721_I20220930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMjAtMy0xLTEtOTQ0MTQ_1c2259d9-7850-4618-8d26-c02ee35970e9">2,651</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0df51b82a6bf4ed3a20acde326a2a355_I20220930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMjAtNS0xLTEtOTQ0MTQ_ae2d04b5-2f84-4443-8c1a-c6fbf36384a2">2,820</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0803cc4f2c64fa7a8e0196a811eaf28_I20220930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMjAtNy0xLTEtOTQ0MTQ_d701a15d-4e25-446f-ab4c-5192fa82199c">4,743</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.870%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee<br/>Benefit<br/>Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign Currency<br/>Translation<br/>Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January 1, 2021, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i754a465cfe674a28bad93eaa56b395ec_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMi0xLTEtMS05NDQxNA_673670f5-09cb-4a0a-a14b-9a5e7a350732">266</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2877989be5ba41eda5048c75789f5d0b_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMi0zLTEtMS05NDQxNA_010c74eb-7346-4786-acb9-b60392902d99">4,540</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifdc463d6e9e74476b4efb5e0ad43ff93_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMi01LTEtMS05NDQxNA_8a21b28e-5b16-4db2-8411-0d12c6c673ab">1,828</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93d7029f006b4d91a535c2e9905f5a89_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMi03LTEtMS05NDQxNA_e09595d6-e787-4978-810b-797b7aea848e">6,634</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46dd5b7c9aab4334a81feabf9ee87525_D20210101-20210930" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMy0xLTEtMS05NDQxNA_5e11b564-5eb6-4c89-9565-d027815657d8">193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a93811c7004483b89e5b2b7d7a47e27_D20210101-20210930" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMy0zLTEtMS05NDQxNA_410d3a69-c273-4f8c-b6c0-f49177d2b716">1,739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5aab13ae412a418dad03dcc21e39fa7f_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMy01LTEtMS05NDQxNA_c419d687-eff3-4851-bf43-c8a61d935281">167</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMy03LTEtMS05NDQxNA_819cf266-8629-48c8-81f8-f0995e987766">1,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46dd5b7c9aab4334a81feabf9ee87525_D20210101-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfNC0xLTEtMS05NDQxNA_5b4f5c3d-3ba8-4f36-ab51-3857e227867f">41</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a93811c7004483b89e5b2b7d7a47e27_D20210101-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfNC0zLTEtMS05NDQxNA_b43f12e4-37dc-4db8-9c4f-b0c90f558018">385</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5aab13ae412a418dad03dcc21e39fa7f_D20210101-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfNC01LTEtMS05NDQxNA_05742b98-19a9-43bb-ac1e-22dd6e61ac45">84</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfNC03LTEtMS05NDQxNA_a2aa1dca-ab28-433f-b437-4fc95db347cd">510</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46dd5b7c9aab4334a81feabf9ee87525_D20210101-20210930" decimals="-6" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfNS0xLTEtMS05NDQxNA_a6354273-6fc5-48cd-9f53-50e421b41687">152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a93811c7004483b89e5b2b7d7a47e27_D20210101-20210930" decimals="-6" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfNS0zLTEtMS05NDQxNA_9b0f7c66-9a36-429f-acc6-88a73ec38eac">1,354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5aab13ae412a418dad03dcc21e39fa7f_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfNS01LTEtMS05NDQxNA_1cd5a59c-155b-420b-90ca-0fcdbb35807f">251</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfNS03LTEtMS05NDQxNA_d591cf5e-fbff-4e25-b03a-6e9a0bcdb632">1,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46dd5b7c9aab4334a81feabf9ee87525_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfNi0xLTEtMS05NDQxNA_5d4eedc7-3e93-4866-8b91-200ccfb1ff78">218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a93811c7004483b89e5b2b7d7a47e27_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfNi0zLTEtMS05NDQxNA_9850ac70-f975-4634-bcaa-ceb2fdb5428f">210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aab13ae412a418dad03dcc21e39fa7f_D20210101-20210930" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfNi01LTEtMS05NDQxNA_153bdac1-7908-40d2-ba08-83d0074530a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfNi03LTEtMS05NDQxNA_f204b481-3664-4f88-8449-f0d4dda0ffcc">428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46dd5b7c9aab4334a81feabf9ee87525_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfNy0xLTEtMS05NDQxNA_b5b9ce8a-f096-4d37-8ac9-0d2c19ce7ee3">46</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a93811c7004483b89e5b2b7d7a47e27_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfNy0zLTEtMS05NDQxNA_ffcc82d0-91f5-45f8-97be-c178ccea9dfa">42</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aab13ae412a418dad03dcc21e39fa7f_D20210101-20210930" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfNy01LTEtMS05NDQxNA_1980e33e-e94a-40cd-8b7b-2cd866d57867">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfNy03LTEtMS05NDQxNA_21dc181e-e71b-4999-90a3-dcc702ed2036">88</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46dd5b7c9aab4334a81feabf9ee87525_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfOC0xLTEtMS05NDQxNA_bf714236-b5ad-40cb-bc79-737a1bb0ca67">172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a93811c7004483b89e5b2b7d7a47e27_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfOC0zLTEtMS05NDQxNA_c85acf48-9aaa-4295-a163-699ebefca882">168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aab13ae412a418dad03dcc21e39fa7f_D20210101-20210930" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfOC01LTEtMS05NDQxNA_b3dd41a6-9723-401e-85a1-7828bfc971a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfOC03LTEtMS05NDQxNA_c3816db0-83f2-4f1e-b7b2-0ad95c3be871">340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46dd5b7c9aab4334a81feabf9ee87525_D20210101-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfOS0xLTEtMS05NDQxNA_48408fa9-360c-46d8-be18-a42809c74750">324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a93811c7004483b89e5b2b7d7a47e27_D20210101-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfOS0zLTEtMS05NDQxNA_9413ca91-d72c-4487-9eab-6ba4749ae915">1,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5aab13ae412a418dad03dcc21e39fa7f_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfOS01LTEtMS05NDQxNA_ef91e996-9753-458f-b86c-26997db42731">251</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfOS03LTEtMS05NDQxNA_eebdba3e-07ad-417d-b60e-8ccf32eb2414">1,595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spin-off of Organon (see Note&#160;2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46dd5b7c9aab4334a81feabf9ee87525_D20210101-20210930" decimals="-6" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTAtMS0xLTEtOTQ0MTQ_0e6b315a-acd3-497b-bff9-a05ad06f156a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a93811c7004483b89e5b2b7d7a47e27_D20210101-20210930" decimals="-6" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTAtMy0xLTEtOTQ0MTQ_27dd9749-afe2-45cd-88c9-d343e7861e7a">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aab13ae412a418dad03dcc21e39fa7f_D20210101-20210930" decimals="-6" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTAtNS0xLTEtOTQ0MTQ_b96bcda1-7bb2-4c31-8be3-b8de63cff1a8">421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43d9233de62a46b78fb5fdd056a05478_D20210101-20210930" decimals="-6" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTAtNy0xLTEtOTQ0MTQ_26507b67-e190-4a26-bca0-dfff467625d7">449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance September 30, 2021, net of taxes</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0ae37c4002d4f7c8945b238b450a3ff_I20210930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTEtMS0xLTEtOTQ0MTQ_5d8f7fb2-d22b-49b9-b49b-6b5cee30c67d">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0de005cbf7c64be2bbb15d3ad2747c39_I20210930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTEtMy0xLTEtOTQ0MTQ_649b560f-eb4c-42f0-a114-24ecfab7e694">2,990</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf6a11570b2f4b75989bbe9a432b4263_I20210930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTEtNS0xLTEtOTQ0MTQ_b90b244e-973e-4a4b-98e1-5cbf32374334">1,658</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99c020a806d84d1cb9f8c8d97329cf8c_I20210930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTEtNy0xLTEtOTQ0MTQ_5b9a70fa-ac44-497d-a58a-10ecb452f4a6">4,590</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January 1, 2022, net of taxes</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01ae4d028c1e4ad69e3c0718f2a9cad7_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTItMS0xLTEtOTQ0MTQ_ca52a4ba-b669-4ced-bb58-7f28a41b392f">144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e2ba0ae31ae4ff3b092f4b0364ad5e6_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTItMy0xLTEtOTQ0MTQ_e5687599-7c64-4f6b-994d-697f6a50f0b3">2,743</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic491ffcc027b4b0ab4d63e1874c095cb_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTItNS0xLTEtOTQ0MTQ_4c7fc094-9c35-47c9-af78-d93a4b71899f">1,830</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54f6686da6db4e38aeb2e4b266dc881f_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTItNy0xLTEtOTQ0MTQ_82767874-275c-4600-9c0e-1fb7bf90f385">4,429</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62ef644e97384716bfc5c3610ba4245e_D20220101-20220930" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTMtMS0xLTEtOTQ0MTQ_04da51b7-5b9a-41d0-bef9-a9b7d968c3c1">1,233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1f9224028414e8f866988517a90edcb_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTMtMy0xLTEtOTQ0MTQ_1ab73ea8-5745-4638-9174-bf5d1cb1296a">125</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie83ec1e38c7b4f8bbfdc941221d33647_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTMtNS0xLTEtOTQ0MTQ_89c4dc8a-3664-4c8d-9d27-440bde6f6db4">1,001</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTMtNy0xLTEtOTQ0MTQ_ed922a70-04e4-448f-8f7b-87fd1a17b809">107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62ef644e97384716bfc5c3610ba4245e_D20220101-20220930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTQtMS0xLTEtOTQ0MTQ_e5509380-795b-48d7-afa8-8a7dcf81fa7e">259</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1f9224028414e8f866988517a90edcb_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTQtMy0xLTEtOTQ0MTQ_1a468044-e51d-4b92-9bd0-ea16d290f328">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie83ec1e38c7b4f8bbfdc941221d33647_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTQtNS0xLTEtOTQ0MTQ_41d173ff-746a-4b68-87dd-07d5107637af">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTQtNy0xLTEtOTQ0MTQ_05338bb0-dbca-415d-92ca-ea346c7b5c2d">223</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62ef644e97384716bfc5c3610ba4245e_D20220101-20220930" decimals="-6" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTUtMS0xLTEtOTQ0MTQ_8a390f26-ba09-495c-a3f2-57c19367dd4e">974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1f9224028414e8f866988517a90edcb_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTUtMy0xLTEtOTQ0MTQ_76efe376-5c21-4ea1-a2ac-3a05c22e05e7">100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie83ec1e38c7b4f8bbfdc941221d33647_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTUtNS0xLTEtOTQ0MTQ_b6ba6341-ac0e-42bb-bf9c-26c48c7acd73">990</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTUtNy0xLTEtOTQ0MTQ_9f3349d9-3ced-48b3-94ee-6b7b2b5c4040">116</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62ef644e97384716bfc5c3610ba4245e_D20220101-20220930" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTYtMS0xLTEtOTQ0MTQ_fcea9427-89d7-4a1e-b553-8c7845cd2a27">493</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1f9224028414e8f866988517a90edcb_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTYtMy0xLTEtOTQ0MTQ_b643f86e-b5cb-4882-8085-674b9f802249">266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie83ec1e38c7b4f8bbfdc941221d33647_D20220101-20220930" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTYtNS0xLTEtOTQ0MTQ_29dfbae1-c9dc-48c5-9db0-814c169fb98a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTYtNy0xLTEtOTQ0MTQ_988938f8-8674-4246-a186-26152bd19cf9">227</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62ef644e97384716bfc5c3610ba4245e_D20220101-20220930" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTctMS0xLTEtOTQ0MTQ_a58d2a79-c8a4-484d-8206-8329d3487be2">103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1f9224028414e8f866988517a90edcb_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTctMy0xLTEtOTQ0MTQ_4f185dc1-751d-4198-acc4-3e7d67096cf3">74</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie83ec1e38c7b4f8bbfdc941221d33647_D20220101-20220930" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTctNS0xLTEtOTQ0MTQ_16dfa83f-6bc6-4735-b1a0-e1d5bcb2d8e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTctNy0xLTEtOTQ0MTQ_60b092b5-4997-4217-89bc-36651c79972d">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62ef644e97384716bfc5c3610ba4245e_D20220101-20220930" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTgtMS0xLTEtOTQ0MTQ_ef5c0efa-d086-4364-a748-bff35fc69e2d">390</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1f9224028414e8f866988517a90edcb_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTgtMy0xLTEtOTQ0MTQ_a1a1db6a-719e-4745-9e03-51ff3011b5f2">192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie83ec1e38c7b4f8bbfdc941221d33647_D20220101-20220930" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTgtNS0xLTEtOTQ0MTQ_d4195150-c4fb-4333-9c40-f084b67a1dab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTgtNy0xLTEtOTQ0MTQ_39a19031-2a69-4bf3-8767-b2d5c5b25984">198</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62ef644e97384716bfc5c3610ba4245e_D20220101-20220930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTktMS0xLTEtOTQ0MTQ_c377d6a6-97a5-4edf-986b-78bdaae31fe4">584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1f9224028414e8f866988517a90edcb_D20220101-20220930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTktMy0xLTEtOTQ0MTQ_20ce908e-6b6d-45b3-a7a7-e2185898e090">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie83ec1e38c7b4f8bbfdc941221d33647_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTktNS0xLTEtOTQ0MTQ_080b7586-08d3-4500-9083-4aeb968afc05">990</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTktNy0xLTEtOTQ0MTQ_ff3723d9-f264-45ac-8569-22484baea0bd">314</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance September 30, 2022, net of taxes</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f45167f24e645d2ad668c47635fc09b_I20220930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMjAtMS0xLTEtOTQ0MTQ_895f8e67-c4af-485b-9d03-51d67da5eb4d">728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b4bb3ccba1a4790beb19a0ca2cd4721_I20220930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMjAtMy0xLTEtOTQ0MTQ_6896e453-9717-433c-ba30-ed304807cc28">2,651</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0df51b82a6bf4ed3a20acde326a2a355_I20220930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMjAtNS0xLTEtOTQ0MTQ_a07b310f-209b-4e04-bdd5-f7b9d3fdc3ec">2,820</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0803cc4f2c64fa7a8e0196a811eaf28_I20220930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMjAtNy0xLTEtOTQ0MTQ_5c19a194-bec4-4b9d-850a-00640b7436d6">4,743</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Primarily relates to foreign currency cash flow hedges that were reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes net amortization of prior service cost and actuarial gains and losses included in net periodic benefit cost (see Note&#160;11).</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i6b4e4280ad2344a5bc7fdcaa77e417f0_76"></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 29 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RleHRyZWdpb246NGRlODU3NTdjYTEyNGIxMTk5MzBjYzBlMDFmZWViMzRfNTQ4Mg_2f5ee191-3698-49f7-85c6-cd8614a7f6f6" continuedAt="ifc074caf8a424439ab0d1624bd459583" escape="true">Segment Reporting</ix:nonNumeric></span></div><ix:continuation id="ifc074caf8a424439ab0d1624bd459583" continuedAt="i0af4fdfe8eae44648ef4ed6e902b32f9"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s operations are principally managed on a product basis and include <ix:nonFraction unitRef="segment" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RleHRyZWdpb246NGRlODU3NTdjYTEyNGIxMTk5MzBjYzBlMDFmZWViMzRfOTI_f2f831f8-0321-4bba-ba54-0c60c71f2bdd">two</ix:nonFraction> operating segments, which are the Pharmaceutical and Animal Health segments, both of which are reportable segments. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. A large component of pediatric and adolescent vaccine sales are made to the U.S.&#160;Centers for Disease Control and Prevention Vaccines for Children program, which is funded by the U.S. government. Additionally, the Company sells vaccines to the Federal government for placement into vaccine stockpiles.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors and animal producers.</span></div></ix:continuation><div style="text-indent:24.75pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 30 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i0af4fdfe8eae44648ef4ed6e902b32f9" continuedAt="ia0a7415454ae484b822cfc0e15d46950"><ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RleHRyZWdpb246NGRlODU3NTdjYTEyNGIxMTk5MzBjYzBlMDFmZWViMzRfNTQ5Nw_4ffdba31-2075-460f-9047-cd1458401b6d" escape="true"><div style="text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of the Company&#8217;s products were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.601%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.309%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.601%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.601%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.309%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.601%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.601%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.601%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.617%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pharmaceutical:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Keytruda</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea72657d01094ffca27df83746971588_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNS0xLTEtMS05NDQxNA_9851b5d4-4cab-44e7-a812-36ddcb4068dc">3,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51f8f155c2a64e689c87b4aa3495476e_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNS0zLTEtMS05NDQxNA_6d8ee384-351c-4757-91f9-5b2f59586749">2,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie356d6063dec4577b2f6d9d0462d8e7e_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNS01LTEtMS05NDQxNA_bf1ce328-bb25-4a76-b196-48b73e631202">5,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4afb690c9224cf998243be692e833e4_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNS03LTEtMS05NDQxNA_2970365d-ac4e-440f-805d-c312e9177edf">2,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecae6fa25eb342d9927a9e48d4dba455_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNS05LTEtMS05NDQxNA_67e1bd42-fbe9-495f-8549-b4426e2ff075">1,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie61d00b2a6bd4ecb9cf24db30e5da1a9_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNS0xMS0xLTEtOTQ0MTQ_42d7108e-f725-4569-9884-7757d3c59302">4,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if011579e71f84295ac8c9b109ec9a4ac_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNS0xMy0xLTEtOTQ0MTQ_65ca02c2-45a9-4614-b62c-7f98febe5e37">9,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide55c02ef5074706a5aa037e6c934afd_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNS0xNS0xLTEtOTQ0MTQ_883b3960-748d-4bbd-951c-466a0948d1dc">6,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95106ae9af4848e58d3a94156cc2bedc_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNS0xNy0xLTEtOTQ0MTQ_e805ff79-1af9-42c5-a3be-89a795ba603f">15,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770403621f9447659861ff7d3c027d04_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNS0xOS0xLTEtOTQ0MTQ_85991979-0e38-49c7-84e6-1299a2e08019">7,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5065fd92c2c5486cb1c8595222c14bcc_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNS0yMS0xLTEtOTQ0MTQ_a2a56154-6e3f-4aec-9cd9-1d1ef4533d9b">5,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia40b9cd0df2a4a739c315a7e10c645be_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNS0yMy0xLTEtOTQ0MTQ_378e04c9-5b00-4c60-91b7-948db37efc3c">12,609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue-Lynparza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i906fb9f369f24ad5bc7c94038e03d844_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNi0xLTEtMS05NDQxNA_5e41cfcf-85ef-4726-89c8-201779b4193e">144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i143fc202262a44e4b14db40020296c68_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNi0zLTEtMS05NDQxNA_9e6cedc8-0505-4089-9a4d-2417e421b74c">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i556dfb6e8e81410c9a188d168e0cdfbe_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNi01LTEtMS05NDQxNA_7ccb7cf0-0f03-4d02-b260-ff9643194c88">284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2efc45c7c6e54f1e8772b6a7d931aa76_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNi03LTEtMS05NDQxNA_368d759b-5d49-446b-b616-4b0466002080">129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f250204e97849f4b2597c9ccfb28c6e_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNi05LTEtMS05NDQxNA_9ce5aea8-9bc1-4712-a5a5-230f7d2b88c6">117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80d8c27dc4c4418ba9ec00bdfd449ac8_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNi0xMS0xLTEtOTQ0MTQ_963096c6-e7c2-45b4-a756-2b67eaed6cfb">246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d2992b75ac049a8adc9368ebd3b710c_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNi0xMy0xLTEtOTQ0MTQ_79ff8496-da4f-409d-890d-06c7a1f07e3c">427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib17fdc41fa4b4440bdb187fc784528ce_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNi0xNS0xLTEtOTQ0MTQ_748cb8a9-c5e6-4c3a-bb16-936fbcaa9423">397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ef1b7a971cb4cf0aa1e17dbdc38ff87_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNi0xNy0xLTEtOTQ0MTQ_340bfdea-9d88-4ff6-bba3-9ea92a0eba01">825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if88c3613f4d7400abeaaf7edc177e242_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNi0xOS0xLTEtOTQ0MTQ_09bb5b16-f25e-4c7c-9799-83672e44301a">371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5b535ea1a074ab0990a6830301b99c8_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNi0yMS0xLTEtOTQ0MTQ_91024a9f-21ae-4e72-83d0-a9a397d77814">350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id41d2a02c14f46749037b85143f80400_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNi0yMy0xLTEtOTQ0MTQ_cdb42c85-c67d-4dea-9298-19bb437310a2">721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue-Lenvima</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i032733796fec487a9ec5363a6de6bb37_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNy0xLTEtMS05NDQxNA_a3c12d6d-624d-40d7-a29f-c0984d0fd909">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7bb2d455a324d85b663449ae922babb_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNy0zLTEtMS05NDQxNA_65732fb3-197c-463f-a536-8b8dab362165">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3725ce6128304af89af87fd977d6dc98_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNy01LTEtMS05NDQxNA_22259bd9-5240-4205-a705-63f45c982b02">202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc093a125435445ba1dc79fbc34e64e1_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNy03LTEtMS05NDQxNA_bb53b705-2d16-453f-9b98-54c7a59f6a78">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e380088b1224143bea2f6722190f293_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNy05LTEtMS05NDQxNA_db9466c0-885b-4d7d-93e0-003e452ebf66">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c913add24e44a0f9348623b21235818_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNy0xMS0xLTEtOTQ0MTQ_445bfdbe-8253-4b81-9175-ff8423921c14">188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58100a918de34961bf23cb6d60b59996_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNy0xMy0xLTEtOTQ0MTQ_f727ad09-0188-482a-85a2-8100ecae0401">426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57645af2264341fb887ea206a381c869_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNy0xNS0xLTEtOTQ0MTQ_2ceb9c9a-50cd-4fa6-af99-5455569d4873">235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if31c285904b6492897698f18cb4e6080_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNy0xNy0xLTEtOTQ0MTQ_6425aedd-cb19-4be3-baac-6b885f1af90b">660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fa27317ec3f442fbd94cf33b21e1eb2_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNy0xOS0xLTEtOTQ0MTQ_6fa020a0-c5db-4db0-8fd1-10f782a42d85">287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id51eb40c9a094ab9a113fb3a71d38030_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNy0yMS0xLTEtOTQ0MTQ_9c19cc5f-4758-44eb-9a5b-0bedffce2abb">211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie892b4d7a041422abdd832f50a0f95cc_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNy0yMy0xLTEtOTQ0MTQ_0072996a-ec94-4e30-ab23-6f3bb75299d9">498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue-Reblozyl</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib48d2e82b97541f38e95af0a653ab27b_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfOC0xLTEtMS05NDQxNA_e720d4fb-c2d4-4d0b-a2e1-bcdfd567777f">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eddcb43b5d249a2af4318c0c246a2fc_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfOC0zLTEtMS05NDQxNA_6e42feb6-872b-4b70-8057-8ce8cc16c6ed">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ab39f8789a4b6fa4f623fa5d27795c_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfOC01LTEtMS05NDQxNA_c37c8f2a-8804-45f2-b9d6-19be54b5986e">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25082e66e59a4337a66ed93fb65581c8_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfOC03LTEtMS05NDQxNA_aab5780f-59ce-4b8c-824d-84d2eb0a55c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia27a4765f6f24c37a3b517d089f2ecde_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfOC05LTEtMS05NDQxNA_404e8f7e-4405-47f7-9671-84d021a982ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ae58919bbbb482997e5aa8e96123089_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfOC0xMS0xLTEtOTQ0MTQ_50d62c84-3d29-4108-b8f4-247364e96d39">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4269d8f661374131bbab73264dcada9f_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfOC0xMy0xLTEtOTQ0MTQ_a4c50694-dead-4936-9aaa-2207c43a56b2">87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04dbdc20bf3942789452bbdc6a5e24da_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfOC0xNS0xLTEtOTQ0MTQ_72459c8a-9b17-41ed-abb0-310f137b953f">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0715d2eaae6e4be98aee0bd0d1931927_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfOC0xNy0xLTEtOTQ0MTQ_895aa20d-816c-4c81-8ea2-5a39b8c48348">124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ae38dadcae24a6686971665f448c5b0_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfOC0xOS0xLTEtOTQ0MTQ_07b8291f-a0d9-420c-8938-6799e73264aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i793c1193aa2f4af6bcef7074919dee8e_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfOC0yMS0xLTEtOTQ0MTQ_cf0b10c9-48d4-4f0d-8bf4-9fdf4c0b1a1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bb7f002f384902b0a86cfd9129bfc2_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfOC0yMy0xLTEtOTQ0MTQ_f5a73739-9ecc-442a-b78b-29f0e432ad9e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vaccines</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7bba4c38acc4bc0bb07a1951b9d31dd_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTAtMS0xLTEtOTQ0MTQ_8fdcb819-ec49-4f5e-9703-7add4c11df80">957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d5c095574c748718095a6fbabbd214c_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTAtMy0xLTEtOTQ0MTQ_a4290ab6-53a9-4ab1-be37-bee5585da352">1,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e3866f93c3d42e8b58a917f29364c00_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTAtNS0xLTEtOTQ0MTQ_6b53b082-0b8a-49c9-a93f-75a17b429419">2,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa2f870185b742c0a08a8329ad6e8053_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTAtNy0xLTEtOTQ0MTQ_dfadaebe-210e-41d1-b36b-bfc59b7e64b7">839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4008d740f8e74af8a6058243d2c4bffb_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTAtOS0xLTEtOTQ0MTQ_12a55608-89ac-4c7a-bf69-6f4e2f8f3a89">1,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90271b2f98e64375a768383e3ac49db9_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTAtMTEtMS0xLTk0NDE0_a64d549e-eb15-4c7d-b576-19cd498a3cb4">1,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c0492792ca04bd3b53c001091f93a58_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTAtMTMtMS0xLTk0NDE0_d89bae8a-4f45-42a0-9886-e40869a4a377">1,803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5efa6e77fc3b43c197b420bd2930d959_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTAtMTUtMS0xLTk0NDE0_cadbd5a0-6028-4aec-b4c4-95a3a61d6b84">3,624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia765dfa77c1847ddb5439dfe5e593cc2_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTAtMTctMS0xLTk0NDE0_f62aaefc-1909-4477-be6a-aeb22a971acb">5,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id754ab9092f541f1bb0c46f84d571073_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTAtMTktMS0xLTk0NDE0_d061adb2-e6ca-4853-a1cd-25361d63c14f">1,605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ea41eae43e44e758d73f10739ebef8f_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTAtMjEtMS0xLTk0NDE0_a81028e8-fb0f-4bbc-a8df-a7a0393eb11b">2,539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d98ee5588f64bb89006d5f3b1ef89ef_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTAtMjMtMS0xLTk0NDE0_cb45a938-8319-4626-82ee-ca28d14fa5e1">4,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">ProQuad/M-M-R </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">II</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">/Varivax</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93650c21d0cb4dce8f66684f468b7f9d_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTEtMS0xLTEtOTQ0MTQ_c6708f0a-7f10-41c7-8807-6907de9538ea">532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i541aec5947cc4f8794cf3d8f132542a0_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTEtMy0xLTEtOTQ0MTQ_1cdeebeb-963c-4df5-9ff6-0032c77be22f">136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63937b576d734bdd874c9b62aff67ca0_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTEtNS0xLTEtOTQ0MTQ_e1b79287-1b8b-4195-8673-a9749404f53a">668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic105ebb39d4f45fdb7e76b65b2f7c268_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTEtNy0xLTEtOTQ0MTQ_e7bca221-2992-41b0-a823-f44fd4bf8a51">537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0270857a4ce04adc87d535004968cca2_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTEtOS0xLTEtOTQ0MTQ_32a52a71-72bc-4937-80b3-c9e530aef9ef">125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20ab8f4749914720b66e1986e30f2490_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTEtMTEtMS0xLTk0NDE0_d5dc4ca4-7611-42b7-92ce-bbfdecda5f22">661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d316c927f914028b471fa7baa8efe76_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTEtMTMtMS0xLTk0NDE0_d0f27d41-980b-4006-8c8d-0e40110b60a7">1,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if90d628440614f1a8b82d9012cf44d19_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTEtMTUtMS0xLTk0NDE0_be89552b-7d17-4d18-b048-69893f189375">379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff0b49e0a2214244b08be408fb0071a8_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTEtMTctMS0xLTk0NDE0_e89d4164-d09c-4d82-9840-7cc45b64065a">1,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie667b194da5b43139fa7eb334e923aea_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTEtMTktMS0xLTk0NDE0_ff1b0ab6-4986-43d3-97f0-61d6883c229d">1,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if75e90d893fe4d2daef008b05cd61801_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTEtMjEtMS0xLTk0NDE0_069f7873-015d-4540-bb19-3a44d420cef0">371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3221816ac6554c0ea0725b82fcbe8866_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTEtMjMtMS0xLTk0NDE0_2283ab09-8649-4dda-a460-c1dfd9624aa3">1,626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">RotaTeq</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8664e2a8ba934ef993c8af9df045661c_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTItMS0xLTEtOTQ0MTQ_4570fa7d-05a4-4ab3-9bd4-2d9ebfddaa81">154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice6230b5dd6b4590816f68ea0611bc32_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTItMy0xLTEtOTQ0MTQ_db6f822a-e352-4c5f-8dae-8a640ae35534">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47949af4a1384b7cb8b878121f95341a_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTItNS0xLTEtOTQ0MTQ_2a112602-e291-489b-8ee1-68e6173c6d0f">256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0fb5867c7f4a1d81c9b8e00f1299c2_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTItNy0xLTEtOTQ0MTQ_19feeee2-46cd-46b3-956a-bddece01929d">135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f6c72e13d24ad5b8a9242d1bef0091_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTItOS0xLTEtOTQ0MTQ_eefd538d-fd51-4447-a915-bce06d8eb205">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81969b509926485a8a666277757c512b_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTItMTEtMS0xLTk0NDE0_fa8e21de-a93e-4aed-942b-e938666b0316">227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e2ff6b002b74a17a257416545ef6e96_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTItMTMtMS0xLTk0NDE0_d3cd318f-95cb-40bf-a2a1-2286ea6d7941">427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib71b6b89fc16436fbbf1fa07b6363b8a_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTItMTUtMS0xLTk0NDE0_57d9ec26-24c8-4ee2-a390-4c0808cfb6c4">218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9222172d1bf54d24871e696a611f9678_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTItMTctMS0xLTk0NDE0_eca42c74-31f4-425b-8e9f-84b7965a8756">644</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a245b712a5e48669e48a3980e039452_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTItMTktMS0xLTk0NDE0_9ef5ff52-514b-44d3-bd6c-774b68279ce7">364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49e1542b3ba3448aa3d564e26fc2446a_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTItMjEtMS0xLTk0NDE0_319a6df4-ca05-4e10-bc80-511934be46db">229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13729599ed214b168aa63442d6acd6de_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTItMjMtMS0xLTk0NDE0_60c8cf92-7428-4b21-a137-d1e79ced7564">593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Pneumovax </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffcb1d041de24e8a98b15f54038962b9_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTMtMS0xLTEtOTQ0MTQ_d8b6c27e-4088-4394-8ef2-97e1ff60316d">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57a185fc411c4db19484a70301bf7c8e_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTMtMy0xLTEtOTQ0MTQ_cb2ad482-0f56-4bba-9e6a-a8e848e20946">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i585b71b55aa241f0a689cb6373aa1fa2_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTMtNS0xLTEtOTQ0MTQ_aaba50a5-8819-4609-ad24-6b668aa9e9e4">131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i225b62c9d0a94897ac8731640188187b_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTMtNy0xLTEtOTQ0MTQ_e4b45318-2674-451d-9f93-bc067e49a699">181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08bd174e76dc49ca8a3aa6f8f34dba50_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTMtOS0xLTEtOTQ0MTQ_a9e98fcf-eb39-4fe7-88cd-02eb52152317">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43dfc854ee5a409bac203fb32dd6d61d_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTMtMTEtMS0xLTk0NDE0_569de5e5-cc06-496f-baf6-fe178da7e322">277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa04548d03764d5bb771484866fddd91_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTMtMTMtMS0xLTk0NDE0_0658fef4-ddf3-4dbc-9cb3-f3e3f5780fb6">280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i443086dbe08048deaf609109e2104c35_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTMtMTUtMS0xLTk0NDE0_b285bc99-2733-4872-b24b-de4d1ab6bf67">177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dc12fb55f1f4323a0b4d26b08dcc080_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTMtMTctMS0xLTk0NDE0_8006c0a0-4f9e-4d00-980e-356bf3ee9fd8">457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddeb3ed477674caaa13204bb072a80e2_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTMtMTktMS0xLTk0NDE0_009b761d-f4fe-4f2f-95ff-500c9fba03cb">354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5ba933b43ec40cbb59d3def6165f9fe_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTMtMjEtMS0xLTk0NDE0_a0d8cb5c-48ff-4168-a36f-d808523b5698">247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eecf1f67c2446fca9b82fda9e4a3949_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTMtMjMtMS0xLTk0NDE0_9743bdc9-0b36-4a77-af04-22ad53433932">600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Vaqta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f6536581b11466c97256e257fb58583_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTQtMS0xLTEtOTQ0MTQ_227ed79e-8b64-4fa2-82a8-2131ba97a991">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idee3f0ae73e249cd86d1e98f97ccfaca_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTQtMy0xLTEtOTQ0MTQ_1af4a0d0-a3bb-4488-8e7d-2521a43f5b7c">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48b01fe75e9e4b59aaff1fce21ed2c4c_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTQtNS0xLTEtOTQ0MTQ_61c4d92a-f31d-4b53-8ca9-72638c003adb">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46c35e3833b04258a27da6cf08e2b9c8_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTQtNy0xLTEtOTQ0MTQ_a427f836-0269-4272-97ab-7f4b2fac51b9">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icaf0413c2916445aa22a3cb92baf44d4_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTQtOS0xLTEtOTQ0MTQ_15ff6d55-bcfc-44a3-bc5c-e48cb67b79d8">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8285527fce2495eaf46116e50f1d995_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTQtMTEtMS0xLTk0NDE0_5a0b85ac-cb77-4325-bb3f-03d807c4e9af">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47293d92044b48e99da891220e8b196c_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTQtMTMtMS0xLTk0NDE0_d5b62f80-b842-458b-af45-37ecdc585190">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3002e359e24742fbbcf884cc6e683e05_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTQtMTUtMS0xLTk0NDE0_0c7507ff-c08b-4cd9-a7ce-b0f41fed44c3">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d13aaae18a24197815774e133bc1254_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTQtMTctMS0xLTk0NDE0_5a48a2f8-afc0-4162-baf7-a3b787f1545a">134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib67c4ec99f724cbd9c5c4fb76245033c_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTQtMTktMS0xLTk0NDE0_c99005b6-3000-40bd-b170-63b0ffcb95c5">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb6d9b7fab874ffe8c1b46f7744ebb79_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTQtMjEtMS0xLTk0NDE0_ebda86e7-aa68-43ea-b7d2-e5c6fb1398be">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97fe20ab999940b48ca93613926a0d93_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTQtMjMtMS0xLTk0NDE0_4bbe9c08-bc89-4dde-a38f-ea4f0ab33c05">138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hospital Acute Care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Bridion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e45830a855742509ff087274006e575_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTYtMS0xLTEtOTQ0MTQ_df1fa743-5f47-497a-acba-78bb61a685a1">233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i296fff24993d4fcd957a26fcdc376978_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTYtMy0xLTEtOTQ0MTQ_dcf301f1-846a-40f4-8515-a0b20a66ebf9">190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dd006ef18ba4a51a0b449e2d732ad40_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTYtNS0xLTEtOTQ0MTQ_e96556c0-92d1-4aeb-be62-74919440de7f">423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i685056aa30374b748c91c804e8696590_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTYtNy0xLTEtOTQ0MTQ_6cf6fb92-330c-4273-ac88-6c4331f7f59c">181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i265d220c8c194add815250d378abc902_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTYtOS0xLTEtOTQ0MTQ_416fa889-7f9b-4b8e-9a83-1b2af91ac96d">188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8a9bf2b9f8d40f5891228af7ee73a36_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTYtMTEtMS0xLTk0NDE0_48fd3100-ea4a-42e1-bbd9-3951e38a7db3">369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81070fb665a64fc9a92e648528dced5c_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTYtMTMtMS0xLTk0NDE0_d985d473-4a6a-4db9-b041-1009081ef487">665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idec7bac0c49d4b1db34ff840907bd798_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTYtMTUtMS0xLTk0NDE0_de37ca47-5edf-405a-8893-762c9fbfae24">579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if971fc9feaff4a3c9a5eb10f74e1957b_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTYtMTctMS0xLTk0NDE0_f8cf85c4-0d4f-4d99-b8b4-3c1c5c8d95f0">1,244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if294e1aa3b5d46f8b28217723b28ef92_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTYtMTktMS0xLTk0NDE0_137f8945-3fe7-47ed-a79a-3884598ce6a9">545</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a7dcef569de4308a78959562aefdfa5_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTYtMjEtMS0xLTk0NDE0_97ed6602-0f68-4793-bed7-ac4d2e3107a3">551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e0a807fffc84f018f4b4464b1bf9072_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTYtMjMtMS0xLTk0NDE0_5d6a9c97-c7f5-4261-b384-45c7713b492f">1,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Prevymis</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1687a5207479439f8e16e57fa7ac046e_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTctMS0xLTEtOTQ0MTQ_8087e7f8-a829-4431-a433-12f29ef5d482">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbcc716f1b8a4294a8ac7755d58d7e4a_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTctMy0xLTEtOTQ0MTQ_5f394388-829a-4424-bf88-e57041726a14">64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60ba948e10b04bf89e609fd126195611_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTctNS0xLTEtOTQ0MTQ_c09fb3a8-a1d9-432c-8ee9-bffabe6226c5">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65e784f938b34793a6b9a65d6d6cc86e_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTctNy0xLTEtOTQ0MTQ_8429d9f6-44d8-4264-bc8e-69f22019fb06">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01d05ced165944a29e318440a8eca779_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTctOS0xLTEtOTQ0MTQ_7c50e09f-10db-47e3-bece-2919fec23120">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9538df57cac43428fedf093f6e753f1_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTctMTEtMS0xLTk0NDE0_4581e48c-7edc-4fc7-8fd2-8c3d182bb687">96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4649f1b3f8614c1fb6696040dc8e573c_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTctMTMtMS0xLTk0NDE0_9d4b7add-1f62-427d-99a4-ea62bc0b90ee">136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac88839387e24360951822241927d01c_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTctMTUtMS0xLTk0NDE0_83c49dab-dec3-4804-88b2-ba8457595b0d">174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc7aacfa4b9410a985e8faec1f16f9e_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTctMTctMS0xLTk0NDE0_0216a1ab-fc31-40f8-ae6a-a05336299974">310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i182af2613ed348cf9d6dc2f9be178a66_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTctMTktMS0xLTk0NDE0_14157c18-a788-4bc0-9393-d13bf1a85656">111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id57f4527272f411e8eec3fcf5da09481_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTctMjEtMS0xLTk0NDE0_92641edd-6f57-48b7-8ffc-dbe6c6d1d2d6">159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifacfb5ed95734fe7b4fc8bba627a8845_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTctMjMtMS0xLTk0NDE0_acfe643a-9edd-4f8d-a2e0-7af14527c5f0">270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Dificid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd682219d26f42589766951ab88e1c3e_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTgtMS0xLTEtMTAzMzg1_858d6a51-9842-4047-a4ae-4412d7d4119d">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86d0c8eba6b548b2980070d44447b21d_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTgtMy0xLTEtMTAzMzg1_a8f0ae8e-013a-4482-9c20-a2b9a6a6f9b3">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieafdddb927484d7aa5ac090781377625_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTgtNS0xLTEtMTAzMzg1_72ea36f7-65aa-4810-a612-13869d83af70">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie32bcc064d0f4de8ba4e1e7150a0afe2_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTgtNy0xLTEtMTAzMzg1_0cb42da9-e296-4988-b75f-7ad70b3b3cb9">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f5e562de1574da48919247a881ec58c_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTgtOS0xLTEtMTAzMzg1_bbb71641-b595-47c1-a1b2-15fd1298af49">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f319f069c14e75848d9f78788ecfd8_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTgtMTEtMS0xLTEwMzM4NQ_b63d3749-fd86-419d-bb5e-1086c7b2a559">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a9aeec04e4fd48e331e0d1ae98fcd_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTgtMTMtMS0xLTEwMzM4NQ_98135b54-a976-458f-ae2c-fae570f746c3">184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26820a66f9dc4af881c3df742b2e0a5a_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTgtMTUtMS0xLTEwMzM4NQ_bdc16cea-e3a8-4ddd-86b6-213353b6d20d">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7115d8a391344fec99e5f60ebfc980dc_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTgtMTctMS0xLTEwMzM4NQ_404ca75e-59b7-468e-8ebd-f2dfc1d8ff8c">196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieab69433fba045ac8b7a8451cd492815_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTgtMTktMS0xLTEwMzM4NQ_193cad6b-a4ba-4629-9ab3-bd5c78ff52ed">108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c1221038a2149c9b97c80c8f611679c_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTgtMjEtMS0xLTEwMzM4NQ_91ea062b-6b7a-4859-b02d-32ff64f8d87b">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36a64ebf107e4f91a169bc853c046233_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTgtMjMtMS0xLTEwMzM4NQ_5e7dd933-8296-4645-b1ad-dc6a9901bc0e">115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Primaxin</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71f41596ea7a4b3e8416589c8c7a8138_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTgtMS0xLTEtOTQ0MTQ_c2402e4e-3c1d-497f-9d04-5e8e52888c9e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad0235b784c4439a674f0deccf68980_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTgtMy0xLTEtOTQ0MTQ_37649f4d-564e-4ec8-8a0b-e0877c720965">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib964e6bb433d42f49dd769839ac28238_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTgtNS0xLTEtOTQ0MTQ_7278c3d3-43ed-435c-a6b7-4f13fbe884ec">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1001be10a5d043f397906bd36d10ee6a_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTgtNy0xLTEtOTQ0MTQ_ac0fc868-f165-40f1-9220-55a0577f4db8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id51b949ade4f41899e4a18fbbbd2a1ff_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTgtOS0xLTEtOTQ0MTQ_658dfd74-a6f1-4825-a81f-fa65b9f8ff00">69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdb4e966b7da4d629f6fe2c428ed1ef1_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTgtMTEtMS0xLTk0NDE0_0f843325-49fc-4788-81ab-7c012b85c21b">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c824b0655ff4c1fb993fba481533fb9_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTgtMTMtMS0xLTk0NDE0_50b1e712-2c52-40ed-a52d-c2ced836cea3">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8e89580305548a490f0bbe9f637440e_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTgtMTUtMS0xLTk0NDE0_0d3d46e0-e38b-417a-adac-b198ac91324a">185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37ba015ecbcd405abc7b38785b7dcfd2_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTgtMTctMS0xLTk0NDE0_dce8e02c-27a6-4535-b1bd-89ab3d713c99">185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cf6dc7c6c1c4858bf616a299a8c6420_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTgtMTktMS0xLTk0NDE0_de460aed-0dca-418c-89ba-d620a7839915">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81ea1f35405a45cebb4edeb8610e28c5_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTgtMjEtMS0xLTk0NDE0_e2d77df7-e936-4235-aa9f-6dd1cd8c7525">194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01c00548f8444dec89b6744b02a85fa3_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTgtMjMtMS0xLTk0NDE0_c401c17f-583f-4a70-a239-1143aadaffb5">194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Noxafil</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd81b81346ae4eca826a989395f148a0_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjAtMS0xLTEtOTQ0MTQ_59d432de-30d9-49be-abea-fcad953ed661">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f785e58506544309ceddc1407668851_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjAtMy0xLTEtOTQ0MTQ_cfb77c94-baa9-4299-aa30-cc3ca1fda255">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07bb128b4a6049b9a45a4721c32a8c32_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjAtNS0xLTEtOTQ0MTQ_5469a214-a6aa-44be-8131-223ba9cf8d15">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85318a4d743d44788fda10cd96301c42_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjAtNy0xLTEtOTQ0MTQ_d504ff40-ea35-42e9-b187-78a9e7d8dea8">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf4fe0a8e4d04a23976ea2fabe3f04e3_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjAtOS0xLTEtOTQ0MTQ_5005ce96-2825-466c-ad11-e8e7b68416b5">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i098c29dbbb064deea26d4c4f34218264_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjAtMTEtMS0xLTk0NDE0_1a91a63b-9c35-4512-80d9-24d38a3686e0">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4a66566cbcd44aa9f077d342fdead01_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjAtMTMtMS0xLTk0NDE0_7fa0afa7-d5f1-4ae0-a8d0-af37804ac2b6">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie28efd140c154386aad5f6975c8566b1_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjAtMTUtMS0xLTk0NDE0_64b5c050-7157-4b50-8071-cb680dc9f69e">141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5585d223173d42a68c6f66af1f246d09_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjAtMTctMS0xLTk0NDE0_22c28dff-ba33-4384-a26d-45b0e9b3f362">180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fef72442c5244cfb5a176eb81962df1_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjAtMTktMS0xLTk0NDE0_281930cf-5e5d-46a5-848d-e351d0a702e8">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie99454bc8d07443483aa94820869b584_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjAtMjEtMS0xLTk0NDE0_b551b175-ad8a-41b8-b0f3-e94925fc7295">149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf5e6b24740e4c4fb42a6d01883937d7_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjAtMjMtMS0xLTk0NDE0_0bdbeb3e-f62a-47f7-95fb-5c026ef01959">197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Invanz</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcf29d14a518483185f8a99cefa1fa46_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjEtMS0xLTEtOTQ0MTQ_d50da028-1714-414c-83fd-42f9b97c9411">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19565b312a7b438cbc10861858b1d449_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjEtMy0xLTEtOTQ0MTQ_7f5c246f-8717-4473-a7a7-d193c88f781a">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icff15fd8bd1a4d6bb79c3beaf3519324_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjEtNS0xLTEtOTQ0MTQ_7e9d3775-a040-4d35-b440-912c12cdfde1">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7d439da126f4be48f56a1860640621b_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjEtNy0xLTEtOTQ0MTQ_3556e3af-f924-4bd1-a983-1afa2ca84399">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2a2dc400d82406cb2a4f1761521e529_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjEtOS0xLTEtOTQ0MTQ_342f5c58-b139-4ac2-a085-ed861b802572">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i819facc7b2e14484a4cb6e0c2a7f93df_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjEtMTEtMS0xLTk0NDE0_2e4662c3-b9fe-4dee-b356-ae6cf0d70cff">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fe58d8dc5984f3cbd65658d904a9481_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjEtMTMtMS0xLTk0NDE0_8d4fb6a2-4c7f-4dd6-af06-0e67b71c6001">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied9c00ac4d8941b4a017cbbccf4329cf_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjEtMTUtMS0xLTk0NDE0_a60fc71d-5d90-4ebf-bbfd-210b850e1e43">144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29dea2ed4a654c42952ab41ac972c731_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjEtMTctMS0xLTk0NDE0_49810a84-5e86-4b79-8221-02c21118125e">148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i099da3aa99d1482b90ff756d321bd102_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjEtMTktMS0xLTk0NDE0_1f83ee22-789c-4be1-86f1-3c7242c18f27">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f2ab84f59744e4aa1b796e01ba81c31_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjEtMjEtMS0xLTk0NDE0_b6d47832-5fd6-4b76-9fff-5826a1dc7135">159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i312d000608614fe586d2aedc23ea4dc0_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjEtMjMtMS0xLTk0NDE0_bba6dd4f-b176-4d4d-bc00-b0c04b1c2aa3">157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Cancidas</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ea07e7b467b4e8ba73b1f10c45b4e02_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjItMS0xLTEtOTQ0MTQ_c9e5de6b-159e-4cf3-a93e-a0dfa3ecf875">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b9ab232d5ee4970b968974b33aa9605_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjItMy0xLTEtOTQ0MTQ_32c540aa-6ae2-4045-b1b0-e8993a7f2503">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46397225389c4799b9e0002cbf9db54c_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjItNS0xLTEtOTQ0MTQ_a51df231-ad56-4ec6-92bd-7061048e3610">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f7b98bc0114fcfac64f5b19a7f97b5_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjItNy0xLTEtOTQ0MTQ_697385ec-dc17-49a6-a1d1-1db6a4e0bc9d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie43d1efcc1f2463a9e6ceb872a750592_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjItOS0xLTEtOTQ0MTQ_e0bf806a-ffcb-45a5-aa10-09d33ae99249">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ddddbcb59e45afa01649b4a5c0df02_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjItMTEtMS0xLTk0NDE0_1192c3cb-6d56-4579-a432-b4f20f382629">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6441c5f89ab7428dbb9ce2a77c7d178c_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjItMTMtMS0xLTk0NDE0_42ed1652-dcd8-4c90-ad99-5c873d99b308">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2859c498f1484388a0c92b4ee1831d83_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjItMTUtMS0xLTk0NDE0_401db23f-efeb-4d34-a695-e44956c95e09">133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if28586c5985c4caeb1cdebafd9ae7432_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjItMTctMS0xLTk0NDE0_797a41e0-ec06-4c32-9af9-39192b61d9b0">138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a21006f6f464cf49d94de523666ae32_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjItMTktMS0xLTk0NDE0_eb6ac9d6-1882-4674-9f20-d04a2d0bfea1">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa337eca3546e49132dfadd33405e8_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjItMjEtMS0xLTk0NDE0_8610ede6-1f76-4a58-b542-99edf0840680">164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64edd776e6f848789f0bcc6abe69aed9_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjItMjMtMS0xLTk0NDE0_84a0b188-0e89-4e1f-97c6-3ff39472c559">168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Zerbaxa</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba160b3c84d4ded8e2ad24897f18196_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjMtMS0xLTEtOTQ0MTQ_7bb98f88-c23b-47c2-9bea-9e118b16caad">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife2e7a726c45443f849fea10fc2e4265_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjMtMy0xLTEtOTQ0MTQ_4f119fda-ab75-4639-8f0e-d3bd5ad474ac">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9b27b189bfb40db8b98e551a462b6d6_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjMtNS0xLTEtOTQ0MTQ_e0f08ae7-9d5c-4988-af00-d38e444eced4">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7ba48e565be4304b70078ffe4498c8c_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjMtNy0xLTEtOTQ0MTQ_27960b85-95b5-4afb-80ee-f2685f75a1bd">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b9d23875fe444829c441808824a5a21_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjMtOS0xLTEtOTQ0MTQ_47a8b8de-9be2-43bf-a61e-cfa937dc9599">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2fc16b785504c63ae17c7cdb9c1c0b0_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjMtMTEtMS0xLTk0NDE0_c4d7e3e2-3ca8-41d9-8413-6de0a379551a">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65ebba197f3740bdb38b629ffcf72ad5_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjMtMTMtMS0xLTk0NDE0_279a3432-2bfa-401f-a534-008f3e07ebeb">64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3da352c9af7146f4810e485c59906a57_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjMtMTUtMS0xLTk0NDE0_da21a938-9593-494e-94af-19f0ba624a77">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097267c7483c4f3baaa83fa953994d7b_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjMtMTctMS0xLTk0NDE0_c7c60828-4f97-42e3-9263-1f38e96769b2">120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id92b88c5c7c54cd897660ab28b07a038_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjMtMTktMS0xLTk0NDE0_e7f94949-b7de-4663-bad0-1ab5405aa0bb">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebc064d77e2e4de99ab716e87a9baf1b_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjMtMjEtMS0xLTk0NDE0_158ffcec-6bc5-4dc2-b9d5-b643fb7efba8">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7010efc10b11415da35666aae647506f_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjMtMjMtMS0xLTk0NDE0_03d4757f-5af2-4772-9bf3-8cfb750aec67">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue-Adempas/Verquvo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6d0e90eb56c49078c2cd876e4644e59_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjUtMS0xLTEtOTQ0MTQ_37e4603b-9db7-4963-97c5-e4dec4137152">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ea29fb65ae64c838799c4c459626dfb_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjUtMy0xLTEtOTQ0MTQ_265a219a-16c2-4d3c-bca7-237610d5f30d">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeca289c0b3048be95fdcdfd0d64787f_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjUtNS0xLTEtOTQ0MTQ_0c81ba3b-eee1-42ae-9ba3-a2c0d33f8410">88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib14fcc9488ae4e079debc5ad6830716e_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjUtNy0xLTEtOTQ0MTQ_bfd229f5-7555-4b04-9642-ecd22fdedde4">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i704a839b6eba4ee4be94748f20064afe_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjUtOS0xLTEtOTQ0MTQ_7e944972-2fad-4cf1-b463-ed18fd335fe0">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3a4ecb829e4aa78305ce022676ad3a_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjUtMTEtMS0xLTk0NDE0_a38a72fe-5782-420f-b7da-1356b4b1c4b5">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9dc2db957bf417fa3ce1024b7aa3b58_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjUtMTMtMS0xLTk0NDE0_3bae974c-8bad-46d5-8061-97edf40be3a9">244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie752e3ceb65d4068848193b5489d1ca3_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjUtMTUtMS0xLTk0NDE0_f62bb2b2-5a27-4525-9152-f9a84a4c8471">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8121dcf41149486dbe2439280ef18566_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjUtMTctMS0xLTk0NDE0_011261da-6d2d-4639-a56b-57fda453e74f">258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1535a34aeb8e4f90b2765beaa325bd11_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjUtMTktMS0xLTk0NDE0_e352c6ab-05ba-46a8-bd6a-bd17c5e5326a">222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4bc4cefe1a64728bdc75ff662c4916e_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjUtMjEtMS0xLTk0NDE0_e3e88cfd-605f-4fc3-8fde-bd60d52436a3">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03f405d0ec044a3ebbf4e986c0cf3fb0_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjUtMjMtMS0xLTk0NDE0_89673ace-ff23-4b63-8056-6da559d325ef">248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adempas</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39b9efc953f44ddb788ea54e6fcb237_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjYtMS0xLTEtOTQ0MTQ_a129ef58-3d32-49c4-8d60-c9fa0ba6761f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17605919063e4da08e1c137da9bd3927_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjYtMy0xLTEtOTQ0MTQ_8bfcdcff-88ae-4f7f-81a9-49ed13f69e03">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64942fccdbcb49f7bde01d647d805b92_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjYtNS0xLTEtOTQ0MTQ_9d8631f9-6e62-458b-8415-e7f3da6bfcb6">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d4ef7a87b2d430ab843f888c43c62b3_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjYtNy0xLTEtOTQ0MTQ_512a373b-289c-4d8c-a350-1fd94d8f61c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i367dd154acc944f59b4091bdf4c3f88e_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjYtOS0xLTEtOTQ0MTQ_88ac67fa-262f-4f9b-b8c2-dbcd744783d6">59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifafb1bde68d54e8e8d59fc667e7ad4db_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjYtMTEtMS0xLTk0NDE0_b337b32d-3a1b-4e70-8acc-7142760fcf0a">59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic98aa56795ec4ca9818d28b0c15c1e2c_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjYtMTMtMS0xLTk0NDE0_f00635c6-3787-42a2-b0b4-be757bee9f6d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d8f2e37a7fd434e9e575af158e4ebe9_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjYtMTUtMS0xLTk0NDE0_4a1affba-d58b-45ca-b5c6-83e35633b4d5">181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf83422a855b450a895434e02b798a86_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjYtMTctMS0xLTk0NDE0_e2997fcc-dfc5-470e-a93c-de179c3accbb">181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba5e8751427840c2bb6a518bf2c47c4f_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjYtMTktMS0xLTk0NDE0_9d9f2830-418a-4a4f-82aa-775422c06c97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica014ad63af547c985fc0232bff3d28d_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjYtMjEtMS0xLTk0NDE0_2ca62048-f067-44d4-8b82-5ce3c1fbc708">188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic864a76a6f394f3c8b7bcf2a3d9f5b0f_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjYtMjMtMS0xLTk0NDE0_91e4d320-bab5-4445-b878-b7451ce61866">188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Virology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Lagevrio</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i143277cfa467423cb7fd3d1598c01536_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjgtMS0xLTEtOTQ0MTQ_91da7a4d-09f7-4933-9e81-3012f0c6773e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fe74c4805104d82a48ee99f39bcc191_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjgtMy0xLTEtOTQ0MTQ_772121e1-48e1-4194-b9d8-521228de6be7">436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida94e955b46346cca755a98f10e0cbd8_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjgtNS0xLTEtOTQ0MTQ_30670029-30ad-4e28-862a-551f117cb7f7">436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1db5110e8cf94c3b870dd8e4773cc5f5_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjgtNy0xLTEtOTQ0MTQ_f349fe7c-1a40-407b-82a4-fb97a45322f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33c340fce6894f5cadf9174aacc50b85_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjgtOS0xLTEtOTQ0MTQ_1441dcb5-e4bf-413a-a01b-ff52465d09dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i541eb2cfc8a1420f8d0c271d8d5b58a0_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjgtMTEtMS0xLTk0NDE0_2e512999-7d67-430a-afd3-19e64c7d7f0b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife50c78eda8146feada734d5de383031_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjgtMTMtMS0xLTk0NDE0_27318225-91f0-452a-bbc1-f30c80983f9f">1,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i715add2286974690806d8b1238a739dd_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjgtMTUtMS0xLTk0NDE0_b1d9b6ce-36cc-4f80-b992-35dc398a9968">3,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88c57ba1eaf34b319e49c2126ff89f7a_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjgtMTctMS0xLTk0NDE0_7877fda3-dc17-43a1-8358-891f25bdc28c">4,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44361401a04e43f58bdac9768e7239c0_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjgtMTktMS0xLTk0NDE0_ff8e4d1d-2c66-4815-a69d-ee637112140e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f94cdf096df4338a0b6aad26feb4378_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjgtMjEtMS0xLTk0NDE0_c7da37a2-bfca-4bd9-a9e1-f75fff08f9a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4a89e0cf61f4161b7a76d02b5e911b6_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjgtMjMtMS0xLTk0NDE0_d19c23c1-51a3-4944-bcaa-3a8eae3f25e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Isentress/Isentress</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">HD</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0219c877aef4d4d9bb018be638aca5a_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjktMS0xLTEtOTQ0MTQ_cef4b112-0a54-4c88-8798-6466fd3d7369">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i141c5ef857bb4d94935c24ab8fdae687_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjktMy0xLTEtOTQ0MTQ_129eb004-d022-406f-af45-f2d3324aa339">93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8cbea9f58646b5a29e12373656d30a_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjktNS0xLTEtOTQ0MTQ_610f300d-da28-4c7c-864d-8f9cce821eca">161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7192b6bdb8d54ccd902726f77a8a569d_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjktNy0xLTEtOTQ0MTQ_cc0a57fe-7b22-464c-a632-eba294d9186c">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cdb131b17ab470c9b46b991b14cadba_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjktOS0xLTEtOTQ0MTQ_c1ad521b-5a0c-49d8-8373-62541c514af1">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20a9ffe89114cf3b00ba22b79b96752_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjktMTEtMS0xLTk0NDE0_64e1bd56-f79b-477a-a5b4-52a3eab4dcca">189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01b61b9f737f4bfeb5d1e650b58a2ff0_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjktMTMtMS0xLTk0NDE0_89217467-c402-49ac-b2bc-cfaa8e499b63">196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i820113b59fbd45409278436c72703385_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjktMTUtMS0xLTk0NDE0_bf759fda-59e9-440c-a760-5800816ca2ed">270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17a30514b5f04fcaa8af426469cdf39a_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjktMTctMS0xLTk0NDE0_9e5da61c-e43f-456f-9190-5476fde22123">466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib31766a1f9ca49ed944d511b368436c8_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjktMTktMS0xLTk0NDE0_483ea208-8778-40e6-a909-aa7893bd8ed1">222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462cdaa6b90e45118710c4ae51e35e3a_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjktMjEtMS0xLTk0NDE0_850bf0cb-9fab-4ed8-ab8a-1bc9ab906187">368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f7a6b941763460e99621c2796d825ab_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjktMjMtMS0xLTk0NDE0_c730413d-78b3-48f7-96c4-1c0f9aa91111">590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Belsomra</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb68c7470877490d9ceaade2f13e2c2e_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzEtMS0xLTEtOTQ0MTQ_e0dafc02-992a-4052-9045-30d051b8d848">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i671e7da6a18b400fbf6ead97234042fc_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzEtMy0xLTEtOTQ0MTQ_d9acd31b-ad86-4b77-9b3a-19b48df19ccb">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5651cfaf52164a8ab6636928219a061e_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzEtNS0xLTEtOTQ0MTQ_c9fc011d-381e-4c8f-b173-a252a4e1f2f2">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c45c8df98804459883ad5bff7805922_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzEtNy0xLTEtOTQ0MTQ_7c23fed1-a18b-4777-a081-ad809a034b95">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i080623730f624bba8919833c19347c19_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzEtOS0xLTEtOTQ0MTQ_b8c1e136-0637-4dca-8dca-fb45ff9c8e51">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf02f0982f4a409b968d6265bca89fa6_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzEtMTEtMS0xLTk0NDE0_05d28c62-3c50-41c9-b29a-04ef8e36e59f">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd09a4e622c048fa8abcdbbf99ea24f5_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzEtMTMtMS0xLTk0NDE0_499ba6f7-7e4c-45de-9559-7882d09d3b11">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f4560eb1ee848ef935cf4f82c3c219b_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzEtMTUtMS0xLTk0NDE0_d0ece9ec-eb92-4ae2-a041-36bc74741684">139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b8b17a1b1c4ca4a2c3921c1d59b492_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzEtMTctMS0xLTk0NDE0_05424810-deed-4beb-bbaa-5c58d5bc15c0">199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29caa9c297504c4895226b55191e48e9_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzEtMTktMS0xLTk0NDE0_490c3e4f-7e2c-45a8-98ec-8467ecf77aa8">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6f8d0cdf8b34365ad1b5066369bb0c6_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzEtMjEtMS0xLTk0NDE0_fe7911a9-fda6-4c46-a41b-aa820837e7f6">183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39f38d6401dc4807878d88582b25ad7a_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzEtMjMtMS0xLTk0NDE0_ecacfccc-7d4d-4512-9b52-a1d550d80543">238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Simponi</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a5b415115604e5eb5904c3c92e949f3_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzMtMS0xLTEtOTQ0MTQ_20864897-e025-4671-a64d-a14da71e4cc6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75c73a0ad09046059e2cacc3ca286709_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzMtMy0xLTEtOTQ0MTQ_998c6b9e-560c-41fd-8698-79aebc056531">173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30253a8fdb944b15bcfad5941879e748_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzMtNS0xLTEtOTQ0MTQ_de9518ee-8f9a-4147-a778-4b9c49001a30">173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i477c1387bccc4478a6df52168a873e5e_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzMtNy0xLTEtOTQ0MTQ_2151a128-b27b-4ae3-890b-505229ee03b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e598d60eca4ef790eea98e2e3cf9fb_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzMtOS0xLTEtOTQ0MTQ_b8ac3a5d-ba71-4a28-b40f-69f0295b5636">203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9c58e91b6e49748dcf2aabec8cefe5_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzMtMTEtMS0xLTk0NDE0_2ca3a955-515a-4b6b-993a-32408fec0847">203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaba7e93e3174a09b5fe7fadb95cf5a8_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzMtMTMtMS0xLTk0NDE0_c3e74b54-7849-4c6b-b779-2d6ac9728a9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id72e0113997c414097828708b9146825_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzMtMTUtMS0xLTk0NDE0_f59d8893-ec5f-40ef-89e4-4d0705ff8e0c">540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31af4a0627894e13a9092294ef53779d_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzMtMTctMS0xLTk0NDE0_b7a5e771-b89f-439c-8037-a38dc4b86279">540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82914b6cb0b04d3b8dfa0c36fcb1e3e1_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzMtMTktMS0xLTk0NDE0_19841a0b-a2f9-4b77-9ba4-28e18953c132">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i875eaced42e244509d41e272f4b64999_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzMtMjEtMS0xLTk0NDE0_467bfda9-6149-41aa-86a8-66d072c16068">619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13f4e544586d4c689babc9b7bb643038_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzMtMjMtMS0xLTk0NDE0_90c67d02-7892-4f4e-a91a-06613d06081c">619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Remicade</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a567b0578254433ab2843507871f589_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzQtMS0xLTEtOTQ0MTQ_8447fddf-389b-4dcc-ba9e-3df796606feb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i803f3b4be6844c91ad48b04634b3d57a_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzQtMy0xLTEtOTQ0MTQ_90e06280-5548-4f7c-ba38-a541ff0d2db3">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bcc18bbe90e47da9b7fffcfbe9b7c7f_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzQtNS0xLTEtOTQ0MTQ_f1ed6ea8-52cd-4320-a644-7965e26bbd11">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34c4ac2cb8084a4192568712dceb7c7b_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzQtNy0xLTEtOTQ0MTQ_03ac330d-fbd6-4ec7-9302-364d4ac57818">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48743be2360640e9b25e34524209acf5_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzQtOS0xLTEtOTQ0MTQ_ff511c8e-def4-4cfd-a047-8c2faa287269">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6df70951a3345f5bef560a3d668c977_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzQtMTEtMS0xLTk0NDE0_4e23c607-5bc5-49f0-900b-120ad47567ec">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b63cc78f284d3cb3291a6b392e691a_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzQtMTMtMS0xLTk0NDE0_9a73f8cb-7b09-4dbc-830a-7559e231423c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida55387137da4467910d468e15316ed5_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzQtMTUtMS0xLTk0NDE0_55cfeabf-0159-4304-8761-30b9ca580db8">163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie22a90598b6444e593ecca7b8a7971cf_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzQtMTctMS0xLTk0NDE0_cbaa0485-59c8-400e-9bde-69d6cb6f03cf">163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c97559608224dfe87e9d5af61432405_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzQtMTktMS0xLTk0NDE0_5c1ed925-647d-43e7-a86d-aef9aaf59c14">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6bbe8c6cf234e73a1885c86ba3a53a6_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzQtMjEtMS0xLTk0NDE0_04c08b7e-379c-4d9d-b435-81a0b3c17b23">233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d352f2ba8364c5eaa02ddd326723d7e_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzQtMjMtMS0xLTk0NDE0_c34d3b53-b638-4290-910d-db9ad7b66250">233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Januvia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifee9f2e555d6447ca4a77928972c53a3_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzYtMS0xLTEtOTQ0MTQ_35ad5db2-a1d2-4fb4-8dba-ae76ffa3e1cb">332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d4d29ca30c43db9f653c0173a02a88_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzYtMy0xLTEtOTQ0MTQ_048eedef-f94c-4098-bd76-30097f877670">385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i907dc799123d4d8a8d59145f2fe460ff_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzYtNS0xLTEtOTQ0MTQ_182eddfc-fb4d-4f9f-8e95-6665c976af15">717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71b8800d43dc425ba37b1e7fbaf13774_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzYtNy0xLTEtOTQ0MTQ_c6bde680-f97c-4fad-9dea-70b3b0595d2e">365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib88e6348738c43e789677fefc86824f0_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzYtOS0xLTEtOTQ0MTQ_64bbf057-49a5-41c6-a051-d980aff9361b">487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2842b6655db442f9b1d51ae4beb1bfbf_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzYtMTEtMS0xLTk0NDE0_d979ed98-634d-4bf3-bae9-ddfa538c79c2">852</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4d05b65c7b54139b25ac70c4ab19df3_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzYtMTMtMS0xLTk0NDE0_6ad6952f-e29e-475c-9388-c5e6886d929a">958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i553b3f72bfd042dabe4870ebbc230630_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzYtMTUtMS0xLTk0NDE0_8a1bf4ab-5263-492d-b2b7-b233472366ec">1,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56d699e134f741c0a256a5bbbd4a83fe_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzYtMTctMS0xLTk0NDE0_1a6a4d98-a758-4bf3-985d-ba8860fd0fe4">2,252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if81ecb7810414c37ac52874e47f9559c_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzYtMTktMS0xLTk0NDE0_2a464fc7-d05e-4c42-8d38-e9b2a771fd30">997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3d729fce8a044979a61be3f06e6bf4a_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzYtMjEtMS0xLTk0NDE0_9e62795c-9a8d-4d68-be48-f1962eb184ef">1,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i039289771e0a4a92a82f0e23c7b58113_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzYtMjMtMS0xLTk0NDE0_b84c2020-c8d2-4671-bd74-8db803119e1e">2,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Janumet</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c94024cf7444cc986c90074aa354bdb_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzctMS0xLTEtOTQ0MTQ_7301a9a5-97b7-497c-ab7a-e79bfd595774">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacc83a958e43414884a750ac18d8715c_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzctMy0xLTEtOTQ0MTQ_b8fd0dbd-35bf-4f12-a09b-937306214956">327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie795535b2e254799b2ec04408e04506f_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzctNS0xLTEtOTQ0MTQ_813691e7-8ab9-4197-b6da-59cf2b9545c1">417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7abdbd57cda413bb900bc952b307246_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzctNy0xLTEtOTQ0MTQ_fdb3b54c-05c8-46d0-a453-aae9e7691792">86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81d29f45ec7442a847822087f81a983_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzctOS0xLTEtOTQ0MTQ_49ccc99b-bef2-4e66-aa56-22d8cfeed2f1">401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb741d79fae4f8c9612915e80120b77_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzctMTEtMS0xLTk0NDE0_7910d83d-644e-485c-b08f-565b3a388e9a">487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91f6e6feded64f13ad8e45634369dff0_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzctMTMtMS0xLTk0NDE0_507f82a3-e184-44a6-9a4b-6f4085b7bf6b">258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if25cccf1ea4a4ce9b81f781649b78865_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzctMTUtMS0xLTk0NDE0_5e16c91d-cd37-48cc-aef1-6849f608cf2f">1,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i242133cf5e834e02a75bc0fb1d5dbaa2_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzctMTctMS0xLTk0NDE0_02d71263-176f-40af-9219-0d03b33641af">1,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0a3898f0f3e4eda824b64c14e338702_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzctMTktMS0xLTk0NDE0_4cb6f05d-77f3-41a8-8299-f3b2f046644d">244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08274445c04f4069980cb990559bb715_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzctMjEtMS0xLTk0NDE0_cdee93ca-3bd7-4bd6-9ee2-47007872d2d4">1,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ffb95f5c9c046ba9c390129a0e69d65_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzctMjMtMS0xLTk0NDE0_64136269-2658-4292-8f7d-0cdcf212c2d7">1,449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other pharmaceutical </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb00fde3c5fe4302aff44ebc212aecc1_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzgtMS0xLTEtOTQ0MTQ_ce16d030-c148-49ed-a838-6cb7c79332fd">244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if513f7a17c0e49989ccf849ee4dc9331_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzgtMy0xLTEtOTQ0MTQ_686e20f0-5c60-4cca-ba66-80cb748ea9be">321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i638069bb860a415daddfd8838b2cdd19_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzgtNS0xLTEtOTQ0MTQ_67679d5d-bfa8-46e2-b81b-381f8d8ff960">564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f7703ad94b54db9a9215c0db5b0cd62_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzgtNy0xLTEtOTQ0MTQ_080c1029-f62a-44b8-bb71-8b4c987af7f8">210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i783f44f8b2654fc4af2d919e37ce22a7_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzgtOS0xLTEtOTQ0MTQ_2edb6a2a-3be5-4644-aa01-1c01cef5175e">306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66a5cfc38a70434b9ceec5c2285168aa_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzgtMTEtMS0xLTk0NDE0_d2021ac0-9b95-4cc4-8c3b-5f4ad48e2122">518</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1310ca8214184c8b9d2a080cfe0da7c0_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzgtMTMtMS0xLTk0NDE0_4fb2e573-cb3b-4386-a634-7f0b8e63924d">616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1abf9ffbfb5d44aeb0a9463ac4398eab_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzgtMTUtMS0xLTk0NDE0_0f8db17c-f66e-4ab2-a7a0-d3ae7797e2eb">949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71b867c3c4ec478abe984d94d0169df7_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzgtMTctMS0xLTk0NDE0_97aec0c1-0f7d-4c02-9bcc-ea707d1077b6">1,565</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i823ae7ab9f7e4d099e7876b9b19ae298_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzgtMTktMS0xLTk0NDE0_b0b14ab0-9ae6-4d0b-bdce-4fe6cf9f2724">637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095b912afc3343538d71712bd5e5af82_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzgtMjEtMS0xLTk0NDE0_b734f57d-d29f-4f6c-98f4-0999525837d3">950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8a3bf7c42c44aea99cef1412e8dbb0_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzgtMjMtMS0xLTk0NDE0_e8cca3c4-0658-4fd9-93a2-404022c6b580">1,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Pharmaceutical segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic22e7e95653e4fb0a95e61763a3569b2_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzktMS0xLTEtOTQ0MTQ_c721bf88-e709-4a98-83e8-5016f38a1a3e">6,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id51e37617d5248369c24578f16a1cf14_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzktMy0xLTEtOTQ0MTQ_643a53cf-dd91-4165-857f-a8f8b42a6b70">6,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44564486e4b54deba76702deafc0f64b_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzktNS0xLTEtOTQ0MTQ_9831f916-9985-4515-af78-7c656985fbc0">12,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1e17bbb1a904f4f9887423378bb5af6_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzktNy0xLTEtOTQ0MTQ_059c2d3f-57fa-407b-93fa-9dedda4f4cf8">5,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07782e31373f44de9555f3b81cdd9628_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzktOS0xLTEtOTQ0MTQ_2a292a46-9e22-4011-9461-7aa63dd1b855">5,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd79168d00974ebc85c149dd99401528_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzktMTEtMS0xLTk0NDE0_06355fda-a411-444a-adc1-d7b4a296d277">11,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if91a5aa8a47941858c207f93c372c557_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzktMTMtMS0xLTk0NDE0_996cd2d9-a4b8-4121-9764-9f0ca220c435">19,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50377394250b4f6eb2cdd388e247c98e_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzktMTUtMS0xLTk0NDE0_9c10ca11-503d-4b85-a4f4-5ad7f48192d8">20,707</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4485c1a08fb843e2a1746a8633829398_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzktMTctMS0xLTk0NDE0_1b78f327-9698-416f-a580-6fd95e2b065c">39,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8da429c5485f4cb78dbd9c99fc97e840_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzktMTktMS0xLTk0NDE0_35f673d7-533f-4b03-ba7d-94394dc1b23b">14,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i241616d8d1cc4bd1a17072d1fe359907_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzktMjEtMS0xLTk0NDE0_c91d982e-d743-4d1c-9253-6242ccf23ee0">16,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3168b97c7cfe40dd968aff24fac21714_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzktMjMtMS0xLTk0NDE0_e0566cf8-94a1-4e24-b93f-7ecff4ecfbae">30,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Animal Health:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Livestock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic827d96e5107479f8a50ac1552243075_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDEtMS0xLTEtOTQ0MTQ_d19a356e-4b07-44f0-8582-767979823522">186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f280f0335f34739a091905a7605c8fb_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDEtMy0xLTEtOTQ0MTQ_7bef67c6-5de5-4b5e-ab83-8cc835f96ca6">643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie50dbb604c9b4e1a89e5a02734c3435e_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDEtNS0xLTEtOTQ0MTQ_7bb54c5a-cddd-4693-ba4e-e2eb3b5a0fdc">829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7e482e96daf4d1aba90f65b4d004d1c_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDEtNy0xLTEtOTQ0MTQ_e3253e2b-2593-4ff1-9804-c74cf3e913d6">190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0984754f7dc14a15ae031293bbf02033_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDEtOS0xLTEtOTQ0MTQ_a04d425f-bb30-43fe-8a91-16bb64cdbec3">675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3bab98f9034f8381e05152809cb5ba_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDEtMTEtMS0xLTk0NDE0_8cc89e18-9031-48d8-b49f-28ac4d5ffce9">864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia409b352549644d08a3f0a4940dba700_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDEtMTMtMS0xLTk0NDE0_d2797c3b-6dc4-491d-9e83-1facb211c7a6">521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d9ec8e3f10a4277a866ec3be3d50f2e_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDEtMTUtMS0xLTk0NDE0_6a556fa0-0f07-41d3-8d06-4da7b678dd8e">1,965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11db00c425ed4fb0885192fe0be29cc9_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDEtMTctMS0xLTk0NDE0_d323a237-43c0-4639-98d6-3b65d8b4ceeb">2,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i839b44dbb9c245789d8af1b83cda8eb5_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDEtMTktMS0xLTk0NDE0_54b9d022-1280-469f-b381-206a7a29e4e2">508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0efc28dad4a44fa5966707fcb540b4b1_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDEtMjEtMS0xLTk0NDE0_7cb4bc8c-3938-4f2a-8ec3-5fd0178ec0d8">1,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1aea48b047e34184a2746ed722f8d736_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDEtMjMtMS0xLTk0NDE0_b3900760-806e-43f6-81eb-9847eb6ec759">2,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Companion Animals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9588db6b282c4b73afec4971984508f9_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDItMS0xLTEtOTQ0MTQ_7ef5e884-f28e-4e96-ba5a-9eb69f841632">289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097a676b323a42889c16acb4a376e3c0_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDItMy0xLTEtOTQ0MTQ_947356e8-b235-4e71-8aa9-838a6fc234b1">253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic40e96203c084d60902d25625a1bc564_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDItNS0xLTEtOTQ0MTQ_f5393dbb-4663-4af0-aeb5-9d81f0c02380">542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6427cb6f43ec40cfa361720f0ac45cd2_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDItNy0xLTEtOTQ0MTQ_f67f0c4a-96c0-482d-a833-c86e76b1bb04">277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43885c95db8a44fe80b17b1fef791c59_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDItOS0xLTEtOTQ0MTQ_0aa18390-c18e-4473-9bc9-ed44a52b18e6">276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38960dddb9404fe98542807220cd75b8_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDItMTEtMS0xLTk0NDE0_49ba7ed9-bc0b-43d8-b16a-50a2ef65c834">553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8993fa041a484e879c4a6485620bebd7_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDItMTMtMS0xLTk0NDE0_964fac6a-8a22-4b92-9b4e-d765dab8e403">904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ee7156a4b614122a54d9522c59d5c78_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDItMTUtMS0xLTk0NDE0_b9a80c3d-da05-4d62-9e21-035a82817a6a">929</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i641cb943aa714600b89da7ddd3df0d89_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDItMTctMS0xLTk0NDE0_374bdc9f-e8a2-476a-862e-c5f634ed1b3d">1,834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71e4576e6394e3780b1fb370ab8eca7_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDItMTktMS0xLTk0NDE0_c918eee6-53f4-4d28-87cc-2f828c9a2950">855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8df911dbd564fbf849019ee57246892_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDItMjEtMS0xLTk0NDE0_e84722b7-a9c5-446f-a19f-57e59b0bb738">948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b5cb0fe57d04ef598a24dd039eef72c_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDItMjMtMS0xLTk0NDE0_99dc730b-7030-4ce6-88eb-b8d3a26bd726">1,804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Animal Health segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54a7afab074f405e8ef80dabdfecdf0e_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDMtMS0xLTEtOTQ0MTQ_514d0033-0a37-40c4-9aed-ebd72d661271">475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31118e3777414395bca00605e465fac7_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDMtMy0xLTEtOTQ0MTQ_04355e51-ef11-47a9-bc9a-01cfa113035c">896</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c738afeb7f541e7a7cee2e74587d6e2_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDMtNS0xLTEtOTQ0MTQ_88303301-17bd-4151-b03d-64f9420e64d6">1,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic630a421623e412e899316999b1d84a3_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDMtNy0xLTEtOTQ0MTQ_81c587f5-1218-4363-80c7-9f2b9ef0b6cf">467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i947ae1e75b3d491087466d3c41d239a4_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDMtOS0xLTEtOTQ0MTQ_d4bd8b12-224c-46d1-b253-2285eada76dd">951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7874341a97d4c089a290cd4c52ca3ef_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDMtMTEtMS0xLTk0NDE0_eb3798e3-e40d-4b3e-bbb9-ed3449fe06e7">1,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3a9a7407ef94ca0a066f8f1b41ac915_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDMtMTMtMS0xLTk0NDE0_656ddf5f-36f3-4f23-bad3-3ddab8899168">1,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie74c0c26e4194d0ca851b4f339b64aff_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDMtMTUtMS0xLTk0NDE0_cf71bfec-1c9e-4aac-a614-72ce55bc61a4">2,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if24d9980d69a415285bcfb8af2e4760a_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDMtMTctMS0xLTk0NDE0_c3597710-219b-468c-a173-73e7919a9cc4">4,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie52d61f419f94c0cafc9a9d7cc18a763_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDMtMTktMS0xLTk0NDE0_8797bfc9-38b4-4c92-a321-6d6e2a33c83b">1,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eaeb3befcf640f7b164ca0a1c2686aa_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDMtMjEtMS0xLTk0NDE0_bc442df7-f3f3-41e8-a49a-23a428cc71c3">2,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d6fe701a40b465cacd7765161ea4559_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDMtMjMtMS0xLTk0NDE0_dbe027a4-addc-427a-8842-6460ab4810c5">4,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total segment sales</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic37bfb89cb3640ad8e236e59f73d6359_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDQtMS0xLTEtOTQ0MTQ_1316c6df-2bef-4489-8426-15cd77731ba1">7,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8fd87789a924ef1962a3681f884ed11_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDQtMy0xLTEtOTQ0MTQ_4c26faf3-a361-4514-ab83-6057d86fd759">7,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736eb61ba964832abed00a756bb99fe_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDQtNS0xLTEtOTQ0MTQ_19e3a2e3-703f-429b-8293-b0cc8a0f59dc">14,334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bf14f8f5d2747e58b18f20cc5051555_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDQtNy0xLTEtOTQ0MTQ_ccfc6600-ee8e-427e-90fc-767b24b25e5a">6,137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30e83259e5b648859b1c791fc219f795_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDQtOS0xLTEtOTQ0MTQ_585a9e58-4ff5-45a2-96ad-44a7d8768eab">6,777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i769a6f6f373c4424a78daa11151e8693_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDQtMTEtMS0xLTk0NDE0_cad00cdb-e167-498b-b5f5-510507adab4d">12,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifae6a5b5be2d4e27b57c8cb59e7b736d_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDQtMTMtMS0xLTk0NDE0_8dcd63f4-cbfb-4caa-8d25-ae50e316b8e0">20,544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4d49c3f485c4a969fc279eae65aea0c_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDQtMTUtMS0xLTk0NDE0_482bc6ab-4b20-4fbf-bd43-09619982d8dc">23,601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic976522683894b2f851b9eb9a9e99339_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDQtMTctMS0xLTk0NDE0_35d5f30f-7529-4451-b3a3-0a5e49d410d9">44,146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6158ef12bd24d40b494575847b10455_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDQtMTktMS0xLTk0NDE0_c449d497-a5a7-4829-8617-002c73da7284">15,974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c9b56c797144ae883e07ceee9eb81ad_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDQtMjEtMS0xLTk0NDE0_3f02db33-0958-47c6-b9f3-004d8c587aed">19,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748adeb1c1b74b4a80ea71f1622e0a83_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDQtMjMtMS0xLTk0NDE0_b5cd72ed-7746-4996-b51d-d15459148016">35,021</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58abc744b88c49d996c9335dc7e4e26a_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDUtMS0xLTEtOTQ0MTQ_62d7479c-12c6-4e6c-b3c8-50921039004e">227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2cdaaadd890437ea5827bcebf07e28c_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDUtMy0xLTEtOTQ0MTQ_0fb3040d-8963-4ab3-8878-aec28e464a2c">398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b6ac35939974a6680f67f6f5cb6cfbd_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDUtNS0xLTEtOTQ0MTQ_d02833c6-175c-43f8-9851-a19bbc7aa5b2">625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifecb5cf258f942c68db448dc19d76074_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDUtNy0xLTEtOTQ0MTQ_c5af9965-bb13-415c-9c15-36b9a0e1be20">139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7452b2558944b89aa0c78702511531b_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDUtOS0xLTEtOTQ0MTQ_3326da6e-01d6-483f-81d8-679ce0c6c4e9">101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie95d0a9de94f48bc9a2edc6e093ccd9d_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDUtMTEtMS0xLTk0NDE0_88e27a3b-3d34-4f8c-be01-061e4251c79b">241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46b3dbdcc4454d4ab3079f2407d0e808_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDUtMTMtMS0xLTk0NDE0_7f6459fd-52df-4018-b0f9-b576c9e8c5ae">383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i997e727369cc4c879b4f65634d5c9167_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDUtMTUtMS0xLTk0NDE0_c6145549-a7c0-41e9-bc38-2f3379141f1e">925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied57d33df852404ea42cbb9249fb4ff7_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDUtMTctMS0xLTk0NDE0_46505535-dd2f-4ccf-ae90-77df5af8fab6">1,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dd1ed9c80f84232aa613ebfc30fce1b_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDUtMTktMS0xLTk0NDE0_8fd366f2-de60-4363-b129-b5c7be339b1c">192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f54658358b74dd2a2602a4b93e49d03_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDUtMjEtMS0xLTk0NDE0_23891760-ec51-40a6-9bef-ec406acf8be5">30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7a6672a05e34d6090ab13ec171a3c16_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDUtMjMtMS0xLTk0NDE0_4a0ce95f-01d2-4ad0-907c-82739bc720b7">162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dbe9922fd544a0e817961eb18397dfb_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDYtMS0xLTEtOTQ0MTQ_c82bcf4c-0589-41c2-a088-f763e8046002">7,322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i998bc7df80cd421c86a31d55b20b2f00_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDYtMy0xLTEtOTQ0MTQ_09348014-f70c-4d8e-8fd0-c1faab53a67b">7,637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDYtNS0xLTEtOTQ0MTQ_fe29e578-1d7e-4575-8cba-2797d8052c68">14,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1501c38c01f24f46ab98fa0918a29aea_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDYtNy0xLTEtOTQ0MTQ_116053bf-86d2-4eed-907a-458e9e52f1d6">6,276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461edb12a6e0421a95ce0ac6c93adbca_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDYtOS0xLTEtOTQ0MTQ_d9c0f04b-fd33-4b50-89c2-3cc1819bdb99">6,878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDYtMTEtMS0xLTk0NDE0_f9c5bfdf-0b74-4dcb-aeb9-df4e4cf1e82c">13,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie95f6e7a4c9a45b98ee10519480bcc57_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDYtMTMtMS0xLTk0NDE0_f93e346c-568f-48c6-9ae1-fbb2edb1de47">20,927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609ee3a20dca4ef2a07a72f3aa7bd472_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDYtMTUtMS0xLTk0NDE0_cf502ab1-0866-4047-b780-1490bbaea063">24,526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDYtMTctMS0xLTk0NDE0_f6844a61-4e2f-4cd2-b7ec-a18beb90ca57">45,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dcd8e73f06541bf90ce68a9090f463c_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDYtMTktMS0xLTk0NDE0_12ebcefd-df7c-4396-bcf3-91b031b0e765">16,166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddf8513030e4e22ab98fead59aa24a8_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDYtMjEtMS0xLTk0NDE0_5e036e63-5ec8-4d29-8de8-c7c8c83bc505">19,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDYtMjMtMS0xLTk0NDE0_f34b0be5-c01c-4a6d-b900-4b8c88645fab">35,183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">U</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">.S. plus international may not equal total due to rounding.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue for Lynparza and Lenvima represents Merck&#8217;s share of profits, which are product sales net of cost of sales and commercialization costs (see Note&#160;4).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue for Reblozyl represents royalties and, for the year-to-date period, a payment received related to the achievement of a regulatory milestone (see Note&#160;4).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue for Adempas/Verquvo represents Merck&#8217;s share of profits from sales in Bayer&#8217;s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note&#160;4).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(4)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(5)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Other is primarily comprised of miscellaneous corporate revenue, including revenue hedging activities, as well as revenue from third-party manufacturing arrangements (including sales to Organon). Other for the nine months ended September&#160;30, 2022 and 2021 also includes $<ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:ProceedsFromSaleOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RleHRyZWdpb246NGRlODU3NTdjYTEyNGIxMTk5MzBjYzBlMDFmZWViMzRfMjc5MA_30d3116c-4cd1-465d-bb9e-7fd19a3a6817">156</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:ProceedsFromSaleOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RleHRyZWdpb246NGRlODU3NTdjYTEyNGIxMTk5MzBjYzBlMDFmZWViMzRfMjc5Nw_db9586ec-c223-4416-a1eb-522c5e629e41">191</ix:nonFraction>&#160;million, respectively, related to upfront and milestone payments received by Merck for out-licensing arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:3pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 31 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="ia0a7415454ae484b822cfc0e15d46950"><div style="margin-top:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales are recorded net of the provision for discounts, including chargebacks, which are customer discounts that occur when a contracted customer purchases through an intermediary wholesale purchaser, and rebates that are owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part D) benefit providers, after the final dispensing of the product by a pharmacy to a benefit plan participant. These discounts, in the aggregate, reduced U.S. sales by $<ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-8" name="mrk:SalesDiscounts" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RleHRyZWdpb246NGRlODU3NTdjYTEyNGIxMTk5MzBjYzBlMDFmZWViMzRfMzQ1MQ_960b3c1c-ada2-472c-9eb0-b48c1f01051b">3.3</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-8" name="mrk:SalesDiscounts" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RleHRyZWdpb246NGRlODU3NTdjYTEyNGIxMTk5MzBjYzBlMDFmZWViMzRfMzQ1OA_8d8354a0-fe4f-423c-a90f-48fa5a65fcb9">3.1</ix:nonFraction> billion for the three months ended September&#160;30, 2022 and 2021, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-8" name="mrk:SalesDiscounts" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RleHRyZWdpb246NGRlODU3NTdjYTEyNGIxMTk5MzBjYzBlMDFmZWViMzRfMzUxNw_1904d887-5d92-419a-a0aa-557191e989e8"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-8" name="mrk:SalesDiscounts" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RleHRyZWdpb246NGRlODU3NTdjYTEyNGIxMTk5MzBjYzBlMDFmZWViMzRfMzUxNw_83a36eec-7753-414a-9245-ab97127536dc">9.1</ix:nonFraction></ix:nonFraction>&#160;billion for both the nine months ended September&#160;30, 2022 and 2021. </span></div><ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RleHRyZWdpb246NGRlODU3NTdjYTEyNGIxMTk5MzBjYzBlMDFmZWViMzRfNTQ3Ng_1951f1c0-a32e-49df-b3e4-dac44756d43b" escape="true"><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated sales by geographic area where derived are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.946%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dbe9922fd544a0e817961eb18397dfb_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfMi0xLTEtMS05NDQxNA_f8f2f519-74b7-4f27-ac09-8a1b61086e20">7,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1501c38c01f24f46ab98fa0918a29aea_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfMi0zLTEtMS05NDQxNA_2498dfba-0e6a-4263-a555-77ddc90a0965">6,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie95f6e7a4c9a45b98ee10519480bcc57_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfMi01LTEtMS05NDQxNA_2b7be72c-bf42-4770-b599-1a7c68b434e8">20,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dcd8e73f06541bf90ce68a9090f463c_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfMi03LTEtMS05NDQxNA_51972058-f104-4cd7-b53a-c591de769ecf">16,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9fd53158404da68f8ed38707c6e730_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfMy0xLTEtMS05NDQxNA_27960502-3333-4289-8956-8a0a91a8278d">3,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5c146f01bfc4a0fb436eac2074cdf40_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfMy0zLTEtMS05NDQxNA_7b394bce-d07a-4ef5-86ff-43c8a2d5237f">3,342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9eb6d9a053c248a8abc9535a66f119f6_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfMy01LTEtMS05NDQxNA_28220b52-b0ea-4095-b8b8-3ac2b577ecc8">11,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95e954dfb89d4490bc7f62728171c3c7_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfMy03LTEtMS05NDQxNA_1449bc69-ab2d-4449-a6fd-de55251aa2df">9,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic896ad83efec4ff7a7a62329387853a7_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfNC0xLTEtMS05NDQxNA_f551a5b6-7fd3-49bc-ab2a-6541622ea7fb">1,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e4b569901524a64b1ef34cb1524a967_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfNC0zLTEtMS05NDQxNA_6e0ae353-437f-4604-a463-22794d08d0cd">1,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fce1d67949c48ccb03f9e12c3e52dae_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfNC01LTEtMS05NDQxNA_b4e26275-1dbb-472c-8c31-bd43bd37de7d">3,957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i050b473f8c3f4780be91b8883989770d_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfNC03LTEtMS05NDQxNA_4fac8b4a-169b-4490-be8c-4b5f66c8ddf3">3,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab0d5373a6143ba8a8971886fd366eb_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfNS0xLTEtMS05NDQxNA_180dd442-9a08-4e37-a560-71d5735f7946">673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94657ee062ab4c07a5644722ec7e5f4d_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfNS0zLTEtMS05NDQxNA_3703275a-41de-4797-929f-50a200c2657e">638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i011ff8ae410c45ee9363ef7b31f62ff6_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfNS01LTEtMS05NDQxNA_1d9eed65-da2c-452e-a4a6-fd5759c97794">2,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ccfec64c8df4db89a86df0ec6e79d66_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfNS03LTEtMS05NDQxNA_bc5f056c-d6b0-45b3-902b-d5c23f009bfa">1,929</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific (other than China and Japan)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bf58675420348dea4421700f6d61b1d_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfNi0xLTEtMS05NDQxNA_b2d44e43-e33f-4566-9a24-c9153913c8f6">854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22eef57a3e534bce9a842560378654e4_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfNi0zLTEtMS05NDQxNA_c2b1f295-9fdf-40c2-960c-1730e7c9c898">613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fe1b46c7e9040539c417e8044482c9a_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfNi01LTEtMS05NDQxNA_86e64967-ab6b-4cbf-9366-ee232632ecce">2,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0820e5db91674b1b9eb3859fb1471846_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfNi03LTEtMS05NDQxNA_5ab5b970-a216-423e-b77a-1fae61275ffc">1,782</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e743f7eaf994261a54320837d8cdc38_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfNy0xLTEtMS05NDQxNA_a8f48443-c68a-461f-b733-8cbf602c016c">684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25e83ccb0774f9f8d3a60252008d95d_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfNy0zLTEtMS05NDQxNA_e97ed0ff-4b14-4fa9-aa98-cfbfb1e22ce9">599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c91091b09d34c3eb1b8f917bf6a6e92_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfNy01LTEtMS05NDQxNA_e3309f51-a526-4fe7-a465-ca84ccf555db">1,933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b5a7c79bc084682a64cd091d3a8258c_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfNy03LTEtMS05NDQxNA_aca3fc6e-842c-4a13-a2be-ccc29f71f868">1,631</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97fa5da6b3924d8d99c2fbceb69c59d9_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfOC0xLTEtMS05NDQxNA_4df31dbe-8503-40e8-ba96-ac3887d6f8f3">698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccf7a7e39a1444609739fe18036ae1a6_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfOC0zLTEtMS05NDQxNA_98e69a17-09af-4510-8705-38b64fa7b55a">379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22490ec2cbf04c3994fd5195617c0cd1_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfOC01LTEtMS05NDQxNA_ba57e2b2-d999-4c00-b155-af7b0c1eeed2">1,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d7cf65513ab4159b2feb11639c2f8b8_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfOC03LTEtMS05NDQxNA_0119df20-7cb4-4da4-9c0e-f774b116d9af">759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfOS0xLTEtMS05NDQxNA_617cbc2a-1d42-41fb-b023-9402239a2e8a">14,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfOS0zLTEtMS05NDQxNA_1e7cfe8f-4131-47cb-ac65-193555db3848">13,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfOS01LTEtMS05NDQxNA_220dbd22-992c-49c6-9256-81b646cbcac4">45,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfOS03LTEtMS05NDQxNA_906b558d-7f88-4076-958c-da55b032b854">35,183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RleHRyZWdpb246NGRlODU3NTdjYTEyNGIxMTk5MzBjYzBlMDFmZWViMzRfNTUwMw_c8000baf-ea03-4e60-bb41-cfeeb95a77ba" escape="true"><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of segment profits to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from Continuing Operations Before Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is as follows:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.531%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical segment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44564486e4b54deba76702deafc0f64b_D20220701-20220930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMy0xLTEtMS05NDQxNA_e74c01c1-cb31-407e-8a29-e4385b035469">9,590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd79168d00974ebc85c149dd99401528_D20210701-20210930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMy0zLTEtMS05NDQxNA_203391c7-9e18-4336-bd59-2a12baa14b22">8,606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4485c1a08fb843e2a1746a8633829398_D20220101-20220930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMy01LTEtMS05NDQxNA_25611ad7-4e65-4ba9-96f4-02b8c28604dd">28,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3168b97c7cfe40dd968aff24fac21714_D20210101-20210930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMy03LTEtMS05NDQxNA_1bfa8bf9-c22b-442f-86b5-e9368d380954">22,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Animal Health segment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c738afeb7f541e7a7cee2e74587d6e2_D20220701-20220930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfNC0xLTEtMS05NDQxNA_dc036efa-1aef-44cb-bc62-052008819817">515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7874341a97d4c089a290cd4c52ca3ef_D20210701-20210930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfNC0zLTEtMS05NDQxNA_24b2367d-460a-4526-8a78-e3b88526d2a4">505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if24d9980d69a415285bcfb8af2e4760a_D20220101-20220930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfNC01LTEtMS05NDQxNA_b3a15056-d305-47fe-8862-8b76c0a42b0e">1,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d6fe701a40b465cacd7765161ea4559_D20210101-20210930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfNC03LTEtMS05NDQxNA_75f33c40-3fc8-4afc-b542-1045030d65c0">1,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment profits</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736eb61ba964832abed00a756bb99fe_D20220701-20220930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfNS0xLTEtMS05NDQxNA_2b131e49-ecf3-4cce-8009-9fb14fd320d5">10,105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i769a6f6f373c4424a78daa11151e8693_D20210701-20210930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfNS0zLTEtMS05NDQxNA_4089f473-e9ef-412b-a18b-ba18e3b73987">9,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic976522683894b2f851b9eb9a9e99339_D20220101-20220930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfNS01LTEtMS05NDQxNA_9c6e71f0-96b5-44e2-b3e2-47a97289ee3d">29,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748adeb1c1b74b4a80ea71f1622e0a83_D20210101-20210930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfNS03LTEtMS05NDQxNA_a696640a-0d8e-49e3-92e9-53ef10da3587">24,079</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other profits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b6ac35939974a6680f67f6f5cb6cfbd_D20220701-20220930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfNi0xLTEtMS05NDQxNA_c4510ec5-f540-4b76-a353-8569d1b93283">377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie95d0a9de94f48bc9a2edc6e093ccd9d_D20210701-20210930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfNi0zLTEtMS05NDQxNA_42d73dec-5b50-45d7-8f0b-4c332166d929">141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied57d33df852404ea42cbb9249fb4ff7_D20220101-20220930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfNi01LTEtMS05NDQxNA_20fd93e0-edcc-4899-9f95-d996bafcada5">831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7a6672a05e34d6090ab13ec171a3c16_D20210101-20210930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfNi03LTEtMS05NDQxNA_fa8469a9-59ed-4890-8ffd-62ca51b214fb">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69959f4306b342dbbb1318e7d3cf276a_D20220701-20220930" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfOC0xLTEtMS05NDQxNA_2d7b765d-a984-4662-83f8-9d31a8e0e944">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59506b8e5aae42f880005525de216ce0_D20210701-20210930" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfOC0zLTEtMS05NDQxNA_aac2a61c-b7e2-4d2b-8c73-f55a9ede64a0">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1091a13b711442e0848bc698d9a73a45_D20220101-20220930" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfOC01LTEtMS05NDQxNA_764c4dcb-9bd9-4e75-822e-eb95a90db5b3">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e3336b01ef433aa8801b345dea8c4d_D20210101-20210930" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfOC03LTEtMS05NDQxNA_508d61ae-502f-416b-8240-127746f8d82c">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69959f4306b342dbbb1318e7d3cf276a_D20220701-20220930" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfOS0xLTEtMS05NDQxNA_4c1705af-4a56-4604-a632-d357d5b01bee">244</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i59506b8e5aae42f880005525de216ce0_D20210701-20210930" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfOS0zLTEtMS05NDQxNA_acbc5eab-22cb-4d12-9c9f-3361b0ef5820">196</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1091a13b711442e0848bc698d9a73a45_D20220101-20220930" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfOS01LTEtMS05NDQxNA_4ced9426-e7f6-4026-82ee-61453b211821">727</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3336b01ef433aa8801b345dea8c4d_D20210101-20210930" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfOS03LTEtMS05NDQxNA_b11db5e8-8245-47d3-a932-875904d296c7">597</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69959f4306b342dbbb1318e7d3cf276a_D20220701-20220930" decimals="-6" name="us-gaap:AdjustmentForAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMTAtMS0xLTEtOTQ0MTQ_93382605-f2ee-4e2a-9dc1-c26384aa12dd">460</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i59506b8e5aae42f880005525de216ce0_D20210701-20210930" decimals="-6" name="us-gaap:AdjustmentForAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMTAtMy0xLTEtOTQ0MTQ_c6387d6b-388c-4660-bacd-677ba27b0ccf">360</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1091a13b711442e0848bc698d9a73a45_D20220101-20220930" decimals="-6" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMTAtNS0xLTEtOTQ0MTQ_7967ebcd-e987-4639-bcd1-1f2dc2d83fc5">1,623</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3336b01ef433aa8801b345dea8c4d_D20210101-20210930" decimals="-6" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMTAtNy0xLTEtOTQ0MTQ_0f9d975e-3ee5-4733-b2bc-04df3bd0043c">1,231</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69959f4306b342dbbb1318e7d3cf276a_D20220701-20220930" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMTEtMS0xLTEtOTQ0MTQ_ad60f4fe-3210-44a8-a5fa-e627e44abf0c">448</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i59506b8e5aae42f880005525de216ce0_D20210701-20210930" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMTEtMy0xLTEtOTQ0MTQ_6758dfa1-5242-47c1-a1cc-814c371e6e8c">358</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1091a13b711442e0848bc698d9a73a45_D20220101-20220930" decimals="-6" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMTEtNS0xLTEtOTQ0MTQ_393c7074-0020-4415-bc4f-48f1257ddbad">1,257</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3336b01ef433aa8801b345dea8c4d_D20210101-20210930" decimals="-6" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMTEtNy0xLTEtOTQ0MTQ_101c5596-609b-4afe-821a-b24cfc616fd6">1,031</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69959f4306b342dbbb1318e7d3cf276a_D20220701-20220930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMTItMS0xLTEtOTQ0MTQ_89fc9d36-2b8c-4116-bc23-df9b0ae770df">4,277</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i59506b8e5aae42f880005525de216ce0_D20210701-20210930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMTItMy0xLTEtOTQ0MTQ_95b27f87-ee3e-435f-9fef-2a9f0af80cb9">2,312</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1091a13b711442e0848bc698d9a73a45_D20220101-20220930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMTItNS0xLTEtOTQ0MTQ_25daa67f-541c-43dc-81d9-bb977021498b">9,374</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3336b01ef433aa8801b345dea8c4d_D20210101-20210930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMTItNy0xLTEtOTQ0MTQ_4ccf5b12-877c-462f-a6c0-c1c48783b9de">8,775</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69959f4306b342dbbb1318e7d3cf276a_D20220701-20220930" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMTMtMS0xLTEtOTQ0MTQ_cbf60e52-377c-4df7-92d2-bc2858214875">94</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i59506b8e5aae42f880005525de216ce0_D20210701-20210930" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMTMtMy0xLTEtOTQ0MTQ_ecec2a5b-26e8-44b5-bf7d-bb4c5bdf2c55">107</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1091a13b711442e0848bc698d9a73a45_D20220101-20220930" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMTMtNS0xLTEtOTQ0MTQ_5b159c41-3eca-4c45-835f-2be7ee0a887a">288</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3336b01ef433aa8801b345dea8c4d_D20210101-20210930" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMTMtNy0xLTEtOTQ0MTQ_8cafb66b-83a6-447c-981a-26595403d643">487</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other unallocated, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69959f4306b342dbbb1318e7d3cf276a_D20220701-20220930" decimals="-6" name="mrk:SegmentReportingUnallocatedOtherExpensesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMTQtMS0xLTEtOTQ0MTQ_3071a8ba-c4cd-435d-bf18-47506bb17141">1,416</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i59506b8e5aae42f880005525de216ce0_D20210701-20210930" decimals="-6" name="mrk:SegmentReportingUnallocatedOtherExpensesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMTQtMy0xLTEtOTQ0MTQ_7c634ffc-dae6-475a-84c8-81fe0a3d1be1">660</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1091a13b711442e0848bc698d9a73a45_D20220101-20220930" decimals="-6" name="mrk:SegmentReportingUnallocatedOtherExpensesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMTQtNS0xLTEtOTQ0MTQ_e65f23bc-e850-4050-9e91-5b46eda8a683">4,628</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3336b01ef433aa8801b345dea8c4d_D20210101-20210930" decimals="-6" name="mrk:SegmentReportingUnallocatedOtherExpensesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMTQtNy0xLTEtOTQ0MTQ_41ac7255-593f-4d5a-97e2-55b629b2be2f">2,044</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMTUtMS0xLTEtOTQ0MTQ_78182dfd-dc5f-4351-af98-04e1c4d13c66">3,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMTUtMy0xLTEtOTQ0MTQ_53fbb069-494b-4faa-8ee2-b1fde51d0c0e">5,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMTUtNS0xLTEtOTQ0MTQ_e8622375-813c-425a-bddf-fad0db7778d4">12,931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMTUtNy0xLTEtOTQ0MTQ_f3cb7a8f-1321-48bd-9876-7d64adb9e451">9,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as selling, general and administrative expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as selling, general and administrative expenses and research and development costs directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, research and development expenses incurred in Merck Research Laboratories, the Company&#8217;s research and development division that focuses on human health-related activities, or general and administrative expenses, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. In addition, costs related to restructuring activities, as well as the amortization of intangible assets and purchase accounting adjustments are not allocated to segments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other profits are primarily comprised of miscellaneous corporate profits, as well as operating profits related to third-party manufacturing arrangements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other unallocated, net, includes expenses from corporate and manufacturing cost centers, goodwill and other intangible asset impairment charges, gains or losses on sales of businesses, expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration, and other miscellaneous income or expense items.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 32 -</span></div></div></div><div id="i6b4e4280ad2344a5bc7fdcaa77e417f0_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div id="i6b4e4280ad2344a5bc7fdcaa77e417f0_82"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Management</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, Merck announced that its board of directors unanimously elected Robert M. Davis, currently Chief Executive Officer and President, to serve as chairman of the board, effective December 1, 2022. He will succeed Kenneth C. Frazier, who will retire on November 30, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Business Developments</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of significant business development activity thus far in 2022. See Note&#160;3 to the condensed consolidated financial statements for additional information.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, Merck exercised its option to jointly develop and commercialize personalized cancer vaccine mRNA-4157/V940 pursuant to the terms of an existing collaboration and license agreement with Moderna, Inc. (Moderna), which resulted in a $250&#160;million charge in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in the third quarter and first nine months of 2022. The payment to Moderna was made in the fourth quarter of 2022. mRNA-4157/V940 is currently being evaluated in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pembrolizumab), Merck&#8217;s anti-PD-1 therapy, as adjuvant treatment for patients with high-risk melanoma in a Phase 2 clinical trial being conducted by Moderna. Under the 2016 agreement, as amended in 2018, Merck and Moderna will collaborate on development and commercialization and will share costs and any profits equally under this worldwide collaboration.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, Merck and Orna Therapeutics (Orna), a biotechnology company pioneering a new investigational class of engineered circular RNA (oRNA) therapies, entered into a collaboration agreement to discover, develop, and commercialize multiple programs, including vaccines and therapeutics in the areas of infectious disease and oncology. Under the terms of the agreement, Merck made an upfront payment to Orna of $150&#160;million, which was recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in the third quarter and first nine months of 2022. In addition, Orna is eligible to receive future contingent development-related payments, as well as regulatory and sales-based milestone payments contingent upon the progress of the multiple vaccine and therapeutic programs, as well as royalties on any approved products derived from the collaboration. Merck also invested $100&#160;million in Orna&#8217;s Series B preferred shares in the fourth quarter of 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, Merck and Orion Corporation (Orion) announced a global co-development and co-commercialization agreement for Orion&#8217;s investigational candidate ODM-208 (MK-5684) and other drugs targeting cytochrome P450 11A1 (CYP11A1), an enzyme important in steroid production. ODM-208 is an oral, non-steroidal inhibitor of CYP11A1 currently being evaluated in a Phase 2 clinical trial for the treatment of patients with metastatic castration-resistant prostate cancer. Merck made an upfront payment to Orion of $290 million, which was recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in the third quarter and first nine months of 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in July 2022, Merck and Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (Kelun-Biotech) closed a license and collaboration agreement in which Merck gained exclusive worldwide rights for the development, manufacture and commercialization of an investigational antibody drug conjugate (ADC) (MK-1200) for the treatment of solid tumors. Under the terms of the agreement, Merck and Kelun-Biotech will collaborate on the early clinical development of the investigational ADC. Merck made an upfront payment of $35 million, which was recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in the third quarter and first nine months of 2022. Kelun-Biotech is also eligible to receive future contingent developmental, regulatory and sales-based milestone payments, as well as tiered royalties on future net sales.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, in connection with an existing arrangement, Merck exercised its option to obtain an exclusive license outside of China for the development, manufacture and commercialization of Kelun-Biotech&#8217;s trophoblast antigen 2 (TROP2)-targeting ADC programs, including its lead compound, SKB-264 (MK-2870). SKB-264 is currently being evaluated in Phase 2 trials for non-small-cell lung cancer (NSCLC) and advanced solid tumors. Under the terms of the agreement, Merck and Kelun-Biotech will collaborate on certain early clinical development plans, including evaluating the potential of SKB-264 as a monotherapy and in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for advanced solid tumors. Upon option exercise, Merck made a payment of $30 million, which was recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in the first nine months of 2022, and agreed to make additional payments upon completion of specified project activities, technology transfer, as well as payments to fund Kelun-Biotech&#8217;s ongoing research and development activities. In addition, Kelun-Biotech is eligible to receive future contingent developmental and sales-based milestone payments and royalties on future net sales. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Spin-Off of Organon &amp; Co.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 2, 2021, Merck completed the spin-off of products from its women&#8217;s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon &amp; Co. (Organon) through a distribution of Organon&#8217;s publicly traded stock to Company shareholders. The distribution is expected to qualify and has been treated as tax-free to the Company and its shareholders for U.S. federal income tax purposes. The established brands included in the transaction consisted of dermatology, non-opioid pain management, respiratory, select cardiovascular products, as well as the rest of Merck&#8217;s diversified brands franchise. Merck&#8217;s existing research pipeline programs continue to be owned and developed </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 33 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within Merck as planned. The historical results of the businesses that were contributed to Organon in the spin-off have been reflected as discontinued operations in the Company&#8217;s consolidated financial statements through the date of the spin-off (see Note&#160;2 to the condensed consolidated financial statements).</span></div><div id="i6b4e4280ad2344a5bc7fdcaa77e417f0_85"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other Developments</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">War in Ukraine</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, Russia invaded Ukraine. The Company&#8217;s primary concerns are the safety and well-being of its employees and ensuring patients and customers have continued access to medicines and vaccines needed for patient and public health. The Company is working cross-functionally across the globe to monitor and mitigate interruptions to business continuity resulting from the war, including its impact on Merck&#8217;s supply chain, operations and clinical trials. For humanitarian reasons, the Company is continuing to supply essential medicines and vaccines in Russia while working to maintain compliance with evolving international sanctions. Merck is donating profits resulting from its operations in Russia to humanitarian causes. The Company does not have research or manufacturing facilities in Russia, currently does not plan to make further investments in Russia, and has suspended screening and enrollment in ongoing clinical trials as well as planning for new studies in Russia, although the Company continues to treat patients already enrolled in existing clinical trials and collect data from these studies. The Company is also using its resources to help alleviate the humanitarian crisis in Ukraine, including through donations of funds and products. The financial impacts of the war were immaterial to the Company&#8217;s consolidated financial statements for the third quarter and first nine months of 2022. Combined sales to Russia and Ukraine were approximately 1% of total Merck consolidated sales for the full year of 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The combination of Russia&#8217;s invasion of Ukraine, as well as the resultant economic sanctions imposed by the U.S., the European Union (EU) and other governments are having pervasive effects in markets worldwide. The Company is unable to determine at this time the future impacts of this war either directly or indirectly on the Company&#8217;s business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although COVID-19-related disruptions had some negative effects on sales for the third quarter and first nine months of 2022, Merck continues to believe that global health systems and patients have largely adapted to the impacts of the COVID-19 pandemic. Merck&#8217;s sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (molnupiravir), an investigational oral antiviral COVID-19 medicine, were $436 million and $4.9 billion in the third quarter and first nine months of 2022, respectively. In the third quarter and first nine months of 2021, COVID-19-related disruptions resulted in an estimated negative impact to Pharmaceutical segment sales of approximately $350 million and $1.3 billion, respectively, because a substantial portion of Merck&#8217;s Pharmaceutical segment revenue is comprised of physician-administered products, which were unfavorably affected by social distancing measures and fewer well visits. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, Merck announced it was discontinuing the development of MK-7110 for the treatment of hospitalized patients with COVID-19, which was obtained as part of Merck&#8217;s acquisition of OncoImmune (see Note&#160;3 to the condensed consolidated financial statements). This decision resulted in charges of $207&#160;million to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the first nine months of 2021. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, Merck announced it had entered into multiple agreements to support efforts to expand manufacturing capacity and supply of SARS-CoV-2/COVID-19 medicines and vaccines. The Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, provided Merck with $102&#160;million of funding in the first quarter of 2022 to adapt and make available a number of existing manufacturing facilities for the production of SARS-CoV-2/COVID-19 vaccines and medicines. The funding was recognized as a reduction to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> over the production period through September 30, 2022, offsetting the depreciation expense related to the amounts that were capitalized in connection with the modification of the manufacturing facilities. Merck and Johnson &amp; Johnson have commenced an arbitration regarding a dispute concerning two agreements pursuant to which Merck was supporting the manufacturing and supply of Johnson &amp; Johnson&#8217;s SARS-CoV-2/COVID 19 vaccine and vaccine drug product. The amounts included in the condensed consolidated financial statements for these agreements were immaterial for the third quarter and first nine months of 2022. Merck does not believe the outcome of the arbitration will have a material impact on the Company&#8217;s financial results.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Pricing</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global efforts toward health care cost containment continue to exert pressure on product pricing and market access worldwide. Changes to the U.S. health care system enacted in prior years as part of health care reform, as well as increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries, have contributed to pricing pressure. In several international markets, government-mandated pricing actions have reduced prices of generic and patented drugs. In addition, the Company&#8217;s sales performance in the first nine months of 2022 was negatively affected by other cost-reduction measures taken by governments and other third parties to lower health care costs. In the U.S., Congress recently passed the Inflation Reduction Act, which makes significant changes to how drugs are covered and paid for under the Medicare </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 34 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">program, including the creation of financial penalties for drugs whose prices rise faster than the rate of inflation, redesign of the Medicare Part D program to require manufacturers to bear more of the liability for certain drug benefits, and government price-setting for certain Medicare Part D drugs, starting in 2026, and Medicare Part B drugs starting in 2028. The Company anticipates all of these actions and additional actions in the future will negatively affect sales and profits.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Supply Chain</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of global macroeconomic conditions, the Company is experiencing some disruption and volatility in its global supply chain network, and the Company may in the future experience disruptions in availability and delays in shipments of raw materials and packaging, as well as related cost inflation.</span></div><div id="i6b4e4280ad2344a5bc7fdcaa77e417f0_88"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Operating Results</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sales</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.955%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding <br/>Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding <br/>Foreign<br/>Exchange</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,322&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,276&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,927&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,166&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,637&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,878&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,526&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,959&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,154&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,453&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,183&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">U.S. plus international may not equal total due to rounding.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide sales grew 14% to $15.0 billion in the third quarter of 2022 primarily due to higher sales in the oncology franchise, largely driven by strong growth of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pembrolizumab) and increased alliance revenue from Reblozyl (luspatercept-aamt) and Lynparza (olaparib), as well as higher sales in the virology franchise driven by </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (molnupiravir). Also contributing to revenue growth in the third quarter of 2022 were higher sales in the vaccines franchise, primarily attributable to growth of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9 (Human Papillomavirus 9-valent Vaccine, Recombinant), as well as higher sales of hospital acute care products, including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (sugammadex) Injection and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ceftolozane and tazobactam). Higher revenue related to third-party manufacturing arrangements also contributed to revenue growth in the third quarter of 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide sales rose 29% to $45.5 billion in the first nine months of 2022. Revenue growth was attributable in part to higher sales in the virology franchise driven by </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Also contributing to revenue growth in the first nine months of 2022 were higher sales in the oncology franchise largely driven by strong growth of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and increased alliance revenue from Lenvima (lenvatinib), Reblozyl and Lynparza, as well as higher sales in the vaccines franchise, primarily attributable to growth of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9. Higher sales of hospital acute care products, including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as well as higher revenue related to third-party manufacturing arrangements also drove revenue growth in the first nine months of 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed above, COVID-19-related disruptions had some negative effects on sales in the third quarter and first nine months of 2022, but to a lesser extent than in the same periods of 2021 which benefited year-over-year sales growth in both periods.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue growth in the third quarter and first nine months of 2022 was partially offset by lower combined sales of diabetes products </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (sitagliptin) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (sitagliptin and metformin HCl), lower sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pneumovax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 23 (pneumococcal vaccine polyvalent) and lower sales of virology products </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Isentress/Isentress HD </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(raltegravir). Lower revenue from the receipt of upfront and milestone payments for out-licensing arrangements also partially offset sales growth in the third quarter and first nine months of 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note&#160;16 to the condensed consolidated financial statements for details on sales of the Company&#8217;s products. A discussion of performance for select products in the franchises follows.</span></div><div id="i6b4e4280ad2344a5bc7fdcaa77e417f0_91"></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 35 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pharmaceutical Segment</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Oncology</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.955%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding <br/>Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding <br/>Foreign<br/>Exchange</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Keytruda</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,426&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,534&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,487&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,609&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance Revenue - Lynparza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lenvima</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance Revenue </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">- </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reblozyl</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">  Alliance revenue represents Merck&#8217;s share of profits, which are product sales net of cost of sales and commercialization costs (see Note&#160;4 to the condensed consolidated financial statements).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an anti-PD-1 (programmed death receptor-1) therapy that has been approved as monotherapy for the treatment of certain patients with cervical cancer, classical Hodgkin lymphoma, cutaneous squamous cell carcinoma, endometrial carcinoma, esophageal or gastroesophageal junction (GEJ) carcinoma, head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma (HCC), NSCLC, melanoma, Merkel cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancer (solid tumors) including MSI-H/dMMR colorectal cancer, primary mediastinal large B-cell lymphoma, tumor mutational burden-high (TMB-H) cancer (solid tumors), and urothelial carcinoma including non-muscle invasive bladder cancer. Additionally, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is approved as monotherapy for the adjuvant treatment of certain patients with renal cell carcinoma (RCC) or stage IIB, IIC or III melanoma. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is also approved for certain patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. In addition, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is approved for the treatment of certain patients in combination with chemotherapy for metastatic squamous and nonsquamous NSCLC, in combination with chemotherapy, with or without bevacizumab for cervical cancer, in combination with chemotherapy for esophageal cancer, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for human epidermal growth factor 2 (HER-2)-positive gastric or GEJ adenocarcinoma, in combination with chemotherapy for HNSCC, in combination with chemotherapy for metastatic TNBC, in combination with axitinib for advanced RCC, and in combination with Lenvima for both endometrial carcinoma and RCC. The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> clinical development program includes studies across a broad range of cancer types. See &#8220;Research and Development Update&#8221; below. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> grew 20% and 23% in the third quarter and first nine months of 2022, respectively. Sales growth was primarily driven by higher demand as the Company continues to launch </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with multiple new indications globally. Sales in the U.S. continue to build across the multiple approved metastatic indications, in particular for the treatment of certain types of RCC, HNSCC, and MSI-H cancers. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales growth in the U.S. also benefited from increased uptake across recent launches in earlier-stage indications including in high-risk, early stage TNBC, as well as certain types of RCC and melanoma. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales growth in international markets reflects continued uptake predominately for the NSCLC, HNSCC and RCC indications, particularly in Europe. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> received the following regulatory approvals thus far in 2022.</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Approval</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2022</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">European Commission (EC) approval as monotherapy for the adjuvant treatment of adults with RCC at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions, based on the KEYNOTE-564 trial.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2022</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Japan Ministry of Health, Labour and Welfare (MHLW) approval of the combination of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> plus Lenvima for radically unresectable or metastatic RCC, based on the CLEAR (Study 307)/KEYNOTE-581 trial.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2022</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Japan Pharmaceuticals and Medical Devices Agency approval for the treatment of adult patients with advanced or recurrent TMB-H solid tumors that have progressed after chemotherapy (limited to use when difficult to treat with standard of care) based on the KEYNOTE-158 trial.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">U.S. Food and Drug Administration (FDA) approval as a single agent for the treatment of patients with advanced endometrial carcinoma that is MSI-H or dMMR who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation, based on the KEYNOTE-158 trial (Cohorts D &amp; K). </span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2022</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">EC approval in combination with chemotherapy, with or without bevacizumab, for the treatment of persistent, recurrent or metastatic cervical cancer in certain adults whose tumors express PD-L1, based on the KEYNOTE-826 trial.</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2022</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">EC approval as monotherapy for the treatment of certain adult patients with unresectable or metastatic MSI-H/dMMR colorectal, gastric, small intestine or biliary cancer, as well as advanced or recurrent MSI-H/dMMR endometrial cancer, based on the KEYNOTE-164 and KEYNOTE-158 trials.</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 36 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2022</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">EC approval in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery for adults with locally advanced or early-stage TNBC at high risk of recurrence, based on the KEYNOTE-522 trial.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2022</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">EC approval as monotherapy for the adjuvant treatment of adults and adolescents aged 12 years and older with stage IIB or IIC melanoma and who have undergone complete resection, based on the KEYNOTE-716 trial. Additionally, EC approval expanding the indications in advanced (unresectable or metastatic) melanoma and stage III melanoma with lymph node involvement (as adjuvant treatment following complete resection) to include adolescent patients aged 12 years and older.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 2022</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Japan MHLW approval in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery for patients with hormone receptor-negative and HER2-negative breast cancer at high risk of recurrence, based on the KEYNOTE-522 trial.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 2022</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Japan MHLW approval as monotherapy for the adjuvant treatment of certain patients with RCC at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions, based on the KEYNOTE-564 trial.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 2022</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Japan MHLW approval in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with advanced or recurrent cervical cancer with no prior chemotherapy who are not amenable to curative treatment, based on the KEYNOTE-826 trial.</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 2022</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Japan MHLW approval as monotherapy for the adjuvant treatment of patients with stage IIB or IIC melanoma after complete resection, based on the KEYNOTE-716 trial.</span></td></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lynparza is an oral poly (ADP-ribose) polymerase (PARP) inhibitor being developed as part of a collaboration with AstraZeneca PLC (AstraZeneca) (see Note&#160;4 to the condensed consolidated financial statements). Lynparza is approved for the treatment of certain types of ovarian, breast, pancreatic and prostate cancers. Alliance revenue related to Lynparza increased 16% and 14% in the third quarter and first nine months of 2022, respectively, largely driven by higher demand globally across the multiple approved indications, particularly in the U.S. largely attributable to uptake in the earlier-stage breast cancer indication following recent approval by the FDA. In March 2022, Lynparza was approved by the FDA for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BRCA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-mutated, HER2-negative high-risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy, followed by approvals in the EU and Japan in August 2022, based on the OlympiA trial. In September 2022, Lynparza was approved in China as first-line maintenance treatment for adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency-positive status. This approval was based on the PAOLA-1 trial.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lenvima is an oral receptor tyrosine kinase inhibitor being developed as part of a collaboration with Eisai Co., Ltd. (Eisai) (see Note&#160;4 to the condensed consolidated financial statements). Lenvima is approved for the treatment of certain types of thyroid cancer, RCC, HCC, in combination with everolimus for certain patients with RCC, and in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for both endometrial carcinoma and RCC. Alliance revenue related to Lenvima grew 7% and 33% in the third quarter and first nine months of 2022, respectively, reflecting uptake in the advanced RCC and advanced endometrial carcinoma indications, particularly in the U.S. Growth in the third quarter was partially offset by the timing of shipments in China.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reblozyl is a first-in-class erythroid maturation recombinant fusion protein obtained as part of Merck&#8217;s November 2021 acquisition of Acceleron Pharma Inc. that is being developed and commercialized through a global collaboration with Bristol Myers Squibb (see Note&#160;4 to the condensed consolidated financial statements). Reblozyl is approved for the treatment of certain types of anemia. Merck recorded alliance revenue of $39 million (consisting of royalties) in the third quarter of 2022 related to this collaboration. Merck recorded alliance revenue of $124 million in the first nine months of 2022, which includes royalties of $104&#160;million, as well as the receipt of a regulatory approval milestone payment of $20&#160;million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vaccines</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.955%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding <br/>Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding <br/>Foreign<br/>Exchange</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,993&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,428&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,144&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">ProQuad</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">M-M-R </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">II</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Varivax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">RotaTeq</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">644&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Pneumovax 23</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 37 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Combined worldwide sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 9, vaccines to help prevent certain cancers and other diseases caused by certain types of human papillomavirus (HPV), grew 15% and 31% in the third quarter and first nine months of 2022, respectively, driven primarily by strong demand outside of the U.S., particularly in China, which also benefited from increased supply. Sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 9 in the U.S. increased in the third quarter and first nine months of 2022 due to public sector buying patterns. </span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">China&#8217;s National Medical Products Administration expanded the use of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 9 for use in girls and women ages 9 to 45. The vaccine was previously approved for use in girls and women ages 16 to 26. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ProQuad</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Measles, Mumps, Rubella and Varicella Virus Vaccine Live), a pediatric combination vaccine to help protect against measles, mumps, rubella and varicella, increased 8% and 7% in the third quarter and first nine months of 2022, respectively, primarily reflecting higher demand in Europe and higher pricing in the U.S.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">M&#8209;M&#8209;R&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">II (Measles, Mumps and Rubella Virus Vaccine Live), a vaccine to help protect against measles, mumps and rubella, grew 12% in the first nine months of 2022 primarily due to higher pricing and demand in the U.S., as well as higher tenders in Latin America.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Varivax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Varicella Virus Vaccine Live), a vaccine to help prevent chickenpox (varicella), grew 2% in the first nine months of 2022 primarily attributable to higher pricing in the U.S., partially offset by lower tenders in Latin America. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RotaTeq </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Rotavirus Vaccine, Live Oral, Pentavalent), a vaccine to help protect against rotavirus gastroenteritis in infants and children, grew 12% and 9% in the third quarter and first nine months of 2022, respectively, primarily due to public sector buying patterns and higher pricing in the U.S. Higher volumes in China also contributed to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RotaTeq</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales growth in the third quarter of 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pneumovax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 23, a vaccine to help prevent pneumococcal disease, declined 53% and 24% in the third quarter and first nine months of 2022, respectively, primarily reflecting lower demand in the U.S. as the market continues to shift toward newer adult pneumococcal conjugate vaccines following changes in the recommendations of the U.S. Centers for Disease Control and Prevention&#8217;s (CDC&#8217;s) Advisory Committee on Immunization Practices (ACIP) in 2021. The Company expects the decline in U.S. sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pneumovax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 23 will continue. Lower demand in Europe also contributed to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pneumovax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 23 sales declines in the third quarter and first nine months of 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the FDA approved an expanded indication for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vaxneuvance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Pneumococcal 15-valent Conjugate Vaccine) to include use in infants and children. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vaxneuvance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is now indicated for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F in individuals 6 weeks of age and older. The FDA&#8217;s approval was based on data from seven randomized, double-blind clinical studies assessing safety, tolerability and immunogenicity of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vaxneuvance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in infants and children. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vaxneuvance </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was previously approved by the FDA in 2021 for use in adults 18 years of age and older. Also in June 2022, the CDC&#8217;s ACIP unanimously voted to include </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vaxneuvance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a recommended option for vaccination in infants and children, including routine use in children under 2 years of age. These recommendations subsequently were adopted by the director of the CDC and the U.S. Department of Health and Human Services, and published in the CDC&#8217;s </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Morbidity and Mortality Weekly Report</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MMWR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). The ACIP also unanimously voted to include </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vaxneuvance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the Vaccines for Children program. In October 2022, the EC approved an expanded indication for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vaxneuvance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to include active immunization for the prevention of invasive disease, pneumonia and acute otitis media caused by </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Streptococcus pneumoniae (S. pneumoniae)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in infants, children and adolescents from 6 weeks to less than 18 years of age. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vaxneuvance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was previously approved for use in the EU for individuals 18 years of age and older. In September 2022, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vaxneuvance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was approved in Japan for use in adult patients. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vaxneuvance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> remains under review in Japan for use in pediatric patients.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hospital Acute Care</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.955%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding <br/>Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding <br/>Foreign<br/>Exchange</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bridion</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,244&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,096&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Zerbaxa</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">*Calculation not meaningful.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the reversal of two types of neuromuscular blocking agents used during surgery, grew 15% and 13% in the third quarter and first nine months of 2022, respectively, due to higher demand globally, particularly in the U.S., largely attributable to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;s growing share among neuromuscular blockade reversal agents and an increase in surgical procedures. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 38 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company temporarily suspended sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a combination antibacterial and beta-lactamase inhibitor for the treatment of certain bacterial infections, and subsequently issued a product recall, following the identification of product sterility issues. The phased resupply for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that was initiated in the fourth quarter of 2021 has been completed during 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cardiovascular</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.955%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding <br/>Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding <br/>Foreign<br/>Exchange</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance Revenue - Adempas/Verquvo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adempas</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Alliance revenue represents Merck&#8217;s share of profits from sales in Bayer&#8217;s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note&#160;4 to the condensed consolidated financial statements).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adempas (riociguat) and Verquvo (vericiguat) are part of a worldwide collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators (see Note&#160;4 to the condensed consolidated financial statements). Adempas is approved for the treatment of certain types of pulmonary arterial hypertension. Verquvo was approved in the U.S. in January 2021 to reduce the risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient intravenous diuretics in adults with symptomatic chronic heart failure and reduced ejection fraction. Verquvo was also approved in Japan in June 2021 and in the EU in July 2021. Alliance revenue from the collaboration declined 12% and grew 4% in the third quarter and first nine months of 2022, respectively. Revenue also includes sales of Adempas and Verquvo in Merck&#8217;s marketing territories. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Virology</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.955%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding <br/>Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding <br/>Foreign<br/>Exchange</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Lagevrio</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,859&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Isentress/Isentress HD</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an investigational oral antiviral COVID-19 medicine being developed in a collaboration with Ridgeback (see Note&#160;4 to the condensed consolidated financial statements). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has received multiple authorizations or approvals worldwide. Sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were $436 million in the third quarter of 2022 primarily consisting of sales in Australia, South Korea, Japan and the United Kingdom (UK). Merck&#8217;s initial supply commitment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the U.S. was fulfilled in the first quarter of 2022; therefore, there were no sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. in the second or third quarters of 2022. Sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were $4.9 billion in the first nine months of 2022 primarily consisting of sales in the U.S., the UK, Japan and Australia. Merck has entered into advance purchase and supply agreements for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in more than 40 markets. The Company expects full-year 2022 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales to be between $5.2 billion and $5.4 billion.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global combined sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Isentress/Isentress HD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an HIV integrase inhibitor for use in combination with other antiretroviral agents for the treatment of HIV-1 infection, declined 15% and 21% in the third quarter and first nine months of 2022, respectively, primarily due to lower global demand, reflecting in part competitive pressure in Europe and the U.S. The Company expects competitive pressure for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Isentress/Isentress HD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to continue.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diabetes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.955%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding <br/>Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding <br/>Foreign<br/>Exchange</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Januvia/Janumet</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,133&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,339&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,599&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,895&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide combined sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, medicines that help lower blood sugar levels in adults with type 2 diabetes, declined 15% and 8% in the third quarter and first nine months of 2022, respectively, primarily reflecting the loss of exclusivity in several markets in Europe and the Asia Pacific region, as well as lower demand in the U.S. The sales decline in the first nine months of 2022 was partially offset by higher demand in China, increased demand in Latin America reflecting in part higher government tenders, as well as the impact of a prior year unfavorable adjustment to rebate reserves in the U.S. The Company anticipates U.S. pricing pressure will unfavorably affect sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in future periods. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> lost patent exclusivity with respect to the sitagliptin compound patent in China in July 2022, although not with respect to the patent claiming the specific sitagliptin salt form, which expires in June 2024. In addition, the Company lost market </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 39 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exclusivity with respect to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the EU in September 2022, and additional exclusivity afforded </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that expires in April 2023 is being challenged. The Company anticipates sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in these markets will decline substantially in future periods following the loss of exclusivity. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will lose sitagliptin compound patent protection for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the U.S. in January 2023. However, in September 2022, the U.S. Court of Appeals for the Federal Circuit ruled in favor of Merck in a patent challenge related to the specific sitagliptin salt form that is the active ingredient in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, affirming the May 2021 decision in Merck&#8217;s favor by the U.S. Patent Office in an </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review. Also in September 2022, the U.S. District Court for the Northern District of West Virginia ruled in favor of the Company in an infringement suit related to the same sitagliptin salt patent, as well as a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> formulation patent, finding both Merck patents valid and infringed. The rulings from the U.S. Court of Appeals and the U.S District Court in West Virginia provide </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patent protection through May 2027; although Merck has settled with multiple generic companies, providing that these generic companies can bring their products to the market in May 2026 or earlier under certain circumstances. The decision from the U.S. District Court in West Virginia is under appeal to the U.S. Court of Appeals for the Federal Circuit. (See Note&#160;9 to the condensed consolidated financial statements.)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Combined sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in China, Europe and the U.S. represented 10%, 21% and 34%, respectively, of total combined </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales for the first nine months of 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to a request from a regulatory authority, Merck evaluated its sitagliptin-containing products for the presence of nitrosamines. Nitrosamines are organic compounds found at trace levels in water and food. Nitrosamines can also result from chemical reactions and can form in drugs either due to the drug&#8217;s manufacturing process, chemical structure, or the conditions in which the drugs are stored or packaged. The Company detected a nitrosamine identified as Nitroso-STG-19 (NTTP) in some batches of its sitagliptin-containing medicines. The Company has engaged with major health authorities around the world and has implemented additional quality controls to ensure its portfolio of sitagliptin-containing products meet health authorities&#8217; interim acceptable NTTP limits for continuing distribution of product to the market. The Company does not anticipate any significant impact on supply of these medicines. </span></div><div id="i6b4e4280ad2344a5bc7fdcaa77e417f0_94"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Animal Health Segment</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.955%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding <br/>Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding <br/>Foreign<br/>Exchange</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Livestock</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,486&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,503&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Companion Animal</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,834&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,804&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of livestock products declined 4% and 1% in the third quarter and first nine months of 2022, respectively. Excluding the unfavorable effect of foreign exchange in both periods, livestock sales performance primarily reflects higher pricing, as well as increased demand for poultry and ruminant products. Sales of companion animal products declined 2% in the third quarter of 2022 and grew 2% in first nine months of 2022. Excluding the unfavorable effect of foreign exchange in both periods, sales performance primarily reflects higher pricing and demand in the companion animal portfolio, led by the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bravecto</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (fluralaner) line of products, partially offset by lower sales of vaccines due to supply constraints. Sales of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bravecto</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> line of products represented approximately 20% of animal health sales in the first nine months of 2022.</span></div><div id="i6b4e4280ad2344a5bc7fdcaa77e417f0_97"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Costs, Expenses and Other</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.951%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,934&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,450&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,530&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,752&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,773&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(450)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,007)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,376&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,888&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,522&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,213&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">*Calculation not meaningful.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Sales</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales increased 14% and 39% in the third quarter and first nine months of 2022, respectively. Cost of sales includes $234 million and $2.6 billion in the third quarter and first nine months of 2022, respectively, related to the collaboration with Ridgeback for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(see Note&#160;4 to the condensed consolidated financial statements). Cost of sales also </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 40 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">includes the amortization of intangible assets recorded in connection with acquisitions, collaborations and licensing arrangements, which totaled $445 million and $346 million in the third quarter of 2022 and 2021, respectively, and $1.6 billion and $1.2 billion in the first nine months of 2022 and 2021, respectively. Amortization expense in the first nine months of 2022 and 2021 includes $250&#160;million and $153&#160;million, respectively, of cumulative catch-up amortization related to Merck&#8217;s collaborations with AstraZeneca and Bayer, respectively, (see Note&#160;4 to the condensed consolidated financial statements). Additionally, costs in the first nine months of 2021 include charges of $225 million related to the discontinuation of COVID-19 development programs. Also included in cost of sales are expenses associated with restructuring activities which amounted to $54 million and $48 million in the third quarter of 2022 and 2021, respectively, and $167 million and $113 million in the first nine months of 2022 and 2021, respectively, including accelerated depreciation and asset write-offs related to the planned sale or closure of manufacturing facilities. Separation costs associated with manufacturing-related headcount reductions have been incurred and are reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as discussed below.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin was 73.7% in the third quarter of 2022 compared with 73.8% in the third quarter of 2021. Gross margin was 70.2% in the first nine months of 2022 compared with 72.3% in the first nine months of 2021. The gross margin declines primarily reflect the impacts of higher revenue from third-party manufacturing arrangements and sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, both of which have lower gross margins, as well as higher amortization of intangible assets (noted above). The gross margin declines were partially offset by the favorable effects of product mix and foreign exchange. The gross margin decline in the first nine months of 2022 was also partially offset by charges in 2021 related to the discontinuation of COVID-19 development programs. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative (SG&amp;A) expenses increased 8% in both the third quarter and first nine months of 2022 primarily due to higher administrative costs, including compensation and benefits, as well as higher promotional spending and restructuring costs, partially offset by the favorable effect of foreign exchange. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development (R&amp;D) expenses increased to $4.4 billion and $9.8 billion in the third quarter and first nine months of 2022, respectively, from $2.4 billion and $9.2 billion in the third quarter and first nine months of 2021, respectively. The increase in both periods was primarily due to $887 million of intangible asset impairment charges related to ArQule, Inc. (see Note&#160;8 to the condensed consolidated financial statements), higher charges related to collaborations and licensing arrangements, increased clinical development spending, increased investments in technology in support of the digital enablement of Merck&#8217;s research operations, as well as higher compensation and benefit costs, partially offset by the favorable effect of foreign exchange. In addition, the increase in R&amp;D expenses in the first nine months of 2022 was partially offset by a $1.7 billion charge in the prior year period related to the acquisition of Pandion Therapeutics, Inc. (Pandion).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses are comprised of the costs directly incurred by Merck Research Laboratories (MRL), the Company&#8217;s research and development division that focuses on human health-related activities, which were $2.0 billion and $1.8 billion for the third quarter of 2022 and 2021, respectively, and were $5.6 billion and $5.3 billion for the first nine months of 2022 and 2021, respectively. Also included in R&amp;D expenses are Animal Health research costs, licensing costs and costs incurred by other divisions in support of R&amp;D activities, including depreciation, production and general and administrative, which in the aggregate were approximately $1.5 billion and $710 million for the third quarter of 2022 and 2021, respectively, and $3.2 billion and $2.1 billion for the first nine months of 2022 and 2021, respectively. The increase in these expenses in the third quarter and first nine months of 2022 compared with the same periods of 2021 largely reflects $690 million of upfront and option payments in the aggregate for collaborations and licensing agreements with Orion, Moderna and Orna. Additionally, R&amp;D expenses in the first nine months of 2022 include $887 million of intangible assets impairment charges and in the first nine months of 2021 include a $1.7 billion charge for the acquisition of Pandion as noted above. See Note&#160;3 for additional information related to business development activity in the current and prior year.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Costs</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, Merck&#160;approved a global restructuring program (Restructuring Program) as part of a worldwide initiative focused on further optimizing the Company&#8217;s manufacturing and supply network, as well as reducing its global real estate footprint.&#160;This program is a continuation of the Company&#8217;s plant rationalization and builds on prior restructuring programs. The actions currently contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $3.5 billion. Merck expects to record charges of approximately $600 million for the full year of 2022 related to the Restructuring Program. The Company anticipates the actions under the Restructuring Program will result in annual net cost savings of approximately $900 million by the end of 2023. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 41 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring costs, primarily representing separation and other related costs associated with these restructuring activities, were $94 million and $107 million for the third quarter of 2022 and 2021, respectively, and $288 million and $487 million for the first nine months of 2022 and 2021, respectively. Separation costs incurred were associated with actual headcount reductions, as well as estimated expenses under existing severance programs for headcount reductions that were probable and could be reasonably estimated. Also included in restructuring costs are asset abandonment, facility shut-down and other related costs, as well as employee-related costs such as curtailment, settlement and termination charges associated with pension and other postretirement benefit plans and share-based compensation plan costs. For segment reporting, restructuring costs are unallocated expenses. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional costs associated with the Company&#8217;s restructuring activities are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> costs. The Company recorded aggregate pretax costs of $175 million and $168 million in the third quarter of 2022 and 2021, respectively, and $559 million and $630 million for the first nine months of 2022 and 2021, respectively, related to restructuring program activities (see Note&#160;5 to the condensed consolidated financial statements). </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (Income) Expense, Net</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (income) expense, net, was $429 million of expense in the third quarter of 2022 compared with $450 million of income in the third quarter of 2021. Other (income) expense, net, was $1.6 billion of expense for the first nine months of 2022 compared with $1.0 billion of income for the first nine months of 2021. The change in both periods is primarily due to net unrealized losses from investments in equity securities recorded in the third quarter and first nine months of 2022 compared with net realized and unrealized gains from investments in equity securities recorded in the third quarter and first nine months of 2021. The unfavorability in both periods was partially offset by lower pension costs. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For details on the components of Other (income) expense, net, see Note&#160;12 to the condensed consolidated financial statements. </span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.700%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment Profits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical segment profits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,590&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,606&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,263&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,450&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Animal Health segment profits</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,629&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,522)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,845)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,004)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,109)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Continuing Operations Before Taxes</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,583&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,266&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,931&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,970&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as SG&amp;A expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as SG&amp;A and R&amp;D expenses directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, R&amp;D expenses incurred by MRL, or general and administrative expenses, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. Also excluded from the determination of segment profits are costs related to restructuring activities and acquisition and divestiture-related costs, including the amortization of intangible assets and amortization of purchase accounting adjustments, intangible asset impairment charges, and expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration. Additionally, segment profits do not reflect other expenses from corporate and manufacturing cost centers and other miscellaneous income or expense. These unallocated items are reflected in &#8220;Other&#8221; in the above table. Also included in &#8220;Other&#8221; are miscellaneous corporate profits (losses), as well as operating profits (losses) related to third-party manufacturing arrangements. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical segment profits increased 11% and 26% in the third quarter and first nine months of 2022, respectively, reflecting higher sales, partially offset by higher administrative and promotional costs, as well as the unfavorable effect of foreign exchange. Animal Health segment profits grew 2% in the third quarter of 2022 reflecting favorable product mix, partially offset by the unfavorable effect of foreign exchange. Animal Health segment profits grew 3% in the first nine months of 2022 reflecting higher sales, partially offset by higher selling and administrative costs and the unfavorable effect of foreign exchange.</span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 42 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Taxes on Income</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective income tax rates from continuing operations were 9.2% and 13.2% for the third quarter of 2022 and 2021, respectively, and 11.0% and 14.4% for the first nine months of 2022 and 2021, respectively. The effective income tax rates from continuing operations reflect the beneficial impact of foreign earnings. The effective income tax rates from continuing operations in the third quarter and first nine months of 2022 also include the favorable impact of net unrealized losses from investments in equity securities and intangible asset impairment charges, which were taxed at the U.S. tax rate. The effective income tax rate from continuing operations in the first nine months of 2021 reflects the unfavorable effect of a charge for the acquisition of Pandion for which no tax benefit was recognized, as well as a net tax benefit of $207&#160;million related to the settlement of certain federal income tax matters as discussed below. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2021, the Internal Revenue Service (IRS) concluded its examinations of Merck&#8217;s 2015-2016 U.S. federal income tax returns. As a result, the Company was required to make a payment of $190&#160;million (of which $172&#160;million related to continuing operations and $18&#160;million related to discontinued operations). The Company&#8217;s reserves for unrecognized tax benefits for the years under examination exceeded the adjustments relating to this examination period and therefore the Company recorded a $236&#160;million net tax benefit in the first nine months of 2021 (of which $207&#160;million related to continuing operations and $29 million related to discontinued operations). This net benefit reflects reductions in reserves for unrecognized tax benefits and other related liabilities for tax positions relating to the years that were under examination.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP Income and Non-GAAP EPS from Continuing Operations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-GAAP income and non-GAAP&#160;EPS are alternative views of the Company&#8217;s performance that Merck is providing because management believes this information enhances investors&#8217; understanding of the Company&#8217;s results since management uses non-GAAP measures to assess performance. Non-GAAP income and non-GAAP EPS exclude certain items because of the nature of these items and the impact that they have on the analysis of underlying business performance and trends. The excluded items (which should not be considered non-recurring) consist of acquisition and divestiture-related costs, restructuring costs, income and losses from investments in equity securities, and certain other items. These excluded items are significant components in understanding and assessing financial performance. Non-GAAP income and non-GAAP&#160;EPS are important internal measures for the Company. Senior management receives a monthly analysis of operating results that includes a non-GAAP&#160;EPS metric. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the Company along with other metrics. In addition, senior management&#8217;s annual compensation is derived in part using a non-GAAP pretax income metric. Since non-GAAP income and non-GAAP&#160;EPS are not measures determined in accordance with GAAP, they have no standardized meaning prescribed by GAAP and, therefore, may not be comparable to the calculation of similar measures of other companies. The information on non-GAAP income and non-GAAP&#160;EPS should be considered in addition to, but not as a substitute for or superior to, net income and EPS prepared in accordance with generally accepted accounting principles in the U.S. (GAAP). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, the Company changed the treatment of certain items for purposes of its non-GAAP reporting. Historically, Merck&#8217;s non-GAAP results excluded expenses for upfront and milestone payments related to collaborations and licensing agreements, as well as charges related to pre-approval assets obtained in transactions accounted for as asset acquisitions, to the extent the charges were considered by the Company to be significant to the results of a particular period (as well as any related adjustments recorded in a subsequent period). Beginning in 2022, Merck&#8217;s non-GAAP results no longer exclude charges related to these items. Prior periods have been recast to conform to the current presentation.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 43 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation between GAAP financial measures and non-GAAP financial measures (from continuing operations) is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.361%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations before taxes as reported under GAAP</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,583&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,266&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,931&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) for excluded items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and divestiture-related costs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,344&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss (income) from investments in equity securities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(684)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,268&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,503)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other items:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges for the discontinuation of COVID-19 development programs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP income from continuing operations before taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,452&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,195&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,270&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,767&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes on income from continuing operations as reported under GAAP</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,423&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,436&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated tax benefit (provision) on excluded items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net tax benefit from the settlement of certain federal income tax matters</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP taxes on income from continuing operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,388&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,727&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP net income from continuing operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,708&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,529&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,882&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,040&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests as reported under GAAP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP net income from continuing operations attributable to Merck&#160;&amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,703&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,525&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,876&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,031&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EPS assuming dilution from continuing operations as reported under GAAP</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.28&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.80&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.53&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.36&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EPS difference</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.02)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP EPS assuming dilution from continuing operations</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.85&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.78&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.86&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.56&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The estimated tax impact on the excluded items is determined by applying the statutory rate of the originating territory of the non-GAAP adjustments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition and Divestiture-Related Costs</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-GAAP income and non-GAAP&#160;EPS exclude the impact of certain amounts recorded in connection with acquisitions and divestitures of businesses. These amounts include the amortization of intangible assets and amortization of purchase accounting adjustments to inventories, as well as intangible asset impairment charges, and expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration. Also excluded are integration, transaction, and certain other costs associated with acquisitions and divestitures of businesses. Non-GAAP income and non-GAAP EPS also exclude amortization of intangible assets related to collaborations and licensing arrangements.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Costs</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-GAAP income and non-GAAP&#160;EPS exclude costs related to restructuring actions (see Note&#160;5 to the condensed consolidated financial statements). These amounts include employee separation costs and accelerated depreciation associated with facilities to be closed or divested. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. Restructuring costs also include asset abandonment, facility shut-down and other related costs, as well as employee-related costs such as curtailment, settlement and termination charges associated with pension and other postretirement benefit plans and share-based compensation costs. </span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income and Losses from Investments in Equity Securities</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-GAAP income and non-GAAP&#160;EPS exclude realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds.</span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Certain Other Items</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-GAAP income and non-GAAP EPS exclude certain other items. These items are adjusted for after evaluating them on an individual basis, considering their quantitative and qualitative aspects. Typically, these consist of items that are unusual in nature, significant to the results of a particular period or not indicative of future operating results. Excluded from non-GAAP income and non-GAAP EPS in 2021 are charges related to the discontinuation of COVID-19 development programs (see Note&#160;3 to the condensed consolidated financial statements) and a net tax benefit related to the settlement of certain federal income tax matters (see Note&#160;13 to the condensed consolidated financial statements). </span></div><div id="i6b4e4280ad2344a5bc7fdcaa77e417f0_100"></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 44 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Update</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently has several candidates under regulatory review in the U.S. and internationally.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MK-4482, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, is an investigational oral antiviral medicine for the treatment of mild to moderate COVID-19 in adults who are at risk for progressing to severe disease. Merck is developing </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in collaboration with Ridgeback. The FDA granted Emergency Use Authorization for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in December 2021; last reissued in October 2022, to authorize </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of mild to moderate COVID-19 in adults with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options approved or authorized by the FDA are not accessible or clinically appropriate. The authorization is based on the Phase 3 MOVe-OUT trial. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is not approved for any use in the U.S. and is authorized only for the duration of the declaration that circumstances exist justifying the authorization of its emergency use under the Food, Drug and Cosmetic Act, unless the authorization is terminated or revoked sooner. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has also received Conditional Marketing Authorization in the UK and Special Approval for Emergency in Japan. In November 2021, the European Medicines Agency (EMA) issued a positive scientific opinion for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is intended to support national decision-making on the possible use of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> prior to marketing authorization. In October 2021, the EMA initiated a rolling review for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of COVID-19 in adults. Merck plans to work with the Committee for Medicinal Products for Human Use of the EMA to complete the rolling review process to facilitate initiating the formal review of the Marketing Authorization Application. Applications to other regulatory bodies are underway. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is also being evaluated for post-exposure prophylaxis in the Phase 3 MOVe-AHEAD trial, which is evaluating the efficacy and safety of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the prevention of COVID-19 in adults who reside with a person with COVID-19. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, Merck provided an update on new clinical and non-clinical studies of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. A preliminary analysis of the University of Oxford&#8217;s PANORAMIC study, conducted in the UK in highly-vaccinated adults mostly over 65 years of age, showed no evidence of a difference between </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> added to usual care compared to usual care alone for the reduction of hospitalizations and deaths through Day 28 (primary endpoint was not met); the incidence of hospitalizations and death through Day 28 was very low overall. The main secondary endpoint (time to first self-reported recovery) in the PANORAMIC study was 6 days shorter with the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> group compared to the usual care group; in addition, the use of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> also was associated with earlier recovery across a wide range of other symptom measures, as compared to the usual care group. Additionally, an analysis of real-world data from a separate study conducted by investigators in Israel (known as the Clalit study) showed that in a cohort of non-hospitalized, high-risk patients, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reduced hospitalizations and mortality due to COVID-19 in patients 65 years and above; no evidence of benefit was found in younger adults ages 40 to 64 years. Also, Merck reported results from a separate, non-clinical 6-month carcinogenicity study in transgenic mice, which demonstrated that </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was not carcinogenic at any dose tested.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MK-7264, gefapixant, is an investigational, orally administered, selective P2X3 receptor antagonist, for the treatment of refractory chronic cough or unexplained chronic cough in adults under review by the FDA and EMA. The marketing applications for gefapixant are based on results from the COUGH-1 and COUGH-2 clinical trials. In January 2022, the FDA issued a Complete Response Letter (CRL) regarding Merck&#8217;s New Drug Application (NDA) for gefapixant. In the CRL, the FDA requested additional information related to the cough counting system that was used to assess efficacy. The CRL was not related to the safety of gefapixant. The Company is performing additional analyses and anticipates submitting this information to the FDA in the first half of 2023 in response to the CRL. The review period in the EU has been extended pending the receipt of additional information from the Company. The Company plans to submit the information to the EMA in the first half of 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MK-3475, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, is an anti-PD-1 therapy approved for the treatment of many cancers that is in clinical development for expanded indications. These approvals were the result of a broad clinical development program that currently consists of more than 1,650 clinical trials, including more than 1,200 trials that combine </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with other cancer treatments. These studies encompass more than 30 cancer types including: biliary, estrogen receptor positive breast cancer, cervical, colorectal, cutaneous squamous cell, endometrial, esophageal, gastric, glioblastoma, head and neck, hepatocellular, Hodgkin lymphoma, non-Hodgkin lymphoma, non-small-cell lung, small-cell lung, melanoma, mesothelioma, ovarian, prostate, renal, triple-negative breast, and urothelial, many of which are currently in Phase 3 clinical development. Further trials are being planned for other cancers.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is under review by the FDA for the treatment of patients with previously treated advanced HCC. This submission is based on data from the Phase 3 KEYNOTE-394 trial along with supportive data from the KEYNOTE-240 and KEYNOTE-224 trials. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is approved for this indication in the U.S. under the FDA&#8217;s accelerated approval process. This submission is to convert the accelerated approval to full (regular) approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is also under review by the FDA for the adjuvant treatment of patients with stage IB (&#8805;4 centimeters), II or IIIA NSCLC following complete surgical resection. The supplemental Biologics License Application is based on data from the pivotal Phase 3 KEYNOTE-091 trial, also known as EORTC-1416-LCG/ETOP-8-15 &#8211; PEARLS. The FDA set a Prescription </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 45 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug User Fee Act (PDUFA) date of January 29, 2023, however, further data may be provided during the review process that may delay this date. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is also under review for this indication in the EU.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, Merck announced that the Phase 3 KEYNOTE-412 trial evaluating </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with concurrent chemoradiation therapy (CRT) followed by </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as maintenance therapy (the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> regimen) did not meet its primary endpoint of event-free survival for the treatment of patients with unresected locally advanced HNSCC. At the final analysis of the study, there was an improvement in event-free survival for patients who received the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> regimen compared to placebo plus CRT; however, these results did not meet statistical significance per the pre-specified statistical plan. Results were presented at the 2022 European Society for Medical Oncology (ESMO) congress.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, Merck announced that the Phase 3 KEYNOTE-921 trial evaluating </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in combination with chemotherapy (docetaxel) compared to chemotherapy alone did not meet its dual primary endpoints of overall survival and radiographic progression-free survival for the treatment of patients with metastatic castration-resistant prostate cancer. In the study, there were modest trends toward an improvement in both overall survival and radiographic progression-free survival for patients who received </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> plus chemotherapy compared with chemotherapy alone; however, these results did not meet statistical significance per the pre-specified statistical plan. Results will be presented at an upcoming medical meeting.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MK-7339, Lynparza, is an oral PARP inhibitor currently approved for certain types of ovarian, breast, pancreatic and prostate cancers being co-developed for multiple cancer types as part of a collaboration with AstraZeneca. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the FDA granted priority review for a supplemental NDA for Lynparza in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer. The supplemental NDA was based on results from the Phase 3 PROpel trial, which were presented at the 2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium and later published in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NEJM Evidence</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The FDA set a PDUFA date in the fourth quarter of 2022. Lynparza is also under review in the EU and Japan for the treatment of certain patients with metastatic castration-resistant prostate cancer based on the PROpel clinical trial. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, Merck announced that it would stop the Phase 3 KEYLYNK-010 trial investigating </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in combination with Lynparza for the treatment of patients with metastatic castration-resistant prostate cancer who progressed after treatment with chemotherapy and either abiraterone acetate or enzalutamide. Merck has discontinued the study following the recommendation of an independent Data Monitoring Committee (DMC) after the DMC reviewed data from a planned interim analysis. At the interim analysis, the combination of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Lynparza did not demonstrate a benefit in overall survival, one of the study&#8217;s dual primary endpoints, compared to the control arm of either abiraterone acetate or enzalutamide. The trial&#8217;s other dual primary endpoint, radiographic progression free survival, was evaluated at an earlier interim analysis and did not demonstrate improvement compared to the control arm. Results from the study were presented at the 2022 ESMO congress.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, Merck announced it will stop the Phase 3 LYNK-003 trial investigating Lynparza with or without bevacizumab for the treatment of patients with unresectable or metastatic colorectal cancer who have not progressed following first-line induction. This action follows the recommendation of an independent DMC, after the DMC reviewed the data from a planned interim analysis. At the pre-specified interim analysis for progression-free survival, the efficacy of Lynparza as a monotherapy and in combination with bevacizumab relative to control met the criteria for futility by the DMC and accordingly, both experimental arms were discontinued. Data from this study will be shared in a future scientific forum.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MK-7902, Lenvima, is an oral receptor tyrosine kinase inhibitor being developed as part of a collaboration with Eisai. Merck and Eisai are studying the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> plus Lenvima combination through the LEAP (LEnvatinib And Pembrolizumab) clinical program.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In August 2022, Merck and Eisai announced that the Phase 3 LEAP-002 trial investigating </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> plus Lenvima versus Lenvima monotherapy did not meet its dual primary endpoints of overall survival and progression-free survival as a first-line treatment for patients with unresectable hepatocellular carcinoma (uHCC). There were trends toward improvement in overall survival and progression-free survival for patients who received</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> plus Lenvima versus Lenvima monotherapy; however, these results did not meet statistical significance per the pre-specified statistical plan. Results were presented at the 2022 ESMO congress.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, Merck and Eisai announced that the FDA issued a CRL regarding Merck&#8217;s and Eisai&#8217;s applications seeking accelerated approval of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> plus Lenvima for the first-line treatment of patients with uHCC based on data from the Phase 1b KEYNOTE-524/Study 116 trial. Given the results of the LEAP-002 trial noted above, Merck no longer intends to pursue the application.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, Merck announced positive top-line results from the pivotal Phase 3 STELLAR trial evaluating the safety and efficacy of sotatercept, an investigational activin receptor type IIA-Fc (ActRIIA-Fc) fusion protein being evaluated as an add-on to stable background therapy for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group 1). The trial met its primary efficacy outcome measure, demonstrating a statistically significant and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 46 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinically meaningful improvement in 6-minute walk distance (6MWD, which measures how far patients can walk in 6 minutes). Eight of nine secondary efficacy outcome measures achieved statistical significance, including the outcome measure of proportion of participants achieving multicomponent improvement (defined as improvement in 6MWD, improvement in N-terminal pro-B-type natriuretic peptide level, and either improvement in WHO Functional Class [FC] or maintenance of WHO FC II), and the outcome measure of time to death or the first occurrence of a clinical worsening event. The Cognitive/Emotional Impacts domain score of PAH-SYMPACT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was assessed as the ninth and final secondary outcome measure, did not achieve statistical significance. Results from the study will be presented at an upcoming scientific congress.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, Merck announced it will initiate a new Phase 3 clinical program with once-daily islatravir for the treatment of people with HIV-1 infection. These new Phase 3 studies will evaluate a once-daily oral combination of doravirine 100 mg and a lower dose of islatravir (DOR/ISL). One study will evaluate DOR/ISL in previously untreated adults with HIV-1 infection and two studies will evaluate DOR/ISL as a switch in antiretroviral therapy in adults with HIV-1 infection who are virologically suppressed. The investigational new drug application for the once-daily oral DOR/ISL treatment program remains under a partial clinical hold for any studies that would use doses higher than the dose to be studied in the new Phase 3 program. The Phase 2 clinical trial evaluating an investigational oral once-weekly combination treatment regimen of islatravir and Gilead Sciences&#8217; lenacapavir in adults with HIV-1 infection who are virologically suppressed will resume under an amended protocol with a lower dose of islatravir. The investigational new drug application under which the islatravir + lenacapavir once-weekly treatment regimen is being investigated remains under a partial clinical hold for any studies that would use weekly oral islatravir doses higher than the doses considered for the revised clinical program. Additionally, Merck announced it will discontinue the development of once-monthly oral islatravir for pre-exposure prophylaxis (PrEP).  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, Merck announced the presentation of positive results from a Phase 1/2 study evaluating the safety, tolerability and immunogenicity of V116, the Company&#8217;s investigational 21-valent pneumococcal conjugate vaccine (PCV), in pneumococcal vaccine-na&#239;ve adults 18-49 years of age (Phase 1) and 50 years of age and older (Phase 2). In both populations, V116 met the primary immunogenicity objectives and was well-tolerated with an overall safety profile generally comparable to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pneumovax </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23 across age groups. In April 2022, Merck announced that V116 received Breakthrough Therapy Designation from the FDA for the prevention of invasive pneumococcal disease and pneumococcal pneumonia caused by Streptococcus pneumoniae serotypes 3, 6A/C, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B/C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, 35B in adults 18 years of age and older. The Breakthrough Therapy Designation is an FDA program designed to expedite the development and review of products intended for serious or life-threatening conditions. To qualify for this designation, preliminary clinical evidence must indicate that the product may demonstrate substantial improvement over currently available options on at least one clinically significant endpoint. Enrollment in several Phase 3 trials evaluating V116 is ongoing. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, Merck and Royalty Pharma plc (Royalty Pharma) entered into a funding arrangement under which Royalty Pharma paid Merck $50&#160;million to co-fund Merck&#8217;s development costs for a Phase 2b trial of MK-8189, an investigational oral Phosphodiesterase 10A (PDE10A) inhibitor, which is being evaluated for the treatment of schizophrenia. Under the agreement, Royalty Pharma has no rights to MK-8189 and has no decision-making authority over the program. If Merck elects to advance MK-8189 into a Phase 3 study, Royalty Pharma has the option to provide additional funding of 50% of the development costs up to $375&#160;million for the Phase 3 trial. If such additional funding is provided, Royalty Pharma becomes eligible to receive future regulatory milestone payments contingent upon certain marketing approvals, as well as royalties. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The charts below reflect the Company&#8217;s research pipeline as of November 3, 2022. Candidates shown in Phase 3 include the date such candidate entered into Phase 3 development. Candidates shown in Phase 2 include the most advanced compound with a specific mechanism or, if listed compounds have the same mechanism, they are each currently intended for commercialization in a given therapeutic area. Small molecules and biologics are given MK-number designations and vaccine candidates are given V-number designations. Except as otherwise noted, candidates in Phase 1, additional indications in the same therapeutic area (other than with respect to cancer) and additional claims, line extensions or formulations for in-line products are not shown.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 47 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:28.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.144%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.490%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Phase 2</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Cancer</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-0482</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%"> </span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;Non-Small-Cell Lung</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-1026 (nemtabrutinib)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;Hematological Malignancies</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-1308 (quavonlimab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Non-Small-Cell Lung</span></div><div style="padding-left:13.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-1308A (quavonlimab+pembrolizumab)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Colorectal</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Hepatocellular </span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Melanoma</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Small-Cell Lung</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-2140 (zilovertamab vedotin)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Breast</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Gastric</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Hematological Malignancies</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Non-Small-Cell Lung</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Ovarian</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Pancreatic</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-2870</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(1)(3)</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Neoplasm Malignant</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-3475 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:110%">Keytruda</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Advanced Solid Tumors</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-4280 (favezelimab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%"> </span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;Non-Small-Cell Lung</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-4280A (favezelimab+pembrolizumab)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;Esophageal</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;Renal Cell</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;Small-Cell Lung</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-4830</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Colorectal</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;Esophageal</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;Melanoma</span></div><div style="padding-left:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Non-Small-Cell Lung</span></div><div style="padding-left:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Ovarian</span></div><div style="padding-left:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Renal Cell</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;Small-Cell Lung</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-5684</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Prostate</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-5890 (boserolimab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;Non-Small-Cell Lung</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;Small-Cell Lung</span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-indent:9pt"><span><br/></span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Cancer</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%">MK-6440 (ladiratuzumab vedotin)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.62pt;vertical-align:baseline">(1)(3)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Breast</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Esophageal</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Gastric</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Head and Neck</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Melanoma</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Non-Small-Cell Lung</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Prostate</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Small-Cell Lung</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%">MK-6482 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:115%">Welireg</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.62pt;vertical-align:baseline">(3)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Biliary</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Colorectal</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Endometrial</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Esophageal</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Hepatocellular</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Pancreatic</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Rare cancers</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Von Hippel-Lindau Disease-Associated Tumors (EU)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-7119 Tukysa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Advanced Solid Tumors</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Biliary</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Bladder</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Cervical</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Endometrial</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Gastric</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Non-Small-Cell Lung</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-7339 Lynparza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(1)(3)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Advanced Solid Tumors</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-7684 (vibostolimab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Melanoma </span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-7684A (vibostolimab+pembrolizumab)</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Biliary</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Breast</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Cervical</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Colorectal</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Endometrial</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Esophageal</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Head and Neck</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Hematological Malignancies</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Hepatocellular</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Prostate</span></div><div style="text-indent:9pt"><span><br/></span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Cancer</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-7902 Lenvima</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(1)(2)</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Biliary</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Glioblastoma</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Pancreatic</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Prostate</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Small-Cell Lung</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">V940</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Melanoma</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Chikungunya Virus Vaccine</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">V184</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Dengue Fever Virus Vaccine</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">V181</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">HIV-1 Infection</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-8591B (islatravir+MK-8507)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(4)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-8591D (islatravir+lenacapavir)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(1)(5)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Hypercholesterolemia</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-0616</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Nonalcoholic Steatohepatitis (NASH)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-3655</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-6024</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Overgrowth Syndrome</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-7075 (miransertib)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Pulmonary Arterial Hypertension</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-5475</span></div><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Pulmonary Hypertension Due To Left Heart Disease</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-7962 (sotatercept)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Schizophrenia</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-8189</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(6)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Thrombosis</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-2060</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Treatment Resistant Depression</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-1942</span></div><div style="text-indent:9pt"><span><br/></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 48 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.946%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.451%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Phase 3 (Phase 3 entry date)</span></td><td colspan="6" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Under Review</span></td></tr><tr style="height:201pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Antiviral COVID-19</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-4482 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:110%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%"> (U.S.) (May 2021)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(1)(7)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Cancer</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-1308A (quavonlimab+pembrolizumab)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Renal Cell (April 2021)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-3475 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:110%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%"> </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Biliary (September 2019)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Cutaneous Squamous Cell (August 2019) (EU)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Gastric (May 2015) (EU)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Hepatocellular (May 2016) (EU)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Mesothelioma (May 2018)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Ovarian (December 2018)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Prostate (May 2019)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Small-Cell Lung (May 2017)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-3475 (pembrolizumab subcutaneous) </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Non-Small-Cell Lung (August 2021)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-4280A (favezelimab+pembrolizumab)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Colorectal (November 2021)</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Hematological Malignancies (October 2022)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-6482 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:110%">Welireg</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(3)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Renal Cell (February 2020)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-7119 Tukysa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Breast (October 2019)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Colorectal (August 2022)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-7339 Lynparza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(1)(3)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Non-Small-Cell Lung (June 2019)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Small-Cell Lung (December 2020)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-7684A (vibostolimab+pembrolizumab)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Non-Small-Cell Lung (April 2021)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Small-Cell Lung (March 2022)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-7902 Lenvima</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(1)(2)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Colorectal (April 2021)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Esophageal (July 2021)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Gastric (December 2020)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Head and Neck (February 2020)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Melanoma (March 2019)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Non-Small-Cell Lung (March 2019)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">HIV-1 Infection</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-8591A (doravirine+islatravir) (February 2020)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(5)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Pneumococcal Vaccine Adult</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">V116 (July 2022)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Pulmonary Arterial Hypertension</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-7962 (sotatercept) (January 2021)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Respiratory Syncytial Virus</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-1654 (clesrovimab) (November 2021)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">New Molecular Entities/Vaccines</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Antiviral COVID-19</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-4482 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:110%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%"> (EU)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Cough</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-7264 (gefapixant) (U.S.)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(8)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%"> (EU)</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="padding-left:27pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:27pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:27pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:27pt;text-indent:-18pt"><span><br/></span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Certain Supplemental Filings</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Cancer</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-3475 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:110%">Keytruda</span></div><div style="padding-left:31.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#8226;    Second-Line Hepatocellular Cancer</span></div><div style="padding-left:31.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">(KEYNOTE-394) (U.S.) </span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#8226;    Adjuvent Non-Small-Cell Lung Cancer</span></div><div style="padding-left:31.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">(KEYNOTE-091) (U.S.) (EU)</span></div><div style="padding-left:27pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-7339 Lynparza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#8226;    First-Line Metastatic Prostate Cancer </span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">(PROpel) (U.S.) (EU) (JPN)</span></div><div style="padding-left:27pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></td></tr><tr style="height:201pt"><td colspan="6" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Footnotes:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Being developed in a collaboration.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">  Being developed in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">  Being developed as monotherapy and/or in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Keytruda.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">  On FDA clinical hold.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">  On FDA partial clinical hold.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">  Phase 2b development costs are being co-funded.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">  Available in the U.S. under Emergency Use Authorization.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(8)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">In response to the CRL received from the FDA for this application in January 2022, Merck is performing additional analyses and anticipates submitting this information to the FDA in the first half of 2023.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span><br/></span></div></td></tr></table></div><div id="i6b4e4280ad2344a5bc7fdcaa77e417f0_103"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,466&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,563&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,394&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt to total liabilities and equity</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by operating activities of continuing operations was $14.7 billion in the first nine months of 2022 compared with $8.0 billion in the first nine months of 2021 reflecting stronger operating performance, including the impact of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(see Note&#160;4 to the condensed consolidated financial statements). Cash provided by operating activities of continuing operations in the first nine months of 2022 was reduced by $1.8&#160;billion of milestone payments related to collaborations compared with $432 million of milestone and option payments related to collaborations in the first nine months of 2021. Cash provided by operating activities of continuing operations continues to be the Company&#8217;s primary source of funds to finance operating needs, with excess cash serving as the primary source of funds to finance capital expenditures, dividends paid to shareholders and treasury stock purchases. As a result of the mandatory change in R&amp;D capitalization rules that are effective for tax years beginning after December 31, 2021 (related to the Tax Cuts and Jobs Act of 2017), the Company has paid higher taxes in the U.S. in the first nine months of 2022 compared with the same prior year period.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in investing activities of continuing operations was $3.2 billion in the first nine months of 2022 compared with $4.4 billion in the first nine months of 2021. The lower use of cash in investing activities of continuing operations was primarily due to lower cash used for acquisitions and higher proceeds from the sale of securities and other investments, partially offset by higher purchases of securities and other investments. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 49 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in financing activities of continuing operations was $7.6 billion in the first nine months of 2022 compared with $2.1 billion in the first nine months of 2021. The increase in cash used in financing activities of continuing operations was primarily due to the cash distribution in 2021 received from Organon in connection with the spin-off (see Note&#160;2 to the condensed consolidated financial statements) coupled with higher payments on long-term debt and higher dividends paid to shareholders in the current period. The increase in cash used in financing activities was partially offset by net repayments of short-term borrowings and treasury stock purchases in the prior year period that did not occur in the current period.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital expenditures totaled $3.2 billion in both the first nine months of 2022 and the first nine months of 2021. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored $2.3 billion and $2.8 billion of accounts receivable at September&#160;30, 2022 and December&#160;31, 2021, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Condensed Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions. The net cash flows relating to these collections are reported as financing activities in the Condensed Consolidated Statement of Cash Flows. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividends paid to stockholders were $5.3 billion and $5.0 billion for the first nine months of 2022 and 2021, respectively.&#160;In May 2022, the Board of Directors declared a quarterly dividend of $0.69 per share on the Company&#8217;s stock for the third quarter that was paid in July 2022. In July 2022, the Board of Directors declared a quarterly dividend of $0.69 per share on the Company&#8217;s stock for the fourth quarter that was paid in October 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, the Company&#8217;s $1.25 billion, 2.35% notes matured in accordance with their terms and were repaid. In September 2022, the Company&#8217;s $1.0&#160;billion, 2.40% notes matured in accordance with their terms and were repaid. In January 2021, the Company&#8217;s $1.15 billion, 3.875% notes matured in accordance with their terms and were repaid. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, Merck&#8217;s Board of Directors authorized purchases of up to $10 billion of Merck&#8217;s common stock for its treasury. The treasury stock purchase authorization has no time limit and will be made over time in open-market transactions, block transactions on or off an exchange, or in privately negotiated transactions. The Company did not purchase any shares of its common stock during the first nine months of 2022. As of September&#160;30, 2022, the Company&#8217;s remaining share repurchase authorization was $5.0&#160;billion. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a $6.0 billion credit facility that matures in June 2026. The facility provides backup liquidity for the Company&#8217;s commercial paper borrowing facility and is to be used for general corporate purposes. The Company has not drawn funding from this facility.</span></div><div id="i6b4e4280ad2344a5bc7fdcaa77e417f0_106"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant accounting policies, which include management&#8217;s best estimates and judgments, are included in Note&#160;2 to the consolidated financial statements for the year ended December&#160;31, 2021 included in Merck&#8217;s Form 10&#8209;K filed on February&#160;25, 2022. See Note&#160;1 to the condensed consolidated financial statements for information on the adoption of new accounting standards during 2022. A discussion of accounting estimates considered critical because of the potential for a significant impact on the financial statements due to the inherent uncertainty in such estimates are disclosed in the Critical Accounting Estimates section of Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations included in Merck&#8217;s Form 10-K. There have been no significant changes in the Company&#8217;s critical accounting estimates since December&#160;31, 2021. </span></div><div id="i6b4e4280ad2344a5bc7fdcaa77e417f0_109"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of recently issued accounting standards, see Note&#160;1 to the condensed consolidated financial statements.</span></div><div id="i6b4e4280ad2344a5bc7fdcaa77e417f0_112"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Item&#160;3. Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in market risk exposures that affect the disclosures presented in &#8220;Item 7A. Quantitative and Qualitative Disclosures about Market Risk&#8221; in the Company&#8217;s 2021 Form 10-K filed on February 25, 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The economy of Turkey was recently determined to be hyperinflationary. Consequently, in accordance with U.S. GAAP, the Company&#8217;s monetary assets and liabilities that are subject to remeasurement as a result of the changes in the Turkish lira changed beginning in the second quarter of 2022. This change had an immaterial impact to Merck&#8217;s condensed consolidated financial statements. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 50 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span><br/></span></div><div id="i6b4e4280ad2344a5bc7fdcaa77e417f0_115"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Item&#160;4. Controls and Procedures</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management of the Company, with the participation of its Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures over financial reporting. Based on their evaluation, the Company&#8217;s Chief Executive Officer and Chief Financial Officer have concluded that as of September&#160;30, 2022, the Company&#8217;s disclosure controls and procedures are effective. For the third quarter of 2022, there were no changes in internal control over financial reporting that materially affected, or are reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting.</span></div><div id="i6b4e4280ad2344a5bc7fdcaa77e417f0_118"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">CAUTIONARY FACTORS THAT MAY AFFECT FUTURE RESULTS</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report and other written reports and oral statements made from time to time by the Company may contain so-called &#8220;forward-looking statements,&#8221; all of which are based on management&#8217;s current expectations and are subject to risks and uncertainties which may cause results to differ materially from those set forth in the statements. One can identify these forward-looking statements by their use of words such as &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;will,&#8221; &#8220;estimates,&#8221; &#8220;forecasts,&#8221; &#8220;projects&#8221; and other words of similar meaning, or negative variations of any of the foregoing. One can&#160;also identify them by the fact that they do not relate strictly to historical or current facts. These statements are likely to address the Company&#8217;s growth strategy, financial results, product approvals, product potential, development programs, environmental or other sustainability initiatives, and may include statements related to the expected impact of the COVID-19 pandemic. One must carefully consider any such statement and should understand that many factors could cause actual results to differ materially from the Company&#8217;s forward-looking statements. These factors include inaccurate assumptions and a broad variety of other risks and uncertainties, including some that are known and some that are not. No forward-looking statement can be guaranteed and actual future results may vary materially.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not assume the obligation to update any forward-looking statement. One should carefully evaluate such statements in light of factors, including risk factors, described in the Company&#8217;s filings with the Securities and Exchange Commission, especially on Forms 10-K, 10-Q and 8-K. In Item&#160;1A. &#8220;Risk Factors&#8221; of the Company&#8217;s Annual Report on Form 10&#8209;K for the year ended December&#160;31, 2021, filed on February&#160;25, 2022, in the Company&#8217;s Form 10-Q for the quarterly period ended March 31, 2022, filed on May 5, 2022, the Company&#8217;s Form 10-Q for the quarterly period ended June 30, 2022, filed on August 5, 2022, and in this Form 10-Q, the Company discusses in&#160;more detail various important risk factors that could cause actual results to differ from expected or historic results. The Company notes these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. One should understand that it is not possible to predict or identify all such factors. Consequently, the reader should not consider any such list&#160;to be a&#160;complete statement of all potential risks or uncertainties.</span></div><div id="i6b4e4280ad2344a5bc7fdcaa77e417f0_121"></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">PART II - Other Information</span></div><div id="i6b4e4280ad2344a5bc7fdcaa77e417f0_124"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Item&#160;1. Legal Proceedings</span></div><div style="margin-top:8pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information called for by this Item is incorporated herein by reference to Note&#160;9 included in Part I, Item&#160;1, Financial Statements (unaudited) &#8212; Notes to Condensed Consolidated Financial Statements.</span></div><div id="i6b4e4280ad2344a5bc7fdcaa77e417f0_127"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Item&#160;1A. Risk Factors</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of risks that affect the Company&#8217;s business, please refer to Part I, Item IA, &#8220;Risk Factors&#8221; in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021.&#160;There have been no material changes to the risk factors as previously disclosed in the Company&#8217;s Annual Report on Form 10-K, except as follows:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The ongoing war between Russia and Ukraine and related global disruptions could adversely affect the Company&#8217;s business, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ongoing war between Russia and Ukraine, and the financial and economic sanctions imposed by the U.S., the European Union and other countries in response, are having pervasive direct and indirect effects on the global economy, and may adversely affect the Company&#8217;s business, results of operations and financial condition. The Company is working cross-functionally across the globe to monitor and mitigate interruptions to business continuity resulting from the war, including its impact on Merck&#8217;s supply chain, operations and clinical trials. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For humanitarian reasons, the Company is continuing to supply essential medicines and vaccines in Russia while working to maintain compliance with evolving international sanctions. Merck is donating profits resulting from its operations in Russia to humanitarian causes. The Company does not have research or manufacturing facilities in Russia, currently does not plan to make further investments in Russia, and has suspended screening and enrollment in ongoing clinical trials as well as </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 51 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">planning for new studies in Russia, although the Company continues to treat patients already enrolled in existing clinical trials and collect data from these studies. The Company is also using its resources to help alleviate the humanitarian crisis in Ukraine, including through donations of funds and products. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial impacts of the war between Russia and Ukraine were immaterial to the Company&#8217;s consolidated financial statements for the third quarter and first nine months of 2022. However, the degree to which the war and related disruptions will impact the Company&#8217;s results for the remainder of 2022 or beyond is difficult to predict and will depend on developments outside of the Company&#8217;s control, including, but not limited to, the duration and severity of the war, ongoing and additional financial and economic sanctions imposed by governments in response, restrictions on travel, regional instability, geopolitical shifts, and adverse effects on fuel and energy costs, supply chains, macroeconomic conditions, currency exchange rates and financial markets. Such developments may negatively impact the Company directly or indirectly as well as the parties with which the Company conducts business. In addition, the effects of the war between Russia and Ukraine could heighten other risks disclosed in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, which could materially adversely affect the Company&#8217;s business, results of operations and financial condition. </span></div><div id="i6b4e4280ad2344a5bc7fdcaa77e417f0_130"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issuer purchases of equity securities for the three months ended September&#160;30, 2022 were as follows:</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:27.366%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.926%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.092%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($&#160;in&#160;millions)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total&#160;Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">of Shares</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Average&#160;Price<br/>Paid Per<br/>Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Approximate&#160;Dollar&#160;Value&#160;of&#160;Shares</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">That May Yet Be Purchased</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Under the Plans or Programs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 1 - July 31</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.00</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5,047</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 1 - August 31</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5,047</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 1 - September 30</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5,047</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.00</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> The Company did not purchase any shares during the three months ended September&#160;30, 2022 under the plan approved by the Board of Directors in October 2018 to purchase up to $10 billion of Merck&#8217;s common stock for its treasury.</span></div><div id="i6b4e4280ad2344a5bc7fdcaa77e417f0_133"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Item&#160;6. Exhibits</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000119312509223917/dex31.htm">Restated Certificate of Incorporation of Merck &amp; Co., Inc. (November 3, 2009) &#8211; Incorporated by reference to Current Report on Form 8-K filed on November&#160;4, 2009 (No. 1-6571)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015822000006/exhibit31-byxlawsasamended.htm">By-Laws of Merck &amp; Co., Inc. (effective March 22, 2022) &#8211; Incorporated by reference to Current Report on Form 8-K filed on March 25, 2022 (No. 1-6571)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311-rule13ax14a15dx.htm">Rule 13a &#8211; 14(a)/15d &#8211; 14(a) Certification of Chief Executive Officer</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312-rule13ax14a15dx.htm">Rule 13a &#8211; 14(a)/15d &#8211; 14(a) Certification of Chief Financial Officer</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321-section1350cert.htm">Section 1350 Certification of Chief Executive Officer</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit322-section1350cert.htm">Section 1350 Certification of Chief Financial Officer</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 52 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i6b4e4280ad2344a5bc7fdcaa77e417f0_136"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Signatures</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MERCK &amp; CO., INC.</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:  November 3, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jennifer Zachary</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JENNIFER ZACHARY</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and General Counsel</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:  November 3, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Rita A. Karachun</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RITA A. KARACHUN</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President Finance - Global Controller</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 53 -</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>exhibit311-rule13ax14a15dx.htm
<DESCRIPTION>EXHIBIT-31.1 RULE 13A-14(A)/15D-14(A) CERTIFICATION OF CEO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ieeddd3c6e2a04342b68a97ce2a988001_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 31.1</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Robert M. Davis, certify that&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form 10-Q of Merck&#160;&#38; Co., Inc.&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;3, 2022 </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:45.614%"><tr><td style="width:1.0%"></td><td style="width:9.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.324%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Robert M. Davis</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROBERT M. DAVIS<br>Chief Executive Officer and President</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>exhibit312-rule13ax14a15dx.htm
<DESCRIPTION>EXHIBIT-31.2 RULE 13A-14(A)/15D-14(A) CERTIFICATION OF CFO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i7db818309f594d0d8c9e260776865abb_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 31.2</font></div><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Caroline Litchfield, certify that&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form 10-Q of Merck&#160;&#38; Co., Inc.&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;&#160;&#160;&#160;November&#160;3, 2022 </font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.345%"><tr><td style="width:1.0%"></td><td style="width:9.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.490%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Caroline Litchfield</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAROLINE LITCHFIELD<br>Executive Vice President, Chief Financial Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>exhibit321-section1350cert.htm
<DESCRIPTION>EXHIBIT-32.1 SECTION 1350 CERTIFICATION OF CEO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i4d2044bec5ef4192a0094fb7b6d5a9b7_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 32.1 </font></div><div style="margin-top:15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;1350 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Chief Executive Officer </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. Section&#160;1350, the undersigned officer of Merck&#160;&#38; Co., Inc. (the &#8220;Company&#8221;), hereby certifies that the Company's Quarterly Report on Form 10-Q for the quarter ended September&#160;30, 2022 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.115%"><tr><td style="width:1.0%"></td><td style="width:50.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.399%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.407%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November&#160;3, 2022</font></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Robert M. Davis</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;<br>Title&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROBERT M. DAVIS<br>Chief&#160;Executive&#160;Officer and President</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>exhibit322-section1350cert.htm
<DESCRIPTION>EXHIBIT-32.2 SECTION 1350 CERTIFICATION OF CFO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i25663fc971ee4982ae08066df6a2a26b_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 32.2 </font></div><div style="margin-top:15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;1350 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Chief Financial Officer </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. Section&#160;1350, the undersigned officer of Merck&#160;&#38; Co., Inc. (the &#8220;Company&#8221;), hereby certifies that the Company's Quarterly Report on Form 10-Q for the quarter ended September&#160;30, 2022 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:50.366%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.351%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.983%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;  November&#160;3, 2022</font></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Caroline Litchfield</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;<br>Title&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAROLINE LITCHFIELD<br>Executive Vice President, Chief Financial Officer</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>mrk-20220930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:18be82ff-6aae-4643-b5c5-ea6de452de6c,g:778f8bae-d5d9-4bda-a4ad-ec173f2835d1-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mrk="http://www.merck.com/20220930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.merck.com/20220930">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrk-20220930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrk-20220930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrk-20220930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrk-20220930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.merck.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME" roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME">
        <link:definition>0000002 - Statement - CONDENSED CONSOLIDATED STATEMENT OF INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME" roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME">
        <link:definition>0000003 - Statement - CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEET" roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET">
        <link:definition>0000004 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical" roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical">
        <link:definition>0000005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS">
        <link:definition>0000006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWSParenthetical" roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWSParenthetical">
        <link:definition>0000007 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentation" roleURI="http://www.merck.com/role/BasisofPresentation">
        <link:definition>0000008 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SpinOffofOrganonCo" roleURI="http://www.merck.com/role/SpinOffofOrganonCo">
        <link:definition>0000009 - Disclosure - Spin-Off of Organon &amp; Co.</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsResearchCollaborationsandLicenseAgreements" roleURI="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreements">
        <link:definition>0000010 - Disclosure - Acquisitions, Research Collaborations and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeArrangements" roleURI="http://www.merck.com/role/CollaborativeArrangements">
        <link:definition>0000011 - Disclosure - Collaborative Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Restructuring" roleURI="http://www.merck.com/role/Restructuring">
        <link:definition>0000012 - Disclosure - Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.merck.com/role/FinancialInstruments">
        <link:definition>0000013 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.merck.com/role/Inventories">
        <link:definition>0000014 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIntangibles" roleURI="http://www.merck.com/role/OtherIntangibles">
        <link:definition>0000015 - Disclosure - Other Intangibles</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Contingencies" roleURI="http://www.merck.com/role/Contingencies">
        <link:definition>0000016 - Disclosure - Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://www.merck.com/role/Equity">
        <link:definition>0000017 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlans" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans">
        <link:definition>0000018 - Disclosure - Pension and Other Postretirement Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeExpenseNet" roleURI="http://www.merck.com/role/OtherIncomeExpenseNet">
        <link:definition>0000019 - Disclosure - Other (Income) Expense, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxesonIncome" roleURI="http://www.merck.com/role/TaxesonIncome">
        <link:definition>0000020 - Disclosure - Taxes on Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.merck.com/role/EarningsPerShare">
        <link:definition>0000021 - Disclosure - Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLoss" roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLoss">
        <link:definition>0000022 - Disclosure - Other Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReporting" roleURI="http://www.merck.com/role/SegmentReporting">
        <link:definition>0000023 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationPolicies" roleURI="http://www.merck.com/role/BasisofPresentationPolicies">
        <link:definition>0000024 - Disclosure - Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SpinOffofOrganonCoTables" roleURI="http://www.merck.com/role/SpinOffofOrganonCoTables">
        <link:definition>0000025 - Disclosure - Spin-Off of Organon &amp; Co. (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeArrangementsTables" roleURI="http://www.merck.com/role/CollaborativeArrangementsTables">
        <link:definition>0000026 - Disclosure - Collaborative Arrangements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringTables" roleURI="http://www.merck.com/role/RestructuringTables">
        <link:definition>0000027 - Disclosure - Restructuring (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.merck.com/role/FinancialInstrumentsTables">
        <link:definition>0000028 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.merck.com/role/InventoriesTables">
        <link:definition>0000029 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityTables" roleURI="http://www.merck.com/role/EquityTables">
        <link:definition>0000030 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlansTables" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables">
        <link:definition>0000031 - Disclosure - Pension and Other Postretirement Benefit Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeExpenseNetTables" roleURI="http://www.merck.com/role/OtherIncomeExpenseNetTables">
        <link:definition>0000032 - Disclosure - Other (Income) Expense, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.merck.com/role/EarningsPerShareTables">
        <link:definition>0000033 - Disclosure - Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLossTables" roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLossTables">
        <link:definition>0000034 - Disclosure - Other Comprehensive Income (Loss) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingTables" roleURI="http://www.merck.com/role/SegmentReportingTables">
        <link:definition>0000035 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SpinOffofOrganonCoNarrativeDetails" roleURI="http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails">
        <link:definition>0000036 - Disclosure - Spin-Off of Organon &amp; Co. - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails" roleURI="http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails">
        <link:definition>0000037 - Disclosure - Spin-Off of Organon &amp; Co. - Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" roleURI="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails">
        <link:definition>0000038 - Disclosure - Acquisitions, Research Collaborations and License Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeArrangementsNarrativeDetails" roleURI="http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails">
        <link:definition>0000039 - Disclosure - Collaborative Arrangements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeArrangementsFinancialInformationDetails" roleURI="http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails">
        <link:definition>0000040 - Disclosure - Collaborative Arrangements - Financial Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringNarrativeDetails" roleURI="http://www.merck.com/role/RestructuringNarrativeDetails">
        <link:definition>0000041 - Disclosure - Restructuring - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesActivitiesbyTypeofCostDetails" roleURI="http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails">
        <link:definition>0000042 - Disclosure - Restructuring - Charges Activities by Type of Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringActivitiesbyProgramDetails" roleURI="http://www.merck.com/role/RestructuringActivitiesbyProgramDetails">
        <link:definition>0000043 - Disclosure - Restructuring - Activities by Program (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsNarrativeDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsNarrativeDetails">
        <link:definition>0000044 - Disclosure - Financial Instruments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsEffectofNetInvestmentHedgesDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails">
        <link:definition>0000045 - Disclosure - Financial Instruments - Effect of Net Investment Hedges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFairValueHedgesDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails">
        <link:definition>0000046 - Disclosure - Financial Instruments - Fair Value Hedges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails">
        <link:definition>0000047 - Disclosure - Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails">
        <link:definition>0000048 - Disclosure - Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails">
        <link:definition>0000049 - Disclosure - Financial Instruments - Location and Amount of Pretax (Gains) Losses of Derivatives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails">
        <link:definition>0000050 - Disclosure - Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails">
        <link:definition>0000051 - Disclosure - Financial Instruments - Information on Available-for-sale Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
        <link:definition>0000052 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails">
        <link:definition>0000053 - Disclosure - Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesScheduleofInventoriesDetails" roleURI="http://www.merck.com/role/InventoriesScheduleofInventoriesDetails">
        <link:definition>0000054 - Disclosure - Inventories - Schedule of Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesScheduleofInventoriesDetails_1" roleURI="http://www.merck.com/role/InventoriesScheduleofInventoriesDetails_1">
        <link:definition>0000054 - Disclosure - Inventories - Schedule of Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesNarrativeDetails" roleURI="http://www.merck.com/role/InventoriesNarrativeDetails">
        <link:definition>0000055 - Disclosure - Inventories - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIntangiblesDetails" roleURI="http://www.merck.com/role/OtherIntangiblesDetails">
        <link:definition>0000056 - Disclosure - Other Intangibles (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesDetails" roleURI="http://www.merck.com/role/ContingenciesDetails">
        <link:definition>0000057 - Disclosure - Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityRollforwardReconciliationsDetails" roleURI="http://www.merck.com/role/EquityRollforwardReconciliationsDetails">
        <link:definition>0000058 - Disclosure - Equity - Rollforward Reconciliations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails">
        <link:definition>0000059 - Disclosure - Pension and Other Postretirement Benefit Plans - Net Benefit Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlansNarrativeDetails" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails">
        <link:definition>0000060 - Disclosure - Pension and Other Postretirement Benefit Plans - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" roleURI="http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails">
        <link:definition>0000061 - Disclosure - Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeExpenseNetNarrativeDetails" roleURI="http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails">
        <link:definition>0000062 - Disclosure - Other (Income) Expense, Net - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxesonIncomeDetails" roleURI="http://www.merck.com/role/TaxesonIncomeDetails">
        <link:definition>0000063 - Disclosure - Taxes on Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareCalculationsofEarningsPerShareDetails" roleURI="http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails">
        <link:definition>0000064 - Disclosure - Earnings Per Share - Calculations of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareNarrativeDetails" roleURI="http://www.merck.com/role/EarningsPerShareNarrativeDetails">
        <link:definition>0000065 - Disclosure - Earnings Per Share - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLossDetails" roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLossDetails">
        <link:definition>0000066 - Disclosure - Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingNarrativeDetails" roleURI="http://www.merck.com/role/SegmentReportingNarrativeDetails">
        <link:definition>0000067 - Disclosure - Segment Reporting - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingSalesfromProductsDetails" roleURI="http://www.merck.com/role/SegmentReportingSalesfromProductsDetails">
        <link:definition>0000068 - Disclosure - Segment Reporting - Sales from Products (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingConsolidatedSalesbyGeographicAreaDetails" roleURI="http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails">
        <link:definition>0000069 - Disclosure - Segment Reporting - Consolidated Sales by Geographic Area (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails" roleURI="http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails">
        <link:definition>0000070 - Disclosure - Segment Reporting - Reconciliation of Segment Profits to Income before Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="mrk_LynparzaMember" abstract="true" name="LynparzaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_DevelopmentMilestonesMember" abstract="true" name="DevelopmentMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_RidgebackBiotherapeuticsLPMember" abstract="true" name="RidgebackBiotherapeuticsLPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_JanuviaAndJanumetMember" abstract="true" name="JanuviaAndJanumetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ArtivaBiotherapeuticsIncMember" abstract="true" name="ArtivaBiotherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_PharmaceuticalsegmentMember" abstract="true" name="PharmaceuticalsegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_FirstCommercialSaleMilestonesMember" abstract="true" name="FirstCommercialSaleMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_GardasilGardasil9Member" abstract="true" name="GardasilGardasil9Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_COVID19Member" abstract="true" name="COVID19Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_VerquvoMember" abstract="true" name="VerquvoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_CollaborativeArrangementSalesNet" abstract="false" name="CollaborativeArrangementSalesNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_SanofiPasteurMember" abstract="true" name="SanofiPasteurMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ChargesRelatedToProgramDiscontinuation" abstract="false" name="ChargesRelatedToProgramDiscontinuation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_RoyaltyRatePercentage" abstract="false" name="RoyaltyRatePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_CompanionAnimalsMember" abstract="true" name="CompanionAnimalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_FemurFractureLitigationMember" abstract="true" name="FemurFractureLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_DisposalGroupInclDiscontinuedOperationsDistributionReceived" abstract="false" name="DisposalGroupInclDiscontinuedOperationsDistributionReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember" abstract="true" name="SichuanKelunBiotechBiopharmaceuticalCoLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember" abstract="true" name="CasesCompanyAgreedToTollStatuteOfLimitationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ComponentofOtherIncomeExpenseofNonoperatingTable" abstract="true" name="ComponentofOtherIncomeExpenseofNonoperatingTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="mrk_ZetiaantitrustlitigationMember" abstract="true" name="ZetiaantitrustlitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_OrionCorporationMember" abstract="true" name="OrionCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" abstract="false" name="UpfrontAndMilestonePaymentsMadeToCollaborativePartner" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_AlliancerevenueLynparzaMember" abstract="true" name="AlliancerevenueLynparzaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_LossContingencyTrialPeriod" abstract="false" name="LossContingencyTrialPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mrk_ProQuadMMRIIVarivaxMember" abstract="true" name="ProQuadMMRIIVarivaxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_RecognizedAsAbstract" abstract="true" name="RecognizedAsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrk_LossContingencyRecoveryFromThirdPartyBenchTrialPeriod" abstract="false" name="LossContingencyRecoveryFromThirdPartyBenchTrialPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mrk_RotateqMember" abstract="true" name="RotateqMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_CollaborativeArrangementNumberOfCollaborationTargets" abstract="false" name="CollaborativeArrangementNumberOfCollaborationTargets" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrk_OrganonCoMember" abstract="true" name="OrganonCoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_PatentInfringementLawsuitAgainstZydusWorldwideDMCCZydusPharmaceuticalsUSAIncAndCadilaHealthcareLtdMember" abstract="true" name="PatentInfringementLawsuitAgainstZydusWorldwideDMCCZydusPharmaceuticalsUSAIncAndCadilaHealthcareLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_CostsExpensesAndOther" abstract="false" name="CostsExpensesAndOther" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_MilestonePaymentsMadetoCollaborativePartner" abstract="false" name="MilestonePaymentsMadetoCollaborativePartner" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_LongTermDebtCurrentMaturitiesMember" abstract="true" name="LongTermDebtCurrentMaturitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_A2.35NotesDue2022Member" abstract="true" name="A2.35NotesDue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_LenvimaMember" abstract="true" name="LenvimaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_BayerAGMember" abstract="true" name="BayerAGMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_BristolMyersSquibbMember" abstract="true" name="BristolMyersSquibbMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_RestructuringReserveIncreaseDecreaseNoncashActivity" abstract="false" name="RestructuringReserveIncreaseDecreaseNoncashActivity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_IsentressIsentressHDMember" abstract="true" name="IsentressIsentressHDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_AllianceRevenueAdempasVerquvoMember" abstract="true" name="AllianceRevenueAdempasVerquvoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_InventoriesProducedinPreparationforProductLaunchesMember" abstract="true" name="InventoriesProducedinPreparationforProductLaunchesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_MilestonePaymentsSalesBased" abstract="false" name="MilestonePaymentsSalesBased" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_EurodominatedNotesMember" abstract="true" name="EurodominatedNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_NoxafilMember" abstract="true" name="NoxafilMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_KeytrudaMember" abstract="true" name="KeytrudaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_InternationalMember" abstract="true" name="InternationalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner" abstract="false" name="UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_CollaborativeArrangementNumberOfResearchPrograms" abstract="false" name="CollaborativeArrangementNumberOfResearchPrograms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrk_ProbableContingentPaymentsCollaborativeArrangement" abstract="false" name="ProbableContingentPaymentsCollaborativeArrangement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_A2.500Notesdue2034Member" abstract="true" name="A2.500Notesdue2034Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_InventoryNetAndInventoryNoncurrent" abstract="false" name="InventoryNetAndInventoryNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_PrimaxinMember" abstract="true" name="PrimaxinMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_MilestonePaymentsToBeMadeToACollaborativePartner" abstract="false" name="MilestonePaymentsToBeMadeToACollaborativePartner" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_MilestonePaymentsAccruedSalesBased" abstract="false" name="MilestonePaymentsAccruedSalesBased" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_LossContingencyClaimsonAppealNumber" abstract="false" name="LossContingencyClaimsonAppealNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrk_SalesDiscounts" abstract="false" name="SalesDiscounts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_AllianceRevenueReblozylMember" abstract="true" name="AllianceRevenueReblozylMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_TransitionServicesAgreementMember" abstract="true" name="TransitionServicesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_RoyaltyRateDeductionPercentage" abstract="false" name="RoyaltyRateDeductionPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_FederalMember" abstract="true" name="FederalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash" abstract="false" name="EstimateOfCumulativePreTaxCostsThatWillBeNoncash" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mrk_SupplyCommitmentRemainingMinimumCoursesCommitted" abstract="false" name="SupplyCommitmentRemainingMinimumCoursesCommitted" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrk_AnimalHealthsegmentMember" abstract="true" name="AnimalHealthsegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_A2.40NotesDue2022Member" abstract="true" name="A2.40NotesDue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_InventoryTable" abstract="true" name="InventoryTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="mrk_LagevrioMember" abstract="true" name="LagevrioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_Pneumovax23Member" abstract="true" name="Pneumovax23Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_BridionMember" abstract="true" name="BridionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember" abstract="true" name="DeferredIncomeTaxesAndOtherAssetsNoncurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_Licenseoptionpaymentrelatedtocollaborativearrangement" abstract="false" name="Licenseoptionpaymentrelatedtocollaborativearrangement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_OtherPharmaceuticalMember" abstract="true" name="OtherPharmaceuticalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_BelsomraMember" abstract="true" name="BelsomraMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_PandionTherapeuticsMember" abstract="true" name="PandionTherapeuticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_DebtSecuritiesandEquitySecuritiesFVNI" abstract="false" name="DebtSecuritiesandEquitySecuritiesFVNI" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_MilestonePaymentToBeMadeToACollaborativePartner" abstract="false" name="MilestonePaymentToBeMadeToACollaborativePartner" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_ContingentPaymentsCollaborativeArrangement" abstract="false" name="ContingentPaymentsCollaborativeArrangement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_CollaborativeArrangementProfitSharing" abstract="false" name="CollaborativeArrangementProfitSharing" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_StockholdersEquityTable" abstract="true" name="StockholdersEquityTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="mrk_InventoryNotExpectedtobeSoldWithinOneYearMember" abstract="true" name="InventoryNotExpectedtobeSoldWithinOneYearMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_AllianceRevenueKoselugoMember" abstract="true" name="AllianceRevenueKoselugoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems" abstract="true" name="ComponentofOtherIncomeExpenseofNonoperatingLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrk_InvanzMember" abstract="true" name="InvanzMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_PotentialFutureMilestonePaymentsRegulatory" abstract="false" name="PotentialFutureMilestonePaymentsRegulatory" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_FosamaxMember" abstract="true" name="FosamaxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_SalesBasedMilestonesMember" abstract="true" name="SalesBasedMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mrk_SegmentReportingUnallocatedOtherExpensesNet" abstract="false" name="SegmentReportingUnallocatedOtherExpensesNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_CollaborativeArrangementsAbstract" abstract="true" name="CollaborativeArrangementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock" abstract="false" name="AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mrk_CancidasMember" abstract="true" name="CancidasMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_SupplyCommitmentMinimumNumberOfMarkets" abstract="false" name="SupplyCommitmentMinimumNumberOfMarkets" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrk_OtherCountriesMember" abstract="true" name="OtherCountriesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_PrevymisMember" abstract="true" name="PrevymisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_A1.875Notesdue2026Member" abstract="true" name="A1.875Notesdue2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ZerbaxaMember" abstract="true" name="ZerbaxaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_PotentialFutureMilestonePaymentsSalesBased" abstract="false" name="PotentialFutureMilestonePaymentsSalesBased" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_SimponiMember" abstract="true" name="SimponiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_LivestockMember" abstract="true" name="LivestockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_OrnaTherapeuticsMember" abstract="true" name="OrnaTherapeuticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_RemicadeMember" abstract="true" name="RemicadeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_LegalDefenseCostsMember" abstract="true" name="LegalDefenseCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_EisaiMember" abstract="true" name="EisaiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" abstract="false" name="EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mrk_DificidMember" abstract="true" name="DificidMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_RegulatoryMilestonesMember" abstract="true" name="RegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_AdempasMember" abstract="true" name="AdempasMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartner" abstract="false" name="ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartner" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_NemtabrutinibMember" abstract="true" name="NemtabrutinibMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_A0.500Notesdue2024Member" abstract="true" name="A0.500Notesdue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ManufacturingAndSupplyAgreementsMember" abstract="true" name="ManufacturingAndSupplyAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_AstraZenecaMember" abstract="true" name="AstraZenecaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_JanuviaMember" abstract="true" name="JanuviaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_AcceleratedDepreciationMember" abstract="true" name="AcceleratedDepreciationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_OffsettingAssetsAndLiabilitiesTableTextBlock" abstract="false" name="OffsettingAssetsAndLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mrk_OtherNonoperatingIncomeExpenseOther" abstract="false" name="OtherNonoperatingIncomeExpenseOther" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_StockholdersEquityLineItems" abstract="true" name="StockholdersEquityLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrk_VaqtaMember" abstract="true" name="VaqtaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_JanumetMember" abstract="true" name="JanumetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_A1.375Notesdue2036Member" abstract="true" name="A1.375Notesdue2036Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_DeferredIncomeTaxesAndOtherAssetsCurrentMember" abstract="true" name="DeferredIncomeTaxesAndOtherAssetsCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet" abstract="false" name="AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>mrk-20220930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:18be82ff-6aae-4643-b5c5-ea6de452de6c,g:778f8bae-d5d9-4bda-a4ad-ec173f2835d1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME" xlink:type="simple" xlink:href="mrk-20220930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_760b70fb-eb06-40c8-8754-08e83c8c6af4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_ed0e6899-e66b-435d-a103-612a74497a30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_760b70fb-eb06-40c8-8754-08e83c8c6af4" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_ed0e6899-e66b-435d-a103-612a74497a30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_5c688bdf-8e3b-4de7-aa6a-8a83776f586f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_760b70fb-eb06-40c8-8754-08e83c8c6af4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_5c688bdf-8e3b-4de7-aa6a-8a83776f586f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_bc63b820-4ae6-41fe-8c4c-86cc22ddb020" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_f45f297d-9aec-48a4-8a68-c8b030439611" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_bc63b820-4ae6-41fe-8c4c-86cc22ddb020" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_f45f297d-9aec-48a4-8a68-c8b030439611" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_f0f3673b-9049-4d7f-aeb2-2246ef755dda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_bc63b820-4ae6-41fe-8c4c-86cc22ddb020" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_f0f3673b-9049-4d7f-aeb2-2246ef755dda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_9197e05d-c774-4246-a44a-54756ca0dd20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_401a6ceb-de06-4920-a09b-f6d54408eec0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_9197e05d-c774-4246-a44a-54756ca0dd20" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_401a6ceb-de06-4920-a09b-f6d54408eec0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e6d4225a-85f6-482e-86d0-6220d17e6384" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_9197e05d-c774-4246-a44a-54756ca0dd20" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e6d4225a-85f6-482e-86d0-6220d17e6384" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_88a2c5de-dff8-43db-a4ad-f4a62bf79220" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_a878293c-f699-4ce1-b9ca-8e84909c6cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_88a2c5de-dff8-43db-a4ad-f4a62bf79220" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_a878293c-f699-4ce1-b9ca-8e84909c6cc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_284fa7af-8ddd-46f2-818f-63d11ce1f7b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_88a2c5de-dff8-43db-a4ad-f4a62bf79220" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_284fa7af-8ddd-46f2-818f-63d11ce1f7b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5b799a14-ed77-4698-8971-4b8915224084" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_5e2f7d02-9d44-4ed5-8dd7-e80d3552fdec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5b799a14-ed77-4698-8971-4b8915224084" xlink:to="loc_us-gaap_Revenues_5e2f7d02-9d44-4ed5-8dd7-e80d3552fdec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CostsExpensesAndOther_1245b95b-2a8c-44f1-98f5-f2300cb5d868" xlink:href="mrk-20220930.xsd#mrk_CostsExpensesAndOther"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5b799a14-ed77-4698-8971-4b8915224084" xlink:to="loc_mrk_CostsExpensesAndOther_1245b95b-2a8c-44f1-98f5-f2300cb5d868" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_e65165fc-ee60-4aed-b27d-f9fa34c3b12a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_4ddba10b-84ea-42fd-a6b8-dc589f1a2caa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_e65165fc-ee60-4aed-b27d-f9fa34c3b12a" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_4ddba10b-84ea-42fd-a6b8-dc589f1a2caa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_09e2824f-2802-402d-a3b0-794364df64b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_e65165fc-ee60-4aed-b27d-f9fa34c3b12a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_09e2824f-2802-402d-a3b0-794364df64b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CostsExpensesAndOther_f719ef74-d208-4e8a-b766-2f36ee73884b" xlink:href="mrk-20220930.xsd#mrk_CostsExpensesAndOther"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_70246ebe-b3ca-49ca-a43a-23d7a9e35017" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_CostsExpensesAndOther_f719ef74-d208-4e8a-b766-2f36ee73884b" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_70246ebe-b3ca-49ca-a43a-23d7a9e35017" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_dc65ecdb-7132-4922-befe-650b38d3c4fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_CostsExpensesAndOther_f719ef74-d208-4e8a-b766-2f36ee73884b" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_dc65ecdb-7132-4922-befe-650b38d3c4fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6e6724d6-39e5-40b6-9dbe-81d3d71dd52d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_CostsExpensesAndOther_f719ef74-d208-4e8a-b766-2f36ee73884b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6e6724d6-39e5-40b6-9dbe-81d3d71dd52d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_06d6e48d-45a6-41a9-abeb-80dae998cafd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_CostsExpensesAndOther_f719ef74-d208-4e8a-b766-2f36ee73884b" xlink:to="loc_us-gaap_RestructuringCharges_06d6e48d-45a6-41a9-abeb-80dae998cafd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_c41f0c28-d8d4-4a14-8e30-2acadf5eccd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_CostsExpensesAndOther_f719ef74-d208-4e8a-b766-2f36ee73884b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_c41f0c28-d8d4-4a14-8e30-2acadf5eccd8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="mrk-20220930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_cd5c6c2e-ede7-49a4-ab65-bb8726782899" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2a13ac02-82b6-467e-a7af-de051ede23eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cd5c6c2e-ede7-49a4-ab65-bb8726782899" xlink:to="loc_us-gaap_NetIncomeLoss_2a13ac02-82b6-467e-a7af-de051ede23eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f0cade4b-f781-45a4-9983-b94dfe4b7e74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cd5c6c2e-ede7-49a4-ab65-bb8726782899" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f0cade4b-f781-45a4-9983-b94dfe4b7e74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_46a9d403-2268-4970-9812-3128e86cad92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_9ffb0489-2379-403f-8ccd-1044ed602c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_46a9d403-2268-4970-9812-3128e86cad92" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_9ffb0489-2379-403f-8ccd-1044ed602c4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_209c2a0f-fa17-4515-a332-a825b48d0cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_46a9d403-2268-4970-9812-3128e86cad92" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_209c2a0f-fa17-4515-a332-a825b48d0cd0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_1172d7b8-f9f5-49bd-8746-edbc0a125810" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_46a9d403-2268-4970-9812-3128e86cad92" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_1172d7b8-f9f5-49bd-8746-edbc0a125810" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" xlink:type="simple" xlink:href="mrk-20220930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEET"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_a96fff97-f406-4463-a471-c64aaff9b216" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4d1626b0-dbd0-4c0e-b45e-139d8406afcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a96fff97-f406-4463-a471-c64aaff9b216" xlink:to="loc_us-gaap_LiabilitiesCurrent_4d1626b0-dbd0-4c0e-b45e-139d8406afcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_1c344ab0-bc5c-4d82-9e96-b3b8f0cacd04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a96fff97-f406-4463-a471-c64aaff9b216" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_1c344ab0-bc5c-4d82-9e96-b3b8f0cacd04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_2c1fa748-bf77-4045-b45a-876a7510d8e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a96fff97-f406-4463-a471-c64aaff9b216" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_2c1fa748-bf77-4045-b45a-876a7510d8e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_9eb7d679-7ab2-4f9e-b13a-efd1f3f95cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a96fff97-f406-4463-a471-c64aaff9b216" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_9eb7d679-7ab2-4f9e-b13a-efd1f3f95cfa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_98e588b4-33a3-43a9-a071-c0376b630377" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a96fff97-f406-4463-a471-c64aaff9b216" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_98e588b4-33a3-43a9-a071-c0376b630377" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_fa3965b1-b65e-4689-a918-83bd2970a17d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_8243645a-4636-4fc6-a867-cf71ba871786" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_fa3965b1-b65e-4689-a918-83bd2970a17d" xlink:to="loc_us-gaap_AccountsPayableCurrent_8243645a-4636-4fc6-a867-cf71ba871786" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_ed59626a-ccfb-49c6-b1e1-a0165d1ed57f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_fa3965b1-b65e-4689-a918-83bd2970a17d" xlink:to="loc_us-gaap_DebtCurrent_ed59626a-ccfb-49c6-b1e1-a0165d1ed57f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_23dd742f-3f5a-49c4-a289-757980d2c13d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_fa3965b1-b65e-4689-a918-83bd2970a17d" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_23dd742f-3f5a-49c4-a289-757980d2c13d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_22e2f21e-7b8a-49aa-822f-92d64da02787" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_fa3965b1-b65e-4689-a918-83bd2970a17d" xlink:to="loc_us-gaap_DividendsPayableCurrent_22e2f21e-7b8a-49aa-822f-92d64da02787" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_1f940a28-a1bc-4d23-bcfb-9e33064ac1b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_fa3965b1-b65e-4689-a918-83bd2970a17d" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_1f940a28-a1bc-4d23-bcfb-9e33064ac1b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f8bf75b0-1de4-44de-af03-cc42bde6102f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_c3d992cc-ce7a-45b6-bfa4-cbd08f674ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f8bf75b0-1de4-44de-af03-cc42bde6102f" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_c3d992cc-ce7a-45b6-bfa4-cbd08f674ad5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d0b856b4-3bc8-4a9f-ad9f-ba049586b2e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f8bf75b0-1de4-44de-af03-cc42bde6102f" xlink:to="loc_us-gaap_Goodwill_d0b856b4-3bc8-4a9f-ad9f-ba049586b2e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_88525cb2-7772-44d8-b3c9-4b0f355b40de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f8bf75b0-1de4-44de-af03-cc42bde6102f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_88525cb2-7772-44d8-b3c9-4b0f355b40de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_a98b16c1-1214-48ee-87fa-dbd5eae270e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f8bf75b0-1de4-44de-af03-cc42bde6102f" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_a98b16c1-1214-48ee-87fa-dbd5eae270e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_14021b28-16c8-456e-8539-ebd5a11b7c89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f8bf75b0-1de4-44de-af03-cc42bde6102f" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_14021b28-16c8-456e-8539-ebd5a11b7c89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a45f9569-d91a-4cb6-a3c7-6c674deb07de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f8bf75b0-1de4-44de-af03-cc42bde6102f" xlink:to="loc_us-gaap_AssetsCurrent_a45f9569-d91a-4cb6-a3c7-6c674deb07de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7f4f80ad-322b-4252-a728-aa7c883b6763" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_229fab1e-b228-499d-9e99-7279562e3020" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7f4f80ad-322b-4252-a728-aa7c883b6763" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_229fab1e-b228-499d-9e99-7279562e3020" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent_367fa9f6-4293-4ba6-9f70-cadccbee07d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7f4f80ad-322b-4252-a728-aa7c883b6763" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent_367fa9f6-4293-4ba6-9f70-cadccbee07d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2c30dbd5-eeea-4797-bd0e-44ded084ab31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7f4f80ad-322b-4252-a728-aa7c883b6763" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2c30dbd5-eeea-4797-bd0e-44ded084ab31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_9333e215-b718-4ade-a6ba-8afccc73361c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7f4f80ad-322b-4252-a728-aa7c883b6763" xlink:to="loc_us-gaap_InventoryNet_9333e215-b718-4ade-a6ba-8afccc73361c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_3950df3e-0d26-40a0-ab0c-930a90d582d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7f4f80ad-322b-4252-a728-aa7c883b6763" xlink:to="loc_us-gaap_ShortTermInvestments_3950df3e-0d26-40a0-ab0c-930a90d582d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_bf824928-49e3-4a92-a671-c627a55de50d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityBeforeTreasuryStock"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_f3c71118-e7db-4cde-9400-71381de8d6f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_bf824928-49e3-4a92-a671-c627a55de50d" xlink:to="loc_us-gaap_CommonStockValue_f3c71118-e7db-4cde-9400-71381de8d6f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_6febc761-fd66-4bf9-b0ba-ee79326d7e55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_bf824928-49e3-4a92-a671-c627a55de50d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_6febc761-fd66-4bf9-b0ba-ee79326d7e55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f8929d6f-f8ad-4fa4-a1ab-0d0025fd964a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_bf824928-49e3-4a92-a671-c627a55de50d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f8929d6f-f8ad-4fa4-a1ab-0d0025fd964a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8f568a93-f099-44b7-a70f-2af564a51c84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_bf824928-49e3-4a92-a671-c627a55de50d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8f568a93-f099-44b7-a70f-2af564a51c84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f37b0bbe-bfb1-4296-b17b-3eefc1b9e07a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_330c9c6c-e1d7-41df-bdf7-b40e27ecc96a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityBeforeTreasuryStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f37b0bbe-bfb1-4296-b17b-3eefc1b9e07a" xlink:to="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_330c9c6c-e1d7-41df-bdf7-b40e27ecc96a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_b4722e9c-caef-49ec-84f4-19bfddde0cae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f37b0bbe-bfb1-4296-b17b-3eefc1b9e07a" xlink:to="loc_us-gaap_TreasuryStockCommonValue_b4722e9c-caef-49ec-84f4-19bfddde0cae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a5a028b3-6b65-411a-880c-8afab8d8d4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_684b388d-1f84-40c6-9133-600c32727bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a5a028b3-6b65-411a-880c-8afab8d8d4b3" xlink:to="loc_us-gaap_StockholdersEquity_684b388d-1f84-40c6-9133-600c32727bd0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_7ebcb1b3-445a-43ae-8d6c-c39c1ee1e411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a5a028b3-6b65-411a-880c-8afab8d8d4b3" xlink:to="loc_us-gaap_MinorityInterest_7ebcb1b3-445a-43ae-8d6c-c39c1ee1e411" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" xlink:type="simple" xlink:href="mrk-20220930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations_b4f7502c-1a27-4aa2-9ea6-0447cfa9edc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_570c73ce-5828-4ece-b62a-650a3f077ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations_b4f7502c-1a27-4aa2-9ea6-0447cfa9edc1" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_570c73ce-5828-4ece-b62a-650a3f077ec6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_56abf76a-df94-44dd-84d6-f32731fc6cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations_b4f7502c-1a27-4aa2-9ea6-0447cfa9edc1" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_56abf76a-df94-44dd-84d6-f32731fc6cb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_e97c251a-f313-402c-8b26-ba97c7654411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations_b4f7502c-1a27-4aa2-9ea6-0447cfa9edc1" xlink:to="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_e97c251a-f313-402c-8b26-ba97c7654411" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_0aedafa3-f20f-4dcd-a467-9070129c5544" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_93d8c286-a317-413a-9bb7-52d22e771387" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_0aedafa3-f20f-4dcd-a467-9070129c5544" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_93d8c286-a317-413a-9bb7-52d22e771387" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_d5f9461c-4af5-45c2-9b2d-8d2178e4657a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_0aedafa3-f20f-4dcd-a467-9070129c5544" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_d5f9461c-4af5-45c2-9b2d-8d2178e4657a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_2aab0c81-64db-425e-8595-6dd75f413994" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_0aedafa3-f20f-4dcd-a467-9070129c5544" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_2aab0c81-64db-425e-8595-6dd75f413994" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_351b5742-6025-4a8c-b621-449da3a45ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_0aedafa3-f20f-4dcd-a467-9070129c5544" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_351b5742-6025-4a8c-b621-449da3a45ec8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_77838278-9751-492e-b173-23c4cb56ba05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_0aedafa3-f20f-4dcd-a467-9070129c5544" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_77838278-9751-492e-b173-23c4cb56ba05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_3f33ac5b-0f85-4a0f-b976-cebf38c22042" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_0aedafa3-f20f-4dcd-a467-9070129c5544" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_3f33ac5b-0f85-4a0f-b976-cebf38c22042" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_398d6e42-b556-4c1a-9294-c1fa0359b33d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_39d4bce7-89a4-4e0e-be39-b9a24b9c6927" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_398d6e42-b556-4c1a-9294-c1fa0359b33d" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_39d4bce7-89a4-4e0e-be39-b9a24b9c6927" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_5f2e23cc-c6e1-46b3-a535-36c6504f1b42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_398d6e42-b556-4c1a-9294-c1fa0359b33d" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_5f2e23cc-c6e1-46b3-a535-36c6504f1b42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_df2d9fb9-b791-435f-8b69-a23ebf240f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_398d6e42-b556-4c1a-9294-c1fa0359b33d" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_df2d9fb9-b791-435f-8b69-a23ebf240f9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_b0e83ef9-d256-445f-8cf7-865e6471596c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_398d6e42-b556-4c1a-9294-c1fa0359b33d" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_b0e83ef9-d256-445f-8cf7-865e6471596c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DisposalGroupInclDiscontinuedOperationsDistributionReceived_314280c4-6615-45cc-a8f3-342c56d9627f" xlink:href="mrk-20220930.xsd#mrk_DisposalGroupInclDiscontinuedOperationsDistributionReceived"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_398d6e42-b556-4c1a-9294-c1fa0359b33d" xlink:to="loc_mrk_DisposalGroupInclDiscontinuedOperationsDistributionReceived_314280c4-6615-45cc-a8f3-342c56d9627f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_658dc487-7b2c-49b5-9074-1bc43b65168e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebt"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_398d6e42-b556-4c1a-9294-c1fa0359b33d" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_658dc487-7b2c-49b5-9074-1bc43b65168e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_1e58d23a-2981-4277-bc0e-39fd4128c703" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_398d6e42-b556-4c1a-9294-c1fa0359b33d" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_1e58d23a-2981-4277-bc0e-39fd4128c703" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_154ad539-9ff0-4b4a-9f77-3bd255477a18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_7309a958-ce3c-44c9-b383-c61cb3256dad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_154ad539-9ff0-4b4a-9f77-3bd255477a18" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_7309a958-ce3c-44c9-b383-c61cb3256dad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_7e6a4104-f0c5-48bb-9eab-648f684ad724" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_154ad539-9ff0-4b4a-9f77-3bd255477a18" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_7e6a4104-f0c5-48bb-9eab-648f684ad724" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_82729461-2d3a-44d4-a877-76006c7e6d72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_154ad539-9ff0-4b4a-9f77-3bd255477a18" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_82729461-2d3a-44d4-a877-76006c7e6d72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c77b5b40-74cd-4069-8f10-c5ec41342237" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_154ad539-9ff0-4b4a-9f77-3bd255477a18" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c77b5b40-74cd-4069-8f10-c5ec41342237" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations_c15a3123-3935-494d-a874-a52adc8afc4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInDiscontinuedOperations"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_154ad539-9ff0-4b4a-9f77-3bd255477a18" xlink:to="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations_c15a3123-3935-494d-a874-a52adc8afc4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_d350a8df-2633-4c70-be4b-ab07b4a81a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapital_bf094c53-558b-4ef6-8b78-6e0f56dff917" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapital"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_d350a8df-2633-4c70-be4b-ab07b4a81a1b" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapital_bf094c53-558b-4ef6-8b78-6e0f56dff917" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_436b7da7-4f90-4f19-af35-d60554e2ebc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_d350a8df-2633-4c70-be4b-ab07b4a81a1b" xlink:to="loc_us-gaap_AdjustmentForAmortization_436b7da7-4f90-4f19-af35-d60554e2ebc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_76eb164e-ee46-49b6-84ac-33b69b66cc7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_d350a8df-2633-4c70-be4b-ab07b4a81a1b" xlink:to="loc_us-gaap_ShareBasedCompensation_76eb164e-ee46-49b6-84ac-33b69b66cc7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b2d16035-f235-4723-9943-60c17beaf884" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_d350a8df-2633-4c70-be4b-ab07b4a81a1b" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b2d16035-f235-4723-9943-60c17beaf884" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_a05808c4-0c47-4020-874f-f1c0a2965cb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_d350a8df-2633-4c70-be4b-ab07b4a81a1b" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_a05808c4-0c47-4020-874f-f1c0a2965cb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_c1de6d15-4e08-42b7-a85f-dc9b816db8d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_d350a8df-2633-4c70-be4b-ab07b4a81a1b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_c1de6d15-4e08-42b7-a85f-dc9b816db8d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_7f10826b-b558-4b76-9d27-f517835a768d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_d350a8df-2633-4c70-be4b-ab07b4a81a1b" xlink:to="loc_us-gaap_Depreciation_7f10826b-b558-4b76-9d27-f517835a768d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_3e78e016-68e3-4c63-a78c-d501526d9aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_d350a8df-2633-4c70-be4b-ab07b4a81a1b" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_3e78e016-68e3-4c63-a78c-d501526d9aa3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_e5cd049d-7c76-40fe-99bb-8ff57548699b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_d350a8df-2633-4c70-be4b-ab07b4a81a1b" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_e5cd049d-7c76-40fe-99bb-8ff57548699b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_f4c5ff15-526d-4320-bd83-0db4f6d5e1e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_d350a8df-2633-4c70-be4b-ab07b4a81a1b" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_f4c5ff15-526d-4320-bd83-0db4f6d5e1e2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_59d43913-3c4d-4cd6-bdc9-9caa146fc10d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_6ee6f4d5-b377-491c-96dc-5600cd70c8c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_59d43913-3c4d-4cd6-bdc9-9caa146fc10d" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_6ee6f4d5-b377-491c-96dc-5600cd70c8c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_8a6912d1-ffd2-494f-9b2f-f58f4f065ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_59d43913-3c4d-4cd6-bdc9-9caa146fc10d" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_8a6912d1-ffd2-494f-9b2f-f58f4f065ec3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_74321a79-f6f1-44b0-80c1-0e4ad4cd2d24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_f36dec1f-26d2-4b4c-90df-58c8c6e90e70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_74321a79-f6f1-44b0-80c1-0e4ad4cd2d24" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_f36dec1f-26d2-4b4c-90df-58c8c6e90e70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_bb0499df-34b0-4bc6-a96b-773ec0936c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_74321a79-f6f1-44b0-80c1-0e4ad4cd2d24" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_bb0499df-34b0-4bc6-a96b-773ec0936c2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_8718f47c-11df-4d00-8a13-c33faba23a40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_e261aec2-1645-46d7-be42-6d39ca90d637" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_8718f47c-11df-4d00-8a13-c33faba23a40" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_e261aec2-1645-46d7-be42-6d39ca90d637" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses_50f238f0-5b23-44b1-ac68-366ff3669d76" xlink:href="mrk-20220930.xsd#mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_8718f47c-11df-4d00-8a13-c33faba23a40" xlink:to="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses_50f238f0-5b23-44b1-ac68-366ff3669d76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts_55851e90-de72-41a1-b2f2-0905dd1e7ff4" xlink:href="mrk-20220930.xsd#mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_8718f47c-11df-4d00-8a13-c33faba23a40" xlink:to="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts_55851e90-de72-41a1-b2f2-0905dd1e7ff4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet_26ead241-ca21-4220-bd1e-33c0da2b3c38" xlink:href="mrk-20220930.xsd#mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_8718f47c-11df-4d00-8a13-c33faba23a40" xlink:to="loc_mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet_26ead241-ca21-4220-bd1e-33c0da2b3c38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_74f020b9-ebd6-477b-8ca6-9d3198c40a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_8718f47c-11df-4d00-8a13-c33faba23a40" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_74f020b9-ebd6-477b-8ca6-9d3198c40a3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_62e7896f-2ab3-4e8a-a994-fd4e276b4d78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_53c4c973-71bd-44df-a175-a47879010145" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_62e7896f-2ab3-4e8a-a994-fd4e276b4d78" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_53c4c973-71bd-44df-a175-a47879010145" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod_41919ed0-f816-49ae-95ac-0a9619fabca8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_62e7896f-2ab3-4e8a-a994-fd4e276b4d78" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod_41919ed0-f816-49ae-95ac-0a9619fabca8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#CollaborativeArrangementsFinancialInformationDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_eeaadc6b-c03f-43a8-b779-f88cf5514338" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementProfitSharing_829c61eb-c2f7-407a-9629-2eee9d35ad9f" xlink:href="mrk-20220930.xsd#mrk_CollaborativeArrangementProfitSharing"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_eeaadc6b-c03f-43a8-b779-f88cf5514338" xlink:to="loc_mrk_CollaborativeArrangementProfitSharing_829c61eb-c2f7-407a-9629-2eee9d35ad9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementSalesNet_70310ed9-9d8e-4429-b9fb-17feef930be9" xlink:href="mrk-20220930.xsd#mrk_CollaborativeArrangementSalesNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_eeaadc6b-c03f-43a8-b779-f88cf5514338" xlink:to="loc_mrk_CollaborativeArrangementSalesNet_70310ed9-9d8e-4429-b9fb-17feef930be9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_c8c39e36-97a5-46c1-aa39-a394e5df1f32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_7bb148d7-6acb-4331-8557-bcdcb3f6a0f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_c8c39e36-97a5-46c1-aa39-a394e5df1f32" xlink:to="loc_us-gaap_DerivativeAssets_7bb148d7-6acb-4331-8557-bcdcb3f6a0f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_7a93caaf-696e-448c-9790-cbbfd373edff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_c8c39e36-97a5-46c1-aa39-a394e5df1f32" xlink:to="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_7a93caaf-696e-448c-9790-cbbfd373edff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash_b1c8850b-0c89-4612-8420-a73f8f4f7dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_c8c39e36-97a5-46c1-aa39-a394e5df1f32" xlink:to="loc_us-gaap_DerivativeCollateralObligationToReturnCash_b1c8850b-0c89-4612-8420-a73f8f4f7dd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_f789fd13-0b9d-48be-9f6b-fe5c5870deef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_66f5fa14-005c-4105-bbaa-2433a5f213ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_f789fd13-0b9d-48be-9f6b-fe5c5870deef" xlink:to="loc_us-gaap_DerivativeLiabilities_66f5fa14-005c-4105-bbaa-2433a5f213ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_7186d523-5989-4bbd-a400-9a39ed2a36d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_f789fd13-0b9d-48be-9f6b-fe5c5870deef" xlink:to="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_7186d523-5989-4bbd-a400-9a39ed2a36d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash_16f2f402-0972-4a01-ae37-f4d55549b753" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_f789fd13-0b9d-48be-9f6b-fe5c5870deef" xlink:to="loc_us-gaap_DerivativeCollateralRightToReclaimCash_16f2f402-0972-4a01-ae37-f4d55549b753" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_895f9e55-32bc-4040-b1b0-3371f7fc4008" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e460d849-38c3-435b-b690-1d41513b02ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_895f9e55-32bc-4040-b1b0-3371f7fc4008" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e460d849-38c3-435b-b690-1d41513b02ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_855440a8-635a-4b28-9bb8-e071e9d5cc61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_895f9e55-32bc-4040-b1b0-3371f7fc4008" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_855440a8-635a-4b28-9bb8-e071e9d5cc61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_16ed8945-37b4-480a-9c23-e6412a7c6f7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_895f9e55-32bc-4040-b1b0-3371f7fc4008" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_16ed8945-37b4-480a-9c23-e6412a7c6f7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI_39990a77-04b6-4abb-b212-ad00fe608a69" xlink:href="mrk-20220930.xsd#mrk_DebtSecuritiesandEquitySecuritiesFVNI"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a203a82e-eef2-4972-8c18-4381ab17e9e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI_39990a77-04b6-4abb-b212-ad00fe608a69" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a203a82e-eef2-4972-8c18-4381ab17e9e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_747e1756-2d8e-42f3-9cbf-de09a272fffc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI_39990a77-04b6-4abb-b212-ad00fe608a69" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_747e1756-2d8e-42f3-9cbf-de09a272fffc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_90133032-3909-45cb-a67c-7fd56a71b97e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities_63f52fed-0578-41a4-90c9-745403e97168" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_90133032-3909-45cb-a67c-7fd56a71b97e" xlink:to="loc_us-gaap_TradingSecurities_63f52fed-0578-41a4-90c9-745403e97168" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_8d7e20c9-b219-4d73-b379-a5132ebbdf6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_90133032-3909-45cb-a67c-7fd56a71b97e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_8d7e20c9-b219-4d73-b379-a5132ebbdf6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_fd9672c0-4410-497c-b6dd-818494171d61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_90133032-3909-45cb-a67c-7fd56a71b97e" xlink:to="loc_us-gaap_DerivativeAssets_fd9672c0-4410-497c-b6dd-818494171d61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_8ecc7ab2-c282-4aaa-9be0-1d70f549c7b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_8ecd5a1e-98e1-4561-92e1-20a2aed79ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_8ecc7ab2-c282-4aaa-9be0-1d70f549c7b4" xlink:to="loc_us-gaap_DerivativeLiabilities_8ecd5a1e-98e1-4561-92e1-20a2aed79ea9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_4138dc7d-6ddb-44fb-8f37-bcec8be88944" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_8ecc7ab2-c282-4aaa-9be0-1d70f549c7b4" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_4138dc7d-6ddb-44fb-8f37-bcec8be88944" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities_c501a837-9f8a-4104-b3da-ae9f301a119f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_04c2d79e-b465-4fcd-bfd2-0d3b53cef912" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_TradingSecurities_c501a837-9f8a-4104-b3da-ae9f301a119f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_04c2d79e-b465-4fcd-bfd2-0d3b53cef912" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_36e61b8e-e2d8-4c75-8970-6a3cfd4f107f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_TradingSecurities_c501a837-9f8a-4104-b3da-ae9f301a119f" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_36e61b8e-e2d8-4c75-8970-6a3cfd4f107f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_954720a2-765a-4a89-82bd-0abd978c3cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_a770b126-e679-4061-9551-398552aa0c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_954720a2-765a-4a89-82bd-0abd978c3cbb" xlink:to="loc_us-gaap_InventoryFinishedGoods_a770b126-e679-4061-9551-398552aa0c2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessAndRawMaterials_995f51ee-e0c1-462c-a989-d26e178fdc6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessAndRawMaterials"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_954720a2-765a-4a89-82bd-0abd978c3cbb" xlink:to="loc_us-gaap_InventoryWorkInProcessAndRawMaterials_995f51ee-e0c1-462c-a989-d26e178fdc6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventorySupplies_5ea1f856-dbc6-4162-aeb8-b9c21b3a3fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInventorySupplies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_954720a2-765a-4a89-82bd-0abd978c3cbb" xlink:to="loc_us-gaap_OtherInventorySupplies_5ea1f856-dbc6-4162-aeb8-b9c21b3a3fb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryNetAndInventoryNoncurrent_954f2e60-b207-4ac3-8544-14fe83ab65a1" xlink:href="mrk-20220930.xsd#mrk_InventoryNetAndInventoryNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_0bfc217c-14dc-4478-82a9-a2c4b76c31a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_InventoryNetAndInventoryNoncurrent_954f2e60-b207-4ac3-8544-14fe83ab65a1" xlink:to="loc_us-gaap_InventoryGross_0bfc217c-14dc-4478-82a9-a2c4b76c31a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLIFOReserve_d99229da-5c57-4ca3-ad58-c535fe46f55e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLIFOReserve"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_InventoryNetAndInventoryNoncurrent_954f2e60-b207-4ac3-8544-14fe83ab65a1" xlink:to="loc_us-gaap_InventoryLIFOReserve_d99229da-5c57-4ca3-ad58-c535fe46f55e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/InventoriesScheduleofInventoriesDetails_1" xlink:type="simple" xlink:href="mrk-20220930.xsd#InventoriesScheduleofInventoriesDetails_1"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/InventoriesScheduleofInventoriesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryNetAndInventoryNoncurrent_3b771e8d-bf30-404f-9bcd-c61e2225a9f4" xlink:href="mrk-20220930.xsd#mrk_InventoryNetAndInventoryNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_83cc2b20-fb50-4f7d-aaab-7cb39b47c05b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_InventoryNetAndInventoryNoncurrent_3b771e8d-bf30-404f-9bcd-c61e2225a9f4" xlink:to="loc_us-gaap_InventoryNet_83cc2b20-fb50-4f7d-aaab-7cb39b47c05b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_e3f62d47-4681-4e16-9d4e-c69a71166ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_InventoryNetAndInventoryNoncurrent_3b771e8d-bf30-404f-9bcd-c61e2225a9f4" xlink:to="loc_us-gaap_InventoryNoncurrent_e3f62d47-4681-4e16-9d4e-c69a71166ed6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_3ed0b3dd-7a27-4df1-b183-3d7d3cce9e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_4307e605-82a5-4634-99b7-f93418e65d64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_3ed0b3dd-7a27-4df1-b183-3d7d3cce9e9b" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_4307e605-82a5-4634-99b7-f93418e65d64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_05f4bd34-e0a2-468d-a614-de7445e3cdc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_3ed0b3dd-7a27-4df1-b183-3d7d3cce9e9b" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_05f4bd34-e0a2-468d-a614-de7445e3cdc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_5d58366d-712e-4b93-90d4-4e9b87920f43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_3ed0b3dd-7a27-4df1-b183-3d7d3cce9e9b" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_5d58366d-712e-4b93-90d4-4e9b87920f43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_0454a1d2-b9c8-48b5-8a9b-3cfcf779ffe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_3ed0b3dd-7a27-4df1-b183-3d7d3cce9e9b" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_0454a1d2-b9c8-48b5-8a9b-3cfcf779ffe2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_541b21cb-effd-4d4a-847c-8aeed1e36d48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_3ed0b3dd-7a27-4df1-b183-3d7d3cce9e9b" xlink:to="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_541b21cb-effd-4d4a-847c-8aeed1e36d48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_34c709a5-3f07-4eff-a754-0051621744b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_3ed0b3dd-7a27-4df1-b183-3d7d3cce9e9b" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_34c709a5-3f07-4eff-a754-0051621744b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_336a8c5e-17a8-492a-9cfe-0b9e967c6217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_3ed0b3dd-7a27-4df1-b183-3d7d3cce9e9b" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_336a8c5e-17a8-492a-9cfe-0b9e967c6217" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_e76ebe32-92cb-4398-b49b-ba81a96f9b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_3ed0b3dd-7a27-4df1-b183-3d7d3cce9e9b" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_e76ebe32-92cb-4398-b49b-ba81a96f9b9a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_76ccde58-f68a-4ca8-b7d9-4845c7cad0ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_07ff1c6b-d69c-47fd-b6b7-a50e80c3cbc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_76ccde58-f68a-4ca8-b7d9-4845c7cad0ee" xlink:to="loc_us-gaap_InvestmentIncomeInterest_07ff1c6b-d69c-47fd-b6b7-a50e80c3cbc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_f7124f5e-236a-49ad-924c-e7f6c26ab463" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_76ccde58-f68a-4ca8-b7d9-4845c7cad0ee" xlink:to="loc_us-gaap_InterestExpense_f7124f5e-236a-49ad-924c-e7f6c26ab463" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_5fd0ce81-afb4-42b8-bb84-5d30d4365b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_76ccde58-f68a-4ca8-b7d9-4845c7cad0ee" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_5fd0ce81-afb4-42b8-bb84-5d30d4365b9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_f820db84-0f6e-4475-9c8b-0b216716b674" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_76ccde58-f68a-4ca8-b7d9-4845c7cad0ee" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_f820db84-0f6e-4475-9c8b-0b216716b674" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_95f22a4c-c67a-4d64-9deb-5af51549be54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_76ccde58-f68a-4ca8-b7d9-4845c7cad0ee" xlink:to="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_95f22a4c-c67a-4d64-9deb-5af51549be54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherNonoperatingIncomeExpenseOther_d8ac81f8-a9d0-4ee3-9b41-4a87abe4205f" xlink:href="mrk-20220930.xsd#mrk_OtherNonoperatingIncomeExpenseOther"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_76ccde58-f68a-4ca8-b7d9-4845c7cad0ee" xlink:to="loc_mrk_OtherNonoperatingIncomeExpenseOther_d8ac81f8-a9d0-4ee3-9b41-4a87abe4205f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#EarningsPerShareCalculationsofEarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_f3d39835-ba09-4c3a-8285-7261d1060534" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_c3527e9d-4af2-4388-800a-846300be6a61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_f3d39835-ba09-4c3a-8285-7261d1060534" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_c3527e9d-4af2-4388-800a-846300be6a61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_ccfcecfb-ef54-49ab-9993-fcb83d4cef5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_f3d39835-ba09-4c3a-8285-7261d1060534" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_ccfcecfb-ef54-49ab-9993-fcb83d4cef5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_099e0bd0-8012-4258-8e64-64f79f9fa1dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_07d6dc08-04f6-4a21-8a2e-b4e766fc0467" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_099e0bd0-8012-4258-8e64-64f79f9fa1dc" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_07d6dc08-04f6-4a21-8a2e-b4e766fc0467" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_1670b3af-9c67-44db-8d77-02238e0d4d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_099e0bd0-8012-4258-8e64-64f79f9fa1dc" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_1670b3af-9c67-44db-8d77-02238e0d4d7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_62a02599-e3f7-40f8-b545-ed762846d5dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a0c3ffd7-7204-44b8-af15-26b8ec7591dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_62a02599-e3f7-40f8-b545-ed762846d5dc" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a0c3ffd7-7204-44b8-af15-26b8ec7591dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_ccff4457-c43b-40b8-b353-ed575fd24b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_62a02599-e3f7-40f8-b545-ed762846d5dc" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_ccff4457-c43b-40b8-b353-ed575fd24b9d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#OtherComprehensiveIncomeLossDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3f88d363-5083-4c1a-95d4-79ffbc9d571a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_284b3154-3f4b-4972-9534-a3259548e0c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3f88d363-5083-4c1a-95d4-79ffbc9d571a" xlink:to="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_284b3154-3f4b-4972-9534-a3259548e0c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_862b9095-5e58-498b-aa49-7d8afa4ceedd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3f88d363-5083-4c1a-95d4-79ffbc9d571a" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_862b9095-5e58-498b-aa49-7d8afa4ceedd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_2e1ed482-4707-4e2b-bea3-4570a4b10f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_4399cfbd-2afe-4a72-a47f-4c0f7c377c08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_2e1ed482-4707-4e2b-bea3-4570a4b10f1e" xlink:to="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_4399cfbd-2afe-4a72-a47f-4c0f7c377c08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_84e9e44c-c8c9-4d6b-9165-12b6c308c9b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_2e1ed482-4707-4e2b-bea3-4570a4b10f1e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_84e9e44c-c8c9-4d6b-9165-12b6c308c9b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_d0bb07af-0031-49f5-8dd5-191e9ee19bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_c2248a15-aa1b-4596-8582-588336bed68f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_d0bb07af-0031-49f5-8dd5-191e9ee19bcb" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_c2248a15-aa1b-4596-8582-588336bed68f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_7d99838d-67e3-442f-9d05-f54cc7683db0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_d0bb07af-0031-49f5-8dd5-191e9ee19bcb" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_7d99838d-67e3-442f-9d05-f54cc7683db0" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>mrk-20220930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:18be82ff-6aae-4643-b5c5-ea6de452de6c,g:778f8bae-d5d9-4bda-a4ad-ec173f2835d1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.merck.com/role/CoverPage" xlink:type="simple" xlink:href="mrk-20220930.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/CoverPage" xlink:type="extended" id="i548d02b3230e4d998b2e6fef04cdfea2_CoverPage">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_02899172-219d-4223-9b36-bd3d2e4d7494" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_DocumentType_02899172-219d-4223-9b36-bd3d2e4d7494" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_1269d9ae-4613-42a9-bf4d-2e64306eadb5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_DocumentQuarterlyReport_1269d9ae-4613-42a9-bf4d-2e64306eadb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_3fdb803b-c4cc-4820-a23d-d348aa6b1a35" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_DocumentPeriodEndDate_3fdb803b-c4cc-4820-a23d-d348aa6b1a35" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_d53796c2-4841-494f-a532-ac331074efe8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_DocumentTransitionReport_d53796c2-4841-494f-a532-ac331074efe8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_78280a67-ef73-4170-abdb-6e86b4259873" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_EntityFileNumber_78280a67-ef73-4170-abdb-6e86b4259873" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_6e198498-90d4-4993-9f56-ad6a443cb467" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_EntityRegistrantName_6e198498-90d4-4993-9f56-ad6a443cb467" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_d963f84f-26f3-4ce9-8406-5e3c57fdb795" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_EntityIncorporationStateCountryCode_d963f84f-26f3-4ce9-8406-5e3c57fdb795" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_17b5715b-e536-45b2-a23e-fafa56a484ce" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_EntityTaxIdentificationNumber_17b5715b-e536-45b2-a23e-fafa56a484ce" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_682fe0ce-38b4-481f-96cb-d88530bdb05d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_EntityAddressAddressLine1_682fe0ce-38b4-481f-96cb-d88530bdb05d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_90adf29d-0fe6-4dd5-ba02-2f0ae76631b5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_EntityAddressCityOrTown_90adf29d-0fe6-4dd5-ba02-2f0ae76631b5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_2748c624-9285-4809-98f8-616b61c2d422" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_EntityAddressStateOrProvince_2748c624-9285-4809-98f8-616b61c2d422" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_65283da9-e318-4d24-88dd-598a06f90535" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_EntityAddressPostalZipCode_65283da9-e318-4d24-88dd-598a06f90535" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_a68dd464-1cf1-4d03-88fe-82b8805f0962" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_CityAreaCode_a68dd464-1cf1-4d03-88fe-82b8805f0962" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_8ba67ea3-b9b5-4eb7-82a4-a378bcb1cbac" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_LocalPhoneNumber_8ba67ea3-b9b5-4eb7-82a4-a378bcb1cbac" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_e7b2ba1e-1675-4c96-8183-4a324a554ad5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_Security12bTitle_e7b2ba1e-1675-4c96-8183-4a324a554ad5" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_ae098a95-76d6-4335-b568-7b2a234565ac" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_TradingSymbol_ae098a95-76d6-4335-b568-7b2a234565ac" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_6f7691d6-9cca-4ee1-bcfa-d3c5dd5ff478" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_SecurityExchangeName_6f7691d6-9cca-4ee1-bcfa-d3c5dd5ff478" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_d80adae2-c64a-4250-9661-0b329156c545" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_EntityCurrentReportingStatus_d80adae2-c64a-4250-9661-0b329156c545" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_021c44b9-6b02-48d7-b451-bf3c9c76bba8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_EntityInteractiveDataCurrent_021c44b9-6b02-48d7-b451-bf3c9c76bba8" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_6e6352ac-c7fd-42b3-bbbf-c9fbcd61f96e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_EntityFilerCategory_6e6352ac-c7fd-42b3-bbbf-c9fbcd61f96e" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_081bdd43-de97-4757-841a-7d16f2762023" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_EntitySmallBusiness_081bdd43-de97-4757-841a-7d16f2762023" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_dc2d3c6b-5f05-4e6e-b817-d008b33cb00f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_EntityEmergingGrowthCompany_dc2d3c6b-5f05-4e6e-b817-d008b33cb00f" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_705a18ab-a35c-4011-b4ad-6a6c2c0b8564" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_EntityShellCompany_705a18ab-a35c-4011-b4ad-6a6c2c0b8564" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_edd4793b-963b-4d69-907e-22f69f72ad70" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_edd4793b-963b-4d69-907e-22f69f72ad70" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_2a187945-54ec-412c-8948-bee913f82fed" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_AmendmentFlag_2a187945-54ec-412c-8948-bee913f82fed" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_ffae1c7b-caa6-4c85-9aaa-b76f1d9bf400" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_DocumentFiscalYearFocus_ffae1c7b-caa6-4c85-9aaa-b76f1d9bf400" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_d6130d99-0e3c-4f4e-a150-579c0d299677" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_DocumentFiscalPeriodFocus_d6130d99-0e3c-4f4e-a150-579c0d299677" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_cc6bc9d9-a05c-48cf-947a-507ebc0ecbd5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_EntityCentralIndexKey_cc6bc9d9-a05c-48cf-947a-507ebc0ecbd5" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_c415ca8b-ebb8-4485-9748-2a4626d7c348" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_CurrentFiscalYearEndDate_c415ca8b-ebb8-4485-9748-2a4626d7c348" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_7113aa42-ebf7-4cb1-b327-32e322904071" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_EntitiesTable_7113aa42-ebf7-4cb1-b327-32e322904071" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_424530f5-eae6-4a02-aeed-21b570c205e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_7113aa42-ebf7-4cb1-b327-32e322904071" xlink:to="loc_us-gaap_StatementClassOfStockAxis_424530f5-eae6-4a02-aeed-21b570c205e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_424530f5-eae6-4a02-aeed-21b570c205e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_424530f5-eae6-4a02-aeed-21b570c205e1" xlink:to="loc_us-gaap_ClassOfStockDomain_424530f5-eae6-4a02-aeed-21b570c205e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_59d290b2-13fb-48c6-b807-47453d702271" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_424530f5-eae6-4a02-aeed-21b570c205e1" xlink:to="loc_us-gaap_ClassOfStockDomain_59d290b2-13fb-48c6-b807-47453d702271" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_91356c4b-6f60-4805-8e36-bb8e428ccb0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_59d290b2-13fb-48c6-b807-47453d702271" xlink:to="loc_us-gaap_CommonStockMember_91356c4b-6f60-4805-8e36-bb8e428ccb0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A0.500Notesdue2024Member_86519de4-0d66-464b-bbc4-5b6eeb5be3bc" xlink:href="mrk-20220930.xsd#mrk_A0.500Notesdue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_59d290b2-13fb-48c6-b807-47453d702271" xlink:to="loc_mrk_A0.500Notesdue2024Member_86519de4-0d66-464b-bbc4-5b6eeb5be3bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.875Notesdue2026Member_a383f5ce-9253-4abc-8fef-257a0fe1560f" xlink:href="mrk-20220930.xsd#mrk_A1.875Notesdue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_59d290b2-13fb-48c6-b807-47453d702271" xlink:to="loc_mrk_A1.875Notesdue2026Member_a383f5ce-9253-4abc-8fef-257a0fe1560f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.500Notesdue2034Member_8ab614b1-a07c-41e3-97d9-3c4429b4f94d" xlink:href="mrk-20220930.xsd#mrk_A2.500Notesdue2034Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_59d290b2-13fb-48c6-b807-47453d702271" xlink:to="loc_mrk_A2.500Notesdue2034Member_8ab614b1-a07c-41e3-97d9-3c4429b4f94d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.375Notesdue2036Member_51ad06d9-1ffa-4747-a2c1-56839d00dd8d" xlink:href="mrk-20220930.xsd#mrk_A1.375Notesdue2036Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_59d290b2-13fb-48c6-b807-47453d702271" xlink:to="loc_mrk_A1.375Notesdue2036Member_51ad06d9-1ffa-4747-a2c1-56839d00dd8d" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" xlink:type="simple" xlink:href="mrk-20220930.xsd#PensionandOtherPostretirementBenefitPlansTables"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" xlink:type="extended" id="i78468cbe5f43472189640cd902fcbea8_PensionandOtherPostretirementBenefitPlansTables">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2989e9d7-59e7-4cd5-a6e2-c56883903abc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_3bcc995d-c6ed-42fb-8755-42789ec66044" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2989e9d7-59e7-4cd5-a6e2-c56883903abc" xlink:to="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_3bcc995d-c6ed-42fb-8755-42789ec66044" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b38980ef-8097-494a-94b6-6214cafc7727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2989e9d7-59e7-4cd5-a6e2-c56883903abc" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b38980ef-8097-494a-94b6-6214cafc7727" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_5b49b1ec-30db-48d0-bf56-37935515a413" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b38980ef-8097-494a-94b6-6214cafc7727" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_5b49b1ec-30db-48d0-bf56-37935515a413" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_5b49b1ec-30db-48d0-bf56-37935515a413_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_5b49b1ec-30db-48d0-bf56-37935515a413" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_5b49b1ec-30db-48d0-bf56-37935515a413_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_e5e2b4d7-a77e-41f9-9da4-136d333c0a98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_5b49b1ec-30db-48d0-bf56-37935515a413" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_e5e2b4d7-a77e-41f9-9da4-136d333c0a98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_9f51901b-2ff6-48e6-bf8e-133d3be70acf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_e5e2b4d7-a77e-41f9-9da4-136d333c0a98" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_9f51901b-2ff6-48e6-bf8e-133d3be70acf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_4e37ad54-b862-4f80-8902-920b1e0253fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_e5e2b4d7-a77e-41f9-9da4-136d333c0a98" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_4e37ad54-b862-4f80-8902-920b1e0253fd" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#SpinOffofOrganonCoNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" xlink:type="extended" id="ibaae5365d079427cb504394cd425914e_SpinOffofOrganonCoNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_926bfe8e-0efa-42ff-b4b4-7b564e6e5dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_271bda9c-5f22-493d-b658-4fe17c6376a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_926bfe8e-0efa-42ff-b4b4-7b564e6e5dd6" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_271bda9c-5f22-493d-b658-4fe17c6376a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_108f197c-05b6-4c7c-9249-751a8316e820" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_926bfe8e-0efa-42ff-b4b4-7b564e6e5dd6" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_108f197c-05b6-4c7c-9249-751a8316e820" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_f6f42f6d-182b-4246-81d9-3eb245b47690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_926bfe8e-0efa-42ff-b4b4-7b564e6e5dd6" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_f6f42f6d-182b-4246-81d9-3eb245b47690" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal_40acca4d-06a2-44af-b65e-ccba8b5bf327" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_926bfe8e-0efa-42ff-b4b4-7b564e6e5dd6" xlink:to="loc_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal_40acca4d-06a2-44af-b65e-ccba8b5bf327" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_184e9476-c6b8-4f9c-938d-9e372f815fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_926bfe8e-0efa-42ff-b4b4-7b564e6e5dd6" xlink:to="loc_us-gaap_RevenueFromRelatedParties_184e9476-c6b8-4f9c-938d-9e372f815fb0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartiesAmountInCostOfSales_209a2262-dc81-426a-90b2-86930a42dbb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartiesAmountInCostOfSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_926bfe8e-0efa-42ff-b4b4-7b564e6e5dd6" xlink:to="loc_us-gaap_RelatedPartiesAmountInCostOfSales_209a2262-dc81-426a-90b2-86930a42dbb3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_4c193f54-43e6-4504-9938-2d99688d2b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_926bfe8e-0efa-42ff-b4b4-7b564e6e5dd6" xlink:to="loc_us-gaap_DueFromRelatedPartiesCurrent_4c193f54-43e6-4504-9938-2d99688d2b5a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_191c86de-6777-4d26-bd97-c2365d076938" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_926bfe8e-0efa-42ff-b4b4-7b564e6e5dd6" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_191c86de-6777-4d26-bd97-c2365d076938" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_2ffe9c2b-7b61-41b7-aa7b-e5227ebc459f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_926bfe8e-0efa-42ff-b4b4-7b564e6e5dd6" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_2ffe9c2b-7b61-41b7-aa7b-e5227ebc459f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_65bbaf45-3e32-4119-97ec-fac095805524" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_926bfe8e-0efa-42ff-b4b4-7b564e6e5dd6" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_65bbaf45-3e32-4119-97ec-fac095805524" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_731a6dc1-adb7-418a-96e1-fc3e18431deb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_65bbaf45-3e32-4119-97ec-fac095805524" xlink:to="loc_dei_LegalEntityAxis_731a6dc1-adb7-418a-96e1-fc3e18431deb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_731a6dc1-adb7-418a-96e1-fc3e18431deb_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_731a6dc1-adb7-418a-96e1-fc3e18431deb" xlink:to="loc_dei_EntityDomain_731a6dc1-adb7-418a-96e1-fc3e18431deb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_7d16f7ed-f886-4dfa-becc-48c6b35c421d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_731a6dc1-adb7-418a-96e1-fc3e18431deb" xlink:to="loc_dei_EntityDomain_7d16f7ed-f886-4dfa-becc-48c6b35c421d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OrganonCoMember_0aa9242d-efaa-4929-b621-33e4d6fe434b" xlink:href="mrk-20220930.xsd#mrk_OrganonCoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_7d16f7ed-f886-4dfa-becc-48c6b35c421d" xlink:to="loc_mrk_OrganonCoMember_0aa9242d-efaa-4929-b621-33e4d6fe434b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c7de8491-c2c5-4d5e-9347-87edcc1d73ad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_65bbaf45-3e32-4119-97ec-fac095805524" xlink:to="loc_srt_RangeAxis_c7de8491-c2c5-4d5e-9347-87edcc1d73ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c7de8491-c2c5-4d5e-9347-87edcc1d73ad_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c7de8491-c2c5-4d5e-9347-87edcc1d73ad" xlink:to="loc_srt_RangeMember_c7de8491-c2c5-4d5e-9347-87edcc1d73ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f3ef73c2-3fee-438b-9c48-5fba3b4e47c5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c7de8491-c2c5-4d5e-9347-87edcc1d73ad" xlink:to="loc_srt_RangeMember_f3ef73c2-3fee-438b-9c48-5fba3b4e47c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a29a3f6f-3785-4bf6-9ba8-d1e73e40dadd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f3ef73c2-3fee-438b-9c48-5fba3b4e47c5" xlink:to="loc_srt_MinimumMember_a29a3f6f-3785-4bf6-9ba8-d1e73e40dadd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_af63107a-5d5b-445b-be5e-4b7451b2e0d6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f3ef73c2-3fee-438b-9c48-5fba3b4e47c5" xlink:to="loc_srt_MaximumMember_af63107a-5d5b-445b-be5e-4b7451b2e0d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_3480582e-2bb7-4926-98dd-e544597b5e95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_65bbaf45-3e32-4119-97ec-fac095805524" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_3480582e-2bb7-4926-98dd-e544597b5e95" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_3480582e-2bb7-4926-98dd-e544597b5e95_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_3480582e-2bb7-4926-98dd-e544597b5e95" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_3480582e-2bb7-4926-98dd-e544597b5e95_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_ce48dee0-1138-43b9-942a-3b045a97e7f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_3480582e-2bb7-4926-98dd-e544597b5e95" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_ce48dee0-1138-43b9-942a-3b045a97e7f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_TransitionServicesAgreementMember_e49fa9d1-be06-45ae-946e-a428fc106bca" xlink:href="mrk-20220930.xsd#mrk_TransitionServicesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_ce48dee0-1138-43b9-942a-3b045a97e7f7" xlink:to="loc_mrk_TransitionServicesAgreementMember_e49fa9d1-be06-45ae-946e-a428fc106bca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ManufacturingAndSupplyAgreementsMember_6964e711-ae34-4f47-b87a-d128ac26d908" xlink:href="mrk-20220930.xsd#mrk_ManufacturingAndSupplyAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_ce48dee0-1138-43b9-942a-3b045a97e7f7" xlink:to="loc_mrk_ManufacturingAndSupplyAgreementsMember_6964e711-ae34-4f47-b87a-d128ac26d908" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7d1ff179-7912-4071-8bbe-7cfbbe6b156d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_65bbaf45-3e32-4119-97ec-fac095805524" xlink:to="loc_srt_CounterpartyNameAxis_7d1ff179-7912-4071-8bbe-7cfbbe6b156d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7d1ff179-7912-4071-8bbe-7cfbbe6b156d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_7d1ff179-7912-4071-8bbe-7cfbbe6b156d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7d1ff179-7912-4071-8bbe-7cfbbe6b156d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_99318653-6a51-4961-bc55-692069d231ad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_7d1ff179-7912-4071-8bbe-7cfbbe6b156d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_99318653-6a51-4961-bc55-692069d231ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OrganonCoMember_14eb50aa-f2e1-4009-9077-1d1fb8a327ad" xlink:href="mrk-20220930.xsd#mrk_OrganonCoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_99318653-6a51-4961-bc55-692069d231ad" xlink:to="loc_mrk_OrganonCoMember_14eb50aa-f2e1-4009-9077-1d1fb8a327ad" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#AcquisitionsResearchCollaborationsandLicenseAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" xlink:type="extended" id="if1c821e734c84d4daeb9b1e7cba868a4_AcquisitionsResearchCollaborationsandLicenseAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_c20fc8ba-5979-401f-b91e-3579e7193485" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_b65e0fa4-83d1-4934-8f27-589501d069fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c20fc8ba-5979-401f-b91e-3579e7193485" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_b65e0fa4-83d1-4934-8f27-589501d069fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts_d336dc95-2d90-448c-acf4-ef3557b48a58" xlink:href="mrk-20220930.xsd#mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c20fc8ba-5979-401f-b91e-3579e7193485" xlink:to="loc_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts_d336dc95-2d90-448c-acf4-ef3557b48a58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding_73084716-ecef-4d21-8ac7-3eba08c842ba" xlink:href="mrk-20220930.xsd#mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c20fc8ba-5979-401f-b91e-3579e7193485" xlink:to="loc_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding_73084716-ecef-4d21-8ac7-3eba08c842ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_e8b81650-9412-48ba-9b60-c82eddaaa4e7" xlink:href="mrk-20220930.xsd#mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c20fc8ba-5979-401f-b91e-3579e7193485" xlink:to="loc_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_e8b81650-9412-48ba-9b60-c82eddaaa4e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ContingentPaymentsCollaborativeArrangement_f5b455c0-a8bf-41a9-bb6b-c299c6a252ec" xlink:href="mrk-20220930.xsd#mrk_ContingentPaymentsCollaborativeArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c20fc8ba-5979-401f-b91e-3579e7193485" xlink:to="loc_mrk_ContingentPaymentsCollaborativeArrangement_f5b455c0-a8bf-41a9-bb6b-c299c6a252ec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RoyaltyRatePercentage_1f1d1dfa-0247-4e9f-b4fb-1c06582f4c5b" xlink:href="mrk-20220930.xsd#mrk_RoyaltyRatePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c20fc8ba-5979-401f-b91e-3579e7193485" xlink:to="loc_mrk_RoyaltyRatePercentage_1f1d1dfa-0247-4e9f-b4fb-1c06582f4c5b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_f1cc6f86-6a34-4625-9e8c-b4bd39c49d93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c20fc8ba-5979-401f-b91e-3579e7193485" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_f1cc6f86-6a34-4625-9e8c-b4bd39c49d93" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MilestonePaymentsToBeMadeToACollaborativePartner_c8dac7f9-a2d4-496c-b835-fc200308d19f" xlink:href="mrk-20220930.xsd#mrk_MilestonePaymentsToBeMadeToACollaborativePartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c20fc8ba-5979-401f-b91e-3579e7193485" xlink:to="loc_mrk_MilestonePaymentsToBeMadeToACollaborativePartner_c8dac7f9-a2d4-496c-b835-fc200308d19f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MilestonePaymentToBeMadeToACollaborativePartner_d76d0fc3-79c8-49ab-bef3-ff4ebfae3dd3" xlink:href="mrk-20220930.xsd#mrk_MilestonePaymentToBeMadeToACollaborativePartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c20fc8ba-5979-401f-b91e-3579e7193485" xlink:to="loc_mrk_MilestonePaymentToBeMadeToACollaborativePartner_d76d0fc3-79c8-49ab-bef3-ff4ebfae3dd3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartner_5b3d1405-50b1-4c82-ad6b-af69eb4086b0" xlink:href="mrk-20220930.xsd#mrk_ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c20fc8ba-5979-401f-b91e-3579e7193485" xlink:to="loc_mrk_ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartner_5b3d1405-50b1-4c82-ad6b-af69eb4086b0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_17212bb2-ba6d-4bd9-851e-16c5425bc524" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c20fc8ba-5979-401f-b91e-3579e7193485" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_17212bb2-ba6d-4bd9-851e-16c5425bc524" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner_29da6c1f-20a4-4080-808d-85b6e8e5f78d" xlink:href="mrk-20220930.xsd#mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c20fc8ba-5979-401f-b91e-3579e7193485" xlink:to="loc_mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner_29da6c1f-20a4-4080-808d-85b6e8e5f78d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ChargesRelatedToProgramDiscontinuation_1ee3ab13-4d07-4339-885d-d571025c64d2" xlink:href="mrk-20220930.xsd#mrk_ChargesRelatedToProgramDiscontinuation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c20fc8ba-5979-401f-b91e-3579e7193485" xlink:to="loc_mrk_ChargesRelatedToProgramDiscontinuation_1ee3ab13-4d07-4339-885d-d571025c64d2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_bb400766-5a60-4cae-88fd-a49288a51a68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c20fc8ba-5979-401f-b91e-3579e7193485" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_bb400766-5a60-4cae-88fd-a49288a51a68" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_5d215c4b-4423-48f1-b31b-5972703bd9a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c20fc8ba-5979-401f-b91e-3579e7193485" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_5d215c4b-4423-48f1-b31b-5972703bd9a1" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet_862bc44d-9d93-4fdc-b71b-e74431fe58e8" xlink:href="mrk-20220930.xsd#mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c20fc8ba-5979-401f-b91e-3579e7193485" xlink:to="loc_mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet_862bc44d-9d93-4fdc-b71b-e74431fe58e8" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementNumberOfResearchPrograms_0b758b32-6608-4068-88ee-8d15dd82a8fb" xlink:href="mrk-20220930.xsd#mrk_CollaborativeArrangementNumberOfResearchPrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c20fc8ba-5979-401f-b91e-3579e7193485" xlink:to="loc_mrk_CollaborativeArrangementNumberOfResearchPrograms_0b758b32-6608-4068-88ee-8d15dd82a8fb" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementNumberOfCollaborationTargets_550c0c42-213d-4935-b315-038f14bb7ff5" xlink:href="mrk-20220930.xsd#mrk_CollaborativeArrangementNumberOfCollaborationTargets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c20fc8ba-5979-401f-b91e-3579e7193485" xlink:to="loc_mrk_CollaborativeArrangementNumberOfCollaborationTargets_550c0c42-213d-4935-b315-038f14bb7ff5" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_921b4bd8-3163-4822-af82-eab2c901b7be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c20fc8ba-5979-401f-b91e-3579e7193485" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_921b4bd8-3163-4822-af82-eab2c901b7be" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8419571a-5679-401b-937f-db861d70d56f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_921b4bd8-3163-4822-af82-eab2c901b7be" xlink:to="loc_srt_ProductOrServiceAxis_8419571a-5679-401b-937f-db861d70d56f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8419571a-5679-401b-937f-db861d70d56f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8419571a-5679-401b-937f-db861d70d56f" xlink:to="loc_srt_ProductsAndServicesDomain_8419571a-5679-401b-937f-db861d70d56f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fff35f0e-a97e-4a08-aa6f-836eca899776" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8419571a-5679-401b-937f-db861d70d56f" xlink:to="loc_srt_ProductsAndServicesDomain_fff35f0e-a97e-4a08-aa6f-836eca899776" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_COVID19Member_24ad068c-e0e4-48dd-b641-b50b2d852cc1" xlink:href="mrk-20220930.xsd#mrk_COVID19Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_fff35f0e-a97e-4a08-aa6f-836eca899776" xlink:to="loc_mrk_COVID19Member_24ad068c-e0e4-48dd-b641-b50b2d852cc1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LynparzaMember_d7e8a02c-75e7-47e2-bcd4-53d1e8fad553" xlink:href="mrk-20220930.xsd#mrk_LynparzaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_fff35f0e-a97e-4a08-aa6f-836eca899776" xlink:to="loc_mrk_LynparzaMember_d7e8a02c-75e7-47e2-bcd4-53d1e8fad553" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d45d2a37-39ac-44d8-a2f1-394b69439f7c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_921b4bd8-3163-4822-af82-eab2c901b7be" xlink:to="loc_srt_CounterpartyNameAxis_d45d2a37-39ac-44d8-a2f1-394b69439f7c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d45d2a37-39ac-44d8-a2f1-394b69439f7c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_d45d2a37-39ac-44d8-a2f1-394b69439f7c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d45d2a37-39ac-44d8-a2f1-394b69439f7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f3fe4f10-2b66-453b-8ffc-5d98c026dc80" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_d45d2a37-39ac-44d8-a2f1-394b69439f7c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f3fe4f10-2b66-453b-8ffc-5d98c026dc80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OrnaTherapeuticsMember_64f70d21-7480-4bc3-a03c-e1db7613bee6" xlink:href="mrk-20220930.xsd#mrk_OrnaTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f3fe4f10-2b66-453b-8ffc-5d98c026dc80" xlink:to="loc_mrk_OrnaTherapeuticsMember_64f70d21-7480-4bc3-a03c-e1db7613bee6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OrionCorporationMember_b32e631e-e026-47b8-937f-6001b3ec7ca5" xlink:href="mrk-20220930.xsd#mrk_OrionCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f3fe4f10-2b66-453b-8ffc-5d98c026dc80" xlink:to="loc_mrk_OrionCorporationMember_b32e631e-e026-47b8-937f-6001b3ec7ca5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember_647ab374-3de7-40ec-b4e5-04c2b26f532a" xlink:href="mrk-20220930.xsd#mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f3fe4f10-2b66-453b-8ffc-5d98c026dc80" xlink:to="loc_mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember_647ab374-3de7-40ec-b4e5-04c2b26f532a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ArtivaBiotherapeuticsIncMember_3f9579e1-37b4-4c7c-be79-ebd9a98ae5e1" xlink:href="mrk-20220930.xsd#mrk_ArtivaBiotherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f3fe4f10-2b66-453b-8ffc-5d98c026dc80" xlink:to="loc_mrk_ArtivaBiotherapeuticsIncMember_3f9579e1-37b4-4c7c-be79-ebd9a98ae5e1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AstraZenecaMember_f0ce5ada-1a2a-41e4-a69d-48f1e9ca0055" xlink:href="mrk-20220930.xsd#mrk_AstraZenecaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f3fe4f10-2b66-453b-8ffc-5d98c026dc80" xlink:to="loc_mrk_AstraZenecaMember_f0ce5ada-1a2a-41e4-a69d-48f1e9ca0055" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_30aa6921-e085-4de3-adab-470e7e4dc25f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_921b4bd8-3163-4822-af82-eab2c901b7be" xlink:to="loc_us-gaap_TypeOfArrangementAxis_30aa6921-e085-4de3-adab-470e7e4dc25f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_30aa6921-e085-4de3-adab-470e7e4dc25f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_30aa6921-e085-4de3-adab-470e7e4dc25f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_30aa6921-e085-4de3-adab-470e7e4dc25f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6c0abf84-04de-450f-9c16-fdf6764ac4d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_30aa6921-e085-4de3-adab-470e7e4dc25f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6c0abf84-04de-450f-9c16-fdf6764ac4d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_50bfe6fb-4452-404e-9d43-7111fd1e0285" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6c0abf84-04de-450f-9c16-fdf6764ac4d1" xlink:to="loc_us-gaap_LicensingAgreementsMember_50bfe6fb-4452-404e-9d43-7111fd1e0285" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_417f4bd0-5d37-4153-9669-f0af6210b140" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6c0abf84-04de-450f-9c16-fdf6764ac4d1" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_417f4bd0-5d37-4153-9669-f0af6210b140" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OrnaTherapeuticsMember_cda037aa-efad-450c-934b-5d2b4612287f" xlink:href="mrk-20220930.xsd#mrk_OrnaTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6c0abf84-04de-450f-9c16-fdf6764ac4d1" xlink:to="loc_mrk_OrnaTherapeuticsMember_cda037aa-efad-450c-934b-5d2b4612287f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_fffbdd06-ac6d-4548-9628-1f51a65ec03a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_921b4bd8-3163-4822-af82-eab2c901b7be" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_fffbdd06-ac6d-4548-9628-1f51a65ec03a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_fffbdd06-ac6d-4548-9628-1f51a65ec03a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_fffbdd06-ac6d-4548-9628-1f51a65ec03a" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_fffbdd06-ac6d-4548-9628-1f51a65ec03a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_88f1cb11-c3be-4960-9284-5eabafd6f3b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_fffbdd06-ac6d-4548-9628-1f51a65ec03a" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_88f1cb11-c3be-4960-9284-5eabafd6f3b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DevelopmentMilestonesMember_c768501d-e733-499d-afc7-723e6e4eb509" xlink:href="mrk-20220930.xsd#mrk_DevelopmentMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_88f1cb11-c3be-4960-9284-5eabafd6f3b5" xlink:to="loc_mrk_DevelopmentMilestonesMember_c768501d-e733-499d-afc7-723e6e4eb509" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RegulatoryMilestonesMember_260c7bb5-1c33-479b-bd87-8de7bf5f0ee9" xlink:href="mrk-20220930.xsd#mrk_RegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_88f1cb11-c3be-4960-9284-5eabafd6f3b5" xlink:to="loc_mrk_RegulatoryMilestonesMember_260c7bb5-1c33-479b-bd87-8de7bf5f0ee9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesBasedMilestonesMember_693801bc-e4d6-4094-8af0-9c760e6fba5c" xlink:href="mrk-20220930.xsd#mrk_SalesBasedMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_88f1cb11-c3be-4960-9284-5eabafd6f3b5" xlink:to="loc_mrk_SalesBasedMilestonesMember_693801bc-e4d6-4094-8af0-9c760e6fba5c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FirstCommercialSaleMilestonesMember_e6fe25d0-5bd7-4b5f-b276-53d7b764d50d" xlink:href="mrk-20220930.xsd#mrk_FirstCommercialSaleMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_88f1cb11-c3be-4960-9284-5eabafd6f3b5" xlink:to="loc_mrk_FirstCommercialSaleMilestonesMember_e6fe25d0-5bd7-4b5f-b276-53d7b764d50d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2fd1ab81-8a21-4239-b937-c6db9985b021" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_921b4bd8-3163-4822-af82-eab2c901b7be" xlink:to="loc_srt_RangeAxis_2fd1ab81-8a21-4239-b937-c6db9985b021" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2fd1ab81-8a21-4239-b937-c6db9985b021_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2fd1ab81-8a21-4239-b937-c6db9985b021" xlink:to="loc_srt_RangeMember_2fd1ab81-8a21-4239-b937-c6db9985b021_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8af25254-f30d-4742-a4d3-172a46441291" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2fd1ab81-8a21-4239-b937-c6db9985b021" xlink:to="loc_srt_RangeMember_8af25254-f30d-4742-a4d3-172a46441291" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9bb7b72b-c531-4109-a211-10c3f8650d7e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8af25254-f30d-4742-a4d3-172a46441291" xlink:to="loc_srt_MinimumMember_9bb7b72b-c531-4109-a211-10c3f8650d7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f64646e4-4d7b-4f02-b2c5-16fa603efbdd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8af25254-f30d-4742-a4d3-172a46441291" xlink:to="loc_srt_MaximumMember_f64646e4-4d7b-4f02-b2c5-16fa603efbdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_6b39283a-813a-4487-a136-0bd835ccfef8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_921b4bd8-3163-4822-af82-eab2c901b7be" xlink:to="loc_us-gaap_AssetAcquisitionAxis_6b39283a-813a-4487-a136-0bd835ccfef8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_6b39283a-813a-4487-a136-0bd835ccfef8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_6b39283a-813a-4487-a136-0bd835ccfef8" xlink:to="loc_us-gaap_AssetAcquisitionDomain_6b39283a-813a-4487-a136-0bd835ccfef8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_037680be-a09c-4d8c-be0a-41a9d94694d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_6b39283a-813a-4487-a136-0bd835ccfef8" xlink:to="loc_us-gaap_AssetAcquisitionDomain_037680be-a09c-4d8c-be0a-41a9d94694d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PandionTherapeuticsMember_f12c9ca9-9a86-4c22-b2ab-3b78aa6752a3" xlink:href="mrk-20220930.xsd#mrk_PandionTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_037680be-a09c-4d8c-be0a-41a9d94694d5" xlink:to="loc_mrk_PandionTherapeuticsMember_f12c9ca9-9a86-4c22-b2ab-3b78aa6752a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_8533dc67-5ba8-47ac-b0ff-cbeaf0154d78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_921b4bd8-3163-4822-af82-eab2c901b7be" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_8533dc67-5ba8-47ac-b0ff-cbeaf0154d78" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8533dc67-5ba8-47ac-b0ff-cbeaf0154d78_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8533dc67-5ba8-47ac-b0ff-cbeaf0154d78" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8533dc67-5ba8-47ac-b0ff-cbeaf0154d78_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fdc43261-0dbc-4cee-afb6-ad4a53b12259" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8533dc67-5ba8-47ac-b0ff-cbeaf0154d78" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fdc43261-0dbc-4cee-afb6-ad4a53b12259" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_02de1204-6e14-4509-8917-2fb04dc2b8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_fdc43261-0dbc-4cee-afb6-ad4a53b12259" xlink:to="loc_us-gaap_SubsequentEventMember_02de1204-6e14-4509-8917-2fb04dc2b8f0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#CollaborativeArrangementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" xlink:type="extended" id="iad1d530367ee46408ea520f60e906d55_CollaborativeArrangementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d2a6bd0d-9583-4028-b1ce-e17f484f2aee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ProbableContingentPaymentsCollaborativeArrangement_c63117aa-95d6-4644-a6fd-7a602f00b2cf" xlink:href="mrk-20220930.xsd#mrk_ProbableContingentPaymentsCollaborativeArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d2a6bd0d-9583-4028-b1ce-e17f484f2aee" xlink:to="loc_mrk_ProbableContingentPaymentsCollaborativeArrangement_c63117aa-95d6-4644-a6fd-7a602f00b2cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_de27463d-300e-455a-8e37-4af81a6b8ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d2a6bd0d-9583-4028-b1ce-e17f484f2aee" xlink:to="loc_us-gaap_Liabilities_de27463d-300e-455a-8e37-4af81a6b8ae0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_0a76ae9b-c846-4161-a891-da5ffdd8d97d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d2a6bd0d-9583-4028-b1ce-e17f484f2aee" xlink:to="loc_us-gaap_AdjustmentForAmortization_0a76ae9b-c846-4161-a891-da5ffdd8d97d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MilestonePaymentsSalesBased_7a811e82-71a6-47f8-b00f-5d888e87fe87" xlink:href="mrk-20220930.xsd#mrk_MilestonePaymentsSalesBased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d2a6bd0d-9583-4028-b1ce-e17f484f2aee" xlink:to="loc_mrk_MilestonePaymentsSalesBased_7a811e82-71a6-47f8-b00f-5d888e87fe87" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MilestonePaymentsAccruedSalesBased_d412af2d-ddd0-41af-9871-7af6209e4ca4" xlink:href="mrk-20220930.xsd#mrk_MilestonePaymentsAccruedSalesBased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d2a6bd0d-9583-4028-b1ce-e17f484f2aee" xlink:to="loc_mrk_MilestonePaymentsAccruedSalesBased_d412af2d-ddd0-41af-9871-7af6209e4ca4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PotentialFutureMilestonePaymentsSalesBased_acbab910-3571-431b-ae1f-18d9862fd76c" xlink:href="mrk-20220930.xsd#mrk_PotentialFutureMilestonePaymentsSalesBased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d2a6bd0d-9583-4028-b1ce-e17f484f2aee" xlink:to="loc_mrk_PotentialFutureMilestonePaymentsSalesBased_acbab910-3571-431b-ae1f-18d9862fd76c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MilestonePaymentsMadetoCollaborativePartner_f37d33e3-fb43-4407-99a5-e5bbdd6e42f7" xlink:href="mrk-20220930.xsd#mrk_MilestonePaymentsMadetoCollaborativePartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d2a6bd0d-9583-4028-b1ce-e17f484f2aee" xlink:to="loc_mrk_MilestonePaymentsMadetoCollaborativePartner_f37d33e3-fb43-4407-99a5-e5bbdd6e42f7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PotentialFutureMilestonePaymentsRegulatory_8b50bfe0-8b3c-4965-861d-0d0498520813" xlink:href="mrk-20220930.xsd#mrk_PotentialFutureMilestonePaymentsRegulatory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d2a6bd0d-9583-4028-b1ce-e17f484f2aee" xlink:to="loc_mrk_PotentialFutureMilestonePaymentsRegulatory_8b50bfe0-8b3c-4965-861d-0d0498520813" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1aab1d19-8a33-4f35-b667-e99a440ecd57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d2a6bd0d-9583-4028-b1ce-e17f484f2aee" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1aab1d19-8a33-4f35-b667-e99a440ecd57" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_Licenseoptionpaymentrelatedtocollaborativearrangement_ed8b5837-3e14-4bff-b0cd-f63e63194b78" xlink:href="mrk-20220930.xsd#mrk_Licenseoptionpaymentrelatedtocollaborativearrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d2a6bd0d-9583-4028-b1ce-e17f484f2aee" xlink:to="loc_mrk_Licenseoptionpaymentrelatedtocollaborativearrangement_ed8b5837-3e14-4bff-b0cd-f63e63194b78" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SupplyCommitmentMinimumNumberOfMarkets_62b75d32-20ea-4c2e-9e56-c1f8810dd13e" xlink:href="mrk-20220930.xsd#mrk_SupplyCommitmentMinimumNumberOfMarkets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d2a6bd0d-9583-4028-b1ce-e17f484f2aee" xlink:to="loc_mrk_SupplyCommitmentMinimumNumberOfMarkets_62b75d32-20ea-4c2e-9e56-c1f8810dd13e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SupplyCommitmentRemainingMinimumCoursesCommitted_1857d68a-eae9-42ce-adab-34594bbe56f0" xlink:href="mrk-20220930.xsd#mrk_SupplyCommitmentRemainingMinimumCoursesCommitted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d2a6bd0d-9583-4028-b1ce-e17f484f2aee" xlink:to="loc_mrk_SupplyCommitmentRemainingMinimumCoursesCommitted_1857d68a-eae9-42ce-adab-34594bbe56f0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RoyaltyRatePercentage_9892afbf-0ea1-430e-ba56-6b13af480863" xlink:href="mrk-20220930.xsd#mrk_RoyaltyRatePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d2a6bd0d-9583-4028-b1ce-e17f484f2aee" xlink:to="loc_mrk_RoyaltyRatePercentage_9892afbf-0ea1-430e-ba56-6b13af480863" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RoyaltyRateDeductionPercentage_2bfc09ee-9fdb-453a-b380-50e54b0ec5e6" xlink:href="mrk-20220930.xsd#mrk_RoyaltyRateDeductionPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d2a6bd0d-9583-4028-b1ce-e17f484f2aee" xlink:to="loc_mrk_RoyaltyRateDeductionPercentage_2bfc09ee-9fdb-453a-b380-50e54b0ec5e6" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ContingentPaymentsCollaborativeArrangement_3233a141-8ffd-4b77-ac47-5ce9fbca055a" xlink:href="mrk-20220930.xsd#mrk_ContingentPaymentsCollaborativeArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d2a6bd0d-9583-4028-b1ce-e17f484f2aee" xlink:to="loc_mrk_ContingentPaymentsCollaborativeArrangement_3233a141-8ffd-4b77-ac47-5ce9fbca055a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_fa3409b2-165c-423c-be02-dd14ee007d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d2a6bd0d-9583-4028-b1ce-e17f484f2aee" xlink:to="loc_us-gaap_Revenues_fa3409b2-165c-423c-be02-dd14ee007d9b" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating_18b84c9c-fc16-43dc-ab04-2d2d9f8812a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d2a6bd0d-9583-4028-b1ce-e17f484f2aee" xlink:to="loc_us-gaap_RoyaltyIncomeNonoperating_18b84c9c-fc16-43dc-ab04-2d2d9f8812a7" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4586c3cb-561a-41ce-8bb5-26e5c4bbd454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d2a6bd0d-9583-4028-b1ce-e17f484f2aee" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4586c3cb-561a-41ce-8bb5-26e5c4bbd454" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1645bb3d-3452-4722-a205-2b0340c592f6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4586c3cb-561a-41ce-8bb5-26e5c4bbd454" xlink:to="loc_srt_CounterpartyNameAxis_1645bb3d-3452-4722-a205-2b0340c592f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1645bb3d-3452-4722-a205-2b0340c592f6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_1645bb3d-3452-4722-a205-2b0340c592f6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1645bb3d-3452-4722-a205-2b0340c592f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5e9f5aa6-1f6a-4436-b4da-53ed17814bbd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_1645bb3d-3452-4722-a205-2b0340c592f6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5e9f5aa6-1f6a-4436-b4da-53ed17814bbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AstraZenecaMember_afb61da2-f41f-4d7d-b9c5-cc64d9bb38d4" xlink:href="mrk-20220930.xsd#mrk_AstraZenecaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5e9f5aa6-1f6a-4436-b4da-53ed17814bbd" xlink:to="loc_mrk_AstraZenecaMember_afb61da2-f41f-4d7d-b9c5-cc64d9bb38d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EisaiMember_727bd3af-8333-48df-b9c3-af2cca935118" xlink:href="mrk-20220930.xsd#mrk_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5e9f5aa6-1f6a-4436-b4da-53ed17814bbd" xlink:to="loc_mrk_EisaiMember_727bd3af-8333-48df-b9c3-af2cca935118" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BayerAGMember_31c55a77-942d-4d96-8447-ff858e1f56f7" xlink:href="mrk-20220930.xsd#mrk_BayerAGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5e9f5aa6-1f6a-4436-b4da-53ed17814bbd" xlink:to="loc_mrk_BayerAGMember_31c55a77-942d-4d96-8447-ff858e1f56f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BristolMyersSquibbMember_d5cb04aa-1204-485e-a289-d67b773eaa0a" xlink:href="mrk-20220930.xsd#mrk_BristolMyersSquibbMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5e9f5aa6-1f6a-4436-b4da-53ed17814bbd" xlink:to="loc_mrk_BristolMyersSquibbMember_d5cb04aa-1204-485e-a289-d67b773eaa0a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_47915342-989d-4d5d-adc5-d9a5e627d12b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4586c3cb-561a-41ce-8bb5-26e5c4bbd454" xlink:to="loc_us-gaap_TypeOfArrangementAxis_47915342-989d-4d5d-adc5-d9a5e627d12b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_47915342-989d-4d5d-adc5-d9a5e627d12b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_47915342-989d-4d5d-adc5-d9a5e627d12b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_47915342-989d-4d5d-adc5-d9a5e627d12b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_12a3799b-8dcd-4e37-95a4-477bb67e0d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_47915342-989d-4d5d-adc5-d9a5e627d12b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_12a3799b-8dcd-4e37-95a4-477bb67e0d4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesBasedMilestonesMember_a6464bcd-5343-42c6-ab38-a937766f7f77" xlink:href="mrk-20220930.xsd#mrk_SalesBasedMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_12a3799b-8dcd-4e37-95a4-477bb67e0d4a" xlink:to="loc_mrk_SalesBasedMilestonesMember_a6464bcd-5343-42c6-ab38-a937766f7f77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_e5c1fdb7-df41-4645-a50e-eac65fff8788" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_12a3799b-8dcd-4e37-95a4-477bb67e0d4a" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_e5c1fdb7-df41-4645-a50e-eac65fff8788" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_5465802a-9281-4b42-b7db-ea131771a14e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_12a3799b-8dcd-4e37-95a4-477bb67e0d4a" xlink:to="loc_us-gaap_LicensingAgreementsMember_5465802a-9281-4b42-b7db-ea131771a14e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RegulatoryMilestonesMember_bd227574-28b2-47fe-b33b-f1154ba2aeca" xlink:href="mrk-20220930.xsd#mrk_RegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_12a3799b-8dcd-4e37-95a4-477bb67e0d4a" xlink:to="loc_mrk_RegulatoryMilestonesMember_bd227574-28b2-47fe-b33b-f1154ba2aeca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ad8c75bf-ab50-4f0d-86f8-803caaa4ea31" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4586c3cb-561a-41ce-8bb5-26e5c4bbd454" xlink:to="loc_srt_ProductOrServiceAxis_ad8c75bf-ab50-4f0d-86f8-803caaa4ea31" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ad8c75bf-ab50-4f0d-86f8-803caaa4ea31_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ad8c75bf-ab50-4f0d-86f8-803caaa4ea31" xlink:to="loc_srt_ProductsAndServicesDomain_ad8c75bf-ab50-4f0d-86f8-803caaa4ea31_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c8d2d4cf-ed3b-434b-ae6d-853f58623b49" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ad8c75bf-ab50-4f0d-86f8-803caaa4ea31" xlink:to="loc_srt_ProductsAndServicesDomain_c8d2d4cf-ed3b-434b-ae6d-853f58623b49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LynparzaMember_a71c8ef9-1f20-4591-b940-8d1e8b66fdff" xlink:href="mrk-20220930.xsd#mrk_LynparzaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c8d2d4cf-ed3b-434b-ae6d-853f58623b49" xlink:to="loc_mrk_LynparzaMember_a71c8ef9-1f20-4591-b940-8d1e8b66fdff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LenvimaMember_d0165e44-7ea3-47e9-9067-df25dedd8b52" xlink:href="mrk-20220930.xsd#mrk_LenvimaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c8d2d4cf-ed3b-434b-ae6d-853f58623b49" xlink:to="loc_mrk_LenvimaMember_d0165e44-7ea3-47e9-9067-df25dedd8b52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VerquvoMember_53d86344-64e7-4a12-84a9-9ac91f424b1e" xlink:href="mrk-20220930.xsd#mrk_VerquvoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c8d2d4cf-ed3b-434b-ae6d-853f58623b49" xlink:to="loc_mrk_VerquvoMember_53d86344-64e7-4a12-84a9-9ac91f424b1e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AdempasMember_88453cb2-6380-44d3-ac93-35926f9d8afd" xlink:href="mrk-20220930.xsd#mrk_AdempasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c8d2d4cf-ed3b-434b-ae6d-853f58623b49" xlink:to="loc_mrk_AdempasMember_88453cb2-6380-44d3-ac93-35926f9d8afd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AllianceRevenueReblozylMember_10e49a8c-9fdf-4235-8672-fa0bfb3258cb" xlink:href="mrk-20220930.xsd#mrk_AllianceRevenueReblozylMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c8d2d4cf-ed3b-434b-ae6d-853f58623b49" xlink:to="loc_mrk_AllianceRevenueReblozylMember_10e49a8c-9fdf-4235-8672-fa0bfb3258cb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1a803fb8-920a-477b-83d1-c0476dc7dbf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4586c3cb-561a-41ce-8bb5-26e5c4bbd454" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1a803fb8-920a-477b-83d1-c0476dc7dbf0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1a803fb8-920a-477b-83d1-c0476dc7dbf0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1a803fb8-920a-477b-83d1-c0476dc7dbf0" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1a803fb8-920a-477b-83d1-c0476dc7dbf0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_54fb9266-a138-44f4-bd04-4ad3944faac1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1a803fb8-920a-477b-83d1-c0476dc7dbf0" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_54fb9266-a138-44f4-bd04-4ad3944faac1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_167df743-8ddd-407d-a000-985c56f9c0ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_54fb9266-a138-44f4-bd04-4ad3944faac1" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_167df743-8ddd-407d-a000-985c56f9c0ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_8ab1cbb8-1210-4589-8d2f-c587b4ca05f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_54fb9266-a138-44f4-bd04-4ad3944faac1" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_8ab1cbb8-1210-4589-8d2f-c587b4ca05f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1aba6ae5-0194-46d5-be61-bf14d8b4aa72" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4586c3cb-561a-41ce-8bb5-26e5c4bbd454" xlink:to="loc_srt_RangeAxis_1aba6ae5-0194-46d5-be61-bf14d8b4aa72" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1aba6ae5-0194-46d5-be61-bf14d8b4aa72_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1aba6ae5-0194-46d5-be61-bf14d8b4aa72" xlink:to="loc_srt_RangeMember_1aba6ae5-0194-46d5-be61-bf14d8b4aa72_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_62621cdf-cb9d-45fb-ac13-4c2441060512" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1aba6ae5-0194-46d5-be61-bf14d8b4aa72" xlink:to="loc_srt_RangeMember_62621cdf-cb9d-45fb-ac13-4c2441060512" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f20cdb25-8dfb-444e-9a7f-d4a6606f1456" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_62621cdf-cb9d-45fb-ac13-4c2441060512" xlink:to="loc_srt_MinimumMember_f20cdb25-8dfb-444e-9a7f-d4a6606f1456" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e86bde4b-91ce-44f2-89ed-486476dfde1f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_62621cdf-cb9d-45fb-ac13-4c2441060512" xlink:to="loc_srt_MaximumMember_e86bde4b-91ce-44f2-89ed-486476dfde1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_5d06c206-9b53-453a-8aed-038527015554" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4586c3cb-561a-41ce-8bb5-26e5c4bbd454" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_5d06c206-9b53-453a-8aed-038527015554" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_5d06c206-9b53-453a-8aed-038527015554_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_5d06c206-9b53-453a-8aed-038527015554" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_5d06c206-9b53-453a-8aed-038527015554_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_f5201572-7826-487a-9fae-abcec18fc308" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_5d06c206-9b53-453a-8aed-038527015554" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_f5201572-7826-487a-9fae-abcec18fc308" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesBasedMilestonesMember_3ce7fc4d-d052-4b84-9cc8-d68b1ce6c1a2" xlink:href="mrk-20220930.xsd#mrk_SalesBasedMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_f5201572-7826-487a-9fae-abcec18fc308" xlink:to="loc_mrk_SalesBasedMilestonesMember_3ce7fc4d-d052-4b84-9cc8-d68b1ce6c1a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RegulatoryMilestonesMember_ebba99be-da66-4edc-8cec-252a1f090785" xlink:href="mrk-20220930.xsd#mrk_RegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_f5201572-7826-487a-9fae-abcec18fc308" xlink:to="loc_mrk_RegulatoryMilestonesMember_ebba99be-da66-4edc-8cec-252a1f090785" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_16591790-c100-42d8-abf0-5bf7542b72d0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4586c3cb-561a-41ce-8bb5-26e5c4bbd454" xlink:to="loc_srt_ConsolidationItemsAxis_16591790-c100-42d8-abf0-5bf7542b72d0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_16591790-c100-42d8-abf0-5bf7542b72d0_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_16591790-c100-42d8-abf0-5bf7542b72d0" xlink:to="loc_srt_ConsolidationItemsDomain_16591790-c100-42d8-abf0-5bf7542b72d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_53c2e0c2-b44b-443f-af4c-236c7efa2769" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_16591790-c100-42d8-abf0-5bf7542b72d0" xlink:to="loc_srt_ConsolidationItemsDomain_53c2e0c2-b44b-443f-af4c-236c7efa2769" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_74528940-823a-4016-8f77-fd92b0ea4805" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_53c2e0c2-b44b-443f-af4c-236c7efa2769" xlink:to="loc_us-gaap_OperatingSegmentsMember_74528940-823a-4016-8f77-fd92b0ea4805" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_614714e0-821f-4733-88c2-644170d5e67c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4586c3cb-561a-41ce-8bb5-26e5c4bbd454" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_614714e0-821f-4733-88c2-644170d5e67c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_614714e0-821f-4733-88c2-644170d5e67c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_614714e0-821f-4733-88c2-644170d5e67c" xlink:to="loc_us-gaap_SegmentDomain_614714e0-821f-4733-88c2-644170d5e67c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_69ebaccb-56e6-4745-aed4-b5c634141974" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_614714e0-821f-4733-88c2-644170d5e67c" xlink:to="loc_us-gaap_SegmentDomain_69ebaccb-56e6-4745-aed4-b5c634141974" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember_c72f3e40-fe91-4213-b5cd-d5c285945678" xlink:href="mrk-20220930.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_69ebaccb-56e6-4745-aed4-b5c634141974" xlink:to="loc_mrk_PharmaceuticalsegmentMember_c72f3e40-fe91-4213-b5cd-d5c285945678" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#CollaborativeArrangementsFinancialInformationDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" xlink:type="extended" id="ia087a96b824847d1bfd790f8d9c5daff_CollaborativeArrangementsFinancialInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e0c6a45f-4cf6-4c77-84a4-4ed008ae59cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementProfitSharing_c5667b8a-6dac-41ec-81bc-811479eb526a" xlink:href="mrk-20220930.xsd#mrk_CollaborativeArrangementProfitSharing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e0c6a45f-4cf6-4c77-84a4-4ed008ae59cb" xlink:to="loc_mrk_CollaborativeArrangementProfitSharing_c5667b8a-6dac-41ec-81bc-811479eb526a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementSalesNet_2a9e67e3-a517-495a-8fc7-0e304c74c73e" xlink:href="mrk-20220930.xsd#mrk_CollaborativeArrangementSalesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e0c6a45f-4cf6-4c77-84a4-4ed008ae59cb" xlink:to="loc_mrk_CollaborativeArrangementSalesNet_2a9e67e3-a517-495a-8fc7-0e304c74c73e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_e3684fa2-bb1f-4e15-9df3-17ad8537456b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e0c6a45f-4cf6-4c77-84a4-4ed008ae59cb" xlink:to="loc_us-gaap_Revenues_e3684fa2-bb1f-4e15-9df3-17ad8537456b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_e6fa7b3a-d301-44d9-a437-bc7b372fcb4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e0c6a45f-4cf6-4c77-84a4-4ed008ae59cb" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_e6fa7b3a-d301-44d9-a437-bc7b372fcb4e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_994f122a-bae5-482e-b91d-73be108f96ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e0c6a45f-4cf6-4c77-84a4-4ed008ae59cb" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_994f122a-bae5-482e-b91d-73be108f96ce" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_aad27c6d-62ed-44de-a681-f799d65ecd15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e0c6a45f-4cf6-4c77-84a4-4ed008ae59cb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_aad27c6d-62ed-44de-a681-f799d65ecd15" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_e4d7f03e-430a-4378-8ca8-4a98c827be61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e0c6a45f-4cf6-4c77-84a4-4ed008ae59cb" xlink:to="loc_us-gaap_ReceivablesNetCurrent_e4d7f03e-430a-4378-8ca8-4a98c827be61" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ca4881cd-a43a-4bed-a795-7296a069948b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e0c6a45f-4cf6-4c77-84a4-4ed008ae59cb" xlink:to="loc_us-gaap_LiabilitiesCurrent_ca4881cd-a43a-4bed-a795-7296a069948b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_079261cc-62f3-4ea7-8a46-fdb1b3d99e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e0c6a45f-4cf6-4c77-84a4-4ed008ae59cb" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_079261cc-62f3-4ea7-8a46-fdb1b3d99e7c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_b41813bd-e3dc-42f9-86b9-35a1cc2a569b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e0c6a45f-4cf6-4c77-84a4-4ed008ae59cb" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_b41813bd-e3dc-42f9-86b9-35a1cc2a569b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_273fc494-f4c4-4f14-9303-93ab0260a1eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e0c6a45f-4cf6-4c77-84a4-4ed008ae59cb" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_273fc494-f4c4-4f14-9303-93ab0260a1eb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_16e361fa-ae77-4162-a32a-13102c629d49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_273fc494-f4c4-4f14-9303-93ab0260a1eb" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_16e361fa-ae77-4162-a32a-13102c629d49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_16e361fa-ae77-4162-a32a-13102c629d49_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_16e361fa-ae77-4162-a32a-13102c629d49" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_16e361fa-ae77-4162-a32a-13102c629d49_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a3ec1d6e-98f1-42ce-b246-91cf6b935b24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_16e361fa-ae77-4162-a32a-13102c629d49" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a3ec1d6e-98f1-42ce-b246-91cf6b935b24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_d540f0bc-f4b7-44cf-9b99-092f8149f75c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a3ec1d6e-98f1-42ce-b246-91cf6b935b24" xlink:to="loc_us-gaap_SalesMember_d540f0bc-f4b7-44cf-9b99-092f8149f75c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_65cffc1f-7d2b-481e-b6ce-d97e0f5dac6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a3ec1d6e-98f1-42ce-b246-91cf6b935b24" xlink:to="loc_us-gaap_CostOfSalesMember_65cffc1f-7d2b-481e-b6ce-d97e0f5dac6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_bbc132f2-e5fa-4133-ae27-7e374eaa315c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a3ec1d6e-98f1-42ce-b246-91cf6b935b24" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_bbc132f2-e5fa-4133-ae27-7e374eaa315c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_dd5d8571-556f-4686-aa16-c1786887b333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a3ec1d6e-98f1-42ce-b246-91cf6b935b24" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_dd5d8571-556f-4686-aa16-c1786887b333" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_555a508c-3279-452c-ae97-932268b44a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_273fc494-f4c4-4f14-9303-93ab0260a1eb" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_555a508c-3279-452c-ae97-932268b44a3e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_555a508c-3279-452c-ae97-932268b44a3e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_555a508c-3279-452c-ae97-932268b44a3e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_555a508c-3279-452c-ae97-932268b44a3e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5278a070-6625-41bb-979a-95ffea146309" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_555a508c-3279-452c-ae97-932268b44a3e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_5278a070-6625-41bb-979a-95ffea146309" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_9693a0a6-f741-4a21-a97d-a95ecbbfc654" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5278a070-6625-41bb-979a-95ffea146309" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_9693a0a6-f741-4a21-a97d-a95ecbbfc654" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_974b5177-b2f6-4c48-a04f-a581f5fdbc74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5278a070-6625-41bb-979a-95ffea146309" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_974b5177-b2f6-4c48-a04f-a581f5fdbc74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_e02e211c-627e-4ace-a46b-77c55f4377c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5278a070-6625-41bb-979a-95ffea146309" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_e02e211c-627e-4ace-a46b-77c55f4377c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7bee547a-0673-4e7f-9381-44bfbf339adc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_273fc494-f4c4-4f14-9303-93ab0260a1eb" xlink:to="loc_srt_CounterpartyNameAxis_7bee547a-0673-4e7f-9381-44bfbf339adc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7bee547a-0673-4e7f-9381-44bfbf339adc_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_7bee547a-0673-4e7f-9381-44bfbf339adc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7bee547a-0673-4e7f-9381-44bfbf339adc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cce926b4-de0a-41f7-af1a-69eb07930e49" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_7bee547a-0673-4e7f-9381-44bfbf339adc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cce926b4-de0a-41f7-af1a-69eb07930e49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AstraZenecaMember_aa226bfa-e089-4a75-9ede-373acc0fa4f4" xlink:href="mrk-20220930.xsd#mrk_AstraZenecaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cce926b4-de0a-41f7-af1a-69eb07930e49" xlink:to="loc_mrk_AstraZenecaMember_aa226bfa-e089-4a75-9ede-373acc0fa4f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EisaiMember_9c9729f8-e051-4934-a5b0-85223dafe14c" xlink:href="mrk-20220930.xsd#mrk_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cce926b4-de0a-41f7-af1a-69eb07930e49" xlink:to="loc_mrk_EisaiMember_9c9729f8-e051-4934-a5b0-85223dafe14c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BayerAGMember_9755e6c0-ccc5-41b4-be76-f2ec0a35e464" xlink:href="mrk-20220930.xsd#mrk_BayerAGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cce926b4-de0a-41f7-af1a-69eb07930e49" xlink:to="loc_mrk_BayerAGMember_9755e6c0-ccc5-41b4-be76-f2ec0a35e464" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RidgebackBiotherapeuticsLPMember_6a41ff68-2aca-496c-9390-85fbb9ee7bb0" xlink:href="mrk-20220930.xsd#mrk_RidgebackBiotherapeuticsLPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cce926b4-de0a-41f7-af1a-69eb07930e49" xlink:to="loc_mrk_RidgebackBiotherapeuticsLPMember_6a41ff68-2aca-496c-9390-85fbb9ee7bb0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_58616646-b2d2-4b64-b4bc-11a3c3eb4f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_273fc494-f4c4-4f14-9303-93ab0260a1eb" xlink:to="loc_us-gaap_TypeOfArrangementAxis_58616646-b2d2-4b64-b4bc-11a3c3eb4f3c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_58616646-b2d2-4b64-b4bc-11a3c3eb4f3c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_58616646-b2d2-4b64-b4bc-11a3c3eb4f3c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_58616646-b2d2-4b64-b4bc-11a3c3eb4f3c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7d8f5900-d20b-4089-a36d-84a3f1bb278f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_58616646-b2d2-4b64-b4bc-11a3c3eb4f3c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7d8f5900-d20b-4089-a36d-84a3f1bb278f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_8a3d3d31-314b-4dba-8d74-c07811254747" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7d8f5900-d20b-4089-a36d-84a3f1bb278f" xlink:to="loc_us-gaap_CollaborativeArrangementMember_8a3d3d31-314b-4dba-8d74-c07811254747" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_662d6211-d0dc-417a-8205-52946288893a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_273fc494-f4c4-4f14-9303-93ab0260a1eb" xlink:to="loc_srt_ProductOrServiceAxis_662d6211-d0dc-417a-8205-52946288893a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_662d6211-d0dc-417a-8205-52946288893a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_662d6211-d0dc-417a-8205-52946288893a" xlink:to="loc_srt_ProductsAndServicesDomain_662d6211-d0dc-417a-8205-52946288893a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_73fe558e-bc08-48e7-be52-d909eda37977" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_662d6211-d0dc-417a-8205-52946288893a" xlink:to="loc_srt_ProductsAndServicesDomain_73fe558e-bc08-48e7-be52-d909eda37977" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AlliancerevenueLynparzaMember_b3a977ba-d0f4-4ea1-9884-7734b8290f40" xlink:href="mrk-20220930.xsd#mrk_AlliancerevenueLynparzaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_73fe558e-bc08-48e7-be52-d909eda37977" xlink:to="loc_mrk_AlliancerevenueLynparzaMember_b3a977ba-d0f4-4ea1-9884-7734b8290f40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AllianceRevenueKoselugoMember_f797f329-d36a-4f40-bb58-bf9753c1e1ec" xlink:href="mrk-20220930.xsd#mrk_AllianceRevenueKoselugoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_73fe558e-bc08-48e7-be52-d909eda37977" xlink:to="loc_mrk_AllianceRevenueKoselugoMember_f797f329-d36a-4f40-bb58-bf9753c1e1ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AdempasMember_fe774b5e-9cc5-455a-ab37-00bfc99ab43c" xlink:href="mrk-20220930.xsd#mrk_AdempasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_73fe558e-bc08-48e7-be52-d909eda37977" xlink:to="loc_mrk_AdempasMember_fe774b5e-9cc5-455a-ab37-00bfc99ab43c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VerquvoMember_80870070-f0d7-492b-b91d-18097eca6fcf" xlink:href="mrk-20220930.xsd#mrk_VerquvoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_73fe558e-bc08-48e7-be52-d909eda37977" xlink:to="loc_mrk_VerquvoMember_80870070-f0d7-492b-b91d-18097eca6fcf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LagevrioMember_00e97513-ca1f-4c0d-88d2-2460b371a347" xlink:href="mrk-20220930.xsd#mrk_LagevrioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_73fe558e-bc08-48e7-be52-d909eda37977" xlink:to="loc_mrk_LagevrioMember_00e97513-ca1f-4c0d-88d2-2460b371a347" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/RestructuringNarrativeDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#RestructuringNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/RestructuringNarrativeDetails" xlink:type="extended" id="i7e2246a959ee4b50a04a51ac90f3cfb8_RestructuringNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_60e7fadb-9431-4140-b90c-605a61df8d62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_1f913d32-a7ad-43f1-8511-a22eb35ba51c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_60e7fadb-9431-4140-b90c-605a61df8d62" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_1f913d32-a7ad-43f1-8511-a22eb35ba51c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays_71be8430-9042-4c8d-a1a3-35542fc38ea6" xlink:href="mrk-20220930.xsd#mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_60e7fadb-9431-4140-b90c-605a61df8d62" xlink:to="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays_71be8430-9042-4c8d-a1a3-35542fc38ea6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash_2c1c41e4-1d2d-4910-9b89-a527386d1217" xlink:href="mrk-20220930.xsd#mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_60e7fadb-9431-4140-b90c-605a61df8d62" xlink:to="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash_2c1c41e4-1d2d-4910-9b89-a527386d1217" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_4235f3f4-58e5-46e5-b84a-f79f11f9a0cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_60e7fadb-9431-4140-b90c-605a61df8d62" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_4235f3f4-58e5-46e5-b84a-f79f11f9a0cb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_55b70976-bf6f-4005-81e9-aeaf6291290d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_60e7fadb-9431-4140-b90c-605a61df8d62" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_55b70976-bf6f-4005-81e9-aeaf6291290d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_496282f9-1ff8-4ebf-9af4-f7762e82c449" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_60e7fadb-9431-4140-b90c-605a61df8d62" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_496282f9-1ff8-4ebf-9af4-f7762e82c449" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_e87ba950-6fe2-40aa-a96d-0212572ce719" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_496282f9-1ff8-4ebf-9af4-f7762e82c449" xlink:to="loc_srt_StatementScenarioAxis_e87ba950-6fe2-40aa-a96d-0212572ce719" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_e87ba950-6fe2-40aa-a96d-0212572ce719_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_e87ba950-6fe2-40aa-a96d-0212572ce719" xlink:to="loc_srt_ScenarioUnspecifiedDomain_e87ba950-6fe2-40aa-a96d-0212572ce719_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_78f6d007-db41-4f3b-b1a0-48156bab85ed" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_e87ba950-6fe2-40aa-a96d-0212572ce719" xlink:to="loc_srt_ScenarioUnspecifiedDomain_78f6d007-db41-4f3b-b1a0-48156bab85ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_e3d5abf8-6e5e-4f76-ade6-c497df474d1a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_78f6d007-db41-4f3b-b1a0-48156bab85ed" xlink:to="loc_srt_ScenarioForecastMember_e3d5abf8-6e5e-4f76-ade6-c497df474d1a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#RestructuringChargesActivitiesbyTypeofCostDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" xlink:type="extended" id="iadc653447ea44264807396ace6077be7_RestructuringChargesActivitiesbyTypeofCostDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_7901ff2b-b584-4fa2-9ad2-1b53cff9aac2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_a3d3ee61-1acd-442e-ae66-91f0395d911f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_7901ff2b-b584-4fa2-9ad2-1b53cff9aac2" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_a3d3ee61-1acd-442e-ae66-91f0395d911f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_200781b1-af18-4892-a8bd-cc071f25f5dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_7901ff2b-b584-4fa2-9ad2-1b53cff9aac2" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_200781b1-af18-4892-a8bd-cc071f25f5dd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_752c5d7a-eaef-4c47-aba9-2458edea4522" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_200781b1-af18-4892-a8bd-cc071f25f5dd" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_752c5d7a-eaef-4c47-aba9-2458edea4522" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_752c5d7a-eaef-4c47-aba9-2458edea4522_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_752c5d7a-eaef-4c47-aba9-2458edea4522" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_752c5d7a-eaef-4c47-aba9-2458edea4522_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_afaf0d92-0546-4b53-8478-3b0a4c195662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_752c5d7a-eaef-4c47-aba9-2458edea4522" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_afaf0d92-0546-4b53-8478-3b0a4c195662" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_6cc0c6a7-dc6a-42f8-9ff1-fe16c15d844f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_afaf0d92-0546-4b53-8478-3b0a4c195662" xlink:to="loc_us-gaap_CostOfSalesMember_6cc0c6a7-dc6a-42f8-9ff1-fe16c15d844f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_926e6406-0d3e-4e24-9c1a-77ec37f85651" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_afaf0d92-0546-4b53-8478-3b0a4c195662" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_926e6406-0d3e-4e24-9c1a-77ec37f85651" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_cd1b698d-3093-4bfa-af5c-f0d8712b022e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_afaf0d92-0546-4b53-8478-3b0a4c195662" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_cd1b698d-3093-4bfa-af5c-f0d8712b022e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_5eeb3c9b-6e93-4e83-9b98-12a078b88dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringChargesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_afaf0d92-0546-4b53-8478-3b0a4c195662" xlink:to="loc_us-gaap_RestructuringChargesMember_5eeb3c9b-6e93-4e83-9b98-12a078b88dd0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_79f28898-5bd4-400d-aae7-5a411b1fa810" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_200781b1-af18-4892-a8bd-cc071f25f5dd" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_79f28898-5bd4-400d-aae7-5a411b1fa810" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_79f28898-5bd4-400d-aae7-5a411b1fa810_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_79f28898-5bd4-400d-aae7-5a411b1fa810" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_79f28898-5bd4-400d-aae7-5a411b1fa810_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_95c7309f-f8f2-436d-88a4-c5cda88c8d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_79f28898-5bd4-400d-aae7-5a411b1fa810" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_95c7309f-f8f2-436d-88a4-c5cda88c8d9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OneTimeTerminationBenefitsMember_951a2132-a955-47a4-a11c-0eee7f5aabcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OneTimeTerminationBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_95c7309f-f8f2-436d-88a4-c5cda88c8d9b" xlink:to="loc_us-gaap_OneTimeTerminationBenefitsMember_951a2132-a955-47a4-a11c-0eee7f5aabcf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcceleratedDepreciationMember_6bf97cea-a5e1-4111-aea5-c1e38a247c91" xlink:href="mrk-20220930.xsd#mrk_AcceleratedDepreciationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_95c7309f-f8f2-436d-88a4-c5cda88c8d9b" xlink:to="loc_mrk_AcceleratedDepreciationMember_6bf97cea-a5e1-4111-aea5-c1e38a247c91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_dd2b9c00-e366-4534-a48a-9761757eece6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_95c7309f-f8f2-436d-88a4-c5cda88c8d9b" xlink:to="loc_us-gaap_OtherRestructuringMember_dd2b9c00-e366-4534-a48a-9761757eece6" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/RestructuringActivitiesbyProgramDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#RestructuringActivitiesbyProgramDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/RestructuringActivitiesbyProgramDetails" xlink:type="extended" id="id69118fa10ff41fcb4508adffca08125_RestructuringActivitiesbyProgramDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_22268def-a8f5-4dbd-a5e6-8635a2bb781a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_9fa6062d-0c91-4ff6-a3a8-acaf10cc8ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_22268def-a8f5-4dbd-a5e6-8635a2bb781a" xlink:to="loc_us-gaap_RestructuringReserveRollForward_9fa6062d-0c91-4ff6-a3a8-acaf10cc8ddd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_c52b4e7a-1377-49cf-b86c-7793cd1337a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_9fa6062d-0c91-4ff6-a3a8-acaf10cc8ddd" xlink:to="loc_us-gaap_RestructuringReserve_c52b4e7a-1377-49cf-b86c-7793cd1337a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_405ab4b1-ed4e-422d-9a68-951b202364da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_9fa6062d-0c91-4ff6-a3a8-acaf10cc8ddd" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_405ab4b1-ed4e-422d-9a68-951b202364da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_f3253c2a-105a-4fee-9624-1584937a46ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_9fa6062d-0c91-4ff6-a3a8-acaf10cc8ddd" xlink:to="loc_us-gaap_PaymentsForRestructuring_f3253c2a-105a-4fee-9624-1584937a46ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity_e441fbe4-c415-42f6-87e9-40a071906e50" xlink:href="mrk-20220930.xsd#mrk_RestructuringReserveIncreaseDecreaseNoncashActivity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_9fa6062d-0c91-4ff6-a3a8-acaf10cc8ddd" xlink:to="loc_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity_e441fbe4-c415-42f6-87e9-40a071906e50" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_e7f2a51b-f747-43c4-ab31-a69eada018bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_addf4f66-3482-4cfe-92c8-3d6942d3269f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_22268def-a8f5-4dbd-a5e6-8635a2bb781a" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_addf4f66-3482-4cfe-92c8-3d6942d3269f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_825ee618-6f91-4de6-af56-8fdc99c5111e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_addf4f66-3482-4cfe-92c8-3d6942d3269f" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_825ee618-6f91-4de6-af56-8fdc99c5111e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_825ee618-6f91-4de6-af56-8fdc99c5111e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_825ee618-6f91-4de6-af56-8fdc99c5111e" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_825ee618-6f91-4de6-af56-8fdc99c5111e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_79d30104-633e-4a22-b984-61fd548a61f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_825ee618-6f91-4de6-af56-8fdc99c5111e" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_79d30104-633e-4a22-b984-61fd548a61f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OneTimeTerminationBenefitsMember_604b6d34-2fcd-4cba-a66f-054e516dd056" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OneTimeTerminationBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_79d30104-633e-4a22-b984-61fd548a61f2" xlink:to="loc_us-gaap_OneTimeTerminationBenefitsMember_604b6d34-2fcd-4cba-a66f-054e516dd056" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcceleratedDepreciationMember_ad49516a-2b29-43a6-86ad-e87746b46b07" xlink:href="mrk-20220930.xsd#mrk_AcceleratedDepreciationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_79d30104-633e-4a22-b984-61fd548a61f2" xlink:to="loc_mrk_AcceleratedDepreciationMember_ad49516a-2b29-43a6-86ad-e87746b46b07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_d31f3568-7b3d-4d93-8a74-1ef3ee562aef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_79d30104-633e-4a22-b984-61fd548a61f2" xlink:to="loc_us-gaap_OtherRestructuringMember_d31f3568-7b3d-4d93-8a74-1ef3ee562aef" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended" id="icc3fb30825894a82ad0705ade812cff8_FinancialInstrumentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_9f4d68df-fa7c-4c40-9fcf-360d4bee6ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAverageRemainingMaturity1_ce2105e8-62a2-48ee-a8df-5d5b33983dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAverageRemainingMaturity1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_9f4d68df-fa7c-4c40-9fcf-360d4bee6ba2" xlink:to="loc_us-gaap_DerivativeAverageRemainingMaturity1_ce2105e8-62a2-48ee-a8df-5d5b33983dc6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfInterestRateDerivativesHeld_6777bfb6-0fd5-4f35-b51b-6081a8da5062" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfInterestRateDerivativesHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_9f4d68df-fa7c-4c40-9fcf-360d4bee6ba2" xlink:to="loc_us-gaap_NumberOfInterestRateDerivativesHeld_6777bfb6-0fd5-4f35-b51b-6081a8da5062" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_7c2b6c86-5856-4580-b411-2015feb52415" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_9f4d68df-fa7c-4c40-9fcf-360d4bee6ba2" xlink:to="loc_us-gaap_DerivativeNotionalAmount_7c2b6c86-5856-4580-b411-2015feb52415" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_fe5f45e1-40cb-4087-8954-284376c1e476" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_9f4d68df-fa7c-4c40-9fcf-360d4bee6ba2" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_fe5f45e1-40cb-4087-8954-284376c1e476" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_203d3624-6b0c-412f-aa21-dc62c2f938cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_9f4d68df-fa7c-4c40-9fcf-360d4bee6ba2" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_203d3624-6b0c-412f-aa21-dc62c2f938cd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_6c83ead1-03f5-4195-a06d-fcae3957b66b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_9f4d68df-fa7c-4c40-9fcf-360d4bee6ba2" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_6c83ead1-03f5-4195-a06d-fcae3957b66b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_7c96109d-7f11-44bf-8dd3-bdab7df0b212" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_9f4d68df-fa7c-4c40-9fcf-360d4bee6ba2" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_7c96109d-7f11-44bf-8dd3-bdab7df0b212" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_b266d09c-7898-4acf-8d3e-4641b39641ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_9f4d68df-fa7c-4c40-9fcf-360d4bee6ba2" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_b266d09c-7898-4acf-8d3e-4641b39641ae" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_3d210366-d22f-4068-8b2b-a2a8950c59b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_9f4d68df-fa7c-4c40-9fcf-360d4bee6ba2" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_3d210366-d22f-4068-8b2b-a2a8950c59b5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_50cd7437-aa89-48be-b70c-fbe83e7341ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_9f4d68df-fa7c-4c40-9fcf-360d4bee6ba2" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_50cd7437-aa89-48be-b70c-fbe83e7341ae" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount_c8616b57-bc3c-48b6-861b-9bd1b68d7c22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_9f4d68df-fa7c-4c40-9fcf-360d4bee6ba2" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount_c8616b57-bc3c-48b6-861b-9bd1b68d7c22" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent_96ed9d37-e21e-46fd-9a71-d27a8544b2c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_9f4d68df-fa7c-4c40-9fcf-360d4bee6ba2" xlink:to="loc_us-gaap_EquitySecuritiesFVNINoncurrent_96ed9d37-e21e-46fd-9a71-d27a8544b2c6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_8711db14-1b0d-4e28-9354-17a8e5b012b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_9f4d68df-fa7c-4c40-9fcf-360d4bee6ba2" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_8711db14-1b0d-4e28-9354-17a8e5b012b7" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_ed21f815-eb0b-433d-88e1-02ea460dd62e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_9f4d68df-fa7c-4c40-9fcf-360d4bee6ba2" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_ed21f815-eb0b-433d-88e1-02ea460dd62e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_142bbd11-67b0-4cf4-abea-916e895e016a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_9f4d68df-fa7c-4c40-9fcf-360d4bee6ba2" xlink:to="loc_us-gaap_DebtInstrumentFairValue_142bbd11-67b0-4cf4-abea-916e895e016a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_2ae2a0cf-11f1-48af-8ee1-9921e8534a91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_9f4d68df-fa7c-4c40-9fcf-360d4bee6ba2" xlink:to="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_2ae2a0cf-11f1-48af-8ee1-9921e8534a91" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableSale_b51d58c7-2b13-4929-b78c-00c5c7b728b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_9f4d68df-fa7c-4c40-9fcf-360d4bee6ba2" xlink:to="loc_us-gaap_AccountsReceivableSale_b51d58c7-2b13-4929-b78c-00c5c7b728b8" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_90fdcab5-d161-4833-a4f8-5186abdcc035" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_9f4d68df-fa7c-4c40-9fcf-360d4bee6ba2" xlink:to="loc_us-gaap_RestrictedCashCurrent_90fdcab5-d161-4833-a4f8-5186abdcc035" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash_7aba8ef3-70c8-4596-856f-761e853aaba8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_9f4d68df-fa7c-4c40-9fcf-360d4bee6ba2" xlink:to="loc_us-gaap_DerivativeCollateralObligationToReturnCash_7aba8ef3-70c8-4596-856f-761e853aaba8" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_1345090b-e8a1-4ac6-b152-aeaac2047f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_9f4d68df-fa7c-4c40-9fcf-360d4bee6ba2" xlink:to="loc_us-gaap_DerivativeTable_1345090b-e8a1-4ac6-b152-aeaac2047f5e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_eaf3ab96-212b-4bb4-a40a-cb04e4a4e04d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1345090b-e8a1-4ac6-b152-aeaac2047f5e" xlink:to="loc_srt_RangeAxis_eaf3ab96-212b-4bb4-a40a-cb04e4a4e04d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_eaf3ab96-212b-4bb4-a40a-cb04e4a4e04d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_eaf3ab96-212b-4bb4-a40a-cb04e4a4e04d" xlink:to="loc_srt_RangeMember_eaf3ab96-212b-4bb4-a40a-cb04e4a4e04d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3341070c-6401-474a-a3af-54ad440db010" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_eaf3ab96-212b-4bb4-a40a-cb04e4a4e04d" xlink:to="loc_srt_RangeMember_3341070c-6401-474a-a3af-54ad440db010" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0a1fa29b-5bc3-48db-b95f-cb12d1163d23" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3341070c-6401-474a-a3af-54ad440db010" xlink:to="loc_srt_MaximumMember_0a1fa29b-5bc3-48db-b95f-cb12d1163d23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_d75d4a08-803f-4041-99dc-5b59e54d1b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1345090b-e8a1-4ac6-b152-aeaac2047f5e" xlink:to="loc_us-gaap_HedgingDesignationAxis_d75d4a08-803f-4041-99dc-5b59e54d1b8c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_d75d4a08-803f-4041-99dc-5b59e54d1b8c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_d75d4a08-803f-4041-99dc-5b59e54d1b8c" xlink:to="loc_us-gaap_HedgingDesignationDomain_d75d4a08-803f-4041-99dc-5b59e54d1b8c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_7a7917da-12d6-4e1f-a281-22cb613bfbb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_d75d4a08-803f-4041-99dc-5b59e54d1b8c" xlink:to="loc_us-gaap_HedgingDesignationDomain_7a7917da-12d6-4e1f-a281-22cb613bfbb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_b7b4b531-7ebe-4eeb-95d6-e49c4ed76d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_7a7917da-12d6-4e1f-a281-22cb613bfbb0" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_b7b4b531-7ebe-4eeb-95d6-e49c4ed76d6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_dead15b6-9d9b-4fa4-814f-ea7382478fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_7a7917da-12d6-4e1f-a281-22cb613bfbb0" xlink:to="loc_us-gaap_NondesignatedMember_dead15b6-9d9b-4fa4-814f-ea7382478fc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_60f4432f-cc6f-40c0-a672-ece60103e376" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1345090b-e8a1-4ac6-b152-aeaac2047f5e" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_60f4432f-cc6f-40c0-a672-ece60103e376" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_60f4432f-cc6f-40c0-a672-ece60103e376_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_60f4432f-cc6f-40c0-a672-ece60103e376" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_60f4432f-cc6f-40c0-a672-ece60103e376_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a5ce6942-1f2d-4f43-8b88-a91325c9bcf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_60f4432f-cc6f-40c0-a672-ece60103e376" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a5ce6942-1f2d-4f43-8b88-a91325c9bcf1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_4ab1c312-73ba-4c62-8b3a-d3862d47a567" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a5ce6942-1f2d-4f43-8b88-a91325c9bcf1" xlink:to="loc_us-gaap_InterestRateSwapMember_4ab1c312-73ba-4c62-8b3a-d3862d47a567" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_4180d89c-8f5e-4a20-ba11-1576cd36f2e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1345090b-e8a1-4ac6-b152-aeaac2047f5e" xlink:to="loc_us-gaap_DebtInstrumentAxis_4180d89c-8f5e-4a20-ba11-1576cd36f2e3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4180d89c-8f5e-4a20-ba11-1576cd36f2e3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_4180d89c-8f5e-4a20-ba11-1576cd36f2e3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4180d89c-8f5e-4a20-ba11-1576cd36f2e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c4fe8e13-e5d3-495e-a136-605f9c5a4619" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_4180d89c-8f5e-4a20-ba11-1576cd36f2e3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c4fe8e13-e5d3-495e-a136-605f9c5a4619" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.35NotesDue2022Member_02f52df0-52b6-499d-abf9-f78c4ca52dd4" xlink:href="mrk-20220930.xsd#mrk_A2.35NotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c4fe8e13-e5d3-495e-a136-605f9c5a4619" xlink:to="loc_mrk_A2.35NotesDue2022Member_02f52df0-52b6-499d-abf9-f78c4ca52dd4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.40NotesDue2022Member_1b8921ea-2f81-40af-8ffa-1dd101ef1439" xlink:href="mrk-20220930.xsd#mrk_A2.40NotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c4fe8e13-e5d3-495e-a136-605f9c5a4619" xlink:to="loc_mrk_A2.40NotesDue2022Member_1b8921ea-2f81-40af-8ffa-1dd101ef1439" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_74bd9df2-faed-4d67-bdd7-654ed3dabb7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1345090b-e8a1-4ac6-b152-aeaac2047f5e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_74bd9df2-faed-4d67-bdd7-654ed3dabb7a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_74bd9df2-faed-4d67-bdd7-654ed3dabb7a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_74bd9df2-faed-4d67-bdd7-654ed3dabb7a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_74bd9df2-faed-4d67-bdd7-654ed3dabb7a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_872c2b0d-b292-4676-9245-99ec3ab848e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_74bd9df2-faed-4d67-bdd7-654ed3dabb7a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_872c2b0d-b292-4676-9245-99ec3ab848e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_72ee264c-a090-4c52-986b-916cb8214dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_872c2b0d-b292-4676-9245-99ec3ab848e2" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_72ee264c-a090-4c52-986b-916cb8214dcb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_4ad88f82-95e9-421e-a027-0e384a66d0e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1345090b-e8a1-4ac6-b152-aeaac2047f5e" xlink:to="loc_us-gaap_InvestmentTypeAxis_4ad88f82-95e9-421e-a027-0e384a66d0e8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_4ad88f82-95e9-421e-a027-0e384a66d0e8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_4ad88f82-95e9-421e-a027-0e384a66d0e8" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_4ad88f82-95e9-421e-a027-0e384a66d0e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_b32c0c10-71cc-4aee-9ea7-42a70e75575f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_4ad88f82-95e9-421e-a027-0e384a66d0e8" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_b32c0c10-71cc-4aee-9ea7-42a70e75575f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFundsMember_6817547f-4613-4ea1-90c4-02d11393155d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b32c0c10-71cc-4aee-9ea7-42a70e75575f" xlink:to="loc_us-gaap_EquityFundsMember_6817547f-4613-4ea1-90c4-02d11393155d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_cbe65738-b7a3-4d46-b13e-fa4f0fc7a5da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1345090b-e8a1-4ac6-b152-aeaac2047f5e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_cbe65738-b7a3-4d46-b13e-fa4f0fc7a5da" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_cbe65738-b7a3-4d46-b13e-fa4f0fc7a5da_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_cbe65738-b7a3-4d46-b13e-fa4f0fc7a5da" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_cbe65738-b7a3-4d46-b13e-fa4f0fc7a5da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e5c58e5c-fe4f-4d01-9f53-8421171c67b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_cbe65738-b7a3-4d46-b13e-fa4f0fc7a5da" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e5c58e5c-fe4f-4d01-9f53-8421171c67b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.35NotesDue2022Member_fe68ac64-3416-48bc-8e9d-361a6c85fa23" xlink:href="mrk-20220930.xsd#mrk_A2.35NotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e5c58e5c-fe4f-4d01-9f53-8421171c67b1" xlink:to="loc_mrk_A2.35NotesDue2022Member_fe68ac64-3416-48bc-8e9d-361a6c85fa23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.40NotesDue2022Member_51ae44e9-5bb6-47e0-a354-6fe975f5f4e4" xlink:href="mrk-20220930.xsd#mrk_A2.40NotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e5c58e5c-fe4f-4d01-9f53-8421171c67b1" xlink:to="loc_mrk_A2.40NotesDue2022Member_51ae44e9-5bb6-47e0-a354-6fe975f5f4e4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#FinancialInstrumentsEffectofNetInvestmentHedgesDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails" xlink:type="extended" id="i8d90dc016be54eb8bff0bf49fd4e6415_FinancialInstrumentsEffectofNetInvestmentHedgesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_6dcdd5fa-6bc6-48d8-9dd0-904aa93c98e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_6f156e5c-06be-49f4-9e0d-c95444312ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_6dcdd5fa-6bc6-48d8-9dd0-904aa93c98e3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_6f156e5c-06be-49f4-9e0d-c95444312ca3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_f5158b0a-a8ca-44f9-a9d5-6c6c47b68613" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_6dcdd5fa-6bc6-48d8-9dd0-904aa93c98e3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_f5158b0a-a8ca-44f9-a9d5-6c6c47b68613" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_8ed6ff05-bce9-484e-a8f6-dd68c4052542" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_6dcdd5fa-6bc6-48d8-9dd0-904aa93c98e3" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_8ed6ff05-bce9-484e-a8f6-dd68c4052542" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_5924676f-4bd6-4fe4-8349-68bba10db344" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_8ed6ff05-bce9-484e-a8f6-dd68c4052542" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_5924676f-4bd6-4fe4-8349-68bba10db344" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_5924676f-4bd6-4fe4-8349-68bba10db344_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5924676f-4bd6-4fe4-8349-68bba10db344" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_5924676f-4bd6-4fe4-8349-68bba10db344_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_5e0e919c-c181-4616-84d0-2af6c09920ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5924676f-4bd6-4fe4-8349-68bba10db344" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_5e0e919c-c181-4616-84d0-2af6c09920ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_908dedc8-455c-4231-9906-b7918c5f4e00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_5e0e919c-c181-4616-84d0-2af6c09920ee" xlink:to="loc_us-gaap_ForeignExchangeContractMember_908dedc8-455c-4231-9906-b7918c5f4e00" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EurodominatedNotesMember_fa5d73f0-769a-498b-9698-c68fd658fc96" xlink:href="mrk-20220930.xsd#mrk_EurodominatedNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_5e0e919c-c181-4616-84d0-2af6c09920ee" xlink:to="loc_mrk_EurodominatedNotesMember_fa5d73f0-769a-498b-9698-c68fd658fc96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ae86c8db-8c20-4308-9541-38de4e629f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_8ed6ff05-bce9-484e-a8f6-dd68c4052542" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ae86c8db-8c20-4308-9541-38de4e629f9c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ae86c8db-8c20-4308-9541-38de4e629f9c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ae86c8db-8c20-4308-9541-38de4e629f9c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ae86c8db-8c20-4308-9541-38de4e629f9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3bec97fe-ee05-47d7-bdfb-8aa6edec6b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ae86c8db-8c20-4308-9541-38de4e629f9c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3bec97fe-ee05-47d7-bdfb-8aa6edec6b3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_6330cb7b-6c81-482d-9682-6b2bcd2c8642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3bec97fe-ee05-47d7-bdfb-8aa6edec6b3a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_6330cb7b-6c81-482d-9682-6b2bcd2c8642" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#FinancialInstrumentsFairValueHedgesDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails" xlink:type="extended" id="i100d24e554f44958b6fe3b6dfa49d041_FinancialInstrumentsFairValueHedgesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_af43c4f6-bd8a-47ff-bb0a-4416b3702a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedge_fa0f1adb-aafe-4454-9f8b-c85799195408" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_af43c4f6-bd8a-47ff-bb0a-4416b3702a6a" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedge_fa0f1adb-aafe-4454-9f8b-c85799195408" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_e1e4033d-9da3-4e61-90d5-81e635d20ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_af43c4f6-bd8a-47ff-bb0a-4416b3702a6a" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_e1e4033d-9da3-4e61-90d5-81e635d20ca5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_81c66d14-5851-47a1-b24e-ce07c89247d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_af43c4f6-bd8a-47ff-bb0a-4416b3702a6a" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_81c66d14-5851-47a1-b24e-ce07c89247d7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_18ab0ee8-e8ce-4741-bdcc-aa5e0fefaf1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_81c66d14-5851-47a1-b24e-ce07c89247d7" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_18ab0ee8-e8ce-4741-bdcc-aa5e0fefaf1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_18ab0ee8-e8ce-4741-bdcc-aa5e0fefaf1d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_18ab0ee8-e8ce-4741-bdcc-aa5e0fefaf1d" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_18ab0ee8-e8ce-4741-bdcc-aa5e0fefaf1d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f15ed20a-2248-437e-b84a-44c189cd16ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_18ab0ee8-e8ce-4741-bdcc-aa5e0fefaf1d" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f15ed20a-2248-437e-b84a-44c189cd16ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtCurrentMaturitiesMember_4ce75c96-3646-4dcd-bfc8-8e5c786d5b54" xlink:href="mrk-20220930.xsd#mrk_LongTermDebtCurrentMaturitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f15ed20a-2248-437e-b84a-44c189cd16ff" xlink:to="loc_mrk_LongTermDebtCurrentMaturitiesMember_4ce75c96-3646-4dcd-bfc8-8e5c786d5b54" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" xlink:type="extended" id="ie24a1d4b9791402786f1c7df5d9444f2_FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_55075ec5-da77-4e43-a1e8-97cf6973d284" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_4f339f95-1630-4f2c-8e53-9a43cd8f1411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_55075ec5-da77-4e43-a1e8-97cf6973d284" xlink:to="loc_us-gaap_DerivativeAssets_4f339f95-1630-4f2c-8e53-9a43cd8f1411" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_7bd315f4-1327-4f76-ba51-729fe1fef408" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_55075ec5-da77-4e43-a1e8-97cf6973d284" xlink:to="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_7bd315f4-1327-4f76-ba51-729fe1fef408" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_300ce29f-103b-4132-9dbc-87d2508f212e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_55075ec5-da77-4e43-a1e8-97cf6973d284" xlink:to="loc_us-gaap_DerivativeLiabilities_300ce29f-103b-4132-9dbc-87d2508f212e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_155896eb-96ac-4cb0-a36f-69d761c3972b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_55075ec5-da77-4e43-a1e8-97cf6973d284" xlink:to="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_155896eb-96ac-4cb0-a36f-69d761c3972b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_ddb77745-5c54-4225-b942-8ae7e976ad4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_55075ec5-da77-4e43-a1e8-97cf6973d284" xlink:to="loc_us-gaap_DerivativeNotionalAmount_ddb77745-5c54-4225-b942-8ae7e976ad4a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_06a1d364-a219-477e-a9d8-5ec19059c773" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_55075ec5-da77-4e43-a1e8-97cf6973d284" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_06a1d364-a219-477e-a9d8-5ec19059c773" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_975a208b-b475-46cb-88aa-50ce30e4c062" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_06a1d364-a219-477e-a9d8-5ec19059c773" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_975a208b-b475-46cb-88aa-50ce30e4c062" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_975a208b-b475-46cb-88aa-50ce30e4c062_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_975a208b-b475-46cb-88aa-50ce30e4c062" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_975a208b-b475-46cb-88aa-50ce30e4c062_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_848780cc-40af-4751-a0cb-2088fd4592ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_975a208b-b475-46cb-88aa-50ce30e4c062" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_848780cc-40af-4751-a0cb-2088fd4592ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_df504062-771b-4d37-89b2-41b2ad5a7c57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_848780cc-40af-4751-a0cb-2088fd4592ce" xlink:to="loc_us-gaap_InterestRateContractMember_df504062-771b-4d37-89b2-41b2ad5a7c57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_0676425c-fe55-4652-952b-efe63d7f43bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_848780cc-40af-4751-a0cb-2088fd4592ce" xlink:to="loc_us-gaap_ForeignExchangeContractMember_0676425c-fe55-4652-952b-efe63d7f43bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_9301673c-915e-4a02-9478-b2b7c3e0923c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_06a1d364-a219-477e-a9d8-5ec19059c773" xlink:to="loc_us-gaap_HedgingDesignationAxis_9301673c-915e-4a02-9478-b2b7c3e0923c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_9301673c-915e-4a02-9478-b2b7c3e0923c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_9301673c-915e-4a02-9478-b2b7c3e0923c" xlink:to="loc_us-gaap_HedgingDesignationDomain_9301673c-915e-4a02-9478-b2b7c3e0923c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_509c789d-f668-4f68-8ebc-24013aff76f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_9301673c-915e-4a02-9478-b2b7c3e0923c" xlink:to="loc_us-gaap_HedgingDesignationDomain_509c789d-f668-4f68-8ebc-24013aff76f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_00b60a05-dfc4-4377-a2ee-06c9d1d6afcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_509c789d-f668-4f68-8ebc-24013aff76f6" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_00b60a05-dfc4-4377-a2ee-06c9d1d6afcf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_5abb24c2-4159-49b9-8b5c-d28d31d5e640" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_509c789d-f668-4f68-8ebc-24013aff76f6" xlink:to="loc_us-gaap_NondesignatedMember_5abb24c2-4159-49b9-8b5c-d28d31d5e640" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_eba86809-afb0-4291-96fc-c3779110dcdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_06a1d364-a219-477e-a9d8-5ec19059c773" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_eba86809-afb0-4291-96fc-c3779110dcdb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_eba86809-afb0-4291-96fc-c3779110dcdb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_eba86809-afb0-4291-96fc-c3779110dcdb" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_eba86809-afb0-4291-96fc-c3779110dcdb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f4806e65-d2e8-4bd5-8b2a-069cac252350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_eba86809-afb0-4291-96fc-c3779110dcdb" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f4806e65-d2e8-4bd5-8b2a-069cac252350" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredIncomeTaxesAndOtherAssetsCurrentMember_93a0321c-2763-4095-bb5f-b31b0c0f6a9c" xlink:href="mrk-20220930.xsd#mrk_DeferredIncomeTaxesAndOtherAssetsCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f4806e65-d2e8-4bd5-8b2a-069cac252350" xlink:to="loc_mrk_DeferredIncomeTaxesAndOtherAssetsCurrentMember_93a0321c-2763-4095-bb5f-b31b0c0f6a9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember_ce7cc355-2d9f-421a-a6b3-c9ccfa267349" xlink:href="mrk-20220930.xsd#mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f4806e65-d2e8-4bd5-8b2a-069cac252350" xlink:to="loc_mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember_ce7cc355-2d9f-421a-a6b3-c9ccfa267349" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_92093896-406c-4676-b8f0-d236814e869a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f4806e65-d2e8-4bd5-8b2a-069cac252350" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_92093896-406c-4676-b8f0-d236814e869a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_fcca3e6e-ef6d-446e-b5fb-b15c718a9da6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f4806e65-d2e8-4bd5-8b2a-069cac252350" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_fcca3e6e-ef6d-446e-b5fb-b15c718a9da6" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" xlink:type="extended" id="i5ffa705289c8417eb5846f0e37f97e75_FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_9ce07c84-7d58-4eca-841a-49f3f6cd90a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_541f3fdf-c567-4571-a23b-65565e852dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_9ce07c84-7d58-4eca-841a-49f3f6cd90a5" xlink:to="loc_us-gaap_Revenues_541f3fdf-c567-4571-a23b-65565e852dd8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_aee089cb-cf73-420f-ba21-8575c47bb098" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_9ce07c84-7d58-4eca-841a-49f3f6cd90a5" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_aee089cb-cf73-420f-ba21-8575c47bb098" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_03cbb03b-76fd-406c-b3a1-9d96161a08c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_9ce07c84-7d58-4eca-841a-49f3f6cd90a5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_03cbb03b-76fd-406c-b3a1-9d96161a08c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_e7d22590-eb0a-44d1-9d15-584a61f9baf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_9ce07c84-7d58-4eca-841a-49f3f6cd90a5" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_e7d22590-eb0a-44d1-9d15-584a61f9baf5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_e8193a52-af5e-46e4-bc52-694009525fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_9ce07c84-7d58-4eca-841a-49f3f6cd90a5" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_e8193a52-af5e-46e4-bc52-694009525fd6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_0e6d65f7-3b54-4d14-b301-c83992a2b501" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_9ce07c84-7d58-4eca-841a-49f3f6cd90a5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_0e6d65f7-3b54-4d14-b301-c83992a2b501" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_bbf6638e-9966-4b96-b3b3-9e6a212dc9fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_9ce07c84-7d58-4eca-841a-49f3f6cd90a5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_bbf6638e-9966-4b96-b3b3-9e6a212dc9fc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_90613756-b989-4c60-bb43-79004da11386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_9ce07c84-7d58-4eca-841a-49f3f6cd90a5" xlink:to="loc_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_90613756-b989-4c60-bb43-79004da11386" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_fedb6f04-855f-4bf2-99dd-10475408f17e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_9ce07c84-7d58-4eca-841a-49f3f6cd90a5" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_fedb6f04-855f-4bf2-99dd-10475408f17e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0f4de4db-dbc2-4767-886a-b08d9e17517a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_9ce07c84-7d58-4eca-841a-49f3f6cd90a5" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0f4de4db-dbc2-4767-886a-b08d9e17517a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_3936c584-e657-4ea6-9280-6e5d1a8c2b10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0f4de4db-dbc2-4767-886a-b08d9e17517a" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_3936c584-e657-4ea6-9280-6e5d1a8c2b10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_3936c584-e657-4ea6-9280-6e5d1a8c2b10_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3936c584-e657-4ea6-9280-6e5d1a8c2b10" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_3936c584-e657-4ea6-9280-6e5d1a8c2b10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_32f154dc-a2d9-482c-b1d5-138ba62b32f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3936c584-e657-4ea6-9280-6e5d1a8c2b10" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_32f154dc-a2d9-482c-b1d5-138ba62b32f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_15d070d4-e02c-4c11-9408-480f9ed6a5bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_32f154dc-a2d9-482c-b1d5-138ba62b32f0" xlink:to="loc_us-gaap_InterestRateSwapMember_15d070d4-e02c-4c11-9408-480f9ed6a5bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_73a1af60-de6f-4d7c-aed2-fd6153c4ca81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_32f154dc-a2d9-482c-b1d5-138ba62b32f0" xlink:to="loc_us-gaap_ForeignExchangeContractMember_73a1af60-de6f-4d7c-aed2-fd6153c4ca81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_37de80bc-d494-4557-9d8b-7bca7c77a5ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0f4de4db-dbc2-4767-886a-b08d9e17517a" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_37de80bc-d494-4557-9d8b-7bca7c77a5ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_37de80bc-d494-4557-9d8b-7bca7c77a5ac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_37de80bc-d494-4557-9d8b-7bca7c77a5ac" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_37de80bc-d494-4557-9d8b-7bca7c77a5ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_6c5cc186-6a7e-4020-ac87-dd9d2eae8f05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_37de80bc-d494-4557-9d8b-7bca7c77a5ac" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_6c5cc186-6a7e-4020-ac87-dd9d2eae8f05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_2898a3e3-32d2-4177-996b-a20616306582" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_6c5cc186-6a7e-4020-ac87-dd9d2eae8f05" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_2898a3e3-32d2-4177-996b-a20616306582" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9c1b6bf6-e7e8-4735-bbce-040c49bd337d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0f4de4db-dbc2-4767-886a-b08d9e17517a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9c1b6bf6-e7e8-4735-bbce-040c49bd337d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9c1b6bf6-e7e8-4735-bbce-040c49bd337d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9c1b6bf6-e7e8-4735-bbce-040c49bd337d" xlink:to="loc_us-gaap_EquityComponentDomain_9c1b6bf6-e7e8-4735-bbce-040c49bd337d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_06ad2369-fec8-4c79-91b7-7c08887a3749" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9c1b6bf6-e7e8-4735-bbce-040c49bd337d" xlink:to="loc_us-gaap_EquityComponentDomain_06ad2369-fec8-4c79-91b7-7c08887a3749" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_1782b3c9-ea79-4c59-acf5-3b0ca408a7eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_06ad2369-fec8-4c79-91b7-7c08887a3749" xlink:to="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_1782b3c9-ea79-4c59-acf5-3b0ca408a7eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ab875408-1065-4754-901a-0f4a96f0be85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0f4de4db-dbc2-4767-886a-b08d9e17517a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ab875408-1065-4754-901a-0f4a96f0be85" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ab875408-1065-4754-901a-0f4a96f0be85_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ab875408-1065-4754-901a-0f4a96f0be85" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ab875408-1065-4754-901a-0f4a96f0be85_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e4a6c30d-4710-43d7-99a2-9df5e2f6e6a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ab875408-1065-4754-901a-0f4a96f0be85" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e4a6c30d-4710-43d7-99a2-9df5e2f6e6a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_01a4df7a-449f-4c34-ae67-875f250d8167" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e4a6c30d-4710-43d7-99a2-9df5e2f6e6a8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_01a4df7a-449f-4c34-ae67-875f250d8167" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" xlink:type="extended" id="iba4174b5d5404b3785aaf9a6cd961c67_FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_ba11dfe5-a178-4e56-8613-9e62a9d3e753" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_4a2e9a65-7953-4faa-aa94-6f766fd22dea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_ba11dfe5-a178-4e56-8613-9e62a9d3e753" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_4a2e9a65-7953-4faa-aa94-6f766fd22dea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_fe31c654-7e92-406a-af45-f07c0fac77d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_ba11dfe5-a178-4e56-8613-9e62a9d3e753" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_fe31c654-7e92-406a-af45-f07c0fac77d5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_3bf90d3d-9eb4-43db-b4c9-a396a71f7ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_fe31c654-7e92-406a-af45-f07c0fac77d5" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_3bf90d3d-9eb4-43db-b4c9-a396a71f7ab8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_3bf90d3d-9eb4-43db-b4c9-a396a71f7ab8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3bf90d3d-9eb4-43db-b4c9-a396a71f7ab8" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_3bf90d3d-9eb4-43db-b4c9-a396a71f7ab8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_fe14355f-a4df-4c6c-a0bb-aba44b0f5ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3bf90d3d-9eb4-43db-b4c9-a396a71f7ab8" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_fe14355f-a4df-4c6c-a0bb-aba44b0f5ee2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_888628c7-aae8-449c-9f38-c4142c8a57b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fe14355f-a4df-4c6c-a0bb-aba44b0f5ee2" xlink:to="loc_us-gaap_CurrencySwapMember_888628c7-aae8-449c-9f38-c4142c8a57b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeFutureMember_a5d00d4d-28d3-4a2f-91e0-2dea894582c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeFutureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fe14355f-a4df-4c6c-a0bb-aba44b0f5ee2" xlink:to="loc_us-gaap_ForeignExchangeFutureMember_a5d00d4d-28d3-4a2f-91e0-2dea894582c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_bc2db728-7529-42af-9e4a-35854dd3dbc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_fe31c654-7e92-406a-af45-f07c0fac77d5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_bc2db728-7529-42af-9e4a-35854dd3dbc3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_bc2db728-7529-42af-9e4a-35854dd3dbc3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_bc2db728-7529-42af-9e4a-35854dd3dbc3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_bc2db728-7529-42af-9e4a-35854dd3dbc3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3f3e48f6-c3ef-409d-b9d3-be227c7e8c84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_bc2db728-7529-42af-9e4a-35854dd3dbc3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3f3e48f6-c3ef-409d-b9d3-be227c7e8c84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_cb316e96-a113-47c9-af0f-a25d78f7cda6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3f3e48f6-c3ef-409d-b9d3-be227c7e8c84" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_cb316e96-a113-47c9-af0f-a25d78f7cda6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_ddf68607-90db-4135-968d-400f31ef989a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3f3e48f6-c3ef-409d-b9d3-be227c7e8c84" xlink:to="loc_us-gaap_SalesMember_ddf68607-90db-4135-968d-400f31ef989a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" xlink:type="extended" id="i9c883d12eb6947b1b8f079d660a3f739_FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ebb40674-40f5-4371-9879-4e9016a3d659" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b7373784-ae39-465b-99b6-6625db6dc2e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ebb40674-40f5-4371-9879-4e9016a3d659" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b7373784-ae39-465b-99b6-6625db6dc2e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4cabb034-5e6d-45e6-8992-54ef7fd5f919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ebb40674-40f5-4371-9879-4e9016a3d659" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4cabb034-5e6d-45e6-8992-54ef7fd5f919" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5a6367c2-dac1-4f7d-ac65-1aeeaed60934" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ebb40674-40f5-4371-9879-4e9016a3d659" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5a6367c2-dac1-4f7d-ac65-1aeeaed60934" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4db6ced4-1546-4de9-9b6b-97b9829024ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ebb40674-40f5-4371-9879-4e9016a3d659" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4db6ced4-1546-4de9-9b6b-97b9829024ec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_202a1da4-88dc-4773-bc9f-900233efa6de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ebb40674-40f5-4371-9879-4e9016a3d659" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_202a1da4-88dc-4773-bc9f-900233efa6de" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI_241f5e2c-d9f7-4e5a-948e-e9a18a57ed29" xlink:href="mrk-20220930.xsd#mrk_DebtSecuritiesandEquitySecuritiesFVNI"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ebb40674-40f5-4371-9879-4e9016a3d659" xlink:to="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI_241f5e2c-d9f7-4e5a-948e-e9a18a57ed29" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_22806f71-326e-4337-9ac3-9359afc095a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ebb40674-40f5-4371-9879-4e9016a3d659" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_22806f71-326e-4337-9ac3-9359afc095a0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_236d7281-81b0-4e1f-98cc-ff1bdc3ee2c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ebb40674-40f5-4371-9879-4e9016a3d659" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_236d7281-81b0-4e1f-98cc-ff1bdc3ee2c9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_4c3356c2-59db-4b58-a2b4-b2a71bb2abb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_236d7281-81b0-4e1f-98cc-ff1bdc3ee2c9" xlink:to="loc_us-gaap_FinancialInstrumentAxis_4c3356c2-59db-4b58-a2b4-b2a71bb2abb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4c3356c2-59db-4b58-a2b4-b2a71bb2abb3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4c3356c2-59db-4b58-a2b4-b2a71bb2abb3" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4c3356c2-59db-4b58-a2b4-b2a71bb2abb3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a357af8a-b8b4-4e3e-8110-b642dce74637" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4c3356c2-59db-4b58-a2b4-b2a71bb2abb3" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a357af8a-b8b4-4e3e-8110-b642dce74637" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_9d5a1603-aa2f-42bb-9f90-f9a5875b2017" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a357af8a-b8b4-4e3e-8110-b642dce74637" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_9d5a1603-aa2f-42bb-9f90-f9a5875b2017" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_a29a14b0-0cab-4183-8097-50250d71992d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a357af8a-b8b4-4e3e-8110-b642dce74637" xlink:to="loc_us-gaap_CommercialPaperMember_a29a14b0-0cab-4183-8097-50250d71992d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_e242c2e2-a583-4a03-ad33-693fb814927c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a357af8a-b8b4-4e3e-8110-b642dce74637" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_e242c2e2-a583-4a03-ad33-693fb814927c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_6f9f5808-7cbb-4a5a-8e01-055cac4b83a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a357af8a-b8b4-4e3e-8110-b642dce74637" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_6f9f5808-7cbb-4a5a-8e01-055cac4b83a9" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended" id="ie7c7cf33ba3d413eb02029238e4d5933_FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c75c3a4f-2cf9-4295-b42b-0ebfc03193e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_a233726b-b836-4c58-a120-4b81b6eb395f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c75c3a4f-2cf9-4295-b42b-0ebfc03193e4" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_a233726b-b836-4c58-a120-4b81b6eb395f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_673fc66a-ffe4-4d59-96bd-567ba6b4f2ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a233726b-b836-4c58-a120-4b81b6eb395f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_673fc66a-ffe4-4d59-96bd-567ba6b4f2ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_9257c215-2e7a-4e71-885b-2cebc59acc38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a233726b-b836-4c58-a120-4b81b6eb395f" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_9257c215-2e7a-4e71-885b-2cebc59acc38" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities_72737bd6-a3f3-4238-96de-1d723be3c3c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a233726b-b836-4c58-a120-4b81b6eb395f" xlink:to="loc_us-gaap_TradingSecurities_72737bd6-a3f3-4238-96de-1d723be3c3c2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_6f43218a-e1d7-494f-9139-f62672fabb06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a233726b-b836-4c58-a120-4b81b6eb395f" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_6f43218a-e1d7-494f-9139-f62672fabb06" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_a7fbcd16-6fca-4809-ac36-ebab3c36adee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a233726b-b836-4c58-a120-4b81b6eb395f" xlink:to="loc_us-gaap_DerivativeAssets_a7fbcd16-6fca-4809-ac36-ebab3c36adee" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_c7dfd052-90eb-4cbb-9931-5e7ceb90367a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a233726b-b836-4c58-a120-4b81b6eb395f" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_c7dfd052-90eb-4cbb-9931-5e7ceb90367a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_ddfc1f14-a9b3-494e-895d-67d24bb3924c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c75c3a4f-2cf9-4295-b42b-0ebfc03193e4" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_ddfc1f14-a9b3-494e-895d-67d24bb3924c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_824b7145-daf0-459c-87fe-3d3524e3b350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_ddfc1f14-a9b3-494e-895d-67d24bb3924c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_824b7145-daf0-459c-87fe-3d3524e3b350" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_84982ace-2c68-42a3-bdad-bcd97ce6b889" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_ddfc1f14-a9b3-494e-895d-67d24bb3924c" xlink:to="loc_us-gaap_DerivativeLiabilities_84982ace-2c68-42a3-bdad-bcd97ce6b889" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_5af5cced-8589-4087-bbf7-c502ba8742ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_ddfc1f14-a9b3-494e-895d-67d24bb3924c" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_5af5cced-8589-4087-bbf7-c502ba8742ef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_88165e8a-80e2-4ad5-904a-c86b4d941739" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c75c3a4f-2cf9-4295-b42b-0ebfc03193e4" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_88165e8a-80e2-4ad5-904a-c86b4d941739" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3478b0b2-991e-444e-bdaa-a20012b1b860" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_88165e8a-80e2-4ad5-904a-c86b4d941739" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3478b0b2-991e-444e-bdaa-a20012b1b860" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3478b0b2-991e-444e-bdaa-a20012b1b860_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3478b0b2-991e-444e-bdaa-a20012b1b860" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_3478b0b2-991e-444e-bdaa-a20012b1b860_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_4cd5314d-c6eb-4469-a98d-d92a959fa90c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3478b0b2-991e-444e-bdaa-a20012b1b860" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_4cd5314d-c6eb-4469-a98d-d92a959fa90c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_6e451874-5f9d-4f35-9e10-4134539bccbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_4cd5314d-c6eb-4469-a98d-d92a959fa90c" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_6e451874-5f9d-4f35-9e10-4134539bccbe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1a41e368-9cdc-437b-b608-b5819f76905e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_88165e8a-80e2-4ad5-904a-c86b4d941739" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1a41e368-9cdc-437b-b608-b5819f76905e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1a41e368-9cdc-437b-b608-b5819f76905e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1a41e368-9cdc-437b-b608-b5819f76905e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1a41e368-9cdc-437b-b608-b5819f76905e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_475284b0-175d-4634-a681-242e8ec215b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1a41e368-9cdc-437b-b608-b5819f76905e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_475284b0-175d-4634-a681-242e8ec215b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_1740a0b0-18ee-4f74-9f0a-9248a3484d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_475284b0-175d-4634-a681-242e8ec215b0" xlink:to="loc_us-gaap_CommercialPaperMember_1740a0b0-18ee-4f74-9f0a-9248a3484d2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_daf5fd5f-63cd-4676-b3b9-251bd15d6f65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_475284b0-175d-4634-a681-242e8ec215b0" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_daf5fd5f-63cd-4676-b3b9-251bd15d6f65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_2f13594e-25e1-4796-b1f2-fd01ab5cb46a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_475284b0-175d-4634-a681-242e8ec215b0" xlink:to="loc_us-gaap_EquitySecuritiesMember_2f13594e-25e1-4796-b1f2-fd01ab5cb46a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_bbaf9584-c71a-4822-804e-dc4f29b36d38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_475284b0-175d-4634-a681-242e8ec215b0" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_bbaf9584-c71a-4822-804e-dc4f29b36d38" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_71f58d2d-a43c-4128-8b7b-0e45ab4e9a32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_475284b0-175d-4634-a681-242e8ec215b0" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_71f58d2d-a43c-4128-8b7b-0e45ab4e9a32" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5410f46f-afd2-407b-bdea-c4cf5085fff5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_88165e8a-80e2-4ad5-904a-c86b4d941739" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5410f46f-afd2-407b-bdea-c4cf5085fff5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5410f46f-afd2-407b-bdea-c4cf5085fff5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5410f46f-afd2-407b-bdea-c4cf5085fff5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5410f46f-afd2-407b-bdea-c4cf5085fff5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3af880dd-edb8-4725-99b4-d9e9b412ff46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5410f46f-afd2-407b-bdea-c4cf5085fff5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3af880dd-edb8-4725-99b4-d9e9b412ff46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_7d349340-f653-4814-853d-87c669aa7050" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3af880dd-edb8-4725-99b4-d9e9b412ff46" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_7d349340-f653-4814-853d-87c669aa7050" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_eee58cbc-6811-41e8-9b67-9d577ba8dc06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3af880dd-edb8-4725-99b4-d9e9b412ff46" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_eee58cbc-6811-41e8-9b67-9d577ba8dc06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3d98ba2b-9b28-4aea-9d38-3e888a6416ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3af880dd-edb8-4725-99b4-d9e9b412ff46" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3d98ba2b-9b28-4aea-9d38-3e888a6416ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_658dee45-23e6-478d-b708-d3e0dfb92d15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_88165e8a-80e2-4ad5-904a-c86b4d941739" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_658dee45-23e6-478d-b708-d3e0dfb92d15" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_658dee45-23e6-478d-b708-d3e0dfb92d15_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_658dee45-23e6-478d-b708-d3e0dfb92d15" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_658dee45-23e6-478d-b708-d3e0dfb92d15_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_70add43d-beb7-42f0-8dea-9ffd952c5d04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_658dee45-23e6-478d-b708-d3e0dfb92d15" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_70add43d-beb7-42f0-8dea-9ffd952c5d04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_acf44696-89f0-48ba-884a-b3519b410ede" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_70add43d-beb7-42f0-8dea-9ffd952c5d04" xlink:to="loc_us-gaap_ForeignExchangeContractMember_acf44696-89f0-48ba-884a-b3519b410ede" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_f8dc16bd-0393-415e-8ff4-8873f4c91c49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_70add43d-beb7-42f0-8dea-9ffd952c5d04" xlink:to="loc_us-gaap_InterestRateSwapMember_f8dc16bd-0393-415e-8ff4-8873f4c91c49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeOptionMember_e352c507-92df-4ce5-9df8-bed4fb6c7aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_70add43d-beb7-42f0-8dea-9ffd952c5d04" xlink:to="loc_us-gaap_ForeignExchangeOptionMember_e352c507-92df-4ce5-9df8-bed4fb6c7aa5" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" xlink:type="extended" id="i9bcc96eaed7b4ec587571a9f25c3ca8d_FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6d33a379-abd4-4aff-8f0f-e56debfdf5f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5381c372-17cb-4288-87ae-e31785da5d71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6d33a379-abd4-4aff-8f0f-e56debfdf5f4" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5381c372-17cb-4288-87ae-e31785da5d71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0c80bec5-32d6-4e6e-b276-8d5b59bc2994" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5381c372-17cb-4288-87ae-e31785da5d71" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0c80bec5-32d6-4e6e-b276-8d5b59bc2994" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_0233eba5-4277-4cd7-aff6-1dd9790871c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5381c372-17cb-4288-87ae-e31785da5d71" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_0233eba5-4277-4cd7-aff6-1dd9790871c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_2df67dbc-4638-4621-b6c8-6f925845417a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5381c372-17cb-4288-87ae-e31785da5d71" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_2df67dbc-4638-4621-b6c8-6f925845417a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther_0a001109-dbaa-43ff-9f4b-cf8752ea6f4e" xlink:href="mrk-20220930.xsd#mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5381c372-17cb-4288-87ae-e31785da5d71" xlink:to="loc_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther_0a001109-dbaa-43ff-9f4b-cf8752ea6f4e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e2c223cb-efba-41ad-b9d8-363bb4381866" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1670d0e5-2e01-40b4-b797-ea294ae49715" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_b53de088-7aac-418f-8419-72a5b5fdc471" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5381c372-17cb-4288-87ae-e31785da5d71" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_b53de088-7aac-418f-8419-72a5b5fdc471" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_b99fb3cf-554c-4293-b634-c590569d81d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5381c372-17cb-4288-87ae-e31785da5d71" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_b99fb3cf-554c-4293-b634-c590569d81d7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_e4453ec3-626a-4ff3-a11a-a2c41587478a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6d33a379-abd4-4aff-8f0f-e56debfdf5f4" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_e4453ec3-626a-4ff3-a11a-a2c41587478a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_7d23c699-cf01-473a-b770-dd5a469777ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_e4453ec3-626a-4ff3-a11a-a2c41587478a" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_7d23c699-cf01-473a-b770-dd5a469777ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_7d23c699-cf01-473a-b770-dd5a469777ad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_7d23c699-cf01-473a-b770-dd5a469777ad" xlink:to="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_7d23c699-cf01-473a-b770-dd5a469777ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_5609e3f5-2c8f-4453-a015-afdf6f0fd9a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_7d23c699-cf01-473a-b770-dd5a469777ad" xlink:to="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_5609e3f5-2c8f-4453-a015-afdf6f0fd9a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SanofiPasteurMember_0dc26e49-d227-485d-b299-020a7a10228c" xlink:href="mrk-20220930.xsd#mrk_SanofiPasteurMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_5609e3f5-2c8f-4453-a015-afdf6f0fd9a6" xlink:to="loc_mrk_SanofiPasteurMember_0dc26e49-d227-485d-b299-020a7a10228c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#InventoriesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/InventoriesNarrativeDetails" xlink:type="extended" id="i82e509f61e894954bc79dfd7c66b09c7_InventoriesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_a5d7620f-23cd-46bb-b70c-c879704517be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_c697978e-a7f0-4062-8567-48feb0154eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_a5d7620f-23cd-46bb-b70c-c879704517be" xlink:to="loc_us-gaap_InventoryNoncurrent_c697978e-a7f0-4062-8567-48feb0154eb5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryTable_87509c72-f1e1-4e90-aa76-f14cd8648dec" xlink:href="mrk-20220930.xsd#mrk_InventoryTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_a5d7620f-23cd-46bb-b70c-c879704517be" xlink:to="loc_mrk_InventoryTable_87509c72-f1e1-4e90-aa76-f14cd8648dec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_1385e5e8-a081-4b1e-bbaa-3f516426df79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrk_InventoryTable_87509c72-f1e1-4e90-aa76-f14cd8648dec" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_1385e5e8-a081-4b1e-bbaa-3f516426df79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_1385e5e8-a081-4b1e-bbaa-3f516426df79_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_1385e5e8-a081-4b1e-bbaa-3f516426df79" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_1385e5e8-a081-4b1e-bbaa-3f516426df79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_70822e0a-8bd9-4601-8d45-a33e99543e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_1385e5e8-a081-4b1e-bbaa-3f516426df79" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_70822e0a-8bd9-4601-8d45-a33e99543e1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember_4f2e537c-0327-4321-82e9-01f244b89aaf" xlink:href="mrk-20220930.xsd#mrk_InventoryNotExpectedtobeSoldWithinOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_70822e0a-8bd9-4601-8d45-a33e99543e1d" xlink:to="loc_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember_4f2e537c-0327-4321-82e9-01f244b89aaf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoriesProducedinPreparationforProductLaunchesMember_e6d098f1-b67b-4a4f-927d-56f5b6573ab1" xlink:href="mrk-20220930.xsd#mrk_InventoriesProducedinPreparationforProductLaunchesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_70822e0a-8bd9-4601-8d45-a33e99543e1d" xlink:to="loc_mrk_InventoriesProducedinPreparationforProductLaunchesMember_e6d098f1-b67b-4a4f-927d-56f5b6573ab1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIntangiblesDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#OtherIntangiblesDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/OtherIntangiblesDetails" xlink:type="extended" id="i0c7b4f5db3524c31b346d07509f0085c_OtherIntangiblesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_d0f4588b-fa18-4beb-ac6b-99fffe57bcc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_68aad744-086a-4e4a-8b44-2f5892a732e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_d0f4588b-fa18-4beb-ac6b-99fffe57bcc4" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_68aad744-086a-4e4a-8b44-2f5892a732e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c97b411d-4196-447a-a575-e7b53bd85c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_d0f4588b-fa18-4beb-ac6b-99fffe57bcc4" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c97b411d-4196-447a-a575-e7b53bd85c7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_23cdab77-54e6-4e7a-999c-851fe94a16be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_d0f4588b-fa18-4beb-ac6b-99fffe57bcc4" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_23cdab77-54e6-4e7a-999c-851fe94a16be" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_068e4193-251a-4938-990e-7307f82224d0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_23cdab77-54e6-4e7a-999c-851fe94a16be" xlink:to="loc_srt_ProductOrServiceAxis_068e4193-251a-4938-990e-7307f82224d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_068e4193-251a-4938-990e-7307f82224d0_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_068e4193-251a-4938-990e-7307f82224d0" xlink:to="loc_srt_ProductsAndServicesDomain_068e4193-251a-4938-990e-7307f82224d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7aeae0ca-9e91-4d73-a495-0cc675fe955b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_068e4193-251a-4938-990e-7307f82224d0" xlink:to="loc_srt_ProductsAndServicesDomain_7aeae0ca-9e91-4d73-a495-0cc675fe955b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NemtabrutinibMember_f5e85214-8dcb-48aa-8c47-5e4cb38390c7" xlink:href="mrk-20220930.xsd#mrk_NemtabrutinibMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7aeae0ca-9e91-4d73-a495-0cc675fe955b" xlink:to="loc_mrk_NemtabrutinibMember_f5e85214-8dcb-48aa-8c47-5e4cb38390c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_508ded94-f60b-4806-a7ba-6dab735ab386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_23cdab77-54e6-4e7a-999c-851fe94a16be" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_508ded94-f60b-4806-a7ba-6dab735ab386" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_508ded94-f60b-4806-a7ba-6dab735ab386_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_508ded94-f60b-4806-a7ba-6dab735ab386" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_508ded94-f60b-4806-a7ba-6dab735ab386_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5e023dd7-0da2-4c95-988f-0119519a6d13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_508ded94-f60b-4806-a7ba-6dab735ab386" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5e023dd7-0da2-4c95-988f-0119519a6d13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_0a587e27-06d9-4a61-84e4-6e20c1add510" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5e023dd7-0da2-4c95-988f-0119519a6d13" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_0a587e27-06d9-4a61-84e4-6e20c1add510" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/ContingenciesDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#ContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/ContingenciesDetails" xlink:type="extended" id="ie5ad42c752c4425f9d97d497ff9c73d8_ContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_790b50ed-dd43-47da-a98c-097e2a2bacda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_6a7944e0-95c0-4f42-b177-9527d8b9e45a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_790b50ed-dd43-47da-a98c-097e2a2bacda" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_6a7944e0-95c0-4f42-b177-9527d8b9e45a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber_f7bc9c64-9e6b-487f-8213-e9a24a2c4d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_790b50ed-dd43-47da-a98c-097e2a2bacda" xlink:to="loc_us-gaap_LossContingencyClaimsDismissedNumber_f7bc9c64-9e6b-487f-8213-e9a24a2c4d9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LossContingencyClaimsonAppealNumber_c567b390-3fe9-465d-9cf1-ea9c17d57ff9" xlink:href="mrk-20220930.xsd#mrk_LossContingencyClaimsonAppealNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_790b50ed-dd43-47da-a98c-097e2a2bacda" xlink:to="loc_mrk_LossContingencyClaimsonAppealNumber_c567b390-3fe9-465d-9cf1-ea9c17d57ff9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_e946bfcb-abb3-4483-b5df-51e85f84567f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_790b50ed-dd43-47da-a98c-097e2a2bacda" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_e946bfcb-abb3-4483-b5df-51e85f84567f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LossContingencyTrialPeriod_13e0c496-d9cd-4a30-84a5-c4f413227f97" xlink:href="mrk-20220930.xsd#mrk_LossContingencyTrialPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_790b50ed-dd43-47da-a98c-097e2a2bacda" xlink:to="loc_mrk_LossContingencyTrialPeriod_13e0c496-d9cd-4a30-84a5-c4f413227f97" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsSettledNumber_893d53f0-20f1-4819-be78-a05b62d6ecfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyClaimsSettledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_790b50ed-dd43-47da-a98c-097e2a2bacda" xlink:to="loc_us-gaap_LossContingencyClaimsSettledNumber_893d53f0-20f1-4819-be78-a05b62d6ecfd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LossContingencyRecoveryFromThirdPartyBenchTrialPeriod_f90148e5-7b6f-4101-95ad-92c3ce944dd7" xlink:href="mrk-20220930.xsd#mrk_LossContingencyRecoveryFromThirdPartyBenchTrialPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_790b50ed-dd43-47da-a98c-097e2a2bacda" xlink:to="loc_mrk_LossContingencyRecoveryFromThirdPartyBenchTrialPeriod_f90148e5-7b6f-4101-95ad-92c3ce944dd7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_f3ec0e24-a59d-45bf-b21b-583a163519ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_790b50ed-dd43-47da-a98c-097e2a2bacda" xlink:to="loc_us-gaap_LitigationReserve_f3ec0e24-a59d-45bf-b21b-583a163519ac" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_fcf3ce6c-7e94-442c-8b51-df9a7f207b85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_790b50ed-dd43-47da-a98c-097e2a2bacda" xlink:to="loc_us-gaap_LossContingenciesTable_fcf3ce6c-7e94-442c-8b51-df9a7f207b85" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a7c4a591-ab68-4910-8a2b-b360c8e6c157" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_fcf3ce6c-7e94-442c-8b51-df9a7f207b85" xlink:to="loc_srt_ProductOrServiceAxis_a7c4a591-ab68-4910-8a2b-b360c8e6c157" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a7c4a591-ab68-4910-8a2b-b360c8e6c157_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a7c4a591-ab68-4910-8a2b-b360c8e6c157" xlink:to="loc_srt_ProductsAndServicesDomain_a7c4a591-ab68-4910-8a2b-b360c8e6c157_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_85f6944e-4495-4d0e-b38a-ccb92b61262f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a7c4a591-ab68-4910-8a2b-b360c8e6c157" xlink:to="loc_srt_ProductsAndServicesDomain_85f6944e-4495-4d0e-b38a-ccb92b61262f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FosamaxMember_4b3c804d-be14-402e-810b-0ab5a1361768" xlink:href="mrk-20220930.xsd#mrk_FosamaxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_85f6944e-4495-4d0e-b38a-ccb92b61262f" xlink:to="loc_mrk_FosamaxMember_4b3c804d-be14-402e-810b-0ab5a1361768" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_JanuviaMember_dc77eefe-fb2f-4a53-84dc-d7c24a219ee8" xlink:href="mrk-20220930.xsd#mrk_JanuviaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_85f6944e-4495-4d0e-b38a-ccb92b61262f" xlink:to="loc_mrk_JanuviaMember_dc77eefe-fb2f-4a53-84dc-d7c24a219ee8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GardasilGardasil9Member_f3324f5b-989e-4d7e-ae34-56abf72a4edb" xlink:href="mrk-20220930.xsd#mrk_GardasilGardasil9Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_85f6944e-4495-4d0e-b38a-ccb92b61262f" xlink:to="loc_mrk_GardasilGardasil9Member_f3324f5b-989e-4d7e-ae34-56abf72a4edb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BridionMember_f94db93a-8838-484b-9ea3-64acf7d17d71" xlink:href="mrk-20220930.xsd#mrk_BridionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_85f6944e-4495-4d0e-b38a-ccb92b61262f" xlink:to="loc_mrk_BridionMember_f94db93a-8838-484b-9ea3-64acf7d17d71" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_JanuviaAndJanumetMember_d8ed1d40-e8c4-4778-a1aa-b0b303c43316" xlink:href="mrk-20220930.xsd#mrk_JanuviaAndJanumetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_85f6944e-4495-4d0e-b38a-ccb92b61262f" xlink:to="loc_mrk_JanuviaAndJanumetMember_d8ed1d40-e8c4-4778-a1aa-b0b303c43316" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_4c9b202d-259f-43c6-8ab0-f0d0b9a48867" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_fcf3ce6c-7e94-442c-8b51-df9a7f207b85" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_4c9b202d-259f-43c6-8ab0-f0d0b9a48867" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_4c9b202d-259f-43c6-8ab0-f0d0b9a48867_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_4c9b202d-259f-43c6-8ab0-f0d0b9a48867" xlink:to="loc_us-gaap_LossContingencyNatureDomain_4c9b202d-259f-43c6-8ab0-f0d0b9a48867_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_abe88682-3199-482c-84fd-a6d41665ed49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_4c9b202d-259f-43c6-8ab0-f0d0b9a48867" xlink:to="loc_us-gaap_LossContingencyNatureDomain_abe88682-3199-482c-84fd-a6d41665ed49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FemurFractureLitigationMember_d6cbd7b5-543f-452d-aa58-0a1aab6e4c7e" xlink:href="mrk-20220930.xsd#mrk_FemurFractureLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_abe88682-3199-482c-84fd-a6d41665ed49" xlink:to="loc_mrk_FemurFractureLitigationMember_d6cbd7b5-543f-452d-aa58-0a1aab6e4c7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember_8ef2e3bd-b425-40fb-8cae-2764856ee6b2" xlink:href="mrk-20220930.xsd#mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_abe88682-3199-482c-84fd-a6d41665ed49" xlink:to="loc_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember_8ef2e3bd-b425-40fb-8cae-2764856ee6b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_a07f9ce7-5441-4d59-8857-4e5f8cdbd6e9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_fcf3ce6c-7e94-442c-8b51-df9a7f207b85" xlink:to="loc_srt_LitigationCaseAxis_a07f9ce7-5441-4d59-8857-4e5f8cdbd6e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_a07f9ce7-5441-4d59-8857-4e5f8cdbd6e9_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_a07f9ce7-5441-4d59-8857-4e5f8cdbd6e9" xlink:to="loc_srt_LitigationCaseTypeDomain_a07f9ce7-5441-4d59-8857-4e5f8cdbd6e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_7a30f9d0-5f80-4ae3-acb3-718f016b3872" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_a07f9ce7-5441-4d59-8857-4e5f8cdbd6e9" xlink:to="loc_srt_LitigationCaseTypeDomain_7a30f9d0-5f80-4ae3-acb3-718f016b3872" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FederalMember_552087d3-b7d3-4d5e-b12d-197c4c0e5f7d" xlink:href="mrk-20220930.xsd#mrk_FederalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_7a30f9d0-5f80-4ae3-acb3-718f016b3872" xlink:to="loc_mrk_FederalMember_552087d3-b7d3-4d5e-b12d-197c4c0e5f7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ZetiaantitrustlitigationMember_2cea1200-2ab5-4834-bf42-194ffe596feb" xlink:href="mrk-20220930.xsd#mrk_ZetiaantitrustlitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_7a30f9d0-5f80-4ae3-acb3-718f016b3872" xlink:to="loc_mrk_ZetiaantitrustlitigationMember_2cea1200-2ab5-4834-bf42-194ffe596feb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_3a315dfc-1e8c-4152-9d8a-1aeb013decf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_7a30f9d0-5f80-4ae3-acb3-718f016b3872" xlink:to="loc_us-gaap_PatentsMember_3a315dfc-1e8c-4152-9d8a-1aeb013decf8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PatentInfringementLawsuitAgainstZydusWorldwideDMCCZydusPharmaceuticalsUSAIncAndCadilaHealthcareLtdMember_128b6ca2-bef5-4491-af01-58f10c6ca2a3" xlink:href="mrk-20220930.xsd#mrk_PatentInfringementLawsuitAgainstZydusWorldwideDMCCZydusPharmaceuticalsUSAIncAndCadilaHealthcareLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_7a30f9d0-5f80-4ae3-acb3-718f016b3872" xlink:to="loc_mrk_PatentInfringementLawsuitAgainstZydusWorldwideDMCCZydusPharmaceuticalsUSAIncAndCadilaHealthcareLtdMember_128b6ca2-bef5-4491-af01-58f10c6ca2a3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_de8dbede-0343-4d3f-8979-5f0845204de5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_fcf3ce6c-7e94-442c-8b51-df9a7f207b85" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_de8dbede-0343-4d3f-8979-5f0845204de5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_de8dbede-0343-4d3f-8979-5f0845204de5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_de8dbede-0343-4d3f-8979-5f0845204de5" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_de8dbede-0343-4d3f-8979-5f0845204de5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_318cadf6-b479-40f7-a30b-478a5f104f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_de8dbede-0343-4d3f-8979-5f0845204de5" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_318cadf6-b479-40f7-a30b-478a5f104f0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LegalDefenseCostsMember_b9db919f-b10c-4ed3-b4c9-ea9cd4268745" xlink:href="mrk-20220930.xsd#mrk_LegalDefenseCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_318cadf6-b479-40f7-a30b-478a5f104f0e" xlink:to="loc_mrk_LegalDefenseCostsMember_b9db919f-b10c-4ed3-b4c9-ea9cd4268745" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_56efbf18-61d4-469b-a733-13c6ff926f86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_fcf3ce6c-7e94-442c-8b51-df9a7f207b85" xlink:to="loc_us-gaap_LitigationStatusAxis_56efbf18-61d4-469b-a733-13c6ff926f86" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_56efbf18-61d4-469b-a733-13c6ff926f86_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_56efbf18-61d4-469b-a733-13c6ff926f86" xlink:to="loc_us-gaap_LitigationStatusDomain_56efbf18-61d4-469b-a733-13c6ff926f86_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_5c47fae6-deb7-4f43-b6f5-6368399cf81a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_56efbf18-61d4-469b-a733-13c6ff926f86" xlink:to="loc_us-gaap_LitigationStatusDomain_5c47fae6-deb7-4f43-b6f5-6368399cf81a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_c8463f13-b03d-41b7-8bb2-825fc54b3286" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_5c47fae6-deb7-4f43-b6f5-6368399cf81a" xlink:to="loc_us-gaap_PendingLitigationMember_c8463f13-b03d-41b7-8bb2-825fc54b3286" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_781b72c5-b870-46cc-ad71-e697cab48ebd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_fcf3ce6c-7e94-442c-8b51-df9a7f207b85" xlink:to="loc_srt_StatementGeographicalAxis_781b72c5-b870-46cc-ad71-e697cab48ebd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_781b72c5-b870-46cc-ad71-e697cab48ebd_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_781b72c5-b870-46cc-ad71-e697cab48ebd" xlink:to="loc_srt_SegmentGeographicalDomain_781b72c5-b870-46cc-ad71-e697cab48ebd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_cd3ca83e-0561-47f2-9893-3e5ca61594d8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_781b72c5-b870-46cc-ad71-e697cab48ebd" xlink:to="loc_srt_SegmentGeographicalDomain_cd3ca83e-0561-47f2-9893-3e5ca61594d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_28a81856-46cc-4869-b606-71b4f1a90a1c" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_cd3ca83e-0561-47f2-9893-3e5ca61594d8" xlink:to="loc_country_US_28a81856-46cc-4869-b606-71b4f1a90a1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_2b18c692-0f55-4517-aede-1ac5418a1347" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_cd3ca83e-0561-47f2-9893-3e5ca61594d8" xlink:to="loc_us-gaap_NonUsMember_2b18c692-0f55-4517-aede-1ac5418a1347" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CO_38c191a9-afd2-43fb-b7de-ec1edecdf939" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CO"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_cd3ca83e-0561-47f2-9893-3e5ca61594d8" xlink:to="loc_country_CO_38c191a9-afd2-43fb-b7de-ec1edecdf939" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_e4a3c233-3172-4e12-8490-119382a8d6e2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_fcf3ce6c-7e94-442c-8b51-df9a7f207b85" xlink:to="loc_srt_StatementScenarioAxis_e4a3c233-3172-4e12-8490-119382a8d6e2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_e4a3c233-3172-4e12-8490-119382a8d6e2_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_e4a3c233-3172-4e12-8490-119382a8d6e2" xlink:to="loc_srt_ScenarioUnspecifiedDomain_e4a3c233-3172-4e12-8490-119382a8d6e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_a7aba0e5-a100-4a2b-ac08-7055ac9a4035" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_e4a3c233-3172-4e12-8490-119382a8d6e2" xlink:to="loc_srt_ScenarioUnspecifiedDomain_a7aba0e5-a100-4a2b-ac08-7055ac9a4035" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_71b0e48f-6a66-413c-8599-628c67b8cbcc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_a7aba0e5-a100-4a2b-ac08-7055ac9a4035" xlink:to="loc_srt_ScenarioForecastMember_71b0e48f-6a66-413c-8599-628c67b8cbcc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/EquityRollforwardReconciliationsDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#EquityRollforwardReconciliationsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/EquityRollforwardReconciliationsDetails" xlink:type="extended" id="i0de0bff5248a4265a51effe49a227b72_EquityRollforwardReconciliationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_StockholdersEquityLineItems_a5c666bd-65f3-4561-999e-a8fab487f186" xlink:href="mrk-20220930.xsd#mrk_StockholdersEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_44a55126-b2b5-4043-a253-05a8c98288d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_StockholdersEquityLineItems_a5c666bd-65f3-4561-999e-a8fab487f186" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_44a55126-b2b5-4043-a253-05a8c98288d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_5e682e48-7b2f-4527-ba47-f15b3cfea78c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_44a55126-b2b5-4043-a253-05a8c98288d8" xlink:to="loc_us-gaap_CommonStockSharesIssued_5e682e48-7b2f-4527-ba47-f15b3cfea78c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_c93f4409-5ba3-46b6-a2a9-8dc3084c0ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_44a55126-b2b5-4043-a253-05a8c98288d8" xlink:to="loc_us-gaap_TreasuryStockCommonShares_c93f4409-5ba3-46b6-a2a9-8dc3084c0ce6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c13afabd-8e58-42f5-be41-73fb2d62d03c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_44a55126-b2b5-4043-a253-05a8c98288d8" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c13afabd-8e58-42f5-be41-73fb2d62d03c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2b541428-12e1-4cf7-9a46-b479d6b8c5f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_44a55126-b2b5-4043-a253-05a8c98288d8" xlink:to="loc_us-gaap_NetIncomeLoss_2b541428-12e1-4cf7-9a46-b479d6b8c5f6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e6c5c3a8-1165-4832-8164-a525af2a315e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_44a55126-b2b5-4043-a253-05a8c98288d8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e6c5c3a8-1165-4832-8164-a525af2a315e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_c1873b31-8d2b-422a-9cab-549d2b6d416e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_44a55126-b2b5-4043-a253-05a8c98288d8" xlink:to="loc_us-gaap_DividendsCommonStockCash_c1873b31-8d2b-422a-9cab-549d2b6d416e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_cfecb109-569c-4120-b9d0-0dc985fb11fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_44a55126-b2b5-4043-a253-05a8c98288d8" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_cfecb109-569c-4120-b9d0-0dc985fb11fb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_d474175b-96fc-4708-a436-d05caf66ca8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_44a55126-b2b5-4043-a253-05a8c98288d8" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_d474175b-96fc-4708-a436-d05caf66ca8b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_b66f960e-b28b-4e9b-9019-4a821365a508" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteSpinoffTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_44a55126-b2b5-4043-a253-05a8c98288d8" xlink:to="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_b66f960e-b28b-4e9b-9019-4a821365a508" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOtherShares_a11224b8-0019-44d7-8699-ebd16b55bd54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOtherShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_44a55126-b2b5-4043-a253-05a8c98288d8" xlink:to="loc_us-gaap_StockholdersEquityOtherShares_a11224b8-0019-44d7-8699-ebd16b55bd54" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_d13a73d3-a592-4fa7-b8e1-b2f2e51e7f26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_44a55126-b2b5-4043-a253-05a8c98288d8" xlink:to="loc_us-gaap_StockholdersEquityOther_d13a73d3-a592-4fa7-b8e1-b2f2e51e7f26" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_caff9f7a-1e5d-496b-92d7-1baa4bc24d19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_44a55126-b2b5-4043-a253-05a8c98288d8" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_caff9f7a-1e5d-496b-92d7-1baa4bc24d19" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_78bb3284-49b8-4cd5-ad08-256e344e58a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_44a55126-b2b5-4043-a253-05a8c98288d8" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_78bb3284-49b8-4cd5-ad08-256e344e58a2" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_c008de89-c623-4ea7-a322-01880577a97c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_ec96bced-4461-44c2-86b2-1773f0226080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_061747d3-e106-4f74-ac18-2a794c2f6507" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_8d225a01-836c-421d-8949-5d012357a7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_StockholdersEquityLineItems_a5c666bd-65f3-4561-999e-a8fab487f186" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_8d225a01-836c-421d-8949-5d012357a7e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_StockholdersEquityTable_40bb3e72-aa2a-4831-9569-b68635500721" xlink:href="mrk-20220930.xsd#mrk_StockholdersEquityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mrk_StockholdersEquityLineItems_a5c666bd-65f3-4561-999e-a8fab487f186" xlink:to="loc_mrk_StockholdersEquityTable_40bb3e72-aa2a-4831-9569-b68635500721" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_42f67fef-d2dc-4602-9566-40918a9b1558" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrk_StockholdersEquityTable_40bb3e72-aa2a-4831-9569-b68635500721" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_42f67fef-d2dc-4602-9566-40918a9b1558" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_42f67fef-d2dc-4602-9566-40918a9b1558_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_42f67fef-d2dc-4602-9566-40918a9b1558" xlink:to="loc_us-gaap_EquityComponentDomain_42f67fef-d2dc-4602-9566-40918a9b1558_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a31e47b1-3e29-4a2f-abd0-44cda2d2df10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_42f67fef-d2dc-4602-9566-40918a9b1558" xlink:to="loc_us-gaap_EquityComponentDomain_a31e47b1-3e29-4a2f-abd0-44cda2d2df10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_82401c64-2671-4e5d-8c4f-7577ab2dfbae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a31e47b1-3e29-4a2f-abd0-44cda2d2df10" xlink:to="loc_us-gaap_CommonStockMember_82401c64-2671-4e5d-8c4f-7577ab2dfbae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_b929225b-89ee-4029-9304-f3b771d13038" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a31e47b1-3e29-4a2f-abd0-44cda2d2df10" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_b929225b-89ee-4029-9304-f3b771d13038" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_26172492-02ec-444c-9a26-a4018320035f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a31e47b1-3e29-4a2f-abd0-44cda2d2df10" xlink:to="loc_us-gaap_RetainedEarningsMember_26172492-02ec-444c-9a26-a4018320035f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_dcc85a27-f425-4d89-87dd-5b5929e144b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a31e47b1-3e29-4a2f-abd0-44cda2d2df10" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_dcc85a27-f425-4d89-87dd-5b5929e144b0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_010f9665-7029-455c-b217-4ca9e4ec6e28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a31e47b1-3e29-4a2f-abd0-44cda2d2df10" xlink:to="loc_us-gaap_TreasuryStockCommonMember_010f9665-7029-455c-b217-4ca9e4ec6e28" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_afcf48b4-d811-458b-b4fa-e74668128e74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a31e47b1-3e29-4a2f-abd0-44cda2d2df10" xlink:to="loc_us-gaap_NoncontrollingInterestMember_afcf48b4-d811-458b-b4fa-e74668128e74" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails" xlink:type="extended" id="idcd4c71caa4f45d68c61ff9ab4181536_PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_12ebfe7b-aedd-4f6a-9145-8093efbba202" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_89d9c297-4a62-4ccb-ba55-689aafe2677c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_12ebfe7b-aedd-4f6a-9145-8093efbba202" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_89d9c297-4a62-4ccb-ba55-689aafe2677c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_664d1491-9fbc-4ee5-8acc-c57f60bee3ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_12ebfe7b-aedd-4f6a-9145-8093efbba202" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_664d1491-9fbc-4ee5-8acc-c57f60bee3ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_1db1aa77-8f2d-40a3-a6b8-f5f36b6728dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_12ebfe7b-aedd-4f6a-9145-8093efbba202" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_1db1aa77-8f2d-40a3-a6b8-f5f36b6728dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_9fdb2650-ff9b-4cf3-9a48-603ebcf1f482" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_12ebfe7b-aedd-4f6a-9145-8093efbba202" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_9fdb2650-ff9b-4cf3-9a48-603ebcf1f482" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_3b488de2-26d8-4a51-ac83-05a35bc0db02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_12ebfe7b-aedd-4f6a-9145-8093efbba202" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_3b488de2-26d8-4a51-ac83-05a35bc0db02" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_2a75060b-aa65-4f7e-b961-9468971d2e63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_12ebfe7b-aedd-4f6a-9145-8093efbba202" xlink:to="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_2a75060b-aa65-4f7e-b961-9468971d2e63" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_427fdeda-c04a-4474-b37d-a582e2fa23a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_12ebfe7b-aedd-4f6a-9145-8093efbba202" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_427fdeda-c04a-4474-b37d-a582e2fa23a2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_d0df34fd-cdeb-4a49-a211-efb2b964d1b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_12ebfe7b-aedd-4f6a-9145-8093efbba202" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_d0df34fd-cdeb-4a49-a211-efb2b964d1b7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_ca7286c0-ca39-4004-82e3-eced1809305e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_12ebfe7b-aedd-4f6a-9145-8093efbba202" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_ca7286c0-ca39-4004-82e3-eced1809305e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_44b34ec1-e211-4662-a4ab-87188e9b00a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_12ebfe7b-aedd-4f6a-9145-8093efbba202" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_44b34ec1-e211-4662-a4ab-87188e9b00a3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_428fa65a-4e22-4990-a0de-e67e81dbaa02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_44b34ec1-e211-4662-a4ab-87188e9b00a3" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_428fa65a-4e22-4990-a0de-e67e81dbaa02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_428fa65a-4e22-4990-a0de-e67e81dbaa02_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_428fa65a-4e22-4990-a0de-e67e81dbaa02" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_428fa65a-4e22-4990-a0de-e67e81dbaa02_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_15beb973-c01a-4448-b4e8-74d55ed561b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_428fa65a-4e22-4990-a0de-e67e81dbaa02" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_15beb973-c01a-4448-b4e8-74d55ed561b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_f8833abd-4409-4c3f-9552-abf219f062b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_15beb973-c01a-4448-b4e8-74d55ed561b0" xlink:to="loc_us-gaap_DomesticPlanMember_f8833abd-4409-4c3f-9552-abf219f062b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_3dc2b126-47db-4ba9-bc38-0e96588d9cb4" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_f8833abd-4409-4c3f-9552-abf219f062b5" xlink:to="loc_country_US_3dc2b126-47db-4ba9-bc38-0e96588d9cb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_5483ec8f-97cd-449a-922a-ee04d1615b81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_15beb973-c01a-4448-b4e8-74d55ed561b0" xlink:to="loc_us-gaap_ForeignPlanMember_5483ec8f-97cd-449a-922a-ee04d1615b81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_aaf28927-7ec3-4bb8-9ba6-e3bb5d472ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_44b34ec1-e211-4662-a4ab-87188e9b00a3" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_aaf28927-7ec3-4bb8-9ba6-e3bb5d472ab9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_aaf28927-7ec3-4bb8-9ba6-e3bb5d472ab9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_aaf28927-7ec3-4bb8-9ba6-e3bb5d472ab9" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_aaf28927-7ec3-4bb8-9ba6-e3bb5d472ab9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_9451885f-57aa-45bd-bc66-1089e1ff7a48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_aaf28927-7ec3-4bb8-9ba6-e3bb5d472ab9" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_9451885f-57aa-45bd-bc66-1089e1ff7a48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_b3c122c6-b824-464e-83f8-413174a563f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_9451885f-57aa-45bd-bc66-1089e1ff7a48" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_b3c122c6-b824-464e-83f8-413174a563f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_0d0201b5-5e17-4251-82ac-ffcd13dc4e77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_9451885f-57aa-45bd-bc66-1089e1ff7a48" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_0d0201b5-5e17-4251-82ac-ffcd13dc4e77" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" xlink:type="extended" id="i83b65bf4e8714f208632fb6e1d522788_OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_c3db401a-8294-4664-bb0c-fee0f0c218f8" xlink:href="mrk-20220930.xsd#mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_fad00a87-4452-4e9b-9892-313a8d6ce2ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_c3db401a-8294-4664-bb0c-fee0f0c218f8" xlink:to="loc_us-gaap_InvestmentIncomeInterest_fad00a87-4452-4e9b-9892-313a8d6ce2ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_4e69b404-b314-420d-9ad4-086c2d5081c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_c3db401a-8294-4664-bb0c-fee0f0c218f8" xlink:to="loc_us-gaap_InterestExpense_4e69b404-b314-420d-9ad4-086c2d5081c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_24698072-3cd0-4841-86c7-10217c942ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_c3db401a-8294-4664-bb0c-fee0f0c218f8" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_24698072-3cd0-4841-86c7-10217c942ad1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_4b748f44-c1cf-4ac4-b875-aaf05ba95aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_c3db401a-8294-4664-bb0c-fee0f0c218f8" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_4b748f44-c1cf-4ac4-b875-aaf05ba95aa4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_ac48e4ac-6ed9-4abc-bc0c-a91345855f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_c3db401a-8294-4664-bb0c-fee0f0c218f8" xlink:to="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_ac48e4ac-6ed9-4abc-bc0c-a91345855f7f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherNonoperatingIncomeExpenseOther_aca782e6-6ea2-4aba-8029-f901acc36f60" xlink:href="mrk-20220930.xsd#mrk_OtherNonoperatingIncomeExpenseOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_c3db401a-8294-4664-bb0c-fee0f0c218f8" xlink:to="loc_mrk_OtherNonoperatingIncomeExpenseOther_aca782e6-6ea2-4aba-8029-f901acc36f60" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_d7bcf6bb-b454-4df5-ab20-aecbf93f6f59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_c3db401a-8294-4664-bb0c-fee0f0c218f8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_d7bcf6bb-b454-4df5-ab20-aecbf93f6f59" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_735b2763-1c90-4051-9de5-df34d4cf458e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_c3db401a-8294-4664-bb0c-fee0f0c218f8" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_735b2763-1c90-4051-9de5-df34d4cf458e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_46d37311-4e5f-4e31-91e2-7a8587f888ee" xlink:href="mrk-20220930.xsd#mrk_ComponentofOtherIncomeExpenseofNonoperatingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_c3db401a-8294-4664-bb0c-fee0f0c218f8" xlink:to="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_46d37311-4e5f-4e31-91e2-7a8587f888ee" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_67d18359-88fb-4b8e-857e-0c40d5cb36da" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_46d37311-4e5f-4e31-91e2-7a8587f888ee" xlink:to="loc_srt_StatementScenarioAxis_67d18359-88fb-4b8e-857e-0c40d5cb36da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_67d18359-88fb-4b8e-857e-0c40d5cb36da_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_67d18359-88fb-4b8e-857e-0c40d5cb36da" xlink:to="loc_srt_ScenarioUnspecifiedDomain_67d18359-88fb-4b8e-857e-0c40d5cb36da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_35d16757-889e-4d1d-b2d6-6576ecf52c70" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_67d18359-88fb-4b8e-857e-0c40d5cb36da" xlink:to="loc_srt_ScenarioUnspecifiedDomain_35d16757-889e-4d1d-b2d6-6576ecf52c70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_b7ff4f89-f51a-4e6c-a993-c96b876d17e9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_35d16757-889e-4d1d-b2d6-6576ecf52c70" xlink:to="loc_srt_ScenarioForecastMember_b7ff4f89-f51a-4e6c-a993-c96b876d17e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_fc96451a-f28d-463b-93d8-7930a7883b78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_46d37311-4e5f-4e31-91e2-7a8587f888ee" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_fc96451a-f28d-463b-93d8-7930a7883b78" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fc96451a-f28d-463b-93d8-7930a7883b78_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fc96451a-f28d-463b-93d8-7930a7883b78" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fc96451a-f28d-463b-93d8-7930a7883b78_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_be24b359-f584-49b2-a930-5c2d8f1bf0c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fc96451a-f28d-463b-93d8-7930a7883b78" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_be24b359-f584-49b2-a930-5c2d8f1bf0c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_c694e71e-4b8f-4e2a-9709-47216b3a8c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_be24b359-f584-49b2-a930-5c2d8f1bf0c3" xlink:to="loc_us-gaap_SubsequentEventMember_c694e71e-4b8f-4e2a-9709-47216b3a8c3b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#TaxesonIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/TaxesonIncomeDetails" xlink:type="extended" id="i14dbac5bab00471c8b6015a6ff86c8a9_TaxesonIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_147a76e3-cd5f-4702-8a1a-a48f5bb75c30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8480cf60-74bd-4e50-9ba8-006679ea6d8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_147a76e3-cd5f-4702-8a1a-a48f5bb75c30" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8480cf60-74bd-4e50-9ba8-006679ea6d8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_3c668b82-1a47-4bd3-a46a-86e618c6fa5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_147a76e3-cd5f-4702-8a1a-a48f5bb75c30" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_3c668b82-1a47-4bd3-a46a-86e618c6fa5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_0e00a611-c54d-40e9-9984-0f5930e560dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_147a76e3-cd5f-4702-8a1a-a48f5bb75c30" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_0e00a611-c54d-40e9-9984-0f5930e560dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_5fadee87-864b-44b4-91ee-64716a9cfc3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_147a76e3-cd5f-4702-8a1a-a48f5bb75c30" xlink:to="loc_us-gaap_IncomeTaxesPaid_5fadee87-864b-44b4-91ee-64716a9cfc3c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_c47359eb-ab7e-4382-978e-d0727e83ddef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_147a76e3-cd5f-4702-8a1a-a48f5bb75c30" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_c47359eb-ab7e-4382-978e-d0727e83ddef" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_428ebc71-8173-4bd0-bfa0-877ab775de19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_c47359eb-ab7e-4382-978e-d0727e83ddef" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_428ebc71-8173-4bd0-bfa0-877ab775de19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_428ebc71-8173-4bd0-bfa0-877ab775de19_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_428ebc71-8173-4bd0-bfa0-877ab775de19" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_428ebc71-8173-4bd0-bfa0-877ab775de19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_0d29f20a-dbd4-49f7-b255-a8a3dadba015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_428ebc71-8173-4bd0-bfa0-877ab775de19" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_0d29f20a-dbd4-49f7-b255-a8a3dadba015" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_188cb3c0-77e6-4e24-b8f1-7ff9b0b988c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_0d29f20a-dbd4-49f7-b255-a8a3dadba015" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_188cb3c0-77e6-4e24-b8f1-7ff9b0b988c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_190b93fe-e5db-47d2-944b-bc9c2a7197b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_c47359eb-ab7e-4382-978e-d0727e83ddef" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_190b93fe-e5db-47d2-944b-bc9c2a7197b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_190b93fe-e5db-47d2-944b-bc9c2a7197b3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_190b93fe-e5db-47d2-944b-bc9c2a7197b3" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_190b93fe-e5db-47d2-944b-bc9c2a7197b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_2c59fed0-7f4e-41ab-a7ac-55db84de8ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_190b93fe-e5db-47d2-944b-bc9c2a7197b3" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_2c59fed0-7f4e-41ab-a7ac-55db84de8ea4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_18844fbb-e38b-4eb6-90c7-c49a4f8d173a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2c59fed0-7f4e-41ab-a7ac-55db84de8ea4" xlink:to="loc_us-gaap_DomesticCountryMember_18844fbb-e38b-4eb6-90c7-c49a4f8d173a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_8ed65f4c-bd07-44bf-8e1a-460590e54150" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_c47359eb-ab7e-4382-978e-d0727e83ddef" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_8ed65f4c-bd07-44bf-8e1a-460590e54150" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_8ed65f4c-bd07-44bf-8e1a-460590e54150_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_8ed65f4c-bd07-44bf-8e1a-460590e54150" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_8ed65f4c-bd07-44bf-8e1a-460590e54150_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_e6151f90-2c3b-4e51-a0d7-93c6d728cce5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_8ed65f4c-bd07-44bf-8e1a-460590e54150" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_e6151f90-2c3b-4e51-a0d7-93c6d728cce5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember_8776e174-8897-41e0-8668-533460bb608f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentContinuingOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_e6151f90-2c3b-4e51-a0d7-93c6d728cce5" xlink:to="loc_us-gaap_SegmentContinuingOperationsMember_8776e174-8897-41e0-8668-533460bb608f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_2144ca90-076a-4833-be0b-b02d00e1b7aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_e6151f90-2c3b-4e51-a0d7-93c6d728cce5" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_2144ca90-076a-4833-be0b-b02d00e1b7aa" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#OtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" xlink:type="extended" id="i9ea4895c13bf47738f06fc971bdceec4_OtherComprehensiveIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_a693bc6e-34d4-4e10-b1b0-3984bad8fe1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_78aa34b8-391d-4e57-b42c-c07f4106a80e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_a693bc6e-34d4-4e10-b1b0-3984bad8fe1a" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_78aa34b8-391d-4e57-b42c-c07f4106a80e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_394fd33e-0495-48bf-bff4-67e2a458c645" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_78aa34b8-391d-4e57-b42c-c07f4106a80e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_394fd33e-0495-48bf-bff4-67e2a458c645" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_15140555-3c62-4915-9843-6d436a19f10d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_78aa34b8-391d-4e57-b42c-c07f4106a80e" xlink:to="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_15140555-3c62-4915-9843-6d436a19f10d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_0c35fa29-6800-4dff-9719-5134985651ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_78aa34b8-391d-4e57-b42c-c07f4106a80e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_0c35fa29-6800-4dff-9719-5134985651ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_ce9d7343-4228-4d31-bdc2-34aad969b2b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_78aa34b8-391d-4e57-b42c-c07f4106a80e" xlink:to="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_ce9d7343-4228-4d31-bdc2-34aad969b2b9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_f4f8b7b2-ca4e-4367-8559-ae4b366491d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_78aa34b8-391d-4e57-b42c-c07f4106a80e" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_f4f8b7b2-ca4e-4367-8559-ae4b366491d5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_94791935-ac9f-4b27-bb72-5148510b138d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_78aa34b8-391d-4e57-b42c-c07f4106a80e" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_94791935-ac9f-4b27-bb72-5148510b138d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_dfed12ee-2be5-4cda-8885-a35d2b87746f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_78aa34b8-391d-4e57-b42c-c07f4106a80e" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_dfed12ee-2be5-4cda-8885-a35d2b87746f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f2977f0a-9768-475e-b8c4-169ac971f3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_78aa34b8-391d-4e57-b42c-c07f4106a80e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f2977f0a-9768-475e-b8c4-169ac971f3f1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_da18d33a-1864-4241-b651-1f16bb336d86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteSpinoffTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_78aa34b8-391d-4e57-b42c-c07f4106a80e" xlink:to="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_da18d33a-1864-4241-b651-1f16bb336d86" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_10e90f1f-1136-42dc-9089-888cf18ec950" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0b41305c-7ed1-4263-b05a-551d70693eab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_a693bc6e-34d4-4e10-b1b0-3984bad8fe1a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0b41305c-7ed1-4263-b05a-551d70693eab" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_048c1761-b798-41a7-be9e-9c2d5822beb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0b41305c-7ed1-4263-b05a-551d70693eab" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_048c1761-b798-41a7-be9e-9c2d5822beb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_048c1761-b798-41a7-be9e-9c2d5822beb6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_048c1761-b798-41a7-be9e-9c2d5822beb6" xlink:to="loc_us-gaap_EquityComponentDomain_048c1761-b798-41a7-be9e-9c2d5822beb6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2a319d2a-c321-4eac-a322-d8cd69990c92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_048c1761-b798-41a7-be9e-9c2d5822beb6" xlink:to="loc_us-gaap_EquityComponentDomain_2a319d2a-c321-4eac-a322-d8cd69990c92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_a8d1ad08-19cc-4ad3-a292-c6014810b65c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2a319d2a-c321-4eac-a322-d8cd69990c92" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_a8d1ad08-19cc-4ad3-a292-c6014810b65c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_5d2cd6ec-9b24-4716-924e-bdf910bc4c37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2a319d2a-c321-4eac-a322-d8cd69990c92" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_5d2cd6ec-9b24-4716-924e-bdf910bc4c37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_868a50cc-e13b-45f1-8a39-6c16bb168147" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2a319d2a-c321-4eac-a322-d8cd69990c92" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_868a50cc-e13b-45f1-8a39-6c16bb168147" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c502c95c-0a62-4b56-a1f1-1eb988db1adc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2a319d2a-c321-4eac-a322-d8cd69990c92" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c502c95c-0a62-4b56-a1f1-1eb988db1adc" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#SegmentReportingSalesfromProductsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" xlink:type="extended" id="icfdce0571e0741248d5effd1a7bf44f3_SegmentReportingSalesfromProductsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_b0e20ffb-f53d-41ac-93d7-efe69856655b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_19e9dc86-a983-4d5f-8b4f-3123eb1e2d43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_b0e20ffb-f53d-41ac-93d7-efe69856655b" xlink:to="loc_us-gaap_Revenues_19e9dc86-a983-4d5f-8b4f-3123eb1e2d43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_d8c12be3-1a37-4576-9c97-47419839b86f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_b0e20ffb-f53d-41ac-93d7-efe69856655b" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_d8c12be3-1a37-4576-9c97-47419839b86f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_42c6cb17-4a07-44f2-82fe-b9fd4af4d2e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_b0e20ffb-f53d-41ac-93d7-efe69856655b" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_42c6cb17-4a07-44f2-82fe-b9fd4af4d2e4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_7e7065b1-b802-4a7f-bf0a-ac2b1fc631c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_42c6cb17-4a07-44f2-82fe-b9fd4af4d2e4" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_7e7065b1-b802-4a7f-bf0a-ac2b1fc631c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_7e7065b1-b802-4a7f-bf0a-ac2b1fc631c9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7e7065b1-b802-4a7f-bf0a-ac2b1fc631c9" xlink:to="loc_us-gaap_SegmentDomain_7e7065b1-b802-4a7f-bf0a-ac2b1fc631c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5d73a7a1-1d9c-445b-ae98-78a25f2e7679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7e7065b1-b802-4a7f-bf0a-ac2b1fc631c9" xlink:to="loc_us-gaap_SegmentDomain_5d73a7a1-1d9c-445b-ae98-78a25f2e7679" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember_6e467dfe-407f-4428-bd7e-782d8172d67a" xlink:href="mrk-20220930.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_5d73a7a1-1d9c-445b-ae98-78a25f2e7679" xlink:to="loc_mrk_PharmaceuticalsegmentMember_6e467dfe-407f-4428-bd7e-782d8172d67a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthsegmentMember_fadc93c0-5297-4e37-82f8-72c8c891d67c" xlink:href="mrk-20220930.xsd#mrk_AnimalHealthsegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_5d73a7a1-1d9c-445b-ae98-78a25f2e7679" xlink:to="loc_mrk_AnimalHealthsegmentMember_fadc93c0-5297-4e37-82f8-72c8c891d67c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_ede22445-6616-4848-a3df-1b83e8ae45b2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_42c6cb17-4a07-44f2-82fe-b9fd4af4d2e4" xlink:to="loc_srt_ConsolidationItemsAxis_ede22445-6616-4848-a3df-1b83e8ae45b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_ede22445-6616-4848-a3df-1b83e8ae45b2_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_ede22445-6616-4848-a3df-1b83e8ae45b2" xlink:to="loc_srt_ConsolidationItemsDomain_ede22445-6616-4848-a3df-1b83e8ae45b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_2cb8919c-b348-4c9d-8f7d-8828066a6ed2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_ede22445-6616-4848-a3df-1b83e8ae45b2" xlink:to="loc_srt_ConsolidationItemsDomain_2cb8919c-b348-4c9d-8f7d-8828066a6ed2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_37b82021-25c4-4225-b3e1-0f89d72d8dab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_2cb8919c-b348-4c9d-8f7d-8828066a6ed2" xlink:to="loc_us-gaap_OperatingSegmentsMember_37b82021-25c4-4225-b3e1-0f89d72d8dab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_c2618d83-cb6b-4e49-8792-01c72f1f2273" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_2cb8919c-b348-4c9d-8f7d-8828066a6ed2" xlink:to="loc_us-gaap_CorporateNonSegmentMember_c2618d83-cb6b-4e49-8792-01c72f1f2273" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_48398ecf-6c9e-4802-b984-1387ca53cdb6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_42c6cb17-4a07-44f2-82fe-b9fd4af4d2e4" xlink:to="loc_srt_ProductOrServiceAxis_48398ecf-6c9e-4802-b984-1387ca53cdb6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_48398ecf-6c9e-4802-b984-1387ca53cdb6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_48398ecf-6c9e-4802-b984-1387ca53cdb6" xlink:to="loc_srt_ProductsAndServicesDomain_48398ecf-6c9e-4802-b984-1387ca53cdb6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_48398ecf-6c9e-4802-b984-1387ca53cdb6" xlink:to="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_KeytrudaMember_db29c77f-535c-4390-bfc2-b09f148ba3df" xlink:href="mrk-20220930.xsd#mrk_KeytrudaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_KeytrudaMember_db29c77f-535c-4390-bfc2-b09f148ba3df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AlliancerevenueLynparzaMember_39bf9bfd-c6af-4a3b-97b5-968dfe6b3383" xlink:href="mrk-20220930.xsd#mrk_AlliancerevenueLynparzaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_AlliancerevenueLynparzaMember_39bf9bfd-c6af-4a3b-97b5-968dfe6b3383" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LenvimaMember_f04742ce-b865-4012-a0dd-e3125c6e31d2" xlink:href="mrk-20220930.xsd#mrk_LenvimaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_LenvimaMember_f04742ce-b865-4012-a0dd-e3125c6e31d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AllianceRevenueReblozylMember_170f9836-7e2e-49b8-9325-09e7643eae82" xlink:href="mrk-20220930.xsd#mrk_AllianceRevenueReblozylMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_AllianceRevenueReblozylMember_170f9836-7e2e-49b8-9325-09e7643eae82" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GardasilGardasil9Member_e5f9fe20-3d97-48c4-8dab-3cf1060ddbba" xlink:href="mrk-20220930.xsd#mrk_GardasilGardasil9Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_GardasilGardasil9Member_e5f9fe20-3d97-48c4-8dab-3cf1060ddbba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ProQuadMMRIIVarivaxMember_16d449a5-e962-4e51-af79-d3b69f87f8c3" xlink:href="mrk-20220930.xsd#mrk_ProQuadMMRIIVarivaxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_ProQuadMMRIIVarivaxMember_16d449a5-e962-4e51-af79-d3b69f87f8c3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RotateqMember_7ab7b0ae-face-4750-a08c-ef9f02fd714c" xlink:href="mrk-20220930.xsd#mrk_RotateqMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_RotateqMember_7ab7b0ae-face-4750-a08c-ef9f02fd714c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_Pneumovax23Member_04c2555c-e5fa-4e54-8ab8-5ff768ffee53" xlink:href="mrk-20220930.xsd#mrk_Pneumovax23Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_Pneumovax23Member_04c2555c-e5fa-4e54-8ab8-5ff768ffee53" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VaqtaMember_030908f1-991d-48d6-b2d2-0172fb13b17c" xlink:href="mrk-20220930.xsd#mrk_VaqtaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_VaqtaMember_030908f1-991d-48d6-b2d2-0172fb13b17c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BridionMember_7edd7526-741a-4eb3-9797-a734212e2d82" xlink:href="mrk-20220930.xsd#mrk_BridionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_BridionMember_7edd7526-741a-4eb3-9797-a734212e2d82" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PrevymisMember_8a2843de-2d1d-4970-a4f6-fdcb7687bf16" xlink:href="mrk-20220930.xsd#mrk_PrevymisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_PrevymisMember_8a2843de-2d1d-4970-a4f6-fdcb7687bf16" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DificidMember_6731df41-0c7d-438f-831b-15175e4e8ed5" xlink:href="mrk-20220930.xsd#mrk_DificidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_DificidMember_6731df41-0c7d-438f-831b-15175e4e8ed5" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PrimaxinMember_8e73dbd3-f15b-4807-aed3-add783160728" xlink:href="mrk-20220930.xsd#mrk_PrimaxinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_PrimaxinMember_8e73dbd3-f15b-4807-aed3-add783160728" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NoxafilMember_827c70ef-2958-424e-8d0b-721018ffbbc4" xlink:href="mrk-20220930.xsd#mrk_NoxafilMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_NoxafilMember_827c70ef-2958-424e-8d0b-721018ffbbc4" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InvanzMember_a3bb4a33-427a-47b9-bc52-2bf01fade5e7" xlink:href="mrk-20220930.xsd#mrk_InvanzMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_InvanzMember_a3bb4a33-427a-47b9-bc52-2bf01fade5e7" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CancidasMember_7cd6eb28-7499-4ffb-bbab-fefbdaf81f0e" xlink:href="mrk-20220930.xsd#mrk_CancidasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_CancidasMember_7cd6eb28-7499-4ffb-bbab-fefbdaf81f0e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ZerbaxaMember_caa57cf2-566c-41ed-ba6d-fd52471e74b4" xlink:href="mrk-20220930.xsd#mrk_ZerbaxaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_ZerbaxaMember_caa57cf2-566c-41ed-ba6d-fd52471e74b4" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AllianceRevenueAdempasVerquvoMember_6e884ba9-11f3-4b2d-9223-fa08bb124f27" xlink:href="mrk-20220930.xsd#mrk_AllianceRevenueAdempasVerquvoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_AllianceRevenueAdempasVerquvoMember_6e884ba9-11f3-4b2d-9223-fa08bb124f27" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AdempasMember_7a8a16e2-2a97-44b7-bf1d-1f3acec35e86" xlink:href="mrk-20220930.xsd#mrk_AdempasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_AdempasMember_7a8a16e2-2a97-44b7-bf1d-1f3acec35e86" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LagevrioMember_7ca9a561-9757-4ccd-8049-1001dc756796" xlink:href="mrk-20220930.xsd#mrk_LagevrioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_LagevrioMember_7ca9a561-9757-4ccd-8049-1001dc756796" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IsentressIsentressHDMember_7ab34de4-dc61-42f5-9bb0-b0edf2655d66" xlink:href="mrk-20220930.xsd#mrk_IsentressIsentressHDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_IsentressIsentressHDMember_7ab34de4-dc61-42f5-9bb0-b0edf2655d66" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BelsomraMember_25366dd7-cbd6-49cb-9c19-dd638b822d26" xlink:href="mrk-20220930.xsd#mrk_BelsomraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_BelsomraMember_25366dd7-cbd6-49cb-9c19-dd638b822d26" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SimponiMember_52f1b73f-789b-4fd3-9953-0ec180ea0c28" xlink:href="mrk-20220930.xsd#mrk_SimponiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_SimponiMember_52f1b73f-789b-4fd3-9953-0ec180ea0c28" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RemicadeMember_d3daf9ae-7dab-4c23-907e-52adb2abc671" xlink:href="mrk-20220930.xsd#mrk_RemicadeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_RemicadeMember_d3daf9ae-7dab-4c23-907e-52adb2abc671" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_JanuviaMember_045645a5-4a0a-425a-a8cc-f6b26b801826" xlink:href="mrk-20220930.xsd#mrk_JanuviaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_JanuviaMember_045645a5-4a0a-425a-a8cc-f6b26b801826" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_JanumetMember_f7decbca-7ac3-4434-a441-dfba11ac7ff0" xlink:href="mrk-20220930.xsd#mrk_JanumetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_JanumetMember_f7decbca-7ac3-4434-a441-dfba11ac7ff0" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherPharmaceuticalMember_272e3314-668f-41d8-a578-935a59ad2ceb" xlink:href="mrk-20220930.xsd#mrk_OtherPharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_OtherPharmaceuticalMember_272e3314-668f-41d8-a578-935a59ad2ceb" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LivestockMember_28480478-82bb-4b55-899f-f70dbe7648cf" xlink:href="mrk-20220930.xsd#mrk_LivestockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_LivestockMember_28480478-82bb-4b55-899f-f70dbe7648cf" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CompanionAnimalsMember_b6ab4204-3901-425b-ae38-ffc094858d45" xlink:href="mrk-20220930.xsd#mrk_CompanionAnimalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_CompanionAnimalsMember_b6ab4204-3901-425b-ae38-ffc094858d45" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_08541792-ecee-4bd4-98bf-30c2ec2a3f12" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_42c6cb17-4a07-44f2-82fe-b9fd4af4d2e4" xlink:to="loc_srt_StatementGeographicalAxis_08541792-ecee-4bd4-98bf-30c2ec2a3f12" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_08541792-ecee-4bd4-98bf-30c2ec2a3f12_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_08541792-ecee-4bd4-98bf-30c2ec2a3f12" xlink:to="loc_srt_SegmentGeographicalDomain_08541792-ecee-4bd4-98bf-30c2ec2a3f12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_04f2935f-72f5-45f3-ba28-419c2ec52f48" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_08541792-ecee-4bd4-98bf-30c2ec2a3f12" xlink:to="loc_srt_SegmentGeographicalDomain_04f2935f-72f5-45f3-ba28-419c2ec52f48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_c328838e-12d8-4f6c-a897-3bd50eecc3e4" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_04f2935f-72f5-45f3-ba28-419c2ec52f48" xlink:to="loc_country_US_c328838e-12d8-4f6c-a897-3bd50eecc3e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InternationalMember_bbaa6204-04bc-4621-b4ff-58bd4fe80d09" xlink:href="mrk-20220930.xsd#mrk_InternationalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_04f2935f-72f5-45f3-ba28-419c2ec52f48" xlink:to="loc_mrk_InternationalMember_bbaa6204-04bc-4621-b4ff-58bd4fe80d09" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#SegmentReportingConsolidatedSalesbyGeographicAreaDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails" xlink:type="extended" id="ie0cf445a5371463da7d4dbd67c3949ba_SegmentReportingConsolidatedSalesbyGeographicAreaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_ba0b4496-77f6-4bc7-a916-2cf2e1e5d7c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_d4567962-aae4-487b-9342-c20c5245c556" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_ba0b4496-77f6-4bc7-a916-2cf2e1e5d7c5" xlink:to="loc_us-gaap_Revenues_d4567962-aae4-487b-9342-c20c5245c556" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_c43bd9a7-8af6-4786-b39f-ba0a147cce0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_ba0b4496-77f6-4bc7-a916-2cf2e1e5d7c5" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_c43bd9a7-8af6-4786-b39f-ba0a147cce0e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4ad5f33b-0791-407d-b334-21a8af7740f6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_c43bd9a7-8af6-4786-b39f-ba0a147cce0e" xlink:to="loc_srt_StatementGeographicalAxis_4ad5f33b-0791-407d-b334-21a8af7740f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4ad5f33b-0791-407d-b334-21a8af7740f6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_4ad5f33b-0791-407d-b334-21a8af7740f6" xlink:to="loc_srt_SegmentGeographicalDomain_4ad5f33b-0791-407d-b334-21a8af7740f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_cac01c44-ad8f-4967-9e07-7c2b55338895" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_4ad5f33b-0791-407d-b334-21a8af7740f6" xlink:to="loc_srt_SegmentGeographicalDomain_cac01c44-ad8f-4967-9e07-7c2b55338895" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b054daa2-fb60-46fc-994f-a3c32f44cdc8" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_cac01c44-ad8f-4967-9e07-7c2b55338895" xlink:to="loc_country_US_b054daa2-fb60-46fc-994f-a3c32f44cdc8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember_3e3f7de4-c1b3-475b-8247-5c09b5e5a320" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EMEAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_cac01c44-ad8f-4967-9e07-7c2b55338895" xlink:to="loc_us-gaap_EMEAMember_3e3f7de4-c1b3-475b-8247-5c09b5e5a320" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_ce6e5afe-39cb-4efe-ae8b-b8ce9cae2bee" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_cac01c44-ad8f-4967-9e07-7c2b55338895" xlink:to="loc_country_CN_ce6e5afe-39cb-4efe-ae8b-b8ce9cae2bee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_95b710fd-c841-415d-ab11-c0581128ece0" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_cac01c44-ad8f-4967-9e07-7c2b55338895" xlink:to="loc_country_JP_95b710fd-c841-415d-ab11-c0581128ece0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember_2a7ced03-11ec-46ba-8eea-9469579299c9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AsiaPacificMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_cac01c44-ad8f-4967-9e07-7c2b55338895" xlink:to="loc_srt_AsiaPacificMember_2a7ced03-11ec-46ba-8eea-9469579299c9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LatinAmericaMember_8f29b134-9fbf-4770-8371-7437066f51cd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LatinAmericaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_cac01c44-ad8f-4967-9e07-7c2b55338895" xlink:to="loc_srt_LatinAmericaMember_8f29b134-9fbf-4770-8371-7437066f51cd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherCountriesMember_0bb6f2cd-3839-4181-8b1a-2c6b1d9a4cbd" xlink:href="mrk-20220930.xsd#mrk_OtherCountriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_cac01c44-ad8f-4967-9e07-7c2b55338895" xlink:to="loc_mrk_OtherCountriesMember_0bb6f2cd-3839-4181-8b1a-2c6b1d9a4cbd" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails" xlink:type="extended" id="ic78b7fbe5a4d4a60b0ee6ef036fdfc2d_SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_77a32b1b-d8a6-44bc-ad01-ef44da9af6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c805a431-a832-4402-9cb3-c81aadd118bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_77a32b1b-d8a6-44bc-ad01-ef44da9af6a2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c805a431-a832-4402-9cb3-c81aadd118bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_df13d927-d693-40d6-9a42-35d5b78c9b61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_77a32b1b-d8a6-44bc-ad01-ef44da9af6a2" xlink:to="loc_us-gaap_InvestmentIncomeInterest_df13d927-d693-40d6-9a42-35d5b78c9b61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_beaa314e-b9f3-4833-a330-67e92350589a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_77a32b1b-d8a6-44bc-ad01-ef44da9af6a2" xlink:to="loc_us-gaap_InterestExpense_beaa314e-b9f3-4833-a330-67e92350589a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_79fba16c-f087-43b1-a109-9e1114398fda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_77a32b1b-d8a6-44bc-ad01-ef44da9af6a2" xlink:to="loc_us-gaap_AdjustmentForAmortization_79fba16c-f087-43b1-a109-9e1114398fda" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_daa1e8d9-7aed-470f-86c3-6072a398ed88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_77a32b1b-d8a6-44bc-ad01-ef44da9af6a2" xlink:to="loc_us-gaap_Depreciation_daa1e8d9-7aed-470f-86c3-6072a398ed88" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_12c98448-2759-49db-9985-2d00e2f72acc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_77a32b1b-d8a6-44bc-ad01-ef44da9af6a2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_12c98448-2759-49db-9985-2d00e2f72acc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_0b79d7fa-443d-4e83-9988-27ad2842ea01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_77a32b1b-d8a6-44bc-ad01-ef44da9af6a2" xlink:to="loc_us-gaap_RestructuringCharges_0b79d7fa-443d-4e83-9988-27ad2842ea01" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SegmentReportingUnallocatedOtherExpensesNet_9795cb6e-3ca0-4a4a-a9f1-b03cbea42b78" xlink:href="mrk-20220930.xsd#mrk_SegmentReportingUnallocatedOtherExpensesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_77a32b1b-d8a6-44bc-ad01-ef44da9af6a2" xlink:to="loc_mrk_SegmentReportingUnallocatedOtherExpensesNet_9795cb6e-3ca0-4a4a-a9f1-b03cbea42b78" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3360cdc1-3c6c-4fef-8368-a7a81acd86b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_77a32b1b-d8a6-44bc-ad01-ef44da9af6a2" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3360cdc1-3c6c-4fef-8368-a7a81acd86b7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_55f8e9c9-c903-4f14-a4c0-7b2289d83eab" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3360cdc1-3c6c-4fef-8368-a7a81acd86b7" xlink:to="loc_srt_ConsolidationItemsAxis_55f8e9c9-c903-4f14-a4c0-7b2289d83eab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_55f8e9c9-c903-4f14-a4c0-7b2289d83eab_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_55f8e9c9-c903-4f14-a4c0-7b2289d83eab" xlink:to="loc_srt_ConsolidationItemsDomain_55f8e9c9-c903-4f14-a4c0-7b2289d83eab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_d35a7ffd-6056-43f4-80e2-a73c79efc0f8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_55f8e9c9-c903-4f14-a4c0-7b2289d83eab" xlink:to="loc_srt_ConsolidationItemsDomain_d35a7ffd-6056-43f4-80e2-a73c79efc0f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_cae9d7fb-d539-4985-abf6-15363114844c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_d35a7ffd-6056-43f4-80e2-a73c79efc0f8" xlink:to="loc_us-gaap_OperatingSegmentsMember_cae9d7fb-d539-4985-abf6-15363114844c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_6ae42ea7-ec16-4af1-a331-b3c1b03103eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_d35a7ffd-6056-43f4-80e2-a73c79efc0f8" xlink:to="loc_us-gaap_CorporateNonSegmentMember_6ae42ea7-ec16-4af1-a331-b3c1b03103eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_7de5f3cc-0c76-442c-8812-010f82f1e670" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_d35a7ffd-6056-43f4-80e2-a73c79efc0f8" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_7de5f3cc-0c76-442c-8812-010f82f1e670" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_6cabf802-6fa2-4781-9bc2-f5e3eee95e27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3360cdc1-3c6c-4fef-8368-a7a81acd86b7" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_6cabf802-6fa2-4781-9bc2-f5e3eee95e27" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_6cabf802-6fa2-4781-9bc2-f5e3eee95e27_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_6cabf802-6fa2-4781-9bc2-f5e3eee95e27" xlink:to="loc_us-gaap_SegmentDomain_6cabf802-6fa2-4781-9bc2-f5e3eee95e27_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_22ad173b-3f80-4c3a-9e0d-2a467e85fa32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_6cabf802-6fa2-4781-9bc2-f5e3eee95e27" xlink:to="loc_us-gaap_SegmentDomain_22ad173b-3f80-4c3a-9e0d-2a467e85fa32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember_b83a1d05-ed92-422a-b9d3-e5b593e48516" xlink:href="mrk-20220930.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_22ad173b-3f80-4c3a-9e0d-2a467e85fa32" xlink:to="loc_mrk_PharmaceuticalsegmentMember_b83a1d05-ed92-422a-b9d3-e5b593e48516" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthsegmentMember_3c897769-bd1b-4b7f-b029-7ead6c34a19b" xlink:href="mrk-20220930.xsd#mrk_AnimalHealthsegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_22ad173b-3f80-4c3a-9e0d-2a467e85fa32" xlink:to="loc_mrk_AnimalHealthsegmentMember_3c897769-bd1b-4b7f-b029-7ead6c34a19b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>mrk-20220930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:18be82ff-6aae-4643-b5c5-ea6de452de6c,g:778f8bae-d5d9-4bda-a4ad-ec173f2835d1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_be2936be-664a-49bc-b8a5-10c0dfec4073_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:to="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_34993a4d-7ed9-423f-a7af-1785e8b11177_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_8b1769ae-6817-4ea1-9254-03f738582326_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, pending claims</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_80c2c475-5891-40ca-8efa-fbd3600c5712_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation earned</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_01b09e6f-b4b0-4c88-bde4-d4f922623ccf_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CollaborativeArrangementsAbstract_d6f2064d-3658-48b1-9ec1-cc259df7b39a_terseLabel_en-US" xlink:label="lab_mrk_CollaborativeArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements [Abstract]</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementsAbstract_label_en-US" xlink:label="lab_mrk_CollaborativeArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements [Abstract]</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementsAbstract_documentation_en-US" xlink:label="lab_mrk_CollaborativeArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementsAbstract" xlink:href="mrk-20220930.xsd#mrk_CollaborativeArrangementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CollaborativeArrangementsAbstract" xlink:to="lab_mrk_CollaborativeArrangementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradingSecurities_c1edd540-b71a-4592-bebc-9600b65669f4_totalLabel_en-US" xlink:label="lab_us-gaap_TradingSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_TradingSecurities_label_en-US" xlink:label="lab_us-gaap_TradingSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradingSecurities" xlink:to="lab_us-gaap_TradingSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_55cc8f35-9b75-4c88-aae8-580ff8e21abf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders Equity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_4da01799-5649-46e1-b90e-beb6c0a2f0ac_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_179b4ca8-de4d-49ab-9b13-2693e3274b22_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives designated as hedging instruments</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_b7e879c6-bb8e-4774-a4d1-efef4385aba8_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid to stockholders</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:to="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_9292886f-d234-439f-a1ce-6a4d2010decd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_fe97f7ef-7796-4408-90c8-7834db3ca841_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of loans payable and long-term debt, including current portion</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_5e3c8e41-e4af-4962-9e88-0202eee6f5d9_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring reserve, beginning balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_8c013c4d-ec0f-4159-809e-bb6653f45186_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring reserve, ending balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_8c849bcf-3a12-42ff-9089-1f2489de92e8_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange contracts</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_1cf62e98-5d25-46e7-9706-98f4bf1f8606_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue related to the sale of the marketing rights</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_e521fb7b-67ce-4524-8cdf-48ca8378a25a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_3bc16453-36d1-4858-8788-fd55ce5b9e30_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LagevrioMember_fe745433-c28f-4353-a23a-6f5c8567151a_terseLabel_en-US" xlink:label="lab_mrk_LagevrioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lagevrio</link:label>
    <link:label id="lab_mrk_LagevrioMember_label_en-US" xlink:label="lab_mrk_LagevrioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lagevrio [Member]</link:label>
    <link:label id="lab_mrk_LagevrioMember_documentation_en-US" xlink:label="lab_mrk_LagevrioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lagevrio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LagevrioMember" xlink:href="mrk-20220930.xsd#mrk_LagevrioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LagevrioMember" xlink:to="lab_mrk_LagevrioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_15c63be1-d040-498a-a965-d03e3f7f4f97_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (Income) Expense, Net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fe886719-7c14-4737-a790-569df0eeee5a_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_bcfb8de2-40c4-4897-af56-caa12ec91986_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_293f0504-7f60-488a-911c-fa641ab65938_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0f03ca6b-0b1b-4f3f-92ff-7548fdc0e4e6_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_d3ddd7d4-2257-497d-a9da-7442fc2c82d2_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_9c8533e5-49a2-42c7-94ec-0bdedbc53bd4_negatedLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_9b385545-0f70-41e7-8a24-067a74702215_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_16b35dea-1aea-4a28-98b6-b49f5201dab6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_d675a316-6906-4d16-91d4-0cabca43b3cc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Location and Amount of Pretax Gains and Losses of Derivatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_87e8631a-2c14-40d6-82ca-917d01d70a3d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember" xlink:to="lab_us-gaap_OtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_e53775d6-2a18-406c-ad9d-c16fe2c927f2_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_9bb10126-82e5-4a38-94c2-b07f4355afff_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic benefit cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_dfa481f6-0efc-4fdb-8b1e-9a6b429eb754_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_9463153d-78ef-4e6a-b4e4-4cd14c9ad3b0_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_8f1d2f33-413a-4e95-a4c0-d6c1e4fab030_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_f5258c56-9b5e-4cbf-9b8c-12d53741885a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:to="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_BayerAGMember_9dbdb592-7c08-4abd-85cb-1850c489732f_terseLabel_en-US" xlink:label="lab_mrk_BayerAGMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer AG</link:label>
    <link:label id="lab_mrk_BayerAGMember_label_en-US" xlink:label="lab_mrk_BayerAGMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer AG [Member]</link:label>
    <link:label id="lab_mrk_BayerAGMember_documentation_en-US" xlink:label="lab_mrk_BayerAGMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer AG [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BayerAGMember" xlink:href="mrk-20220930.xsd#mrk_BayerAGMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_BayerAGMember" xlink:to="lab_mrk_BayerAGMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_734afc4a-7197-41e6-85fe-d700d189c33b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_MilestonePaymentsAccruedSalesBased_857871f0-1a13-4b48-8324-7abe3cc0a091_terseLabel_en-US" xlink:label="lab_mrk_MilestonePaymentsAccruedSalesBased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments accrued but not yet paid</link:label>
    <link:label id="lab_mrk_MilestonePaymentsAccruedSalesBased_label_en-US" xlink:label="lab_mrk_MilestonePaymentsAccruedSalesBased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Accrued Sales Based</link:label>
    <link:label id="lab_mrk_MilestonePaymentsAccruedSalesBased_documentation_en-US" xlink:label="lab_mrk_MilestonePaymentsAccruedSalesBased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Accrued Sales Based</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MilestonePaymentsAccruedSalesBased" xlink:href="mrk-20220930.xsd#mrk_MilestonePaymentsAccruedSalesBased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_MilestonePaymentsAccruedSalesBased" xlink:to="lab_mrk_MilestonePaymentsAccruedSalesBased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_a11a4137-518a-411c-8399-45f053342d5c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock shares purchased</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_77dd4b9f-b5dc-48c1-b97d-b7adf29206aa_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income Attributable to Merck &amp; Co., Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_4712834c-988b-461b-a027-e2638b4e2046_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income Attributable to Merck&#160;&amp; Co., Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_ae2d8fc3-9d33-43b0-9c6f-278e2993fbc7_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Merck&#160;&amp; Co., Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6d80b5cc-ddc9-4e4c-bbda-17b26bac8582_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive shares (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_a6ea5f16-3859-4839-a160-8f7d56a89d88_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_ab019294-5634-4711-b150-29497261bee5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_d5f4db4f-d988-4d51-841e-e9d90a6c1fb9_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of unrecognized prior service credit</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Prior Service Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_1f1a96c2-25c9-4aef-8dbd-145b32ec1171_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalEntityTypeOfCounterpartyDomain_4cd17f44-72e5-495f-a9a3-b39e074eb271_terseLabel_en-US" xlink:label="lab_us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity Type of Counterparty [Domain]</link:label>
    <link:label id="lab_us-gaap_LegalEntityTypeOfCounterpartyDomain_label_en-US" xlink:label="lab_us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity Type of Counterparty [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="lab_us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember_9a984b26-94e1-418e-a325-f628e5f4caed_terseLabel_en-US" xlink:label="lab_mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.</link:label>
    <link:label id="lab_mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember_label_en-US" xlink:label="lab_mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. [Member]</link:label>
    <link:label id="lab_mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember_documentation_en-US" xlink:label="lab_mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember" xlink:href="mrk-20220930.xsd#mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember" xlink:to="lab_mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_576fff49-c8f4-4108-9f0d-f1895d605c50_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_d1847689-cf59-47f6-827f-bd193e18fe56_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Operating Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_cbe2b2bd-45ab-44d9-ad98-fd959f27ce29_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_f89b704d-fd46-43b8-b203-33bd66119ed5_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_44cdad0b-3331-4298-a085-b747bc594ffe_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfInterestRateDerivativesHeld_74e02221-31b9-45e5-ae5d-bff394507b86_verboseLabel_en-US" xlink:label="lab_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of interest rate swaps held (in interest rate swaps)</link:label>
    <link:label id="lab_us-gaap_NumberOfInterestRateDerivativesHeld_label_en-US" xlink:label="lab_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Interest Rate Derivatives Held</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfInterestRateDerivativesHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:to="lab_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember_2b312f9c-bd24-4e3f-bedf-dd50f8c3f76b_terseLabel_en-US" xlink:label="lab_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cases Company Agreed To Toll Statute Of Limitations</link:label>
    <link:label id="lab_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember_label_en-US" xlink:label="lab_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cases Company Agreed ToToll Statute Of Limitations [Member]</link:label>
    <link:label id="lab_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember_documentation_en-US" xlink:label="lab_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cases Company Agreed To Toll Statute Of Limitations[Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember" xlink:href="mrk-20220930.xsd#mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember" xlink:to="lab_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LegalDefenseCostsMember_ee6ef642-2883-4a0c-b5e2-85d61d1fb7ae_terseLabel_en-US" xlink:label="lab_mrk_LegalDefenseCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Defense Costs</link:label>
    <link:label id="lab_mrk_LegalDefenseCostsMember_label_en-US" xlink:label="lab_mrk_LegalDefenseCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Defense Costs [Member]</link:label>
    <link:label id="lab_mrk_LegalDefenseCostsMember_documentation_en-US" xlink:label="lab_mrk_LegalDefenseCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Defense Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LegalDefenseCostsMember" xlink:href="mrk-20220930.xsd#mrk_LegalDefenseCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LegalDefenseCostsMember" xlink:to="lab_mrk_LegalDefenseCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_881aa2e4-20d0-4117-ab84-75043757ea62_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less treasury stock, at cost: 1,043,697,097 shares in 2022 and 1,049,499,023 shares in 2021</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonValue" xlink:to="lab_us-gaap_TreasuryStockCommonValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_73bbde2c-20a5-4ec0-a553-743385b1feee_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6d2a895b-04a0-4009-bcbe-21c4fccd2230_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_82856516-51d4-44cc-9d71-cd64611b3a73_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_043e50b7-078d-4a36-8946-2387f8d18941_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from Continuing Operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_b5c5bc06-7a5b-4da3-8546-60da21c9dfbb_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_b8af9d3e-3238-4465-b782-d265d87a1df7_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SalesDiscounts_50355088-3caa-4bc7-b81e-3fe105296aa2_terseLabel_en-US" xlink:label="lab_mrk_SalesDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales discounts</link:label>
    <link:label id="lab_mrk_SalesDiscounts_label_en-US" xlink:label="lab_mrk_SalesDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Discounts</link:label>
    <link:label id="lab_mrk_SalesDiscounts_documentation_en-US" xlink:label="lab_mrk_SalesDiscounts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesDiscounts" xlink:href="mrk-20220930.xsd#mrk_SalesDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SalesDiscounts" xlink:to="lab_mrk_SalesDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_f88b5275-c088-473a-a58c-b694ba59e531_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables included in Other Noncurrent Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AstraZenecaMember_5a90fbe9-c2d3-4479-9a5e-ea52e1bbab70_terseLabel_en-US" xlink:label="lab_mrk_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca</link:label>
    <link:label id="lab_mrk_AstraZenecaMember_label_en-US" xlink:label="lab_mrk_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca [Member]</link:label>
    <link:label id="lab_mrk_AstraZenecaMember_documentation_en-US" xlink:label="lab_mrk_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AstraZenecaMember" xlink:href="mrk-20220930.xsd#mrk_AstraZenecaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AstraZenecaMember" xlink:to="lab_mrk_AstraZenecaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_aa2efef0-b28a-46ec-9402-387190df949f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_b29e1ebb-4065-4da9-973b-97f03b197437_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_b7c9fed1-24a1-4d3d-a323-3d9050b93f45_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_2732af02-9c53-4c48-ae59-e1377e4d5b4d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Loss) Income Net of Taxes:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentOperatingActivitiesDomain_58324810-740f-436e-9d55-6b859803417a_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentOperatingActivitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentOperatingActivitiesDomain_label_en-US" xlink:label="lab_us-gaap_SegmentOperatingActivitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain" xlink:to="lab_us-gaap_SegmentOperatingActivitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_39062371-7c7b-4497-a09d-4a6bc357da8b_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit recognized related to settlement</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_fd209374-51b4-47bf-9a9b-b30c90d24436_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_f764213d-2a37-4980-b5e9-4d10a55a8001_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Derivative, Asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_1478d882-d3aa-4af2-84c4-6a1091f680d6_netLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross amounts recognized in the consolidated balance sheet, asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_2b4da5df-6c8b-4da9-bc0c-b540bc374bb0_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_ff5b9d3c-77d0-43fd-aebf-198b47791f8e_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_24926ce9-688e-4055-a713-b4e27a131376_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding_1e24f6d8-c069-49c3-9c55-2334f84ea149_terseLabel_en-US" xlink:label="lab_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional funding by others, development costs subject to funding</link:label>
    <link:label id="lab_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding_label_en-US" xlink:label="lab_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Additional Funding By Others, Development Costs Subject To Funding</link:label>
    <link:label id="lab_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding_documentation_en-US" xlink:label="lab_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Additional Funding By Others, Development Costs Subject To Funding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding" xlink:href="mrk-20220930.xsd#mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding" xlink:to="lab_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_9cbf0ecb-d2e3-48ff-9aff-6ea0b7671970_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_128a74e1-2007-43f6-b0d3-a3b5b44c4e4f_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs, Expenses and Other</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_3bda71ed-41f3-4256-b323-e66e42ffe593_terseLabel_en-US" xlink:label="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic defined benefit plan (credit) cost other than service cost</link:label>
    <link:label id="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_label_en-US" xlink:label="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:to="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_41d41798-d46d-47a7-b8f6-72262ced9d6b_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected restructuring and related cost</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AnimalHealthsegmentMember_1384881c-4015-46db-8180-eca9d783a6c1_terseLabel_en-US" xlink:label="lab_mrk_AnimalHealthsegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Animal Health</link:label>
    <link:label id="lab_mrk_AnimalHealthsegmentMember_76fc8a78-cfee-4a2d-8c70-9eb769f10230_verboseLabel_en-US" xlink:label="lab_mrk_AnimalHealthsegmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Animal Health segment</link:label>
    <link:label id="lab_mrk_AnimalHealthsegmentMember_label_en-US" xlink:label="lab_mrk_AnimalHealthsegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Animal Health segment [Member]</link:label>
    <link:label id="lab_mrk_AnimalHealthsegmentMember_documentation_en-US" xlink:label="lab_mrk_AnimalHealthsegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Animal Health segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthsegmentMember" xlink:href="mrk-20220930.xsd#mrk_AnimalHealthsegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AnimalHealthsegmentMember" xlink:to="lab_mrk_AnimalHealthsegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_47e0780b-6f5a-4797-ba7c-c5d7986005e3_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessAndRawMaterials_4fce8405-db00-47a6-a09e-8adffa842ef4_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials and work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessAndRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process and Raw Materials</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessAndRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:to="lab_us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_473f76e9-06b3-4976-b159-aa7c5f1a950d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_7b3f026a-538d-4d1b-999f-14c23b3af255_terseLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_21d8ddd0-b97f-46e9-b405-284e27510993_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Discontinued Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AllianceRevenueKoselugoMember_7ab138aa-560b-424c-a1ec-758021bc4595_terseLabel_en-US" xlink:label="lab_mrk_AllianceRevenueKoselugoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Koselugo</link:label>
    <link:label id="lab_mrk_AllianceRevenueKoselugoMember_label_en-US" xlink:label="lab_mrk_AllianceRevenueKoselugoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Koselugo [Member]</link:label>
    <link:label id="lab_mrk_AllianceRevenueKoselugoMember_documentation_en-US" xlink:label="lab_mrk_AllianceRevenueKoselugoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Koselugo</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AllianceRevenueKoselugoMember" xlink:href="mrk-20220930.xsd#mrk_AllianceRevenueKoselugoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AllianceRevenueKoselugoMember" xlink:to="lab_mrk_AllianceRevenueKoselugoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_93216e69-d3ce-42b1-aed2-89c64a942733_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d5ff9aa0-3d5f-49dc-9880-d1b12bda7899_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Investing Activities of Continuing Operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_e687e31d-6170-4013-97f8-2c36389b5511_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_775ae481-ce5f-4ceb-8763-1707faee87f3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_3c7f7e1e-3f02-48e3-801e-6de835264c39_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangements</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_61be2b0a-72c5-47ca-a663-312192c60be8_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_c22e8637-5226-4916-9a75-8bda9517802d_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from Discontinued Operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableSale_666a1d1e-a2fe-4dbe-9a7d-cfd2ded349d5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Factored accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableSale_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableSale" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableSale" xlink:to="lab_us-gaap_AccountsReceivableSale" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_a18e1785-6393-49e5-93d1-d7f6e6917867_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_d2cf10b2-a8a7-4c97-91dc-8509cd65fc54_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Pandion Therapeutics, Inc., net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Business Two, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_4fd30e61-c824-41a8-b7d2-a1dbb8df9e3a_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_fc581050-0df7-4470-b5d1-e859061b2063_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_bccb818b-3785-47a2-9b09-7b1f9af32fe5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_a52a2786-3cbe-481d-a990-0256ed2a2ab6_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_0703b3d5-9286-4a3d-904c-fd5578745840_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_feea7b39-e26c-4273-8785-52928c9cc940_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_677aa0c9-f7bc-46ce-a40b-bb3242b005de_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_75ab5780-c3af-4a3d-8895-012cfd0cf4b4_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_d67cf63f-a3a3-4f17-a907-621b28dabcb9_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_e42e39a8-408e-42ac-bdde-9d9451852bb1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_c866055e-7a43-42f8-a240-f50866303ec5_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_MilestonePaymentsMadetoCollaborativePartner_c20aa52a-514a-4933-984c-96f7fb6a240d_terseLabel_en-US" xlink:label="lab_mrk_MilestonePaymentsMadetoCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized milestone payment</link:label>
    <link:label id="lab_mrk_MilestonePaymentsMadetoCollaborativePartner_label_en-US" xlink:label="lab_mrk_MilestonePaymentsMadetoCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Made to Collaborative Partner</link:label>
    <link:label id="lab_mrk_MilestonePaymentsMadetoCollaborativePartner_documentation_en-US" xlink:label="lab_mrk_MilestonePaymentsMadetoCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Made to Collaborative Partner</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MilestonePaymentsMadetoCollaborativePartner" xlink:href="mrk-20220930.xsd#mrk_MilestonePaymentsMadetoCollaborativePartner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_MilestonePaymentsMadetoCollaborativePartner" xlink:to="lab_mrk_MilestonePaymentsMadetoCollaborativePartner" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_dec63171-fc14-4c55-afaf-3bb68348372e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of gain (loss) recognized in OCI on derivatives</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_4e411665-f39c-48b3-815d-02e847fb3edc_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_c40f5f74-4a78-4f59-b251-c857f62535a8_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SanofiPasteurMember_f87d505b-22bb-4cf2-bdbe-f0c3fb0fb473_terseLabel_en-US" xlink:label="lab_mrk_SanofiPasteurMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur</link:label>
    <link:label id="lab_mrk_SanofiPasteurMember_label_en-US" xlink:label="lab_mrk_SanofiPasteurMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur [Member]</link:label>
    <link:label id="lab_mrk_SanofiPasteurMember_documentation_en-US" xlink:label="lab_mrk_SanofiPasteurMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SanofiPasteurMember" xlink:href="mrk-20220930.xsd#mrk_SanofiPasteurMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SanofiPasteurMember" xlink:to="lab_mrk_SanofiPasteurMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_bd15c6ac-00d3-44cf-b3e8-84dc6e0d84a7_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_8945148e-6bc8-4aef-b1fa-50865f4d114e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_50cb9492-9b4e-401a-a034-e434a7ac1075_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_aef04d8f-45c1-4bf4-abe1-8d299dc9fd52_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationTable" xlink:to="lab_us-gaap_IncomeTaxExaminationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_JanuviaMember_dc289ae8-dad7-43f4-bc88-9707cf84224a_terseLabel_en-US" xlink:label="lab_mrk_JanuviaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Januvia</link:label>
    <link:label id="lab_mrk_JanuviaMember_label_en-US" xlink:label="lab_mrk_JanuviaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Januvia [Member]</link:label>
    <link:label id="lab_mrk_JanuviaMember_documentation_en-US" xlink:label="lab_mrk_JanuviaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Januvia [Member] .</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_JanuviaMember" xlink:href="mrk-20220930.xsd#mrk_JanuviaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_JanuviaMember" xlink:to="lab_mrk_JanuviaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_2e99eae9-3097-4650-966c-25885d7ccba5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_75a4dd0b-cf5b-4ac9-8f90-9074085a3d9a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CollaborativeArrangementProfitSharing_ef0bc96e-194a-4a6e-86a2-0dad70539a6b_terseLabel_en-US" xlink:label="lab_mrk_CollaborativeArrangementProfitSharing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - profit sharing</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementProfitSharing_label_en-US" xlink:label="lab_mrk_CollaborativeArrangementProfitSharing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Profit Sharing</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementProfitSharing_documentation_en-US" xlink:label="lab_mrk_CollaborativeArrangementProfitSharing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Profit Sharing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementProfitSharing" xlink:href="mrk-20220930.xsd#mrk_CollaborativeArrangementProfitSharing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CollaborativeArrangementProfitSharing" xlink:to="lab_mrk_CollaborativeArrangementProfitSharing" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_6d79726f-7226-41a8-b360-b75bf44db189_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_c7191272-3f79-458a-ae57-da6747bf5392_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in AOCI by Component</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_4f309dca-c08f-4aa9-8e7a-83067ff59f09_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_MilestonePaymentsToBeMadeToACollaborativePartner_90421193-afd4-4b99-a698-256445e64d73_terseLabel_en-US" xlink:label="lab_mrk_MilestonePaymentsToBeMadeToACollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments to be made to a collaborative partner</link:label>
    <link:label id="lab_mrk_MilestonePaymentsToBeMadeToACollaborativePartner_label_en-US" xlink:label="lab_mrk_MilestonePaymentsToBeMadeToACollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments to be Made to a Collaborative Partner</link:label>
    <link:label id="lab_mrk_MilestonePaymentsToBeMadeToACollaborativePartner_documentation_en-US" xlink:label="lab_mrk_MilestonePaymentsToBeMadeToACollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments to be Made to a Collaborative Partner</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MilestonePaymentsToBeMadeToACollaborativePartner" xlink:href="mrk-20220930.xsd#mrk_MilestonePaymentsToBeMadeToACollaborativePartner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_MilestonePaymentsToBeMadeToACollaborativePartner" xlink:to="lab_mrk_MilestonePaymentsToBeMadeToACollaborativePartner" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_be1fc439-cae9-4004-8a3c-7e5cfd4ffd7a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Used in Financing Activities of Continuing Operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_da3bb7e7-485c-4848-a4a1-eef1725be3fb_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_0eb338bf-b0c7-4309-b575-b7c481f8d6ee_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_5d3e83bf-877e-491b-bf43-a3d2772926cd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeOptionMember_fcc5f01d-291c-4cc9-9364-bb14891dfee0_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency options</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeOptionMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeOptionMember" xlink:to="lab_us-gaap_ForeignExchangeOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_83b87c1c-5c2c-442c-aec6-3a587a799252_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Publicly traded equity securities, fair value</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_ba21ea31-187b-442c-8f7b-148c6d804c92_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Publicly traded equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DeferredIncomeTaxesAndOtherAssetsCurrentMember_84db5bd1-6a1f-4242-a288-24467ddc880a_terseLabel_en-US" xlink:label="lab_mrk_DeferredIncomeTaxesAndOtherAssetsCurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_mrk_DeferredIncomeTaxesAndOtherAssetsCurrentMember_label_en-US" xlink:label="lab_mrk_DeferredIncomeTaxesAndOtherAssetsCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Other Assets, Current [Member]</link:label>
    <link:label id="lab_mrk_DeferredIncomeTaxesAndOtherAssetsCurrentMember_documentation_en-US" xlink:label="lab_mrk_DeferredIncomeTaxesAndOtherAssetsCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredIncomeTaxesAndOtherAssetsCurrentMember" xlink:href="mrk-20220930.xsd#mrk_DeferredIncomeTaxesAndOtherAssetsCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DeferredIncomeTaxesAndOtherAssetsCurrentMember" xlink:to="lab_mrk_DeferredIncomeTaxesAndOtherAssetsCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_ce7cfaa6-df91-4b01-a381-0f89aeb2131a_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap contracts</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_963cdc4f-da4c-48f6-bf58-c3fa83e07f2c_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swaps</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b9b166e8-7590-4196-be6a-4eca2fc7c48e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ArtivaBiotherapeuticsIncMember_67db1d0b-783b-48e2-863d-330b708a58f4_terseLabel_en-US" xlink:label="lab_mrk_ArtivaBiotherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Artiva Biotherapeutics, Inc.</link:label>
    <link:label id="lab_mrk_ArtivaBiotherapeuticsIncMember_label_en-US" xlink:label="lab_mrk_ArtivaBiotherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Artiva Biotherapeutics, Inc. [Member]</link:label>
    <link:label id="lab_mrk_ArtivaBiotherapeuticsIncMember_documentation_en-US" xlink:label="lab_mrk_ArtivaBiotherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Artiva Biotherapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ArtivaBiotherapeuticsIncMember" xlink:href="mrk-20220930.xsd#mrk_ArtivaBiotherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ArtivaBiotherapeuticsIncMember" xlink:to="lab_mrk_ArtivaBiotherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A2.40NotesDue2022Member_e37f12b2-9aba-40d0-abbd-63173206493d_terseLabel_en-US" xlink:label="lab_mrk_A2.40NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.40% Notes Due 2022</link:label>
    <link:label id="lab_mrk_A2.40NotesDue2022Member_label_en-US" xlink:label="lab_mrk_A2.40NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.40% Notes Due 2022 [Member]</link:label>
    <link:label id="lab_mrk_A2.40NotesDue2022Member_documentation_en-US" xlink:label="lab_mrk_A2.40NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.40% Notes Due 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.40NotesDue2022Member" xlink:href="mrk-20220930.xsd#mrk_A2.40NotesDue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A2.40NotesDue2022Member" xlink:to="lab_mrk_A2.40NotesDue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_c3534172-2cfe-4c02-a0f4-25b46d348245_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustments, net of taxes</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_9f8bff88-026b-499e-a09e-caba87e0409d_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck&#160;&amp; Co., Inc. Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_65cbc9a6-5651-4925-8898-0c183d1fab3a_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from Continuing Operations Before Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a00395e2-16ad-4dfe-93c8-6625563c8c9d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profits</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RotateqMember_3533b369-abc9-4895-aeef-cdd64d3111af_terseLabel_en-US" xlink:label="lab_mrk_RotateqMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RotaTeq</link:label>
    <link:label id="lab_mrk_RotateqMember_label_en-US" xlink:label="lab_mrk_RotateqMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rotateq [Member]</link:label>
    <link:label id="lab_mrk_RotateqMember_documentation_en-US" xlink:label="lab_mrk_RotateqMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RotaTeq [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RotateqMember" xlink:href="mrk-20220930.xsd#mrk_RotateqMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RotateqMember" xlink:to="lab_mrk_RotateqMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAverageRemainingMaturity1_623b4ee8-fc1e-4a9b-84cf-deaf1aeeec78_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAverageRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum average period of maturities of contracts in years (less than)</link:label>
    <link:label id="lab_us-gaap_DerivativeAverageRemainingMaturity1_label_en-US" xlink:label="lab_us-gaap_DerivativeAverageRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Average Remaining Maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAverageRemainingMaturity1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAverageRemainingMaturity1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAverageRemainingMaturity1" xlink:to="lab_us-gaap_DerivativeAverageRemainingMaturity1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_93f1b767-2a07-4073-9a3e-d92efc32cdbd_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_TransitionServicesAgreementMember_9e57cefa-d033-4788-b588-e400d08a1ed1_terseLabel_en-US" xlink:label="lab_mrk_TransitionServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition services agreement</link:label>
    <link:label id="lab_mrk_TransitionServicesAgreementMember_label_en-US" xlink:label="lab_mrk_TransitionServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition services agreement [Member]</link:label>
    <link:label id="lab_mrk_TransitionServicesAgreementMember_documentation_en-US" xlink:label="lab_mrk_TransitionServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition services agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_TransitionServicesAgreementMember" xlink:href="mrk-20220930.xsd#mrk_TransitionServicesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_TransitionServicesAgreementMember" xlink:to="lab_mrk_TransitionServicesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_b5c5245d-3f04-4b27-8368-dc2ce6b59d72_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Recorded on Balance Sheet Related to Fair Value Hedges</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet_306c5faa-1b59-4167-9c29-eb27d314069c_terseLabel_en-US" xlink:label="lab_mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net assets</link:label>
    <link:label id="lab_mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet_label_en-US" xlink:label="lab_mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Other Assets and Liabilities Recognized, Net</link:label>
    <link:label id="lab_mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet_documentation_en-US" xlink:label="lab_mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Other Assets and Liabilities Recognized, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet" xlink:href="mrk-20220930.xsd#mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet" xlink:to="lab_mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_f4a5acf6-7ed7-418f-9659-63222205cc24_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaid_73330579-9514-4820-8bcc-9faaf4213189_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaid_label_en-US" xlink:label="lab_us-gaap_InterestPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Including Capitalized Interest, Operating and Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaid" xlink:to="lab_us-gaap_InterestPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_621c16c5-2017-4815-a636-c68f676c3b2b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Interest Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:to="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_6581794f-117b-45b2-bd8d-bdc54e3b9986_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyClaimsSettledNumber_c1110c46-483f-470a-9f88-97977f5707e9_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsSettledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, claims settled</link:label>
    <link:label id="lab_us-gaap_LossContingencyClaimsSettledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsSettledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Settled, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsSettledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyClaimsSettledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyClaimsSettledNumber" xlink:to="lab_us-gaap_LossContingencyClaimsSettledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_13bc59e8-a3b7-476f-89e7-b83b122e79a7_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_db243e1f-441d-44ce-b543-86db0d9cccf2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Derivatives on a Gross Basis Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_1da0e20c-020b-4474-811c-b89678ada449_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Investing Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OtherPharmaceuticalMember_cde156b3-9a65-4d0f-a22f-e8e450df923a_terseLabel_en-US" xlink:label="lab_mrk_OtherPharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other pharmaceutical</link:label>
    <link:label id="lab_mrk_OtherPharmaceuticalMember_label_en-US" xlink:label="lab_mrk_OtherPharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Pharmaceutical [Member]</link:label>
    <link:label id="lab_mrk_OtherPharmaceuticalMember_documentation_en-US" xlink:label="lab_mrk_OtherPharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other pharmaceutical.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherPharmaceuticalMember" xlink:href="mrk-20220930.xsd#mrk_OtherPharmaceuticalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OtherPharmaceuticalMember" xlink:to="lab_mrk_OtherPharmaceuticalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_23d44f68-8071-47c7-8ae7-0e19facf1989_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_c7ebbcbe-271f-48a8-b366-142f25e86ac5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CollaborativeArrangementNumberOfResearchPrograms_ef6b518d-6c0d-4bd3-bfac-4935b2992d80_terseLabel_en-US" xlink:label="lab_mrk_CollaborativeArrangementNumberOfResearchPrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of research programs</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementNumberOfResearchPrograms_label_en-US" xlink:label="lab_mrk_CollaborativeArrangementNumberOfResearchPrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Research Programs</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementNumberOfResearchPrograms_documentation_en-US" xlink:label="lab_mrk_CollaborativeArrangementNumberOfResearchPrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Research Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementNumberOfResearchPrograms" xlink:href="mrk-20220930.xsd#mrk_CollaborativeArrangementNumberOfResearchPrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CollaborativeArrangementNumberOfResearchPrograms" xlink:to="lab_mrk_CollaborativeArrangementNumberOfResearchPrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_195f5e47-35ec-4fb3-93e5-f5dbec49969a_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CO_09dedd31-7c86-4ece-ac6d-bc8dcb9030cf_terseLabel_en-US" xlink:label="lab_country_CO" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COLOMBIA</link:label>
    <link:label id="lab_country_CO_label_en-US" xlink:label="lab_country_CO" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COLOMBIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CO" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CO"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CO" xlink:to="lab_country_CO" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CN_ccc28f69-e9b4-4965-b7c5-20e26d8f108c_terseLabel_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">China</link:label>
    <link:label id="lab_country_CN_label_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CN" xlink:to="lab_country_CN" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_1e7a0c5d-d138-4c7f-8d0f-088e27193dfd_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_97321187-ce67-40bd-ba0d-126887ce4639_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Adjustment</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PatentsMember_0a8ffea0-b336-4bd1-b16f-5df8c2c6db70_terseLabel_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents</link:label>
    <link:label id="lab_us-gaap_PatentsMember_label_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PatentsMember" xlink:to="lab_us-gaap_PatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_5ef2ea89-dd85-40b5-94d4-f9f8aac366fe_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_BelsomraMember_71a55bab-0c6e-4738-96ca-29cdf8a14c9e_terseLabel_en-US" xlink:label="lab_mrk_BelsomraMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Belsomra</link:label>
    <link:label id="lab_mrk_BelsomraMember_label_en-US" xlink:label="lab_mrk_BelsomraMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Belsomra [Member]</link:label>
    <link:label id="lab_mrk_BelsomraMember_documentation_en-US" xlink:label="lab_mrk_BelsomraMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Belsomra [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BelsomraMember" xlink:href="mrk-20220930.xsd#mrk_BelsomraMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_BelsomraMember" xlink:to="lab_mrk_BelsomraMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_4871c116-934b-4656-a563-830b9402262d_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and Other Postretirement Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_Pneumovax23Member_0604cdca-5a84-4944-866b-0508afe969dd_terseLabel_en-US" xlink:label="lab_mrk_Pneumovax23Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pneumovax 23</link:label>
    <link:label id="lab_mrk_Pneumovax23Member_label_en-US" xlink:label="lab_mrk_Pneumovax23Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pneumovax 23 [Member]</link:label>
    <link:label id="lab_mrk_Pneumovax23Member_documentation_en-US" xlink:label="lab_mrk_Pneumovax23Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pneumovax 23[Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_Pneumovax23Member" xlink:href="mrk-20220930.xsd#mrk_Pneumovax23Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_Pneumovax23Member" xlink:to="lab_mrk_Pneumovax23Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EMEAMember_1b1a44e8-c125-47af-9bbd-cdf1b1e82140_terseLabel_en-US" xlink:label="lab_us-gaap_EMEAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe, Middle East and Africa</link:label>
    <link:label id="lab_us-gaap_EMEAMember_label_en-US" xlink:label="lab_us-gaap_EMEAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EMEA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EMEAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EMEAMember" xlink:to="lab_us-gaap_EMEAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_f3628982-71ae-429e-bf17-1a4761be29e4_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4131ef06-54c4-45e2-b6c7-e7da72012dcc_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_861510b8-284c-43db-8e9d-bd8cf219d52c_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3dc1f940-739e-4c52-8284-05715238117d_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A0.500Notesdue2024Member_091bab38-641f-4d05-b195-b792ef711db8_terseLabel_en-US" xlink:label="lab_mrk_A0.500Notesdue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.500% Notes due 2024</link:label>
    <link:label id="lab_mrk_A0.500Notesdue2024Member_label_en-US" xlink:label="lab_mrk_A0.500Notesdue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.500% Notes due 2024 [Member]</link:label>
    <link:label id="lab_mrk_A0.500Notesdue2024Member_documentation_en-US" xlink:label="lab_mrk_A0.500Notesdue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.500% Notes due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A0.500Notesdue2024Member" xlink:href="mrk-20220930.xsd#mrk_A0.500Notesdue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A0.500Notesdue2024Member" xlink:to="lab_mrk_A0.500Notesdue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LenvimaMember_2b31169f-81ec-492d-8c78-461eeb40f448_verboseLabel_en-US" xlink:label="lab_mrk_LenvimaMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lenvima</link:label>
    <link:label id="lab_mrk_LenvimaMember_7d0e9dd2-5ab2-45c9-8c72-b84c137b2451_terseLabel_en-US" xlink:label="lab_mrk_LenvimaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Lenvima</link:label>
    <link:label id="lab_mrk_LenvimaMember_label_en-US" xlink:label="lab_mrk_LenvimaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lenvima [Member]</link:label>
    <link:label id="lab_mrk_LenvimaMember_documentation_en-US" xlink:label="lab_mrk_LenvimaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lenvima [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LenvimaMember" xlink:href="mrk-20220930.xsd#mrk_LenvimaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LenvimaMember" xlink:to="lab_mrk_LenvimaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalCostsPolicyTextBlock_258942aa-28a9-4c6d-8750-fc74c809c1c3_terseLabel_en-US" xlink:label="lab_us-gaap_LegalCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Costs</link:label>
    <link:label id="lab_us-gaap_LegalCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalCostsPolicyTextBlock" xlink:to="lab_us-gaap_LegalCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_b1395473-a155-4453-a3e7-2d16c4330577_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_2478693e-c13a-415b-8fb5-f5276db64bb6_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_c54c8082-ad38-4a7d-8f48-3fd8686182cd_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_4b844de0-472c-447b-9a38-e9de17cacd4c_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_69211d53-fb71-488f-9790-53fe98918881_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_46706321-4f1e-473e-955b-7354c17b72b8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss) before Reclassifications, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_28669e36-cb95-4113-825a-7a305f838200_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems" xlink:to="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3669a1f1-c449-4e04-a11e-21adc4a21522_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_73aa509e-39e9-4be7-b8db-2e32b563de1a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_6c014864-93f8-431f-b52d-18b43dab3abb_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">&#160; Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_81e635ea-4d18-40a5-bd1b-c031af23461b_terseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plans</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:to="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_7d09606c-f5d9-4579-a4cd-f7f710795bd9_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_c52cd615-317b-45f8-9ca0-c260cae65357_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_ceb75399-d298-492f-a372-cf229037a5e6_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangibles</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A1.875Notesdue2026Member_29350cb4-955d-4747-b71d-3e4709976483_terseLabel_en-US" xlink:label="lab_mrk_A1.875Notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.875% Notes due 2026</link:label>
    <link:label id="lab_mrk_A1.875Notesdue2026Member_label_en-US" xlink:label="lab_mrk_A1.875Notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.875% Notes due 2026 [Member]</link:label>
    <link:label id="lab_mrk_A1.875Notesdue2026Member_documentation_en-US" xlink:label="lab_mrk_A1.875Notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.875% Notes due 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.875Notesdue2026Member" xlink:href="mrk-20220930.xsd#mrk_A1.875Notesdue2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A1.875Notesdue2026Member" xlink:to="lab_mrk_A1.875Notesdue2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_StockholdersEquityLineItems_522638e7-9cd7-43ae-ab97-d149b29ac4a8_terseLabel_en-US" xlink:label="lab_mrk_StockholdersEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders Equity [Line Items]</link:label>
    <link:label id="lab_mrk_StockholdersEquityLineItems_label_en-US" xlink:label="lab_mrk_StockholdersEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders Equity [Line Items]</link:label>
    <link:label id="lab_mrk_StockholdersEquityLineItems_documentation_en-US" xlink:label="lab_mrk_StockholdersEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Stockholders Equity [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_StockholdersEquityLineItems" xlink:href="mrk-20220930.xsd#mrk_StockholdersEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_StockholdersEquityLineItems" xlink:to="lab_mrk_StockholdersEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_f4d9d372-b6e6-4584-bcef-37af2a2cb021_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_3299f724-877a-4f5a-9cc0-8d9bbe4dc2b2_periodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_10b0c0ac-effe-4e49-91cd-d9052b7ea75b_periodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax_401c457a-d2b5-4714-af77-627d74cd5ec3_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from AOCI, Current Period, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOperatingActivitiesSegmentAxis_74464787-9884-4a47-a5a1-134dbd91d1bf_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementOperatingActivitiesSegmentAxis_label_en-US" xlink:label="lab_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:to="lab_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_081d6593-4584-4b5d-86df-8092a7f03c9e_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LossContingencyClaimsonAppealNumber_c199c56d-ef4e-44ff-9d26-3fbc89614537_terseLabel_en-US" xlink:label="lab_mrk_LossContingencyClaimsonAppealNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, claims on appeal</link:label>
    <link:label id="lab_mrk_LossContingencyClaimsonAppealNumber_label_en-US" xlink:label="lab_mrk_LossContingencyClaimsonAppealNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims on Appeal, Number</link:label>
    <link:label id="lab_mrk_LossContingencyClaimsonAppealNumber_documentation_en-US" xlink:label="lab_mrk_LossContingencyClaimsonAppealNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims on Appeal, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LossContingencyClaimsonAppealNumber" xlink:href="mrk-20220930.xsd#mrk_LossContingencyClaimsonAppealNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LossContingencyClaimsonAppealNumber" xlink:to="lab_mrk_LossContingencyClaimsonAppealNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_7ec7c483-76fb-43ea-b9d3-dc6ae829111b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_d5e3ffa4-b87e-486a-8cbc-79ee08338d91_negatedLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInventorySupplies_8770cf26-c35b-4487-acd0-0beef90ed4fc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInventorySupplies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplies</link:label>
    <link:label id="lab_us-gaap_OtherInventorySupplies_label_en-US" xlink:label="lab_us-gaap_OtherInventorySupplies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Inventory, Supplies, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventorySupplies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInventorySupplies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInventorySupplies" xlink:to="lab_us-gaap_OtherInventorySupplies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_ada2161d-73af-474a-8d71-fe99f290cd90_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ProbableContingentPaymentsCollaborativeArrangement_1029f2f7-87a2-43e0-ac4a-b5b8354ad148_terseLabel_en-US" xlink:label="lab_mrk_ProbableContingentPaymentsCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probable contingent payments</link:label>
    <link:label id="lab_mrk_ProbableContingentPaymentsCollaborativeArrangement_label_en-US" xlink:label="lab_mrk_ProbableContingentPaymentsCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probable Contingent Payments Collaborative Arrangement</link:label>
    <link:label id="lab_mrk_ProbableContingentPaymentsCollaborativeArrangement_documentation_en-US" xlink:label="lab_mrk_ProbableContingentPaymentsCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probable Contingent Payments Collaborative Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ProbableContingentPaymentsCollaborativeArrangement" xlink:href="mrk-20220930.xsd#mrk_ProbableContingentPaymentsCollaborativeArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ProbableContingentPaymentsCollaborativeArrangement" xlink:to="lab_mrk_ProbableContingentPaymentsCollaborativeArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_d9baa941-a105-4ef3-b9f0-c1111b7acf76_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_9f725507-7192-47a9-bbf1-328cd54dfa77_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e9ff8f42-d21c-4d97-82e9-5f6efd0c532b_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_f6c791ca-e555-4815-a193-0951deb3a268_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs, Expenses and Other</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueFromRelatedPartiesCurrent_37c3ac8f-3683-4944-ad43-12f67268f2da_terseLabel_en-US" xlink:label="lab_us-gaap_DueFromRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from related parties, current</link:label>
    <link:label id="lab_us-gaap_DueFromRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_DueFromRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromRelatedPartiesCurrent" xlink:to="lab_us-gaap_DueFromRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_IsentressIsentressHDMember_3ea3365c-2a41-4b11-a3fa-4cc9b6d836c1_terseLabel_en-US" xlink:label="lab_mrk_IsentressIsentressHDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Isentress/Isentress HD</link:label>
    <link:label id="lab_mrk_IsentressIsentressHDMember_label_en-US" xlink:label="lab_mrk_IsentressIsentressHDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Isentress/Isentress HD [Member]</link:label>
    <link:label id="lab_mrk_IsentressIsentressHDMember_documentation_en-US" xlink:label="lab_mrk_IsentressIsentressHDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Isentress/Isentress HD [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IsentressIsentressHDMember" xlink:href="mrk-20220930.xsd#mrk_IsentressIsentressHDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_IsentressIsentressHDMember" xlink:to="lab_mrk_IsentressIsentressHDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_c270c7a4-8884-46f4-b7d4-d6b3b971a6da_verboseLabel_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount</link:label>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:to="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_COVID19Member_28371fc7-96c6-4818-99df-d57a3cc56e16_terseLabel_en-US" xlink:label="lab_mrk_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19</link:label>
    <link:label id="lab_mrk_COVID19Member_label_en-US" xlink:label="lab_mrk_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 [Member]</link:label>
    <link:label id="lab_mrk_COVID19Member_documentation_en-US" xlink:label="lab_mrk_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_COVID19Member" xlink:href="mrk-20220930.xsd#mrk_COVID19Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_COVID19Member" xlink:to="lab_mrk_COVID19Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_59b56d7d-caed-48bb-8463-5652837b181b_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_us-gaap_Revenues_def0ca7e-b661-4199-9ffa-3c10a2a6796c_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_InventoryTable_41ccdb9b-4453-4f50-94ea-c6321b06d45f_terseLabel_en-US" xlink:label="lab_mrk_InventoryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Table]</link:label>
    <link:label id="lab_mrk_InventoryTable_label_en-US" xlink:label="lab_mrk_InventoryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Table]</link:label>
    <link:label id="lab_mrk_InventoryTable_documentation_en-US" xlink:label="lab_mrk_InventoryTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryTable" xlink:href="mrk-20220930.xsd#mrk_InventoryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_InventoryTable" xlink:to="lab_mrk_InventoryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_479aced8-5201-4a85-b43b-bcc1139b8d91_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative costs since program inception</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Cost Incurred to Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_0fb1c545-e989-436d-b451-759727c6ddd9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes on Income</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_8a4a25d0-791d-4130-8a04-4923558ec9fd_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from related party</link:label>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromRelatedParties" xlink:to="lab_us-gaap_RevenueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_7d0462ad-a828-4234-86bf-aba5680aacf5_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income from Continuing Operations Attributable to Merck&#160;&amp; Co., Inc.</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_208a6312-b877-409d-9d2e-7f9678e51771_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income from Continuing Operations Attributable to Merck&#160;&amp; Co., Inc.</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_b4cfddb2-982c-450c-bf6a-ab2f656e7a5e_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_a0c9a889-83de-4f1c-85e9-f75d60a30647_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_17142864-e3eb-4fe1-a48c-e5d24d48bbed_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount_6898b831-8d4c-448b-b109-c4e534aa9cd0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, carrying amount</link:label>
    <link:label id="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount_label_en-US" xlink:label="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Long-Term and Short-Term, Combined Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:to="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_7087bd16-8213-44d1-97c7-29fe9a7a6440_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RecognizedAsAbstract_d658d211-2839-4b68-89b7-bfc3a10fac0c_terseLabel_en-US" xlink:label="lab_mrk_RecognizedAsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized as:</link:label>
    <link:label id="lab_mrk_RecognizedAsAbstract_label_en-US" xlink:label="lab_mrk_RecognizedAsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized As [Abstract]</link:label>
    <link:label id="lab_mrk_RecognizedAsAbstract_documentation_en-US" xlink:label="lab_mrk_RecognizedAsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized as.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RecognizedAsAbstract" xlink:href="mrk-20220930.xsd#mrk_RecognizedAsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RecognizedAsAbstract" xlink:to="lab_mrk_RecognizedAsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_ba96a1d4-8329-4c11-93e8-9107f4d678a2_terseLabel_en-US" xlink:label="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Component of Other Income / Expense of Nonoperating [Table]</link:label>
    <link:label id="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_label_en-US" xlink:label="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Component of Other Income / Expense of Nonoperating [Table]</link:label>
    <link:label id="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_documentation_en-US" xlink:label="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Component of Other Income / Expense of Nonoperating [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable" xlink:href="mrk-20220930.xsd#mrk_ComponentofOtherIncomeExpenseofNonoperatingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable" xlink:to="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_ad9d665a-866d-4854-940d-7511d96fe3bd_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_316dbe19-fafe-43bf-b179-b4a51a562845_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_d58ed7db-2b92-4a84-a337-9d2eca95610f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PrimaxinMember_d6367a77-44df-4540-ad01-de610e3652a3_terseLabel_en-US" xlink:label="lab_mrk_PrimaxinMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Primaxin</link:label>
    <link:label id="lab_mrk_PrimaxinMember_label_en-US" xlink:label="lab_mrk_PrimaxinMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Primaxin [Member]</link:label>
    <link:label id="lab_mrk_PrimaxinMember_documentation_en-US" xlink:label="lab_mrk_PrimaxinMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Primaxin [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PrimaxinMember" xlink:href="mrk-20220930.xsd#mrk_PrimaxinMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PrimaxinMember" xlink:to="lab_mrk_PrimaxinMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_Licenseoptionpaymentrelatedtocollaborativearrangement_9b1ed05a-9d6f-4bd9-aab8-4bd126c30764_terseLabel_en-US" xlink:label="lab_mrk_Licenseoptionpaymentrelatedtocollaborativearrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License option payment related to collaborative arrangement</link:label>
    <link:label id="lab_mrk_Licenseoptionpaymentrelatedtocollaborativearrangement_label_en-US" xlink:label="lab_mrk_Licenseoptionpaymentrelatedtocollaborativearrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License option payment related to collaborative arrangement</link:label>
    <link:label id="lab_mrk_Licenseoptionpaymentrelatedtocollaborativearrangement_documentation_en-US" xlink:label="lab_mrk_Licenseoptionpaymentrelatedtocollaborativearrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License option payment related to collaborative arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_Licenseoptionpaymentrelatedtocollaborativearrangement" xlink:href="mrk-20220930.xsd#mrk_Licenseoptionpaymentrelatedtocollaborativearrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_Licenseoptionpaymentrelatedtocollaborativearrangement" xlink:to="lab_mrk_Licenseoptionpaymentrelatedtocollaborativearrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_e1c47c3f-c22c-45d9-816a-898636c39c67_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_49afbeb2-1546-4f99-917d-eae1d271ec88_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_d1ce5f41-4713-4d50-949b-b3ab57adc951_terseLabel_en-US" xlink:label="lab_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments</link:label>
    <link:label id="lab_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_label_en-US" xlink:label="lab_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront And Milestone Payments Made To Collaborative Partner</link:label>
    <link:label id="lab_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_documentation_en-US" xlink:label="lab_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments made to partner as part of collaborative arrangement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:href="mrk-20220930.xsd#mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:to="lab_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_51267cd0-fb3c-4626-bb61-b1f5214b32ef_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Merck&#160;&amp; Co., Inc. stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_f9acd1b0-9612-4866-af64-722fcbad69b6_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition costs</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Transaction Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays_53804653-99d0-4a2c-9c04-7cb955a8f0f9_terseLabel_en-US" xlink:label="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of cumulative pre tax costs that will result in cash outlays</link:label>
    <link:label id="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays_label_en-US" xlink:label="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate Of Cumulative Pre Tax Costs That Will Result In Cash Outlays</link:label>
    <link:label id="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays_documentation_en-US" xlink:label="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of cumulative pre tax costs that will result in cash outlays (primarily from employee separation expense).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" xlink:href="mrk-20220930.xsd#mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" xlink:to="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_bc09ee32-5bd9-494f-bce1-da0af4b81920_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_aeb0893b-f6f7-45bd-ad07-8288f910b350_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_VaqtaMember_3fcf1a48-685b-486e-93f9-b5fa1c9088e6_terseLabel_en-US" xlink:label="lab_mrk_VaqtaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaqta</link:label>
    <link:label id="lab_mrk_VaqtaMember_label_en-US" xlink:label="lab_mrk_VaqtaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaqta [Member]</link:label>
    <link:label id="lab_mrk_VaqtaMember_documentation_en-US" xlink:label="lab_mrk_VaqtaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaqta [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VaqtaMember" xlink:href="mrk-20220930.xsd#mrk_VaqtaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_VaqtaMember" xlink:to="lab_mrk_VaqtaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther_841bc552-84c6-43b3-a037-5a3180f0f357_negatedTerseLabel_en-US" xlink:label="lab_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther_label_en-US" xlink:label="lab_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Other</link:label>
    <link:label id="lab_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther_documentation_en-US" xlink:label="lab_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther" xlink:href="mrk-20220930.xsd#mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther" xlink:to="lab_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SupplyCommitmentRemainingMinimumCoursesCommitted_604137db-a026-4db2-b373-08b71945f87f_terseLabel_en-US" xlink:label="lab_mrk_SupplyCommitmentRemainingMinimumCoursesCommitted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining minimum courses committed (in courses)</link:label>
    <link:label id="lab_mrk_SupplyCommitmentRemainingMinimumCoursesCommitted_label_en-US" xlink:label="lab_mrk_SupplyCommitmentRemainingMinimumCoursesCommitted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment, Remaining Minimum Courses Committed</link:label>
    <link:label id="lab_mrk_SupplyCommitmentRemainingMinimumCoursesCommitted_documentation_en-US" xlink:label="lab_mrk_SupplyCommitmentRemainingMinimumCoursesCommitted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment, Remaining Minimum Courses Committed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SupplyCommitmentRemainingMinimumCoursesCommitted" xlink:href="mrk-20220930.xsd#mrk_SupplyCommitmentRemainingMinimumCoursesCommitted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SupplyCommitmentRemainingMinimumCoursesCommitted" xlink:to="lab_mrk_SupplyCommitmentRemainingMinimumCoursesCommitted" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartner_52150292-b97e-474b-b755-d3255c1f1c01_terseLabel_en-US" xlink:label="lab_mrk_ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development payments to be made to a collaborative partner (up to)</link:label>
    <link:label id="lab_mrk_ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartner_label_en-US" xlink:label="lab_mrk_ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Payments to be Made to a Collaborative Partner</link:label>
    <link:label id="lab_mrk_ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartner_documentation_en-US" xlink:label="lab_mrk_ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Payments to be Made to a Collaborative Partner</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartner" xlink:href="mrk-20220930.xsd#mrk_ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartner" xlink:to="lab_mrk_ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartner" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_3f12d9b2-cda5-4c93-b70d-3a8bc0648423_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information About the Changes in Liabilities for Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_fd4014e3-1d78-4b2f-ae78-0caa86bc0af7_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DevelopmentMilestonesMember_4f32a889-8db7-4bba-95c6-4ac7021a19a4_terseLabel_en-US" xlink:label="lab_mrk_DevelopmentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestones</link:label>
    <link:label id="lab_mrk_DevelopmentMilestonesMember_label_en-US" xlink:label="lab_mrk_DevelopmentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestones [Member]</link:label>
    <link:label id="lab_mrk_DevelopmentMilestonesMember_documentation_en-US" xlink:label="lab_mrk_DevelopmentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestones [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DevelopmentMilestonesMember" xlink:href="mrk-20220930.xsd#mrk_DevelopmentMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DevelopmentMilestonesMember" xlink:to="lab_mrk_DevelopmentMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_c014d46e-d698-447b-982c-4adda42d6b05_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_76d3282c-cc2a-46bf-aee3-9e9868ba13e0_negatedLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends declared on common stock</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash" xlink:to="lab_us-gaap_DividendsCommonStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_dd609cef-92d7-4926-a5e5-054fc16d1750_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PotentialFutureMilestonePaymentsSalesBased_699f4646-a7ed-45f6-861e-9f924641432b_terseLabel_en-US" xlink:label="lab_mrk_PotentialFutureMilestonePaymentsSalesBased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future sales-based milestone payments</link:label>
    <link:label id="lab_mrk_PotentialFutureMilestonePaymentsSalesBased_label_en-US" xlink:label="lab_mrk_PotentialFutureMilestonePaymentsSalesBased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Future Milestone Payments Sales-Based</link:label>
    <link:label id="lab_mrk_PotentialFutureMilestonePaymentsSalesBased_documentation_en-US" xlink:label="lab_mrk_PotentialFutureMilestonePaymentsSalesBased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Future Milestone Payments Sales-Based</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PotentialFutureMilestonePaymentsSalesBased" xlink:href="mrk-20220930.xsd#mrk_PotentialFutureMilestonePaymentsSalesBased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PotentialFutureMilestonePaymentsSalesBased" xlink:to="lab_mrk_PotentialFutureMilestonePaymentsSalesBased" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_NoxafilMember_ec25835f-d2a9-4252-a1e7-ff9568fe21b2_terseLabel_en-US" xlink:label="lab_mrk_NoxafilMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noxafil</link:label>
    <link:label id="lab_mrk_NoxafilMember_label_en-US" xlink:label="lab_mrk_NoxafilMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noxafil [Member]</link:label>
    <link:label id="lab_mrk_NoxafilMember_documentation_en-US" xlink:label="lab_mrk_NoxafilMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noxafil [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NoxafilMember" xlink:href="mrk-20220930.xsd#mrk_NoxafilMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_NoxafilMember" xlink:to="lab_mrk_NoxafilMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusDomain_37318244-897c-4f85-bb0f-6c45aec9b0c8_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_db894bfe-c9c8-4c2c-8624-b73962af4cce_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock ($0.50&#160;par value)</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_758d4dec-5e53-4611-8d72-c428df594ead_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">&#160;&#160; Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3ae3dd8f-7f74-4373-93c0-3df645afb9d2_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of taxes</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_86420c39-63b5-4396-9c2f-b385867c0360_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_0c74efb1-7284-4052-8099-4aaf37f6e986_totalLabel_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss) before reclassification adjustments, net of taxes</link:label>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, before Reclassifications, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:to="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_8be22a47-d60f-4a86-b33e-8358337d7a14_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of treasury stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapital_b08d5e14-ebb2-4521-b708-d8c5236da23f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapital" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net changes in assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapital_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapital" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_2a8c8b4d-8657-4035-a79e-b90ae8c9ddb3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_7402d3ba-4aef-4467-b0f6-1a21597215a2_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, beginning balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_e5be9f45-83b5-4682-b0e7-4bd1b6275905_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, ending balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_5c648490-5237-464c-86ea-aa01f9429887_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_4c82b7ae-11cc-4d24-a892-05b28ea4908c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_f117fe46-d3ad-4e1f-869c-ccd1ee9c3c2b_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_fabd3e13-31b0-4c4e-9402-5e66ffa97988_verboseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables included in Other current assets</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_9e56ae32-465d-43fa-89cd-3ec7aef7dabe_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_9cb6d3c6-49de-49d4-ab05-93e8b9aad587_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_8c8a07ab-6b3c-4e05-a5ec-a6a92afa7eec_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_008c0e0c-cd5b-47dd-9916-945e273f5a17_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_f65b0ee0-3a57-49e2-aedd-6f792de7dd9e_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit plan net (loss) gain and prior service (cost) credit, net of amortization</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_99d7e0d0-ad2d-4df1-94bc-9d17d1519d60_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_496d49f8-a0e0-4447-bacc-c3d19cbd6d25_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charge for the acquisition of Pandion Therapeutics, Inc.</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Asset Acquired Other than Through Business Combination, Written-off</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:to="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_fa2be14f-6655-48d9-a8ba-e2d7fb6d4952_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock shares purchased (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_59390c9b-6f69-4a8a-a5e5-858f6497f0b5_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_c3e7f70f-6346-4c07-b73c-1ab12191b41c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Income of discontinued operations attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_JanuviaAndJanumetMember_59be21a2-edc3-413b-9cad-19e068997e7b_terseLabel_en-US" xlink:label="lab_mrk_JanuviaAndJanumetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Januvia and Janumet</link:label>
    <link:label id="lab_mrk_JanuviaAndJanumetMember_label_en-US" xlink:label="lab_mrk_JanuviaAndJanumetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Januvia and Janumet [Member]</link:label>
    <link:label id="lab_mrk_JanuviaAndJanumetMember_documentation_en-US" xlink:label="lab_mrk_JanuviaAndJanumetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Januvia and Janumet</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_JanuviaAndJanumetMember" xlink:href="mrk-20220930.xsd#mrk_JanuviaAndJanumetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_JanuviaAndJanumetMember" xlink:to="lab_mrk_JanuviaAndJanumetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_75ae9b00-2269-4e7b-92fb-38dee3d6d29e_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_1fbf5442-773b-49fa-b21a-37f58a6f2897_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_649c7f88-eae7-485f-9ce2-564acd8c580e_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ProQuadMMRIIVarivaxMember_72470baf-7b44-4b89-9cfc-13fd97cefc69_terseLabel_en-US" xlink:label="lab_mrk_ProQuadMMRIIVarivaxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProQuad/M-M-R II/Varivax</link:label>
    <link:label id="lab_mrk_ProQuadMMRIIVarivaxMember_label_en-US" xlink:label="lab_mrk_ProQuadMMRIIVarivaxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProQuad MMR II Varivax [Member]</link:label>
    <link:label id="lab_mrk_ProQuadMMRIIVarivaxMember_documentation_en-US" xlink:label="lab_mrk_ProQuadMMRIIVarivaxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProQuad/M-M-R II/Varivax [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ProQuadMMRIIVarivaxMember" xlink:href="mrk-20220930.xsd#mrk_ProQuadMMRIIVarivaxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ProQuadMMRIIVarivaxMember" xlink:to="lab_mrk_ProQuadMMRIIVarivaxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_79c298f6-1f4d-4907-b833-ed65f155ed6c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:to="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_d6541f73-fce0-45e2-9785-45607c999f62_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_0a816b74-c43a-4c9a-a149-2d912fff2333_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable (net of allowance for doubtful accounts of $77 in 2022 and $62 in 2021)</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_469c1a9f-cd10-4b95-84ab-fdf8844e05ed_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of securities and other investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_6ac8804b-fcd4-4e56-b63a-9627ed50fe37_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_b21aeafb-f9ab-4b2d-8cc4-fa4e59fb6368_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_6908eeef-d094-4dd4-999a-c01f2784b76b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_9b038618-b978-4e81-a0ad-bf7fb51ad57c_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock_32e50e2f-6010-470c-a9a9-9ff46aaae8e6_terseLabel_en-US" xlink:label="lab_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis</link:label>
    <link:label id="lab_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offsetting Assets And Liabilities [Table Text Block]</link:label>
    <link:label id="lab_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock_documentation_en-US" xlink:label="lab_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of derivative positions subject to master netting arrangements as if they were presented on a net basis.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock" xlink:href="mrk-20220930.xsd#mrk_OffsettingAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_beec20a3-8587-41b3-babd-ad3fa4d425aa_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignPlanMember_f3b35de8-133c-4c21-b8f1-ccd5b1134953_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_ForeignPlanMember_label_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignPlanMember" xlink:to="lab_us-gaap_ForeignPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet_467b9c32-d342-4ec9-a1f1-b226deae6916_negatedTerseLabel_en-US" xlink:label="lab_mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense, net</link:label>
    <link:label id="lab_mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet_label_en-US" xlink:label="lab_mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Income (Expense), Net</link:label>
    <link:label id="lab_mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet_documentation_en-US" xlink:label="lab_mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet" xlink:href="mrk-20220930.xsd#mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet" xlink:to="lab_mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash_f8dcecf6-eb97-4d45-b736-31561f6b4f56_terseLabel_en-US" xlink:label="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of cumulative pre tax costs that will be noncash</link:label>
    <link:label id="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash_label_en-US" xlink:label="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate Of Cumulative Pre Tax Costs That Will Be Noncash</link:label>
    <link:label id="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash_documentation_en-US" xlink:label="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of cumulative pre tax costs that will be noncash.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash" xlink:href="mrk-20220930.xsd#mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash" xlink:to="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_bc0c21a9-0238-42f8-9f5f-f5231d7f5d5a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Operating Activities of Continuing Operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SimponiMember_b87adfc0-8b52-4fd0-8391-e68a9c333517_terseLabel_en-US" xlink:label="lab_mrk_SimponiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Simponi</link:label>
    <link:label id="lab_mrk_SimponiMember_label_en-US" xlink:label="lab_mrk_SimponiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Simponi [Member]</link:label>
    <link:label id="lab_mrk_SimponiMember_documentation_en-US" xlink:label="lab_mrk_SimponiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Simponi [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SimponiMember" xlink:href="mrk-20220930.xsd#mrk_SimponiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SimponiMember" xlink:to="lab_mrk_SimponiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DebtSecuritiesandEquitySecuritiesFVNI_641eb644-90a9-4c76-9589-b52b65d58c20_totalLabel_en-US" xlink:label="lab_mrk_DebtSecuritiesandEquitySecuritiesFVNI" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt and publicly traded equity securities, fair value</link:label>
    <link:label id="lab_mrk_DebtSecuritiesandEquitySecuritiesFVNI_label_en-US" xlink:label="lab_mrk_DebtSecuritiesandEquitySecuritiesFVNI" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities and Equity Securities, FV-NI</link:label>
    <link:label id="lab_mrk_DebtSecuritiesandEquitySecuritiesFVNI_documentation_en-US" xlink:label="lab_mrk_DebtSecuritiesandEquitySecuritiesFVNI" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities and Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI" xlink:href="mrk-20220930.xsd#mrk_DebtSecuritiesandEquitySecuritiesFVNI"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI" xlink:to="lab_mrk_DebtSecuritiesandEquitySecuritiesFVNI" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_1967c1f5-b4e1-4e3d-92df-331c63f21d81_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration received</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_3da115eb-c6f1-4f3a-8d62-813efe9da8d9_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_a8bf5fa4-b61e-43ad-828d-30074686a18f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LossContingencyRecoveryFromThirdPartyBenchTrialPeriod_f26dec29-6fef-4fdf-8cc8-0a940873b1d7_terseLabel_en-US" xlink:label="lab_mrk_LossContingencyRecoveryFromThirdPartyBenchTrialPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, recovery from third party, bench trial period</link:label>
    <link:label id="lab_mrk_LossContingencyRecoveryFromThirdPartyBenchTrialPeriod_label_en-US" xlink:label="lab_mrk_LossContingencyRecoveryFromThirdPartyBenchTrialPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Recovery From Third Party, Bench Trial Period</link:label>
    <link:label id="lab_mrk_LossContingencyRecoveryFromThirdPartyBenchTrialPeriod_documentation_en-US" xlink:label="lab_mrk_LossContingencyRecoveryFromThirdPartyBenchTrialPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Recovery From Third Party, Bench Trial Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LossContingencyRecoveryFromThirdPartyBenchTrialPeriod" xlink:href="mrk-20220930.xsd#mrk_LossContingencyRecoveryFromThirdPartyBenchTrialPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LossContingencyRecoveryFromThirdPartyBenchTrialPeriod" xlink:to="lab_mrk_LossContingencyRecoveryFromThirdPartyBenchTrialPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_def195ed-d504-41a8-9a1d-f4c028cc9362_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_20271569-c0ac-46db-b018-cfebc758f87b_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_7d69674a-5714-4086-9859-b8f0d46bcf80_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_994951e5-2726-4f89-98b5-5fd3f14fe13f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in estimated fair value</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_77495484-c71d-438a-8802-434713b7571f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0c737aa8-f3dd-48d9-b830-26aed5b7a882_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_abb8d0d5-c5a0-48e1-b176-0da4d9264911_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_8fe8a822-d56f-4aad-98ad-cb9978e247b9_negatedLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustments, pretax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from AOCI, Current Period, before Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LongTermDebtCurrentMaturitiesMember_05e8949e-d88c-4a41-8ccf-aeb9302fd3d1_terseLabel_en-US" xlink:label="lab_mrk_LongTermDebtCurrentMaturitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans payable and current portion of long-term debt</link:label>
    <link:label id="lab_mrk_LongTermDebtCurrentMaturitiesMember_label_en-US" xlink:label="lab_mrk_LongTermDebtCurrentMaturitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt, Current Maturities [Member]</link:label>
    <link:label id="lab_mrk_LongTermDebtCurrentMaturitiesMember_documentation_en-US" xlink:label="lab_mrk_LongTermDebtCurrentMaturitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt, Current Maturities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtCurrentMaturitiesMember" xlink:href="mrk-20220930.xsd#mrk_LongTermDebtCurrentMaturitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LongTermDebtCurrentMaturitiesMember" xlink:to="lab_mrk_LongTermDebtCurrentMaturitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity_7d43a78e-388e-4179-9b36-508451db6e4c_terseLabel_en-US" xlink:label="lab_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash activity</link:label>
    <link:label id="lab_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity_label_en-US" xlink:label="lab_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve, Increase (Decrease) Noncash Activity</link:label>
    <link:label id="lab_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity_documentation_en-US" xlink:label="lab_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash activity affecting the restructuring reserve, including accelerated depreciation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity" xlink:href="mrk-20220930.xsd#mrk_RestructuringReserveIncreaseDecreaseNoncashActivity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity" xlink:to="lab_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_3389b2d6-8257-4b0f-ab97-b1a7cfd869a1_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount_6495826c-3c92-4a00-8509-2c97d5327469_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative unrealized losses on investments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDiscontinuedOperationsMember_0212f188-a087-40ab-b161-e1282bf2137f_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_SegmentDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_SegmentDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDiscontinuedOperationsMember" xlink:to="lab_us-gaap_SegmentDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_FosamaxMember_c0172491-d008-48a9-abdf-a48d21681f8d_terseLabel_en-US" xlink:label="lab_mrk_FosamaxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fosamax</link:label>
    <link:label id="lab_mrk_FosamaxMember_label_en-US" xlink:label="lab_mrk_FosamaxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fosamax [Member]</link:label>
    <link:label id="lab_mrk_FosamaxMember_documentation_en-US" xlink:label="lab_mrk_FosamaxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fosamax [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FosamaxMember" xlink:href="mrk-20220930.xsd#mrk_FosamaxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_FosamaxMember" xlink:to="lab_mrk_FosamaxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_658c621e-b306-49cc-8643-894cb7f7bf98_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OtherNonoperatingIncomeExpenseOther_f2f9dfb8-4b6c-48ba-8ad4-60b3ddfa32f4_negatedLabel_en-US" xlink:label="lab_mrk_OtherNonoperatingIncomeExpenseOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_mrk_OtherNonoperatingIncomeExpenseOther_label_en-US" xlink:label="lab_mrk_OtherNonoperatingIncomeExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income Expense, Other</link:label>
    <link:label id="lab_mrk_OtherNonoperatingIncomeExpenseOther_documentation_en-US" xlink:label="lab_mrk_OtherNonoperatingIncomeExpenseOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other nonoperating income and expense items not separately disclosed.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherNonoperatingIncomeExpenseOther" xlink:href="mrk-20220930.xsd#mrk_OtherNonoperatingIncomeExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OtherNonoperatingIncomeExpenseOther" xlink:to="lab_mrk_OtherNonoperatingIncomeExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_ad09b9b3-b235-46ec-be10-afa22c134ecf_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_2a4c6709-a165-42fe-83ba-d41b1635831e_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_ff044e3c-a32a-428a-b821-d433ac13c251_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_c9305c0b-b5d5-4175-9703-543a0624d55d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity of Counterparty, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity of Counterparty, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_974e0697-f084-4b2e-bd5e-a0c1b07d2d43_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Standards and Recently Issued Accounting Standards Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusAxis_e745014a-a406-4656-8aef-04fb23dac52a_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_KeytrudaMember_94b01fc4-a45b-4e60-92e3-f3b05ec1bf65_terseLabel_en-US" xlink:label="lab_mrk_KeytrudaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Keytruda</link:label>
    <link:label id="lab_mrk_KeytrudaMember_label_en-US" xlink:label="lab_mrk_KeytrudaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Keytruda [Member]</link:label>
    <link:label id="lab_mrk_KeytrudaMember_documentation_en-US" xlink:label="lab_mrk_KeytrudaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Keytruda [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_KeytrudaMember" xlink:href="mrk-20220930.xsd#mrk_KeytrudaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_KeytrudaMember" xlink:to="lab_mrk_KeytrudaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_511656cb-7eeb-4c17-aee1-74670dbb3b7c_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investments without readily determinable fair values</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LossContingencyTrialPeriod_f6512ea2-4a8b-4774-ae70-a9cf9ba1053a_terseLabel_en-US" xlink:label="lab_mrk_LossContingencyTrialPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, trial period</link:label>
    <link:label id="lab_mrk_LossContingencyTrialPeriod_label_en-US" xlink:label="lab_mrk_LossContingencyTrialPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Trial Period</link:label>
    <link:label id="lab_mrk_LossContingencyTrialPeriod_documentation_en-US" xlink:label="lab_mrk_LossContingencyTrialPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Trial Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LossContingencyTrialPeriod" xlink:href="mrk-20220930.xsd#mrk_LossContingencyTrialPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LossContingencyTrialPeriod" xlink:to="lab_mrk_LossContingencyTrialPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_60345eb0-54c6-45bf-9c68-5ab7fa36fb34_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total (approximates current cost)</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_e6c90ac9-4431-419c-a56b-a1765a73ca4d_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_36b7dab3-af3b-4e8f-ab32-483d63fd8442_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_6237c837-c0c7-4d61-88f7-876f2160273a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_b1668b1d-ae0b-4456-b297-3efdddd8b608_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityFundsMember_2ae6295d-23a6-4ed6-9545-40f5fe3550e6_terseLabel_en-US" xlink:label="lab_us-gaap_EquityFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Funds</link:label>
    <link:label id="lab_us-gaap_EquityFundsMember_label_en-US" xlink:label="lab_us-gaap_EquityFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityFundsMember" xlink:to="lab_us-gaap_EquityFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AllianceRevenueAdempasVerquvoMember_d4fe0408-6bec-423e-b441-e31c77905973_terseLabel_en-US" xlink:label="lab_mrk_AllianceRevenueAdempasVerquvoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Adempas/Verquvo</link:label>
    <link:label id="lab_mrk_AllianceRevenueAdempasVerquvoMember_label_en-US" xlink:label="lab_mrk_AllianceRevenueAdempasVerquvoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Adempas/Verquvo [Member]</link:label>
    <link:label id="lab_mrk_AllianceRevenueAdempasVerquvoMember_documentation_en-US" xlink:label="lab_mrk_AllianceRevenueAdempasVerquvoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Adempas/Verquvo</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AllianceRevenueAdempasVerquvoMember" xlink:href="mrk-20220930.xsd#mrk_AllianceRevenueAdempasVerquvoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AllianceRevenueAdempasVerquvoMember" xlink:to="lab_mrk_AllianceRevenueAdempasVerquvoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b9f3dc41-6ae6-41d1-92ab-ba9d3f0f7122_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income from continuing operations to net cash provided by operating activities of continuing operations:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_e1be0f2b-a886-476a-993e-95fcc0580979_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes on Income from Continuing Operations</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_14b62722-44b9-4b55-91ee-d8605daeabeb_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3b249cc4-1cf7-4db3-9c3e-65e0515102a7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_121f73cb-458c-45cc-acdb-e7853aa89561_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_7f94c109-6ee3-47bb-9264-d49308bddd70_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_a2a4e64d-92d6-48d4-8a1d-525923e98a37_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_0d35998f-c89a-442a-9154-6ae43c343294_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_f9b076e4-c7b7-41b3-b7c1-087799f54733_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_14bb3fa6-f013-4f68-b038-128328fc52ae_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_a53b3890-869d-4d91-95d1-e634264c2b1b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:to="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SalesBasedMilestonesMember_1086b447-e1b3-4047-82ce-6897f1bb7e21_terseLabel_en-US" xlink:label="lab_mrk_SalesBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Milestones</link:label>
    <link:label id="lab_mrk_SalesBasedMilestonesMember_label_en-US" xlink:label="lab_mrk_SalesBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Milestones [Member]</link:label>
    <link:label id="lab_mrk_SalesBasedMilestonesMember_documentation_en-US" xlink:label="lab_mrk_SalesBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Milestones [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesBasedMilestonesMember" xlink:href="mrk-20220930.xsd#mrk_SalesBasedMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SalesBasedMilestonesMember" xlink:to="lab_mrk_SalesBasedMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_9f64f3ad-cc0b-44cf-9841-b04866f118f8_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic Earnings per Common Share Attributable to Merck &amp; Co., Inc. Common Shareholders:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_9e29fe24-9cbf-45f5-85e5-71e2846316e8_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_12369569-4572-4bbc-9156-72ad2d8993ce_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average common shares outstanding assuming dilution (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_2a58ac9b-18b9-4296-b40e-aecbeb1b682b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeCollateralRightToReclaimCash_040eb117-55b2-46fc-b298-266c273f7c42_negatedLabel_en-US" xlink:label="lab_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash collateral received, liability</link:label>
    <link:label id="lab_us-gaap_DerivativeCollateralRightToReclaimCash_label_en-US" xlink:label="lab_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Cash Not Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:to="lab_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_c5e3b849-f4d5-4664-8ba0-cc04b72f5ef1_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Derivative, Liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_bd9b6a4a-9583-4b12-96bc-8aa326e25b65_netLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross amounts recognized in the consolidated balance sheet, liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_74a7014b-59d2-44db-a697-fbc48cf82585_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0c8d92a9-f838-4da3-b4aa-1a813d407eaa_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_476f48ba-5190-45e6-ab0e-35f038c7b85f_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_cfba367b-f7ee-4bb8-96c5-1563f3f48366_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_8258e404-35a4-4879-8214-39b6b4324088_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFVNINoncurrent_dea84999-8419-445c-a6b9-3706cb146322_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities, noncurrent</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFVNINoncurrent_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b1409fb4-729b-45ac-9781-2f366167337e_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_acbfe855-452a-4ac4-8e07-40a6b7dfe1a7_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized losses recognized on investments in equity securities without readily determinable fair values</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_949c0f8d-436f-4ef3-8c76-c190a6cb955f_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6de8add9-46ae-4afb-ba8c-9c794e56d27e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ManufacturingAndSupplyAgreementsMember_7bc2a696-2d44-4dce-84c1-1e1bcbc0ba71_terseLabel_en-US" xlink:label="lab_mrk_ManufacturingAndSupplyAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing and supply agreements</link:label>
    <link:label id="lab_mrk_ManufacturingAndSupplyAgreementsMember_label_en-US" xlink:label="lab_mrk_ManufacturingAndSupplyAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing and supply agreements [Member]</link:label>
    <link:label id="lab_mrk_ManufacturingAndSupplyAgreementsMember_documentation_en-US" xlink:label="lab_mrk_ManufacturingAndSupplyAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing and supply agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ManufacturingAndSupplyAgreementsMember" xlink:href="mrk-20220930.xsd#mrk_ManufacturingAndSupplyAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ManufacturingAndSupplyAgreementsMember" xlink:to="lab_mrk_ManufacturingAndSupplyAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_34e2eae7-64a7-47a2-b333-2ec5a6283fee_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information on Investments in Debt and Equity Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_bec3e1bf-d59c-4981-9cc3-0293955c2a9c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2022 and 2021</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringChargesMember_51d793ea-ea3e-42c9-9a27-89b5925a6e00_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring costs</link:label>
    <link:label id="lab_us-gaap_RestructuringChargesMember_label_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringChargesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringChargesMember" xlink:to="lab_us-gaap_RestructuringChargesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartiesAmountInCostOfSales_eda2436c-643a-418c-b431-16bc2449b6cf_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartiesAmountInCostOfSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party amount in cost of sales</link:label>
    <link:label id="lab_us-gaap_RelatedPartiesAmountInCostOfSales_label_en-US" xlink:label="lab_us-gaap_RelatedPartiesAmountInCostOfSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Parties Amount in Cost of Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartiesAmountInCostOfSales" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartiesAmountInCostOfSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartiesAmountInCostOfSales" xlink:to="lab_us-gaap_RelatedPartiesAmountInCostOfSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_1cece64d-91e0-41b8-be0a-cea9c0e54a30_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from Discontinued Operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_282bd813-5d20-4908-b787-4a5f0fa4f6d6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LynparzaMember_84458c84-5a3a-4441-a707-2ce7e89ed332_terseLabel_en-US" xlink:label="lab_mrk_LynparzaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lynparza</link:label>
    <link:label id="lab_mrk_LynparzaMember_label_en-US" xlink:label="lab_mrk_LynparzaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lynparza [Member]</link:label>
    <link:label id="lab_mrk_LynparzaMember_documentation_en-US" xlink:label="lab_mrk_LynparzaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lynparza [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LynparzaMember" xlink:href="mrk-20220930.xsd#mrk_LynparzaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LynparzaMember" xlink:to="lab_mrk_LynparzaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AsiaPacificMember_8c38b5aa-00cb-4de1-99c9-c2e0ec7865d7_terseLabel_en-US" xlink:label="lab_srt_AsiaPacificMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia Pacific (other than China and Japan)</link:label>
    <link:label id="lab_srt_AsiaPacificMember_label_en-US" xlink:label="lab_srt_AsiaPacificMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia Pacific [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AsiaPacificMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AsiaPacificMember" xlink:to="lab_srt_AsiaPacificMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_dca84ba3-03e4-488c-9419-7ae61cc14ad2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_01bb0b83-ea2c-43b0-9f53-d04dad13ab6d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_e0225956-64fa-4a55-b02b-b74ece3491e8_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_InventoryNetAndInventoryNoncurrent_6e5c1308-9b19-4490-a3f8-cd48e8d81a97_totalLabel_en-US" xlink:label="lab_mrk_InventoryNetAndInventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current and noncurrent inventories</link:label>
    <link:label id="lab_mrk_InventoryNetAndInventoryNoncurrent_label_en-US" xlink:label="lab_mrk_InventoryNetAndInventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Net And Inventory Noncurrent</link:label>
    <link:label id="lab_mrk_InventoryNetAndInventoryNoncurrent_documentation_en-US" xlink:label="lab_mrk_InventoryNetAndInventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total of current and noncurrent inventories.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryNetAndInventoryNoncurrent" xlink:href="mrk-20220930.xsd#mrk_InventoryNetAndInventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_InventoryNetAndInventoryNoncurrent" xlink:to="lab_mrk_InventoryNetAndInventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_2838eac9-9347-4697-8ad0-08e08310a888_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Costs of Goods Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_ee2fadd7-9afd-4047-9aaf-92a3fccb40c4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Net Investment Hedges on OCI and the Consolidated Statement of Income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_944481d5-abc4-427a-8be7-7349c54aad08_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $71 and $103 at January 1, 2022 and 2021, respectively, included in Other current assets)</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e10cafc4-4297-4be5-9fad-7b52207f97c1_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $134 and $30 at September&#160;30, 2022 and 2021, respectively, included in Other current assets)</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ZetiaantitrustlitigationMember_07f1ac4c-e1a1-4239-9a47-41e8962e2489_terseLabel_en-US" xlink:label="lab_mrk_ZetiaantitrustlitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zetia antitrust litigation</link:label>
    <link:label id="lab_mrk_ZetiaantitrustlitigationMember_label_en-US" xlink:label="lab_mrk_ZetiaantitrustlitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zetia antitrust litigation [Member]</link:label>
    <link:label id="lab_mrk_ZetiaantitrustlitigationMember_documentation_en-US" xlink:label="lab_mrk_ZetiaantitrustlitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zetia antitrust litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ZetiaantitrustlitigationMember" xlink:href="mrk-20220930.xsd#mrk_ZetiaantitrustlitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ZetiaantitrustlitigationMember" xlink:to="lab_mrk_ZetiaantitrustlitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_fbfbfba6-324a-44fb-a920-3ad3df4d2d5b_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock_36f06e9c-ef2b-4bab-8993-a0cf3a35380e_terseLabel_en-US" xlink:label="lab_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, Research Collaborations and License Agreements</link:label>
    <link:label id="lab_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock_label_en-US" xlink:label="lab_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions Research Collaborations And License Agreements [Text Block]</link:label>
    <link:label id="lab_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock_documentation_en-US" xlink:label="lab_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information related to acquisitions, divestitures, research collaborations and license agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock" xlink:href="mrk-20220930.xsd#mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock" xlink:to="lab_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2c8a2729-3b72-42f7-9499-b52e73232523_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts_0cefdc51-5c1a-45b8-ad3e-4e53c04130ed_terseLabel_en-US" xlink:label="lab_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional funding by others, percentage of development costs</link:label>
    <link:label id="lab_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts_label_en-US" xlink:label="lab_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Additional Funding By Others, Percentage Of Development Costs</link:label>
    <link:label id="lab_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts_documentation_en-US" xlink:label="lab_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Additional Funding By Others, Percentage Of Development Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts" xlink:href="mrk-20220930.xsd#mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts" xlink:to="lab_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_c1c552b5-31a0-44be-9020-6102c75303c5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_57143302-d5d7-419f-b367-265fd6214ae2_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Merck &amp; Co., Inc., basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_2691faed-015d-40b7-a9bb-6c2b2885f753_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_769249be-a882-4ddf-8c99-3440c1b62d84_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Curtailments</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:to="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_311a1fbd-9ea8-43f3-a2cf-d6059f1eb384_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_205615d3-9775-4e2f-9d58-48589d150f78_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_76c4eee1-da06-4a13-b689-d5b89fe4cc11_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PatentInfringementLawsuitAgainstZydusWorldwideDMCCZydusPharmaceuticalsUSAIncAndCadilaHealthcareLtdMember_64a0d71f-c98b-4298-b648-baf40a64b846_terseLabel_en-US" xlink:label="lab_mrk_PatentInfringementLawsuitAgainstZydusWorldwideDMCCZydusPharmaceuticalsUSAIncAndCadilaHealthcareLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent Infringement Lawsuit Against Zydus</link:label>
    <link:label id="lab_mrk_PatentInfringementLawsuitAgainstZydusWorldwideDMCCZydusPharmaceuticalsUSAIncAndCadilaHealthcareLtdMember_label_en-US" xlink:label="lab_mrk_PatentInfringementLawsuitAgainstZydusWorldwideDMCCZydusPharmaceuticalsUSAIncAndCadilaHealthcareLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent Infringement Lawsuit Against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc. And Cadila Healthcare Ltd. [Member]</link:label>
    <link:label id="lab_mrk_PatentInfringementLawsuitAgainstZydusWorldwideDMCCZydusPharmaceuticalsUSAIncAndCadilaHealthcareLtdMember_documentation_en-US" xlink:label="lab_mrk_PatentInfringementLawsuitAgainstZydusWorldwideDMCCZydusPharmaceuticalsUSAIncAndCadilaHealthcareLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent Infringement Lawsuit Against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc. And Cadila Healthcare Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PatentInfringementLawsuitAgainstZydusWorldwideDMCCZydusPharmaceuticalsUSAIncAndCadilaHealthcareLtdMember" xlink:href="mrk-20220930.xsd#mrk_PatentInfringementLawsuitAgainstZydusWorldwideDMCCZydusPharmaceuticalsUSAIncAndCadilaHealthcareLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PatentInfringementLawsuitAgainstZydusWorldwideDMCCZydusPharmaceuticalsUSAIncAndCadilaHealthcareLtdMember" xlink:to="lab_mrk_PatentInfringementLawsuitAgainstZydusWorldwideDMCCZydusPharmaceuticalsUSAIncAndCadilaHealthcareLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A1.375Notesdue2036Member_ec06eacc-9514-4165-bc13-1320fe60af62_terseLabel_en-US" xlink:label="lab_mrk_A1.375Notesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% Notes due 2036</link:label>
    <link:label id="lab_mrk_A1.375Notesdue2036Member_label_en-US" xlink:label="lab_mrk_A1.375Notesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% Notes due 2036 [Member]</link:label>
    <link:label id="lab_mrk_A1.375Notesdue2036Member_documentation_en-US" xlink:label="lab_mrk_A1.375Notesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% Notes due 2036 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.375Notesdue2036Member" xlink:href="mrk-20220930.xsd#mrk_A1.375Notesdue2036Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A1.375Notesdue2036Member" xlink:to="lab_mrk_A1.375Notesdue2036Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_73243370-8da7-423e-bf56-5fadd25eee5a_negatedLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange losses</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_e9251db0-9158-4b41-abf5-6fb0d52fb06c_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_831531fa-1e2a-413c-aebb-45eceff6cf8a_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_bc4aabf7-94bf-4233-8b8d-9df3df5cd32b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fbb58f02-d80d-4407-ba4c-864676297308_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Assets and Liabilities Measured at Fair Value on Recurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AllianceRevenueReblozylMember_6f484c21-f637-4e07-9a53-13caab7f5cbb_terseLabel_en-US" xlink:label="lab_mrk_AllianceRevenueReblozylMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance Revenue - Reblozyl</link:label>
    <link:label id="lab_mrk_AllianceRevenueReblozylMember_label_en-US" xlink:label="lab_mrk_AllianceRevenueReblozylMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance Revenue - Reblozyl [Member]</link:label>
    <link:label id="lab_mrk_AllianceRevenueReblozylMember_documentation_en-US" xlink:label="lab_mrk_AllianceRevenueReblozylMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance Revenue - Reblozyl</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AllianceRevenueReblozylMember" xlink:href="mrk-20220930.xsd#mrk_AllianceRevenueReblozylMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AllianceRevenueReblozylMember" xlink:to="lab_mrk_AllianceRevenueReblozylMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_e16ac0df-8eba-441b-ad4a-70c8f9b952c3_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_00bb4f20-13cf-485d-a34d-1d24fc2ed714_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amounts, asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:to="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_a3a29d20-8bc2-4a4e-bbdc-8e2df9e7a07b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face amount of debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_48a0e1a6-14f1-41bf-9b36-ff5942366770_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_29d1a907-1377-44f0-844d-402876a2dd3d_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS)</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_d1934879-fc0d-4c92-ac3b-33351632bd64_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_d077f010-6a67-426a-ad46-bdb4d5b8ac85_totalLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from discontinued operations before taxes</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, before Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_499a323e-32f0-40a5-a8f0-9e66aa1d62f0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of taxes</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_83637780-33a8-4145-aab3-67edf9969e90_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, new claims filed</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_4a82db22-b67d-4b8f-a196-af156a63992e_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income Attributable to Merck&#160;&amp; Co., Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CancidasMember_202a8f7e-c93f-46a8-a19f-a15e4cc089ea_terseLabel_en-US" xlink:label="lab_mrk_CancidasMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancidas</link:label>
    <link:label id="lab_mrk_CancidasMember_label_en-US" xlink:label="lab_mrk_CancidasMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancidas [Member]</link:label>
    <link:label id="lab_mrk_CancidasMember_documentation_en-US" xlink:label="lab_mrk_CancidasMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancidas [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CancidasMember" xlink:href="mrk-20220930.xsd#mrk_CancidasMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CancidasMember" xlink:to="lab_mrk_CancidasMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_8cab44e3-e745-4ae5-bb0f-deb2770e5235_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_40ef1d5f-7990-47f4-9361-f165962d31bf_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by Operating Activities of Continuing Operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_76e8684b-8919-4f7e-80ea-e8120df6ee36_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Used in Investing Activities of Continuing Operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PotentialFutureMilestonePaymentsRegulatory_669c55d9-cd30-4a2f-84e4-c4f5eed0bf33_terseLabel_en-US" xlink:label="lab_mrk_PotentialFutureMilestonePaymentsRegulatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future regulatory milestone payments</link:label>
    <link:label id="lab_mrk_PotentialFutureMilestonePaymentsRegulatory_label_en-US" xlink:label="lab_mrk_PotentialFutureMilestonePaymentsRegulatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Future Milestone Payments Regulatory</link:label>
    <link:label id="lab_mrk_PotentialFutureMilestonePaymentsRegulatory_documentation_en-US" xlink:label="lab_mrk_PotentialFutureMilestonePaymentsRegulatory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Future Milestone Payments Regulatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PotentialFutureMilestonePaymentsRegulatory" xlink:href="mrk-20220930.xsd#mrk_PotentialFutureMilestonePaymentsRegulatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PotentialFutureMilestonePaymentsRegulatory" xlink:to="lab_mrk_PotentialFutureMilestonePaymentsRegulatory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2ff0a19a-42f4-40ce-a545-2df1f451ccea_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_679e989c-30c1-42e8-909a-a6a9ef7231b7_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_231cc7c8-5894-488b-b621-40d512452ce9_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_486ed6b9-c4ed-4559-a766-51ea1107cd11_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_156abb02-b380-424a-829a-0883a082bad7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RidgebackBiotherapeuticsLPMember_c377b82b-9623-452a-bcbc-5725131eab74_terseLabel_en-US" xlink:label="lab_mrk_RidgebackBiotherapeuticsLPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ridgeback Biotherapeutics LP</link:label>
    <link:label id="lab_mrk_RidgebackBiotherapeuticsLPMember_label_en-US" xlink:label="lab_mrk_RidgebackBiotherapeuticsLPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ridgeback Biotherapeutics LP [Member]</link:label>
    <link:label id="lab_mrk_RidgebackBiotherapeuticsLPMember_documentation_en-US" xlink:label="lab_mrk_RidgebackBiotherapeuticsLPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ridgeback Biotherapeutics LP</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RidgebackBiotherapeuticsLPMember" xlink:href="mrk-20220930.xsd#mrk_RidgebackBiotherapeuticsLPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RidgebackBiotherapeuticsLPMember" xlink:to="lab_mrk_RidgebackBiotherapeuticsLPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_FirstCommercialSaleMilestonesMember_50d390e0-b50a-4618-bb8c-061ab2febaed_terseLabel_en-US" xlink:label="lab_mrk_FirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Commercial Sale Milestones</link:label>
    <link:label id="lab_mrk_FirstCommercialSaleMilestonesMember_label_en-US" xlink:label="lab_mrk_FirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Commercial Sale Milestones [Member]</link:label>
    <link:label id="lab_mrk_FirstCommercialSaleMilestonesMember_documentation_en-US" xlink:label="lab_mrk_FirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Commercial Sale Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FirstCommercialSaleMilestonesMember" xlink:href="mrk-20220930.xsd#mrk_FirstCommercialSaleMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_FirstCommercialSaleMilestonesMember" xlink:to="lab_mrk_FirstCommercialSaleMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_76a57611-fdc7-4f86-9903-72a0290873da_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_d789f9a0-4201-49be-9555-922ca698c2c4_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from discontinued operations, net of taxes and amounts attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_5c871de1-4209-440a-a705-b8ba5877bdb4_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Payments) receipts, net</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CostsExpensesAndOther_06fd8485-641a-48eb-8c22-395a2a6f4c41_totalLabel_en-US" xlink:label="lab_mrk_CostsExpensesAndOther" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Costs, Expenses and Other</link:label>
    <link:label id="lab_mrk_CostsExpensesAndOther_label_en-US" xlink:label="lab_mrk_CostsExpensesAndOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs Expenses And Other</link:label>
    <link:label id="lab_mrk_CostsExpensesAndOther_documentation_en-US" xlink:label="lab_mrk_CostsExpensesAndOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total of cost of sales, operating expenses and nonoperating income or expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CostsExpensesAndOther" xlink:href="mrk-20220930.xsd#mrk_CostsExpensesAndOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CostsExpensesAndOther" xlink:to="lab_mrk_CostsExpensesAndOther" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_BristolMyersSquibbMember_36d0f047-f914-4ed1-a88d-dfca65a473b4_terseLabel_en-US" xlink:label="lab_mrk_BristolMyersSquibbMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol Myers Squibb</link:label>
    <link:label id="lab_mrk_BristolMyersSquibbMember_label_en-US" xlink:label="lab_mrk_BristolMyersSquibbMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol Myers Squibb [Member]</link:label>
    <link:label id="lab_mrk_BristolMyersSquibbMember_documentation_en-US" xlink:label="lab_mrk_BristolMyersSquibbMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol Myers Squibb</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BristolMyersSquibbMember" xlink:href="mrk-20220930.xsd#mrk_BristolMyersSquibbMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_BristolMyersSquibbMember" xlink:to="lab_mrk_BristolMyersSquibbMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_JP_98818de4-8db6-46ae-bd43-6d967cf4e0cb_terseLabel_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan</link:label>
    <link:label id="lab_country_JP_label_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyIncomeNonoperating_bb5c636a-01b9-4548-8e67-b8314e692001_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties</link:label>
    <link:label id="lab_us-gaap_RoyaltyIncomeNonoperating_label_en-US" xlink:label="lab_us-gaap_RoyaltyIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Income, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyIncomeNonoperating" xlink:to="lab_us-gaap_RoyaltyIncomeNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RegulatoryMilestonesMember_491544bc-7818-4474-8d21-0d1c08f231db_terseLabel_en-US" xlink:label="lab_mrk_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones</link:label>
    <link:label id="lab_mrk_RegulatoryMilestonesMember_label_en-US" xlink:label="lab_mrk_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:label id="lab_mrk_RegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_mrk_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RegulatoryMilestonesMember" xlink:href="mrk-20220930.xsd#mrk_RegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RegulatoryMilestonesMember" xlink:to="lab_mrk_RegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RoyaltyRatePercentage_7379fb44-3b24-412c-b12b-118433b985e4_terseLabel_en-US" xlink:label="lab_mrk_RoyaltyRatePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty rate</link:label>
    <link:label id="lab_mrk_RoyaltyRatePercentage_label_en-US" xlink:label="lab_mrk_RoyaltyRatePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Rate, Percentage</link:label>
    <link:label id="lab_mrk_RoyaltyRatePercentage_documentation_en-US" xlink:label="lab_mrk_RoyaltyRatePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Rate, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RoyaltyRatePercentage" xlink:href="mrk-20220930.xsd#mrk_RoyaltyRatePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RoyaltyRatePercentage" xlink:to="lab_mrk_RoyaltyRatePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_9b91a21b-d8b9-4baf-9b74-25d2851521ce_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_2db15b79-1ce3-4c52-a888-636ad56be67a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement_4d8002d8-0b34-40eb-98dc-815c3433033d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase to pension liabilities due to remeasurement</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Remeasurement due to Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_d97a4058-60fa-4696-8b3e-e1486b877022_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DisposalGroupInclDiscontinuedOperationsDistributionReceived_d4741504-9e5d-436e-b201-41a11d669e48_terseLabel_en-US" xlink:label="lab_mrk_DisposalGroupInclDiscontinuedOperationsDistributionReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution from Organon &amp; Co.</link:label>
    <link:label id="lab_mrk_DisposalGroupInclDiscontinuedOperationsDistributionReceived_label_en-US" xlink:label="lab_mrk_DisposalGroupInclDiscontinuedOperationsDistributionReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Incl. Discontinued Operations Distribution Received</link:label>
    <link:label id="lab_mrk_DisposalGroupInclDiscontinuedOperationsDistributionReceived_documentation_en-US" xlink:label="lab_mrk_DisposalGroupInclDiscontinuedOperationsDistributionReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Incl. Discontinued Operations Distribution Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DisposalGroupInclDiscontinuedOperationsDistributionReceived" xlink:href="mrk-20220930.xsd#mrk_DisposalGroupInclDiscontinuedOperationsDistributionReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DisposalGroupInclDiscontinuedOperationsDistributionReceived" xlink:to="lab_mrk_DisposalGroupInclDiscontinuedOperationsDistributionReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_FemurFractureLitigationMember_6489343d-c257-4648-b26a-f1398b0cbca2_terseLabel_en-US" xlink:label="lab_mrk_FemurFractureLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Femur Fracture Litigation</link:label>
    <link:label id="lab_mrk_FemurFractureLitigationMember_label_en-US" xlink:label="lab_mrk_FemurFractureLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Femur Fracture Litigation [Member]</link:label>
    <link:label id="lab_mrk_FemurFractureLitigationMember_documentation_en-US" xlink:label="lab_mrk_FemurFractureLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Femur Fracture litigation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FemurFractureLitigationMember" xlink:href="mrk-20220930.xsd#mrk_FemurFractureLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_FemurFractureLitigationMember" xlink:to="lab_mrk_FemurFractureLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_39de56f2-abca-426e-b933-f41d1af0511f_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_b2ae9c87-bff7-459e-b5a7-1a4d7bc67cfc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation plans and other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dba446e7-3543-4d06-a383-1a709c1f2900_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_95ca46c1-f79d-459d-8976-be45a4edf4b1_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f8d7da25-f68e-4bb2-85cd-478db173a29b_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_16a7ab7c-cc60-4789-abaf-502dc754158c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, at cost, net of accumulated depreciation of $17,921 in 2022 and $18,192 in 2021</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_98a0c4aa-bac4-4a60-9828-22d069f7b1df_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_423fb311-a160-4534-ba1d-18f0dc521675_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments on debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticPlanMember_982bac08-02a0-4222-abc3-120d63eb7aee_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Plan</link:label>
    <link:label id="lab_us-gaap_DomesticPlanMember_label_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticPlanMember" xlink:to="lab_us-gaap_DomesticPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OtherCountriesMember_79c18848-f108-46ee-98a0-4614f9caa2ba_terseLabel_en-US" xlink:label="lab_mrk_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_mrk_OtherCountriesMember_label_en-US" xlink:label="lab_mrk_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Countries [Member]</link:label>
    <link:label id="lab_mrk_OtherCountriesMember_documentation_en-US" xlink:label="lab_mrk_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Countries [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherCountriesMember" xlink:href="mrk-20220930.xsd#mrk_OtherCountriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OtherCountriesMember" xlink:to="lab_mrk_OtherCountriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_129b8618-422e-4be1-990f-af503c891978_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (Income) Expense, Net</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Other Expense Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:to="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_df93c719-a8b0-47d4-8349-1bd7ad7d5d13_totalLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_3769364e-42ed-4c51-88a4-b35e26f5ad50_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_af7b6240-c1d1-4bb5-8946-6ed4809651b2_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_5c3140c9-78f4-4f41-a3df-996e87209b40_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_ee4894ab-56f4-4bd9-9e37-d4a0e1419778_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_760aa08f-4736-4b6e-803a-7099088a2b96_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_1fc5f11c-16f2-4f67-bb00-5e3151dc12aa_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_08c9c32b-70a5-479e-a61c-949b1b61a867_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, authorized (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_b9f7f405-d8a1-427e-a676-ec8ed1b4977b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Derivative Pretax (Gain) Loss Recognized in Income</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_8c2699c7-0502-4631-978d-4c23322a3e4b_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_05463951-1370-470e-a5a9-c4578d1f8182_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_19cf8ba9-43b5-471c-af85-840022aa9403_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_0604b0ab-397b-498b-8acf-2c7d5f09e893_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_878d209f-8d47-4937-936b-54a6868c8a0b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales from Products</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_89b0af6e-c566-41bf-9241-b440e0dde859_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_5f44927c-1a71-45ef-a71d-8c0fd85b8a08_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Sales by Geographic Area</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_5dd9289e-f0c1-4027-91df-c2644cab9ee3_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5a84da69-1ac0-4087-9de8-89baa757b255_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_bd27fabe-6513-4ca7-b495-cf6a8b770218_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Effects of Derivatives Not Designated as Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives Not Designated as Hedging Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_77ee6657-2e60-4d6b-8a05-f9cdfb95d9d1_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations_aedf2d4d-2ab4-4b77-aa9d-497e52f3d827_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Flows Provided by Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_b4985858-3e6a-45f9-830f-91844a86bfc5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss (income) from investments in equity securities, net</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_3f00bbff-baf6-415f-8583-cde902740aa4_negatedLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss (income) from investments in equity securities, net</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_bd78d8fe-5ffc-4043-9e73-a82b05005b54_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_700ef862-86dd-4a77-b484-7d6356513cd4_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives Designated as Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_c510dfb0-3aef-4894-85db-1fa832890767_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination benefits</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Cost of Providing Special and Contractual Termination Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:to="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_a9925a13-704c-4b64-883a-91e1f91a26a8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_3ecf57eb-8884-4567-a350-93d2339cb46d_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_6d011d38-e22b-4a8f-be70-35f828f60dd0_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain on derivatives, net of reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_adb5f7ea-6825-4696-8b67-9608585e8d5f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_af765aff-bc7c-4e0f-abb7-efb5cad0f072_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_12fe1ba8-c8be-4c51-8f82-28dff2447e26_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends declared on common stock (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_4d257b0b-53bc-412a-a68b-ac9ec4b1db26_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Benefit Costs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Benefit Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_c7a2879a-d497-4add-a7a7-5dd9d80bf322_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_bf15dee8-74e8-4527-8c8b-153e2b5853cb_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income from Continuing Operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_6e48bd06-ed1d-4905-b0c5-0a87e1e36f42_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_78d0bfff-ee61-4aa8-ab76-4db9b8d538aa_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PrevymisMember_864a9681-1dd4-4665-8088-d190e3d70c18_terseLabel_en-US" xlink:label="lab_mrk_PrevymisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prevymis</link:label>
    <link:label id="lab_mrk_PrevymisMember_label_en-US" xlink:label="lab_mrk_PrevymisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prevymis [Member]</link:label>
    <link:label id="lab_mrk_PrevymisMember_documentation_en-US" xlink:label="lab_mrk_PrevymisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prevymis [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PrevymisMember" xlink:href="mrk-20220930.xsd#mrk_PrevymisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PrevymisMember" xlink:to="lab_mrk_PrevymisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_VerquvoMember_3d354bbb-368c-4463-bf01-c02a77ea78c9_terseLabel_en-US" xlink:label="lab_mrk_VerquvoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verquvo</link:label>
    <link:label id="lab_mrk_VerquvoMember_label_en-US" xlink:label="lab_mrk_VerquvoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verquvo [Member]</link:label>
    <link:label id="lab_mrk_VerquvoMember_documentation_en-US" xlink:label="lab_mrk_VerquvoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verquvo</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VerquvoMember" xlink:href="mrk-20220930.xsd#mrk_VerquvoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_VerquvoMember" xlink:to="lab_mrk_VerquvoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_FederalMember_c1599077-78de-4a95-bf9c-288201ad7914_terseLabel_en-US" xlink:label="lab_mrk_FederalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_mrk_FederalMember_label_en-US" xlink:label="lab_mrk_FederalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal [Member]</link:label>
    <link:label id="lab_mrk_FederalMember_documentation_en-US" xlink:label="lab_mrk_FederalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FederalMember" xlink:href="mrk-20220930.xsd#mrk_FederalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_FederalMember" xlink:to="lab_mrk_FederalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_d1ad903c-4c07-4ea7-9d75-da74065c9c9a_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A2.500Notesdue2034Member_07182b5c-c97c-40ec-aeb8-31b9a298a895_terseLabel_en-US" xlink:label="lab_mrk_A2.500Notesdue2034Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.500% Notes due 2034</link:label>
    <link:label id="lab_mrk_A2.500Notesdue2034Member_label_en-US" xlink:label="lab_mrk_A2.500Notesdue2034Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.500% Notes due 2034 [Member]</link:label>
    <link:label id="lab_mrk_A2.500Notesdue2034Member_documentation_en-US" xlink:label="lab_mrk_A2.500Notesdue2034Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.500% Notes due 2034 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.500Notesdue2034Member" xlink:href="mrk-20220930.xsd#mrk_A2.500Notesdue2034Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A2.500Notesdue2034Member" xlink:to="lab_mrk_A2.500Notesdue2034Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3a699532-fa59-4e5f-a3e4-1a1479450fbf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_cb4dbcc5-5233-4e67-9e3e-052e1b0d2d83_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of securities and other investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_ff0067ea-188d-4bcc-a17a-23227d5e8425_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_a061f3f1-5246-4f1a-a8f5-1c2785e6b5d2_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_MilestonePaymentsSalesBased_c92a0536-45e8-479f-8064-049f264176a8_terseLabel_en-US" xlink:label="lab_mrk_MilestonePaymentsSalesBased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-based milestone payments</link:label>
    <link:label id="lab_mrk_MilestonePaymentsSalesBased_label_en-US" xlink:label="lab_mrk_MilestonePaymentsSalesBased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Sales-Based</link:label>
    <link:label id="lab_mrk_MilestonePaymentsSalesBased_documentation_en-US" xlink:label="lab_mrk_MilestonePaymentsSalesBased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Sales-Based</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MilestonePaymentsSalesBased" xlink:href="mrk-20220930.xsd#mrk_MilestonePaymentsSalesBased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_MilestonePaymentsSalesBased" xlink:to="lab_mrk_MilestonePaymentsSalesBased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_2a1a5341-bc23-414d-aca4-01b13a0eefd9_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Financing Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts_0db01e3f-ab4d-4de3-846f-46a1930ca9a2_terseLabel_en-US" xlink:label="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring costs</link:label>
    <link:label id="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts_label_en-US" xlink:label="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Restructuring Costs</link:label>
    <link:label id="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts_documentation_en-US" xlink:label="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Restructuring Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts" xlink:href="mrk-20220930.xsd#mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts" xlink:to="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_209ee768-620f-47dc-9c8d-c2a6320e662c_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government and agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_632d0ac8-6e6d-478e-822b-407f506f071a_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b105d1e3-7ba6-4f00-93a1-3e881f853631_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_83d2be71-ec75-4b91-8419-03b6d3b43d03_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_447f4499-52c9-4f77-93cd-7a79422a93d8_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of gain recognized in Other (income) expense, net on derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_33478e13-7a3e-49c7-a261-1236ff4de3eb_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_8a6f705f-892f-4a56-9a60-decbce9f1829_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_877c3035-bec9-49f8-9367-2929e5865cd1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_edd38ed4-78da-407c-b9a9-c7c2c0f56a12_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_5c802787-9616-407c-b84c-9408b4f562e1_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative unrealized gains on investments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_78132af5-6b4f-48cc-a9a2-56b63f382ed6_terseLabel_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss) before reclassification adjustments, pretax</link:label>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, before Reclassifications, before Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:to="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EurodominatedNotesMember_41f9f986-5a62-479a-88a6-7c0685586322_terseLabel_en-US" xlink:label="lab_mrk_EurodominatedNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro-denominated notes</link:label>
    <link:label id="lab_mrk_EurodominatedNotesMember_label_en-US" xlink:label="lab_mrk_EurodominatedNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro-dominated Notes [Member]</link:label>
    <link:label id="lab_mrk_EurodominatedNotesMember_documentation_en-US" xlink:label="lab_mrk_EurodominatedNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro-dominated Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EurodominatedNotesMember" xlink:href="mrk-20220930.xsd#mrk_EurodominatedNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EurodominatedNotesMember" xlink:to="lab_mrk_EurodominatedNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_4fc78a6e-9d70-4311-b799-0001fb05110c_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories (excludes inventories of $2,641 in 2022 and $2,194 in 2021 classified in Other assets - see Note&#160;7)</link:label>
    <link:label id="lab_us-gaap_InventoryNet_3a998a97-0ba4-4c97-a749-4c4f50d22d3f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_42130603-3c78-4316-9a17-c9dcc36de7e1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_e748b282-d54c-4b2d-9358-976d4b78ff9e_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring costs</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_72ded8c5-c6a9-4ecb-81dd-9e7b0bd1ebff_negatedLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring costs</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_630bb344-06d8-4004-bee9-20b8fe678043_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal_20e3c933-72da-4f14-9acb-174a80fc0170_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of continuing involvement after disposal</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Period of Continuing Involvement after Disposal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" xlink:to="lab_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RoyaltyRateDeductionPercentage_00667f4b-d8a3-4519-8a4f-936f923b3a9f_terseLabel_en-US" xlink:label="lab_mrk_RoyaltyRateDeductionPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty rate, deduction</link:label>
    <link:label id="lab_mrk_RoyaltyRateDeductionPercentage_label_en-US" xlink:label="lab_mrk_RoyaltyRateDeductionPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Rate, Deduction, Percentage</link:label>
    <link:label id="lab_mrk_RoyaltyRateDeductionPercentage_documentation_en-US" xlink:label="lab_mrk_RoyaltyRateDeductionPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Rate, Deduction, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RoyaltyRateDeductionPercentage" xlink:href="mrk-20220930.xsd#mrk_RoyaltyRateDeductionPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RoyaltyRateDeductionPercentage" xlink:to="lab_mrk_RoyaltyRateDeductionPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_2f85d640-1c65-4e94-aa04-be8b9a3e1884_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from Continuing Operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_c759cb98-6e9d-4e6f-bd20-9a81c6a0c6a8_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_c026ffb2-3b41-4eea-912c-2b51b470649c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_10d043e3-2bed-4711-8c7f-be7a86e82c18_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8d74e955-a461-45e0-a10b-eadf7704bf7d_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_BridionMember_a81f20c2-e2a7-4164-86cf-c6e033c31acc_terseLabel_en-US" xlink:label="lab_mrk_BridionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridion</link:label>
    <link:label id="lab_mrk_BridionMember_label_en-US" xlink:label="lab_mrk_BridionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridion [Member]</link:label>
    <link:label id="lab_mrk_BridionMember_documentation_en-US" xlink:label="lab_mrk_BridionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridion [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BridionMember" xlink:href="mrk-20220930.xsd#mrk_BridionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_BridionMember" xlink:to="lab_mrk_BridionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_6016658d-fd11-40a6-b1ca-387dca763c54_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_83ea4705-4692-4311-abfe-9c5334262d1b_verboseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_c4265193-ac35-4d42-acad-50a17f190c89_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_7b67176d-855f-4813-8c93-bcc10cd24c83_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EisaiMember_5148e3fe-9bd3-4c7a-8c1e-fb6e53b30d28_terseLabel_en-US" xlink:label="lab_mrk_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eisai</link:label>
    <link:label id="lab_mrk_EisaiMember_label_en-US" xlink:label="lab_mrk_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eisai [Member]</link:label>
    <link:label id="lab_mrk_EisaiMember_documentation_en-US" xlink:label="lab_mrk_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eisai [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EisaiMember" xlink:href="mrk-20220930.xsd#mrk_EisaiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EisaiMember" xlink:to="lab_mrk_EisaiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferred_d34bad1d-5387-461e-8cb3-4cac5c13ce56_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred, asset acquisition</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferred_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_68c7c084-82fa-4b4a-878c-0751ee35a781_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_24a910a2-2a92-4888-98c1-6bb110f04bc3_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amounts, liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:to="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_InternationalMember_65300e77-39a9-4c6e-8797-cdd1099d8323_terseLabel_en-US" xlink:label="lab_mrk_InternationalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Int&#8217;l</link:label>
    <link:label id="lab_mrk_InternationalMember_label_en-US" xlink:label="lab_mrk_InternationalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International [Member]</link:label>
    <link:label id="lab_mrk_InternationalMember_documentation_en-US" xlink:label="lab_mrk_InternationalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InternationalMember" xlink:href="mrk-20220930.xsd#mrk_InternationalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_InternationalMember" xlink:to="lab_mrk_InternationalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_56997039-8f49-4518-ab30-308e0b48ccc6_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total swap notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_65af2053-b9c4-45db-b123-9eca9dcc20ba_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S Dollar Notional Amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_0843b1a1-3e8c-455e-8dc5-4c3efc79240b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in Sales as a result of AOCL reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_64f329c7-d008-487c-af8d-5de7acc780ad_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_5149a175-6c72-48fa-8ff2-5ebb68e8cd9f_terseLabel_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reconciling Items</link:label>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_label_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reconciling Items [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaterialReconcilingItemsMember" xlink:to="lab_us-gaap_MaterialReconcilingItemsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_27b46765-0e53-4bac-a05d-444c30dab764_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:to="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityBeforeTreasuryStock_b4f25f8c-dae7-439d-aea8-2aad9a583d79_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity before deduction for treasury stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityBeforeTreasuryStock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity before Treasury Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityBeforeTreasuryStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:to="lab_us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent_f35c97f4-1ef0-4b96-8b2c-6408f3eb7fb5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_0796fc2b-6405-41b3-b3ca-02fca2bd5fa7_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Service Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:to="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CollaborativeArrangementNumberOfCollaborationTargets_0e7d9691-d0d3-4399-a00e-590eff8d29d6_terseLabel_en-US" xlink:label="lab_mrk_CollaborativeArrangementNumberOfCollaborationTargets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of collaboration targets</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementNumberOfCollaborationTargets_label_en-US" xlink:label="lab_mrk_CollaborativeArrangementNumberOfCollaborationTargets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Collaboration Targets</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementNumberOfCollaborationTargets_documentation_en-US" xlink:label="lab_mrk_CollaborativeArrangementNumberOfCollaborationTargets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Collaboration Targets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementNumberOfCollaborationTargets" xlink:href="mrk-20220930.xsd#mrk_CollaborativeArrangementNumberOfCollaborationTargets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CollaborativeArrangementNumberOfCollaborationTargets" xlink:to="lab_mrk_CollaborativeArrangementNumberOfCollaborationTargets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtCurrent_220fa12f-1779-43c2-8ae2-da2a67dd799f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans payable and current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_label_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent" xlink:to="lab_us-gaap_DebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_5b87b8c9-2c10-4e15-9207-2662d27a8162_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PendingLitigationMember_301b8796-432c-41b1-8a40-cdd2fd3be748_terseLabel_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation</link:label>
    <link:label id="lab_us-gaap_PendingLitigationMember_label_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PendingLitigationMember" xlink:to="lab_us-gaap_PendingLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_9f3de2c7-e0d1-46e4-bbf6-54f520f7e253_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PharmaceuticalsegmentMember_956f586d-539d-45f7-9667-57cc01f20a41_terseLabel_en-US" xlink:label="lab_mrk_PharmaceuticalsegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical</link:label>
    <link:label id="lab_mrk_PharmaceuticalsegmentMember_a0d6b07d-d51d-4c3c-8770-2cd23b605713_verboseLabel_en-US" xlink:label="lab_mrk_PharmaceuticalsegmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical segment</link:label>
    <link:label id="lab_mrk_PharmaceuticalsegmentMember_label_en-US" xlink:label="lab_mrk_PharmaceuticalsegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical segment [Member]</link:label>
    <link:label id="lab_mrk_PharmaceuticalsegmentMember_documentation_en-US" xlink:label="lab_mrk_PharmaceuticalsegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical segment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember" xlink:href="mrk-20220930.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PharmaceuticalsegmentMember" xlink:to="lab_mrk_PharmaceuticalsegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_a18ebe6c-8f12-47e6-be16-d8468284ee1b_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_a0e63720-89c1-4137-bf05-cc2c8fdf0e29_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember_9edd6c0b-6f30-4f2b-a372-e1769cc6125d_terseLabel_en-US" xlink:label="lab_mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember_label_en-US" xlink:label="lab_mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes And Other Assets, Noncurrent [Member]</link:label>
    <link:label id="lab_mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember_documentation_en-US" xlink:label="lab_mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes And Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember" xlink:href="mrk-20220930.xsd#mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember" xlink:to="lab_mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_3e48f228-68e4-4b78-bda5-2899c9caa4b0_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_4b612d56-8f4d-4099-85ec-f76c13158474_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non- controlling Interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_f4386d3f-a282-4106-a8bc-eb027994c33e_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_ca652c17-85b7-4a68-87ab-4784f10b6205_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total pretax restructuring costs</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_6185e502-db80-43ce-8ade-2d51ae8d696c_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Incurred Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:to="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_762e4d6d-3950-47ff-8f4b-6de0df1cc15c_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_ab22b346-fac0-4ffb-af8b-4c68a4a453da_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss amortization</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_c39e479a-072f-4f34-815d-adbc683a398a_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_28f6aaf0-8aca-4f1f-b386-1c21baedcb88_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_a9afc743-bb54-49d2-91dc-ce2e0702b008_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged items</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_e8aeff0c-e654-4d27-8435-45960dd4e66a_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOtherShares_08be3b52-510f-403f-9f59-d1e481382b16_negatedLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOtherShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation plans and other (in shares)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOtherShares_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOtherShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOtherShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOtherShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOtherShares" xlink:to="lab_us-gaap_StockholdersEquityOtherShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_9cc4b12d-2445-46e4-b90c-69c692d37729_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per Common Share Assuming Dilution Attributable to Merck &amp; Co., Inc. Common Shareholders:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_b97344f1-799c-4407-9cde-fbb47bb2d671_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per Common Share Assuming Dilution Attributable to Merck &amp; Co., Inc. Common Shareholders:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_6e61f9c6-c87c-4c3a-8d7f-6a6478842aa1_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesMember_8ea08155-86e6-41dc-81b0-195150d444eb_verboseLabel_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesMember_45140263-3043-45fe-be48-a8c7a0a68de7_terseLabel_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_us-gaap_SalesMember_label_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember" xlink:to="lab_us-gaap_SalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_038e875a-dc82-4ab9-91e2-6b15442755c3_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_MilestonePaymentToBeMadeToACollaborativePartner_3cce5908-bbad-49a0-ae57-9ecf9bf7110a_terseLabel_en-US" xlink:label="lab_mrk_MilestonePaymentToBeMadeToACollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment to be made to a collaborative partner</link:label>
    <link:label id="lab_mrk_MilestonePaymentToBeMadeToACollaborativePartner_label_en-US" xlink:label="lab_mrk_MilestonePaymentToBeMadeToACollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment to be Made to a Collaborative Partner</link:label>
    <link:label id="lab_mrk_MilestonePaymentToBeMadeToACollaborativePartner_documentation_en-US" xlink:label="lab_mrk_MilestonePaymentToBeMadeToACollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment to be Made to a Collaborative Partner</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MilestonePaymentToBeMadeToACollaborativePartner" xlink:href="mrk-20220930.xsd#mrk_MilestonePaymentToBeMadeToACollaborativePartner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_MilestonePaymentToBeMadeToACollaborativePartner" xlink:to="lab_mrk_MilestonePaymentToBeMadeToACollaborativePartner" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f9e6cb9e-e153-4b5c-b208-6b7d5738c756_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_InventoriesProducedinPreparationforProductLaunchesMember_f248fc82-fded-4969-91b6-3fe189c16796_terseLabel_en-US" xlink:label="lab_mrk_InventoriesProducedinPreparationforProductLaunchesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories Produced in Preparation for Product Launches</link:label>
    <link:label id="lab_mrk_InventoriesProducedinPreparationforProductLaunchesMember_label_en-US" xlink:label="lab_mrk_InventoriesProducedinPreparationforProductLaunchesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories Produced in Preparation for Product Launches [Member]</link:label>
    <link:label id="lab_mrk_InventoriesProducedinPreparationforProductLaunchesMember_documentation_en-US" xlink:label="lab_mrk_InventoriesProducedinPreparationforProductLaunchesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories Produced in Preparation for Product Launches [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoriesProducedinPreparationforProductLaunchesMember" xlink:href="mrk-20220930.xsd#mrk_InventoriesProducedinPreparationforProductLaunchesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_InventoriesProducedinPreparationforProductLaunchesMember" xlink:to="lab_mrk_InventoriesProducedinPreparationforProductLaunchesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_b705649f-e4af-43af-b8ac-4951c14b139c_verboseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives Not Designated as Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_4a583898-74e5-4385-af01-ec28f899dd6f_terseLabel_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_label_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:to="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_412f588c-4146-4a55-8c02-50f78780fc83_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other acquisitions, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_328fa242-f447-42e6-ad7b-fe4e9f2ecfac_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_9d2aeab4-65ac-467a-8925-4e60d4808a97_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Segment Profits to Income before Taxes</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_ae35d010-2d64-4969-82c6-b8d16b3a1292_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount paid for investment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_4673862f-6357-445c-babe-5f59949a30ba_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_81e69135-8f18-4eab-bd2f-b789ac45b6d9_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Merck &amp; Co., Inc., diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_a991e507-fad3-47bf-99c7-d743d1ad71ad_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangibles, Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_d36bd8d0-8e63-4170-9362-a918250b2900_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_0d4cf5e2-a1d1-41a4-89d8-8d8426240e9a_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_581b5a77-7c10-4194-8d54-ba8de6414649_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction_f893eae5-d94a-4416-8a26-9e4123c4ef17_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spin-off of Organon &amp; Co.</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Spinoff Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteSpinoffTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction" xlink:to="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_e37b88d8-dd98-41fe-9fea-eca924ce27af_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_8d297904-aab7-4c2f-9cec-0b295ac3f4e8_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_7c606a24-3ff4-4caa-b40f-eee41d67209d_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock conversion ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_GardasilGardasil9Member_bf2ad48f-2908-4fc5-b442-8c14eff825fa_terseLabel_en-US" xlink:label="lab_mrk_GardasilGardasil9Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gardasil/Gardasil 9</link:label>
    <link:label id="lab_mrk_GardasilGardasil9Member_label_en-US" xlink:label="lab_mrk_GardasilGardasil9Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gardasil/Gardasil 9 [Member]</link:label>
    <link:label id="lab_mrk_GardasilGardasil9Member_documentation_en-US" xlink:label="lab_mrk_GardasilGardasil9Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gardasil/Gardasil 9 [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GardasilGardasil9Member" xlink:href="mrk-20220930.xsd#mrk_GardasilGardasil9Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_GardasilGardasil9Member" xlink:to="lab_mrk_GardasilGardasil9Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_1c301827-1aac-4dc9-ae5c-457fc22aa89f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:to="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_a2b4865c-945a-4dde-a151-8128ae9b2b14_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_2820fb3a-1472-44bd-952e-eff58bb1273f_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_7b099121-d2ae-4f55-a5e3-495045a67882_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains recognized on investments in equity securities without readily determinable fair value</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_5f162316-eb4e-4958-b300-08dade3b01dc_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_9b86e179-082c-41a1-8140-08e02842b3ce_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables included in Accrued and other liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherRestructuringMember_78ad8766-b493-49be-a1c9-c3bc55a0208b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherRestructuringMember_label_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Restructuring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestructuringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherRestructuringMember" xlink:to="lab_us-gaap_OtherRestructuringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RemicadeMember_e8d13d72-7b08-408f-a6eb-8a5154f39342_terseLabel_en-US" xlink:label="lab_mrk_RemicadeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remicade</link:label>
    <link:label id="lab_mrk_RemicadeMember_label_en-US" xlink:label="lab_mrk_RemicadeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remicade [Member]</link:label>
    <link:label id="lab_mrk_RemicadeMember_documentation_en-US" xlink:label="lab_mrk_RemicadeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remicade [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RemicadeMember" xlink:href="mrk-20220930.xsd#mrk_RemicadeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RemicadeMember" xlink:to="lab_mrk_RemicadeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_StockholdersEquityTable_a7a42f5b-5c8f-4718-a9a9-a3f63583ad28_terseLabel_en-US" xlink:label="lab_mrk_StockholdersEquityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders Equity [Table]</link:label>
    <link:label id="lab_mrk_StockholdersEquityTable_label_en-US" xlink:label="lab_mrk_StockholdersEquityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders Equity [Table]</link:label>
    <link:label id="lab_mrk_StockholdersEquityTable_documentation_en-US" xlink:label="lab_mrk_StockholdersEquityTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders Equity [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_StockholdersEquityTable" xlink:href="mrk-20220930.xsd#mrk_StockholdersEquityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_StockholdersEquityTable" xlink:to="lab_mrk_StockholdersEquityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_d8fd98fe-2802-4aba-a662-6374a036b419_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Publicly traded equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_768c3c35-da51-4137-91d1-b33d5b243be4_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_a37902ff-621a-478b-8a3e-4256a08d5653_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spin-Off of Organon &amp; Co.</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_JanumetMember_a7b1dd24-1d2a-4146-ba8e-434f4be9f1f2_terseLabel_en-US" xlink:label="lab_mrk_JanumetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janumet</link:label>
    <link:label id="lab_mrk_JanumetMember_label_en-US" xlink:label="lab_mrk_JanumetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janumet [Member]</link:label>
    <link:label id="lab_mrk_JanumetMember_documentation_en-US" xlink:label="lab_mrk_JanumetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janumet [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_JanumetMember" xlink:href="mrk-20220930.xsd#mrk_JanumetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_JanumetMember" xlink:to="lab_mrk_JanumetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_5cc1aabc-3707-4d7e-8c8c-455b95461e9c_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate notes and bonds</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_a5291ff7-2da6-42c0-a619-552eb6fc1f76_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_9ba8110e-2742-439d-9672-de60ff053347_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized net (gains) losses</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_7f897b99-5936-42d1-ac6e-0de9c7e6c553_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from discontinued operations, net of taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_7ec1c051-597a-40b6-abb0-e5c110198dd9_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_85f0f2c2-db76-4fcc-a9ab-35540807e02a_negatedLabel_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_label_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentForAmortization" xlink:to="lab_us-gaap_AdjustmentForAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_7477f7f1-b1ca-46f1-ba97-6223cb236b10_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign government bonds</link:label>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security, Government, Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner_32d9cd67-db0c-49e7-8253-c2f7a803b264_terseLabel_en-US" xlink:label="lab_mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments to be made</link:label>
    <link:label id="lab_mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner_label_en-US" xlink:label="lab_mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and Milestone Payments to be Made to Collaborative Partner</link:label>
    <link:label id="lab_mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner_documentation_en-US" xlink:label="lab_mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and Milestone Payments to be Made to Collaborative Partner</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner" xlink:href="mrk-20220930.xsd#mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner" xlink:to="lab_mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_812bf9c2-06e8-4ffd-b400-02ce97990189_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_2028e65f-e0fc-4ac6-a7dc-8b64f53515d7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_5e806fff-dea1-49d0-a2cb-6406960f205a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ZerbaxaMember_f38ac2ae-6c0f-47ba-a447-9f56da82b7f8_terseLabel_en-US" xlink:label="lab_mrk_ZerbaxaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zerbaxa</link:label>
    <link:label id="lab_mrk_ZerbaxaMember_label_en-US" xlink:label="lab_mrk_ZerbaxaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zerbaxa [Member]</link:label>
    <link:label id="lab_mrk_ZerbaxaMember_documentation_en-US" xlink:label="lab_mrk_ZerbaxaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zerbaxa [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ZerbaxaMember" xlink:href="mrk-20220930.xsd#mrk_ZerbaxaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ZerbaxaMember" xlink:to="lab_mrk_ZerbaxaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_1a8d1583-8033-43d6-a1ee-77098a22ab81_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment charge</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_47a5e882-9bd4-4853-85cf-f76907e28e27_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DificidMember_49e2d187-a305-4bc6-95fb-5fa46bd872eb_terseLabel_en-US" xlink:label="lab_mrk_DificidMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dificid</link:label>
    <link:label id="lab_mrk_DificidMember_label_en-US" xlink:label="lab_mrk_DificidMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dificid [Member]</link:label>
    <link:label id="lab_mrk_DificidMember_documentation_en-US" xlink:label="lab_mrk_DificidMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dificid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DificidMember" xlink:href="mrk-20220930.xsd#mrk_DificidMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DificidMember" xlink:to="lab_mrk_DificidMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_7ddcbef6-3fee-4362-b0b9-cdd9b212400d_terseLabel_en-US" xlink:label="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Component of Other Income / Expense of Nonoperating [Line Items]</link:label>
    <link:label id="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_label_en-US" xlink:label="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Component of Other Income / Expense of Nonoperating [Line Items]</link:label>
    <link:label id="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_documentation_en-US" xlink:label="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Component of Other Income / Expense of Nonoperating [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems" xlink:href="mrk-20220930.xsd#mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems" xlink:to="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyClaimsDismissedNumber_b196ce47-7ab3-4b1e-80a3-e40e3a7aae7a_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, claims dismissed</link:label>
    <link:label id="lab_us-gaap_LossContingencyClaimsDismissedNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Dismissed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyClaimsDismissedNumber" xlink:to="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_14cb97f5-457a-49b3-8a71-09997b1c4d63_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_c24ac094-9e39-45b5-a1a3-764bcecaea2f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in short-term borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Repayments of) Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_f789fee8-cfbf-48b8-9ff6-6a8c48efd32e_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_4f4d91a8-af24-4415-a375-0c68104d63bd_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeCollateralObligationToReturnCash_cd16df9e-2938-4566-810c-b206e9cbc3e3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash collateral received from counterparties</link:label>
    <link:label id="lab_us-gaap_DerivativeCollateralObligationToReturnCash_fba3a80f-dd52-43de-b420-bb70afab7003_negatedLabel_en-US" xlink:label="lab_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash collateral received, asset</link:label>
    <link:label id="lab_us-gaap_DerivativeCollateralObligationToReturnCash_label_en-US" xlink:label="lab_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Cash Not Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:to="lab_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_c0ed5f46-6302-42fb-b8e8-e6f1d6500373_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_31a173db-6a04-427f-9e8b-080cc2d87dc7_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_93fa7959-77b2-4cf8-90ef-ad3c5c4b942b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_5cfb51c6-409d-40e4-9971-753e13f2214a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pretax net unrealized gains on derivatives maturing within next 12 months estimated to be reclassified from AOCI to sales</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_336527e8-e8f3-4c95-bd82-a31d244b40a0_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNoncurrent_1823835e-e0db-475e-9f74-b9c3e6de7da4_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories classified in Other assets</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_6068a812-d52d-47ec-b5c7-0670d9e4b3fb_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent" xlink:to="lab_us-gaap_InventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_19f8c350-f1d8-45c9-8850-69cdd8b25cd2_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_489c537a-cee7-4f7d-b837-c6063fb580db_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AcceleratedDepreciationMember_a9cc5839-d76b-4ee6-86fa-05633ef2f2c3_terseLabel_en-US" xlink:label="lab_mrk_AcceleratedDepreciationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Depreciation</link:label>
    <link:label id="lab_mrk_AcceleratedDepreciationMember_label_en-US" xlink:label="lab_mrk_AcceleratedDepreciationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Depreciation [Member]</link:label>
    <link:label id="lab_mrk_AcceleratedDepreciationMember_documentation_en-US" xlink:label="lab_mrk_AcceleratedDepreciationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Depreciation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcceleratedDepreciationMember" xlink:href="mrk-20220930.xsd#mrk_AcceleratedDepreciationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AcceleratedDepreciationMember" xlink:to="lab_mrk_AcceleratedDepreciationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AdempasMember_f021da51-6de7-4510-afeb-5265df53adaf_terseLabel_en-US" xlink:label="lab_mrk_AdempasMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adempas</link:label>
    <link:label id="lab_mrk_AdempasMember_label_en-US" xlink:label="lab_mrk_AdempasMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adempas [Member]</link:label>
    <link:label id="lab_mrk_AdempasMember_documentation_en-US" xlink:label="lab_mrk_AdempasMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adempas</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AdempasMember" xlink:href="mrk-20220930.xsd#mrk_AdempasMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AdempasMember" xlink:to="lab_mrk_AdempasMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_abc3c8ba-dc44-4027-b7f4-3e8bfa3e2cfe_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_a7ddf9ed-29d0-4ad9-8c41-5b70f05f8384_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal group, other expense</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_0b7a440a-4c31-4f01-a297-3f0ffc52771a_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLIFOReserve_c4e1322b-5a77-4949-9573-fe01ac49e698_negatedLabel_en-US" xlink:label="lab_us-gaap_InventoryLIFOReserve" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease to LIFO cost</link:label>
    <link:label id="lab_us-gaap_InventoryLIFOReserve_label_en-US" xlink:label="lab_us-gaap_InventoryLIFOReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, LIFO Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLIFOReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLIFOReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLIFOReserve" xlink:to="lab_us-gaap_InventoryLIFOReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_bdea947b-60c9-4a0d-ac20-90e1ea0ea1f4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_1efbf994-4d70-469e-882e-58a160146420_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AlliancerevenueLynparzaMember_7d3d8151-9436-497d-8c21-4f69889c9935_terseLabel_en-US" xlink:label="lab_mrk_AlliancerevenueLynparzaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Lynparza</link:label>
    <link:label id="lab_mrk_AlliancerevenueLynparzaMember_label_en-US" xlink:label="lab_mrk_AlliancerevenueLynparzaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Lynparza [Member]</link:label>
    <link:label id="lab_mrk_AlliancerevenueLynparzaMember_documentation_en-US" xlink:label="lab_mrk_AlliancerevenueLynparzaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Lynparza [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AlliancerevenueLynparzaMember" xlink:href="mrk-20220930.xsd#mrk_AlliancerevenueLynparzaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AlliancerevenueLynparzaMember" xlink:to="lab_mrk_AlliancerevenueLynparzaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_NemtabrutinibMember_8dd8fcf8-5e64-457f-afd0-97b6820de5d3_terseLabel_en-US" xlink:label="lab_mrk_NemtabrutinibMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">nemtabrutinib</link:label>
    <link:label id="lab_mrk_NemtabrutinibMember_label_en-US" xlink:label="lab_mrk_NemtabrutinibMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">nemtabrutinib [Member]</link:label>
    <link:label id="lab_mrk_NemtabrutinibMember_documentation_en-US" xlink:label="lab_mrk_NemtabrutinibMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">nemtabrutinib</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NemtabrutinibMember" xlink:href="mrk-20220930.xsd#mrk_NemtabrutinibMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_NemtabrutinibMember" xlink:to="lab_mrk_NemtabrutinibMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LivestockMember_15911b98-59c1-43c6-ae4a-7063150db9a6_terseLabel_en-US" xlink:label="lab_mrk_LivestockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Livestock</link:label>
    <link:label id="lab_mrk_LivestockMember_label_en-US" xlink:label="lab_mrk_LivestockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Livestock [Member]</link:label>
    <link:label id="lab_mrk_LivestockMember_documentation_en-US" xlink:label="lab_mrk_LivestockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Livestock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LivestockMember" xlink:href="mrk-20220930.xsd#mrk_LivestockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LivestockMember" xlink:to="lab_mrk_LivestockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_433563a4-2f92-4a90-b54f-81f21fa783c3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedge_75280b01-0411-45f4-93f3-416ba867a950_terseLabel_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount of Hedged Liabilities</link:label>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedge_label_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Liability, Fair Value Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedge" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedLiabilityFairValueHedge" xlink:to="lab_us-gaap_HedgedLiabilityFairValueHedge" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SegmentReportingUnallocatedOtherExpensesNet_d4e0182c-a8a4-4cbd-b3c6-4cfa3e3e693d_negatedLabel_en-US" xlink:label="lab_mrk_SegmentReportingUnallocatedOtherExpensesNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other unallocated, net</link:label>
    <link:label id="lab_mrk_SegmentReportingUnallocatedOtherExpensesNet_label_en-US" xlink:label="lab_mrk_SegmentReportingUnallocatedOtherExpensesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Unallocated Other Expenses Net</link:label>
    <link:label id="lab_mrk_SegmentReportingUnallocatedOtherExpensesNet_documentation_en-US" xlink:label="lab_mrk_SegmentReportingUnallocatedOtherExpensesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other net expenses not allocated to segments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SegmentReportingUnallocatedOtherExpensesNet" xlink:href="mrk-20220930.xsd#mrk_SegmentReportingUnallocatedOtherExpensesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SegmentReportingUnallocatedOtherExpensesNet" xlink:to="lab_mrk_SegmentReportingUnallocatedOtherExpensesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SupplyCommitmentMinimumNumberOfMarkets_05f0ccf6-333c-48b9-84b0-0b8107cb9f0e_terseLabel_en-US" xlink:label="lab_mrk_SupplyCommitmentMinimumNumberOfMarkets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of markets (more than)</link:label>
    <link:label id="lab_mrk_SupplyCommitmentMinimumNumberOfMarkets_label_en-US" xlink:label="lab_mrk_SupplyCommitmentMinimumNumberOfMarkets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment, Minimum, Number of Markets</link:label>
    <link:label id="lab_mrk_SupplyCommitmentMinimumNumberOfMarkets_documentation_en-US" xlink:label="lab_mrk_SupplyCommitmentMinimumNumberOfMarkets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment, Minimum, Number of Markets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SupplyCommitmentMinimumNumberOfMarkets" xlink:href="mrk-20220930.xsd#mrk_SupplyCommitmentMinimumNumberOfMarkets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SupplyCommitmentMinimumNumberOfMarkets" xlink:to="lab_mrk_SupplyCommitmentMinimumNumberOfMarkets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_44837ae5-9cda-41d9-b732-a5cb62c94c49_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends payable</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrent" xlink:to="lab_us-gaap_DividendsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember_71863a3d-1971-410c-a9ed-ca6b076f07fd_terseLabel_en-US" xlink:label="lab_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories Not Expected to be Sold Within One Year</link:label>
    <link:label id="lab_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember_label_en-US" xlink:label="lab_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Not Expected to be Sold Within One Year [Member]</link:label>
    <link:label id="lab_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember_documentation_en-US" xlink:label="lab_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Not Expected to be Sold Within One Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember" xlink:href="mrk-20220930.xsd#mrk_InventoryNotExpectedtobeSoldWithinOneYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember" xlink:to="lab_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeFutureMember_b75f1469-2666-49ed-8a60-5e941b04acb3_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeFutureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Future</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeFutureMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeFutureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Future [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeFutureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeFutureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeFutureMember" xlink:to="lab_us-gaap_ForeignExchangeFutureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_88421656-6e3d-4832-9018-9832899a6004_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrencySwapMember_5c8c7b8e-03a7-4961-b194-322f3280cc33_terseLabel_en-US" xlink:label="lab_us-gaap_CurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency Swap</link:label>
    <link:label id="lab_us-gaap_CurrencySwapMember_label_en-US" xlink:label="lab_us-gaap_CurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrencySwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrencySwapMember" xlink:to="lab_us-gaap_CurrencySwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_967d438c-6816-420f-8d83-94230463ec71_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Increase in Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_11d45a6f-c23c-4913-ae3b-9e3de49af20c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charges and Spending Relating to Restructuring Activities by Program</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_af4aa48f-9f0c-4520-b1d7-57161ad72834_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares issuable (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_1cbc842e-9be8-4675-9b1c-81fead4d4fde_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charges Related to Restructuring Program Activities by Type of Cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_cb232300-6a35-4358-abc5-5cbac6646554_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, measurement input, discount rate</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_5a95e7f4-ca6d-4b8f-b51a-bed2b72a789c_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_6b15b976-c74b-45e9-8eb4-83a5866319e4_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_8fcb7d38-be17-48c7-aff9-1aa0f3fa058a_negatedLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_c2ecf065-308f-4e26-8cb5-1e60c0b3db2e_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_6100d6f0-bd21-49b1-a81f-ed8c841b050b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LatinAmericaMember_1534717c-5e33-413a-a648-3cf6551ad008_terseLabel_en-US" xlink:label="lab_srt_LatinAmericaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Latin America</link:label>
    <link:label id="lab_srt_LatinAmericaMember_label_en-US" xlink:label="lab_srt_LatinAmericaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Latin America [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LatinAmericaMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LatinAmericaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LatinAmericaMember" xlink:to="lab_srt_LatinAmericaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OrnaTherapeuticsMember_669131eb-9cdf-4586-acdd-261cfe4466e6_terseLabel_en-US" xlink:label="lab_mrk_OrnaTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orna Therapeutics</link:label>
    <link:label id="lab_mrk_OrnaTherapeuticsMember_label_en-US" xlink:label="lab_mrk_OrnaTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orna Therapeutics [Member]</link:label>
    <link:label id="lab_mrk_OrnaTherapeuticsMember_documentation_en-US" xlink:label="lab_mrk_OrnaTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orna Therapeutics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OrnaTherapeuticsMember" xlink:href="mrk-20220930.xsd#mrk_OrnaTherapeuticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OrnaTherapeuticsMember" xlink:to="lab_mrk_OrnaTherapeuticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_f34718d5-9ce3-484c-9f40-3e468ba69c5f_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit resulting from acquisition</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_c9712940-06b8-41f0-b183-9a1935acba8a_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OneTimeTerminationBenefitsMember_c132156c-de3a-4394-84e0-4af9b2cb0d48_terseLabel_en-US" xlink:label="lab_us-gaap_OneTimeTerminationBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separation Costs</link:label>
    <link:label id="lab_us-gaap_OneTimeTerminationBenefitsMember_label_en-US" xlink:label="lab_us-gaap_OneTimeTerminationBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One-time Termination Benefits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OneTimeTerminationBenefitsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OneTimeTerminationBenefitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OneTimeTerminationBenefitsMember" xlink:to="lab_us-gaap_OneTimeTerminationBenefitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PandionTherapeuticsMember_db3c6044-3857-458e-97df-aa780ecab1fc_terseLabel_en-US" xlink:label="lab_mrk_PandionTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pandion Therapeutics</link:label>
    <link:label id="lab_mrk_PandionTherapeuticsMember_label_en-US" xlink:label="lab_mrk_PandionTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pandion Therapeutics [Member]</link:label>
    <link:label id="lab_mrk_PandionTherapeuticsMember_documentation_en-US" xlink:label="lab_mrk_PandionTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pandion Therapeutics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PandionTherapeuticsMember" xlink:href="mrk-20220930.xsd#mrk_PandionTherapeuticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PandionTherapeuticsMember" xlink:to="lab_mrk_PandionTherapeuticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserve_a49b58a4-6405-42c5-8387-19681310bf20_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal defense costs reserve</link:label>
    <link:label id="lab_us-gaap_LitigationReserve_label_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserve" xlink:to="lab_us-gaap_LitigationReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_a4acc065-878f-4eb9-b7bf-37d067521f3c_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_c1b12ead-e2df-42c9-892e-00048129d624_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A2.35NotesDue2022Member_73f3e18a-3163-4021-8539-fe460b432273_terseLabel_en-US" xlink:label="lab_mrk_A2.35NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.35% Notes Due 2022</link:label>
    <link:label id="lab_mrk_A2.35NotesDue2022Member_label_en-US" xlink:label="lab_mrk_A2.35NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.35% Notes Due 2022 [Member]</link:label>
    <link:label id="lab_mrk_A2.35NotesDue2022Member_documentation_en-US" xlink:label="lab_mrk_A2.35NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.35% Notes Due 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.35NotesDue2022Member" xlink:href="mrk-20220930.xsd#mrk_A2.35NotesDue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A2.35NotesDue2022Member" xlink:to="lab_mrk_A2.35NotesDue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_03dee270-97ec-44cf-8c8f-ca32e05b2717_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_d4dce5b4-364d-40ea-8f4f-250753492239_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_bef4f16e-246e-4869-9808-0e415e34cc0e_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset impairment charges</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_0ab60643-cd4c-466c-a5a1-330ee2abac64_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_5761202c-7d33-46db-a820-97ee5bca8499_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CompanionAnimalsMember_26657b95-246c-4788-852b-755c17fa4697_terseLabel_en-US" xlink:label="lab_mrk_CompanionAnimalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Companion Animals</link:label>
    <link:label id="lab_mrk_CompanionAnimalsMember_label_en-US" xlink:label="lab_mrk_CompanionAnimalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Companion Animals [Member]</link:label>
    <link:label id="lab_mrk_CompanionAnimalsMember_documentation_en-US" xlink:label="lab_mrk_CompanionAnimalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Companion Animals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CompanionAnimalsMember" xlink:href="mrk-20220930.xsd#mrk_CompanionAnimalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CompanionAnimalsMember" xlink:to="lab_mrk_CompanionAnimalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod_c9f925a3-d874-4e26-ae87-0d5f67a9897e_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Tax Effect of Income (Loss) from Discontinued Operation During Phase-out Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod" xlink:to="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses_9314d9b8-f01a-445c-8286-92857c54fc9f_terseLabel_en-US" xlink:label="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses_label_en-US" xlink:label="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Research and Development Expenses</link:label>
    <link:label id="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses_documentation_en-US" xlink:label="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Research and Development Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses" xlink:href="mrk-20220930.xsd#mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses" xlink:to="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_5a5ca4f0-3ed3-4878-9459-d0f427c9ae7b_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to related parties, current</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8e338a87-6669-4468-b643-86633a51644f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Financing Activities of Continuing Operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ContingentPaymentsCollaborativeArrangement_75d25b13-696d-44d8-a13e-3f4f2a88bbbc_terseLabel_en-US" xlink:label="lab_mrk_ContingentPaymentsCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent milestone payments collaborative arrangement</link:label>
    <link:label id="lab_mrk_ContingentPaymentsCollaborativeArrangement_label_en-US" xlink:label="lab_mrk_ContingentPaymentsCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Payments Collaborative Arrangement</link:label>
    <link:label id="lab_mrk_ContingentPaymentsCollaborativeArrangement_documentation_en-US" xlink:label="lab_mrk_ContingentPaymentsCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents payments that may be made in the future contingent upon the achievement of regulatory and/or sales milestones as part of a collaborative arrangement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ContingentPaymentsCollaborativeArrangement" xlink:href="mrk-20220930.xsd#mrk_ContingentPaymentsCollaborativeArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ContingentPaymentsCollaborativeArrangement" xlink:to="lab_mrk_ContingentPaymentsCollaborativeArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_95a124c0-6e5a-40fe-af43-433d9957bcad_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_InvanzMember_e837602d-1bc2-4b2f-ba6b-71b211cde9a7_terseLabel_en-US" xlink:label="lab_mrk_InvanzMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Invanz</link:label>
    <link:label id="lab_mrk_InvanzMember_label_en-US" xlink:label="lab_mrk_InvanzMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Invanz [Member]</link:label>
    <link:label id="lab_mrk_InvanzMember_documentation_en-US" xlink:label="lab_mrk_InvanzMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Invanz [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InvanzMember" xlink:href="mrk-20220930.xsd#mrk_InvanzMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_InvanzMember" xlink:to="lab_mrk_InvanzMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OrionCorporationMember_09226657-4cab-4eb9-bfff-ee47159a778b_terseLabel_en-US" xlink:label="lab_mrk_OrionCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orion Corporation</link:label>
    <link:label id="lab_mrk_OrionCorporationMember_label_en-US" xlink:label="lab_mrk_OrionCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orion Corporation [Member]</link:label>
    <link:label id="lab_mrk_OrionCorporationMember_documentation_en-US" xlink:label="lab_mrk_OrionCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orion Corporation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OrionCorporationMember" xlink:href="mrk-20220930.xsd#mrk_OrionCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OrionCorporationMember" xlink:to="lab_mrk_OrionCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ChargesRelatedToProgramDiscontinuation_deb1953d-b88e-4fb4-ac9f-d0e41531fa3c_terseLabel_en-US" xlink:label="lab_mrk_ChargesRelatedToProgramDiscontinuation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charges related to program discontinuation</link:label>
    <link:label id="lab_mrk_ChargesRelatedToProgramDiscontinuation_label_en-US" xlink:label="lab_mrk_ChargesRelatedToProgramDiscontinuation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charges related to program discontinuation</link:label>
    <link:label id="lab_mrk_ChargesRelatedToProgramDiscontinuation_documentation_en-US" xlink:label="lab_mrk_ChargesRelatedToProgramDiscontinuation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charges related to program discontinuation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ChargesRelatedToProgramDiscontinuation" xlink:href="mrk-20220930.xsd#mrk_ChargesRelatedToProgramDiscontinuation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ChargesRelatedToProgramDiscontinuation" xlink:to="lab_mrk_ChargesRelatedToProgramDiscontinuation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_db028023-0129-41cc-96c8-8c8d9c09f87d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateContractMember_f37151a0-dd78-4fa7-b317-de01b36e1cf1_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Contract</link:label>
    <link:label id="lab_us-gaap_InterestRateContractMember_label_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateContractMember" xlink:to="lab_us-gaap_InterestRateContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentContinuingOperationsMember_f7102168-7ed0-4c9d-af76-cd30e7423ee0_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentContinuingOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing Operations</link:label>
    <link:label id="lab_us-gaap_SegmentContinuingOperationsMember_label_en-US" xlink:label="lab_us-gaap_SegmentContinuingOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentContinuingOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentContinuingOperationsMember" xlink:to="lab_us-gaap_SegmentContinuingOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_3e9e93f0-fec1-4b86-8ee0-08f85ea427f6_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_58873afb-e626-4964-8179-34d08e3628af_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Calculations of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OrganonCoMember_1d216128-9baf-41d6-820b-0e39da35db20_terseLabel_en-US" xlink:label="lab_mrk_OrganonCoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organon &amp; Co.</link:label>
    <link:label id="lab_mrk_OrganonCoMember_label_en-US" xlink:label="lab_mrk_OrganonCoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organon &amp; Co. [Member]</link:label>
    <link:label id="lab_mrk_OrganonCoMember_documentation_en-US" xlink:label="lab_mrk_OrganonCoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organon &amp; Co.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OrganonCoMember" xlink:href="mrk-20220930.xsd#mrk_OrganonCoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OrganonCoMember" xlink:to="lab_mrk_OrganonCoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_c0829f7f-cff9-4359-9b8b-206be6ba92ad_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_fba836ef-52f7-4c2c-af33-5ce1a3ac5f70_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CollaborativeArrangementSalesNet_3667f0d0-c81e-4782-901a-8b5d122e3a08_terseLabel_en-US" xlink:label="lab_mrk_CollaborativeArrangementSalesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net sales by Merck</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementSalesNet_label_en-US" xlink:label="lab_mrk_CollaborativeArrangementSalesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Sales, Net</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementSalesNet_documentation_en-US" xlink:label="lab_mrk_CollaborativeArrangementSalesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Sales, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementSalesNet" xlink:href="mrk-20220930.xsd#mrk_CollaborativeArrangementSalesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CollaborativeArrangementSalesNet" xlink:to="lab_mrk_CollaborativeArrangementSalesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_c8405126-8304-4371-8fad-fd2027e2159d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefit Plans</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefits Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:to="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_31ec11f1-9462-4b12-8f60-b99139708688_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net Income Attributable to Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>mrk-20220930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:18be82ff-6aae-4643-b5c5-ea6de452de6c,g:778f8bae-d5d9-4bda-a4ad-ec173f2835d1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.merck.com/role/CoverPage" xlink:type="simple" xlink:href="mrk-20220930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_bf11c01b-1a51-44f0-a461-3ae36cccd1a1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_7113aa42-ebf7-4cb1-b327-32e322904071" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bf11c01b-1a51-44f0-a461-3ae36cccd1a1" xlink:to="loc_dei_EntitiesTable_7113aa42-ebf7-4cb1-b327-32e322904071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_424530f5-eae6-4a02-aeed-21b570c205e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_7113aa42-ebf7-4cb1-b327-32e322904071" xlink:to="loc_us-gaap_StatementClassOfStockAxis_424530f5-eae6-4a02-aeed-21b570c205e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_59d290b2-13fb-48c6-b807-47453d702271" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_424530f5-eae6-4a02-aeed-21b570c205e1" xlink:to="loc_us-gaap_ClassOfStockDomain_59d290b2-13fb-48c6-b807-47453d702271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_91356c4b-6f60-4805-8e36-bb8e428ccb0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_59d290b2-13fb-48c6-b807-47453d702271" xlink:to="loc_us-gaap_CommonStockMember_91356c4b-6f60-4805-8e36-bb8e428ccb0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A0.500Notesdue2024Member_86519de4-0d66-464b-bbc4-5b6eeb5be3bc" xlink:href="mrk-20220930.xsd#mrk_A0.500Notesdue2024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_59d290b2-13fb-48c6-b807-47453d702271" xlink:to="loc_mrk_A0.500Notesdue2024Member_86519de4-0d66-464b-bbc4-5b6eeb5be3bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.875Notesdue2026Member_a383f5ce-9253-4abc-8fef-257a0fe1560f" xlink:href="mrk-20220930.xsd#mrk_A1.875Notesdue2026Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_59d290b2-13fb-48c6-b807-47453d702271" xlink:to="loc_mrk_A1.875Notesdue2026Member_a383f5ce-9253-4abc-8fef-257a0fe1560f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.500Notesdue2034Member_8ab614b1-a07c-41e3-97d9-3c4429b4f94d" xlink:href="mrk-20220930.xsd#mrk_A2.500Notesdue2034Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_59d290b2-13fb-48c6-b807-47453d702271" xlink:to="loc_mrk_A2.500Notesdue2034Member_8ab614b1-a07c-41e3-97d9-3c4429b4f94d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.375Notesdue2036Member_51ad06d9-1ffa-4747-a2c1-56839d00dd8d" xlink:href="mrk-20220930.xsd#mrk_A1.375Notesdue2036Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_59d290b2-13fb-48c6-b807-47453d702271" xlink:to="loc_mrk_A1.375Notesdue2036Member_51ad06d9-1ffa-4747-a2c1-56839d00dd8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_7113aa42-ebf7-4cb1-b327-32e322904071" xlink:to="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_02899172-219d-4223-9b36-bd3d2e4d7494" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_DocumentType_02899172-219d-4223-9b36-bd3d2e4d7494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_1269d9ae-4613-42a9-bf4d-2e64306eadb5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_DocumentQuarterlyReport_1269d9ae-4613-42a9-bf4d-2e64306eadb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_3fdb803b-c4cc-4820-a23d-d348aa6b1a35" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_DocumentPeriodEndDate_3fdb803b-c4cc-4820-a23d-d348aa6b1a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_d53796c2-4841-494f-a532-ac331074efe8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_DocumentTransitionReport_d53796c2-4841-494f-a532-ac331074efe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_78280a67-ef73-4170-abdb-6e86b4259873" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_EntityFileNumber_78280a67-ef73-4170-abdb-6e86b4259873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_6e198498-90d4-4993-9f56-ad6a443cb467" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_EntityRegistrantName_6e198498-90d4-4993-9f56-ad6a443cb467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_d963f84f-26f3-4ce9-8406-5e3c57fdb795" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_EntityIncorporationStateCountryCode_d963f84f-26f3-4ce9-8406-5e3c57fdb795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_17b5715b-e536-45b2-a23e-fafa56a484ce" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_EntityTaxIdentificationNumber_17b5715b-e536-45b2-a23e-fafa56a484ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_682fe0ce-38b4-481f-96cb-d88530bdb05d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_EntityAddressAddressLine1_682fe0ce-38b4-481f-96cb-d88530bdb05d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_90adf29d-0fe6-4dd5-ba02-2f0ae76631b5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_EntityAddressCityOrTown_90adf29d-0fe6-4dd5-ba02-2f0ae76631b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_2748c624-9285-4809-98f8-616b61c2d422" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_EntityAddressStateOrProvince_2748c624-9285-4809-98f8-616b61c2d422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_65283da9-e318-4d24-88dd-598a06f90535" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_EntityAddressPostalZipCode_65283da9-e318-4d24-88dd-598a06f90535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_a68dd464-1cf1-4d03-88fe-82b8805f0962" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_CityAreaCode_a68dd464-1cf1-4d03-88fe-82b8805f0962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_8ba67ea3-b9b5-4eb7-82a4-a378bcb1cbac" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_LocalPhoneNumber_8ba67ea3-b9b5-4eb7-82a4-a378bcb1cbac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_e7b2ba1e-1675-4c96-8183-4a324a554ad5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_Security12bTitle_e7b2ba1e-1675-4c96-8183-4a324a554ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_ae098a95-76d6-4335-b568-7b2a234565ac" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_TradingSymbol_ae098a95-76d6-4335-b568-7b2a234565ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_6f7691d6-9cca-4ee1-bcfa-d3c5dd5ff478" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_SecurityExchangeName_6f7691d6-9cca-4ee1-bcfa-d3c5dd5ff478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_d80adae2-c64a-4250-9661-0b329156c545" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_EntityCurrentReportingStatus_d80adae2-c64a-4250-9661-0b329156c545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_021c44b9-6b02-48d7-b451-bf3c9c76bba8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_EntityInteractiveDataCurrent_021c44b9-6b02-48d7-b451-bf3c9c76bba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_6e6352ac-c7fd-42b3-bbbf-c9fbcd61f96e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_EntityFilerCategory_6e6352ac-c7fd-42b3-bbbf-c9fbcd61f96e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_081bdd43-de97-4757-841a-7d16f2762023" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_EntitySmallBusiness_081bdd43-de97-4757-841a-7d16f2762023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_dc2d3c6b-5f05-4e6e-b817-d008b33cb00f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_EntityEmergingGrowthCompany_dc2d3c6b-5f05-4e6e-b817-d008b33cb00f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_705a18ab-a35c-4011-b4ad-6a6c2c0b8564" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_EntityShellCompany_705a18ab-a35c-4011-b4ad-6a6c2c0b8564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_edd4793b-963b-4d69-907e-22f69f72ad70" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_edd4793b-963b-4d69-907e-22f69f72ad70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_2a187945-54ec-412c-8948-bee913f82fed" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_AmendmentFlag_2a187945-54ec-412c-8948-bee913f82fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_ffae1c7b-caa6-4c85-9aaa-b76f1d9bf400" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_DocumentFiscalYearFocus_ffae1c7b-caa6-4c85-9aaa-b76f1d9bf400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_d6130d99-0e3c-4f4e-a150-579c0d299677" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_DocumentFiscalPeriodFocus_d6130d99-0e3c-4f4e-a150-579c0d299677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_cc6bc9d9-a05c-48cf-947a-507ebc0ecbd5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_EntityCentralIndexKey_cc6bc9d9-a05c-48cf-947a-507ebc0ecbd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_c415ca8b-ebb8-4485-9748-2a4626d7c348" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_17ef21ec-89d8-4d79-a121-05d8a35fd74f" xlink:to="loc_dei_CurrentFiscalYearEndDate_c415ca8b-ebb8-4485-9748-2a4626d7c348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME" xlink:type="simple" xlink:href="mrk-20220930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_a9221a96-6cc6-4656-9e06-90d42a5f5d02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_24fd4369-bbad-49c8-adb8-2a3680786906" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a9221a96-6cc6-4656-9e06-90d42a5f5d02" xlink:to="loc_us-gaap_Revenues_24fd4369-bbad-49c8-adb8-2a3680786906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_1c8d5102-28f2-403a-af69-de1c13a58692" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a9221a96-6cc6-4656-9e06-90d42a5f5d02" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_1c8d5102-28f2-403a-af69-de1c13a58692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_90b60e30-c05c-49be-9224-3a516832d3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1c8d5102-28f2-403a-af69-de1c13a58692" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_90b60e30-c05c-49be-9224-3a516832d3dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_67ed5e5b-d8b1-41fd-8476-f6da9c462ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1c8d5102-28f2-403a-af69-de1c13a58692" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_67ed5e5b-d8b1-41fd-8476-f6da9c462ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_06603803-e29f-4a93-b584-50689c1dab2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1c8d5102-28f2-403a-af69-de1c13a58692" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_06603803-e29f-4a93-b584-50689c1dab2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_99256523-4d37-4fd8-9007-7642fac87d46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1c8d5102-28f2-403a-af69-de1c13a58692" xlink:to="loc_us-gaap_RestructuringCharges_99256523-4d37-4fd8-9007-7642fac87d46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_a078c4fe-12fd-4b0b-b380-8480a331f2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1c8d5102-28f2-403a-af69-de1c13a58692" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_a078c4fe-12fd-4b0b-b380-8480a331f2f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CostsExpensesAndOther_1f8dd9ad-94ed-453b-aedd-96804562b0be" xlink:href="mrk-20220930.xsd#mrk_CostsExpensesAndOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1c8d5102-28f2-403a-af69-de1c13a58692" xlink:to="loc_mrk_CostsExpensesAndOther_1f8dd9ad-94ed-453b-aedd-96804562b0be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a513c32b-496a-4180-939b-0da45330a78d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a9221a96-6cc6-4656-9e06-90d42a5f5d02" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a513c32b-496a-4180-939b-0da45330a78d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b7e9c58d-90f9-4775-9451-f17fbccaa1df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a9221a96-6cc6-4656-9e06-90d42a5f5d02" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b7e9c58d-90f9-4775-9451-f17fbccaa1df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_b43f4d44-79d3-4b14-ac46-407329d92cde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a9221a96-6cc6-4656-9e06-90d42a5f5d02" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_b43f4d44-79d3-4b14-ac46-407329d92cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_376b2f0f-c7f0-46e1-9b06-ef2cb179481e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a9221a96-6cc6-4656-9e06-90d42a5f5d02" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_376b2f0f-c7f0-46e1-9b06-ef2cb179481e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_ab54f5cf-3880-488f-99c7-5a4b2d6e0fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a9221a96-6cc6-4656-9e06-90d42a5f5d02" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_ab54f5cf-3880-488f-99c7-5a4b2d6e0fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_71b0274a-dc37-4178-ad4c-4651b1be77fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a9221a96-6cc6-4656-9e06-90d42a5f5d02" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_71b0274a-dc37-4178-ad4c-4651b1be77fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_605b2939-1a71-4ca4-a8ad-0bbf06fc7446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a9221a96-6cc6-4656-9e06-90d42a5f5d02" xlink:to="loc_us-gaap_NetIncomeLoss_605b2939-1a71-4ca4-a8ad-0bbf06fc7446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_2b3afc56-52c1-41b8-adac-5b42df46160c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a9221a96-6cc6-4656-9e06-90d42a5f5d02" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_2b3afc56-52c1-41b8-adac-5b42df46160c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_9b14ef9b-d8c7-471d-8767-50a653ad3f1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_2b3afc56-52c1-41b8-adac-5b42df46160c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_9b14ef9b-d8c7-471d-8767-50a653ad3f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_7f7583a2-98d3-43ae-9ce9-4a215d330353" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_2b3afc56-52c1-41b8-adac-5b42df46160c" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_7f7583a2-98d3-43ae-9ce9-4a215d330353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_9ab7724f-6904-4435-a429-c22ce3746a75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_2b3afc56-52c1-41b8-adac-5b42df46160c" xlink:to="loc_us-gaap_EarningsPerShareBasic_9ab7724f-6904-4435-a429-c22ce3746a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_e10737f0-831a-4a2e-87d5-ce3ceedc0976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a9221a96-6cc6-4656-9e06-90d42a5f5d02" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_e10737f0-831a-4a2e-87d5-ce3ceedc0976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_97666721-4e6d-4b8e-92b2-638cc3bac696" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_e10737f0-831a-4a2e-87d5-ce3ceedc0976" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_97666721-4e6d-4b8e-92b2-638cc3bac696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_d75a7d36-dd56-48fe-8d9a-58c7e1a62e20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_e10737f0-831a-4a2e-87d5-ce3ceedc0976" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_d75a7d36-dd56-48fe-8d9a-58c7e1a62e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_cf979253-f525-4c31-86d7-347ead697d71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_e10737f0-831a-4a2e-87d5-ce3ceedc0976" xlink:to="loc_us-gaap_EarningsPerShareDiluted_cf979253-f525-4c31-86d7-347ead697d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="mrk-20220930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7605d4f3-d3f9-49b3-9906-9cdb06cb741c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8a03a480-3de2-4691-aa83-4cab2f486e24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7605d4f3-d3f9-49b3-9906-9cdb06cb741c" xlink:to="loc_us-gaap_NetIncomeLoss_8a03a480-3de2-4691-aa83-4cab2f486e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_75381db7-d6e1-4d39-9f7b-da8eef7dee13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7605d4f3-d3f9-49b3-9906-9cdb06cb741c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_75381db7-d6e1-4d39-9f7b-da8eef7dee13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_13e57a97-d7ce-4130-83f1-563fcf98d5f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_75381db7-d6e1-4d39-9f7b-da8eef7dee13" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_13e57a97-d7ce-4130-83f1-563fcf98d5f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_a7eadb9f-a735-436e-a816-362ea2db0fed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_75381db7-d6e1-4d39-9f7b-da8eef7dee13" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_a7eadb9f-a735-436e-a816-362ea2db0fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_35982439-4675-4427-b1f6-7301f16e0052" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_75381db7-d6e1-4d39-9f7b-da8eef7dee13" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_35982439-4675-4427-b1f6-7301f16e0052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1eeeb8ff-558b-4127-b5fa-e524d4bd7869" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_75381db7-d6e1-4d39-9f7b-da8eef7dee13" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1eeeb8ff-558b-4127-b5fa-e524d4bd7869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_50ea0b78-1736-4cd7-9dff-b7d7ff5bff86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7605d4f3-d3f9-49b3-9906-9cdb06cb741c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_50ea0b78-1736-4cd7-9dff-b7d7ff5bff86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" xlink:type="simple" xlink:href="mrk-20220930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEET"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_49cef729-74ac-4c5c-ab79-98567d528797" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_b64b94b8-a5ac-4c20-9b8d-01bcf6f02dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_49cef729-74ac-4c5c-ab79-98567d528797" xlink:to="loc_us-gaap_AssetsAbstract_b64b94b8-a5ac-4c20-9b8d-01bcf6f02dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_8b7429f4-8e4d-4f93-8a9a-493ccd2f8c61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b64b94b8-a5ac-4c20-9b8d-01bcf6f02dd0" xlink:to="loc_us-gaap_AssetsCurrentAbstract_8b7429f4-8e4d-4f93-8a9a-493ccd2f8c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f7c1e968-b17f-4e7b-bbe9-7cb2c15d5ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8b7429f4-8e4d-4f93-8a9a-493ccd2f8c61" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f7c1e968-b17f-4e7b-bbe9-7cb2c15d5ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_826feb8b-ef38-491d-bcc3-218bb6ba9ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8b7429f4-8e4d-4f93-8a9a-493ccd2f8c61" xlink:to="loc_us-gaap_ShortTermInvestments_826feb8b-ef38-491d-bcc3-218bb6ba9ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_c79c60d1-1205-48de-a8c8-a0a6b76b6602" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8b7429f4-8e4d-4f93-8a9a-493ccd2f8c61" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_c79c60d1-1205-48de-a8c8-a0a6b76b6602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_2777a690-31de-4995-aab7-4513ec1e3816" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8b7429f4-8e4d-4f93-8a9a-493ccd2f8c61" xlink:to="loc_us-gaap_InventoryNet_2777a690-31de-4995-aab7-4513ec1e3816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent_8b9d04f9-a8f4-4c01-8787-ab1ea599eea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8b7429f4-8e4d-4f93-8a9a-493ccd2f8c61" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent_8b9d04f9-a8f4-4c01-8787-ab1ea599eea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_2b652869-319c-4544-84e5-bd3057943e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8b7429f4-8e4d-4f93-8a9a-493ccd2f8c61" xlink:to="loc_us-gaap_AssetsCurrent_2b652869-319c-4544-84e5-bd3057943e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_49c4f2f7-5c93-4135-b032-2103f22500c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b64b94b8-a5ac-4c20-9b8d-01bcf6f02dd0" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_49c4f2f7-5c93-4135-b032-2103f22500c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_93177d99-9bce-494a-8f71-d17992180429" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b64b94b8-a5ac-4c20-9b8d-01bcf6f02dd0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_93177d99-9bce-494a-8f71-d17992180429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_888460c1-9909-4758-9f7e-517af6f8e224" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b64b94b8-a5ac-4c20-9b8d-01bcf6f02dd0" xlink:to="loc_us-gaap_Goodwill_888460c1-9909-4758-9f7e-517af6f8e224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4d55aecb-fc36-49f0-bb32-78260ca251c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b64b94b8-a5ac-4c20-9b8d-01bcf6f02dd0" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4d55aecb-fc36-49f0-bb32-78260ca251c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_ade10252-8b9d-4cd9-afec-0e0461b92847" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b64b94b8-a5ac-4c20-9b8d-01bcf6f02dd0" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_ade10252-8b9d-4cd9-afec-0e0461b92847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_621c7e99-7340-4cc8-b4a8-80f23dfb28bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b64b94b8-a5ac-4c20-9b8d-01bcf6f02dd0" xlink:to="loc_us-gaap_Assets_621c7e99-7340-4cc8-b4a8-80f23dfb28bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_53906ef4-ea68-4a2e-a385-60296b09f228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_49cef729-74ac-4c5c-ab79-98567d528797" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_53906ef4-ea68-4a2e-a385-60296b09f228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_8b46ee22-df4b-4e71-9a7c-68f3c9c71ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_53906ef4-ea68-4a2e-a385-60296b09f228" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_8b46ee22-df4b-4e71-9a7c-68f3c9c71ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_e7ce2f49-de73-42b1-ac26-f90963c0c939" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8b46ee22-df4b-4e71-9a7c-68f3c9c71ee0" xlink:to="loc_us-gaap_DebtCurrent_e7ce2f49-de73-42b1-ac26-f90963c0c939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_ede58f88-3fba-44da-91d9-b93f4af2ea71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8b46ee22-df4b-4e71-9a7c-68f3c9c71ee0" xlink:to="loc_us-gaap_AccountsPayableCurrent_ede58f88-3fba-44da-91d9-b93f4af2ea71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_2289296d-bce5-4da1-b83f-6163e9da0e83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8b46ee22-df4b-4e71-9a7c-68f3c9c71ee0" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_2289296d-bce5-4da1-b83f-6163e9da0e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_beb8c0a5-34a3-4c78-a408-9b1593967259" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8b46ee22-df4b-4e71-9a7c-68f3c9c71ee0" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_beb8c0a5-34a3-4c78-a408-9b1593967259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_e3f0077f-cf40-4ac9-b601-b2c45997b367" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8b46ee22-df4b-4e71-9a7c-68f3c9c71ee0" xlink:to="loc_us-gaap_DividendsPayableCurrent_e3f0077f-cf40-4ac9-b601-b2c45997b367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3c8ab364-b9a3-4a55-bd9f-f98fcb13aaa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8b46ee22-df4b-4e71-9a7c-68f3c9c71ee0" xlink:to="loc_us-gaap_LiabilitiesCurrent_3c8ab364-b9a3-4a55-bd9f-f98fcb13aaa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_8a1fa8be-5a33-408f-96a7-8a3297eff655" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_53906ef4-ea68-4a2e-a385-60296b09f228" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_8a1fa8be-5a33-408f-96a7-8a3297eff655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_4534ff75-ac4d-4c68-b64a-9764a324a724" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_53906ef4-ea68-4a2e-a385-60296b09f228" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_4534ff75-ac4d-4c68-b64a-9764a324a724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_bf948c98-ac9a-47f7-ae4f-cedff7e84f77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_53906ef4-ea68-4a2e-a385-60296b09f228" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_bf948c98-ac9a-47f7-ae4f-cedff7e84f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_86abeefe-5b61-4933-904a-30411900b38b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_53906ef4-ea68-4a2e-a385-60296b09f228" xlink:to="loc_us-gaap_StockholdersEquityAbstract_86abeefe-5b61-4933-904a-30411900b38b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_9b7f0d74-2282-4602-971c-b70299e52fce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_86abeefe-5b61-4933-904a-30411900b38b" xlink:to="loc_us-gaap_CommonStockValue_9b7f0d74-2282-4602-971c-b70299e52fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_9d69c64b-eb88-4ef0-aa6e-1a931469f935" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_86abeefe-5b61-4933-904a-30411900b38b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_9d69c64b-eb88-4ef0-aa6e-1a931469f935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e6d8c76a-c5ca-4d92-a199-890273de7362" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_86abeefe-5b61-4933-904a-30411900b38b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e6d8c76a-c5ca-4d92-a199-890273de7362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b3994d9b-9041-49fc-b0ae-5e86c67d2c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_86abeefe-5b61-4933-904a-30411900b38b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b3994d9b-9041-49fc-b0ae-5e86c67d2c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_8ccf47c9-522a-4c17-8985-754b4f16b1a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityBeforeTreasuryStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_86abeefe-5b61-4933-904a-30411900b38b" xlink:to="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_8ccf47c9-522a-4c17-8985-754b4f16b1a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_9c7a3374-bcd5-4e6a-b541-a8e83a43debb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_86abeefe-5b61-4933-904a-30411900b38b" xlink:to="loc_us-gaap_TreasuryStockCommonValue_9c7a3374-bcd5-4e6a-b541-a8e83a43debb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_42863c61-1cac-4d80-8194-793989b5c447" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_86abeefe-5b61-4933-904a-30411900b38b" xlink:to="loc_us-gaap_StockholdersEquity_42863c61-1cac-4d80-8194-793989b5c447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_a780879e-9100-4e78-adf2-b35ffc5f8bda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_86abeefe-5b61-4933-904a-30411900b38b" xlink:to="loc_us-gaap_MinorityInterest_a780879e-9100-4e78-adf2-b35ffc5f8bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2c071178-ce88-4029-8319-ae877102dfb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_86abeefe-5b61-4933-904a-30411900b38b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2c071178-ce88-4029-8319-ae877102dfb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_0afbf955-825e-42ec-8ef1-5f91455a4500" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_53906ef4-ea68-4a2e-a385-60296b09f228" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_0afbf955-825e-42ec-8ef1-5f91455a4500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical" xlink:type="simple" xlink:href="mrk-20220930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_d768438c-f278-4546-bb0e-bc6029edaf54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_6d77e79d-a747-43ce-ad21-8694a7f02683" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d768438c-f278-4546-bb0e-bc6029edaf54" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_6d77e79d-a747-43ce-ad21-8694a7f02683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_bc6e866b-5191-4833-b6a4-9ae1344aa994" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d768438c-f278-4546-bb0e-bc6029edaf54" xlink:to="loc_us-gaap_InventoryNoncurrent_bc6e866b-5191-4833-b6a4-9ae1344aa994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e5acc37e-c8ff-46be-b221-31a9aee98c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d768438c-f278-4546-bb0e-bc6029edaf54" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e5acc37e-c8ff-46be-b221-31a9aee98c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_0ce4d9dd-7023-4ee4-bbe6-faa58575eb1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d768438c-f278-4546-bb0e-bc6029edaf54" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_0ce4d9dd-7023-4ee4-bbe6-faa58575eb1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2d967c8e-e8b8-42d0-96f1-b0dfde850895" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d768438c-f278-4546-bb0e-bc6029edaf54" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2d967c8e-e8b8-42d0-96f1-b0dfde850895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_b94af9f4-068e-4567-b525-34761ae73f67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d768438c-f278-4546-bb0e-bc6029edaf54" xlink:to="loc_us-gaap_CommonStockSharesIssued_b94af9f4-068e-4567-b525-34761ae73f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_af362fbb-8dbb-4c1a-9d66-d76396e24e88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d768438c-f278-4546-bb0e-bc6029edaf54" xlink:to="loc_us-gaap_TreasuryStockCommonShares_af362fbb-8dbb-4c1a-9d66-d76396e24e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" xlink:type="simple" xlink:href="mrk-20220930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_172bb343-3d1d-41f0-bf91-8fd4652a2b71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_40187ce1-90d6-4155-8f04-43526d0049b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_172bb343-3d1d-41f0-bf91-8fd4652a2b71" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_40187ce1-90d6-4155-8f04-43526d0049b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_91c3f932-291b-4237-87f9-d4a0025fa269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_40187ce1-90d6-4155-8f04-43526d0049b9" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_91c3f932-291b-4237-87f9-d4a0025fa269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4fcba32b-413d-4fe2-81c6-d323ff20ee1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_40187ce1-90d6-4155-8f04-43526d0049b9" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4fcba32b-413d-4fe2-81c6-d323ff20ee1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_30a3e54b-154a-4a16-8899-2e683a3229a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4fcba32b-413d-4fe2-81c6-d323ff20ee1f" xlink:to="loc_us-gaap_AdjustmentForAmortization_30a3e54b-154a-4a16-8899-2e683a3229a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_c8f0f699-1a18-408a-a750-a539fc407cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4fcba32b-413d-4fe2-81c6-d323ff20ee1f" xlink:to="loc_us-gaap_Depreciation_c8f0f699-1a18-408a-a750-a539fc407cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_4355614d-502d-4dd6-ad36-1e8c7291a488" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4fcba32b-413d-4fe2-81c6-d323ff20ee1f" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_4355614d-502d-4dd6-ad36-1e8c7291a488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_653aa3ab-0688-4fdc-9f7f-246fa29ab888" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4fcba32b-413d-4fe2-81c6-d323ff20ee1f" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_653aa3ab-0688-4fdc-9f7f-246fa29ab888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_91dfbfa5-7ade-4700-b9df-834a6b616d78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4fcba32b-413d-4fe2-81c6-d323ff20ee1f" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_91dfbfa5-7ade-4700-b9df-834a6b616d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_540901bd-af9e-4973-a691-1e0014a910db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4fcba32b-413d-4fe2-81c6-d323ff20ee1f" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_540901bd-af9e-4973-a691-1e0014a910db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_e39273f2-f1a8-4ab7-974c-bbb4fd93f3ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4fcba32b-413d-4fe2-81c6-d323ff20ee1f" xlink:to="loc_us-gaap_ShareBasedCompensation_e39273f2-f1a8-4ab7-974c-bbb4fd93f3ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_d3ef4466-d6b1-4a1f-a0e8-c7f5f31548c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4fcba32b-413d-4fe2-81c6-d323ff20ee1f" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_d3ef4466-d6b1-4a1f-a0e8-c7f5f31548c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapital_2f633053-1504-4d3f-869e-cdc2b12507ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapital"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4fcba32b-413d-4fe2-81c6-d323ff20ee1f" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapital_2f633053-1504-4d3f-869e-cdc2b12507ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_101e05c6-a71a-419d-a969-3b50657dce4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4fcba32b-413d-4fe2-81c6-d323ff20ee1f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_101e05c6-a71a-419d-a969-3b50657dce4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b8d50405-d426-41c2-8ab2-75a60751374b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_172bb343-3d1d-41f0-bf91-8fd4652a2b71" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b8d50405-d426-41c2-8ab2-75a60751374b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_8f1b8c16-b844-43f2-b595-b245e299e6cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b8d50405-d426-41c2-8ab2-75a60751374b" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_8f1b8c16-b844-43f2-b595-b245e299e6cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_feb79316-4739-45d8-b6c0-2776a80ab8c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b8d50405-d426-41c2-8ab2-75a60751374b" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_feb79316-4739-45d8-b6c0-2776a80ab8c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_64eeb545-256d-42b4-bf58-8332ba074ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b8d50405-d426-41c2-8ab2-75a60751374b" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_64eeb545-256d-42b4-bf58-8332ba074ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_a567f15c-abe6-4ae3-8f8e-d94467c5a4d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b8d50405-d426-41c2-8ab2-75a60751374b" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_a567f15c-abe6-4ae3-8f8e-d94467c5a4d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_ec879910-f7cf-4122-8cb8-6ffb9140425a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b8d50405-d426-41c2-8ab2-75a60751374b" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_ec879910-f7cf-4122-8cb8-6ffb9140425a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_a17a4dd7-80f7-4922-8f17-04504cc47192" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b8d50405-d426-41c2-8ab2-75a60751374b" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_a17a4dd7-80f7-4922-8f17-04504cc47192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_4a85437f-3e99-44a1-a41e-f5074c6bfa2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b8d50405-d426-41c2-8ab2-75a60751374b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_4a85437f-3e99-44a1-a41e-f5074c6bfa2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_594cd8f9-f936-4876-b93f-809b65923cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_172bb343-3d1d-41f0-bf91-8fd4652a2b71" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_594cd8f9-f936-4876-b93f-809b65923cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_eb5f3b8d-37d6-416c-b8a1-d0c455cb8c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_594cd8f9-f936-4876-b93f-809b65923cbb" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_eb5f3b8d-37d6-416c-b8a1-d0c455cb8c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_f9293e6c-ab28-41fe-82dd-6402b84de5d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_594cd8f9-f936-4876-b93f-809b65923cbb" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_f9293e6c-ab28-41fe-82dd-6402b84de5d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DisposalGroupInclDiscontinuedOperationsDistributionReceived_1be58dfa-69b0-44a7-91df-790b5d9eb7f4" xlink:href="mrk-20220930.xsd#mrk_DisposalGroupInclDiscontinuedOperationsDistributionReceived"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_594cd8f9-f936-4876-b93f-809b65923cbb" xlink:to="loc_mrk_DisposalGroupInclDiscontinuedOperationsDistributionReceived_1be58dfa-69b0-44a7-91df-790b5d9eb7f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_8ea1a710-105f-40cd-9026-04bfbe9ed0a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_594cd8f9-f936-4876-b93f-809b65923cbb" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_8ea1a710-105f-40cd-9026-04bfbe9ed0a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_6cea29da-8c58-48e1-822e-b43f212761ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_594cd8f9-f936-4876-b93f-809b65923cbb" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_6cea29da-8c58-48e1-822e-b43f212761ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_bafcfad7-edcd-4278-ad8d-f156984af7c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_594cd8f9-f936-4876-b93f-809b65923cbb" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_bafcfad7-edcd-4278-ad8d-f156984af7c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_579fc4a7-e764-4585-bedd-f115b76227a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_594cd8f9-f936-4876-b93f-809b65923cbb" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_579fc4a7-e764-4585-bedd-f115b76227a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_c053dd91-8b1d-49ab-955e-8a09b3ed063e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_594cd8f9-f936-4876-b93f-809b65923cbb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_c053dd91-8b1d-49ab-955e-8a09b3ed063e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_0ee6ca47-7a19-438b-a7cb-7af2e009b154" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_594cd8f9-f936-4876-b93f-809b65923cbb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_0ee6ca47-7a19-438b-a7cb-7af2e009b154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_a1d6c6e9-252c-467c-96fe-64c3c90bd7be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_0ee6ca47-7a19-438b-a7cb-7af2e009b154" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_a1d6c6e9-252c-467c-96fe-64c3c90bd7be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_56545676-243a-479b-af66-9d708ae915c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_0ee6ca47-7a19-438b-a7cb-7af2e009b154" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_56545676-243a-479b-af66-9d708ae915c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_5b11730a-fce3-4a54-9c80-73f0e9a136bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_0ee6ca47-7a19-438b-a7cb-7af2e009b154" xlink:to="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_5b11730a-fce3-4a54-9c80-73f0e9a136bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations_b2e6f475-97cd-4db2-9dd6-2adf39f361eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInDiscontinuedOperations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_0ee6ca47-7a19-438b-a7cb-7af2e009b154" xlink:to="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations_b2e6f475-97cd-4db2-9dd6-2adf39f361eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f032dc7e-647d-459a-a26a-f408d97f61cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_172bb343-3d1d-41f0-bf91-8fd4652a2b71" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f032dc7e-647d-459a-a26a-f408d97f61cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f7b94745-72cf-4a2e-895f-5016fe27c760" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_172bb343-3d1d-41f0-bf91-8fd4652a2b71" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f7b94745-72cf-4a2e-895f-5016fe27c760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d76c945f-4be1-4e8b-a549-756290033374" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_172bb343-3d1d-41f0-bf91-8fd4652a2b71" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d76c945f-4be1-4e8b-a549-756290033374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_44fce653-1e09-4559-b53a-70cd96a2a0cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_172bb343-3d1d-41f0-bf91-8fd4652a2b71" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_44fce653-1e09-4559-b53a-70cd96a2a0cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWSParenthetical" xlink:type="simple" xlink:href="mrk-20220930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWSParenthetical"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_d4155a94-1095-45d7-82a9-055609f8b705" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_a2522c5b-a246-4d91-9e56-ff510f38a4f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d4155a94-1095-45d7-82a9-055609f8b705" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_a2522c5b-a246-4d91-9e56-ff510f38a4f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/BasisofPresentation" xlink:type="simple" xlink:href="mrk-20220930.xsd#BasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/BasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_38bfbb81-26c8-45b5-8aad-3a18173cdcbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_d0afd389-e868-4675-aa51-e51ebd7ccb20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_38bfbb81-26c8-45b5-8aad-3a18173cdcbb" xlink:to="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_d0afd389-e868-4675-aa51-e51ebd7ccb20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SpinOffofOrganonCo" xlink:type="simple" xlink:href="mrk-20220930.xsd#SpinOffofOrganonCo"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SpinOffofOrganonCo" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_da4ff091-f923-47f4-8b24-50f48365af98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_06e92c20-de58-4cf8-925e-61efa4a83a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_da4ff091-f923-47f4-8b24-50f48365af98" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_06e92c20-de58-4cf8-925e-61efa4a83a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreements" xlink:type="simple" xlink:href="mrk-20220930.xsd#AcquisitionsResearchCollaborationsandLicenseAgreements"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1b18efb8-b344-4f03-a3fa-cc272bbd08ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock_8e453f42-79dc-4e68-9718-8add7aa2afe2" xlink:href="mrk-20220930.xsd#mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1b18efb8-b344-4f03-a3fa-cc272bbd08ce" xlink:to="loc_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock_8e453f42-79dc-4e68-9718-8add7aa2afe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CollaborativeArrangements" xlink:type="simple" xlink:href="mrk-20220930.xsd#CollaborativeArrangements"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/CollaborativeArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementsAbstract_5de41c79-851b-466f-9254-b104510dd0aa" xlink:href="mrk-20220930.xsd#mrk_CollaborativeArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_d436f4fa-0848-42ac-b9fc-178799b6dbab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_CollaborativeArrangementsAbstract_5de41c79-851b-466f-9254-b104510dd0aa" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_d436f4fa-0848-42ac-b9fc-178799b6dbab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/Restructuring" xlink:type="simple" xlink:href="mrk-20220930.xsd#Restructuring"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/Restructuring" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3dc7887f-6294-4429-a069-a71ea98e1aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_ebd96ce5-98c0-49b7-94fb-362bf91ff980" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3dc7887f-6294-4429-a069-a71ea98e1aa9" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_ebd96ce5-98c0-49b7-94fb-362bf91ff980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstruments" xlink:type="simple" xlink:href="mrk-20220930.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_a3d0319b-b5ef-4718-9a75-01347ed836cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_eb914af3-b312-4e52-900d-b1473d3c7a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_a3d0319b-b5ef-4718-9a75-01347ed836cb" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_eb914af3-b312-4e52-900d-b1473d3c7a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/Inventories" xlink:type="simple" xlink:href="mrk-20220930.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_f0ad2ce5-502d-4b2d-87ac-37ddaaf133c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_bf901b8d-7e9a-4d80-9a6b-b985b9283ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_f0ad2ce5-502d-4b2d-87ac-37ddaaf133c2" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_bf901b8d-7e9a-4d80-9a6b-b985b9283ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIntangibles" xlink:type="simple" xlink:href="mrk-20220930.xsd#OtherIntangibles"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/OtherIntangibles" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2f211595-fd5a-4e35-9355-91ff10971612" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_8940a8d2-f926-4bf1-8e70-4471bab96ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2f211595-fd5a-4e35-9355-91ff10971612" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_8940a8d2-f926-4bf1-8e70-4471bab96ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/Contingencies" xlink:type="simple" xlink:href="mrk-20220930.xsd#Contingencies"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/Contingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b1e1d741-e779-43b5-935d-7835fa5ccb3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_7978ac28-6272-4321-8483-c8bf2bc46a92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b1e1d741-e779-43b5-935d-7835fa5ccb3c" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_7978ac28-6272-4321-8483-c8bf2bc46a92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/Equity" xlink:type="simple" xlink:href="mrk-20220930.xsd#Equity"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/Equity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_325e1c41-7c8f-498c-802e-821de038b30c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_eb2cc48c-1e24-417b-8739-ce7168d96a13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_325e1c41-7c8f-498c-802e-821de038b30c" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_eb2cc48c-1e24-417b-8739-ce7168d96a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans" xlink:type="simple" xlink:href="mrk-20220930.xsd#PensionandOtherPostretirementBenefitPlans"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1b419b79-ca13-45d9-9b95-6e42a7c28a08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_a23ae9b9-6e0f-4b51-889f-ddb91c839068" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1b419b79-ca13-45d9-9b95-6e42a7c28a08" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_a23ae9b9-6e0f-4b51-889f-ddb91c839068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIncomeExpenseNet" xlink:type="simple" xlink:href="mrk-20220930.xsd#OtherIncomeExpenseNet"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/OtherIncomeExpenseNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_cbcd398a-61c5-4fc0-b5bc-a4e2c2ba65f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_a3d5d373-0cc1-4fa9-a0d1-d957bc9d2512" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_cbcd398a-61c5-4fc0-b5bc-a4e2c2ba65f4" xlink:to="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_a3d5d373-0cc1-4fa9-a0d1-d957bc9d2512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncome" xlink:type="simple" xlink:href="mrk-20220930.xsd#TaxesonIncome"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/TaxesonIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ff3f73d2-673f-4cd3-806e-bacf7fb6cf4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_d5d53db8-44ba-4c8c-975b-b34eb2a8df6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ff3f73d2-673f-4cd3-806e-bacf7fb6cf4a" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_d5d53db8-44ba-4c8c-975b-b34eb2a8df6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/EarningsPerShare" xlink:type="simple" xlink:href="mrk-20220930.xsd#EarningsPerShare"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_88139f46-89a9-4f48-b1a9-3560e28a69a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_e4cde7bf-f11e-499f-ab49-680ae093a347" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_88139f46-89a9-4f48-b1a9-3560e28a69a0" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_e4cde7bf-f11e-499f-ab49-680ae093a347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLoss" xlink:type="simple" xlink:href="mrk-20220930.xsd#OtherComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/OtherComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_0b7923e8-9728-41e8-8d4b-87babb2a4314" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_f914fa4a-9640-4595-9a15-675a7ea08bca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0b7923e8-9728-41e8-8d4b-87babb2a4314" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_f914fa4a-9640-4595-9a15-675a7ea08bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReporting" xlink:type="simple" xlink:href="mrk-20220930.xsd#SegmentReporting"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SegmentReporting" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_c10da30f-c3ad-481d-a360-e273bd6ff749" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_a6dca0b3-463e-4969-9e54-ef044742c1e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c10da30f-c3ad-481d-a360-e273bd6ff749" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_a6dca0b3-463e-4969-9e54-ef044742c1e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/BasisofPresentationPolicies" xlink:type="simple" xlink:href="mrk-20220930.xsd#BasisofPresentationPolicies"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/BasisofPresentationPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_58fed663-d40f-40c9-a553-819467f910f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6bf848dc-2cba-48a1-b96f-7b3e0f210051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_58fed663-d40f-40c9-a553-819467f910f7" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6bf848dc-2cba-48a1-b96f-7b3e0f210051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_dcd64318-f56a-4d27-8bfa-bee22bf10917" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_58fed663-d40f-40c9-a553-819467f910f7" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_dcd64318-f56a-4d27-8bfa-bee22bf10917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalCostsPolicyTextBlock_d7ae46f5-4171-4aac-838c-8f566a393228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalCostsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_58fed663-d40f-40c9-a553-819467f910f7" xlink:to="loc_us-gaap_LegalCostsPolicyTextBlock_d7ae46f5-4171-4aac-838c-8f566a393228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SpinOffofOrganonCoTables" xlink:type="simple" xlink:href="mrk-20220930.xsd#SpinOffofOrganonCoTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SpinOffofOrganonCoTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_ec7eb9f4-7309-4bc7-af6b-ef59ad77e190" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_2b73b78b-ab85-4032-9de4-8e0f051cd1f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_ec7eb9f4-7309-4bc7-af6b-ef59ad77e190" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_2b73b78b-ab85-4032-9de4-8e0f051cd1f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CollaborativeArrangementsTables" xlink:type="simple" xlink:href="mrk-20220930.xsd#CollaborativeArrangementsTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/CollaborativeArrangementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementsAbstract_b2d52851-93aa-4113-9759-7a01075f2ed0" xlink:href="mrk-20220930.xsd#mrk_CollaborativeArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_7eaf33f4-60ae-4e62-9dac-51d68072e423" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_CollaborativeArrangementsAbstract_b2d52851-93aa-4113-9759-7a01075f2ed0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_7eaf33f4-60ae-4e62-9dac-51d68072e423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/RestructuringTables" xlink:type="simple" xlink:href="mrk-20220930.xsd#RestructuringTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/RestructuringTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_b248aafd-f19b-483c-9e76-cd674605ccd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_78478d59-de7b-40ec-b522-bde140e8f774" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_b248aafd-f19b-483c-9e76-cd674605ccd7" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_78478d59-de7b-40ec-b522-bde140e8f774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_03e25af8-db33-42cb-af05-cd4fe9f90136" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_b248aafd-f19b-483c-9e76-cd674605ccd7" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_03e25af8-db33-42cb-af05-cd4fe9f90136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="mrk-20220930.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_b2e78c49-054c-406d-92cc-2992f50bdbc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_ff9c5862-5d60-43c6-abf7-36f86deaef40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_b2e78c49-054c-406d-92cc-2992f50bdbc7" xlink:to="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_ff9c5862-5d60-43c6-abf7-36f86deaef40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_7be781f3-c576-4c81-b17f-9ce7a48c53e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_b2e78c49-054c-406d-92cc-2992f50bdbc7" xlink:to="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_7be781f3-c576-4c81-b17f-9ce7a48c53e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_8122f494-d810-4695-8ea2-46c96b891d05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_b2e78c49-054c-406d-92cc-2992f50bdbc7" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_8122f494-d810-4695-8ea2-46c96b891d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock_1b9d1c6a-afe5-44cd-94f8-625c54feb975" xlink:href="mrk-20220930.xsd#mrk_OffsettingAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_b2e78c49-054c-406d-92cc-2992f50bdbc7" xlink:to="loc_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock_1b9d1c6a-afe5-44cd-94f8-625c54feb975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_c73eefcc-9c45-4c39-bf8f-1e302bb7ce86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_b2e78c49-054c-406d-92cc-2992f50bdbc7" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_c73eefcc-9c45-4c39-bf8f-1e302bb7ce86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_1f842f65-7220-4e07-8138-dac7634aaa65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_b2e78c49-054c-406d-92cc-2992f50bdbc7" xlink:to="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_1f842f65-7220-4e07-8138-dac7634aaa65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_81f904e5-2029-479d-86e6-21bd78b67fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_b2e78c49-054c-406d-92cc-2992f50bdbc7" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_81f904e5-2029-479d-86e6-21bd78b67fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1b1a8eba-98fb-412c-bc3d-42b3c9312c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_b2e78c49-054c-406d-92cc-2992f50bdbc7" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1b1a8eba-98fb-412c-bc3d-42b3c9312c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_0ce96982-2f54-4359-b6ee-ebaa484f1b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_b2e78c49-054c-406d-92cc-2992f50bdbc7" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_0ce96982-2f54-4359-b6ee-ebaa484f1b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/InventoriesTables" xlink:type="simple" xlink:href="mrk-20220930.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_0ddf718b-bbe5-4611-baca-cc064c2b64c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_f58bdf46-bcb2-41d7-b318-0edcd24d22bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0ddf718b-bbe5-4611-baca-cc064c2b64c9" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_f58bdf46-bcb2-41d7-b318-0edcd24d22bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/EquityTables" xlink:type="simple" xlink:href="mrk-20220930.xsd#EquityTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/EquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_4ca3c099-45de-42c4-b3ab-467c43045fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_05619963-c02e-4b32-af54-8b4e47f1d438" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4ca3c099-45de-42c4-b3ab-467c43045fa9" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_05619963-c02e-4b32-af54-8b4e47f1d438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" xlink:type="simple" xlink:href="mrk-20220930.xsd#PensionandOtherPostretirementBenefitPlansTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_57ca2605-b096-424f-8386-23b207516ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b38980ef-8097-494a-94b6-6214cafc7727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_57ca2605-b096-424f-8386-23b207516ad8" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b38980ef-8097-494a-94b6-6214cafc7727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_5b49b1ec-30db-48d0-bf56-37935515a413" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b38980ef-8097-494a-94b6-6214cafc7727" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_5b49b1ec-30db-48d0-bf56-37935515a413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_e5e2b4d7-a77e-41f9-9da4-136d333c0a98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_5b49b1ec-30db-48d0-bf56-37935515a413" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_e5e2b4d7-a77e-41f9-9da4-136d333c0a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_9f51901b-2ff6-48e6-bf8e-133d3be70acf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_e5e2b4d7-a77e-41f9-9da4-136d333c0a98" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_9f51901b-2ff6-48e6-bf8e-133d3be70acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_4e37ad54-b862-4f80-8902-920b1e0253fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_e5e2b4d7-a77e-41f9-9da4-136d333c0a98" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_4e37ad54-b862-4f80-8902-920b1e0253fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2989e9d7-59e7-4cd5-a6e2-c56883903abc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b38980ef-8097-494a-94b6-6214cafc7727" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2989e9d7-59e7-4cd5-a6e2-c56883903abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_3bcc995d-c6ed-42fb-8755-42789ec66044" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2989e9d7-59e7-4cd5-a6e2-c56883903abc" xlink:to="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_3bcc995d-c6ed-42fb-8755-42789ec66044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIncomeExpenseNetTables" xlink:type="simple" xlink:href="mrk-20220930.xsd#OtherIncomeExpenseNetTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/OtherIncomeExpenseNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_678e2417-d65f-41f9-bd4c-b136441e4457" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_a168b49e-3094-4277-bbdf-c3520ee0c2b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_678e2417-d65f-41f9-bd4c-b136441e4457" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_a168b49e-3094-4277-bbdf-c3520ee0c2b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="mrk-20220930.xsd#EarningsPerShareTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_444c6c89-1a94-4280-8092-e4ea14ce5501" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_9cb258a9-3a3b-46a5-bebd-d10b9c304b60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_444c6c89-1a94-4280-8092-e4ea14ce5501" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_9cb258a9-3a3b-46a5-bebd-d10b9c304b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLossTables" xlink:type="simple" xlink:href="mrk-20220930.xsd#OtherComprehensiveIncomeLossTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/OtherComprehensiveIncomeLossTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_b52a8606-e7f9-4cc6-a881-6c9ca2e82a65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_04e81f97-da60-43a4-99fc-b33bb80cba3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b52a8606-e7f9-4cc6-a881-6c9ca2e82a65" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_04e81f97-da60-43a4-99fc-b33bb80cba3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="mrk-20220930.xsd#SegmentReportingTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SegmentReportingTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_98deda3f-1465-4463-a8e8-6defd5904e79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_c6e3202f-9fc9-451e-87ea-b91bad47c6b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_98deda3f-1465-4463-a8e8-6defd5904e79" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_c6e3202f-9fc9-451e-87ea-b91bad47c6b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_e580e3e5-67fa-4be0-b2a7-9c4206367728" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_98deda3f-1465-4463-a8e8-6defd5904e79" xlink:to="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_e580e3e5-67fa-4be0-b2a7-9c4206367728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_04edae15-f2b3-4158-b7dc-adf7453aa57b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_98deda3f-1465-4463-a8e8-6defd5904e79" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_04edae15-f2b3-4158-b7dc-adf7453aa57b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#SpinOffofOrganonCoNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_ea4f8878-699c-4eaf-8729-f9a683b4ded0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_65bbaf45-3e32-4119-97ec-fac095805524" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_ea4f8878-699c-4eaf-8729-f9a683b4ded0" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_65bbaf45-3e32-4119-97ec-fac095805524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_731a6dc1-adb7-418a-96e1-fc3e18431deb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_65bbaf45-3e32-4119-97ec-fac095805524" xlink:to="loc_dei_LegalEntityAxis_731a6dc1-adb7-418a-96e1-fc3e18431deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_7d16f7ed-f886-4dfa-becc-48c6b35c421d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_731a6dc1-adb7-418a-96e1-fc3e18431deb" xlink:to="loc_dei_EntityDomain_7d16f7ed-f886-4dfa-becc-48c6b35c421d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OrganonCoMember_0aa9242d-efaa-4929-b621-33e4d6fe434b" xlink:href="mrk-20220930.xsd#mrk_OrganonCoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_7d16f7ed-f886-4dfa-becc-48c6b35c421d" xlink:to="loc_mrk_OrganonCoMember_0aa9242d-efaa-4929-b621-33e4d6fe434b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c7de8491-c2c5-4d5e-9347-87edcc1d73ad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_65bbaf45-3e32-4119-97ec-fac095805524" xlink:to="loc_srt_RangeAxis_c7de8491-c2c5-4d5e-9347-87edcc1d73ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f3ef73c2-3fee-438b-9c48-5fba3b4e47c5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c7de8491-c2c5-4d5e-9347-87edcc1d73ad" xlink:to="loc_srt_RangeMember_f3ef73c2-3fee-438b-9c48-5fba3b4e47c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a29a3f6f-3785-4bf6-9ba8-d1e73e40dadd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f3ef73c2-3fee-438b-9c48-5fba3b4e47c5" xlink:to="loc_srt_MinimumMember_a29a3f6f-3785-4bf6-9ba8-d1e73e40dadd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_af63107a-5d5b-445b-be5e-4b7451b2e0d6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f3ef73c2-3fee-438b-9c48-5fba3b4e47c5" xlink:to="loc_srt_MaximumMember_af63107a-5d5b-445b-be5e-4b7451b2e0d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_3480582e-2bb7-4926-98dd-e544597b5e95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_65bbaf45-3e32-4119-97ec-fac095805524" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_3480582e-2bb7-4926-98dd-e544597b5e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_ce48dee0-1138-43b9-942a-3b045a97e7f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_3480582e-2bb7-4926-98dd-e544597b5e95" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_ce48dee0-1138-43b9-942a-3b045a97e7f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_TransitionServicesAgreementMember_e49fa9d1-be06-45ae-946e-a428fc106bca" xlink:href="mrk-20220930.xsd#mrk_TransitionServicesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_ce48dee0-1138-43b9-942a-3b045a97e7f7" xlink:to="loc_mrk_TransitionServicesAgreementMember_e49fa9d1-be06-45ae-946e-a428fc106bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ManufacturingAndSupplyAgreementsMember_6964e711-ae34-4f47-b87a-d128ac26d908" xlink:href="mrk-20220930.xsd#mrk_ManufacturingAndSupplyAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_ce48dee0-1138-43b9-942a-3b045a97e7f7" xlink:to="loc_mrk_ManufacturingAndSupplyAgreementsMember_6964e711-ae34-4f47-b87a-d128ac26d908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7d1ff179-7912-4071-8bbe-7cfbbe6b156d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_65bbaf45-3e32-4119-97ec-fac095805524" xlink:to="loc_srt_CounterpartyNameAxis_7d1ff179-7912-4071-8bbe-7cfbbe6b156d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_99318653-6a51-4961-bc55-692069d231ad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_7d1ff179-7912-4071-8bbe-7cfbbe6b156d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_99318653-6a51-4961-bc55-692069d231ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OrganonCoMember_14eb50aa-f2e1-4009-9077-1d1fb8a327ad" xlink:href="mrk-20220930.xsd#mrk_OrganonCoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_99318653-6a51-4961-bc55-692069d231ad" xlink:to="loc_mrk_OrganonCoMember_14eb50aa-f2e1-4009-9077-1d1fb8a327ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_926bfe8e-0efa-42ff-b4b4-7b564e6e5dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_65bbaf45-3e32-4119-97ec-fac095805524" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_926bfe8e-0efa-42ff-b4b4-7b564e6e5dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_271bda9c-5f22-493d-b658-4fe17c6376a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_926bfe8e-0efa-42ff-b4b4-7b564e6e5dd6" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_271bda9c-5f22-493d-b658-4fe17c6376a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_108f197c-05b6-4c7c-9249-751a8316e820" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_926bfe8e-0efa-42ff-b4b4-7b564e6e5dd6" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_108f197c-05b6-4c7c-9249-751a8316e820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_f6f42f6d-182b-4246-81d9-3eb245b47690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_926bfe8e-0efa-42ff-b4b4-7b564e6e5dd6" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_f6f42f6d-182b-4246-81d9-3eb245b47690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal_40acca4d-06a2-44af-b65e-ccba8b5bf327" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_926bfe8e-0efa-42ff-b4b4-7b564e6e5dd6" xlink:to="loc_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal_40acca4d-06a2-44af-b65e-ccba8b5bf327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_184e9476-c6b8-4f9c-938d-9e372f815fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_926bfe8e-0efa-42ff-b4b4-7b564e6e5dd6" xlink:to="loc_us-gaap_RevenueFromRelatedParties_184e9476-c6b8-4f9c-938d-9e372f815fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartiesAmountInCostOfSales_209a2262-dc81-426a-90b2-86930a42dbb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartiesAmountInCostOfSales"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_926bfe8e-0efa-42ff-b4b4-7b564e6e5dd6" xlink:to="loc_us-gaap_RelatedPartiesAmountInCostOfSales_209a2262-dc81-426a-90b2-86930a42dbb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_4c193f54-43e6-4504-9938-2d99688d2b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_926bfe8e-0efa-42ff-b4b4-7b564e6e5dd6" xlink:to="loc_us-gaap_DueFromRelatedPartiesCurrent_4c193f54-43e6-4504-9938-2d99688d2b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_191c86de-6777-4d26-bd97-c2365d076938" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_926bfe8e-0efa-42ff-b4b4-7b564e6e5dd6" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_191c86de-6777-4d26-bd97-c2365d076938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_2ffe9c2b-7b61-41b7-aa7b-e5227ebc459f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_926bfe8e-0efa-42ff-b4b4-7b564e6e5dd6" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_2ffe9c2b-7b61-41b7-aa7b-e5227ebc459f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_fcb667f0-23eb-4985-b2c5-32a117699309" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_e64bd85c-5915-4178-a57b-679faf861c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_fcb667f0-23eb-4985-b2c5-32a117699309" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_e64bd85c-5915-4178-a57b-679faf861c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_f94e2da8-cf87-4f79-a074-a946ae41645c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_fcb667f0-23eb-4985-b2c5-32a117699309" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_f94e2da8-cf87-4f79-a074-a946ae41645c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_1b001a11-cf45-4b12-8553-e2af1884ae4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_f94e2da8-cf87-4f79-a074-a946ae41645c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_1b001a11-cf45-4b12-8553-e2af1884ae4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_75c58672-d00c-4ed3-950c-2f8fd44e4578" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_f94e2da8-cf87-4f79-a074-a946ae41645c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_75c58672-d00c-4ed3-950c-2f8fd44e4578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses_a028a5bd-129e-45b1-aa74-92024db77c1d" xlink:href="mrk-20220930.xsd#mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_f94e2da8-cf87-4f79-a074-a946ae41645c" xlink:to="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses_a028a5bd-129e-45b1-aa74-92024db77c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts_3c7d1519-e3a0-48d9-8d57-32caacd20347" xlink:href="mrk-20220930.xsd#mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_f94e2da8-cf87-4f79-a074-a946ae41645c" xlink:to="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts_3c7d1519-e3a0-48d9-8d57-32caacd20347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet_103a9a6e-6c34-453d-9ecf-951eb622303b" xlink:href="mrk-20220930.xsd#mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_f94e2da8-cf87-4f79-a074-a946ae41645c" xlink:to="loc_mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet_103a9a6e-6c34-453d-9ecf-951eb622303b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_f9dcfb37-c66a-4a48-80f7-ca20d684e5fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_f94e2da8-cf87-4f79-a074-a946ae41645c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_f9dcfb37-c66a-4a48-80f7-ca20d684e5fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_32660eda-c6e6-4274-b2e0-1915371ec977" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_fcb667f0-23eb-4985-b2c5-32a117699309" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_32660eda-c6e6-4274-b2e0-1915371ec977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod_44124a22-c8e2-4fb2-b378-96601b48c0d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_fcb667f0-23eb-4985-b2c5-32a117699309" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod_44124a22-c8e2-4fb2-b378-96601b48c0d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_b386b43c-2b06-49ba-839a-850c9169d57c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_fcb667f0-23eb-4985-b2c5-32a117699309" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_b386b43c-2b06-49ba-839a-850c9169d57c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_c66b066b-b0bb-4f89-a0ea-90f359862bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_fcb667f0-23eb-4985-b2c5-32a117699309" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_c66b066b-b0bb-4f89-a0ea-90f359862bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_8f94cdde-26ff-48af-b0a1-b3b2a3f6b815" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_fcb667f0-23eb-4985-b2c5-32a117699309" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_8f94cdde-26ff-48af-b0a1-b3b2a3f6b815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#AcquisitionsResearchCollaborationsandLicenseAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_2a0fe7ad-206a-4779-8c55-e5cf9fdccd84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_921b4bd8-3163-4822-af82-eab2c901b7be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_2a0fe7ad-206a-4779-8c55-e5cf9fdccd84" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_921b4bd8-3163-4822-af82-eab2c901b7be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8419571a-5679-401b-937f-db861d70d56f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_921b4bd8-3163-4822-af82-eab2c901b7be" xlink:to="loc_srt_ProductOrServiceAxis_8419571a-5679-401b-937f-db861d70d56f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fff35f0e-a97e-4a08-aa6f-836eca899776" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8419571a-5679-401b-937f-db861d70d56f" xlink:to="loc_srt_ProductsAndServicesDomain_fff35f0e-a97e-4a08-aa6f-836eca899776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_COVID19Member_24ad068c-e0e4-48dd-b641-b50b2d852cc1" xlink:href="mrk-20220930.xsd#mrk_COVID19Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_fff35f0e-a97e-4a08-aa6f-836eca899776" xlink:to="loc_mrk_COVID19Member_24ad068c-e0e4-48dd-b641-b50b2d852cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LynparzaMember_d7e8a02c-75e7-47e2-bcd4-53d1e8fad553" xlink:href="mrk-20220930.xsd#mrk_LynparzaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_fff35f0e-a97e-4a08-aa6f-836eca899776" xlink:to="loc_mrk_LynparzaMember_d7e8a02c-75e7-47e2-bcd4-53d1e8fad553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d45d2a37-39ac-44d8-a2f1-394b69439f7c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_921b4bd8-3163-4822-af82-eab2c901b7be" xlink:to="loc_srt_CounterpartyNameAxis_d45d2a37-39ac-44d8-a2f1-394b69439f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f3fe4f10-2b66-453b-8ffc-5d98c026dc80" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_d45d2a37-39ac-44d8-a2f1-394b69439f7c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f3fe4f10-2b66-453b-8ffc-5d98c026dc80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OrnaTherapeuticsMember_64f70d21-7480-4bc3-a03c-e1db7613bee6" xlink:href="mrk-20220930.xsd#mrk_OrnaTherapeuticsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f3fe4f10-2b66-453b-8ffc-5d98c026dc80" xlink:to="loc_mrk_OrnaTherapeuticsMember_64f70d21-7480-4bc3-a03c-e1db7613bee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OrionCorporationMember_b32e631e-e026-47b8-937f-6001b3ec7ca5" xlink:href="mrk-20220930.xsd#mrk_OrionCorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f3fe4f10-2b66-453b-8ffc-5d98c026dc80" xlink:to="loc_mrk_OrionCorporationMember_b32e631e-e026-47b8-937f-6001b3ec7ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember_647ab374-3de7-40ec-b4e5-04c2b26f532a" xlink:href="mrk-20220930.xsd#mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f3fe4f10-2b66-453b-8ffc-5d98c026dc80" xlink:to="loc_mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember_647ab374-3de7-40ec-b4e5-04c2b26f532a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ArtivaBiotherapeuticsIncMember_3f9579e1-37b4-4c7c-be79-ebd9a98ae5e1" xlink:href="mrk-20220930.xsd#mrk_ArtivaBiotherapeuticsIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f3fe4f10-2b66-453b-8ffc-5d98c026dc80" xlink:to="loc_mrk_ArtivaBiotherapeuticsIncMember_3f9579e1-37b4-4c7c-be79-ebd9a98ae5e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AstraZenecaMember_f0ce5ada-1a2a-41e4-a69d-48f1e9ca0055" xlink:href="mrk-20220930.xsd#mrk_AstraZenecaMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f3fe4f10-2b66-453b-8ffc-5d98c026dc80" xlink:to="loc_mrk_AstraZenecaMember_f0ce5ada-1a2a-41e4-a69d-48f1e9ca0055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_30aa6921-e085-4de3-adab-470e7e4dc25f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_921b4bd8-3163-4822-af82-eab2c901b7be" xlink:to="loc_us-gaap_TypeOfArrangementAxis_30aa6921-e085-4de3-adab-470e7e4dc25f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6c0abf84-04de-450f-9c16-fdf6764ac4d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_30aa6921-e085-4de3-adab-470e7e4dc25f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6c0abf84-04de-450f-9c16-fdf6764ac4d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_50bfe6fb-4452-404e-9d43-7111fd1e0285" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6c0abf84-04de-450f-9c16-fdf6764ac4d1" xlink:to="loc_us-gaap_LicensingAgreementsMember_50bfe6fb-4452-404e-9d43-7111fd1e0285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_417f4bd0-5d37-4153-9669-f0af6210b140" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6c0abf84-04de-450f-9c16-fdf6764ac4d1" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_417f4bd0-5d37-4153-9669-f0af6210b140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OrnaTherapeuticsMember_cda037aa-efad-450c-934b-5d2b4612287f" xlink:href="mrk-20220930.xsd#mrk_OrnaTherapeuticsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6c0abf84-04de-450f-9c16-fdf6764ac4d1" xlink:to="loc_mrk_OrnaTherapeuticsMember_cda037aa-efad-450c-934b-5d2b4612287f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_fffbdd06-ac6d-4548-9628-1f51a65ec03a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_921b4bd8-3163-4822-af82-eab2c901b7be" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_fffbdd06-ac6d-4548-9628-1f51a65ec03a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_88f1cb11-c3be-4960-9284-5eabafd6f3b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_fffbdd06-ac6d-4548-9628-1f51a65ec03a" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_88f1cb11-c3be-4960-9284-5eabafd6f3b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DevelopmentMilestonesMember_c768501d-e733-499d-afc7-723e6e4eb509" xlink:href="mrk-20220930.xsd#mrk_DevelopmentMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_88f1cb11-c3be-4960-9284-5eabafd6f3b5" xlink:to="loc_mrk_DevelopmentMilestonesMember_c768501d-e733-499d-afc7-723e6e4eb509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RegulatoryMilestonesMember_260c7bb5-1c33-479b-bd87-8de7bf5f0ee9" xlink:href="mrk-20220930.xsd#mrk_RegulatoryMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_88f1cb11-c3be-4960-9284-5eabafd6f3b5" xlink:to="loc_mrk_RegulatoryMilestonesMember_260c7bb5-1c33-479b-bd87-8de7bf5f0ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesBasedMilestonesMember_693801bc-e4d6-4094-8af0-9c760e6fba5c" xlink:href="mrk-20220930.xsd#mrk_SalesBasedMilestonesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_88f1cb11-c3be-4960-9284-5eabafd6f3b5" xlink:to="loc_mrk_SalesBasedMilestonesMember_693801bc-e4d6-4094-8af0-9c760e6fba5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FirstCommercialSaleMilestonesMember_e6fe25d0-5bd7-4b5f-b276-53d7b764d50d" xlink:href="mrk-20220930.xsd#mrk_FirstCommercialSaleMilestonesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_88f1cb11-c3be-4960-9284-5eabafd6f3b5" xlink:to="loc_mrk_FirstCommercialSaleMilestonesMember_e6fe25d0-5bd7-4b5f-b276-53d7b764d50d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2fd1ab81-8a21-4239-b937-c6db9985b021" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_921b4bd8-3163-4822-af82-eab2c901b7be" xlink:to="loc_srt_RangeAxis_2fd1ab81-8a21-4239-b937-c6db9985b021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8af25254-f30d-4742-a4d3-172a46441291" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2fd1ab81-8a21-4239-b937-c6db9985b021" xlink:to="loc_srt_RangeMember_8af25254-f30d-4742-a4d3-172a46441291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9bb7b72b-c531-4109-a211-10c3f8650d7e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8af25254-f30d-4742-a4d3-172a46441291" xlink:to="loc_srt_MinimumMember_9bb7b72b-c531-4109-a211-10c3f8650d7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f64646e4-4d7b-4f02-b2c5-16fa603efbdd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8af25254-f30d-4742-a4d3-172a46441291" xlink:to="loc_srt_MaximumMember_f64646e4-4d7b-4f02-b2c5-16fa603efbdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_6b39283a-813a-4487-a136-0bd835ccfef8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_921b4bd8-3163-4822-af82-eab2c901b7be" xlink:to="loc_us-gaap_AssetAcquisitionAxis_6b39283a-813a-4487-a136-0bd835ccfef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_037680be-a09c-4d8c-be0a-41a9d94694d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_6b39283a-813a-4487-a136-0bd835ccfef8" xlink:to="loc_us-gaap_AssetAcquisitionDomain_037680be-a09c-4d8c-be0a-41a9d94694d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PandionTherapeuticsMember_f12c9ca9-9a86-4c22-b2ab-3b78aa6752a3" xlink:href="mrk-20220930.xsd#mrk_PandionTherapeuticsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_037680be-a09c-4d8c-be0a-41a9d94694d5" xlink:to="loc_mrk_PandionTherapeuticsMember_f12c9ca9-9a86-4c22-b2ab-3b78aa6752a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_8533dc67-5ba8-47ac-b0ff-cbeaf0154d78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_921b4bd8-3163-4822-af82-eab2c901b7be" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_8533dc67-5ba8-47ac-b0ff-cbeaf0154d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fdc43261-0dbc-4cee-afb6-ad4a53b12259" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8533dc67-5ba8-47ac-b0ff-cbeaf0154d78" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fdc43261-0dbc-4cee-afb6-ad4a53b12259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_02de1204-6e14-4509-8917-2fb04dc2b8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_fdc43261-0dbc-4cee-afb6-ad4a53b12259" xlink:to="loc_us-gaap_SubsequentEventMember_02de1204-6e14-4509-8917-2fb04dc2b8f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_c20fc8ba-5979-401f-b91e-3579e7193485" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_921b4bd8-3163-4822-af82-eab2c901b7be" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_c20fc8ba-5979-401f-b91e-3579e7193485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_b65e0fa4-83d1-4934-8f27-589501d069fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c20fc8ba-5979-401f-b91e-3579e7193485" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_b65e0fa4-83d1-4934-8f27-589501d069fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts_d336dc95-2d90-448c-acf4-ef3557b48a58" xlink:href="mrk-20220930.xsd#mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c20fc8ba-5979-401f-b91e-3579e7193485" xlink:to="loc_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts_d336dc95-2d90-448c-acf4-ef3557b48a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding_73084716-ecef-4d21-8ac7-3eba08c842ba" xlink:href="mrk-20220930.xsd#mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c20fc8ba-5979-401f-b91e-3579e7193485" xlink:to="loc_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding_73084716-ecef-4d21-8ac7-3eba08c842ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_e8b81650-9412-48ba-9b60-c82eddaaa4e7" xlink:href="mrk-20220930.xsd#mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c20fc8ba-5979-401f-b91e-3579e7193485" xlink:to="loc_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_e8b81650-9412-48ba-9b60-c82eddaaa4e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ContingentPaymentsCollaborativeArrangement_f5b455c0-a8bf-41a9-bb6b-c299c6a252ec" xlink:href="mrk-20220930.xsd#mrk_ContingentPaymentsCollaborativeArrangement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c20fc8ba-5979-401f-b91e-3579e7193485" xlink:to="loc_mrk_ContingentPaymentsCollaborativeArrangement_f5b455c0-a8bf-41a9-bb6b-c299c6a252ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RoyaltyRatePercentage_1f1d1dfa-0247-4e9f-b4fb-1c06582f4c5b" xlink:href="mrk-20220930.xsd#mrk_RoyaltyRatePercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c20fc8ba-5979-401f-b91e-3579e7193485" xlink:to="loc_mrk_RoyaltyRatePercentage_1f1d1dfa-0247-4e9f-b4fb-1c06582f4c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_f1cc6f86-6a34-4625-9e8c-b4bd39c49d93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c20fc8ba-5979-401f-b91e-3579e7193485" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_f1cc6f86-6a34-4625-9e8c-b4bd39c49d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MilestonePaymentsToBeMadeToACollaborativePartner_c8dac7f9-a2d4-496c-b835-fc200308d19f" xlink:href="mrk-20220930.xsd#mrk_MilestonePaymentsToBeMadeToACollaborativePartner"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c20fc8ba-5979-401f-b91e-3579e7193485" xlink:to="loc_mrk_MilestonePaymentsToBeMadeToACollaborativePartner_c8dac7f9-a2d4-496c-b835-fc200308d19f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MilestonePaymentToBeMadeToACollaborativePartner_d76d0fc3-79c8-49ab-bef3-ff4ebfae3dd3" xlink:href="mrk-20220930.xsd#mrk_MilestonePaymentToBeMadeToACollaborativePartner"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c20fc8ba-5979-401f-b91e-3579e7193485" xlink:to="loc_mrk_MilestonePaymentToBeMadeToACollaborativePartner_d76d0fc3-79c8-49ab-bef3-ff4ebfae3dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartner_5b3d1405-50b1-4c82-ad6b-af69eb4086b0" xlink:href="mrk-20220930.xsd#mrk_ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartner"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c20fc8ba-5979-401f-b91e-3579e7193485" xlink:to="loc_mrk_ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartner_5b3d1405-50b1-4c82-ad6b-af69eb4086b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_17212bb2-ba6d-4bd9-851e-16c5425bc524" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c20fc8ba-5979-401f-b91e-3579e7193485" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_17212bb2-ba6d-4bd9-851e-16c5425bc524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner_29da6c1f-20a4-4080-808d-85b6e8e5f78d" xlink:href="mrk-20220930.xsd#mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c20fc8ba-5979-401f-b91e-3579e7193485" xlink:to="loc_mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner_29da6c1f-20a4-4080-808d-85b6e8e5f78d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ChargesRelatedToProgramDiscontinuation_1ee3ab13-4d07-4339-885d-d571025c64d2" xlink:href="mrk-20220930.xsd#mrk_ChargesRelatedToProgramDiscontinuation"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c20fc8ba-5979-401f-b91e-3579e7193485" xlink:to="loc_mrk_ChargesRelatedToProgramDiscontinuation_1ee3ab13-4d07-4339-885d-d571025c64d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_bb400766-5a60-4cae-88fd-a49288a51a68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c20fc8ba-5979-401f-b91e-3579e7193485" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_bb400766-5a60-4cae-88fd-a49288a51a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_5d215c4b-4423-48f1-b31b-5972703bd9a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c20fc8ba-5979-401f-b91e-3579e7193485" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_5d215c4b-4423-48f1-b31b-5972703bd9a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet_862bc44d-9d93-4fdc-b71b-e74431fe58e8" xlink:href="mrk-20220930.xsd#mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c20fc8ba-5979-401f-b91e-3579e7193485" xlink:to="loc_mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet_862bc44d-9d93-4fdc-b71b-e74431fe58e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementNumberOfResearchPrograms_0b758b32-6608-4068-88ee-8d15dd82a8fb" xlink:href="mrk-20220930.xsd#mrk_CollaborativeArrangementNumberOfResearchPrograms"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c20fc8ba-5979-401f-b91e-3579e7193485" xlink:to="loc_mrk_CollaborativeArrangementNumberOfResearchPrograms_0b758b32-6608-4068-88ee-8d15dd82a8fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementNumberOfCollaborationTargets_550c0c42-213d-4935-b315-038f14bb7ff5" xlink:href="mrk-20220930.xsd#mrk_CollaborativeArrangementNumberOfCollaborationTargets"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c20fc8ba-5979-401f-b91e-3579e7193485" xlink:to="loc_mrk_CollaborativeArrangementNumberOfCollaborationTargets_550c0c42-213d-4935-b315-038f14bb7ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#CollaborativeArrangementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementsAbstract_cbbddac2-b2ec-49f2-8f52-d0d1f6eb3cb1" xlink:href="mrk-20220930.xsd#mrk_CollaborativeArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4586c3cb-561a-41ce-8bb5-26e5c4bbd454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_CollaborativeArrangementsAbstract_cbbddac2-b2ec-49f2-8f52-d0d1f6eb3cb1" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4586c3cb-561a-41ce-8bb5-26e5c4bbd454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1645bb3d-3452-4722-a205-2b0340c592f6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4586c3cb-561a-41ce-8bb5-26e5c4bbd454" xlink:to="loc_srt_CounterpartyNameAxis_1645bb3d-3452-4722-a205-2b0340c592f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5e9f5aa6-1f6a-4436-b4da-53ed17814bbd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_1645bb3d-3452-4722-a205-2b0340c592f6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5e9f5aa6-1f6a-4436-b4da-53ed17814bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AstraZenecaMember_afb61da2-f41f-4d7d-b9c5-cc64d9bb38d4" xlink:href="mrk-20220930.xsd#mrk_AstraZenecaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5e9f5aa6-1f6a-4436-b4da-53ed17814bbd" xlink:to="loc_mrk_AstraZenecaMember_afb61da2-f41f-4d7d-b9c5-cc64d9bb38d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EisaiMember_727bd3af-8333-48df-b9c3-af2cca935118" xlink:href="mrk-20220930.xsd#mrk_EisaiMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5e9f5aa6-1f6a-4436-b4da-53ed17814bbd" xlink:to="loc_mrk_EisaiMember_727bd3af-8333-48df-b9c3-af2cca935118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BayerAGMember_31c55a77-942d-4d96-8447-ff858e1f56f7" xlink:href="mrk-20220930.xsd#mrk_BayerAGMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5e9f5aa6-1f6a-4436-b4da-53ed17814bbd" xlink:to="loc_mrk_BayerAGMember_31c55a77-942d-4d96-8447-ff858e1f56f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BristolMyersSquibbMember_d5cb04aa-1204-485e-a289-d67b773eaa0a" xlink:href="mrk-20220930.xsd#mrk_BristolMyersSquibbMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5e9f5aa6-1f6a-4436-b4da-53ed17814bbd" xlink:to="loc_mrk_BristolMyersSquibbMember_d5cb04aa-1204-485e-a289-d67b773eaa0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_47915342-989d-4d5d-adc5-d9a5e627d12b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4586c3cb-561a-41ce-8bb5-26e5c4bbd454" xlink:to="loc_us-gaap_TypeOfArrangementAxis_47915342-989d-4d5d-adc5-d9a5e627d12b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_12a3799b-8dcd-4e37-95a4-477bb67e0d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_47915342-989d-4d5d-adc5-d9a5e627d12b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_12a3799b-8dcd-4e37-95a4-477bb67e0d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesBasedMilestonesMember_a6464bcd-5343-42c6-ab38-a937766f7f77" xlink:href="mrk-20220930.xsd#mrk_SalesBasedMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_12a3799b-8dcd-4e37-95a4-477bb67e0d4a" xlink:to="loc_mrk_SalesBasedMilestonesMember_a6464bcd-5343-42c6-ab38-a937766f7f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_e5c1fdb7-df41-4645-a50e-eac65fff8788" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_12a3799b-8dcd-4e37-95a4-477bb67e0d4a" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_e5c1fdb7-df41-4645-a50e-eac65fff8788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_5465802a-9281-4b42-b7db-ea131771a14e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_12a3799b-8dcd-4e37-95a4-477bb67e0d4a" xlink:to="loc_us-gaap_LicensingAgreementsMember_5465802a-9281-4b42-b7db-ea131771a14e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RegulatoryMilestonesMember_bd227574-28b2-47fe-b33b-f1154ba2aeca" xlink:href="mrk-20220930.xsd#mrk_RegulatoryMilestonesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_12a3799b-8dcd-4e37-95a4-477bb67e0d4a" xlink:to="loc_mrk_RegulatoryMilestonesMember_bd227574-28b2-47fe-b33b-f1154ba2aeca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ad8c75bf-ab50-4f0d-86f8-803caaa4ea31" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4586c3cb-561a-41ce-8bb5-26e5c4bbd454" xlink:to="loc_srt_ProductOrServiceAxis_ad8c75bf-ab50-4f0d-86f8-803caaa4ea31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c8d2d4cf-ed3b-434b-ae6d-853f58623b49" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ad8c75bf-ab50-4f0d-86f8-803caaa4ea31" xlink:to="loc_srt_ProductsAndServicesDomain_c8d2d4cf-ed3b-434b-ae6d-853f58623b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LynparzaMember_a71c8ef9-1f20-4591-b940-8d1e8b66fdff" xlink:href="mrk-20220930.xsd#mrk_LynparzaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c8d2d4cf-ed3b-434b-ae6d-853f58623b49" xlink:to="loc_mrk_LynparzaMember_a71c8ef9-1f20-4591-b940-8d1e8b66fdff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LenvimaMember_d0165e44-7ea3-47e9-9067-df25dedd8b52" xlink:href="mrk-20220930.xsd#mrk_LenvimaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c8d2d4cf-ed3b-434b-ae6d-853f58623b49" xlink:to="loc_mrk_LenvimaMember_d0165e44-7ea3-47e9-9067-df25dedd8b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VerquvoMember_53d86344-64e7-4a12-84a9-9ac91f424b1e" xlink:href="mrk-20220930.xsd#mrk_VerquvoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c8d2d4cf-ed3b-434b-ae6d-853f58623b49" xlink:to="loc_mrk_VerquvoMember_53d86344-64e7-4a12-84a9-9ac91f424b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AdempasMember_88453cb2-6380-44d3-ac93-35926f9d8afd" xlink:href="mrk-20220930.xsd#mrk_AdempasMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c8d2d4cf-ed3b-434b-ae6d-853f58623b49" xlink:to="loc_mrk_AdempasMember_88453cb2-6380-44d3-ac93-35926f9d8afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AllianceRevenueReblozylMember_10e49a8c-9fdf-4235-8672-fa0bfb3258cb" xlink:href="mrk-20220930.xsd#mrk_AllianceRevenueReblozylMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c8d2d4cf-ed3b-434b-ae6d-853f58623b49" xlink:to="loc_mrk_AllianceRevenueReblozylMember_10e49a8c-9fdf-4235-8672-fa0bfb3258cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1a803fb8-920a-477b-83d1-c0476dc7dbf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4586c3cb-561a-41ce-8bb5-26e5c4bbd454" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1a803fb8-920a-477b-83d1-c0476dc7dbf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_54fb9266-a138-44f4-bd04-4ad3944faac1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1a803fb8-920a-477b-83d1-c0476dc7dbf0" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_54fb9266-a138-44f4-bd04-4ad3944faac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_167df743-8ddd-407d-a000-985c56f9c0ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_54fb9266-a138-44f4-bd04-4ad3944faac1" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_167df743-8ddd-407d-a000-985c56f9c0ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_8ab1cbb8-1210-4589-8d2f-c587b4ca05f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_54fb9266-a138-44f4-bd04-4ad3944faac1" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_8ab1cbb8-1210-4589-8d2f-c587b4ca05f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1aba6ae5-0194-46d5-be61-bf14d8b4aa72" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4586c3cb-561a-41ce-8bb5-26e5c4bbd454" xlink:to="loc_srt_RangeAxis_1aba6ae5-0194-46d5-be61-bf14d8b4aa72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_62621cdf-cb9d-45fb-ac13-4c2441060512" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1aba6ae5-0194-46d5-be61-bf14d8b4aa72" xlink:to="loc_srt_RangeMember_62621cdf-cb9d-45fb-ac13-4c2441060512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f20cdb25-8dfb-444e-9a7f-d4a6606f1456" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_62621cdf-cb9d-45fb-ac13-4c2441060512" xlink:to="loc_srt_MinimumMember_f20cdb25-8dfb-444e-9a7f-d4a6606f1456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e86bde4b-91ce-44f2-89ed-486476dfde1f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_62621cdf-cb9d-45fb-ac13-4c2441060512" xlink:to="loc_srt_MaximumMember_e86bde4b-91ce-44f2-89ed-486476dfde1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_5d06c206-9b53-453a-8aed-038527015554" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4586c3cb-561a-41ce-8bb5-26e5c4bbd454" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_5d06c206-9b53-453a-8aed-038527015554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_f5201572-7826-487a-9fae-abcec18fc308" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_5d06c206-9b53-453a-8aed-038527015554" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_f5201572-7826-487a-9fae-abcec18fc308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesBasedMilestonesMember_3ce7fc4d-d052-4b84-9cc8-d68b1ce6c1a2" xlink:href="mrk-20220930.xsd#mrk_SalesBasedMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_f5201572-7826-487a-9fae-abcec18fc308" xlink:to="loc_mrk_SalesBasedMilestonesMember_3ce7fc4d-d052-4b84-9cc8-d68b1ce6c1a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RegulatoryMilestonesMember_ebba99be-da66-4edc-8cec-252a1f090785" xlink:href="mrk-20220930.xsd#mrk_RegulatoryMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_f5201572-7826-487a-9fae-abcec18fc308" xlink:to="loc_mrk_RegulatoryMilestonesMember_ebba99be-da66-4edc-8cec-252a1f090785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_16591790-c100-42d8-abf0-5bf7542b72d0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4586c3cb-561a-41ce-8bb5-26e5c4bbd454" xlink:to="loc_srt_ConsolidationItemsAxis_16591790-c100-42d8-abf0-5bf7542b72d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_53c2e0c2-b44b-443f-af4c-236c7efa2769" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_16591790-c100-42d8-abf0-5bf7542b72d0" xlink:to="loc_srt_ConsolidationItemsDomain_53c2e0c2-b44b-443f-af4c-236c7efa2769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_74528940-823a-4016-8f77-fd92b0ea4805" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_53c2e0c2-b44b-443f-af4c-236c7efa2769" xlink:to="loc_us-gaap_OperatingSegmentsMember_74528940-823a-4016-8f77-fd92b0ea4805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_614714e0-821f-4733-88c2-644170d5e67c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4586c3cb-561a-41ce-8bb5-26e5c4bbd454" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_614714e0-821f-4733-88c2-644170d5e67c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_69ebaccb-56e6-4745-aed4-b5c634141974" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_614714e0-821f-4733-88c2-644170d5e67c" xlink:to="loc_us-gaap_SegmentDomain_69ebaccb-56e6-4745-aed4-b5c634141974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember_c72f3e40-fe91-4213-b5cd-d5c285945678" xlink:href="mrk-20220930.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_69ebaccb-56e6-4745-aed4-b5c634141974" xlink:to="loc_mrk_PharmaceuticalsegmentMember_c72f3e40-fe91-4213-b5cd-d5c285945678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d2a6bd0d-9583-4028-b1ce-e17f484f2aee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4586c3cb-561a-41ce-8bb5-26e5c4bbd454" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d2a6bd0d-9583-4028-b1ce-e17f484f2aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ProbableContingentPaymentsCollaborativeArrangement_c63117aa-95d6-4644-a6fd-7a602f00b2cf" xlink:href="mrk-20220930.xsd#mrk_ProbableContingentPaymentsCollaborativeArrangement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d2a6bd0d-9583-4028-b1ce-e17f484f2aee" xlink:to="loc_mrk_ProbableContingentPaymentsCollaborativeArrangement_c63117aa-95d6-4644-a6fd-7a602f00b2cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_de27463d-300e-455a-8e37-4af81a6b8ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d2a6bd0d-9583-4028-b1ce-e17f484f2aee" xlink:to="loc_us-gaap_Liabilities_de27463d-300e-455a-8e37-4af81a6b8ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_0a76ae9b-c846-4161-a891-da5ffdd8d97d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d2a6bd0d-9583-4028-b1ce-e17f484f2aee" xlink:to="loc_us-gaap_AdjustmentForAmortization_0a76ae9b-c846-4161-a891-da5ffdd8d97d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MilestonePaymentsSalesBased_7a811e82-71a6-47f8-b00f-5d888e87fe87" xlink:href="mrk-20220930.xsd#mrk_MilestonePaymentsSalesBased"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d2a6bd0d-9583-4028-b1ce-e17f484f2aee" xlink:to="loc_mrk_MilestonePaymentsSalesBased_7a811e82-71a6-47f8-b00f-5d888e87fe87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MilestonePaymentsAccruedSalesBased_d412af2d-ddd0-41af-9871-7af6209e4ca4" xlink:href="mrk-20220930.xsd#mrk_MilestonePaymentsAccruedSalesBased"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d2a6bd0d-9583-4028-b1ce-e17f484f2aee" xlink:to="loc_mrk_MilestonePaymentsAccruedSalesBased_d412af2d-ddd0-41af-9871-7af6209e4ca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PotentialFutureMilestonePaymentsSalesBased_acbab910-3571-431b-ae1f-18d9862fd76c" xlink:href="mrk-20220930.xsd#mrk_PotentialFutureMilestonePaymentsSalesBased"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d2a6bd0d-9583-4028-b1ce-e17f484f2aee" xlink:to="loc_mrk_PotentialFutureMilestonePaymentsSalesBased_acbab910-3571-431b-ae1f-18d9862fd76c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MilestonePaymentsMadetoCollaborativePartner_f37d33e3-fb43-4407-99a5-e5bbdd6e42f7" xlink:href="mrk-20220930.xsd#mrk_MilestonePaymentsMadetoCollaborativePartner"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d2a6bd0d-9583-4028-b1ce-e17f484f2aee" xlink:to="loc_mrk_MilestonePaymentsMadetoCollaborativePartner_f37d33e3-fb43-4407-99a5-e5bbdd6e42f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PotentialFutureMilestonePaymentsRegulatory_8b50bfe0-8b3c-4965-861d-0d0498520813" xlink:href="mrk-20220930.xsd#mrk_PotentialFutureMilestonePaymentsRegulatory"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d2a6bd0d-9583-4028-b1ce-e17f484f2aee" xlink:to="loc_mrk_PotentialFutureMilestonePaymentsRegulatory_8b50bfe0-8b3c-4965-861d-0d0498520813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1aab1d19-8a33-4f35-b667-e99a440ecd57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d2a6bd0d-9583-4028-b1ce-e17f484f2aee" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1aab1d19-8a33-4f35-b667-e99a440ecd57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_Licenseoptionpaymentrelatedtocollaborativearrangement_ed8b5837-3e14-4bff-b0cd-f63e63194b78" xlink:href="mrk-20220930.xsd#mrk_Licenseoptionpaymentrelatedtocollaborativearrangement"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d2a6bd0d-9583-4028-b1ce-e17f484f2aee" xlink:to="loc_mrk_Licenseoptionpaymentrelatedtocollaborativearrangement_ed8b5837-3e14-4bff-b0cd-f63e63194b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SupplyCommitmentMinimumNumberOfMarkets_62b75d32-20ea-4c2e-9e56-c1f8810dd13e" xlink:href="mrk-20220930.xsd#mrk_SupplyCommitmentMinimumNumberOfMarkets"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d2a6bd0d-9583-4028-b1ce-e17f484f2aee" xlink:to="loc_mrk_SupplyCommitmentMinimumNumberOfMarkets_62b75d32-20ea-4c2e-9e56-c1f8810dd13e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SupplyCommitmentRemainingMinimumCoursesCommitted_1857d68a-eae9-42ce-adab-34594bbe56f0" xlink:href="mrk-20220930.xsd#mrk_SupplyCommitmentRemainingMinimumCoursesCommitted"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d2a6bd0d-9583-4028-b1ce-e17f484f2aee" xlink:to="loc_mrk_SupplyCommitmentRemainingMinimumCoursesCommitted_1857d68a-eae9-42ce-adab-34594bbe56f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RoyaltyRatePercentage_9892afbf-0ea1-430e-ba56-6b13af480863" xlink:href="mrk-20220930.xsd#mrk_RoyaltyRatePercentage"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d2a6bd0d-9583-4028-b1ce-e17f484f2aee" xlink:to="loc_mrk_RoyaltyRatePercentage_9892afbf-0ea1-430e-ba56-6b13af480863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RoyaltyRateDeductionPercentage_2bfc09ee-9fdb-453a-b380-50e54b0ec5e6" xlink:href="mrk-20220930.xsd#mrk_RoyaltyRateDeductionPercentage"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d2a6bd0d-9583-4028-b1ce-e17f484f2aee" xlink:to="loc_mrk_RoyaltyRateDeductionPercentage_2bfc09ee-9fdb-453a-b380-50e54b0ec5e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ContingentPaymentsCollaborativeArrangement_3233a141-8ffd-4b77-ac47-5ce9fbca055a" xlink:href="mrk-20220930.xsd#mrk_ContingentPaymentsCollaborativeArrangement"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d2a6bd0d-9583-4028-b1ce-e17f484f2aee" xlink:to="loc_mrk_ContingentPaymentsCollaborativeArrangement_3233a141-8ffd-4b77-ac47-5ce9fbca055a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_fa3409b2-165c-423c-be02-dd14ee007d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d2a6bd0d-9583-4028-b1ce-e17f484f2aee" xlink:to="loc_us-gaap_Revenues_fa3409b2-165c-423c-be02-dd14ee007d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating_18b84c9c-fc16-43dc-ab04-2d2d9f8812a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d2a6bd0d-9583-4028-b1ce-e17f484f2aee" xlink:to="loc_us-gaap_RoyaltyIncomeNonoperating_18b84c9c-fc16-43dc-ab04-2d2d9f8812a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#CollaborativeArrangementsFinancialInformationDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementsAbstract_60b763f5-f05f-48ed-91e5-04323858c8f5" xlink:href="mrk-20220930.xsd#mrk_CollaborativeArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_273fc494-f4c4-4f14-9303-93ab0260a1eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_CollaborativeArrangementsAbstract_60b763f5-f05f-48ed-91e5-04323858c8f5" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_273fc494-f4c4-4f14-9303-93ab0260a1eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_16e361fa-ae77-4162-a32a-13102c629d49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_273fc494-f4c4-4f14-9303-93ab0260a1eb" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_16e361fa-ae77-4162-a32a-13102c629d49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a3ec1d6e-98f1-42ce-b246-91cf6b935b24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_16e361fa-ae77-4162-a32a-13102c629d49" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a3ec1d6e-98f1-42ce-b246-91cf6b935b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_d540f0bc-f4b7-44cf-9b99-092f8149f75c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a3ec1d6e-98f1-42ce-b246-91cf6b935b24" xlink:to="loc_us-gaap_SalesMember_d540f0bc-f4b7-44cf-9b99-092f8149f75c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_65cffc1f-7d2b-481e-b6ce-d97e0f5dac6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a3ec1d6e-98f1-42ce-b246-91cf6b935b24" xlink:to="loc_us-gaap_CostOfSalesMember_65cffc1f-7d2b-481e-b6ce-d97e0f5dac6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_bbc132f2-e5fa-4133-ae27-7e374eaa315c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a3ec1d6e-98f1-42ce-b246-91cf6b935b24" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_bbc132f2-e5fa-4133-ae27-7e374eaa315c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_dd5d8571-556f-4686-aa16-c1786887b333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a3ec1d6e-98f1-42ce-b246-91cf6b935b24" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_dd5d8571-556f-4686-aa16-c1786887b333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_555a508c-3279-452c-ae97-932268b44a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_273fc494-f4c4-4f14-9303-93ab0260a1eb" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_555a508c-3279-452c-ae97-932268b44a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5278a070-6625-41bb-979a-95ffea146309" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_555a508c-3279-452c-ae97-932268b44a3e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_5278a070-6625-41bb-979a-95ffea146309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_9693a0a6-f741-4a21-a97d-a95ecbbfc654" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5278a070-6625-41bb-979a-95ffea146309" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_9693a0a6-f741-4a21-a97d-a95ecbbfc654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_974b5177-b2f6-4c48-a04f-a581f5fdbc74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5278a070-6625-41bb-979a-95ffea146309" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_974b5177-b2f6-4c48-a04f-a581f5fdbc74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_e02e211c-627e-4ace-a46b-77c55f4377c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5278a070-6625-41bb-979a-95ffea146309" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_e02e211c-627e-4ace-a46b-77c55f4377c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7bee547a-0673-4e7f-9381-44bfbf339adc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_273fc494-f4c4-4f14-9303-93ab0260a1eb" xlink:to="loc_srt_CounterpartyNameAxis_7bee547a-0673-4e7f-9381-44bfbf339adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cce926b4-de0a-41f7-af1a-69eb07930e49" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_7bee547a-0673-4e7f-9381-44bfbf339adc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cce926b4-de0a-41f7-af1a-69eb07930e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AstraZenecaMember_aa226bfa-e089-4a75-9ede-373acc0fa4f4" xlink:href="mrk-20220930.xsd#mrk_AstraZenecaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cce926b4-de0a-41f7-af1a-69eb07930e49" xlink:to="loc_mrk_AstraZenecaMember_aa226bfa-e089-4a75-9ede-373acc0fa4f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EisaiMember_9c9729f8-e051-4934-a5b0-85223dafe14c" xlink:href="mrk-20220930.xsd#mrk_EisaiMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cce926b4-de0a-41f7-af1a-69eb07930e49" xlink:to="loc_mrk_EisaiMember_9c9729f8-e051-4934-a5b0-85223dafe14c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BayerAGMember_9755e6c0-ccc5-41b4-be76-f2ec0a35e464" xlink:href="mrk-20220930.xsd#mrk_BayerAGMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cce926b4-de0a-41f7-af1a-69eb07930e49" xlink:to="loc_mrk_BayerAGMember_9755e6c0-ccc5-41b4-be76-f2ec0a35e464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RidgebackBiotherapeuticsLPMember_6a41ff68-2aca-496c-9390-85fbb9ee7bb0" xlink:href="mrk-20220930.xsd#mrk_RidgebackBiotherapeuticsLPMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cce926b4-de0a-41f7-af1a-69eb07930e49" xlink:to="loc_mrk_RidgebackBiotherapeuticsLPMember_6a41ff68-2aca-496c-9390-85fbb9ee7bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_58616646-b2d2-4b64-b4bc-11a3c3eb4f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_273fc494-f4c4-4f14-9303-93ab0260a1eb" xlink:to="loc_us-gaap_TypeOfArrangementAxis_58616646-b2d2-4b64-b4bc-11a3c3eb4f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7d8f5900-d20b-4089-a36d-84a3f1bb278f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_58616646-b2d2-4b64-b4bc-11a3c3eb4f3c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7d8f5900-d20b-4089-a36d-84a3f1bb278f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_8a3d3d31-314b-4dba-8d74-c07811254747" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7d8f5900-d20b-4089-a36d-84a3f1bb278f" xlink:to="loc_us-gaap_CollaborativeArrangementMember_8a3d3d31-314b-4dba-8d74-c07811254747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_662d6211-d0dc-417a-8205-52946288893a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_273fc494-f4c4-4f14-9303-93ab0260a1eb" xlink:to="loc_srt_ProductOrServiceAxis_662d6211-d0dc-417a-8205-52946288893a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_73fe558e-bc08-48e7-be52-d909eda37977" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_662d6211-d0dc-417a-8205-52946288893a" xlink:to="loc_srt_ProductsAndServicesDomain_73fe558e-bc08-48e7-be52-d909eda37977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AlliancerevenueLynparzaMember_b3a977ba-d0f4-4ea1-9884-7734b8290f40" xlink:href="mrk-20220930.xsd#mrk_AlliancerevenueLynparzaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_73fe558e-bc08-48e7-be52-d909eda37977" xlink:to="loc_mrk_AlliancerevenueLynparzaMember_b3a977ba-d0f4-4ea1-9884-7734b8290f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AllianceRevenueKoselugoMember_f797f329-d36a-4f40-bb58-bf9753c1e1ec" xlink:href="mrk-20220930.xsd#mrk_AllianceRevenueKoselugoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_73fe558e-bc08-48e7-be52-d909eda37977" xlink:to="loc_mrk_AllianceRevenueKoselugoMember_f797f329-d36a-4f40-bb58-bf9753c1e1ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AdempasMember_fe774b5e-9cc5-455a-ab37-00bfc99ab43c" xlink:href="mrk-20220930.xsd#mrk_AdempasMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_73fe558e-bc08-48e7-be52-d909eda37977" xlink:to="loc_mrk_AdempasMember_fe774b5e-9cc5-455a-ab37-00bfc99ab43c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VerquvoMember_80870070-f0d7-492b-b91d-18097eca6fcf" xlink:href="mrk-20220930.xsd#mrk_VerquvoMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_73fe558e-bc08-48e7-be52-d909eda37977" xlink:to="loc_mrk_VerquvoMember_80870070-f0d7-492b-b91d-18097eca6fcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LagevrioMember_00e97513-ca1f-4c0d-88d2-2460b371a347" xlink:href="mrk-20220930.xsd#mrk_LagevrioMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_73fe558e-bc08-48e7-be52-d909eda37977" xlink:to="loc_mrk_LagevrioMember_00e97513-ca1f-4c0d-88d2-2460b371a347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e0c6a45f-4cf6-4c77-84a4-4ed008ae59cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_273fc494-f4c4-4f14-9303-93ab0260a1eb" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e0c6a45f-4cf6-4c77-84a4-4ed008ae59cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementProfitSharing_c5667b8a-6dac-41ec-81bc-811479eb526a" xlink:href="mrk-20220930.xsd#mrk_CollaborativeArrangementProfitSharing"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e0c6a45f-4cf6-4c77-84a4-4ed008ae59cb" xlink:to="loc_mrk_CollaborativeArrangementProfitSharing_c5667b8a-6dac-41ec-81bc-811479eb526a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementSalesNet_2a9e67e3-a517-495a-8fc7-0e304c74c73e" xlink:href="mrk-20220930.xsd#mrk_CollaborativeArrangementSalesNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e0c6a45f-4cf6-4c77-84a4-4ed008ae59cb" xlink:to="loc_mrk_CollaborativeArrangementSalesNet_2a9e67e3-a517-495a-8fc7-0e304c74c73e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_e3684fa2-bb1f-4e15-9df3-17ad8537456b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e0c6a45f-4cf6-4c77-84a4-4ed008ae59cb" xlink:to="loc_us-gaap_Revenues_e3684fa2-bb1f-4e15-9df3-17ad8537456b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_e6fa7b3a-d301-44d9-a437-bc7b372fcb4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e0c6a45f-4cf6-4c77-84a4-4ed008ae59cb" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_e6fa7b3a-d301-44d9-a437-bc7b372fcb4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_994f122a-bae5-482e-b91d-73be108f96ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e0c6a45f-4cf6-4c77-84a4-4ed008ae59cb" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_994f122a-bae5-482e-b91d-73be108f96ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_aad27c6d-62ed-44de-a681-f799d65ecd15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e0c6a45f-4cf6-4c77-84a4-4ed008ae59cb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_aad27c6d-62ed-44de-a681-f799d65ecd15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_e4d7f03e-430a-4378-8ca8-4a98c827be61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e0c6a45f-4cf6-4c77-84a4-4ed008ae59cb" xlink:to="loc_us-gaap_ReceivablesNetCurrent_e4d7f03e-430a-4378-8ca8-4a98c827be61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ca4881cd-a43a-4bed-a795-7296a069948b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e0c6a45f-4cf6-4c77-84a4-4ed008ae59cb" xlink:to="loc_us-gaap_LiabilitiesCurrent_ca4881cd-a43a-4bed-a795-7296a069948b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_079261cc-62f3-4ea7-8a46-fdb1b3d99e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e0c6a45f-4cf6-4c77-84a4-4ed008ae59cb" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_079261cc-62f3-4ea7-8a46-fdb1b3d99e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_b41813bd-e3dc-42f9-86b9-35a1cc2a569b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e0c6a45f-4cf6-4c77-84a4-4ed008ae59cb" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_b41813bd-e3dc-42f9-86b9-35a1cc2a569b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/RestructuringNarrativeDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#RestructuringNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/RestructuringNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_2530eac9-aba8-479d-b5d5-08e595b6697d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_496282f9-1ff8-4ebf-9af4-f7762e82c449" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_2530eac9-aba8-479d-b5d5-08e595b6697d" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_496282f9-1ff8-4ebf-9af4-f7762e82c449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_e87ba950-6fe2-40aa-a96d-0212572ce719" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_496282f9-1ff8-4ebf-9af4-f7762e82c449" xlink:to="loc_srt_StatementScenarioAxis_e87ba950-6fe2-40aa-a96d-0212572ce719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_78f6d007-db41-4f3b-b1a0-48156bab85ed" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_e87ba950-6fe2-40aa-a96d-0212572ce719" xlink:to="loc_srt_ScenarioUnspecifiedDomain_78f6d007-db41-4f3b-b1a0-48156bab85ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_e3d5abf8-6e5e-4f76-ade6-c497df474d1a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_78f6d007-db41-4f3b-b1a0-48156bab85ed" xlink:to="loc_srt_ScenarioForecastMember_e3d5abf8-6e5e-4f76-ade6-c497df474d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_60e7fadb-9431-4140-b90c-605a61df8d62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_496282f9-1ff8-4ebf-9af4-f7762e82c449" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_60e7fadb-9431-4140-b90c-605a61df8d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_1f913d32-a7ad-43f1-8511-a22eb35ba51c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_60e7fadb-9431-4140-b90c-605a61df8d62" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_1f913d32-a7ad-43f1-8511-a22eb35ba51c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays_71be8430-9042-4c8d-a1a3-35542fc38ea6" xlink:href="mrk-20220930.xsd#mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_60e7fadb-9431-4140-b90c-605a61df8d62" xlink:to="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays_71be8430-9042-4c8d-a1a3-35542fc38ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash_2c1c41e4-1d2d-4910-9b89-a527386d1217" xlink:href="mrk-20220930.xsd#mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_60e7fadb-9431-4140-b90c-605a61df8d62" xlink:to="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash_2c1c41e4-1d2d-4910-9b89-a527386d1217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_4235f3f4-58e5-46e5-b84a-f79f11f9a0cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_60e7fadb-9431-4140-b90c-605a61df8d62" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_4235f3f4-58e5-46e5-b84a-f79f11f9a0cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_55b70976-bf6f-4005-81e9-aeaf6291290d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_60e7fadb-9431-4140-b90c-605a61df8d62" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_55b70976-bf6f-4005-81e9-aeaf6291290d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#RestructuringChargesActivitiesbyTypeofCostDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_1cdcadeb-7a6a-4190-a797-6043a5b99f01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_200781b1-af18-4892-a8bd-cc071f25f5dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_1cdcadeb-7a6a-4190-a797-6043a5b99f01" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_200781b1-af18-4892-a8bd-cc071f25f5dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_752c5d7a-eaef-4c47-aba9-2458edea4522" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_200781b1-af18-4892-a8bd-cc071f25f5dd" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_752c5d7a-eaef-4c47-aba9-2458edea4522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_afaf0d92-0546-4b53-8478-3b0a4c195662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_752c5d7a-eaef-4c47-aba9-2458edea4522" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_afaf0d92-0546-4b53-8478-3b0a4c195662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_6cc0c6a7-dc6a-42f8-9ff1-fe16c15d844f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_afaf0d92-0546-4b53-8478-3b0a4c195662" xlink:to="loc_us-gaap_CostOfSalesMember_6cc0c6a7-dc6a-42f8-9ff1-fe16c15d844f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_926e6406-0d3e-4e24-9c1a-77ec37f85651" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_afaf0d92-0546-4b53-8478-3b0a4c195662" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_926e6406-0d3e-4e24-9c1a-77ec37f85651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_cd1b698d-3093-4bfa-af5c-f0d8712b022e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_afaf0d92-0546-4b53-8478-3b0a4c195662" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_cd1b698d-3093-4bfa-af5c-f0d8712b022e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_5eeb3c9b-6e93-4e83-9b98-12a078b88dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringChargesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_afaf0d92-0546-4b53-8478-3b0a4c195662" xlink:to="loc_us-gaap_RestructuringChargesMember_5eeb3c9b-6e93-4e83-9b98-12a078b88dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_79f28898-5bd4-400d-aae7-5a411b1fa810" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_200781b1-af18-4892-a8bd-cc071f25f5dd" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_79f28898-5bd4-400d-aae7-5a411b1fa810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_95c7309f-f8f2-436d-88a4-c5cda88c8d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_79f28898-5bd4-400d-aae7-5a411b1fa810" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_95c7309f-f8f2-436d-88a4-c5cda88c8d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OneTimeTerminationBenefitsMember_951a2132-a955-47a4-a11c-0eee7f5aabcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OneTimeTerminationBenefitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_95c7309f-f8f2-436d-88a4-c5cda88c8d9b" xlink:to="loc_us-gaap_OneTimeTerminationBenefitsMember_951a2132-a955-47a4-a11c-0eee7f5aabcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcceleratedDepreciationMember_6bf97cea-a5e1-4111-aea5-c1e38a247c91" xlink:href="mrk-20220930.xsd#mrk_AcceleratedDepreciationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_95c7309f-f8f2-436d-88a4-c5cda88c8d9b" xlink:to="loc_mrk_AcceleratedDepreciationMember_6bf97cea-a5e1-4111-aea5-c1e38a247c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_dd2b9c00-e366-4534-a48a-9761757eece6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestructuringMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_95c7309f-f8f2-436d-88a4-c5cda88c8d9b" xlink:to="loc_us-gaap_OtherRestructuringMember_dd2b9c00-e366-4534-a48a-9761757eece6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_7901ff2b-b584-4fa2-9ad2-1b53cff9aac2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_200781b1-af18-4892-a8bd-cc071f25f5dd" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_7901ff2b-b584-4fa2-9ad2-1b53cff9aac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_a3d3ee61-1acd-442e-ae66-91f0395d911f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_7901ff2b-b584-4fa2-9ad2-1b53cff9aac2" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_a3d3ee61-1acd-442e-ae66-91f0395d911f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/RestructuringActivitiesbyProgramDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#RestructuringActivitiesbyProgramDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/RestructuringActivitiesbyProgramDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_86695953-7059-431c-9786-1e028f072735" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_addf4f66-3482-4cfe-92c8-3d6942d3269f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_86695953-7059-431c-9786-1e028f072735" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_addf4f66-3482-4cfe-92c8-3d6942d3269f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_825ee618-6f91-4de6-af56-8fdc99c5111e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_addf4f66-3482-4cfe-92c8-3d6942d3269f" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_825ee618-6f91-4de6-af56-8fdc99c5111e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_79d30104-633e-4a22-b984-61fd548a61f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_825ee618-6f91-4de6-af56-8fdc99c5111e" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_79d30104-633e-4a22-b984-61fd548a61f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OneTimeTerminationBenefitsMember_604b6d34-2fcd-4cba-a66f-054e516dd056" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OneTimeTerminationBenefitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_79d30104-633e-4a22-b984-61fd548a61f2" xlink:to="loc_us-gaap_OneTimeTerminationBenefitsMember_604b6d34-2fcd-4cba-a66f-054e516dd056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcceleratedDepreciationMember_ad49516a-2b29-43a6-86ad-e87746b46b07" xlink:href="mrk-20220930.xsd#mrk_AcceleratedDepreciationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_79d30104-633e-4a22-b984-61fd548a61f2" xlink:to="loc_mrk_AcceleratedDepreciationMember_ad49516a-2b29-43a6-86ad-e87746b46b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_d31f3568-7b3d-4d93-8a74-1ef3ee562aef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestructuringMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_79d30104-633e-4a22-b984-61fd548a61f2" xlink:to="loc_us-gaap_OtherRestructuringMember_d31f3568-7b3d-4d93-8a74-1ef3ee562aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_22268def-a8f5-4dbd-a5e6-8635a2bb781a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_addf4f66-3482-4cfe-92c8-3d6942d3269f" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_22268def-a8f5-4dbd-a5e6-8635a2bb781a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_9fa6062d-0c91-4ff6-a3a8-acaf10cc8ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_22268def-a8f5-4dbd-a5e6-8635a2bb781a" xlink:to="loc_us-gaap_RestructuringReserveRollForward_9fa6062d-0c91-4ff6-a3a8-acaf10cc8ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_c52b4e7a-1377-49cf-b86c-7793cd1337a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_9fa6062d-0c91-4ff6-a3a8-acaf10cc8ddd" xlink:to="loc_us-gaap_RestructuringReserve_c52b4e7a-1377-49cf-b86c-7793cd1337a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_405ab4b1-ed4e-422d-9a68-951b202364da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_9fa6062d-0c91-4ff6-a3a8-acaf10cc8ddd" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_405ab4b1-ed4e-422d-9a68-951b202364da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_f3253c2a-105a-4fee-9624-1584937a46ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_9fa6062d-0c91-4ff6-a3a8-acaf10cc8ddd" xlink:to="loc_us-gaap_PaymentsForRestructuring_f3253c2a-105a-4fee-9624-1584937a46ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity_e441fbe4-c415-42f6-87e9-40a071906e50" xlink:href="mrk-20220930.xsd#mrk_RestructuringReserveIncreaseDecreaseNoncashActivity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_9fa6062d-0c91-4ff6-a3a8-acaf10cc8ddd" xlink:to="loc_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity_e441fbe4-c415-42f6-87e9-40a071906e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_e7f2a51b-f747-43c4-ab31-a69eada018bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_9fa6062d-0c91-4ff6-a3a8-acaf10cc8ddd" xlink:to="loc_us-gaap_RestructuringReserve_e7f2a51b-f747-43c4-ab31-a69eada018bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_448275e5-6b1c-4720-8192-1dd171c37ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_1345090b-e8a1-4ac6-b152-aeaac2047f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_448275e5-6b1c-4720-8192-1dd171c37ef9" xlink:to="loc_us-gaap_DerivativeTable_1345090b-e8a1-4ac6-b152-aeaac2047f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_eaf3ab96-212b-4bb4-a40a-cb04e4a4e04d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1345090b-e8a1-4ac6-b152-aeaac2047f5e" xlink:to="loc_srt_RangeAxis_eaf3ab96-212b-4bb4-a40a-cb04e4a4e04d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3341070c-6401-474a-a3af-54ad440db010" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_eaf3ab96-212b-4bb4-a40a-cb04e4a4e04d" xlink:to="loc_srt_RangeMember_3341070c-6401-474a-a3af-54ad440db010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0a1fa29b-5bc3-48db-b95f-cb12d1163d23" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3341070c-6401-474a-a3af-54ad440db010" xlink:to="loc_srt_MaximumMember_0a1fa29b-5bc3-48db-b95f-cb12d1163d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_d75d4a08-803f-4041-99dc-5b59e54d1b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1345090b-e8a1-4ac6-b152-aeaac2047f5e" xlink:to="loc_us-gaap_HedgingDesignationAxis_d75d4a08-803f-4041-99dc-5b59e54d1b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_7a7917da-12d6-4e1f-a281-22cb613bfbb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_d75d4a08-803f-4041-99dc-5b59e54d1b8c" xlink:to="loc_us-gaap_HedgingDesignationDomain_7a7917da-12d6-4e1f-a281-22cb613bfbb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_b7b4b531-7ebe-4eeb-95d6-e49c4ed76d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_7a7917da-12d6-4e1f-a281-22cb613bfbb0" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_b7b4b531-7ebe-4eeb-95d6-e49c4ed76d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_dead15b6-9d9b-4fa4-814f-ea7382478fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_7a7917da-12d6-4e1f-a281-22cb613bfbb0" xlink:to="loc_us-gaap_NondesignatedMember_dead15b6-9d9b-4fa4-814f-ea7382478fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_60f4432f-cc6f-40c0-a672-ece60103e376" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1345090b-e8a1-4ac6-b152-aeaac2047f5e" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_60f4432f-cc6f-40c0-a672-ece60103e376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a5ce6942-1f2d-4f43-8b88-a91325c9bcf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_60f4432f-cc6f-40c0-a672-ece60103e376" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a5ce6942-1f2d-4f43-8b88-a91325c9bcf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_4ab1c312-73ba-4c62-8b3a-d3862d47a567" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a5ce6942-1f2d-4f43-8b88-a91325c9bcf1" xlink:to="loc_us-gaap_InterestRateSwapMember_4ab1c312-73ba-4c62-8b3a-d3862d47a567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_4180d89c-8f5e-4a20-ba11-1576cd36f2e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1345090b-e8a1-4ac6-b152-aeaac2047f5e" xlink:to="loc_us-gaap_DebtInstrumentAxis_4180d89c-8f5e-4a20-ba11-1576cd36f2e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c4fe8e13-e5d3-495e-a136-605f9c5a4619" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_4180d89c-8f5e-4a20-ba11-1576cd36f2e3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c4fe8e13-e5d3-495e-a136-605f9c5a4619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.35NotesDue2022Member_02f52df0-52b6-499d-abf9-f78c4ca52dd4" xlink:href="mrk-20220930.xsd#mrk_A2.35NotesDue2022Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c4fe8e13-e5d3-495e-a136-605f9c5a4619" xlink:to="loc_mrk_A2.35NotesDue2022Member_02f52df0-52b6-499d-abf9-f78c4ca52dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.40NotesDue2022Member_1b8921ea-2f81-40af-8ffa-1dd101ef1439" xlink:href="mrk-20220930.xsd#mrk_A2.40NotesDue2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c4fe8e13-e5d3-495e-a136-605f9c5a4619" xlink:to="loc_mrk_A2.40NotesDue2022Member_1b8921ea-2f81-40af-8ffa-1dd101ef1439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_74bd9df2-faed-4d67-bdd7-654ed3dabb7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1345090b-e8a1-4ac6-b152-aeaac2047f5e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_74bd9df2-faed-4d67-bdd7-654ed3dabb7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_872c2b0d-b292-4676-9245-99ec3ab848e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_74bd9df2-faed-4d67-bdd7-654ed3dabb7a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_872c2b0d-b292-4676-9245-99ec3ab848e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_72ee264c-a090-4c52-986b-916cb8214dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_872c2b0d-b292-4676-9245-99ec3ab848e2" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_72ee264c-a090-4c52-986b-916cb8214dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_4ad88f82-95e9-421e-a027-0e384a66d0e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1345090b-e8a1-4ac6-b152-aeaac2047f5e" xlink:to="loc_us-gaap_InvestmentTypeAxis_4ad88f82-95e9-421e-a027-0e384a66d0e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_b32c0c10-71cc-4aee-9ea7-42a70e75575f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_4ad88f82-95e9-421e-a027-0e384a66d0e8" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_b32c0c10-71cc-4aee-9ea7-42a70e75575f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFundsMember_6817547f-4613-4ea1-90c4-02d11393155d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b32c0c10-71cc-4aee-9ea7-42a70e75575f" xlink:to="loc_us-gaap_EquityFundsMember_6817547f-4613-4ea1-90c4-02d11393155d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_cbe65738-b7a3-4d46-b13e-fa4f0fc7a5da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1345090b-e8a1-4ac6-b152-aeaac2047f5e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_cbe65738-b7a3-4d46-b13e-fa4f0fc7a5da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e5c58e5c-fe4f-4d01-9f53-8421171c67b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_cbe65738-b7a3-4d46-b13e-fa4f0fc7a5da" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e5c58e5c-fe4f-4d01-9f53-8421171c67b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.35NotesDue2022Member_fe68ac64-3416-48bc-8e9d-361a6c85fa23" xlink:href="mrk-20220930.xsd#mrk_A2.35NotesDue2022Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e5c58e5c-fe4f-4d01-9f53-8421171c67b1" xlink:to="loc_mrk_A2.35NotesDue2022Member_fe68ac64-3416-48bc-8e9d-361a6c85fa23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.40NotesDue2022Member_51ae44e9-5bb6-47e0-a354-6fe975f5f4e4" xlink:href="mrk-20220930.xsd#mrk_A2.40NotesDue2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e5c58e5c-fe4f-4d01-9f53-8421171c67b1" xlink:to="loc_mrk_A2.40NotesDue2022Member_51ae44e9-5bb6-47e0-a354-6fe975f5f4e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_9f4d68df-fa7c-4c40-9fcf-360d4bee6ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1345090b-e8a1-4ac6-b152-aeaac2047f5e" xlink:to="loc_us-gaap_DerivativeLineItems_9f4d68df-fa7c-4c40-9fcf-360d4bee6ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAverageRemainingMaturity1_ce2105e8-62a2-48ee-a8df-5d5b33983dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAverageRemainingMaturity1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_9f4d68df-fa7c-4c40-9fcf-360d4bee6ba2" xlink:to="loc_us-gaap_DerivativeAverageRemainingMaturity1_ce2105e8-62a2-48ee-a8df-5d5b33983dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfInterestRateDerivativesHeld_6777bfb6-0fd5-4f35-b51b-6081a8da5062" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfInterestRateDerivativesHeld"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_9f4d68df-fa7c-4c40-9fcf-360d4bee6ba2" xlink:to="loc_us-gaap_NumberOfInterestRateDerivativesHeld_6777bfb6-0fd5-4f35-b51b-6081a8da5062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_7c2b6c86-5856-4580-b411-2015feb52415" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_9f4d68df-fa7c-4c40-9fcf-360d4bee6ba2" xlink:to="loc_us-gaap_DerivativeNotionalAmount_7c2b6c86-5856-4580-b411-2015feb52415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_fe5f45e1-40cb-4087-8954-284376c1e476" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_9f4d68df-fa7c-4c40-9fcf-360d4bee6ba2" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_fe5f45e1-40cb-4087-8954-284376c1e476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_203d3624-6b0c-412f-aa21-dc62c2f938cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_9f4d68df-fa7c-4c40-9fcf-360d4bee6ba2" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_203d3624-6b0c-412f-aa21-dc62c2f938cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_6c83ead1-03f5-4195-a06d-fcae3957b66b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_9f4d68df-fa7c-4c40-9fcf-360d4bee6ba2" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_6c83ead1-03f5-4195-a06d-fcae3957b66b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_7c96109d-7f11-44bf-8dd3-bdab7df0b212" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_9f4d68df-fa7c-4c40-9fcf-360d4bee6ba2" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_7c96109d-7f11-44bf-8dd3-bdab7df0b212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_b266d09c-7898-4acf-8d3e-4641b39641ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_9f4d68df-fa7c-4c40-9fcf-360d4bee6ba2" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_b266d09c-7898-4acf-8d3e-4641b39641ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_3d210366-d22f-4068-8b2b-a2a8950c59b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_9f4d68df-fa7c-4c40-9fcf-360d4bee6ba2" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_3d210366-d22f-4068-8b2b-a2a8950c59b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_50cd7437-aa89-48be-b70c-fbe83e7341ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_9f4d68df-fa7c-4c40-9fcf-360d4bee6ba2" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_50cd7437-aa89-48be-b70c-fbe83e7341ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount_c8616b57-bc3c-48b6-861b-9bd1b68d7c22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_9f4d68df-fa7c-4c40-9fcf-360d4bee6ba2" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount_c8616b57-bc3c-48b6-861b-9bd1b68d7c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent_96ed9d37-e21e-46fd-9a71-d27a8544b2c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_9f4d68df-fa7c-4c40-9fcf-360d4bee6ba2" xlink:to="loc_us-gaap_EquitySecuritiesFVNINoncurrent_96ed9d37-e21e-46fd-9a71-d27a8544b2c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_8711db14-1b0d-4e28-9354-17a8e5b012b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_9f4d68df-fa7c-4c40-9fcf-360d4bee6ba2" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_8711db14-1b0d-4e28-9354-17a8e5b012b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_ed21f815-eb0b-433d-88e1-02ea460dd62e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_9f4d68df-fa7c-4c40-9fcf-360d4bee6ba2" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_ed21f815-eb0b-433d-88e1-02ea460dd62e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_142bbd11-67b0-4cf4-abea-916e895e016a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_9f4d68df-fa7c-4c40-9fcf-360d4bee6ba2" xlink:to="loc_us-gaap_DebtInstrumentFairValue_142bbd11-67b0-4cf4-abea-916e895e016a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_2ae2a0cf-11f1-48af-8ee1-9921e8534a91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_9f4d68df-fa7c-4c40-9fcf-360d4bee6ba2" xlink:to="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_2ae2a0cf-11f1-48af-8ee1-9921e8534a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableSale_b51d58c7-2b13-4929-b78c-00c5c7b728b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableSale"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_9f4d68df-fa7c-4c40-9fcf-360d4bee6ba2" xlink:to="loc_us-gaap_AccountsReceivableSale_b51d58c7-2b13-4929-b78c-00c5c7b728b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_90fdcab5-d161-4833-a4f8-5186abdcc035" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_9f4d68df-fa7c-4c40-9fcf-360d4bee6ba2" xlink:to="loc_us-gaap_RestrictedCashCurrent_90fdcab5-d161-4833-a4f8-5186abdcc035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash_7aba8ef3-70c8-4596-856f-761e853aaba8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_9f4d68df-fa7c-4c40-9fcf-360d4bee6ba2" xlink:to="loc_us-gaap_DerivativeCollateralObligationToReturnCash_7aba8ef3-70c8-4596-856f-761e853aaba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#FinancialInstrumentsEffectofNetInvestmentHedgesDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_4600c682-ac6e-4f87-ae70-698641d713cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_8ed6ff05-bce9-484e-a8f6-dd68c4052542" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_4600c682-ac6e-4f87-ae70-698641d713cf" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_8ed6ff05-bce9-484e-a8f6-dd68c4052542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_5924676f-4bd6-4fe4-8349-68bba10db344" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_8ed6ff05-bce9-484e-a8f6-dd68c4052542" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_5924676f-4bd6-4fe4-8349-68bba10db344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_5e0e919c-c181-4616-84d0-2af6c09920ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5924676f-4bd6-4fe4-8349-68bba10db344" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_5e0e919c-c181-4616-84d0-2af6c09920ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_908dedc8-455c-4231-9906-b7918c5f4e00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_5e0e919c-c181-4616-84d0-2af6c09920ee" xlink:to="loc_us-gaap_ForeignExchangeContractMember_908dedc8-455c-4231-9906-b7918c5f4e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EurodominatedNotesMember_fa5d73f0-769a-498b-9698-c68fd658fc96" xlink:href="mrk-20220930.xsd#mrk_EurodominatedNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_5e0e919c-c181-4616-84d0-2af6c09920ee" xlink:to="loc_mrk_EurodominatedNotesMember_fa5d73f0-769a-498b-9698-c68fd658fc96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ae86c8db-8c20-4308-9541-38de4e629f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_8ed6ff05-bce9-484e-a8f6-dd68c4052542" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ae86c8db-8c20-4308-9541-38de4e629f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3bec97fe-ee05-47d7-bdfb-8aa6edec6b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ae86c8db-8c20-4308-9541-38de4e629f9c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3bec97fe-ee05-47d7-bdfb-8aa6edec6b3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_6330cb7b-6c81-482d-9682-6b2bcd2c8642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3bec97fe-ee05-47d7-bdfb-8aa6edec6b3a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_6330cb7b-6c81-482d-9682-6b2bcd2c8642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_6dcdd5fa-6bc6-48d8-9dd0-904aa93c98e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_8ed6ff05-bce9-484e-a8f6-dd68c4052542" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_6dcdd5fa-6bc6-48d8-9dd0-904aa93c98e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_6f156e5c-06be-49f4-9e0d-c95444312ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_6dcdd5fa-6bc6-48d8-9dd0-904aa93c98e3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_6f156e5c-06be-49f4-9e0d-c95444312ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_f5158b0a-a8ca-44f9-a9d5-6c6c47b68613" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_6dcdd5fa-6bc6-48d8-9dd0-904aa93c98e3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_f5158b0a-a8ca-44f9-a9d5-6c6c47b68613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#FinancialInstrumentsFairValueHedgesDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_3afda260-8d45-4645-8b14-ff90795d82e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_81c66d14-5851-47a1-b24e-ce07c89247d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_3afda260-8d45-4645-8b14-ff90795d82e3" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_81c66d14-5851-47a1-b24e-ce07c89247d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_18ab0ee8-e8ce-4741-bdcc-aa5e0fefaf1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_81c66d14-5851-47a1-b24e-ce07c89247d7" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_18ab0ee8-e8ce-4741-bdcc-aa5e0fefaf1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f15ed20a-2248-437e-b84a-44c189cd16ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_18ab0ee8-e8ce-4741-bdcc-aa5e0fefaf1d" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f15ed20a-2248-437e-b84a-44c189cd16ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtCurrentMaturitiesMember_4ce75c96-3646-4dcd-bfc8-8e5c786d5b54" xlink:href="mrk-20220930.xsd#mrk_LongTermDebtCurrentMaturitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f15ed20a-2248-437e-b84a-44c189cd16ff" xlink:to="loc_mrk_LongTermDebtCurrentMaturitiesMember_4ce75c96-3646-4dcd-bfc8-8e5c786d5b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_af43c4f6-bd8a-47ff-bb0a-4416b3702a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_81c66d14-5851-47a1-b24e-ce07c89247d7" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_af43c4f6-bd8a-47ff-bb0a-4416b3702a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedge_fa0f1adb-aafe-4454-9f8b-c85799195408" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedge"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_af43c4f6-bd8a-47ff-bb0a-4416b3702a6a" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedge_fa0f1adb-aafe-4454-9f8b-c85799195408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_e1e4033d-9da3-4e61-90d5-81e635d20ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_af43c4f6-bd8a-47ff-bb0a-4416b3702a6a" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_e1e4033d-9da3-4e61-90d5-81e635d20ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f1baac9a-95b6-4421-b369-ce8ea9f4a92e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_06a1d364-a219-477e-a9d8-5ec19059c773" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f1baac9a-95b6-4421-b369-ce8ea9f4a92e" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_06a1d364-a219-477e-a9d8-5ec19059c773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_975a208b-b475-46cb-88aa-50ce30e4c062" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_06a1d364-a219-477e-a9d8-5ec19059c773" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_975a208b-b475-46cb-88aa-50ce30e4c062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_848780cc-40af-4751-a0cb-2088fd4592ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_975a208b-b475-46cb-88aa-50ce30e4c062" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_848780cc-40af-4751-a0cb-2088fd4592ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_df504062-771b-4d37-89b2-41b2ad5a7c57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_848780cc-40af-4751-a0cb-2088fd4592ce" xlink:to="loc_us-gaap_InterestRateContractMember_df504062-771b-4d37-89b2-41b2ad5a7c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_0676425c-fe55-4652-952b-efe63d7f43bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_848780cc-40af-4751-a0cb-2088fd4592ce" xlink:to="loc_us-gaap_ForeignExchangeContractMember_0676425c-fe55-4652-952b-efe63d7f43bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_9301673c-915e-4a02-9478-b2b7c3e0923c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_06a1d364-a219-477e-a9d8-5ec19059c773" xlink:to="loc_us-gaap_HedgingDesignationAxis_9301673c-915e-4a02-9478-b2b7c3e0923c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_509c789d-f668-4f68-8ebc-24013aff76f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_9301673c-915e-4a02-9478-b2b7c3e0923c" xlink:to="loc_us-gaap_HedgingDesignationDomain_509c789d-f668-4f68-8ebc-24013aff76f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_00b60a05-dfc4-4377-a2ee-06c9d1d6afcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_509c789d-f668-4f68-8ebc-24013aff76f6" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_00b60a05-dfc4-4377-a2ee-06c9d1d6afcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_5abb24c2-4159-49b9-8b5c-d28d31d5e640" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_509c789d-f668-4f68-8ebc-24013aff76f6" xlink:to="loc_us-gaap_NondesignatedMember_5abb24c2-4159-49b9-8b5c-d28d31d5e640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_eba86809-afb0-4291-96fc-c3779110dcdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_06a1d364-a219-477e-a9d8-5ec19059c773" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_eba86809-afb0-4291-96fc-c3779110dcdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f4806e65-d2e8-4bd5-8b2a-069cac252350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_eba86809-afb0-4291-96fc-c3779110dcdb" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f4806e65-d2e8-4bd5-8b2a-069cac252350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredIncomeTaxesAndOtherAssetsCurrentMember_93a0321c-2763-4095-bb5f-b31b0c0f6a9c" xlink:href="mrk-20220930.xsd#mrk_DeferredIncomeTaxesAndOtherAssetsCurrentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f4806e65-d2e8-4bd5-8b2a-069cac252350" xlink:to="loc_mrk_DeferredIncomeTaxesAndOtherAssetsCurrentMember_93a0321c-2763-4095-bb5f-b31b0c0f6a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember_ce7cc355-2d9f-421a-a6b3-c9ccfa267349" xlink:href="mrk-20220930.xsd#mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f4806e65-d2e8-4bd5-8b2a-069cac252350" xlink:to="loc_mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember_ce7cc355-2d9f-421a-a6b3-c9ccfa267349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_92093896-406c-4676-b8f0-d236814e869a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f4806e65-d2e8-4bd5-8b2a-069cac252350" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_92093896-406c-4676-b8f0-d236814e869a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_fcca3e6e-ef6d-446e-b5fb-b15c718a9da6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f4806e65-d2e8-4bd5-8b2a-069cac252350" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_fcca3e6e-ef6d-446e-b5fb-b15c718a9da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_55075ec5-da77-4e43-a1e8-97cf6973d284" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_06a1d364-a219-477e-a9d8-5ec19059c773" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_55075ec5-da77-4e43-a1e8-97cf6973d284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_4f339f95-1630-4f2c-8e53-9a43cd8f1411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_55075ec5-da77-4e43-a1e8-97cf6973d284" xlink:to="loc_us-gaap_DerivativeAssets_4f339f95-1630-4f2c-8e53-9a43cd8f1411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_7bd315f4-1327-4f76-ba51-729fe1fef408" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_55075ec5-da77-4e43-a1e8-97cf6973d284" xlink:to="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_7bd315f4-1327-4f76-ba51-729fe1fef408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_300ce29f-103b-4132-9dbc-87d2508f212e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_55075ec5-da77-4e43-a1e8-97cf6973d284" xlink:to="loc_us-gaap_DerivativeLiabilities_300ce29f-103b-4132-9dbc-87d2508f212e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_155896eb-96ac-4cb0-a36f-69d761c3972b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_55075ec5-da77-4e43-a1e8-97cf6973d284" xlink:to="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_155896eb-96ac-4cb0-a36f-69d761c3972b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_ddb77745-5c54-4225-b942-8ae7e976ad4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_55075ec5-da77-4e43-a1e8-97cf6973d284" xlink:to="loc_us-gaap_DerivativeNotionalAmount_ddb77745-5c54-4225-b942-8ae7e976ad4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_7466cd64-1748-4733-a0d9-8aa0ca43071b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_c8a9fdfa-af63-46fe-8204-2bf15f30001b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_7466cd64-1748-4733-a0d9-8aa0ca43071b" xlink:to="loc_us-gaap_DerivativeAssets_c8a9fdfa-af63-46fe-8204-2bf15f30001b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_a3bb352f-9e66-41e2-b7a4-1f8b7564bd87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_7466cd64-1748-4733-a0d9-8aa0ca43071b" xlink:to="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_a3bb352f-9e66-41e2-b7a4-1f8b7564bd87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash_2d3d2c89-3327-45a9-a2ae-fb4d47a8cd6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_7466cd64-1748-4733-a0d9-8aa0ca43071b" xlink:to="loc_us-gaap_DerivativeCollateralObligationToReturnCash_2d3d2c89-3327-45a9-a2ae-fb4d47a8cd6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_c8f83965-bfa9-4d36-9ad1-f451a9737dca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_7466cd64-1748-4733-a0d9-8aa0ca43071b" xlink:to="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_c8f83965-bfa9-4d36-9ad1-f451a9737dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_4e5fb730-a887-4ccf-95fe-46c155d4d5e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_7466cd64-1748-4733-a0d9-8aa0ca43071b" xlink:to="loc_us-gaap_DerivativeLiabilities_4e5fb730-a887-4ccf-95fe-46c155d4d5e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_1c72023b-d9af-4010-b336-c370caaae11f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_7466cd64-1748-4733-a0d9-8aa0ca43071b" xlink:to="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_1c72023b-d9af-4010-b336-c370caaae11f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash_e2558311-1d4c-4b4d-aeee-e5cdaedf7ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_7466cd64-1748-4733-a0d9-8aa0ca43071b" xlink:to="loc_us-gaap_DerivativeCollateralRightToReclaimCash_e2558311-1d4c-4b4d-aeee-e5cdaedf7ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_30b393cc-f2b3-4a5f-85dd-f06bd86d419e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_7466cd64-1748-4733-a0d9-8aa0ca43071b" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_30b393cc-f2b3-4a5f-85dd-f06bd86d419e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_51cf8cbe-4c90-4b03-b6e6-e707de285b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0f4de4db-dbc2-4767-886a-b08d9e17517a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_51cf8cbe-4c90-4b03-b6e6-e707de285b5e" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0f4de4db-dbc2-4767-886a-b08d9e17517a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_3936c584-e657-4ea6-9280-6e5d1a8c2b10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0f4de4db-dbc2-4767-886a-b08d9e17517a" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_3936c584-e657-4ea6-9280-6e5d1a8c2b10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_32f154dc-a2d9-482c-b1d5-138ba62b32f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3936c584-e657-4ea6-9280-6e5d1a8c2b10" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_32f154dc-a2d9-482c-b1d5-138ba62b32f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_15d070d4-e02c-4c11-9408-480f9ed6a5bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_32f154dc-a2d9-482c-b1d5-138ba62b32f0" xlink:to="loc_us-gaap_InterestRateSwapMember_15d070d4-e02c-4c11-9408-480f9ed6a5bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_73a1af60-de6f-4d7c-aed2-fd6153c4ca81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_32f154dc-a2d9-482c-b1d5-138ba62b32f0" xlink:to="loc_us-gaap_ForeignExchangeContractMember_73a1af60-de6f-4d7c-aed2-fd6153c4ca81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_37de80bc-d494-4557-9d8b-7bca7c77a5ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0f4de4db-dbc2-4767-886a-b08d9e17517a" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_37de80bc-d494-4557-9d8b-7bca7c77a5ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_6c5cc186-6a7e-4020-ac87-dd9d2eae8f05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_37de80bc-d494-4557-9d8b-7bca7c77a5ac" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_6c5cc186-6a7e-4020-ac87-dd9d2eae8f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_2898a3e3-32d2-4177-996b-a20616306582" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_6c5cc186-6a7e-4020-ac87-dd9d2eae8f05" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_2898a3e3-32d2-4177-996b-a20616306582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9c1b6bf6-e7e8-4735-bbce-040c49bd337d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0f4de4db-dbc2-4767-886a-b08d9e17517a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9c1b6bf6-e7e8-4735-bbce-040c49bd337d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_06ad2369-fec8-4c79-91b7-7c08887a3749" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9c1b6bf6-e7e8-4735-bbce-040c49bd337d" xlink:to="loc_us-gaap_EquityComponentDomain_06ad2369-fec8-4c79-91b7-7c08887a3749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_1782b3c9-ea79-4c59-acf5-3b0ca408a7eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_06ad2369-fec8-4c79-91b7-7c08887a3749" xlink:to="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_1782b3c9-ea79-4c59-acf5-3b0ca408a7eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ab875408-1065-4754-901a-0f4a96f0be85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0f4de4db-dbc2-4767-886a-b08d9e17517a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ab875408-1065-4754-901a-0f4a96f0be85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e4a6c30d-4710-43d7-99a2-9df5e2f6e6a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ab875408-1065-4754-901a-0f4a96f0be85" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e4a6c30d-4710-43d7-99a2-9df5e2f6e6a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_01a4df7a-449f-4c34-ae67-875f250d8167" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e4a6c30d-4710-43d7-99a2-9df5e2f6e6a8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_01a4df7a-449f-4c34-ae67-875f250d8167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_9ce07c84-7d58-4eca-841a-49f3f6cd90a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0f4de4db-dbc2-4767-886a-b08d9e17517a" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_9ce07c84-7d58-4eca-841a-49f3f6cd90a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_541f3fdf-c567-4571-a23b-65565e852dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_9ce07c84-7d58-4eca-841a-49f3f6cd90a5" xlink:to="loc_us-gaap_Revenues_541f3fdf-c567-4571-a23b-65565e852dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_aee089cb-cf73-420f-ba21-8575c47bb098" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_9ce07c84-7d58-4eca-841a-49f3f6cd90a5" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_aee089cb-cf73-420f-ba21-8575c47bb098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_03cbb03b-76fd-406c-b3a1-9d96161a08c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_9ce07c84-7d58-4eca-841a-49f3f6cd90a5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_03cbb03b-76fd-406c-b3a1-9d96161a08c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_e7d22590-eb0a-44d1-9d15-584a61f9baf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_9ce07c84-7d58-4eca-841a-49f3f6cd90a5" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_e7d22590-eb0a-44d1-9d15-584a61f9baf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_e8193a52-af5e-46e4-bc52-694009525fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_9ce07c84-7d58-4eca-841a-49f3f6cd90a5" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_e8193a52-af5e-46e4-bc52-694009525fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_0e6d65f7-3b54-4d14-b301-c83992a2b501" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_9ce07c84-7d58-4eca-841a-49f3f6cd90a5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_0e6d65f7-3b54-4d14-b301-c83992a2b501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_bbf6638e-9966-4b96-b3b3-9e6a212dc9fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_9ce07c84-7d58-4eca-841a-49f3f6cd90a5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_bbf6638e-9966-4b96-b3b3-9e6a212dc9fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_90613756-b989-4c60-bb43-79004da11386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_9ce07c84-7d58-4eca-841a-49f3f6cd90a5" xlink:to="loc_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_90613756-b989-4c60-bb43-79004da11386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_fedb6f04-855f-4bf2-99dd-10475408f17e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_9ce07c84-7d58-4eca-841a-49f3f6cd90a5" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_fedb6f04-855f-4bf2-99dd-10475408f17e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_740acbdf-ec91-4a6d-92b6-6b023230e023" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_fe31c654-7e92-406a-af45-f07c0fac77d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_740acbdf-ec91-4a6d-92b6-6b023230e023" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_fe31c654-7e92-406a-af45-f07c0fac77d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_3bf90d3d-9eb4-43db-b4c9-a396a71f7ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_fe31c654-7e92-406a-af45-f07c0fac77d5" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_3bf90d3d-9eb4-43db-b4c9-a396a71f7ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_fe14355f-a4df-4c6c-a0bb-aba44b0f5ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3bf90d3d-9eb4-43db-b4c9-a396a71f7ab8" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_fe14355f-a4df-4c6c-a0bb-aba44b0f5ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_888628c7-aae8-449c-9f38-c4142c8a57b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrencySwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fe14355f-a4df-4c6c-a0bb-aba44b0f5ee2" xlink:to="loc_us-gaap_CurrencySwapMember_888628c7-aae8-449c-9f38-c4142c8a57b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeFutureMember_a5d00d4d-28d3-4a2f-91e0-2dea894582c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeFutureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fe14355f-a4df-4c6c-a0bb-aba44b0f5ee2" xlink:to="loc_us-gaap_ForeignExchangeFutureMember_a5d00d4d-28d3-4a2f-91e0-2dea894582c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_bc2db728-7529-42af-9e4a-35854dd3dbc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_fe31c654-7e92-406a-af45-f07c0fac77d5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_bc2db728-7529-42af-9e4a-35854dd3dbc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3f3e48f6-c3ef-409d-b9d3-be227c7e8c84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_bc2db728-7529-42af-9e4a-35854dd3dbc3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3f3e48f6-c3ef-409d-b9d3-be227c7e8c84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_cb316e96-a113-47c9-af0f-a25d78f7cda6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3f3e48f6-c3ef-409d-b9d3-be227c7e8c84" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_cb316e96-a113-47c9-af0f-a25d78f7cda6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_ddf68607-90db-4135-968d-400f31ef989a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3f3e48f6-c3ef-409d-b9d3-be227c7e8c84" xlink:to="loc_us-gaap_SalesMember_ddf68607-90db-4135-968d-400f31ef989a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_ba11dfe5-a178-4e56-8613-9e62a9d3e753" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_fe31c654-7e92-406a-af45-f07c0fac77d5" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_ba11dfe5-a178-4e56-8613-9e62a9d3e753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_4a2e9a65-7953-4faa-aa94-6f766fd22dea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_ba11dfe5-a178-4e56-8613-9e62a9d3e753" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_4a2e9a65-7953-4faa-aa94-6f766fd22dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_fb5e46fd-06fc-4593-98a2-e93d9e6efabf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_236d7281-81b0-4e1f-98cc-ff1bdc3ee2c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_fb5e46fd-06fc-4593-98a2-e93d9e6efabf" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_236d7281-81b0-4e1f-98cc-ff1bdc3ee2c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_4c3356c2-59db-4b58-a2b4-b2a71bb2abb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_236d7281-81b0-4e1f-98cc-ff1bdc3ee2c9" xlink:to="loc_us-gaap_FinancialInstrumentAxis_4c3356c2-59db-4b58-a2b4-b2a71bb2abb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a357af8a-b8b4-4e3e-8110-b642dce74637" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4c3356c2-59db-4b58-a2b4-b2a71bb2abb3" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a357af8a-b8b4-4e3e-8110-b642dce74637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_9d5a1603-aa2f-42bb-9f90-f9a5875b2017" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a357af8a-b8b4-4e3e-8110-b642dce74637" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_9d5a1603-aa2f-42bb-9f90-f9a5875b2017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_a29a14b0-0cab-4183-8097-50250d71992d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a357af8a-b8b4-4e3e-8110-b642dce74637" xlink:to="loc_us-gaap_CommercialPaperMember_a29a14b0-0cab-4183-8097-50250d71992d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_e242c2e2-a583-4a03-ad33-693fb814927c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a357af8a-b8b4-4e3e-8110-b642dce74637" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_e242c2e2-a583-4a03-ad33-693fb814927c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_6f9f5808-7cbb-4a5a-8e01-055cac4b83a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a357af8a-b8b4-4e3e-8110-b642dce74637" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_6f9f5808-7cbb-4a5a-8e01-055cac4b83a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ebb40674-40f5-4371-9879-4e9016a3d659" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_236d7281-81b0-4e1f-98cc-ff1bdc3ee2c9" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ebb40674-40f5-4371-9879-4e9016a3d659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b7373784-ae39-465b-99b6-6625db6dc2e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ebb40674-40f5-4371-9879-4e9016a3d659" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b7373784-ae39-465b-99b6-6625db6dc2e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4cabb034-5e6d-45e6-8992-54ef7fd5f919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ebb40674-40f5-4371-9879-4e9016a3d659" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4cabb034-5e6d-45e6-8992-54ef7fd5f919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5a6367c2-dac1-4f7d-ac65-1aeeaed60934" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ebb40674-40f5-4371-9879-4e9016a3d659" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5a6367c2-dac1-4f7d-ac65-1aeeaed60934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4db6ced4-1546-4de9-9b6b-97b9829024ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ebb40674-40f5-4371-9879-4e9016a3d659" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4db6ced4-1546-4de9-9b6b-97b9829024ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_202a1da4-88dc-4773-bc9f-900233efa6de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ebb40674-40f5-4371-9879-4e9016a3d659" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_202a1da4-88dc-4773-bc9f-900233efa6de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI_241f5e2c-d9f7-4e5a-948e-e9a18a57ed29" xlink:href="mrk-20220930.xsd#mrk_DebtSecuritiesandEquitySecuritiesFVNI"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ebb40674-40f5-4371-9879-4e9016a3d659" xlink:to="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI_241f5e2c-d9f7-4e5a-948e-e9a18a57ed29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_22806f71-326e-4337-9ac3-9359afc095a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ebb40674-40f5-4371-9879-4e9016a3d659" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_22806f71-326e-4337-9ac3-9359afc095a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_06cac143-71b3-4add-bd03-af8af0bedf0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_88165e8a-80e2-4ad5-904a-c86b4d941739" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_06cac143-71b3-4add-bd03-af8af0bedf0a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_88165e8a-80e2-4ad5-904a-c86b4d941739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3478b0b2-991e-444e-bdaa-a20012b1b860" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_88165e8a-80e2-4ad5-904a-c86b4d941739" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3478b0b2-991e-444e-bdaa-a20012b1b860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_4cd5314d-c6eb-4469-a98d-d92a959fa90c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3478b0b2-991e-444e-bdaa-a20012b1b860" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_4cd5314d-c6eb-4469-a98d-d92a959fa90c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_6e451874-5f9d-4f35-9e10-4134539bccbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_4cd5314d-c6eb-4469-a98d-d92a959fa90c" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_6e451874-5f9d-4f35-9e10-4134539bccbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1a41e368-9cdc-437b-b608-b5819f76905e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_88165e8a-80e2-4ad5-904a-c86b4d941739" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1a41e368-9cdc-437b-b608-b5819f76905e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_475284b0-175d-4634-a681-242e8ec215b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1a41e368-9cdc-437b-b608-b5819f76905e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_475284b0-175d-4634-a681-242e8ec215b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_1740a0b0-18ee-4f74-9f0a-9248a3484d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_475284b0-175d-4634-a681-242e8ec215b0" xlink:to="loc_us-gaap_CommercialPaperMember_1740a0b0-18ee-4f74-9f0a-9248a3484d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_daf5fd5f-63cd-4676-b3b9-251bd15d6f65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_475284b0-175d-4634-a681-242e8ec215b0" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_daf5fd5f-63cd-4676-b3b9-251bd15d6f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_2f13594e-25e1-4796-b1f2-fd01ab5cb46a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_475284b0-175d-4634-a681-242e8ec215b0" xlink:to="loc_us-gaap_EquitySecuritiesMember_2f13594e-25e1-4796-b1f2-fd01ab5cb46a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_bbaf9584-c71a-4822-804e-dc4f29b36d38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_475284b0-175d-4634-a681-242e8ec215b0" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_bbaf9584-c71a-4822-804e-dc4f29b36d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_71f58d2d-a43c-4128-8b7b-0e45ab4e9a32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_475284b0-175d-4634-a681-242e8ec215b0" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_71f58d2d-a43c-4128-8b7b-0e45ab4e9a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5410f46f-afd2-407b-bdea-c4cf5085fff5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_88165e8a-80e2-4ad5-904a-c86b4d941739" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5410f46f-afd2-407b-bdea-c4cf5085fff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3af880dd-edb8-4725-99b4-d9e9b412ff46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5410f46f-afd2-407b-bdea-c4cf5085fff5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3af880dd-edb8-4725-99b4-d9e9b412ff46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_7d349340-f653-4814-853d-87c669aa7050" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3af880dd-edb8-4725-99b4-d9e9b412ff46" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_7d349340-f653-4814-853d-87c669aa7050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_eee58cbc-6811-41e8-9b67-9d577ba8dc06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3af880dd-edb8-4725-99b4-d9e9b412ff46" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_eee58cbc-6811-41e8-9b67-9d577ba8dc06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3d98ba2b-9b28-4aea-9d38-3e888a6416ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3af880dd-edb8-4725-99b4-d9e9b412ff46" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3d98ba2b-9b28-4aea-9d38-3e888a6416ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_658dee45-23e6-478d-b708-d3e0dfb92d15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_88165e8a-80e2-4ad5-904a-c86b4d941739" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_658dee45-23e6-478d-b708-d3e0dfb92d15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_70add43d-beb7-42f0-8dea-9ffd952c5d04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_658dee45-23e6-478d-b708-d3e0dfb92d15" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_70add43d-beb7-42f0-8dea-9ffd952c5d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_acf44696-89f0-48ba-884a-b3519b410ede" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_70add43d-beb7-42f0-8dea-9ffd952c5d04" xlink:to="loc_us-gaap_ForeignExchangeContractMember_acf44696-89f0-48ba-884a-b3519b410ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_f8dc16bd-0393-415e-8ff4-8873f4c91c49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_70add43d-beb7-42f0-8dea-9ffd952c5d04" xlink:to="loc_us-gaap_InterestRateSwapMember_f8dc16bd-0393-415e-8ff4-8873f4c91c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeOptionMember_e352c507-92df-4ce5-9df8-bed4fb6c7aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_70add43d-beb7-42f0-8dea-9ffd952c5d04" xlink:to="loc_us-gaap_ForeignExchangeOptionMember_e352c507-92df-4ce5-9df8-bed4fb6c7aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c75c3a4f-2cf9-4295-b42b-0ebfc03193e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_88165e8a-80e2-4ad5-904a-c86b4d941739" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c75c3a4f-2cf9-4295-b42b-0ebfc03193e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_a233726b-b836-4c58-a120-4b81b6eb395f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c75c3a4f-2cf9-4295-b42b-0ebfc03193e4" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_a233726b-b836-4c58-a120-4b81b6eb395f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_673fc66a-ffe4-4d59-96bd-567ba6b4f2ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a233726b-b836-4c58-a120-4b81b6eb395f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_673fc66a-ffe4-4d59-96bd-567ba6b4f2ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_9257c215-2e7a-4e71-885b-2cebc59acc38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a233726b-b836-4c58-a120-4b81b6eb395f" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_9257c215-2e7a-4e71-885b-2cebc59acc38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities_72737bd6-a3f3-4238-96de-1d723be3c3c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a233726b-b836-4c58-a120-4b81b6eb395f" xlink:to="loc_us-gaap_TradingSecurities_72737bd6-a3f3-4238-96de-1d723be3c3c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_6f43218a-e1d7-494f-9139-f62672fabb06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a233726b-b836-4c58-a120-4b81b6eb395f" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_6f43218a-e1d7-494f-9139-f62672fabb06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_a7fbcd16-6fca-4809-ac36-ebab3c36adee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a233726b-b836-4c58-a120-4b81b6eb395f" xlink:to="loc_us-gaap_DerivativeAssets_a7fbcd16-6fca-4809-ac36-ebab3c36adee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_c7dfd052-90eb-4cbb-9931-5e7ceb90367a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a233726b-b836-4c58-a120-4b81b6eb395f" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_c7dfd052-90eb-4cbb-9931-5e7ceb90367a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_ddfc1f14-a9b3-494e-895d-67d24bb3924c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c75c3a4f-2cf9-4295-b42b-0ebfc03193e4" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_ddfc1f14-a9b3-494e-895d-67d24bb3924c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_824b7145-daf0-459c-87fe-3d3524e3b350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_ddfc1f14-a9b3-494e-895d-67d24bb3924c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_824b7145-daf0-459c-87fe-3d3524e3b350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_84982ace-2c68-42a3-bdad-bcd97ce6b889" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_ddfc1f14-a9b3-494e-895d-67d24bb3924c" xlink:to="loc_us-gaap_DerivativeLiabilities_84982ace-2c68-42a3-bdad-bcd97ce6b889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_5af5cced-8589-4087-bbf7-c502ba8742ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_ddfc1f14-a9b3-494e-895d-67d24bb3924c" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_5af5cced-8589-4087-bbf7-c502ba8742ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_d6113d75-ad70-4543-955d-8890ce752e27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_e4453ec3-626a-4ff3-a11a-a2c41587478a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_d6113d75-ad70-4543-955d-8890ce752e27" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_e4453ec3-626a-4ff3-a11a-a2c41587478a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_7d23c699-cf01-473a-b770-dd5a469777ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_e4453ec3-626a-4ff3-a11a-a2c41587478a" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_7d23c699-cf01-473a-b770-dd5a469777ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_5609e3f5-2c8f-4453-a015-afdf6f0fd9a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_7d23c699-cf01-473a-b770-dd5a469777ad" xlink:to="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_5609e3f5-2c8f-4453-a015-afdf6f0fd9a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SanofiPasteurMember_0dc26e49-d227-485d-b299-020a7a10228c" xlink:href="mrk-20220930.xsd#mrk_SanofiPasteurMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_5609e3f5-2c8f-4453-a015-afdf6f0fd9a6" xlink:to="loc_mrk_SanofiPasteurMember_0dc26e49-d227-485d-b299-020a7a10228c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6d33a379-abd4-4aff-8f0f-e56debfdf5f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_e4453ec3-626a-4ff3-a11a-a2c41587478a" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6d33a379-abd4-4aff-8f0f-e56debfdf5f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5381c372-17cb-4288-87ae-e31785da5d71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6d33a379-abd4-4aff-8f0f-e56debfdf5f4" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5381c372-17cb-4288-87ae-e31785da5d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0c80bec5-32d6-4e6e-b276-8d5b59bc2994" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5381c372-17cb-4288-87ae-e31785da5d71" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0c80bec5-32d6-4e6e-b276-8d5b59bc2994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_0233eba5-4277-4cd7-aff6-1dd9790871c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5381c372-17cb-4288-87ae-e31785da5d71" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_0233eba5-4277-4cd7-aff6-1dd9790871c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_2df67dbc-4638-4621-b6c8-6f925845417a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5381c372-17cb-4288-87ae-e31785da5d71" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_2df67dbc-4638-4621-b6c8-6f925845417a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther_0a001109-dbaa-43ff-9f4b-cf8752ea6f4e" xlink:href="mrk-20220930.xsd#mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5381c372-17cb-4288-87ae-e31785da5d71" xlink:to="loc_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther_0a001109-dbaa-43ff-9f4b-cf8752ea6f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e2c223cb-efba-41ad-b9d8-363bb4381866" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5381c372-17cb-4288-87ae-e31785da5d71" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e2c223cb-efba-41ad-b9d8-363bb4381866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1670d0e5-2e01-40b4-b797-ea294ae49715" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5381c372-17cb-4288-87ae-e31785da5d71" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1670d0e5-2e01-40b4-b797-ea294ae49715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_b53de088-7aac-418f-8419-72a5b5fdc471" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5381c372-17cb-4288-87ae-e31785da5d71" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_b53de088-7aac-418f-8419-72a5b5fdc471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_b99fb3cf-554c-4293-b634-c590569d81d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5381c372-17cb-4288-87ae-e31785da5d71" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_b99fb3cf-554c-4293-b634-c590569d81d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_0ebe75ef-2ae8-4b8d-8b86-a079922904a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_a67fce1f-2031-410a-a094-21c9c34d2208" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0ebe75ef-2ae8-4b8d-8b86-a079922904a4" xlink:to="loc_us-gaap_InventoryFinishedGoods_a67fce1f-2031-410a-a094-21c9c34d2208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessAndRawMaterials_ac1baab5-5fde-48ff-87da-9f3c10289652" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessAndRawMaterials"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0ebe75ef-2ae8-4b8d-8b86-a079922904a4" xlink:to="loc_us-gaap_InventoryWorkInProcessAndRawMaterials_ac1baab5-5fde-48ff-87da-9f3c10289652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventorySupplies_be2d35d6-5b82-4e3a-8fa7-6ed7baf534f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInventorySupplies"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0ebe75ef-2ae8-4b8d-8b86-a079922904a4" xlink:to="loc_us-gaap_OtherInventorySupplies_be2d35d6-5b82-4e3a-8fa7-6ed7baf534f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_155063c2-e7fc-4d67-9a8a-208683aadb70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0ebe75ef-2ae8-4b8d-8b86-a079922904a4" xlink:to="loc_us-gaap_InventoryGross_155063c2-e7fc-4d67-9a8a-208683aadb70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLIFOReserve_0af07a3f-c8ae-4cc8-9519-35165e0317bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLIFOReserve"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0ebe75ef-2ae8-4b8d-8b86-a079922904a4" xlink:to="loc_us-gaap_InventoryLIFOReserve_0af07a3f-c8ae-4cc8-9519-35165e0317bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryNetAndInventoryNoncurrent_73df4ff9-7ae2-48a2-9537-5a133482279c" xlink:href="mrk-20220930.xsd#mrk_InventoryNetAndInventoryNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0ebe75ef-2ae8-4b8d-8b86-a079922904a4" xlink:to="loc_mrk_InventoryNetAndInventoryNoncurrent_73df4ff9-7ae2-48a2-9537-5a133482279c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RecognizedAsAbstract_44612851-c0e7-4e1b-a895-ceace78d4119" xlink:href="mrk-20220930.xsd#mrk_RecognizedAsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0ebe75ef-2ae8-4b8d-8b86-a079922904a4" xlink:to="loc_mrk_RecognizedAsAbstract_44612851-c0e7-4e1b-a895-ceace78d4119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_b4e959a6-2d26-44a3-865f-e1deb211ae61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_RecognizedAsAbstract_44612851-c0e7-4e1b-a895-ceace78d4119" xlink:to="loc_us-gaap_InventoryNet_b4e959a6-2d26-44a3-865f-e1deb211ae61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_ccd459a8-6ee7-4485-a555-9e5ed24d0516" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_RecognizedAsAbstract_44612851-c0e7-4e1b-a895-ceace78d4119" xlink:to="loc_us-gaap_InventoryNoncurrent_ccd459a8-6ee7-4485-a555-9e5ed24d0516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/InventoriesScheduleofInventoriesDetails_1" xlink:type="simple" xlink:href="mrk-20220930.xsd#InventoriesScheduleofInventoriesDetails_1"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/InventoriesScheduleofInventoriesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#InventoriesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/InventoriesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_5ab26b1d-5bbe-44f0-93bf-0dd17f33e908" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryTable_87509c72-f1e1-4e90-aa76-f14cd8648dec" xlink:href="mrk-20220930.xsd#mrk_InventoryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_5ab26b1d-5bbe-44f0-93bf-0dd17f33e908" xlink:to="loc_mrk_InventoryTable_87509c72-f1e1-4e90-aa76-f14cd8648dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_1385e5e8-a081-4b1e-bbaa-3f516426df79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_InventoryTable_87509c72-f1e1-4e90-aa76-f14cd8648dec" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_1385e5e8-a081-4b1e-bbaa-3f516426df79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_70822e0a-8bd9-4601-8d45-a33e99543e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_1385e5e8-a081-4b1e-bbaa-3f516426df79" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_70822e0a-8bd9-4601-8d45-a33e99543e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember_4f2e537c-0327-4321-82e9-01f244b89aaf" xlink:href="mrk-20220930.xsd#mrk_InventoryNotExpectedtobeSoldWithinOneYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_70822e0a-8bd9-4601-8d45-a33e99543e1d" xlink:to="loc_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember_4f2e537c-0327-4321-82e9-01f244b89aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoriesProducedinPreparationforProductLaunchesMember_e6d098f1-b67b-4a4f-927d-56f5b6573ab1" xlink:href="mrk-20220930.xsd#mrk_InventoriesProducedinPreparationforProductLaunchesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_70822e0a-8bd9-4601-8d45-a33e99543e1d" xlink:to="loc_mrk_InventoriesProducedinPreparationforProductLaunchesMember_e6d098f1-b67b-4a4f-927d-56f5b6573ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_a5d7620f-23cd-46bb-b70c-c879704517be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_InventoryTable_87509c72-f1e1-4e90-aa76-f14cd8648dec" xlink:to="loc_us-gaap_InventoryLineItems_a5d7620f-23cd-46bb-b70c-c879704517be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_c697978e-a7f0-4062-8567-48feb0154eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_a5d7620f-23cd-46bb-b70c-c879704517be" xlink:to="loc_us-gaap_InventoryNoncurrent_c697978e-a7f0-4062-8567-48feb0154eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIntangiblesDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#OtherIntangiblesDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/OtherIntangiblesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5511ed98-ff30-4a29-a4b9-e608ef1d1373" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_23cdab77-54e6-4e7a-999c-851fe94a16be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5511ed98-ff30-4a29-a4b9-e608ef1d1373" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_23cdab77-54e6-4e7a-999c-851fe94a16be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_068e4193-251a-4938-990e-7307f82224d0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_23cdab77-54e6-4e7a-999c-851fe94a16be" xlink:to="loc_srt_ProductOrServiceAxis_068e4193-251a-4938-990e-7307f82224d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7aeae0ca-9e91-4d73-a495-0cc675fe955b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_068e4193-251a-4938-990e-7307f82224d0" xlink:to="loc_srt_ProductsAndServicesDomain_7aeae0ca-9e91-4d73-a495-0cc675fe955b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NemtabrutinibMember_f5e85214-8dcb-48aa-8c47-5e4cb38390c7" xlink:href="mrk-20220930.xsd#mrk_NemtabrutinibMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7aeae0ca-9e91-4d73-a495-0cc675fe955b" xlink:to="loc_mrk_NemtabrutinibMember_f5e85214-8dcb-48aa-8c47-5e4cb38390c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_508ded94-f60b-4806-a7ba-6dab735ab386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_23cdab77-54e6-4e7a-999c-851fe94a16be" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_508ded94-f60b-4806-a7ba-6dab735ab386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5e023dd7-0da2-4c95-988f-0119519a6d13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_508ded94-f60b-4806-a7ba-6dab735ab386" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5e023dd7-0da2-4c95-988f-0119519a6d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_0a587e27-06d9-4a61-84e4-6e20c1add510" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5e023dd7-0da2-4c95-988f-0119519a6d13" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_0a587e27-06d9-4a61-84e4-6e20c1add510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_d0f4588b-fa18-4beb-ac6b-99fffe57bcc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_23cdab77-54e6-4e7a-999c-851fe94a16be" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_d0f4588b-fa18-4beb-ac6b-99fffe57bcc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_68aad744-086a-4e4a-8b44-2f5892a732e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_d0f4588b-fa18-4beb-ac6b-99fffe57bcc4" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_68aad744-086a-4e4a-8b44-2f5892a732e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c97b411d-4196-447a-a575-e7b53bd85c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_d0f4588b-fa18-4beb-ac6b-99fffe57bcc4" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c97b411d-4196-447a-a575-e7b53bd85c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ContingenciesDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#ContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_978110c6-42a4-4e2a-9cb1-583fdb3aaaa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_fcf3ce6c-7e94-442c-8b51-df9a7f207b85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_978110c6-42a4-4e2a-9cb1-583fdb3aaaa6" xlink:to="loc_us-gaap_LossContingenciesTable_fcf3ce6c-7e94-442c-8b51-df9a7f207b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a7c4a591-ab68-4910-8a2b-b360c8e6c157" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_fcf3ce6c-7e94-442c-8b51-df9a7f207b85" xlink:to="loc_srt_ProductOrServiceAxis_a7c4a591-ab68-4910-8a2b-b360c8e6c157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_85f6944e-4495-4d0e-b38a-ccb92b61262f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a7c4a591-ab68-4910-8a2b-b360c8e6c157" xlink:to="loc_srt_ProductsAndServicesDomain_85f6944e-4495-4d0e-b38a-ccb92b61262f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FosamaxMember_4b3c804d-be14-402e-810b-0ab5a1361768" xlink:href="mrk-20220930.xsd#mrk_FosamaxMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_85f6944e-4495-4d0e-b38a-ccb92b61262f" xlink:to="loc_mrk_FosamaxMember_4b3c804d-be14-402e-810b-0ab5a1361768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_JanuviaMember_dc77eefe-fb2f-4a53-84dc-d7c24a219ee8" xlink:href="mrk-20220930.xsd#mrk_JanuviaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_85f6944e-4495-4d0e-b38a-ccb92b61262f" xlink:to="loc_mrk_JanuviaMember_dc77eefe-fb2f-4a53-84dc-d7c24a219ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GardasilGardasil9Member_f3324f5b-989e-4d7e-ae34-56abf72a4edb" xlink:href="mrk-20220930.xsd#mrk_GardasilGardasil9Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_85f6944e-4495-4d0e-b38a-ccb92b61262f" xlink:to="loc_mrk_GardasilGardasil9Member_f3324f5b-989e-4d7e-ae34-56abf72a4edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BridionMember_f94db93a-8838-484b-9ea3-64acf7d17d71" xlink:href="mrk-20220930.xsd#mrk_BridionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_85f6944e-4495-4d0e-b38a-ccb92b61262f" xlink:to="loc_mrk_BridionMember_f94db93a-8838-484b-9ea3-64acf7d17d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_JanuviaAndJanumetMember_d8ed1d40-e8c4-4778-a1aa-b0b303c43316" xlink:href="mrk-20220930.xsd#mrk_JanuviaAndJanumetMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_85f6944e-4495-4d0e-b38a-ccb92b61262f" xlink:to="loc_mrk_JanuviaAndJanumetMember_d8ed1d40-e8c4-4778-a1aa-b0b303c43316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_4c9b202d-259f-43c6-8ab0-f0d0b9a48867" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_fcf3ce6c-7e94-442c-8b51-df9a7f207b85" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_4c9b202d-259f-43c6-8ab0-f0d0b9a48867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_abe88682-3199-482c-84fd-a6d41665ed49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_4c9b202d-259f-43c6-8ab0-f0d0b9a48867" xlink:to="loc_us-gaap_LossContingencyNatureDomain_abe88682-3199-482c-84fd-a6d41665ed49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FemurFractureLitigationMember_d6cbd7b5-543f-452d-aa58-0a1aab6e4c7e" xlink:href="mrk-20220930.xsd#mrk_FemurFractureLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_abe88682-3199-482c-84fd-a6d41665ed49" xlink:to="loc_mrk_FemurFractureLitigationMember_d6cbd7b5-543f-452d-aa58-0a1aab6e4c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember_8ef2e3bd-b425-40fb-8cae-2764856ee6b2" xlink:href="mrk-20220930.xsd#mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_abe88682-3199-482c-84fd-a6d41665ed49" xlink:to="loc_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember_8ef2e3bd-b425-40fb-8cae-2764856ee6b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_a07f9ce7-5441-4d59-8857-4e5f8cdbd6e9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_fcf3ce6c-7e94-442c-8b51-df9a7f207b85" xlink:to="loc_srt_LitigationCaseAxis_a07f9ce7-5441-4d59-8857-4e5f8cdbd6e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_7a30f9d0-5f80-4ae3-acb3-718f016b3872" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_a07f9ce7-5441-4d59-8857-4e5f8cdbd6e9" xlink:to="loc_srt_LitigationCaseTypeDomain_7a30f9d0-5f80-4ae3-acb3-718f016b3872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FederalMember_552087d3-b7d3-4d5e-b12d-197c4c0e5f7d" xlink:href="mrk-20220930.xsd#mrk_FederalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_7a30f9d0-5f80-4ae3-acb3-718f016b3872" xlink:to="loc_mrk_FederalMember_552087d3-b7d3-4d5e-b12d-197c4c0e5f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ZetiaantitrustlitigationMember_2cea1200-2ab5-4834-bf42-194ffe596feb" xlink:href="mrk-20220930.xsd#mrk_ZetiaantitrustlitigationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_7a30f9d0-5f80-4ae3-acb3-718f016b3872" xlink:to="loc_mrk_ZetiaantitrustlitigationMember_2cea1200-2ab5-4834-bf42-194ffe596feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_3a315dfc-1e8c-4152-9d8a-1aeb013decf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_7a30f9d0-5f80-4ae3-acb3-718f016b3872" xlink:to="loc_us-gaap_PatentsMember_3a315dfc-1e8c-4152-9d8a-1aeb013decf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PatentInfringementLawsuitAgainstZydusWorldwideDMCCZydusPharmaceuticalsUSAIncAndCadilaHealthcareLtdMember_128b6ca2-bef5-4491-af01-58f10c6ca2a3" xlink:href="mrk-20220930.xsd#mrk_PatentInfringementLawsuitAgainstZydusWorldwideDMCCZydusPharmaceuticalsUSAIncAndCadilaHealthcareLtdMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_7a30f9d0-5f80-4ae3-acb3-718f016b3872" xlink:to="loc_mrk_PatentInfringementLawsuitAgainstZydusWorldwideDMCCZydusPharmaceuticalsUSAIncAndCadilaHealthcareLtdMember_128b6ca2-bef5-4491-af01-58f10c6ca2a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_de8dbede-0343-4d3f-8979-5f0845204de5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_fcf3ce6c-7e94-442c-8b51-df9a7f207b85" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_de8dbede-0343-4d3f-8979-5f0845204de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_318cadf6-b479-40f7-a30b-478a5f104f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_de8dbede-0343-4d3f-8979-5f0845204de5" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_318cadf6-b479-40f7-a30b-478a5f104f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LegalDefenseCostsMember_b9db919f-b10c-4ed3-b4c9-ea9cd4268745" xlink:href="mrk-20220930.xsd#mrk_LegalDefenseCostsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_318cadf6-b479-40f7-a30b-478a5f104f0e" xlink:to="loc_mrk_LegalDefenseCostsMember_b9db919f-b10c-4ed3-b4c9-ea9cd4268745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_56efbf18-61d4-469b-a733-13c6ff926f86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_fcf3ce6c-7e94-442c-8b51-df9a7f207b85" xlink:to="loc_us-gaap_LitigationStatusAxis_56efbf18-61d4-469b-a733-13c6ff926f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_5c47fae6-deb7-4f43-b6f5-6368399cf81a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_56efbf18-61d4-469b-a733-13c6ff926f86" xlink:to="loc_us-gaap_LitigationStatusDomain_5c47fae6-deb7-4f43-b6f5-6368399cf81a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_c8463f13-b03d-41b7-8bb2-825fc54b3286" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_5c47fae6-deb7-4f43-b6f5-6368399cf81a" xlink:to="loc_us-gaap_PendingLitigationMember_c8463f13-b03d-41b7-8bb2-825fc54b3286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_781b72c5-b870-46cc-ad71-e697cab48ebd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_fcf3ce6c-7e94-442c-8b51-df9a7f207b85" xlink:to="loc_srt_StatementGeographicalAxis_781b72c5-b870-46cc-ad71-e697cab48ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_cd3ca83e-0561-47f2-9893-3e5ca61594d8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_781b72c5-b870-46cc-ad71-e697cab48ebd" xlink:to="loc_srt_SegmentGeographicalDomain_cd3ca83e-0561-47f2-9893-3e5ca61594d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_28a81856-46cc-4869-b606-71b4f1a90a1c" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_cd3ca83e-0561-47f2-9893-3e5ca61594d8" xlink:to="loc_country_US_28a81856-46cc-4869-b606-71b4f1a90a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_2b18c692-0f55-4517-aede-1ac5418a1347" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_cd3ca83e-0561-47f2-9893-3e5ca61594d8" xlink:to="loc_us-gaap_NonUsMember_2b18c692-0f55-4517-aede-1ac5418a1347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CO_38c191a9-afd2-43fb-b7de-ec1edecdf939" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CO"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_cd3ca83e-0561-47f2-9893-3e5ca61594d8" xlink:to="loc_country_CO_38c191a9-afd2-43fb-b7de-ec1edecdf939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_e4a3c233-3172-4e12-8490-119382a8d6e2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_fcf3ce6c-7e94-442c-8b51-df9a7f207b85" xlink:to="loc_srt_StatementScenarioAxis_e4a3c233-3172-4e12-8490-119382a8d6e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_a7aba0e5-a100-4a2b-ac08-7055ac9a4035" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_e4a3c233-3172-4e12-8490-119382a8d6e2" xlink:to="loc_srt_ScenarioUnspecifiedDomain_a7aba0e5-a100-4a2b-ac08-7055ac9a4035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_71b0e48f-6a66-413c-8599-628c67b8cbcc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_a7aba0e5-a100-4a2b-ac08-7055ac9a4035" xlink:to="loc_srt_ScenarioForecastMember_71b0e48f-6a66-413c-8599-628c67b8cbcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_790b50ed-dd43-47da-a98c-097e2a2bacda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_fcf3ce6c-7e94-442c-8b51-df9a7f207b85" xlink:to="loc_us-gaap_LossContingenciesLineItems_790b50ed-dd43-47da-a98c-097e2a2bacda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_6a7944e0-95c0-4f42-b177-9527d8b9e45a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_790b50ed-dd43-47da-a98c-097e2a2bacda" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_6a7944e0-95c0-4f42-b177-9527d8b9e45a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber_f7bc9c64-9e6b-487f-8213-e9a24a2c4d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_790b50ed-dd43-47da-a98c-097e2a2bacda" xlink:to="loc_us-gaap_LossContingencyClaimsDismissedNumber_f7bc9c64-9e6b-487f-8213-e9a24a2c4d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LossContingencyClaimsonAppealNumber_c567b390-3fe9-465d-9cf1-ea9c17d57ff9" xlink:href="mrk-20220930.xsd#mrk_LossContingencyClaimsonAppealNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_790b50ed-dd43-47da-a98c-097e2a2bacda" xlink:to="loc_mrk_LossContingencyClaimsonAppealNumber_c567b390-3fe9-465d-9cf1-ea9c17d57ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_e946bfcb-abb3-4483-b5df-51e85f84567f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_790b50ed-dd43-47da-a98c-097e2a2bacda" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_e946bfcb-abb3-4483-b5df-51e85f84567f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LossContingencyTrialPeriod_13e0c496-d9cd-4a30-84a5-c4f413227f97" xlink:href="mrk-20220930.xsd#mrk_LossContingencyTrialPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_790b50ed-dd43-47da-a98c-097e2a2bacda" xlink:to="loc_mrk_LossContingencyTrialPeriod_13e0c496-d9cd-4a30-84a5-c4f413227f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsSettledNumber_893d53f0-20f1-4819-be78-a05b62d6ecfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyClaimsSettledNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_790b50ed-dd43-47da-a98c-097e2a2bacda" xlink:to="loc_us-gaap_LossContingencyClaimsSettledNumber_893d53f0-20f1-4819-be78-a05b62d6ecfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LossContingencyRecoveryFromThirdPartyBenchTrialPeriod_f90148e5-7b6f-4101-95ad-92c3ce944dd7" xlink:href="mrk-20220930.xsd#mrk_LossContingencyRecoveryFromThirdPartyBenchTrialPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_790b50ed-dd43-47da-a98c-097e2a2bacda" xlink:to="loc_mrk_LossContingencyRecoveryFromThirdPartyBenchTrialPeriod_f90148e5-7b6f-4101-95ad-92c3ce944dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_f3ec0e24-a59d-45bf-b21b-583a163519ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserve"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_790b50ed-dd43-47da-a98c-097e2a2bacda" xlink:to="loc_us-gaap_LitigationReserve_f3ec0e24-a59d-45bf-b21b-583a163519ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/EquityRollforwardReconciliationsDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#EquityRollforwardReconciliationsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/EquityRollforwardReconciliationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_30a22481-52b6-4d0f-bcf2-56ce3d7dc5a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_StockholdersEquityTable_40bb3e72-aa2a-4831-9569-b68635500721" xlink:href="mrk-20220930.xsd#mrk_StockholdersEquityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_30a22481-52b6-4d0f-bcf2-56ce3d7dc5a8" xlink:to="loc_mrk_StockholdersEquityTable_40bb3e72-aa2a-4831-9569-b68635500721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_42f67fef-d2dc-4602-9566-40918a9b1558" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_StockholdersEquityTable_40bb3e72-aa2a-4831-9569-b68635500721" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_42f67fef-d2dc-4602-9566-40918a9b1558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a31e47b1-3e29-4a2f-abd0-44cda2d2df10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_42f67fef-d2dc-4602-9566-40918a9b1558" xlink:to="loc_us-gaap_EquityComponentDomain_a31e47b1-3e29-4a2f-abd0-44cda2d2df10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_82401c64-2671-4e5d-8c4f-7577ab2dfbae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a31e47b1-3e29-4a2f-abd0-44cda2d2df10" xlink:to="loc_us-gaap_CommonStockMember_82401c64-2671-4e5d-8c4f-7577ab2dfbae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_b929225b-89ee-4029-9304-f3b771d13038" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a31e47b1-3e29-4a2f-abd0-44cda2d2df10" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_b929225b-89ee-4029-9304-f3b771d13038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_26172492-02ec-444c-9a26-a4018320035f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a31e47b1-3e29-4a2f-abd0-44cda2d2df10" xlink:to="loc_us-gaap_RetainedEarningsMember_26172492-02ec-444c-9a26-a4018320035f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_dcc85a27-f425-4d89-87dd-5b5929e144b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a31e47b1-3e29-4a2f-abd0-44cda2d2df10" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_dcc85a27-f425-4d89-87dd-5b5929e144b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_010f9665-7029-455c-b217-4ca9e4ec6e28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a31e47b1-3e29-4a2f-abd0-44cda2d2df10" xlink:to="loc_us-gaap_TreasuryStockCommonMember_010f9665-7029-455c-b217-4ca9e4ec6e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_afcf48b4-d811-458b-b4fa-e74668128e74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a31e47b1-3e29-4a2f-abd0-44cda2d2df10" xlink:to="loc_us-gaap_NoncontrollingInterestMember_afcf48b4-d811-458b-b4fa-e74668128e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_StockholdersEquityLineItems_a5c666bd-65f3-4561-999e-a8fab487f186" xlink:href="mrk-20220930.xsd#mrk_StockholdersEquityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_StockholdersEquityTable_40bb3e72-aa2a-4831-9569-b68635500721" xlink:to="loc_mrk_StockholdersEquityLineItems_a5c666bd-65f3-4561-999e-a8fab487f186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_44a55126-b2b5-4043-a253-05a8c98288d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_StockholdersEquityLineItems_a5c666bd-65f3-4561-999e-a8fab487f186" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_44a55126-b2b5-4043-a253-05a8c98288d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_5e682e48-7b2f-4527-ba47-f15b3cfea78c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_44a55126-b2b5-4043-a253-05a8c98288d8" xlink:to="loc_us-gaap_CommonStockSharesIssued_5e682e48-7b2f-4527-ba47-f15b3cfea78c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_c93f4409-5ba3-46b6-a2a9-8dc3084c0ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_44a55126-b2b5-4043-a253-05a8c98288d8" xlink:to="loc_us-gaap_TreasuryStockCommonShares_c93f4409-5ba3-46b6-a2a9-8dc3084c0ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c13afabd-8e58-42f5-be41-73fb2d62d03c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_44a55126-b2b5-4043-a253-05a8c98288d8" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c13afabd-8e58-42f5-be41-73fb2d62d03c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2b541428-12e1-4cf7-9a46-b479d6b8c5f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_44a55126-b2b5-4043-a253-05a8c98288d8" xlink:to="loc_us-gaap_NetIncomeLoss_2b541428-12e1-4cf7-9a46-b479d6b8c5f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e6c5c3a8-1165-4832-8164-a525af2a315e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_44a55126-b2b5-4043-a253-05a8c98288d8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e6c5c3a8-1165-4832-8164-a525af2a315e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_c1873b31-8d2b-422a-9cab-549d2b6d416e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_44a55126-b2b5-4043-a253-05a8c98288d8" xlink:to="loc_us-gaap_DividendsCommonStockCash_c1873b31-8d2b-422a-9cab-549d2b6d416e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_cfecb109-569c-4120-b9d0-0dc985fb11fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_44a55126-b2b5-4043-a253-05a8c98288d8" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_cfecb109-569c-4120-b9d0-0dc985fb11fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_d474175b-96fc-4708-a436-d05caf66ca8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_44a55126-b2b5-4043-a253-05a8c98288d8" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_d474175b-96fc-4708-a436-d05caf66ca8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_b66f960e-b28b-4e9b-9019-4a821365a508" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteSpinoffTransaction"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_44a55126-b2b5-4043-a253-05a8c98288d8" xlink:to="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_b66f960e-b28b-4e9b-9019-4a821365a508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOtherShares_a11224b8-0019-44d7-8699-ebd16b55bd54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOtherShares"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_44a55126-b2b5-4043-a253-05a8c98288d8" xlink:to="loc_us-gaap_StockholdersEquityOtherShares_a11224b8-0019-44d7-8699-ebd16b55bd54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_d13a73d3-a592-4fa7-b8e1-b2f2e51e7f26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_44a55126-b2b5-4043-a253-05a8c98288d8" xlink:to="loc_us-gaap_StockholdersEquityOther_d13a73d3-a592-4fa7-b8e1-b2f2e51e7f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_caff9f7a-1e5d-496b-92d7-1baa4bc24d19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_44a55126-b2b5-4043-a253-05a8c98288d8" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_caff9f7a-1e5d-496b-92d7-1baa4bc24d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_78bb3284-49b8-4cd5-ad08-256e344e58a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_44a55126-b2b5-4043-a253-05a8c98288d8" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_78bb3284-49b8-4cd5-ad08-256e344e58a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_c008de89-c623-4ea7-a322-01880577a97c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_44a55126-b2b5-4043-a253-05a8c98288d8" xlink:to="loc_us-gaap_CommonStockSharesIssued_c008de89-c623-4ea7-a322-01880577a97c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_ec96bced-4461-44c2-86b2-1773f0226080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_44a55126-b2b5-4043-a253-05a8c98288d8" xlink:to="loc_us-gaap_TreasuryStockCommonShares_ec96bced-4461-44c2-86b2-1773f0226080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_061747d3-e106-4f74-ac18-2a794c2f6507" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_44a55126-b2b5-4043-a253-05a8c98288d8" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_061747d3-e106-4f74-ac18-2a794c2f6507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_8d225a01-836c-421d-8949-5d012357a7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_StockholdersEquityLineItems_a5c666bd-65f3-4561-999e-a8fab487f186" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_8d225a01-836c-421d-8949-5d012357a7e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3435e0a3-6658-4ef0-bb3b-4e4df0609998" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_44b34ec1-e211-4662-a4ab-87188e9b00a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3435e0a3-6658-4ef0-bb3b-4e4df0609998" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_44b34ec1-e211-4662-a4ab-87188e9b00a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_428fa65a-4e22-4990-a0de-e67e81dbaa02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_44b34ec1-e211-4662-a4ab-87188e9b00a3" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_428fa65a-4e22-4990-a0de-e67e81dbaa02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_15beb973-c01a-4448-b4e8-74d55ed561b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_428fa65a-4e22-4990-a0de-e67e81dbaa02" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_15beb973-c01a-4448-b4e8-74d55ed561b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_f8833abd-4409-4c3f-9552-abf219f062b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_15beb973-c01a-4448-b4e8-74d55ed561b0" xlink:to="loc_us-gaap_DomesticPlanMember_f8833abd-4409-4c3f-9552-abf219f062b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_3dc2b126-47db-4ba9-bc38-0e96588d9cb4" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_f8833abd-4409-4c3f-9552-abf219f062b5" xlink:to="loc_country_US_3dc2b126-47db-4ba9-bc38-0e96588d9cb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_5483ec8f-97cd-449a-922a-ee04d1615b81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_15beb973-c01a-4448-b4e8-74d55ed561b0" xlink:to="loc_us-gaap_ForeignPlanMember_5483ec8f-97cd-449a-922a-ee04d1615b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_aaf28927-7ec3-4bb8-9ba6-e3bb5d472ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_44b34ec1-e211-4662-a4ab-87188e9b00a3" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_aaf28927-7ec3-4bb8-9ba6-e3bb5d472ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_9451885f-57aa-45bd-bc66-1089e1ff7a48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_aaf28927-7ec3-4bb8-9ba6-e3bb5d472ab9" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_9451885f-57aa-45bd-bc66-1089e1ff7a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_b3c122c6-b824-464e-83f8-413174a563f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_9451885f-57aa-45bd-bc66-1089e1ff7a48" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_b3c122c6-b824-464e-83f8-413174a563f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_0d0201b5-5e17-4251-82ac-ffcd13dc4e77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_9451885f-57aa-45bd-bc66-1089e1ff7a48" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_0d0201b5-5e17-4251-82ac-ffcd13dc4e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_12ebfe7b-aedd-4f6a-9145-8093efbba202" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_44b34ec1-e211-4662-a4ab-87188e9b00a3" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_12ebfe7b-aedd-4f6a-9145-8093efbba202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_89d9c297-4a62-4ccb-ba55-689aafe2677c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_12ebfe7b-aedd-4f6a-9145-8093efbba202" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_89d9c297-4a62-4ccb-ba55-689aafe2677c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_664d1491-9fbc-4ee5-8acc-c57f60bee3ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_12ebfe7b-aedd-4f6a-9145-8093efbba202" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_664d1491-9fbc-4ee5-8acc-c57f60bee3ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_1db1aa77-8f2d-40a3-a6b8-f5f36b6728dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_12ebfe7b-aedd-4f6a-9145-8093efbba202" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_1db1aa77-8f2d-40a3-a6b8-f5f36b6728dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_9fdb2650-ff9b-4cf3-9a48-603ebcf1f482" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_12ebfe7b-aedd-4f6a-9145-8093efbba202" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_9fdb2650-ff9b-4cf3-9a48-603ebcf1f482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_3b488de2-26d8-4a51-ac83-05a35bc0db02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_12ebfe7b-aedd-4f6a-9145-8093efbba202" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_3b488de2-26d8-4a51-ac83-05a35bc0db02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_2a75060b-aa65-4f7e-b961-9468971d2e63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_12ebfe7b-aedd-4f6a-9145-8093efbba202" xlink:to="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_2a75060b-aa65-4f7e-b961-9468971d2e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_427fdeda-c04a-4474-b37d-a582e2fa23a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_12ebfe7b-aedd-4f6a-9145-8093efbba202" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_427fdeda-c04a-4474-b37d-a582e2fa23a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_d0df34fd-cdeb-4a49-a211-efb2b964d1b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_12ebfe7b-aedd-4f6a-9145-8093efbba202" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_d0df34fd-cdeb-4a49-a211-efb2b964d1b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_ca7286c0-ca39-4004-82e3-eced1809305e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_12ebfe7b-aedd-4f6a-9145-8093efbba202" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_ca7286c0-ca39-4004-82e3-eced1809305e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#PensionandOtherPostretirementBenefitPlansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ea3c6d15-4d31-4d44-8008-77d0a49f87c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement_1f929264-04e4-41eb-811a-d32a5f68e143" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ea3c6d15-4d31-4d44-8008-77d0a49f87c6" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement_1f929264-04e4-41eb-811a-d32a5f68e143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_89e1cdba-ee43-4173-bb0c-a2efd7296d65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_46d37311-4e5f-4e31-91e2-7a8587f888ee" xlink:href="mrk-20220930.xsd#mrk_ComponentofOtherIncomeExpenseofNonoperatingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_89e1cdba-ee43-4173-bb0c-a2efd7296d65" xlink:to="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_46d37311-4e5f-4e31-91e2-7a8587f888ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_67d18359-88fb-4b8e-857e-0c40d5cb36da" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_46d37311-4e5f-4e31-91e2-7a8587f888ee" xlink:to="loc_srt_StatementScenarioAxis_67d18359-88fb-4b8e-857e-0c40d5cb36da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_35d16757-889e-4d1d-b2d6-6576ecf52c70" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_67d18359-88fb-4b8e-857e-0c40d5cb36da" xlink:to="loc_srt_ScenarioUnspecifiedDomain_35d16757-889e-4d1d-b2d6-6576ecf52c70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_b7ff4f89-f51a-4e6c-a993-c96b876d17e9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_35d16757-889e-4d1d-b2d6-6576ecf52c70" xlink:to="loc_srt_ScenarioForecastMember_b7ff4f89-f51a-4e6c-a993-c96b876d17e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_fc96451a-f28d-463b-93d8-7930a7883b78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_46d37311-4e5f-4e31-91e2-7a8587f888ee" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_fc96451a-f28d-463b-93d8-7930a7883b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_be24b359-f584-49b2-a930-5c2d8f1bf0c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fc96451a-f28d-463b-93d8-7930a7883b78" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_be24b359-f584-49b2-a930-5c2d8f1bf0c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_c694e71e-4b8f-4e2a-9709-47216b3a8c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_be24b359-f584-49b2-a930-5c2d8f1bf0c3" xlink:to="loc_us-gaap_SubsequentEventMember_c694e71e-4b8f-4e2a-9709-47216b3a8c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_c3db401a-8294-4664-bb0c-fee0f0c218f8" xlink:href="mrk-20220930.xsd#mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_46d37311-4e5f-4e31-91e2-7a8587f888ee" xlink:to="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_c3db401a-8294-4664-bb0c-fee0f0c218f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_fad00a87-4452-4e9b-9892-313a8d6ce2ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_c3db401a-8294-4664-bb0c-fee0f0c218f8" xlink:to="loc_us-gaap_InvestmentIncomeInterest_fad00a87-4452-4e9b-9892-313a8d6ce2ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_4e69b404-b314-420d-9ad4-086c2d5081c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_c3db401a-8294-4664-bb0c-fee0f0c218f8" xlink:to="loc_us-gaap_InterestExpense_4e69b404-b314-420d-9ad4-086c2d5081c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_24698072-3cd0-4841-86c7-10217c942ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_c3db401a-8294-4664-bb0c-fee0f0c218f8" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_24698072-3cd0-4841-86c7-10217c942ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_4b748f44-c1cf-4ac4-b875-aaf05ba95aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_c3db401a-8294-4664-bb0c-fee0f0c218f8" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_4b748f44-c1cf-4ac4-b875-aaf05ba95aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_ac48e4ac-6ed9-4abc-bc0c-a91345855f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_c3db401a-8294-4664-bb0c-fee0f0c218f8" xlink:to="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_ac48e4ac-6ed9-4abc-bc0c-a91345855f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherNonoperatingIncomeExpenseOther_aca782e6-6ea2-4aba-8029-f901acc36f60" xlink:href="mrk-20220930.xsd#mrk_OtherNonoperatingIncomeExpenseOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_c3db401a-8294-4664-bb0c-fee0f0c218f8" xlink:to="loc_mrk_OtherNonoperatingIncomeExpenseOther_aca782e6-6ea2-4aba-8029-f901acc36f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_d7bcf6bb-b454-4df5-ab20-aecbf93f6f59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_c3db401a-8294-4664-bb0c-fee0f0c218f8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_d7bcf6bb-b454-4df5-ab20-aecbf93f6f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_735b2763-1c90-4051-9de5-df34d4cf458e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_c3db401a-8294-4664-bb0c-fee0f0c218f8" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_735b2763-1c90-4051-9de5-df34d4cf458e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#OtherIncomeExpenseNetNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_946a776f-c6a8-49fe-8b81-fc789114fb45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaid_540d2d90-035e-453e-bc5d-e2f8dc484f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_946a776f-c6a8-49fe-8b81-fc789114fb45" xlink:to="loc_us-gaap_InterestPaid_540d2d90-035e-453e-bc5d-e2f8dc484f3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#TaxesonIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/TaxesonIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6ed53e2f-a81e-4b6f-8a11-fee08f154f06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_c47359eb-ab7e-4382-978e-d0727e83ddef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6ed53e2f-a81e-4b6f-8a11-fee08f154f06" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_c47359eb-ab7e-4382-978e-d0727e83ddef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_428ebc71-8173-4bd0-bfa0-877ab775de19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_c47359eb-ab7e-4382-978e-d0727e83ddef" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_428ebc71-8173-4bd0-bfa0-877ab775de19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_0d29f20a-dbd4-49f7-b255-a8a3dadba015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_428ebc71-8173-4bd0-bfa0-877ab775de19" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_0d29f20a-dbd4-49f7-b255-a8a3dadba015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_188cb3c0-77e6-4e24-b8f1-7ff9b0b988c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_0d29f20a-dbd4-49f7-b255-a8a3dadba015" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_188cb3c0-77e6-4e24-b8f1-7ff9b0b988c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_190b93fe-e5db-47d2-944b-bc9c2a7197b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_c47359eb-ab7e-4382-978e-d0727e83ddef" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_190b93fe-e5db-47d2-944b-bc9c2a7197b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_2c59fed0-7f4e-41ab-a7ac-55db84de8ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_190b93fe-e5db-47d2-944b-bc9c2a7197b3" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_2c59fed0-7f4e-41ab-a7ac-55db84de8ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_18844fbb-e38b-4eb6-90c7-c49a4f8d173a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2c59fed0-7f4e-41ab-a7ac-55db84de8ea4" xlink:to="loc_us-gaap_DomesticCountryMember_18844fbb-e38b-4eb6-90c7-c49a4f8d173a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_8ed65f4c-bd07-44bf-8e1a-460590e54150" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_c47359eb-ab7e-4382-978e-d0727e83ddef" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_8ed65f4c-bd07-44bf-8e1a-460590e54150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_e6151f90-2c3b-4e51-a0d7-93c6d728cce5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_8ed65f4c-bd07-44bf-8e1a-460590e54150" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_e6151f90-2c3b-4e51-a0d7-93c6d728cce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember_8776e174-8897-41e0-8668-533460bb608f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentContinuingOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_e6151f90-2c3b-4e51-a0d7-93c6d728cce5" xlink:to="loc_us-gaap_SegmentContinuingOperationsMember_8776e174-8897-41e0-8668-533460bb608f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_2144ca90-076a-4833-be0b-b02d00e1b7aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_e6151f90-2c3b-4e51-a0d7-93c6d728cce5" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_2144ca90-076a-4833-be0b-b02d00e1b7aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_147a76e3-cd5f-4702-8a1a-a48f5bb75c30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_c47359eb-ab7e-4382-978e-d0727e83ddef" xlink:to="loc_us-gaap_IncomeTaxExaminationLineItems_147a76e3-cd5f-4702-8a1a-a48f5bb75c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8480cf60-74bd-4e50-9ba8-006679ea6d8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_147a76e3-cd5f-4702-8a1a-a48f5bb75c30" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8480cf60-74bd-4e50-9ba8-006679ea6d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_3c668b82-1a47-4bd3-a46a-86e618c6fa5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_147a76e3-cd5f-4702-8a1a-a48f5bb75c30" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_3c668b82-1a47-4bd3-a46a-86e618c6fa5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_0e00a611-c54d-40e9-9984-0f5930e560dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_147a76e3-cd5f-4702-8a1a-a48f5bb75c30" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_0e00a611-c54d-40e9-9984-0f5930e560dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_5fadee87-864b-44b4-91ee-64716a9cfc3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_147a76e3-cd5f-4702-8a1a-a48f5bb75c30" xlink:to="loc_us-gaap_IncomeTaxesPaid_5fadee87-864b-44b4-91ee-64716a9cfc3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#EarningsPerShareCalculationsofEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5dc974f1-0cbd-4912-8f29-1934034b85bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_a61a1ccd-657b-42ff-871e-a14308ee50ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5dc974f1-0cbd-4912-8f29-1934034b85bd" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_a61a1ccd-657b-42ff-871e-a14308ee50ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_8202065d-3fd0-4800-a2ae-15f86b93bed4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5dc974f1-0cbd-4912-8f29-1934034b85bd" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_8202065d-3fd0-4800-a2ae-15f86b93bed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2724f7b7-61ff-4c50-b5b0-cdf6d1d3934f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5dc974f1-0cbd-4912-8f29-1934034b85bd" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2724f7b7-61ff-4c50-b5b0-cdf6d1d3934f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_e36f58a5-edd5-4ebf-8b37-aa8126f53a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5dc974f1-0cbd-4912-8f29-1934034b85bd" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_e36f58a5-edd5-4ebf-8b37-aa8126f53a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a64624ea-68b6-4ba7-aaa8-b9e90c99969e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5dc974f1-0cbd-4912-8f29-1934034b85bd" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a64624ea-68b6-4ba7-aaa8-b9e90c99969e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_fecabcd0-bd41-4baa-9457-2385f7d5c56e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5dc974f1-0cbd-4912-8f29-1934034b85bd" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_fecabcd0-bd41-4baa-9457-2385f7d5c56e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6663c612-83b3-4dea-82a8-3d6cc33a4267" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5dc974f1-0cbd-4912-8f29-1934034b85bd" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6663c612-83b3-4dea-82a8-3d6cc33a4267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_8e6a4dc6-9bf3-4275-b715-92f585d34668" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5dc974f1-0cbd-4912-8f29-1934034b85bd" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_8e6a4dc6-9bf3-4275-b715-92f585d34668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_38d1cc94-723c-45c7-a8f9-28160e17a690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_8e6a4dc6-9bf3-4275-b715-92f585d34668" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_38d1cc94-723c-45c7-a8f9-28160e17a690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_2bff8f5d-24a8-4fed-b6d7-d7e739d73004" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_8e6a4dc6-9bf3-4275-b715-92f585d34668" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_2bff8f5d-24a8-4fed-b6d7-d7e739d73004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_804f415a-fe65-4736-9c22-3f9271b00a30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_8e6a4dc6-9bf3-4275-b715-92f585d34668" xlink:to="loc_us-gaap_EarningsPerShareBasic_804f415a-fe65-4736-9c22-3f9271b00a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_d438a7cb-6757-492d-9f1f-ab04ffcf79fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5dc974f1-0cbd-4912-8f29-1934034b85bd" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_d438a7cb-6757-492d-9f1f-ab04ffcf79fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_063d0d4f-5048-4a07-880a-e42e30f370cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_d438a7cb-6757-492d-9f1f-ab04ffcf79fd" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_063d0d4f-5048-4a07-880a-e42e30f370cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_d5f914d8-a221-473f-84a5-8d2948048df0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_d438a7cb-6757-492d-9f1f-ab04ffcf79fd" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_d5f914d8-a221-473f-84a5-8d2948048df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_784daf7c-528f-4e2e-940b-e311d3603c59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_d438a7cb-6757-492d-9f1f-ab04ffcf79fd" xlink:to="loc_us-gaap_EarningsPerShareDiluted_784daf7c-528f-4e2e-940b-e311d3603c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/EarningsPerShareNarrativeDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#EarningsPerShareNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/EarningsPerShareNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2763faaa-6c70-4f41-9355-33d114633eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_dca54f8b-d986-4815-a65e-9a2f5b2b7a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2763faaa-6c70-4f41-9355-33d114633eb7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_dca54f8b-d986-4815-a65e-9a2f5b2b7a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#OtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_89a2f4b6-6480-4a9f-91be-9776c93dcd39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0b41305c-7ed1-4263-b05a-551d70693eab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_89a2f4b6-6480-4a9f-91be-9776c93dcd39" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0b41305c-7ed1-4263-b05a-551d70693eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_048c1761-b798-41a7-be9e-9c2d5822beb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0b41305c-7ed1-4263-b05a-551d70693eab" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_048c1761-b798-41a7-be9e-9c2d5822beb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2a319d2a-c321-4eac-a322-d8cd69990c92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_048c1761-b798-41a7-be9e-9c2d5822beb6" xlink:to="loc_us-gaap_EquityComponentDomain_2a319d2a-c321-4eac-a322-d8cd69990c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_a8d1ad08-19cc-4ad3-a292-c6014810b65c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2a319d2a-c321-4eac-a322-d8cd69990c92" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_a8d1ad08-19cc-4ad3-a292-c6014810b65c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_5d2cd6ec-9b24-4716-924e-bdf910bc4c37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2a319d2a-c321-4eac-a322-d8cd69990c92" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_5d2cd6ec-9b24-4716-924e-bdf910bc4c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_868a50cc-e13b-45f1-8a39-6c16bb168147" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2a319d2a-c321-4eac-a322-d8cd69990c92" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_868a50cc-e13b-45f1-8a39-6c16bb168147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c502c95c-0a62-4b56-a1f1-1eb988db1adc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2a319d2a-c321-4eac-a322-d8cd69990c92" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c502c95c-0a62-4b56-a1f1-1eb988db1adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_a693bc6e-34d4-4e10-b1b0-3984bad8fe1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0b41305c-7ed1-4263-b05a-551d70693eab" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_a693bc6e-34d4-4e10-b1b0-3984bad8fe1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_78aa34b8-391d-4e57-b42c-c07f4106a80e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_a693bc6e-34d4-4e10-b1b0-3984bad8fe1a" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_78aa34b8-391d-4e57-b42c-c07f4106a80e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_394fd33e-0495-48bf-bff4-67e2a458c645" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_78aa34b8-391d-4e57-b42c-c07f4106a80e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_394fd33e-0495-48bf-bff4-67e2a458c645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_15140555-3c62-4915-9843-6d436a19f10d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_78aa34b8-391d-4e57-b42c-c07f4106a80e" xlink:to="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_15140555-3c62-4915-9843-6d436a19f10d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_0c35fa29-6800-4dff-9719-5134985651ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_78aa34b8-391d-4e57-b42c-c07f4106a80e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_0c35fa29-6800-4dff-9719-5134985651ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_ce9d7343-4228-4d31-bdc2-34aad969b2b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_78aa34b8-391d-4e57-b42c-c07f4106a80e" xlink:to="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_ce9d7343-4228-4d31-bdc2-34aad969b2b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_f4f8b7b2-ca4e-4367-8559-ae4b366491d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_78aa34b8-391d-4e57-b42c-c07f4106a80e" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_f4f8b7b2-ca4e-4367-8559-ae4b366491d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_94791935-ac9f-4b27-bb72-5148510b138d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_78aa34b8-391d-4e57-b42c-c07f4106a80e" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_94791935-ac9f-4b27-bb72-5148510b138d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_dfed12ee-2be5-4cda-8885-a35d2b87746f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_78aa34b8-391d-4e57-b42c-c07f4106a80e" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_dfed12ee-2be5-4cda-8885-a35d2b87746f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f2977f0a-9768-475e-b8c4-169ac971f3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_78aa34b8-391d-4e57-b42c-c07f4106a80e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f2977f0a-9768-475e-b8c4-169ac971f3f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_da18d33a-1864-4241-b651-1f16bb336d86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteSpinoffTransaction"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_78aa34b8-391d-4e57-b42c-c07f4106a80e" xlink:to="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_da18d33a-1864-4241-b651-1f16bb336d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_10e90f1f-1136-42dc-9089-888cf18ec950" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_78aa34b8-391d-4e57-b42c-c07f4106a80e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_10e90f1f-1136-42dc-9089-888cf18ec950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingNarrativeDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#SegmentReportingNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SegmentReportingNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_1c6d8f60-be5d-4f8f-babe-360ebd85f7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_fbd4a586-bb56-4844-b5fe-66c45035f86a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1c6d8f60-be5d-4f8f-babe-360ebd85f7cc" xlink:to="loc_us-gaap_NumberOfOperatingSegments_fbd4a586-bb56-4844-b5fe-66c45035f86a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesDiscounts_4f4c5f71-b68d-4e88-a208-d3f16141b55d" xlink:href="mrk-20220930.xsd#mrk_SalesDiscounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1c6d8f60-be5d-4f8f-babe-360ebd85f7cc" xlink:to="loc_mrk_SalesDiscounts_4f4c5f71-b68d-4e88-a208-d3f16141b55d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#SegmentReportingSalesfromProductsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_bfdb5e55-d817-4154-a90f-c29b5bdbd8a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_42c6cb17-4a07-44f2-82fe-b9fd4af4d2e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_bfdb5e55-d817-4154-a90f-c29b5bdbd8a0" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_42c6cb17-4a07-44f2-82fe-b9fd4af4d2e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_7e7065b1-b802-4a7f-bf0a-ac2b1fc631c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_42c6cb17-4a07-44f2-82fe-b9fd4af4d2e4" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_7e7065b1-b802-4a7f-bf0a-ac2b1fc631c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5d73a7a1-1d9c-445b-ae98-78a25f2e7679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7e7065b1-b802-4a7f-bf0a-ac2b1fc631c9" xlink:to="loc_us-gaap_SegmentDomain_5d73a7a1-1d9c-445b-ae98-78a25f2e7679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember_6e467dfe-407f-4428-bd7e-782d8172d67a" xlink:href="mrk-20220930.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_5d73a7a1-1d9c-445b-ae98-78a25f2e7679" xlink:to="loc_mrk_PharmaceuticalsegmentMember_6e467dfe-407f-4428-bd7e-782d8172d67a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthsegmentMember_fadc93c0-5297-4e37-82f8-72c8c891d67c" xlink:href="mrk-20220930.xsd#mrk_AnimalHealthsegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_5d73a7a1-1d9c-445b-ae98-78a25f2e7679" xlink:to="loc_mrk_AnimalHealthsegmentMember_fadc93c0-5297-4e37-82f8-72c8c891d67c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_ede22445-6616-4848-a3df-1b83e8ae45b2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_42c6cb17-4a07-44f2-82fe-b9fd4af4d2e4" xlink:to="loc_srt_ConsolidationItemsAxis_ede22445-6616-4848-a3df-1b83e8ae45b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_2cb8919c-b348-4c9d-8f7d-8828066a6ed2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_ede22445-6616-4848-a3df-1b83e8ae45b2" xlink:to="loc_srt_ConsolidationItemsDomain_2cb8919c-b348-4c9d-8f7d-8828066a6ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_37b82021-25c4-4225-b3e1-0f89d72d8dab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_2cb8919c-b348-4c9d-8f7d-8828066a6ed2" xlink:to="loc_us-gaap_OperatingSegmentsMember_37b82021-25c4-4225-b3e1-0f89d72d8dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_c2618d83-cb6b-4e49-8792-01c72f1f2273" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_2cb8919c-b348-4c9d-8f7d-8828066a6ed2" xlink:to="loc_us-gaap_CorporateNonSegmentMember_c2618d83-cb6b-4e49-8792-01c72f1f2273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_48398ecf-6c9e-4802-b984-1387ca53cdb6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_42c6cb17-4a07-44f2-82fe-b9fd4af4d2e4" xlink:to="loc_srt_ProductOrServiceAxis_48398ecf-6c9e-4802-b984-1387ca53cdb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_48398ecf-6c9e-4802-b984-1387ca53cdb6" xlink:to="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_KeytrudaMember_db29c77f-535c-4390-bfc2-b09f148ba3df" xlink:href="mrk-20220930.xsd#mrk_KeytrudaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_KeytrudaMember_db29c77f-535c-4390-bfc2-b09f148ba3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AlliancerevenueLynparzaMember_39bf9bfd-c6af-4a3b-97b5-968dfe6b3383" xlink:href="mrk-20220930.xsd#mrk_AlliancerevenueLynparzaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_AlliancerevenueLynparzaMember_39bf9bfd-c6af-4a3b-97b5-968dfe6b3383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LenvimaMember_f04742ce-b865-4012-a0dd-e3125c6e31d2" xlink:href="mrk-20220930.xsd#mrk_LenvimaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_LenvimaMember_f04742ce-b865-4012-a0dd-e3125c6e31d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AllianceRevenueReblozylMember_170f9836-7e2e-49b8-9325-09e7643eae82" xlink:href="mrk-20220930.xsd#mrk_AllianceRevenueReblozylMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_AllianceRevenueReblozylMember_170f9836-7e2e-49b8-9325-09e7643eae82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GardasilGardasil9Member_e5f9fe20-3d97-48c4-8dab-3cf1060ddbba" xlink:href="mrk-20220930.xsd#mrk_GardasilGardasil9Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_GardasilGardasil9Member_e5f9fe20-3d97-48c4-8dab-3cf1060ddbba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ProQuadMMRIIVarivaxMember_16d449a5-e962-4e51-af79-d3b69f87f8c3" xlink:href="mrk-20220930.xsd#mrk_ProQuadMMRIIVarivaxMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_ProQuadMMRIIVarivaxMember_16d449a5-e962-4e51-af79-d3b69f87f8c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RotateqMember_7ab7b0ae-face-4750-a08c-ef9f02fd714c" xlink:href="mrk-20220930.xsd#mrk_RotateqMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_RotateqMember_7ab7b0ae-face-4750-a08c-ef9f02fd714c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_Pneumovax23Member_04c2555c-e5fa-4e54-8ab8-5ff768ffee53" xlink:href="mrk-20220930.xsd#mrk_Pneumovax23Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_Pneumovax23Member_04c2555c-e5fa-4e54-8ab8-5ff768ffee53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VaqtaMember_030908f1-991d-48d6-b2d2-0172fb13b17c" xlink:href="mrk-20220930.xsd#mrk_VaqtaMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_VaqtaMember_030908f1-991d-48d6-b2d2-0172fb13b17c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BridionMember_7edd7526-741a-4eb3-9797-a734212e2d82" xlink:href="mrk-20220930.xsd#mrk_BridionMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_BridionMember_7edd7526-741a-4eb3-9797-a734212e2d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PrevymisMember_8a2843de-2d1d-4970-a4f6-fdcb7687bf16" xlink:href="mrk-20220930.xsd#mrk_PrevymisMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_PrevymisMember_8a2843de-2d1d-4970-a4f6-fdcb7687bf16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DificidMember_6731df41-0c7d-438f-831b-15175e4e8ed5" xlink:href="mrk-20220930.xsd#mrk_DificidMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_DificidMember_6731df41-0c7d-438f-831b-15175e4e8ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PrimaxinMember_8e73dbd3-f15b-4807-aed3-add783160728" xlink:href="mrk-20220930.xsd#mrk_PrimaxinMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_PrimaxinMember_8e73dbd3-f15b-4807-aed3-add783160728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NoxafilMember_827c70ef-2958-424e-8d0b-721018ffbbc4" xlink:href="mrk-20220930.xsd#mrk_NoxafilMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_NoxafilMember_827c70ef-2958-424e-8d0b-721018ffbbc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InvanzMember_a3bb4a33-427a-47b9-bc52-2bf01fade5e7" xlink:href="mrk-20220930.xsd#mrk_InvanzMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_InvanzMember_a3bb4a33-427a-47b9-bc52-2bf01fade5e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CancidasMember_7cd6eb28-7499-4ffb-bbab-fefbdaf81f0e" xlink:href="mrk-20220930.xsd#mrk_CancidasMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_CancidasMember_7cd6eb28-7499-4ffb-bbab-fefbdaf81f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ZerbaxaMember_caa57cf2-566c-41ed-ba6d-fd52471e74b4" xlink:href="mrk-20220930.xsd#mrk_ZerbaxaMember"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_ZerbaxaMember_caa57cf2-566c-41ed-ba6d-fd52471e74b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AllianceRevenueAdempasVerquvoMember_6e884ba9-11f3-4b2d-9223-fa08bb124f27" xlink:href="mrk-20220930.xsd#mrk_AllianceRevenueAdempasVerquvoMember"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_AllianceRevenueAdempasVerquvoMember_6e884ba9-11f3-4b2d-9223-fa08bb124f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AdempasMember_7a8a16e2-2a97-44b7-bf1d-1f3acec35e86" xlink:href="mrk-20220930.xsd#mrk_AdempasMember"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_AdempasMember_7a8a16e2-2a97-44b7-bf1d-1f3acec35e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LagevrioMember_7ca9a561-9757-4ccd-8049-1001dc756796" xlink:href="mrk-20220930.xsd#mrk_LagevrioMember"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_LagevrioMember_7ca9a561-9757-4ccd-8049-1001dc756796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IsentressIsentressHDMember_7ab34de4-dc61-42f5-9bb0-b0edf2655d66" xlink:href="mrk-20220930.xsd#mrk_IsentressIsentressHDMember"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_IsentressIsentressHDMember_7ab34de4-dc61-42f5-9bb0-b0edf2655d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BelsomraMember_25366dd7-cbd6-49cb-9c19-dd638b822d26" xlink:href="mrk-20220930.xsd#mrk_BelsomraMember"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_BelsomraMember_25366dd7-cbd6-49cb-9c19-dd638b822d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SimponiMember_52f1b73f-789b-4fd3-9953-0ec180ea0c28" xlink:href="mrk-20220930.xsd#mrk_SimponiMember"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_SimponiMember_52f1b73f-789b-4fd3-9953-0ec180ea0c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RemicadeMember_d3daf9ae-7dab-4c23-907e-52adb2abc671" xlink:href="mrk-20220930.xsd#mrk_RemicadeMember"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_RemicadeMember_d3daf9ae-7dab-4c23-907e-52adb2abc671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_JanuviaMember_045645a5-4a0a-425a-a8cc-f6b26b801826" xlink:href="mrk-20220930.xsd#mrk_JanuviaMember"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_JanuviaMember_045645a5-4a0a-425a-a8cc-f6b26b801826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_JanumetMember_f7decbca-7ac3-4434-a441-dfba11ac7ff0" xlink:href="mrk-20220930.xsd#mrk_JanumetMember"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_JanumetMember_f7decbca-7ac3-4434-a441-dfba11ac7ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherPharmaceuticalMember_272e3314-668f-41d8-a578-935a59ad2ceb" xlink:href="mrk-20220930.xsd#mrk_OtherPharmaceuticalMember"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_OtherPharmaceuticalMember_272e3314-668f-41d8-a578-935a59ad2ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LivestockMember_28480478-82bb-4b55-899f-f70dbe7648cf" xlink:href="mrk-20220930.xsd#mrk_LivestockMember"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_LivestockMember_28480478-82bb-4b55-899f-f70dbe7648cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CompanionAnimalsMember_b6ab4204-3901-425b-ae38-ffc094858d45" xlink:href="mrk-20220930.xsd#mrk_CompanionAnimalsMember"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0f6b8be1-1b7d-4999-acf8-2502da39457d" xlink:to="loc_mrk_CompanionAnimalsMember_b6ab4204-3901-425b-ae38-ffc094858d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_08541792-ecee-4bd4-98bf-30c2ec2a3f12" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_42c6cb17-4a07-44f2-82fe-b9fd4af4d2e4" xlink:to="loc_srt_StatementGeographicalAxis_08541792-ecee-4bd4-98bf-30c2ec2a3f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_04f2935f-72f5-45f3-ba28-419c2ec52f48" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_08541792-ecee-4bd4-98bf-30c2ec2a3f12" xlink:to="loc_srt_SegmentGeographicalDomain_04f2935f-72f5-45f3-ba28-419c2ec52f48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_c328838e-12d8-4f6c-a897-3bd50eecc3e4" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_04f2935f-72f5-45f3-ba28-419c2ec52f48" xlink:to="loc_country_US_c328838e-12d8-4f6c-a897-3bd50eecc3e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InternationalMember_bbaa6204-04bc-4621-b4ff-58bd4fe80d09" xlink:href="mrk-20220930.xsd#mrk_InternationalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_04f2935f-72f5-45f3-ba28-419c2ec52f48" xlink:to="loc_mrk_InternationalMember_bbaa6204-04bc-4621-b4ff-58bd4fe80d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_b0e20ffb-f53d-41ac-93d7-efe69856655b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_42c6cb17-4a07-44f2-82fe-b9fd4af4d2e4" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_b0e20ffb-f53d-41ac-93d7-efe69856655b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_19e9dc86-a983-4d5f-8b4f-3123eb1e2d43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_b0e20ffb-f53d-41ac-93d7-efe69856655b" xlink:to="loc_us-gaap_Revenues_19e9dc86-a983-4d5f-8b4f-3123eb1e2d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_d8c12be3-1a37-4576-9c97-47419839b86f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_b0e20ffb-f53d-41ac-93d7-efe69856655b" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_d8c12be3-1a37-4576-9c97-47419839b86f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#SegmentReportingConsolidatedSalesbyGeographicAreaDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_c3a91746-0e76-4c26-8737-ac984d62e7a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_c43bd9a7-8af6-4786-b39f-ba0a147cce0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c3a91746-0e76-4c26-8737-ac984d62e7a1" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_c43bd9a7-8af6-4786-b39f-ba0a147cce0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4ad5f33b-0791-407d-b334-21a8af7740f6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_c43bd9a7-8af6-4786-b39f-ba0a147cce0e" xlink:to="loc_srt_StatementGeographicalAxis_4ad5f33b-0791-407d-b334-21a8af7740f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_cac01c44-ad8f-4967-9e07-7c2b55338895" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_4ad5f33b-0791-407d-b334-21a8af7740f6" xlink:to="loc_srt_SegmentGeographicalDomain_cac01c44-ad8f-4967-9e07-7c2b55338895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b054daa2-fb60-46fc-994f-a3c32f44cdc8" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_cac01c44-ad8f-4967-9e07-7c2b55338895" xlink:to="loc_country_US_b054daa2-fb60-46fc-994f-a3c32f44cdc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember_3e3f7de4-c1b3-475b-8247-5c09b5e5a320" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EMEAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_cac01c44-ad8f-4967-9e07-7c2b55338895" xlink:to="loc_us-gaap_EMEAMember_3e3f7de4-c1b3-475b-8247-5c09b5e5a320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_ce6e5afe-39cb-4efe-ae8b-b8ce9cae2bee" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_cac01c44-ad8f-4967-9e07-7c2b55338895" xlink:to="loc_country_CN_ce6e5afe-39cb-4efe-ae8b-b8ce9cae2bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_95b710fd-c841-415d-ab11-c0581128ece0" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_cac01c44-ad8f-4967-9e07-7c2b55338895" xlink:to="loc_country_JP_95b710fd-c841-415d-ab11-c0581128ece0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember_2a7ced03-11ec-46ba-8eea-9469579299c9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AsiaPacificMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_cac01c44-ad8f-4967-9e07-7c2b55338895" xlink:to="loc_srt_AsiaPacificMember_2a7ced03-11ec-46ba-8eea-9469579299c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LatinAmericaMember_8f29b134-9fbf-4770-8371-7437066f51cd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LatinAmericaMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_cac01c44-ad8f-4967-9e07-7c2b55338895" xlink:to="loc_srt_LatinAmericaMember_8f29b134-9fbf-4770-8371-7437066f51cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherCountriesMember_0bb6f2cd-3839-4181-8b1a-2c6b1d9a4cbd" xlink:href="mrk-20220930.xsd#mrk_OtherCountriesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_cac01c44-ad8f-4967-9e07-7c2b55338895" xlink:to="loc_mrk_OtherCountriesMember_0bb6f2cd-3839-4181-8b1a-2c6b1d9a4cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_ba0b4496-77f6-4bc7-a916-2cf2e1e5d7c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_c43bd9a7-8af6-4786-b39f-ba0a147cce0e" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_ba0b4496-77f6-4bc7-a916-2cf2e1e5d7c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_d4567962-aae4-487b-9342-c20c5245c556" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_ba0b4496-77f6-4bc7-a916-2cf2e1e5d7c5" xlink:to="loc_us-gaap_Revenues_d4567962-aae4-487b-9342-c20c5245c556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails" xlink:type="simple" xlink:href="mrk-20220930.xsd#SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_15c52502-0448-4ff9-907b-a37823e65465" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3360cdc1-3c6c-4fef-8368-a7a81acd86b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_15c52502-0448-4ff9-907b-a37823e65465" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3360cdc1-3c6c-4fef-8368-a7a81acd86b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_55f8e9c9-c903-4f14-a4c0-7b2289d83eab" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3360cdc1-3c6c-4fef-8368-a7a81acd86b7" xlink:to="loc_srt_ConsolidationItemsAxis_55f8e9c9-c903-4f14-a4c0-7b2289d83eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_d35a7ffd-6056-43f4-80e2-a73c79efc0f8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_55f8e9c9-c903-4f14-a4c0-7b2289d83eab" xlink:to="loc_srt_ConsolidationItemsDomain_d35a7ffd-6056-43f4-80e2-a73c79efc0f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_cae9d7fb-d539-4985-abf6-15363114844c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_d35a7ffd-6056-43f4-80e2-a73c79efc0f8" xlink:to="loc_us-gaap_OperatingSegmentsMember_cae9d7fb-d539-4985-abf6-15363114844c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_6ae42ea7-ec16-4af1-a331-b3c1b03103eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_d35a7ffd-6056-43f4-80e2-a73c79efc0f8" xlink:to="loc_us-gaap_CorporateNonSegmentMember_6ae42ea7-ec16-4af1-a331-b3c1b03103eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_7de5f3cc-0c76-442c-8812-010f82f1e670" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_d35a7ffd-6056-43f4-80e2-a73c79efc0f8" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_7de5f3cc-0c76-442c-8812-010f82f1e670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_6cabf802-6fa2-4781-9bc2-f5e3eee95e27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3360cdc1-3c6c-4fef-8368-a7a81acd86b7" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_6cabf802-6fa2-4781-9bc2-f5e3eee95e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_22ad173b-3f80-4c3a-9e0d-2a467e85fa32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_6cabf802-6fa2-4781-9bc2-f5e3eee95e27" xlink:to="loc_us-gaap_SegmentDomain_22ad173b-3f80-4c3a-9e0d-2a467e85fa32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember_b83a1d05-ed92-422a-b9d3-e5b593e48516" xlink:href="mrk-20220930.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_22ad173b-3f80-4c3a-9e0d-2a467e85fa32" xlink:to="loc_mrk_PharmaceuticalsegmentMember_b83a1d05-ed92-422a-b9d3-e5b593e48516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthsegmentMember_3c897769-bd1b-4b7f-b029-7ead6c34a19b" xlink:href="mrk-20220930.xsd#mrk_AnimalHealthsegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_22ad173b-3f80-4c3a-9e0d-2a467e85fa32" xlink:to="loc_mrk_AnimalHealthsegmentMember_3c897769-bd1b-4b7f-b029-7ead6c34a19b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_77a32b1b-d8a6-44bc-ad01-ef44da9af6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3360cdc1-3c6c-4fef-8368-a7a81acd86b7" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_77a32b1b-d8a6-44bc-ad01-ef44da9af6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c805a431-a832-4402-9cb3-c81aadd118bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_77a32b1b-d8a6-44bc-ad01-ef44da9af6a2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c805a431-a832-4402-9cb3-c81aadd118bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_df13d927-d693-40d6-9a42-35d5b78c9b61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_77a32b1b-d8a6-44bc-ad01-ef44da9af6a2" xlink:to="loc_us-gaap_InvestmentIncomeInterest_df13d927-d693-40d6-9a42-35d5b78c9b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_beaa314e-b9f3-4833-a330-67e92350589a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_77a32b1b-d8a6-44bc-ad01-ef44da9af6a2" xlink:to="loc_us-gaap_InterestExpense_beaa314e-b9f3-4833-a330-67e92350589a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_79fba16c-f087-43b1-a109-9e1114398fda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_77a32b1b-d8a6-44bc-ad01-ef44da9af6a2" xlink:to="loc_us-gaap_AdjustmentForAmortization_79fba16c-f087-43b1-a109-9e1114398fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_daa1e8d9-7aed-470f-86c3-6072a398ed88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_77a32b1b-d8a6-44bc-ad01-ef44da9af6a2" xlink:to="loc_us-gaap_Depreciation_daa1e8d9-7aed-470f-86c3-6072a398ed88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_12c98448-2759-49db-9985-2d00e2f72acc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_77a32b1b-d8a6-44bc-ad01-ef44da9af6a2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_12c98448-2759-49db-9985-2d00e2f72acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_0b79d7fa-443d-4e83-9988-27ad2842ea01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_77a32b1b-d8a6-44bc-ad01-ef44da9af6a2" xlink:to="loc_us-gaap_RestructuringCharges_0b79d7fa-443d-4e83-9988-27ad2842ea01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SegmentReportingUnallocatedOtherExpensesNet_9795cb6e-3ca0-4a4a-a9f1-b03cbea42b78" xlink:href="mrk-20220930.xsd#mrk_SegmentReportingUnallocatedOtherExpensesNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_77a32b1b-d8a6-44bc-ad01-ef44da9af6a2" xlink:to="loc_mrk_SegmentReportingUnallocatedOtherExpensesNet_9795cb6e-3ca0-4a4a-a9f1-b03cbea42b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303302200144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-6571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Merck&#160;& Co., Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">22-1918501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">126 East Lincoln Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rahway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(908)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">740-4000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,535,395,974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000310158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock ($0.50&#160;par value)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock ($0.50&#160;par value)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MRK<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mrk_A0.500Notesdue2024Member', window );">0.500% Notes due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.500% Notes due 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MRK 24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mrk_A1.875Notesdue2026Member', window );">1.875% Notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.875% Notes due 2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MRK/26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mrk_A2.500Notesdue2034Member', window );">2.500% Notes due 2034</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">2.500% Notes due 2034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MRK/34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mrk_A1.375Notesdue2036Member', window );">1.375% Notes due 2036</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.375% Notes due 2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MRK 36A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mrk_A0.500Notesdue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mrk_A0.500Notesdue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mrk_A1.875Notesdue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mrk_A1.875Notesdue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mrk_A2.500Notesdue2034Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mrk_A2.500Notesdue2034Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mrk_A1.375Notesdue2036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mrk_A1.375Notesdue2036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303301407120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENT OF INCOME - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">$ 14,959<span></span>
</td>
<td class="nump">$ 13,154<span></span>
</td>
<td class="nump">$ 45,453<span></span>
</td>
<td class="nump">$ 35,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs, Expenses and Other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">3,934<span></span>
</td>
<td class="nump">3,450<span></span>
</td>
<td class="nump">13,530<span></span>
</td>
<td class="nump">9,752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">2,520<span></span>
</td>
<td class="nump">2,336<span></span>
</td>
<td class="nump">7,355<span></span>
</td>
<td class="nump">6,804<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">4,399<span></span>
</td>
<td class="nump">2,445<span></span>
</td>
<td class="nump">9,773<span></span>
</td>
<td class="nump">9,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">107<span></span>
</td>
<td class="nump">288<span></span>
</td>
<td class="nump">487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="nump">429<span></span>
</td>
<td class="num">(450)<span></span>
</td>
<td class="nump">1,576<span></span>
</td>
<td class="num">(1,007)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_CostsExpensesAndOther', window );">Total Costs, Expenses and Other</a></td>
<td class="nump">11,376<span></span>
</td>
<td class="nump">7,888<span></span>
</td>
<td class="nump">32,522<span></span>
</td>
<td class="nump">25,213<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from Continuing Operations Before Taxes</a></td>
<td class="nump">3,583<span></span>
</td>
<td class="nump">5,266<span></span>
</td>
<td class="nump">12,931<span></span>
</td>
<td class="nump">9,970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Taxes on Income from Continuing Operations</a></td>
<td class="nump">330<span></span>
</td>
<td class="nump">695<span></span>
</td>
<td class="nump">1,423<span></span>
</td>
<td class="nump">1,436<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net Income from Continuing Operations</a></td>
<td class="nump">3,253<span></span>
</td>
<td class="nump">4,571<span></span>
</td>
<td class="nump">11,508<span></span>
</td>
<td class="nump">8,534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity', window );">Less: Net Income Attributable to Noncontrolling Interests</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net Income from Continuing Operations Attributable to Merck&#160;&amp; Co., Inc.</a></td>
<td class="nump">3,248<span></span>
</td>
<td class="nump">4,567<span></span>
</td>
<td class="nump">11,502<span></span>
</td>
<td class="nump">8,525<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">766<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income Attributable to Merck &amp; Co., Inc.</a></td>
<td class="nump">$ 3,248<span></span>
</td>
<td class="nump">$ 4,567<span></span>
</td>
<td class="nump">$ 11,502<span></span>
</td>
<td class="nump">$ 9,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic Earnings per Common Share Attributable to Merck &amp; Co., Inc. Common Shareholders:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Income from Continuing Operations (in dollars per share)</a></td>
<td class="nump">$ 1.28<span></span>
</td>
<td class="nump">$ 1.81<span></span>
</td>
<td class="nump">$ 4.55<span></span>
</td>
<td class="nump">$ 3.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare', window );">Income from Discontinued Operations (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.30<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net Income (in dollars per share)</a></td>
<td class="nump">1.28<span></span>
</td>
<td class="nump">1.81<span></span>
</td>
<td class="nump">4.55<span></span>
</td>
<td class="nump">3.67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Earnings per Common Share Assuming Dilution Attributable to Merck &amp; Co., Inc. Common Shareholders:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Income from Continuing Operations (in dollars per share)</a></td>
<td class="nump">1.28<span></span>
</td>
<td class="nump">1.80<span></span>
</td>
<td class="nump">4.53<span></span>
</td>
<td class="nump">3.36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Income from Discontinued Operations (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.30<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net Income (in dollars per share)</a></td>
<td class="nump">$ 1.28<span></span>
</td>
<td class="nump">$ 1.80<span></span>
</td>
<td class="nump">$ 4.53<span></span>
</td>
<td class="nump">$ 3.66<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_CostsExpensesAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of cost of sales, operating expenses and nonoperating income or expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_CostsExpensesAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4613673-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303305454688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income Attributable to Merck&#160;&amp; Co., Inc.</a></td>
<td class="nump">$ 3,248<span></span>
</td>
<td class="nump">$ 4,567<span></span>
</td>
<td class="nump">$ 11,502<span></span>
</td>
<td class="nump">$ 9,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other Comprehensive (Loss) Income Net of Taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent', window );">Net unrealized gain on derivatives, net of reclassifications</a></td>
<td class="nump">338<span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="nump">584<span></span>
</td>
<td class="nump">324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent', window );">Benefit plan net (loss) gain and prior service (cost) credit, net of amortization</a></td>
<td class="num">(186)<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="nump">1,522<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Cumulative translation adjustment</a></td>
<td class="num">(568)<span></span>
</td>
<td class="num">(84)<span></span>
</td>
<td class="num">(990)<span></span>
</td>
<td class="num">(251)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="num">(416)<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="num">(314)<span></span>
</td>
<td class="nump">1,595<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive Income Attributable to Merck&#160;&amp; Co., Inc.</a></td>
<td class="nump">$ 2,832<span></span>
</td>
<td class="nump">$ 4,605<span></span>
</td>
<td class="nump">$ 11,188<span></span>
</td>
<td class="nump">$ 10,886<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303298857296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEET - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 11,145<span></span>
</td>
<td class="nump">$ 8,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable (net of allowance for doubtful accounts of $77 in 2022 and $62 in 2021)</a></td>
<td class="nump">9,482<span></span>
</td>
<td class="nump">9,230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories (excludes inventories of $2,641 in 2022 and $2,194 in 2021 classified in Other assets - see Note&#160;7)</a></td>
<td class="nump">5,614<span></span>
</td>
<td class="nump">5,953<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">7,217<span></span>
</td>
<td class="nump">6,987<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">33,561<span></span>
</td>
<td class="nump">30,266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Investments</a></td>
<td class="nump">984<span></span>
</td>
<td class="nump">370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, Plant and Equipment, at cost, net of accumulated depreciation of $17,921 in 2022 and $18,192 in 2021</a></td>
<td class="nump">20,424<span></span>
</td>
<td class="nump">19,279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">21,160<span></span>
</td>
<td class="nump">21,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other Intangibles, Net</a></td>
<td class="nump">21,368<span></span>
</td>
<td class="nump">22,933<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent', window );">Other Assets</a></td>
<td class="nump">9,584<span></span>
</td>
<td class="nump">11,582<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">107,081<span></span>
</td>
<td class="nump">105,694<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Loans payable and current portion of long-term debt</a></td>
<td class="nump">1,936<span></span>
</td>
<td class="nump">2,412<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Trade accounts payable</a></td>
<td class="nump">3,371<span></span>
</td>
<td class="nump">4,609<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">14,222<span></span>
</td>
<td class="nump">13,859<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">1,698<span></span>
</td>
<td class="nump">1,224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividends payable</a></td>
<td class="nump">1,771<span></span>
</td>
<td class="nump">1,768<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">22,998<span></span>
</td>
<td class="nump">23,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">28,482<span></span>
</td>
<td class="nump">30,690<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred Income Taxes</a></td>
<td class="nump">2,417<span></span>
</td>
<td class="nump">3,441<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other Noncurrent Liabilities</a></td>
<td class="nump">8,660<span></span>
</td>
<td class="nump">9,434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Merck&#160;&amp; Co., Inc. Stockholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2022 and 2021</a></td>
<td class="nump">1,788<span></span>
</td>
<td class="nump">1,788<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Other paid-in capital</a></td>
<td class="nump">44,243<span></span>
</td>
<td class="nump">44,238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">59,928<span></span>
</td>
<td class="nump">53,696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(4,743)<span></span>
</td>
<td class="num">(4,429)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityBeforeTreasuryStock', window );">Stockholders' equity before deduction for treasury stock</a></td>
<td class="nump">101,216<span></span>
</td>
<td class="nump">95,293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Less treasury stock, at cost: 1,043,697,097 shares in 2022 and 1,049,499,023 shares in 2021</a></td>
<td class="nump">56,758<span></span>
</td>
<td class="nump">57,109<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Merck&#160;&amp; Co., Inc. stockholders&#8217; equity</a></td>
<td class="nump">44,458<span></span>
</td>
<td class="nump">38,184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling Interests</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">44,524<span></span>
</td>
<td class="nump">38,257<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Liabilities and Equity</a></td>
<td class="nump">$ 107,081<span></span>
</td>
<td class="nump">$ 105,694<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other assets expected to be realized or consumed within one year or normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other assets expected to be realized or consumed after one year or normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityBeforeTreasuryStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total amount of stockholders' equity (deficit) items including stock value, paid in capital, retained earnings and including equity attributable to noncontrolling interests and before deducting the carrying value of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityBeforeTreasuryStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303302602048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 77<span></span>
</td>
<td class="nump">$ 62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventories classified in Other assets</a></td>
<td class="nump">2,641<span></span>
</td>
<td class="nump">2,194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">$ 17,921<span></span>
</td>
<td class="nump">$ 18,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (shares)</a></td>
<td class="nump">6,500,000,000<span></span>
</td>
<td class="nump">6,500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">3,577,103,522<span></span>
</td>
<td class="nump">3,577,103,522<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock (in shares)</a></td>
<td class="nump">1,043,697,097<span></span>
</td>
<td class="nump">1,049,499,023<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303298694624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities of Continuing Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net income from continuing operations</a></td>
<td class="nump">$ 11,508<span></span>
</td>
<td class="nump">$ 8,534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income from continuing operations to net cash provided by operating activities of continuing operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">1,623<span></span>
</td>
<td class="nump">1,231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">1,394<span></span>
</td>
<td class="nump">1,148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairment charges</a></td>
<td class="nump">910<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Loss (income) from investments in equity securities, net</a></td>
<td class="nump">1,361<span></span>
</td>
<td class="num">(1,535)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Charge for the acquisition of Pandion Therapeutics, Inc.</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(1,261)<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">396<span></span>
</td>
<td class="nump">360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">1,169<span></span>
</td>
<td class="nump">499<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapital', window );">Net changes in assets and liabilities</a></td>
<td class="num">(2,435)<span></span>
</td>
<td class="num">(3,794)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net Cash Provided by Operating Activities of Continuing Operations</a></td>
<td class="nump">14,665<span></span>
</td>
<td class="nump">8,027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities of Continuing Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Capital expenditures</a></td>
<td class="num">(3,239)<span></span>
</td>
<td class="num">(3,240)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of securities and other investments</a></td>
<td class="num">(710)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from sales of securities and other investments</a></td>
<td class="nump">709<span></span>
</td>
<td class="nump">497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired', window );">Acquisition of Pandion Therapeutics, Inc., net of cash acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,554)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Other acquisitions, net of cash acquired</a></td>
<td class="num">(121)<span></span>
</td>
<td class="num">(89)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="nump">149<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net Cash Used in Investing Activities of Continuing Operations</a></td>
<td class="num">(3,212)<span></span>
</td>
<td class="num">(4,372)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities of Continuing Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfShortTermDebt', window );">Net change in short-term borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,983)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Payments on debt</a></td>
<td class="num">(2,250)<span></span>
</td>
<td class="num">(1,153)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_DisposalGroupInclDiscontinuedOperationsDistributionReceived', window );">Distribution from Organon &amp; Co.</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of treasury stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(822)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsCommonStock', window );">Dividends paid to stockholders</a></td>
<td class="num">(5,262)<span></span>
</td>
<td class="num">(4,967)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">119<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="num">(172)<span></span>
</td>
<td class="num">(253)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net Cash Used in Financing Activities of Continuing Operations</a></td>
<td class="num">(7,565)<span></span>
</td>
<td class="num">(2,110)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract', window );"><strong>Cash Flows from Discontinued Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Net cash provided by operating activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,051<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations', window );">Net cash used in investing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(134)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations', window );">Net cash used in financing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(504)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations', window );">Net Cash Flows Provided by Discontinued Operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">413<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="num">(776)<span></span>
</td>
<td class="num">(65)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net Increase in Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="nump">3,112<span></span>
</td>
<td class="nump">1,893<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $71 and $103 at January 1, 2022 and 2021, respectively, included in Other current assets)</a></td>
<td class="nump">8,167<span></span>
</td>
<td class="nump">8,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $134 and $30 at September&#160;30, 2022 and 2021, respectively, included in Other current assets)</a></td>
<td class="nump">$ 11,279<span></span>
</td>
<td class="nump">$ 10,046<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_DisposalGroupInclDiscontinuedOperationsDistributionReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group Incl. Discontinued Operations Distribution Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_DisposalGroupInclDiscontinuedOperationsDistributionReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period of all assets and liabilities used in operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in cash associated with the entity's discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with a second acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303302193648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">$ 134<span></span>
</td>
<td class="nump">$ 71<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">$ 103<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303303452048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of Presentation<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements of Merck&#160;&amp; Co., Inc. (Merck or the Company) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the United States (U.S.) (GAAP) for complete consolidated financial statements are not included herein. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Merck&#8217;s Form 10-K filed on February&#160;25, 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company&#8217;s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Spin-Off of Organon &amp; Co.</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 2, 2021, Merck completed the spin-off of products from its women&#8217;s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon &amp; Co. (Organon) through a distribution of Organon&#8217;s publicly traded stock to Company shareholders. The distribution is expected to qualify and has been treated as tax-free to the Company and its shareholders for U.S. federal income tax purposes. The established brands included in the transaction consisted of dermatology, non-opioid pain management, respiratory, select cardiovascular products, as well as the rest of Merck&#8217;s diversified brands franchise. Merck&#8217;s existing research pipeline programs continue to be owned and developed within Merck as planned. The historical results of the businesses that were contributed to Organon in the spin-off have been reflected as discontinued operations in the Company&#8217;s consolidated financial statements through the date of the spin-off (see Note&#160;2).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Financial Accounting Standards Board (FASB) issued amended guidance on the accounting for convertible instruments and contracts in an entity&#8217;s own equity. The guidance removes the separation model for convertible debt instruments and preferred stock, amends requirements for conversion options to be classified in equity as well as amends diluted earnings per share (EPS) calculations for certain convertible debt instruments. The Company adopted the new guidance on January 1, 2022 using a modified retrospective approach. There was no impact to the Company&#8217;s consolidated financial statements upon adoption.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the FASB issued new guidance to increase the transparency of transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. The guidance requires annual disclosures of such transactions to include the nature of the transactions and the significant terms and conditions, the accounting treatment and the impact to a company&#8217;s financial statements. The Company adopted the new guidance on January 1, 2022 on a prospective basis. There was no material impact to the Company&#8217;s consolidated financial statements upon adoption.</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting and subsequently issued clarifying amendments. The guidance provides optional expedients and exceptions for accounting for contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (LIBOR) or another reference rate expected to be discontinued because of reference rate reform. The Company adopted the optional guidance on July 1, 2022 on a prospective basis. There was no material impact to the Company&#8217;s consolidated financial statements upon adoption. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Standards Not Yet Adopted</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued amended guidance that requires acquiring entities to recognize and measure contract assets and liabilities in a business combination in accordance with existing revenue recognition guidance. The amended guidance is effective for interim and annual periods in 2023 and is to be applied prospectively. Early adoption is permitted on a retrospective basis to the beginning of the fiscal year of adoption. The adoption of this guidance will not have an impact on the Company&#8217;s consolidated financial statements for prior acquisitions; however, the impact in future periods will be dependent upon the contract assets and contract liabilities acquired in future business combinations.</span></div>In June 2022, the FASB issued guidance related to the fair value measurement of an equity security subject to contractual restrictions that prohibit the sale of the equity security. The new guidance also introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. The amended guidance is effective for interim and annual periods in 2024 and is to be applied prospectively. Early adoption is permitted for both interim and annual periods. The Company is currently evaluating the impact of adoption on its consolidated financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI https://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303303448480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Spin-Off of Organon &amp; Co.<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Spin-Off of Organon &amp; Co.</a></td>
<td class="text">Spin-Off of Organon &amp; Co. <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 2, 2021, Merck completed the spin-off of Organon through a distribution of Organon&#8217;s publicly traded stock to Company shareholders. In connection with the spin-off, each Merck shareholder received one tenth of a share of Organon&#8217;s common stock for each share of Merck common stock held by such shareholder. The distribution is expected to qualify and has been treated as tax free to Merck and its shareholders for U.S. federal income tax purposes. Indebtedness of $9.5&#160;billion principal amount, consisting of term loans and senior notes, was issued in 2021 in connection with the spin-off and assumed by Organon. Merck is no longer the obligor of any Organon debt or financing arrangements. Cash proceeds of $9.0&#160;billion were distributed by Organon to Merck in connection with the spin-off. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in connection with the spin-off, Merck and Organon entered into a separation and distribution agreement and also entered into various other agreements to effect the spin-off and provide a framework for the relationship between Merck and Organon after the spin-off, including a transition services agreement (TSA), manufacturing and supply agreements (MSAs), trademark license agreements, intellectual property license agreements, an employee matters agreement, a tax matters agreement and certain other commercial agreements. Under the TSA, Merck is providing Organon various services and, similarly, Organon is providing Merck various services. The provision of services under the TSA generally will terminate within 25 months following the spin-off; however, the provision of certain services has been extended to 31 months. Merck and Organon also entered into a series of interim operating agreements pursuant to which in various jurisdictions where Merck held licenses, permits and other rights in connection with marketing, import and/or distribution of Organon products prior to the separation, Merck is continuing to market, import and distribute such products until such time as the relevant licenses and permits are transferred to Organon. Under such interim operating agreements and in accordance with the separation and distribution agreement, Merck is continuing operations in the affected markets on behalf of Organon, with Organon receiving all of the economic benefits and burdens of such activities. Additionally, Merck and Organon entered into a number of MSAs pursuant to which Merck is (a) manufacturing and supplying certain active pharmaceutical ingredients for Organon, (b) manufacturing and supplying certain formulated pharmaceutical products for Organon, and (c) packaging and labeling certain finished pharmaceutical products for Organon. Similarly, Organon and Merck entered into a number of MSAs pursuant to which Organon is (a) manufacturing and supplying certain formulated pharmaceutical products for Merck, and (b) packaging and labeling certain finished pharmaceutical products for Merck. The terms of the MSAs range in initial duration from four years to ten years. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts included in the condensed consolidated statement of income for the above MSAs include sales of $100&#160;million and $293&#160;million and related cost of sales of $104&#160;million and $312&#160;million for the three and nine months ended September&#160;30, 2022, respectively. The amounts included in the condensed consolidated statement of income for the MSAs in the same periods of 2021 were immaterial. Amounts included in the condensed consolidated statement of income for the TSAs were immaterial for the three and nine months ended September&#160;30, 2022 and September&#160;30, 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts due from Organon under all of the above agreements were $567&#160;million and $964&#160;million at September&#160;30, 2022 and December&#160;31, 2021, respectively, and are reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amounts due to Organon under these agreements were $333&#160;million and $400&#160;million at September&#160;30, 2022 and December&#160;31, 2021, respectively, and are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of the women&#8217;s health, biosimilars and established brands businesses (previously included in the Pharmaceutical segment) that were contributed to Organon in the spin-off, as well as interest expense related to the debt issuance in 2021, have been reflected as discontinued operations in the Company&#8217;s condensed consolidated statement of income as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for periods prior to the spin-off on June 2, 2021. Merck incurred separation costs of $556&#160;million for the nine months ended September&#160;30, 2021 related to the spin-off of Organon, which are also included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. These costs primarily relate to professional fees for separation activities within finance, tax, legal and information technology functions, as well as investment banking fees. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.574%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,512&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs, Expenses and Other</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,755&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations before taxes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, net of taxes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">769&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Income of discontinued operations attributable to noncontrolling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Reflects amounts through the June 2, 2021 spin-off date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303385008400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Research Collaborations and License Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock', window );">Acquisitions, Research Collaborations and License Agreements</a></td>
<td class="text">Acquisitions, Research Collaborations and License Agreements<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to pursue acquisitions and the establishment of external alliances such as research collaborations and licensing agreements to complement its internal research capabilities. These arrangements often include upfront payments, as well as expense reimbursements or payments to the third party, and milestone, royalty or profit share arrangements, contingent upon the occurrence of certain future events linked to the success of the asset in development. The Company also reviews its marketed products and pipeline to examine candidates which may provide more value through out-licensing and, as part of its portfolio assessment process, may also divest certain assets. Pro forma financial information for acquired businesses is not presented if the historical financial results of the acquired entity are not significant when compared with the Company&#8217;s financial results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Transactions</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, Merck and Royalty Pharma plc (Royalty Pharma) entered into a funding arrangement under which Royalty Pharma paid Merck $50&#160;million to co-fund Merck&#8217;s development costs for a Phase 2b trial of MK-8189, an investigational oral Phosphodiesterase 10A (PDE10A) inhibitor, which is being evaluated for the treatment of schizophrenia. Under the agreement, Royalty Pharma has no rights to MK-8189 and has no decision-making authority over the program. If Merck elects to advance MK-8189 into a Phase 3 study, Royalty Pharma has the option to provide additional funding of 50% of the development costs up to $375&#160;million for the Phase 3 trial. If such additional funding is provided, Royalty Pharma becomes eligible to receive future regulatory milestone payments contingent upon certain marketing approvals, as well as royalties. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, Merck exercised its option to jointly develop and commercialize personalized cancer vaccine mRNA-4157/V940 pursuant to the terms of an existing collaboration and license agreement with Moderna, Inc. (Moderna), which resulted in a $250&#160;million charge in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in the third quarter and first nine months of 2022. The payment to Moderna was made in the fourth quarter of 2022. mRNA-4157/V940 is currently being evaluated in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pembrolizumab), Merck&#8217;s anti-PD-1 therapy, as adjuvant treatment for patients with high-risk melanoma in a Phase 2 clinical trial being conducted by Moderna. Under the 2016 agreement, as amended in 2018, Merck and Moderna will collaborate on development and commercialization and will share costs and any profits equally under this worldwide collaboration. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, Merck and Orna Therapeutics (Orna), a biotechnology company pioneering a new investigational class of engineered circular RNA (oRNA) therapies, entered into a collaboration agreement to discover, develop, and commercialize multiple programs, including vaccines and therapeutics in the areas of infectious disease and oncology. Under the terms of the agreement, Merck made an upfront payment to Orna of $150&#160;million, which was recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in the third quarter and first nine months of 2022. In addition, Orna is eligible to receive future contingent development-related payments aggregating up to $440 million, $675 million in regulatory milestones, and $2.4 billion in sales milestones associated with the progress of the multiple vaccine and therapeutic programs, as well as royalties </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ranging from a high-single-digit rate to a low-double-digit rate on any approved products derived from the collaboration. Merck also invested $100&#160;million in Orna&#8217;s Series B preferred shares in the fourth quarter of 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, Merck and Orion Corporation (Orion) announced a global co-development and co-commercialization agreement for Orion&#8217;s investigational candidate ODM-208 (MK-5684) and other drugs targeting cytochrome P450 11A1 (CYP11A1), an enzyme important in steroid production. ODM-208 is an oral, non-steroidal inhibitor of CYP11A1 currently being evaluated in a Phase 2 clinical trial for the treatment of patients with metastatic castration-resistant prostate cancer. Merck made an upfront payment to Orion of $290&#160;million, which was recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in the third quarter and first nine months of 2022. Orion is responsible for the manufacture of clinical and commercial supply of ODM-208. In addition, the contract provides both parties with an option to convert the initial co-development and co-commercialization agreement into a global exclusive license to Merck. If the option is exercised, Merck would assume full responsibility for all past development and commercialization expenses associated with the program since inception of the agreement, as well as all future development and commercialization expenses. In addition, Orion would be eligible to receive milestone payments associated with progress in the development and commercialization of ODM-208 as well as tiered double-digit royalties on sales if the product is approved. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in July 2022, Merck and Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (Kelun-Biotech) closed a license and collaboration agreement in which Merck gained exclusive worldwide rights for the development, manufacture and commercialization of an investigational antibody drug conjugate (ADC) (MK-1200) for the treatment of solid tumors. Under the terms of the agreement, Merck and Kelun-Biotech will collaborate on the early clinical development of the investigational ADC. Merck made an upfront payment of $35&#160;million, which was recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in the third quarter and first nine months of 2022. Kelun-Biotech is also eligible to receive future contingent milestone payments aggregating up to $82&#160;million in developmental milestones, $334&#160;million in regulatory milestones, and $485&#160;million in sales-based milestones. The agreement also provides for Merck to pay tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, in connection with an existing arrangement, Merck exercised its option to obtain an exclusive license outside of China for the development, manufacture and commercialization of Kelun-Biotech&#8217;s trophoblast antigen 2 (TROP2)-targeting ADC programs, including its lead compound, SKB-264 (MK-2870). SKB-264 is currently being evaluated in Phase 2 trials for non-small-cell lung cancer and advanced solid tumors. Under the terms of the agreement, Merck and Kelun-Biotech will collaborate on certain early clinical development plans, including evaluating the potential of SKB-264 as a monotherapy and in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for advanced solid tumors. Upon option exercise, Merck made a payment of $30&#160;million, which was recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in the first nine months of 2022, and agreed to make additional payments of $30&#160;million upon completion of specified project activities and $25&#160;million upon technology transfer. Merck also agreed to make quarterly payments in 2022 and 2023 aggregating up to $101&#160;million to fund Kelun-Biotech&#8217;s ongoing research and development activities. In addition, Kelun-Biotech is eligible to receive future contingent milestone payments (which includes all program compounds) aggregating up to $90&#160;million in developmental milestones, $290&#160;million in first commercial sale milestones, and $780&#160;million in sales-based milestones. The agreement also provides for Merck to pay tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Transactions</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, Merck acquired Pandion Therapeutics, Inc. (Pandion), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases. Pandion is advancing a pipeline of precision immune modulators targeting critical immune control nodes. Total consideration paid of $1.9 billion included $147&#160;million of costs primarily comprised of share-based compensation payments to settle equity awards. The transaction was accounted for as an acquisition of an asset. Merck recorded net assets of $156 million (primarily cash) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses of $1.7 billion in the first nine months of 2021 related to the transaction. There are no future contingent payments associated with the acquisition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, Merck entered into an exclusive license and research collaboration agreement with Artiva Biotherapeutics, Inc. (Artiva) to discover, develop and manufacture CAR-NK cells that target certain solid tumors using Artiva&#8217;s proprietary platform. Merck and Artiva agreed to engage in up to three different research programs, each covering a collaboration target. Merck has sole responsibility for all development and commercialization activities (including regulatory filing and approval). Under the terms of the agreement, Merck made an upfront payment of $30&#160;million, which was included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in the first nine months of 2021, for license and other rights for the first two collaboration targets and agreed to make another upfront payment of $15&#160;million for license and other rights for the third collaboration target when it is selected by Merck and accepted by Artiva. In addition, Artiva is eligible to receive future contingent milestone payments (which span all three collaboration targets), aggregating up to $217.5&#160;million in developmental milestones, $570&#160;million in regulatory milestones, and $1.05&#160;billion in sales-based milestones. The agreement also provides for Merck to pay tiered royalties ranging from 7% to 14% on future sales.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of Merck&#8217;s 2020 acquisition of OncoImmune, Merck obtained MK-7110, a therapeutic candidate that was being evaluated for the treatment of patients hospitalized with COVID-19. In 2021, Merck received feedback from the U.S. Food and Drug Administration (FDA) that additional data would be needed to support a potential Emergency Use Authorization application and therefore the Company did not expect MK-7110 would become available until the first half of 2022. Given this timeline and the technical, clinical and regulatory uncertainties, the availability of a number of medicines for patients hospitalized with COVID-19, and the need to concentrate Merck&#8217;s resources on accelerating the development and manufacture of the most viable therapeutics and vaccines, Merck decided to discontinue development of MK-7110 for the treatment of COVID-19. Due to the discontinuation, the Company recorded charges of $207&#160;million in the first nine months of 2021, which are reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and relate to fixed assets and materials written off, as well as the recognition of liabilities for purchase commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Information related to acquisitions, divestitures, research collaborations and license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303303253968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Arrangements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_CollaborativeArrangementsAbstract', window );"><strong>Collaborative Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Arrangements</a></td>
<td class="text">Collaborative Arrangements<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. Both parties in these arrangements are active participants and exposed to significant risks and rewards dependent on the commercial success of the activities of the collaboration. Merck&#8217;s more significant collaborative arrangements are discussed below. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AstraZeneca</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, Merck and AstraZeneca PLC (AstraZeneca) entered into a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca&#8217;s Lynparza (olaparib) for multiple cancer types. Independently, Merck and AstraZeneca will develop and commercialize Lynparza in combinations with their respective PD-1 and PD-L1 medicines, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Imfinzi. The companies are also jointly developing and commercializing AstraZeneca&#8217;s Koselugo (selumetinib) for multiple indications. Under the terms of the agreement, AstraZeneca and Merck will share the development and commercialization costs for Lynparza and Koselugo&#160;monotherapy and non-PD-L1/PD-1 combination therapy opportunities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Profits from Lynparza and Koselugo&#160;product sales generated through monotherapies or combination therapies are shared equally. AstraZeneca is the principal on Lynparza and Koselugo sales transactions. Merck records its share of Lynparza and Koselugo product sales, net of cost of sales and commercialization costs, as alliance revenue and its share of development costs associated with the collaboration as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses. Reimbursements received from AstraZeneca for research and development expenses are recognized as reductions to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the agreement, Merck made an upfront payment to AstraZeneca and also made payments over a multi-year period for certain license options. In addition, the agreement provides for contingent payments from Merck to AstraZeneca related to the successful achievement of sales-based and regulatory milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2022, Merck determined it was probable that sales of Lynparza in the future would trigger a $600&#160;million sales-based milestone payment from Merck to AstraZeneca. Accordingly, Merck recorded a $600&#160;million liability and a corresponding increase to the intangible asset related to Lynparza. Merck also recognized $250&#160;million of cumulative amortization catch-up expense related to the recognition of this milestone in the first quarter of 2022. In the first nine months of 2022, Merck made a sales-based milestone payment to AstraZeneca (which had been previously accrued for) of $400&#160;million. As of September&#160;30, 2022, sales-based milestone payments accrued but not yet paid totaled $600&#160;million. Potential future sales-based milestone payments of $2.1 billion have not yet been accrued as they are not deemed by the Company to be probable at this time. In the first nine months of 2022, Lynparza received regulatory approvals triggering capitalized milestone payments of $250&#160;million from Merck to AstraZeneca. Potential future regulatory milestone payments of $1.2 billion remain under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible asset balance related to Lynparza (which includes capitalized sales-based and regulatory milestone payments) was $1.5 billion at September&#160;30, 2022 and is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amount is being amortized over its estimated useful life through 2028 as supported by projected future cash flows, subject to impairment testing.</span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:63.364%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.123%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.713%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Koselugo</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total alliance revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from AstraZeneca included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Trade accounts payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments. Amount in the first nine months of 2022 includes $250&#160;million of cumulative amortization catch-up expense as noted above.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued milestone payments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Eisai</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, Merck and Eisai Co., Ltd. (Eisai) announced a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima (lenvatinib), an orally available tyrosine kinase inhibitor discovered by Eisai. Under the agreement, Merck and Eisai will develop and commercialize Lenvima jointly, both as monotherapy and in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Eisai records Lenvima product sales globally (Eisai is the principal on Lenvima sales transactions) and Merck and Eisai share applicable profits equally. Merck records its share of Lenvima product sales, net of cost of sales and commercialization costs, as alliance revenue. Expenses incurred during co-development are shared by the two companies in accordance with the collaboration agreement and reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expenses. Certain expenses incurred solely by Merck or Eisai are not shareable under the collaboration agreement, including costs incurred in excess of agreed upon caps and costs related to certain combination studies of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Lenvima.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the agreement, Merck made an upfront payment to Eisai and also made payments over a multi-year period for certain option rights (of which the final $125 million option payment was made in March 2021). In addition, the agreement provides for contingent payments from Merck to Eisai related to the successful achievement of sales-based and regulatory milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first nine months of 2022, Merck made sales-based milestone payments to Eisai (which had been previously accrued for) aggregating $600 million. Potential future sales-based milestone payments of $2.6 billion have not yet been accrued as they are not deemed by the Company to be probable at this time. In the first nine months of 2022, Lenvima received regulatory approvals triggering capitalized milestone payments of $50&#160;million from Merck to Eisai. There are no regulatory milestone payments remaining under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible asset balance related to Lenvima (which includes capitalized sales-based and regulatory milestone payments) was $867 million at September&#160;30, 2022 and is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amount is being amortized over its estimated useful life through 2026 as supported by projected future cash flows, subject to impairment testing.</span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.678%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from Eisai included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Eisai included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments.</span></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Amount as of December 31, 2021 includes accrued milestone payments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bayer AG</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators including Bayer&#8217;s Adempas (riociguat). The two companies have implemented a joint development and commercialization strategy. The collaboration also includes development of Bayer&#8217;s Verquvo (vericiguat), which was approved in the U.S. in January 2021, in Japan in June 2021 and in the EU in July 2021. Under the agreement, Bayer commercializes Adempas in the Americas, while Merck commercializes in the rest of the world. For Verquvo, Merck commercializes in the U.S. and Bayer commercializes in the rest of the world. Both companies share in development costs and profits on sales. Merck records sales of Adempas and Verquvo in its marketing territories, as well as alliance revenue. Alliance revenue represents Merck&#8217;s share of profits from sales of Adempas and Verquvo in Bayer&#8217;s marketing territories, which are product sales net of cost of sales and commercialization costs. Cost of sales includes Bayer&#8217;s share of profits from sales in Merck&#8217;s marketing territories. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the agreement provided for contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones. In January 2022, Merck made the final $400 million sales-based milestone payment under this collaboration to Bayer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible asset balances related to Adempas (which includes the acquired intangible asset balance, as well as capitalized sales-based milestone payments attributed to Adempas) and Verquvo (which reflects the portion of the final sales-based milestone payment that was attributed to Verquvo) were $597 million and $53 million, respectively, at September&#160;30, 2022 and are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The assets are being amortized over their estimated useful lives (through 2027 for Adempas and through 2031 for Verquvo) as supported by projected future cash flows, subject to impairment testing. </span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.947%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Adempas/Verquvo</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales of Adempas recorded by Merck</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales of Verquvo recorded by Merck</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from Bayer included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Bayer included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Includes amortization of intangible assets. Amount in the first nine months of 2021 includes $153&#160;million of cumulative amortization catch-up expense. In addition, cost of sales includes Bayer&#8217;s share of profits from sales in Merck&#8217;s marketing territories.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Amount as of December 31, 2021 includes accrued milestone payment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ridgeback Biotherapeutics LP</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, Merck and Ridgeback Biotherapeutics LP (Ridgeback), a closely held biotechnology company, entered into a collaboration agreement to develop </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (molnupiravir), an orally available antiviral candidate in clinical development for the treatment of patients with COVID-19. Merck gained exclusive worldwide rights to develop and commercialize </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and related molecules. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Ridgeback received an upfront payment and is eligible to receive future contingent payments dependent upon the achievement of certain developmental and regulatory approval milestones. The agreement also provides for Merck to reimburse Ridgeback for a portion of certain third-party contingent milestone payments and royalties on net sales, which is part of the profit sharing calculation. Merck is the principal on sales transactions, recognizing sales and related costs, with profit sharing amounts recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Profits from the collaboration are split equally between the partners. Reimbursements from Ridgeback for its share of research and development costs (deducted from Ridgeback&#8217;s share of profits) are reflected as decreases to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has received multiple authorizations or approvals worldwide and Merck has entered into advance purchase and supply agreements for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in more than 40 markets. As of September&#160;30, 2022, the Company has 0.8 million remaining courses to be supplied under these agreements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.947%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> sales</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,859&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Ridgeback included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Includes royalty expense and amortization of capitalized milestone payments.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Includes accrued royalty and milestone payments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bristol Myers Squibb</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reblozyl (luspatercept-aamt) is a first-in-class erythroid maturation recombinant fusion protein obtained as part of Merck&#8217;s November 2021 acquisition of Acceleron Pharma Inc. that is being developed and commercialized through a global collaboration with Bristol Myers Squibb (BMS). Reblozyl is approved in the U.S., Europe, Canada and Australia for the treatment of anemia in certain rare blood disorders and is also being evaluated for additional indications for hematology therapies. BMS is the principal on sales transactions for Reblozyl; however, Merck co-promotes Reblozyl (and will co-promote all future products approved under this collaboration) in North America, which is reimbursed by BMS. Merck receives a 20% sales royalty from BMS which could increase to a maximum of 24% based on sales levels. This royalty will be reduced by 50% upon the earlier of patent expiry or generic entry on an indication-by-indication basis in each market. Additionally, Merck is eligible to receive future contingent sales-based milestone payments of up to $80&#160;million. Merck recorded alliance revenue of $39 million (consisting of royalties) within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the third quarter of 2022 related to this collaboration. Merck recorded alliance revenue of $124 million in the first nine months of 2022, which includes royalties of $104&#160;million, as well as the receipt of a regulatory approval milestone payment of $20&#160;million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_CollaborativeArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_CollaborativeArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303303253968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring</a></td>
<td class="text">Restructuring<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, Merck&#160;approved a global restructuring program (Restructuring Program) as part of a worldwide initiative focused on further optimizing the Company&#8217;s manufacturing and supply network, as well as reducing its global real estate footprint.&#160;This program is a continuation of the Company&#8217;s plant rationalization and builds on prior restructuring programs. The actions currently contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $3.5 billion. The Company estimates that approximately 70% of the cumulative pretax costs will result in cash outlays, primarily related to employee separation expense and facility shut-down costs. Approximately 30% of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded total pretax costs of $175 million and $168 million in the third quarter of 2022 and 2021, respectively, and $559 million and $630 million for the first nine months of 2022 and 2021, respectively, related to </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">restructuring program activities. Since inception of the Restructuring Program through September&#160;30, 2022, Merck has recorded total pretax accumulated costs of approximately $3.2 billion. For the full year of 2022, the Company expects to record charges of approximately $600 million related to the Restructuring Program. For segment reporting, restructuring charges are unallocated expenses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the charges related to restructuring program activities by type of cost:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.953%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">630&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separation costs are associated with actual headcount reductions, as well as those headcount reductions which were probable and could be reasonably estimated. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated depreciation costs primarily relate to manufacturing, research and administrative facilities and equipment to be sold or closed as part of the program. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. All the sites have and will continue to operate up through the respective closure dates and, since future undiscounted cash flows are sufficient to recover the respective book values, Merck is recording accelerated depreciation over the revised useful life of the site assets. Anticipated site closure dates, particularly related to manufacturing locations, have been and may continue to be adjusted to reflect changes resulting from regulatory or other factors.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other activity in 2022 and 2021 includes asset abandonment, facility shut-down and other related costs, as well as pretax gains and losses resulting from the sales of facilities and related assets. Additionally, other activity includes certain employee-related costs associated with pension and other postretirement benefit plans (see Note&#160;11) and share-based compensation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the charges and spending relating to restructuring program activities for the nine months ended September&#160;30, 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserves January&#160;1, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">596&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">637&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Payments) receipts, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(303)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(458)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(761)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserves September&#160;30, 2022 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)The remaining cash outlays are expected to be substantially completed by the end of 2023.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI https://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303305385856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Financial Instruments</a></td>
<td class="text">Financial Instruments<div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derivative Instruments and Hedging Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages the impact of foreign exchange rate movements and interest rate movements on its earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of the Company&#8217;s revenues and earnings in foreign affiliates is exposed to changes in foreign exchange rates. The objectives of and accounting related to the Company&#8217;s foreign currency risk management program, as well as its interest rate risk management activities are discussed below.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Risk Management</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has established revenue hedging, balance sheet risk management and net investment hedging programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by changes in foreign exchange rates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The objective of the revenue hedging program is to reduce the variability caused by changes in foreign exchange rates that would affect the U.S. dollar value of future cash flows derived from foreign currency denominated sales, primarily the euro, Japanese yen and Chinese renminbi. To achieve this objective, the Company will hedge a portion of its forecasted foreign currency denominated third-party and intercompany distributor entity sales (forecasted sales) that are expected to occur over its planning cycle, typically no more than two years into the future. The Company will layer in hedges over time, increasing the portion of forecasted sales hedged as it gets closer to the expected date of the forecasted sales. The portion of forecasted sales hedged is based on assessments of cost-benefit profiles that consider natural offsetting exposures, revenue and exchange rate volatilities and correlations, and the cost of hedging instruments. The Company manages its anticipated transaction exposure principally with purchased local currency put options, forward contracts and purchased collar options. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the Condensed Consolidated Balance Sheet. Changes in the fair value of derivative contracts are recorded each period in either current earnings or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (OCI), depending on whether the derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash flow hedges, the unrealized gains or losses on these contracts are recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated Other Comprehensive Loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCL)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and reclassified into </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> when the hedged anticipated revenue is recognized. For those derivatives which are not designated as cash flow hedges, but serve as economic hedges of forecasted sales, unrealized gains or losses are recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> each period. The cash&#160;flows from both designated and non-designated contracts are reported as operating activities&#160;in the Condensed Consolidated Statement of&#160;Cash Flows. The Company does not enter into derivatives for trading or speculative purposes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages operating activities and net asset positions at each local subsidiary in order to mitigate the effects of exchange on monetary assets and liabilities. The Company also uses a balance sheet risk management program to mitigate the exposure of net monetary assets that are denominated in a currency other than a subsidiary&#8217;s functional currency from the effects of volatility in foreign exchange. In these instances, Merck principally utilizes forward exchange contracts to offset the effects of exchange on exposures denominated in developed country currencies, primarily the euro, Japanese yen, British pound, Canadian dollar and Swiss franc. For exposures in developing country currencies, including the Chinese renminbi, the Company will enter into forward contracts to offset the effects of exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the exchange rate and the cost of the hedging instrument. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The forward contracts are not designated as hedges and are marked to market through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than one year.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also uses forward exchange contracts to hedge a portion of its net investment in foreign operations against movements in exchange rates. The forward contracts are designated as hedges of the net investment in a foreign operation. The unrealized gains or losses on these contracts are recorded in foreign currency translation adjustment within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and remain in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> until either the sale or complete or substantially complete liquidation of the subsidiary. The Company excludes certain portions of the change in fair value of its derivative instruments from the assessment of hedge effectiveness (excluded components). Changes in fair value of the excluded components are recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company recognizes in earnings the initial value of the excluded components on a straight-line basis over the life of the derivative instrument, rather than using the mark-to-market approach. The cash flows from these contracts are reported as investing activities in the Condensed Consolidated Statement of Cash Flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange risk is also managed through the use of foreign currency debt. The Company&#8217;s senior unsecured euro-denominated notes have been designated as, and are effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in foreign currency translation adjustment within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effects of the Company&#8217;s net investment hedges on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the Consolidated Statement of Income are shown below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.366%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> for Amounts Excluded from Effectiveness Testing</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Relationships</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro-denominated notes</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(250)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(431)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(199)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> No amounts were reclassified from AOCL into income related to the sale of a subsidiary.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk Management</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes and to reduce its overall cost of borrowing. The Company does not use leveraged swaps and, in general, does not leverage any of its investment activities that would put principal at risk. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022,&#160;five&#160;interest rate swap contracts with a total notional amount of&#160;$1.25 billion matured. These swaps effectively converted the Company&#8217;s&#160;$1.25 billion,&#160;2.35%&#160;fixed-rate notes due 2022 to variable rate debt.&#160;In September 2022, four interest rate swap contracts with a total notional amount of $1.0&#160;billion matured. These swaps effectively converted the Company&#8217;s $1.0&#160;billion, 2.40% fixed rate notes due 2022 to variable rate debt. The interest rate swap contracts were designated hedges of the fair value changes in the notes attributable to changes in the benchmark LIBOR swap rate. The fair value changes in the notes attributable to changes in the LIBOR swap rate were recorded in interest expense along with the offsetting fair value changes in the swap contracts. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows. The Company is not currently a party to any interest rate swaps.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the location of amounts recorded in the Condensed Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.338%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.040%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Amount of Hedged Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Line Item in which Hedged Item is Included</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loans payable and current portion of long-term debt</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,263&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.367%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.241%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair&#160;Value&#160;of&#160;Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.&#160;Dollar<br/>Notional</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair&#160;Value&#160;of&#160;Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.&#160;Dollar<br/>Notional</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Designated as Hedging Instruments</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNC0xLTEtMS0xMDUwNTY_4beacbd1-84ea-489f-8ac6-b09392c17877"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNC0xLTEtMS0xMDUwNTY_4c50954f-2f04-4bb2-9e7e-854b1813a13f">Other current assets</span></span></span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNS0xLTEtMS05NDQxNA_2a5d2377-4bbd-47ad-9925-404ca9a51736"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNS0xLTEtMS05NDQxNA_c6df00f3-bff8-4562-abe7-498764d34146">Other current assets</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNi0xLTEtMS05NDQxNA_6baf831a-4ac8-4464-8eb1-254345d36853"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNi0xLTEtMS05NDQxNA_95f68aac-d3b4-4319-9f3d-70e85b1424c4">Other Assets</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNy0xLTEtMS05NDQxNA_6a9babb4-e747-4df0-a56c-3595290d8927"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNy0xLTEtMS05NDQxNA_ae73e90d-8b40-4bfe-b1e5-b0c0132d4407">Accrued and other current liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfOC0xLTEtMS05NDQxNA_3d168174-838c-4aa7-834d-0305c0dea6db"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfOC0xLTEtMS05NDQxNA_8a78e2f6-5d79-40d5-8cfd-da850ad40e02">Other Noncurrent Liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">911&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,788&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTEtMS0xLTEtMTA1MTE3_0942da13-4366-4941-8d73-f86fd1003d65"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTEtMS0xLTEtMTA1MTE3_ed1a83b6-f315-4484-ba3e-ac3634db5ded">Other current assets</span></span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,523&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,073&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTItMS0xLTEtMTA1MTE5_35d04908-60bc-47a5-b559-4d800d70da91"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTItMS0xLTEtMTA1MTE5_f4049782-8c11-4ab1-9f60-0268bac9cd63">Accrued and other current liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,238&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,713&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,508&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,026&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,958&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, the Company records its derivatives on a gross basis in the Condensed Consolidated Balance Sheet. The Company has master netting agreements with several of its financial institution counterparties (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentrations of Credit Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below). The following table provides information on the Company&#8217;s derivative positions subject to these master </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:64.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.105%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross amounts recognized in the condensed consolidated balance sheet</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,508&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(217)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(217)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash collateral received</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(794)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(164)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net amounts</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">497&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides information regarding the location and amount of pretax gains and losses of derivatives designated in fair value or cash flow hedging relationships:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.636%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.907%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Financial Statement Line Items in which Effects of Fair Value or Cash Flow Hedges are Recorded</span></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other (income) expense, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other (income) expense, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">14,959&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">13,154&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(450)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(416)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">45,453&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">35,183&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,576&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1,007)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(314)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,595&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(Gain) loss on fair value hedging relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Hedged items</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Impact of cash flow hedging relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of gain recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Increase (decrease) in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> as a result of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">AOCL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> reclassifications</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(253)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">491&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(219)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(491)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTMtMC0xLTEtOTQ0MTQ_415ec0c9-4bba-4fb9-aa01-b4c7b84244a9"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTMtMC0xLTEtOTQ0MTQ_a2ea2169-dd57-478e-b872-7cc7be5bf76a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTMtMC0xLTEtOTQ0MTQ_c6f59e51-c8a0-4c45-930c-4ef2ed96eb20"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTMtMC0xLTEtOTQ0MTQ_ff915512-cf0d-456d-a25d-7aab715fc26c"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of gain recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></span></span></span></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of loss recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Interest expense is a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.362%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Derivative Pretax (Gain) Loss Recognized in Income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Income Statement Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates. Amount in the first nine months of 2021 includes a loss on forward exchange contracts entered into in conjunction with the spin-off of Organon.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> These derivative contracts serve as economic hedges of forecasted transactions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2022, the Company estimates $864 million of pretax net unrealized gains on derivatives maturing within the next 12 months that hedge foreign currency denominated sales over that same period will be reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amount ultimately reclassified to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments in Debt and Equity Securities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information on investments in debt and equity securities is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross&#160;Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross&#160;Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,334&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,647&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt and publicly traded equity securities</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,410&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Unrealized net losses of $221&#160;million and $415 million were recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> in the third quarter and first nine months of 2022, respectively, on equity securities still held at September&#160;30, 2022. Unrealized net (gains) losses of $(90) million and $109&#160;million were recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> in the third quarter and first nine months of 2021, respectively, on equity securities still held at September&#160;30, 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2022 and September&#160;30, 2021, the Company also had $705 million and $578 million, respectively, of equity investments without readily determinable fair values included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company records unrealized gains on these equity investments based on favorable observable price changes from transactions involving similar investments of the same investee and records unrealized losses based on unfavorable observable price changes, which are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. During the first nine months</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company recorded unrealized gains of $21 million and unrealized net losses of $12&#160;million related to certain of these equity investments still held at September&#160;30, 2022. During the first nine months</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company recorded unrealized gains of $104&#160;million and unrealized losses of $1&#160;million related to certain of these investments still held at September&#160;30, 2021. Cumulative unrealized gains and cumulative unrealized losses based on observable price changes for investments in equity investments without readily determinable fair values still held at September&#160;30, 2022 were $255 million and $19 million, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2022 and September&#160;30, 2021, the Company also had $655&#160;million and $1.2&#160;billion, respectively, recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for equity securities held through ownership interests in investment funds. Losses (gains) recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> relating to these investment funds were $141&#160;million and $(391)&#160;million for the third quarter of 2022 and 2021, respectively, and were $952&#160;million and $(893)&#160;million for the first nine months of 2022 and 2021, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level&#160;1 having the highest priority and Level 3 having the lowest: </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Quoted prices (unadjusted) in active markets for identical assets or liabilities; </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Unobservable inputs that are supported by little or no market activity. Level 3 assets or liabilities are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as assets or liabilities for which the determination of fair value requires significant judgment or estimation. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities measured at fair value on a recurring basis are summarized below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.654%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,081&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,081&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,081&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,087&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,363&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,363&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivative assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased currency options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,508&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,508&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,404&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,514&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,918&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,731&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,282&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivative liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Written currency options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">898&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt"> Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company&#8217;s own credit risk, the effects of which were not significant.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022 and December&#160;31, 2021, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included $10.0 billion and $6.8 billion of cash equivalents, respectively (which would be considered Level 2 in the fair value hierarchy). </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information about the changes in the fair value of liabilities for contingent consideration associated with business combinations is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:80.424%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.846%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(156)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value September 30 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">  Recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cost of sales, Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> expenses, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">. Includes cumulative translation adjustments.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">At September&#160;30, 2022, $358 million of the liabilities relate to the 2016 termination of the Sanofi Pasteur MSD joint venture. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate to present value the cash flows. Balance at September&#160;30, 2022 includes $139 million recorded as a current liability for amounts expected to be paid within the next 12 months.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The payments of contingent consideration in 2022 relate to the Sanofi Pasteur MSD liabilities described above.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Fair Value Measurements</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the Company&#8217;s financial instruments, such as cash and cash equivalents, receivables and payables, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of loans payable and long-term debt (including current portion) at September&#160;30, 2022, was $25.9 billion compared with a carrying value of $30.4 billion and at December&#160;31, 2021, was $35.7 billion compared with a carrying value of $33.1 billion. Fair value was estimated using recent observable market prices and would be considered Level 2 in the fair value hierarchy. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, the Company monitors concentrations of credit risk associated with corporate and government issuers of securities and financial institutions with which it conducts business. Credit exposure limits are established to limit a concentration with any single issuer or institution. Cash and investments are placed in instruments that meet high credit quality standards as specified in the Company&#8217;s investment policy guidelines. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company&#8217;s accounts receivable arise from product sales in the U.S., Europe and China and are primarily due from drug wholesalers and retailers, hospitals and government agencies.&#160;The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company also continues to monitor global economic conditions, including the volatility associated with international sovereign economies, and associated impacts on the financial markets and its business. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored $2.3 billion and $2.8 billion of accounts receivable as of September&#160;30, 2022 and December&#160;31, 2021, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Condensed Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions. As of September&#160;30, 2022 and December&#160;31, 2021, the Company had collected $55&#160;million and $62&#160;million, respectively, on behalf of the financial institutions, which is reflected as restricted cash in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the related obligation to remit the cash within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company remitted the cash to the financial institutions in October 2022 and January 2022, respectively. The net cash flows related to these collections are reported as financing activities in the Condensed Consolidated Statement of Cash Flows. The cost of factoring such accounts receivable was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de minimis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements. The master agreements with several of the Company&#8217;s financial institution counterparties also include credit support annexes. These annexes contain provisions that require collateral to be exchanged depending on the value of the derivative assets and liabilities, the Company&#8217;s credit rating, and the credit rating of the counterparty. Cash collateral received by the Company from various counterparties was $794 million and $164&#160;million at September&#160;30, 2022 and December&#160;31, 2021, respectively. The obligation to return such collateral is recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span>.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303303253968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">Inventories<div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,683&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,747&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total (approximates current cost)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,442&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,163&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease to LIFO cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(187)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,255&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,147&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,641&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,194&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are comprised almost entirely of raw materials and work in process inventories. At September&#160;30, 2022 and December&#160;31, 2021, these amounts included $2.2 billion and $1.9 billion, respectively, of inventories not expected to be sold within one year. In addition, these amounts included $417 million and $256 million at September&#160;30, 2022 and December&#160;31, 2021, respectively, of inventories produced in preparation for product launches.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303396614800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Intangibles<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Other Intangibles</a></td>
<td class="text">Other Intangibles<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2022, the Company recorded $887 million of impairment charges within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses related to intangible assets obtained in connection with the 2020 acquisition of ArQule, Inc. Of this amount, $807 million represents an in-process research and development (IPR&amp;D) impairment charge related to nemtabrutinib (MK-1026), a novel, oral BTK inhibitor currently being evaluated for the treatment of B-cell malignancies. Following discussions with regulatory authorities in the third quarter, the development period for nemtabrutinib was extended, which constituted a triggering event that required the evaluation of the nemtabrutinib intangible asset for impairment. The Company estimated the current fair value of nemtabrutinib utilizing an income approach which calculates the present value of projected future cash flows. The market participant assumptions used to derive the forecasted cash flows were updated to reflect a delay in the anticipated launch date for nemtabrutinib, which resulted in lower cumulative revenue forecasts and a reduction in the estimated fair value. The revised estimated fair value of nemtabrutinib when compared with its related carrying value resulted in the IPR&amp;D impairment charge noted above. The remaining IPR&amp;D intangible asset related to nemtabrutinib is $1.2 billion. If the assumptions used to estimate the fair value of nemtabrutinib prove to be incorrect and the development of nemtabrutinib does not progress as anticipated thereby adversely affecting projected future cash flows, the Company may record an additional impairment charge in the future and such charge could be material.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144471<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303385126240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Contingencies</a></td>
<td class="text">Contingencies<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property, and commercial litigation, as well as certain additional matters including governmental and environmental matters. In the opinion of the Company, it is unlikely that the resolution of these matters will be material to the Company&#8217;s financial condition, results of operations or cash flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the nature of the litigation discussed below and the complexities involved in these matters, the Company is unable to reasonably estimate a possible loss or range of possible loss for such matters until the Company knows, among other factors, (i)&#160;what claims, if any, will survive dispositive motion practice, (ii)&#160;the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii)&#160;how the discovery process will affect the litigation, (iv)&#160;the settlement posture of the other parties to the litigation and (v)&#160;any other factors that may have a material effect on the litigation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. For product liability claims, a portion of the overall accrual is actuarially determined and considers such factors as past experience, number of claims reported and estimates of claims incurred but not yet reported. Individually significant contingent losses are accrued when probable and reasonably estimable. Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such decisions are made. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability Litigation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fosamax</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, Merck is a defendant in product liability lawsuits in the U.S. involving Fosamax (alendronate sodium) (Fosamax Litigation). As of September&#160;30, 2022, approximately 3,450 cases are pending against Merck in either a federal multidistrict litigation (Femur Fracture MDL) or state court. Plaintiffs in the vast majority of these cases generally allege that they sustained femur fractures and/or other bone injuries (Femur Fractures) in association with the use of Fosamax.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2014, the Femur Fracture MDL court dismissed with prejudice approximately 650 cases on preemption grounds. Plaintiffs in approximately 515 of those cases appealed that decision to the U.S. Court of Appeals for the Third Circuit (Third Circuit). In March 2017, the Third Circuit issued a decision reversing the Femur Fracture MDL court&#8217;s preemption ruling and remanding the appealed cases back to the Femur Fracture MDL court. In May 2019, the U.S. Supreme Court decided that the Third Circuit had incorrectly concluded that the issue of preemption should be resolved by a jury, and accordingly vacated the judgment of the Third Circuit and remanded the proceedings back to the Third Circuit to address the issue in a manner consistent with the Supreme Court&#8217;s opinion. In November 2019, the Third Circuit remanded the cases back to the District Court in order to allow that court to determine in the first instance whether the plaintiffs&#8217; state law claims are preempted by federal law under the standards described by the Supreme Court in its opinion. On March 23, 2022, the District Court granted Merck&#8217;s motion and ruled that plaintiffs&#8217; failure to warn claims are preempted as a matter of law to the extent they </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assert that Merck should have added a warning or precaution regarding atypical femur fractures prior to September 2010. Plaintiffs have indicated that they do not intend to move forward with any other claims at this point and intend to appeal the District Court&#8217;s preemption ruling to the Third Circuit.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discovery is presently stayed in the Femur Fracture MDL. As part of the spin-off of Organon, Organon is required to indemnify Merck for all liabilities relating to, arising from, or resulting from the Fosamax Litigation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia/Janumet</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, Merck is a defendant in product liability lawsuits in the U.S. involving </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (sitagliptin) and/or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (sitagliptin and metformin HCl). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most claims were filed in multidistrict litigation before the U.S. District Court for the Southern District of California (MDL). In March 2021, the MDL court issued an omnibus order granting defendants&#8217; summary judgment motions based on preemption and failure to establish general causation, as well as granting defendants&#8217; motions to exclude plaintiffs&#8217; expert witnesses. The plaintiffs appealed that order. Since that time, more than half of these claims have been dismissed with prejudice as to Merck, and in October 2021, the U.S. Court of Appeals for the Ninth Circuit dismissed the appeal as to Merck and two of its codefendants. The MDL court&#8217;s judgment is now final and no longer appealable with respect to remaining claims.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside of the MDL, the majority of claims were filed in coordinated proceedings before the Superior Court of California, County of Los Angeles (California State Court). On April 6, 2021, the court in California issued an omnibus order granting defendants&#8217; summary judgment motions and also granting defendants&#8217; motions to exclude plaintiffs&#8217; expert witnesses. On May 31, 2022, the court entered judgment in favor of Merck as to all of the claims pending against Merck in that jurisdiction.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the claims noted above, the Company has agreed to toll the statute of limitations for approximately 50 additional claims. The Company intends to continue defending against any remaining lawsuits.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil/Gardasil 9</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck is a defendant in product liability lawsuits in the U.S. involving </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 9 (Human Papillomavirus 9-valent Vaccine, Recombinant). As of September&#160;30, 2022, approximately 65 cases were filed and pending against Merck in either federal or state court. In these actions, plaintiffs allege, among other things, that they suffered various personal injuries after vaccination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 9, with postural orthostatic tachycardia syndrome as a predominate alleged injury. In August 2022, the Judicial Panel on Multidistrict Litigation ordered that </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil/Gardasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 9 product liability cases pending in federal courts nationwide be transferred to Judge Robert J. Conrad in the Western District of North Carolina for coordinated pre-trial proceedings. There are fewer than 15 product liability cases pending outside the U.S., including one purported class action in Colombia.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governmental Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, from time to time, the Company&#8217;s subsidiaries in China receive inquiries regarding their operations from various Chinese governmental agencies. Some of these inquiries may be related to matters involving other multinational pharmaceutical companies, as well as Chinese entities doing business with such companies. The Company&#8217;s policy is to cooperate with these authorities and to provide responses as appropriate.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, from time to time, the Company receives inquiries and is the subject of preliminary investigation activities from competition and other governmental authorities in markets outside the U.S. These authorities may include regulators, administrative authorities, and law enforcement and other similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials, inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings. Should those proceedings be determined adversely to the Company, monetary fines and/or remedial undertakings may be required.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercial and Other Litigation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zetia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antitrust Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, Merck, MSD, Schering Corporation, Schering-Plough Corporation, and MSP Singapore Company LLC (collectively, the Merck Defendants) are defendants in a number of lawsuits filed in 2018 on behalf of direct and indirect purchasers of Zetia (ezetimibe) alleging violations of federal and state antitrust laws, as well as other state statutory and common law causes of action. The cases were consolidated in a federal multidistrict litigation (the Zetia MDL) before Judge Rebecca Beach Smith in the Eastern District of Virginia.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, the direct purchaser plaintiffs and the indirect purchaser plaintiffs filed motions for class certification. In August 2020, the district court granted in part the direct purchasers&#8217; motion for class certification and certified a class of 35 direct purchasers. In August 2021, the Fourth Circuit vacated the district court&#8217;s class certification order and remanded for further proceedings consistent with the court&#8217;s ruling. In September 2021, the direct purchaser plaintiffs filed a renewed motion for class certification. On January 25, 2022, the magistrate judge recommended that the district court deny the motion for class certification. On February 8, 2022, the direct purchaser plaintiffs filed objections to the recommendation. On April 13, 2022, the district court denied the direct purchaser plaintiffs&#8217; renewed motion for class certification. In August 2021, the district court granted certification of a class of indirect purchasers.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020 and 2021, United Healthcare Services, Inc., Humana Inc., Centene Corporation and others, and Kaiser Foundation Health Plan, Inc. (collectively, the Insurer Plaintiffs), each filed a lawsuit in a jurisdiction outside of the Eastern District of Virginia against the Merck Defendants and others, making similar allegations as those made in the Zetia MDL, as well as additional allegations about Vytorin. These cases have been transferred to the Eastern District of Virginia to proceed with the Zetia MDL.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 9, 2022, the Insurer Plaintiffs filed amended complaints. On March 2, 2022, the Merck Defendants, jointly with other defendants, moved to dismiss certain aspects of the Insurer Plaintiffs&#8217; complaints, including any claims for Vytorin damages. That motion to dismiss the Vytorin-related claims is still pending.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, the direct purchaser plaintiffs moved for an order setting a deadline for direct purchasers of Zetia not currently parties to the case to file cases against defendants in order for those cases to be coordinated for trial with the existing direct purchaser plaintiffs and other MDL plaintiff groups. The court granted that motion, setting a deadline of June 30, 2022 for unnamed direct purchasers to file claims. On June 30, 2022, 23 new entities, many related, brought new complaints against defendants or otherwise sought to intervene. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 2, 2022, the Magistrate Judge issued a Report and Recommendation denying the Merck Defendants&#8217; and Glenmark Defendants&#8217; motions for summary judgment. Defendants have objected to the Report and Recommendation, and are awaiting a final decision from Judge Smith. The court has scheduled trial for all plaintiffs other than the Insurer Plaintiffs for April 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">340B Program Litigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck has filed a complaint in the U.S. District Court for the District of Columbia to challenge the letter Merck received from the Health Resources and Services Administration (HRSA) in May 2022 regarding Merck&#8217;s 340B Program integrity initiative. HRSA&#8217;s letter to Merck asserts that Merck is in violation of the 340B statute. HRSA further claims that continued failure to provide the 340B price to covered entities using contract pharmacies may result in civil monetary penalties for each instance of alleged overcharging, in addition to repayment for any instance of overcharging. The letter is very similar to letters HRSA has sent to other manufacturers, which letters have been held to be unlawful by multiple federal courts. Merck disagrees with HRSA&#8217;s assertion. Merck remains committed to the 340B Program and to providing 340B discounts to eligible covered entities. Merck&#8217;s 340B Program integrity initiative is consistent with the requirements of the 340B statute and is intended to ensure the integrity and sustainability of the 340B statute by reducing prohibited duplicate discounts and diversion and putting patients back at the center of the program. Merck continues to offer all of the Company&#8217;s covered outpatient drugs to all 340B covered entities for purchase at or below the 340B ceiling price. On September 13, 2022, the court stayed the case pending the D.C. Circuit&#8217;s ruling in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Novartis Pharmaceuticals Corp. v. Johnson and United Therapeutics Corp. v. Johnson</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent Litigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, generic manufacturers of pharmaceutical products file abbreviated New Drug Applications (NDAs) with the FDA seeking to market generic forms of the Company&#8217;s products prior to the expiration of relevant patents owned by the Company. To protect its patent rights, the Company may file patent infringement lawsuits against such generic companies. Similar lawsuits defending the Company&#8217;s patent rights may exist in other countries. The Company intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. As with any litigation, there can be no assurance of the outcomes, which, if adverse, could result in significantly shortened periods of exclusivity for these products and, with respect to products acquired through acquisitions accounted for as business combinations, potentially significant intangible asset impairment charges.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, between January and November 2020, the Company received multiple Paragraph IV Certification Letters under the Hatch-Waxman Act notifying the Company that generic drug companies have filed applications to the FDA seeking pre-patent expiry approval to sell generic versions of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (sugammadex) Injection.&#160;In March, April and December 2020, the Company filed patent infringement lawsuits in the U.S. District Courts for the District of New Jersey and the Northern District of West Virginia against those generic companies.&#160;All actions in the District of New Jersey have been consolidated. These lawsuits, which assert one or more patents covering sugammadex and methods of using sugammadex, automatically stay FDA approval of the generic applications until June 2023 or until adverse court decisions, if </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any, whichever may occur earlier. The West Virginia case was jointly dismissed with prejudice on August 8, 2022 in favor of proceeding in New Jersey. The remaining defendants in the New Jersey action have stipulated to infringement of the asserted claims and have stated they are withdrawing all remaining claims and defenses other than a defense seeking to shorten the patent term extension of the sugammadex patent to December 2022. In light of this, the U.S. District Court for the District of New Jersey cancelled the scheduled trial and scheduled a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81NS9mcmFnOjNiNDE0ZjBmNjBmMDQwMzliNDRkNjY1ODhlODBiYTcyL3RleHRyZWdpb246M2I0MTRmMGY2MGYwNDAzOWI0NGQ2NjU4OGU4MGJhNzJfMTY0OTI2NzQ4NjEyNg_dc252ca0-1f84-47f5-aa4a-e30b0bbfb328">one</span>-day trial on December 19, 2022 on this remaining patent term extension calculation defense.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has settled with five generic companies providing that these generic companies can bring their generic versions of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the market in January 2026 (which may be delayed by any applicable pediatric exclusivity) or earlier under certain circumstances. The Company has agreed to stay the lawsuit filed against two generic companies, which in exchange agreed to be bound by a judgment on the merits of the consolidated action in the District of New Jersey. One of the generic companies in the consolidated action requested dismissal of the action against it and the Company did not oppose this request, which was subsequently granted by the court. The Company does not expect this company to bring its generic version of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the market before January 2026 or later, depending on any applicable pediatric exclusivity, unless the Company receives an adverse court decision.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia, Janumet, Janumet XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; As previously disclosed, the FDA has granted pediatric exclusivity with respect to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (sitagliptin and metformin HCl extended-release), which provides a further six months of exclusivity in the U.S. beyond the expiration of all patents listed in the FDA&#8217;s Orange Book. Adding this exclusivity to the term of the key patent protection extends exclusivity on these products to January 2023. However, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contain sitagliptin phosphate monohydrate and the Company has another patent covering certain phosphate salt and polymorphic forms of sitagliptin that expires in May 2027, including pediatric exclusivity (2027 salt/polymorph patent). In 2019, Par Pharmaceutical filed suit against the Company in the U.S. District Court for the District of New Jersey, seeking a declaratory judgment of invalidity of the 2027 salt/polymorph patent. In response, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Par Pharmaceutical and additional companies that also indicated an intent to market generic versions of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> following expiration of key patent protection, but prior to the expiration of the 2027 salt/polymorph patent, and a later granted patent owned by the Company covering the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> formulation where its term plus the pediatric exclusivity ends in 2029. The Company also filed a patent infringement lawsuit against Mylan in the Northern District of West Virginia. The Judicial Panel on Multidistrict Litigation entered an order transferring the Company&#8217;s lawsuit against Mylan to the U.S. District Court for the District of Delaware for coordinated and consolidated pretrial proceedings with the other cases pending in that district.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the beginning of the scheduled October 2021 trial in the U.S. District Court for the District of Delaware on invalidity issues, the Company settled with all defendants scheduled to participate in that trial. In the Company&#8217;s case against Mylan, a bench trial was held in December 2021 in the U.S. District Court for the Northern District of West Virginia, and the closing arguments were held on April 13, 2022. On September 21, 2022, the District Court for the Northern District of West Virginia issued a decision in the Company&#8217;s favor, upholding all asserted patent claims. Mylan (now Viatris) has appealed to the U.S. Court of Appeals for the Federal Circuit.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In total, the Company has settled with 22 generic companies providing that these generic companies can bring their generic versions of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the market in May 2026 or earlier under certain circumstances, and their generic versions of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the market in July 2026 or earlier under certain circumstances.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in 2019, Mylan filed a petition for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review (IPR) at the U.S. Patent and Trademark Office (USPTO) seeking invalidity of some, but not all, of the claims of the 2027 salt/polymorph patent. The USPTO instituted IPR proceedings in May 2020, finding a reasonable likelihood that the challenged claims are not valid. A trial was held in February 2021 and a final decision was rendered in May 2021, holding that all of the challenged claims were not invalid. Mylan appealed the USPTO&#8217;s decision to the U.S. Court of Appeals for the Federal Circuit, and a hearing was held on August 2, 2022. On September 29, 2022, the Court of Appeals for the Federal Circuit ruled in the Company&#8217;s favor, upholding the USPTO&#8217;s decision.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc., and Cadila Healthcare Ltd. (collectively, Zydus). In that lawsuit, the Company alleged infringement of the 2027 salt/polymorph patent based on the filing of Zydus&#8217;s application seeking approval of its sitagliptin tablets. While the U.S. District Court for the District of Delaware originally set a three-day bench trial in this matter beginning on October 31, 2022, the trial date has been moved to January 9, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generic companies have sought revocation of the Supplementary Protection Certificate (SPC) for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in a number of European countries. In February 2022, a Finnish court referred certain questions to the Court of Justice of the European Union that could determine the validity of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SPCs in Europe. In June 2021, a German court decided that the SPC for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is invalid, which decision the Company has appealed. The validity of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SPC was upheld in the Czech Republic in March 2022 in a first instance decision, which has been appealed. In June 2022, a Romanian court decided </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that the SPC for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was invalid in a first instance decision. In August 2022, the validity of the SPC for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was upheld in Sweden in a first instance decision, which decision has been appealed. MSD has filed injunction actions against generic companies in Belgium, Finland, France, Greece, Ireland and Portugal. In September 2022, the following decisions were issued: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex-parte</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> preliminary injunctions were granted in Finland; a preliminary injunction was granted in France, and the validity of the SPC and the associated patent were held to be </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">prima facie</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> valid in these proceedings; and a temporary restraining order was granted in Greece. In October 2022, requests for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex parte</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> preliminary injunctions were refused in Portugal.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Litigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are various other pending legal proceedings involving the Company, principally product liability and intellectual property lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of the Company, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to the Company&#8217;s financial condition, results of operations or cash flows either individually or in the aggregate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Defense Reserves</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by the Company; the development of the Company&#8217;s legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against the Company; the costs and outcomes of completed trials and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The amount of legal defense reserves as of September&#160;30, 2022 and December&#160;31, 2021 of approximately $230 million represents the Company&#8217;s best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by the Company. The Company will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303303358016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text">Equity<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:29.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.795%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-<br/>controlling<br/>Interests</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ and shares in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Par&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at July 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,039&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48,777&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,628)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,044&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56,682)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,388&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck&#160;&amp; Co., Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($0.65 per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,653)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,653)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock shares purchased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(583)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(583)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,149&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51,691&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,590)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,052&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(57,244)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,863&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at July 1, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,115&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,437&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,327)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,044&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56,770)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,318&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck&#160;&amp; Co., Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(416)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(416)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($0.69 per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,757)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,757)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,243&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59,928&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,743)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,044&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56,758)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,524&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.747%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.775%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-<br/>controlling<br/>Interests</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ and shares in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Par&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January&#160;1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,588&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47,362&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,634)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,047&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56,787)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,404&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck&#160;&amp; Co., Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,595&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,595&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($1.95 per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,962)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,962)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock shares purchased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(822)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(822)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spin-off of Organon &amp; Co.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,149&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51,691&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,590)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,052&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(57,244)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,863&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January&#160;1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,238&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,696&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,429)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,049&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(57,109)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,257&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck&#160;&amp; Co., Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(314)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(314)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($2.07 per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,270)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,270)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,243&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59,928&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,743)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,044&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56,758)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,524&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303303468272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Other Postretirement Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Pension and Other Postretirement Benefit Plans</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has defined benefit pension plans covering eligible employees in the U.S. and in certain of its international subsidiaries. The net periodic benefit cost of such plans (including certain costs reported as part of discontinued operations in the first nine months of 2021) consisted of the following components:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.096%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(576)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(292)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(568)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(313)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of unrecognized prior service credit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides medical benefits, principally to its eligible U.S. retirees and similar benefits to their dependents, through its other postretirement benefit plans. The net credit of such plans consisted of the following components:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.947%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of unrecognized prior service credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net periodic benefit cost (credit) for pension and other postretirement benefit plans in the first nine months of 2021 includes expenses for curtailments, settlements and termination benefits provided to certain employees in connection with the spin-off of Organon.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with restructuring actions (see Note&#160;5), termination charges were recorded on pension plans related to expanded eligibility for certain employees e</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iting Merck. Also, in connection with these restructuring activities, curtailments and settlements were recorded on certain pension plans. In addition, lump sum payments to U.S. pension plan participants triggered partial settlement charges in the third quarter and first nine months of 2022 and 2021. These partial settlements triggered remeasurements of some of the Company&#8217;s U.S. pension plans. The third quarter 2022 remeasurement, which was calculated using discount rates and asset values as of September 30, 2022, resulted in a net increase of $296&#160;million to net pension liabilities and also resulted in a related adjustment to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Remeasurements during the first nine months of 2022 have resulted in a net increase of $131&#160;million to net pension liabilities with related adjustments to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCL.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net periodic benefit cost (credit) other than the service cost component are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (see Note&#160;12), with the exception of certain amounts for termination benefits, curtailments and settlements, which are recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> if the event giving rise to the termination benefits, curtailment or settlement is related to restructuring actions or in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> if related to the spin-off of Organon (each as noted above).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303303229888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Income) Expense, Net<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock', window );">Other (Income) Expense, Net</a></td>
<td class="text">Other (Income) Expense, Net<div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (income) expense, net, consisted of:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss (income) from investments in equity securities, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(683)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,535)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic defined benefit plan (credit) cost other than service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(208)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(462)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(450)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,576&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,007)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest paid for the nine months ended September&#160;30, 2022 and 2021 was $660 million and $570 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -URI https://asc.fasb.org/topic&amp;trid=2122503<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 610<br> -URI https://asc.fasb.org/topic&amp;trid=49130413<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303303259488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Taxes on Income</a></td>
<td class="text">Taxes on Income<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective income tax rates from continuing operations were 9.2% and 13.2% for the third quarter of 2022 and 2021, respectively, and 11.0% and 14.4% for the first nine months of 2022 and 2021, respectively. The effective income tax rates from continuing operations reflect the beneficial impact of foreign earnings. The effective income tax rates from continuing operations in the third quarter and first nine months of 2022 also include the favorable impact of net unrealized losses from investments in equity securities and intangible asset impairment charges, which were taxed at the U.S. tax rate. The effective income tax rate from continuing operations in the first nine months of 2021 reflects the unfavorable effect of a charge for the acquisition of Pandion for which no tax benefit was recognized, as well as a net tax benefit of $207&#160;million related to the settlement of certain federal income tax matters as discussed below. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2021, the Internal Revenue Service (IRS) concluded its examinations of Merck&#8217;s 2015-2016 U.S. federal income tax returns. As a result, the Company was required to make a payment of $190&#160;million (of which $172&#160;million related to continuing operations and $18&#160;million related to discontinued operations). The Company&#8217;s reserves for unrecognized tax benefits for the years under examination exceeded the adjustments relating to this examination period and therefore the Company recorded a $236&#160;million net tax benefit in the first nine months of 2021 (of which $207&#160;million related to continuing operations and $29&#160;million related to discontinued operations). This net benefit reflects reductions in reserves for unrecognized tax benefits and other related liabilities for tax positions relating to the years that were under examination.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303303312144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text">Earnings Per Share<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculations of earnings per share are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.677%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ and shares in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income from Continuing Operations Attributable to Merck&#160;&amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,248&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,567&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,502&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,525&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income Attributable to Merck&#160;&amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,248&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,567&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,502&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,291&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,533&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,530&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,531&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,531&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares issuable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average common shares outstanding assuming dilution </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,542&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,536&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,540&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,539&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic Earnings per Common Share Attributable to Merck &amp; Co., Inc. Common Shareholders:</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Continuing Operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Discontinued Operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.28&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.81&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.55&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.67&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per Common Share Assuming Dilution Attributable to Merck &amp; Co., Inc. Common Shareholders:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Continuing Operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Discontinued Operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.28&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.80&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.53&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.66&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt">Issuable primarily under share-based compensation plans.</span></div>For the third quarter of 2022 and 2021, 2 million and 8 million, respectively, and for the first nine months of 2022 and 2021, 5 million and 10 million, respectively, of common shares issuable under share-based compensation plans were excluded from the computation of earnings per common share assuming dilution because the effect would have been antidilutive.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303303340128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Other Comprehensive Income (Loss)</a></td>
<td class="text">Other Comprehensive Income (Loss)<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in each component of other comprehensive income (loss) are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.531%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.870%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee<br/>Benefit<br/>Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign Currency<br/>Translation<br/>Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance July 1, 2021, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,028)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,574)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,628)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(96)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance September 30, 2021, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,990)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,658)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,590)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance July 1, 2022, net of taxes</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">390&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,465)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,252)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,327)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(294)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(618)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(230)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(143)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(232)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(568)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(261)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(254)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(177)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(155)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(186)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(568)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(416)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance September 30, 2022, net of taxes</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,651)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,820)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,743)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.531%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.870%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee<br/>Benefit<br/>Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign Currency<br/>Translation<br/>Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January 1, 2021, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(266)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,540)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,828)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,634)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(167)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(385)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(510)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,354&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(251)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,255&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">340&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,522&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(251)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,595&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spin-off of Organon (see Note&#160;2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance September 30, 2021, net of taxes</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,990)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,658)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,590)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January 1, 2022, net of taxes</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,743)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,830)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,429)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,001)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(259)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(223)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">974&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(990)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(493)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(227)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(390)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(198)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">584&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(990)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(314)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance September 30, 2022, net of taxes</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,651)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,820)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,743)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Primarily relates to foreign currency cash flow hedges that were reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes net amortization of prior service cost and actuarial gains and losses included in net periodic benefit cost (see Note&#160;11).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI https://asc.fasb.org/topic&amp;trid=2134417<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303305354816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text">Segment Reporting<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s operations are principally managed on a product basis and include two operating segments, which are the Pharmaceutical and Animal Health segments, both of which are reportable segments. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. A large component of pediatric and adolescent vaccine sales are made to the U.S.&#160;Centers for Disease Control and Prevention Vaccines for Children program, which is funded by the U.S. government. Additionally, the Company sells vaccines to the Federal government for placement into vaccine stockpiles.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors and animal producers.</span></div><div style="text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of the Company&#8217;s products were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.461%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.617%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pharmaceutical:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Keytruda</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,609&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue-Lynparza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue-Lenvima</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">660&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue-Reblozyl</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vaccines</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,803&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,624&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">ProQuad/M-M-R </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">II</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">/Varivax</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">RotaTeq</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">644&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Pneumovax </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Vaqta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hospital Acute Care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Bridion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">545&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Prevymis</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Dificid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Primaxin</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Noxafil</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Invanz</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Cancidas</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Zerbaxa</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue-Adempas/Verquvo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adempas</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Virology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Lagevrio</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,523&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Isentress/Isentress</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">HD</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Belsomra</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Simponi</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">619&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">619&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Remicade</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Januvia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">852&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Janumet</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,089&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,205&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,449&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other pharmaceutical </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">518&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">616&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,565&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">637&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Pharmaceutical segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,620&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,343&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,963&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,670&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,826&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11,496&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,119&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20,707&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39,826&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,611&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16,103&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30,714&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Animal Health:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Livestock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,965&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Companion Animals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">929&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,834&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Animal Health segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">896&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,371&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">951&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,417&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,425&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,894&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,320&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,363&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,944&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,307&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total segment sales</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,095&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,239&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,334&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,137&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,777&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,913&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20,544&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23,601&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44,146&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,974&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,047&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35,021&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">625&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">383&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">925&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,307&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,322&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,637&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,959&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,276&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,878&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,154&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20,927&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24,526&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">45,453&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16,166&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,017&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35,183&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">U</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">.S. plus international may not equal total due to rounding.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue for Lynparza and Lenvima represents Merck&#8217;s share of profits, which are product sales net of cost of sales and commercialization costs (see Note&#160;4).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue for Reblozyl represents royalties and, for the year-to-date period, a payment received related to the achievement of a regulatory milestone (see Note&#160;4).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue for Adempas/Verquvo represents Merck&#8217;s share of profits from sales in Bayer&#8217;s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note&#160;4).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(4)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(5)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Other is primarily comprised of miscellaneous corporate revenue, including revenue hedging activities, as well as revenue from third-party manufacturing arrangements (including sales to Organon). Other for the nine months ended September&#160;30, 2022 and 2021 also includes $156&#160;million and $191&#160;million, respectively, related to upfront and milestone payments received by Merck for out-licensing arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales are recorded net of the provision for discounts, including chargebacks, which are customer discounts that occur when a contracted customer purchases through an intermediary wholesale purchaser, and rebates that are owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part D) benefit providers, after the final dispensing of the product by a pharmacy to a benefit plan participant. These discounts, in the aggregate, reduced U.S. sales by $3.3 billion and $3.1 billion for the three months ended September&#160;30, 2022 and 2021, respectively, and $9.1&#160;billion for both the nine months ended September&#160;30, 2022 and 2021. </span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated sales by geographic area where derived are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.946%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,322&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,276&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,927&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,166&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,957&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,929&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific (other than China and Japan)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,782&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,631&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,959&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,154&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,453&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,183&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of segment profits to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from Continuing Operations Before Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is as follows:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.531%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical segment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,606&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Animal Health segment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment profits</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,105&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,111&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,935&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,079&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other profits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(244)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(727)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(597)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(460)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(360)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,623)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,231)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(448)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(358)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,257)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,031)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,277)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,312)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,374)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,775)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(288)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(487)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other unallocated, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,416)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(660)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,628)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,044)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,583&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,266&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,931&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,970&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as selling, general and administrative expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as selling, general and administrative expenses and research and development costs directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, research and development expenses incurred in Merck Research Laboratories, the Company&#8217;s research and development division that focuses on human health-related activities, or general and administrative expenses, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. In addition, costs related to restructuring activities, as well as the amortization of intangible assets and purchase accounting adjustments are not allocated to segments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other profits are primarily comprised of miscellaneous corporate profits, as well as operating profits related to third-party manufacturing arrangements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other unallocated, net, includes expenses from corporate and manufacturing cost centers, goodwill and other intangible asset impairment charges, gains or losses on sales of businesses, expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration, and other miscellaneous income or expense items.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303301458048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of PresentationThe accompanying unaudited condensed consolidated financial statements of Merck&#160;&amp; Co., Inc. (Merck or the Company) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the United States (U.S.) (GAAP) for complete consolidated financial statements are not included herein. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Merck&#8217;s Form 10-K filed on February&#160;25, 2022. The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company&#8217;s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Standards and Recently Issued Accounting Standards Not Yet Adopted</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Financial Accounting Standards Board (FASB) issued amended guidance on the accounting for convertible instruments and contracts in an entity&#8217;s own equity. The guidance removes the separation model for convertible debt instruments and preferred stock, amends requirements for conversion options to be classified in equity as well as amends diluted earnings per share (EPS) calculations for certain convertible debt instruments. The Company adopted the new guidance on January 1, 2022 using a modified retrospective approach. There was no impact to the Company&#8217;s consolidated financial statements upon adoption.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the FASB issued new guidance to increase the transparency of transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. The guidance requires annual disclosures of such transactions to include the nature of the transactions and the significant terms and conditions, the accounting treatment and the impact to a company&#8217;s financial statements. The Company adopted the new guidance on January 1, 2022 on a prospective basis. There was no material impact to the Company&#8217;s consolidated financial statements upon adoption.</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting and subsequently issued clarifying amendments. The guidance provides optional expedients and exceptions for accounting for contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (LIBOR) or another reference rate expected to be discontinued because of reference rate reform. The Company adopted the optional guidance on July 1, 2022 on a prospective basis. There was no material impact to the Company&#8217;s consolidated financial statements upon adoption. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Standards Not Yet Adopted</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued amended guidance that requires acquiring entities to recognize and measure contract assets and liabilities in a business combination in accordance with existing revenue recognition guidance. The amended guidance is effective for interim and annual periods in 2023 and is to be applied prospectively. Early adoption is permitted on a retrospective basis to the beginning of the fiscal year of adoption. The adoption of this guidance will not have an impact on the Company&#8217;s consolidated financial statements for prior acquisitions; however, the impact in future periods will be dependent upon the contract assets and contract liabilities acquired in future business combinations.</span></div>In June 2022, the FASB issued guidance related to the fair value measurement of an equity security subject to contractual restrictions that prohibit the sale of the equity security. The new guidance also introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. The amended guidance is effective for interim and annual periods in 2024 and is to be applied prospectively. Early adoption is permitted for both interim and annual periods. The Company is currently evaluating the impact of adoption on its consolidated financial statements.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalCostsPolicyTextBlock', window );">Legal Costs</a></td>
<td class="text">Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=27011672&amp;loc=d3e149975-122751<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303303468272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Spin-Off of Organon &amp; Co. (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Disposal Groups, Including Discontinued Operations</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.574%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,512&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs, Expenses and Other</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,755&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations before taxes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, net of taxes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">769&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Income of discontinued operations attributable to noncontrolling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Reflects amounts through the June 2, 2021 spin-off date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1474-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721677-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721659-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721671-107760<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721663-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303303406976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Arrangements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_CollaborativeArrangementsAbstract', window );"><strong>Collaborative Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Collaboration Arrangements</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:63.364%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.123%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.713%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Koselugo</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total alliance revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from AstraZeneca included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Trade accounts payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments. Amount in the first nine months of 2022 includes $250&#160;million of cumulative amortization catch-up expense as noted above.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued milestone payments.</span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.678%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from Eisai included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Eisai included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments.</span></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Amount as of December 31, 2021 includes accrued milestone payments.</span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.947%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Adempas/Verquvo</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales of Adempas recorded by Merck</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales of Verquvo recorded by Merck</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from Bayer included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Bayer included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Includes amortization of intangible assets. Amount in the first nine months of 2021 includes $153&#160;million of cumulative amortization catch-up expense. In addition, cost of sales includes Bayer&#8217;s share of profits from sales in Merck&#8217;s marketing territories.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Amount as of December 31, 2021 includes accrued milestone payment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.947%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> sales</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,859&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Ridgeback included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Includes royalty expense and amortization of capitalized milestone payments.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Includes accrued royalty and milestone payments.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_CollaborativeArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_CollaborativeArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303303302128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Charges Related to Restructuring Program Activities by Type of Cost</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the charges related to restructuring program activities by type of cost:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.953%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">630&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Charges and Spending Relating to Restructuring Activities by Program</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the charges and spending relating to restructuring program activities for the nine months ended September&#160;30, 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserves January&#160;1, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">596&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">637&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Payments) receipts, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(303)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(458)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(761)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserves September&#160;30, 2022 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)The remaining cash outlays are expected to be substantially completed by the end of 2023.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303298511632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Effect of Net Investment Hedges on OCI and the Consolidated Statement of Income</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effects of the Company&#8217;s net investment hedges on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the Consolidated Statement of Income are shown below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.366%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> for Amounts Excluded from Effectiveness Testing</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Relationships</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro-denominated notes</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(250)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(431)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(199)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> No amounts were reclassified from AOCL into income related to the sale of a subsidiary.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Amounts Recorded on Balance Sheet Related to Fair Value Hedges</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the location of amounts recorded in the Condensed Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.338%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.040%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Amount of Hedged Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Line Item in which Hedged Item is Included</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loans payable and current portion of long-term debt</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,263&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Fair Value of Derivatives on a Gross Basis Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.367%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.241%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair&#160;Value&#160;of&#160;Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.&#160;Dollar<br/>Notional</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair&#160;Value&#160;of&#160;Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.&#160;Dollar<br/>Notional</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Designated as Hedging Instruments</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNC0xLTEtMS0xMDUwNTY_4beacbd1-84ea-489f-8ac6-b09392c17877"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNC0xLTEtMS0xMDUwNTY_4c50954f-2f04-4bb2-9e7e-854b1813a13f">Other current assets</span></span></span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNS0xLTEtMS05NDQxNA_2a5d2377-4bbd-47ad-9925-404ca9a51736"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNS0xLTEtMS05NDQxNA_c6df00f3-bff8-4562-abe7-498764d34146">Other current assets</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNi0xLTEtMS05NDQxNA_6baf831a-4ac8-4464-8eb1-254345d36853"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNi0xLTEtMS05NDQxNA_95f68aac-d3b4-4319-9f3d-70e85b1424c4">Other Assets</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNy0xLTEtMS05NDQxNA_6a9babb4-e747-4df0-a56c-3595290d8927"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNy0xLTEtMS05NDQxNA_ae73e90d-8b40-4bfe-b1e5-b0c0132d4407">Accrued and other current liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfOC0xLTEtMS05NDQxNA_3d168174-838c-4aa7-834d-0305c0dea6db"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfOC0xLTEtMS05NDQxNA_8a78e2f6-5d79-40d5-8cfd-da850ad40e02">Other Noncurrent Liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">911&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,788&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTEtMS0xLTEtMTA1MTE3_0942da13-4366-4941-8d73-f86fd1003d65"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTEtMS0xLTEtMTA1MTE3_ed1a83b6-f315-4484-ba3e-ac3634db5ded">Other current assets</span></span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,523&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,073&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTItMS0xLTEtMTA1MTE5_35d04908-60bc-47a5-b559-4d800d70da91"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTItMS0xLTEtMTA1MTE5_f4049782-8c11-4ab1-9f60-0268bac9cd63">Accrued and other current liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,238&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,713&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,508&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,026&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,958&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock', window );">Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis</a></td>
<td class="text">The following table provides information on the Company&#8217;s derivative positions subject to these master <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:64.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.105%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross amounts recognized in the condensed consolidated balance sheet</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,508&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(217)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(217)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash collateral received</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(794)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(164)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net amounts</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">497&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Location and Amount of Pretax Gains and Losses of Derivatives</a></td>
<td class="text"><div style="margin-top:4pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides information regarding the location and amount of pretax gains and losses of derivatives designated in fair value or cash flow hedging relationships:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.636%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.907%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Financial Statement Line Items in which Effects of Fair Value or Cash Flow Hedges are Recorded</span></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other (income) expense, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other (income) expense, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">14,959&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">13,154&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(450)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(416)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">45,453&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">35,183&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,576&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1,007)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(314)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,595&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(Gain) loss on fair value hedging relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Hedged items</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Impact of cash flow hedging relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of gain recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Increase (decrease) in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> as a result of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">AOCL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> reclassifications</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(253)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">491&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(219)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(491)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTMtMC0xLTEtOTQ0MTQ_415ec0c9-4bba-4fb9-aa01-b4c7b84244a9"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTMtMC0xLTEtOTQ0MTQ_a2ea2169-dd57-478e-b872-7cc7be5bf76a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTMtMC0xLTEtOTQ0MTQ_c6f59e51-c8a0-4c45-930c-4ef2ed96eb20"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTMtMC0xLTEtOTQ0MTQ_ff915512-cf0d-456d-a25d-7aab715fc26c"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of gain recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></span></span></span></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of loss recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Interest expense is a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Income Statement Effects of Derivatives Not Designated as Hedging Instruments</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.362%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Derivative Pretax (Gain) Loss Recognized in Income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Income Statement Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates. Amount in the first nine months of 2021 includes a loss on forward exchange contracts entered into in conjunction with the spin-off of Organon.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> These derivative contracts serve as economic hedges of forecasted transactions.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Information on Investments in Debt and Equity Securities</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information on investments in debt and equity securities is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross&#160;Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross&#160;Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,334&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,647&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt and publicly traded equity securities</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,410&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Unrealized net losses of $221&#160;million and $415 million were recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> in the third quarter and first nine months of 2022, respectively, on equity securities still held at September&#160;30, 2022. Unrealized net (gains) losses of $(90) million and $109&#160;million were recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> in the third quarter and first nine months of 2021, respectively, on equity securities still held at September&#160;30, 2021.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities measured at fair value on a recurring basis are summarized below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.654%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,081&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,081&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,081&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,087&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,363&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,363&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivative assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased currency options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,508&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,508&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,404&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,514&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,918&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,731&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,282&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivative liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Written currency options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">898&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt"> Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company&#8217;s own credit risk, the effects of which were not significant.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Information About the Changes in Liabilities for Contingent Consideration</a></td>
<td class="text"><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information about the changes in the fair value of liabilities for contingent consideration associated with business combinations is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:80.424%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.846%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(156)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value September 30 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">  Recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cost of sales, Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> expenses, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">. Includes cumulative translation adjustments.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">At September&#160;30, 2022, $358 million of the liabilities relate to the 2016 termination of the Sanofi Pasteur MSD joint venture. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate to present value the cash flows. Balance at September&#160;30, 2022 includes $139 million recorded as a current liability for amounts expected to be paid within the next 12 months.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative positions subject to master netting arrangements as if they were presented on a net basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_OffsettingAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for fair value hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303303369936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventories</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,683&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,747&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total (approximates current cost)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,442&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,163&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease to LIFO cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(187)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,255&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,147&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,641&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,194&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303303340128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock', window );">Schedule of Equity</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:29.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.795%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-<br/>controlling<br/>Interests</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ and shares in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Par&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at July 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,039&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48,777&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,628)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,044&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56,682)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,388&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck&#160;&amp; Co., Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($0.65 per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,653)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,653)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock shares purchased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(583)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(583)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,149&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51,691&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,590)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,052&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(57,244)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,863&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at July 1, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,115&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,437&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,327)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,044&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56,770)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,318&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck&#160;&amp; Co., Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(416)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(416)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($0.69 per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,757)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,757)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,243&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59,928&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,743)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,044&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56,758)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,524&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.747%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.775%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-<br/>controlling<br/>Interests</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ and shares in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Par&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January&#160;1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,588&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47,362&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,634)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,047&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56,787)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,404&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck&#160;&amp; Co., Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,595&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,595&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($1.95 per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,962)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,962)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock shares purchased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(822)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(822)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spin-off of Organon &amp; Co.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,149&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51,691&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,590)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,052&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(57,244)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,863&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January&#160;1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,238&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,696&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,429)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,049&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(57,109)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,257&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck&#160;&amp; Co., Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(314)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(314)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($2.07 per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,270)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,270)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,243&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59,928&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,743)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,044&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56,758)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,524&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303301470784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Other Postretirement Benefit Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock', window );">Net Benefit Costs</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has defined benefit pension plans covering eligible employees in the U.S. and in certain of its international subsidiaries. The net periodic benefit cost of such plans (including certain costs reported as part of discontinued operations in the first nine months of 2021) consisted of the following components:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.096%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(576)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(292)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(568)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(313)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of unrecognized prior service credit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Postretirement Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock', window );">Net Benefit Costs</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides medical benefits, principally to its eligible U.S. retirees and similar benefits to their dependents, through its other postretirement benefit plans. The net credit of such plans consisted of the following components:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.947%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of unrecognized prior service credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetBenefitCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303302166800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Income) Expense, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Other (Income) Expense, Net</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (income) expense, net, consisted of:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss (income) from investments in equity securities, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(683)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,535)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic defined benefit plan (credit) cost other than service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(208)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(462)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(450)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,576&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,007)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)&#160;&#160;&#160;&#160;Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303303318304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Calculations of Earnings Per Share</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculations of earnings per share are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.677%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ and shares in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income from Continuing Operations Attributable to Merck&#160;&amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,248&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,567&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,502&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,525&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income Attributable to Merck&#160;&amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,248&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,567&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,502&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,291&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,533&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,530&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,531&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,531&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares issuable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average common shares outstanding assuming dilution </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,542&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,536&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,540&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,539&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic Earnings per Common Share Attributable to Merck &amp; Co., Inc. Common Shareholders:</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Continuing Operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Discontinued Operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.28&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.81&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.55&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.67&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per Common Share Assuming Dilution Attributable to Merck &amp; Co., Inc. Common Shareholders:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Continuing Operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Discontinued Operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.28&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.80&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.53&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.66&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt">Issuable primarily under share-based compensation plans.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303303365216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Changes in AOCI by Component</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in each component of other comprehensive income (loss) are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.531%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.870%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee<br/>Benefit<br/>Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign Currency<br/>Translation<br/>Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance July 1, 2021, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,028)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,574)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,628)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(96)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance September 30, 2021, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,990)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,658)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,590)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance July 1, 2022, net of taxes</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">390&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,465)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,252)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,327)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(294)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(618)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(230)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(143)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(232)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(568)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(261)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(254)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(177)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(155)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(186)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(568)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(416)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance September 30, 2022, net of taxes</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,651)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,820)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,743)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.531%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.870%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee<br/>Benefit<br/>Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign Currency<br/>Translation<br/>Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January 1, 2021, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(266)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,540)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,828)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,634)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(167)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(385)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(510)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,354&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(251)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,255&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">340&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,522&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(251)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,595&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spin-off of Organon (see Note&#160;2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance September 30, 2021, net of taxes</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,990)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,658)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,590)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January 1, 2022, net of taxes</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,743)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,830)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,429)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,001)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(259)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(223)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">974&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(990)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(493)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(227)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(390)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(198)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">584&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(990)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(314)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance September 30, 2022, net of taxes</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,651)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,820)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,743)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Primarily relates to foreign currency cash flow hedges that were reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes net amortization of prior service cost and actuarial gains and losses included in net periodic benefit cost (see Note&#160;11).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303303435936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Sales from Products</a></td>
<td class="text"><div style="text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of the Company&#8217;s products were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.461%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.617%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pharmaceutical:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Keytruda</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,609&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue-Lynparza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue-Lenvima</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">660&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue-Reblozyl</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vaccines</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,803&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,624&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">ProQuad/M-M-R </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">II</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">/Varivax</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">RotaTeq</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">644&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Pneumovax </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Vaqta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hospital Acute Care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Bridion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">545&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Prevymis</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Dificid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Primaxin</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Noxafil</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Invanz</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Cancidas</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Zerbaxa</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue-Adempas/Verquvo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adempas</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Virology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Lagevrio</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,523&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Isentress/Isentress</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">HD</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Belsomra</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Simponi</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">619&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">619&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Remicade</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Januvia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">852&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Janumet</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,089&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,205&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,449&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other pharmaceutical </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">518&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">616&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,565&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">637&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Pharmaceutical segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,620&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,343&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,963&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,670&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,826&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11,496&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,119&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20,707&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39,826&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,611&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16,103&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30,714&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Animal Health:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Livestock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,965&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Companion Animals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">929&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,834&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Animal Health segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">896&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,371&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">951&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,417&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,425&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,894&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,320&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,363&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,944&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,307&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total segment sales</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,095&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,239&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,334&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,137&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,777&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,913&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20,544&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23,601&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44,146&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,974&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,047&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35,021&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">625&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">383&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">925&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,307&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,322&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,637&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,959&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,276&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,878&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,154&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20,927&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24,526&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">45,453&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16,166&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,017&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35,183&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">U</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">.S. plus international may not equal total due to rounding.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue for Lynparza and Lenvima represents Merck&#8217;s share of profits, which are product sales net of cost of sales and commercialization costs (see Note&#160;4).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue for Reblozyl represents royalties and, for the year-to-date period, a payment received related to the achievement of a regulatory milestone (see Note&#160;4).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue for Adempas/Verquvo represents Merck&#8217;s share of profits from sales in Bayer&#8217;s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note&#160;4).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(4)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(5)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Other is primarily comprised of miscellaneous corporate revenue, including revenue hedging activities, as well as revenue from third-party manufacturing arrangements (including sales to Organon). Other for the nine months ended September&#160;30, 2022 and 2021 also includes $156&#160;million and $191&#160;million, respectively, related to upfront and milestone payments received by Merck for out-licensing arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock', window );">Consolidated Sales by Geographic Area</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated sales by geographic area where derived are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.946%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,322&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,276&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,927&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,166&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,957&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,929&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific (other than China and Japan)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,782&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,631&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,959&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,154&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,453&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,183&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Reconciliation of Segment Profits to Income before Taxes</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of segment profits to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from Continuing Operations Before Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is as follows:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.531%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical segment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,606&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Animal Health segment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment profits</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,105&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,111&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,935&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,079&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other profits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(244)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(727)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(597)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(460)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(360)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,623)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,231)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(448)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(358)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,257)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,031)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,277)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,312)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,374)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,775)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(288)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(487)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other unallocated, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,416)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(660)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,628)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,044)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,583&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,266&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,931&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,970&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303298408400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Spin-Off of Organon &amp; Co. - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 02, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Consideration received</a></td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense', window );">Disposal group, other expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_OrganonCoMember', window );">Organon &amp; Co.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock conversion ratio</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 293<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartiesAmountInCostOfSales', window );">Related party amount in cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">312<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Due from related parties, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 964<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related parties, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Transition services agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal', window );">Period of continuing involvement after disposal</a></td>
<td class="text">25 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Manufacturing and supply agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal', window );">Period of continuing involvement after disposal</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Transition services agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal', window );">Period of continuing involvement after disposal</a></td>
<td class="text">31 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Manufacturing and supply agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal', window );">Period of continuing involvement after disposal</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=mrk_OrganonCoMember', window );">Organon &amp; Co.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of debt</a></td>
<td class="nump">$ 9,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of expected continuing involvement with a discontinued operation after the disposal date, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartiesAmountInCostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount included in cost of sales related to transactions with related parties incurred and recorded in the statement of operations for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartiesAmountInCostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_OrganonCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_OrganonCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=mrk_TransitionServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=mrk_TransitionServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=mrk_ManufacturingAndSupplyAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=mrk_ManufacturingAndSupplyAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mrk_OrganonCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mrk_OrganonCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303305336496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Spin-Off of Organon &amp; Co. - Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract', window );"><strong>Costs, Expenses and Other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold', window );">Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">877<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts', window );">Restructuring costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet', window );">Other (income) expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense', window );">Operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,755<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax', window );">Income from discontinued operations before taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">757<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod', window );">Income tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Income from discontinued operations, net of taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest', window );">Less: Income of discontinued operations attributable to noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Income from discontinued operations, net of taxes and amounts attributable to noncontrolling interests</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 766<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Other Income (Expense), Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operations, Research and Development Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operations, Restructuring Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from operations classified as a discontinued operation. Excludes gain (loss) on disposal and provision for gain (loss) until its disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) attributable to income (loss) from operations classified as a discontinued operation. Excludes tax expense (benefit) for gain (loss) on disposal and for provision for gain (loss) until disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303295620240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Research Collaborations and License Agreements (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($) </div>
<div>research_program </div>
<div>collaboration_target</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,399.0<span></span>
</td>
<td class="nump">$ 2,445.0<span></span>
</td>
<td class="nump">$ 9,773.0<span></span>
</td>
<td class="nump">$ 9,177.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Compensation earned</a></td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts', window );">Additional funding by others, percentage of development costs</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding', window );">Additional funding by others, development costs subject to funding</a></td>
<td class="nump">$ 375.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=mrk_PandionTherapeuticsMember', window );">Pandion Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Consideration transferred, asset acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost', window );">Asset acquisition costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet', window );">Net assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 156.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrk_OrnaTherapeuticsMember', window );">Orna Therapeutics | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Amount paid for investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_OrnaTherapeuticsMember', window );">Orna Therapeutics | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_OrnaTherapeuticsMember', window );">Orna Therapeutics | Licensing Agreements | Development Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent milestone payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">440.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_OrnaTherapeuticsMember', window );">Orna Therapeutics | Licensing Agreements | Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent milestone payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">675.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_OrnaTherapeuticsMember', window );">Orna Therapeutics | Licensing Agreements | Sales-Based Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent milestone payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_OrionCorporationMember', window );">Orion Corporation | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 290.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember', window );">Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.0<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_MilestonePaymentsToBeMadeToACollaborativePartner', window );">Milestone payments to be made to a collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_MilestonePaymentToBeMadeToACollaborativePartner', window );">Milestone payment to be made to a collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartner', window );">Research and development payments to be made to a collaborative partner (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember', window );">Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Licensing Agreements | Development Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent milestone payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.0<span></span>
</td>
<td class="nump">90.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember', window );">Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Licensing Agreements | Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent milestone payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">334.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember', window );">Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Licensing Agreements | Sales-Based Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent milestone payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 485.0<span></span>
</td>
<td class="nump">780.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember', window );">Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Licensing Agreements | First Commercial Sale Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent milestone payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 290.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_ArtivaBiotherapeuticsIncMember', window );">Artiva Biotherapeutics, Inc. | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner', window );">Upfront and milestone payments to be made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_CollaborativeArrangementNumberOfResearchPrograms', window );">Number of research programs | research_program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_CollaborativeArrangementNumberOfCollaborationTargets', window );">Number of collaboration targets | collaboration_target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_ArtivaBiotherapeuticsIncMember', window );">Artiva Biotherapeutics, Inc. | Licensing Agreements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_RoyaltyRatePercentage', window );">Royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_ArtivaBiotherapeuticsIncMember', window );">Artiva Biotherapeutics, Inc. | Licensing Agreements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_RoyaltyRatePercentage', window );">Royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_ArtivaBiotherapeuticsIncMember', window );">Artiva Biotherapeutics, Inc. | Licensing Agreements | Development Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent milestone payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 217.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_ArtivaBiotherapeuticsIncMember', window );">Artiva Biotherapeutics, Inc. | Licensing Agreements | Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent milestone payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">570.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_ArtivaBiotherapeuticsIncMember', window );">Artiva Biotherapeutics, Inc. | Licensing Agreements | Sales-Based Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent milestone payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,050.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_COVID19Member', window );">COVID-19</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ChargesRelatedToProgramDiscontinuation', window );">Charges related to program discontinuation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 207.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Other Assets and Liabilities Recognized, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ChargesRelatedToProgramDiscontinuation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Charges related to program discontinuation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ChargesRelatedToProgramDiscontinuation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_CollaborativeArrangementNumberOfCollaborationTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Number Of Collaboration Targets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_CollaborativeArrangementNumberOfCollaborationTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_CollaborativeArrangementNumberOfResearchPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Number Of Research Programs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_CollaborativeArrangementNumberOfResearchPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ContingentPaymentsCollaborativeArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents payments that may be made in the future contingent upon the achievement of regulatory and/or sales milestones as part of a collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ContingentPaymentsCollaborativeArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_MilestonePaymentToBeMadeToACollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment to be Made to a Collaborative Partner</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_MilestonePaymentToBeMadeToACollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_MilestonePaymentsToBeMadeToACollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments to be Made to a Collaborative Partner</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_MilestonePaymentsToBeMadeToACollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Additional Funding By Others, Development Costs Subject To Funding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Additional Funding By Others, Percentage Of Development Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Payments to be Made to a Collaborative Partner</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_RoyaltyRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Rate, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_RoyaltyRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront and milestone payments made to partner as part of collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront and Milestone Payments to be Made to Collaborative Partner</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 55<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6829253&amp;loc=SL6831962-166255<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction cost incurred as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 55<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6829253&amp;loc=SL6831962-166255<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=mrk_PandionTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=mrk_PandionTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mrk_OrnaTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mrk_OrnaTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_OrnaTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_OrnaTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_DevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=mrk_DevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=mrk_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_SalesBasedMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=mrk_SalesBasedMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_OrionCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_OrionCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_FirstCommercialSaleMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=mrk_FirstCommercialSaleMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_ArtivaBiotherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_ArtivaBiotherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_COVID19Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_COVID19Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303295111824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Arrangements - Narrative (Details)<br> course in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>course</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>market </div>
<div>course</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,623<span></span>
</td>
<td class="nump">$ 1,231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_SupplyCommitmentMinimumNumberOfMarkets', window );">Number of markets (more than) | market</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_SupplyCommitmentRemainingMinimumCoursesCommitted', window );">Remaining minimum courses committed (in courses) | course</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,154<span></span>
</td>
<td class="nump">$ 45,453<span></span>
</td>
<td class="nump">35,183<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,913<span></span>
</td>
<td class="nump">44,146<span></span>
</td>
<td class="nump">35,021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,496<span></span>
</td>
<td class="nump">39,826<span></span>
</td>
<td class="nump">30,714<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_LynparzaMember', window );">Lynparza</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_LynparzaMember', window );">Lynparza | Other Noncurrent Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_LenvimaMember', window );">Lenvima | Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188<span></span>
</td>
<td class="nump">660<span></span>
</td>
<td class="nump">498<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_LenvimaMember', window );">Lenvima | Other Noncurrent Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_VerquvoMember', window );">Verquvo | Other Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_AdempasMember', window );">Adempas | Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="nump">181<span></span>
</td>
<td class="nump">188<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_AdempasMember', window );">Adempas | Other Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_AllianceRevenueReblozylMember', window );">Alliance Revenue - Reblozyl | Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">124<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_AstraZenecaMember', window );">AstraZeneca | Sales-Based Milestones | Lynparza</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ProbableContingentPaymentsCollaborativeArrangement', window );">Probable contingent payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_MilestonePaymentsAccruedSalesBased', window );">Milestone payments accrued but not yet paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_AstraZenecaMember', window );">AstraZeneca | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Lynparza</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_MilestonePaymentsSalesBased', window );">Sales-based milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_PotentialFutureMilestonePaymentsSalesBased', window );">Potential future sales-based milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_MilestonePaymentsMadetoCollaborativePartner', window );">Capitalized milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_PotentialFutureMilestonePaymentsRegulatory', window );">Potential future regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_Licenseoptionpaymentrelatedtocollaborativearrangement', window );">License option payment related to collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_EisaiMember', window );">Eisai | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Lenvima</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_MilestonePaymentsSalesBased', window );">Sales-based milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_PotentialFutureMilestonePaymentsSalesBased', window );">Potential future sales-based milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_MilestonePaymentsMadetoCollaborativePartner', window );">Capitalized milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_BayerAGMember', window );">Bayer AG | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_MilestonePaymentsSalesBased', window );">Sales-based milestone payments</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_BristolMyersSquibbMember', window );">Bristol Myers Squibb | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_RoyaltyRateDeductionPercentage', window );">Royalty rate, deduction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyIncomeNonoperating', window );">Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_BristolMyersSquibbMember', window );">Bristol Myers Squibb | Licensing Agreements | Sales-Based Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent milestone payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_BristolMyersSquibbMember', window );">Bristol Myers Squibb | Licensing Agreements | Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent milestone payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_BristolMyersSquibbMember', window );">Bristol Myers Squibb | Licensing Agreements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_RoyaltyRatePercentage', window );">Royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_BristolMyersSquibbMember', window );">Bristol Myers Squibb | Licensing Agreements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_RoyaltyRatePercentage', window );">Royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ContingentPaymentsCollaborativeArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents payments that may be made in the future contingent upon the achievement of regulatory and/or sales milestones as part of a collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ContingentPaymentsCollaborativeArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_Licenseoptionpaymentrelatedtocollaborativearrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License option payment related to collaborative arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_Licenseoptionpaymentrelatedtocollaborativearrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_MilestonePaymentsAccruedSalesBased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments Accrued Sales Based</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_MilestonePaymentsAccruedSalesBased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_MilestonePaymentsMadetoCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments Made to Collaborative Partner</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_MilestonePaymentsMadetoCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_MilestonePaymentsSalesBased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments Sales-Based</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_MilestonePaymentsSalesBased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_PotentialFutureMilestonePaymentsRegulatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Future Milestone Payments Regulatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_PotentialFutureMilestonePaymentsRegulatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_PotentialFutureMilestonePaymentsSalesBased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Future Milestone Payments Sales-Based</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_PotentialFutureMilestonePaymentsSalesBased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ProbableContingentPaymentsCollaborativeArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Probable Contingent Payments Collaborative Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ProbableContingentPaymentsCollaborativeArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_RoyaltyRateDeductionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Rate, Deduction, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_RoyaltyRateDeductionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_RoyaltyRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Rate, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_RoyaltyRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_SupplyCommitmentMinimumNumberOfMarkets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supply Commitment, Minimum, Number of Markets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_SupplyCommitmentMinimumNumberOfMarkets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_SupplyCommitmentRemainingMinimumCoursesCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supply Commitment, Remaining Minimum Courses Committed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_SupplyCommitmentRemainingMinimumCoursesCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_LynparzaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_LynparzaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_LenvimaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_LenvimaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_VerquvoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_VerquvoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_AdempasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_AdempasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_AllianceRevenueReblozylMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_AllianceRevenueReblozylMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_AstraZenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_AstraZenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mrk_SalesBasedMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mrk_SalesBasedMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_BayerAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_BayerAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_BristolMyersSquibbMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_BristolMyersSquibbMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_SalesBasedMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=mrk_SalesBasedMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=mrk_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303294707536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Arrangements - Financial Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">$ 14,959<span></span>
</td>
<td class="nump">$ 13,154<span></span>
</td>
<td class="nump">$ 45,453<span></span>
</td>
<td class="nump">$ 35,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">3,934<span></span>
</td>
<td class="nump">3,450<span></span>
</td>
<td class="nump">13,530<span></span>
</td>
<td class="nump">9,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">2,520<span></span>
</td>
<td class="nump">2,336<span></span>
</td>
<td class="nump">7,355<span></span>
</td>
<td class="nump">6,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">4,399<span></span>
</td>
<td class="nump">2,445<span></span>
</td>
<td class="nump">9,773<span></span>
</td>
<td class="nump">9,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Payables included in Accrued and other liabilities</a></td>
<td class="nump">22,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,872<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | AstraZeneca | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables included in Other current assets</a></td>
<td class="nump">290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Eisai | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables included in Other current assets</a></td>
<td class="nump">202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Bayer AG | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables included in Other current assets</a></td>
<td class="nump">144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember', window );">Accounts Payable and Accrued Liabilities | AstraZeneca | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Payables included in Accrued and other liabilities</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">415<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember', window );">Accounts Payable and Accrued Liabilities | Eisai | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Payables included in Accrued and other liabilities</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">625<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember', window );">Accounts Payable and Accrued Liabilities | Bayer AG | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Payables included in Accrued and other liabilities</a></td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">472<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember', window );">Accounts Payable and Accrued Liabilities | Ridgeback Biotherapeutics LP | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Payables included in Accrued and other liabilities</a></td>
<td class="nump">193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">283<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities | AstraZeneca | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Payables included in Other Noncurrent Liabilities</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Revenue | AstraZeneca | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_CollaborativeArrangementProfitSharing', window );">Alliance revenue - profit sharing</a></td>
<td class="nump">294<span></span>
</td>
<td class="nump">252<span></span>
</td>
<td class="nump">868<span></span>
</td>
<td class="nump">741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Revenue | AstraZeneca | Collaborative Arrangement | Alliance revenue - Lynparza</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_CollaborativeArrangementProfitSharing', window );">Alliance revenue - profit sharing</a></td>
<td class="nump">284<span></span>
</td>
<td class="nump">246<span></span>
</td>
<td class="nump">825<span></span>
</td>
<td class="nump">721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Revenue | AstraZeneca | Collaborative Arrangement | Alliance revenue - Koselugo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_CollaborativeArrangementProfitSharing', window );">Alliance revenue - profit sharing</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Revenue | Eisai | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_CollaborativeArrangementProfitSharing', window );">Alliance revenue - profit sharing</a></td>
<td class="nump">202<span></span>
</td>
<td class="nump">188<span></span>
</td>
<td class="nump">660<span></span>
</td>
<td class="nump">498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Revenue | Bayer AG | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_CollaborativeArrangementProfitSharing', window );">Alliance revenue - profit sharing</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">258<span></span>
</td>
<td class="nump">248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">151<span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="nump">454<span></span>
</td>
<td class="nump">439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Revenue | Bayer AG | Collaborative Arrangement | Adempas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_CollaborativeArrangementSalesNet', window );">Net sales by Merck</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="nump">181<span></span>
</td>
<td class="nump">188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Revenue | Bayer AG | Collaborative Arrangement | Verquvo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_CollaborativeArrangementSalesNet', window );">Net sales by Merck</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Revenue | Ridgeback Biotherapeutics LP | Collaborative Arrangement | Lagevrio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">436<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,859<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales | AstraZeneca | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="nump">425<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales | Eisai | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="nump">159<span></span>
</td>
<td class="nump">143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales | Bayer AG | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="nump">158<span></span>
</td>
<td class="nump">328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales | Ridgeback Biotherapeutics LP | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">234<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">2,580<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | AstraZeneca | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Eisai | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="nump">115<span></span>
</td>
<td class="nump">88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Bayer AG | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">107<span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Ridgeback Biotherapeutics LP | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | AstraZeneca | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="nump">87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Eisai | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="nump">128<span></span>
</td>
<td class="nump">165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Bayer AG | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Ridgeback Biotherapeutics LP | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 58<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">$ 167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_CollaborativeArrangementProfitSharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Profit Sharing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_CollaborativeArrangementProfitSharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_CollaborativeArrangementSalesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Sales, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_CollaborativeArrangementSalesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_AstraZenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_AstraZenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_BayerAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_BayerAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_RidgebackBiotherapeuticsLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_RidgebackBiotherapeuticsLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_AlliancerevenueLynparzaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_AlliancerevenueLynparzaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_AllianceRevenueKoselugoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_AllianceRevenueKoselugoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_AdempasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_AdempasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_VerquvoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_VerquvoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_LagevrioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_LagevrioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303301576608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Expected restructuring and related cost</a></td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays', window );">Estimate of cumulative pre tax costs that will result in cash outlays</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash', window );">Estimate of cumulative pre tax costs that will be noncash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">$ 168<span></span>
</td>
<td class="nump">$ 559<span></span>
</td>
<td class="nump">$ 630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Cumulative costs since program inception</a></td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Expected restructuring and related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimate of cumulative pre tax costs that will be noncash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimate of cumulative pre tax costs that will result in cash outlays (primarily from employee separation expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of costs incurred to date for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostCostIncurredToDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostIncurredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostIncurredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303301891568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Charges Activities by Type of Cost (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">$ 175<span></span>
</td>
<td class="nump">$ 168<span></span>
</td>
<td class="nump">$ 559<span></span>
</td>
<td class="nump">$ 630<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember', window );">Separation Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">197<span></span>
</td>
<td class="nump">310<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=mrk_AcceleratedDepreciationMember', window );">Accelerated Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">129<span></span>
</td>
<td class="nump">265<span></span>
</td>
<td class="nump">260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="nump">167<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales | Separation Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales | Accelerated Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Separation Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Accelerated Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Separation Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Accelerated Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember', window );">Restructuring costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">107<span></span>
</td>
<td class="nump">288<span></span>
</td>
<td class="nump">487<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember', window );">Restructuring costs | Separation Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">197<span></span>
</td>
<td class="nump">310<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember', window );">Restructuring costs | Accelerated Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember', window );">Restructuring costs | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="nump">$ 91<span></span>
</td>
<td class="nump">$ 177<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostIncurredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostIncurredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=mrk_AcceleratedDepreciationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=mrk_AcceleratedDepreciationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303297964400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Activities by Program (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Expense</a></td>
<td class="nump">$ 175<span></span>
</td>
<td class="nump">$ 168<span></span>
</td>
<td class="nump">559<span></span>
</td>
<td class="nump">$ 630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">(Payments) receipts, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(761)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity', window );">Non-cash activity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, ending balance</a></td>
<td class="nump">521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember', window );">Separation Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Expense</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">197<span></span>
</td>
<td class="nump">310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">(Payments) receipts, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(303)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity', window );">Non-cash activity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, ending balance</a></td>
<td class="nump">490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=mrk_AcceleratedDepreciationMember', window );">Accelerated Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Expense</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">(Payments) receipts, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity', window );">Non-cash activity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(97)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Expense</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">$ 129<span></span>
</td>
<td class="nump">265<span></span>
</td>
<td class="nump">$ 260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">(Payments) receipts, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(458)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity', window );">Non-cash activity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, ending balance</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash activity affecting the restructuring reserve, including accelerated depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_RestructuringReserveIncreaseDecreaseNoncashActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostIncurredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostIncurredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=mrk_AcceleratedDepreciationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=mrk_AcceleratedDepreciationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303305098288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>interest_rate_swap</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>interest_rate_swap</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2022 </div>
<div>USD ($) </div>
<div>interest_rate_swap</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Total swap notional amount</a></td>
<td class="nump">$ 26,026,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,026,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,958,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Pretax net unrealized gains on derivatives maturing within next 12 months estimated to be reclassified from AOCI to sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">864,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity investments without readily determinable fair values</a></td>
<td class="nump">705,000,000<span></span>
</td>
<td class="nump">$ 578,000,000<span></span>
</td>
<td class="nump">705,000,000<span></span>
</td>
<td class="nump">$ 578,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount', window );">Unrealized gains recognized on investments in equity securities without readily determinable fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,000,000<span></span>
</td>
<td class="nump">104,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount', window );">Unrealized losses recognized on investments in equity securities without readily determinable fair values</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount', window );">Cumulative unrealized gains on investments</a></td>
<td class="nump">255,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">255,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount', window );">Cumulative unrealized losses on investments</a></td>
<td class="nump">19,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFVNINoncurrent', window );">Equity securities, noncurrent</a></td>
<td class="nump">655,000,000<span></span>
</td>
<td class="nump">1,200,000,000<span></span>
</td>
<td class="nump">655,000,000<span></span>
</td>
<td class="nump">1,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Loss (income) from investments in equity securities, net</a></td>
<td class="nump">371,000,000<span></span>
</td>
<td class="num">(683,000,000)<span></span>
</td>
<td class="nump">1,361,000,000<span></span>
</td>
<td class="num">(1,535,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of loans payable and long-term debt, including current portion</a></td>
<td class="nump">25,900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtLongtermAndShorttermCombinedAmount', window );">Debt, carrying amount</a></td>
<td class="nump">30,400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableSale', window );">Factored accounts receivable</a></td>
<td class="nump">2,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">55,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeCollateralObligationToReturnCash', window );">Cash collateral received from counterparties</a></td>
<td class="nump">794,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">794,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=mrk_A2.40NotesDue2022Member', window );">2.40% Notes Due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of debt</a></td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_EquityFundsMember', window );">Equity Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Loss (income) from investments in equity securities, net</a></td>
<td class="nump">141,000,000<span></span>
</td>
<td class="num">$ (391,000,000)<span></span>
</td>
<td class="nump">952,000,000<span></span>
</td>
<td class="num">$ (893,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 10,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A2.35NotesDue2022Member', window );">2.35% Notes Due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.35%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A2.40NotesDue2022Member', window );">2.40% Notes Due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfInterestRateDerivativesHeld', window );">Number of interest rate swaps held (in interest rate swaps) | interest_rate_swap</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap contracts | 2.35% Notes Due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Total swap notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap contracts | 2.40% Notes Due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Total swap notional amount</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives Designated as Hedging Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Total swap notional amount</a></td>
<td class="nump">8,788,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,788,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,245,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Derivatives Not Designated as Hedging Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Total swap notional amount</a></td>
<td class="nump">$ 17,238,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,238,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,713,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Derivatives Designated as Hedging Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAverageRemainingMaturity1', window );">Maximum average period of maturities of contracts in years (less than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Derivatives Not Designated as Hedging Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAverageRemainingMaturity1', window );">Maximum average period of maturities of contracts in years (less than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease from sale of accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919244-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtLongtermAndShorttermCombinedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate of total long-term debt, including current maturities and short-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtLongtermAndShorttermCombinedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAverageRemainingMaturity1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Average remaining period until maturity of the derivative contract, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAverageRemainingMaturity1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCollateralObligationToReturnCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226038-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41678-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCollateralObligationToReturnCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated value of gains (losses), net anticipated to be transferred in the future from accumulated other comprehensive income into earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80845-113994<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFVNINoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFVNINoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from downward price adjustment on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative loss from downward price adjustment on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain from upward price adjustment on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative gain from upward price adjustment on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfInterestRateDerivativesHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of interest rate derivative instruments held by the entity at the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfInterestRateDerivativesHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=mrk_A2.40NotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=mrk_A2.40NotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_EquityFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_EquityFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A2.35NotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A2.35NotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A2.40NotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A2.40NotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=mrk_A2.35NotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=mrk_A2.35NotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303304543664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Effect of Net Investment Hedges (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">$ (47)<span></span>
</td>
<td class="num">$ (27)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Other (income) expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax', window );">Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=mrk_EurodominatedNotesMember', window );">Euro-denominated notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</a></td>
<td class="num">(250)<span></span>
</td>
<td class="num">(77)<span></span>
</td>
<td class="num">(431)<span></span>
</td>
<td class="num">(199)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=mrk_EurodominatedNotesMember', window );">Euro-denominated notes | Other (income) expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax', window );">Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=mrk_EurodominatedNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=mrk_EurodominatedNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303307860208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Fair Value Hedges (Details) - Loans payable and current portion of long-term debt - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedge', window );">Carrying Amount of Hedged Liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease', window );">Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityFairValueHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability hedged in fair value hedging relationship.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityFairValueHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=mrk_LongTermDebtCurrentMaturitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=mrk_LongTermDebtCurrentMaturitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303294861152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Fair Value of Derivative, Asset</a></td>
<td class="nump">$ 1,508<span></span>
</td>
<td class="nump">$ 549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative, Liability</a></td>
<td class="nump">242<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S Dollar Notional Amount</a></td>
<td class="nump">26,026<span></span>
</td>
<td class="nump">32,958<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives Designated as Hedging Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Fair Value of Derivative, Asset</a></td>
<td class="nump">911<span></span>
</td>
<td class="nump">328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative, Liability</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S Dollar Notional Amount</a></td>
<td class="nump">8,788<span></span>
</td>
<td class="nump">12,245<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Derivatives Not Designated as Hedging Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Fair Value of Derivative, Asset</a></td>
<td class="nump">597<span></span>
</td>
<td class="nump">221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative, Liability</a></td>
<td class="nump">240<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S Dollar Notional Amount</a></td>
<td class="nump">17,238<span></span>
</td>
<td class="nump">20,713<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest Rate Contract | Derivatives Designated as Hedging Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Fair Value of Derivative, Asset</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other current assets<span></span>
</td>
<td class="text">Other current assets<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest Rate Contract | Derivatives Designated as Hedging Instruments | Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S Dollar Notional Amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Fair Value of Derivative, Asset</a></td>
<td class="nump">$ 826<span></span>
</td>
<td class="nump">$ 271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other current assets<span></span>
</td>
<td class="text">Other current assets<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S Dollar Notional Amount</a></td>
<td class="nump">$ 7,250<span></span>
</td>
<td class="nump">$ 6,778<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Fair Value of Derivative, Asset</a></td>
<td class="nump">$ 85<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other Assets<span></span>
</td>
<td class="text">Other Assets<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S Dollar Notional Amount</a></td>
<td class="nump">$ 1,408<span></span>
</td>
<td class="nump">$ 1,551<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Accrued and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative, Liability</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Accrued and other current liabilities<span></span>
</td>
<td class="text">Accrued and other current liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S Dollar Notional Amount</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 1,623<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Other Noncurrent Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative, Liability</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other Noncurrent Liabilities<span></span>
</td>
<td class="text">Other Noncurrent Liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S Dollar Notional Amount</a></td>
<td class="nump">$ 93<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Derivatives Not Designated as Hedging Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Fair Value of Derivative, Asset</a></td>
<td class="nump">$ 597<span></span>
</td>
<td class="nump">$ 221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other current assets<span></span>
</td>
<td class="text">Other current assets<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative, Liability</a></td>
<td class="nump">$ 240<span></span>
</td>
<td class="nump">$ 96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Accrued and other current liabilities<span></span>
</td>
<td class="text">Accrued and other current liabilities<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Derivatives Not Designated as Hedging Instruments | Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S Dollar Notional Amount</a></td>
<td class="nump">$ 9,523<span></span>
</td>
<td class="nump">$ 10,073<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Derivatives Not Designated as Hedging Instruments | Accrued and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S Dollar Notional Amount</a></td>
<td class="nump">$ 7,715<span></span>
</td>
<td class="nump">$ 10,640<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes derivative asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=mrk_DeferredIncomeTaxesAndOtherAssetsCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=mrk_DeferredIncomeTaxesAndOtherAssetsCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303295559056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Gross amounts recognized in the consolidated balance sheet, asset</a></td>
<td class="nump">$ 1,508<span></span>
</td>
<td class="nump">$ 549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction', window );">Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, asset</a></td>
<td class="num">(217)<span></span>
</td>
<td class="num">(110)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeCollateralObligationToReturnCash', window );">Cash collateral received, asset</a></td>
<td class="num">(794)<span></span>
</td>
<td class="num">(164)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection', window );">Net amounts, asset</a></td>
<td class="nump">497<span></span>
</td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Gross amounts recognized in the consolidated balance sheet, liability</a></td>
<td class="nump">242<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction', window );">Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, liability</a></td>
<td class="num">(217)<span></span>
</td>
<td class="num">(110)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeCollateralRightToReclaimCash', window );">Cash collateral received, liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection', window );">Net amounts, liability</a></td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after effects of master netting arrangements, deduction of assets not subject to a master netting arrangement and elected not to be offset, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against an obligation to return collateral.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset, subject to master netting arrangement or similar agreement and not elected or qualified to offset, deducted from derivative asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCollateralObligationToReturnCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226038-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41678-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCollateralObligationToReturnCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCollateralRightToReclaimCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of right to receive cash collateral under master netting arrangements that have not been offset against derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226038-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41678-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCollateralRightToReclaimCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after effects of master netting arrangements, deduction of liabilities not subject to a master netting arrangement and elected not to be offset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against the right to receive collateral.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset, subject to master netting arrangement or similar agreement and not elected or qualified to offset, deducted from derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303298534944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Location and Amount of Pretax (Gains) Losses of Derivatives (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">$ 14,959<span></span>
</td>
<td class="nump">$ 13,154<span></span>
</td>
<td class="nump">$ 45,453<span></span>
</td>
<td class="nump">$ 35,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="nump">429<span></span>
</td>
<td class="num">(450)<span></span>
</td>
<td class="nump">1,576<span></span>
</td>
<td class="num">(1,007)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">$ (416)<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="num">$ (314)<span></span>
</td>
<td class="nump">$ 1,595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Other (income) expense, net<span></span>
</td>
<td class="text">Other (income) expense, net<span></span>
</td>
<td class="text">Other (income) expense, net<span></span>
</td>
<td class="text">Other (income) expense, net<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Amount of gain (loss) recognized in OCI on derivatives</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Amount of gain recognized in Other (income) expense, net on derivatives</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap contracts | Other (income) expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1', window );">Hedged items</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1', window );">Derivatives designated as hedging instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Amount of gain (loss) recognized in OCI on derivatives</a></td>
<td class="nump">682<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="nump">1,233<span></span>
</td>
<td class="nump">193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Increase (decrease) in Sales as a result of AOCL reclassifications</a></td>
<td class="num">(253)<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="num">(491)<span></span>
</td>
<td class="nump">219<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Reclassification out of Accumulated Other Comprehensive Income | Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">$ 253<span></span>
</td>
<td class="num">$ (36)<span></span>
</td>
<td class="nump">$ 491<span></span>
</td>
<td class="num">$ (219)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes gain (loss) from derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303307652064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember', window );">Currency Swap | Other (income) expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Amount of Derivative Pretax (Gain) Loss Recognized in Income</a></td>
<td class="num">$ (41)<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="num">$ (77)<span></span>
</td>
<td class="nump">$ 234<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeFutureMember', window );">Foreign Exchange Future | Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Amount of Derivative Pretax (Gain) Loss Recognized in Income</a></td>
<td class="num">$ (4)<span></span>
</td>
<td class="num">$ (4)<span></span>
</td>
<td class="num">$ (42)<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeFutureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeFutureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303295574512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Information on Available-for-sale Investments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, amortized cost</a></td>
<td class="nump">$ 76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, fair value</a></td>
<td class="nump">76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Publicly traded equity securities, fair value</a></td>
<td class="nump">1,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,647<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_DebtSecuritiesandEquitySecuritiesFVNI', window );">Total debt and publicly traded equity securities, fair value</a></td>
<td class="nump">1,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,733<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized net (gains) losses</a></td>
<td class="nump">221<span></span>
</td>
<td class="num">$ (90)<span></span>
</td>
<td class="nump">415<span></span>
</td>
<td class="nump">$ 109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, amortized cost</a></td>
<td class="nump">67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, fair value</a></td>
<td class="nump">67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, amortized cost</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, fair value</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate notes and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, amortized cost</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, fair value</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Foreign government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, amortized cost</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, fair value</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_DebtSecuritiesandEquitySecuritiesFVNI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities and Equity Securities, FV-NI</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_DebtSecuritiesandEquitySecuritiesFVNI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303296662784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">$ 76<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Publicly traded equity securities</a></td>
<td class="nump">1,334<span></span>
</td>
<td class="nump">1,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">1,508<span></span>
</td>
<td class="nump">549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">499<span></span>
</td>
<td class="nump">777<span></span>
</td>
<td class="nump">$ 902<span></span>
</td>
<td class="nump">$ 841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">242<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Foreign government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate notes and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Investments</a></td>
<td class="nump">1,087<span></span>
</td>
<td class="nump">370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">323<span></span>
</td>
<td class="nump">1,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">1,508<span></span>
</td>
<td class="nump">549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">2,918<span></span>
</td>
<td class="nump">2,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">499<span></span>
</td>
<td class="nump">777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">242<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">741<span></span>
</td>
<td class="nump">898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">945<span></span>
</td>
<td class="nump">351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">242<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Currency options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">563<span></span>
</td>
<td class="nump">184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Investments</a></td>
<td class="nump">1,081<span></span>
</td>
<td class="nump">368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">323<span></span>
</td>
<td class="nump">1,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">1,404<span></span>
</td>
<td class="nump">1,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Currency options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Investments</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">1,508<span></span>
</td>
<td class="nump">549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">1,514<span></span>
</td>
<td class="nump">551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">242<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">242<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">945<span></span>
</td>
<td class="nump">351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">242<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Currency options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">563<span></span>
</td>
<td class="nump">184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">499<span></span>
</td>
<td class="nump">777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">499<span></span>
</td>
<td class="nump">777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Currency options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Commercial paper | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Commercial paper | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Commercial paper | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Foreign government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Foreign government bonds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Foreign government bonds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Foreign government bonds | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Publicly traded equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Publicly traded equity securities</a></td>
<td class="nump">1,081<span></span>
</td>
<td class="nump">368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">253<span></span>
</td>
<td class="nump">1,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Publicly traded equity securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Publicly traded equity securities</a></td>
<td class="nump">1,081<span></span>
</td>
<td class="nump">368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">253<span></span>
</td>
<td class="nump">1,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Publicly traded equity securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Publicly traded equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Publicly traded equity securities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Publicly traded equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. government and agency securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. government and agency securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. government and agency securities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate notes and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate notes and bonds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate notes and bonds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate notes and bonds | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303304634016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, beginning balance</a></td>
<td class="nump">$ 777<span></span>
</td>
<td class="nump">$ 841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Changes in estimated fair value</a></td>
<td class="num">(156)<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="num">(119)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther', window );">Other</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, ending balance</a></td>
<td class="nump">499<span></span>
</td>
<td class="nump">902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">499<span></span>
</td>
<td class="nump">$ 902<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current liability</a></td>
<td class="nump">139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=mrk_SanofiPasteurMember', window );">Sanofi Pasteur</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, ending balance</a></td>
<td class="nump">358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">$ 358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration, measurement input, discount rate</a></td>
<td class="nump">0.115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Other</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=mrk_SanofiPasteurMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=mrk_SanofiPasteurMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303295562256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories - Schedule of Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">$ 1,683<span></span>
</td>
<td class="nump">$ 1,747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessAndRawMaterials', window );">Raw materials and work in process</a></td>
<td class="nump">6,532<span></span>
</td>
<td class="nump">6,220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInventorySupplies', window );">Supplies</a></td>
<td class="nump">227<span></span>
</td>
<td class="nump">196<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total (approximates current cost)</a></td>
<td class="nump">8,442<span></span>
</td>
<td class="nump">8,163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLIFOReserve', window );">Decrease to LIFO cost</a></td>
<td class="num">(187)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_InventoryNetAndInventoryNoncurrent', window );">Total current and noncurrent inventories</a></td>
<td class="nump">8,255<span></span>
</td>
<td class="nump">8,147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_RecognizedAsAbstract', window );"><strong>Recognized as:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">5,614<span></span>
</td>
<td class="nump">5,953<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Other assets</a></td>
<td class="nump">$ 2,641<span></span>
</td>
<td class="nump">$ 2,194<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_InventoryNetAndInventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of current and noncurrent inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_InventoryNetAndInventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_RecognizedAsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recognized as.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_RecognizedAsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLIFOReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which inventory stated at last-in first-out (LIFO) is less than (in excess of) inventory stated at other inventory cost methods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLIFOReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessAndRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate carrying amount as of the balance sheet date of items held by the entity which are partially completed at the time of measurement and unprocessed items that will go through the production process and become part of the final product. Includes supplies used directly or indirectly in the manufacturing or production process. This element may be used when the reporting entity combines work in process and raw materials into an aggregate amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessAndRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInventorySupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of other supplies used within the manufacturing or production process expected to be consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInventorySupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303298527712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventories classified in Other assets</a></td>
<td class="nump">$ 2,641<span></span>
</td>
<td class="nump">$ 2,194<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=mrk_InventoryNotExpectedtobeSoldWithinOneYearMember', window );">Inventories Not Expected to be Sold Within One Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventories classified in Other assets</a></td>
<td class="nump">2,200<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=mrk_InventoriesProducedinPreparationforProductLaunchesMember', window );">Inventories Produced in Preparation for Product Launches</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventories classified in Other assets</a></td>
<td class="nump">$ 417<span></span>
</td>
<td class="nump">$ 256<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=mrk_InventoryNotExpectedtobeSoldWithinOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=mrk_InventoryNotExpectedtobeSoldWithinOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=mrk_InventoriesProducedinPreparationforProductLaunchesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=mrk_InventoriesProducedinPreparationforProductLaunchesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303294960544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Intangibles (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets</a></td>
<td class="nump">$ 21,368<span></span>
</td>
<td class="nump">$ 22,933<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment charge</a></td>
<td class="nump">887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_NemtabrutinibMember', window );">nemtabrutinib | In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment charge</a></td>
<td class="nump">807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets</a></td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_NemtabrutinibMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_NemtabrutinibMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303294794832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 09, 2023</div></th>
<th class="th"><div>Dec. 19, 2022</div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>claim</div>
</th>
<th class="th">
<div>Mar. 31, 2014 </div>
<div>case</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>case </div>
<div>claim</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>claim</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=mrk_LegalDefenseCostsMember', window );">Legal Defense Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationReserve', window );">Legal defense costs reserve | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230<span></span>
</td>
<td class="nump">$ 230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mrk_ZetiaantitrustlitigationMember', window );">Zetia antitrust litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Loss contingency, pending claims | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mrk_ZetiaantitrustlitigationMember', window );">Zetia antitrust litigation | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Loss contingency, new claims filed | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mrk_PatentInfringementLawsuitAgainstZydusWorldwideDMCCZydusPharmaceuticalsUSAIncAndCadilaHealthcareLtdMember', window );">Patent Infringement Lawsuit Against Zydus | Pending Litigation | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_LossContingencyRecoveryFromThirdPartyBenchTrialPeriod', window );">Loss contingency, recovery from third party, bench trial period</a></td>
<td class="text">3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_FosamaxMember', window );">Fosamax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Loss contingency, pending claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_FosamaxMember', window );">Fosamax | Femur Fracture Litigation | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyClaimsDismissedNumber', window );">Loss contingency, claims dismissed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_LossContingencyClaimsonAppealNumber', window );">Loss contingency, claims on appeal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_JanuviaMember', window );">Januvia | Cases Company Agreed To Toll Statute Of Limitations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Loss contingency, pending claims | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member', window );">Gardasil/Gardasil 9 | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Loss contingency, pending claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member', window );">Gardasil/Gardasil 9 | Non-US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Loss contingency, pending claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member', window );">Gardasil/Gardasil 9 | COLOMBIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Loss contingency, pending claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_BridionMember', window );">Bridion | Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyClaimsSettledNumber', window );">Loss contingency, claims settled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_BridionMember', window );">Bridion | Patents | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Loss contingency, pending claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_BridionMember', window );">Bridion | Patents | Pending Litigation | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_LossContingencyTrialPeriod', window );">Loss contingency, trial period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_JanuviaAndJanumetMember', window );">Januvia and Janumet | Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyClaimsSettledNumber', window );">Loss contingency, claims settled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_LossContingencyClaimsonAppealNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Claims on Appeal, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_LossContingencyClaimsonAppealNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_LossContingencyRecoveryFromThirdPartyBenchTrialPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Recovery From Third Party, Bench Trial Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_LossContingencyRecoveryFromThirdPartyBenchTrialPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_LossContingencyTrialPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Trial Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_LossContingencyTrialPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyClaimsDismissedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of claims dismissed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyClaimsDismissedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyClaimsSettledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of claims settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyClaimsSettledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=mrk_LegalDefenseCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=mrk_LegalDefenseCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mrk_ZetiaantitrustlitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mrk_ZetiaantitrustlitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mrk_PatentInfringementLawsuitAgainstZydusWorldwideDMCCZydusPharmaceuticalsUSAIncAndCadilaHealthcareLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mrk_PatentInfringementLawsuitAgainstZydusWorldwideDMCCZydusPharmaceuticalsUSAIncAndCadilaHealthcareLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_FosamaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_FosamaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=mrk_FemurFractureLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=mrk_FemurFractureLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mrk_FederalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mrk_FederalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_JanuviaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_JanuviaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CO">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CO</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_BridionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_BridionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_JanuviaAndJanumetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_JanuviaAndJanumetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303295009152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Rollforward Reconciliations (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,577,103,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,049,499,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance</a></td>
<td class="nump">$ 43,318<span></span>
</td>
<td class="nump">$ 33,388<span></span>
</td>
<td class="nump">$ 38,257<span></span>
</td>
<td class="nump">$ 25,404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Merck&#160;&amp; Co., Inc.</a></td>
<td class="nump">3,248<span></span>
</td>
<td class="nump">4,567<span></span>
</td>
<td class="nump">11,502<span></span>
</td>
<td class="nump">9,291<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="num">(416)<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="num">(314)<span></span>
</td>
<td class="nump">1,595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends declared on common stock</a></td>
<td class="num">(1,757)<span></span>
</td>
<td class="num">(1,653)<span></span>
</td>
<td class="num">(5,270)<span></span>
</td>
<td class="num">(4,962)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury stock shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(583)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(822)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSpinoffTransaction', window );">Spin-off of Organon &amp; Co.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,091<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Share-based compensation plans and other</a></td>
<td class="nump">140<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="nump">356<span></span>
</td>
<td class="nump">283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to noncontrolling interests</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions attributable to noncontrolling interests</a></td>
<td class="num">$ (14)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="num">$ (13)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, ending balance (in shares)</a></td>
<td class="nump">3,577,103,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,577,103,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, ending balance (in shares)</a></td>
<td class="nump">1,043,697,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,043,697,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance</a></td>
<td class="nump">$ 44,524<span></span>
</td>
<td class="nump">$ 35,863<span></span>
</td>
<td class="nump">$ 44,524<span></span>
</td>
<td class="nump">$ 35,863<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Cash dividends declared on common stock (in dollars per share)</a></td>
<td class="nump">$ 0.69<span></span>
</td>
<td class="nump">$ 0.65<span></span>
</td>
<td class="nump">$ 2.07<span></span>
</td>
<td class="nump">$ 1.95<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">&#160;&#160; Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, beginning balance (in shares)</a></td>
<td class="nump">3,577,000,000<span></span>
</td>
<td class="nump">3,577,000,000<span></span>
</td>
<td class="nump">3,577,000,000<span></span>
</td>
<td class="nump">3,577,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance</a></td>
<td class="nump">$ 1,788<span></span>
</td>
<td class="nump">$ 1,788<span></span>
</td>
<td class="nump">$ 1,788<span></span>
</td>
<td class="nump">$ 1,788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, ending balance (in shares)</a></td>
<td class="nump">3,577,000,000<span></span>
</td>
<td class="nump">3,577,000,000<span></span>
</td>
<td class="nump">3,577,000,000<span></span>
</td>
<td class="nump">3,577,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance</a></td>
<td class="nump">$ 1,788<span></span>
</td>
<td class="nump">$ 1,788<span></span>
</td>
<td class="nump">$ 1,788<span></span>
</td>
<td class="nump">$ 1,788<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Other Paid-In Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance</a></td>
<td class="nump">44,115<span></span>
</td>
<td class="nump">44,039<span></span>
</td>
<td class="nump">44,238<span></span>
</td>
<td class="nump">39,588<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSpinoffTransaction', window );">Spin-off of Organon &amp; Co.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Share-based compensation plans and other</a></td>
<td class="nump">128<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="num">(82)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance</a></td>
<td class="nump">44,243<span></span>
</td>
<td class="nump">44,149<span></span>
</td>
<td class="nump">44,243<span></span>
</td>
<td class="nump">44,149<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance</a></td>
<td class="nump">58,437<span></span>
</td>
<td class="nump">48,777<span></span>
</td>
<td class="nump">53,696<span></span>
</td>
<td class="nump">47,362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Merck&#160;&amp; Co., Inc.</a></td>
<td class="nump">3,248<span></span>
</td>
<td class="nump">4,567<span></span>
</td>
<td class="nump">11,502<span></span>
</td>
<td class="nump">9,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends declared on common stock</a></td>
<td class="num">(1,757)<span></span>
</td>
<td class="num">(1,653)<span></span>
</td>
<td class="num">(5,270)<span></span>
</td>
<td class="num">(4,962)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance</a></td>
<td class="nump">59,928<span></span>
</td>
<td class="nump">51,691<span></span>
</td>
<td class="nump">59,928<span></span>
</td>
<td class="nump">51,691<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance</a></td>
<td class="num">(4,327)<span></span>
</td>
<td class="num">(4,628)<span></span>
</td>
<td class="num">(4,429)<span></span>
</td>
<td class="num">(6,634)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="num">(416)<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="num">(314)<span></span>
</td>
<td class="nump">1,595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSpinoffTransaction', window );">Spin-off of Organon &amp; Co.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">449<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance</a></td>
<td class="num">$ (4,743)<span></span>
</td>
<td class="num">$ (4,590)<span></span>
</td>
<td class="num">$ (4,743)<span></span>
</td>
<td class="num">$ (4,590)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember', window );">&#160; Treasury Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, beginning balance (in shares)</a></td>
<td class="nump">1,044,000,000<span></span>
</td>
<td class="nump">1,044,000,000<span></span>
</td>
<td class="nump">1,049,000,000<span></span>
</td>
<td class="nump">1,047,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance</a></td>
<td class="num">$ (56,770)<span></span>
</td>
<td class="num">$ (56,682)<span></span>
</td>
<td class="num">$ (57,109)<span></span>
</td>
<td class="num">$ (56,787)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury stock shares purchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury stock shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (583)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (822)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOtherShares', window );">Share-based compensation plans and other (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,000,000)<span></span>
</td>
<td class="num">(6,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Share-based compensation plans and other</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">$ 351<span></span>
</td>
<td class="nump">$ 365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, ending balance (in shares)</a></td>
<td class="nump">1,044,000,000<span></span>
</td>
<td class="nump">1,052,000,000<span></span>
</td>
<td class="nump">1,044,000,000<span></span>
</td>
<td class="nump">1,052,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance</a></td>
<td class="num">$ (56,758)<span></span>
</td>
<td class="num">$ (57,244)<span></span>
</td>
<td class="num">$ (56,758)<span></span>
</td>
<td class="num">$ (57,244)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember', window );">Non- controlling Interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSpinoffTransaction', window );">Spin-off of Organon &amp; Co.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to noncontrolling interests</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions attributable to noncontrolling interests</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance</a></td>
<td class="nump">$ 66<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteSpinoffTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The change in equity as a result of a spin-off transaction (a regular or reverse spin-off) which is based on the recorded amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 60<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6406278&amp;loc=d3e26268-112671<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteSpinoffTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOtherShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of increase (decrease) in shares of stock classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOtherShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303304989232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Other Postretirement Benefit Plans - Net Benefit Costs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Postretirement Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="num">(64)<span></span>
</td>
<td class="num">(59)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of unrecognized prior service credit</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Net loss amortization</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="num">(32)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod', window );">Termination benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments', window );">Curtailments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost</a></td>
<td class="num">(24)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="num">(69)<span></span>
</td>
<td class="num">(58)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">U.S. | Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="nump">289<span></span>
</td>
<td class="nump">302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">123<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="nump">330<span></span>
</td>
<td class="nump">305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(182)<span></span>
</td>
<td class="num">(188)<span></span>
</td>
<td class="num">(576)<span></span>
</td>
<td class="num">(568)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of unrecognized prior service credit</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Net loss amortization</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="nump">122<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod', window );">Termination benefits</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments', window );">Curtailments</a></td>
<td class="nump">3<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlements</a></td>
<td class="nump">79<span></span>
</td>
<td class="nump">139<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost</a></td>
<td class="nump">117<span></span>
</td>
<td class="nump">224<span></span>
</td>
<td class="nump">334<span></span>
</td>
<td class="nump">436<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="nump">213<span></span>
</td>
<td class="nump">254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(93)<span></span>
</td>
<td class="num">(105)<span></span>
</td>
<td class="num">(292)<span></span>
</td>
<td class="num">(313)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of unrecognized prior service credit</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Net loss amortization</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod', window );">Termination benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments', window );">Curtailments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost</a></td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">$ 95<span></span>
</td>
<td class="nump">$ 109<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost of providing special or contractual termination benefits payable from defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit from event reducing expected years of future service of present employees or eliminating accrual of defined benefits for some or all future services of present employees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(7)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(7)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(7)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(7)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303304714784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Other Postretirement Benefit Plans - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement', window );">Increase to pension liabilities due to remeasurement</a></td>
<td class="nump">$ 296<span></span>
</td>
<td class="nump">$ 131<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of (increase) decrease to benefit obligation of defined benefit plan from remeasurement due to settlement. Excludes decrease to benefit obligation for settlement payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(10)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303294982432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems', window );"><strong>Component of Other Income / Expense of Nonoperating [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="num">$ (40)<span></span>
</td>
<td class="num">$ (7)<span></span>
</td>
<td class="num">$ (62)<span></span>
</td>
<td class="num">$ (27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">244<span></span>
</td>
<td class="nump">196<span></span>
</td>
<td class="nump">727<span></span>
</td>
<td class="nump">597<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Exchange losses</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="nump">220<span></span>
</td>
<td class="nump">202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Loss (income) from investments in equity securities, net</a></td>
<td class="nump">371<span></span>
</td>
<td class="num">(683)<span></span>
</td>
<td class="nump">1,361<span></span>
</td>
<td class="num">(1,535)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent', window );">Net periodic defined benefit plan (credit) cost other than service cost</a></td>
<td class="num">(60)<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="num">(208)<span></span>
</td>
<td class="num">(159)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_OtherNonoperatingIncomeExpenseOther', window );">Other, net</a></td>
<td class="num">(182)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
<td class="num">(462)<span></span>
</td>
<td class="num">(85)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="nump">429<span></span>
</td>
<td class="num">(450)<span></span>
</td>
<td class="nump">1,576<span></span>
</td>
<td class="num">(1,007)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized net (gains) losses</a></td>
<td class="nump">$ 221<span></span>
</td>
<td class="num">$ (90)<span></span>
</td>
<td class="nump">$ 415<span></span>
</td>
<td class="nump">$ 109<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Component of Other Income / Expense of Nonoperating [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_OtherNonoperatingIncomeExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other nonoperating income and expense items not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_OtherNonoperatingIncomeExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for net periodic benefit cost components, excluding service cost component, of defined benefit plan. Amount includes, but is not limited to, interest cost, expected (return) loss on plan asset, amortization of prior service cost (credit), amortization of (gain) loss, amortization of transition (asset) obligation, settlement (gain) loss, curtailment (gain) loss and certain termination benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303304693552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Income) Expense, Net - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest paid</a></td>
<td class="nump">$ 660<span></span>
</td>
<td class="nump">$ 570<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303301583696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">9.20%<span></span>
</td>
<td class="nump">13.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">14.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition', window );">Tax benefit resulting from acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Internal Revenue Service (IRS) | Domestic Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Tax benefit recognized related to settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">236,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 190,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Internal Revenue Service (IRS) | Domestic Tax Authority | Continuing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Tax benefit recognized related to settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">207,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Internal Revenue Service (IRS) | Domestic Tax Authority | Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Tax benefit recognized related to settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303305341328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Calculations of Earnings Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net Income from Continuing Operations Attributable to Merck&#160;&amp; Co., Inc.</a></td>
<td class="nump">$ 3,248<span></span>
</td>
<td class="nump">$ 4,567<span></span>
</td>
<td class="nump">$ 11,502<span></span>
</td>
<td class="nump">$ 8,525<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">766<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income attributable to Merck &amp; Co., Inc., basic</a></td>
<td class="nump">3,248<span></span>
</td>
<td class="nump">4,567<span></span>
</td>
<td class="nump">11,502<span></span>
</td>
<td class="nump">9,291<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income attributable to Merck &amp; Co., Inc., diluted</a></td>
<td class="nump">$ 3,248<span></span>
</td>
<td class="nump">$ 4,567<span></span>
</td>
<td class="nump">$ 11,502<span></span>
</td>
<td class="nump">$ 9,291<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Average common shares outstanding (in shares)</a></td>
<td class="nump">2,533<span></span>
</td>
<td class="nump">2,530<span></span>
</td>
<td class="nump">2,531<span></span>
</td>
<td class="nump">2,531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Common shares issuable (in shares)</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Average common shares outstanding assuming dilution (in shares)</a></td>
<td class="nump">2,542<span></span>
</td>
<td class="nump">2,536<span></span>
</td>
<td class="nump">2,540<span></span>
</td>
<td class="nump">2,539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic Earnings per Common Share Attributable to Merck &amp; Co., Inc. Common Shareholders:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Income from Continuing Operations (in dollars per share)</a></td>
<td class="nump">$ 1.28<span></span>
</td>
<td class="nump">$ 1.81<span></span>
</td>
<td class="nump">$ 4.55<span></span>
</td>
<td class="nump">$ 3.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare', window );">Income from Discontinued Operations (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net Income (in dollars per share)</a></td>
<td class="nump">1.28<span></span>
</td>
<td class="nump">1.81<span></span>
</td>
<td class="nump">4.55<span></span>
</td>
<td class="nump">3.67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Earnings per Common Share Assuming Dilution Attributable to Merck &amp; Co., Inc. Common Shareholders:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Income from Continuing Operations (in dollars per share)</a></td>
<td class="nump">1.28<span></span>
</td>
<td class="nump">1.80<span></span>
</td>
<td class="nump">4.53<span></span>
</td>
<td class="nump">3.36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Income from Discontinued Operations (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net Income (in dollars per share)</a></td>
<td class="nump">$ 1.28<span></span>
</td>
<td class="nump">$ 1.80<span></span>
</td>
<td class="nump">$ 4.53<span></span>
</td>
<td class="nump">$ 3.66<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4613673-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303303638432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Narrative (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares (in shares)</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303301445840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance</a></td>
<td class="nump">$ 43,318<span></span>
</td>
<td class="nump">$ 33,388<span></span>
</td>
<td class="nump">$ 38,257<span></span>
</td>
<td class="nump">$ 25,404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassification adjustments, pretax</a></td>
<td class="num">(230)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="nump">107<span></span>
</td>
<td class="nump">1,765<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Tax</a></td>
<td class="num">(31)<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="num">(223)<span></span>
</td>
<td class="num">(510)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassification adjustments, net of taxes</a></td>
<td class="num">(261)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
<td class="num">(116)<span></span>
</td>
<td class="nump">1,255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Reclassification adjustments, pretax</a></td>
<td class="num">(177)<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="num">(227)<span></span>
</td>
<td class="nump">428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Tax</a></td>
<td class="nump">22<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="num">(88)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Reclassification adjustments, net of taxes</a></td>
<td class="num">(155)<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="num">(198)<span></span>
</td>
<td class="nump">340<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="num">(416)<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="num">(314)<span></span>
</td>
<td class="nump">1,595<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSpinoffTransaction', window );">Spin-off of Organon &amp; Co.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance</a></td>
<td class="nump">44,524<span></span>
</td>
<td class="nump">35,863<span></span>
</td>
<td class="nump">44,524<span></span>
</td>
<td class="nump">35,863<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance</a></td>
<td class="nump">390<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="nump">144<span></span>
</td>
<td class="num">(266)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassification adjustments, pretax</a></td>
<td class="nump">682<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="nump">1,233<span></span>
</td>
<td class="nump">193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Tax</a></td>
<td class="num">(143)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="num">(259)<span></span>
</td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassification adjustments, net of taxes</a></td>
<td class="nump">539<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="nump">974<span></span>
</td>
<td class="nump">152<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Reclassification adjustments, pretax</a></td>
<td class="num">(254)<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="num">(493)<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Tax</a></td>
<td class="nump">53<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="num">(46)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Reclassification adjustments, net of taxes</a></td>
<td class="num">(201)<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="num">(390)<span></span>
</td>
<td class="nump">172<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="nump">338<span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="nump">584<span></span>
</td>
<td class="nump">324<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSpinoffTransaction', window );">Spin-off of Organon &amp; Co.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance</a></td>
<td class="nump">728<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="nump">728<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Employee Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance</a></td>
<td class="num">(2,465)<span></span>
</td>
<td class="num">(3,028)<span></span>
</td>
<td class="num">(2,743)<span></span>
</td>
<td class="num">(4,540)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassification adjustments, pretax</a></td>
<td class="num">(294)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="num">(125)<span></span>
</td>
<td class="nump">1,739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Tax</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="num">(385)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassification adjustments, net of taxes</a></td>
<td class="num">(232)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="nump">1,354<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Reclassification adjustments, pretax</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="nump">266<span></span>
</td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Tax</a></td>
<td class="num">(31)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="num">(74)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Reclassification adjustments, net of taxes</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="nump">192<span></span>
</td>
<td class="nump">168<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="num">(186)<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="nump">1,522<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSpinoffTransaction', window );">Spin-off of Organon &amp; Co.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance</a></td>
<td class="num">(2,651)<span></span>
</td>
<td class="num">(2,990)<span></span>
</td>
<td class="num">(2,651)<span></span>
</td>
<td class="num">(2,990)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign Currency Translation Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance</a></td>
<td class="num">(2,252)<span></span>
</td>
<td class="num">(1,574)<span></span>
</td>
<td class="num">(1,830)<span></span>
</td>
<td class="num">(1,828)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassification adjustments, pretax</a></td>
<td class="num">(618)<span></span>
</td>
<td class="num">(96)<span></span>
</td>
<td class="num">(1,001)<span></span>
</td>
<td class="num">(167)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Tax</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="num">(84)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassification adjustments, net of taxes</a></td>
<td class="num">(568)<span></span>
</td>
<td class="num">(84)<span></span>
</td>
<td class="num">(990)<span></span>
</td>
<td class="num">(251)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Reclassification adjustments, pretax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Reclassification adjustments, net of taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="num">(568)<span></span>
</td>
<td class="num">(84)<span></span>
</td>
<td class="num">(990)<span></span>
</td>
<td class="num">(251)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSpinoffTransaction', window );">Spin-off of Organon &amp; Co.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance</a></td>
<td class="num">(2,820)<span></span>
</td>
<td class="num">(1,658)<span></span>
</td>
<td class="num">(2,820)<span></span>
</td>
<td class="num">(1,658)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance</a></td>
<td class="num">(4,327)<span></span>
</td>
<td class="num">(4,628)<span></span>
</td>
<td class="num">(4,429)<span></span>
</td>
<td class="num">(6,634)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSpinoffTransaction', window );">Spin-off of Organon &amp; Co.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">449<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance</a></td>
<td class="num">$ (4,743)<span></span>
</td>
<td class="num">$ (4,590)<span></span>
</td>
<td class="num">$ (4,743)<span></span>
</td>
<td class="num">$ (4,590)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AOCIAttributableToParentNetOfTaxRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss) before reclassification adjustment from accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteSpinoffTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The change in equity as a result of a spin-off transaction (a regular or reverse spin-off) which is based on the recorded amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 60<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6406278&amp;loc=d3e26268-112671<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteSpinoffTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303307852944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Narrative (Details)<br> $ in Billions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_SalesDiscounts', window );">Sales discounts | $</a></td>
<td class="nump">$ 3.3<span></span>
</td>
<td class="nump">$ 3.1<span></span>
</td>
<td class="nump">$ 9.1<span></span>
</td>
<td class="nump">$ 9.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_SalesDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales Discounts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_SalesDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303290389488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Sales from Products (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">$ 14,959<span></span>
</td>
<td class="nump">$ 13,154<span></span>
</td>
<td class="nump">$ 45,453<span></span>
</td>
<td class="nump">$ 35,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfIntangibleAssets', window );">Revenue related to the sale of the marketing rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156<span></span>
</td>
<td class="nump">191<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">7,322<span></span>
</td>
<td class="nump">6,276<span></span>
</td>
<td class="nump">20,927<span></span>
</td>
<td class="nump">16,166<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">7,637<span></span>
</td>
<td class="nump">6,878<span></span>
</td>
<td class="nump">24,526<span></span>
</td>
<td class="nump">19,017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">14,334<span></span>
</td>
<td class="nump">12,913<span></span>
</td>
<td class="nump">44,146<span></span>
</td>
<td class="nump">35,021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">7,095<span></span>
</td>
<td class="nump">6,137<span></span>
</td>
<td class="nump">20,544<span></span>
</td>
<td class="nump">15,974<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">7,239<span></span>
</td>
<td class="nump">6,777<span></span>
</td>
<td class="nump">23,601<span></span>
</td>
<td class="nump">19,047<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate, Non-Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">625<span></span>
</td>
<td class="nump">241<span></span>
</td>
<td class="nump">1,307<span></span>
</td>
<td class="nump">162<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate, Non-Segment | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">227<span></span>
</td>
<td class="nump">139<span></span>
</td>
<td class="nump">383<span></span>
</td>
<td class="nump">192<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate, Non-Segment | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">398<span></span>
</td>
<td class="nump">101<span></span>
</td>
<td class="nump">925<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">12,963<span></span>
</td>
<td class="nump">11,496<span></span>
</td>
<td class="nump">39,826<span></span>
</td>
<td class="nump">30,714<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">6,620<span></span>
</td>
<td class="nump">5,670<span></span>
</td>
<td class="nump">19,119<span></span>
</td>
<td class="nump">14,611<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">6,343<span></span>
</td>
<td class="nump">5,826<span></span>
</td>
<td class="nump">20,707<span></span>
</td>
<td class="nump">16,103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Keytruda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">5,426<span></span>
</td>
<td class="nump">4,534<span></span>
</td>
<td class="nump">15,487<span></span>
</td>
<td class="nump">12,609<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Keytruda | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">3,331<span></span>
</td>
<td class="nump">2,580<span></span>
</td>
<td class="nump">9,307<span></span>
</td>
<td class="nump">7,108<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Keytruda | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">2,095<span></span>
</td>
<td class="nump">1,954<span></span>
</td>
<td class="nump">6,180<span></span>
</td>
<td class="nump">5,501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Alliance revenue - Lynparza</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">284<span></span>
</td>
<td class="nump">246<span></span>
</td>
<td class="nump">825<span></span>
</td>
<td class="nump">721<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Alliance revenue - Lynparza | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">144<span></span>
</td>
<td class="nump">129<span></span>
</td>
<td class="nump">427<span></span>
</td>
<td class="nump">371<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Alliance revenue - Lynparza | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">140<span></span>
</td>
<td class="nump">117<span></span>
</td>
<td class="nump">397<span></span>
</td>
<td class="nump">350<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Alliance revenue - Lenvima</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">202<span></span>
</td>
<td class="nump">188<span></span>
</td>
<td class="nump">660<span></span>
</td>
<td class="nump">498<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Alliance revenue - Lenvima | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">142<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="nump">426<span></span>
</td>
<td class="nump">287<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Alliance revenue - Lenvima | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="nump">235<span></span>
</td>
<td class="nump">211<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Alliance Revenue - Reblozyl</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">124<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Alliance Revenue - Reblozyl | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">87<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Alliance Revenue - Reblozyl | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Gardasil/Gardasil 9</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">2,294<span></span>
</td>
<td class="nump">1,993<span></span>
</td>
<td class="nump">5,428<span></span>
</td>
<td class="nump">4,144<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Gardasil/Gardasil 9 | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">957<span></span>
</td>
<td class="nump">839<span></span>
</td>
<td class="nump">1,803<span></span>
</td>
<td class="nump">1,605<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Gardasil/Gardasil 9 | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1,337<span></span>
</td>
<td class="nump">1,154<span></span>
</td>
<td class="nump">3,624<span></span>
</td>
<td class="nump">2,539<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | ProQuad/M-M-R II/Varivax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">668<span></span>
</td>
<td class="nump">661<span></span>
</td>
<td class="nump">1,716<span></span>
</td>
<td class="nump">1,626<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | ProQuad/M-M-R II/Varivax | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">532<span></span>
</td>
<td class="nump">537<span></span>
</td>
<td class="nump">1,337<span></span>
</td>
<td class="nump">1,255<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | ProQuad/M-M-R II/Varivax | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">136<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="nump">379<span></span>
</td>
<td class="nump">371<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | RotaTeq</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">256<span></span>
</td>
<td class="nump">227<span></span>
</td>
<td class="nump">644<span></span>
</td>
<td class="nump">593<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | RotaTeq | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">154<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="nump">427<span></span>
</td>
<td class="nump">364<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | RotaTeq | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="nump">218<span></span>
</td>
<td class="nump">229<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Pneumovax 23</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">131<span></span>
</td>
<td class="nump">277<span></span>
</td>
<td class="nump">457<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Pneumovax 23 | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">181<span></span>
</td>
<td class="nump">280<span></span>
</td>
<td class="nump">354<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Pneumovax 23 | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Vaqta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="nump">134<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Vaqta | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Vaqta | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Bridion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">423<span></span>
</td>
<td class="nump">369<span></span>
</td>
<td class="nump">1,244<span></span>
</td>
<td class="nump">1,096<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Bridion | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">233<span></span>
</td>
<td class="nump">181<span></span>
</td>
<td class="nump">665<span></span>
</td>
<td class="nump">545<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Bridion | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">190<span></span>
</td>
<td class="nump">188<span></span>
</td>
<td class="nump">579<span></span>
</td>
<td class="nump">551<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Prevymis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="nump">310<span></span>
</td>
<td class="nump">270<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Prevymis | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Prevymis | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="nump">174<span></span>
</td>
<td class="nump">159<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Dificid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="nump">196<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Dificid | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">72<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="nump">184<span></span>
</td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Dificid | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Primaxin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="nump">185<span></span>
</td>
<td class="nump">194<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Primaxin | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Primaxin | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="nump">185<span></span>
</td>
<td class="nump">194<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Noxafil</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="nump">197<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Noxafil | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Noxafil | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">141<span></span>
</td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Invanz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="nump">148<span></span>
</td>
<td class="nump">157<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Invanz | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Invanz | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="nump">144<span></span>
</td>
<td class="nump">159<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Cancidas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="nump">138<span></span>
</td>
<td class="nump">168<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Cancidas | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Cancidas | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="nump">133<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Zerbaxa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">43<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Zerbaxa | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">24<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Zerbaxa | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">19<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Alliance revenue - Adempas/Verquvo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">258<span></span>
</td>
<td class="nump">248<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Alliance revenue - Adempas/Verquvo | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="nump">244<span></span>
</td>
<td class="nump">222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Alliance revenue - Adempas/Verquvo | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Adempas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="nump">181<span></span>
</td>
<td class="nump">188<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Adempas | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Adempas | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="nump">181<span></span>
</td>
<td class="nump">188<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Lagevrio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">436<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,859<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Lagevrio | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,523<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Lagevrio | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">436<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,336<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Isentress/Isentress HD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">161<span></span>
</td>
<td class="nump">189<span></span>
</td>
<td class="nump">466<span></span>
</td>
<td class="nump">590<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Isentress/Isentress HD | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="nump">196<span></span>
</td>
<td class="nump">222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Isentress/Isentress HD | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">93<span></span>
</td>
<td class="nump">112<span></span>
</td>
<td class="nump">270<span></span>
</td>
<td class="nump">368<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Belsomra</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="nump">199<span></span>
</td>
<td class="nump">238<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Belsomra | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Belsomra | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="nump">139<span></span>
</td>
<td class="nump">183<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Simponi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">173<span></span>
</td>
<td class="nump">203<span></span>
</td>
<td class="nump">540<span></span>
</td>
<td class="nump">619<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Simponi | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Simponi | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">173<span></span>
</td>
<td class="nump">203<span></span>
</td>
<td class="nump">540<span></span>
</td>
<td class="nump">619<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Remicade</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="nump">163<span></span>
</td>
<td class="nump">233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Remicade | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Remicade | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="nump">163<span></span>
</td>
<td class="nump">233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Januvia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">717<span></span>
</td>
<td class="nump">852<span></span>
</td>
<td class="nump">2,252<span></span>
</td>
<td class="nump">2,445<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Januvia | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">332<span></span>
</td>
<td class="nump">365<span></span>
</td>
<td class="nump">958<span></span>
</td>
<td class="nump">997<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Januvia | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">385<span></span>
</td>
<td class="nump">487<span></span>
</td>
<td class="nump">1,294<span></span>
</td>
<td class="nump">1,448<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Janumet</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">417<span></span>
</td>
<td class="nump">487<span></span>
</td>
<td class="nump">1,347<span></span>
</td>
<td class="nump">1,449<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Janumet | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="nump">258<span></span>
</td>
<td class="nump">244<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Janumet | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">327<span></span>
</td>
<td class="nump">401<span></span>
</td>
<td class="nump">1,089<span></span>
</td>
<td class="nump">1,205<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Other pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">564<span></span>
</td>
<td class="nump">518<span></span>
</td>
<td class="nump">1,565<span></span>
</td>
<td class="nump">1,589<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Other pharmaceutical | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">244<span></span>
</td>
<td class="nump">210<span></span>
</td>
<td class="nump">616<span></span>
</td>
<td class="nump">637<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Other pharmaceutical | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">321<span></span>
</td>
<td class="nump">306<span></span>
</td>
<td class="nump">949<span></span>
</td>
<td class="nump">950<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember', window );">Animal Health | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1,371<span></span>
</td>
<td class="nump">1,417<span></span>
</td>
<td class="nump">4,320<span></span>
</td>
<td class="nump">4,307<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember', window );">Animal Health | Operating Segments | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">475<span></span>
</td>
<td class="nump">467<span></span>
</td>
<td class="nump">1,425<span></span>
</td>
<td class="nump">1,363<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember', window );">Animal Health | Operating Segments | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">896<span></span>
</td>
<td class="nump">951<span></span>
</td>
<td class="nump">2,894<span></span>
</td>
<td class="nump">2,944<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember', window );">Animal Health | Operating Segments | Livestock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">829<span></span>
</td>
<td class="nump">864<span></span>
</td>
<td class="nump">2,486<span></span>
</td>
<td class="nump">2,503<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember', window );">Animal Health | Operating Segments | Livestock | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">186<span></span>
</td>
<td class="nump">190<span></span>
</td>
<td class="nump">521<span></span>
</td>
<td class="nump">508<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember', window );">Animal Health | Operating Segments | Livestock | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">643<span></span>
</td>
<td class="nump">675<span></span>
</td>
<td class="nump">1,965<span></span>
</td>
<td class="nump">1,996<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember', window );">Animal Health | Operating Segments | Companion Animals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">542<span></span>
</td>
<td class="nump">553<span></span>
</td>
<td class="nump">1,834<span></span>
</td>
<td class="nump">1,804<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember', window );">Animal Health | Operating Segments | Companion Animals | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">289<span></span>
</td>
<td class="nump">277<span></span>
</td>
<td class="nump">904<span></span>
</td>
<td class="nump">855<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember', window );">Animal Health | Operating Segments | Companion Animals | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">$ 253<span></span>
</td>
<td class="nump">$ 276<span></span>
</td>
<td class="nump">$ 929<span></span>
</td>
<td class="nump">$ 948<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=mrk_InternationalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=mrk_InternationalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_KeytrudaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_KeytrudaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_AlliancerevenueLynparzaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_AlliancerevenueLynparzaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_LenvimaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_LenvimaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_AllianceRevenueReblozylMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_AllianceRevenueReblozylMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_ProQuadMMRIIVarivaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_ProQuadMMRIIVarivaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_RotateqMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_RotateqMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_Pneumovax23Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_Pneumovax23Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_VaqtaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_VaqtaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_BridionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_BridionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_PrevymisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_PrevymisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_DificidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_DificidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_PrimaxinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_PrimaxinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_NoxafilMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_NoxafilMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_InvanzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_InvanzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_CancidasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_CancidasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_ZerbaxaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_ZerbaxaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_AllianceRevenueAdempasVerquvoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_AllianceRevenueAdempasVerquvoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_AdempasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_AdempasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_LagevrioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_LagevrioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_IsentressIsentressHDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_IsentressIsentressHDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_BelsomraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_BelsomraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_SimponiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_SimponiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_RemicadeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_RemicadeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_JanuviaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_JanuviaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_JanumetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_JanumetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_OtherPharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_OtherPharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_LivestockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_LivestockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_CompanionAnimalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_CompanionAnimalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303301925728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Consolidated Sales by Geographic Area (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">$ 14,959<span></span>
</td>
<td class="nump">$ 13,154<span></span>
</td>
<td class="nump">$ 45,453<span></span>
</td>
<td class="nump">$ 35,183<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">7,322<span></span>
</td>
<td class="nump">6,276<span></span>
</td>
<td class="nump">20,927<span></span>
</td>
<td class="nump">16,166<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_EMEAMember', window );">Europe, Middle East and Africa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">3,286<span></span>
</td>
<td class="nump">3,342<span></span>
</td>
<td class="nump">11,228<span></span>
</td>
<td class="nump">9,912<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1,442<span></span>
</td>
<td class="nump">1,307<span></span>
</td>
<td class="nump">3,957<span></span>
</td>
<td class="nump">3,004<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">673<span></span>
</td>
<td class="nump">638<span></span>
</td>
<td class="nump">2,776<span></span>
</td>
<td class="nump">1,929<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember', window );">Asia Pacific (other than China and Japan)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">854<span></span>
</td>
<td class="nump">613<span></span>
</td>
<td class="nump">2,792<span></span>
</td>
<td class="nump">1,782<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_LatinAmericaMember', window );">Latin America</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">684<span></span>
</td>
<td class="nump">599<span></span>
</td>
<td class="nump">1,933<span></span>
</td>
<td class="nump">1,631<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_OtherCountriesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">$ 698<span></span>
</td>
<td class="nump">$ 379<span></span>
</td>
<td class="nump">$ 1,840<span></span>
</td>
<td class="nump">$ 759<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_EMEAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_EMEAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_AsiaPacificMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_LatinAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_LatinAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=mrk_OtherCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=mrk_OtherCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303294531328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Reconciliation of Segment Profits to Income before Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Profits</a></td>
<td class="nump">$ 3,583<span></span>
</td>
<td class="nump">$ 5,266<span></span>
</td>
<td class="nump">$ 12,931<span></span>
</td>
<td class="nump">$ 9,970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(244)<span></span>
</td>
<td class="num">(196)<span></span>
</td>
<td class="num">(727)<span></span>
</td>
<td class="num">(597)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,623)<span></span>
</td>
<td class="num">(1,231)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,394)<span></span>
</td>
<td class="num">(1,148)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">(4,399)<span></span>
</td>
<td class="num">(2,445)<span></span>
</td>
<td class="num">(9,773)<span></span>
</td>
<td class="num">(9,177)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="num">(94)<span></span>
</td>
<td class="num">(107)<span></span>
</td>
<td class="num">(288)<span></span>
</td>
<td class="num">(487)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Profits</a></td>
<td class="nump">10,105<span></span>
</td>
<td class="nump">9,111<span></span>
</td>
<td class="nump">29,935<span></span>
</td>
<td class="nump">24,079<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Profits</a></td>
<td class="nump">9,590<span></span>
</td>
<td class="nump">8,606<span></span>
</td>
<td class="nump">28,263<span></span>
</td>
<td class="nump">22,450<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Animal Health segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Profits</a></td>
<td class="nump">515<span></span>
</td>
<td class="nump">505<span></span>
</td>
<td class="nump">1,672<span></span>
</td>
<td class="nump">1,629<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate, Non-Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Profits</a></td>
<td class="nump">377<span></span>
</td>
<td class="nump">141<span></span>
</td>
<td class="nump">831<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Segment Reconciling Items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(244)<span></span>
</td>
<td class="num">(196)<span></span>
</td>
<td class="num">(727)<span></span>
</td>
<td class="num">(597)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="num">(460)<span></span>
</td>
<td class="num">(360)<span></span>
</td>
<td class="num">(1,623)<span></span>
</td>
<td class="num">(1,231)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="num">(448)<span></span>
</td>
<td class="num">(358)<span></span>
</td>
<td class="num">(1,257)<span></span>
</td>
<td class="num">(1,031)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">(4,277)<span></span>
</td>
<td class="num">(2,312)<span></span>
</td>
<td class="num">(9,374)<span></span>
</td>
<td class="num">(8,775)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="num">(94)<span></span>
</td>
<td class="num">(107)<span></span>
</td>
<td class="num">(288)<span></span>
</td>
<td class="num">(487)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_SegmentReportingUnallocatedOtherExpensesNet', window );">Other unallocated, net</a></td>
<td class="num">$ (1,416)<span></span>
</td>
<td class="num">$ (660)<span></span>
</td>
<td class="num">$ (4,628)<span></span>
</td>
<td class="num">$ (2,044)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_SegmentReportingUnallocatedOtherExpensesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other net expenses not allocated to segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_SegmentReportingUnallocatedOtherExpensesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>mrk-20220930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mrk="http://www.merck.com/20220930"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mrk-20220930.xsd" xlink:type="simple"/>
    <context id="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id0e20af91c5143088498043650185a6c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7000ad694c3b4ad882a0d1dfafbd3864_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mrk:A0.500Notesdue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5f2be8ca05e84092be3101ab17e36630_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mrk:A1.875Notesdue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id4c29ff612c740d08bbaa6fdd4e76510_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mrk:A2.500Notesdue2034Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i143bd665f1bf44a2a2623915d83f6b2b_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mrk:A1.375Notesdue2036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if3f74b51a5dc4dc6b59e6013885b63ab_I20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib9490e02538244c88fb94e67f0f84467_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6b76c3e2ce274f17b07c82ae1459e9f9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i48930a09b1404293820fbeb015eb6729_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i602313dd11d54187bb2dce59c76d9f21_I20210602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mrk:OrganonCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-02</instant>
        </period>
    </context>
    <context id="ic7ff920b80fa44a2bb7838de95556452_I20210602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <instant>2021-06-02</instant>
        </period>
    </context>
    <context id="i16de1f9b952c486594ae6f32e5927154_D20210602-20210602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrk:TransitionServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-02</startDate>
            <endDate>2021-06-02</endDate>
        </period>
    </context>
    <context id="iab8a608181a042f2beef71b113878321_D20210602-20210602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrk:TransitionServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-02</startDate>
            <endDate>2021-06-02</endDate>
        </period>
    </context>
    <context id="i06897842e70e4eeda8309f8e1ee91277_D20210602-20210602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrk:ManufacturingAndSupplyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-02</startDate>
            <endDate>2021-06-02</endDate>
        </period>
    </context>
    <context id="i47ff0bcc16874008b1f561555e4a69e4_D20210602-20210602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrk:ManufacturingAndSupplyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-02</startDate>
            <endDate>2021-06-02</endDate>
        </period>
    </context>
    <context id="i54368f9911b347738909e680bf95d53e_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrganonCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic18b206b366941b3bc21e6598f14fb5a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrganonCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i13d3cfa7934c4d6088d6cd23cfa71865_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrganonCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i32aa48e818164158ab6157217075e834_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrganonCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i11700d15290f425cb74a002a0cd2a29e_D20210602-20210602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrganonCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-02</startDate>
            <endDate>2021-06-02</endDate>
        </period>
    </context>
    <context id="i6533dbb8649144648ffc4f4c1244c7c9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrganonCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i26b4f40fba294c2ab11871350926ecda_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrganonCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9bca04a61d0b44f38244083585df424c_D20221001-20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="ie8c7d497ea31438baaf4030a8d162610_D20220801-20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrnaTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="i75ee5a60ce374caea61b986d91c7b118_D20220801-20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrnaTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:DevelopmentMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="i7cce51215fdf4e1f8b49f6ac5e538125_D20220801-20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrnaTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="i1d770d493ee2465aad2e7a4f35310a08_D20220801-20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrnaTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="ie81fe052a58c4ac79c6c1914541dbb46_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:OrnaTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifc75b85439f349c791c677badeda87e6_D20220701-20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrionCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="ib486ae5e04ba46c792826e98b7405eb9_D20220701-20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="ifca4efa458684a00b6c8c8e3b1f41518_D20220701-20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:DevelopmentMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="ia4a01db11db64f5285ad73bae142f347_D20220701-20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="ic0e7fb5afd034fe49f7ea947b722c5af_D20220701-20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="i0bc205e805cf4d5f9d260e0bc1e150de_D20220501-20220531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="i039f123196e246019e2836c6f6bb9e91_D20220501-20220531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:DevelopmentMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="iddd9e1044d91482a92ae2a06341f0748_D20220501-20220531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:FirstCommercialSaleMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="i4d354163674a44d68678d3dc0bf63d9a_D20220501-20220531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="i043e841d659649cfaea941c020c82892_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:PandionTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="idacd23b3b6ae489b89729f7dc49d6220_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:PandionTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="idcccabd6edb749bf9c5977174f86658e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:PandionTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie491bc3ce3bf4fcab2d52425ea46de0a_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:ArtivaBiotherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="ic3a1ed78727c4d759751ea2f43de095d_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:ArtivaBiotherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:DevelopmentMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i4629f08bbd144fe582e499da3dad8b06_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:ArtivaBiotherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i7bce0692a5b4447e9a52850be6e554f4_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:ArtivaBiotherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i6dcf6134f32d478dbe1941c9aea8779c_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:ArtivaBiotherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i2347cdd094484cb5b876055e05600443_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:ArtivaBiotherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="ie42db3b5c5b74f21afa507c6dc74632e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:COVID19Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i21912ec93da743c79ae9ba5d3f089bd9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic8f4acef9645432a86030dbdecb44682_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iaefdc2743e3b4f459d997a63fcf5409f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3afa0051e006445592494b5f1781aead_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4bf3affc3e9f436d8fceb9cc9572407c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i1907a491b1ab4494bcb5711a999a46d8_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia10ed00bf75d4fe2a88f22919b63e42d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if40bc016be9844ffacc5e3a61649fd8f_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i05a4a8f891ea43e9b071e6f036172468_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2d0093add0344d4bb0ff3793ac7752e2_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iba2c1ce6973c439cb0304ebd132fa0fd_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i30533c21f6874363adc26d834802514f_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueKoselugoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8a6d8edecf524875b4d7cadcf837faa0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueKoselugoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9e730ddeb7ba4b2ba74c9e90f63cce43_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueKoselugoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4589c546fa744a2c966fbe3b84783265_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueKoselugoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia817e4175b9a4610b08f54e5e830ee23_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2bbde3b507d74bd89695b20384edb9a3_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if25ae27f28a94974802d948c498415fd_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i398ea6779f6a4327a6a7e64c91583bf4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i039199e857634ca4ba7aafc3dbc79228_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5897251afffb44088ec89b19d1bdc84a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9da90caa29d94f0a8da61f2d1f19ae81_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1589a04249264c3daa20424018a01187_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic5050d3fe45a40b8a7b4a69b944c22a9_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i587510372b604b139812c4dd9779e273_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ieb2de2469e144d4893a6dcc97d4e3c99_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5ed206b7f8a24c26b903ee925c1c1961_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4ee4ac5f1b264ca69d35cbb50d96ea05_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i138101fbf41c4f9dafc07d2a4e620fca_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i613c1d9fab0f431fade5cfdf29823c97_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iccffbf6b9b604242a9e75a41475ad0f0_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id481255ba6384775831f82ad3ae7549e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id55d4ae3b325406e91eef2de4b2e7b99_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia80cb9af76954141b50f85baffdadb69_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="icbdca7f63bbb466b9c0edf3825db2b0e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1b48257a883b4a79aca85a1019943388_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iaf53d38799a3490799f7eac25c464fe4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib322c590099749b29efd1012a6436a56_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8d3c8bd139d14d1c9571445aad6c4723_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ieab0ff535a8a4357924a2ea4759b4813_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie403795b3c984fa5adccd65ae3284b98_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i144701b5635f49b6a87e388b5a112a0c_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iaa0c7c07509a49b2bba97e430289c5a0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id8782c7cfeac4f45be3816e9c23d40e2_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i981c732452864a0a89b0bdd4ea1ca966_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4e9c637f23f8498097ccb65785974c6e_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if9a88c5549694dec907e06fa69cae667_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7893a61b773e42eaa4750e61ccc3e264_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i42218d013fb34f1f8c1048bf798e322e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic860b4ba2f6b47eb8e120d99349e2f88_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ife92a3473bc4415aaff470cb4cf0a01c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7a3be947f65b41ad82a9e53d652dd2b0_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ide4d6dda5b9e4f48ac02ead988fe068f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie590418643204f47816759f2195d86d2_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i366906fcc328447985b2dd9207bbfdb0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idb33f80f44364328b49c32741943ae6f_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i67dfa7f3e534416abfb0f9c1ea1869c5_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7ae012bcf60c4cd692cca1d41ea9a0e7_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7be328837202423290bff8758c427630_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7ac2724c045a44b1815128ce8f6b20f4_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i683cd7e98cb547bfb87dc770c0d74e58_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaf806d58f30c4be4bca6c3be1abe66c9_D20220101-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="if15ad2dc23594b05a094920b78cb9281_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ifbf925ccbf934ad1bbd6105bd116f495_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VerquvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia903414baf944a4c85e8b48c1ec54218_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if192c98d9a7e4b0c881c0a5da15bd44c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i061a8128f7d54a66b9329be138104804_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if960063333f14939a78490bbd9873025_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i35d4d64303ab483e97f9f6829d296385_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iba08ab1ba316433da1eb64e967da1f14_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i81c4bab0b60647bba82d1e4ad7faa825_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9c06ca35260641c481956f20cb681bb1_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i519e6b6f4af34d2e9581f65447c1311f_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VerquvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9ddb0dd7fa034178a6eb152be9603780_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VerquvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic9999b3f45ca41a4a2542f94612afb3d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VerquvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i212e8f35bf4a468cb7a86750d3383cf4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VerquvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i90dd98ecefa24e27863c524456240e09_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i186331a72ef04ac9b7b6241c63ffaf24_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iedf5c07624db4e01a7cf689fdcff82a5_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i27f892355464487d8539768fc6061eb5_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib78cfd0dce084d31981552de8a046a04_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i30d1694e33a8460db578cfe950cf06d2_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i56264076164d4059af8de0e8936319cc_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie9f07ed930f14354adbe45102b20b9c4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0bdc458f37d94074bbb7340625918b7c_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i323143b5b858466db34d0d2c5c944f28_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia91b5a3c675c4ef88e4f8f57394a5380_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5053a9df2c864fa090b207df72bef585_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3525e1187e8a48de986cf4be04ae95f4_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia7be680bb4e346ee9310c38a476bb72e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i58b09de6ba674b5b96551d497a48a9b5_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0771df2198d740108535caf3238d43d7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3723cbf2e9d946a999ed600588ab4dcf_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if65526f98e4a40e2b1e489150cc1a2ab_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iccbbed27ee8c445fa7d6d65e80591a7a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8fdf0be182b9481c8354305d8e3858bf_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icd2d41565b6f42a997d55a3d36cb68d1_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id5885bf545144e9fbc3756e4e3d7b93a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idb36d80fe9584e529d590578a9d319d2_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3627424b141f4c858a9b7d5990d0cd74_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibccd6eb894bd4564a6c0a0c44c562587_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic9f5d07a2f4c4a9f82674c37fd6d528a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i17a18d3e962d4cd9b3dd760b10d9798b_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i434e35353dae4fc0b4b54dc274539d65_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib23b0153d3f34c168976ed88f8d51ecf_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1c3f6bda0cc24696bb0a6048cab3d8ad_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7e9026c7a16e448aa12d13cee7a70f46_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ida58e25739ea40aab501d63f8e5ca681_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i39554fdd833642dcb810f17c8dc0e061_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i425575da0166424ea1fd3084934e226f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i27570eaa57364d34ba707b5178e9750a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i82096e190c7a476a960b881f6f4ec492_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9a2d8c4a46554ddebb3ddc81810f3b42_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6730c99096144e189cec49f74ada9510_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie6ab39f8789a4b6fa4f623fa5d27795c_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueReblozylMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0715d2eaae6e4be98aee0bd0d1931927_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueReblozylMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6f62c15a0dd94e4a890739e8dafcc0e8_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id6564f481b634b6fa99cd7e8116cf98f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i607e39f2759d4b5691b37d2c9b39dcc7_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1ec10c038b504097b605bfddb4195539_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6fb3a552dc224a94b2299fd6c6cf8889_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic03376b1c2a3499d90e8c3ebcf2e8843_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i67cab3cf205f49af9b2cbd5c33f66aaa_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i940e1b01bd364068818c54a265d128b1_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i72dc17aba95d4c5dbc3a2194bd16fbbd_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iec1e587d8b0d40bdb598eb257221971d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i70303f64175d4dc4b0012ac52b4f5e26_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3578096e6ff448caa0f52989e5f64761_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0ad3e04cc3e3418cb4a53a75ae5c3e2c_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8849203e046e46cbad3f2f952d1f4e26_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2c93d3a120f84e38a20a1a70937efcd7_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iaece706c71314f32b319a33cc075cdd3_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i310bfcc0be584465a56866ddaad54dde_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i521c621370414b959a6f7126a06cd3db_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i45b5fd4276104c17a8bc518c8e4ee367_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id015ab72aa4f4666af512c49587ba178_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie78da687a4494c7fb93cf5f0da80fd52_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i92d26b2795bd42e49f6d1a0b2f14a67e_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie67e7f4f21244b38ac40aac5e3a31725_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ica35ec1eb9ea4c119a570c9e6bd607d1_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9bf969645ea14edeb5fb224b37851e85_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6cf8194e2b5745f0bb10f0b19e79ef0d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="idae084acd38849fea32bf72eca48cb01_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic7e6f52cb1c84ad79bc614920f692b13_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1fedc08d43254caca03ecd529c042551_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9bc054b6f538473eadeef1645e9b4c4b_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9362212891c34b43a1bd670fb2f4062f_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6a992f86ee914509b7bdf62709a6811d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5aff9663fce2448c99f02618375e2e64_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3b0c1dffc5964f349f9a75222d0c1430_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic0106fbddb424e3aa3b3ba43ca616389_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id8d2797912764a54a9b0c8b56a5cb401_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iba55b4c871c84cf8aff0cc19a6430038_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5a2cfacf23e041649e6e810a01b78367_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id6578e5480804aaabbdd710e9e7d4dec_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie5f3b77e795a4cecb84d959b27d815f5_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i53cc7f522cf94a9ba8b27371253d34fd_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i37502c19e33b478ba485f3769f7edde9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3dbf94fcba07458c9985b487a4e8e11a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i897e9c4831fe4162b3092f6346596330_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1b3871ab9cbd41ffabab932a2f1a7a00_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic248a691eef3457980491b2190cd4476_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2181ab62a29c4f39995a887b7394ab97_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icae4aa9b209147aa9d9bf757f4c8c2e5_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0582722a90814a31816b9004352bfa16_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia278f201fcb0483ea8de813bd868a23b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie582a185448546fc8001d7759a7730db_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i36d4bd762ee74c8b99495575010c996f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie6ccd75209b14ac48e453f8ae771b430_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i90654f8e2de64d88a4d14ff9c355cff7_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iae11b50969c44470b085b71a202c369b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1fef4e3614274432a2cb07854dd86e09_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i14b940f93da941d89457a0cb5087dc05_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4f0e3061236541d88cb6730bdf73a36c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7fe0bb2d87cc463ba0afd98a1d4f6c49_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8fde48e69dd3472e9819a95aa4746a43_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id0f98d96c0344d749893dc7317abd393_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1f83f5cfdae84508a28c38bc5dc977cb_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i727f0dd97e804d1cab3731ca3b4c50cb_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i98e34a5cb81241399b51495bac59245a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2e4b050ead3647479f62f1237a1c63c5_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i309f819f3951487382595bf493061e13_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i874c7a8482d9491690e6210b479df219_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5db3736668d14dc8ad614ba24ea70f21_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i12cf63265e33426a9ac172ae9d1f6ad3_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5216105f6e064bba87cac0aa0ae94efd_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i955e203846ca40e1adf9d2507ef80695_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4afc7e4c5b9a43a7af38307f4daa99e9_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie766e05eb57f41bea33a66d0f8d1fa6c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ieb61cb5684ff4b9c828cf20066ed6299_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ieb5b904f4f0748a6aa9b86108608f108_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i86d01d6cbe2846bab4a8e80b2c1c31d2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id3f2085cbdba410eb279bbb464b3ec8e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id6edbfe83866410d981411c92bc94739_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic795a5720c194aaaa03944a5d453e5e9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2a52aaf7232745dbbf9787cba14d23ca_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if340c59c3f4d4832acc93316ac66cbcf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i87df032ae149438c8311b443f96f3fa1_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i79ed206618d34ac9b28a27e2dc6fb6b3_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7f9135826ed64fa09549e1defcc31184_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic2de9fcd183e42f8bd39ac5db830d924_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9c8be2269d6c4eb4bc6e4bcb3ddcfc30_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie27e3a1d731a4e8aab46753956e07c5d_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5ae35cdeb80c488d9810adba90ad5a22_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id5ffef0aa5134d30a7bc87c2f1471202_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8f49cd47d7c34c2db675a1a70530cbc8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ieab5e8f43e5e4ecb92c95a699771341a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i01953d66b4ed43759d677deacf2426b3_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib6c315ba79954d888131d6d2b08f5b46_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1ac58f37e82a4b95ab6c2445433ee541_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6f5e74c553ad4cea9c9915ab749a9781_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2e5bf65d147a4bdc965896b6d99c4860_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3e5ed55b09f84d5498e328aa1b4f5417_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i772590a293ba478db2f7600cf2cb3eb4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i099e48fafeba46d08da6b31e799e3b7f_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i03e7ee1c569b46239abaca544705e805_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia780135900c240e5b9abf1b31ee64f6e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i92c75e458aed405ab0daac044db42401_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0e0dd76b1ff5456f8f9ea13bb5b3d393_I20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="if00c71a39ce54be38bef228f86d7f5bf_I20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mrk:A2.35NotesDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="if3f2b646e97448bb985e896a02467668_I20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.35NotesDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="iea3f69b723254e88a143cf7acb00abe9_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i486ffaa742a0496f9d919416396e1c12_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mrk:A2.40NotesDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i6c212ea75a92431aa81258fd9e8294ba_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mrk:A2.40NotesDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i2e5951a5bcea4965af6bb7344a6a099d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.40NotesDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ibdb46049abd240818d8639edc52d2396_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:LongTermDebtCurrentMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ibc438baf83774566bb16844255c68486_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:LongTermDebtCurrentMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i53f76af88d63418dba6b1ea3a71d7ecb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic7eb7aa0cad44ae481279be50ead5cf3_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i45b3ae0db3cf41c3acafc444ed25c107_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:DeferredIncomeTaxesAndOtherAssetsCurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if41d8f4f2079476e813d82c9d789e8fc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:DeferredIncomeTaxesAndOtherAssetsCurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i92c41baff7714a72894f9c962e96d0a8_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:DeferredIncomeTaxesAndOtherAssetsCurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i97bb92e54ef74a8db32f912747efe346_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:DeferredIncomeTaxesAndOtherAssetsCurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i92c868d7e8f9475893857146e49ffbb1_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:DeferredIncomeTaxesAndOtherAssetsNoncurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8f6e2cbf96bd4896863dbb8f79fdf2b1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:DeferredIncomeTaxesAndOtherAssetsNoncurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i338b3ccaae68438b96b0f370fd0bb963_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic2398c81940b40eabe737fa14c821b96_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ifa0ad26fa2f64d7ca0cf4d95ae5c7567_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib67ea4886b8c40868d422b24ac9e580d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaf409d1f24c84ee6b661d53c0d63d271_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i15d7e32d159245d8962254b1ac043b09_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7382fed477fc47e3acfc51cf0827f22a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ieba4d46f4e9b4513aa30046a1640a2d1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if8bb1afef334464cafe180cee4605e3b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:DeferredIncomeTaxesAndOtherAssetsCurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i6964796fa04f4808aa3493a670881eca_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:DeferredIncomeTaxesAndOtherAssetsCurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8f8b8b04c81b4fb99373775effba54e1_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id74f2287203447e1b810c5fa36a1ed55_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5cdb1dee02174c02a0606014cbbae99e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i54c9fc9da50e4192912b25f5131e50fc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic44487f92a5448159923c27c8d731670_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie4d2e0c5ba4449618b901ef68baa6ea0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic76064667e0a419bb6d0e5c3426be249_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia325483b4883403c90d79d1be19c51da_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2090286591394c9fa952301d7aa1370f_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie4bbf795a5864635b793460597f6ab25_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibe3cb650f6ab4c9b92198643023e4afa_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i408273e5bb4c48509f2537d97a208c52_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1a250ba5d2eb4f398ca0d688c55ce97b_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib4884545f3a04d2592a0a6552ec37a9e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3adbbede1e4c4a219df434d3b02b9d73_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i24ff49aba1234e2089a06728556f905e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8487d36b908947f3b19f1402064fea62_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic7aadf0e5ed8498e968fa72fc5dd2235_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id156cdfb0da54388a5c8bd98db65a8b3_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1673663dc72f4e86a51bc9229008f01d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i047a084a24b645f68be7cd35a8fc04a6_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeFutureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic0264f6f727c4a4b966ea14b2e2a52ac_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeFutureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic1f6dbfb4c7146b99019ed98f23895de_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeFutureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0e75809733d64f339d96ee9714ec260e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeFutureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4720a53a91d5435188a1da01bfe210fa_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7d9a78619aff46ea84120beb595fcb13_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iffb605e60b334d25829964639aa3cf58_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i9df8f1a7ad004c23af8f2239cda6077b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id736b7b8bba944b58bf0232a18e5113e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i4bfa097e481a425fb4b73f31bdcecc30_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if8ea7018241f4bbe9b73f4cb4ecc1d8c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i4a1c00996a864ae7bc40a0fbc771bd76_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i010c9478893544c28a5d7f544dc8e662_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i099b739b13c44281a0c6d085f13b276d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if9e54f6ced9e4ef1b0e99ea06c1e9ef7_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3580944146354ced840addc5a64825b3_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i734d905417484b12868c71bc4c409e5a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic41821eed5a14d76af729b6ab39c2ea7_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i51e48c4224c04c2a8bdb9693ed998b0f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iba9a552130db4292b0e26dabff225e15_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i2d25405b868b4e26aefbe7888fc41f43_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1426949b23ca4b71afa632f63d710aad_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8d7092dc98a44dff9517d3c284f1849b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie37c5d029c6648c8a2ed03a8d89af9b2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia1509e49abe14db0828288f4c189b466_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iac3cf219c1b341109243396f0c18a2ba_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="icaf187dd1d10491f92cbfb112d50b31f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie5dfb72ba12644a297b93978abb2da49_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i24b11ce36fae442893c46a0e7203cdfa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i37c6e32ba0824ee38f745770cec9a2d3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib7c90958615d4c819c1023d563e55db5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3eec1411691a43719325ad418681ac13_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7584c66c93fc49e79ea35b57c4e39390_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic7fc87b646454715bebf1e86eed2c3f4_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i1317ac689e934a98bcc9a08673feae09_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="icd40f186b450434689326d7a01e529ba_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i805bffc3fe574f44bdab78a3217cffd8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9ad98dd1519d4e5ba2a6d482e01bb026_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9e5b8eb982b3417191aa735376241712_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i23d23f5244de4df5a78fbcc38021abc9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id5cc583b3ac545afb27d7011fbd7878e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id7b005680367482db7f6c5526d8a8330_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i5806d7d6752145c89d6aed6b12c0de58_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i03d038eb8e67488896fcaf65d65f5a4c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i88cb48af3d36483bb4a106b4973f8a8b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib9b5923422814e839a9eace38e185dc2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i53252463645d40a49cf3666fc9496c89_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i95e44cbbb3c8441db74551146976a2b5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib55137ada6674e97b937072f652336fc_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia34cec2011844b3abbbecd5c96aa140b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib9d82f620e50424d92c3ec570c9584c7_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i96a1014d1ffc460ea40f01ffc40ca637_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie4a852e542ad490499c3bbfa84c21253_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id0249004b56d4566adef1bedb1ae2649_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if7d1ba12651d49ca9605e8d70b0465db_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i62dc854b928b49a1945ab2a202ed9435_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic7bca4ee680b4b53bd3c893bfc03df3a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if02abc99fb924ec7b0925ad5b953f9a0_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7eedae5d638b46e08efb6239577ce6a7_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i30c84521440546809e99309ada3e6429_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i66af9dda5d5a4116ac1581f86efa6274_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iec03db9221fc48e3aae39a8b07057d6b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7c3110d2fc4241989477e58acec0f4b3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id4589bd6805f421980e686f3847f3f2a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1a48ff5c326b4d30a9df72d6f4e2cc4e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i4f242540e8e74ae39f0f26f08bedea4b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia57d77b66d2f4f38a0d399ea6f3efb81_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if2e22773379b440b9fd05bd8ebbb205a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i1a773b58a7504fb78494693a086bafcb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i05efb95673774e31aaf4d68427669b60_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6b85ae7b23754291aed374cfe63220b4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i77e75274a39649d087e97960c6fdb1da_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0f4e74eaf7314a6f9b6f0534ffb3fad5_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i06b468d5994c457b9893c14bd393221a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if123e3f18ada47ea9d007bf17e6267a0_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i2d2873d5334e4202befee01684ddbb00_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i2e6b581a6b0347088dff9d709ad77eec_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i891d6272e42a4cb2afb1b6651756ea76_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idf235de4a0b04bebbe52a604c0a5aec9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i78a40cfbe8af4bbaa128d619556eef8d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2b8fe718d6fd40a2bb40eac7eb3ec7a5_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i891529025c4d453c984c2df2e720aabc_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i2c660dcc9c53431ea4f8bf9732b7f414_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i16903db8243d43c6a0558e66c138694a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i4220f301677a4e66966080b9f99d020c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icc979a929d5b473dac3eb798c69af53e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3256ceaea4e54171a07f3e8e012df401_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if57cd225864c49d1b3170aa0a6cc6eac_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ief790689a028402aa25ab7e36ca0ef81_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if556bca6c6704fee88ef4a1501269201_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8f6c358374a442b8908f3ddffb11dba7_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">mrk:SanofiPasteurMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia921450fc1e646fdb798d9bdb31e85e7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5a678e64e2774577a007e2d6f57ae9e6_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoryNotExpectedtobeSoldWithinOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i9b4bff14a1a9425cb5bf3661e7e1e54d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoryNotExpectedtobeSoldWithinOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i816e17e24e684044addf68e60f3d7cdd_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoriesProducedinPreparationforProductLaunchesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i871e3e80b793441c8f0be12b7c62ca4b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoriesProducedinPreparationforProductLaunchesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0b998b01dd7b4aedbe8d12d9cd13b5db_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i06851cb5c98f4da69ac686f6c2411879_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NemtabrutinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1c885d79a0554b91bbfa7bc3397951e7_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NemtabrutinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib3ff202f9b6d48749d7758af33b9b823_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FosamaxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i367d0d796d80424da91051e66c46b38a_D20140301-20140331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:FederalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FosamaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mrk:FemurFractureLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-03-01</startDate>
            <endDate>2014-03-31</endDate>
        </period>
    </context>
    <context id="if701c2dad3a448b8baf48efce7ff3da8_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mrk:CasesCompanyAgreedToTollStatuteOfLimitationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i23dfb067c82241afa5f99f21bef689a1_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i3433b64365a54af2b3af67c46a542197_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie980ee86472c42588cfeec3bc06a4e83_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CO</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i5268335c17cf4ff1ba48ee77aa8846cb_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:ZetiaantitrustlitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i5302423c142d450a83f2d69d472c5fd6_D20220630-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:ZetiaantitrustlitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-30</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6f0b5b41d05242aba7c807e0dd337a4d_D20221219-20221219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-19</startDate>
            <endDate>2022-12-19</endDate>
        </period>
    </context>
    <context id="i5d703348a1634fdbb823234f6176f03a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i251ca90ae959435d934e00a6b5636367_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ied8204c596b34fe69666b537c6dd68ed_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaAndJanumetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i623b3d56da7f44d9a270d2a0c4de1efe_D20230109-20230109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:PatentInfringementLawsuitAgainstZydusWorldwideDMCCZydusPharmaceuticalsUSAIncAndCadilaHealthcareLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-09</startDate>
            <endDate>2023-01-09</endDate>
        </period>
    </context>
    <context id="i5e7203ee8afa4167bcbca2845a05174c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">mrk:LegalDefenseCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iab20286c913c43ab9d138d102915562b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">mrk:LegalDefenseCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7dee7788157d45e1a5392aebf32b5f84_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i769035208b1b48838e202af7a6565d8e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i9efdb7d75087494cbe98cd19e691e3fa_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if7e47c5bf82f40adb471e36675ba4ee6_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iaab9e1dfa7444fc3bae3cc093d6fe99b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id23a801131ac4b8c945a76709e53ab57_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i3afe38f10fec457498b49dc2c46ff07d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iff86b236dd274c4686ba706b239b2836_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2ecbfa0ca4994647873a7f5f0bd59cdd_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8928a318d22448f497a03f892bcee237_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia4df4b3c64fe4fa28360813d66561107_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5c45ff5f83594356b2993ac3c0f1c8c0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie32bbd59665e48c4ab1a7a2fb3b32c83_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib8d08e2935f04a3892dc8bf49cba95aa_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ieeb453ea070a4057ad9c6dd3435f8906_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i99c020a806d84d1cb9f8c8d97329cf8c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3750629558d54ed8b2491825206bbff1_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4bec43526f964113b92ba5a981053063_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i6fc33f512e4c4f3dbfc4ffd56fbaacfb_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i163092cff85f4f96832f89ece004f615_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i45e71d3b257b4deaa9068f76e93341ed_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9864609863b94d00aa7ba3ced3bea441_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6a2cf1e51feb4bf9bf40f48b1eb15164_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia75bfa90c3194a5d875d56f842b27bff_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0d5f781c87ab40f58ea21a9500d8154a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if014c4b837bd4c0d8e2b84afeadf9c75_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if2a2791bc9db4ced8a0f57eebcf50852_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9706bcf110ad4f7e9558da712a96dfba_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6c57e5ba569c45d99424f3d170f677b8_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib76e902784e74151b5da455c02992dd8_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if3d50d8ac75f45d487c729ce8817f47e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i01a43e0ab33146bcad94c2c546eac8bf_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0fb137c2da28404fade360f5042d137a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie0803cc4f2c64fa7a8e0196a811eaf28_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia6aaba1fa4024e1cae697b7460337046_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia63f0e081f0a42f198e5d12dcd18cba3_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie8266a2de763495e917e7346aae13f81_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i46979b5fbfcf4bcfbe34ca9f2816df20_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idb58c93066b54a02965539a527ce9165_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i93d7029f006b4d91a535c2e9905f5a89_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibf444f353af04455b87e388e584fc395_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icc4cef6237e84b5f977c6f638148d150_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idfb7a35d7d0e432f9e66dd2215b3116e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i43d9233de62a46b78fb5fdd056a05478_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iac51e60463f94de2b9a560820ae84413_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8a2bd52c5dca47a292248a21f88ae298_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib23f7298a6c6404c9b917d37bd3494f3_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i58a9ea166bd8462bb92f1bde0e0c38ed_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i54fbdd4b47aa41a69dfd52ac2443383f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idf1f3c1c1c05447abdc62cc369de9b5f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i54f6686da6db4e38aeb2e4b266dc881f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id2b77295046047d1b7a851bf3bc457b3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifb6e56eb418d416f86418139727649f6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i69b491e8b3b84d76b979f1d2543f1bec_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="idd52fe4f8612434abba6e97f4c0f64e5_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i398ce1837bda4dd2867a24cf3db019b2_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iac4516ad133342f381e01ac656921924_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i65949c6818b4456e8bda505693b348eb_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i320809a777744dfdb73841889368aa2c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i09a399429407463c94fb6f4a770e06ca_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia48fc689e3e9494a8b708e96f1579dd7_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i37b081294e5b4b8e9e5a11799924a2f4_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i129ad2aa2cbf44d79bda671ff94c6b3a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3f56c3589dcf455e940e768c35266f9a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3f795846dbf2495a9b51d25b57687dbd_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i113e99a5148f4c19a209d84850a178e7_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i49a0549eef484d24b04fa8fcdb43efe2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifcb20618db4549fa96838e2cc81877ae_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie3dcb6bbb4364846bb3cb11e71d7614c_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if26b7f13a9ad441d8310410aad545b78_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5cf6fed6709947cdb2d2ccc2ee3bea72_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i38abb5b6d35e4640ae278494162794cb_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i355d324b4b084fcd9897163416bb017d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5747fab0a16f42f8b7a20235e05fc43d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib62f00b41eb24b118fee32484d16e6ed_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i76c87fa1c62a44db871fbb8b83163687_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i52a4807b00fd4898baafe70f646f2a51_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia164fd181a4240bb9f3e9e496fc60bb0_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i04361801595c41ef86be85e444162b27_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i998f48f9bf1e4663850834c5e23fe862_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i79db0e250e4c4f81b2bbcc5c8fefea2d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2fbc79b742df422b8eb80da9c3923e51_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i871670fc66504079bbcb712e2def07e3_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if0ae37c4002d4f7c8945b238b450a3ff_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0de005cbf7c64be2bbb15d3ad2747c39_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="idf6a11570b2f4b75989bbe9a432b4263_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if4376d5e08b3472d9cdbcc59389ab13f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i940d159cf6fc4de7a976d223e5df88bd_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i820aa0a4094e46508f3d90c1102a977b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if3d89e2baf3b40f3b69759154662da14_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="idc4cbcf7fafb47afaea1141b1ace9b8c_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9b887851ae3f40518c8ab99172a256c1_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0f45167f24e645d2ad668c47635fc09b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7b4bb3ccba1a4790beb19a0ca2cd4721_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0df51b82a6bf4ed3a20acde326a2a355_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i754a465cfe674a28bad93eaa56b395ec_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2877989be5ba41eda5048c75789f5d0b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifdc463d6e9e74476b4efb5e0ad43ff93_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i46dd5b7c9aab4334a81feabf9ee87525_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4a93811c7004483b89e5b2b7d7a47e27_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5aab13ae412a418dad03dcc21e39fa7f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i01ae4d028c1e4ad69e3c0718f2a9cad7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4e2ba0ae31ae4ff3b092f4b0364ad5e6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic491ffcc027b4b0ab4d63e1874c095cb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i62ef644e97384716bfc5c3610ba4245e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib1f9224028414e8f866988517a90edcb_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie83ec1e38c7b4f8bbfdc941221d33647_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iea72657d01094ffca27df83746971588_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i51f8f155c2a64e689c87b4aa3495476e_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie356d6063dec4577b2f6d9d0462d8e7e_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib4afb690c9224cf998243be692e833e4_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iecae6fa25eb342d9927a9e48d4dba455_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie61d00b2a6bd4ecb9cf24db30e5da1a9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if011579e71f84295ac8c9b109ec9a4ac_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ide55c02ef5074706a5aa037e6c934afd_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i95106ae9af4848e58d3a94156cc2bedc_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i770403621f9447659861ff7d3c027d04_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5065fd92c2c5486cb1c8595222c14bcc_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia40b9cd0df2a4a739c315a7e10c645be_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i906fb9f369f24ad5bc7c94038e03d844_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i143fc202262a44e4b14db40020296c68_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i556dfb6e8e81410c9a188d168e0cdfbe_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2efc45c7c6e54f1e8772b6a7d931aa76_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7f250204e97849f4b2597c9ccfb28c6e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i80d8c27dc4c4418ba9ec00bdfd449ac8_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8d2992b75ac049a8adc9368ebd3b710c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib17fdc41fa4b4440bdb187fc784528ce_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0ef1b7a971cb4cf0aa1e17dbdc38ff87_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if88c3613f4d7400abeaaf7edc177e242_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic5b535ea1a074ab0990a6830301b99c8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id41d2a02c14f46749037b85143f80400_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i032733796fec487a9ec5363a6de6bb37_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia7bb2d455a324d85b663449ae922babb_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3725ce6128304af89af87fd977d6dc98_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ibc093a125435445ba1dc79fbc34e64e1_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0e380088b1224143bea2f6722190f293_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6c913add24e44a0f9348623b21235818_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i58100a918de34961bf23cb6d60b59996_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i57645af2264341fb887ea206a381c869_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if31c285904b6492897698f18cb4e6080_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3fa27317ec3f442fbd94cf33b21e1eb2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id51eb40c9a094ab9a113fb3a71d38030_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie892b4d7a041422abdd832f50a0f95cc_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib48d2e82b97541f38e95af0a653ab27b_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueReblozylMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1eddcb43b5d249a2af4318c0c246a2fc_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueReblozylMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i25082e66e59a4337a66ed93fb65581c8_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueReblozylMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia27a4765f6f24c37a3b517d089f2ecde_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueReblozylMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7ae58919bbbb482997e5aa8e96123089_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueReblozylMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4269d8f661374131bbab73264dcada9f_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueReblozylMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i04dbdc20bf3942789452bbdc6a5e24da_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueReblozylMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8ae38dadcae24a6686971665f448c5b0_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueReblozylMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i793c1193aa2f4af6bcef7074919dee8e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueReblozylMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i67bb7f002f384902b0a86cfd9129bfc2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueReblozylMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia7bba4c38acc4bc0bb07a1951b9d31dd_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5d5c095574c748718095a6fbabbd214c_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2e3866f93c3d42e8b58a917f29364c00_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ifa2f870185b742c0a08a8329ad6e8053_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4008d740f8e74af8a6058243d2c4bffb_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i90271b2f98e64375a768383e3ac49db9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3c0492792ca04bd3b53c001091f93a58_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5efa6e77fc3b43c197b420bd2930d959_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia765dfa77c1847ddb5439dfe5e593cc2_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id754ab9092f541f1bb0c46f84d571073_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8ea41eae43e44e758d73f10739ebef8f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6d98ee5588f64bb89006d5f3b1ef89ef_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i93650c21d0cb4dce8f66684f468b7f9d_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i541aec5947cc4f8794cf3d8f132542a0_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i63937b576d734bdd874c9b62aff67ca0_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic105ebb39d4f45fdb7e76b65b2f7c268_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0270857a4ce04adc87d535004968cca2_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i20ab8f4749914720b66e1986e30f2490_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2d316c927f914028b471fa7baa8efe76_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if90d628440614f1a8b82d9012cf44d19_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iff0b49e0a2214244b08be408fb0071a8_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie667b194da5b43139fa7eb334e923aea_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if75e90d893fe4d2daef008b05cd61801_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3221816ac6554c0ea0725b82fcbe8866_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8664e2a8ba934ef993c8af9df045661c_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ice6230b5dd6b4590816f68ea0611bc32_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i47949af4a1384b7cb8b878121f95341a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ica0fb5867c7f4a1d81c9b8e00f1299c2_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i02f6c72e13d24ad5b8a9242d1bef0091_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i81969b509926485a8a666277757c512b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4e2ff6b002b74a17a257416545ef6e96_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib71b6b89fc16436fbbf1fa07b6363b8a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9222172d1bf54d24871e696a611f9678_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8a245b712a5e48669e48a3980e039452_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i49e1542b3ba3448aa3d564e26fc2446a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i13729599ed214b168aa63442d6acd6de_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iffcb1d041de24e8a98b15f54038962b9_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i57a185fc411c4db19484a70301bf7c8e_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i585b71b55aa241f0a689cb6373aa1fa2_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i225b62c9d0a94897ac8731640188187b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i08bd174e76dc49ca8a3aa6f8f34dba50_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i43dfc854ee5a409bac203fb32dd6d61d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iaa04548d03764d5bb771484866fddd91_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i443086dbe08048deaf609109e2104c35_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2dc12fb55f1f4323a0b4d26b08dcc080_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iddeb3ed477674caaa13204bb072a80e2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib5ba933b43ec40cbb59d3def6165f9fe_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7eecf1f67c2446fca9b82fda9e4a3949_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1f6536581b11466c97256e257fb58583_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="idee3f0ae73e249cd86d1e98f97ccfaca_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i48b01fe75e9e4b59aaff1fce21ed2c4c_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i46c35e3833b04258a27da6cf08e2b9c8_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icaf0413c2916445aa22a3cb92baf44d4_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib8285527fce2495eaf46116e50f1d995_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i47293d92044b48e99da891220e8b196c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3002e359e24742fbbcf884cc6e683e05_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6d13aaae18a24197815774e133bc1254_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib67c4ec99f724cbd9c5c4fb76245033c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ieb6d9b7fab874ffe8c1b46f7744ebb79_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i97fe20ab999940b48ca93613926a0d93_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9e45830a855742509ff087274006e575_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i296fff24993d4fcd957a26fcdc376978_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4dd006ef18ba4a51a0b449e2d732ad40_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i685056aa30374b748c91c804e8696590_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i265d220c8c194add815250d378abc902_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia8a9bf2b9f8d40f5891228af7ee73a36_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i81070fb665a64fc9a92e648528dced5c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="idec7bac0c49d4b1db34ff840907bd798_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if971fc9feaff4a3c9a5eb10f74e1957b_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if294e1aa3b5d46f8b28217723b28ef92_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0a7dcef569de4308a78959562aefdfa5_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4e0a807fffc84f018f4b4464b1bf9072_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1687a5207479439f8e16e57fa7ac046e_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ibbcc716f1b8a4294a8ac7755d58d7e4a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i60ba948e10b04bf89e609fd126195611_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i65e784f938b34793a6b9a65d6d6cc86e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i01d05ced165944a29e318440a8eca779_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id9538df57cac43428fedf093f6e753f1_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4649f1b3f8614c1fb6696040dc8e573c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iac88839387e24360951822241927d01c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iccc7aacfa4b9410a985e8faec1f16f9e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i182af2613ed348cf9d6dc2f9be178a66_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id57f4527272f411e8eec3fcf5da09481_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifacfb5ed95734fe7b4fc8bba627a8845_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifd682219d26f42589766951ab88e1c3e_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i86d0c8eba6b548b2980070d44447b21d_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ieafdddb927484d7aa5ac090781377625_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie32bcc064d0f4de8ba4e1e7150a0afe2_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8f5e562de1574da48919247a881ec58c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i98f319f069c14e75848d9f78788ecfd8_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i461a9aeec04e4fd48e331e0d1ae98fcd_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i26820a66f9dc4af881c3df742b2e0a5a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7115d8a391344fec99e5f60ebfc980dc_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ieab69433fba045ac8b7a8451cd492815_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8c1221038a2149c9b97c80c8f611679c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i36a64ebf107e4f91a169bc853c046233_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i71f41596ea7a4b3e8416589c8c7a8138_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1ad0235b784c4439a674f0deccf68980_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib964e6bb433d42f49dd769839ac28238_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1001be10a5d043f397906bd36d10ee6a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id51b949ade4f41899e4a18fbbbd2a1ff_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibdb4e966b7da4d629f6fe2c428ed1ef1_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8c824b0655ff4c1fb993fba481533fb9_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia8e89580305548a490f0bbe9f637440e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i37ba015ecbcd405abc7b38785b7dcfd2_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7cf6dc7c6c1c4858bf616a299a8c6420_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i81ea1f35405a45cebb4edeb8610e28c5_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i01c00548f8444dec89b6744b02a85fa3_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icd81b81346ae4eca826a989395f148a0_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0f785e58506544309ceddc1407668851_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i07bb128b4a6049b9a45a4721c32a8c32_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i85318a4d743d44788fda10cd96301c42_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idf4fe0a8e4d04a23976ea2fabe3f04e3_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i098c29dbbb064deea26d4c4f34218264_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib4a66566cbcd44aa9f077d342fdead01_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie28efd140c154386aad5f6975c8566b1_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5585d223173d42a68c6f66af1f246d09_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3fef72442c5244cfb5a176eb81962df1_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie99454bc8d07443483aa94820869b584_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icf5e6b24740e4c4fb42a6d01883937d7_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idcf29d14a518483185f8a99cefa1fa46_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i19565b312a7b438cbc10861858b1d449_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="icff15fd8bd1a4d6bb79c3beaf3519324_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia7d439da126f4be48f56a1860640621b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia2a2dc400d82406cb2a4f1761521e529_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i819facc7b2e14484a4cb6e0c2a7f93df_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7fe58d8dc5984f3cbd65658d904a9481_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ied9c00ac4d8941b4a017cbbccf4329cf_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i29dea2ed4a654c42952ab41ac972c731_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i099da3aa99d1482b90ff756d321bd102_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3f2ab84f59744e4aa1b796e01ba81c31_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i312d000608614fe586d2aedc23ea4dc0_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3ea07e7b467b4e8ba73b1f10c45b4e02_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4b9ab232d5ee4970b968974b33aa9605_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i46397225389c4799b9e0002cbf9db54c_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i38f7b98bc0114fcfac64f5b19a7f97b5_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie43d1efcc1f2463a9e6ceb872a750592_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i08ddddbcb59e45afa01649b4a5c0df02_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6441c5f89ab7428dbb9ce2a77c7d178c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2859c498f1484388a0c92b4ee1831d83_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if28586c5985c4caeb1cdebafd9ae7432_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3a21006f6f464cf49d94de523666ae32_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9bfa337eca3546e49132dfadd33405e8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i64edd776e6f848789f0bcc6abe69aed9_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idba160b3c84d4ded8e2ad24897f18196_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ife2e7a726c45443f849fea10fc2e4265_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie9b27b189bfb40db8b98e551a462b6d6_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie7ba48e565be4304b70078ffe4498c8c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5b9d23875fe444829c441808824a5a21_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib2fc16b785504c63ae17c7cdb9c1c0b0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i65ebba197f3740bdb38b629ffcf72ad5_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3da352c9af7146f4810e485c59906a57_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i097267c7483c4f3baaa83fa953994d7b_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id92b88c5c7c54cd897660ab28b07a038_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iebc064d77e2e4de99ab716e87a9baf1b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7010efc10b11415da35666aae647506f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic6d0e90eb56c49078c2cd876e4644e59_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7ea29fb65ae64c838799c4c459626dfb_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ifeca289c0b3048be95fdcdfd0d64787f_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib14fcc9488ae4e079debc5ad6830716e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i704a839b6eba4ee4be94748f20064afe_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0a3a4ecb829e4aa78305ce022676ad3a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic9dc2db957bf417fa3ce1024b7aa3b58_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie752e3ceb65d4068848193b5489d1ca3_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8121dcf41149486dbe2439280ef18566_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1535a34aeb8e4f90b2765beaa325bd11_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id4bc4cefe1a64728bdc75ff662c4916e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i03f405d0ec044a3ebbf4e986c0cf3fb0_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id39b9efc953f44ddb788ea54e6fcb237_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i17605919063e4da08e1c137da9bd3927_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i64942fccdbcb49f7bde01d647d805b92_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9d4ef7a87b2d430ab843f888c43c62b3_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i367dd154acc944f59b4091bdf4c3f88e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifafb1bde68d54e8e8d59fc667e7ad4db_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic98aa56795ec4ca9818d28b0c15c1e2c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7d8f2e37a7fd434e9e575af158e4ebe9_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="icf83422a855b450a895434e02b798a86_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iba5e8751427840c2bb6a518bf2c47c4f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ica014ad63af547c985fc0232bff3d28d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic864a76a6f394f3c8b7bcf2a3d9f5b0f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i143277cfa467423cb7fd3d1598c01536_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4fe74c4805104d82a48ee99f39bcc191_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ida94e955b46346cca755a98f10e0cbd8_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1db5110e8cf94c3b870dd8e4773cc5f5_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i33c340fce6894f5cadf9174aacc50b85_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i541eb2cfc8a1420f8d0c271d8d5b58a0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ife50c78eda8146feada734d5de383031_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i715add2286974690806d8b1238a739dd_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i88c57ba1eaf34b319e49c2126ff89f7a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i44361401a04e43f58bdac9768e7239c0_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9f94cdf096df4338a0b6aad26feb4378_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if4a89e0cf61f4161b7a76d02b5e911b6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic0219c877aef4d4d9bb018be638aca5a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i141c5ef857bb4d94935c24ab8fdae687_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ied8cbea9f58646b5a29e12373656d30a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7192b6bdb8d54ccd902726f77a8a569d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4cdb131b17ab470c9b46b991b14cadba_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie20a9ffe89114cf3b00ba22b79b96752_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i01b61b9f737f4bfeb5d1e650b58a2ff0_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i820113b59fbd45409278436c72703385_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i17a30514b5f04fcaa8af426469cdf39a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib31766a1f9ca49ed944d511b368436c8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i462cdaa6b90e45118710c4ae51e35e3a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3f7a6b941763460e99621c2796d825ab_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifb68c7470877490d9ceaade2f13e2c2e_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i671e7da6a18b400fbf6ead97234042fc_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5651cfaf52164a8ab6636928219a061e_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0c45c8df98804459883ad5bff7805922_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i080623730f624bba8919833c19347c19_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idf02f0982f4a409b968d6265bca89fa6_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idd09a4e622c048fa8abcdbbf99ea24f5_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0f4560eb1ee848ef935cf4f82c3c219b_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i28b8b17a1b1c4ca4a2c3921c1d59b492_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i29caa9c297504c4895226b55191e48e9_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib6f8d0cdf8b34365ad1b5066369bb0c6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i39f38d6401dc4807878d88582b25ad7a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8a5b415115604e5eb5904c3c92e949f3_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i75c73a0ad09046059e2cacc3ca286709_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i30253a8fdb944b15bcfad5941879e748_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i477c1387bccc4478a6df52168a873e5e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if6e598d60eca4ef790eea98e2e3cf9fb_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ide9c58e91b6e49748dcf2aabec8cefe5_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifaba7e93e3174a09b5fe7fadb95cf5a8_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id72e0113997c414097828708b9146825_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i31af4a0627894e13a9092294ef53779d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i82914b6cb0b04d3b8dfa0c36fcb1e3e1_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i875eaced42e244509d41e272f4b64999_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i13f4e544586d4c689babc9b7bb643038_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4a567b0578254433ab2843507871f589_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i803f3b4be6844c91ad48b04634b3d57a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1bcc18bbe90e47da9b7fffcfbe9b7c7f_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i34c4ac2cb8084a4192568712dceb7c7b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i48743be2360640e9b25e34524209acf5_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie6df70951a3345f5bef560a3d668c977_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i04b63cc78f284d3cb3291a6b392e691a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ida55387137da4467910d468e15316ed5_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie22a90598b6444e593ecca7b8a7971cf_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7c97559608224dfe87e9d5af61432405_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie6bbe8c6cf234e73a1885c86ba3a53a6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3d352f2ba8364c5eaa02ddd326723d7e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifee9f2e555d6447ca4a77928972c53a3_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i29d4d29ca30c43db9f653c0173a02a88_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i907dc799123d4d8a8d59145f2fe460ff_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i71b8800d43dc425ba37b1e7fbaf13774_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib88e6348738c43e789677fefc86824f0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2842b6655db442f9b1d51ae4beb1bfbf_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if4d05b65c7b54139b25ac70c4ab19df3_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i553b3f72bfd042dabe4870ebbc230630_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i56d699e134f741c0a256a5bbbd4a83fe_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if81ecb7810414c37ac52874e47f9559c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie3d729fce8a044979a61be3f06e6bf4a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i039289771e0a4a92a82f0e23c7b58113_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4c94024cf7444cc986c90074aa354bdb_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iacc83a958e43414884a750ac18d8715c_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie795535b2e254799b2ec04408e04506f_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic7abdbd57cda413bb900bc952b307246_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie81d29f45ec7442a847822087f81a983_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iaeb741d79fae4f8c9612915e80120b77_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i91f6e6feded64f13ad8e45634369dff0_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if25cccf1ea4a4ce9b81f781649b78865_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i242133cf5e834e02a75bc0fb1d5dbaa2_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic0a3898f0f3e4eda824b64c14e338702_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i08274445c04f4069980cb990559bb715_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2ffb95f5c9c046ba9c390129a0e69d65_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibb00fde3c5fe4302aff44ebc212aecc1_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if513f7a17c0e49989ccf849ee4dc9331_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i638069bb860a415daddfd8838b2cdd19_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9f7703ad94b54db9a9215c0db5b0cd62_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i783f44f8b2654fc4af2d919e37ce22a7_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i66a5cfc38a70434b9ceec5c2285168aa_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1310ca8214184c8b9d2a080cfe0da7c0_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1abf9ffbfb5d44aeb0a9463ac4398eab_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i71b867c3c4ec478abe984d94d0169df7_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i823ae7ab9f7e4d099e7876b9b19ae298_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i095b912afc3343538d71712bd5e5af82_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1f8a3bf7c42c44aea99cef1412e8dbb0_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic22e7e95653e4fb0a95e61763a3569b2_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id51e37617d5248369c24578f16a1cf14_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i44564486e4b54deba76702deafc0f64b_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id1e17bbb1a904f4f9887423378bb5af6_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i07782e31373f44de9555f3b81cdd9628_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibd79168d00974ebc85c149dd99401528_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if91a5aa8a47941858c207f93c372c557_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i50377394250b4f6eb2cdd388e247c98e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4485c1a08fb843e2a1746a8633829398_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8da429c5485f4cb78dbd9c99fc97e840_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i241616d8d1cc4bd1a17072d1fe359907_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3168b97c7cfe40dd968aff24fac21714_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic827d96e5107479f8a50ac1552243075_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9f280f0335f34739a091905a7605c8fb_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie50dbb604c9b4e1a89e5a02734c3435e_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie7e482e96daf4d1aba90f65b4d004d1c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0984754f7dc14a15ae031293bbf02033_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icb3bab98f9034f8381e05152809cb5ba_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia409b352549644d08a3f0a4940dba700_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3d9ec8e3f10a4277a866ec3be3d50f2e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i11db00c425ed4fb0885192fe0be29cc9_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i839b44dbb9c245789d8af1b83cda8eb5_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0efc28dad4a44fa5966707fcb540b4b1_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1aea48b047e34184a2746ed722f8d736_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9588db6b282c4b73afec4971984508f9_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i097a676b323a42889c16acb4a376e3c0_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic40e96203c084d60902d25625a1bc564_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6427cb6f43ec40cfa361720f0ac45cd2_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i43885c95db8a44fe80b17b1fef791c59_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i38960dddb9404fe98542807220cd75b8_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8993fa041a484e879c4a6485620bebd7_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9ee7156a4b614122a54d9522c59d5c78_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i641cb943aa714600b89da7ddd3df0d89_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia71e4576e6394e3780b1fb370ab8eca7_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if8df911dbd564fbf849019ee57246892_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7b5cb0fe57d04ef598a24dd039eef72c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i54a7afab074f405e8ef80dabdfecdf0e_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i31118e3777414395bca00605e465fac7_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0c738afeb7f541e7a7cee2e74587d6e2_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic630a421623e412e899316999b1d84a3_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i947ae1e75b3d491087466d3c41d239a4_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic7874341a97d4c089a290cd4c52ca3ef_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic3a9a7407ef94ca0a066f8f1b41ac915_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie74c0c26e4194d0ca851b4f339b64aff_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if24d9980d69a415285bcfb8af2e4760a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie52d61f419f94c0cafc9a9d7cc18a763_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0eaeb3befcf640f7b164ca0a1c2686aa_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0d6fe701a40b465cacd7765161ea4559_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic37bfb89cb3640ad8e236e59f73d6359_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if8fd87789a924ef1962a3681f884ed11_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie736eb61ba964832abed00a756bb99fe_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2bf14f8f5d2747e58b18f20cc5051555_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i30e83259e5b648859b1c791fc219f795_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i769a6f6f373c4424a78daa11151e8693_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifae6a5b5be2d4e27b57c8cb59e7b736d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia4d49c3f485c4a969fc279eae65aea0c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic976522683894b2f851b9eb9a9e99339_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id6158ef12bd24d40b494575847b10455_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6c9b56c797144ae883e07ceee9eb81ad_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i748adeb1c1b74b4a80ea71f1622e0a83_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i58abc744b88c49d996c9335dc7e4e26a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia2cdaaadd890437ea5827bcebf07e28c_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3b6ac35939974a6680f67f6f5cb6cfbd_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ifecb5cf258f942c68db448dc19d76074_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id7452b2558944b89aa0c78702511531b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie95d0a9de94f48bc9a2edc6e093ccd9d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i46b3dbdcc4454d4ab3079f2407d0e808_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i997e727369cc4c879b4f65634d5c9167_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ied57d33df852404ea42cbb9249fb4ff7_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3dd1ed9c80f84232aa613ebfc30fce1b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2f54658358b74dd2a2602a4b93e49d03_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic7a6672a05e34d6090ab13ec171a3c16_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9dbe9922fd544a0e817961eb18397dfb_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i998bc7df80cd421c86a31d55b20b2f00_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1501c38c01f24f46ab98fa0918a29aea_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i461edb12a6e0421a95ce0ac6c93adbca_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie95f6e7a4c9a45b98ee10519480bcc57_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i609ee3a20dca4ef2a07a72f3aa7bd472_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5dcd8e73f06541bf90ce68a9090f463c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6ddf8513030e4e22ab98fead59aa24a8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ide9fd53158404da68f8ed38707c6e730_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia5c146f01bfc4a0fb436eac2074cdf40_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9eb6d9a053c248a8abc9535a66f119f6_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i95e954dfb89d4490bc7f62728171c3c7_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic896ad83efec4ff7a7a62329387853a7_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0e4b569901524a64b1ef34cb1524a967_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3fce1d67949c48ccb03f9e12c3e52dae_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i050b473f8c3f4780be91b8883989770d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icab0d5373a6143ba8a8971886fd366eb_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i94657ee062ab4c07a5644722ec7e5f4d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i011ff8ae410c45ee9363ef7b31f62ff6_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8ccfec64c8df4db89a86df0ec6e79d66_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6bf58675420348dea4421700f6d61b1d_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i22eef57a3e534bce9a842560378654e4_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7fe1b46c7e9040539c417e8044482c9a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0820e5db91674b1b9eb3859fb1471846_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3e743f7eaf994261a54320837d8cdc38_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic25e83ccb0774f9f8d3a60252008d95d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2c91091b09d34c3eb1b8f917bf6a6e92_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8b5a7c79bc084682a64cd091d3a8258c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i97fa5da6b3924d8d99c2fbceb69c59d9_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iccf7a7e39a1444609739fe18036ae1a6_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i22490ec2cbf04c3994fd5195617c0cd1_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3d7cf65513ab4159b2feb11639c2f8b8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i69959f4306b342dbbb1318e7d3cf276a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i59506b8e5aae42f880005525de216ce0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1091a13b711442e0848bc698d9a73a45_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id9e3336b01ef433aa8801b345dea8c4d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="research_program">
        <measure>mrk:research_program</measure>
    </unit>
    <unit id="collaboration_target">
        <measure>mrk:collaboration_target</measure>
    </unit>
    <unit id="market">
        <measure>mrk:market</measure>
    </unit>
    <unit id="course">
        <measure>mrk:course</measure>
    </unit>
    <unit id="interest_rate_swap">
        <measure>mrk:interest_rate_swap</measure>
    </unit>
    <unit id="case">
        <measure>mrk:case</measure>
    </unit>
    <unit id="claim">
        <measure>mrk:claim</measure>
    </unit>
    <unit id="segment">
        <measure>mrk:segment</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80L2ZyYWc6NWU3MWY0Yjg4MWJmNDA1NzkyZTk3ODc1YTkxNDU5NzcvdGFibGU6NTMwODk3ODI2MTUzNDA1MzkxMzc3ZGFmYjhjMjE2OTgvdGFibGVyYW5nZTo1MzA4OTc4MjYxNTM0MDUzOTEzNzdkYWZiOGMyMTY5OF8zLTEtMS0xLTk0NDE0_ecc8260c-b71f-4c56-8c7f-34ea4ea18108">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80L2ZyYWc6NWU3MWY0Yjg4MWJmNDA1NzkyZTk3ODc1YTkxNDU5NzcvdGFibGU6NTMwODk3ODI2MTUzNDA1MzkxMzc3ZGFmYjhjMjE2OTgvdGFibGVyYW5nZTo1MzA4OTc4MjYxNTM0MDUzOTEzNzdkYWZiOGMyMTY5OF80LTEtMS0xLTk0NDE0_81c2931f-4b09-421e-843f-a2e18d03b188">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80L2ZyYWc6NWU3MWY0Yjg4MWJmNDA1NzkyZTk3ODc1YTkxNDU5NzcvdGFibGU6NTMwODk3ODI2MTUzNDA1MzkxMzc3ZGFmYjhjMjE2OTgvdGFibGVyYW5nZTo1MzA4OTc4MjYxNTM0MDUzOTEzNzdkYWZiOGMyMTY5OF81LTEtMS0xLTk0NDE0_1fc3e71f-6ba0-43de-b92f-0a3cfb92061a">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80L2ZyYWc6NWU3MWY0Yjg4MWJmNDA1NzkyZTk3ODc1YTkxNDU5NzcvdGFibGU6NTMwODk3ODI2MTUzNDA1MzkxMzc3ZGFmYjhjMjE2OTgvdGFibGVyYW5nZTo1MzA4OTc4MjYxNTM0MDUzOTEzNzdkYWZiOGMyMTY5OF82LTEtMS0xLTk0NDE0_f2dfa510-cdbd-46b6-9cee-d5ec4db4eb6a">0000310158</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80L2ZyYWc6NWU3MWY0Yjg4MWJmNDA1NzkyZTk3ODc1YTkxNDU5NzcvdGFibGU6NTMwODk3ODI2MTUzNDA1MzkxMzc3ZGFmYjhjMjE2OTgvdGFibGVyYW5nZTo1MzA4OTc4MjYxNTM0MDUzOTEzNzdkYWZiOGMyMTY5OF83LTEtMS0xLTk0NDE0_a9164299-306f-42d1-a5e2-4fbf82fd6df5">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="i11700d15290f425cb74a002a0cd2a29e_D20210602-20210602"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNy9mcmFnOjFlOTcwNGY2ZThhYjRiOGZhNzVmZjkyNGNjMTllNjdjL3RleHRyZWdpb246MWU5NzA0ZjZlOGFiNGI4ZmE3NWZmOTI0Y2MxOWU2N2NfMjc_ce3969f9-8ade-43ef-be7f-ce7c58774a5d"
      unitRef="number">0.1</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i6533dbb8649144648ffc4f4c1244c7c9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNy9mcmFnOjFlOTcwNGY2ZThhYjRiOGZhNzVmZjkyNGNjMTllNjdjL3RleHRyZWdpb246MWU5NzA0ZjZlOGFiNGI4ZmE3NWZmOTI0Y2MxOWU2N2NfMTky_3bc21732-98e4-459d-9b41-8b93143cb8e6"
      unitRef="usd">0</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i26b4f40fba294c2ab11871350926ecda_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNy9mcmFnOjFlOTcwNGY2ZThhYjRiOGZhNzVmZjkyNGNjMTllNjdjL3RleHRyZWdpb246MWU5NzA0ZjZlOGFiNGI4ZmE3NWZmOTI0Y2MxOWU2N2NfMTk1_ec1da32d-feec-4e1e-b9b7-39754c320fc2"
      unitRef="usd">0</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RelatedPartiesAmountInCostOfSales
      contextRef="i6533dbb8649144648ffc4f4c1244c7c9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNy9mcmFnOjFlOTcwNGY2ZThhYjRiOGZhNzVmZjkyNGNjMTllNjdjL3RleHRyZWdpb246MWU5NzA0ZjZlOGFiNGI4ZmE3NWZmOTI0Y2MxOWU2N2NfMTk4_18b17651-2424-4945-9705-217c5851688a"
      unitRef="usd">0</us-gaap:RelatedPartiesAmountInCostOfSales>
    <us-gaap:RelatedPartiesAmountInCostOfSales
      contextRef="i26b4f40fba294c2ab11871350926ecda_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNy9mcmFnOjFlOTcwNGY2ZThhYjRiOGZhNzVmZjkyNGNjMTllNjdjL3RleHRyZWdpb246MWU5NzA0ZjZlOGFiNGI4ZmE3NWZmOTI0Y2MxOWU2N2NfMjAx_e3851a61-43c4-40c7-aaaf-610be71b16c4"
      unitRef="usd">0</us-gaap:RelatedPartiesAmountInCostOfSales>
    <us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration
      contextRef="i53f76af88d63418dba6b1ea3a71d7ecb_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNC0xLTEtMS0xMDUwNTY_4beacbd1-84ea-489f-8ac6-b09392c17877">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrent</us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration
      contextRef="ic7eb7aa0cad44ae481279be50ead5cf3_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNC0xLTEtMS0xMDUwNTY_4c50954f-2f04-4bb2-9e7e-854b1813a13f">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrent</us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration
      contextRef="i92c41baff7714a72894f9c962e96d0a8_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNS0xLTEtMS05NDQxNA_2a5d2377-4bbd-47ad-9925-404ca9a51736">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrent</us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration
      contextRef="i97bb92e54ef74a8db32f912747efe346_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNS0xLTEtMS05NDQxNA_c6df00f3-bff8-4562-abe7-498764d34146">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrent</us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration
      contextRef="i92c868d7e8f9475893857146e49ffbb1_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNi0xLTEtMS05NDQxNA_6baf831a-4ac8-4464-8eb1-254345d36853">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsNoncurrent</us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration
      contextRef="i8f6e2cbf96bd4896863dbb8f79fdf2b1_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNi0xLTEtMS05NDQxNA_95f68aac-d3b4-4319-9f3d-70e85b1424c4">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsNoncurrent</us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
      contextRef="i338b3ccaae68438b96b0f370fd0bb963_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNy0xLTEtMS05NDQxNA_6a9babb4-e747-4df0-a56c-3595290d8927">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
      contextRef="ic2398c81940b40eabe737fa14c821b96_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNy0xLTEtMS05NDQxNA_ae73e90d-8b40-4bfe-b1e5-b0c0132d4407">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
      contextRef="ifa0ad26fa2f64d7ca0cf4d95ae5c7567_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfOC0xLTEtMS05NDQxNA_3d168174-838c-4aa7-834d-0305c0dea6db">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
      contextRef="ib67ea4886b8c40868d422b24ac9e580d_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfOC0xLTEtMS05NDQxNA_8a78e2f6-5d79-40d5-8cfd-da850ad40e02">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration
      contextRef="i7382fed477fc47e3acfc51cf0827f22a_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTEtMS0xLTEtMTA1MTE3_0942da13-4366-4941-8d73-f86fd1003d65">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrent</us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration
      contextRef="ieba4d46f4e9b4513aa30046a1640a2d1_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTEtMS0xLTEtMTA1MTE3_ed1a83b6-f315-4484-ba3e-ac3634db5ded">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrent</us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
      contextRef="i7382fed477fc47e3acfc51cf0827f22a_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTItMS0xLTEtMTA1MTE5_35d04908-60bc-47a5-b559-4d800d70da91">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
      contextRef="ieba4d46f4e9b4513aa30046a1640a2d1_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTItMS0xLTEtMTA1MTE5_f4049782-8c11-4ab1-9f60-0268bac9cd63">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTMtMC0xLTEtOTQ0MTQ_415ec0c9-4bba-4fb9-aa01-b4c7b84244a9">http://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpense</us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTMtMC0xLTEtOTQ0MTQ_a2ea2169-dd57-478e-b872-7cc7be5bf76a">http://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpense</us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTMtMC0xLTEtOTQ0MTQ_c6f59e51-c8a0-4c45-930c-4ef2ed96eb20">http://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpense</us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTMtMC0xLTEtOTQ0MTQ_ff915512-cf0d-456d-a25d-7aab715fc26c">http://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpense</us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <mrk:LossContingencyTrialPeriod
      contextRef="i6f0b5b41d05242aba7c807e0dd337a4d_D20221219-20221219"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81NS9mcmFnOjNiNDE0ZjBmNjBmMDQwMzliNDRkNjY1ODhlODBiYTcyL3RleHRyZWdpb246M2I0MTRmMGY2MGYwNDAzOWI0NGQ2NjU4OGU4MGJhNzJfMTY0OTI2NzQ4NjEyNg_dc252ca0-1f84-47f5-aa4a-e30b0bbfb328">P1D</mrk:LossContingencyTrialPeriod>
    <dei:DocumentType
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGV4dHJlZ2lvbjpmNjU1OWQ4NzkzMzA0OTQ5YWZiMjYwY2RlNTk2MTU2NV8xODk3_13118461-31b2-4299-9ca0-7f2395d4f07d">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGFibGU6MmU2NmY1MjQzOGZiNGJkODg1NWExOTBjN2Y5ZTNjMmQvdGFibGVyYW5nZToyZTY2ZjUyNDM4ZmI0YmQ4ODU1YTE5MGM3ZjllM2MyZF8wLTAtMS0xLTk0NDE0_38557a66-9fbe-406a-80a6-627684a224bb">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGV4dHJlZ2lvbjpmNjU1OWQ4NzkzMzA0OTQ5YWZiMjYwY2RlNTk2MTU2NV8xNDA_f46a70dc-1ded-480e-b2a1-e9ddb219bcc6">2022-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGFibGU6YjFiOTYxNWI4Yjk3NDg0ODliOTA3ODZlNzFhZjkyMTAvdGFibGVyYW5nZTpiMWI5NjE1YjhiOTc0ODQ4OWI5MDc4NmU3MWFmOTIxMF8wLTAtMS0xLTk0NDE0_892da2ca-49cb-4e25-8322-2034cca0c9b5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGV4dHJlZ2lvbjpmNjU1OWQ4NzkzMzA0OTQ5YWZiMjYwY2RlNTk2MTU2NV8xODkw_247dfb0b-7f67-4bb6-816f-ebf25ee179b2">1-6571</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGV4dHJlZ2lvbjpmNjU1OWQ4NzkzMzA0OTQ5YWZiMjYwY2RlNTk2MTU2NV8xODkx_97068807-b3c2-4936-8614-7e0b5d3e48a5">Merck&#160;&amp; Co., Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGFibGU6ZmM1N2EzNmIzZjY4NDlhNWIyYTg0YjEyY2E5NTdlNTUvdGFibGVyYW5nZTpmYzU3YTM2YjNmNjg0OWE1YjJhODRiMTJjYTk1N2U1NV8wLTAtMS0xLTk0NDE0_486a57cc-51b7-4e36-bab2-9cefc73011af">NJ</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGFibGU6ZmM1N2EzNmIzZjY4NDlhNWIyYTg0YjEyY2E5NTdlNTUvdGFibGVyYW5nZTpmYzU3YTM2YjNmNjg0OWE1YjJhODRiMTJjYTk1N2U1NV8wLTEtMS0xLTk0NDE0_5240791a-4165-49dc-b452-8acfdcec3fa4">22-1918501</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGFibGU6ZmM1N2EzNmIzZjY4NDlhNWIyYTg0YjEyY2E5NTdlNTUvdGFibGVyYW5nZTpmYzU3YTM2YjNmNjg0OWE1YjJhODRiMTJjYTk1N2U1NV8zLTAtMS0xLTk0NDE0_532a32a2-74da-4649-a946-8330d94ecfc6">126 East Lincoln Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGFibGU6ZmM1N2EzNmIzZjY4NDlhNWIyYTg0YjEyY2E5NTdlNTUvdGFibGVyYW5nZTpmYzU3YTM2YjNmNjg0OWE1YjJhODRiMTJjYTk1N2U1NV80LTAtMS0xLTk0NDE0_1164c88f-1265-40b5-b2fc-f2aad993b6bb">Rahway</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGFibGU6ZmM1N2EzNmIzZjY4NDlhNWIyYTg0YjEyY2E5NTdlNTUvdGFibGVyYW5nZTpmYzU3YTM2YjNmNjg0OWE1YjJhODRiMTJjYTk1N2U1NV80LTEtMS0xLTk0NDE0_8b776d7b-31d9-4745-8781-da0d9b7863b5">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGFibGU6ZmM1N2EzNmIzZjY4NDlhNWIyYTg0YjEyY2E5NTdlNTUvdGFibGVyYW5nZTpmYzU3YTM2YjNmNjg0OWE1YjJhODRiMTJjYTk1N2U1NV80LTItMS0xLTk0NDE0_a3bd47a4-beeb-4d2b-85ea-609d47df7055">07065</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGV4dHJlZ2lvbjpmNjU1OWQ4NzkzMzA0OTQ5YWZiMjYwY2RlNTk2MTU2NV8xODky_025829a9-da23-4e6d-967c-804ce049d6de">(908)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGV4dHJlZ2lvbjpmNjU1OWQ4NzkzMzA0OTQ5YWZiMjYwY2RlNTk2MTU2NV8xODkz_8305c08c-facd-4625-9b68-f458033a52cc">740-4000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="id0e20af91c5143088498043650185a6c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGFibGU6ZWNjOGNhOTBiZjk4NGNkNGE4OTFhNTM2Y2M5MjFiYTUvdGFibGVyYW5nZTplY2M4Y2E5MGJmOTg0Y2Q0YTg5MWE1MzZjYzkyMWJhNV8yLTAtMS0xLTk0NDE0_4f5b5464-b067-458a-a678-937f2d412e27">Common Stock ($0.50&#160;par value)</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="id0e20af91c5143088498043650185a6c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGFibGU6ZWNjOGNhOTBiZjk4NGNkNGE4OTFhNTM2Y2M5MjFiYTUvdGFibGVyYW5nZTplY2M4Y2E5MGJmOTg0Y2Q0YTg5MWE1MzZjYzkyMWJhNV8yLTEtMS0xLTk0NDE0_363d23ca-ab16-42ea-a2d7-fa9fb0ba281f">MRK</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="id0e20af91c5143088498043650185a6c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGFibGU6ZWNjOGNhOTBiZjk4NGNkNGE4OTFhNTM2Y2M5MjFiYTUvdGFibGVyYW5nZTplY2M4Y2E5MGJmOTg0Y2Q0YTg5MWE1MzZjYzkyMWJhNV8yLTItMS0xLTk0NDE0_be5e0b2b-61f5-4427-95e4-81008d49d450">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i7000ad694c3b4ad882a0d1dfafbd3864_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGFibGU6ZWNjOGNhOTBiZjk4NGNkNGE4OTFhNTM2Y2M5MjFiYTUvdGFibGVyYW5nZTplY2M4Y2E5MGJmOTg0Y2Q0YTg5MWE1MzZjYzkyMWJhNV8zLTAtMS0xLTk0NDE0_7186ea8e-4fe7-4b1c-ab93-4c6dcfc8a777">0.500% Notes due 2024</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i7000ad694c3b4ad882a0d1dfafbd3864_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGFibGU6ZWNjOGNhOTBiZjk4NGNkNGE4OTFhNTM2Y2M5MjFiYTUvdGFibGVyYW5nZTplY2M4Y2E5MGJmOTg0Y2Q0YTg5MWE1MzZjYzkyMWJhNV8zLTEtMS0xLTk0NDE0_3562408a-b201-4298-b53a-f9793ae3452d">MRK 24</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i7000ad694c3b4ad882a0d1dfafbd3864_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGFibGU6ZWNjOGNhOTBiZjk4NGNkNGE4OTFhNTM2Y2M5MjFiYTUvdGFibGVyYW5nZTplY2M4Y2E5MGJmOTg0Y2Q0YTg5MWE1MzZjYzkyMWJhNV8zLTItMS0xLTk0NDE0_f0b5a440-5673-44da-817f-d731abb40d0c">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i5f2be8ca05e84092be3101ab17e36630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGFibGU6ZWNjOGNhOTBiZjk4NGNkNGE4OTFhNTM2Y2M5MjFiYTUvdGFibGVyYW5nZTplY2M4Y2E5MGJmOTg0Y2Q0YTg5MWE1MzZjYzkyMWJhNV80LTAtMS0xLTk0NDE0_afbcfdd8-908f-488e-857d-e71642e62b64">1.875% Notes due 2026</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i5f2be8ca05e84092be3101ab17e36630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGFibGU6ZWNjOGNhOTBiZjk4NGNkNGE4OTFhNTM2Y2M5MjFiYTUvdGFibGVyYW5nZTplY2M4Y2E5MGJmOTg0Y2Q0YTg5MWE1MzZjYzkyMWJhNV80LTEtMS0xLTk0NDE0_0a7acd41-a56a-4635-a18f-9e4d5147bfce">MRK/26</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i5f2be8ca05e84092be3101ab17e36630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGFibGU6ZWNjOGNhOTBiZjk4NGNkNGE4OTFhNTM2Y2M5MjFiYTUvdGFibGVyYW5nZTplY2M4Y2E5MGJmOTg0Y2Q0YTg5MWE1MzZjYzkyMWJhNV80LTItMS0xLTk0NDE0_fbe2a2ed-6b6b-463f-a4b7-5628535d410a">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="id4c29ff612c740d08bbaa6fdd4e76510_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGFibGU6ZWNjOGNhOTBiZjk4NGNkNGE4OTFhNTM2Y2M5MjFiYTUvdGFibGVyYW5nZTplY2M4Y2E5MGJmOTg0Y2Q0YTg5MWE1MzZjYzkyMWJhNV81LTAtMS0xLTk0NDE0_c27c6419-e78f-49b1-9070-8d546792ad83">2.500% Notes due 2034</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="id4c29ff612c740d08bbaa6fdd4e76510_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGFibGU6ZWNjOGNhOTBiZjk4NGNkNGE4OTFhNTM2Y2M5MjFiYTUvdGFibGVyYW5nZTplY2M4Y2E5MGJmOTg0Y2Q0YTg5MWE1MzZjYzkyMWJhNV81LTEtMS0xLTk0NDE0_1899a022-49a0-4beb-8a78-36798e5c402f">MRK/34</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="id4c29ff612c740d08bbaa6fdd4e76510_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGFibGU6ZWNjOGNhOTBiZjk4NGNkNGE4OTFhNTM2Y2M5MjFiYTUvdGFibGVyYW5nZTplY2M4Y2E5MGJmOTg0Y2Q0YTg5MWE1MzZjYzkyMWJhNV81LTItMS0xLTk0NDE0_5a9a1d82-a0ae-4ecb-aa85-6d4f50245777">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i143bd665f1bf44a2a2623915d83f6b2b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGFibGU6ZWNjOGNhOTBiZjk4NGNkNGE4OTFhNTM2Y2M5MjFiYTUvdGFibGVyYW5nZTplY2M4Y2E5MGJmOTg0Y2Q0YTg5MWE1MzZjYzkyMWJhNV82LTAtMS0xLTk0NDE0_7711d788-16bd-47f8-aaff-7e08516e3c70">1.375% Notes due 2036</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i143bd665f1bf44a2a2623915d83f6b2b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGFibGU6ZWNjOGNhOTBiZjk4NGNkNGE4OTFhNTM2Y2M5MjFiYTUvdGFibGVyYW5nZTplY2M4Y2E5MGJmOTg0Y2Q0YTg5MWE1MzZjYzkyMWJhNV82LTEtMS0xLTk0NDE0_f3c0f58c-bc9d-426e-b14a-d54b2cc5181c">MRK 36A</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i143bd665f1bf44a2a2623915d83f6b2b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGFibGU6ZWNjOGNhOTBiZjk4NGNkNGE4OTFhNTM2Y2M5MjFiYTUvdGFibGVyYW5nZTplY2M4Y2E5MGJmOTg0Y2Q0YTg5MWE1MzZjYzkyMWJhNV82LTItMS0xLTk0NDE0_59c9f8bf-526b-4ef9-99da-de6591d9c425">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGV4dHJlZ2lvbjpmNjU1OWQ4NzkzMzA0OTQ5YWZiMjYwY2RlNTk2MTU2NV8xODk0_ccf12b35-0944-4344-aeb5-02a3f6458909">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGV4dHJlZ2lvbjpmNjU1OWQ4NzkzMzA0OTQ5YWZiMjYwY2RlNTk2MTU2NV8xODk1_25fa19a8-81cd-4d89-8b3f-b4461b1a7c38">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGFibGU6NWUzYjA4MGQ1ZjA0NGQyZGExNjJjN2U4NDM5ZTRmMjcvdGFibGVyYW5nZTo1ZTNiMDgwZDVmMDQ0ZDJkYTE2MmM3ZTg0MzllNGYyN18wLTAtMS0xLTk0NDE0_b3e17b2e-7d26-41b5-9329-c45e5ec078f6">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGFibGU6NWUzYjA4MGQ1ZjA0NGQyZGExNjJjN2U4NDM5ZTRmMjcvdGFibGVyYW5nZTo1ZTNiMDgwZDVmMDQ0ZDJkYTE2MmM3ZTg0MzllNGYyN18yLTMtMS0xLTk0NDE0_5f47d8d4-d254-4214-9848-300f6b2ffbaf">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGFibGU6NWUzYjA4MGQ1ZjA0NGQyZGExNjJjN2U4NDM5ZTRmMjcvdGFibGVyYW5nZTo1ZTNiMDgwZDVmMDQ0ZDJkYTE2MmM3ZTg0MzllNGYyN180LTMtMS0xLTk0NDE0_a9970143-df18-43e9-8d8d-89fc0f204bc4">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGV4dHJlZ2lvbjpmNjU1OWQ4NzkzMzA0OTQ5YWZiMjYwY2RlNTk2MTU2NV8xODk2_4eef1dfe-406d-4c8c-b801-d2c6f381e26e">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="if3f74b51a5dc4dc6b59e6013885b63ab_I20221031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xL2ZyYWc6ZjY1NTlkODc5MzMwNDk0OWFmYjI2MGNkZTU5NjE1NjUvdGV4dHJlZ2lvbjpmNjU1OWQ4NzkzMzA0OTQ5YWZiMjYwY2RlNTk2MTU2NV8xODg3_fa744165-ce60-41d0-a095-6cc007f83571"
      unitRef="shares">2535395974</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Revenues
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMi0xLTEtMS05NDQxNA_6f1eac12-5c2c-41fd-ac77-39963b7135eb"
      unitRef="usd">14959000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMi0zLTEtMS05NDQxNA_7c9e15ac-9811-439e-84e6-e6b6358bcdd1"
      unitRef="usd">13154000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMi01LTEtMS05NDQxNA_93be19a2-92d3-44b5-b71c-13e4fcfbeb64"
      unitRef="usd">45453000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMi03LTEtMS05NDQxNA_0d5bd26d-2afc-4501-b448-9026aedf7176"
      unitRef="usd">35183000000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfNC0xLTEtMS05NDQxNA_f7417167-1e04-41d3-8912-48071813d73b"
      unitRef="usd">3934000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfNC0zLTEtMS05NDQxNA_706351fc-53a1-411d-8335-5b2f3aa0aee1"
      unitRef="usd">3450000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfNC01LTEtMS05NDQxNA_11424b05-f72f-4356-8588-40cd3ffdf6a8"
      unitRef="usd">13530000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfNC03LTEtMS05NDQxNA_25ab2b96-912e-406c-86a8-32eefb7f0c57"
      unitRef="usd">9752000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfNS0xLTEtMS05NDQxNA_5947444d-0abc-4cca-b183-ebeb69b88811"
      unitRef="usd">2520000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfNS0zLTEtMS05NDQxNA_9899ecf5-36f2-46b6-ace4-e215a5e15d79"
      unitRef="usd">2336000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfNS01LTEtMS05NDQxNA_c49d0b51-f73a-4d71-b0db-15f2c24a625a"
      unitRef="usd">7355000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfNS03LTEtMS05NDQxNA_7c594f2b-3e6f-45c5-b8e0-4faa1eec1e8a"
      unitRef="usd">6804000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfNi0xLTEtMS05NDQxNA_e8682ad2-3cfb-4df8-8c83-ff7a319c92a2"
      unitRef="usd">4399000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfNi0zLTEtMS05NDQxNA_445d6066-9e7a-46f6-9d86-ce5b36e00a17"
      unitRef="usd">2445000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfNi01LTEtMS05NDQxNA_52232775-dd1c-4a95-904f-4a3d85cf175f"
      unitRef="usd">9773000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfNi03LTEtMS05NDQxNA_551fc86a-d45a-42bb-8d83-b7a885f85813"
      unitRef="usd">9177000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:RestructuringCharges
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfNy0xLTEtMS05NDQxNA_3b467474-7449-4e07-88ab-41c1e8d35d0f"
      unitRef="usd">94000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfNy0zLTEtMS05NDQxNA_c3cfaddb-c615-406a-ba26-8d0a3180b811"
      unitRef="usd">107000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfNy01LTEtMS05NDQxNA_2f329723-52c9-4fde-8599-95400497c1ae"
      unitRef="usd">288000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfNy03LTEtMS05NDQxNA_6cfc9cbf-634a-43bc-b5af-38d64c7e1e47"
      unitRef="usd">487000000</us-gaap:RestructuringCharges>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfOC0xLTEtMS05NDQxNA_98a35210-07de-4355-b4b4-18c86704965a"
      unitRef="usd">-429000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfOC0zLTEtMS05NDQxNA_8362a6f4-b404-4ce2-8bf4-7d60a2a82159"
      unitRef="usd">450000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfOC01LTEtMS05NDQxNA_929c0cda-d181-4452-ac66-b60ec2a3bdd6"
      unitRef="usd">-1576000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfOC03LTEtMS05NDQxNA_676d5b83-5c23-4cf8-ac8a-80374ad66dd3"
      unitRef="usd">1007000000</us-gaap:OtherNonoperatingIncomeExpense>
    <mrk:CostsExpensesAndOther
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfOS0xLTEtMS05NDQxNA_3356f8ac-2fa1-45a7-a1e4-012f038de813"
      unitRef="usd">11376000000</mrk:CostsExpensesAndOther>
    <mrk:CostsExpensesAndOther
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfOS0zLTEtMS05NDQxNA_8164411f-7dd9-4bbe-b36a-7b97202bf13b"
      unitRef="usd">7888000000</mrk:CostsExpensesAndOther>
    <mrk:CostsExpensesAndOther
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfOS01LTEtMS05NDQxNA_895773cd-5396-4ce2-9ab7-c98f4cdc9ed2"
      unitRef="usd">32522000000</mrk:CostsExpensesAndOther>
    <mrk:CostsExpensesAndOther
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfOS03LTEtMS05NDQxNA_15de6d62-c5e7-4816-b45e-6ed651f48e80"
      unitRef="usd">25213000000</mrk:CostsExpensesAndOther>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTAtMS0xLTEtOTQ0MTQ_93aac89d-1ae8-4936-8994-890787581275"
      unitRef="usd">3583000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTAtMy0xLTEtOTQ0MTQ_ccb8c8d0-9930-4c49-93a8-6221f343eeba"
      unitRef="usd">5266000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTAtNS0xLTEtOTQ0MTQ_dcabfccf-bc0f-4cfa-86df-04d0d653bbf9"
      unitRef="usd">12931000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTAtNy0xLTEtOTQ0MTQ_27a78b47-68d9-4b62-beab-b167d1a2940a"
      unitRef="usd">9970000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTEtMS0xLTEtOTQ0MTQ_4a3e459c-1d78-4aef-bde5-17b47f871429"
      unitRef="usd">330000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTEtMy0xLTEtOTQ0MTQ_cc7b145f-94fe-4959-b271-36cee1ca4dcd"
      unitRef="usd">695000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTEtNS0xLTEtOTQ0MTQ_e8a7122c-197b-4890-a721-a79a536b3b2e"
      unitRef="usd">1423000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTEtNy0xLTEtOTQ0MTQ_4452e434-e435-44aa-bc59-c4df8f544263"
      unitRef="usd">1436000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTItMS0xLTEtOTQ0MTQ_90becf3a-b86c-4df5-9d94-4392645edff4"
      unitRef="usd">3253000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTItMy0xLTEtOTQ0MTQ_c043ca3f-92d7-4d01-aa9b-b7d3da25b04b"
      unitRef="usd">4571000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTItNS0xLTEtOTQ0MTQ_58b890b4-aa82-40e9-a3af-04aad8bc691b"
      unitRef="usd">11508000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTItNy0xLTEtOTQ0MTQ_c1b7ea98-a513-4f40-8d52-7e7fef16b379"
      unitRef="usd">8534000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTMtMS0xLTEtOTQ0MTQ_53c9f10a-e01d-4843-8fd6-5f185d9ea2f2"
      unitRef="usd">5000000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTMtMy0xLTEtOTQ0MTQ_112acf93-19e2-45a1-a5e2-22e128597abd"
      unitRef="usd">4000000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTMtNS0xLTEtOTQ0MTQ_9df0039f-e542-4c25-8922-de321eb20b7c"
      unitRef="usd">6000000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTMtNy0xLTEtOTQ0MTQ_d6b7e219-1fda-4ee5-9751-c7ddea0d122e"
      unitRef="usd">9000000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTQtMS0xLTEtOTQ0MTQ_3ca4fb79-2e29-4af2-a284-adf416c3b9f8"
      unitRef="usd">3248000000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTQtMy0xLTEtOTQ0MTQ_5812de08-569d-469a-af9e-d851870321b3"
      unitRef="usd">4567000000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTQtNS0xLTEtOTQ0MTQ_7cdcc5ce-d4ba-4741-ac11-20906dab718c"
      unitRef="usd">11502000000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTQtNy0xLTEtOTQ0MTQ_091c3483-969e-4f7c-b615-0cb0e9de901e"
      unitRef="usd">8525000000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTUtMS0xLTEtOTQ0MTQ_67b64335-4261-4169-a8ea-27702368cc44"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTUtMy0xLTEtOTQ0MTQ_7773b34f-6432-49d2-abe6-1c03d5e56861"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTUtNS0xLTEtOTQ0MTQ_c4d81f46-a89c-4457-886a-20adec386e0f"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTUtNy0xLTEtOTQ0MTQ_429fa82d-8885-4e45-8d43-2e19ea30525d"
      unitRef="usd">766000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:NetIncomeLoss
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTYtMS0xLTEtOTQ0MTQ_f37d7260-ed4c-448f-88a2-3153a34b4e6d"
      unitRef="usd">3248000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTYtMy0xLTEtOTQ0MTQ_20551ccc-e7f7-4be6-8e28-b954ff1340c5"
      unitRef="usd">4567000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTYtNS0xLTEtOTQ0MTQ_7d874c72-8553-405a-a5d7-562195f53654"
      unitRef="usd">11502000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTYtNy0xLTEtOTQ0MTQ_f91f3ff0-e0af-4bd8-8b6d-d179f866d588"
      unitRef="usd">9291000000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTgtMS0xLTEtOTQ0MTQ_bf5c0d36-73a0-4506-9f3f-08c22af2bba2"
      unitRef="usdPerShare">1.28</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTgtMy0xLTEtOTQ0MTQ_237b80b7-03d4-4c9d-b340-ae5908132a86"
      unitRef="usdPerShare">1.81</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTgtNS0xLTEtOTQ0MTQ_caaddab5-d9cd-49e9-887f-c505090a9c69"
      unitRef="usdPerShare">4.55</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTgtNy0xLTEtOTQ0MTQ_9ee0e920-2f1c-4fe9-af03-e1075e60c747"
      unitRef="usdPerShare">3.37</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTktMS0xLTEtOTQ0MTQ_1dcbad67-4f2a-43e8-9972-45b281a08e55"
      unitRef="usdPerShare">0</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTktMy0xLTEtOTQ0MTQ_971f30c8-4660-403f-ab31-27d9a6e520e9"
      unitRef="usdPerShare">0</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTktNS0xLTEtOTQ0MTQ_33d5ddba-eb32-42d3-a77d-4c08fe830753"
      unitRef="usdPerShare">0</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMTktNy0xLTEtOTQ0MTQ_adb031cb-8d6a-401e-ab11-b0cfcae0c0ed"
      unitRef="usdPerShare">0.30</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMjAtMS0xLTEtOTQ0MTQ_c960d90a-4255-45c4-871e-18d013d7d0c3"
      unitRef="usdPerShare">1.28</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMjAtMy0xLTEtOTQ0MTQ_76bddf48-670e-4651-8b91-41300e0273eb"
      unitRef="usdPerShare">1.81</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMjAtNS0xLTEtOTQ0MTQ_199865b8-762c-47ec-b476-7c28c4de9c9a"
      unitRef="usdPerShare">4.55</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMjAtNy0xLTEtOTQ0MTQ_300e090e-7275-408f-88f9-9bfa9c2ec253"
      unitRef="usdPerShare">3.67</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMjItMS0xLTEtOTQ0MTQ_aec9e309-f8db-4fda-8a0a-f0da178b7b42"
      unitRef="usdPerShare">1.28</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMjItMy0xLTEtOTQ0MTQ_48d4c42d-eeb6-4c04-926b-ab329aadb069"
      unitRef="usdPerShare">1.80</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMjItNS0xLTEtOTQ0MTQ_cdd7dbdf-b68a-41e2-906f-03f06ad2c6d6"
      unitRef="usdPerShare">4.53</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMjItNy0xLTEtOTQ0MTQ_ab226745-1aaf-49d6-8b49-edbff717f9c0"
      unitRef="usdPerShare">3.36</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMjMtMS0xLTEtOTQ0MTQ_12cbe9ce-8252-4cdc-83de-121a03c05b97"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMjMtMy0xLTEtOTQ0MTQ_6f7dba63-a4cb-47cb-b980-74f97aed8f4e"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMjMtNS0xLTEtOTQ0MTQ_ac74df35-3419-4b05-a793-10879ef6b1e3"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMjMtNy0xLTEtOTQ0MTQ_05f3fd1a-bfab-4612-8cc1-a6d0c03eb363"
      unitRef="usdPerShare">0.30</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMjQtMS0xLTEtOTQ0MTQ_3187c599-8fa4-485e-a559-69ae5d36e8d9"
      unitRef="usdPerShare">1.28</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMjQtMy0xLTEtOTQ0MTQ_067bedc9-ce1f-404e-b7eb-d6418b2d2179"
      unitRef="usdPerShare">1.80</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMjQtNS0xLTEtOTQ0MTQ_183fce9f-e95b-4195-b50a-05a70fcf86f9"
      unitRef="usdPerShare">4.53</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xNi9mcmFnOmUyZjdlMDg5ZWIxOTQ4MDA4NGU3OTMyZWE4NDY0OTMzL3RhYmxlOjk2YTc4NWU4NGJhNjQyYjBhMDc3Y2VjNmMxMzgzNWZkL3RhYmxlcmFuZ2U6OTZhNzg1ZTg0YmE2NDJiMGEwNzdjZWM2YzEzODM1ZmRfMjQtNy0xLTEtOTQ0MTQ_1459728d-2197-4ed1-aaac-d1605cb4e5a4"
      unitRef="usdPerShare">3.66</us-gaap:EarningsPerShareDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xOS9mcmFnOjI1M2U1Mzc0MjMyYTRiZDZiZGNlMjM1N2ZmN2EyMzMxL3RhYmxlOjcyNzkwNTY5ODMwNTQ5MTU5MTgxYTFkMjdmNzEwYWU0L3RhYmxlcmFuZ2U6NzI3OTA1Njk4MzA1NDkxNTkxODFhMWQyN2Y3MTBhZTRfMi0xLTEtMS05NDQxNA_f6ce972c-1072-4318-989f-f3be8a726f69"
      unitRef="usd">3248000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xOS9mcmFnOjI1M2U1Mzc0MjMyYTRiZDZiZGNlMjM1N2ZmN2EyMzMxL3RhYmxlOjcyNzkwNTY5ODMwNTQ5MTU5MTgxYTFkMjdmNzEwYWU0L3RhYmxlcmFuZ2U6NzI3OTA1Njk4MzA1NDkxNTkxODFhMWQyN2Y3MTBhZTRfMi0zLTEtMS05NDQxNA_23650903-1550-4bf9-a53e-7186b6c2410f"
      unitRef="usd">4567000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xOS9mcmFnOjI1M2U1Mzc0MjMyYTRiZDZiZGNlMjM1N2ZmN2EyMzMxL3RhYmxlOjcyNzkwNTY5ODMwNTQ5MTU5MTgxYTFkMjdmNzEwYWU0L3RhYmxlcmFuZ2U6NzI3OTA1Njk4MzA1NDkxNTkxODFhMWQyN2Y3MTBhZTRfMi01LTEtMS05NDQxNA_2941608e-e12f-41ba-b71a-adb7bb7cddde"
      unitRef="usd">11502000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xOS9mcmFnOjI1M2U1Mzc0MjMyYTRiZDZiZGNlMjM1N2ZmN2EyMzMxL3RhYmxlOjcyNzkwNTY5ODMwNTQ5MTU5MTgxYTFkMjdmNzEwYWU0L3RhYmxlcmFuZ2U6NzI3OTA1Njk4MzA1NDkxNTkxODFhMWQyN2Y3MTBhZTRfMi03LTEtMS05NDQxNA_7b5a420a-4e8f-473f-befe-905fd73a678a"
      unitRef="usd">9291000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xOS9mcmFnOjI1M2U1Mzc0MjMyYTRiZDZiZGNlMjM1N2ZmN2EyMzMxL3RhYmxlOjcyNzkwNTY5ODMwNTQ5MTU5MTgxYTFkMjdmNzEwYWU0L3RhYmxlcmFuZ2U6NzI3OTA1Njk4MzA1NDkxNTkxODFhMWQyN2Y3MTBhZTRfNC0xLTEtMS05NDQxNA_c61569b9-9814-481b-883a-dcbf79f11187"
      unitRef="usd">338000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xOS9mcmFnOjI1M2U1Mzc0MjMyYTRiZDZiZGNlMjM1N2ZmN2EyMzMxL3RhYmxlOjcyNzkwNTY5ODMwNTQ5MTU5MTgxYTFkMjdmNzEwYWU0L3RhYmxlcmFuZ2U6NzI3OTA1Njk4MzA1NDkxNTkxODFhMWQyN2Y3MTBhZTRfNC0zLTEtMS05NDQxNA_53377e23-3f2e-490c-b98d-3fa1c3a128fe"
      unitRef="usd">84000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xOS9mcmFnOjI1M2U1Mzc0MjMyYTRiZDZiZGNlMjM1N2ZmN2EyMzMxL3RhYmxlOjcyNzkwNTY5ODMwNTQ5MTU5MTgxYTFkMjdmNzEwYWU0L3RhYmxlcmFuZ2U6NzI3OTA1Njk4MzA1NDkxNTkxODFhMWQyN2Y3MTBhZTRfNC01LTEtMS05NDQxNA_b7b9a8b2-2057-499e-b99c-5b49a5931fce"
      unitRef="usd">584000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xOS9mcmFnOjI1M2U1Mzc0MjMyYTRiZDZiZGNlMjM1N2ZmN2EyMzMxL3RhYmxlOjcyNzkwNTY5ODMwNTQ5MTU5MTgxYTFkMjdmNzEwYWU0L3RhYmxlcmFuZ2U6NzI3OTA1Njk4MzA1NDkxNTkxODFhMWQyN2Y3MTBhZTRfNC03LTEtMS05NDQxNA_46683567-061f-43f5-ab08-6c5a4d05789f"
      unitRef="usd">324000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xOS9mcmFnOjI1M2U1Mzc0MjMyYTRiZDZiZGNlMjM1N2ZmN2EyMzMxL3RhYmxlOjcyNzkwNTY5ODMwNTQ5MTU5MTgxYTFkMjdmNzEwYWU0L3RhYmxlcmFuZ2U6NzI3OTA1Njk4MzA1NDkxNTkxODFhMWQyN2Y3MTBhZTRfNS0xLTEtMS05NDQxNA_dc8868fc-8c94-49d9-90f6-b01d79f91337"
      unitRef="usd">186000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xOS9mcmFnOjI1M2U1Mzc0MjMyYTRiZDZiZGNlMjM1N2ZmN2EyMzMxL3RhYmxlOjcyNzkwNTY5ODMwNTQ5MTU5MTgxYTFkMjdmNzEwYWU0L3RhYmxlcmFuZ2U6NzI3OTA1Njk4MzA1NDkxNTkxODFhMWQyN2Y3MTBhZTRfNS0zLTEtMS05NDQxNA_b72a35f1-67a3-4a3d-980c-c13422b81165"
      unitRef="usd">-38000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xOS9mcmFnOjI1M2U1Mzc0MjMyYTRiZDZiZGNlMjM1N2ZmN2EyMzMxL3RhYmxlOjcyNzkwNTY5ODMwNTQ5MTU5MTgxYTFkMjdmNzEwYWU0L3RhYmxlcmFuZ2U6NzI3OTA1Njk4MzA1NDkxNTkxODFhMWQyN2Y3MTBhZTRfNS01LTEtMS05NDQxNA_59ac5fe0-41ef-4599-8ec8-1439fdf08324"
      unitRef="usd">-92000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xOS9mcmFnOjI1M2U1Mzc0MjMyYTRiZDZiZGNlMjM1N2ZmN2EyMzMxL3RhYmxlOjcyNzkwNTY5ODMwNTQ5MTU5MTgxYTFkMjdmNzEwYWU0L3RhYmxlcmFuZ2U6NzI3OTA1Njk4MzA1NDkxNTkxODFhMWQyN2Y3MTBhZTRfNS03LTEtMS05NDQxNA_b99ad749-969b-41a3-ae55-6b2be5758a55"
      unitRef="usd">-1522000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xOS9mcmFnOjI1M2U1Mzc0MjMyYTRiZDZiZGNlMjM1N2ZmN2EyMzMxL3RhYmxlOjcyNzkwNTY5ODMwNTQ5MTU5MTgxYTFkMjdmNzEwYWU0L3RhYmxlcmFuZ2U6NzI3OTA1Njk4MzA1NDkxNTkxODFhMWQyN2Y3MTBhZTRfNi0xLTEtMS05NDQxNA_215101c7-ee57-4b67-8d9b-a14845afcdc2"
      unitRef="usd">-568000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xOS9mcmFnOjI1M2U1Mzc0MjMyYTRiZDZiZGNlMjM1N2ZmN2EyMzMxL3RhYmxlOjcyNzkwNTY5ODMwNTQ5MTU5MTgxYTFkMjdmNzEwYWU0L3RhYmxlcmFuZ2U6NzI3OTA1Njk4MzA1NDkxNTkxODFhMWQyN2Y3MTBhZTRfNi0zLTEtMS05NDQxNA_bdd08fed-30e2-42bd-80c7-91d85b2cebce"
      unitRef="usd">-84000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xOS9mcmFnOjI1M2U1Mzc0MjMyYTRiZDZiZGNlMjM1N2ZmN2EyMzMxL3RhYmxlOjcyNzkwNTY5ODMwNTQ5MTU5MTgxYTFkMjdmNzEwYWU0L3RhYmxlcmFuZ2U6NzI3OTA1Njk4MzA1NDkxNTkxODFhMWQyN2Y3MTBhZTRfNi01LTEtMS05NDQxNA_a5c2482c-6f26-4b0e-acef-13030823b80f"
      unitRef="usd">-990000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xOS9mcmFnOjI1M2U1Mzc0MjMyYTRiZDZiZGNlMjM1N2ZmN2EyMzMxL3RhYmxlOjcyNzkwNTY5ODMwNTQ5MTU5MTgxYTFkMjdmNzEwYWU0L3RhYmxlcmFuZ2U6NzI3OTA1Njk4MzA1NDkxNTkxODFhMWQyN2Y3MTBhZTRfNi03LTEtMS05NDQxNA_5166aa5d-085a-4d3a-a1f0-71298e70a03f"
      unitRef="usd">-251000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xOS9mcmFnOjI1M2U1Mzc0MjMyYTRiZDZiZGNlMjM1N2ZmN2EyMzMxL3RhYmxlOjcyNzkwNTY5ODMwNTQ5MTU5MTgxYTFkMjdmNzEwYWU0L3RhYmxlcmFuZ2U6NzI3OTA1Njk4MzA1NDkxNTkxODFhMWQyN2Y3MTBhZTRfNy0xLTEtMS05NDQxNA_ecc7e171-50f9-4ea8-a6c1-f45040b84323"
      unitRef="usd">-416000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xOS9mcmFnOjI1M2U1Mzc0MjMyYTRiZDZiZGNlMjM1N2ZmN2EyMzMxL3RhYmxlOjcyNzkwNTY5ODMwNTQ5MTU5MTgxYTFkMjdmNzEwYWU0L3RhYmxlcmFuZ2U6NzI3OTA1Njk4MzA1NDkxNTkxODFhMWQyN2Y3MTBhZTRfNy0zLTEtMS05NDQxNA_aeb6184f-6920-4dee-aa1a-9d80de5b37cc"
      unitRef="usd">38000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xOS9mcmFnOjI1M2U1Mzc0MjMyYTRiZDZiZGNlMjM1N2ZmN2EyMzMxL3RhYmxlOjcyNzkwNTY5ODMwNTQ5MTU5MTgxYTFkMjdmNzEwYWU0L3RhYmxlcmFuZ2U6NzI3OTA1Njk4MzA1NDkxNTkxODFhMWQyN2Y3MTBhZTRfNy01LTEtMS05NDQxNA_f72a47c5-76d2-4263-82d9-4b052712e6b6"
      unitRef="usd">-314000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xOS9mcmFnOjI1M2U1Mzc0MjMyYTRiZDZiZGNlMjM1N2ZmN2EyMzMxL3RhYmxlOjcyNzkwNTY5ODMwNTQ5MTU5MTgxYTFkMjdmNzEwYWU0L3RhYmxlcmFuZ2U6NzI3OTA1Njk4MzA1NDkxNTkxODFhMWQyN2Y3MTBhZTRfNy03LTEtMS05NDQxNA_ef44f324-3bf9-4fb8-ab4f-5b5e6f735430"
      unitRef="usd">1595000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xOS9mcmFnOjI1M2U1Mzc0MjMyYTRiZDZiZGNlMjM1N2ZmN2EyMzMxL3RhYmxlOjcyNzkwNTY5ODMwNTQ5MTU5MTgxYTFkMjdmNzEwYWU0L3RhYmxlcmFuZ2U6NzI3OTA1Njk4MzA1NDkxNTkxODFhMWQyN2Y3MTBhZTRfOC0xLTEtMS05NDQxNA_eb581d19-09f7-42d0-ba7c-e5c50be97127"
      unitRef="usd">2832000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xOS9mcmFnOjI1M2U1Mzc0MjMyYTRiZDZiZGNlMjM1N2ZmN2EyMzMxL3RhYmxlOjcyNzkwNTY5ODMwNTQ5MTU5MTgxYTFkMjdmNzEwYWU0L3RhYmxlcmFuZ2U6NzI3OTA1Njk4MzA1NDkxNTkxODFhMWQyN2Y3MTBhZTRfOC0zLTEtMS05NDQxNA_21427ea0-ba0f-4bde-98af-50c9b6e5b26f"
      unitRef="usd">4605000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xOS9mcmFnOjI1M2U1Mzc0MjMyYTRiZDZiZGNlMjM1N2ZmN2EyMzMxL3RhYmxlOjcyNzkwNTY5ODMwNTQ5MTU5MTgxYTFkMjdmNzEwYWU0L3RhYmxlcmFuZ2U6NzI3OTA1Njk4MzA1NDkxNTkxODFhMWQyN2Y3MTBhZTRfOC01LTEtMS05NDQxNA_40035125-0da8-4bdc-ac12-7cad1398467b"
      unitRef="usd">11188000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xOS9mcmFnOjI1M2U1Mzc0MjMyYTRiZDZiZGNlMjM1N2ZmN2EyMzMxL3RhYmxlOjcyNzkwNTY5ODMwNTQ5MTU5MTgxYTFkMjdmNzEwYWU0L3RhYmxlcmFuZ2U6NzI3OTA1Njk4MzA1NDkxNTkxODFhMWQyN2Y3MTBhZTRfOC03LTEtMS05NDQxNA_ce9cdafc-02fd-45b6-aacd-5df110e9ad47"
      unitRef="usd">10886000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMy0xLTEtMS05NDQxNA_fe816bb7-30c8-4e0d-a48b-6aba101923db"
      unitRef="usd">11145000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMy0zLTEtMS05NDQxNA_337b864f-94d2-4ad7-b45d-f5ba6a4b664e"
      unitRef="usd">8096000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfNC0xLTEtMS05NDQxNA_874874e9-cea3-432c-af85-6e76adda437c"
      unitRef="usd">103000000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfNC0zLTEtMS05NDQxNA_05bdbaef-c967-4596-977d-b238535f97c6"
      unitRef="usd">0</us-gaap:ShortTermInvestments>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfNS0wLTEtMS05NDQxNC90ZXh0cmVnaW9uOjdiZmE4NjUwZTljZDQ5YWE4YTJlZmZmZWI0NzFjMDEwXzY3_77ef4f52-6c47-4ca8-bca8-0b5d5d361c51"
      unitRef="usd">77000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfNS0wLTEtMS05NDQxNC90ZXh0cmVnaW9uOjdiZmE4NjUwZTljZDQ5YWE4YTJlZmZmZWI0NzFjMDEwXzgx_d03efed6-02aa-468b-ae76-ed1826f1c629"
      unitRef="usd">62000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfNS0xLTEtMS05NDQxNA_780f56c5-8f28-44f5-aeae-430f7420a030"
      unitRef="usd">9482000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfNS0zLTEtMS05NDQxNA_b1262537-8ed0-44a2-9b29-7991ac4c1948"
      unitRef="usd">9230000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfNi0wLTEtMS05NDQxNC90ZXh0cmVnaW9uOjE5NDhjMzk0MmFlNDQ0NTBhYmQyOWYwMjhhMTJlYWU5XzQy_68bee09b-def8-4884-92ea-38a3167a6267"
      unitRef="usd">2641000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfNi0wLTEtMS05NDQxNC90ZXh0cmVnaW9uOjE5NDhjMzk0MmFlNDQ0NTBhYmQyOWYwMjhhMTJlYWU5XzU1_46c1e742-8ab4-4004-8f69-00f3ee17b4fe"
      unitRef="usd">2194000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNet
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfNi0xLTEtMS05NDQxNA_14c0139b-f125-45db-9d77-e8a59c763218"
      unitRef="usd">5614000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfNi0zLTEtMS05NDQxNA_0d264b47-4b78-4a1d-bf77-6d210993393b"
      unitRef="usd">5953000000</us-gaap:InventoryNet>
    <us-gaap:DeferredIncomeTaxesAndOtherAssetsCurrent
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfNy0xLTEtMS05NDQxNA_bc38e30b-1ecc-484e-9a1d-00fbef431128"
      unitRef="usd">7217000000</us-gaap:DeferredIncomeTaxesAndOtherAssetsCurrent>
    <us-gaap:DeferredIncomeTaxesAndOtherAssetsCurrent
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfNy0zLTEtMS05NDQxNA_e1fce653-b54b-4440-a55b-3d30438755fb"
      unitRef="usd">6987000000</us-gaap:DeferredIncomeTaxesAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfOC0xLTEtMS05NDQxNA_f68a753f-a025-4363-b3a0-ccf52d39f2bb"
      unitRef="usd">33561000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfOC0zLTEtMS05NDQxNA_fbbd7d75-2ef8-4b4d-bbcb-677610ae68ee"
      unitRef="usd">30266000000</us-gaap:AssetsCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfOS0xLTEtMS05NDQxNA_5ca599f7-2900-42bb-a014-5e527dc44eb4"
      unitRef="usd">984000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfOS0zLTEtMS05NDQxNA_e63d356b-f134-4950-96b3-3d2e968da9fe"
      unitRef="usd">370000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMTAtMC0xLTEtOTQ0MTQvdGV4dHJlZ2lvbjo1OTk1ZmY4YzA5Yjg0YTg5YmI0ZDMwNDlmMDkwYmRlMV83OQ_d7bb6a10-c690-48ea-91ec-b1735c28729f"
      unitRef="usd">17921000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMTAtMC0xLTEtOTQ0MTQvdGV4dHJlZ2lvbjo1OTk1ZmY4YzA5Yjg0YTg5YmI0ZDMwNDlmMDkwYmRlMV85Mg_3b929f44-365a-41d1-81eb-fc90be394852"
      unitRef="usd">18192000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMTAtMS0xLTEtOTQ0MTQ_e210a328-661a-4232-99e2-3c974c8d699f"
      unitRef="usd">20424000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMTAtMy0xLTEtOTQ0MTQ_90df69bb-92fd-4ede-a6f3-2a5a94bf1670"
      unitRef="usd">19279000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMTEtMS0xLTEtOTQ0MTQ_17badbdf-2f36-4aef-9c3a-b8cb7d3aa7de"
      unitRef="usd">21160000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMTEtMy0xLTEtOTQ0MTQ_ecf91b08-78ea-4cfc-a14a-4759a0684fc1"
      unitRef="usd">21264000000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMTItMS0xLTEtOTQ0MTQ_f1edd0ca-9b5f-4bc0-9bdf-40048757905e"
      unitRef="usd">21368000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMTItMy0xLTEtOTQ0MTQ_6dfaa11d-f749-4299-a98a-1a2b11fb53d6"
      unitRef="usd">22933000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMTMtMS0xLTEtOTQ0MTQ_9a5237f2-dbb4-49cb-9be7-4b0380ee6e1c"
      unitRef="usd">9584000000</us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent>
    <us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMTMtMy0xLTEtOTQ0MTQ_bb142150-834d-4ba3-83bd-6078a4daa62a"
      unitRef="usd">11582000000</us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMTQtMS0xLTEtOTQ0MTQ_b32a4da7-289b-4b55-aaa9-f39df5149a27"
      unitRef="usd">107081000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMTQtMy0xLTEtOTQ0MTQ_782d8e5e-dc00-490a-b914-8f86f87ec606"
      unitRef="usd">105694000000</us-gaap:Assets>
    <us-gaap:DebtCurrent
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMTctMS0xLTEtOTQ0MTQ_ce01946f-d8d4-436c-afcc-943a2e6ddc49"
      unitRef="usd">1936000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMTctMy0xLTEtOTQ0MTQ_37963b77-6d33-48b6-b19c-d29c1c892209"
      unitRef="usd">2412000000</us-gaap:DebtCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMTgtMS0xLTEtOTQ0MTQ_5187f488-fbe6-4bb4-baa7-2fca92a1bb20"
      unitRef="usd">3371000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMTgtMy0xLTEtOTQ0MTQ_24cfd80c-9a1c-4982-9f0a-b03dd1390590"
      unitRef="usd">4609000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMTktMS0xLTEtOTQ0MTQ_106ee3f1-22f0-4133-b162-fc40a0a75171"
      unitRef="usd">14222000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMTktMy0xLTEtOTQ0MTQ_4a39e243-9c2d-401f-b425-b20cb8693a61"
      unitRef="usd">13859000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMjAtMS0xLTEtOTQ0MTQ_ae9a8b1c-f59d-41b0-8f59-17354f9c66ad"
      unitRef="usd">1698000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMjAtMy0xLTEtOTQ0MTQ_438c29b0-7dd2-424c-a8ef-5d4464b1d660"
      unitRef="usd">1224000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMjEtMS0xLTEtOTQ0MTQ_85c9c705-fe37-4e77-bf82-246748dc0042"
      unitRef="usd">1771000000</us-gaap:DividendsPayableCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMjEtMy0xLTEtOTQ0MTQ_3ba47ea0-1cc4-49f4-b81e-fb1de8e8d95f"
      unitRef="usd">1768000000</us-gaap:DividendsPayableCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMjItMS0xLTEtOTQ0MTQ_91a13c65-e519-4df4-9aa2-022b9f35c555"
      unitRef="usd">22998000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMjItMy0xLTEtOTQ0MTQ_89999e93-ecc9-4554-b7e1-62b3ab0a61b9"
      unitRef="usd">23872000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMjMtMS0xLTEtOTQ0MTQ_fedeae10-7b48-41f4-97c6-f43012e6a868"
      unitRef="usd">28482000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMjMtMy0xLTEtOTQ0MTQ_2e8f42c4-0457-476e-a4d8-6135873187d3"
      unitRef="usd">30690000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMjQtMS0xLTEtOTQ0MTQ_1d85af4a-7863-4263-9604-8e1e10ebfbe7"
      unitRef="usd">2417000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMjQtMy0xLTEtOTQ0MTQ_91bb3c37-cc1a-407b-b8ae-e68ca3096a87"
      unitRef="usd">3441000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMjUtMS0xLTEtOTQ0MTQ_83f96891-6912-470e-9b2e-123d1b9903d7"
      unitRef="usd">8660000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMjUtMy0xLTEtOTQ0MTQ_0a37a1b6-70e3-41b2-8d81-ebbdb59e320c"
      unitRef="usd">9434000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMjctMC0xLTEtOTQ0MTQvdGV4dHJlZ2lvbjpmMGRkMzMwNTliYzE0ZmMyOGE4MjA3MWZmYWUxNjViMl8xOQ_8756d8ec-bf52-4045-bf60-9fcb3bdfa775"
      unitRef="usdPerShare">0.50</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMjctMC0xLTEtOTQ0MTQvdGV4dHJlZ2lvbjpmMGRkMzMwNTliYzE0ZmMyOGE4MjA3MWZmYWUxNjViMl8xOQ_912be4aa-2245-4234-b81d-36be69babd5d"
      unitRef="usdPerShare">0.50</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMjctMC0xLTEtOTQ0MTQvdGV4dHJlZ2lvbjpmMGRkMzMwNTliYzE0ZmMyOGE4MjA3MWZmYWUxNjViMl80NQ_40997d64-4f8f-4f90-be19-fa68385871b6"
      unitRef="shares">6500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMjctMC0xLTEtOTQ0MTQvdGV4dHJlZ2lvbjpmMGRkMzMwNTliYzE0ZmMyOGE4MjA3MWZmYWUxNjViMl80NQ_f884c983-a783-4afe-b85f-c56efb33da64"
      unitRef="shares">6500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMjctMC0xLTEtOTQ0MTQvdGV4dHJlZ2lvbjpmMGRkMzMwNTliYzE0ZmMyOGE4MjA3MWZmYWUxNjViMl82NA_21931a48-a39f-40f5-894b-47b76e4139cc"
      unitRef="shares">3577103522</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMjctMC0xLTEtOTQ0MTQvdGV4dHJlZ2lvbjpmMGRkMzMwNTliYzE0ZmMyOGE4MjA3MWZmYWUxNjViMl82NA_f2ce5382-e4e0-4a12-b2e2-e78e53985c38"
      unitRef="shares">3577103522</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMjctMS0xLTEtOTQ0MTQ_049bbac7-5f52-4cf4-8523-d9dd65c91a29"
      unitRef="usd">1788000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMjctMy0xLTEtOTQ0MTQ_e73a8b07-205a-4e9c-a786-cba069937085"
      unitRef="usd">1788000000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMjgtMS0xLTEtOTQ0MTQ_e80ec825-ea7c-44e7-9717-48a1098bb4fc"
      unitRef="usd">44243000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMjgtMy0xLTEtOTQ0MTQ_a3ca1387-e083-4316-a116-a601e3c20bab"
      unitRef="usd">44238000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMjktMS0xLTEtOTQ0MTQ_5bb480bf-15ad-4598-b66d-80c1dfa0580c"
      unitRef="usd">59928000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMjktMy0xLTEtOTQ0MTQ_a9ed350f-523f-4b18-a2f0-b12a6e8ae274"
      unitRef="usd">53696000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMzAtMS0xLTEtOTQ0MTQ_95804bc9-db42-402a-b452-a6303e7072a0"
      unitRef="usd">-4743000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMzAtMy0xLTEtOTQ0MTQ_a1a0c539-0113-4c09-a320-2c381e62cad8"
      unitRef="usd">-4429000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityBeforeTreasuryStock
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMzEtMS0xLTEtOTQ0MTQ_67eba5d3-ce84-4244-8bac-07a1bafcda7f"
      unitRef="usd">101216000000</us-gaap:StockholdersEquityBeforeTreasuryStock>
    <us-gaap:StockholdersEquityBeforeTreasuryStock
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMzEtMy0xLTEtOTQ0MTQ_757fbf64-d8eb-4a17-9fa8-ed62fbdc7c27"
      unitRef="usd">95293000000</us-gaap:StockholdersEquityBeforeTreasuryStock>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMzItMC0xLTEtOTQ0MTQvdGV4dHJlZ2lvbjo5MjVlZWI1ZDE1ZjQ0Mzg3YWU3NWQ5NGU3YjQxZWUzZV8zNQ_5b3ae06e-e1b0-4a10-a5f5-f9b8c365eaff"
      unitRef="shares">1043697097</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMzItMC0xLTEtOTQ0MTQvdGV4dHJlZ2lvbjo5MjVlZWI1ZDE1ZjQ0Mzg3YWU3NWQ5NGU3YjQxZWUzZV81NQ_95d1e336-7cf0-4176-b439-4a414dac4766"
      unitRef="shares">1049499023</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMzItMS0xLTEtOTQ0MTQ_7ff95959-1e04-45a0-9826-36ff54d16293"
      unitRef="usd">56758000000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMzItMy0xLTEtOTQ0MTQ_66a0b57d-3a7f-457e-bcec-6576bee5daa3"
      unitRef="usd">57109000000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:StockholdersEquity
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMzMtMS0xLTEtOTQ0MTQ_7646b2c9-355e-45c8-ba03-a4cb3b7743e7"
      unitRef="usd">44458000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMzMtMy0xLTEtOTQ0MTQ_7bee0107-162f-4627-af39-5ffdc06be234"
      unitRef="usd">38184000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMzQtMS0xLTEtOTQ0MTQ_533dd312-d391-4144-9d8f-a0b4bd3badd6"
      unitRef="usd">66000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMzQtMy0xLTEtOTQ0MTQ_4bded0de-9d68-4e09-8d8d-baf960d0a3e1"
      unitRef="usd">73000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMzUtMS0xLTEtOTQ0MTQ_7c9fa102-9f24-4cff-bf09-d5cca77e2db6"
      unitRef="usd">44524000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMzUtMy0xLTEtOTQ0MTQ_4f7d693e-49c7-4c2c-b372-3fd5501bfca2"
      unitRef="usd">38257000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMzYtMS0xLTEtOTQ0MTQ_89f66c13-5d47-4c67-97ba-e9c614170d56"
      unitRef="usd">107081000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yMi9mcmFnOjBlNzYwNDBhNmQ4MDRkOWRhODQxZDYwNjFhZDRkMzZiL3RhYmxlOjZmNjUzMDI5ZjJhODQwMWViYjcwMTIwNzZkMjhkYjA1L3RhYmxlcmFuZ2U6NmY2NTMwMjlmMmE4NDAxZWJiNzAxMjA3NmQyOGRiMDVfMzYtMy0xLTEtOTQ0MTQ_abfef1da-11a4-4125-a112-be534c772a4d"
      unitRef="usd">105694000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMy0xLTEtMS05NDQxNA_a9656176-0b12-4494-bd9e-074a7793092c"
      unitRef="usd">11508000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMy0zLTEtMS05NDQxNA_09b457fe-e2a6-4fe0-85d5-bca09d5ea82f"
      unitRef="usd">8534000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentForAmortization
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfNS0xLTEtMS05NDQxNA_7c7a490b-e934-4e58-b8f4-acf184d217d0"
      unitRef="usd">1623000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfNS0zLTEtMS05NDQxNA_04eecbc1-5976-467e-adb6-e7a212ae9533"
      unitRef="usd">1231000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:Depreciation
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfNi0xLTEtMS05NDQxNA_a449bc7d-05de-4e7f-97d0-e9b409df2e17"
      unitRef="usd">1394000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfNi0zLTEtMS05NDQxNA_3fe9b10e-739d-4678-ab29-921e1ff194ce"
      unitRef="usd">1148000000</us-gaap:Depreciation>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfNy0xLTEtMS05NDQxNA_726ef460-ccbd-440c-ae7f-7e7f364cd53d"
      unitRef="usd">910000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfNy0zLTEtMS05NDQxNA_6f4913a4-f5c4-40c3-a7b6-ffd10168a82c"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfOC0xLTEtMS05NDQxNA_3d4b918c-0138-4883-995b-12af34761b52"
      unitRef="usd">-1361000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfOC0zLTEtMS05NDQxNA_01aaea91-dc4b-4ccb-9bdb-cf10d7912332"
      unitRef="usd">1535000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfOS0xLTEtMS05NDQxNA_4b7450c8-62bc-4700-8c59-74d1a016275b"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfOS0zLTEtMS05NDQxNA_6a22f692-2b97-43ae-b97e-f284d94fe733"
      unitRef="usd">1556000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMTAtMS0xLTEtOTQ0MTQ_699c7491-34eb-4232-b11e-8a5fc4b693e1"
      unitRef="usd">-1261000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMTAtMy0xLTEtOTQ0MTQ_643e7565-6112-4f5b-90ab-af41287ccf1b"
      unitRef="usd">28000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ShareBasedCompensation
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMTEtMS0xLTEtOTQ0MTQ_aa64cdd6-9bfa-40af-8cd4-7d146301ecfe"
      unitRef="usd">396000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMTEtMy0xLTEtOTQ0MTQ_a4786b19-f00c-4e40-a7d9-898a06186da6"
      unitRef="usd">360000000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMTItMS0xLTEtOTQ0MTQ_a7a3fef9-8954-4963-9435-217b0c9e11fa"
      unitRef="usd">-1169000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMTItMy0xLTEtOTQ0MTQ_7b978b1c-36ef-402a-a836-985978443422"
      unitRef="usd">-499000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInOperatingCapital
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMTMtMS0xLTEtOTQ0MTQ_c9859a3c-29c6-4a90-8437-3ef1b04b33a0"
      unitRef="usd">2435000000</us-gaap:IncreaseDecreaseInOperatingCapital>
    <us-gaap:IncreaseDecreaseInOperatingCapital
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMTMtMy0xLTEtOTQ0MTQ_99a57ef0-43db-4547-a21e-8de2458d761c"
      unitRef="usd">3794000000</us-gaap:IncreaseDecreaseInOperatingCapital>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMTQtMS0xLTEtOTQ0MTQ_6fe41570-65f2-41ec-b5e8-026ea361dd51"
      unitRef="usd">14665000000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMTQtMy0xLTEtOTQ0MTQ_aaee9313-787f-4760-8aa3-36442ca2b23c"
      unitRef="usd">8027000000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMTYtMS0xLTEtOTQ0MTQ_4e22f3db-6302-4d62-9f5d-a31c5af3bfde"
      unitRef="usd">3239000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMTYtMy0xLTEtOTQ0MTQ_2778bc18-6063-4a6e-ab0c-6a6badb2be5b"
      unitRef="usd">3240000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMTctMS0xLTEtOTQ0MTQ_94aae18d-2242-4eb6-b51c-ffb05ceb618b"
      unitRef="usd">710000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMTctMy0xLTEtOTQ0MTQ_d408d7ac-91ab-4326-8e4c-bbc5232d67e8"
      unitRef="usd">1000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMTgtMS0xLTEtOTQ0MTQ_3503ff3e-f0de-4c7a-8355-518da8bbea2b"
      unitRef="usd">709000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMTgtMy0xLTEtOTQ0MTQ_e8503b5a-3d3c-494a-b0f7-f05447d0a9b5"
      unitRef="usd">497000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMTktMS0xLTEtOTQ0MTQ_095693c0-fd67-44f0-ac99-c114ad5ee086"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMTktMy0xLTEtOTQ0MTQ_f1b7c489-1388-495a-9baf-e3ae1c0ccd4e"
      unitRef="usd">1554000000</us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMjAtMS0xLTEtOTQ0MTQ_529767f3-bc15-43fd-a666-67bd7d3f73e9"
      unitRef="usd">121000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMjAtMy0xLTEtOTQ0MTQ_738ae9d3-1d3d-41d0-80a7-c282b4008c2b"
      unitRef="usd">89000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMjEtMS0xLTEtOTQ0MTQ_01920ee1-14cd-4a94-8432-64610ddf687e"
      unitRef="usd">-149000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMjEtMy0xLTEtOTQ0MTQ_67325e8a-be0c-4fb5-840e-1b5bdd1a96ee"
      unitRef="usd">-15000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMjItMS0xLTEtOTQ0MTQ_c0e9f939-8fe6-4b65-8954-726465eae313"
      unitRef="usd">-3212000000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMjItMy0xLTEtOTQ0MTQ_32b6125f-71b8-48ee-83b3-8042747a1a26"
      unitRef="usd">-4372000000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebt
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMjQtMS0xLTEtOTQ0MTQ_1db70ac0-44a4-4e7f-ada7-5cc1672fb1e3"
      unitRef="usd">0</us-gaap:ProceedsFromRepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebt
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMjQtMy0xLTEtOTQ0MTQ_e775c648-3010-44aa-9ea9-82d94a49c86a"
      unitRef="usd">-3983000000</us-gaap:ProceedsFromRepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMjUtMS0xLTEtOTQ0MTQ_8fabce80-c1ec-4b06-9222-577cc33ab7a3"
      unitRef="usd">2250000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMjUtMy0xLTEtOTQ0MTQ_8d2e98b7-766a-4fb6-ab4c-250bd89ae8b8"
      unitRef="usd">1153000000</us-gaap:RepaymentsOfLongTermDebt>
    <mrk:DisposalGroupInclDiscontinuedOperationsDistributionReceived
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMjYtMS0xLTEtOTQ0MTQ_ef39a6d8-568c-4ea3-8b8b-c1d947eca874"
      unitRef="usd">0</mrk:DisposalGroupInclDiscontinuedOperationsDistributionReceived>
    <mrk:DisposalGroupInclDiscontinuedOperationsDistributionReceived
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMjYtMy0xLTEtOTQ0MTQ_f3189d82-303e-4825-9053-a523c8b5b9b4"
      unitRef="usd">9000000000</mrk:DisposalGroupInclDiscontinuedOperationsDistributionReceived>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMjctMS0xLTEtOTQ0MTQ_53e7bf3a-4678-42a5-9d5b-f7e8dd21938a"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMjctMy0xLTEtOTQ0MTQ_cea12228-4576-4ce2-a0ef-5f0d5120ec17"
      unitRef="usd">822000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMjgtMS0xLTEtOTQ0MTQ_c1917464-5c90-47ad-8e63-eb2b8254a3b3"
      unitRef="usd">5262000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMjgtMy0xLTEtOTQ0MTQ_0a2b0735-3c8e-4d50-a139-21ea1a0f28e8"
      unitRef="usd">4967000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMjktMS0xLTEtOTQ0MTQ_28ad0636-f069-4cc2-8163-548fe600d2b0"
      unitRef="usd">119000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMjktMy0xLTEtOTQ0MTQ_32d7792e-961d-4d0d-8a05-7abde4c7a03c"
      unitRef="usd">68000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMzAtMS0xLTEtOTQ0MTQ_780fd8ea-b594-4d7b-aed7-e75993b24350"
      unitRef="usd">-172000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMzAtMy0xLTEtOTQ0MTQ_7c6d3500-ce2f-4441-a527-8ec74f11ec08"
      unitRef="usd">-253000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMzEtMS0xLTEtOTQ0MTQ_becc37ce-da32-4555-9f30-8b01b108eb94"
      unitRef="usd">-7565000000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMzEtMy0xLTEtOTQ0MTQ_a0e9c8e5-865e-41b7-8891-912cb794a67a"
      unitRef="usd">-2110000000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMzMtMS0xLTEtOTQ0MTQ_d2b6a683-ca51-4b8b-962c-7443c7472db3"
      unitRef="usd">0</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMzMtMy0xLTEtOTQ0MTQ_4107c568-9dd9-4153-8f1a-07996492fa00"
      unitRef="usd">1051000000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMzQtMS0xLTEtOTQ0MTQ_23e9a99d-9dcb-43b5-bbe5-03cd5b8372ad"
      unitRef="usd">0</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMzQtMy0xLTEtOTQ0MTQ_6c5d06ae-7ba3-4fa1-b8be-639869693a14"
      unitRef="usd">-134000000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMzUtMS0xLTEtOTQ0MTQ_945c4114-e12d-4836-90fc-c2cce32f55aa"
      unitRef="usd">0</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMzUtMy0xLTEtOTQ0MTQ_5845881a-9355-442a-8896-19fe7c58ccb3"
      unitRef="usd">-504000000</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInDiscontinuedOperations
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMzYtMS0xLTEtOTQ0MTQ_ed033934-7fd2-4909-b2a1-ef5d0b7c0575"
      unitRef="usd">0</us-gaap:NetCashProvidedByUsedInDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInDiscontinuedOperations
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMzYtMy0xLTEtOTQ0MTQ_fb071b66-433f-468c-b4f9-56b35449858d"
      unitRef="usd">413000000</us-gaap:NetCashProvidedByUsedInDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMzctMS0xLTEtOTQ0MTQ_46a9f020-87ba-4017-8c3c-1f0b37f26b46"
      unitRef="usd">-776000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMzctMy0xLTEtOTQ0MTQ_42e07120-dcfa-4841-85d4-f09ab2f7856e"
      unitRef="usd">-65000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMzgtMS0xLTEtOTQ0MTQ_4d702447-a934-4aaf-b1c6-5b2a6e8b8e06"
      unitRef="usd">3112000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMzgtMy0xLTEtOTQ0MTQ_e265f53c-118d-48dc-8b1d-bc2dc6d9a2f7"
      unitRef="usd">1893000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMzktMC0xLTEtOTQ0MTQvdGV4dHJlZ2lvbjphZGViOGJmZjBiMGY0MWY2YmUzM2Q3NGRiZWViMTVlNl85OA_d18da6a6-512a-4eed-ad39-3681b8fe78ee"
      unitRef="usd">71000000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i6b76c3e2ce274f17b07c82ae1459e9f9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMzktMC0xLTEtOTQ0MTQvdGV4dHJlZ2lvbjphZGViOGJmZjBiMGY0MWY2YmUzM2Q3NGRiZWViMTVlNl8xMDU_92e422dc-8b8b-4c75-b316-858b94398684"
      unitRef="usd">103000000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMzktMS0xLTEtOTQ0MTQ_ba743f91-114e-416e-ba6d-bdbd8be8f540"
      unitRef="usd">8167000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6b76c3e2ce274f17b07c82ae1459e9f9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfMzktMy0xLTEtOTQ0MTQ_491551c1-30a6-4d10-9bd0-d8d017962418"
      unitRef="usd">8153000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfNDAtMC0xLTEtOTQ0MTQvdGV4dHJlZ2lvbjpjYWMzZDZhMDU2MzY0N2U1YTVjY2E4ZTdkZTkzNWM0ZV85Mw_3ab52448-5c83-4f88-9bde-f3e7d31e427f"
      unitRef="usd">134000000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i48930a09b1404293820fbeb015eb6729_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfNDAtMC0xLTEtOTQ0MTQvdGV4dHJlZ2lvbjpjYWMzZDZhMDU2MzY0N2U1YTVjY2E4ZTdkZTkzNWM0ZV8xMDE_07560286-8648-4e0a-81fd-572359cfa837"
      unitRef="usd">30000000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfNDAtMS0xLTEtOTQ0MTQ_2217932c-21ba-45f3-b026-2e3e835ab8dc"
      unitRef="usd">11279000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i48930a09b1404293820fbeb015eb6729_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8yNS9mcmFnOjgwNDZiOTNhMGQ4YTQ3NjNiNmY4NDY1ZTU3NDg1ZDEzL3RhYmxlOjliYTkxYmY4ZWUzYTQzOGViMDhkZDQyMzEwNTdhNjRmL3RhYmxlcmFuZ2U6OWJhOTFiZjhlZTNhNDM4ZWIwOGRkNDIzMTA1N2E2NGZfNDAtMy0xLTEtOTQ0MTQ_9a8cc49c-496a-497f-bf6a-f2c0561b3ffb"
      unitRef="usd">10046000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zMS9mcmFnOmYyNTNiNGIyZTJkYzRjZjRiZjAyOTg3NWZjZmJhZjNjL3RleHRyZWdpb246ZjI1M2I0YjJlMmRjNGNmNGJmMDI5ODc1ZmNmYmFmM2NfNjE2Ng_bcba8da3-4176-426a-baff-8dc72132f1e8">Basis of Presentation&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements of Merck&#160;&amp;amp; Co., Inc. (Merck or the Company) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the United States (U.S.) (GAAP) for complete consolidated financial statements are not included herein. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Merck&#x2019;s Form 10-K filed on February&#160;25, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company&#x2019;s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Spin-Off of Organon &amp;amp; Co.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 2, 2021, Merck completed the spin-off of products from its women&#x2019;s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon &amp;amp; Co. (Organon) through a distribution of Organon&#x2019;s publicly traded stock to Company shareholders. The distribution is expected to qualify and has been treated as tax-free to the Company and its shareholders for U.S. federal income tax purposes. The established brands included in the transaction consisted of dermatology, non-opioid pain management, respiratory, select cardiovascular products, as well as the rest of Merck&#x2019;s diversified brands franchise. Merck&#x2019;s existing research pipeline programs continue to be owned and developed within Merck as planned. The historical results of the businesses that were contributed to Organon in the spin-off have been reflected as discontinued operations in the Company&#x2019;s consolidated financial statements through the date of the spin-off (see Note&#160;2).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the Financial Accounting Standards Board (FASB) issued amended guidance on the accounting for convertible instruments and contracts in an entity&#x2019;s own equity. The guidance removes the separation model for convertible debt instruments and preferred stock, amends requirements for conversion options to be classified in equity as well as amends diluted earnings per share (EPS) calculations for certain convertible debt instruments. The Company adopted the new guidance on January 1, 2022 using a modified retrospective approach. There was no impact to the Company&#x2019;s consolidated financial statements upon adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2021, the FASB issued new guidance to increase the transparency of transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. The guidance requires annual disclosures of such transactions to include the nature of the transactions and the significant terms and conditions, the accounting treatment and the impact to a company&#x2019;s financial statements. The Company adopted the new guidance on January 1, 2022 on a prospective basis. There was no material impact to the Company&#x2019;s consolidated financial statements upon adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting and subsequently issued clarifying amendments. The guidance provides optional expedients and exceptions for accounting for contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (LIBOR) or another reference rate expected to be discontinued because of reference rate reform. The Company adopted the optional guidance on July 1, 2022 on a prospective basis. There was no material impact to the Company&#x2019;s consolidated financial statements upon adoption. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Issued Accounting Standards Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the FASB issued amended guidance that requires acquiring entities to recognize and measure contract assets and liabilities in a business combination in accordance with existing revenue recognition guidance. The amended guidance is effective for interim and annual periods in 2023 and is to be applied prospectively. Early adoption is permitted on a retrospective basis to the beginning of the fiscal year of adoption. The adoption of this guidance will not have an impact on the Company&#x2019;s consolidated financial statements for prior acquisitions; however, the impact in future periods will be dependent upon the contract assets and contract liabilities acquired in future business combinations.&lt;/span&gt;&lt;/div&gt;In June 2022, the FASB issued guidance related to the fair value measurement of an equity security subject to contractual restrictions that prohibit the sale of the equity security. The new guidance also introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. The amended guidance is effective for interim and annual periods in 2024 and is to be applied prospectively. Early adoption is permitted for both interim and annual periods. The Company is currently evaluating the impact of adoption on its consolidated financial statements.</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zMS9mcmFnOmYyNTNiNGIyZTJkYzRjZjRiZjAyOTg3NWZjZmJhZjNjL3RleHRyZWdpb246ZjI1M2I0YjJlMmRjNGNmNGJmMDI5ODc1ZmNmYmFmM2NfNjE4MQ_92aa83c9-ecfd-4f88-81c2-1f7fb1706993">Basis of PresentationThe accompanying unaudited condensed consolidated financial statements of Merck&#160;&amp;amp; Co., Inc. (Merck or the Company) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the United States (U.S.) (GAAP) for complete consolidated financial statements are not included herein. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Merck&#x2019;s Form 10-K filed on February&#160;25, 2022. The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company&#x2019;s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zMS9mcmFnOmYyNTNiNGIyZTJkYzRjZjRiZjAyOTg3NWZjZmJhZjNjL3RleHRyZWdpb246ZjI1M2I0YjJlMmRjNGNmNGJmMDI5ODc1ZmNmYmFmM2NfNjE4NQ_badf433e-26e3-4e0d-baf4-ffd5b18c5cd4">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the Financial Accounting Standards Board (FASB) issued amended guidance on the accounting for convertible instruments and contracts in an entity&#x2019;s own equity. The guidance removes the separation model for convertible debt instruments and preferred stock, amends requirements for conversion options to be classified in equity as well as amends diluted earnings per share (EPS) calculations for certain convertible debt instruments. The Company adopted the new guidance on January 1, 2022 using a modified retrospective approach. There was no impact to the Company&#x2019;s consolidated financial statements upon adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2021, the FASB issued new guidance to increase the transparency of transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. The guidance requires annual disclosures of such transactions to include the nature of the transactions and the significant terms and conditions, the accounting treatment and the impact to a company&#x2019;s financial statements. The Company adopted the new guidance on January 1, 2022 on a prospective basis. There was no material impact to the Company&#x2019;s consolidated financial statements upon adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting and subsequently issued clarifying amendments. The guidance provides optional expedients and exceptions for accounting for contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (LIBOR) or another reference rate expected to be discontinued because of reference rate reform. The Company adopted the optional guidance on July 1, 2022 on a prospective basis. There was no material impact to the Company&#x2019;s consolidated financial statements upon adoption. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Issued Accounting Standards Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the FASB issued amended guidance that requires acquiring entities to recognize and measure contract assets and liabilities in a business combination in accordance with existing revenue recognition guidance. The amended guidance is effective for interim and annual periods in 2023 and is to be applied prospectively. Early adoption is permitted on a retrospective basis to the beginning of the fiscal year of adoption. The adoption of this guidance will not have an impact on the Company&#x2019;s consolidated financial statements for prior acquisitions; however, the impact in future periods will be dependent upon the contract assets and contract liabilities acquired in future business combinations.&lt;/span&gt;&lt;/div&gt;In June 2022, the FASB issued guidance related to the fair value measurement of an equity security subject to contractual restrictions that prohibit the sale of the equity security. The new guidance also introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. The amended guidance is effective for interim and annual periods in 2024 and is to be applied prospectively. Early adoption is permitted for both interim and annual periods. The Company is currently evaluating the impact of adoption on its consolidated financial statements.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RleHRyZWdpb246MDdlMjdjMTQwZDFhNGI3NTkyNTc2OTFmMGJkOTVmMjNfNDg5OQ_11f28c54-e64c-4cdc-b145-8acdcd22940e">Spin-Off of Organon &amp;amp; Co. &lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 2, 2021, Merck completed the spin-off of Organon through a distribution of Organon&#x2019;s publicly traded stock to Company shareholders. In connection with the spin-off, each Merck shareholder received one tenth of a share of Organon&#x2019;s common stock for each share of Merck common stock held by such shareholder. The distribution is expected to qualify and has been treated as tax free to Merck and its shareholders for U.S. federal income tax purposes. Indebtedness of $9.5&#160;billion principal amount, consisting of term loans and senior notes, was issued in 2021 in connection with the spin-off and assumed by Organon. Merck is no longer the obligor of any Organon debt or financing arrangements. Cash proceeds of $9.0&#160;billion were distributed by Organon to Merck in connection with the spin-off. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also in connection with the spin-off, Merck and Organon entered into a separation and distribution agreement and also entered into various other agreements to effect the spin-off and provide a framework for the relationship between Merck and Organon after the spin-off, including a transition services agreement (TSA), manufacturing and supply agreements (MSAs), trademark license agreements, intellectual property license agreements, an employee matters agreement, a tax matters agreement and certain other commercial agreements. Under the TSA, Merck is providing Organon various services and, similarly, Organon is providing Merck various services. The provision of services under the TSA generally will terminate within 25 months following the spin-off; however, the provision of certain services has been extended to 31 months. Merck and Organon also entered into a series of interim operating agreements pursuant to which in various jurisdictions where Merck held licenses, permits and other rights in connection with marketing, import and/or distribution of Organon products prior to the separation, Merck is continuing to market, import and distribute such products until such time as the relevant licenses and permits are transferred to Organon. Under such interim operating agreements and in accordance with the separation and distribution agreement, Merck is continuing operations in the affected markets on behalf of Organon, with Organon receiving all of the economic benefits and burdens of such activities. Additionally, Merck and Organon entered into a number of MSAs pursuant to which Merck is (a) manufacturing and supplying certain active pharmaceutical ingredients for Organon, (b) manufacturing and supplying certain formulated pharmaceutical products for Organon, and (c) packaging and labeling certain finished pharmaceutical products for Organon. Similarly, Organon and Merck entered into a number of MSAs pursuant to which Organon is (a) manufacturing and supplying certain formulated pharmaceutical products for Merck, and (b) packaging and labeling certain finished pharmaceutical products for Merck. The terms of the MSAs range in initial duration from four years to ten years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amounts included in the condensed consolidated statement of income for the above MSAs include sales of $100&#160;million and $293&#160;million and related cost of sales of $104&#160;million and $312&#160;million for the three and nine months ended September&#160;30, 2022, respectively. The amounts included in the condensed consolidated statement of income for the MSAs in the same periods of 2021 were immaterial. Amounts included in the condensed consolidated statement of income for the TSAs were immaterial for the three and nine months ended September&#160;30, 2022 and September&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amounts due from Organon under all of the above agreements were $567&#160;million and $964&#160;million at September&#160;30, 2022 and December&#160;31, 2021, respectively, and are reflected in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The amounts due to Organon under these agreements were $333&#160;million and $400&#160;million at September&#160;30, 2022 and December&#160;31, 2021, respectively, and are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results of the women&#x2019;s health, biosimilars and established brands businesses (previously included in the Pharmaceutical segment) that were contributed to Organon in the spin-off, as well as interest expense related to the debt issuance in 2021, have been reflected as discontinued operations in the Company&#x2019;s condensed consolidated statement of income as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for periods prior to the spin-off on June 2, 2021. Merck incurred separation costs of $556&#160;million for the nine months ended September&#160;30, 2021 related to the spin-off of Organon, which are also included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. These costs primarily relate to professional fees for separation activities within finance, tax, legal and information technology functions, as well as investment banking fees. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Details of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.574%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Costs, Expenses and Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations before taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Income of discontinued operations attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reflects amounts through the June 2, 2021 spin-off date.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i602313dd11d54187bb2dce59c76d9f21_I20210602"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RleHRyZWdpb246MDdlMjdjMTQwZDFhNGI3NTkyNTc2OTFmMGJkOTVmMjNfNDgx_924b9d01-5687-49d4-a2ee-61a82a5e303a"
      unitRef="usd">9500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration
      contextRef="ic7ff920b80fa44a2bb7838de95556452_I20210602"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RleHRyZWdpb246MDdlMjdjMTQwZDFhNGI3NTkyNTc2OTFmMGJkOTVmMjNfNzE1_acf09f46-aeda-4f27-8b19-a86aefa942b7"
      unitRef="usd">9000000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal
      contextRef="i16de1f9b952c486594ae6f32e5927154_D20210602-20210602"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RleHRyZWdpb246MDdlMjdjMTQwZDFhNGI3NTkyNTc2OTFmMGJkOTVmMjNfMTUxMg_575dcb40-1298-4301-90a0-2d14bc5c9813">P25M</us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal>
    <us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal
      contextRef="iab8a608181a042f2beef71b113878321_D20210602-20210602"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RleHRyZWdpb246MDdlMjdjMTQwZDFhNGI3NTkyNTc2OTFmMGJkOTVmMjNfMTYwMw_3dfa4512-251f-462d-afc3-2c94041f6e39">P31M</us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal>
    <us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal
      contextRef="i06897842e70e4eeda8309f8e1ee91277_D20210602-20210602"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RleHRyZWdpb246MDdlMjdjMTQwZDFhNGI3NTkyNTc2OTFmMGJkOTVmMjNfMjk1NQ_907319df-19f3-44e5-8f62-2a0ee224dfae">P4Y</us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal>
    <us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal
      contextRef="i47ff0bcc16874008b1f561555e4a69e4_D20210602-20210602"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RleHRyZWdpb246MDdlMjdjMTQwZDFhNGI3NTkyNTc2OTFmMGJkOTVmMjNfMjk2MQ_8e476f6a-e4ef-4635-a3d8-35e4c17abc93">P10Y</us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i54368f9911b347738909e680bf95d53e_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RleHRyZWdpb246MDdlMjdjMTQwZDFhNGI3NTkyNTc2OTFmMGJkOTVmMjNfMzA2OQ_fa1f1321-4f06-41c0-986e-4a8b4ce8607a"
      unitRef="usd">100000000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="ic18b206b366941b3bc21e6598f14fb5a_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RleHRyZWdpb246MDdlMjdjMTQwZDFhNGI3NTkyNTc2OTFmMGJkOTVmMjNfMzA3Ng_9b7f6ce8-83fb-44a1-993f-1d93f6fc65c9"
      unitRef="usd">293000000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RelatedPartiesAmountInCostOfSales
      contextRef="i54368f9911b347738909e680bf95d53e_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RleHRyZWdpb246MDdlMjdjMTQwZDFhNGI3NTkyNTc2OTFmMGJkOTVmMjNfMzEwOA_a811f2ec-790c-4c2a-ac6d-2084cebe387d"
      unitRef="usd">104000000</us-gaap:RelatedPartiesAmountInCostOfSales>
    <us-gaap:RelatedPartiesAmountInCostOfSales
      contextRef="ic18b206b366941b3bc21e6598f14fb5a_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RleHRyZWdpb246MDdlMjdjMTQwZDFhNGI3NTkyNTc2OTFmMGJkOTVmMjNfMzExNQ_e5f7dba0-241c-46da-82ae-b854278deb92"
      unitRef="usd">312000000</us-gaap:RelatedPartiesAmountInCostOfSales>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="i13d3cfa7934c4d6088d6cd23cfa71865_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RleHRyZWdpb246MDdlMjdjMTQwZDFhNGI3NTkyNTc2OTFmMGJkOTVmMjNfMzQ5OQ_80bc9041-88cd-48d1-a7d6-1dd209e6e685"
      unitRef="usd">567000000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="i32aa48e818164158ab6157217075e834_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RleHRyZWdpb246MDdlMjdjMTQwZDFhNGI3NTkyNTc2OTFmMGJkOTVmMjNfMzUwNg_4ac5b8f6-e3d7-4250-a176-8cccc57367ce"
      unitRef="usd">964000000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="i13d3cfa7934c4d6088d6cd23cfa71865_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RleHRyZWdpb246MDdlMjdjMTQwZDFhNGI3NTkyNTc2OTFmMGJkOTVmMjNfMzY1MA_336a9560-31c6-4277-9ebf-376352fef485"
      unitRef="usd">333000000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="i32aa48e818164158ab6157217075e834_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RleHRyZWdpb246MDdlMjdjMTQwZDFhNGI3NTkyNTc2OTFmMGJkOTVmMjNfMzY1Nw_3941b87b-d24b-4fef-bd64-953d9e5bd352"
      unitRef="usd">400000000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RleHRyZWdpb246MDdlMjdjMTQwZDFhNGI3NTkyNTc2OTFmMGJkOTVmMjNfNDMxNw_e6ab1d55-40f2-4edd-a456-e71b9452b7d5"
      unitRef="usd">556000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RleHRyZWdpb246MDdlMjdjMTQwZDFhNGI3NTkyNTc2OTFmMGJkOTVmMjNfNDkwMA_1b5b2611-42e1-47de-a70a-63440718e2c6">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Details of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.574%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Costs, Expenses and Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations before taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Income of discontinued operations attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reflects amounts through the June 2, 2021 spin-off date.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RhYmxlOmQ3MWEzODE3NjkwZTRiMTI5NjFhZjc3YmE4NDA4NjkxL3RhYmxlcmFuZ2U6ZDcxYTM4MTc2OTBlNGIxMjk2MWFmNzdiYTg0MDg2OTFfMi0zLTEtMS05NDQxNA_15604e95-57bc-4554-a5f8-1013e22e9981"
      unitRef="usd">2512000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RhYmxlOmQ3MWEzODE3NjkwZTRiMTI5NjFhZjc3YmE4NDA4NjkxL3RhYmxlcmFuZ2U6ZDcxYTM4MTc2OTBlNGIxMjk2MWFmNzdiYTg0MDg2OTFfNC0zLTEtMS05NDQxNA_f3cb1a0a-d76b-4ace-9d5b-f12e21276576"
      unitRef="usd">789000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RhYmxlOmQ3MWEzODE3NjkwZTRiMTI5NjFhZjc3YmE4NDA4NjkxL3RhYmxlcmFuZ2U6ZDcxYTM4MTc2OTBlNGIxMjk2MWFmNzdiYTg0MDg2OTFfNS0zLTEtMS05NDQxNA_ce2d6051-bcd9-4976-b2fe-267ede42281c"
      unitRef="usd">877000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <mrk:DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RhYmxlOmQ3MWEzODE3NjkwZTRiMTI5NjFhZjc3YmE4NDA4NjkxL3RhYmxlcmFuZ2U6ZDcxYTM4MTc2OTBlNGIxMjk2MWFmNzdiYTg0MDg2OTFfNi0zLTEtMS05NDQxNA_991d5365-c2af-4f72-acf9-8373e36907a9"
      unitRef="usd">103000000</mrk:DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses>
    <mrk:DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RhYmxlOmQ3MWEzODE3NjkwZTRiMTI5NjFhZjc3YmE4NDA4NjkxL3RhYmxlcmFuZ2U6ZDcxYTM4MTc2OTBlNGIxMjk2MWFmNzdiYTg0MDg2OTFfNy0zLTEtMS05NDQxNA_9eee0f0b-be74-46d4-ad27-3191d9898c3d"
      unitRef="usd">1000000</mrk:DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts>
    <mrk:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RhYmxlOmQ3MWEzODE3NjkwZTRiMTI5NjFhZjc3YmE4NDA4NjkxL3RhYmxlcmFuZ2U6ZDcxYTM4MTc2OTBlNGIxMjk2MWFmNzdiYTg0MDg2OTFfOC0zLTEtMS05NDQxNA_58d95f50-44e6-41db-b52b-3f3ae756cf59"
      unitRef="usd">15000000</mrk:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RhYmxlOmQ3MWEzODE3NjkwZTRiMTI5NjFhZjc3YmE4NDA4NjkxL3RhYmxlcmFuZ2U6ZDcxYTM4MTc2OTBlNGIxMjk2MWFmNzdiYTg0MDg2OTFfOS0zLTEtMS05NDQxNA_d97fbf2e-df70-4fa2-be3f-a5de605728a5"
      unitRef="usd">1755000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RhYmxlOmQ3MWEzODE3NjkwZTRiMTI5NjFhZjc3YmE4NDA4NjkxL3RhYmxlcmFuZ2U6ZDcxYTM4MTc2OTBlNGIxMjk2MWFmNzdiYTg0MDg2OTFfMTAtMy0xLTEtOTQ0MTQ_21097342-72f6-42a1-b550-ac1516bcddae"
      unitRef="usd">757000000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RhYmxlOmQ3MWEzODE3NjkwZTRiMTI5NjFhZjc3YmE4NDA4NjkxL3RhYmxlcmFuZ2U6ZDcxYTM4MTc2OTBlNGIxMjk2MWFmNzdiYTg0MDg2OTFfMTEtMy0xLTEtOTQ0MTQ_032d4a45-5f84-48aa-bba5-2716ff761428"
      unitRef="usd">-12000000</us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RhYmxlOmQ3MWEzODE3NjkwZTRiMTI5NjFhZjc3YmE4NDA4NjkxL3RhYmxlcmFuZ2U6ZDcxYTM4MTc2OTBlNGIxMjk2MWFmNzdiYTg0MDg2OTFfMTItMy0xLTEtOTQ0MTQ_7cab9a5a-c469-4664-97fa-6ce99d33f5ca"
      unitRef="usd">769000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RhYmxlOmQ3MWEzODE3NjkwZTRiMTI5NjFhZjc3YmE4NDA4NjkxL3RhYmxlcmFuZ2U6ZDcxYTM4MTc2OTBlNGIxMjk2MWFmNzdiYTg0MDg2OTFfMTMtMy0xLTEtOTQ0MTQ_0f03aa91-ee36-4b81-9472-219f867a25ff"
      unitRef="usd">3000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8zNC9mcmFnOjA3ZTI3YzE0MGQxYTRiNzU5MjU3NjkxZjBiZDk1ZjIzL3RhYmxlOmQ3MWEzODE3NjkwZTRiMTI5NjFhZjc3YmE4NDA4NjkxL3RhYmxlcmFuZ2U6ZDcxYTM4MTc2OTBlNGIxMjk2MWFmNzdiYTg0MDg2OTFfMTQtMy0xLTEtOTQ0MTQ_938bd17a-675e-4aeb-8353-84bb4d64e666"
      unitRef="usd">766000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <mrk:AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfNzg1MQ_628c0e60-06fb-46ac-ae5b-6ee3d9991820">Acquisitions, Research Collaborations and License Agreements&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continues to pursue acquisitions and the establishment of external alliances such as research collaborations and licensing agreements to complement its internal research capabilities. These arrangements often include upfront payments, as well as expense reimbursements or payments to the third party, and milestone, royalty or profit share arrangements, contingent upon the occurrence of certain future events linked to the success of the asset in development. The Company also reviews its marketed products and pipeline to examine candidates which may provide more value through out-licensing and, as part of its portfolio assessment process, may also divest certain assets. Pro forma financial information for acquired businesses is not presented if the historical financial results of the acquired entity are not significant when compared with the Company&#x2019;s financial results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2022 Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2022, Merck and Royalty Pharma plc (Royalty Pharma) entered into a funding arrangement under which Royalty Pharma paid Merck $50&#160;million to co-fund Merck&#x2019;s development costs for a Phase 2b trial of MK-8189, an investigational oral Phosphodiesterase 10A (PDE10A) inhibitor, which is being evaluated for the treatment of schizophrenia. Under the agreement, Royalty Pharma has no rights to MK-8189 and has no decision-making authority over the program. If Merck elects to advance MK-8189 into a Phase 3 study, Royalty Pharma has the option to provide additional funding of 50% of the development costs up to $375&#160;million for the Phase 3 trial. If such additional funding is provided, Royalty Pharma becomes eligible to receive future regulatory milestone payments contingent upon certain marketing approvals, as well as royalties. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2022, Merck exercised its option to jointly develop and commercialize personalized cancer vaccine mRNA-4157/V940 pursuant to the terms of an existing collaboration and license agreement with Moderna, Inc. (Moderna), which resulted in a $250&#160;million charge in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses in the third quarter and first nine months of 2022. The payment to Moderna was made in the fourth quarter of 2022. mRNA-4157/V940 is currently being evaluated in combination with &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (pembrolizumab), Merck&#x2019;s anti-PD-1 therapy, as adjuvant treatment for patients with high-risk melanoma in a Phase 2 clinical trial being conducted by Moderna. Under the 2016 agreement, as amended in 2018, Merck and Moderna will collaborate on development and commercialization and will share costs and any profits equally under this worldwide collaboration. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2022, Merck and Orna Therapeutics (Orna), a biotechnology company pioneering a new investigational class of engineered circular RNA (oRNA) therapies, entered into a collaboration agreement to discover, develop, and commercialize multiple programs, including vaccines and therapeutics in the areas of infectious disease and oncology. Under the terms of the agreement, Merck made an upfront payment to Orna of $150&#160;million, which was recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses in the third quarter and first nine months of 2022. In addition, Orna is eligible to receive future contingent development-related payments aggregating up to $440 million, $675 million in regulatory milestones, and $2.4 billion in sales milestones associated with the progress of the multiple vaccine and therapeutic programs, as well as royalties &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ranging from a high-single-digit rate to a low-double-digit rate on any approved products derived from the collaboration. Merck also invested $100&#160;million in Orna&#x2019;s Series B preferred shares in the fourth quarter of 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2022, Merck and Orion Corporation (Orion) announced a global co-development and co-commercialization agreement for Orion&#x2019;s investigational candidate ODM-208 (MK-5684) and other drugs targeting cytochrome P450 11A1 (CYP11A1), an enzyme important in steroid production. ODM-208 is an oral, non-steroidal inhibitor of CYP11A1 currently being evaluated in a Phase 2 clinical trial for the treatment of patients with metastatic castration-resistant prostate cancer. Merck made an upfront payment to Orion of $290&#160;million, which was recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses in the third quarter and first nine months of 2022. Orion is responsible for the manufacture of clinical and commercial supply of ODM-208. In addition, the contract provides both parties with an option to convert the initial co-development and co-commercialization agreement into a global exclusive license to Merck. If the option is exercised, Merck would assume full responsibility for all past development and commercialization expenses associated with the program since inception of the agreement, as well as all future development and commercialization expenses. In addition, Orion would be eligible to receive milestone payments associated with progress in the development and commercialization of ODM-208 as well as tiered double-digit royalties on sales if the product is approved. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also in July 2022, Merck and Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (Kelun-Biotech) closed a license and collaboration agreement in which Merck gained exclusive worldwide rights for the development, manufacture and commercialization of an investigational antibody drug conjugate (ADC) (MK-1200) for the treatment of solid tumors. Under the terms of the agreement, Merck and Kelun-Biotech will collaborate on the early clinical development of the investigational ADC. Merck made an upfront payment of $35&#160;million, which was recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses in the third quarter and first nine months of 2022. Kelun-Biotech is also eligible to receive future contingent milestone payments aggregating up to $82&#160;million in developmental milestones, $334&#160;million in regulatory milestones, and $485&#160;million in sales-based milestones. The agreement also provides for Merck to pay tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2022, in connection with an existing arrangement, Merck exercised its option to obtain an exclusive license outside of China for the development, manufacture and commercialization of Kelun-Biotech&#x2019;s trophoblast antigen 2 (TROP2)-targeting ADC programs, including its lead compound, SKB-264 (MK-2870). SKB-264 is currently being evaluated in Phase 2 trials for non-small-cell lung cancer and advanced solid tumors. Under the terms of the agreement, Merck and Kelun-Biotech will collaborate on certain early clinical development plans, including evaluating the potential of SKB-264 as a monotherapy and in combination with &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for advanced solid tumors. Upon option exercise, Merck made a payment of $30&#160;million, which was recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses in the first nine months of 2022, and agreed to make additional payments of $30&#160;million upon completion of specified project activities and $25&#160;million upon technology transfer. Merck also agreed to make quarterly payments in 2022 and 2023 aggregating up to $101&#160;million to fund Kelun-Biotech&#x2019;s ongoing research and development activities. In addition, Kelun-Biotech is eligible to receive future contingent milestone payments (which includes all program compounds) aggregating up to $90&#160;million in developmental milestones, $290&#160;million in first commercial sale milestones, and $780&#160;million in sales-based milestones. The agreement also provides for Merck to pay tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2021 Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, Merck acquired Pandion Therapeutics, Inc. (Pandion), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases. Pandion is advancing a pipeline of precision immune modulators targeting critical immune control nodes. Total consideration paid of $1.9 billion included $147&#160;million of costs primarily comprised of share-based compensation payments to settle equity awards. The transaction was accounted for as an acquisition of an asset. Merck recorded net assets of $156 million (primarily cash) and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses of $1.7 billion in the first nine months of 2021 related to the transaction. There are no future contingent payments associated with the acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, Merck entered into an exclusive license and research collaboration agreement with Artiva Biotherapeutics, Inc. (Artiva) to discover, develop and manufacture CAR-NK cells that target certain solid tumors using Artiva&#x2019;s proprietary platform. Merck and Artiva agreed to engage in up to three different research programs, each covering a collaboration target. Merck has sole responsibility for all development and commercialization activities (including regulatory filing and approval). Under the terms of the agreement, Merck made an upfront payment of $30&#160;million, which was included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses in the first nine months of 2021, for license and other rights for the first two collaboration targets and agreed to make another upfront payment of $15&#160;million for license and other rights for the third collaboration target when it is selected by Merck and accepted by Artiva. In addition, Artiva is eligible to receive future contingent milestone payments (which span all three collaboration targets), aggregating up to $217.5&#160;million in developmental milestones, $570&#160;million in regulatory milestones, and $1.05&#160;billion in sales-based milestones. The agreement also provides for Merck to pay tiered royalties ranging from 7% to 14% on future sales.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of Merck&#x2019;s 2020 acquisition of OncoImmune, Merck obtained MK-7110, a therapeutic candidate that was being evaluated for the treatment of patients hospitalized with COVID-19. In 2021, Merck received feedback from the U.S. Food and Drug Administration (FDA) that additional data would be needed to support a potential Emergency Use Authorization application and therefore the Company did not expect MK-7110 would become available until the first half of 2022. Given this timeline and the technical, clinical and regulatory uncertainties, the availability of a number of medicines for patients hospitalized with COVID-19, and the need to concentrate Merck&#x2019;s resources on accelerating the development and manufacture of the most viable therapeutics and vaccines, Merck decided to discontinue development of MK-7110 for the treatment of COVID-19. Due to the discontinuation, the Company recorded charges of $207&#160;million in the first nine months of 2021, which are reflected in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and relate to fixed assets and materials written off, as well as the recognition of liabilities for purchase commitments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;</mrk:AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="i9bca04a61d0b44f38244083585df424c_D20221001-20221031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfMTA5OTUxMTY0ODM4Mw_833c9f24-b2c1-466b-be3f-af96813eb4ee"
      unitRef="usd">50000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <mrk:ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts
      contextRef="i9bca04a61d0b44f38244083585df424c_D20221001-20221031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfMTA5OTUxMTY1MjE0OA_60b0971a-2463-472d-94c5-1a2d90526e13"
      unitRef="number">0.50</mrk:ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts>
    <mrk:ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding
      contextRef="i9bca04a61d0b44f38244083585df424c_D20221001-20221031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfMTA5OTUxMTY1MDkxNw_c50cf5ab-d1d0-41a7-9193-8e516c691dc3"
      unitRef="usd">375000000</mrk:ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding>
    <mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfNTQ5NzU1ODQ3MTQy_17adfb19-194c-4ef2-a709-605128a2280a"
      unitRef="usd">250000000</mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfNTQ5NzU1ODQ3MTQy_7386307e-9b87-4bcb-a79e-f0d991066522"
      unitRef="usd">250000000</mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="ie8c7d497ea31438baaf4030a8d162610_D20220801-20220831"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfMTA5OTUxMTY0Nzc4Nw_7866b727-3e8f-45ee-8d91-9883d88693be"
      unitRef="usd">150000000</mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="i75ee5a60ce374caea61b986d91c7b118_D20220801-20220831"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfMTA5OTUxMTY0NjgzMQ_ff2bc861-b0f8-4556-948b-a620b613bd59"
      unitRef="usd">440000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="i7cce51215fdf4e1f8b49f6ac5e538125_D20220801-20220831"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfMTA5OTUxMTY0Njg1Mg_cca02bfe-209d-4292-9ad9-af813e0b9c92"
      unitRef="usd">675000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="i1d770d493ee2465aad2e7a4f35310a08_D20220801-20220831"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfMTA5OTUxMTY0Njg3Ng_27d427e5-4f07-4668-a677-814a81705cc8"
      unitRef="usd">2400000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="ie81fe052a58c4ac79c6c1914541dbb46_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfMTA5OTUxMTY0NjkyNA_fda591fd-b32c-4893-9fd0-fa757d6765ab"
      unitRef="usd">100000000</us-gaap:PaymentsToAcquireInvestments>
    <mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="ifc75b85439f349c791c677badeda87e6_D20220701-20220731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfMTQxNQ_3afbfac0-d699-4ed8-841d-6a00f5ab3bc5"
      unitRef="usd">290000000</mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="ib486ae5e04ba46c792826e98b7405eb9_D20220701-20220731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfMjc2OQ_1f48c80b-2b2e-493a-9f1f-cb72d7e033a8"
      unitRef="usd">35000000</mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="ifca4efa458684a00b6c8c8e3b1f41518_D20220701-20220731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfMjk2MA_9166ffda-5456-405d-979a-231d36c04e02"
      unitRef="usd">82000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="ia4a01db11db64f5285ad73bae142f347_D20220701-20220731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfMjk5Mg_cbd5117b-ddaa-4c97-8e8e-e87db72a1422"
      unitRef="usd">334000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="ic0e7fb5afd034fe49f7ea947b722c5af_D20220701-20220731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfMzAyNQ_32dd15c6-b81a-4806-ac26-5873da2d928f"
      unitRef="usd">485000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="i0bc205e805cf4d5f9d260e0bc1e150de_D20220501-20220531"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfMzkyOA_5f043ae6-677e-4b05-bc02-a070079831c0"
      unitRef="usd">30000000</mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <mrk:MilestonePaymentsToBeMadeToACollaborativePartner
      contextRef="i0bc205e805cf4d5f9d260e0bc1e150de_D20220501-20220531"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfNDA2MQ_7507a655-9087-4ef1-a894-016f21ae2735"
      unitRef="usd">30000000</mrk:MilestonePaymentsToBeMadeToACollaborativePartner>
    <mrk:MilestonePaymentToBeMadeToACollaborativePartner
      contextRef="i0bc205e805cf4d5f9d260e0bc1e150de_D20220501-20220531"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfNDExNg_8f59e70f-211d-43df-8afb-40a19c2a3197"
      unitRef="usd">25000000</mrk:MilestonePaymentToBeMadeToACollaborativePartner>
    <mrk:ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartner
      contextRef="i0bc205e805cf4d5f9d260e0bc1e150de_D20220501-20220531"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfNDIxOQ_f7bfd318-ad84-4c00-8d85-1b02d6c5a910"
      unitRef="usd">101000000</mrk:ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartner>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="i039f123196e246019e2836c6f6bb9e91_D20220501-20220531"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfNDQzNQ_1b6072bc-4358-441f-9abd-b02fee90537b"
      unitRef="usd">90000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="iddd9e1044d91482a92ae2a06341f0748_D20220501-20220531"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfNDQ2Nw_51f9a7c4-3201-4baf-975c-b1a7e58e7725"
      unitRef="usd">290000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="i4d354163674a44d68678d3dc0bf63d9a_D20220501-20220531"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfNDUxMQ_a2f83e90-4724-49b1-b7ef-2a6bbe0bc2e0"
      unitRef="usd">780000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="i043e841d659649cfaea941c020c82892_D20210401-20210430"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfNTAzOA_5b186f78-fb70-42eb-b24a-080a82f6c4f4"
      unitRef="usd">1900000000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost
      contextRef="i043e841d659649cfaea941c020c82892_D20210401-20210430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfNTA1MA_c5760d8a-81d7-4662-9bcc-51e6bc66b4b9"
      unitRef="usd">147000000</us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost>
    <mrk:AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet
      contextRef="idacd23b3b6ae489b89729f7dc49d6220_I20210430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfNTI1MA_14f00d22-ed5d-4bf7-9630-a2c6a83a2416"
      unitRef="usd">156000000</mrk:AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="idcccabd6edb749bf9c5977174f86658e_D20210101-20210930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfNTMxMQ_b80692b8-3db0-44d0-93cd-1174c24ab11d"
      unitRef="usd">1700000000</us-gaap:ResearchAndDevelopmentExpense>
    <mrk:CollaborativeArrangementNumberOfResearchPrograms
      contextRef="ie491bc3ce3bf4fcab2d52425ea46de0a_D20210101-20210131"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfMTY0OTI2NzQ3NzgyNA_dcfe3321-8c42-4fee-9eaa-8cf725290fca"
      unitRef="research_program">3</mrk:CollaborativeArrangementNumberOfResearchPrograms>
    <mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="ie491bc3ce3bf4fcab2d52425ea46de0a_D20210101-20210131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfNjAzMg_52dd084e-05ff-407b-9a7e-f9f4779636a4"
      unitRef="usd">30000000</mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <mrk:UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner
      contextRef="ie491bc3ce3bf4fcab2d52425ea46de0a_D20210101-20210131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfNjIzOQ_51239237-f1ac-496a-89da-bee29e2baebb"
      unitRef="usd">15000000</mrk:UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner>
    <mrk:CollaborativeArrangementNumberOfCollaborationTargets
      contextRef="ie491bc3ce3bf4fcab2d52425ea46de0a_D20210101-20210131"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfMTY0OTI2NzQ3NzgxNA_b055e88f-49c3-41a4-8ab4-97db1714b9ba"
      unitRef="collaboration_target">3</mrk:CollaborativeArrangementNumberOfCollaborationTargets>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="ic3a1ed78727c4d759751ea2f43de095d_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfNjUwNA_c0cbb74c-aa35-4410-b4f0-de9d722ca489"
      unitRef="usd">217500000</mrk:ContingentPaymentsCollaborativeArrangement>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="i4629f08bbd144fe582e499da3dad8b06_D20210101-20210131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfNjUzNg_b831f6cd-e4f8-4c5f-b611-acd84938f493"
      unitRef="usd">570000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="i7bce0692a5b4447e9a52850be6e554f4_D20210101-20210131"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfNjU2OQ_b41f3edf-96ae-4c93-8623-8fcacf5c49cc"
      unitRef="usd">1050000000.00</mrk:ContingentPaymentsCollaborativeArrangement>
    <mrk:RoyaltyRatePercentage
      contextRef="i6dcf6134f32d478dbe1941c9aea8779c_D20210101-20210131"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfNjY3NA_c881b7cf-8fe5-4dfe-a360-61ad7198ce41"
      unitRef="number">0.07</mrk:RoyaltyRatePercentage>
    <mrk:RoyaltyRatePercentage
      contextRef="i2347cdd094484cb5b876055e05600443_D20210101-20210131"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfNjY4MA_4b828a81-12a9-47f3-bb3c-c8c2b13371b8"
      unitRef="number">0.14</mrk:RoyaltyRatePercentage>
    <mrk:ChargesRelatedToProgramDiscontinuation
      contextRef="ie42db3b5c5b74f21afa507c6dc74632e_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80MC9mcmFnOmMwNmRlZjZmMmQwYTQxZDg4OTdjOTc5YTE0MjQ1OWZlL3RleHRyZWdpb246YzA2ZGVmNmYyZDBhNDFkODg5N2M5NzlhMTQyNDU5ZmVfNzYxNw_e5d668ab-345e-4a87-96a3-4f61893516d6"
      unitRef="usd">207000000</mrk:ChargesRelatedToProgramDiscontinuation>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfMTE3NTU_41272532-f8a1-4197-b1ed-45f38cda2a9c">Collaborative Arrangements&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. Both parties in these arrangements are active participants and exposed to significant risks and rewards dependent on the commercial success of the activities of the collaboration. Merck&#x2019;s more significant collaborative arrangements are discussed below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;AstraZeneca&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, Merck and AstraZeneca PLC (AstraZeneca) entered into a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca&#x2019;s Lynparza (olaparib) for multiple cancer types. Independently, Merck and AstraZeneca will develop and commercialize Lynparza in combinations with their respective PD-1 and PD-L1 medicines, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Imfinzi. The companies are also jointly developing and commercializing AstraZeneca&#x2019;s Koselugo (selumetinib) for multiple indications. Under the terms of the agreement, AstraZeneca and Merck will share the development and commercialization costs for Lynparza and Koselugo&#160;monotherapy and non-PD-L1/PD-1 combination therapy opportunities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Profits from Lynparza and Koselugo&#160;product sales generated through monotherapies or combination therapies are shared equally. AstraZeneca is the principal on Lynparza and Koselugo sales transactions. Merck records its share of Lynparza and Koselugo product sales, net of cost of sales and commercialization costs, as alliance revenue and its share of development costs associated with the collaboration as part of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses. Reimbursements received from AstraZeneca for research and development expenses are recognized as reductions to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the agreement, Merck made an upfront payment to AstraZeneca and also made payments over a multi-year period for certain license options. In addition, the agreement provides for contingent payments from Merck to AstraZeneca related to the successful achievement of sales-based and regulatory milestones. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter of 2022, Merck determined it was probable that sales of Lynparza in the future would trigger a $600&#160;million sales-based milestone payment from Merck to AstraZeneca. Accordingly, Merck recorded a $600&#160;million liability and a corresponding increase to the intangible asset related to Lynparza. Merck also recognized $250&#160;million of cumulative amortization catch-up expense related to the recognition of this milestone in the first quarter of 2022. In the first nine months of 2022, Merck made a sales-based milestone payment to AstraZeneca (which had been previously accrued for) of $400&#160;million. As of September&#160;30, 2022, sales-based milestone payments accrued but not yet paid totaled $600&#160;million. Potential future sales-based milestone payments of $2.1 billion have not yet been accrued as they are not deemed by the Company to be probable at this time. In the first nine months of 2022, Lynparza received regulatory approvals triggering capitalized milestone payments of $250&#160;million from Merck to AstraZeneca. Potential future regulatory milestone payments of $1.2 billion remain under the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The intangible asset balance related to Lynparza (which includes capitalized sales-based and regulatory milestone payments) was $1.5 billion at September&#160;30, 2022 and is included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Intangibles, Net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The amount is being amortized over its estimated useful life through 2028 as supported by projected future cash flows, subject to impairment testing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized financial information related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.364%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.123%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.713%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Lynparza&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Koselugo&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total alliance revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables from AstraZeneca included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payables to AstraZeneca included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Trade accounts payable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payables to AstraZeneca included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Noncurrent Liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Represents amortization of capitalized milestone payments. Amount in the first nine months of 2022 includes $250&#160;million of cumulative amortization catch-up expense as noted above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes accrued milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Eisai&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, Merck and Eisai Co., Ltd. (Eisai) announced a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima (lenvatinib), an orally available tyrosine kinase inhibitor discovered by Eisai. Under the agreement, Merck and Eisai will develop and commercialize Lenvima jointly, both as monotherapy and in combination with &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Eisai records Lenvima product sales globally (Eisai is the principal on Lenvima sales transactions) and Merck and Eisai share applicable profits equally. Merck records its share of Lenvima product sales, net of cost of sales and commercialization costs, as alliance revenue. Expenses incurred during co-development are shared by the two companies in accordance with the collaboration agreement and reflected in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;expenses. Certain expenses incurred solely by Merck or Eisai are not shareable under the collaboration agreement, including costs incurred in excess of agreed upon caps and costs related to certain combination studies of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Lenvima.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the agreement, Merck made an upfront payment to Eisai and also made payments over a multi-year period for certain option rights (of which the final $125 million option payment was made in March 2021). In addition, the agreement provides for contingent payments from Merck to Eisai related to the successful achievement of sales-based and regulatory milestones. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first nine months of 2022, Merck made sales-based milestone payments to Eisai (which had been previously accrued for) aggregating $600 million. Potential future sales-based milestone payments of $2.6 billion have not yet been accrued as they are not deemed by the Company to be probable at this time. In the first nine months of 2022, Lenvima received regulatory approvals triggering capitalized milestone payments of $50&#160;million from Merck to Eisai. There are no regulatory milestone payments remaining under the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The intangible asset balance related to Lenvima (which includes capitalized sales-based and regulatory milestone payments) was $867 million at September&#160;30, 2022 and is included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Intangibles, Net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The amount is being amortized over its estimated useful life through 2026 as supported by projected future cash flows, subject to impairment testing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized financial information related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Lenvima&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables from Eisai included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payables to Eisai included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Represents amortization of capitalized milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amount as of December 31, 2021 includes accrued milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Bayer AG&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators including Bayer&#x2019;s Adempas (riociguat). The two companies have implemented a joint development and commercialization strategy. The collaboration also includes development of Bayer&#x2019;s Verquvo (vericiguat), which was approved in the U.S. in January 2021, in Japan in June 2021 and in the EU in July 2021. Under the agreement, Bayer commercializes Adempas in the Americas, while Merck commercializes in the rest of the world. For Verquvo, Merck commercializes in the U.S. and Bayer commercializes in the rest of the world. Both companies share in development costs and profits on sales. Merck records sales of Adempas and Verquvo in its marketing territories, as well as alliance revenue. Alliance revenue represents Merck&#x2019;s share of profits from sales of Adempas and Verquvo in Bayer&#x2019;s marketing territories, which are product sales net of cost of sales and commercialization costs. Cost of sales includes Bayer&#x2019;s share of profits from sales in Merck&#x2019;s marketing territories. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the agreement provided for contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones. In January 2022, Merck made the final $400 million sales-based milestone payment under this collaboration to Bayer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The intangible asset balances related to Adempas (which includes the acquired intangible asset balance, as well as capitalized sales-based milestone payments attributed to Adempas) and Verquvo (which reflects the portion of the final sales-based milestone payment that was attributed to Verquvo) were $597 million and $53 million, respectively, at September&#160;30, 2022 and are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Intangibles, Net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The assets are being amortized over their estimated useful lives (through 2027 for Adempas and through 2031 for Verquvo) as supported by projected future cash flows, subject to impairment testing. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized financial information related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.947%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Adempas/Verquvo&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net sales of Adempas recorded by Merck&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net sales of Verquvo recorded by Merck&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables from Bayer included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payables to Bayer included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Includes amortization of intangible assets. Amount in the first nine months of 2021 includes $153&#160;million of cumulative amortization catch-up expense. In addition, cost of sales includes Bayer&#x2019;s share of profits from sales in Merck&#x2019;s marketing territories.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Amount as of December 31, 2021 includes accrued milestone payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Ridgeback Biotherapeutics LP&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, Merck and Ridgeback Biotherapeutics LP (Ridgeback), a closely held biotechnology company, entered into a collaboration agreement to develop &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lagevrio&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (molnupiravir), an orally available antiviral candidate in clinical development for the treatment of patients with COVID-19. Merck gained exclusive worldwide rights to develop and commercialize &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lagevrio&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and related molecules. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, Ridgeback received an upfront payment and is eligible to receive future contingent payments dependent upon the achievement of certain developmental and regulatory approval milestones. The agreement also provides for Merck to reimburse Ridgeback for a portion of certain third-party contingent milestone payments and royalties on net sales, which is part of the profit sharing calculation. Merck is the principal on sales transactions, recognizing sales and related costs, with profit sharing amounts recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Profits from the collaboration are split equally between the partners. Reimbursements from Ridgeback for its share of research and development costs (deducted from Ridgeback&#x2019;s share of profits) are reflected as decreases to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lagevrio&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; has received multiple authorizations or approvals worldwide and Merck has entered into advance purchase and supply agreements for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lagevrio&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in more than 40 markets. As of September&#160;30, 2022, the Company has 0.8 million remaining courses to be supplied under these agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized financial information related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.947%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Lagevrio&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payables to Ridgeback included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Includes royalty expense and amortization of capitalized milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Includes accrued royalty and milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Bristol Myers Squibb&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reblozyl (luspatercept-aamt) is a first-in-class erythroid maturation recombinant fusion protein obtained as part of Merck&#x2019;s November 2021 acquisition of Acceleron Pharma Inc. that is being developed and commercialized through a global collaboration with Bristol Myers Squibb (BMS). Reblozyl is approved in the U.S., Europe, Canada and Australia for the treatment of anemia in certain rare blood disorders and is also being evaluated for additional indications for hematology therapies. BMS is the principal on sales transactions for Reblozyl; however, Merck co-promotes Reblozyl (and will co-promote all future products approved under this collaboration) in North America, which is reimbursed by BMS. Merck receives a 20% sales royalty from BMS which could increase to a maximum of 24% based on sales levels. This royalty will be reduced by 50% upon the earlier of patent expiry or generic entry on an indication-by-indication basis in each market. Additionally, Merck is eligible to receive future contingent sales-based milestone payments of up to $80&#160;million. Merck recorded alliance revenue of $39 million (consisting of royalties) within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the third quarter of 2022 related to this collaboration. Merck recorded alliance revenue of $124 million in the first nine months of 2022, which includes royalties of $104&#160;million, as well as the receipt of a regulatory approval milestone payment of $20&#160;million.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <mrk:ProbableContingentPaymentsCollaborativeArrangement
      contextRef="i21912ec93da743c79ae9ba5d3f089bd9_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfMjE3Mw_85096ebb-9fc8-4933-bc84-733637243a7a"
      unitRef="usd">600000000</mrk:ProbableContingentPaymentsCollaborativeArrangement>
    <us-gaap:Liabilities
      contextRef="ic8f4acef9645432a86030dbdecb44682_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfMjI2Mw_de2dcef3-7d0d-40ce-bd93-52626b071d5a"
      unitRef="usd">600000000</us-gaap:Liabilities>
    <us-gaap:AdjustmentForAmortization
      contextRef="iaefdc2743e3b4f459d997a63fcf5409f_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfMjM3Mg_06e2ce8c-ea91-41a1-98ce-c30fbde803d7"
      unitRef="usd">250000000</us-gaap:AdjustmentForAmortization>
    <mrk:MilestonePaymentsSalesBased
      contextRef="i3afa0051e006445592494b5f1781aead_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfMjYyNw_955e36a7-b28d-45bc-81ec-e0bc60328e21"
      unitRef="usd">400000000</mrk:MilestonePaymentsSalesBased>
    <mrk:MilestonePaymentsAccruedSalesBased
      contextRef="i4bf3affc3e9f436d8fceb9cc9572407c_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfMjcwNQ_6977d33f-3371-4d0f-8445-e44b8cc135e2"
      unitRef="usd">600000000</mrk:MilestonePaymentsAccruedSalesBased>
    <mrk:PotentialFutureMilestonePaymentsSalesBased
      contextRef="i1907a491b1ab4494bcb5711a999a46d8_I20220930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfMjc2MA_4e8948dd-dc38-48b0-b8eb-32ff7041632e"
      unitRef="usd">2100000000</mrk:PotentialFutureMilestonePaymentsSalesBased>
    <mrk:MilestonePaymentsMadetoCollaborativePartner
      contextRef="i3afa0051e006445592494b5f1781aead_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfMjk3NA_2ef9d228-ad24-4feb-be82-8a07b5bcc1bd"
      unitRef="usd">250000000</mrk:MilestonePaymentsMadetoCollaborativePartner>
    <mrk:PotentialFutureMilestonePaymentsRegulatory
      contextRef="i1907a491b1ab4494bcb5711a999a46d8_I20220930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfMzA1NA_e6ab3e85-c0e0-4bac-8f0f-abbc39f85f8d"
      unitRef="usd">1200000000</mrk:PotentialFutureMilestonePaymentsRegulatory>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ia10ed00bf75d4fe2a88f22919b63e42d_I20220930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfMzIxMw_abb862df-ece8-4687-8b2c-e243f97bf6a2"
      unitRef="usd">1500000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfMTE3NjI_c61eabb4-b365-4e24-a69c-9b70813ae48a">&lt;div style="margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized financial information related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.364%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.123%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.713%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Lynparza&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Koselugo&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total alliance revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables from AstraZeneca included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payables to AstraZeneca included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Trade accounts payable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payables to AstraZeneca included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Noncurrent Liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Represents amortization of capitalized milestone payments. Amount in the first nine months of 2022 includes $250&#160;million of cumulative amortization catch-up expense as noted above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes accrued milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized financial information related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Lenvima&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables from Eisai included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payables to Eisai included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Represents amortization of capitalized milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amount as of December 31, 2021 includes accrued milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized financial information related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.947%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Adempas/Verquvo&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net sales of Adempas recorded by Merck&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net sales of Verquvo recorded by Merck&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables from Bayer included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payables to Bayer included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Includes amortization of intangible assets. Amount in the first nine months of 2021 includes $153&#160;million of cumulative amortization catch-up expense. In addition, cost of sales includes Bayer&#x2019;s share of profits from sales in Merck&#x2019;s marketing territories.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Amount as of December 31, 2021 includes accrued milestone payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized financial information related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.947%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Lagevrio&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payables to Ridgeback included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Includes royalty expense and amortization of capitalized milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Includes accrued royalty and milestone payments.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="if40bc016be9844ffacc5e3a61649fd8f_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfMi0xLTEtMS05NDQxNA_dcf142c4-a181-4b4a-b082-4ae6b3fa8a15"
      unitRef="usd">284000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="i05a4a8f891ea43e9b071e6f036172468_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfMi0zLTEtMS05NDQxNA_5628a980-8a88-4a84-812a-a66f156f06fa"
      unitRef="usd">246000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="i2d0093add0344d4bb0ff3793ac7752e2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfMi01LTEtMS05NDQxNA_b3778277-dd99-4102-b64a-c52c232d819c"
      unitRef="usd">825000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="iba2c1ce6973c439cb0304ebd132fa0fd_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfMi03LTEtMS05NDQxNA_b7e6fb29-b167-42af-a232-3d0fe426f398"
      unitRef="usd">721000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="i30533c21f6874363adc26d834802514f_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfMy0xLTEtMS05NDQxNA_85c10d10-7c01-4732-804e-176037015090"
      unitRef="usd">10000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="i8a6d8edecf524875b4d7cadcf837faa0_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfMy0zLTEtMS05NDQxNA_4b803af9-90ed-43dd-8f32-92cccab4f107"
      unitRef="usd">6000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="i9e730ddeb7ba4b2ba74c9e90f63cce43_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfMy01LTEtMS05NDQxNA_14bbe4f9-5f5b-4b9c-a0fc-18eb959720de"
      unitRef="usd">43000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="i4589c546fa744a2c966fbe3b84783265_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfMy03LTEtMS05NDQxNA_fac063a3-0b89-4aeb-9c0f-93a8e6f12b68"
      unitRef="usd">20000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="ia817e4175b9a4610b08f54e5e830ee23_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfNC0xLTEtMS05NDQxNA_6a83224a-b5e5-476c-a6aa-cb831d9cb8cb"
      unitRef="usd">294000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="i2bbde3b507d74bd89695b20384edb9a3_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfNC0zLTEtMS05NDQxNA_3b52d313-6a91-420c-9205-4984fc9ae7dc"
      unitRef="usd">252000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="if25ae27f28a94974802d948c498415fd_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfNC01LTEtMS05NDQxNA_04980c34-6d0a-4536-812e-c732454f007c"
      unitRef="usd">868000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="i398ea6779f6a4327a6a7e64c91583bf4_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfNC03LTEtMS05NDQxNA_a8c683e6-50b8-427e-a04b-15ef39378084"
      unitRef="usd">741000000</mrk:CollaborativeArrangementProfitSharing>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i039199e857634ca4ba7aafc3dbc79228_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfNi0xLTEtMS05NDQxNA_dd7a7e8b-d879-41aa-bee7-3d907f87c4e1"
      unitRef="usd">64000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i5897251afffb44088ec89b19d1bdc84a_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfNi0zLTEtMS05NDQxNA_80be44dc-5041-4be2-9496-1766c2dc0356"
      unitRef="usd">42000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i9da90caa29d94f0a8da61f2d1f19ae81_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfNi01LTEtMS05NDQxNA_aaba9502-df1f-4a3e-b017-579a0fbf7667"
      unitRef="usd">425000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i1589a04249264c3daa20424018a01187_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfNi03LTEtMS05NDQxNA_f2448ccb-aa2e-4694-9e31-4a030a81d05c"
      unitRef="usd">125000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ic5050d3fe45a40b8a7b4a69b944c22a9_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfNy0xLTEtMS05NDQxNA_c2da9ea0-bf07-46e3-96f1-0e93f6435d6b"
      unitRef="usd">45000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i587510372b604b139812c4dd9779e273_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfNy0zLTEtMS05NDQxNA_7cadfaad-8b33-4185-aba5-62ea36183c8a"
      unitRef="usd">44000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ieb2de2469e144d4893a6dcc97d4e3c99_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfNy01LTEtMS05NDQxNA_30b36ff8-75c3-4f49-9611-b9b2423cc54a"
      unitRef="usd">135000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i5ed206b7f8a24c26b903ee925c1c1961_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfNy03LTEtMS05NDQxNA_9e012967-af13-4aa5-9a75-1e9fd1e59403"
      unitRef="usd">127000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i4ee4ac5f1b264ca69d35cbb50d96ea05_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfOC0xLTEtMS05NDQxNA_82dde18b-be21-4e88-bd63-af629ff46048"
      unitRef="usd">28000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i138101fbf41c4f9dafc07d2a4e620fca_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfOC0zLTEtMS05NDQxNA_1456bfc3-a022-47dd-94fa-adcbd6abc4f1"
      unitRef="usd">27000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i613c1d9fab0f431fade5cfdf29823c97_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfOC01LTEtMS05NDQxNA_a983f925-6992-49ee-90a0-32583682f71d"
      unitRef="usd">79000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iccffbf6b9b604242a9e75a41475ad0f0_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfOC03LTEtMS05NDQxNA_4e4d46cf-4941-49a3-8fd5-29ef8b54be8c"
      unitRef="usd">87000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ReceivablesNetCurrent
      contextRef="id481255ba6384775831f82ad3ae7549e_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfMTEtNS0xLTEtOTQ0MTQ_05b1d746-585e-429d-86e2-8c97eb550028"
      unitRef="usd">290000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="id55d4ae3b325406e91eef2de4b2e7b99_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfMTEtNy0xLTEtOTQ0MTQ_040f408f-73c9-45af-9c7d-4fa7725e9021"
      unitRef="usd">271000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ia80cb9af76954141b50f85baffdadb69_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfMTItNS0xLTEtOTQ0MTQ_2671b1ef-3d26-4cc4-ad5f-b46de55bdf42"
      unitRef="usd">12000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="icbdca7f63bbb466b9c0edf3825db2b0e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfMTItNy0xLTEtOTQ0MTQ_4e001997-7c8c-4666-a138-ffff6a333ed7"
      unitRef="usd">415000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i1b48257a883b4a79aca85a1019943388_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfMTMtNS0xLTEtOTQ0MTQ_ad6acfcc-97b6-48b2-b037-9af6e0342b3e"
      unitRef="usd">600000000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="iaf53d38799a3490799f7eac25c464fe4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjNkNjc4ODQ0MDcwNDQ4MzZhODdjZGVmMmMzNTBiZTY4L3RhYmxlcmFuZ2U6M2Q2Nzg4NDQwNzA0NDgzNmE4N2NkZWYyYzM1MGJlNjhfMTMtNy0xLTEtOTQ0MTQ_efaa794c-090e-4e72-8aa7-dba9913fa66f"
      unitRef="usd">0</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i9da90caa29d94f0a8da61f2d1f19ae81_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfMzYwNg_dc66ee21-f929-41fc-96b8-b08af4df2a4c"
      unitRef="usd">250000000</us-gaap:AmortizationOfIntangibleAssets>
    <mrk:Licenseoptionpaymentrelatedtocollaborativearrangement
      contextRef="ib322c590099749b29efd1012a6436a56_D20210301-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfNDkxOA_a423e885-c303-4e64-b7b2-3f4e81c432d6"
      unitRef="usd">125000000</mrk:Licenseoptionpaymentrelatedtocollaborativearrangement>
    <mrk:MilestonePaymentsSalesBased
      contextRef="i8d3c8bd139d14d1c9571445aad6c4723_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfNTI1Ng_87b5c2a5-c142-41cc-8bc0-ca3a382737b4"
      unitRef="usd">600000000</mrk:MilestonePaymentsSalesBased>
    <mrk:PotentialFutureMilestonePaymentsSalesBased
      contextRef="ieab0ff535a8a4357924a2ea4759b4813_I20220930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfNTMxMQ_b9fa220a-f8ad-4435-9143-7f95cb60d693"
      unitRef="usd">2600000000</mrk:PotentialFutureMilestonePaymentsSalesBased>
    <mrk:MilestonePaymentsMadetoCollaborativePartner
      contextRef="i8d3c8bd139d14d1c9571445aad6c4723_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfNTUyNA_251a1499-95b0-4b2c-bb70-8d5b7107f2c5"
      unitRef="usd">50000000</mrk:MilestonePaymentsMadetoCollaborativePartner>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie403795b3c984fa5adccd65ae3284b98_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfNTg4NQ_fc674bde-1a67-4e98-b324-a94a8d36c455"
      unitRef="usd">867000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="i144701b5635f49b6a87e388b5a112a0c_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjlhODYxNDk5NGE5ZjQzOTI5YTY3ZmQ1NjAzMmU0ZGE5L3RhYmxlcmFuZ2U6OWE4NjE0OTk0YTlmNDM5MjlhNjdmZDU2MDMyZTRkYTlfMi0xLTEtMS05NDQxNA_06883aba-0062-4809-afbb-91be12df0fa8"
      unitRef="usd">202000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="iaa0c7c07509a49b2bba97e430289c5a0_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjlhODYxNDk5NGE5ZjQzOTI5YTY3ZmQ1NjAzMmU0ZGE5L3RhYmxlcmFuZ2U6OWE4NjE0OTk0YTlmNDM5MjlhNjdmZDU2MDMyZTRkYTlfMi0zLTEtMS05NDQxNA_dde316ac-71db-48bf-b510-f2475bf03fb9"
      unitRef="usd">188000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="id8782c7cfeac4f45be3816e9c23d40e2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjlhODYxNDk5NGE5ZjQzOTI5YTY3ZmQ1NjAzMmU0ZGE5L3RhYmxlcmFuZ2U6OWE4NjE0OTk0YTlmNDM5MjlhNjdmZDU2MDMyZTRkYTlfMi01LTEtMS05NDQxNA_b58d7f64-a2e6-402d-990f-c01e4af13d38"
      unitRef="usd">660000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="i981c732452864a0a89b0bdd4ea1ca966_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjlhODYxNDk5NGE5ZjQzOTI5YTY3ZmQ1NjAzMmU0ZGE5L3RhYmxlcmFuZ2U6OWE4NjE0OTk0YTlmNDM5MjlhNjdmZDU2MDMyZTRkYTlfMi03LTEtMS05NDQxNA_76b169d5-e158-4a5c-a646-0f0e8e04d7ba"
      unitRef="usd">498000000</mrk:CollaborativeArrangementProfitSharing>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i4e9c637f23f8498097ccb65785974c6e_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjlhODYxNDk5NGE5ZjQzOTI5YTY3ZmQ1NjAzMmU0ZGE5L3RhYmxlcmFuZ2U6OWE4NjE0OTk0YTlmNDM5MjlhNjdmZDU2MDMyZTRkYTlfNC0xLTEtMS05NDQxNA_b32f5b65-824b-4625-b12d-4a30430e3a5a"
      unitRef="usd">53000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="if9a88c5549694dec907e06fa69cae667_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjlhODYxNDk5NGE5ZjQzOTI5YTY3ZmQ1NjAzMmU0ZGE5L3RhYmxlcmFuZ2U6OWE4NjE0OTk0YTlmNDM5MjlhNjdmZDU2MDMyZTRkYTlfNC0zLTEtMS05NDQxNA_8cc185bd-96e6-495e-b9da-f610b3bbcd4b"
      unitRef="usd">49000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i7893a61b773e42eaa4750e61ccc3e264_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjlhODYxNDk5NGE5ZjQzOTI5YTY3ZmQ1NjAzMmU0ZGE5L3RhYmxlcmFuZ2U6OWE4NjE0OTk0YTlmNDM5MjlhNjdmZDU2MDMyZTRkYTlfNC01LTEtMS05NDQxNA_f0d0aa5a-4e09-4081-a3d4-5c659720bbc3"
      unitRef="usd">159000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i42218d013fb34f1f8c1048bf798e322e_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjlhODYxNDk5NGE5ZjQzOTI5YTY3ZmQ1NjAzMmU0ZGE5L3RhYmxlcmFuZ2U6OWE4NjE0OTk0YTlmNDM5MjlhNjdmZDU2MDMyZTRkYTlfNC03LTEtMS05NDQxNA_ab5ed1f0-1edd-492a-ab22-ebd161eaee5b"
      unitRef="usd">143000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ic860b4ba2f6b47eb8e120d99349e2f88_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjlhODYxNDk5NGE5ZjQzOTI5YTY3ZmQ1NjAzMmU0ZGE5L3RhYmxlcmFuZ2U6OWE4NjE0OTk0YTlmNDM5MjlhNjdmZDU2MDMyZTRkYTlfNS0xLTEtMS05NDQxNA_f0fe3e1f-eff0-42cb-8a86-8657d07fdff4"
      unitRef="usd">42000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ife92a3473bc4415aaff470cb4cf0a01c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjlhODYxNDk5NGE5ZjQzOTI5YTY3ZmQ1NjAzMmU0ZGE5L3RhYmxlcmFuZ2U6OWE4NjE0OTk0YTlmNDM5MjlhNjdmZDU2MDMyZTRkYTlfNS0zLTEtMS05NDQxNA_13971ecb-ab92-4a47-855d-4d3496060031"
      unitRef="usd">34000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i7a3be947f65b41ad82a9e53d652dd2b0_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjlhODYxNDk5NGE5ZjQzOTI5YTY3ZmQ1NjAzMmU0ZGE5L3RhYmxlcmFuZ2U6OWE4NjE0OTk0YTlmNDM5MjlhNjdmZDU2MDMyZTRkYTlfNS01LTEtMS05NDQxNA_ffcb2617-3fbb-4426-81f6-97ccdfffedba"
      unitRef="usd">115000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ide4d6dda5b9e4f48ac02ead988fe068f_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjlhODYxNDk5NGE5ZjQzOTI5YTY3ZmQ1NjAzMmU0ZGE5L3RhYmxlcmFuZ2U6OWE4NjE0OTk0YTlmNDM5MjlhNjdmZDU2MDMyZTRkYTlfNS03LTEtMS05NDQxNA_75860e94-57c1-4c79-a23f-ea0d6b3914b0"
      unitRef="usd">88000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ie590418643204f47816759f2195d86d2_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjlhODYxNDk5NGE5ZjQzOTI5YTY3ZmQ1NjAzMmU0ZGE5L3RhYmxlcmFuZ2U6OWE4NjE0OTk0YTlmNDM5MjlhNjdmZDU2MDMyZTRkYTlfNi0xLTEtMS05NDQxNA_b0cc3447-75f0-4f94-ae4a-41bc22fa183b"
      unitRef="usd">24000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i366906fcc328447985b2dd9207bbfdb0_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjlhODYxNDk5NGE5ZjQzOTI5YTY3ZmQ1NjAzMmU0ZGE5L3RhYmxlcmFuZ2U6OWE4NjE0OTk0YTlmNDM5MjlhNjdmZDU2MDMyZTRkYTlfNi0zLTEtMS05NDQxNA_3fdcdc3b-2eb4-49d8-a33d-2c8b50824779"
      unitRef="usd">43000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="idb33f80f44364328b49c32741943ae6f_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjlhODYxNDk5NGE5ZjQzOTI5YTY3ZmQ1NjAzMmU0ZGE5L3RhYmxlcmFuZ2U6OWE4NjE0OTk0YTlmNDM5MjlhNjdmZDU2MDMyZTRkYTlfNi01LTEtMS05NDQxNA_36dc4ddc-f8f7-45d1-81ff-f6d66d9d25bc"
      unitRef="usd">128000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i67dfa7f3e534416abfb0f9c1ea1869c5_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjlhODYxNDk5NGE5ZjQzOTI5YTY3ZmQ1NjAzMmU0ZGE5L3RhYmxlcmFuZ2U6OWE4NjE0OTk0YTlmNDM5MjlhNjdmZDU2MDMyZTRkYTlfNi03LTEtMS05NDQxNA_7142ffa9-5b3a-417c-99e9-86906034d574"
      unitRef="usd">165000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i7ae012bcf60c4cd692cca1d41ea9a0e7_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjlhODYxNDk5NGE5ZjQzOTI5YTY3ZmQ1NjAzMmU0ZGE5L3RhYmxlcmFuZ2U6OWE4NjE0OTk0YTlmNDM5MjlhNjdmZDU2MDMyZTRkYTlfOS01LTEtMS05NDQxNA_3c2f2659-5739-4906-8767-af9480ea530d"
      unitRef="usd">202000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i7be328837202423290bff8758c427630_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjlhODYxNDk5NGE5ZjQzOTI5YTY3ZmQ1NjAzMmU0ZGE5L3RhYmxlcmFuZ2U6OWE4NjE0OTk0YTlmNDM5MjlhNjdmZDU2MDMyZTRkYTlfOS03LTEtMS05NDQxNA_7cd9658a-f5c2-46fc-a9ae-922273cb9e59"
      unitRef="usd">200000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i7ac2724c045a44b1815128ce8f6b20f4_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjlhODYxNDk5NGE5ZjQzOTI5YTY3ZmQ1NjAzMmU0ZGE5L3RhYmxlcmFuZ2U6OWE4NjE0OTk0YTlmNDM5MjlhNjdmZDU2MDMyZTRkYTlfMTAtNS0xLTEtOTQ0MTQ_aff3b9c7-b5bb-4643-b934-3eca40968b44"
      unitRef="usd">1000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i683cd7e98cb547bfb87dc770c0d74e58_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjlhODYxNDk5NGE5ZjQzOTI5YTY3ZmQ1NjAzMmU0ZGE5L3RhYmxlcmFuZ2U6OWE4NjE0OTk0YTlmNDM5MjlhNjdmZDU2MDMyZTRkYTlfMTAtNy0xLTEtOTQ0MTQ_385778d5-cf44-4ef1-a0b8-988a84319d8e"
      unitRef="usd">625000000</us-gaap:LiabilitiesCurrent>
    <mrk:MilestonePaymentsSalesBased
      contextRef="iaf806d58f30c4be4bca6c3be1abe66c9_D20220101-20220131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfNzYwNw_59a107f5-1aae-463e-98cb-7b16edd38ea3"
      unitRef="usd">400000000</mrk:MilestonePaymentsSalesBased>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="if15ad2dc23594b05a094920b78cb9281_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfNzk3Ng_45c85203-d967-4622-bc25-05b7ef935507"
      unitRef="usd">597000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ifbf925ccbf934ad1bbd6105bd116f495_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfNzk4Mw_2594e6f3-cf67-4ae4-bf4d-e91d13009a73"
      unitRef="usd">53000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="ia903414baf944a4c85e8b48c1ec54218_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfMi0xLTEtMS05NDQxNA_f8a9d9eb-cc71-4977-98fc-35d2ae4afa32"
      unitRef="usd">88000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="if192c98d9a7e4b0c881c0a5da15bd44c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfMi0zLTEtMS05NDQxNA_83299deb-26db-430d-868e-4ca53bd331ae"
      unitRef="usd">100000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="i061a8128f7d54a66b9329be138104804_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfMi01LTEtMS05NDQxNA_32e19cce-db0e-4757-9954-4f84d8e2c60f"
      unitRef="usd">258000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="if960063333f14939a78490bbd9873025_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfMi03LTEtMS05NDQxNA_d32cc261-4064-481b-a880-b4669c625bf3"
      unitRef="usd">248000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementSalesNet
      contextRef="i35d4d64303ab483e97f9f6829d296385_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfMy0xLTEtMS05NDQxNA_762ae048-8259-4f59-ad01-db8247396a12"
      unitRef="usd">57000000</mrk:CollaborativeArrangementSalesNet>
    <mrk:CollaborativeArrangementSalesNet
      contextRef="iba08ab1ba316433da1eb64e967da1f14_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfMy0zLTEtMS05NDQxNA_f6c340d0-7d2e-4c88-9a58-7c6cfcbf9277"
      unitRef="usd">59000000</mrk:CollaborativeArrangementSalesNet>
    <mrk:CollaborativeArrangementSalesNet
      contextRef="i81c4bab0b60647bba82d1e4ad7faa825_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfMy01LTEtMS05NDQxNA_725e1f90-2e68-4342-97dc-1f91611d7f0e"
      unitRef="usd">181000000</mrk:CollaborativeArrangementSalesNet>
    <mrk:CollaborativeArrangementSalesNet
      contextRef="i9c06ca35260641c481956f20cb681bb1_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfMy03LTEtMS05NDQxNA_94e7eab8-6a09-4991-9eeb-6acb3ca48c9d"
      unitRef="usd">188000000</mrk:CollaborativeArrangementSalesNet>
    <mrk:CollaborativeArrangementSalesNet
      contextRef="i519e6b6f4af34d2e9581f65447c1311f_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfNC0xLTEtMS05NDQxNA_0f327e0c-40be-407d-9dac-6373e9e96f05"
      unitRef="usd">6000000</mrk:CollaborativeArrangementSalesNet>
    <mrk:CollaborativeArrangementSalesNet
      contextRef="i9ddb0dd7fa034178a6eb152be9603780_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfNC0zLTEtMS05NDQxNA_a651ecda-adc3-4dbb-a132-471fc3befbfe"
      unitRef="usd">2000000</mrk:CollaborativeArrangementSalesNet>
    <mrk:CollaborativeArrangementSalesNet
      contextRef="ic9999b3f45ca41a4a2542f94612afb3d_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfNC01LTEtMS05NDQxNA_1c317170-811e-415c-8d9c-f5d230aa0e74"
      unitRef="usd">15000000</mrk:CollaborativeArrangementSalesNet>
    <mrk:CollaborativeArrangementSalesNet
      contextRef="i212e8f35bf4a468cb7a86750d3383cf4_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfNC03LTEtMS05NDQxNA_9bd17d7b-2e07-4e28-a120-eda7b03df9b6"
      unitRef="usd">3000000</mrk:CollaborativeArrangementSalesNet>
    <us-gaap:Revenues
      contextRef="ia903414baf944a4c85e8b48c1ec54218_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfNS0xLTEtMS05NDQxNA_dc582f3a-6b01-49eb-a512-8bc9829b1680"
      unitRef="usd">151000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if192c98d9a7e4b0c881c0a5da15bd44c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfNS0zLTEtMS05NDQxNA_e15bfc6e-a75e-40dd-bcf0-4499bd0105db"
      unitRef="usd">161000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i061a8128f7d54a66b9329be138104804_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfNS01LTEtMS05NDQxNA_97018b61-fca1-4bc3-823c-261b633e35c8"
      unitRef="usd">454000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if960063333f14939a78490bbd9873025_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfNS03LTEtMS05NDQxNA_ff2eacd6-1b0d-46e6-a03d-70a48ee3b8da"
      unitRef="usd">439000000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i90dd98ecefa24e27863c524456240e09_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfNy0xLTEtMS05NDQxNA_fa948360-6465-4ee2-9ea2-3b163281971f"
      unitRef="usd">55000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i186331a72ef04ac9b7b6241c63ffaf24_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfNy0zLTEtMS05NDQxNA_11c78758-c656-48da-9f07-8e0c11147bc5"
      unitRef="usd">53000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="iedf5c07624db4e01a7cf689fdcff82a5_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfNy01LTEtMS05NDQxNA_71896952-53ed-4a62-87aa-897d64939e1d"
      unitRef="usd">158000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i27f892355464487d8539768fc6061eb5_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfNy03LTEtMS05NDQxNA_1a641f99-8f7b-49ad-913f-1791cdc30aa6"
      unitRef="usd">328000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ib78cfd0dce084d31981552de8a046a04_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfOC0xLTEtMS05NDQxNA_99cf64d4-fd0e-44de-924c-52478e20012b"
      unitRef="usd">42000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i30d1694e33a8460db578cfe950cf06d2_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfOC0zLTEtMS05NDQxNA_75737937-6521-44cb-937f-e2b614cde264"
      unitRef="usd">31000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i56264076164d4059af8de0e8936319cc_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfOC01LTEtMS05NDQxNA_e92fbf0b-1d31-4be8-be0d-9e05c3d77212"
      unitRef="usd">107000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ie9f07ed930f14354adbe45102b20b9c4_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfOC03LTEtMS05NDQxNA_aa0bfc6b-2055-4235-bdc9-77448ece9930"
      unitRef="usd">84000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0bdc458f37d94074bbb7340625918b7c_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfOS0xLTEtMS05NDQxNA_e7a8fc82-8472-4386-910c-873ba73c6a65"
      unitRef="usd">18000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i323143b5b858466db34d0d2c5c944f28_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfOS0zLTEtMS05NDQxNA_ba149d1c-cbe9-4fbc-92bf-b3646a3531f4"
      unitRef="usd">16000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia91b5a3c675c4ef88e4f8f57394a5380_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfOS01LTEtMS05NDQxNA_c03b514a-94db-4ff6-909c-8d2b3155c50b"
      unitRef="usd">52000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i5053a9df2c864fa090b207df72bef585_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfOS03LTEtMS05NDQxNA_1a3bece2-c892-4d29-87e5-df1b1b06d81c"
      unitRef="usd">36000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i3525e1187e8a48de986cf4be04ae95f4_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfMTEtNS0xLTEtOTQ0MTQ_045387b3-0a60-44f3-9cd4-1f0fe2035aea"
      unitRef="usd">144000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="ia7be680bb4e346ee9310c38a476bb72e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfMTEtNy0xLTEtOTQ0MTQ_124f97cb-c76a-4103-91df-727a6e17ed9e"
      unitRef="usd">114000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i58b09de6ba674b5b96551d497a48a9b5_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfMTItNS0xLTEtOTQ0MTQ_c095d008-1524-493e-ba30-438425c0762d"
      unitRef="usd">75000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i0771df2198d740108535caf3238d43d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjRjYjVkODdmNTI0ZjRiNWY5NzFiYTZhNDA0NjJhMTk4L3RhYmxlcmFuZ2U6NGNiNWQ4N2Y1MjRmNGI1Zjk3MWJhNmE0MDQ2MmExOThfMTItNy0xLTEtOTQ0MTQ_29b50e56-0d61-46f0-b4c1-8c7164d83a5b"
      unitRef="usd">472000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i27f892355464487d8539768fc6061eb5_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfODQyNQ_09777f70-7056-4339-ae38-9b70b0f59930"
      unitRef="usd">153000000</us-gaap:AmortizationOfIntangibleAssets>
    <mrk:SupplyCommitmentMinimumNumberOfMarkets
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-1"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfMTAwNDU_d0ab995b-3936-48b6-a2e2-780dca4b45d8"
      unitRef="market">40</mrk:SupplyCommitmentMinimumNumberOfMarkets>
    <mrk:SupplyCommitmentRemainingMinimumCoursesCommitted
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfMTAwODM_6f7c26df-8102-4f6a-92bc-5a8aa30437d8"
      unitRef="course">800000</mrk:SupplyCommitmentRemainingMinimumCoursesCommitted>
    <us-gaap:Revenues
      contextRef="i3723cbf2e9d946a999ed600588ab4dcf_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjVlODRiZGE1OWI5ODQ4NmViNGYyMmU4MDIzMTZiN2UxL3RhYmxlcmFuZ2U6NWU4NGJkYTU5Yjk4NDg2ZWI0ZjIyZTgwMjMxNmI3ZTFfMi0xLTEtMS05NDQxNA_6be0eda9-33c8-4d41-afa1-d3ca3df23b48"
      unitRef="usd">436000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if65526f98e4a40e2b1e489150cc1a2ab_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjVlODRiZGE1OWI5ODQ4NmViNGYyMmU4MDIzMTZiN2UxL3RhYmxlcmFuZ2U6NWU4NGJkYTU5Yjk4NDg2ZWI0ZjIyZTgwMjMxNmI3ZTFfMi0zLTEtMS05NDQxNA_ef4f363c-731c-4541-bcd2-bdfb58ede5c6"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iccbbed27ee8c445fa7d6d65e80591a7a_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjVlODRiZGE1OWI5ODQ4NmViNGYyMmU4MDIzMTZiN2UxL3RhYmxlcmFuZ2U6NWU4NGJkYTU5Yjk4NDg2ZWI0ZjIyZTgwMjMxNmI3ZTFfMi01LTEtMS05NDQxNA_d5192687-b0bd-4c1c-9dec-c896852321dc"
      unitRef="usd">4859000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8fdf0be182b9481c8354305d8e3858bf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjVlODRiZGE1OWI5ODQ4NmViNGYyMmU4MDIzMTZiN2UxL3RhYmxlcmFuZ2U6NWU4NGJkYTU5Yjk4NDg2ZWI0ZjIyZTgwMjMxNmI3ZTFfMi03LTEtMS05NDQxNA_326e50d6-9033-4191-9484-25afc3f66bf5"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="icd2d41565b6f42a997d55a3d36cb68d1_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjVlODRiZGE1OWI5ODQ4NmViNGYyMmU4MDIzMTZiN2UxL3RhYmxlcmFuZ2U6NWU4NGJkYTU5Yjk4NDg2ZWI0ZjIyZTgwMjMxNmI3ZTFfNC0xLTEtMS05NDQxNA_a2940711-e109-402d-a116-a7e91700c4b7"
      unitRef="usd">234000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="id5885bf545144e9fbc3756e4e3d7b93a_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjVlODRiZGE1OWI5ODQ4NmViNGYyMmU4MDIzMTZiN2UxL3RhYmxlcmFuZ2U6NWU4NGJkYTU5Yjk4NDg2ZWI0ZjIyZTgwMjMxNmI3ZTFfNC0zLTEtMS05NDQxNA_ccadfa11-6dc9-4df5-a253-5e90aac85678"
      unitRef="usd">4000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="idb36d80fe9584e529d590578a9d319d2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjVlODRiZGE1OWI5ODQ4NmViNGYyMmU4MDIzMTZiN2UxL3RhYmxlcmFuZ2U6NWU4NGJkYTU5Yjk4NDg2ZWI0ZjIyZTgwMjMxNmI3ZTFfNC01LTEtMS05NDQxNA_255a11bb-d768-4c46-9087-5ccc6218b701"
      unitRef="usd">2580000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i3627424b141f4c858a9b7d5990d0cd74_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjVlODRiZGE1OWI5ODQ4NmViNGYyMmU4MDIzMTZiN2UxL3RhYmxlcmFuZ2U6NWU4NGJkYTU5Yjk4NDg2ZWI0ZjIyZTgwMjMxNmI3ZTFfNC03LTEtMS05NDQxNA_e2bdb00b-9905-4d1a-b67c-5e36f296b3dd"
      unitRef="usd">56000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ibccd6eb894bd4564a6c0a0c44c562587_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjVlODRiZGE1OWI5ODQ4NmViNGYyMmU4MDIzMTZiN2UxL3RhYmxlcmFuZ2U6NWU4NGJkYTU5Yjk4NDg2ZWI0ZjIyZTgwMjMxNmI3ZTFfNS0xLTEtMS05NDQxNA_61af584e-7baf-404f-a020-d5fc1d6f8992"
      unitRef="usd">41000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ic9f5d07a2f4c4a9f82674c37fd6d528a_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjVlODRiZGE1OWI5ODQ4NmViNGYyMmU4MDIzMTZiN2UxL3RhYmxlcmFuZ2U6NWU4NGJkYTU5Yjk4NDg2ZWI0ZjIyZTgwMjMxNmI3ZTFfNS0zLTEtMS05NDQxNA_c480e443-36a6-42b3-876e-5770567cb426"
      unitRef="usd">6000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i17a18d3e962d4cd9b3dd760b10d9798b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjVlODRiZGE1OWI5ODQ4NmViNGYyMmU4MDIzMTZiN2UxL3RhYmxlcmFuZ2U6NWU4NGJkYTU5Yjk4NDg2ZWI0ZjIyZTgwMjMxNmI3ZTFfNS01LTEtMS05NDQxNA_c7f2c76e-263c-4518-83ea-f593151d6345"
      unitRef="usd">105000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i434e35353dae4fc0b4b54dc274539d65_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjVlODRiZGE1OWI5ODQ4NmViNGYyMmU4MDIzMTZiN2UxL3RhYmxlcmFuZ2U6NWU4NGJkYTU5Yjk4NDg2ZWI0ZjIyZTgwMjMxNmI3ZTFfNS03LTEtMS05NDQxNA_1d2dc433-1f59-474a-8c88-46ae0fea89d7"
      unitRef="usd">13000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ib23b0153d3f34c168976ed88f8d51ecf_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjVlODRiZGE1OWI5ODQ4NmViNGYyMmU4MDIzMTZiN2UxL3RhYmxlcmFuZ2U6NWU4NGJkYTU5Yjk4NDg2ZWI0ZjIyZTgwMjMxNmI3ZTFfNi0xLTEtMS05NDQxNA_c16f6eb8-3a94-4fef-a5e0-a0c48d005d90"
      unitRef="usd">8000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i1c3f6bda0cc24696bb0a6048cab3d8ad_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjVlODRiZGE1OWI5ODQ4NmViNGYyMmU4MDIzMTZiN2UxL3RhYmxlcmFuZ2U6NWU4NGJkYTU5Yjk4NDg2ZWI0ZjIyZTgwMjMxNmI3ZTFfNi0zLTEtMS05NDQxNA_f2b65935-67b6-49c7-a7a2-b1830c6f7520"
      unitRef="usd">58000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i7e9026c7a16e448aa12d13cee7a70f46_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjVlODRiZGE1OWI5ODQ4NmViNGYyMmU4MDIzMTZiN2UxL3RhYmxlcmFuZ2U6NWU4NGJkYTU5Yjk4NDg2ZWI0ZjIyZTgwMjMxNmI3ZTFfNi01LTEtMS05NDQxNA_c2246a78-7112-4b1f-b3bd-bef964446003"
      unitRef="usd">29000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ida58e25739ea40aab501d63f8e5ca681_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjVlODRiZGE1OWI5ODQ4NmViNGYyMmU4MDIzMTZiN2UxL3RhYmxlcmFuZ2U6NWU4NGJkYTU5Yjk4NDg2ZWI0ZjIyZTgwMjMxNmI3ZTFfNi03LTEtMS05NDQxNA_fdd9fa06-0ef5-44af-9994-1419312285a6"
      unitRef="usd">167000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:LiabilitiesCurrent
      contextRef="i39554fdd833642dcb810f17c8dc0e061_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjVlODRiZGE1OWI5ODQ4NmViNGYyMmU4MDIzMTZiN2UxL3RhYmxlcmFuZ2U6NWU4NGJkYTU5Yjk4NDg2ZWI0ZjIyZTgwMjMxNmI3ZTFfOS01LTEtMS05NDQxNA_804a4537-2f8d-49be-af58-0cc95d70b2ca"
      unitRef="usd">193000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i425575da0166424ea1fd3084934e226f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RhYmxlOjVlODRiZGE1OWI5ODQ4NmViNGYyMmU4MDIzMTZiN2UxL3RhYmxlcmFuZ2U6NWU4NGJkYTU5Yjk4NDg2ZWI0ZjIyZTgwMjMxNmI3ZTFfOS03LTEtMS05NDQxNA_81fec732-543d-4e42-8a54-5489df606a90"
      unitRef="usd">283000000</us-gaap:LiabilitiesCurrent>
    <mrk:RoyaltyRatePercentage
      contextRef="i27570eaa57364d34ba707b5178e9750a_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfMTExMDU_e4b5ce3a-e0b0-4a21-8203-39a7b5979742"
      unitRef="number">0.20</mrk:RoyaltyRatePercentage>
    <mrk:RoyaltyRatePercentage
      contextRef="i82096e190c7a476a960b881f6f4ec492_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfMTExNjg_93fcfb28-7c25-4b38-892a-f836c3481870"
      unitRef="number">0.24</mrk:RoyaltyRatePercentage>
    <mrk:RoyaltyRateDeductionPercentage
      contextRef="i9a2d8c4a46554ddebb3ddc81810f3b42_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfMTEyMjY_a646eccf-4a06-488e-8469-5ff07a3940b7"
      unitRef="number">0.50</mrk:RoyaltyRateDeductionPercentage>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="i6730c99096144e189cec49f74ada9510_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfMTE0MzQ_7ecd27ec-8cd5-44bb-9bb3-94504d012c6b"
      unitRef="usd">80000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <us-gaap:Revenues
      contextRef="ie6ab39f8789a4b6fa4f623fa5d27795c_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfMTE0NzM_c37c8f2a-8804-45f2-b9d6-19be54b5986e"
      unitRef="usd">39000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0715d2eaae6e4be98aee0bd0d1931927_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfMTA5OTUxMTYzOTg5NQ_895aa20d-816c-4c81-8ea2-5a39b8c48348"
      unitRef="usd">124000000</us-gaap:Revenues>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="i9a2d8c4a46554ddebb3ddc81810f3b42_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfMTE2NzA_e59a0130-32dd-4908-8326-c59751a01d76"
      unitRef="usd">104000000</us-gaap:RoyaltyIncomeNonoperating>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="i6f62c15a0dd94e4a890739e8dafcc0e8_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80My9mcmFnOjIzZWFiNWRiNjU3NDRjYjhiNzAwMWQwNjIwZGFkNTllL3RleHRyZWdpb246MjNlYWI1ZGI2NTc0NGNiOGI3MDAxZDA2MjBkYWQ1OWVfMTE3NDM_dc583625-9323-43c6-8042-94557a2d366c"
      unitRef="usd">20000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RleHRyZWdpb246M2E2NDYyY2Y1Y2U5NDVkNGFkN2RmODRlZTllNGNkMDVfMzMzMg_2800087c-4481-41ff-9c45-9c1124c42320">Restructuring&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, Merck&#160;approved a global restructuring program (Restructuring Program) as part of a worldwide initiative focused on further optimizing the Company&#x2019;s manufacturing and supply network, as well as reducing its global real estate footprint.&#160;This program is a continuation of the Company&#x2019;s plant rationalization and builds on prior restructuring programs. The actions currently contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $3.5 billion. The Company estimates that approximately 70% of the cumulative pretax costs will result in cash outlays, primarily related to employee separation expense and facility shut-down costs. Approximately 30% of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded total pretax costs of $175 million and $168 million in the third quarter of 2022 and 2021, respectively, and $559 million and $630 million for the first nine months of 2022 and 2021, respectively, related to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;restructuring program activities. Since inception of the Restructuring Program through September&#160;30, 2022, Merck has recorded total pretax accumulated costs of approximately $3.2 billion. For the full year of 2022, the Company expects to record charges of approximately $600 million related to the Restructuring Program. For segment reporting, restructuring charges are unallocated expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the charges related to restructuring program activities by type of cost:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Separation&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accelerated&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Separation&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accelerated&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Separation&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accelerated&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Separation&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accelerated&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Separation costs are associated with actual headcount reductions, as well as those headcount reductions which were probable and could be reasonably estimated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accelerated depreciation costs primarily relate to manufacturing, research and administrative facilities and equipment to be sold or closed as part of the program. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. All the sites have and will continue to operate up through the respective closure dates and, since future undiscounted cash flows are sufficient to recover the respective book values, Merck is recording accelerated depreciation over the revised useful life of the site assets. Anticipated site closure dates, particularly related to manufacturing locations, have been and may continue to be adjusted to reflect changes resulting from regulatory or other factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other activity in 2022 and 2021 includes asset abandonment, facility shut-down and other related costs, as well as pretax gains and losses resulting from the sales of facilities and related assets. Additionally, other activity includes certain employee-related costs associated with pension and other postretirement benefit plans (see Note&#160;11) and share-based compensation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the charges and spending relating to restructuring program activities for the nine months ended September&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Separation&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accelerated&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserves January&#160;1, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Payments) receipts, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(303)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(458)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(761)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-cash activity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(97)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserves September&#160;30, 2022 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1)The remaining cash outlays are expected to be substantially completed by the end of 2023.</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RleHRyZWdpb246M2E2NDYyY2Y1Y2U5NDVkNGFkN2RmODRlZTllNGNkMDVfNjE5_53638959-f9cb-41d1-aabb-3ab31a01a121"
      unitRef="usd">3500000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <mrk:EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RleHRyZWdpb246M2E2NDYyY2Y1Y2U5NDVkNGFkN2RmODRlZTllNGNkMDVfNjY0_a5b20b26-73b6-49c4-a04c-6201f5fba7e0"
      unitRef="number">0.70</mrk:EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays>
    <mrk:EstimateOfCumulativePreTaxCostsThatWillBeNoncash
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RleHRyZWdpb246M2E2NDYyY2Y1Y2U5NDVkNGFkN2RmODRlZTllNGNkMDVfODIw_dadfd7ab-113d-4ee9-b8b3-2a4d5f5e25d9"
      unitRef="number">0.30</mrk:EstimateOfCumulativePreTaxCostsThatWillBeNoncash>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RleHRyZWdpb246M2E2NDYyY2Y1Y2U5NDVkNGFkN2RmODRlZTllNGNkMDVfMTAwNw_ec921359-6b46-4b42-bc9f-59760a0099a9"
      unitRef="usd">175000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RleHRyZWdpb246M2E2NDYyY2Y1Y2U5NDVkNGFkN2RmODRlZTllNGNkMDVfMTAxNA_2b513efe-5379-4a53-99ed-34ea2080efca"
      unitRef="usd">168000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RleHRyZWdpb246M2E2NDYyY2Y1Y2U5NDVkNGFkN2RmODRlZTllNGNkMDVfMTA2Nw_5ca7e339-3743-4c30-8feb-097203757283"
      unitRef="usd">559000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RleHRyZWdpb246M2E2NDYyY2Y1Y2U5NDVkNGFkN2RmODRlZTllNGNkMDVfMTA3NA_0d24fe8c-5c23-438b-9802-5a9cc3a3aebf"
      unitRef="usd">630000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RleHRyZWdpb246M2E2NDYyY2Y1Y2U5NDVkNGFkN2RmODRlZTllNGNkMDVfMTMwMg_89fc3c3b-907b-49ef-8fc9-884b848ce0c0"
      unitRef="usd">3200000000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="id6564f481b634b6fa99cd7e8116cf98f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RleHRyZWdpb246M2E2NDYyY2Y1Y2U5NDVkNGFkN2RmODRlZTllNGNkMDVfMTM4Ng_0651fc56-49f2-4864-b244-1b12f07d1705"
      unitRef="usd">600000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RleHRyZWdpb246M2E2NDYyY2Y1Y2U5NDVkNGFkN2RmODRlZTllNGNkMDVfMzMyOQ_5aa97547-f98d-42fe-9c8e-1ab0404ac53d">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the charges related to restructuring program activities by type of cost:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Separation&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accelerated&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Separation&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accelerated&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Separation&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accelerated&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Separation&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accelerated&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i607e39f2759d4b5691b37d2c9b39dcc7_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfMi0xLTEtMS05NDQxNA_0e5f7d56-78dc-4a47-a76d-b413a936551a"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i1ec10c038b504097b605bfddb4195539_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfMi0zLTEtMS05NDQxNA_de5d9f9a-3486-4fed-99d9-958da1a8a812"
      unitRef="usd">16000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i6fb3a552dc224a94b2299fd6c6cf8889_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfMi01LTEtMS05NDQxNA_a16c9184-5598-4d03-b1e1-4f3d138c2a9d"
      unitRef="usd">38000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ic03376b1c2a3499d90e8c3ebcf2e8843_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfMi03LTEtMS05NDQxNA_75c42477-a4b1-4b81-9131-19393619ac46"
      unitRef="usd">54000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i67cab3cf205f49af9b2cbd5c33f66aaa_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfMi05LTEtMS05NDQxNA_c92dda0c-e77b-4456-8e0a-01325ec3eee1"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i940e1b01bd364068818c54a265d128b1_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfMi0xMS0xLTEtOTQ0MTQ_9682c58a-69ec-47a7-9dad-4bc94b5c5f3a"
      unitRef="usd">51000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i72dc17aba95d4c5dbc3a2194bd16fbbd_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfMi0xMy0xLTEtOTQ0MTQ_325cd004-f4bf-4d29-8aa6-6fcd9e67b346"
      unitRef="usd">116000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="iec1e587d8b0d40bdb598eb257221971d_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfMi0xNS0xLTEtOTQ0MTQ_fb1bacfd-9d7a-4b9e-8222-3ac91c3847fe"
      unitRef="usd">167000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i70303f64175d4dc4b0012ac52b4f5e26_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfMy0xLTEtMS05NDQxNA_55d34c45-61c6-4aa3-aae4-ace9d0dc93af"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i3578096e6ff448caa0f52989e5f64761_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfMy0zLTEtMS05NDQxNA_a650dd46-87a8-4490-8229-66f40d4a58bb"
      unitRef="usd">5000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i0ad3e04cc3e3418cb4a53a75ae5c3e2c_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfMy01LTEtMS05NDQxNA_f70f8df3-98d2-4c8f-8a47-ba554365f501"
      unitRef="usd">21000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i8849203e046e46cbad3f2f952d1f4e26_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfMy03LTEtMS05NDQxNA_2aa48ef8-2f78-43d1-9314-dd6a9524f3d8"
      unitRef="usd">26000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i2c93d3a120f84e38a20a1a70937efcd7_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfMy05LTEtMS05NDQxNA_eb81f5a7-38e5-4c97-ad50-4b5feb18613c"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="iaece706c71314f32b319a33cc075cdd3_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfMy0xMS0xLTEtOTQ0MTQ_e9532c1f-16e3-4bd3-9352-f091d41445fc"
      unitRef="usd">17000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i310bfcc0be584465a56866ddaad54dde_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfMy0xMy0xLTEtOTQ0MTQ_b704bd89-7c5c-4d85-bd1c-99d8da4f4252"
      unitRef="usd">57000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i521c621370414b959a6f7126a06cd3db_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfMy0xNS0xLTEtOTQ0MTQ_b136df86-bb6c-4cb9-9b82-0a72ca4e5a5e"
      unitRef="usd">74000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i45b5fd4276104c17a8bc518c8e4ee367_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfNC0xLTEtMS05NDQxNA_ea83645a-5806-4d4e-9fc9-486e40076cef"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="id015ab72aa4f4666af512c49587ba178_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfNC0zLTEtMS05NDQxNA_d2cecbe9-3983-43a3-a323-87789c35e82e"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ie78da687a4494c7fb93cf5f0da80fd52_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfNC01LTEtMS05NDQxNA_1918f6f7-8055-4a50-8bb6-4c58f1fed3d2"
      unitRef="usd">1000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i92d26b2795bd42e49f6d1a0b2f14a67e_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfNC03LTEtMS05NDQxNA_ee136006-e202-43cc-a6f1-bd25d0c2bb1f"
      unitRef="usd">1000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ie67e7f4f21244b38ac40aac5e3a31725_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfNC05LTEtMS05NDQxNA_65cacadb-72ea-4ff1-867f-8c42da186959"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ica35ec1eb9ea4c119a570c9e6bd607d1_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfNC0xMS0xLTEtOTQ0MTQ_70c99c0c-e350-4659-ab28-528fcf9934e6"
      unitRef="usd">29000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i9bf969645ea14edeb5fb224b37851e85_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfNC0xMy0xLTEtOTQ0MTQ_7419fd6e-5d12-4429-ab33-b918bedb1334"
      unitRef="usd">1000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i6cf8194e2b5745f0bb10f0b19e79ef0d_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfNC0xNS0xLTEtOTQ0MTQ_03826c76-5b85-4fac-8ea8-103c019d11df"
      unitRef="usd">30000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="idae084acd38849fea32bf72eca48cb01_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfNS0xLTEtMS05NDQxNA_e2aa5a6c-dd3a-4851-a280-76b7629ae1e6"
      unitRef="usd">65000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ic7e6f52cb1c84ad79bc614920f692b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfNS0zLTEtMS05NDQxNA_cf660b35-6565-4eae-bc10-6789ad585d1f"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i1fedc08d43254caca03ecd529c042551_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfNS01LTEtMS05NDQxNA_2c1bcbdc-868f-432f-b1d3-efc6bd400153"
      unitRef="usd">29000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i9bc054b6f538473eadeef1645e9b4c4b_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfNS03LTEtMS05NDQxNA_2239d380-8699-40b6-a616-f725fd471849"
      unitRef="usd">94000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i9362212891c34b43a1bd670fb2f4062f_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfNS05LTEtMS05NDQxNA_e3c5c2e1-7813-4b02-bf86-a5849966c3a8"
      unitRef="usd">197000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i6a992f86ee914509b7bdf62709a6811d_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfNS0xMS0xLTEtOTQ0MTQ_091d4a78-7413-4dbf-b7a0-79b3e9635d07"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i5aff9663fce2448c99f02618375e2e64_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfNS0xMy0xLTEtOTQ0MTQ_1b11114e-23dd-4eab-bf86-6704891f213d"
      unitRef="usd">91000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i3b0c1dffc5964f349f9a75222d0c1430_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfNS0xNS0xLTEtOTQ0MTQ_347b5eff-2346-4384-a7cc-fb57d23212d5"
      unitRef="usd">288000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ic0106fbddb424e3aa3b3ba43ca616389_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfNi0xLTEtMS05NDQxNA_2dfd952c-9ee2-47a9-9f60-573395e56f4d"
      unitRef="usd">65000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="id8d2797912764a54a9b0c8b56a5cb401_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfNi0zLTEtMS05NDQxNA_0f2f5802-b8d7-46d3-94e9-232f29eaec87"
      unitRef="usd">21000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="iba55b4c871c84cf8aff0cc19a6430038_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfNi01LTEtMS05NDQxNA_500943ff-f7d0-4c86-bb3c-fbf8062e83b2"
      unitRef="usd">89000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfNi03LTEtMS05NDQxNA_87391279-e3c4-432b-becc-ae0fb25b8ead"
      unitRef="usd">175000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i5a2cfacf23e041649e6e810a01b78367_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfNi05LTEtMS05NDQxNA_897e5874-d923-425a-98ff-4b104adfa025"
      unitRef="usd">197000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="id6578e5480804aaabbdd710e9e7d4dec_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfNi0xMS0xLTEtOTQ0MTQ_eefb34bf-adfd-4544-9995-5a2dbcfb9eb3"
      unitRef="usd">97000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ie5f3b77e795a4cecb84d959b27d815f5_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfNi0xMy0xLTEtOTQ0MTQ_f8adf823-c61b-4612-b117-0d7d44e71b67"
      unitRef="usd">265000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjRmMjkyMDY1NjAzNjQwZDI4M2FkNzY5YmIzZjlkZWU4L3RhYmxlcmFuZ2U6NGYyOTIwNjU2MDM2NDBkMjgzYWQ3NjliYjNmOWRlZThfNi0xNS0xLTEtOTQ0MTQ_abc85dac-7ca0-4c11-a5ea-c126b03baba9"
      unitRef="usd">559000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i53cc7f522cf94a9ba8b27371253d34fd_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfMi0xLTEtMS05NDQxNA_6733d648-7326-4d2d-87a1-89f322340862"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i37502c19e33b478ba485f3769f7edde9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfMi0zLTEtMS05NDQxNA_2136448e-4648-4a29-9fc5-486f564be167"
      unitRef="usd">11000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i3dbf94fcba07458c9985b487a4e8e11a_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfMi01LTEtMS05NDQxNA_f456f2a1-ae3b-4ad5-aa57-9681660709da"
      unitRef="usd">37000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i897e9c4831fe4162b3092f6346596330_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfMi03LTEtMS05NDQxNA_4c3d19e0-91eb-47d0-93d9-1940d13c47c9"
      unitRef="usd">48000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i1b3871ab9cbd41ffabab932a2f1a7a00_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfMi05LTEtMS05NDQxNA_5d90b6a2-2278-436a-a944-91348309230e"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ic248a691eef3457980491b2190cd4476_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfMi0xMS0xLTEtOTQ0MTQ_49b82507-58c4-480c-afa4-a1ed1484a40a"
      unitRef="usd">32000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i2181ab62a29c4f39995a887b7394ab97_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfMi0xMy0xLTEtOTQ0MTQ_21d7d1b9-6b49-40ce-a337-3d9c85672c1a"
      unitRef="usd">81000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="icae4aa9b209147aa9d9bf757f4c8c2e5_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfMi0xNS0xLTEtOTQ0MTQ_c6b60479-d66d-4932-893d-815c502efcdf"
      unitRef="usd">113000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i0582722a90814a31816b9004352bfa16_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfMy0xLTEtMS05NDQxNA_4b822805-7033-41f6-b2f7-d3eca2fb4d05"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ia278f201fcb0483ea8de813bd868a23b_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfMy0zLTEtMS05NDQxNA_01e3e47d-aa9e-48d1-870f-89dff53c19a3"
      unitRef="usd">4000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ie582a185448546fc8001d7759a7730db_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfMy01LTEtMS05NDQxNA_a5e2664c-a332-4feb-addf-f2dec0eea7f6"
      unitRef="usd">1000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i36d4bd762ee74c8b99495575010c996f_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfMy03LTEtMS05NDQxNA_e58d5916-b4ed-4850-9cd9-517fe0921b64"
      unitRef="usd">5000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ie6ccd75209b14ac48e453f8ae771b430_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfMy05LTEtMS05NDQxNA_d513db36-afb0-49f5-921a-143d04932887"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i90654f8e2de64d88a4d14ff9c355cff7_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfMy0xMS0xLTEtOTQ0MTQ_a4bb2b91-3b64-4afb-9435-f8a7548dc7e6"
      unitRef="usd">8000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="iae11b50969c44470b085b71a202c369b_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfMy0xMy0xLTEtOTQ0MTQ_0225aa40-3ca4-4376-b4af-b08cb921cf96"
      unitRef="usd">1000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i1fef4e3614274432a2cb07854dd86e09_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfMy0xNS0xLTEtOTQ0MTQ_9297bf80-8be5-4ed4-8687-fde016251272"
      unitRef="usd">9000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i14b940f93da941d89457a0cb5087dc05_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfNC0xLTEtMS05NDQxNA_937cee3a-7c89-4fb1-bd29-f9ade0088032"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i4f0e3061236541d88cb6730bdf73a36c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfNC0zLTEtMS05NDQxNA_3de9135c-e43b-4696-b145-09ca5413ed2f"
      unitRef="usd">7000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i7fe0bb2d87cc463ba0afd98a1d4f6c49_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfNC01LTEtMS05NDQxNA_b8d46664-4a7b-4c56-acc1-d361dcb0dc41"
      unitRef="usd">1000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i8fde48e69dd3472e9819a95aa4746a43_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfNC03LTEtMS05NDQxNA_614ba670-bd56-49bd-9c67-e4403ef4be30"
      unitRef="usd">8000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="id0f98d96c0344d749893dc7317abd393_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfNC05LTEtMS05NDQxNA_93c42c55-1f50-44a4-b9c3-8c19684f2b69"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i1f83f5cfdae84508a28c38bc5dc977cb_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfNC0xMS0xLTEtOTQ0MTQ_f4e07aa4-a776-40ad-bbd2-9c4048d0f076"
      unitRef="usd">20000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i727f0dd97e804d1cab3731ca3b4c50cb_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfNC0xMy0xLTEtOTQ0MTQ_eeb526ac-4af3-4e0b-9216-10f41a8595ae"
      unitRef="usd">1000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i98e34a5cb81241399b51495bac59245a_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfNC0xNS0xLTEtOTQ0MTQ_5e6f7c5b-60e1-4099-9732-257fc2c50e01"
      unitRef="usd">21000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i2e4b050ead3647479f62f1237a1c63c5_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfNS0xLTEtMS05NDQxNA_2c4fc7af-34d4-48f7-b1d9-8d984d240cec"
      unitRef="usd">17000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i309f819f3951487382595bf493061e13_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfNS0zLTEtMS05NDQxNA_d0af2e42-0fb1-4a28-b11f-383de46b972b"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i874c7a8482d9491690e6210b479df219_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfNS01LTEtMS05NDQxNA_82cc48f0-e1f6-4acd-9311-6116838c0675"
      unitRef="usd">90000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i5db3736668d14dc8ad614ba24ea70f21_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfNS03LTEtMS05NDQxNA_10b17197-937b-4ece-85cb-a3017025b7c4"
      unitRef="usd">107000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i12cf63265e33426a9ac172ae9d1f6ad3_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfNS05LTEtMS05NDQxNA_fa8de0bd-354f-4685-9d03-cd6577f26ffa"
      unitRef="usd">310000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i5216105f6e064bba87cac0aa0ae94efd_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfNS0xMS0xLTEtOTQ0MTQ_a1c1e174-ad1e-4580-8ce3-c25d1a3c0425"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i955e203846ca40e1adf9d2507ef80695_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfNS0xMy0xLTEtOTQ0MTQ_13a3c154-2caa-41e9-8e80-4de53e5afd03"
      unitRef="usd">177000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i4afc7e4c5b9a43a7af38307f4daa99e9_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfNS0xNS0xLTEtOTQ0MTQ_1836f5e8-2375-469e-83ad-48a09b65ab29"
      unitRef="usd">487000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ie766e05eb57f41bea33a66d0f8d1fa6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfNi0xLTEtMS05NDQxNA_96ba594c-88f8-4acd-8f06-50e252863c36"
      unitRef="usd">17000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ieb61cb5684ff4b9c828cf20066ed6299_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfNi0zLTEtMS05NDQxNA_4df006f7-8d3a-4b2a-bf35-24f48b4325e3"
      unitRef="usd">22000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ieb5b904f4f0748a6aa9b86108608f108_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfNi01LTEtMS05NDQxNA_b2415017-663c-4daa-a33c-2c3e1cd99297"
      unitRef="usd">129000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfNi03LTEtMS05NDQxNA_788775fb-0434-45d0-a38a-8990b033d996"
      unitRef="usd">168000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i86d01d6cbe2846bab4a8e80b2c1c31d2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfNi05LTEtMS05NDQxNA_94453f26-d505-4f19-9c06-f672feda9a62"
      unitRef="usd">310000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="id3f2085cbdba410eb279bbb464b3ec8e_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfNi0xMS0xLTEtOTQ0MTQ_b8d0658f-8e7d-4208-b326-97fc04c1a9e2"
      unitRef="usd">60000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="id6edbfe83866410d981411c92bc94739_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfNi0xMy0xLTEtOTQ0MTQ_a424a81f-dacf-4b79-839b-481cb04b14b0"
      unitRef="usd">260000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOjQwMWUzNTFmNzZkYjRkMjVhY2M5YTg0ZjQzYzgxYjFkL3RhYmxlcmFuZ2U6NDAxZTM1MWY3NmRiNGQyNWFjYzlhODRmNDNjODFiMWRfNi0xNS0xLTEtOTQ0MTQ_ba32d3eb-624b-40e3-81c5-9e9860f9fe7e"
      unitRef="usd">630000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RleHRyZWdpb246M2E2NDYyY2Y1Y2U5NDVkNGFkN2RmODRlZTllNGNkMDVfMzM0NQ_be03bdad-3589-4407-9f52-52a7ed7a779a">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the charges and spending relating to restructuring program activities for the nine months ended September&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Separation&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accelerated&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserves January&#160;1, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Payments) receipts, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(303)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(458)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(761)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-cash activity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(97)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserves September&#160;30, 2022 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1)The remaining cash outlays are expected to be substantially completed by the end of 2023.</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="ic795a5720c194aaaa03944a5d453e5e9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOmIzN2ZjNDAyNjYyZjQxNzc4MGYzYmI3YmMwYjk2MTUyL3RhYmxlcmFuZ2U6YjM3ZmM0MDI2NjJmNDE3NzgwZjNiYjdiYzBiOTYxNTJfMS0xLTEtMS05NDQxNA_33388dfd-72fc-4a4a-a5d7-35e3a10f2434"
      unitRef="usd">596000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i2a52aaf7232745dbbf9787cba14d23ca_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOmIzN2ZjNDAyNjYyZjQxNzc4MGYzYmI3YmMwYjk2MTUyL3RhYmxlcmFuZ2U6YjM3ZmM0MDI2NjJmNDE3NzgwZjNiYjdiYzBiOTYxNTJfMS0zLTEtMS05NDQxNA_6774eec8-ecfb-43e6-ac1f-b1d0b7664f47"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="if340c59c3f4d4832acc93316ac66cbcf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOmIzN2ZjNDAyNjYyZjQxNzc4MGYzYmI3YmMwYjk2MTUyL3RhYmxlcmFuZ2U6YjM3ZmM0MDI2NjJmNDE3NzgwZjNiYjdiYzBiOTYxNTJfMS01LTEtMS05NDQxNA_daeaca82-3be3-461f-be64-db7e80064288"
      unitRef="usd">41000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOmIzN2ZjNDAyNjYyZjQxNzc4MGYzYmI3YmMwYjk2MTUyL3RhYmxlcmFuZ2U6YjM3ZmM0MDI2NjJmNDE3NzgwZjNiYjdiYzBiOTYxNTJfMS03LTEtMS05NDQxNA_66765bc0-8c27-4bc4-ab5b-c09ba37dde1d"
      unitRef="usd">637000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i5a2cfacf23e041649e6e810a01b78367_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOmIzN2ZjNDAyNjYyZjQxNzc4MGYzYmI3YmMwYjk2MTUyL3RhYmxlcmFuZ2U6YjM3ZmM0MDI2NjJmNDE3NzgwZjNiYjdiYzBiOTYxNTJfMi0xLTEtMS05NDQxNA_b20b423c-dba8-473e-9203-bf0fb197fbee"
      unitRef="usd">197000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="id6578e5480804aaabbdd710e9e7d4dec_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOmIzN2ZjNDAyNjYyZjQxNzc4MGYzYmI3YmMwYjk2MTUyL3RhYmxlcmFuZ2U6YjM3ZmM0MDI2NjJmNDE3NzgwZjNiYjdiYzBiOTYxNTJfMi0zLTEtMS05NDQxNA_595c76e1-5007-47f8-b084-5089e06a41a8"
      unitRef="usd">97000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ie5f3b77e795a4cecb84d959b27d815f5_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOmIzN2ZjNDAyNjYyZjQxNzc4MGYzYmI3YmMwYjk2MTUyL3RhYmxlcmFuZ2U6YjM3ZmM0MDI2NjJmNDE3NzgwZjNiYjdiYzBiOTYxNTJfMi01LTEtMS05NDQxNA_51884691-b797-4245-8784-b85c0119b855"
      unitRef="usd">265000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOmIzN2ZjNDAyNjYyZjQxNzc4MGYzYmI3YmMwYjk2MTUyL3RhYmxlcmFuZ2U6YjM3ZmM0MDI2NjJmNDE3NzgwZjNiYjdiYzBiOTYxNTJfMi03LTEtMS05NDQxNA_2053f498-a51f-441c-8cf8-3afb4495af5f"
      unitRef="usd">559000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:PaymentsForRestructuring
      contextRef="i5a2cfacf23e041649e6e810a01b78367_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOmIzN2ZjNDAyNjYyZjQxNzc4MGYzYmI3YmMwYjk2MTUyL3RhYmxlcmFuZ2U6YjM3ZmM0MDI2NjJmNDE3NzgwZjNiYjdiYzBiOTYxNTJfMy0xLTEtMS05NDQxNA_93cdf7fa-eb1d-4c61-8686-0ef06855cf46"
      unitRef="usd">303000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="id6578e5480804aaabbdd710e9e7d4dec_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOmIzN2ZjNDAyNjYyZjQxNzc4MGYzYmI3YmMwYjk2MTUyL3RhYmxlcmFuZ2U6YjM3ZmM0MDI2NjJmNDE3NzgwZjNiYjdiYzBiOTYxNTJfMy0zLTEtMS05NDQxNA_7a7cd64a-eb55-41d2-b09d-60cd744f39de"
      unitRef="usd">0</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="ie5f3b77e795a4cecb84d959b27d815f5_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOmIzN2ZjNDAyNjYyZjQxNzc4MGYzYmI3YmMwYjk2MTUyL3RhYmxlcmFuZ2U6YjM3ZmM0MDI2NjJmNDE3NzgwZjNiYjdiYzBiOTYxNTJfMy01LTEtMS05NDQxNA_a7261165-34fe-4df8-9b6b-a31f2cb39371"
      unitRef="usd">458000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOmIzN2ZjNDAyNjYyZjQxNzc4MGYzYmI3YmMwYjk2MTUyL3RhYmxlcmFuZ2U6YjM3ZmM0MDI2NjJmNDE3NzgwZjNiYjdiYzBiOTYxNTJfMy03LTEtMS05NDQxNA_6d54b55a-018c-4f49-8bcf-4e1036ee4e16"
      unitRef="usd">761000000</us-gaap:PaymentsForRestructuring>
    <mrk:RestructuringReserveIncreaseDecreaseNoncashActivity
      contextRef="i5a2cfacf23e041649e6e810a01b78367_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOmIzN2ZjNDAyNjYyZjQxNzc4MGYzYmI3YmMwYjk2MTUyL3RhYmxlcmFuZ2U6YjM3ZmM0MDI2NjJmNDE3NzgwZjNiYjdiYzBiOTYxNTJfNC0xLTEtMS05NDQxNA_d72cb9d2-c9b2-45ed-b1c7-5cab531b30dd"
      unitRef="usd">0</mrk:RestructuringReserveIncreaseDecreaseNoncashActivity>
    <mrk:RestructuringReserveIncreaseDecreaseNoncashActivity
      contextRef="id6578e5480804aaabbdd710e9e7d4dec_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOmIzN2ZjNDAyNjYyZjQxNzc4MGYzYmI3YmMwYjk2MTUyL3RhYmxlcmFuZ2U6YjM3ZmM0MDI2NjJmNDE3NzgwZjNiYjdiYzBiOTYxNTJfNC0zLTEtMS05NDQxNA_b04933d0-0d75-4ae9-bfa9-b68ca6152435"
      unitRef="usd">-97000000</mrk:RestructuringReserveIncreaseDecreaseNoncashActivity>
    <mrk:RestructuringReserveIncreaseDecreaseNoncashActivity
      contextRef="ie5f3b77e795a4cecb84d959b27d815f5_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOmIzN2ZjNDAyNjYyZjQxNzc4MGYzYmI3YmMwYjk2MTUyL3RhYmxlcmFuZ2U6YjM3ZmM0MDI2NjJmNDE3NzgwZjNiYjdiYzBiOTYxNTJfNC01LTEtMS05NDQxNA_cceb9168-0f63-41d9-9611-0759b6ef58e9"
      unitRef="usd">183000000</mrk:RestructuringReserveIncreaseDecreaseNoncashActivity>
    <mrk:RestructuringReserveIncreaseDecreaseNoncashActivity
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOmIzN2ZjNDAyNjYyZjQxNzc4MGYzYmI3YmMwYjk2MTUyL3RhYmxlcmFuZ2U6YjM3ZmM0MDI2NjJmNDE3NzgwZjNiYjdiYzBiOTYxNTJfNC03LTEtMS05NDQxNA_17a4a322-6dc4-4df0-a96d-f58c040a9087"
      unitRef="usd">86000000</mrk:RestructuringReserveIncreaseDecreaseNoncashActivity>
    <us-gaap:RestructuringReserve
      contextRef="i87df032ae149438c8311b443f96f3fa1_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOmIzN2ZjNDAyNjYyZjQxNzc4MGYzYmI3YmMwYjk2MTUyL3RhYmxlcmFuZ2U6YjM3ZmM0MDI2NjJmNDE3NzgwZjNiYjdiYzBiOTYxNTJfNS0xLTEtMS05NDQxNA_3d76b89c-7e39-4a4c-8781-8d21f2ea45f2"
      unitRef="usd">490000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i79ed206618d34ac9b28a27e2dc6fb6b3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOmIzN2ZjNDAyNjYyZjQxNzc4MGYzYmI3YmMwYjk2MTUyL3RhYmxlcmFuZ2U6YjM3ZmM0MDI2NjJmNDE3NzgwZjNiYjdiYzBiOTYxNTJfNS0zLTEtMS05NDQxNA_1fd9e5ae-4f61-4c66-9367-f7764c449262"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i7f9135826ed64fa09549e1defcc31184_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOmIzN2ZjNDAyNjYyZjQxNzc4MGYzYmI3YmMwYjk2MTUyL3RhYmxlcmFuZ2U6YjM3ZmM0MDI2NjJmNDE3NzgwZjNiYjdiYzBiOTYxNTJfNS01LTEtMS05NDQxNA_11e046ca-05ba-4423-a892-5be2946ec769"
      unitRef="usd">31000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80Ni9mcmFnOjNhNjQ2MmNmNWNlOTQ1ZDRhZDdkZjg0ZWU5ZTRjZDA1L3RhYmxlOmIzN2ZjNDAyNjYyZjQxNzc4MGYzYmI3YmMwYjk2MTUyL3RhYmxlcmFuZ2U6YjM3ZmM0MDI2NjJmNDE3NzgwZjNiYjdiYzBiOTYxNTJfNS03LTEtMS05NDQxNA_ad03e150-472c-42cd-be61-d0e5e9c7e5cc"
      unitRef="usd">521000000</us-gaap:RestructuringReserve>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTkyODY_f146ccb7-9846-4ac2-989e-406560a70948">Financial Instruments&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Derivative Instruments and Hedging Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company manages the impact of foreign exchange rate movements and interest rate movements on its earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A significant portion of the Company&#x2019;s revenues and earnings in foreign affiliates is exposed to changes in foreign exchange rates. The objectives of and accounting related to the Company&#x2019;s foreign currency risk management program, as well as its interest rate risk management activities are discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign Currency Risk Management&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has established revenue hedging, balance sheet risk management and net investment hedging programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by changes in foreign exchange rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The objective of the revenue hedging program is to reduce the variability caused by changes in foreign exchange rates that would affect the U.S. dollar value of future cash flows derived from foreign currency denominated sales, primarily the euro, Japanese yen and Chinese renminbi. To achieve this objective, the Company will hedge a portion of its forecasted foreign currency denominated third-party and intercompany distributor entity sales (forecasted sales) that are expected to occur over its planning cycle, typically no more than two years into the future. The Company will layer in hedges over time, increasing the portion of forecasted sales hedged as it gets closer to the expected date of the forecasted sales. The portion of forecasted sales hedged is based on assessments of cost-benefit profiles that consider natural offsetting exposures, revenue and exchange rate volatilities and correlations, and the cost of hedging instruments. The Company manages its anticipated transaction exposure principally with purchased local currency put options, forward contracts and purchased collar options. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the Condensed Consolidated Balance Sheet. Changes in the fair value of derivative contracts are recorded each period in either current earnings or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other comprehensive income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (OCI), depending on whether the derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash flow hedges, the unrealized gains or losses on these contracts are recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AOCL)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and reclassified into &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; when the hedged anticipated revenue is recognized. For those derivatives which are not designated as cash flow hedges, but serve as economic hedges of forecasted sales, unrealized gains or losses are recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; each period. The cash&#160;flows from both designated and non-designated contracts are reported as operating activities&#160;in the Condensed Consolidated Statement of&#160;Cash Flows. The Company does not enter into derivatives for trading or speculative purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company manages operating activities and net asset positions at each local subsidiary in order to mitigate the effects of exchange on monetary assets and liabilities. The Company also uses a balance sheet risk management program to mitigate the exposure of net monetary assets that are denominated in a currency other than a subsidiary&#x2019;s functional currency from the effects of volatility in foreign exchange. In these instances, Merck principally utilizes forward exchange contracts to offset the effects of exchange on exposures denominated in developed country currencies, primarily the euro, Japanese yen, British pound, Canadian dollar and Swiss franc. For exposures in developing country currencies, including the Chinese renminbi, the Company will enter into forward contracts to offset the effects of exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the exchange rate and the cost of the hedging instrument. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The forward contracts are not designated as hedges and are marked to market through &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also uses forward exchange contracts to hedge a portion of its net investment in foreign operations against movements in exchange rates. The forward contracts are designated as hedges of the net investment in a foreign operation. The unrealized gains or losses on these contracts are recorded in foreign currency translation adjustment within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and remain in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AOCL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; until either the sale or complete or substantially complete liquidation of the subsidiary. The Company excludes certain portions of the change in fair value of its derivative instruments from the assessment of hedge effectiveness (excluded components). Changes in fair value of the excluded components are recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company recognizes in earnings the initial value of the excluded components on a straight-line basis over the life of the derivative instrument, rather than using the mark-to-market approach. The cash flows from these contracts are reported as investing activities in the Condensed Consolidated Statement of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign exchange risk is also managed through the use of foreign currency debt. The Company&#x2019;s senior unsecured euro-denominated notes have been designated as, and are effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in foreign currency translation adjustment within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effects of the Company&#x2019;s net investment hedges on &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and the Consolidated Statement of Income are shown below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.366%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amount of Pretax (Gain) Loss Recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; for Amounts Excluded from Effectiveness Testing&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Net Investment Hedging Relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Euro-denominated notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(199)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; No amounts were reclassified from AOCL into income related to the sale of a subsidiary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest Rate Risk Management&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes and to reduce its overall cost of borrowing. The Company does not use leveraged swaps and, in general, does not leverage any of its investment activities that would put principal at risk. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2022,&#160;five&#160;interest rate swap contracts with a total notional amount of&#160;$1.25 billion matured. These swaps effectively converted the Company&#x2019;s&#160;$1.25 billion,&#160;2.35%&#160;fixed-rate notes due 2022 to variable rate debt.&#160;In September 2022, four interest rate swap contracts with a total notional amount of $1.0&#160;billion matured. These swaps effectively converted the Company&#x2019;s $1.0&#160;billion, 2.40% fixed rate notes due 2022 to variable rate debt. The interest rate swap contracts were designated hedges of the fair value changes in the notes attributable to changes in the benchmark LIBOR swap rate. The fair value changes in the notes attributable to changes in the LIBOR swap rate were recorded in interest expense along with the offsetting fair value changes in the swap contracts. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows. The Company is not currently a party to any interest rate swaps.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the location of amounts recorded in the Condensed Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.338%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.040%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying Amount of Hedged Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance Sheet Line Item in which Hedged Item is Included&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loans payable and current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.241%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair&#160;Value&#160;of&#160;Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&#160;Dollar&lt;br/&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair&#160;Value&#160;of&#160;Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&#160;Dollar&lt;br/&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives Designated as Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance Sheet Caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNC0xLTEtMS0xMDUwNTY_4beacbd1-84ea-489f-8ac6-b09392c17877"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNC0xLTEtMS0xMDUwNTY_4c50954f-2f04-4bb2-9e7e-854b1813a13f"&gt;Other current assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNS0xLTEtMS05NDQxNA_2a5d2377-4bbd-47ad-9925-404ca9a51736"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNS0xLTEtMS05NDQxNA_c6df00f3-bff8-4562-abe7-498764d34146"&gt;Other current assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNi0xLTEtMS05NDQxNA_6baf831a-4ac8-4464-8eb1-254345d36853"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNi0xLTEtMS05NDQxNA_95f68aac-d3b4-4319-9f3d-70e85b1424c4"&gt;Other Assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNy0xLTEtMS05NDQxNA_6a9babb4-e747-4df0-a56c-3595290d8927"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNy0xLTEtMS05NDQxNA_ae73e90d-8b40-4bfe-b1e5-b0c0132d4407"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfOC0xLTEtMS05NDQxNA_3d168174-838c-4aa7-834d-0305c0dea6db"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfOC0xLTEtMS05NDQxNA_8a78e2f6-5d79-40d5-8cfd-da850ad40e02"&gt;Other Noncurrent Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives Not Designated as Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance Sheet Caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTEtMS0xLTEtMTA1MTE3_0942da13-4366-4941-8d73-f86fd1003d65"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTEtMS0xLTEtMTA1MTE3_ed1a83b6-f315-4484-ba3e-ac3634db5ded"&gt;Other current assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTItMS0xLTEtMTA1MTE5_35d04908-60bc-47a5-b559-4d800d70da91"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTItMS0xLTEtMTA1MTE5_f4049782-8c11-4ab1-9f60-0268bac9cd63"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As noted above, the Company records its derivatives on a gross basis in the Condensed Consolidated Balance Sheet. The Company has master netting agreements with several of its financial institution counterparties (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; below). The following table provides information on the Company&#x2019;s derivative positions subject to these master &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.341%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross amounts recognized in the condensed consolidated balance sheet&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(217)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(217)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash collateral received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(794)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net amounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below provides information regarding the location and amount of pretax gains and losses of derivatives designated in fair value or cash flow hedging relationships:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.636%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.907%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Financial Statement Line Items in which Effects of Fair Value or Cash Flow Hedges are Recorded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Other (income) expense, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Other (income) expense, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;14,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;13,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(450)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(416)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;45,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;35,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1,007)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(314)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(Gain) loss on fair value hedging relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Hedged items&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Impact of cash flow hedging relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Amount of gain recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt; on derivatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Increase (decrease) in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt; as a result of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;AOCL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt; reclassifications&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(253)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(219)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(491)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-4.5pt"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTMtMC0xLTEtOTQ0MTQ_415ec0c9-4bba-4fb9-aa01-b4c7b84244a9"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTMtMC0xLTEtOTQ0MTQ_a2ea2169-dd57-478e-b872-7cc7be5bf76a"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTMtMC0xLTEtOTQ0MTQ_c6f59e51-c8a0-4c45-930c-4ef2ed96eb20"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTMtMC0xLTEtOTQ0MTQ_ff915512-cf0d-456d-a25d-7aab715fc26c"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Amount of gain recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt; on derivatives&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Amount of loss recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt; on derivatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Interest expense is a component of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.362%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amount of Derivative Pretax (Gain) Loss Recognized in Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives Not Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Income Statement Caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates. Amount in the first nine months of 2021 includes a loss on forward exchange contracts entered into in conjunction with the spin-off of Organon.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; These derivative contracts serve as economic hedges of forecasted transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September&#160;30, 2022, the Company estimates $864 million of pretax net unrealized gains on derivatives maturing within the next 12 months that hedge foreign currency denominated sales over that same period will be reclassified from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AOCL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The amount ultimately reclassified to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Investments in Debt and Equity Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information on investments in debt and equity securities is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&#160;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&#160;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign government bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Publicly traded equity securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total debt and publicly traded equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Unrealized net losses of $221&#160;million and $415 million were recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; in the third quarter and first nine months of 2022, respectively, on equity securities still held at September&#160;30, 2022. Unrealized net (gains) losses of $(90) million and $109&#160;million were recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; in the third quarter and first nine months of 2021, respectively, on equity securities still held at September&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September&#160;30, 2022 and September&#160;30, 2021, the Company also had $705 million and $578 million, respectively, of equity investments without readily determinable fair values included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company records unrealized gains on these equity investments based on favorable observable price changes from transactions involving similar investments of the same investee and records unrealized losses based on unfavorable observable price changes, which are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. During the first nine months&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the Company recorded unrealized gains of $21 million and unrealized net losses of $12&#160;million related to certain of these equity investments still held at September&#160;30, 2022. During the first nine months&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the Company recorded unrealized gains of $104&#160;million and unrealized losses of $1&#160;million related to certain of these investments still held at September&#160;30, 2021. Cumulative unrealized gains and cumulative unrealized losses based on observable price changes for investments in equity investments without readily determinable fair values still held at September&#160;30, 2022 were $255 million and $19 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September&#160;30, 2022 and September&#160;30, 2021, the Company also had $655&#160;million and $1.2&#160;billion, respectively, recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for equity securities held through ownership interests in investment funds. Losses (gains) recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; relating to these investment funds were $141&#160;million and $(391)&#160;million for the third quarter of 2022 and 2021, respectively, and were $952&#160;million and $(893)&#160;million for the first nine months of 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level&#160;1 having the highest priority and Level 3 having the lowest: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - Quoted prices (unadjusted) in active markets for identical assets or liabilities; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - Unobservable inputs that are supported by little or no market activity. Level 3 assets or liabilities are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as assets or liabilities for which the determination of fair value requires significant judgment or estimation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets and liabilities measured at fair value on a recurring basis are summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign government bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Publicly traded equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Publicly traded equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivative assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchased currency options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivative liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Written currency options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt"&gt; Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company&#x2019;s own credit risk, the effects of which were not significant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022 and December&#160;31, 2021, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; included $10.0 billion and $6.8 billion of cash equivalents, respectively (which would be considered Level 2 in the fair value hierarchy). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized information about the changes in the fair value of liabilities for contingent consideration associated with business combinations is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.424%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value January 1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in estimated fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(156)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value September 30 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;  Recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Cost of sales, Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; expenses, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;. Includes cumulative translation adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;At September&#160;30, 2022, $358 million of the liabilities relate to the 2016 termination of the Sanofi Pasteur MSD joint venture. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate to present value the cash flows. Balance at September&#160;30, 2022 includes $139 million recorded as a current liability for amounts expected to be paid within the next 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The payments of contingent consideration in 2022 relate to the Sanofi Pasteur MSD liabilities described above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Some of the Company&#x2019;s financial instruments, such as cash and cash equivalents, receivables and payables, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of loans payable and long-term debt (including current portion) at September&#160;30, 2022, was $25.9 billion compared with a carrying value of $30.4 billion and at December&#160;31, 2021, was $35.7 billion compared with a carrying value of $33.1 billion. Fair value was estimated using recent observable market prices and would be considered Level 2 in the fair value hierarchy. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On an ongoing basis, the Company monitors concentrations of credit risk associated with corporate and government issuers of securities and financial institutions with which it conducts business. Credit exposure limits are established to limit a concentration with any single issuer or institution. Cash and investments are placed in instruments that meet high credit quality standards as specified in the Company&#x2019;s investment policy guidelines. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of the Company&#x2019;s accounts receivable arise from product sales in the U.S., Europe and China and are primarily due from drug wholesalers and retailers, hospitals and government agencies.&#160;The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company also continues to monitor global economic conditions, including the volatility associated with international sovereign economies, and associated impacts on the financial markets and its business. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored $2.3 billion and $2.8 billion of accounts receivable as of September&#160;30, 2022 and December&#160;31, 2021, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Condensed Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions. As of September&#160;30, 2022 and December&#160;31, 2021, the Company had collected $55&#160;million and $62&#160;million, respectively, on behalf of the financial institutions, which is reflected as restricted cash in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and the related obligation to remit the cash within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company remitted the cash to the financial institutions in October 2022 and January 2022, respectively. The net cash flows related to these collections are reported as financing activities in the Condensed Consolidated Statement of Cash Flows. The cost of factoring such accounts receivable was &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;de minimis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements. The master agreements with several of the Company&#x2019;s financial institution counterparties also include credit support annexes. These annexes contain provisions that require collateral to be exchanged depending on the value of the derivative assets and liabilities, the Company&#x2019;s credit rating, and the credit rating of the counterparty. Cash collateral received by the Company from various counterparties was $794 million and $164&#160;million at September&#160;30, 2022 and December&#160;31, 2021, respectively. The obligation to return such collateral is recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accrued and other current liabilities&lt;/span&gt;.</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:DerivativeAverageRemainingMaturity1
      contextRef="ic2de9fcd183e42f8bd39ac5db830d924_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTQ2Ng_532b0cb7-fcc2-403a-bacf-2cf0ad230237">P2Y</us-gaap:DerivativeAverageRemainingMaturity1>
    <us-gaap:DerivativeAverageRemainingMaturity1
      contextRef="i9c8be2269d6c4eb4bc6e4bcb3ddcfc30_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfNTA2Mg_a9ab8636-8132-4f2c-b120-0c1751e0ea00">P1Y</us-gaap:DerivativeAverageRemainingMaturity1>
    <us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTkyMjM_5976179b-17a7-411a-afdd-604dfdea1fd3">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effects of the Company&#x2019;s net investment hedges on &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and the Consolidated Statement of Income are shown below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.366%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amount of Pretax (Gain) Loss Recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; for Amounts Excluded from Effectiveness Testing&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Net Investment Hedging Relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Euro-denominated notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(199)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; No amounts were reclassified from AOCL into income related to the sale of a subsidiary.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="ie27e3a1d731a4e8aab46753956e07c5d_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjlmNTRmZGZhZjlhYjQ3MTdiOGQ3MTFmNjY2OGJhOTkwL3RhYmxlcmFuZ2U6OWY1NGZkZmFmOWFiNDcxN2I4ZDcxMWY2NjY4YmE5OTBfNC0xLTEtMS05NDQxNA_ffc5f871-d3c3-4cb7-8978-945687274431"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i5ae35cdeb80c488d9810adba90ad5a22_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjlmNTRmZGZhZjlhYjQ3MTdiOGQ3MTFmNjY2OGJhOTkwL3RhYmxlcmFuZ2U6OWY1NGZkZmFmOWFiNDcxN2I4ZDcxMWY2NjY4YmE5OTBfNC0zLTEtMS05NDQxNA_4af7685a-f285-4b0c-80e4-e25b4d9f14d5"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="id5ffef0aa5134d30a7bc87c2f1471202_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjlmNTRmZGZhZjlhYjQ3MTdiOGQ3MTFmNjY2OGJhOTkwL3RhYmxlcmFuZ2U6OWY1NGZkZmFmOWFiNDcxN2I4ZDcxMWY2NjY4YmE5OTBfNC01LTEtMS05NDQxNA_eda0085f-b303-475d-bec0-d9fdb0539fd6"
      unitRef="usd">47000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i8f49cd47d7c34c2db675a1a70530cbc8_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjlmNTRmZGZhZjlhYjQ3MTdiOGQ3MTFmNjY2OGJhOTkwL3RhYmxlcmFuZ2U6OWY1NGZkZmFmOWFiNDcxN2I4ZDcxMWY2NjY4YmE5OTBfNC03LTEtMS05NDQxNA_c07059e3-65c4-428a-b6fe-3ca95aa36ae2"
      unitRef="usd">27000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="ieab5e8f43e5e4ecb92c95a699771341a_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjlmNTRmZGZhZjlhYjQ3MTdiOGQ3MTFmNjY2OGJhOTkwL3RhYmxlcmFuZ2U6OWY1NGZkZmFmOWFiNDcxN2I4ZDcxMWY2NjY4YmE5OTBfNC05LTEtMS05NDQxNA_6d2eca35-8cd8-442d-9f7f-843e96fd7cab"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="i01953d66b4ed43759d677deacf2426b3_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjlmNTRmZGZhZjlhYjQ3MTdiOGQ3MTFmNjY2OGJhOTkwL3RhYmxlcmFuZ2U6OWY1NGZkZmFmOWFiNDcxN2I4ZDcxMWY2NjY4YmE5OTBfNC0xMS0xLTEtOTQ0MTQ_d4735afb-e3af-4693-bcbb-9d1839e00a7b"
      unitRef="usd">4000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="ib6c315ba79954d888131d6d2b08f5b46_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjlmNTRmZGZhZjlhYjQ3MTdiOGQ3MTFmNjY2OGJhOTkwL3RhYmxlcmFuZ2U6OWY1NGZkZmFmOWFiNDcxN2I4ZDcxMWY2NjY4YmE5OTBfNC0xMy0xLTEtOTQ0MTQ_9869162a-950d-43c5-9e04-cc2960e0aa19"
      unitRef="usd">2000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="i1ac58f37e82a4b95ab6c2445433ee541_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjlmNTRmZGZhZjlhYjQ3MTdiOGQ3MTFmNjY2OGJhOTkwL3RhYmxlcmFuZ2U6OWY1NGZkZmFmOWFiNDcxN2I4ZDcxMWY2NjY4YmE5OTBfNC0xNS0xLTEtOTQ0MTQ_f266deeb-1fcf-44a3-ae47-fe25df5dbd3c"
      unitRef="usd">12000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i6f5e74c553ad4cea9c9915ab749a9781_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjlmNTRmZGZhZjlhYjQ3MTdiOGQ3MTFmNjY2OGJhOTkwL3RhYmxlcmFuZ2U6OWY1NGZkZmFmOWFiNDcxN2I4ZDcxMWY2NjY4YmE5OTBfNS0xLTEtMS05NDQxNA_f75ed8d8-6e52-4ba8-8e81-3d729e1e2ae0"
      unitRef="usd">250000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i2e5bf65d147a4bdc965896b6d99c4860_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjlmNTRmZGZhZjlhYjQ3MTdiOGQ3MTFmNjY2OGJhOTkwL3RhYmxlcmFuZ2U6OWY1NGZkZmFmOWFiNDcxN2I4ZDcxMWY2NjY4YmE5OTBfNS0zLTEtMS05NDQxNA_e7f90261-a7be-44dc-b164-3d7905ed8093"
      unitRef="usd">77000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i3e5ed55b09f84d5498e328aa1b4f5417_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjlmNTRmZGZhZjlhYjQ3MTdiOGQ3MTFmNjY2OGJhOTkwL3RhYmxlcmFuZ2U6OWY1NGZkZmFmOWFiNDcxN2I4ZDcxMWY2NjY4YmE5OTBfNS01LTEtMS05NDQxNA_86440834-ad0b-4fcd-9995-387d1562d3d7"
      unitRef="usd">431000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i772590a293ba478db2f7600cf2cb3eb4_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjlmNTRmZGZhZjlhYjQ3MTdiOGQ3MTFmNjY2OGJhOTkwL3RhYmxlcmFuZ2U6OWY1NGZkZmFmOWFiNDcxN2I4ZDcxMWY2NjY4YmE5OTBfNS03LTEtMS05NDQxNA_6aa360e3-db45-4eae-b949-da670c3f96bb"
      unitRef="usd">199000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="i099e48fafeba46d08da6b31e799e3b7f_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjlmNTRmZGZhZjlhYjQ3MTdiOGQ3MTFmNjY2OGJhOTkwL3RhYmxlcmFuZ2U6OWY1NGZkZmFmOWFiNDcxN2I4ZDcxMWY2NjY4YmE5OTBfNS05LTEtMS05NDQxNA_c5c133ed-2b79-431f-92db-6eb4e3865da6"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="i03e7ee1c569b46239abaca544705e805_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjlmNTRmZGZhZjlhYjQ3MTdiOGQ3MTFmNjY2OGJhOTkwL3RhYmxlcmFuZ2U6OWY1NGZkZmFmOWFiNDcxN2I4ZDcxMWY2NjY4YmE5OTBfNS0xMS0xLTEtOTQ0MTQ_97f5c252-be9c-4ab4-b711-73f99184cd21"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="ia780135900c240e5b9abf1b31ee64f6e_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjlmNTRmZGZhZjlhYjQ3MTdiOGQ3MTFmNjY2OGJhOTkwL3RhYmxlcmFuZ2U6OWY1NGZkZmFmOWFiNDcxN2I4ZDcxMWY2NjY4YmE5OTBfNS0xMy0xLTEtOTQ0MTQ_87d0990e-e430-47e8-ae45-1b79cc87c5cd"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="i92c75e458aed405ab0daac044db42401_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjlmNTRmZGZhZjlhYjQ3MTdiOGQ3MTFmNjY2OGJhOTkwL3RhYmxlcmFuZ2U6OWY1NGZkZmFmOWFiNDcxN2I4ZDcxMWY2NjY4YmE5OTBfNS0xNS0xLTEtOTQ0MTQ_ed78ecae-5f4b-47a7-9342-9f0baf3fb0f0"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:NumberOfInterestRateDerivativesHeld
      contextRef="i0e0dd76b1ff5456f8f9ea13bb5b3d393_I20220228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfNzEzNw_0bf4ef41-f82e-45bd-a5a8-8dca7252c8df"
      unitRef="interest_rate_swap">5</us-gaap:NumberOfInterestRateDerivativesHeld>
    <us-gaap:DerivativeNotionalAmount
      contextRef="if00c71a39ce54be38bef228f86d7f5bf_I20220228"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfNzE5Mg_b6319fe0-d7fd-481a-ae1b-3ae658920aa3"
      unitRef="usd">1250000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="if3f2b646e97448bb985e896a02467668_I20220228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfNzI1Mg_b1a77ea3-65a4-478f-a3ea-d3dc12c5cca8"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if3f2b646e97448bb985e896a02467668_I20220228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfNzI1Ng_a9e3f1a1-f59e-4a8d-b5ed-1cc2e27d1dc6"
      unitRef="number">0.0235</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:NumberOfInterestRateDerivativesHeld
      contextRef="iea3f69b723254e88a143cf7acb00abe9_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfNzM0Mg_487d42a0-003a-4da0-b4b3-b11b6d682110"
      unitRef="interest_rate_swap">4</us-gaap:NumberOfInterestRateDerivativesHeld>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i486ffaa742a0496f9d919416396e1c12_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfNTQ5NzU1ODMzNTc4_a24061df-5476-40c9-a41e-ed508aa99b6b"
      unitRef="usd">1000000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i6c212ea75a92431aa81258fd9e8294ba_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfNTQ5NzU1ODMzNTky_a49a1879-f7bc-4253-8b65-d4ccb1968b64"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2e5951a5bcea4965af6bb7344a6a099d_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfNTQ5NzU1ODMzNjA2_533b7209-843d-4028-b183-6cd4ecfed284"
      unitRef="number">0.0240</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTkyMTk_c84e2bef-d4e1-443d-b7a6-91fb4f58a1ca">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the location of amounts recorded in the Condensed Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.338%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.040%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying Amount of Hedged Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance Sheet Line Item in which Hedged Item is Included&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loans payable and current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="ibdb46049abd240818d8639edc52d2396_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmMzODRkN2JkYjY1YjQ0ZGNiZDVkMjQyZDM2MzNhNDE0L3RhYmxlcmFuZ2U6YzM4NGQ3YmRiNjViNDRkY2JkNWQyNDJkMzYzM2E0MTRfMy0xLTEtMS05NDQxNA_b82486df-cbe5-4935-8b12-83757533031d"
      unitRef="usd">0</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="ibc438baf83774566bb16844255c68486_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmMzODRkN2JkYjY1YjQ0ZGNiZDVkMjQyZDM2MzNhNDE0L3RhYmxlcmFuZ2U6YzM4NGQ3YmRiNjViNDRkY2JkNWQyNDJkMzYzM2E0MTRfMy0zLTEtMS05NDQxNA_761e3059-ec26-41c8-96f5-ede50a13e3fa"
      unitRef="usd">2263000000</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="ibdb46049abd240818d8639edc52d2396_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmMzODRkN2JkYjY1YjQ0ZGNiZDVkMjQyZDM2MzNhNDE0L3RhYmxlcmFuZ2U6YzM4NGQ3YmRiNjViNDRkY2JkNWQyNDJkMzYzM2E0MTRfMy01LTEtMS05NDQxNA_89c7e23e-0969-4d67-8817-042324b67d01"
      unitRef="usd">0</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="ibc438baf83774566bb16844255c68486_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmMzODRkN2JkYjY1YjQ0ZGNiZDVkMjQyZDM2MzNhNDE0L3RhYmxlcmFuZ2U6YzM4NGQ3YmRiNjViNDRkY2JkNWQyNDJkMzYzM2E0MTRfMy03LTEtMS05NDQxNA_d8ead55c-c505-4810-a84e-88dc3563e8e3"
      unitRef="usd">13000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTkyMjU_80436299-1f7e-4694-8e23-3031062eacfd">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.241%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair&#160;Value&#160;of&#160;Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&#160;Dollar&lt;br/&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair&#160;Value&#160;of&#160;Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&#160;Dollar&lt;br/&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives Designated as Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance Sheet Caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNC0xLTEtMS0xMDUwNTY_4beacbd1-84ea-489f-8ac6-b09392c17877"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNC0xLTEtMS0xMDUwNTY_4c50954f-2f04-4bb2-9e7e-854b1813a13f"&gt;Other current assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNS0xLTEtMS05NDQxNA_2a5d2377-4bbd-47ad-9925-404ca9a51736"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNS0xLTEtMS05NDQxNA_c6df00f3-bff8-4562-abe7-498764d34146"&gt;Other current assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNi0xLTEtMS05NDQxNA_6baf831a-4ac8-4464-8eb1-254345d36853"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNi0xLTEtMS05NDQxNA_95f68aac-d3b4-4319-9f3d-70e85b1424c4"&gt;Other Assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNy0xLTEtMS05NDQxNA_6a9babb4-e747-4df0-a56c-3595290d8927"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNy0xLTEtMS05NDQxNA_ae73e90d-8b40-4bfe-b1e5-b0c0132d4407"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfOC0xLTEtMS05NDQxNA_3d168174-838c-4aa7-834d-0305c0dea6db"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfOC0xLTEtMS05NDQxNA_8a78e2f6-5d79-40d5-8cfd-da850ad40e02"&gt;Other Noncurrent Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives Not Designated as Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance Sheet Caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTEtMS0xLTEtMTA1MTE3_0942da13-4366-4941-8d73-f86fd1003d65"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTEtMS0xLTEtMTA1MTE3_ed1a83b6-f315-4484-ba3e-ac3634db5ded"&gt;Other current assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTItMS0xLTEtMTA1MTE5_35d04908-60bc-47a5-b559-4d800d70da91"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTItMS0xLTEtMTA1MTE5_f4049782-8c11-4ab1-9f60-0268bac9cd63"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeAssets
      contextRef="ic7eb7aa0cad44ae481279be50ead5cf3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNC0yLTEtMS05NDQxNA_268490c5-e313-4361-b8d6-a2cb153978cd"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i45b3ae0db3cf41c3acafc444ed25c107_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNC02LTEtMS05NDQxNA_8c7e87fb-347e-427c-bb08-3d9cb9bcc214"
      unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i53f76af88d63418dba6b1ea3a71d7ecb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNC04LTEtMS05NDQxNA_28611bd7-4881-401c-8c34-6b22db6bfb51"
      unitRef="usd">14000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="if41d8f4f2079476e813d82c9d789e8fc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNC0xMi0xLTEtOTQ0MTQ_38edebdf-a030-4445-95b3-cb27e2fb4925"
      unitRef="usd">2250000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i92c41baff7714a72894f9c962e96d0a8_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNS0yLTEtMS05NDQxNA_7572e690-f69e-415e-ba7a-babc3f1166fe"
      unitRef="usd">826000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i92c41baff7714a72894f9c962e96d0a8_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNS02LTEtMS05NDQxNA_c650a149-96ce-44d2-99ce-ea0d8a5adf8b"
      unitRef="usd">7250000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i97bb92e54ef74a8db32f912747efe346_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNS04LTEtMS05NDQxNA_8aaaed19-bf0f-4b65-abbf-eeab15b8d723"
      unitRef="usd">271000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i97bb92e54ef74a8db32f912747efe346_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNS0xMi0xLTEtOTQ0MTQ_9beb4d52-bdba-48d2-87da-7a99e3f93a44"
      unitRef="usd">6778000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i92c868d7e8f9475893857146e49ffbb1_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNi0yLTEtMS05NDQxNA_e808b6f1-93ad-4a77-b3d1-5e5ab8b2ee1a"
      unitRef="usd">85000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i92c868d7e8f9475893857146e49ffbb1_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNi02LTEtMS05NDQxNA_ae85dbc8-dfa3-4984-bd44-41ebd6f92dcb"
      unitRef="usd">1408000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i8f6e2cbf96bd4896863dbb8f79fdf2b1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNi04LTEtMS05NDQxNA_4759f3dd-135b-4f9e-939b-de0e67f344bf"
      unitRef="usd">43000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i8f6e2cbf96bd4896863dbb8f79fdf2b1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNi0xMi0xLTEtOTQ0MTQ_e525fdfa-a963-4a00-8037-26cfcce42c46"
      unitRef="usd">1551000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="ic2398c81940b40eabe737fa14c821b96_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNy00LTEtMS05NDQxNA_0248917f-8b6f-4b6e-a38f-1ab1606b1b57"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ic2398c81940b40eabe737fa14c821b96_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNy02LTEtMS05NDQxNA_5b93829b-dadb-42cd-9cc7-2510f7735c24"
      unitRef="usd">37000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="i338b3ccaae68438b96b0f370fd0bb963_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNy0xMC0xLTEtOTQ0MTQ_aa89d3da-a4ad-4932-9cc4-30820844c0b1"
      unitRef="usd">24000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i338b3ccaae68438b96b0f370fd0bb963_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNy0xMi0xLTEtOTQ0MTQ_a8e70c8f-6ba5-4779-b998-1aa5a77d80d7"
      unitRef="usd">1623000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="ifa0ad26fa2f64d7ca0cf4d95ae5c7567_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfOC00LTEtMS05NDQxNA_8977ac65-37e5-4207-8906-1ab7d4b7870f"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ifa0ad26fa2f64d7ca0cf4d95ae5c7567_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfOC02LTEtMS05NDQxNA_eaf38c10-3075-43cf-9961-70c407bd4d70"
      unitRef="usd">93000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="ib67ea4886b8c40868d422b24ac9e580d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfOC0xMC0xLTEtOTQ0MTQ_d314dd5b-fd21-43e0-8224-1ce4959ca409"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ib67ea4886b8c40868d422b24ac9e580d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfOC0xMi0xLTEtOTQ0MTQ_89221e33-d77e-455c-afe0-dda1f9346a48"
      unitRef="usd">43000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="iaf409d1f24c84ee6b661d53c0d63d271_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfOS0yLTEtMS05NDQxNA_8594e1f6-a023-4152-bc75-1477dc581e26"
      unitRef="usd">911000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="iaf409d1f24c84ee6b661d53c0d63d271_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfOS00LTEtMS05NDQxNA_e0ac6a42-50e7-407f-9010-5e8b451d5420"
      unitRef="usd">2000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="iaf409d1f24c84ee6b661d53c0d63d271_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfOS02LTEtMS05NDQxNA_a09762cb-efc6-44da-aca8-09478449e388"
      unitRef="usd">8788000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i15d7e32d159245d8962254b1ac043b09_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfOS04LTEtMS05NDQxNA_bb5d7b19-3dae-46c4-8ba8-12dfe75644f4"
      unitRef="usd">328000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i15d7e32d159245d8962254b1ac043b09_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfOS0xMC0xLTEtOTQ0MTQ_441b8d17-37dd-4dc4-9fe3-c2946c1e73ca"
      unitRef="usd">25000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i15d7e32d159245d8962254b1ac043b09_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfOS0xMi0xLTEtOTQ0MTQ_9e2d5f6a-9c38-449c-bd35-8df0682f20cd"
      unitRef="usd">12245000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i7382fed477fc47e3acfc51cf0827f22a_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTEtMi0xLTEtOTQ0MTQ_3d65d989-a2e1-4391-b3d2-9a8218a11a81"
      unitRef="usd">597000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="if8bb1afef334464cafe180cee4605e3b_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTEtNi0xLTEtOTQ0MTQ_bf55d6f3-ae64-44f4-9a2f-c8182c58f011"
      unitRef="usd">9523000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="ieba4d46f4e9b4513aa30046a1640a2d1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTEtOC0xLTEtOTQ0MTQ_95354b91-1ef3-4b41-91de-c2763d3f58f1"
      unitRef="usd">221000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i6964796fa04f4808aa3493a670881eca_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTEtMTItMS0xLTk0NDE0_0207734c-52ca-4007-a6b1-c9a082196757"
      unitRef="usd">10073000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="i7382fed477fc47e3acfc51cf0827f22a_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTItNC0xLTEtOTQ0MTQ_edc24b3d-1e8a-416d-bdac-0a30b4110064"
      unitRef="usd">240000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i8f8b8b04c81b4fb99373775effba54e1_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTItNi0xLTEtOTQ0MTQ_71f50cbe-5d3b-40c9-8526-15e6023984a9"
      unitRef="usd">7715000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="ieba4d46f4e9b4513aa30046a1640a2d1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTItMTAtMS0xLTk0NDE0_392da74b-efc9-43bb-977c-6e1030f25627"
      unitRef="usd">96000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="id74f2287203447e1b810c5fa36a1ed55_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTItMTItMS0xLTk0NDE0_db0efdbc-5cda-4015-973b-a613783cf129"
      unitRef="usd">10640000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i5cdb1dee02174c02a0606014cbbae99e_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTMtMi0xLTEtOTQ0MTQ_12d7b2b8-1bd3-4a26-ab88-42639f2ef19c"
      unitRef="usd">597000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i5cdb1dee02174c02a0606014cbbae99e_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTMtNC0xLTEtOTQ0MTQ_20765a6a-b034-445b-97ae-1deffef95890"
      unitRef="usd">240000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i5cdb1dee02174c02a0606014cbbae99e_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTMtNi0xLTEtOTQ0MTQ_d344c14d-24b8-4dad-9cac-34ad36a83833"
      unitRef="usd">17238000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i54c9fc9da50e4192912b25f5131e50fc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTMtOC0xLTEtOTQ0MTQ_7a0a208a-e49a-4361-af0b-6491283d5d07"
      unitRef="usd">221000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i54c9fc9da50e4192912b25f5131e50fc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTMtMTAtMS0xLTk0NDE0_1982b2d8-a6bf-4e66-a4bc-1b9e7ad92ed9"
      unitRef="usd">96000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i54c9fc9da50e4192912b25f5131e50fc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTMtMTItMS0xLTk0NDE0_52ef7029-42ef-4fdd-a9b5-7169278dd96b"
      unitRef="usd">20713000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTQtMi0xLTEtOTQ0MTQ_c3d219e2-3750-4aa9-9073-9f9aea636bb7"
      unitRef="usd">1508000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTQtNC0xLTEtOTQ0MTQ_b09780e2-d345-4433-8616-bf768c2fd050"
      unitRef="usd">242000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTQtNi0xLTEtOTQ0MTQ_bacdb8d7-10c0-4a5c-afda-74916b648c26"
      unitRef="usd">26026000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTQtOC0xLTEtOTQ0MTQ_ad74e337-d21f-45eb-a116-aa1c49c636a0"
      unitRef="usd">549000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTQtMTAtMS0xLTk0NDE0_faafa25c-8cf9-4573-8d94-8a69ac6e34c2"
      unitRef="usd">121000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTQtMTItMS0xLTk0NDE0_f6c10b3a-99e3-4f85-b35e-20634231987b"
      unitRef="usd">32958000000</us-gaap:DerivativeNotionalAmount>
    <mrk:OffsettingAssetsAndLiabilitiesTableTextBlock
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTkyNDM_0fd15bb1-ddc1-4ca3-a1ff-c2bbf8d77e8b">The following table provides information on the Company&#x2019;s derivative positions subject to these master &lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.341%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross amounts recognized in the condensed consolidated balance sheet&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(217)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(217)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash collateral received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(794)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net amounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</mrk:OffsettingAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DerivativeAssets
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjY3NTU2ODVjN2IzYjQwNDBhMzVlZmQ4YzY1NmJlYTVjL3RhYmxlcmFuZ2U6Njc1NTY4NWM3YjNiNDA0MGEzNWVmZDhjNjU2YmVhNWNfMi0xLTEtMS05NDQxNA_c6b96c6f-cccc-421b-a3b8-fb94ed592beb"
      unitRef="usd">1508000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjY3NTU2ODVjN2IzYjQwNDBhMzVlZmQ4YzY1NmJlYTVjL3RhYmxlcmFuZ2U6Njc1NTY4NWM3YjNiNDA0MGEzNWVmZDhjNjU2YmVhNWNfMi0zLTEtMS05NDQxNA_9f6f0534-018f-4642-bee0-7b33fd7e934a"
      unitRef="usd">242000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeAssets
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjY3NTU2ODVjN2IzYjQwNDBhMzVlZmQ4YzY1NmJlYTVjL3RhYmxlcmFuZ2U6Njc1NTY4NWM3YjNiNDA0MGEzNWVmZDhjNjU2YmVhNWNfMi01LTEtMS05NDQxNA_dd634436-357f-40f2-a431-93a87a6c9b98"
      unitRef="usd">549000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjY3NTU2ODVjN2IzYjQwNDBhMzVlZmQ4YzY1NmJlYTVjL3RhYmxlcmFuZ2U6Njc1NTY4NWM3YjNiNDA0MGEzNWVmZDhjNjU2YmVhNWNfMi03LTEtMS05NDQxNA_d0ce3bbe-6ce5-455d-9c26-115c026ba317"
      unitRef="usd">121000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjY3NTU2ODVjN2IzYjQwNDBhMzVlZmQ4YzY1NmJlYTVjL3RhYmxlcmFuZ2U6Njc1NTY4NWM3YjNiNDA0MGEzNWVmZDhjNjU2YmVhNWNfMy0xLTEtMS05NDQxNA_d5336f2c-1660-4838-abed-44322989e7a2"
      unitRef="usd">217000000</us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjY3NTU2ODVjN2IzYjQwNDBhMzVlZmQ4YzY1NmJlYTVjL3RhYmxlcmFuZ2U6Njc1NTY4NWM3YjNiNDA0MGEzNWVmZDhjNjU2YmVhNWNfMy0zLTEtMS05NDQxNA_a9ee8e5d-f1e1-44e2-9b62-26ea1825201c"
      unitRef="usd">217000000</us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjY3NTU2ODVjN2IzYjQwNDBhMzVlZmQ4YzY1NmJlYTVjL3RhYmxlcmFuZ2U6Njc1NTY4NWM3YjNiNDA0MGEzNWVmZDhjNjU2YmVhNWNfMy01LTEtMS05NDQxNA_efb61867-55ea-42cf-aecc-8f803a466917"
      unitRef="usd">110000000</us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjY3NTU2ODVjN2IzYjQwNDBhMzVlZmQ4YzY1NmJlYTVjL3RhYmxlcmFuZ2U6Njc1NTY4NWM3YjNiNDA0MGEzNWVmZDhjNjU2YmVhNWNfMy03LTEtMS05NDQxNA_12edb302-a417-4abf-a044-5a2facafab02"
      unitRef="usd">110000000</us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeCollateralObligationToReturnCash
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjY3NTU2ODVjN2IzYjQwNDBhMzVlZmQ4YzY1NmJlYTVjL3RhYmxlcmFuZ2U6Njc1NTY4NWM3YjNiNDA0MGEzNWVmZDhjNjU2YmVhNWNfNC0xLTEtMS05NDQxNA_84b4130d-1358-49bd-932c-2693aeaf98fe"
      unitRef="usd">794000000</us-gaap:DerivativeCollateralObligationToReturnCash>
    <us-gaap:DerivativeCollateralRightToReclaimCash
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjY3NTU2ODVjN2IzYjQwNDBhMzVlZmQ4YzY1NmJlYTVjL3RhYmxlcmFuZ2U6Njc1NTY4NWM3YjNiNDA0MGEzNWVmZDhjNjU2YmVhNWNfNC0zLTEtMS05NDQxNA_283b303c-205c-4db6-9b86-ced7c2042664"
      unitRef="usd">0</us-gaap:DerivativeCollateralRightToReclaimCash>
    <us-gaap:DerivativeCollateralObligationToReturnCash
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjY3NTU2ODVjN2IzYjQwNDBhMzVlZmQ4YzY1NmJlYTVjL3RhYmxlcmFuZ2U6Njc1NTY4NWM3YjNiNDA0MGEzNWVmZDhjNjU2YmVhNWNfNC01LTEtMS05NDQxNA_368dc513-772b-43d1-a5e3-9a74090b052f"
      unitRef="usd">164000000</us-gaap:DerivativeCollateralObligationToReturnCash>
    <us-gaap:DerivativeCollateralRightToReclaimCash
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjY3NTU2ODVjN2IzYjQwNDBhMzVlZmQ4YzY1NmJlYTVjL3RhYmxlcmFuZ2U6Njc1NTY4NWM3YjNiNDA0MGEzNWVmZDhjNjU2YmVhNWNfNC03LTEtMS05NDQxNA_fdaa5103-7dbd-4557-88fd-29740e599a81"
      unitRef="usd">0</us-gaap:DerivativeCollateralRightToReclaimCash>
    <us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjY3NTU2ODVjN2IzYjQwNDBhMzVlZmQ4YzY1NmJlYTVjL3RhYmxlcmFuZ2U6Njc1NTY4NWM3YjNiNDA0MGEzNWVmZDhjNjU2YmVhNWNfNS0xLTEtMS05NDQxNA_fc588340-1da6-44b6-858c-d96f6ab1e52b"
      unitRef="usd">497000000</us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection>
    <us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjY3NTU2ODVjN2IzYjQwNDBhMzVlZmQ4YzY1NmJlYTVjL3RhYmxlcmFuZ2U6Njc1NTY4NWM3YjNiNDA0MGEzNWVmZDhjNjU2YmVhNWNfNS0zLTEtMS05NDQxNA_56eafd3c-c104-4c4d-a30d-ca917df84c6d"
      unitRef="usd">25000000</us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection>
    <us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjY3NTU2ODVjN2IzYjQwNDBhMzVlZmQ4YzY1NmJlYTVjL3RhYmxlcmFuZ2U6Njc1NTY4NWM3YjNiNDA0MGEzNWVmZDhjNjU2YmVhNWNfNS01LTEtMS05NDQxNA_defb3505-8f62-44d5-8ea7-dc0716d28bca"
      unitRef="usd">275000000</us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection>
    <us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjY3NTU2ODVjN2IzYjQwNDBhMzVlZmQ4YzY1NmJlYTVjL3RhYmxlcmFuZ2U6Njc1NTY4NWM3YjNiNDA0MGEzNWVmZDhjNjU2YmVhNWNfNS03LTEtMS05NDQxNA_d88ff3ba-b3a0-4522-963f-20ef471fd4b0"
      unitRef="usd">11000000</us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTkyNjQ_814d54ec-1376-43bf-9474-dc77eb95d183">&lt;div style="margin-top:4pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below provides information regarding the location and amount of pretax gains and losses of derivatives designated in fair value or cash flow hedging relationships:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.636%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.907%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Financial Statement Line Items in which Effects of Fair Value or Cash Flow Hedges are Recorded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Other (income) expense, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Other (income) expense, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;14,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;13,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(450)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(416)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;45,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;35,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1,007)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(314)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(Gain) loss on fair value hedging relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Hedged items&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Impact of cash flow hedging relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Amount of gain recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt; on derivatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Increase (decrease) in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt; as a result of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;AOCL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt; reclassifications&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(253)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(219)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(491)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-4.5pt"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTMtMC0xLTEtOTQ0MTQ_415ec0c9-4bba-4fb9-aa01-b4c7b84244a9"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTMtMC0xLTEtOTQ0MTQ_a2ea2169-dd57-478e-b872-7cc7be5bf76a"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTMtMC0xLTEtOTQ0MTQ_c6f59e51-c8a0-4c45-930c-4ef2ed96eb20"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTMtMC0xLTEtOTQ0MTQ_ff915512-cf0d-456d-a25d-7aab715fc26c"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Amount of gain recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt; on derivatives&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Amount of loss recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt; on derivatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Interest expense is a component of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:Revenues
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMy0xLTEtMS05NDQxNA_6f1eac12-5c2c-41fd-ac77-39963b7135eb"
      unitRef="usd">14959000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMy0zLTEtMS05NDQxNA_7c9e15ac-9811-439e-84e6-e6b6358bcdd1"
      unitRef="usd">13154000000</us-gaap:Revenues>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMy01LTEtMS05NDQxNA_98a35210-07de-4355-b4b4-18c86704965a"
      unitRef="usd">-429000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMy03LTEtMS05NDQxNA_8362a6f4-b404-4ce2-8bf4-7d60a2a82159"
      unitRef="usd">450000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMy05LTEtMS05NDQxNA_80b80e71-f490-4500-a64d-b908330b5506"
      unitRef="usd">-416000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMy0xMS0xLTEtOTQ0MTQ_fa0fef12-42e9-4908-87b8-16701e1aedbf"
      unitRef="usd">38000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:Revenues
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMy0xMy0xLTEtOTQ0MTQ_93be19a2-92d3-44b5-b71c-13e4fcfbeb64"
      unitRef="usd">45453000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMy0xNS0xLTEtOTQ0MTQ_0d5bd26d-2afc-4501-b448-9026aedf7176"
      unitRef="usd">35183000000</us-gaap:Revenues>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMy0xNy0xLTEtOTQ0MTQ_929c0cda-d181-4452-ac66-b60ec2a3bdd6"
      unitRef="usd">-1576000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMy0xOS0xLTEtOTQ0MTQ_676d5b83-5c23-4cf8-ac8a-80374ad66dd3"
      unitRef="usd">1007000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMy0yMS0xLTEtOTQ0MTQ_f72a47c5-76d2-4263-82d9-4b052712e6b6"
      unitRef="usd">-314000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMy0yMy0xLTEtOTQ0MTQ_ef44f324-3bf9-4fb8-ab4f-5b5e6f735430"
      unitRef="usd">1595000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="ic44487f92a5448159923c27c8d731670_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfNi01LTEtMS05NDQxNA_1456f5eb-e50b-4618-ab5b-71fc083d0405"
      unitRef="usd">-1000000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="ie4d2e0c5ba4449618b901ef68baa6ea0_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfNi03LTEtMS05NDQxNA_3cb71ea2-1b8f-48a9-a5de-1e59447699e7"
      unitRef="usd">9000000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="ic76064667e0a419bb6d0e5c3426be249_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfNi0xNy0xLTEtOTQ0MTQ_37f9f92b-4e51-43de-ae52-a4926be283c5"
      unitRef="usd">13000000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="ia325483b4883403c90d79d1be19c51da_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfNi0xOS0xLTEtOTQ0MTQ_ee792f9d-92cc-4c74-8f78-62a4e7bbc29c"
      unitRef="usd">29000000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="ic44487f92a5448159923c27c8d731670_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfNy01LTEtMS05NDQxNA_eac7b6bd-ec70-4de7-a8d7-cc1b83d47b1d"
      unitRef="usd">0</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="ie4d2e0c5ba4449618b901ef68baa6ea0_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfNy03LTEtMS05NDQxNA_39c0d6c4-e3e6-4a09-b92d-68d6737d99b5"
      unitRef="usd">1000000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="ic76064667e0a419bb6d0e5c3426be249_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfNy0xNy0xLTEtOTQ0MTQ_4027d05b-05e2-4aa5-a7da-a20c5f1a2106"
      unitRef="usd">-4000000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="ia325483b4883403c90d79d1be19c51da_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfNy0xOS0xLTEtOTQ0MTQ_1ab4e228-ea85-4cd4-8ae3-17a8b5d16ed0"
      unitRef="usd">1000000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="ie27e3a1d731a4e8aab46753956e07c5d_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTAtOS0xLTEtOTQ0MTQ_bc29177c-2788-4101-8640-5826f5d99e31"
      unitRef="usd">682000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i5ae35cdeb80c488d9810adba90ad5a22_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTAtMTEtMS0xLTk0NDE0_04647d35-f750-475c-9aee-1b1a87054577"
      unitRef="usd">72000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="id5ffef0aa5134d30a7bc87c2f1471202_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTAtMjEtMS0xLTk0NDE0_c0e512f2-575d-4288-a2d6-2003ba58490b"
      unitRef="usd">1233000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i8f49cd47d7c34c2db675a1a70530cbc8_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTAtMjMtMS0xLTk0NDE0_f494d756-ddc9-458d-884c-1808093bc0f3"
      unitRef="usd">193000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:Revenues
      contextRef="i2090286591394c9fa952301d7aa1370f_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTEtMS0xLTEtOTQ0MTQ_6553e07e-a8f8-4e3c-8ca0-de9b00cb5b51"
      unitRef="usd">253000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie4bbf795a5864635b793460597f6ab25_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTEtMy0xLTEtOTQ0MTQ_33162687-9fac-4a53-9859-127ec7546804"
      unitRef="usd">-36000000</us-gaap:Revenues>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="ie27e3a1d731a4e8aab46753956e07c5d_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTEtOS0xLTEtOTQ0MTQ_b94fd6b8-7362-4195-8e23-84b2850dce43"
      unitRef="usd">-253000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i5ae35cdeb80c488d9810adba90ad5a22_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTEtMTEtMS0xLTk0NDE0_721dd2be-91ef-4204-babf-dcc2a634bb59"
      unitRef="usd">36000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:Revenues
      contextRef="ibe3cb650f6ab4c9b92198643023e4afa_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTEtMTMtMS0xLTk0NDE0_b03b1681-e82a-4725-ac15-b486d2e85405"
      unitRef="usd">491000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i408273e5bb4c48509f2537d97a208c52_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTEtMTUtMS0xLTk0NDE0_8b9906b5-c668-44fc-a880-444a52025f17"
      unitRef="usd">-219000000</us-gaap:Revenues>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="id5ffef0aa5134d30a7bc87c2f1471202_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTEtMjEtMS0xLTk0NDE0_7b13a4d6-df32-483a-9699-50b72a720ae7"
      unitRef="usd">-491000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i8f49cd47d7c34c2db675a1a70530cbc8_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTEtMjMtMS0xLTk0NDE0_6b906737-3a8f-488f-8cfa-126ed06e758b"
      unitRef="usd">219000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i1a250ba5d2eb4f398ca0d688c55ce97b_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTMtNS0xLTEtOTQ0MTQ_279d8d1e-9009-45b3-833c-55edf17d9e0f"
      unitRef="usd">-1000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="ib4884545f3a04d2592a0a6552ec37a9e_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTMtNy0xLTEtOTQ0MTQ_ac82776b-3fa1-4610-9c23-7042dc534afb"
      unitRef="usd">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i3adbbede1e4c4a219df434d3b02b9d73_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTMtMTctMS0xLTk0NDE0_244cee6d-22a7-4470-95a2-e6c1a31cb614"
      unitRef="usd">-2000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i24ff49aba1234e2089a06728556f905e_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTMtMTktMS0xLTk0NDE0_5ef1ea0a-0fe6-4e64-9a72-215bca64b5ae"
      unitRef="usd">-2000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i1a250ba5d2eb4f398ca0d688c55ce97b_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTQtOS0xLTEtOTQ0MTQ_117144f1-c241-4cfc-b436-ec90004127c8"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="ib4884545f3a04d2592a0a6552ec37a9e_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTQtMTEtMS0xLTk0NDE0_37fab61f-70aa-4a6e-9f0b-35bfc74a8b1f"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i3adbbede1e4c4a219df434d3b02b9d73_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTQtMjEtMS0xLTk0NDE0_520eac66-2f39-4e91-859a-aee4a64cd19b"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i24ff49aba1234e2089a06728556f905e_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTQtMjMtMS0xLTk0NDE0_e8e4022d-31f1-48ac-988f-95ababb758d7"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTkyODI_bd94eed6-43de-478c-9e6a-8d34d4373790">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.362%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amount of Derivative Pretax (Gain) Loss Recognized in Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives Not Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Income Statement Caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates. Amount in the first nine months of 2021 includes a loss on forward exchange contracts entered into in conjunction with the spin-off of Organon.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; These derivative contracts serve as economic hedges of forecasted transactions.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i8487d36b908947f3b19f1402064fea62_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjBjOWI4NmU4M2Q0YjQ4ZGQ4M2M1ODFhMTFmNWVmMThjL3RhYmxlcmFuZ2U6MGM5Yjg2ZTgzZDRiNDhkZDgzYzU4MWExMWY1ZWYxOGNfNC0zLTEtMS05NDQxNA_31334573-ba68-49f0-90de-a99b225a85c6"
      unitRef="usd">41000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="ic7aadf0e5ed8498e968fa72fc5dd2235_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjBjOWI4NmU4M2Q0YjQ4ZGQ4M2M1ODFhMTFmNWVmMThjL3RhYmxlcmFuZ2U6MGM5Yjg2ZTgzZDRiNDhkZDgzYzU4MWExMWY1ZWYxOGNfNC01LTEtMS05NDQxNA_64adb809-983f-4375-b799-1939fd93f119"
      unitRef="usd">-18000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="id156cdfb0da54388a5c8bd98db65a8b3_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjBjOWI4NmU4M2Q0YjQ4ZGQ4M2M1ODFhMTFmNWVmMThjL3RhYmxlcmFuZ2U6MGM5Yjg2ZTgzZDRiNDhkZDgzYzU4MWExMWY1ZWYxOGNfNC03LTEtMS05NDQxNA_b249c7f2-1fa2-409e-9f62-31b047e7ff79"
      unitRef="usd">77000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i1673663dc72f4e86a51bc9229008f01d_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjBjOWI4NmU4M2Q0YjQ4ZGQ4M2M1ODFhMTFmNWVmMThjL3RhYmxlcmFuZ2U6MGM5Yjg2ZTgzZDRiNDhkZDgzYzU4MWExMWY1ZWYxOGNfNC05LTEtMS05NDQxNA_cd42d019-7a09-4ecd-bcf4-153d006f7d23"
      unitRef="usd">-234000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i047a084a24b645f68be7cd35a8fc04a6_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjBjOWI4NmU4M2Q0YjQ4ZGQ4M2M1ODFhMTFmNWVmMThjL3RhYmxlcmFuZ2U6MGM5Yjg2ZTgzZDRiNDhkZDgzYzU4MWExMWY1ZWYxOGNfNS0zLTEtMS05NDQxNA_69c95b74-b1da-42a0-9528-558c34e4e29b"
      unitRef="usd">4000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="ic0264f6f727c4a4b966ea14b2e2a52ac_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjBjOWI4NmU4M2Q0YjQ4ZGQ4M2M1ODFhMTFmNWVmMThjL3RhYmxlcmFuZ2U6MGM5Yjg2ZTgzZDRiNDhkZDgzYzU4MWExMWY1ZWYxOGNfNS01LTEtMS05NDQxNA_1fb0af6b-37d4-427c-b217-57f47b5d41e3"
      unitRef="usd">4000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="ic1f6dbfb4c7146b99019ed98f23895de_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjBjOWI4NmU4M2Q0YjQ4ZGQ4M2M1ODFhMTFmNWVmMThjL3RhYmxlcmFuZ2U6MGM5Yjg2ZTgzZDRiNDhkZDgzYzU4MWExMWY1ZWYxOGNfNS03LTEtMS05NDQxNA_a81308cf-9abc-45c5-a690-7b7a4d049601"
      unitRef="usd">42000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i0e75809733d64f339d96ee9714ec260e_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjBjOWI4NmU4M2Q0YjQ4ZGQ4M2M1ODFhMTFmNWVmMThjL3RhYmxlcmFuZ2U6MGM5Yjg2ZTgzZDRiNDhkZDgzYzU4MWExMWY1ZWYxOGNfNS05LTEtMS05NDQxNA_88c9db8b-92c5-4b0d-a8b0-e673b23676f2"
      unitRef="usd">-6000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfOTg5NQ_d14be63d-ae54-4535-a4fc-f68f56f4a534"
      unitRef="usd">864000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTkyMjE_0c1464b4-327f-4262-8267-da356daf355e">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information on investments in debt and equity securities is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&#160;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&#160;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign government bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Publicly traded equity securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total debt and publicly traded equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Unrealized net losses of $221&#160;million and $415 million were recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; in the third quarter and first nine months of 2022, respectively, on equity securities still held at September&#160;30, 2022. Unrealized net (gains) losses of $(90) million and $109&#160;million were recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; in the third quarter and first nine months of 2021, respectively, on equity securities still held at September&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4720a53a91d5435188a1da01bfe210fa_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNC0xLTEtMS05NDQxNA_c3534b15-128a-4adc-ac35-74c0929d2165"
      unitRef="usd">67000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4720a53a91d5435188a1da01bfe210fa_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNC0zLTEtMS05NDQxNA_041ea68e-0f19-4f44-aae0-95f6ea59e2ed"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4720a53a91d5435188a1da01bfe210fa_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNC01LTEtMS05NDQxNA_460588f4-4ec4-492d-aa5a-9f7ac7842e6e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4720a53a91d5435188a1da01bfe210fa_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNC03LTEtMS05NDQxNA_2dbbef94-e981-445f-9219-a3fab5d6035b"
      unitRef="usd">67000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7d9a78619aff46ea84120beb595fcb13_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNC05LTEtMS05NDQxNA_efbd1242-ed11-4e11-a59c-b3ecb1c7c802"
      unitRef="usd">80000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7d9a78619aff46ea84120beb595fcb13_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNC0xMS0xLTEtOTQ0MTQ_3dbe39c7-a9f6-400f-80f0-6ef2cfce409e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7d9a78619aff46ea84120beb595fcb13_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNC0xMy0xLTEtOTQ0MTQ_a962f30a-a040-48c4-b544-8b67764be73a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7d9a78619aff46ea84120beb595fcb13_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNC0xNS0xLTEtOTQ0MTQ_34edc051-234f-4266-be2e-3358abd4cead"
      unitRef="usd">80000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iffb605e60b334d25829964639aa3cf58_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNS0xLTEtMS0xMDU3MjA_a7cbe398-2b41-4781-a10d-3705a098ed65"
      unitRef="usd">4000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iffb605e60b334d25829964639aa3cf58_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNS0zLTEtMS0xMDU3MjA_c07d43d3-a0c1-496b-b725-d1f9103cdd47"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iffb605e60b334d25829964639aa3cf58_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNS01LTEtMS0xMDU3MjA_8eb999f0-b22a-42d7-ae35-86c130edf9a3"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iffb605e60b334d25829964639aa3cf58_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNS03LTEtMS0xMDU3MjA_e321f960-3f8a-4a76-981e-e21bf07141b4"
      unitRef="usd">4000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9df8f1a7ad004c23af8f2239cda6077b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNS05LTEtMS0xMDU3MjA_da563196-6570-4266-ad1d-99813ed04005"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9df8f1a7ad004c23af8f2239cda6077b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNS0xMS0xLTEtMTA1NzIw_9c0892b3-e6c3-4903-a2bd-7f23679043eb"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9df8f1a7ad004c23af8f2239cda6077b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNS0xMy0xLTEtMTA1NzIw_f6a69593-ee2c-430b-b50a-1392adf46155"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9df8f1a7ad004c23af8f2239cda6077b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNS0xNS0xLTEtMTA1NzIw_f0995756-cd3e-4024-a8d8-9b4b36f8aa80"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id736b7b8bba944b58bf0232a18e5113e_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNS0xLTEtMS05NDQxNA_48400644-3466-40f7-b209-4c983034a6b9"
      unitRef="usd">3000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id736b7b8bba944b58bf0232a18e5113e_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNS0zLTEtMS05NDQxNA_95b494e4-b7e6-4e96-9d8d-1fe007f68bdc"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id736b7b8bba944b58bf0232a18e5113e_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNS01LTEtMS05NDQxNA_afb1ded8-d790-4a06-b183-9da56a7f9386"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id736b7b8bba944b58bf0232a18e5113e_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNS03LTEtMS05NDQxNA_6ea7d612-10c4-49fd-9a74-067cee218f17"
      unitRef="usd">3000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4bfa097e481a425fb4b73f31bdcecc30_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNS05LTEtMS05NDQxNA_065e694a-e761-4ec7-b2a0-42b56b267976"
      unitRef="usd">4000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4bfa097e481a425fb4b73f31bdcecc30_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNS0xMS0xLTEtOTQ0MTQ_09e6698e-a701-40f3-b8ef-fef546c273dd"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4bfa097e481a425fb4b73f31bdcecc30_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNS0xMy0xLTEtOTQ0MTQ_3ad38b35-d25c-4409-9f38-b012bc8b215c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4bfa097e481a425fb4b73f31bdcecc30_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNS0xNS0xLTEtOTQ0MTQ_a9832f52-1bdb-4e41-9b66-0de6ccc5e843"
      unitRef="usd">4000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if8ea7018241f4bbe9b73f4cb4ecc1d8c_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNi0xLTEtMS05NDQxNA_a6d5b18b-8165-4564-93bb-5e3715cecb6a"
      unitRef="usd">2000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if8ea7018241f4bbe9b73f4cb4ecc1d8c_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNi0zLTEtMS05NDQxNA_b16b2f7e-89db-4e2a-b77f-b39ca40a7560"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if8ea7018241f4bbe9b73f4cb4ecc1d8c_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNi01LTEtMS05NDQxNA_876e569f-b969-4d5b-ba4f-938894db37b1"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if8ea7018241f4bbe9b73f4cb4ecc1d8c_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNi03LTEtMS05NDQxNA_d50fa134-cbdb-47cb-bdf2-dabc8190e7dd"
      unitRef="usd">2000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4a1c00996a864ae7bc40a0fbc771bd76_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNi05LTEtMS05NDQxNA_e248bb7e-3e93-445e-b4d6-5d4611b6ac9e"
      unitRef="usd">2000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4a1c00996a864ae7bc40a0fbc771bd76_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNi0xMS0xLTEtOTQ0MTQ_2c7fb09e-0661-47d6-8dc1-344e4c39a745"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4a1c00996a864ae7bc40a0fbc771bd76_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNi0xMy0xLTEtOTQ0MTQ_70149f3d-8af9-4845-9041-d49dade26c32"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4a1c00996a864ae7bc40a0fbc771bd76_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNi0xNS0xLTEtOTQ0MTQ_82d1dc2e-0c26-49db-86b6-ea0ed8d48890"
      unitRef="usd">2000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNy0xLTEtMS05NDQxNA_69fd3d09-ad55-4b7e-b378-612456b39b96"
      unitRef="usd">76000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNy0zLTEtMS05NDQxNA_13e3162b-d16c-472b-b877-8e49990726c5"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNy01LTEtMS05NDQxNA_83d9c11c-1578-41c4-8e68-b2d3a4148e54"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNy03LTEtMS05NDQxNA_ce4cb1ca-68a9-4a19-82d4-dd6fefff89e2"
      unitRef="usd">76000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNy05LTEtMS05NDQxNA_bc852421-cbca-4040-919f-8ca289716fe2"
      unitRef="usd">86000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNy0xMS0xLTEtOTQ0MTQ_c3099606-1f0d-453c-9edb-f9d7306fced6"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNy0xMy0xLTEtOTQ0MTQ_5f8f4b2f-bcc4-4f55-8c64-ba36682bf786"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfNy0xNS0xLTEtOTQ0MTQ_1a7997cb-0769-40de-b052-7afbde890c89"
      unitRef="usd">86000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfOC03LTEtMS05NDQxNA_fe7425eb-39a9-4f59-891c-b54a01d749a1"
      unitRef="usd">1334000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfOC0xNS0xLTEtOTQ0MTQ_733faedc-b801-4f82-bd0c-7cdd0176a904"
      unitRef="usd">1647000000</us-gaap:EquitySecuritiesFvNi>
    <mrk:DebtSecuritiesandEquitySecuritiesFVNI
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfOS03LTEtMS05NDQxNA_8971e2f1-8f28-4ce4-b581-b2c9bbde021e"
      unitRef="usd">1410000000</mrk:DebtSecuritiesandEquitySecuritiesFVNI>
    <mrk:DebtSecuritiesandEquitySecuritiesFVNI
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmM0OTJjZjMwMjBjMzQ1MGVhNmU5ODdiYTVhNDEzNGIyL3RhYmxlcmFuZ2U6YzQ5MmNmMzAyMGMzNDUwZWE2ZTk4N2JhNWE0MTM0YjJfOS0xNS0xLTEtOTQ0MTQ_70c71f78-0abe-4175-8add-c987fc321bd7"
      unitRef="usd">1733000000</mrk:DebtSecuritiesandEquitySecuritiesFVNI>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTA0MjI_fcb5dbe0-ad7e-40b2-97d1-1a36b19a7285"
      unitRef="usd">-221000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTA0Mjk_ed420029-2385-408a-a210-4622ffaa02d9"
      unitRef="usd">-415000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTA2MDA_ced0df1c-e2d2-4777-b84d-7cc87ceab5b7"
      unitRef="usd">90000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTA2MDc_59b67774-071f-4dde-b0dd-02eb2a3995ed"
      unitRef="usd">-109000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTA3ODg_6978b2f8-fd61-4bd3-9b1f-714a8bd5b8b2"
      unitRef="usd">705000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i48930a09b1404293820fbeb015eb6729_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTA3OTU_0c17702a-deb9-4c1d-8a42-7c1a184c6906"
      unitRef="usd">578000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTEyODM_0a8c9754-57d9-4122-893d-32f73d95a1c5"
      unitRef="usd">21000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTEzMTU_a059a9d0-5bdd-4ae0-8675-2d2fdc2314f3"
      unitRef="usd">12000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTE0NTg_ecf0e497-b3b8-4de4-8a3d-7124e590ba96"
      unitRef="usd">104000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTE0ODY_6e97b954-68bf-4d4c-8ed5-1f765d4e9342"
      unitRef="usd">1000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTE3NDM_349d6d40-9d15-4f76-b9a9-9eed02b04195"
      unitRef="usd">255000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTE3NTA_3ad83157-998a-41c4-a77a-5461d75f2b2d"
      unitRef="usd">19000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTE4MDQ_68acee95-2d76-4c0e-bfab-49c054ade4de"
      unitRef="usd">655000000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="i48930a09b1404293820fbeb015eb6729_I20210930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTE4MTE_4994c71a-e45b-450d-9e68-d3daa60bacc0"
      unitRef="usd">1200000000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i010c9478893544c28a5d7f544dc8e662_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTIwMjU_dbe71c33-901c-48c5-874f-e73b42761c87"
      unitRef="usd">-141000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i099b739b13c44281a0c6d085f13b276d_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTIwMzI_1bcb4535-1e6a-4486-a7b7-66a514ad5395"
      unitRef="usd">391000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="if9e54f6ced9e4ef1b0e99ea06c1e9ef7_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTIwOTU_169771a9-f26a-4b78-bd61-5b0cf36f4191"
      unitRef="usd">-952000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i3580944146354ced840addc5a64825b3_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTIxMDI_aba125ac-b6d6-4523-808e-473808ee4f80"
      unitRef="usd">893000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTkyNjA_d9054666-6e0d-4476-95d6-6dee9622d3f4">&lt;div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets and liabilities measured at fair value on a recurring basis are summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign government bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Publicly traded equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Publicly traded equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivative assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchased currency options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivative liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Written currency options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt"&gt; Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company&#x2019;s own credit risk, the effects of which were not significant.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i734d905417484b12868c71bc4c409e5a_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfNS0xLTEtMS05NDQxNA_a6df7511-479d-454d-a305-1a5e66f2add2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic41821eed5a14d76af729b6ab39c2ea7_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfNS0zLTEtMS05NDQxNA_c2e1a492-073c-4501-95dc-7d77d9395e6e"
      unitRef="usd">4000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i51e48c4224c04c2a8bdb9693ed998b0f_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfNS01LTEtMS05NDQxNA_f82fba55-b5d5-4970-be7c-3303f73234d4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iba9a552130db4292b0e26dabff225e15_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfNS03LTEtMS05NDQxNA_b810b08d-08a7-4237-85f3-ca02610130ae"
      unitRef="usd">4000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2d25405b868b4e26aefbe7888fc41f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfNS05LTEtMS05NDQxNA_88d26e59-8928-4ad1-82bb-943745092638"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1426949b23ca4b71afa632f63d710aad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfNS0xMS0xLTEtOTQ0MTQ_49ca1a5b-e1ba-4938-aaa9-7e4588454573"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8d7092dc98a44dff9517d3c284f1849b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfNS0xMy0xLTEtOTQ0MTQ_fa6929e7-42b7-48b8-96be-75fb121e9b3c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie37c5d029c6648c8a2ed03a8d89af9b2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfNS0xNS0xLTEtOTQ0MTQ_81c64365-3b94-4459-bf17-73eac2d50808"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia1509e49abe14db0828288f4c189b466_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfNi0xLTEtMS05NDQxNA_06fed069-9edf-4700-becb-e49d1f401367"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iac3cf219c1b341109243396f0c18a2ba_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfNi0zLTEtMS05NDQxNA_3afabf92-0250-4d84-bc5d-8bb307c552bf"
      unitRef="usd">2000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icaf187dd1d10491f92cbfb112d50b31f_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfNi01LTEtMS05NDQxNA_0a5b0e8b-6347-4978-a4f9-f59761b42b38"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie5dfb72ba12644a297b93978abb2da49_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfNi03LTEtMS05NDQxNA_158cd9a9-6fdd-482d-bad0-75f812b09981"
      unitRef="usd">2000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i24b11ce36fae442893c46a0e7203cdfa_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfNi05LTEtMS05NDQxNA_b3fb9b1a-8634-4a8f-815b-95b084638f28"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i37c6e32ba0824ee38f745770cec9a2d3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfNi0xMS0xLTEtOTQ0MTQ_e33bbb1c-7dd3-4e58-ab3e-5c9ab4873772"
      unitRef="usd">2000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib7c90958615d4c819c1023d563e55db5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfNi0xMy0xLTEtOTQ0MTQ_52c661df-af00-411f-bf7a-594e5ccb76f5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3eec1411691a43719325ad418681ac13_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfNi0xNS0xLTEtOTQ0MTQ_8d2f718f-edc2-40b0-9825-5a42fbfd0480"
      unitRef="usd">2000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i7584c66c93fc49e79ea35b57c4e39390_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfNy0xLTEtMS05NDQxNA_77ba06ef-ef39-421d-822e-937661c286d6"
      unitRef="usd">1081000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ic7fc87b646454715bebf1e86eed2c3f4_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfNy0zLTEtMS05NDQxNA_087fc90f-e84e-4403-a6b4-4073c12fe7ca"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i1317ac689e934a98bcc9a08673feae09_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfNy01LTEtMS05NDQxNA_1fdd11a0-b960-4fef-97ba-a39924f288c3"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="icd40f186b450434689326d7a01e529ba_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfNy03LTEtMS05NDQxNA_b037a75f-06ea-4a87-88fd-bb7543e7e849"
      unitRef="usd">1081000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i805bffc3fe574f44bdab78a3217cffd8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfNy05LTEtMS05NDQxNA_c82c7a04-01e3-4eeb-bb41-32050368121f"
      unitRef="usd">368000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i9ad98dd1519d4e5ba2a6d482e01bb026_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfNy0xMS0xLTEtOTQ0MTQ_f9bc2637-d7d5-4434-ba4f-870b449541cf"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i9e5b8eb982b3417191aa735376241712_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfNy0xMy0xLTEtOTQ0MTQ_d97a2a1d-faf4-47ae-bed8-42c6adc84ce5"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i23d23f5244de4df5a78fbcc38021abc9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfNy0xNS0xLTEtOTQ0MTQ_5cde5302-8ad1-4b68-a26e-2be581908010"
      unitRef="usd">368000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:TradingSecurities
      contextRef="id5cc583b3ac545afb27d7011fbd7878e_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfOC0xLTEtMS05NDQxNA_6db504b9-4010-46d2-a783-e04c9e80bfbd"
      unitRef="usd">1081000000</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="id7b005680367482db7f6c5526d8a8330_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfOC0zLTEtMS05NDQxNA_5891350d-17e1-4e68-b9cf-96f969f605e9"
      unitRef="usd">6000000</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i5806d7d6752145c89d6aed6b12c0de58_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfOC01LTEtMS05NDQxNA_9f95aca8-fc25-4d34-95d8-40f71914c8ca"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i03d038eb8e67488896fcaf65d65f5a4c_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfOC03LTEtMS05NDQxNA_e2349a0e-4040-435c-9570-6bf044bbf74c"
      unitRef="usd">1087000000</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i88cb48af3d36483bb4a106b4973f8a8b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfOC05LTEtMS05NDQxNA_27499acf-550f-4391-84c2-5dca21412bd2"
      unitRef="usd">368000000</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="ib9b5923422814e839a9eace38e185dc2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfOC0xMS0xLTEtOTQ0MTQ_e41ab672-f568-45ad-8d65-03fd740e6d06"
      unitRef="usd">2000000</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i53252463645d40a49cf3666fc9496c89_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfOC0xMy0xLTEtOTQ0MTQ_d2195e16-f9a9-4792-8e15-48da99fc0431"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i95e44cbbb3c8441db74551146976a2b5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfOC0xNS0xLTEtOTQ0MTQ_d42f9612-ca60-4587-9698-04e9cbbf2b2e"
      unitRef="usd">370000000</us-gaap:TradingSecurities>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ib55137ada6674e97b937072f652336fc_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTAtMS0xLTEtOTQ0MTQ_4d24ce9d-6792-4a22-aac3-d970ce7b5239"
      unitRef="usd">67000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ia34cec2011844b3abbbecd5c96aa140b_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTAtMy0xLTEtOTQ0MTQ_c585ae2c-2684-4cf0-9f5a-4bd7b4c529e7"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ib9d82f620e50424d92c3ec570c9584c7_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTAtNS0xLTEtOTQ0MTQ_1f61379f-0c74-4d8b-a144-63aa18be8725"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i96a1014d1ffc460ea40f01ffc40ca637_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTAtNy0xLTEtOTQ0MTQ_a6770a60-2196-4f71-9080-ebf523f8ef39"
      unitRef="usd">67000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ie4a852e542ad490499c3bbfa84c21253_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTAtOS0xLTEtOTQ0MTQ_3671d444-2222-4da4-a804-54022a5dd09b"
      unitRef="usd">80000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id0249004b56d4566adef1bedb1ae2649_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTAtMTEtMS0xLTk0NDE0_15630d0f-718e-45d3-b2a8-335f76823caf"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="if7d1ba12651d49ca9605e8d70b0465db_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTAtMTMtMS0xLTk0NDE0_c5176db1-c798-4da8-b561-d1043fd6b426"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i62dc854b928b49a1945ab2a202ed9435_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTAtMTUtMS0xLTk0NDE0_3f2c7387-44ef-44b0-9684-fb44e6f77d4d"
      unitRef="usd">80000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ic7bca4ee680b4b53bd3c893bfc03df3a_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTEtMS0xLTEtOTQ0MTQ_82f35496-0d06-4ffa-85c7-8a8a85ab2801"
      unitRef="usd">3000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="if02abc99fb924ec7b0925ad5b953f9a0_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTEtMy0xLTEtOTQ0MTQ_0cc2fb2d-d557-4ca3-8018-5dcf9516bfd4"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i7eedae5d638b46e08efb6239577ce6a7_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTEtNS0xLTEtOTQ0MTQ_770e6bd8-55c0-4064-894f-b4330cf9250d"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i30c84521440546809e99309ada3e6429_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTEtNy0xLTEtOTQ0MTQ_4ae584cf-b912-46c2-ad06-4aba89d2aaab"
      unitRef="usd">3000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i66af9dda5d5a4116ac1581f86efa6274_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTEtOS0xLTEtOTQ0MTQ_3a178a6b-78cb-49a0-98b1-cfc47a6854d2"
      unitRef="usd">4000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="iec03db9221fc48e3aae39a8b07057d6b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTEtMTEtMS0xLTk0NDE0_e5e5ad3a-6ca5-4929-bc6b-1508e5a4f1c0"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i7c3110d2fc4241989477e58acec0f4b3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTEtMTMtMS0xLTk0NDE0_7840442d-99e6-4da9-a543-e811767100d5"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id4589bd6805f421980e686f3847f3f2a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTEtMTUtMS0xLTk0NDE0_86069fc5-727b-493f-b6dd-b20f323e65a2"
      unitRef="usd">4000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i7584c66c93fc49e79ea35b57c4e39390_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTItMS0xLTEtOTQ0MTQ_f91b682a-b4ba-4125-a883-b6d481fbd915"
      unitRef="usd">253000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ic7fc87b646454715bebf1e86eed2c3f4_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTItMy0xLTEtOTQ0MTQ_30a761d2-021d-4689-9084-dbe3a398c810"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i1317ac689e934a98bcc9a08673feae09_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTItNS0xLTEtOTQ0MTQ_ad9d08c5-c746-46a2-abee-38334d9f1ed1"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="icd40f186b450434689326d7a01e529ba_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTItNy0xLTEtOTQ0MTQ_f7d81f58-d107-4486-808c-bf025b817950"
      unitRef="usd">253000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i805bffc3fe574f44bdab78a3217cffd8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTItOS0xLTEtOTQ0MTQ_ec429086-c062-408f-86a4-26d37ea1efcf"
      unitRef="usd">1279000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i9ad98dd1519d4e5ba2a6d482e01bb026_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTItMTEtMS0xLTk0NDE0_ec5101a0-684d-41a6-869d-6f709b9cb23d"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i9e5b8eb982b3417191aa735376241712_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTItMTMtMS0xLTk0NDE0_6e3d7ca9-8c2a-413c-ba48-58f230b0b493"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i23d23f5244de4df5a78fbcc38021abc9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTItMTUtMS0xLTk0NDE0_7415717b-ad23-4f34-a222-1af5389c34cb"
      unitRef="usd">1279000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id5cc583b3ac545afb27d7011fbd7878e_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTMtMS0xLTEtOTQ0MTQ_374ac586-3734-442d-a353-a73486895792"
      unitRef="usd">323000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id7b005680367482db7f6c5526d8a8330_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTMtMy0xLTEtOTQ0MTQ_d512a7c1-0804-4d2a-9443-342b3d893169"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i5806d7d6752145c89d6aed6b12c0de58_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTMtNS0xLTEtOTQ0MTQ_af0f31d1-0238-4765-baa0-97c818e1e716"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i03d038eb8e67488896fcaf65d65f5a4c_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTMtNy0xLTEtOTQ0MTQ_13b0b3a0-78d8-481d-b14c-fa4775c87025"
      unitRef="usd">323000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i88cb48af3d36483bb4a106b4973f8a8b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTMtOS0xLTEtOTQ0MTQ_33fc0cbd-a640-46ab-ad93-f647a3b7caf5"
      unitRef="usd">1363000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ib9b5923422814e839a9eace38e185dc2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTMtMTEtMS0xLTk0NDE0_773d4b9c-28e7-4fbb-85cd-94cf62b4257b"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i53252463645d40a49cf3666fc9496c89_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTMtMTMtMS0xLTk0NDE0_0421b263-efbd-48c4-9a26-a579fb87d8d1"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i95e44cbbb3c8441db74551146976a2b5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTMtMTUtMS0xLTk0NDE0_d26b2c54-4394-4ef1-88a6-1250b882bb1a"
      unitRef="usd">1363000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:DerivativeAssets
      contextRef="i1a48ff5c326b4d30a9df72d6f4e2cc4e_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTUtMS0xLTEtOTQ0MTQ_43af1133-c7b5-4103-8c14-1d5d8e6979fb"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i4f242540e8e74ae39f0f26f08bedea4b_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTUtMy0xLTEtOTQ0MTQ_b1a656da-d2a5-4883-8993-19afe37bf0bf"
      unitRef="usd">945000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ia57d77b66d2f4f38a0d399ea6f3efb81_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTUtNS0xLTEtOTQ0MTQ_f4b1da32-f1e8-46a8-9de6-a6bb26ed1315"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="if2e22773379b440b9fd05bd8ebbb205a_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTUtNy0xLTEtOTQ0MTQ_5d32682d-9a5c-4305-b9f3-71f21234f017"
      unitRef="usd">945000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i1a773b58a7504fb78494693a086bafcb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTUtOS0xLTEtOTQ0MTQ_f691d700-77f4-44cb-a607-0e7880af2983"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i05efb95673774e31aaf4d68427669b60_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTUtMTEtMS0xLTk0NDE0_ff2db091-51a0-44c4-a603-c7fd7569d0ff"
      unitRef="usd">351000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i6b85ae7b23754291aed374cfe63220b4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTUtMTMtMS0xLTk0NDE0_80665c19-ba6c-476b-baad-25884533c776"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i77e75274a39649d087e97960c6fdb1da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTUtMTUtMS0xLTk0NDE0_9cfc2cab-b204-4221-b924-6e6decc129f9"
      unitRef="usd">351000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i0f4e74eaf7314a6f9b6f0534ffb3fad5_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTYtMS0xLTEtOTQ0MTQ_261df952-851c-4a79-95cc-d97a2c7d96ab"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i06b468d5994c457b9893c14bd393221a_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTYtMy0xLTEtOTQ0MTQ_b9200c3e-206c-48a4-a03d-d380e10e617a"
      unitRef="usd">563000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="if123e3f18ada47ea9d007bf17e6267a0_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTYtNS0xLTEtOTQ0MTQ_d92f6917-fd81-41c3-ab3a-2291f09cc493"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i2d2873d5334e4202befee01684ddbb00_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTYtNy0xLTEtOTQ0MTQ_3d97eb8d-060f-4a09-894d-4708579e6f30"
      unitRef="usd">563000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i2e6b581a6b0347088dff9d709ad77eec_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTYtOS0xLTEtOTQ0MTQ_d126a65a-bdd1-4a8c-b828-3a1dacfadbf2"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i891d6272e42a4cb2afb1b6651756ea76_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTYtMTEtMS0xLTk0NDE0_b7b71b8a-3c1a-4a65-b710-82d2bc131ed7"
      unitRef="usd">184000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="idf235de4a0b04bebbe52a604c0a5aec9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTYtMTMtMS0xLTk0NDE0_6a5d030e-1b42-47cd-aed3-4b4780f9c38a"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i78a40cfbe8af4bbaa128d619556eef8d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTYtMTUtMS0xLTk0NDE0_d0054cc2-b4fe-4d5e-893a-f9ae3afc61fd"
      unitRef="usd">184000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i2b8fe718d6fd40a2bb40eac7eb3ec7a5_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTctMS0xLTEtOTQ0MTQ_f628c17a-21d8-457f-811d-9866e93dbc6d"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i891529025c4d453c984c2df2e720aabc_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTctMy0xLTEtOTQ0MTQ_c91fb8f8-3e27-4ba5-9f1e-6f48cbebb866"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i2c660dcc9c53431ea4f8bf9732b7f414_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTctNS0xLTEtOTQ0MTQ_13793bd0-962e-415b-b389-55ec117e75bf"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i16903db8243d43c6a0558e66c138694a_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTctNy0xLTEtOTQ0MTQ_49e71e04-b32a-4a89-82ca-2ebfb588da94"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i4220f301677a4e66966080b9f99d020c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTctOS0xLTEtOTQ0MTQ_3f867772-605f-4f20-b26f-2c8e37a8eeee"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="icc979a929d5b473dac3eb798c69af53e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTctMTEtMS0xLTk0NDE0_1b6e21e7-fe64-4c4e-86e2-e72838ab7834"
      unitRef="usd">14000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i3256ceaea4e54171a07f3e8e012df401_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTctMTMtMS0xLTk0NDE0_9d321dc8-63ee-49bd-9d7d-8c1de1343478"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="if57cd225864c49d1b3170aa0a6cc6eac_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTctMTUtMS0xLTk0NDE0_8ee15369-eff6-4560-a0b3-098020100a3e"
      unitRef="usd">14000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="id5cc583b3ac545afb27d7011fbd7878e_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTgtMS0xLTEtOTQ0MTQ_d6e3e1df-959e-4864-942b-e8a538405ce9"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="id7b005680367482db7f6c5526d8a8330_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTgtMy0xLTEtOTQ0MTQ_34cef064-4d28-4a25-a42a-220fb14c3a8c"
      unitRef="usd">1508000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i5806d7d6752145c89d6aed6b12c0de58_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTgtNS0xLTEtOTQ0MTQ_bc9636b4-a834-4226-9937-da1b28a522f0"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i03d038eb8e67488896fcaf65d65f5a4c_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTgtNy0xLTEtOTQ0MTQ_806d5580-ed82-4907-b561-b1c517439a57"
      unitRef="usd">1508000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i88cb48af3d36483bb4a106b4973f8a8b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTgtOS0xLTEtOTQ0MTQ_81ddf86a-d0f7-441c-aed7-c58a791158d1"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ib9b5923422814e839a9eace38e185dc2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTgtMTEtMS0xLTk0NDE0_bb107b96-73e1-485f-90ec-45e9cfd15504"
      unitRef="usd">549000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i53252463645d40a49cf3666fc9496c89_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTgtMTMtMS0xLTk0NDE0_0b755268-c64f-476d-aae3-0623c398ec60"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i95e44cbbb3c8441db74551146976a2b5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTgtMTUtMS0xLTk0NDE0_fb80da29-8dcf-41ae-a912-32129de679a9"
      unitRef="usd">549000000</us-gaap:DerivativeAssets>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id5cc583b3ac545afb27d7011fbd7878e_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTktMS0xLTEtOTQ0MTQ_43c35596-cde7-4f87-a920-606e11c509c4"
      unitRef="usd">1404000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id7b005680367482db7f6c5526d8a8330_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTktMy0xLTEtOTQ0MTQ_ec702633-41de-4e91-9bf4-bb9b4f13454a"
      unitRef="usd">1514000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5806d7d6752145c89d6aed6b12c0de58_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTktNS0xLTEtOTQ0MTQ_e22c9d7d-fb1e-4c47-966f-8f77d9b30f9d"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i03d038eb8e67488896fcaf65d65f5a4c_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTktNy0xLTEtOTQ0MTQ_99aa03bc-6697-4246-a595-fd2ec857de9e"
      unitRef="usd">2918000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i88cb48af3d36483bb4a106b4973f8a8b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTktOS0xLTEtOTQ0MTQ_a8a312a0-ce51-461d-942d-437e233abd5d"
      unitRef="usd">1731000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib9b5923422814e839a9eace38e185dc2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTktMTEtMS0xLTk0NDE0_1874e57e-7ed9-4404-93a1-216e32a0fca3"
      unitRef="usd">551000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i53252463645d40a49cf3666fc9496c89_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTktMTMtMS0xLTk0NDE0_5c1e8ac1-fd6a-4935-921e-ebc992063ceb"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i95e44cbbb3c8441db74551146976a2b5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMTktMTUtMS0xLTk0NDE0_f1f3e64c-e2c8-4866-9fbe-539fd99389c9"
      unitRef="usd">2282000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="id5cc583b3ac545afb27d7011fbd7878e_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjItMS0xLTEtOTQ0MTQ_1e6a7b3a-3052-466e-9395-af6ce9c27af5"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="id7b005680367482db7f6c5526d8a8330_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjItMy0xLTEtOTQ0MTQ_4dd4eea3-a9d0-4c91-96f1-3f56afc2d7c4"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i5806d7d6752145c89d6aed6b12c0de58_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjItNS0xLTEtOTQ0MTQ_d8e68af6-0484-4070-8fdd-815f3b574d4b"
      unitRef="usd">499000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i03d038eb8e67488896fcaf65d65f5a4c_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjItNy0xLTEtOTQ0MTQ_e78de016-17e5-472e-8e79-5fc4ee3c61b1"
      unitRef="usd">499000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i88cb48af3d36483bb4a106b4973f8a8b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjItOS0xLTEtOTQ0MTQ_5c5eddf8-5c71-4c96-938d-0444226bb04c"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ib9b5923422814e839a9eace38e185dc2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjItMTEtMS0xLTk0NDE0_91e51720-45d6-4588-a9bb-613e6ec7444c"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i53252463645d40a49cf3666fc9496c89_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjItMTMtMS0xLTk0NDE0_119ba0ce-5269-4fce-b480-d528cdb8dfbb"
      unitRef="usd">777000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i95e44cbbb3c8441db74551146976a2b5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjItMTUtMS0xLTk0NDE0_75e216ae-cae2-4feb-b80e-fa61dbf3fd9c"
      unitRef="usd">777000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:DerivativeLiabilities
      contextRef="i1a48ff5c326b4d30a9df72d6f4e2cc4e_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjQtMS0xLTEtOTQ0MTQ_327ecd6a-3a2d-4982-b705-dabd46f337b9"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i4f242540e8e74ae39f0f26f08bedea4b_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjQtMy0xLTEtOTQ0MTQ_c441ca73-6fb7-4047-8e99-98c0a9d8682c"
      unitRef="usd">242000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ia57d77b66d2f4f38a0d399ea6f3efb81_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjQtNS0xLTEtOTQ0MTQ_53d6fc4d-1153-44a6-a23f-3887ac3b0711"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="if2e22773379b440b9fd05bd8ebbb205a_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjQtNy0xLTEtOTQ0MTQ_aa506155-0fcb-4152-b94a-741e34440d14"
      unitRef="usd">242000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i1a773b58a7504fb78494693a086bafcb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjQtOS0xLTEtOTQ0MTQ_1e7c84cd-093d-4368-ad8c-488700701dee"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i05efb95673774e31aaf4d68427669b60_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjQtMTEtMS0xLTk0NDE0_ec8065be-f753-4090-83a9-4c3ed493096a"
      unitRef="usd">120000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i6b85ae7b23754291aed374cfe63220b4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjQtMTMtMS0xLTk0NDE0_062d3516-1633-47c0-bfb2-356da0ad968a"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i77e75274a39649d087e97960c6fdb1da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjQtMTUtMS0xLTk0NDE0_8f8dd627-fc70-49be-a5de-301a0669b454"
      unitRef="usd">120000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i0f4e74eaf7314a6f9b6f0534ffb3fad5_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjUtMS0xLTEtOTQ0MTQ_95e9c726-2873-46a2-bc06-9f332e627c42"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i06b468d5994c457b9893c14bd393221a_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjUtMy0xLTEtOTQ0MTQ_f32248b1-f4ad-4f01-a3b0-87595175ec4d"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="if123e3f18ada47ea9d007bf17e6267a0_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjUtNS0xLTEtOTQ0MTQ_7eb35128-16ac-46dc-ae68-6c65fc676e21"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i2d2873d5334e4202befee01684ddbb00_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjUtNy0xLTEtOTQ0MTQ_50786daf-ef47-4688-ad4e-ad2e06044516"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i2e6b581a6b0347088dff9d709ad77eec_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjUtOS0xLTEtOTQ0MTQ_af0cbf7e-c468-4751-80b2-7967fd02b683"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i891d6272e42a4cb2afb1b6651756ea76_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjUtMTEtMS0xLTk0NDE0_526710ea-d2a9-4d7b-a428-f1744b1bcb06"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="idf235de4a0b04bebbe52a604c0a5aec9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjUtMTMtMS0xLTk0NDE0_8cfb0b1e-5117-43c1-80c0-4ce83227b0ba"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i78a40cfbe8af4bbaa128d619556eef8d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjUtMTUtMS0xLTk0NDE0_c3e906c8-828b-4a22-9549-b1346ce5c28c"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="id5cc583b3ac545afb27d7011fbd7878e_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjYtMS0xLTEtOTQ0MTQ_dedc2665-25fb-4b98-9ba1-5335b3dacf32"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="id7b005680367482db7f6c5526d8a8330_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjYtMy0xLTEtOTQ0MTQ_15e6d9d7-d147-4ed8-9a35-311e1a181af6"
      unitRef="usd">242000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i5806d7d6752145c89d6aed6b12c0de58_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjYtNS0xLTEtOTQ0MTQ_e6b07422-0859-48ee-9170-69afc01ce43f"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i03d038eb8e67488896fcaf65d65f5a4c_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjYtNy0xLTEtOTQ0MTQ_35d50d1f-0039-415e-8867-33170ddeff6b"
      unitRef="usd">242000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i88cb48af3d36483bb4a106b4973f8a8b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjYtOS0xLTEtOTQ0MTQ_660525b7-6711-4d47-8afd-ecd5ed56d45c"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ib9b5923422814e839a9eace38e185dc2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjYtMTEtMS0xLTk0NDE0_4bda484b-f8d4-44f4-8f21-bc7b1e83f8f6"
      unitRef="usd">121000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i53252463645d40a49cf3666fc9496c89_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjYtMTMtMS0xLTk0NDE0_d5b39aa0-8710-456b-ba68-f1540f3396e8"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i95e44cbbb3c8441db74551146976a2b5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjYtMTUtMS0xLTk0NDE0_fe17c222-ed44-4981-9069-8a0f3f4f95c5"
      unitRef="usd">121000000</us-gaap:DerivativeLiabilities>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="id5cc583b3ac545afb27d7011fbd7878e_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjctMS0xLTEtOTQ0MTQ_dbe6e8e0-2f5e-4a7a-b497-42c104c2f9db"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="id7b005680367482db7f6c5526d8a8330_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjctMy0xLTEtOTQ0MTQ_51828f7b-5a5d-4f5e-a16a-d65d8c6c9050"
      unitRef="usd">242000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i5806d7d6752145c89d6aed6b12c0de58_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjctNS0xLTEtOTQ0MTQ_b5aa8dad-86af-4b72-85c1-79e66aef60d1"
      unitRef="usd">499000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i03d038eb8e67488896fcaf65d65f5a4c_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjctNy0xLTEtOTQ0MTQ_6b345452-01fe-45c2-8429-17e35eca10bc"
      unitRef="usd">741000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i88cb48af3d36483bb4a106b4973f8a8b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjctOS0xLTEtOTQ0MTQ_d44ec871-79d0-42d9-9189-ae0e8d0bdd38"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ib9b5923422814e839a9eace38e185dc2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjctMTEtMS0xLTk0NDE0_6633cb31-b46c-4f7b-a59b-d74f1ee8419f"
      unitRef="usd">121000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i53252463645d40a49cf3666fc9496c89_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjctMTMtMS0xLTk0NDE0_96037f7b-5f52-4994-8351-e96ba1016cd9"
      unitRef="usd">777000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i95e44cbbb3c8441db74551146976a2b5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJiNTczNDAyNTQyYTQwMTQ5MjFiMWE4ODkyODU4OGI1L3RhYmxlcmFuZ2U6YmI1NzM0MDI1NDJhNDAxNDkyMWIxYTg4OTI4NTg4YjVfMjctMTUtMS0xLTk0NDE0_7b66c4db-a060-4cee-974a-e955ea782988"
      unitRef="usd">898000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="ief790689a028402aa25ab7e36ca0ef81_I20220930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTQzMDE_5b61e7a9-e94f-46df-a99c-7615b32795b2"
      unitRef="usd">10000000000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="if556bca6c6704fee88ef4a1501269201_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTQzMDg_68202e59-36ca-40de-9981-70cb202a00e3"
      unitRef="usd">6800000000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTkyMzk_38d9973a-fc5b-44b1-a62f-3c3ba80e3981">&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized information about the changes in the fair value of liabilities for contingent consideration associated with business combinations is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.424%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value January 1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in estimated fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(156)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value September 30 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;  Recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Cost of sales, Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; expenses, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;. Includes cumulative translation adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;At September&#160;30, 2022, $358 million of the liabilities relate to the 2016 termination of the Sanofi Pasteur MSD joint venture. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate to present value the cash flows. Balance at September&#160;30, 2022 includes $139 million recorded as a current liability for amounts expected to be paid within the next 12 months.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJhNWNlODY4OWU2OTRiOThiN2Y1ZGUxMTUwMGQwMDMyL3RhYmxlcmFuZ2U6YmE1Y2U4Njg5ZTY5NGI5OGI3ZjVkZTExNTAwZDAwMzJfMS0xLTEtMS05NDQxNA_12ca51fb-5f43-4cb5-8ffb-c4c83402fc99"
      unitRef="usd">777000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i6b76c3e2ce274f17b07c82ae1459e9f9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJhNWNlODY4OWU2OTRiOThiN2Y1ZGUxMTUwMGQwMDMyL3RhYmxlcmFuZ2U6YmE1Y2U4Njg5ZTY5NGI5OGI3ZjVkZTExNTAwZDAwMzJfMS0zLTEtMS05NDQxNA_3e388d22-8429-42d9-bf6e-7eb3d852ec1b"
      unitRef="usd">841000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJhNWNlODY4OWU2OTRiOThiN2Y1ZGUxMTUwMGQwMDMyL3RhYmxlcmFuZ2U6YmE1Y2U4Njg5ZTY5NGI5OGI3ZjVkZTExNTAwZDAwMzJfMi0xLTEtMS05NDQxNA_c531e231-6a2d-4198-8d91-64de581cf067"
      unitRef="usd">-156000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJhNWNlODY4OWU2OTRiOThiN2Y1ZGUxMTUwMGQwMDMyL3RhYmxlcmFuZ2U6YmE1Y2U4Njg5ZTY5NGI5OGI3ZjVkZTExNTAwZDAwMzJfMi0zLTEtMS05NDQxNA_14844ce1-cb82-440c-9ecf-9b2fd4771cce"
      unitRef="usd">73000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJhNWNlODY4OWU2OTRiOThiN2Y1ZGUxMTUwMGQwMDMyL3RhYmxlcmFuZ2U6YmE1Y2U4Njg5ZTY5NGI5OGI3ZjVkZTExNTAwZDAwMzJfMy0xLTEtMS05NDQxNA_62d17b36-9bbf-4777-89d9-58108b266a34"
      unitRef="usd">119000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJhNWNlODY4OWU2OTRiOThiN2Y1ZGUxMTUwMGQwMDMyL3RhYmxlcmFuZ2U6YmE1Y2U4Njg5ZTY5NGI5OGI3ZjVkZTExNTAwZDAwMzJfMy0zLTEtMS05NDQxNA_ffa47c61-6d08-45f0-a494-f978670a6de2"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <mrk:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJhNWNlODY4OWU2OTRiOThiN2Y1ZGUxMTUwMGQwMDMyL3RhYmxlcmFuZ2U6YmE1Y2U4Njg5ZTY5NGI5OGI3ZjVkZTExNTAwZDAwMzJfNC0xLTEtMS05NDQxNA_760639be-4315-4683-bb1e-9a8aa1ae4693"
      unitRef="usd">3000000</mrk:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther>
    <mrk:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJhNWNlODY4OWU2OTRiOThiN2Y1ZGUxMTUwMGQwMDMyL3RhYmxlcmFuZ2U6YmE1Y2U4Njg5ZTY5NGI5OGI3ZjVkZTExNTAwZDAwMzJfNC0zLTEtMS05NDQxNA_d7a55987-17d0-4a99-b40b-6b38d1dd8afc"
      unitRef="usd">12000000</mrk:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJhNWNlODY4OWU2OTRiOThiN2Y1ZGUxMTUwMGQwMDMyL3RhYmxlcmFuZ2U6YmE1Y2U4Njg5ZTY5NGI5OGI3ZjVkZTExNTAwZDAwMzJfNS0xLTEtMS05NDQxNA_dcfe808a-7b94-45a9-a54d-bed8be5a88d1"
      unitRef="usd">499000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i48930a09b1404293820fbeb015eb6729_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmJhNWNlODY4OWU2OTRiOThiN2Y1ZGUxMTUwMGQwMDMyL3RhYmxlcmFuZ2U6YmE1Y2U4Njg5ZTY5NGI5OGI3ZjVkZTExNTAwZDAwMzJfNS0zLTEtMS05NDQxNA_07fc6bbc-825d-4485-b660-901621e6c075"
      unitRef="usd">902000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i8f6c358374a442b8908f3ddffb11dba7_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTQ3NTE_274dda3f-22e7-4054-acb8-55b44851de53"
      unitRef="usd">358000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i8f6c358374a442b8908f3ddffb11dba7_I20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTQ5NDI_602be6cf-1436-42c3-bc11-79e22a0964b2"
      unitRef="number">0.115</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTU0NDI_2a20f9d9-14db-4db3-bd4b-1547089e3107"
      unitRef="usd">139000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTYwMDA_6870bd9f-8691-47c6-84a1-4b0971a8fdc3"
      unitRef="usd">25900000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTYwMzc_7a0bf3ca-b1e9-4c3a-b96b-5263067b81a2"
      unitRef="usd">30400000000</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <us-gaap:DebtInstrumentFairValue
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTYwNTU_a9655b08-3b77-42ef-93ad-52f6feef5c5c"
      unitRef="usd">35700000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTYwOTI_b23135e8-6c67-4b89-80f9-b80ad5b4e292"
      unitRef="usd">33100000000</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <us-gaap:AccountsReceivableSale
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTc0ODM_295c3301-3b47-4a77-8f40-92869b34b7af"
      unitRef="usd">2300000000</us-gaap:AccountsReceivableSale>
    <us-gaap:AccountsReceivableSale
      contextRef="ia921450fc1e646fdb798d9bdb31e85e7_D20210101-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTc0OTA_bdb5edae-4863-40d5-9440-0225de28c549"
      unitRef="usd">2800000000</us-gaap:AccountsReceivableSale>
    <us-gaap:RestrictedCashCurrent
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTgwMjI_fe0516b2-cf46-4c7a-a2df-de6b15ec6e49"
      unitRef="usd">55000000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTgwMjk_6e1c9b88-a79b-448b-a9fb-523f32e26daf"
      unitRef="usd">62000000</us-gaap:RestrictedCashCurrent>
    <us-gaap:DerivativeCollateralObligationToReturnCash
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTkwNzc_ff076615-7dd9-4322-8472-9f960095011a"
      unitRef="usd">794000000</us-gaap:DerivativeCollateralObligationToReturnCash>
    <us-gaap:DerivativeCollateralObligationToReturnCash
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RleHRyZWdpb246ZGI3MDMwNDA5OGE0NDQ5Nzk3YTkyMGEzNjY3ODdmOTFfMTkwODQ_8a4916a6-2d68-4013-91c0-9a62f5830d13"
      unitRef="usd">164000000</us-gaap:DerivativeCollateralObligationToReturnCash>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81Mi9mcmFnOjcyMjUyYjhjOTBmNzQ4MzFiNDQyZTBhYjhiZTViZWNlL3RleHRyZWdpb246NzIyNTJiOGM5MGY3NDgzMWI0NDJlMGFiOGJlNWJlY2VfNDA2_cb7d7576-90ce-42d7-8dad-9e02202e33bd">Inventories&lt;div style="margin-top:5pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total (approximates current cost)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decrease to LIFO cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(187)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts recognized as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; are comprised almost entirely of raw materials and work in process inventories. At September&#160;30, 2022 and December&#160;31, 2021, these amounts included $2.2 billion and $1.9 billion, respectively, of inventories not expected to be sold within one year. In addition, these amounts included $417 million and $256 million at September&#160;30, 2022 and December&#160;31, 2021, respectively, of inventories produced in preparation for product launches.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81Mi9mcmFnOjcyMjUyYjhjOTBmNzQ4MzFiNDQyZTBhYjhiZTViZWNlL3RleHRyZWdpb246NzIyNTJiOGM5MGY3NDgzMWI0NDJlMGFiOGJlNWJlY2VfNDI0_0cb2f779-e2d7-4324-a725-2c5065a674b2">&lt;div style="margin-top:5pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total (approximates current cost)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decrease to LIFO cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(187)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoods
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81Mi9mcmFnOjcyMjUyYjhjOTBmNzQ4MzFiNDQyZTBhYjhiZTViZWNlL3RhYmxlOjJkMWU3ZDgwMmY0MDQ1NTE5MTZiZjk5NjYxYzBjYzIyL3RhYmxlcmFuZ2U6MmQxZTdkODAyZjQwNDU1MTkxNmJmOTk2NjFjMGNjMjJfMS0xLTEtMS05NDQxNA_7e80f696-e7e1-4372-8c63-11d7a0441c18"
      unitRef="usd">1683000000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81Mi9mcmFnOjcyMjUyYjhjOTBmNzQ4MzFiNDQyZTBhYjhiZTViZWNlL3RhYmxlOjJkMWU3ZDgwMmY0MDQ1NTE5MTZiZjk5NjYxYzBjYzIyL3RhYmxlcmFuZ2U6MmQxZTdkODAyZjQwNDU1MTkxNmJmOTk2NjFjMGNjMjJfMS0zLTEtMS05NDQxNA_9b072ee5-9930-4316-84b6-54ec79d60445"
      unitRef="usd">1747000000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryWorkInProcessAndRawMaterials
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81Mi9mcmFnOjcyMjUyYjhjOTBmNzQ4MzFiNDQyZTBhYjhiZTViZWNlL3RhYmxlOjJkMWU3ZDgwMmY0MDQ1NTE5MTZiZjk5NjYxYzBjYzIyL3RhYmxlcmFuZ2U6MmQxZTdkODAyZjQwNDU1MTkxNmJmOTk2NjFjMGNjMjJfMi0xLTEtMS05NDQxNA_a3d56c3d-8e44-4a1e-9e60-79736f10f6a0"
      unitRef="usd">6532000000</us-gaap:InventoryWorkInProcessAndRawMaterials>
    <us-gaap:InventoryWorkInProcessAndRawMaterials
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81Mi9mcmFnOjcyMjUyYjhjOTBmNzQ4MzFiNDQyZTBhYjhiZTViZWNlL3RhYmxlOjJkMWU3ZDgwMmY0MDQ1NTE5MTZiZjk5NjYxYzBjYzIyL3RhYmxlcmFuZ2U6MmQxZTdkODAyZjQwNDU1MTkxNmJmOTk2NjFjMGNjMjJfMi0zLTEtMS05NDQxNA_cfdd7184-a7c0-4c14-b697-7d392739b8ed"
      unitRef="usd">6220000000</us-gaap:InventoryWorkInProcessAndRawMaterials>
    <us-gaap:OtherInventorySupplies
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81Mi9mcmFnOjcyMjUyYjhjOTBmNzQ4MzFiNDQyZTBhYjhiZTViZWNlL3RhYmxlOjJkMWU3ZDgwMmY0MDQ1NTE5MTZiZjk5NjYxYzBjYzIyL3RhYmxlcmFuZ2U6MmQxZTdkODAyZjQwNDU1MTkxNmJmOTk2NjFjMGNjMjJfMy0xLTEtMS05NDQxNA_ab665606-0b85-4339-bb2f-141e967a6947"
      unitRef="usd">227000000</us-gaap:OtherInventorySupplies>
    <us-gaap:OtherInventorySupplies
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81Mi9mcmFnOjcyMjUyYjhjOTBmNzQ4MzFiNDQyZTBhYjhiZTViZWNlL3RhYmxlOjJkMWU3ZDgwMmY0MDQ1NTE5MTZiZjk5NjYxYzBjYzIyL3RhYmxlcmFuZ2U6MmQxZTdkODAyZjQwNDU1MTkxNmJmOTk2NjFjMGNjMjJfMy0zLTEtMS05NDQxNA_21ca209a-8e55-4e43-94be-ae144070e745"
      unitRef="usd">196000000</us-gaap:OtherInventorySupplies>
    <us-gaap:InventoryGross
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81Mi9mcmFnOjcyMjUyYjhjOTBmNzQ4MzFiNDQyZTBhYjhiZTViZWNlL3RhYmxlOjJkMWU3ZDgwMmY0MDQ1NTE5MTZiZjk5NjYxYzBjYzIyL3RhYmxlcmFuZ2U6MmQxZTdkODAyZjQwNDU1MTkxNmJmOTk2NjFjMGNjMjJfNC0xLTEtMS05NDQxNA_4aad6675-a4e7-403f-8607-3962eea74fb5"
      unitRef="usd">8442000000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81Mi9mcmFnOjcyMjUyYjhjOTBmNzQ4MzFiNDQyZTBhYjhiZTViZWNlL3RhYmxlOjJkMWU3ZDgwMmY0MDQ1NTE5MTZiZjk5NjYxYzBjYzIyL3RhYmxlcmFuZ2U6MmQxZTdkODAyZjQwNDU1MTkxNmJmOTk2NjFjMGNjMjJfNC0zLTEtMS05NDQxNA_868c0dec-0065-4cdc-b1a5-a8f34c9dd9dd"
      unitRef="usd">8163000000</us-gaap:InventoryGross>
    <us-gaap:InventoryLIFOReserve
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81Mi9mcmFnOjcyMjUyYjhjOTBmNzQ4MzFiNDQyZTBhYjhiZTViZWNlL3RhYmxlOjJkMWU3ZDgwMmY0MDQ1NTE5MTZiZjk5NjYxYzBjYzIyL3RhYmxlcmFuZ2U6MmQxZTdkODAyZjQwNDU1MTkxNmJmOTk2NjFjMGNjMjJfNS0xLTEtMS05NDQxNA_a07cdd76-fdb6-4566-8825-be0f33e59a39"
      unitRef="usd">187000000</us-gaap:InventoryLIFOReserve>
    <us-gaap:InventoryLIFOReserve
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81Mi9mcmFnOjcyMjUyYjhjOTBmNzQ4MzFiNDQyZTBhYjhiZTViZWNlL3RhYmxlOjJkMWU3ZDgwMmY0MDQ1NTE5MTZiZjk5NjYxYzBjYzIyL3RhYmxlcmFuZ2U6MmQxZTdkODAyZjQwNDU1MTkxNmJmOTk2NjFjMGNjMjJfNS0zLTEtMS05NDQxNA_bd54e327-1b46-43c3-857c-3a7efc2921ae"
      unitRef="usd">16000000</us-gaap:InventoryLIFOReserve>
    <mrk:InventoryNetAndInventoryNoncurrent
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81Mi9mcmFnOjcyMjUyYjhjOTBmNzQ4MzFiNDQyZTBhYjhiZTViZWNlL3RhYmxlOjJkMWU3ZDgwMmY0MDQ1NTE5MTZiZjk5NjYxYzBjYzIyL3RhYmxlcmFuZ2U6MmQxZTdkODAyZjQwNDU1MTkxNmJmOTk2NjFjMGNjMjJfNi0xLTEtMS05NDQxNA_079e69c0-c80d-4e45-81c6-4f3b8722e644"
      unitRef="usd">8255000000</mrk:InventoryNetAndInventoryNoncurrent>
    <mrk:InventoryNetAndInventoryNoncurrent
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81Mi9mcmFnOjcyMjUyYjhjOTBmNzQ4MzFiNDQyZTBhYjhiZTViZWNlL3RhYmxlOjJkMWU3ZDgwMmY0MDQ1NTE5MTZiZjk5NjYxYzBjYzIyL3RhYmxlcmFuZ2U6MmQxZTdkODAyZjQwNDU1MTkxNmJmOTk2NjFjMGNjMjJfNi0zLTEtMS05NDQxNA_d4cabe87-2fbd-4271-9b92-62284e3f397f"
      unitRef="usd">8147000000</mrk:InventoryNetAndInventoryNoncurrent>
    <us-gaap:InventoryNet
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81Mi9mcmFnOjcyMjUyYjhjOTBmNzQ4MzFiNDQyZTBhYjhiZTViZWNlL3RhYmxlOjJkMWU3ZDgwMmY0MDQ1NTE5MTZiZjk5NjYxYzBjYzIyL3RhYmxlcmFuZ2U6MmQxZTdkODAyZjQwNDU1MTkxNmJmOTk2NjFjMGNjMjJfOC0xLTEtMS05NDQxNA_d21b7409-6559-4d16-94b0-2128ce08cd08"
      unitRef="usd">5614000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81Mi9mcmFnOjcyMjUyYjhjOTBmNzQ4MzFiNDQyZTBhYjhiZTViZWNlL3RhYmxlOjJkMWU3ZDgwMmY0MDQ1NTE5MTZiZjk5NjYxYzBjYzIyL3RhYmxlcmFuZ2U6MmQxZTdkODAyZjQwNDU1MTkxNmJmOTk2NjFjMGNjMjJfOC0zLTEtMS05NDQxNA_53759065-484d-4a37-ab6e-2545fb81655d"
      unitRef="usd">5953000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNoncurrent
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81Mi9mcmFnOjcyMjUyYjhjOTBmNzQ4MzFiNDQyZTBhYjhiZTViZWNlL3RhYmxlOjJkMWU3ZDgwMmY0MDQ1NTE5MTZiZjk5NjYxYzBjYzIyL3RhYmxlcmFuZ2U6MmQxZTdkODAyZjQwNDU1MTkxNmJmOTk2NjFjMGNjMjJfOS0xLTEtMS05NDQxNA_e467bf93-71f6-4569-be74-e22a467af6f5"
      unitRef="usd">2641000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81Mi9mcmFnOjcyMjUyYjhjOTBmNzQ4MzFiNDQyZTBhYjhiZTViZWNlL3RhYmxlOjJkMWU3ZDgwMmY0MDQ1NTE5MTZiZjk5NjYxYzBjYzIyL3RhYmxlcmFuZ2U6MmQxZTdkODAyZjQwNDU1MTkxNmJmOTk2NjFjMGNjMjJfOS0zLTEtMS05NDQxNA_22c93b26-fb26-4bd5-8395-f0c58a9ddf72"
      unitRef="usd">2194000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i5a678e64e2774577a007e2d6f57ae9e6_I20220930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81Mi9mcmFnOjcyMjUyYjhjOTBmNzQ4MzFiNDQyZTBhYjhiZTViZWNlL3RleHRyZWdpb246NzIyNTJiOGM5MGY3NDgzMWI0NDJlMGFiOGJlNWJlY2VfMTky_4bae9858-7dc4-4194-a96f-720b8724044c"
      unitRef="usd">2200000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i9b4bff14a1a9425cb5bf3661e7e1e54d_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81Mi9mcmFnOjcyMjUyYjhjOTBmNzQ4MzFiNDQyZTBhYjhiZTViZWNlL3RleHRyZWdpb246NzIyNTJiOGM5MGY3NDgzMWI0NDJlMGFiOGJlNWJlY2VfMTk5_c6059b97-f460-41bf-b98b-1966d58421c0"
      unitRef="usd">1900000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i816e17e24e684044addf68e60f3d7cdd_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81Mi9mcmFnOjcyMjUyYjhjOTBmNzQ4MzFiNDQyZTBhYjhiZTViZWNlL3RleHRyZWdpb246NzIyNTJiOGM5MGY3NDgzMWI0NDJlMGFiOGJlNWJlY2VfMzA5_2f014cd3-1583-4797-98dd-0ccc4e287477"
      unitRef="usd">417000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i871e3e80b793441c8f0be12b7c62ca4b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81Mi9mcmFnOjcyMjUyYjhjOTBmNzQ4MzFiNDQyZTBhYjhiZTViZWNlL3RleHRyZWdpb246NzIyNTJiOGM5MGY3NDgzMWI0NDJlMGFiOGJlNWJlY2VfMzE2_dcce17af-802f-4e07-871b-299dad04ff56"
      unitRef="usd">256000000</us-gaap:InventoryNoncurrent>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xMzEzL2ZyYWc6MzU4ODJlZTI1NTkxNDkwNGEyOWFjOTEzNDZjYzVjMDEvdGV4dHJlZ2lvbjozNTg4MmVlMjU1OTE0OTA0YTI5YWM5MTM0NmNjNWMwMV81NDk3NTU4MTcyMDc_d54935b3-0865-48c7-81c2-093d90b772ae">Other Intangibles&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the third quarter of 2022, the Company recorded $887 million of impairment charges within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses related to intangible assets obtained in connection with the 2020 acquisition of ArQule, Inc. Of this amount, $807 million represents an in-process research and development (IPR&amp;amp;D) impairment charge related to nemtabrutinib (MK-1026), a novel, oral BTK inhibitor currently being evaluated for the treatment of B-cell malignancies. Following discussions with regulatory authorities in the third quarter, the development period for nemtabrutinib was extended, which constituted a triggering event that required the evaluation of the nemtabrutinib intangible asset for impairment. The Company estimated the current fair value of nemtabrutinib utilizing an income approach which calculates the present value of projected future cash flows. The market participant assumptions used to derive the forecasted cash flows were updated to reflect a delay in the anticipated launch date for nemtabrutinib, which resulted in lower cumulative revenue forecasts and a reduction in the estimated fair value. The revised estimated fair value of nemtabrutinib when compared with its related carrying value resulted in the IPR&amp;amp;D impairment charge noted above. The remaining IPR&amp;amp;D intangible asset related to nemtabrutinib is $1.2 billion. If the assumptions used to estimate the fair value of nemtabrutinib prove to be incorrect and the development of nemtabrutinib does not progress as anticipated thereby adversely affecting projected future cash flows, the Company may record an additional impairment charge in the future and such charge could be material.&lt;/span&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i0b998b01dd7b4aedbe8d12d9cd13b5db_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xMzEzL2ZyYWc6MzU4ODJlZTI1NTkxNDkwNGEyOWFjOTEzNDZjYzVjMDEvdGV4dHJlZ2lvbjozNTg4MmVlMjU1OTE0OTA0YTI5YWM5MTM0NmNjNWMwMV81NDk3NTU4MTcyMzI_0f6007c1-784f-4ed1-89f6-1c86809a6062"
      unitRef="usd">887000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i06851cb5c98f4da69ac686f6c2411879_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xMzEzL2ZyYWc6MzU4ODJlZTI1NTkxNDkwNGEyOWFjOTEzNDZjYzVjMDEvdGV4dHJlZ2lvbjozNTg4MmVlMjU1OTE0OTA0YTI5YWM5MTM0NmNjNWMwMV81NDk3NTU4MTcyMjc_aac7a104-93d2-4945-983f-0d073d8f7a30"
      unitRef="usd">807000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i1c885d79a0554b91bbfa7bc3397951e7_I20220930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF8xMzEzL2ZyYWc6MzU4ODJlZTI1NTkxNDkwNGEyOWFjOTEzNDZjYzVjMDEvdGV4dHJlZ2lvbjozNTg4MmVlMjU1OTE0OTA0YTI5YWM5MTM0NmNjNWMwMV81NDk3NTU4MTcyMDQ_24524a57-11d7-4f6c-822a-0c147ac52df9"
      unitRef="usd">1200000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81NS9mcmFnOjNiNDE0ZjBmNjBmMDQwMzliNDRkNjY1ODhlODBiYTcyL3RleHRyZWdpb246M2I0MTRmMGY2MGYwNDAzOWI0NGQ2NjU4OGU4MGJhNzJfMjU1Njg_f904b421-1958-42df-8632-d6c1b82639ba">Contingencies&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property, and commercial litigation, as well as certain additional matters including governmental and environmental matters. In the opinion of the Company, it is unlikely that the resolution of these matters will be material to the Company&#x2019;s financial condition, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Given the nature of the litigation discussed below and the complexities involved in these matters, the Company is unable to reasonably estimate a possible loss or range of possible loss for such matters until the Company knows, among other factors, (i)&#160;what claims, if any, will survive dispositive motion practice, (ii)&#160;the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii)&#160;how the discovery process will affect the litigation, (iv)&#160;the settlement posture of the other parties to the litigation and (v)&#160;any other factors that may have a material effect on the litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. For product liability claims, a portion of the overall accrual is actuarially determined and considers such factors as past experience, number of claims reported and estimates of claims incurred but not yet reported. Individually significant contingent losses are accrued when probable and reasonably estimable. Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such decisions are made. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Liability Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fosamax&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed, Merck is a defendant in product liability lawsuits in the U.S. involving Fosamax (alendronate sodium) (Fosamax Litigation). As of September&#160;30, 2022, approximately 3,450 cases are pending against Merck in either a federal multidistrict litigation (Femur Fracture MDL) or state court. Plaintiffs in the vast majority of these cases generally allege that they sustained femur fractures and/or other bone injuries (Femur Fractures) in association with the use of Fosamax.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2014, the Femur Fracture MDL court dismissed with prejudice approximately 650 cases on preemption grounds. Plaintiffs in approximately 515 of those cases appealed that decision to the U.S. Court of Appeals for the Third Circuit (Third Circuit). In March 2017, the Third Circuit issued a decision reversing the Femur Fracture MDL court&#x2019;s preemption ruling and remanding the appealed cases back to the Femur Fracture MDL court. In May 2019, the U.S. Supreme Court decided that the Third Circuit had incorrectly concluded that the issue of preemption should be resolved by a jury, and accordingly vacated the judgment of the Third Circuit and remanded the proceedings back to the Third Circuit to address the issue in a manner consistent with the Supreme Court&#x2019;s opinion. In November 2019, the Third Circuit remanded the cases back to the District Court in order to allow that court to determine in the first instance whether the plaintiffs&#x2019; state law claims are preempted by federal law under the standards described by the Supreme Court in its opinion. On March 23, 2022, the District Court granted Merck&#x2019;s motion and ruled that plaintiffs&#x2019; failure to warn claims are preempted as a matter of law to the extent they &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;assert that Merck should have added a warning or precaution regarding atypical femur fractures prior to September 2010. Plaintiffs have indicated that they do not intend to move forward with any other claims at this point and intend to appeal the District Court&#x2019;s preemption ruling to the Third Circuit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Discovery is presently stayed in the Femur Fracture MDL. As part of the spin-off of Organon, Organon is required to indemnify Merck for all liabilities relating to, arising from, or resulting from the Fosamax Litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Januvia/Janumet&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed, Merck is a defendant in product liability lawsuits in the U.S. involving &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Januvia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (sitagliptin) and/or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (sitagliptin and metformin HCl). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Most claims were filed in multidistrict litigation before the U.S. District Court for the Southern District of California (MDL). In March 2021, the MDL court issued an omnibus order granting defendants&#x2019; summary judgment motions based on preemption and failure to establish general causation, as well as granting defendants&#x2019; motions to exclude plaintiffs&#x2019; expert witnesses. The plaintiffs appealed that order. Since that time, more than half of these claims have been dismissed with prejudice as to Merck, and in October 2021, the U.S. Court of Appeals for the Ninth Circuit dismissed the appeal as to Merck and two of its codefendants. The MDL court&#x2019;s judgment is now final and no longer appealable with respect to remaining claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outside of the MDL, the majority of claims were filed in coordinated proceedings before the Superior Court of California, County of Los Angeles (California State Court). On April 6, 2021, the court in California issued an omnibus order granting defendants&#x2019; summary judgment motions and also granting defendants&#x2019; motions to exclude plaintiffs&#x2019; expert witnesses. On May 31, 2022, the court entered judgment in favor of Merck as to all of the claims pending against Merck in that jurisdiction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the claims noted above, the Company has agreed to toll the statute of limitations for approximately 50 additional claims. The Company intends to continue defending against any remaining lawsuits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Gardasil/Gardasil 9&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Merck is a defendant in product liability lawsuits in the U.S. involving &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Gardasil &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant) and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Gardasil&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 9 (Human Papillomavirus 9-valent Vaccine, Recombinant). As of September&#160;30, 2022, approximately 65 cases were filed and pending against Merck in either federal or state court. In these actions, plaintiffs allege, among other things, that they suffered various personal injuries after vaccination with &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Gardasil &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Gardasil&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 9, with postural orthostatic tachycardia syndrome as a predominate alleged injury. In August 2022, the Judicial Panel on Multidistrict Litigation ordered that &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Gardasil/Gardasil&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 9 product liability cases pending in federal courts nationwide be transferred to Judge Robert J. Conrad in the Western District of North Carolina for coordinated pre-trial proceedings. There are fewer than 15 product liability cases pending outside the U.S., including one purported class action in Colombia.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Governmental Proceedings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed, from time to time, the Company&#x2019;s subsidiaries in China receive inquiries regarding their operations from various Chinese governmental agencies. Some of these inquiries may be related to matters involving other multinational pharmaceutical companies, as well as Chinese entities doing business with such companies. The Company&#x2019;s policy is to cooperate with these authorities and to provide responses as appropriate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed, from time to time, the Company receives inquiries and is the subject of preliminary investigation activities from competition and other governmental authorities in markets outside the U.S. These authorities may include regulators, administrative authorities, and law enforcement and other similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials, inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings. Should those proceedings be determined adversely to the Company, monetary fines and/or remedial undertakings may be required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Commercial and Other Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Zetia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Antitrust Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed, Merck, MSD, Schering Corporation, Schering-Plough Corporation, and MSP Singapore Company LLC (collectively, the Merck Defendants) are defendants in a number of lawsuits filed in 2018 on behalf of direct and indirect purchasers of Zetia (ezetimibe) alleging violations of federal and state antitrust laws, as well as other state statutory and common law causes of action. The cases were consolidated in a federal multidistrict litigation (the Zetia MDL) before Judge Rebecca Beach Smith in the Eastern District of Virginia.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2019, the direct purchaser plaintiffs and the indirect purchaser plaintiffs filed motions for class certification. In August 2020, the district court granted in part the direct purchasers&#x2019; motion for class certification and certified a class of 35 direct purchasers. In August 2021, the Fourth Circuit vacated the district court&#x2019;s class certification order and remanded for further proceedings consistent with the court&#x2019;s ruling. In September 2021, the direct purchaser plaintiffs filed a renewed motion for class certification. On January 25, 2022, the magistrate judge recommended that the district court deny the motion for class certification. On February 8, 2022, the direct purchaser plaintiffs filed objections to the recommendation. On April 13, 2022, the district court denied the direct purchaser plaintiffs&#x2019; renewed motion for class certification. In August 2021, the district court granted certification of a class of indirect purchasers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020 and 2021, United Healthcare Services, Inc., Humana Inc., Centene Corporation and others, and Kaiser Foundation Health Plan, Inc. (collectively, the Insurer Plaintiffs), each filed a lawsuit in a jurisdiction outside of the Eastern District of Virginia against the Merck Defendants and others, making similar allegations as those made in the Zetia MDL, as well as additional allegations about Vytorin. These cases have been transferred to the Eastern District of Virginia to proceed with the Zetia MDL.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 9, 2022, the Insurer Plaintiffs filed amended complaints. On March 2, 2022, the Merck Defendants, jointly with other defendants, moved to dismiss certain aspects of the Insurer Plaintiffs&#x2019; complaints, including any claims for Vytorin damages. That motion to dismiss the Vytorin-related claims is still pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2022, the direct purchaser plaintiffs moved for an order setting a deadline for direct purchasers of Zetia not currently parties to the case to file cases against defendants in order for those cases to be coordinated for trial with the existing direct purchaser plaintiffs and other MDL plaintiff groups. The court granted that motion, setting a deadline of June 30, 2022 for unnamed direct purchasers to file claims. On June 30, 2022, 23 new entities, many related, brought new complaints against defendants or otherwise sought to intervene. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 2, 2022, the Magistrate Judge issued a Report and Recommendation denying the Merck Defendants&#x2019; and Glenmark Defendants&#x2019; motions for summary judgment. Defendants have objected to the Report and Recommendation, and are awaiting a final decision from Judge Smith. The court has scheduled trial for all plaintiffs other than the Insurer Plaintiffs for April 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;340B Program Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Merck has filed a complaint in the U.S. District Court for the District of Columbia to challenge the letter Merck received from the Health Resources and Services Administration (HRSA) in May 2022 regarding Merck&#x2019;s 340B Program integrity initiative. HRSA&#x2019;s letter to Merck asserts that Merck is in violation of the 340B statute. HRSA further claims that continued failure to provide the 340B price to covered entities using contract pharmacies may result in civil monetary penalties for each instance of alleged overcharging, in addition to repayment for any instance of overcharging. The letter is very similar to letters HRSA has sent to other manufacturers, which letters have been held to be unlawful by multiple federal courts. Merck disagrees with HRSA&#x2019;s assertion. Merck remains committed to the 340B Program and to providing 340B discounts to eligible covered entities. Merck&#x2019;s 340B Program integrity initiative is consistent with the requirements of the 340B statute and is intended to ensure the integrity and sustainability of the 340B statute by reducing prohibited duplicate discounts and diversion and putting patients back at the center of the program. Merck continues to offer all of the Company&#x2019;s covered outpatient drugs to all 340B covered entities for purchase at or below the 340B ceiling price. On September 13, 2022, the court stayed the case pending the D.C. Circuit&#x2019;s ruling in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Novartis Pharmaceuticals Corp. v. Johnson and United Therapeutics Corp. v. Johnson&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, generic manufacturers of pharmaceutical products file abbreviated New Drug Applications (NDAs) with the FDA seeking to market generic forms of the Company&#x2019;s products prior to the expiration of relevant patents owned by the Company. To protect its patent rights, the Company may file patent infringement lawsuits against such generic companies. Similar lawsuits defending the Company&#x2019;s patent rights may exist in other countries. The Company intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. As with any litigation, there can be no assurance of the outcomes, which, if adverse, could result in significantly shortened periods of exclusivity for these products and, with respect to products acquired through acquisitions accounted for as business combinations, potentially significant intangible asset impairment charges.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bridion &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed, between January and November 2020, the Company received multiple Paragraph IV Certification Letters under the Hatch-Waxman Act notifying the Company that generic drug companies have filed applications to the FDA seeking pre-patent expiry approval to sell generic versions of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bridion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (sugammadex) Injection.&#160;In March, April and December 2020, the Company filed patent infringement lawsuits in the U.S. District Courts for the District of New Jersey and the Northern District of West Virginia against those generic companies.&#160;All actions in the District of New Jersey have been consolidated. These lawsuits, which assert one or more patents covering sugammadex and methods of using sugammadex, automatically stay FDA approval of the generic applications until June 2023 or until adverse court decisions, if &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;any, whichever may occur earlier. The West Virginia case was jointly dismissed with prejudice on August 8, 2022 in favor of proceeding in New Jersey. The remaining defendants in the New Jersey action have stipulated to infringement of the asserted claims and have stated they are withdrawing all remaining claims and defenses other than a defense seeking to shorten the patent term extension of the sugammadex patent to December 2022. In light of this, the U.S. District Court for the District of New Jersey cancelled the scheduled trial and scheduled a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81NS9mcmFnOjNiNDE0ZjBmNjBmMDQwMzliNDRkNjY1ODhlODBiYTcyL3RleHRyZWdpb246M2I0MTRmMGY2MGYwNDAzOWI0NGQ2NjU4OGU4MGJhNzJfMTY0OTI2NzQ4NjEyNg_dc252ca0-1f84-47f5-aa4a-e30b0bbfb328"&gt;one&lt;/span&gt;-day trial on December 19, 2022 on this remaining patent term extension calculation defense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has settled with five generic companies providing that these generic companies can bring their generic versions of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bridion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to the market in January 2026 (which may be delayed by any applicable pediatric exclusivity) or earlier under certain circumstances. The Company has agreed to stay the lawsuit filed against two generic companies, which in exchange agreed to be bound by a judgment on the merits of the consolidated action in the District of New Jersey. One of the generic companies in the consolidated action requested dismissal of the action against it and the Company did not oppose this request, which was subsequently granted by the court. The Company does not expect this company to bring its generic version of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bridion &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to the market before January 2026 or later, depending on any applicable pediatric exclusivity, unless the Company receives an adverse court decision.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Januvia, Janumet, Janumet XR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; As previously disclosed, the FDA has granted pediatric exclusivity with respect to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Januvia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet XR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (sitagliptin and metformin HCl extended-release), which provides a further six months of exclusivity in the U.S. beyond the expiration of all patents listed in the FDA&#x2019;s Orange Book. Adding this exclusivity to the term of the key patent protection extends exclusivity on these products to January 2023. However, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Januvia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet XR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; contain sitagliptin phosphate monohydrate and the Company has another patent covering certain phosphate salt and polymorphic forms of sitagliptin that expires in May 2027, including pediatric exclusivity (2027 salt/polymorph patent). In 2019, Par Pharmaceutical filed suit against the Company in the U.S. District Court for the District of New Jersey, seeking a declaratory judgment of invalidity of the 2027 salt/polymorph patent. In response, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Par Pharmaceutical and additional companies that also indicated an intent to market generic versions of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Januvia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet XR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; following expiration of key patent protection, but prior to the expiration of the 2027 salt/polymorph patent, and a later granted patent owned by the Company covering the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; formulation where its term plus the pediatric exclusivity ends in 2029. The Company also filed a patent infringement lawsuit against Mylan in the Northern District of West Virginia. The Judicial Panel on Multidistrict Litigation entered an order transferring the Company&#x2019;s lawsuit against Mylan to the U.S. District Court for the District of Delaware for coordinated and consolidated pretrial proceedings with the other cases pending in that district.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the beginning of the scheduled October 2021 trial in the U.S. District Court for the District of Delaware on invalidity issues, the Company settled with all defendants scheduled to participate in that trial. In the Company&#x2019;s case against Mylan, a bench trial was held in December 2021 in the U.S. District Court for the Northern District of West Virginia, and the closing arguments were held on April 13, 2022. On September 21, 2022, the District Court for the Northern District of West Virginia issued a decision in the Company&#x2019;s favor, upholding all asserted patent claims. Mylan (now Viatris) has appealed to the U.S. Court of Appeals for the Federal Circuit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In total, the Company has settled with 22 generic companies providing that these generic companies can bring their generic versions of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Januvia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to the market in May 2026 or earlier under certain circumstances, and their generic versions of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet XR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to the market in July 2026 or earlier under certain circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, in 2019, Mylan filed a petition for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;inter partes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; review (IPR) at the U.S. Patent and Trademark Office (USPTO) seeking invalidity of some, but not all, of the claims of the 2027 salt/polymorph patent. The USPTO instituted IPR proceedings in May 2020, finding a reasonable likelihood that the challenged claims are not valid. A trial was held in February 2021 and a final decision was rendered in May 2021, holding that all of the challenged claims were not invalid. Mylan appealed the USPTO&#x2019;s decision to the U.S. Court of Appeals for the Federal Circuit, and a hearing was held on August 2, 2022. On September 29, 2022, the Court of Appeals for the Federal Circuit ruled in the Company&#x2019;s favor, upholding the USPTO&#x2019;s decision.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2021, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc., and Cadila Healthcare Ltd. (collectively, Zydus). In that lawsuit, the Company alleged infringement of the 2027 salt/polymorph patent based on the filing of Zydus&#x2019;s application seeking approval of its sitagliptin tablets. While the U.S. District Court for the District of Delaware originally set a three-day bench trial in this matter beginning on October 31, 2022, the trial date has been moved to January 9, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Generic companies have sought revocation of the Supplementary Protection Certificate (SPC) for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in a number of European countries. In February 2022, a Finnish court referred certain questions to the Court of Justice of the European Union that could determine the validity of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; SPCs in Europe. In June 2021, a German court decided that the SPC for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is invalid, which decision the Company has appealed. The validity of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; SPC was upheld in the Czech Republic in March 2022 in a first instance decision, which has been appealed. In June 2022, a Romanian court decided &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;that the SPC for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was invalid in a first instance decision. In August 2022, the validity of the SPC for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was upheld in Sweden in a first instance decision, which decision has been appealed. MSD has filed injunction actions against generic companies in Belgium, Finland, France, Greece, Ireland and Portugal. In September 2022, the following decisions were issued: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ex-parte&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; preliminary injunctions were granted in Finland; a preliminary injunction was granted in France, and the validity of the SPC and the associated patent were held to be &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;prima facie&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; valid in these proceedings; and a temporary restraining order was granted in Greece. In October 2022, requests for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ex parte&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; preliminary injunctions were refused in Portugal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are various other pending legal proceedings involving the Company, principally product liability and intellectual property lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of the Company, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to the Company&#x2019;s financial condition, results of operations or cash flows either individually or in the aggregate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Legal Defense Reserves&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by the Company; the development of the Company&#x2019;s legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against the Company; the costs and outcomes of completed trials and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The amount of legal defense reserves as of September&#160;30, 2022 and December&#160;31, 2021 of approximately $230 million represents the Company&#x2019;s best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by the Company. The Company will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LegalCostsPolicyTextBlock
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81NS9mcmFnOjNiNDE0ZjBmNjBmMDQwMzliNDRkNjY1ODhlODBiYTcyL3RleHRyZWdpb246M2I0MTRmMGY2MGYwNDAzOWI0NGQ2NjU4OGU4MGJhNzJfMjU1NzM_512f0a15-2ec3-4351-9d34-84d931a1136f">Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.</us-gaap:LegalCostsPolicyTextBlock>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ib3ff202f9b6d48749d7758af33b9b823_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81NS9mcmFnOjNiNDE0ZjBmNjBmMDQwMzliNDRkNjY1ODhlODBiYTcyL3RleHRyZWdpb246M2I0MTRmMGY2MGYwNDAzOWI0NGQ2NjU4OGU4MGJhNzJfMjQzNg_77592c90-a843-4e15-82c6-b0165fe10e96"
      unitRef="case">3450</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyClaimsDismissedNumber
      contextRef="i367d0d796d80424da91051e66c46b38a_D20140301-20140331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81NS9mcmFnOjNiNDE0ZjBmNjBmMDQwMzliNDRkNjY1ODhlODBiYTcyL3RleHRyZWdpb246M2I0MTRmMGY2MGYwNDAzOWI0NGQ2NjU4OGU4MGJhNzJfMjgyMQ_33320ec5-e992-47f5-addb-2c68ee59107b"
      unitRef="case">650</us-gaap:LossContingencyClaimsDismissedNumber>
    <mrk:LossContingencyClaimsonAppealNumber
      contextRef="i367d0d796d80424da91051e66c46b38a_D20140301-20140331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81NS9mcmFnOjNiNDE0ZjBmNjBmMDQwMzliNDRkNjY1ODhlODBiYTcyL3RleHRyZWdpb246M2I0MTRmMGY2MGYwNDAzOWI0NGQ2NjU4OGU4MGJhNzJfMjg4MQ_63bc3c7e-eda7-4c35-9b0e-5b129ab30c2b"
      unitRef="case">515</mrk:LossContingencyClaimsonAppealNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="if701c2dad3a448b8baf48efce7ff3da8_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81NS9mcmFnOjNiNDE0ZjBmNjBmMDQwMzliNDRkNjY1ODhlODBiYTcyL3RleHRyZWdpb246M2I0MTRmMGY2MGYwNDAzOWI0NGQ2NjU4OGU4MGJhNzJfNzI2MA_b65ec96e-8330-4b38-8c65-5c1da52af88b"
      unitRef="claim">50</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i23dfb067c82241afa5f99f21bef689a1_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81NS9mcmFnOjNiNDE0ZjBmNjBmMDQwMzliNDRkNjY1ODhlODBiYTcyL3RleHRyZWdpb246M2I0MTRmMGY2MGYwNDAzOWI0NGQ2NjU4OGU4MGJhNzJfNTQ5NzU1ODQzODk4_bb9d0318-86e1-4dd5-a25e-5cc70ba5d89f"
      unitRef="case">65</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i3433b64365a54af2b3af67c46a542197_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81NS9mcmFnOjNiNDE0ZjBmNjBmMDQwMzliNDRkNjY1ODhlODBiYTcyL3RleHRyZWdpb246M2I0MTRmMGY2MGYwNDAzOWI0NGQ2NjU4OGU4MGJhNzJfNTQ5NzU1ODQzODk0_2c0e6c49-0753-4084-ac60-a15df8a4c756"
      unitRef="case">15</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ie980ee86472c42588cfeec3bc06a4e83_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81NS9mcmFnOjNiNDE0ZjBmNjBmMDQwMzliNDRkNjY1ODhlODBiYTcyL3RleHRyZWdpb246M2I0MTRmMGY2MGYwNDAzOWI0NGQ2NjU4OGU4MGJhNzJfMTY0OTI2NzQ4NjE0OQ_49dd8454-efdc-4fa7-aef2-131daa87f968"
      unitRef="case">1</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i5268335c17cf4ff1ba48ee77aa8846cb_I20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81NS9mcmFnOjNiNDE0ZjBmNjBmMDQwMzliNDRkNjY1ODhlODBiYTcyL3RleHRyZWdpb246M2I0MTRmMGY2MGYwNDAzOWI0NGQ2NjU4OGU4MGJhNzJfOTQ3Mw_b939c661-a4a0-4bbe-a880-5ad2d8df9536"
      unitRef="claim">35</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i5302423c142d450a83f2d69d472c5fd6_D20220630-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81NS9mcmFnOjNiNDE0ZjBmNjBmMDQwMzliNDRkNjY1ODhlODBiYTcyL3RleHRyZWdpb246M2I0MTRmMGY2MGYwNDAzOWI0NGQ2NjU4OGU4MGJhNzJfMTEzODk_841dc8a8-d5bf-4294-95a4-a8088b1cd7f4"
      unitRef="claim">23</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyClaimsSettledNumber
      contextRef="i5d703348a1634fdbb823234f6176f03a_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81NS9mcmFnOjNiNDE0ZjBmNjBmMDQwMzliNDRkNjY1ODhlODBiYTcyL3RleHRyZWdpb246M2I0MTRmMGY2MGYwNDAzOWI0NGQ2NjU4OGU4MGJhNzJfMTc4NTI_710dce89-11bb-4f76-b72a-f6b89b3f4dd8"
      unitRef="case">5</us-gaap:LossContingencyClaimsSettledNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i251ca90ae959435d934e00a6b5636367_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81NS9mcmFnOjNiNDE0ZjBmNjBmMDQwMzliNDRkNjY1ODhlODBiYTcyL3RleHRyZWdpb246M2I0MTRmMGY2MGYwNDAzOWI0NGQ2NjU4OGU4MGJhNzJfMTgxNDY_e9f97edf-cab1-4688-9248-4bf2922c92f0"
      unitRef="case">2</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyClaimsSettledNumber
      contextRef="ied8204c596b34fe69666b537c6dd68ed_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81NS9mcmFnOjNiNDE0ZjBmNjBmMDQwMzliNDRkNjY1ODhlODBiYTcyL3RleHRyZWdpb246M2I0MTRmMGY2MGYwNDAzOWI0NGQ2NjU4OGU4MGJhNzJfMjEyNjM_b313607b-2e23-48b9-a194-6442262f165e"
      unitRef="case">22</us-gaap:LossContingencyClaimsSettledNumber>
    <mrk:LossContingencyRecoveryFromThirdPartyBenchTrialPeriod
      contextRef="i623b3d56da7f44d9a270d2a0c4de1efe_D20230109-20230109"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81NS9mcmFnOjNiNDE0ZjBmNjBmMDQwMzliNDRkNjY1ODhlODBiYTcyL3RleHRyZWdpb246M2I0MTRmMGY2MGYwNDAzOWI0NGQ2NjU4OGU4MGJhNzJfMTY0OTI2NzQ4NjE3MQ_fbc8a1d9-ac8d-4f64-a8d8-7f92380ec80a">P3D</mrk:LossContingencyRecoveryFromThirdPartyBenchTrialPeriod>
    <us-gaap:LitigationReserve
      contextRef="i5e7203ee8afa4167bcbca2845a05174c_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81NS9mcmFnOjNiNDE0ZjBmNjBmMDQwMzliNDRkNjY1ODhlODBiYTcyL3RleHRyZWdpb246M2I0MTRmMGY2MGYwNDAzOWI0NGQ2NjU4OGU4MGJhNzJfMjQ5NDI_1b470a5a-1edb-4dfb-b3e6-ed4a31e86521"
      unitRef="usd">230000000</us-gaap:LitigationReserve>
    <us-gaap:LitigationReserve
      contextRef="iab20286c913c43ab9d138d102915562b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81NS9mcmFnOjNiNDE0ZjBmNjBmMDQwMzliNDRkNjY1ODhlODBiYTcyL3RleHRyZWdpb246M2I0MTRmMGY2MGYwNDAzOWI0NGQ2NjU4OGU4MGJhNzJfMjQ5NDI_43e5c687-7d9d-4758-b55c-52351d7aec0c"
      unitRef="usd">230000000</us-gaap:LitigationReserve>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RleHRyZWdpb246OGRkYzBmNDFhMjY1NDVmZGEyZTcwYmJiMTA5M2RhYmRfMzI_dc0b5d29-ca1d-4400-9b0b-aca9ab3688d7">Equity&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;br/&gt;Paid-In&lt;br/&gt;Capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Retained&lt;br/&gt;Earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Other&lt;br/&gt;Comprehensive&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Treasury Stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-&lt;br/&gt;controlling&lt;br/&gt;Interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ and shares in millions except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Par&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at July 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,628)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(56,682)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to Merck&#160;&amp;amp; Co., Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash dividends declared on common stock ($0.65 per share)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,653)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,653)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Treasury stock shares purchased&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(583)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(583)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation plans and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to noncontrolling interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Distributions attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,590)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(57,244)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at July 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,327)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(56,770)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to Merck&#160;&amp;amp; Co., Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(416)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(416)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash dividends declared on common stock ($0.69 per share)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,757)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,757)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation plans and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Distributions attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,743)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(56,758)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.747%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;br/&gt;Paid-In&lt;br/&gt;Capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Retained&lt;br/&gt;Earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Other&lt;br/&gt;Comprehensive&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Treasury Stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-&lt;br/&gt;controlling&lt;br/&gt;Interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ and shares in millions except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Par&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at January&#160;1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,634)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(56,787)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to Merck&#160;&amp;amp; Co., Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash dividends declared on common stock ($1.95 per share)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,962)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,962)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Treasury stock shares purchased&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(822)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(822)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Spin-off of Organon &amp;amp; Co.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation plans and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Distributions attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,590)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(57,244)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at January&#160;1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(57,109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to Merck&#160;&amp;amp; Co., Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(314)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(314)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash dividends declared on common stock ($2.07 per share)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,270)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,270)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation plans and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to noncontrolling interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Distributions attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,743)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(56,758)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityTableTextBlock
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RleHRyZWdpb246OGRkYzBmNDFhMjY1NDVmZGEyZTcwYmJiMTA5M2RhYmRfMzM_f6b46002-20a7-416d-9475-b7c88df56a41">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;br/&gt;Paid-In&lt;br/&gt;Capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Retained&lt;br/&gt;Earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Other&lt;br/&gt;Comprehensive&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Treasury Stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-&lt;br/&gt;controlling&lt;br/&gt;Interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ and shares in millions except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Par&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at July 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,628)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(56,682)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to Merck&#160;&amp;amp; Co., Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash dividends declared on common stock ($0.65 per share)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,653)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,653)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Treasury stock shares purchased&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(583)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(583)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation plans and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to noncontrolling interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Distributions attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,590)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(57,244)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at July 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,327)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(56,770)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to Merck&#160;&amp;amp; Co., Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(416)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(416)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash dividends declared on common stock ($0.69 per share)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,757)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,757)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation plans and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Distributions attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,743)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(56,758)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.747%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;br/&gt;Paid-In&lt;br/&gt;Capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Retained&lt;br/&gt;Earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Other&lt;br/&gt;Comprehensive&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Treasury Stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-&lt;br/&gt;controlling&lt;br/&gt;Interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ and shares in millions except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Par&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at January&#160;1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,634)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(56,787)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to Merck&#160;&amp;amp; Co., Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash dividends declared on common stock ($1.95 per share)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,962)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,962)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Treasury stock shares purchased&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(822)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(822)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Spin-off of Organon &amp;amp; Co.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation plans and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Distributions attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,590)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(57,244)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at January&#160;1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(57,109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to Merck&#160;&amp;amp; Co., Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(314)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(314)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash dividends declared on common stock ($2.07 per share)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,270)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,270)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation plans and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to noncontrolling interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Distributions attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,743)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(56,758)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityTableTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="i7dee7788157d45e1a5392aebf32b5f84_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMy0xLTEtMS05NDQxNA_64cb7ebf-b956-459c-ab4f-272d598710b8"
      unitRef="shares">3577000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7dee7788157d45e1a5392aebf32b5f84_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMy0yLTEtMS05NDQxNA_6cbcb773-b056-4377-bb21-eb8ff0cc6758"
      unitRef="usd">1788000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i769035208b1b48838e202af7a6565d8e_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMy0zLTEtMS05NDQxNA_993c98b9-7f97-437c-a6f0-6fe78de4d409"
      unitRef="usd">44039000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9efdb7d75087494cbe98cd19e691e3fa_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMy00LTEtMS05NDQxNA_98c8725c-5204-48f2-a164-ac7d904ef54e"
      unitRef="usd">48777000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if7e47c5bf82f40adb471e36675ba4ee6_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMy01LTEtMS05NDQxNA_1c123418-a297-49de-bad7-93e1666a028b"
      unitRef="usd">-4628000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="iaab9e1dfa7444fc3bae3cc093d6fe99b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMy02LTEtMS05NDQxNA_306e08d2-2eb8-4c3e-99a8-5a88992b3098"
      unitRef="shares">1044000000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaab9e1dfa7444fc3bae3cc093d6fe99b_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMy03LTEtMS05NDQxNA_fd5fa5ea-8435-4b43-bf64-44982b08be4a"
      unitRef="usd">-56682000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id23a801131ac4b8c945a76709e53ab57_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMy04LTEtMS05NDQxNA_f0969ec4-c269-4e18-9bbd-799e65d4fffe"
      unitRef="usd">94000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3afe38f10fec457498b49dc2c46ff07d_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMy05LTEtMS05NDQxNA_207c161b-0eea-4204-bd70-43c8aa26d6ff"
      unitRef="usd">33388000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="iff86b236dd274c4686ba706b239b2836_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfNC00LTEtMS05NDQxNA_935cd3d8-56bd-4883-9492-5d9176a67030"
      unitRef="usd">4567000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfNC05LTEtMS05NDQxNA_00bb8028-b325-4fc1-a42e-094c978b07d0"
      unitRef="usd">4567000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i2ecbfa0ca4994647873a7f5f0bd59cdd_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfNS01LTEtMS05NDQxNA_e59ed4da-bc76-4047-b871-358dbbab68e3"
      unitRef="usd">38000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfNS05LTEtMS05NDQxNA_6bb62076-8744-496f-a813-9676be94106f"
      unitRef="usd">38000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfNi0wLTEtMS05NDQxNC90ZXh0cmVnaW9uOjYwM2U1YzJjZWViZjQ4NjNhYmEwOGU0NDBhNWI4OTMwXzQ1_f4937f2e-e680-46e0-802d-48abaa2891f0"
      unitRef="usdPerShare">0.65</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="iff86b236dd274c4686ba706b239b2836_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfNi00LTEtMS05NDQxNA_20813833-cc57-4aa2-81c5-90c4de680434"
      unitRef="usd">1653000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfNi05LTEtMS05NDQxNA_7c06da24-b0b6-4772-81b3-988a6f7691ff"
      unitRef="usd">1653000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i8928a318d22448f497a03f892bcee237_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfNy02LTEtMS05NDQxNA_3956fbda-33b0-45a5-86fb-243b1531b2f4"
      unitRef="shares">8000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i8928a318d22448f497a03f892bcee237_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfNy03LTEtMS05NDQxNA_8ac8acfd-ef04-449c-8703-f38dfa1a305a"
      unitRef="usd">583000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfNy05LTEtMS05NDQxNA_3101acc4-ea16-440e-b465-83fcf8644179"
      unitRef="usd">583000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockholdersEquityOther
      contextRef="ia4df4b3c64fe4fa28360813d66561107_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfOS0zLTEtMS05NDQxNA_ffd24c37-3971-48f1-8e71-2043bb6ea067"
      unitRef="usd">-110000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i8928a318d22448f497a03f892bcee237_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfOS03LTEtMS05NDQxNA_712869c8-6591-4722-a435-80947f5261f4"
      unitRef="usd">-21000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfOS05LTEtMS05NDQxNA_eb76f829-5d7c-4004-8238-50376932b22f"
      unitRef="usd">-131000000</us-gaap:StockholdersEquityOther>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i5c45ff5f83594356b2993ac3c0f1c8c0_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTAtOC0xLTEtOTQ0MTQ_43e09d7b-84d9-4395-9999-98ed1f3aef3f"
      unitRef="usd">4000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTAtOS0xLTEtOTQ0MTQ_63212a31-4671-4627-8611-85b55434a18e"
      unitRef="usd">4000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i5c45ff5f83594356b2993ac3c0f1c8c0_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTAtOC0xLTEtOTc2MTg_a45417d6-fb83-44ae-b7db-cf8d862ce12d"
      unitRef="usd">29000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTAtOS0xLTEtOTc2MTg_58de95be-106c-4040-b035-733fc2b018d7"
      unitRef="usd">29000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:CommonStockSharesIssued
      contextRef="ie32bbd59665e48c4ab1a7a2fb3b32c83_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTEtMS0xLTEtOTQ0MTQ_22a8068b-1af8-435c-a1d5-fc3bb47f10c3"
      unitRef="shares">3577000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie32bbd59665e48c4ab1a7a2fb3b32c83_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTEtMi0xLTEtOTQ0MTQ_d50fb371-31b7-4a8e-ab6f-fa440c1169b5"
      unitRef="usd">1788000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib8d08e2935f04a3892dc8bf49cba95aa_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTEtMy0xLTEtOTQ0MTQ_5a83d7da-9206-4cf4-97bf-604c7c347152"
      unitRef="usd">44149000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ieeb453ea070a4057ad9c6dd3435f8906_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTEtNC0xLTEtOTQ0MTQ_4b8084da-750a-4dd8-b233-69330bc47047"
      unitRef="usd">51691000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i99c020a806d84d1cb9f8c8d97329cf8c_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTEtNS0xLTEtOTQ0MTQ_b866b508-abef-4da0-8b76-dd655411ce81"
      unitRef="usd">-4590000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i3750629558d54ed8b2491825206bbff1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTEtNi0xLTEtOTQ0MTQ_6bbbf776-f778-4999-ac3c-320ace91a4c7"
      unitRef="shares">1052000000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3750629558d54ed8b2491825206bbff1_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTEtNy0xLTEtOTQ0MTQ_544fea57-8620-4efb-b10e-047a237197e6"
      unitRef="usd">-57244000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4bec43526f964113b92ba5a981053063_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTEtOC0xLTEtOTQ0MTQ_9b1d0e38-97fe-4b2e-92ec-72372dd5689e"
      unitRef="usd">69000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i48930a09b1404293820fbeb015eb6729_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTEtOS0xLTEtOTQ0MTQ_f517c25e-2d89-47b4-b996-2588587f3749"
      unitRef="usd">35863000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="i6fc33f512e4c4f3dbfc4ffd56fbaacfb_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTItMS0xLTEtOTQ0MTQ_4634bc75-ebae-4f08-9a2f-3c4f9db01ade"
      unitRef="shares">3577000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6fc33f512e4c4f3dbfc4ffd56fbaacfb_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTItMi0xLTEtOTQ0MTQ_a3de8d53-4e78-42bb-a3dc-0103e925834f"
      unitRef="usd">1788000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i163092cff85f4f96832f89ece004f615_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTItMy0xLTEtOTQ0MTQ_4a713922-f129-4147-8172-53eac9444a84"
      unitRef="usd">44115000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i45e71d3b257b4deaa9068f76e93341ed_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTItNC0xLTEtOTQ0MTQ_da0b9ca0-503a-442f-bcf5-3fbbc667ea3b"
      unitRef="usd">58437000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9864609863b94d00aa7ba3ced3bea441_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTItNS0xLTEtOTQ0MTQ_b8918473-eabe-4d06-9545-0516ab77ce5a"
      unitRef="usd">-4327000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i6a2cf1e51feb4bf9bf40f48b1eb15164_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTItNi0xLTEtOTQ0MTQ_c7332946-f758-4f18-ba62-990d0eac4387"
      unitRef="shares">1044000000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6a2cf1e51feb4bf9bf40f48b1eb15164_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTItNy0xLTEtOTQ0MTQ_c7c83b29-3a35-46ac-a0d2-3af4284f82d3"
      unitRef="usd">-56770000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia75bfa90c3194a5d875d56f842b27bff_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTItOC0xLTEtOTQ0MTQ_16687ab0-4553-4ef4-9868-7f334c9aaeaa"
      unitRef="usd">75000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0d5f781c87ab40f58ea21a9500d8154a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTItOS0xLTEtOTQ0MTQ_09c0a655-c44d-4dda-9646-7867a2607e6d"
      unitRef="usd">43318000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="if014c4b837bd4c0d8e2b84afeadf9c75_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTMtNC0xLTEtOTQ0MTQ_54dfe33f-4aa2-4064-8f22-6a21ede5691a"
      unitRef="usd">3248000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTMtOS0xLTEtOTQ0MTQ_1a5d239b-8cbb-4687-99a9-7ce53e261129"
      unitRef="usd">3248000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if2a2791bc9db4ced8a0f57eebcf50852_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTQtNS0xLTEtOTQ0MTQ_b3a0079e-76ae-44bd-9b8e-a35ac4e8cf0d"
      unitRef="usd">-416000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTQtOS0xLTEtOTQ0MTQ_78589d84-f26a-421d-9e43-19ba9828bbba"
      unitRef="usd">-416000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTUtMC0xLTEtOTQ0MTQvdGV4dHJlZ2lvbjoyYzQxYThhNzE3NzA0Nzc3OTA2MmU4N2ZkYzlmODQ4Ml80NQ_d000e483-56f7-4a63-b43e-b2af0c488eec"
      unitRef="usdPerShare">0.69</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="if014c4b837bd4c0d8e2b84afeadf9c75_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTUtNC0xLTEtOTQ0MTQ_c33b732a-5c06-4291-926c-12fa07cd7e5c"
      unitRef="usd">1757000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTUtOS0xLTEtOTQ0MTQ_ea96325a-4cf0-4b8d-9a19-378197a935a8"
      unitRef="usd">1757000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:StockholdersEquityOther
      contextRef="i9706bcf110ad4f7e9558da712a96dfba_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTYtMy0xLTEtOTQ0MTQ_d45054b2-6877-4eb0-b87f-a7449ba41dab"
      unitRef="usd">-128000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i6c57e5ba569c45d99424f3d170f677b8_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTYtNy0xLTEtOTQ0MTQ_2b04d0a5-b044-4b56-b737-0866363999de"
      unitRef="usd">-12000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTYtOS0xLTEtOTQ0MTQ_8eb3149b-eb0f-41d8-8a48-124be35d9235"
      unitRef="usd">-140000000</us-gaap:StockholdersEquityOther>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ib76e902784e74151b5da455c02992dd8_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTctOC0xLTEtOTQ0MTQ_90085d68-36aa-4eea-be9d-0833ba0af4b8"
      unitRef="usd">5000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTctOS0xLTEtOTQ0MTQ_59f70184-5b3c-4bfd-8017-e8141359694b"
      unitRef="usd">5000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ib76e902784e74151b5da455c02992dd8_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTgtOC0xLTEtMTA1NDM0_7ad073cd-df25-4367-b1b6-4c49b88406f8"
      unitRef="usd">14000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTgtOS0xLTEtMTA1NDM0_6a8fd511-aea8-4917-9c84-1007a8785701"
      unitRef="usd">14000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:CommonStockSharesIssued
      contextRef="if3d50d8ac75f45d487c729ce8817f47e_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTgtMS0xLTEtOTQ0MTQ_5c6169f5-f203-4320-b3f3-d102c5321716"
      unitRef="shares">3577000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if3d50d8ac75f45d487c729ce8817f47e_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTgtMi0xLTEtOTQ0MTQ_a70dbea4-8a9c-4f8f-b646-8f86396d4402"
      unitRef="usd">1788000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i01a43e0ab33146bcad94c2c546eac8bf_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTgtMy0xLTEtOTQ0MTQ_086bf1d5-77ac-416b-9a91-2ebcc030cc92"
      unitRef="usd">44243000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0fb137c2da28404fade360f5042d137a_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTgtNC0xLTEtOTQ0MTQ_f6f9fcb0-4812-4919-a50c-cda1bbb3f32e"
      unitRef="usd">59928000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie0803cc4f2c64fa7a8e0196a811eaf28_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTgtNS0xLTEtOTQ0MTQ_f9b978ba-2098-4659-8bd8-05da9a2b4fc2"
      unitRef="usd">-4743000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="ia6aaba1fa4024e1cae697b7460337046_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTgtNi0xLTEtOTQ0MTQ_03ad54b7-3d40-4934-8d1d-2f2405d14fe5"
      unitRef="shares">1044000000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia6aaba1fa4024e1cae697b7460337046_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTgtNy0xLTEtOTQ0MTQ_684c33f7-b97f-4d63-8af6-5112088818f6"
      unitRef="usd">-56758000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia63f0e081f0a42f198e5d12dcd18cba3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTgtOC0xLTEtOTQ0MTQ_7329a9fa-27ac-446e-b832-88350499a6d7"
      unitRef="usd">66000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjUwNTFlNDAwZDcyNjQzYTZhNDgwMzUzMTgyYzlkMjQ5L3RhYmxlcmFuZ2U6NTA1MWU0MDBkNzI2NDNhNmE0ODAzNTMxODJjOWQyNDlfMTgtOS0xLTEtOTQ0MTQ_dded5457-ec65-451d-8181-ae220e96d621"
      unitRef="usd">44524000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="ie8266a2de763495e917e7346aae13f81_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMy0xLTEtMS05NDQxNA_ece24c35-bf41-4e10-af5b-92fdf5323866"
      unitRef="shares">3577000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie8266a2de763495e917e7346aae13f81_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMy0yLTEtMS05NDQxNA_3ef8a692-16f1-4fca-95f8-a349d47384fb"
      unitRef="usd">1788000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i46979b5fbfcf4bcfbe34ca9f2816df20_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMy0zLTEtMS05NDQxNA_d8505f3d-c15c-4015-a4cd-0297cd40fbbf"
      unitRef="usd">39588000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idb58c93066b54a02965539a527ce9165_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMy00LTEtMS05NDQxNA_d03bcfa3-e650-44de-8652-6b6b6ee5680a"
      unitRef="usd">47362000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i93d7029f006b4d91a535c2e9905f5a89_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMy01LTEtMS05NDQxNA_e18eb790-a4ef-4a83-982f-d00cb85c9927"
      unitRef="usd">-6634000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="ibf444f353af04455b87e388e584fc395_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMy02LTEtMS05NDQxNA_57732c9e-d49e-4043-9dca-f639d0a10d93"
      unitRef="shares">1047000000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibf444f353af04455b87e388e584fc395_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMy03LTEtMS05NDQxNA_4743bd07-11f0-492c-a84b-9d9006703647"
      unitRef="usd">-56787000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icc4cef6237e84b5f977c6f638148d150_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMy04LTEtMS05NDQxNA_ce443f96-ffb6-4c4c-b46f-e55910d05ad7"
      unitRef="usd">87000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6b76c3e2ce274f17b07c82ae1459e9f9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMy05LTEtMS05NDQxNA_9c63082e-973a-442c-8259-94c5f89cf079"
      unitRef="usd">25404000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="idfb7a35d7d0e432f9e66dd2215b3116e_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfNC00LTEtMS05NDQxNA_827372d1-360f-4377-89f0-51021862e3f8"
      unitRef="usd">9291000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfNC05LTEtMS05NDQxNA_e8e2709d-5286-46bd-b5f2-6024bfcd2809"
      unitRef="usd">9291000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i43d9233de62a46b78fb5fdd056a05478_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfNS01LTEtMS05NDQxNA_25c415c5-f360-4fd1-a918-e7fa71ba390e"
      unitRef="usd">1595000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfNS05LTEtMS05NDQxNA_57f25084-cdbc-4cc7-a21d-05e24db44834"
      unitRef="usd">1595000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfNi0wLTEtMS05NDQxNC90ZXh0cmVnaW9uOjdhYWVjNTI1NzczZjRjY2FiZjQ1NmJjZTY1OWM4YzM1XzQ1_abaab81d-6f92-4dd7-936d-627d0767878d"
      unitRef="usdPerShare">1.95</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="idfb7a35d7d0e432f9e66dd2215b3116e_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfNi00LTEtMS05NDQxNA_72a2a40f-c669-4840-ab35-48ad3d215586"
      unitRef="usd">4962000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfNi05LTEtMS05NDQxNA_a4e9ce11-504f-46d9-9acb-461b1aed1656"
      unitRef="usd">4962000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="iac51e60463f94de2b9a560820ae84413_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfNy02LTEtMS05NDQxNA_98e114ef-7764-4051-900c-56a800782a24"
      unitRef="shares">11000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="iac51e60463f94de2b9a560820ae84413_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfNy03LTEtMS05NDQxNA_1bb62bc2-f45e-49f0-9f2d-79af83cf0510"
      unitRef="usd">822000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfNy05LTEtMS05NDQxNA_cf13cefa-fb18-4c60-a257-1cd6d822dd12"
      unitRef="usd">822000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction
      contextRef="i8a2bd52c5dca47a292248a21f88ae298_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfOC0zLTEtMS05NDQxNA_5732fda2-ec7b-484c-8dac-bc88d888017e"
      unitRef="usd">4643000000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction
      contextRef="i43d9233de62a46b78fb5fdd056a05478_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfOC01LTEtMS05NDQxNA_525af297-2d98-46ab-bea0-c3ff60a987ef"
      unitRef="usd">449000000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction
      contextRef="ib23f7298a6c6404c9b917d37bd3494f3_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfOC04LTEtMS05NDQxNA_3964beae-4c3f-4434-b99c-7cdfba6e7aeb"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfOC05LTEtMS05NDQxNA_3e81aef1-182a-47dc-97b8-e9188f636322"
      unitRef="usd">5091000000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:StockholdersEquityOther
      contextRef="i8a2bd52c5dca47a292248a21f88ae298_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfOS0zLTEtMS05NDQxNA_c053aa3d-4de4-4465-a1f9-19f68dd09be4"
      unitRef="usd">82000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="iac51e60463f94de2b9a560820ae84413_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfOS02LTEtMS05NDQxNA_15ed690c-1a4d-4ea8-9c61-a7a75dd4dc79"
      unitRef="shares">6000000</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOther
      contextRef="iac51e60463f94de2b9a560820ae84413_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfOS03LTEtMS05NDQxNA_b6363215-e046-451f-bf6e-eda60543c007"
      unitRef="usd">-365000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfOS05LTEtMS05NDQxNA_835e7024-bb4e-4bca-8080-396c670026c1"
      unitRef="usd">-283000000</us-gaap:StockholdersEquityOther>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ib23f7298a6c6404c9b917d37bd3494f3_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTAtOC0xLTEtOTQ0MTQ_884eaec3-b853-498c-a35e-23d05dfa660f"
      unitRef="usd">12000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTAtOS0xLTEtOTQ0MTQ_aa3b9244-fbbb-4b92-ae23-859cc190feff"
      unitRef="usd">12000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ib23f7298a6c6404c9b917d37bd3494f3_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTEtOC0xLTEtOTc5MDI_3fb1e46b-5d73-471b-af76-9c8029b8768b"
      unitRef="usd">29000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTEtOS0xLTEtOTc5MTI_464178c4-d341-479c-944d-4db2bba1b95f"
      unitRef="usd">29000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:CommonStockSharesIssued
      contextRef="ie32bbd59665e48c4ab1a7a2fb3b32c83_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTEtMS0xLTEtOTQ0MTQ_2845172d-aaf1-4a2b-9337-31960dc1bf3e"
      unitRef="shares">3577000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie32bbd59665e48c4ab1a7a2fb3b32c83_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTEtMi0xLTEtOTQ0MTQ_87a4f501-28c5-4d75-9830-42ee166d1545"
      unitRef="usd">1788000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib8d08e2935f04a3892dc8bf49cba95aa_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTEtMy0xLTEtOTQ0MTQ_4052df59-8ba1-4b71-a45c-e718a93ff4a2"
      unitRef="usd">44149000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ieeb453ea070a4057ad9c6dd3435f8906_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTEtNC0xLTEtOTQ0MTQ_c4694d9f-86e4-4612-988d-10446901692d"
      unitRef="usd">51691000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i99c020a806d84d1cb9f8c8d97329cf8c_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTEtNS0xLTEtOTQ0MTQ_755db335-8572-4558-a20f-db3d0c2d6b78"
      unitRef="usd">-4590000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i3750629558d54ed8b2491825206bbff1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTEtNi0xLTEtOTQ0MTQ_f1dd91a2-26a9-436e-875c-23fab4ca3ff6"
      unitRef="shares">1052000000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3750629558d54ed8b2491825206bbff1_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTEtNy0xLTEtOTQ0MTQ_45bdf8bf-c6c6-4635-9036-9e6f88c4448c"
      unitRef="usd">-57244000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4bec43526f964113b92ba5a981053063_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTEtOC0xLTEtOTQ0MTQ_99edf337-542f-46e6-9f6a-5e11127169a9"
      unitRef="usd">69000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i48930a09b1404293820fbeb015eb6729_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTEtOS0xLTEtOTQ0MTQ_8c32535a-2581-4935-b062-05411c0f701b"
      unitRef="usd">35863000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="i58a9ea166bd8462bb92f1bde0e0c38ed_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTItMS0xLTEtOTQ0MTQ_50a65c00-23ff-4d83-ac31-5c2ae3cbcc07"
      unitRef="shares">3577000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i58a9ea166bd8462bb92f1bde0e0c38ed_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTItMi0xLTEtOTQ0MTQ_e9a4c8c2-094a-46b8-9954-5da0f4b3c03a"
      unitRef="usd">1788000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i54fbdd4b47aa41a69dfd52ac2443383f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTItMy0xLTEtOTQ0MTQ_5fb54794-7ce3-4ea3-83f5-59e64d0a2ad0"
      unitRef="usd">44238000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idf1f3c1c1c05447abdc62cc369de9b5f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTItNC0xLTEtOTQ0MTQ_81309222-3b6b-44f1-b5ac-3bf64a350c2c"
      unitRef="usd">53696000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i54f6686da6db4e38aeb2e4b266dc881f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTItNS0xLTEtOTQ0MTQ_c26beb8c-5bbb-4ed4-92dc-8409c16733f6"
      unitRef="usd">-4429000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="id2b77295046047d1b7a851bf3bc457b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTItNi0xLTEtOTQ0MTQ_cede6346-a99e-4e31-b5be-7d5f5ce34c68"
      unitRef="shares">1049000000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id2b77295046047d1b7a851bf3bc457b3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTItNy0xLTEtOTQ0MTQ_cf7b990f-9930-40a0-87bf-4b69fe70bcb1"
      unitRef="usd">-57109000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifb6e56eb418d416f86418139727649f6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTItOC0xLTEtOTQ0MTQ_8df27c0e-e0fb-49ee-8e4b-168a20515900"
      unitRef="usd">73000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib9490e02538244c88fb94e67f0f84467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTItOS0xLTEtOTQ0MTQ_f9fefd90-0b0c-4037-a026-02e10e6df889"
      unitRef="usd">38257000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i69b491e8b3b84d76b979f1d2543f1bec_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTMtNC0xLTEtOTQ0MTQ_68d04d04-8efc-40bf-9946-425e2143f9dc"
      unitRef="usd">11502000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTMtOS0xLTEtOTQ0MTQ_2ceddacb-32a9-452f-8cbf-59f7d490b468"
      unitRef="usd">11502000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="idd52fe4f8612434abba6e97f4c0f64e5_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTQtNS0xLTEtOTQ0MTQ_cb820084-0fac-4620-a415-59a328088967"
      unitRef="usd">-314000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTQtOS0xLTEtOTQ0MTQ_15da704b-693b-4169-ab73-7874704a32c5"
      unitRef="usd">-314000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTUtMC0xLTEtOTQ0MTQvdGV4dHJlZ2lvbjpjMTIyODUzMDU1ZGY0OWUwOGNkZjUwMWM5ZDgyOTJmMV80NQ_b5ad7427-749a-493d-accb-319ab602b6c6"
      unitRef="usdPerShare">2.07</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="i69b491e8b3b84d76b979f1d2543f1bec_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTUtNC0xLTEtOTQ0MTQ_410485d1-fce8-4e39-928f-390db62864ff"
      unitRef="usd">5270000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTUtOS0xLTEtOTQ0MTQ_ee51f1d6-2c3c-496a-84e6-e59b1c01fafe"
      unitRef="usd">5270000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:StockholdersEquityOther
      contextRef="i398ce1837bda4dd2867a24cf3db019b2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTctMy0xLTEtOTQ0MTQ_23a59ddb-1cb0-4030-91cd-4d6883ad777e"
      unitRef="usd">-5000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="iac4516ad133342f381e01ac656921924_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTctNi0xLTEtOTQ0MTQ_250dc3c6-1c27-46d5-9c84-f38f2139fc06"
      unitRef="shares">5000000</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOther
      contextRef="iac4516ad133342f381e01ac656921924_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTctNy0xLTEtOTQ0MTQ_7b435ce7-d26a-4c6a-8b28-c672f9587009"
      unitRef="usd">-351000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTctOS0xLTEtOTQ0MTQ_af2af770-19da-44f8-8672-c68d3eca9bd3"
      unitRef="usd">-356000000</us-gaap:StockholdersEquityOther>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i65949c6818b4456e8bda505693b348eb_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTgtOC0xLTEtOTQ0MTQ_457ff5dc-787a-4b6e-997a-042898e3f91b"
      unitRef="usd">6000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTgtOS0xLTEtOTQ0MTQ_7a200c6e-e72c-4ecf-9e18-48308114cad6"
      unitRef="usd">6000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i65949c6818b4456e8bda505693b348eb_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTktOC0xLTEtOTQ0MTQ_e55ee3d8-9560-4b94-9240-f3ff442b15a7"
      unitRef="usd">13000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMTktOS0xLTEtOTQ0MTQ_89861775-2830-44d4-a633-e615a57ab6cb"
      unitRef="usd">13000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:CommonStockSharesIssued
      contextRef="if3d50d8ac75f45d487c729ce8817f47e_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMjAtMS0xLTEtOTQ0MTQ_37608e41-4a51-4188-bf73-0429a76e3561"
      unitRef="shares">3577000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if3d50d8ac75f45d487c729ce8817f47e_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMjAtMi0xLTEtOTQ0MTQ_f0f111fb-9813-4fcb-8e6b-6bc28f7378ce"
      unitRef="usd">1788000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i01a43e0ab33146bcad94c2c546eac8bf_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMjAtMy0xLTEtOTQ0MTQ_c85342ac-86b0-4ffe-a42f-476ae0a813c0"
      unitRef="usd">44243000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0fb137c2da28404fade360f5042d137a_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMjAtNC0xLTEtOTQ0MTQ_65328f76-191a-4c59-98c6-9a243b9a04a0"
      unitRef="usd">59928000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie0803cc4f2c64fa7a8e0196a811eaf28_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMjAtNS0xLTEtOTQ0MTQ_6c24c916-6fae-411b-a08f-34685e870138"
      unitRef="usd">-4743000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="ia6aaba1fa4024e1cae697b7460337046_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMjAtNi0xLTEtOTQ0MTQ_9adfa049-f322-4b7a-bc4d-8c91480dc60e"
      unitRef="shares">1044000000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia6aaba1fa4024e1cae697b7460337046_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMjAtNy0xLTEtOTQ0MTQ_83d1211b-c189-4193-aa33-29e61988c3f7"
      unitRef="usd">-56758000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia63f0e081f0a42f198e5d12dcd18cba3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMjAtOC0xLTEtOTQ0MTQ_b7263505-df6c-4508-b3a9-d1dc57829552"
      unitRef="usd">66000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81OC9mcmFnOjhkZGMwZjQxYTI2NTQ1ZmRhMmU3MGJiYjEwOTNkYWJkL3RhYmxlOjgyMTJhZjFjNDQ1NDQ0OTU5ZDM2ZTRjZDcyMTQ2YjM0L3RhYmxlcmFuZ2U6ODIxMmFmMWM0NDU0NDQ5NTlkMzZlNGNkNzIxNDZiMzRfMjAtOS0xLTEtOTQ0MTQ_5dcd6f53-6298-408a-b709-d9800eb66a9e"
      unitRef="usd">44524000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RleHRyZWdpb246MjRmZDBlZmNhYWM2NDIxMTg2Mzg3NTJkNzhiNzZkZWVfMjIzNA_95e59c73-c528-458a-a46e-75069d3ed68c">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has defined benefit pension plans covering eligible employees in the U.S. and in certain of its international subsidiaries. The net periodic benefit cost of such plans (including certain costs reported as part of discontinued operations in the first nine months of 2021) consisted of the following components:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.096%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(182)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(93)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(188)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(576)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(292)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(568)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(313)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of unrecognized prior service credit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Curtailments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides medical benefits, principally to its eligible U.S. retirees and similar benefits to their dependents, through its other postretirement benefit plans. The net credit of such plans consisted of the following components:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.947%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of unrecognized prior service credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net gain amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Curtailments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net periodic benefit cost (credit) for pension and other postretirement benefit plans in the first nine months of 2021 includes expenses for curtailments, settlements and termination benefits provided to certain employees in connection with the spin-off of Organon.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with restructuring actions (see Note&#160;5), termination charges were recorded on pension plans related to expanded eligibility for certain employees e&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;x&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;iting Merck. Also, in connection with these restructuring activities, curtailments and settlements were recorded on certain pension plans. In addition, lump sum payments to U.S. pension plan participants triggered partial settlement charges in the third quarter and first nine months of 2022 and 2021. These partial settlements triggered remeasurements of some of the Company&#x2019;s U.S. pension plans. The third quarter 2022 remeasurement, which was calculated using discount rates and asset values as of September 30, 2022, resulted in a net increase of $296&#160;million to net pension liabilities and also resulted in a related adjustment to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AOCL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Remeasurements during the first nine months of 2022 have resulted in a net increase of $131&#160;million to net pension liabilities with related adjustments to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AOCL.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of net periodic benefit cost (credit) other than the service cost component are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (see Note&#160;12), with the exception of certain amounts for termination benefits, curtailments and settlements, which are recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restructuring costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; if the event giving rise to the termination benefits, curtailment or settlement is related to restructuring actions or in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; if related to the spin-off of Organon (each as noted above).&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:ScheduleOfNetBenefitCostsTableTextBlock
      contextRef="i320809a777744dfdb73841889368aa2c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RleHRyZWdpb246MjRmZDBlZmNhYWM2NDIxMTg2Mzg3NTJkNzhiNzZkZWVfMjIyOA_46693c5f-ee68-4db3-bad3-bc36995b4483">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has defined benefit pension plans covering eligible employees in the U.S. and in certain of its international subsidiaries. The net periodic benefit cost of such plans (including certain costs reported as part of discontinued operations in the first nine months of 2021) consisted of the following components:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.096%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(182)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(93)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(188)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(576)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(292)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(568)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(313)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of unrecognized prior service credit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Curtailments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetBenefitCostsTableTextBlock>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i09a399429407463c94fb6f4a770e06ca_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfMy0xLTEtMS05NDQxNA_e028775b-d79b-4fa3-b847-a6d74b67bfb7"
      unitRef="usd">91000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ia48fc689e3e9494a8b708e96f1579dd7_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfMy0zLTEtMS05NDQxNA_1e922a99-5ef7-4506-aa9a-97fb9b638228"
      unitRef="usd">66000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i37b081294e5b4b8e9e5a11799924a2f4_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfMy01LTEtMS05NDQxNA_93d3cec8-7912-4018-a22d-ab11627771cb"
      unitRef="usd">104000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i129ad2aa2cbf44d79bda671ff94c6b3a_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfMy03LTEtMS05NDQxNA_26f329c9-53f3-4355-bf45-1911d80e4fbb"
      unitRef="usd">75000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i3f56c3589dcf455e940e768c35266f9a_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfMy05LTEtMS05NDQxNA_5218432c-191d-42cf-82ed-28e9c371fa98"
      unitRef="usd">289000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i3f795846dbf2495a9b51d25b57687dbd_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfMy0xMS0xLTEtOTQ0MTQ_853cb53b-c9c5-4caf-a7dd-e39de40ddce2"
      unitRef="usd">213000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i113e99a5148f4c19a209d84850a178e7_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfMy0xMy0xLTEtOTQ0MTQ_ba92644e-3c47-4b18-b66d-ab1565f55324"
      unitRef="usd">302000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i49a0549eef484d24b04fa8fcdb43efe2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfMy0xNS0xLTEtOTQ0MTQ_23d20afb-0430-4f61-bf21-56b5cc4dd4ce"
      unitRef="usd">254000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i09a399429407463c94fb6f4a770e06ca_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNC0xLTEtMS05NDQxNA_2760b5f8-eac9-4938-a139-93c3b3ff21fb"
      unitRef="usd">123000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ia48fc689e3e9494a8b708e96f1579dd7_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNC0zLTEtMS05NDQxNA_5e83ab7d-3ea6-4f7e-9593-3fece5019c77"
      unitRef="usd">35000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i37b081294e5b4b8e9e5a11799924a2f4_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNC01LTEtMS05NDQxNA_2822a217-c7ad-4f92-b96a-58e8479637f3"
      unitRef="usd">102000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i129ad2aa2cbf44d79bda671ff94c6b3a_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNC03LTEtMS05NDQxNA_48349d79-fa42-474c-92a1-02c4113a530f"
      unitRef="usd">33000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i3f56c3589dcf455e940e768c35266f9a_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNC05LTEtMS05NDQxNA_f322edf9-ba17-4c67-a59f-c56b0323ffc6"
      unitRef="usd">330000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i3f795846dbf2495a9b51d25b57687dbd_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNC0xMS0xLTEtOTQ0MTQ_f41fd58f-55db-4fb7-b258-06565c816a77"
      unitRef="usd">110000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i113e99a5148f4c19a209d84850a178e7_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNC0xMy0xLTEtOTQ0MTQ_7dd257d1-1586-4aa9-bf66-c82c5b6e9391"
      unitRef="usd">305000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i49a0549eef484d24b04fa8fcdb43efe2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNC0xNS0xLTEtOTQ0MTQ_b64cd2d1-0d08-4965-bb85-bf9318f04551"
      unitRef="usd">92000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i09a399429407463c94fb6f4a770e06ca_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNS0xLTEtMS05NDQxNA_6bf01b6c-7e53-46db-ab7d-6b365d68a69a"
      unitRef="usd">182000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ia48fc689e3e9494a8b708e96f1579dd7_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNS0zLTEtMS05NDQxNA_1b91a374-2c0b-488b-bddb-74a97131794b"
      unitRef="usd">93000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i37b081294e5b4b8e9e5a11799924a2f4_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNS01LTEtMS05NDQxNA_c16fe4dd-489f-479b-9659-e1043cbe83e7"
      unitRef="usd">188000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i129ad2aa2cbf44d79bda671ff94c6b3a_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNS03LTEtMS05NDQxNA_7ae9c7d6-5cda-4084-84c5-d4c7c58451a1"
      unitRef="usd">105000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i3f56c3589dcf455e940e768c35266f9a_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNS05LTEtMS05NDQxNA_f24ac7a1-b261-42bd-bfcc-4c8aec94ca4b"
      unitRef="usd">576000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i3f795846dbf2495a9b51d25b57687dbd_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNS0xMS0xLTEtOTQ0MTQ_e99164fa-5e44-4b78-8dd3-0238965e6c23"
      unitRef="usd">292000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i113e99a5148f4c19a209d84850a178e7_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNS0xMy0xLTEtOTQ0MTQ_c9e349a3-e4bd-4a33-bdc9-a01cb0d1b009"
      unitRef="usd">568000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i49a0549eef484d24b04fa8fcdb43efe2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNS0xNS0xLTEtOTQ0MTQ_609456b7-f1c9-494d-b67a-ccf15109bbb9"
      unitRef="usd">313000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i09a399429407463c94fb6f4a770e06ca_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNi0xLTEtMS05NDQxNA_f02a11cb-6e8b-4b77-b35f-c408e378bb30"
      unitRef="usd">-8000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ia48fc689e3e9494a8b708e96f1579dd7_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNi0zLTEtMS05NDQxNA_1967749b-9ec9-4865-9f49-1c912f66f723"
      unitRef="usd">-3000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i37b081294e5b4b8e9e5a11799924a2f4_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNi01LTEtMS05NDQxNA_ac93615b-ff91-4db9-9995-585917e936ad"
      unitRef="usd">-9000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i129ad2aa2cbf44d79bda671ff94c6b3a_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNi03LTEtMS05NDQxNA_0f26add7-9145-47d5-9a8e-f44e4f9e8971"
      unitRef="usd">-3000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i3f56c3589dcf455e940e768c35266f9a_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNi05LTEtMS05NDQxNA_b9a9e1f3-2ef3-4a72-9b4c-2201874be3c5"
      unitRef="usd">-24000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i3f795846dbf2495a9b51d25b57687dbd_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNi0xMS0xLTEtOTQ0MTQ_e7c20c15-c139-4115-ab92-171f2e58fdf4"
      unitRef="usd">-10000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i113e99a5148f4c19a209d84850a178e7_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNi0xMy0xLTEtOTQ0MTQ_157a50ec-2dda-41f2-9299-034acd37da81"
      unitRef="usd">-29000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i49a0549eef484d24b04fa8fcdb43efe2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNi0xNS0xLTEtOTQ0MTQ_9841aaaf-1317-4471-8f8d-af957bf5aa6b"
      unitRef="usd">-12000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i09a399429407463c94fb6f4a770e06ca_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNy0xLTEtMS05NDQxNA_a3d8d25e-7a26-41ca-aa89-2260a9e8eb9a"
      unitRef="usd">-10000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="ia48fc689e3e9494a8b708e96f1579dd7_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNy0zLTEtMS05NDQxNA_202031b9-c6cb-42dd-b414-fbea6b81621c"
      unitRef="usd">-24000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i37b081294e5b4b8e9e5a11799924a2f4_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNy01LTEtMS05NDQxNA_fefa716e-6826-4f64-a248-ba70c914334c"
      unitRef="usd">-75000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i129ad2aa2cbf44d79bda671ff94c6b3a_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNy03LTEtMS05NDQxNA_fa63113d-cbb4-4189-bbfe-e86f9d39913e"
      unitRef="usd">-32000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i3f56c3589dcf455e940e768c35266f9a_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNy05LTEtMS05NDQxNA_96bdb878-233d-4a54-94c2-7c280233cdc2"
      unitRef="usd">-122000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i3f795846dbf2495a9b51d25b57687dbd_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNy0xMS0xLTEtOTQ0MTQ_f7ee1735-0fc7-4141-ab15-a803db990db6"
      unitRef="usd">-73000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i113e99a5148f4c19a209d84850a178e7_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNy0xMy0xLTEtOTQ0MTQ_0fe1c20f-4c8e-4989-adf2-821a9db60ba3"
      unitRef="usd">-218000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i49a0549eef484d24b04fa8fcdb43efe2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfNy0xNS0xLTEtOTQ0MTQ_52892b7a-2d73-4ce3-a50d-b21283c3958c"
      unitRef="usd">-110000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i09a399429407463c94fb6f4a770e06ca_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfOC0xLTEtMS05NDQxNA_7b2a52e9-0f6b-49e7-988a-4197681b9742"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="ia48fc689e3e9494a8b708e96f1579dd7_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfOC0zLTEtMS05NDQxNA_cf4ba818-b8ba-4b8e-b2da-c14a1a282496"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i37b081294e5b4b8e9e5a11799924a2f4_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfOC01LTEtMS05NDQxNA_363da7c5-1825-460b-8aa2-aa8b0cd71533"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i129ad2aa2cbf44d79bda671ff94c6b3a_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfOC03LTEtMS05NDQxNA_8b1e977a-89af-4049-9459-d782da1c72d5"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i3f56c3589dcf455e940e768c35266f9a_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfOC05LTEtMS05NDQxNA_bfa27aca-c4a0-4bd3-b9ad-359558dcc827"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i3f795846dbf2495a9b51d25b57687dbd_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfOC0xMS0xLTEtOTQ0MTQ_3cc233c5-749d-44c4-b71d-5543ec7e205c"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i113e99a5148f4c19a209d84850a178e7_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfOC0xMy0xLTEtOTQ0MTQ_76043064-7d46-4517-aff7-ae1e4f2cb180"
      unitRef="usd">54000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i49a0549eef484d24b04fa8fcdb43efe2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfOC0xNS0xLTEtOTQ0MTQ_d002f1b1-8db1-42e6-a68e-4b6834c6788b"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i09a399429407463c94fb6f4a770e06ca_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfOS0xLTEtMS05NDQxNA_0c9a76e6-035a-4a1d-b331-69c9154aee1f"
      unitRef="usd">-3000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="ia48fc689e3e9494a8b708e96f1579dd7_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfOS0zLTEtMS05NDQxNA_b681b5ca-7cf4-482a-a2f7-d2d53a52c3e9"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i37b081294e5b4b8e9e5a11799924a2f4_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfOS01LTEtMS05NDQxNA_36ae592e-d72b-4f7f-9480-0416006c371f"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i129ad2aa2cbf44d79bda671ff94c6b3a_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfOS03LTEtMS05NDQxNA_8cc6f6b1-2788-4540-94aa-22a1b8b919ef"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i3f56c3589dcf455e940e768c35266f9a_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfOS05LTEtMS05NDQxNA_92d57b3c-82ad-4b3c-96a1-7b6fb7f30134"
      unitRef="usd">-11000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i3f795846dbf2495a9b51d25b57687dbd_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfOS0xMS0xLTEtOTQ0MTQ_60802cb1-016c-43ad-953b-7b59e71f4dc9"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i113e99a5148f4c19a209d84850a178e7_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfOS0xMy0xLTEtOTQ0MTQ_f89a99bd-7c7e-4414-80c8-39fd967f74e3"
      unitRef="usd">-15000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i49a0549eef484d24b04fa8fcdb43efe2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfOS0xNS0xLTEtOTQ0MTQ_8cdadfe6-586a-4ea0-b56f-b5c4c1933c5d"
      unitRef="usd">27000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i09a399429407463c94fb6f4a770e06ca_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfMTAtMS0xLTEtOTQ0MTQ_80755380-5482-4910-9106-d80a2ebce42e"
      unitRef="usd">-79000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="ia48fc689e3e9494a8b708e96f1579dd7_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfMTAtMy0xLTEtOTQ0MTQ_ac99177f-f834-4836-9049-da3c8ef39195"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i37b081294e5b4b8e9e5a11799924a2f4_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfMTAtNS0xLTEtOTQ0MTQ_6ce874ff-cd9b-41a9-93a6-702b383865f4"
      unitRef="usd">-139000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i129ad2aa2cbf44d79bda671ff94c6b3a_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfMTAtNy0xLTEtOTQ0MTQ_a4777e14-0cb9-4f9f-b913-dcefe31b0856"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i3f56c3589dcf455e940e768c35266f9a_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfMTAtOS0xLTEtOTQ0MTQ_a76a0455-2688-4c07-9c83-ac2afbbf0670"
      unitRef="usd">-180000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i3f795846dbf2495a9b51d25b57687dbd_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfMTAtMTEtMS0xLTk0NDE0_ba802a36-c8cd-445b-b1bb-5f7cd405369b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i113e99a5148f4c19a209d84850a178e7_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfMTAtMTMtMS0xLTk0NDE0_f9720efc-e335-4c7b-9204-6d7160ddded6"
      unitRef="usd">-139000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i49a0549eef484d24b04fa8fcdb43efe2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfMTAtMTUtMS0xLTk0NDE0_6f007c8d-fc12-4a9b-9582-440031cda650"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i09a399429407463c94fb6f4a770e06ca_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfMTEtMS0xLTEtOTQ0MTQ_c3ba1cae-7aac-40b6-9567-c9606ce0765d"
      unitRef="usd">117000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ia48fc689e3e9494a8b708e96f1579dd7_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfMTEtMy0xLTEtOTQ0MTQ_a5c34211-ce3f-4e4c-acee-96138d0517aa"
      unitRef="usd">29000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i37b081294e5b4b8e9e5a11799924a2f4_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfMTEtNS0xLTEtOTQ0MTQ_8f07d36f-3a51-40bf-a77b-25aedf019566"
      unitRef="usd">224000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i129ad2aa2cbf44d79bda671ff94c6b3a_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfMTEtNy0xLTEtOTQ0MTQ_3aba6686-049c-461c-8b1e-d7c6f6afa5a0"
      unitRef="usd">32000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i3f56c3589dcf455e940e768c35266f9a_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfMTEtOS0xLTEtOTQ0MTQ_8124d608-0e3a-4f9a-a1ba-30e45ea34e5b"
      unitRef="usd">334000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i3f795846dbf2495a9b51d25b57687dbd_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfMTEtMTEtMS0xLTk0NDE0_bae17095-5d63-48d5-88a3-365ece9b80dc"
      unitRef="usd">95000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i113e99a5148f4c19a209d84850a178e7_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfMTEtMTMtMS0xLTk0NDE0_d6baa7b1-62d8-4407-b2bf-bad7a1279292"
      unitRef="usd">436000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i49a0549eef484d24b04fa8fcdb43efe2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjA1Nzg1ZmY3ZjAwYTRjYzVhZjE2MGZhN2ZjYjMzMzk4L3RhYmxlcmFuZ2U6MDU3ODVmZjdmMDBhNGNjNWFmMTYwZmE3ZmNiMzMzOThfMTEtMTUtMS0xLTk0NDE0_4a894dbc-7bfb-49c8-a766-b7eb7ba0d5da"
      unitRef="usd">109000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:ScheduleOfNetBenefitCostsTableTextBlock
      contextRef="ifcb20618db4549fa96838e2cc81877ae_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RleHRyZWdpb246MjRmZDBlZmNhYWM2NDIxMTg2Mzg3NTJkNzhiNzZkZWVfMjIyNw_9d65a98d-218b-41be-abbd-f412a4ff3b75">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides medical benefits, principally to its eligible U.S. retirees and similar benefits to their dependents, through its other postretirement benefit plans. The net credit of such plans consisted of the following components:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.947%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of unrecognized prior service credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net gain amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Curtailments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetBenefitCostsTableTextBlock>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ie3dcb6bbb4364846bb3cb11e71d7614c_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfMi0xLTEtMS05NDQxNA_e23bb35d-fce6-4283-b075-707e5ac80887"
      unitRef="usd">11000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="if26b7f13a9ad441d8310410aad545b78_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfMi0zLTEtMS05NDQxNA_a0095ad0-5654-4ffd-9839-036a67bbfff0"
      unitRef="usd">11000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ifcb20618db4549fa96838e2cc81877ae_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfMi01LTEtMS05NDQxNA_20bb1756-aad1-4836-bd3d-9203df861e3a"
      unitRef="usd">36000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i5cf6fed6709947cdb2d2ccc2ee3bea72_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfMi03LTEtMS05NDQxNA_e887a38d-63d5-4953-a21c-8b32a1212bd5"
      unitRef="usd">37000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ie3dcb6bbb4364846bb3cb11e71d7614c_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfMy0xLTEtMS05NDQxNA_22fb173e-cb3f-42cd-86f9-511be295ce4b"
      unitRef="usd">11000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="if26b7f13a9ad441d8310410aad545b78_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfMy0zLTEtMS05NDQxNA_8a6318f6-c350-4a08-b214-b3724dff7f86"
      unitRef="usd">12000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ifcb20618db4549fa96838e2cc81877ae_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfMy01LTEtMS05NDQxNA_fdc07ff0-3fd2-46fc-91df-0ea4d151d83f"
      unitRef="usd">34000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i5cf6fed6709947cdb2d2ccc2ee3bea72_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfMy03LTEtMS05NDQxNA_1da4749b-5df6-4ebe-9048-149494d24fff"
      unitRef="usd">34000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ie3dcb6bbb4364846bb3cb11e71d7614c_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfNC0xLTEtMS05NDQxNA_57897539-8c88-4ec6-bfbb-d7d8c419bbf5"
      unitRef="usd">21000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="if26b7f13a9ad441d8310410aad545b78_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfNC0zLTEtMS05NDQxNA_4e83b9b3-74ce-4d8d-b6d9-e31ebf35411c"
      unitRef="usd">20000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ifcb20618db4549fa96838e2cc81877ae_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfNC01LTEtMS05NDQxNA_4e458d61-4a20-432a-a73f-9ab0a653d44f"
      unitRef="usd">64000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i5cf6fed6709947cdb2d2ccc2ee3bea72_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfNC03LTEtMS05NDQxNA_7f17b075-a817-45c4-bfd5-e97c45764b62"
      unitRef="usd">59000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ie3dcb6bbb4364846bb3cb11e71d7614c_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfNS0xLTEtMS05NDQxNA_96c21875-2384-456c-b5f4-e12bb97188c9"
      unitRef="usd">-14000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="if26b7f13a9ad441d8310410aad545b78_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfNS0zLTEtMS05NDQxNA_680c79db-e70b-4225-a6c7-5f909506f9a0"
      unitRef="usd">-16000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ifcb20618db4549fa96838e2cc81877ae_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfNS01LTEtMS05NDQxNA_313ebb09-968c-464c-ac3a-b81fd75ef0a9"
      unitRef="usd">-42000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i5cf6fed6709947cdb2d2ccc2ee3bea72_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfNS03LTEtMS05NDQxNA_f8421418-3c67-4ceb-a978-1f8b82a6532e"
      unitRef="usd">-48000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="ie3dcb6bbb4364846bb3cb11e71d7614c_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfNi0xLTEtMS05NDQxNA_a04ffb59-8040-49a3-bbd1-a56f6c55e205"
      unitRef="usd">11000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="if26b7f13a9ad441d8310410aad545b78_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfNi0zLTEtMS05NDQxNA_994bff74-6f05-454e-b921-04fafaf9dee5"
      unitRef="usd">12000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="ifcb20618db4549fa96838e2cc81877ae_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfNi01LTEtMS05NDQxNA_56edeb94-d62c-4f3c-87ed-343bb6459807"
      unitRef="usd">32000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i5cf6fed6709947cdb2d2ccc2ee3bea72_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfNi03LTEtMS05NDQxNA_5dc3c548-1c95-4fa6-9280-affb0286fa8f"
      unitRef="usd">30000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="ie3dcb6bbb4364846bb3cb11e71d7614c_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfNy0xLTEtMS05NDQxNA_207fc446-18c6-479b-9a37-16f971c879c8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="if26b7f13a9ad441d8310410aad545b78_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfNy0zLTEtMS05NDQxNA_a0ac3248-de31-4feb-a82f-482879e5f8f9"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="ifcb20618db4549fa96838e2cc81877ae_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfNy01LTEtMS05NDQxNA_de914cf0-8624-4baa-9935-52cc056ee3a8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i5cf6fed6709947cdb2d2ccc2ee3bea72_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfNy03LTEtMS05NDQxNA_bc92fb1b-7d0d-4a83-8f98-1bea2cac1fe2"
      unitRef="usd">37000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="ie3dcb6bbb4364846bb3cb11e71d7614c_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfOC0xLTEtMS05NDQxNA_55a70fde-3601-412e-831c-dbcce8f87ac2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="if26b7f13a9ad441d8310410aad545b78_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfOC0zLTEtMS05NDQxNA_d944352d-8915-4bfc-9004-c7f3bd3916d2"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="ifcb20618db4549fa96838e2cc81877ae_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfOC01LTEtMS05NDQxNA_71b6f431-1db9-4695-8f64-2037e6c70167"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i5cf6fed6709947cdb2d2ccc2ee3bea72_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfOC03LTEtMS05NDQxNA_57489a80-6aea-47a2-b0f9-51393e00098f"
      unitRef="usd">29000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ie3dcb6bbb4364846bb3cb11e71d7614c_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfOS0xLTEtMS05NDQxNA_0f578dd5-f0e2-4662-977e-8f6f9a067401"
      unitRef="usd">-24000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="if26b7f13a9ad441d8310410aad545b78_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfOS0zLTEtMS05NDQxNA_e5edfe7d-4b7b-4666-9ce3-ab8a5b4abae2"
      unitRef="usd">-26000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ifcb20618db4549fa96838e2cc81877ae_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfOS01LTEtMS05NDQxNA_ce83228d-8757-4bf9-8c88-6ac4b2149645"
      unitRef="usd">-69000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i5cf6fed6709947cdb2d2ccc2ee3bea72_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RhYmxlOjI2NGFkZjcwOGY1ZjRiYzA5YjM0ZTQwZTEwMmU4NDllL3RhYmxlcmFuZ2U6MjY0YWRmNzA4ZjVmNGJjMDliMzRlNDBlMTAyZTg0OWVfOS03LTEtMS05NDQxNA_e079aad5-6509-40f1-a386-7882159540c7"
      unitRef="usd">-58000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RleHRyZWdpb246MjRmZDBlZmNhYWM2NDIxMTg2Mzg3NTJkNzhiNzZkZWVfMTU1OQ_8435fb50-fab4-4e9d-a38a-d34077cc0e8b"
      unitRef="usd">-296000000</us-gaap:DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement>
    <us-gaap:DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82MS9mcmFnOjI0ZmQwZWZjYWFjNjQyMTE4NjM4NzUyZDc4Yjc2ZGVlL3RleHRyZWdpb246MjRmZDBlZmNhYWM2NDIxMTg2Mzg3NTJkNzhiNzZkZWVfNTQ5NzU1ODE3MjIx_b94f92b6-18bb-4dfa-a686-c37c2152573a"
      unitRef="usd">-131000000</us-gaap:DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement>
    <us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RleHRyZWdpb246YTBjYTUyNjlkMWVhNGY1YzkxYWFkMTIxN2ViOTA4YmVfNjc5_e821adbc-7330-4dfb-bbeb-fe667241c49a">Other (Income) Expense, Net&lt;div style="margin-top:5pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net, consisted of:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exchange losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss (income) from investments in equity securities, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(683)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,535)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic defined benefit plan (credit) cost other than service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(208)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(159)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(182)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(462)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(450)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,007)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest paid for the nine months ended September&#160;30, 2022 and 2021 was $660 million and $570 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RleHRyZWdpb246YTBjYTUyNjlkMWVhNGY1YzkxYWFkMTIxN2ViOTA4YmVfNjg5_c5491800-908f-44ec-8ff6-4fe2ab34d0c4">&lt;div style="margin-top:5pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net, consisted of:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exchange losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss (income) from investments in equity securities, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(683)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,535)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic defined benefit plan (credit) cost other than service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(208)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(159)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(182)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(462)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(450)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,007)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1)&#160;&#160;&#160;&#160;Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag.</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfMi0xLTEtMS05NDQxNA_8bbee8e8-73b1-441f-b541-88baed42fb41"
      unitRef="usd">40000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfMi0zLTEtMS05NDQxNA_d1674cd7-58e1-40f7-a1b2-f641423e0174"
      unitRef="usd">7000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfMi01LTEtMS05NDQxNA_b55f9dfe-f7bb-4085-b246-f2240148d1d0"
      unitRef="usd">62000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfMi03LTEtMS05NDQxNA_7587bae7-5d77-481d-8d2d-80fd15ad9886"
      unitRef="usd">27000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfMy0xLTEtMS05NDQxNA_35430208-9210-4edd-8f7d-e5cf4e636325"
      unitRef="usd">244000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfMy0zLTEtMS05NDQxNA_8dd6b1cc-f393-46cf-a21d-dcaa643bb730"
      unitRef="usd">196000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfMy01LTEtMS05NDQxNA_cb4082c1-39d6-4fd5-a348-19ae70deb767"
      unitRef="usd">727000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfMy03LTEtMS05NDQxNA_3db23abf-5139-4e71-8d12-d09fcc4d3a85"
      unitRef="usd">597000000</us-gaap:InterestExpense>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfNC0xLTEtMS05NDQxNA_3f4a5835-5066-4f23-abba-2b01005a207d"
      unitRef="usd">-96000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfNC0zLTEtMS05NDQxNA_e7876461-2a41-4e93-b326-0950d00ef807"
      unitRef="usd">-46000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfNC01LTEtMS05NDQxNA_a956b2dc-628a-4600-b7da-c7b2ecae9926"
      unitRef="usd">-220000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfNC03LTEtMS05NDQxNA_e04ffb67-61bc-4abf-99e5-9a0898ceca1f"
      unitRef="usd">-202000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfNS0xLTEtMS05NDQxNA_965201a2-0fdf-46a2-ba00-3b4dfa55fcf1"
      unitRef="usd">-371000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfNS0zLTEtMS05NDQxNA_8ceaf6da-f2f6-4908-b3b1-9bd147e08f81"
      unitRef="usd">683000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfNS01LTEtMS05NDQxNA_699ddf86-569e-48d6-8b8f-a4a412aa906c"
      unitRef="usd">-1361000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfNS03LTEtMS05NDQxNA_5537c502-7851-4147-9e35-504781b8973c"
      unitRef="usd">1535000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfNi0xLTEtMS05NDQxNA_ab741f0c-b747-46e7-a068-b1f97bd7c0d0"
      unitRef="usd">-60000000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfNi0zLTEtMS05NDQxNA_0195cc26-362e-4831-90b6-ea5edae7b4ab"
      unitRef="usd">40000000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfNi01LTEtMS05NDQxNA_09914e82-2d75-44e8-9f48-ff0b8edf9011"
      unitRef="usd">-208000000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfNi03LTEtMS05NDQxNA_f7d95d40-8f58-4df8-8c6d-40e3f7b7fbbc"
      unitRef="usd">-159000000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <mrk:OtherNonoperatingIncomeExpenseOther
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfNy0xLTEtMS05NDQxNA_c2dee8d9-d7b2-4473-b4f2-68ae9d61d8aa"
      unitRef="usd">182000000</mrk:OtherNonoperatingIncomeExpenseOther>
    <mrk:OtherNonoperatingIncomeExpenseOther
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfNy0zLTEtMS05NDQxNA_82c9afec-d52f-4fc3-a7fb-dd00249ec344"
      unitRef="usd">42000000</mrk:OtherNonoperatingIncomeExpenseOther>
    <mrk:OtherNonoperatingIncomeExpenseOther
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfNy01LTEtMS05NDQxNA_eebf23d4-5ed8-40df-95a0-6a54be1266db"
      unitRef="usd">462000000</mrk:OtherNonoperatingIncomeExpenseOther>
    <mrk:OtherNonoperatingIncomeExpenseOther
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfNy03LTEtMS05NDQxNA_0dfa6716-59c3-4f33-9cef-721e628acb8b"
      unitRef="usd">85000000</mrk:OtherNonoperatingIncomeExpenseOther>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfOC0xLTEtMS05NDQxNA_e193fbb0-aff0-410c-9d95-c37cb94ff474"
      unitRef="usd">-429000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfOC0zLTEtMS05NDQxNA_2252623b-301e-4740-a60a-7a80af0c63ba"
      unitRef="usd">450000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfOC01LTEtMS05NDQxNA_3a7fa95a-e7a8-4437-abc7-129b020c5f30"
      unitRef="usd">-1576000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RhYmxlOjk0MDM5ODNkNGIwMTQxOTA4NzY3NTY2YmI2ZmQ1ZTNkL3RhYmxlcmFuZ2U6OTQwMzk4M2Q0YjAxNDE5MDg3Njc1NjZiYjZmZDVlM2RfOC03LTEtMS05NDQxNA_8c1b2ea9-9688-478f-8086-2ec33d2346c0"
      unitRef="usd">1007000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InterestPaid
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RleHRyZWdpb246YTBjYTUyNjlkMWVhNGY1YzkxYWFkMTIxN2ViOTA4YmVfNjU2_71ca59fd-30d8-4402-840e-554d194cc4eb"
      unitRef="usd">660000000</us-gaap:InterestPaid>
    <us-gaap:InterestPaid
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82NC9mcmFnOmEwY2E1MjY5ZDFlYTRmNWM5MWFhZDEyMTdlYjkwOGJlL3RleHRyZWdpb246YTBjYTUyNjlkMWVhNGY1YzkxYWFkMTIxN2ViOTA4YmVfNjYz_e882fbf1-7ae1-4921-92ee-81489241e62c"
      unitRef="usd">570000000</us-gaap:InterestPaid>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82Ny9mcmFnOjMxYjJmMmVhYmVmNTQyMjdhOWU5OTYzYzEwM2RhYzgyL3RleHRyZWdpb246MzFiMmYyZWFiZWY1NDIyN2E5ZTk5NjNjMTAzZGFjODJfMTU1OQ_2b64ff65-6757-4bd4-a671-0ea4877c6fd0">Taxes on Income&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective income tax rates from continuing operations were 9.2% and 13.2% for the third quarter of 2022 and 2021, respectively, and 11.0% and 14.4% for the first nine months of 2022 and 2021, respectively. The effective income tax rates from continuing operations reflect the beneficial impact of foreign earnings. The effective income tax rates from continuing operations in the third quarter and first nine months of 2022 also include the favorable impact of net unrealized losses from investments in equity securities and intangible asset impairment charges, which were taxed at the U.S. tax rate. The effective income tax rate from continuing operations in the first nine months of 2021 reflects the unfavorable effect of a charge for the acquisition of Pandion for which no tax benefit was recognized, as well as a net tax benefit of $207&#160;million related to the settlement of certain federal income tax matters as discussed below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter of 2021, the Internal Revenue Service (IRS) concluded its examinations of Merck&#x2019;s 2015-2016 U.S. federal income tax returns. As a result, the Company was required to make a payment of $190&#160;million (of which $172&#160;million related to continuing operations and $18&#160;million related to discontinued operations). The Company&#x2019;s reserves for unrecognized tax benefits for the years under examination exceeded the adjustments relating to this examination period and therefore the Company recorded a $236&#160;million net tax benefit in the first nine months of 2021 (of which $207&#160;million related to continuing operations and $29&#160;million related to discontinued operations). This net benefit reflects reductions in reserves for unrecognized tax benefits and other related liabilities for tax positions relating to the years that were under examination.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82Ny9mcmFnOjMxYjJmMmVhYmVmNTQyMjdhOWU5OTYzYzEwM2RhYzgyL3RleHRyZWdpb246MzFiMmYyZWFiZWY1NDIyN2E5ZTk5NjNjMTAzZGFjODJfNzU_01f88c04-8169-4c71-a76d-702a367ad247"
      unitRef="number">0.092</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82Ny9mcmFnOjMxYjJmMmVhYmVmNTQyMjdhOWU5OTYzYzEwM2RhYzgyL3RleHRyZWdpb246MzFiMmYyZWFiZWY1NDIyN2E5ZTk5NjNjMTAzZGFjODJfODI_50512536-9941-49f3-834f-37b00ef27800"
      unitRef="number">0.132</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82Ny9mcmFnOjMxYjJmMmVhYmVmNTQyMjdhOWU5OTYzYzEwM2RhYzgyL3RleHRyZWdpb246MzFiMmYyZWFiZWY1NDIyN2E5ZTk5NjNjMTAzZGFjODJfMTM2_e4334660-b6da-473a-98ff-b3e101cdbb49"
      unitRef="number">0.110</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82Ny9mcmFnOjMxYjJmMmVhYmVmNTQyMjdhOWU5OTYzYzEwM2RhYzgyL3RleHRyZWdpb246MzFiMmYyZWFiZWY1NDIyN2E5ZTk5NjNjMTAzZGFjODJfMTQz_f8af046c-5d22-4d99-85b4-23ebfe051c77"
      unitRef="number">0.144</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82Ny9mcmFnOjMxYjJmMmVhYmVmNTQyMjdhOWU5OTYzYzEwM2RhYzgyL3RleHRyZWdpb246MzFiMmYyZWFiZWY1NDIyN2E5ZTk5NjNjMTAzZGFjODJfNTE3_4c37ab6d-36c8-4f99-a858-1250380ece6f"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82Ny9mcmFnOjMxYjJmMmVhYmVmNTQyMjdhOWU5OTYzYzEwM2RhYzgyL3RleHRyZWdpb246MzFiMmYyZWFiZWY1NDIyN2E5ZTk5NjNjMTAzZGFjODJfNTE3_aa43912b-533f-42e7-85b6-26a7ce0e7a5f"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i38abb5b6d35e4640ae278494162794cb_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82Ny9mcmFnOjMxYjJmMmVhYmVmNTQyMjdhOWU5OTYzYzEwM2RhYzgyL3RleHRyZWdpb246MzFiMmYyZWFiZWY1NDIyN2E5ZTk5NjNjMTAzZGFjODJfNjcy_8eb31327-52dc-46da-bc95-59af8ce5030e"
      unitRef="usd">207000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:IncomeTaxesPaid
      contextRef="i355d324b4b084fcd9897163416bb017d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82Ny9mcmFnOjMxYjJmMmVhYmVmNTQyMjdhOWU5OTYzYzEwM2RhYzgyL3RleHRyZWdpb246MzFiMmYyZWFiZWY1NDIyN2E5ZTk5NjNjMTAzZGFjODJfOTY1_7c82e5e7-b8e2-416b-9a42-a64e1d74fd04"
      unitRef="usd">190000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i5747fab0a16f42f8b7a20235e05fc43d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82Ny9mcmFnOjMxYjJmMmVhYmVmNTQyMjdhOWU5OTYzYzEwM2RhYzgyL3RleHRyZWdpb246MzFiMmYyZWFiZWY1NDIyN2E5ZTk5NjNjMTAzZGFjODJfOTc4_f04849a5-2833-4a08-82f6-3a7d2bbe4946"
      unitRef="usd">172000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="ib62f00b41eb24b118fee32484d16e6ed_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82Ny9mcmFnOjMxYjJmMmVhYmVmNTQyMjdhOWU5OTYzYzEwM2RhYzgyL3RleHRyZWdpb246MzFiMmYyZWFiZWY1NDIyN2E5ZTk5NjNjMTAzZGFjODJfMTAxOA_20b300c1-a57b-4642-ae0e-9fdfeb55b26c"
      unitRef="usd">18000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i76c87fa1c62a44db871fbb8b83163687_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82Ny9mcmFnOjMxYjJmMmVhYmVmNTQyMjdhOWU5OTYzYzEwM2RhYzgyL3RleHRyZWdpb246MzFiMmYyZWFiZWY1NDIyN2E5ZTk5NjNjMTAzZGFjODJfMTI0MQ_8ffb8aaa-6d96-49bb-bce4-5c6a7e4413db"
      unitRef="usd">236000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i38abb5b6d35e4640ae278494162794cb_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82Ny9mcmFnOjMxYjJmMmVhYmVmNTQyMjdhOWU5OTYzYzEwM2RhYzgyL3RleHRyZWdpb246MzFiMmYyZWFiZWY1NDIyN2E5ZTk5NjNjMTAzZGFjODJfMTMwMQ_8eb31327-52dc-46da-bc95-59af8ce5030e"
      unitRef="usd">207000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i52a4807b00fd4898baafe70f646f2a51_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF82Ny9mcmFnOjMxYjJmMmVhYmVmNTQyMjdhOWU5OTYzYzEwM2RhYzgyL3RleHRyZWdpb246MzFiMmYyZWFiZWY1NDIyN2E5ZTk5NjNjMTAzZGFjODJfMTM0MQ_d571b384-c603-457b-8dc6-e942568fa0a3"
      unitRef="usd">29000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RleHRyZWdpb246NGFhODQyNmI1YzE2NDk1YWE0MWE5MWY4MTUzNzcyZWRfNDUz_a2f27cab-95b0-41ab-a322-ac38bd714e02">Earnings Per Share&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The calculations of earnings per share are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ and shares in millions except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net Income from Continuing Operations Attributable to Merck&#160;&amp;amp; Co., Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net Income Attributable to Merck&#160;&amp;amp; Co., Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common shares issuable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average common shares outstanding assuming dilution &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic Earnings per Common Share Attributable to Merck &amp;amp; Co., Inc. Common Shareholders:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from Continuing Operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from Discontinued Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net Income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings per Common Share Assuming Dilution Attributable to Merck &amp;amp; Co., Inc. Common Shareholders:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from Continuing Operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from Discontinued Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net Income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Issuable primarily under share-based compensation plans.&lt;/span&gt;&lt;/div&gt;For the third quarter of 2022 and 2021, 2 million and 8 million, respectively, and for the first nine months of 2022 and 2021, 5 million and 10 million, respectively, of common shares issuable under share-based compensation plans were excluded from the computation of earnings per common share assuming dilution because the effect would have been antidilutive.</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RleHRyZWdpb246NGFhODQyNmI1YzE2NDk1YWE0MWE5MWY4MTUzNzcyZWRfNDYw_e15e72ea-eb9a-45c2-ba24-913b6b95eb73">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The calculations of earnings per share are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ and shares in millions except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net Income from Continuing Operations Attributable to Merck&#160;&amp;amp; Co., Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net Income Attributable to Merck&#160;&amp;amp; Co., Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common shares issuable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average common shares outstanding assuming dilution &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic Earnings per Common Share Attributable to Merck &amp;amp; Co., Inc. Common Shareholders:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from Continuing Operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from Discontinued Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net Income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings per Common Share Assuming Dilution Attributable to Merck &amp;amp; Co., Inc. Common Shareholders:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from Continuing Operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from Discontinued Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net Income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Issuable primarily under share-based compensation plans.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMi0xLTEtMS05NDQxNA_3f2505fd-6e8f-4373-a3ad-5bfd3bfb31a3"
      unitRef="usd">3248000000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMi0zLTEtMS05NDQxNA_fea73ef0-8701-419c-9f43-21f745ce79d0"
      unitRef="usd">4567000000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMi01LTEtMS05NDQxNA_0236d342-2b66-420b-a945-c3c873913a25"
      unitRef="usd">11502000000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMi03LTEtMS05NDQxNA_649901eb-0139-4f06-bc46-90dbd8748102"
      unitRef="usd">8525000000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMy0xLTEtMS05NDQxNA_5ac82b44-7fa0-45f8-ad3f-aa6ffe7e010a"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMy0zLTEtMS05NDQxNA_cd1c2db2-1958-494e-a447-8808cb1ecf54"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMy01LTEtMS05NDQxNA_dc73a092-2044-4c0d-abc3-0b8a413befc8"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMy03LTEtMS05NDQxNA_6d44aa4a-f521-4de4-b637-aee6df038345"
      unitRef="usd">766000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfNC0xLTEtMS05NDQxNA_3c516582-1dcb-4ee6-8196-27995f766d90"
      unitRef="usd">3248000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfNC0xLTEtMS05NDQxNA_5a455bc8-6389-46d5-82b7-7d3d64dbd252"
      unitRef="usd">3248000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfNC0zLTEtMS05NDQxNA_219cf3f1-118c-4f60-8758-422cbf0a8454"
      unitRef="usd">4567000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfNC0zLTEtMS05NDQxNA_55ac1b45-4ce1-4f44-82e0-617c3a2ae9f9"
      unitRef="usd">4567000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfNC01LTEtMS05NDQxNA_ebb04da4-054f-42fd-a62c-db45d9212215"
      unitRef="usd">11502000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfNC01LTEtMS05NDQxNA_f70ba8f4-1387-4bc1-8177-af028b3c8981"
      unitRef="usd">11502000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfNC03LTEtMS05NDQxNA_3d25d310-a789-49a9-a7b9-73f3691767b0"
      unitRef="usd">9291000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfNC03LTEtMS05NDQxNA_84a0351b-2979-483c-b609-5103abd6ca39"
      unitRef="usd">9291000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfNS0xLTEtMS05NDQxNA_6ca42779-bd08-47c3-a3bb-db2bbeba553e"
      unitRef="shares">2533000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfNS0zLTEtMS05NDQxNA_e4a30f04-ac4b-441d-a1c0-55d0f178be6c"
      unitRef="shares">2530000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfNS01LTEtMS05NDQxNA_1673320c-daa4-40b9-a84c-ddcaf42be7db"
      unitRef="shares">2531000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfNS03LTEtMS05NDQxNA_2602e0a5-2a29-458e-b319-a000f41241f5"
      unitRef="shares">2531000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfNi0xLTEtMS05NDQxNA_60f97169-fc8e-4a6b-9312-691847704790"
      unitRef="shares">9000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfNi0zLTEtMS05NDQxNA_0c608936-1f97-461b-b7a4-d3f436876921"
      unitRef="shares">6000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfNi01LTEtMS05NDQxNA_c365e45b-aed5-43eb-856f-b4c7eb6d2c12"
      unitRef="shares">9000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfNi03LTEtMS05NDQxNA_8fb73287-c62d-46da-8150-56325f146d5d"
      unitRef="shares">8000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfNy0xLTEtMS05NDQxNA_5b43792a-42e5-400b-9ba7-558b9e03fc4b"
      unitRef="shares">2542000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfNy0zLTEtMS05NDQxNA_4ec103aa-f7f3-4857-8c90-7b2d1ecf0bdd"
      unitRef="shares">2536000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfNy01LTEtMS05NDQxNA_9324611f-44b2-4099-a105-1d7bf83fe625"
      unitRef="shares">2540000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfNy03LTEtMS05NDQxNA_ae0bd9d8-b7cc-431c-af30-9323ff52bf88"
      unitRef="shares">2539000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfOS0xLTEtMS05NDQxNA_9a4f2acf-5229-480c-ba5a-0263348fd2b2"
      unitRef="usdPerShare">1.28</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfOS0zLTEtMS05NDQxNA_2e5615bb-7449-4a3e-a0a9-f071d7c14ec1"
      unitRef="usdPerShare">1.81</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfOS01LTEtMS05NDQxNA_94cf5496-c99f-4246-9b7e-d67586733aa9"
      unitRef="usdPerShare">4.55</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfOS03LTEtMS05NDQxNA_087ce0b5-6158-49f0-9904-35ced729e690"
      unitRef="usdPerShare">3.37</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMTAtMS0xLTEtOTQ0MTQ_6eec1e00-bc47-40e9-aed7-a837d967fcd2"
      unitRef="usdPerShare">0</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMTAtMy0xLTEtOTQ0MTQ_bde97e50-c559-449e-b47a-5f49153dbad6"
      unitRef="usdPerShare">0</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMTAtNS0xLTEtOTQ0MTQ_a668527d-967a-44df-8f43-dfdaca0687c5"
      unitRef="usdPerShare">0</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMTAtNy0xLTEtOTQ0MTQ_9fd03cd7-1b53-45c2-8bf2-d9d2a5232e15"
      unitRef="usdPerShare">0.30</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMTEtMS0xLTEtOTQ0MTQ_2ec81bed-e7d5-4b07-8470-65e3b3efcd9c"
      unitRef="usdPerShare">1.28</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMTEtMy0xLTEtOTQ0MTQ_15fa60cb-9d78-4973-8fa3-44c8d82a93a1"
      unitRef="usdPerShare">1.81</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMTEtNS0xLTEtOTQ0MTQ_60dfdb0f-2cbf-4562-9a42-951481ebacb8"
      unitRef="usdPerShare">4.55</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMTEtNy0xLTEtOTQ0MTQ_887df273-c91b-4bd1-823c-736c47431313"
      unitRef="usdPerShare">3.67</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMTMtMS0xLTEtOTQ0MTQ_d7dd3c06-6980-4d4f-bc71-559890f43b72"
      unitRef="usdPerShare">1.28</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMTMtMy0xLTEtOTQ0MTQ_dccb4172-0650-4e99-a590-966561db0835"
      unitRef="usdPerShare">1.80</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMTMtNS0xLTEtOTQ0MTQ_7b95200f-6ae3-4a26-b40d-4a84a5ef0a2e"
      unitRef="usdPerShare">4.53</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMTMtNy0xLTEtOTQ0MTQ_e7a94198-bdea-4e23-a456-bc82f3e7ca69"
      unitRef="usdPerShare">3.36</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMTQtMS0xLTEtOTQ0MTQ_9ad16bfe-ef12-4cca-8aff-1c2fc4134fd2"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMTQtMy0xLTEtOTQ0MTQ_e66db743-c155-451b-9b6e-f5cd5794840f"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMTQtNS0xLTEtOTQ0MTQ_44ee97ea-c809-4248-96b1-5bfe27d13ecb"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMTQtNy0xLTEtOTQ0MTQ_f6f42b46-cc84-4c49-b5ce-6d0598095e4b"
      unitRef="usdPerShare">0.30</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMTUtMS0xLTEtOTQ0MTQ_e7850f85-ebfa-4c65-a172-52e5e3ee997b"
      unitRef="usdPerShare">1.28</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMTUtMy0xLTEtOTQ0MTQ_8ea49180-3a10-4ecf-b0c5-6472ce2fdfaf"
      unitRef="usdPerShare">1.80</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMTUtNS0xLTEtOTQ0MTQ_cb692d6a-e3df-432d-89c0-76126a9f0a83"
      unitRef="usdPerShare">4.53</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RhYmxlOmQ0MGMzMzM4MjE2MTQ3ODlhN2M5ODkzNWIxOWQ3NmY4L3RhYmxlcmFuZ2U6ZDQwYzMzMzgyMTYxNDc4OWE3Yzk4OTM1YjE5ZDc2ZjhfMTUtNy0xLTEtOTQ0MTQ_0044e863-5788-4148-9bf8-86e21c1817ff"
      unitRef="usdPerShare">3.66</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RleHRyZWdpb246NGFhODQyNmI1YzE2NDk1YWE0MWE5MWY4MTUzNzcyZWRfMTYx_452ce140-e4d0-4935-b723-1caba5c67069"
      unitRef="shares">2000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RleHRyZWdpb246NGFhODQyNmI1YzE2NDk1YWE0MWE5MWY4MTUzNzcyZWRfMTY4_adaf6588-dde2-46e3-9e19-14d38e4354f5"
      unitRef="shares">8000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RleHRyZWdpb246NGFhODQyNmI1YzE2NDk1YWE0MWE5MWY4MTUzNzcyZWRfMjMy_c91d4303-e3e5-4211-a3d9-c7dbbbada964"
      unitRef="shares">5000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83MC9mcmFnOjRhYTg0MjZiNWMxNjQ5NWFhNDFhOTFmODE1Mzc3MmVkL3RleHRyZWdpb246NGFhODQyNmI1YzE2NDk1YWE0MWE5MWY4MTUzNzcyZWRfMjM5_a4925bc2-a245-46fc-a761-15841fe80e54"
      unitRef="shares">10000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RleHRyZWdpb246YTlkZWZkY2FiOGEwNDhjYzg1ODMzMzgyNDg1YjUwYWFfMzM4_964363be-a13a-489e-9098-e0fb2f36b531">Other Comprehensive Income (Loss)&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in each component of other comprehensive income (loss) are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.531%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee&lt;br/&gt;Benefit&lt;br/&gt;Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign Currency&lt;br/&gt;Translation&lt;br/&gt;Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated Other&lt;br/&gt;Comprehensive&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance July 1, 2021, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,028)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,574)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,628)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(96)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss), net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance September 30, 2021, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,990)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,658)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,590)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance July 1, 2022, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,465)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,252)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,327)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(294)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(618)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(143)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(568)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(261)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(254)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(177)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(201)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(155)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss), net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(568)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(416)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance September 30, 2022, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,820)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,743)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.531%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee&lt;br/&gt;Benefit&lt;br/&gt;Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign Currency&lt;br/&gt;Translation&lt;br/&gt;Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated Other&lt;br/&gt;Comprehensive&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance January 1, 2021, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(266)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,540)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,828)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,634)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(167)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(385)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(510)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss), net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Spin-off of Organon (see Note&#160;2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance September 30, 2021, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,990)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,658)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,590)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance January 1, 2022, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,743)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,830)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(125)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,001)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(259)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(223)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(990)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(493)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(227)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(390)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(198)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss), net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(990)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(314)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance September 30, 2022, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,820)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,743)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Primarily relates to foreign currency cash flow hedges that were reclassified from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AOCL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes net amortization of prior service cost and actuarial gains and losses included in net periodic benefit cost (see Note&#160;11).&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RleHRyZWdpb246YTlkZWZkY2FiOGEwNDhjYzg1ODMzMzgyNDg1YjUwYWFfMzQ2_2601487c-5444-4f12-b4b1-b674491bf96a">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in each component of other comprehensive income (loss) are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.531%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee&lt;br/&gt;Benefit&lt;br/&gt;Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign Currency&lt;br/&gt;Translation&lt;br/&gt;Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated Other&lt;br/&gt;Comprehensive&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance July 1, 2021, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,028)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,574)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,628)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(96)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss), net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance September 30, 2021, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,990)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,658)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,590)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance July 1, 2022, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,465)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,252)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,327)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(294)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(618)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(143)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(568)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(261)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(254)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(177)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(201)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(155)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss), net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(568)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(416)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance September 30, 2022, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,820)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,743)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.531%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee&lt;br/&gt;Benefit&lt;br/&gt;Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign Currency&lt;br/&gt;Translation&lt;br/&gt;Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated Other&lt;br/&gt;Comprehensive&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance January 1, 2021, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(266)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,540)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,828)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,634)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(167)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(385)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(510)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss), net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Spin-off of Organon (see Note&#160;2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance September 30, 2021, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,990)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,658)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,590)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance January 1, 2022, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,743)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,830)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(125)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,001)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(259)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(223)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(990)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(493)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(227)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(390)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(198)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss), net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(990)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(314)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance September 30, 2022, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,820)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,743)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Primarily relates to foreign currency cash flow hedges that were reclassified from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AOCL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes net amortization of prior service cost and actuarial gains and losses included in net periodic benefit cost (see Note&#160;11).&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia164fd181a4240bb9f3e9e496fc60bb0_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMi0xLTEtMS05NDQxNA_d506c6c1-d33d-4ffb-ad80-be66113a3812"
      unitRef="usd">-26000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i04361801595c41ef86be85e444162b27_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMi0zLTEtMS05NDQxNA_989040b1-70d7-4411-87fe-e5dabba0b925"
      unitRef="usd">-3028000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i998f48f9bf1e4663850834c5e23fe862_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMi01LTEtMS05NDQxNA_f913cc8c-c440-4af5-935b-489a8f465f85"
      unitRef="usd">-1574000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if7e47c5bf82f40adb471e36675ba4ee6_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMi03LTEtMS05NDQxNA_b9f1bc5b-6dc0-4286-b549-aeae93f4ff8c"
      unitRef="usd">-4628000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i79db0e250e4c4f81b2bbcc5c8fefea2d_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMy0xLTEtMS05NDQxNA_b2cb3b9f-2559-41fb-a9a1-df21185c8011"
      unitRef="usd">72000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i2fbc79b742df422b8eb80da9c3923e51_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMy0zLTEtMS05NDQxNA_f443fb83-c7d0-46a5-b987-9200ea5fc77f"
      unitRef="usd">-24000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i871670fc66504079bbcb712e2def07e3_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMy01LTEtMS05NDQxNA_b63bf210-7002-45ea-9006-1b01657cfb5c"
      unitRef="usd">-96000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMy03LTEtMS05NDQxNA_c37b1391-02ad-41f1-84eb-91eaa923ccb4"
      unitRef="usd">-48000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i79db0e250e4c4f81b2bbcc5c8fefea2d_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfNC0xLTEtMS05NDQxNA_209395ca-cac6-43d3-8da4-60cd6273250e"
      unitRef="usd">16000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i2fbc79b742df422b8eb80da9c3923e51_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfNC0zLTEtMS05NDQxNA_e2ddb5de-8e5d-47a2-82b7-ddb249beeb37"
      unitRef="usd">-16000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i871670fc66504079bbcb712e2def07e3_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfNC01LTEtMS05NDQxNA_52872b14-b79a-46ca-88e5-42e076f5eaa6"
      unitRef="usd">-12000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfNC03LTEtMS05NDQxNA_3f64fddf-5b68-4302-9103-87c685314aa1"
      unitRef="usd">-12000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i79db0e250e4c4f81b2bbcc5c8fefea2d_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfNS0xLTEtMS05NDQxNA_eddeaa96-732f-4402-87bc-9e1369fefcc4"
      unitRef="usd">56000000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i2fbc79b742df422b8eb80da9c3923e51_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfNS0zLTEtMS05NDQxNA_c75d0dea-6cbc-48d3-afdf-1b14672a9008"
      unitRef="usd">-8000000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i871670fc66504079bbcb712e2def07e3_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfNS01LTEtMS05NDQxNA_9b965fe3-4116-4e25-ae75-ad959a0d8b38"
      unitRef="usd">-84000000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfNS03LTEtMS05NDQxNA_d329940a-74fd-49b0-91ed-638d2d636708"
      unitRef="usd">-36000000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i79db0e250e4c4f81b2bbcc5c8fefea2d_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfNi0xLTEtMS05NDQxNA_1a1f1139-92dd-44fa-8b0a-db42b01cbfe6"
      unitRef="usd">-36000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i2fbc79b742df422b8eb80da9c3923e51_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfNi0zLTEtMS05NDQxNA_9e654d49-1c09-4a18-9936-6b8268442f8e"
      unitRef="usd">-68000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i871670fc66504079bbcb712e2def07e3_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfNi01LTEtMS05NDQxNA_ce31a905-111a-45c1-bb5a-746b323a155d"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfNi03LTEtMS05NDQxNA_88893410-75d7-4b34-999d-0d7dd075ad6c"
      unitRef="usd">-104000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i79db0e250e4c4f81b2bbcc5c8fefea2d_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfNy0xLTEtMS05NDQxNA_35ab004b-58fd-4841-8249-3fd316918e45"
      unitRef="usd">-8000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i2fbc79b742df422b8eb80da9c3923e51_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfNy0zLTEtMS05NDQxNA_9e07bad7-b6de-41b1-9793-8b34b233597c"
      unitRef="usd">-22000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i871670fc66504079bbcb712e2def07e3_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfNy01LTEtMS05NDQxNA_b4dbbaf7-1d95-4823-abb6-952775f6df9b"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfNy03LTEtMS05NDQxNA_020dab1c-d7f4-4152-83ac-3ee8eb0657aa"
      unitRef="usd">-30000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i79db0e250e4c4f81b2bbcc5c8fefea2d_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfOC0xLTEtMS05NDQxNA_98da9d40-d179-4846-af44-67ba76af4e52"
      unitRef="usd">-28000000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i2fbc79b742df422b8eb80da9c3923e51_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfOC0zLTEtMS05NDQxNA_b8ba3346-a330-4639-a771-706b6649e677"
      unitRef="usd">-46000000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i871670fc66504079bbcb712e2def07e3_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfOC01LTEtMS05NDQxNA_0b679184-399f-4469-90fe-e45143bbe97f"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfOC03LTEtMS05NDQxNA_790e25de-a771-4525-be23-2d8c9428cc4c"
      unitRef="usd">-74000000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i79db0e250e4c4f81b2bbcc5c8fefea2d_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfOS0xLTEtMS05NDQxNA_f90f0dbe-6a54-423b-bf5a-dd35f16f8d7e"
      unitRef="usd">84000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i2fbc79b742df422b8eb80da9c3923e51_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfOS0zLTEtMS05NDQxNA_47f86251-57ed-465e-931c-21b85fd9a23c"
      unitRef="usd">38000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i871670fc66504079bbcb712e2def07e3_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfOS01LTEtMS05NDQxNA_d9582a81-b93b-46cb-94dc-390f0d089c9c"
      unitRef="usd">-84000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfOS03LTEtMS05NDQxNA_be9f0d7a-3d04-4afb-ae47-3913a0bd7475"
      unitRef="usd">38000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if0ae37c4002d4f7c8945b238b450a3ff_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTEtMS0xLTEtOTQ0MTQ_e7f0a931-349b-471a-9ace-9534a6d6e969"
      unitRef="usd">58000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0de005cbf7c64be2bbb15d3ad2747c39_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTEtMy0xLTEtOTQ0MTQ_230f2500-c120-434d-81b5-c609bfbbee7f"
      unitRef="usd">-2990000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idf6a11570b2f4b75989bbe9a432b4263_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTEtNS0xLTEtOTQ0MTQ_32a92e4b-1891-48ca-9097-2fa267fae228"
      unitRef="usd">-1658000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i99c020a806d84d1cb9f8c8d97329cf8c_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTEtNy0xLTEtOTQ0MTQ_f446f676-a21c-4fab-a10e-4ac3ae51d3bc"
      unitRef="usd">-4590000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if4376d5e08b3472d9cdbcc59389ab13f_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTItMS0xLTEtOTQ0MTQ_74fe5953-2638-4356-bdc6-df4b666b0b43"
      unitRef="usd">390000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i940d159cf6fc4de7a976d223e5df88bd_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTItMy0xLTEtOTQ0MTQ_4ad0aef5-5eda-41dc-98c2-72a405409c08"
      unitRef="usd">-2465000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i820aa0a4094e46508f3d90c1102a977b_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTItNS0xLTEtOTQ0MTQ_a29d7aa4-05c7-474f-b51b-a30fa5d5016f"
      unitRef="usd">-2252000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9864609863b94d00aa7ba3ced3bea441_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTItNy0xLTEtOTQ0MTQ_e66d4cb3-71a7-43a2-92fa-b7184786e6b9"
      unitRef="usd">-4327000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="if3d89e2baf3b40f3b69759154662da14_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTMtMS0xLTEtOTQ0MTQ_e2f192fb-c270-453b-9415-9cfc59314811"
      unitRef="usd">682000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="idc4cbcf7fafb47afaea1141b1ace9b8c_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTMtMy0xLTEtOTQ0MTQ_797e27db-f772-4a0d-9983-1f6e09483524"
      unitRef="usd">-294000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i9b887851ae3f40518c8ab99172a256c1_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTMtNS0xLTEtOTQ0MTQ_43390bbd-bcae-465f-b07b-b4a364b717de"
      unitRef="usd">-618000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTMtNy0xLTEtOTQ0MTQ_6e9c59a4-15c1-4de2-b8a9-374bd73b4772"
      unitRef="usd">-230000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="if3d89e2baf3b40f3b69759154662da14_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTQtMS0xLTEtOTQ0MTQ_8535b243-c115-4411-8cfc-a19c4269e1d0"
      unitRef="usd">143000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="idc4cbcf7fafb47afaea1141b1ace9b8c_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTQtMy0xLTEtOTQ0MTQ_5f999ce9-bd59-4968-81f0-f38d2589779d"
      unitRef="usd">-62000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i9b887851ae3f40518c8ab99172a256c1_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTQtNS0xLTEtOTQ0MTQ_8ea4b44c-f793-4c74-b386-666708fb632a"
      unitRef="usd">-50000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTQtNy0xLTEtOTQ0MTQ_30d9b197-c283-4e44-8fd8-c64b2d39d92d"
      unitRef="usd">31000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="if3d89e2baf3b40f3b69759154662da14_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTUtMS0xLTEtOTQ0MTQ_55109df5-6dcb-4d3a-908e-b125befeed77"
      unitRef="usd">539000000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="idc4cbcf7fafb47afaea1141b1ace9b8c_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTUtMy0xLTEtOTQ0MTQ_1384d9a3-5e71-4541-9074-80b8b30198ec"
      unitRef="usd">-232000000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i9b887851ae3f40518c8ab99172a256c1_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTUtNS0xLTEtOTQ0MTQ_811f7b46-6dc1-4b78-87c1-7e04800ad7d0"
      unitRef="usd">-568000000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTUtNy0xLTEtOTQ0MTQ_af8017e8-204a-40fd-b208-47ec9a592015"
      unitRef="usd">-261000000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="if3d89e2baf3b40f3b69759154662da14_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTYtMS0xLTEtOTQ0MTQ_12c833ca-606a-4487-bf83-8ee6da34af88"
      unitRef="usd">254000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="idc4cbcf7fafb47afaea1141b1ace9b8c_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTYtMy0xLTEtOTQ0MTQ_c8426025-274e-4957-a396-3afc5d01fc9a"
      unitRef="usd">-77000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i9b887851ae3f40518c8ab99172a256c1_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTYtNS0xLTEtOTQ0MTQ_862f7f64-fe28-4dfa-8942-803bbe1bec7e"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTYtNy0xLTEtOTQ0MTQ_5490f4da-a8c6-4d6c-98c4-627ce61da96d"
      unitRef="usd">177000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="if3d89e2baf3b40f3b69759154662da14_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTctMS0xLTEtOTQ0MTQ_e2da8d8f-f02d-46c1-9c5c-5560815ea7ad"
      unitRef="usd">53000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="idc4cbcf7fafb47afaea1141b1ace9b8c_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTctMy0xLTEtOTQ0MTQ_21990bde-9e59-448a-94e3-03b2703da8d5"
      unitRef="usd">-31000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i9b887851ae3f40518c8ab99172a256c1_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTctNS0xLTEtOTQ0MTQ_662228da-2e31-4bcc-a366-ef16990f3673"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTctNy0xLTEtOTQ0MTQ_650c77d0-79af-436d-8293-7116a0736638"
      unitRef="usd">22000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="if3d89e2baf3b40f3b69759154662da14_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTgtMS0xLTEtOTQ0MTQ_ab831fae-53cd-4fa0-8c3a-cc42cadddf1b"
      unitRef="usd">201000000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="idc4cbcf7fafb47afaea1141b1ace9b8c_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTgtMy0xLTEtOTQ0MTQ_5afdcbd9-b0a0-4da4-954d-6de459b94b3b"
      unitRef="usd">-46000000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i9b887851ae3f40518c8ab99172a256c1_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTgtNS0xLTEtOTQ0MTQ_a3c1a9fa-750e-457f-a216-f631a6d09fc6"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTgtNy0xLTEtOTQ0MTQ_f103f269-243e-4bf0-a45a-716c3d7d17c5"
      unitRef="usd">155000000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="if3d89e2baf3b40f3b69759154662da14_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTktMS0xLTEtOTQ0MTQ_b863c34c-72a2-4ad5-b009-9aa51e762ed8"
      unitRef="usd">338000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="idc4cbcf7fafb47afaea1141b1ace9b8c_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTktMy0xLTEtOTQ0MTQ_1b5b9690-f56b-4f8d-bbc9-76ebed038380"
      unitRef="usd">-186000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i9b887851ae3f40518c8ab99172a256c1_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTktNS0xLTEtOTQ0MTQ_9344766c-1d91-4890-8495-2f5e25b5c765"
      unitRef="usd">-568000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMTktNy0xLTEtOTQ0MTQ_4f087568-1ebb-4d72-8943-79bfd490d995"
      unitRef="usd">-416000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0f45167f24e645d2ad668c47635fc09b_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMjAtMS0xLTEtOTQ0MTQ_301684b8-945e-4280-b8fc-17a0f6090795"
      unitRef="usd">728000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7b4bb3ccba1a4790beb19a0ca2cd4721_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMjAtMy0xLTEtOTQ0MTQ_1c2259d9-7850-4618-8d26-c02ee35970e9"
      unitRef="usd">-2651000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0df51b82a6bf4ed3a20acde326a2a355_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMjAtNS0xLTEtOTQ0MTQ_ae2d04b5-2f84-4443-8c1a-c6fbf36384a2"
      unitRef="usd">-2820000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie0803cc4f2c64fa7a8e0196a811eaf28_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOmFlYmNjM2ViNDQyMDRjNDk4MzI1YzEzNTk1ODZlY2QxL3RhYmxlcmFuZ2U6YWViY2MzZWI0NDIwNGM0OTgzMjVjMTM1OTU4NmVjZDFfMjAtNy0xLTEtOTQ0MTQ_d701a15d-4e25-446f-ab4c-5192fa82199c"
      unitRef="usd">-4743000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i754a465cfe674a28bad93eaa56b395ec_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMi0xLTEtMS05NDQxNA_673670f5-09cb-4a0a-a14b-9a5e7a350732"
      unitRef="usd">-266000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2877989be5ba41eda5048c75789f5d0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMi0zLTEtMS05NDQxNA_010c74eb-7346-4786-acb9-b60392902d99"
      unitRef="usd">-4540000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifdc463d6e9e74476b4efb5e0ad43ff93_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMi01LTEtMS05NDQxNA_8a21b28e-5b16-4db2-8411-0d12c6c673ab"
      unitRef="usd">-1828000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i93d7029f006b4d91a535c2e9905f5a89_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMi03LTEtMS05NDQxNA_e09595d6-e787-4978-810b-797b7aea848e"
      unitRef="usd">-6634000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i46dd5b7c9aab4334a81feabf9ee87525_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMy0xLTEtMS05NDQxNA_5e11b564-5eb6-4c89-9565-d027815657d8"
      unitRef="usd">193000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i4a93811c7004483b89e5b2b7d7a47e27_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMy0zLTEtMS05NDQxNA_410d3a69-c273-4f8c-b6c0-f49177d2b716"
      unitRef="usd">1739000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i5aab13ae412a418dad03dcc21e39fa7f_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMy01LTEtMS05NDQxNA_c419d687-eff3-4851-bf43-c8a61d935281"
      unitRef="usd">-167000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMy03LTEtMS05NDQxNA_819cf266-8629-48c8-81f8-f0995e987766"
      unitRef="usd">1765000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i46dd5b7c9aab4334a81feabf9ee87525_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfNC0xLTEtMS05NDQxNA_5b4f5c3d-3ba8-4f36-ab51-3857e227867f"
      unitRef="usd">41000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i4a93811c7004483b89e5b2b7d7a47e27_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfNC0zLTEtMS05NDQxNA_b43f12e4-37dc-4db8-9c4f-b0c90f558018"
      unitRef="usd">385000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i5aab13ae412a418dad03dcc21e39fa7f_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfNC01LTEtMS05NDQxNA_05742b98-19a9-43bb-ac1e-22dd6e61ac45"
      unitRef="usd">84000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfNC03LTEtMS05NDQxNA_a2aa1dca-ab28-433f-b437-4fc95db347cd"
      unitRef="usd">510000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i46dd5b7c9aab4334a81feabf9ee87525_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfNS0xLTEtMS05NDQxNA_a6354273-6fc5-48cd-9f53-50e421b41687"
      unitRef="usd">152000000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i4a93811c7004483b89e5b2b7d7a47e27_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfNS0zLTEtMS05NDQxNA_9b0f7c66-9a36-429f-acc6-88a73ec38eac"
      unitRef="usd">1354000000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i5aab13ae412a418dad03dcc21e39fa7f_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfNS01LTEtMS05NDQxNA_1cd5a59c-155b-420b-90ca-0fcdbb35807f"
      unitRef="usd">-251000000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfNS03LTEtMS05NDQxNA_d591cf5e-fbff-4e25-b03a-6e9a0bcdb632"
      unitRef="usd">1255000000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i46dd5b7c9aab4334a81feabf9ee87525_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfNi0xLTEtMS05NDQxNA_5d4eedc7-3e93-4866-8b91-200ccfb1ff78"
      unitRef="usd">-218000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i4a93811c7004483b89e5b2b7d7a47e27_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfNi0zLTEtMS05NDQxNA_9850ac70-f975-4634-bcaa-ceb2fdb5428f"
      unitRef="usd">-210000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i5aab13ae412a418dad03dcc21e39fa7f_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfNi01LTEtMS05NDQxNA_153bdac1-7908-40d2-ba08-83d0074530a9"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfNi03LTEtMS05NDQxNA_f204b481-3664-4f88-8449-f0d4dda0ffcc"
      unitRef="usd">-428000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i46dd5b7c9aab4334a81feabf9ee87525_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfNy0xLTEtMS05NDQxNA_b5b9ce8a-f096-4d37-8ac9-0d2c19ce7ee3"
      unitRef="usd">-46000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i4a93811c7004483b89e5b2b7d7a47e27_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfNy0zLTEtMS05NDQxNA_ffcc82d0-91f5-45f8-97be-c178ccea9dfa"
      unitRef="usd">-42000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i5aab13ae412a418dad03dcc21e39fa7f_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfNy01LTEtMS05NDQxNA_1980e33e-e94a-40cd-8b7b-2cd866d57867"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfNy03LTEtMS05NDQxNA_21dc181e-e71b-4999-90a3-dcc702ed2036"
      unitRef="usd">-88000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i46dd5b7c9aab4334a81feabf9ee87525_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfOC0xLTEtMS05NDQxNA_bf714236-b5ad-40cb-bc79-737a1bb0ca67"
      unitRef="usd">-172000000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i4a93811c7004483b89e5b2b7d7a47e27_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfOC0zLTEtMS05NDQxNA_c85acf48-9aaa-4295-a163-699ebefca882"
      unitRef="usd">-168000000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i5aab13ae412a418dad03dcc21e39fa7f_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfOC01LTEtMS05NDQxNA_b3dd41a6-9723-401e-85a1-7828bfc971a5"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfOC03LTEtMS05NDQxNA_c3816db0-83f2-4f1e-b7b2-0ad95c3be871"
      unitRef="usd">-340000000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i46dd5b7c9aab4334a81feabf9ee87525_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfOS0xLTEtMS05NDQxNA_48408fa9-360c-46d8-be18-a42809c74750"
      unitRef="usd">324000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i4a93811c7004483b89e5b2b7d7a47e27_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfOS0zLTEtMS05NDQxNA_9413ca91-d72c-4487-9eab-6ba4749ae915"
      unitRef="usd">1522000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i5aab13ae412a418dad03dcc21e39fa7f_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfOS01LTEtMS05NDQxNA_ef91e996-9753-458f-b86c-26997db42731"
      unitRef="usd">-251000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfOS03LTEtMS05NDQxNA_eebdba3e-07ad-417d-b60e-8ccf32eb2414"
      unitRef="usd">1595000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction
      contextRef="i46dd5b7c9aab4334a81feabf9ee87525_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTAtMS0xLTEtOTQ0MTQ_0e6b315a-acd3-497b-bff9-a05ad06f156a"
      unitRef="usd">0</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction
      contextRef="i4a93811c7004483b89e5b2b7d7a47e27_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTAtMy0xLTEtOTQ0MTQ_27dd9749-afe2-45cd-88c9-d343e7861e7a"
      unitRef="usd">28000000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction
      contextRef="i5aab13ae412a418dad03dcc21e39fa7f_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTAtNS0xLTEtOTQ0MTQ_b96bcda1-7bb2-4c31-8be3-b8de63cff1a8"
      unitRef="usd">421000000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction
      contextRef="i43d9233de62a46b78fb5fdd056a05478_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTAtNy0xLTEtOTQ0MTQ_26507b67-e190-4a26-bca0-dfff467625d7"
      unitRef="usd">449000000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if0ae37c4002d4f7c8945b238b450a3ff_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTEtMS0xLTEtOTQ0MTQ_5d8f7fb2-d22b-49b9-b49b-6b5cee30c67d"
      unitRef="usd">58000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0de005cbf7c64be2bbb15d3ad2747c39_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTEtMy0xLTEtOTQ0MTQ_649b560f-eb4c-42f0-a114-24ecfab7e694"
      unitRef="usd">-2990000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idf6a11570b2f4b75989bbe9a432b4263_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTEtNS0xLTEtOTQ0MTQ_b90b244e-973e-4a4b-98e1-5cbf32374334"
      unitRef="usd">-1658000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i99c020a806d84d1cb9f8c8d97329cf8c_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTEtNy0xLTEtOTQ0MTQ_5b9a70fa-ac44-497d-a58a-10ecb452f4a6"
      unitRef="usd">-4590000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i01ae4d028c1e4ad69e3c0718f2a9cad7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTItMS0xLTEtOTQ0MTQ_ca52a4ba-b669-4ced-bb58-7f28a41b392f"
      unitRef="usd">144000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4e2ba0ae31ae4ff3b092f4b0364ad5e6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTItMy0xLTEtOTQ0MTQ_e5687599-7c64-4f6b-994d-697f6a50f0b3"
      unitRef="usd">-2743000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic491ffcc027b4b0ab4d63e1874c095cb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTItNS0xLTEtOTQ0MTQ_4c7fc094-9c35-47c9-af78-d93a4b71899f"
      unitRef="usd">-1830000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i54f6686da6db4e38aeb2e4b266dc881f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTItNy0xLTEtOTQ0MTQ_82767874-275c-4600-9c0e-1fb7bf90f385"
      unitRef="usd">-4429000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i62ef644e97384716bfc5c3610ba4245e_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTMtMS0xLTEtOTQ0MTQ_04da51b7-5b9a-41d0-bef9-a9b7d968c3c1"
      unitRef="usd">1233000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="ib1f9224028414e8f866988517a90edcb_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTMtMy0xLTEtOTQ0MTQ_1ab73ea8-5745-4638-9174-bf5d1cb1296a"
      unitRef="usd">-125000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="ie83ec1e38c7b4f8bbfdc941221d33647_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTMtNS0xLTEtOTQ0MTQ_89c4dc8a-3664-4c8d-9d27-440bde6f6db4"
      unitRef="usd">-1001000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTMtNy0xLTEtOTQ0MTQ_ed922a70-04e4-448f-8f7b-87fd1a17b809"
      unitRef="usd">107000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i62ef644e97384716bfc5c3610ba4245e_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTQtMS0xLTEtOTQ0MTQ_e5509380-795b-48d7-afa8-8a7dcf81fa7e"
      unitRef="usd">259000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="ib1f9224028414e8f866988517a90edcb_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTQtMy0xLTEtOTQ0MTQ_1a468044-e51d-4b92-9bd0-ea16d290f328"
      unitRef="usd">-25000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="ie83ec1e38c7b4f8bbfdc941221d33647_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTQtNS0xLTEtOTQ0MTQ_41d173ff-746a-4b68-87dd-07d5107637af"
      unitRef="usd">-11000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTQtNy0xLTEtOTQ0MTQ_05338bb0-dbca-415d-92ca-ea346c7b5c2d"
      unitRef="usd">223000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i62ef644e97384716bfc5c3610ba4245e_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTUtMS0xLTEtOTQ0MTQ_8a390f26-ba09-495c-a3f2-57c19367dd4e"
      unitRef="usd">974000000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="ib1f9224028414e8f866988517a90edcb_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTUtMy0xLTEtOTQ0MTQ_76efe376-5c21-4ea1-a2ac-3a05c22e05e7"
      unitRef="usd">-100000000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="ie83ec1e38c7b4f8bbfdc941221d33647_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTUtNS0xLTEtOTQ0MTQ_b6ba6341-ac0e-42bb-bf9c-26c48c7acd73"
      unitRef="usd">-990000000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTUtNy0xLTEtOTQ0MTQ_9f3349d9-3ced-48b3-94ee-6b7b2b5c4040"
      unitRef="usd">-116000000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i62ef644e97384716bfc5c3610ba4245e_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTYtMS0xLTEtOTQ0MTQ_fcea9427-89d7-4a1e-b553-8c7845cd2a27"
      unitRef="usd">493000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="ib1f9224028414e8f866988517a90edcb_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTYtMy0xLTEtOTQ0MTQ_b643f86e-b5cb-4882-8085-674b9f802249"
      unitRef="usd">-266000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="ie83ec1e38c7b4f8bbfdc941221d33647_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTYtNS0xLTEtOTQ0MTQ_29dfbae1-c9dc-48c5-9db0-814c169fb98a"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTYtNy0xLTEtOTQ0MTQ_988938f8-8674-4246-a186-26152bd19cf9"
      unitRef="usd">227000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i62ef644e97384716bfc5c3610ba4245e_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTctMS0xLTEtOTQ0MTQ_a58d2a79-c8a4-484d-8206-8329d3487be2"
      unitRef="usd">103000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="ib1f9224028414e8f866988517a90edcb_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTctMy0xLTEtOTQ0MTQ_4f185dc1-751d-4198-acc4-3e7d67096cf3"
      unitRef="usd">-74000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="ie83ec1e38c7b4f8bbfdc941221d33647_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTctNS0xLTEtOTQ0MTQ_16dfa83f-6bc6-4735-b1a0-e1d5bcb2d8e9"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTctNy0xLTEtOTQ0MTQ_60b092b5-4997-4217-89bc-36651c79972d"
      unitRef="usd">29000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i62ef644e97384716bfc5c3610ba4245e_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTgtMS0xLTEtOTQ0MTQ_ef5c0efa-d086-4364-a748-bff35fc69e2d"
      unitRef="usd">390000000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="ib1f9224028414e8f866988517a90edcb_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTgtMy0xLTEtOTQ0MTQ_a1a1db6a-719e-4745-9e03-51ff3011b5f2"
      unitRef="usd">-192000000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="ie83ec1e38c7b4f8bbfdc941221d33647_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTgtNS0xLTEtOTQ0MTQ_d4195150-c4fb-4333-9c40-f084b67a1dab"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTgtNy0xLTEtOTQ0MTQ_39a19031-2a69-4bf3-8767-b2d5c5b25984"
      unitRef="usd">198000000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i62ef644e97384716bfc5c3610ba4245e_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTktMS0xLTEtOTQ0MTQ_c377d6a6-97a5-4edf-986b-78bdaae31fe4"
      unitRef="usd">584000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ib1f9224028414e8f866988517a90edcb_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTktMy0xLTEtOTQ0MTQ_20ce908e-6b6d-45b3-a7a7-e2185898e090"
      unitRef="usd">92000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ie83ec1e38c7b4f8bbfdc941221d33647_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTktNS0xLTEtOTQ0MTQ_080b7586-08d3-4500-9083-4aeb968afc05"
      unitRef="usd">-990000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMTktNy0xLTEtOTQ0MTQ_ff3723d9-f264-45ac-8569-22484baea0bd"
      unitRef="usd">-314000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0f45167f24e645d2ad668c47635fc09b_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMjAtMS0xLTEtOTQ0MTQ_895f8e67-c4af-485b-9d03-51d67da5eb4d"
      unitRef="usd">728000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7b4bb3ccba1a4790beb19a0ca2cd4721_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMjAtMy0xLTEtOTQ0MTQ_6896e453-9717-433c-ba30-ed304807cc28"
      unitRef="usd">-2651000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0df51b82a6bf4ed3a20acde326a2a355_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMjAtNS0xLTEtOTQ0MTQ_a07b310f-209b-4e04-bdd5-f7b9d3fdc3ec"
      unitRef="usd">-2820000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie0803cc4f2c64fa7a8e0196a811eaf28_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83My9mcmFnOmE5ZGVmZGNhYjhhMDQ4Y2M4NTgzMzM4MjQ4NWI1MGFhL3RhYmxlOjgyMGI5ODljMzgzNjQxNzJiNjQxOGQ5ZmVmNDQ0MTcwL3RhYmxlcmFuZ2U6ODIwYjk4OWMzODM2NDE3MmI2NDE4ZDlmZWY0NDQxNzBfMjAtNy0xLTEtOTQ0MTQ_5c19a194-bec4-4b9d-850a-00640b7436d6"
      unitRef="usd">-4743000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RleHRyZWdpb246NGRlODU3NTdjYTEyNGIxMTk5MzBjYzBlMDFmZWViMzRfNTQ4Mg_2f5ee191-3698-49f7-85c6-cd8614a7f6f6">Segment Reporting&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s operations are principally managed on a product basis and include two operating segments, which are the Pharmaceutical and Animal Health segments, both of which are reportable segments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. A large component of pediatric and adolescent vaccine sales are made to the U.S.&#160;Centers for Disease Control and Prevention Vaccines for Children program, which is funded by the U.S. government. Additionally, the Company sells vaccines to the Federal government for placement into vaccine stockpiles.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors and animal producers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales of the Company&#x2019;s products were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.461%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Int&#x2019;l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Int&#x2019;l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Int&#x2019;l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Int&#x2019;l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Pharmaceutical:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Keytruda&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Alliance revenue-Lynparza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Alliance revenue-Lenvima&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Alliance revenue-Reblozyl&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Vaccines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Gardasil/Gardasil &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;ProQuad/M-M-R &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;II&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;/Varivax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;RotaTeq&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Pneumovax &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Vaqta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Hospital Acute Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Bridion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Prevymis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Dificid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Primaxin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Noxafil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Invanz&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cancidas&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Zerbaxa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cardiovascular&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Alliance revenue-Adempas/Verquvo &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Adempas&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Virology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Lagevrio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Isentress/Isentress&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;HD&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Belsomra&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Simponi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Remicade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Januvia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Janumet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other pharmaceutical &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total Pharmaceutical segment sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;39,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;30,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Animal Health:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Livestock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Companion Animals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total Animal Health segment sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total segment sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;44,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;35,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;45,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;35,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;U&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;.S. plus international may not equal total due to rounding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Alliance revenue for Lynparza and Lenvima represents Merck&#x2019;s share of profits, which are product sales net of cost of sales and commercialization costs (see Note&#160;4).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Alliance revenue for Reblozyl represents royalties and, for the year-to-date period, a payment received related to the achievement of a regulatory milestone (see Note&#160;4).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(3)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Alliance revenue for Adempas/Verquvo represents Merck&#x2019;s share of profits from sales in Bayer&#x2019;s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note&#160;4).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(4)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(5)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other is primarily comprised of miscellaneous corporate revenue, including revenue hedging activities, as well as revenue from third-party manufacturing arrangements (including sales to Organon). Other for the nine months ended September&#160;30, 2022 and 2021 also includes $156&#160;million and $191&#160;million, respectively, related to upfront and milestone payments received by Merck for out-licensing arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product sales are recorded net of the provision for discounts, including chargebacks, which are customer discounts that occur when a contracted customer purchases through an intermediary wholesale purchaser, and rebates that are owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part D) benefit providers, after the final dispensing of the product by a pharmacy to a benefit plan participant. These discounts, in the aggregate, reduced U.S. sales by $3.3 billion and $3.1 billion for the three months ended September&#160;30, 2022 and 2021, respectively, and $9.1&#160;billion for both the nine months ended September&#160;30, 2022 and 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consolidated sales by geographic area where derived are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.946%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe, Middle East and Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asia Pacific (other than China and Japan)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Latin America&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of segment profits to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income from Continuing Operations Before Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.531%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment profits:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical segment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Animal Health segment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total segment profits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other profits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unallocated:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(244)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(727)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(597)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(460)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(360)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,623)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,231)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(448)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(358)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,257)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,031)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,312)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,775)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(288)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(487)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other unallocated, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,416)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,628)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,044)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as selling, general and administrative expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as selling, general and administrative expenses and research and development costs directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, research and development expenses incurred in Merck Research Laboratories, the Company&#x2019;s research and development division that focuses on human health-related activities, or general and administrative expenses, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. In addition, costs related to restructuring activities, as well as the amortization of intangible assets and purchase accounting adjustments are not allocated to segments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other profits are primarily comprised of miscellaneous corporate profits, as well as operating profits related to third-party manufacturing arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other unallocated, net, includes expenses from corporate and manufacturing cost centers, goodwill and other intangible asset impairment charges, gains or losses on sales of businesses, expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration, and other miscellaneous income or expense items.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RleHRyZWdpb246NGRlODU3NTdjYTEyNGIxMTk5MzBjYzBlMDFmZWViMzRfOTI_f2f831f8-0321-4bba-ba54-0c60c71f2bdd"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RleHRyZWdpb246NGRlODU3NTdjYTEyNGIxMTk5MzBjYzBlMDFmZWViMzRfNTQ5Nw_4ffdba31-2075-460f-9047-cd1458401b6d">&lt;div style="text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales of the Company&#x2019;s products were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.461%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Int&#x2019;l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Int&#x2019;l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Int&#x2019;l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Int&#x2019;l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Pharmaceutical:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Keytruda&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Alliance revenue-Lynparza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Alliance revenue-Lenvima&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Alliance revenue-Reblozyl&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Vaccines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Gardasil/Gardasil &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;ProQuad/M-M-R &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;II&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;/Varivax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;RotaTeq&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Pneumovax &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Vaqta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Hospital Acute Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Bridion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Prevymis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Dificid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Primaxin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Noxafil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Invanz&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cancidas&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Zerbaxa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cardiovascular&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Alliance revenue-Adempas/Verquvo &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Adempas&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Virology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Lagevrio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Isentress/Isentress&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;HD&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Belsomra&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Simponi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Remicade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Januvia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Janumet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other pharmaceutical &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total Pharmaceutical segment sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;39,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;30,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Animal Health:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Livestock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Companion Animals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total Animal Health segment sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total segment sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;44,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;35,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;45,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;35,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;U&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;.S. plus international may not equal total due to rounding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Alliance revenue for Lynparza and Lenvima represents Merck&#x2019;s share of profits, which are product sales net of cost of sales and commercialization costs (see Note&#160;4).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Alliance revenue for Reblozyl represents royalties and, for the year-to-date period, a payment received related to the achievement of a regulatory milestone (see Note&#160;4).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(3)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Alliance revenue for Adempas/Verquvo represents Merck&#x2019;s share of profits from sales in Bayer&#x2019;s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note&#160;4).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(4)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(5)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other is primarily comprised of miscellaneous corporate revenue, including revenue hedging activities, as well as revenue from third-party manufacturing arrangements (including sales to Organon). Other for the nine months ended September&#160;30, 2022 and 2021 also includes $156&#160;million and $191&#160;million, respectively, related to upfront and milestone payments received by Merck for out-licensing arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:Revenues
      contextRef="iea72657d01094ffca27df83746971588_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNS0xLTEtMS05NDQxNA_9851b5d4-4cab-44e7-a812-36ddcb4068dc"
      unitRef="usd">3331000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i51f8f155c2a64e689c87b4aa3495476e_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNS0zLTEtMS05NDQxNA_6d8ee384-351c-4757-91f9-5b2f59586749"
      unitRef="usd">2095000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie356d6063dec4577b2f6d9d0462d8e7e_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNS01LTEtMS05NDQxNA_bf1ce328-bb25-4a76-b196-48b73e631202"
      unitRef="usd">5426000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib4afb690c9224cf998243be692e833e4_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNS03LTEtMS05NDQxNA_2970365d-ac4e-440f-805d-c312e9177edf"
      unitRef="usd">2580000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iecae6fa25eb342d9927a9e48d4dba455_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNS05LTEtMS05NDQxNA_67e1bd42-fbe9-495f-8549-b4426e2ff075"
      unitRef="usd">1954000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie61d00b2a6bd4ecb9cf24db30e5da1a9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNS0xMS0xLTEtOTQ0MTQ_42d7108e-f725-4569-9884-7757d3c59302"
      unitRef="usd">4534000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if011579e71f84295ac8c9b109ec9a4ac_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNS0xMy0xLTEtOTQ0MTQ_65ca02c2-45a9-4614-b62c-7f98febe5e37"
      unitRef="usd">9307000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ide55c02ef5074706a5aa037e6c934afd_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNS0xNS0xLTEtOTQ0MTQ_883b3960-748d-4bbd-951c-466a0948d1dc"
      unitRef="usd">6180000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i95106ae9af4848e58d3a94156cc2bedc_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNS0xNy0xLTEtOTQ0MTQ_e805ff79-1af9-42c5-a3be-89a795ba603f"
      unitRef="usd">15487000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i770403621f9447659861ff7d3c027d04_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNS0xOS0xLTEtOTQ0MTQ_85991979-0e38-49c7-84e6-1299a2e08019"
      unitRef="usd">7108000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5065fd92c2c5486cb1c8595222c14bcc_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNS0yMS0xLTEtOTQ0MTQ_a2a56154-6e3f-4aec-9cd9-1d1ef4533d9b"
      unitRef="usd">5501000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia40b9cd0df2a4a739c315a7e10c645be_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNS0yMy0xLTEtOTQ0MTQ_378e04c9-5b00-4c60-91b7-948db37efc3c"
      unitRef="usd">12609000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i906fb9f369f24ad5bc7c94038e03d844_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNi0xLTEtMS05NDQxNA_5e41cfcf-85ef-4726-89c8-201779b4193e"
      unitRef="usd">144000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i143fc202262a44e4b14db40020296c68_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNi0zLTEtMS05NDQxNA_9e6cedc8-0505-4089-9a4d-2417e421b74c"
      unitRef="usd">140000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i556dfb6e8e81410c9a188d168e0cdfbe_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNi01LTEtMS05NDQxNA_7ccb7cf0-0f03-4d02-b260-ff9643194c88"
      unitRef="usd">284000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2efc45c7c6e54f1e8772b6a7d931aa76_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNi03LTEtMS05NDQxNA_368d759b-5d49-446b-b616-4b0466002080"
      unitRef="usd">129000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7f250204e97849f4b2597c9ccfb28c6e_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNi05LTEtMS05NDQxNA_9ce5aea8-9bc1-4712-a5a5-230f7d2b88c6"
      unitRef="usd">117000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i80d8c27dc4c4418ba9ec00bdfd449ac8_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNi0xMS0xLTEtOTQ0MTQ_963096c6-e7c2-45b4-a756-2b67eaed6cfb"
      unitRef="usd">246000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8d2992b75ac049a8adc9368ebd3b710c_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNi0xMy0xLTEtOTQ0MTQ_79ff8496-da4f-409d-890d-06c7a1f07e3c"
      unitRef="usd">427000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib17fdc41fa4b4440bdb187fc784528ce_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNi0xNS0xLTEtOTQ0MTQ_748cb8a9-c5e6-4c3a-bb16-936fbcaa9423"
      unitRef="usd">397000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0ef1b7a971cb4cf0aa1e17dbdc38ff87_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNi0xNy0xLTEtOTQ0MTQ_340bfdea-9d88-4ff6-bba3-9ea92a0eba01"
      unitRef="usd">825000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if88c3613f4d7400abeaaf7edc177e242_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNi0xOS0xLTEtOTQ0MTQ_09bb5b16-f25e-4c7c-9799-83672e44301a"
      unitRef="usd">371000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic5b535ea1a074ab0990a6830301b99c8_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNi0yMS0xLTEtOTQ0MTQ_91024a9f-21ae-4e72-83d0-a9a397d77814"
      unitRef="usd">350000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id41d2a02c14f46749037b85143f80400_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNi0yMy0xLTEtOTQ0MTQ_cdb42c85-c67d-4dea-9298-19bb437310a2"
      unitRef="usd">721000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i032733796fec487a9ec5363a6de6bb37_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNy0xLTEtMS05NDQxNA_a3c12d6d-624d-40d7-a29f-c0984d0fd909"
      unitRef="usd">142000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia7bb2d455a324d85b663449ae922babb_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNy0zLTEtMS05NDQxNA_65732fb3-197c-463f-a536-8b8dab362165"
      unitRef="usd">60000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3725ce6128304af89af87fd977d6dc98_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNy01LTEtMS05NDQxNA_22259bd9-5240-4205-a705-63f45c982b02"
      unitRef="usd">202000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibc093a125435445ba1dc79fbc34e64e1_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNy03LTEtMS05NDQxNA_bb53b705-2d16-453f-9b98-54c7a59f6a78"
      unitRef="usd">114000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0e380088b1224143bea2f6722190f293_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNy05LTEtMS05NDQxNA_db9466c0-885b-4d7d-93e0-003e452ebf66"
      unitRef="usd">74000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6c913add24e44a0f9348623b21235818_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNy0xMS0xLTEtOTQ0MTQ_445bfdbe-8253-4b81-9175-ff8423921c14"
      unitRef="usd">188000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i58100a918de34961bf23cb6d60b59996_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNy0xMy0xLTEtOTQ0MTQ_f727ad09-0188-482a-85a2-8100ecae0401"
      unitRef="usd">426000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i57645af2264341fb887ea206a381c869_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNy0xNS0xLTEtOTQ0MTQ_2ceb9c9a-50cd-4fa6-af99-5455569d4873"
      unitRef="usd">235000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if31c285904b6492897698f18cb4e6080_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNy0xNy0xLTEtOTQ0MTQ_6425aedd-cb19-4be3-baac-6b885f1af90b"
      unitRef="usd">660000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3fa27317ec3f442fbd94cf33b21e1eb2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNy0xOS0xLTEtOTQ0MTQ_6fa020a0-c5db-4db0-8fd1-10f782a42d85"
      unitRef="usd">287000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id51eb40c9a094ab9a113fb3a71d38030_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNy0yMS0xLTEtOTQ0MTQ_9c19cc5f-4758-44eb-9a5b-0bedffce2abb"
      unitRef="usd">211000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie892b4d7a041422abdd832f50a0f95cc_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNy0yMy0xLTEtOTQ0MTQ_0072996a-ec94-4e30-ab23-6f3bb75299d9"
      unitRef="usd">498000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib48d2e82b97541f38e95af0a653ab27b_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfOC0xLTEtMS05NDQxNA_e720d4fb-c2d4-4d0b-a2e1-bcdfd567777f"
      unitRef="usd">32000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1eddcb43b5d249a2af4318c0c246a2fc_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfOC0zLTEtMS05NDQxNA_6e42feb6-872b-4b70-8057-8ce8cc16c6ed"
      unitRef="usd">7000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie6ab39f8789a4b6fa4f623fa5d27795c_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfOC01LTEtMS05NDQxNA_c37c8f2a-8804-45f2-b9d6-19be54b5986e"
      unitRef="usd">39000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i25082e66e59a4337a66ed93fb65581c8_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfOC03LTEtMS05NDQxNA_aab5780f-59ce-4b8c-824d-84d2eb0a55c1"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia27a4765f6f24c37a3b517d089f2ecde_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfOC05LTEtMS05NDQxNA_404e8f7e-4405-47f7-9671-84d021a982ca"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7ae58919bbbb482997e5aa8e96123089_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfOC0xMS0xLTEtOTQ0MTQ_50d62c84-3d29-4108-b8f4-247364e96d39"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4269d8f661374131bbab73264dcada9f_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfOC0xMy0xLTEtOTQ0MTQ_a4c50694-dead-4936-9aaa-2207c43a56b2"
      unitRef="usd">87000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i04dbdc20bf3942789452bbdc6a5e24da_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfOC0xNS0xLTEtOTQ0MTQ_72459c8a-9b17-41ed-abb0-310f137b953f"
      unitRef="usd">37000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0715d2eaae6e4be98aee0bd0d1931927_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfOC0xNy0xLTEtOTQ0MTQ_895aa20d-816c-4c81-8ea2-5a39b8c48348"
      unitRef="usd">124000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8ae38dadcae24a6686971665f448c5b0_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfOC0xOS0xLTEtOTQ0MTQ_07b8291f-a0d9-420c-8938-6799e73264aa"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i793c1193aa2f4af6bcef7074919dee8e_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfOC0yMS0xLTEtOTQ0MTQ_cf0b10c9-48d4-4f0d-8bf4-9fdf4c0b1a1b"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i67bb7f002f384902b0a86cfd9129bfc2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfOC0yMy0xLTEtOTQ0MTQ_f5a73739-9ecc-442a-b78b-29f0e432ad9e"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia7bba4c38acc4bc0bb07a1951b9d31dd_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTAtMS0xLTEtOTQ0MTQ_8fdcb819-ec49-4f5e-9703-7add4c11df80"
      unitRef="usd">957000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5d5c095574c748718095a6fbabbd214c_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTAtMy0xLTEtOTQ0MTQ_a4290ab6-53a9-4ab1-be37-bee5585da352"
      unitRef="usd">1337000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2e3866f93c3d42e8b58a917f29364c00_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTAtNS0xLTEtOTQ0MTQ_6b53b082-0b8a-49c9-a93f-75a17b429419"
      unitRef="usd">2294000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifa2f870185b742c0a08a8329ad6e8053_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTAtNy0xLTEtOTQ0MTQ_dfadaebe-210e-41d1-b36b-bfc59b7e64b7"
      unitRef="usd">839000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4008d740f8e74af8a6058243d2c4bffb_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTAtOS0xLTEtOTQ0MTQ_12a55608-89ac-4c7a-bf69-6f4e2f8f3a89"
      unitRef="usd">1154000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i90271b2f98e64375a768383e3ac49db9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTAtMTEtMS0xLTk0NDE0_a64d549e-eb15-4c7d-b576-19cd498a3cb4"
      unitRef="usd">1993000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3c0492792ca04bd3b53c001091f93a58_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTAtMTMtMS0xLTk0NDE0_d89bae8a-4f45-42a0-9886-e40869a4a377"
      unitRef="usd">1803000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5efa6e77fc3b43c197b420bd2930d959_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTAtMTUtMS0xLTk0NDE0_cadbd5a0-6028-4aec-b4c4-95a3a61d6b84"
      unitRef="usd">3624000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia765dfa77c1847ddb5439dfe5e593cc2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTAtMTctMS0xLTk0NDE0_f62aaefc-1909-4477-be6a-aeb22a971acb"
      unitRef="usd">5428000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id754ab9092f541f1bb0c46f84d571073_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTAtMTktMS0xLTk0NDE0_d061adb2-e6ca-4853-a1cd-25361d63c14f"
      unitRef="usd">1605000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8ea41eae43e44e758d73f10739ebef8f_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTAtMjEtMS0xLTk0NDE0_a81028e8-fb0f-4bbc-a8df-a7a0393eb11b"
      unitRef="usd">2539000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6d98ee5588f64bb89006d5f3b1ef89ef_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTAtMjMtMS0xLTk0NDE0_cb45a938-8319-4626-82ee-ca28d14fa5e1"
      unitRef="usd">4144000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i93650c21d0cb4dce8f66684f468b7f9d_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTEtMS0xLTEtOTQ0MTQ_c6708f0a-7f10-41c7-8807-6907de9538ea"
      unitRef="usd">532000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i541aec5947cc4f8794cf3d8f132542a0_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTEtMy0xLTEtOTQ0MTQ_1cdeebeb-963c-4df5-9ff6-0032c77be22f"
      unitRef="usd">136000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i63937b576d734bdd874c9b62aff67ca0_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTEtNS0xLTEtOTQ0MTQ_e1b79287-1b8b-4195-8673-a9749404f53a"
      unitRef="usd">668000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic105ebb39d4f45fdb7e76b65b2f7c268_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTEtNy0xLTEtOTQ0MTQ_e7bca221-2992-41b0-a823-f44fd4bf8a51"
      unitRef="usd">537000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0270857a4ce04adc87d535004968cca2_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTEtOS0xLTEtOTQ0MTQ_32a52a71-72bc-4937-80b3-c9e530aef9ef"
      unitRef="usd">125000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i20ab8f4749914720b66e1986e30f2490_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTEtMTEtMS0xLTk0NDE0_d5dc4ca4-7611-42b7-92ce-bbfdecda5f22"
      unitRef="usd">661000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2d316c927f914028b471fa7baa8efe76_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTEtMTMtMS0xLTk0NDE0_d0f27d41-980b-4006-8c8d-0e40110b60a7"
      unitRef="usd">1337000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if90d628440614f1a8b82d9012cf44d19_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTEtMTUtMS0xLTk0NDE0_be89552b-7d17-4d18-b048-69893f189375"
      unitRef="usd">379000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iff0b49e0a2214244b08be408fb0071a8_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTEtMTctMS0xLTk0NDE0_e89d4164-d09c-4d82-9840-7cc45b64065a"
      unitRef="usd">1716000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie667b194da5b43139fa7eb334e923aea_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTEtMTktMS0xLTk0NDE0_ff1b0ab6-4986-43d3-97f0-61d6883c229d"
      unitRef="usd">1255000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if75e90d893fe4d2daef008b05cd61801_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTEtMjEtMS0xLTk0NDE0_069f7873-015d-4540-bb19-3a44d420cef0"
      unitRef="usd">371000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3221816ac6554c0ea0725b82fcbe8866_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTEtMjMtMS0xLTk0NDE0_2283ab09-8649-4dda-a460-c1dfd9624aa3"
      unitRef="usd">1626000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8664e2a8ba934ef993c8af9df045661c_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTItMS0xLTEtOTQ0MTQ_4570fa7d-05a4-4ab3-9bd4-2d9ebfddaa81"
      unitRef="usd">154000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ice6230b5dd6b4590816f68ea0611bc32_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTItMy0xLTEtOTQ0MTQ_db6f822a-e352-4c5f-8dae-8a640ae35534"
      unitRef="usd">102000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i47949af4a1384b7cb8b878121f95341a_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTItNS0xLTEtOTQ0MTQ_2a112602-e291-489b-8ee1-68e6173c6d0f"
      unitRef="usd">256000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ica0fb5867c7f4a1d81c9b8e00f1299c2_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTItNy0xLTEtOTQ0MTQ_19feeee2-46cd-46b3-956a-bddece01929d"
      unitRef="usd">135000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i02f6c72e13d24ad5b8a9242d1bef0091_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTItOS0xLTEtOTQ0MTQ_eefd538d-fd51-4447-a915-bce06d8eb205"
      unitRef="usd">92000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i81969b509926485a8a666277757c512b_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTItMTEtMS0xLTk0NDE0_fa8e21de-a93e-4aed-942b-e938666b0316"
      unitRef="usd">227000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4e2ff6b002b74a17a257416545ef6e96_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTItMTMtMS0xLTk0NDE0_d3cd318f-95cb-40bf-a2a1-2286ea6d7941"
      unitRef="usd">427000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib71b6b89fc16436fbbf1fa07b6363b8a_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTItMTUtMS0xLTk0NDE0_57d9ec26-24c8-4ee2-a390-4c0808cfb6c4"
      unitRef="usd">218000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9222172d1bf54d24871e696a611f9678_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTItMTctMS0xLTk0NDE0_eca42c74-31f4-425b-8e9f-84b7965a8756"
      unitRef="usd">644000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8a245b712a5e48669e48a3980e039452_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTItMTktMS0xLTk0NDE0_9ef5ff52-514b-44d3-bd6c-774b68279ce7"
      unitRef="usd">364000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i49e1542b3ba3448aa3d564e26fc2446a_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTItMjEtMS0xLTk0NDE0_319a6df4-ca05-4e10-bc80-511934be46db"
      unitRef="usd">229000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i13729599ed214b168aa63442d6acd6de_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTItMjMtMS0xLTk0NDE0_60c8cf92-7428-4b21-a137-d1e79ced7564"
      unitRef="usd">593000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iffcb1d041de24e8a98b15f54038962b9_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTMtMS0xLTEtOTQ0MTQ_d8b6c27e-4088-4394-8ef2-97e1ff60316d"
      unitRef="usd">68000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i57a185fc411c4db19484a70301bf7c8e_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTMtMy0xLTEtOTQ0MTQ_cb2ad482-0f56-4bba-9e6a-a8e848e20946"
      unitRef="usd">63000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i585b71b55aa241f0a689cb6373aa1fa2_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTMtNS0xLTEtOTQ0MTQ_aaba50a5-8819-4609-ad24-6b668aa9e9e4"
      unitRef="usd">131000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i225b62c9d0a94897ac8731640188187b_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTMtNy0xLTEtOTQ0MTQ_e4b45318-2674-451d-9f93-bc067e49a699"
      unitRef="usd">181000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i08bd174e76dc49ca8a3aa6f8f34dba50_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTMtOS0xLTEtOTQ0MTQ_a9e98fcf-eb39-4fe7-88cd-02eb52152317"
      unitRef="usd">97000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i43dfc854ee5a409bac203fb32dd6d61d_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTMtMTEtMS0xLTk0NDE0_569de5e5-cc06-496f-baf6-fe178da7e322"
      unitRef="usd">277000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaa04548d03764d5bb771484866fddd91_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTMtMTMtMS0xLTk0NDE0_0658fef4-ddf3-4dbc-9cb3-f3e3f5780fb6"
      unitRef="usd">280000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i443086dbe08048deaf609109e2104c35_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTMtMTUtMS0xLTk0NDE0_b285bc99-2733-4872-b24b-de4d1ab6bf67"
      unitRef="usd">177000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2dc12fb55f1f4323a0b4d26b08dcc080_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTMtMTctMS0xLTk0NDE0_8006c0a0-4f9e-4d00-980e-356bf3ee9fd8"
      unitRef="usd">457000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iddeb3ed477674caaa13204bb072a80e2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTMtMTktMS0xLTk0NDE0_009b761d-f4fe-4f2f-95ff-500c9fba03cb"
      unitRef="usd">354000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib5ba933b43ec40cbb59d3def6165f9fe_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTMtMjEtMS0xLTk0NDE0_a0d8cb5c-48ff-4168-a36f-d808523b5698"
      unitRef="usd">247000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7eecf1f67c2446fca9b82fda9e4a3949_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTMtMjMtMS0xLTk0NDE0_9743bdc9-0b36-4a77-af04-22ad53433932"
      unitRef="usd">600000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1f6536581b11466c97256e257fb58583_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTQtMS0xLTEtOTQ0MTQ_227ed79e-8b64-4fa2-82a8-2131ba97a991"
      unitRef="usd">27000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idee3f0ae73e249cd86d1e98f97ccfaca_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTQtMy0xLTEtOTQ0MTQ_1af4a0d0-a3bb-4488-8e7d-2521a43f5b7c"
      unitRef="usd">36000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i48b01fe75e9e4b59aaff1fce21ed2c4c_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTQtNS0xLTEtOTQ0MTQ_61c4d92a-f31d-4b53-8ca9-72638c003adb"
      unitRef="usd">64000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i46c35e3833b04258a27da6cf08e2b9c8_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTQtNy0xLTEtOTQ0MTQ_a427f836-0269-4272-97ab-7f4b2fac51b9"
      unitRef="usd">32000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icaf0413c2916445aa22a3cb92baf44d4_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTQtOS0xLTEtOTQ0MTQ_15ff6d55-bcfc-44a3-bc5c-e48cb67b79d8"
      unitRef="usd">16000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib8285527fce2495eaf46116e50f1d995_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTQtMTEtMS0xLTk0NDE0_5a0b85ac-cb77-4325-bb3f-03d807c4e9af"
      unitRef="usd">48000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i47293d92044b48e99da891220e8b196c_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTQtMTMtMS0xLTk0NDE0_d5b62f80-b842-458b-af45-37ecdc585190"
      unitRef="usd">72000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3002e359e24742fbbcf884cc6e683e05_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTQtMTUtMS0xLTk0NDE0_0c7507ff-c08b-4cd9-a7ce-b0f41fed44c3"
      unitRef="usd">62000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6d13aaae18a24197815774e133bc1254_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTQtMTctMS0xLTk0NDE0_5a48a2f8-afc0-4162-baf7-a3b787f1545a"
      unitRef="usd">134000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib67c4ec99f724cbd9c5c4fb76245033c_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTQtMTktMS0xLTk0NDE0_c99005b6-3000-40bd-b170-63b0ffcb95c5"
      unitRef="usd">80000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ieb6d9b7fab874ffe8c1b46f7744ebb79_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTQtMjEtMS0xLTk0NDE0_ebda86e7-aa68-43ea-b7d2-e5c6fb1398be"
      unitRef="usd">58000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i97fe20ab999940b48ca93613926a0d93_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTQtMjMtMS0xLTk0NDE0_4bbe9c08-bc89-4dde-a38f-ea4f0ab33c05"
      unitRef="usd">138000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9e45830a855742509ff087274006e575_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTYtMS0xLTEtOTQ0MTQ_df1fa743-5f47-497a-acba-78bb61a685a1"
      unitRef="usd">233000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i296fff24993d4fcd957a26fcdc376978_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTYtMy0xLTEtOTQ0MTQ_dcf301f1-846a-40f4-8515-a0b20a66ebf9"
      unitRef="usd">190000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4dd006ef18ba4a51a0b449e2d732ad40_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTYtNS0xLTEtOTQ0MTQ_e96556c0-92d1-4aeb-be62-74919440de7f"
      unitRef="usd">423000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i685056aa30374b748c91c804e8696590_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTYtNy0xLTEtOTQ0MTQ_6cf6fb92-330c-4273-ac88-6c4331f7f59c"
      unitRef="usd">181000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i265d220c8c194add815250d378abc902_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTYtOS0xLTEtOTQ0MTQ_416fa889-7f9b-4b8e-9a83-1b2af91ac96d"
      unitRef="usd">188000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia8a9bf2b9f8d40f5891228af7ee73a36_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTYtMTEtMS0xLTk0NDE0_48fd3100-ea4a-42e1-bbd9-3951e38a7db3"
      unitRef="usd">369000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i81070fb665a64fc9a92e648528dced5c_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTYtMTMtMS0xLTk0NDE0_d985d473-4a6a-4db9-b041-1009081ef487"
      unitRef="usd">665000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idec7bac0c49d4b1db34ff840907bd798_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTYtMTUtMS0xLTk0NDE0_de37ca47-5edf-405a-8893-762c9fbfae24"
      unitRef="usd">579000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if971fc9feaff4a3c9a5eb10f74e1957b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTYtMTctMS0xLTk0NDE0_f8cf85c4-0d4f-4d99-b8b4-3c1c5c8d95f0"
      unitRef="usd">1244000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if294e1aa3b5d46f8b28217723b28ef92_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTYtMTktMS0xLTk0NDE0_137f8945-3fe7-47ed-a79a-3884598ce6a9"
      unitRef="usd">545000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0a7dcef569de4308a78959562aefdfa5_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTYtMjEtMS0xLTk0NDE0_97ed6602-0f68-4793-bed7-ac4d2e3107a3"
      unitRef="usd">551000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4e0a807fffc84f018f4b4464b1bf9072_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTYtMjMtMS0xLTk0NDE0_5d6a9c97-c7f5-4261-b384-45c7713b492f"
      unitRef="usd">1096000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1687a5207479439f8e16e57fa7ac046e_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTctMS0xLTEtOTQ0MTQ_8087e7f8-a829-4431-a433-12f29ef5d482"
      unitRef="usd">49000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibbcc716f1b8a4294a8ac7755d58d7e4a_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTctMy0xLTEtOTQ0MTQ_5f394388-829a-4424-bf88-e57041726a14"
      unitRef="usd">64000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i60ba948e10b04bf89e609fd126195611_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTctNS0xLTEtOTQ0MTQ_c09fb3a8-a1d9-432c-8ee9-bffabe6226c5"
      unitRef="usd">114000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i65e784f938b34793a6b9a65d6d6cc86e_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTctNy0xLTEtOTQ0MTQ_8429d9f6-44d8-4264-bc8e-69f22019fb06"
      unitRef="usd">39000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i01d05ced165944a29e318440a8eca779_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTctOS0xLTEtOTQ0MTQ_7c50e09f-10db-47e3-bece-2919fec23120"
      unitRef="usd">57000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id9538df57cac43428fedf093f6e753f1_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTctMTEtMS0xLTk0NDE0_4581e48c-7edc-4fc7-8fd2-8c3d182bb687"
      unitRef="usd">96000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4649f1b3f8614c1fb6696040dc8e573c_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTctMTMtMS0xLTk0NDE0_9d4b7add-1f62-427d-99a4-ea62bc0b90ee"
      unitRef="usd">136000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iac88839387e24360951822241927d01c_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTctMTUtMS0xLTk0NDE0_83c49dab-dec3-4804-88b2-ba8457595b0d"
      unitRef="usd">174000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iccc7aacfa4b9410a985e8faec1f16f9e_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTctMTctMS0xLTk0NDE0_0216a1ab-fc31-40f8-ae6a-a05336299974"
      unitRef="usd">310000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i182af2613ed348cf9d6dc2f9be178a66_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTctMTktMS0xLTk0NDE0_14157c18-a788-4bc0-9393-d13bf1a85656"
      unitRef="usd">111000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id57f4527272f411e8eec3fcf5da09481_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTctMjEtMS0xLTk0NDE0_92641edd-6f57-48b7-8ffc-dbe6c6d1d2d6"
      unitRef="usd">159000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifacfb5ed95734fe7b4fc8bba627a8845_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTctMjMtMS0xLTk0NDE0_acfe643a-9edd-4f8d-a2e0-7af14527c5f0"
      unitRef="usd">270000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifd682219d26f42589766951ab88e1c3e_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTgtMS0xLTEtMTAzMzg1_858d6a51-9842-4047-a4ae-4412d7d4119d"
      unitRef="usd">72000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i86d0c8eba6b548b2980070d44447b21d_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTgtMy0xLTEtMTAzMzg1_a8f0ae8e-013a-4482-9c20-a2b9a6a6f9b3"
      unitRef="usd">6000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ieafdddb927484d7aa5ac090781377625_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTgtNS0xLTEtMTAzMzg1_72ea36f7-65aa-4810-a612-13869d83af70"
      unitRef="usd">77000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie32bcc064d0f4de8ba4e1e7150a0afe2_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTgtNy0xLTEtMTAzMzg1_0cb42da9-e296-4988-b75f-7ad70b3b3cb9"
      unitRef="usd">52000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8f5e562de1574da48919247a881ec58c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTgtOS0xLTEtMTAzMzg1_bbb71641-b595-47c1-a1b2-15fd1298af49"
      unitRef="usd">2000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i98f319f069c14e75848d9f78788ecfd8_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTgtMTEtMS0xLTEwMzM4NQ_b63d3749-fd86-419d-bb5e-1086c7b2a559"
      unitRef="usd">54000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i461a9aeec04e4fd48e331e0d1ae98fcd_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTgtMTMtMS0xLTEwMzM4NQ_98135b54-a976-458f-ae2c-fae570f746c3"
      unitRef="usd">184000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i26820a66f9dc4af881c3df742b2e0a5a_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTgtMTUtMS0xLTEwMzM4NQ_bdc16cea-e3a8-4ddd-86b6-213353b6d20d"
      unitRef="usd">12000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7115d8a391344fec99e5f60ebfc980dc_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTgtMTctMS0xLTEwMzM4NQ_404ca75e-59b7-468e-8ebd-f2dfc1d8ff8c"
      unitRef="usd">196000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ieab69433fba045ac8b7a8451cd492815_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTgtMTktMS0xLTEwMzM4NQ_193cad6b-a4ba-4629-9ab3-bd5c78ff52ed"
      unitRef="usd">108000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8c1221038a2149c9b97c80c8f611679c_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTgtMjEtMS0xLTEwMzM4NQ_91ea062b-6b7a-4859-b02d-32ff64f8d87b"
      unitRef="usd">7000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i36a64ebf107e4f91a169bc853c046233_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTgtMjMtMS0xLTEwMzM4NQ_5e7dd933-8296-4645-b1ad-dc6a9901bc0e"
      unitRef="usd">115000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i71f41596ea7a4b3e8416589c8c7a8138_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTgtMS0xLTEtOTQ0MTQ_c2402e4e-3c1d-497f-9d04-5e8e52888c9e"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1ad0235b784c4439a674f0deccf68980_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTgtMy0xLTEtOTQ0MTQ_37649f4d-564e-4ec8-8a0b-e0877c720965"
      unitRef="usd">63000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib964e6bb433d42f49dd769839ac28238_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTgtNS0xLTEtOTQ0MTQ_7278c3d3-43ed-435c-a6b7-4f13fbe884ec"
      unitRef="usd">63000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1001be10a5d043f397906bd36d10ee6a_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTgtNy0xLTEtOTQ0MTQ_ac0fc868-f165-40f1-9220-55a0577f4db8"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id51b949ade4f41899e4a18fbbbd2a1ff_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTgtOS0xLTEtOTQ0MTQ_658dfd74-a6f1-4825-a81f-fa65b9f8ff00"
      unitRef="usd">69000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibdb4e966b7da4d629f6fe2c428ed1ef1_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTgtMTEtMS0xLTk0NDE0_0f843325-49fc-4788-81ab-7c012b85c21b"
      unitRef="usd">70000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8c824b0655ff4c1fb993fba481533fb9_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTgtMTMtMS0xLTk0NDE0_50b1e712-2c52-40ed-a52d-c2ced836cea3"
      unitRef="usd">1000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia8e89580305548a490f0bbe9f637440e_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTgtMTUtMS0xLTk0NDE0_0d3d46e0-e38b-417a-adac-b198ac91324a"
      unitRef="usd">185000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i37ba015ecbcd405abc7b38785b7dcfd2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTgtMTctMS0xLTk0NDE0_dce8e02c-27a6-4535-b1bd-89ab3d713c99"
      unitRef="usd">185000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7cf6dc7c6c1c4858bf616a299a8c6420_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTgtMTktMS0xLTk0NDE0_de460aed-0dca-418c-89ba-d620a7839915"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i81ea1f35405a45cebb4edeb8610e28c5_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTgtMjEtMS0xLTk0NDE0_e2d77df7-e936-4235-aa9f-6dd1cd8c7525"
      unitRef="usd">194000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i01c00548f8444dec89b6744b02a85fa3_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMTgtMjMtMS0xLTk0NDE0_c401c17f-583f-4a70-a239-1143aadaffb5"
      unitRef="usd">194000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icd81b81346ae4eca826a989395f148a0_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjAtMS0xLTEtOTQ0MTQ_59d432de-30d9-49be-abea-fcad953ed661"
      unitRef="usd">13000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0f785e58506544309ceddc1407668851_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjAtMy0xLTEtOTQ0MTQ_cfb77c94-baa9-4299-aa30-cc3ca1fda255"
      unitRef="usd">49000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i07bb128b4a6049b9a45a4721c32a8c32_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjAtNS0xLTEtOTQ0MTQ_5469a214-a6aa-44be-8131-223ba9cf8d15"
      unitRef="usd">62000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i85318a4d743d44788fda10cd96301c42_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjAtNy0xLTEtOTQ0MTQ_d504ff40-ea35-42e9-b187-78a9e7d8dea8"
      unitRef="usd">19000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idf4fe0a8e4d04a23976ea2fabe3f04e3_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjAtOS0xLTEtOTQ0MTQ_5005ce96-2825-466c-ad11-e8e7b68416b5"
      unitRef="usd">45000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i098c29dbbb064deea26d4c4f34218264_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjAtMTEtMS0xLTk0NDE0_1a91a63b-9c35-4512-80d9-24d38a3686e0"
      unitRef="usd">64000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib4a66566cbcd44aa9f077d342fdead01_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjAtMTMtMS0xLTk0NDE0_7fa0afa7-d5f1-4ae0-a8d0-af37804ac2b6"
      unitRef="usd">39000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie28efd140c154386aad5f6975c8566b1_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjAtMTUtMS0xLTk0NDE0_64b5c050-7157-4b50-8071-cb680dc9f69e"
      unitRef="usd">141000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5585d223173d42a68c6f66af1f246d09_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjAtMTctMS0xLTk0NDE0_22c28dff-ba33-4384-a26d-45b0e9b3f362"
      unitRef="usd">180000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3fef72442c5244cfb5a176eb81962df1_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjAtMTktMS0xLTk0NDE0_281930cf-5e5d-46a5-848d-e351d0a702e8"
      unitRef="usd">48000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie99454bc8d07443483aa94820869b584_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjAtMjEtMS0xLTk0NDE0_b551b175-ad8a-41b8-b0f3-e94925fc7295"
      unitRef="usd">149000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icf5e6b24740e4c4fb42a6d01883937d7_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjAtMjMtMS0xLTk0NDE0_0bdbeb3e-f62a-47f7-95fb-5c026ef01959"
      unitRef="usd">197000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idcf29d14a518483185f8a99cefa1fa46_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjEtMS0xLTEtOTQ0MTQ_d50da028-1714-414c-83fd-42f9b97c9411"
      unitRef="usd">2000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i19565b312a7b438cbc10861858b1d449_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjEtMy0xLTEtOTQ0MTQ_7f5c246f-8717-4473-a7a7-d193c88f781a"
      unitRef="usd">48000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icff15fd8bd1a4d6bb79c3beaf3519324_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjEtNS0xLTEtOTQ0MTQ_7e9d3775-a040-4d35-b440-912c12cdfde1"
      unitRef="usd">50000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia7d439da126f4be48f56a1860640621b_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjEtNy0xLTEtOTQ0MTQ_3556e3af-f924-4bd1-a983-1afa2ca84399"
      unitRef="usd">-2000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia2a2dc400d82406cb2a4f1761521e529_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjEtOS0xLTEtOTQ0MTQ_342f5c58-b139-4ac2-a085-ed861b802572"
      unitRef="usd">55000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i819facc7b2e14484a4cb6e0c2a7f93df_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjEtMTEtMS0xLTk0NDE0_2e4662c3-b9fe-4dee-b356-ae6cf0d70cff"
      unitRef="usd">53000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7fe58d8dc5984f3cbd65658d904a9481_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjEtMTMtMS0xLTk0NDE0_8d4fb6a2-4c7f-4dd6-af06-0e67b71c6001"
      unitRef="usd">4000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ied9c00ac4d8941b4a017cbbccf4329cf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjEtMTUtMS0xLTk0NDE0_a60fc71d-5d90-4ebf-bbfd-210b850e1e43"
      unitRef="usd">144000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i29dea2ed4a654c42952ab41ac972c731_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjEtMTctMS0xLTk0NDE0_49810a84-5e86-4b79-8221-02c21118125e"
      unitRef="usd">148000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i099da3aa99d1482b90ff756d321bd102_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjEtMTktMS0xLTk0NDE0_1f83ee22-789c-4be1-86f1-3c7242c18f27"
      unitRef="usd">-2000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3f2ab84f59744e4aa1b796e01ba81c31_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjEtMjEtMS0xLTk0NDE0_b6d47832-5fd6-4b76-9fff-5826a1dc7135"
      unitRef="usd">159000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i312d000608614fe586d2aedc23ea4dc0_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjEtMjMtMS0xLTk0NDE0_bba6dd4f-b176-4d4d-bc00-b0c04b1c2aa3"
      unitRef="usd">157000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3ea07e7b467b4e8ba73b1f10c45b4e02_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjItMS0xLTEtOTQ0MTQ_c9e5de6b-159e-4cf3-a93e-a0dfa3ecf875"
      unitRef="usd">1000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4b9ab232d5ee4970b968974b33aa9605_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjItMy0xLTEtOTQ0MTQ_32c540aa-6ae2-4045-b1b0-e8993a7f2503"
      unitRef="usd">42000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i46397225389c4799b9e0002cbf9db54c_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjItNS0xLTEtOTQ0MTQ_a51df231-ad56-4ec6-92bd-7061048e3610"
      unitRef="usd">43000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i38f7b98bc0114fcfac64f5b19a7f97b5_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjItNy0xLTEtOTQ0MTQ_697385ec-dc17-49a6-a1d1-1db6a4e0bc9d"
      unitRef="usd">1000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie43d1efcc1f2463a9e6ceb872a750592_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjItOS0xLTEtOTQ0MTQ_e0bf806a-ffcb-45a5-aa10-09d33ae99249"
      unitRef="usd">56000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i08ddddbcb59e45afa01649b4a5c0df02_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjItMTEtMS0xLTk0NDE0_1192c3cb-6d56-4579-a432-b4f20f382629"
      unitRef="usd">56000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6441c5f89ab7428dbb9ce2a77c7d178c_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjItMTMtMS0xLTk0NDE0_42ed1652-dcd8-4c90-ad99-5c873d99b308"
      unitRef="usd">5000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2859c498f1484388a0c92b4ee1831d83_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjItMTUtMS0xLTk0NDE0_401db23f-efeb-4d34-a695-e44956c95e09"
      unitRef="usd">133000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if28586c5985c4caeb1cdebafd9ae7432_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjItMTctMS0xLTk0NDE0_797a41e0-ec06-4c32-9af9-39192b61d9b0"
      unitRef="usd">138000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3a21006f6f464cf49d94de523666ae32_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjItMTktMS0xLTk0NDE0_eb6ac9d6-1882-4674-9f20-d04a2d0bfea1"
      unitRef="usd">4000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9bfa337eca3546e49132dfadd33405e8_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjItMjEtMS0xLTk0NDE0_8610ede6-1f76-4a58-b542-99edf0840680"
      unitRef="usd">164000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i64edd776e6f848789f0bcc6abe69aed9_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjItMjMtMS0xLTk0NDE0_84a0b188-0e89-4e1f-97c6-3ff39472c559"
      unitRef="usd">168000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idba160b3c84d4ded8e2ad24897f18196_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjMtMS0xLTEtOTQ0MTQ_7bb98f88-c23b-47c2-9bea-9e118b16caad"
      unitRef="usd">24000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ife2e7a726c45443f849fea10fc2e4265_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjMtMy0xLTEtOTQ0MTQ_4f119fda-ab75-4639-8f0e-d3bd5ad474ac"
      unitRef="usd">19000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie9b27b189bfb40db8b98e551a462b6d6_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjMtNS0xLTEtOTQ0MTQ_e0f08ae7-9d5c-4988-af00-d38e444eced4"
      unitRef="usd">43000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie7ba48e565be4304b70078ffe4498c8c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjMtNy0xLTEtOTQ0MTQ_27960b85-95b5-4afb-80ee-f2685f75a1bd"
      unitRef="usd">-1000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5b9d23875fe444829c441808824a5a21_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjMtOS0xLTEtOTQ0MTQ_47a8b8de-9be2-43bf-a61e-cfa937dc9599"
      unitRef="usd">-1000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib2fc16b785504c63ae17c7cdb9c1c0b0_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjMtMTEtMS0xLTk0NDE0_c4d7e3e2-3ca8-41d9-8413-6de0a379551a"
      unitRef="usd">-2000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i65ebba197f3740bdb38b629ffcf72ad5_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjMtMTMtMS0xLTk0NDE0_279a3432-2bfa-401f-a534-008f3e07ebeb"
      unitRef="usd">64000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3da352c9af7146f4810e485c59906a57_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjMtMTUtMS0xLTk0NDE0_da21a938-9593-494e-94af-19f0ba624a77"
      unitRef="usd">55000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i097267c7483c4f3baaa83fa953994d7b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjMtMTctMS0xLTk0NDE0_c7c60828-4f97-42e3-9263-1f38e96769b2"
      unitRef="usd">120000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id92b88c5c7c54cd897660ab28b07a038_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjMtMTktMS0xLTk0NDE0_e7f94949-b7de-4663-bad0-1ab5405aa0bb"
      unitRef="usd">-5000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iebc064d77e2e4de99ab716e87a9baf1b_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjMtMjEtMS0xLTk0NDE0_158ffcec-6bc5-4dc2-b9d5-b643fb7efba8"
      unitRef="usd">-6000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7010efc10b11415da35666aae647506f_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjMtMjMtMS0xLTk0NDE0_03d4757f-5af2-4772-9bf3-8cfb750aec67"
      unitRef="usd">-11000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic6d0e90eb56c49078c2cd876e4644e59_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjUtMS0xLTEtOTQ0MTQ_37e4603b-9db7-4963-97c5-e4dec4137152"
      unitRef="usd">85000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7ea29fb65ae64c838799c4c459626dfb_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjUtMy0xLTEtOTQ0MTQ_265a219a-16c2-4d3c-bca7-237610d5f30d"
      unitRef="usd">3000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifeca289c0b3048be95fdcdfd0d64787f_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjUtNS0xLTEtOTQ0MTQ_0c81ba3b-eee1-42ae-9ba3-a2c0d33f8410"
      unitRef="usd">88000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib14fcc9488ae4e079debc5ad6830716e_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjUtNy0xLTEtOTQ0MTQ_bfd229f5-7555-4b04-9642-ecd22fdedde4"
      unitRef="usd">73000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i704a839b6eba4ee4be94748f20064afe_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjUtOS0xLTEtOTQ0MTQ_7e944972-2fad-4cf1-b463-ed18fd335fe0"
      unitRef="usd">27000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0a3a4ecb829e4aa78305ce022676ad3a_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjUtMTEtMS0xLTk0NDE0_a38a72fe-5782-420f-b7da-1356b4b1c4b5"
      unitRef="usd">100000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic9dc2db957bf417fa3ce1024b7aa3b58_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjUtMTMtMS0xLTk0NDE0_3bae974c-8bad-46d5-8061-97edf40be3a9"
      unitRef="usd">244000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie752e3ceb65d4068848193b5489d1ca3_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjUtMTUtMS0xLTk0NDE0_f62bb2b2-5a27-4525-9152-f9a84a4c8471"
      unitRef="usd">14000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8121dcf41149486dbe2439280ef18566_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjUtMTctMS0xLTk0NDE0_011261da-6d2d-4639-a56b-57fda453e74f"
      unitRef="usd">258000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1535a34aeb8e4f90b2765beaa325bd11_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjUtMTktMS0xLTk0NDE0_e352c6ab-05ba-46a8-bd6a-bd17c5e5326a"
      unitRef="usd">222000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id4bc4cefe1a64728bdc75ff662c4916e_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjUtMjEtMS0xLTk0NDE0_e3e88cfd-605f-4fc3-8fde-bd60d52436a3"
      unitRef="usd">26000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i03f405d0ec044a3ebbf4e986c0cf3fb0_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjUtMjMtMS0xLTk0NDE0_89673ace-ff23-4b63-8056-6da559d325ef"
      unitRef="usd">248000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id39b9efc953f44ddb788ea54e6fcb237_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjYtMS0xLTEtOTQ0MTQ_a129ef58-3d32-49c4-8d60-c9fa0ba6761f"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i17605919063e4da08e1c137da9bd3927_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjYtMy0xLTEtOTQ0MTQ_8bfcdcff-88ae-4f7f-81a9-49ed13f69e03"
      unitRef="usd">57000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i64942fccdbcb49f7bde01d647d805b92_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjYtNS0xLTEtOTQ0MTQ_9d8631f9-6e62-458b-8415-e7f3da6bfcb6"
      unitRef="usd">57000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9d4ef7a87b2d430ab843f888c43c62b3_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjYtNy0xLTEtOTQ0MTQ_512a373b-289c-4d8c-a350-1fd94d8f61c6"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i367dd154acc944f59b4091bdf4c3f88e_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjYtOS0xLTEtOTQ0MTQ_88ac67fa-262f-4f9b-b8c2-dbcd744783d6"
      unitRef="usd">59000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifafb1bde68d54e8e8d59fc667e7ad4db_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjYtMTEtMS0xLTk0NDE0_b337b32d-3a1b-4e70-8acc-7142760fcf0a"
      unitRef="usd">59000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic98aa56795ec4ca9818d28b0c15c1e2c_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjYtMTMtMS0xLTk0NDE0_f00635c6-3787-42a2-b0b4-be757bee9f6d"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7d8f2e37a7fd434e9e575af158e4ebe9_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjYtMTUtMS0xLTk0NDE0_4a1affba-d58b-45ca-b5c6-83e35633b4d5"
      unitRef="usd">181000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icf83422a855b450a895434e02b798a86_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjYtMTctMS0xLTk0NDE0_e2997fcc-dfc5-470e-a93c-de179c3accbb"
      unitRef="usd">181000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iba5e8751427840c2bb6a518bf2c47c4f_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjYtMTktMS0xLTk0NDE0_9d9f2830-418a-4a4f-82aa-775422c06c97"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ica014ad63af547c985fc0232bff3d28d_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjYtMjEtMS0xLTk0NDE0_2ca62048-f067-44d4-8b82-5ce3c1fbc708"
      unitRef="usd">188000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic864a76a6f394f3c8b7bcf2a3d9f5b0f_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjYtMjMtMS0xLTk0NDE0_91e4d320-bab5-4445-b878-b7451ce61866"
      unitRef="usd">188000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i143277cfa467423cb7fd3d1598c01536_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjgtMS0xLTEtOTQ0MTQ_91da7a4d-09f7-4933-9e81-3012f0c6773e"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4fe74c4805104d82a48ee99f39bcc191_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjgtMy0xLTEtOTQ0MTQ_772121e1-48e1-4194-b9d8-521228de6be7"
      unitRef="usd">436000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ida94e955b46346cca755a98f10e0cbd8_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjgtNS0xLTEtOTQ0MTQ_30670029-30ad-4e28-862a-551f117cb7f7"
      unitRef="usd">436000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1db5110e8cf94c3b870dd8e4773cc5f5_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjgtNy0xLTEtOTQ0MTQ_f349fe7c-1a40-407b-82a4-fb97a45322f6"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i33c340fce6894f5cadf9174aacc50b85_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjgtOS0xLTEtOTQ0MTQ_1441dcb5-e4bf-413a-a01b-ff52465d09dc"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i541eb2cfc8a1420f8d0c271d8d5b58a0_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjgtMTEtMS0xLTk0NDE0_2e512999-7d67-430a-afd3-19e64c7d7f0b"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ife50c78eda8146feada734d5de383031_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjgtMTMtMS0xLTk0NDE0_27318225-91f0-452a-bbc1-f30c80983f9f"
      unitRef="usd">1523000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i715add2286974690806d8b1238a739dd_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjgtMTUtMS0xLTk0NDE0_b1d9b6ce-36cc-4f80-b992-35dc398a9968"
      unitRef="usd">3336000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i88c57ba1eaf34b319e49c2126ff89f7a_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjgtMTctMS0xLTk0NDE0_7877fda3-dc17-43a1-8358-891f25bdc28c"
      unitRef="usd">4859000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i44361401a04e43f58bdac9768e7239c0_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjgtMTktMS0xLTk0NDE0_ff8e4d1d-2c66-4815-a69d-ee637112140e"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9f94cdf096df4338a0b6aad26feb4378_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjgtMjEtMS0xLTk0NDE0_c7da37a2-bfca-4bd9-a9e1-f75fff08f9a3"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if4a89e0cf61f4161b7a76d02b5e911b6_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjgtMjMtMS0xLTk0NDE0_d19c23c1-51a3-4944-bcaa-3a8eae3f25e4"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic0219c877aef4d4d9bb018be638aca5a_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjktMS0xLTEtOTQ0MTQ_cef4b112-0a54-4c88-8798-6466fd3d7369"
      unitRef="usd">68000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i141c5ef857bb4d94935c24ab8fdae687_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjktMy0xLTEtOTQ0MTQ_129eb004-d022-406f-af45-f2d3324aa339"
      unitRef="usd">93000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ied8cbea9f58646b5a29e12373656d30a_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjktNS0xLTEtOTQ0MTQ_610f300d-da28-4c7c-864d-8f9cce821eca"
      unitRef="usd">161000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7192b6bdb8d54ccd902726f77a8a569d_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjktNy0xLTEtOTQ0MTQ_cc0a57fe-7b22-464c-a632-eba294d9186c"
      unitRef="usd">77000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4cdb131b17ab470c9b46b991b14cadba_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjktOS0xLTEtOTQ0MTQ_c1ad521b-5a0c-49d8-8373-62541c514af1"
      unitRef="usd">112000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie20a9ffe89114cf3b00ba22b79b96752_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjktMTEtMS0xLTk0NDE0_64e1bd56-f79b-477a-a5b4-52a3eab4dcca"
      unitRef="usd">189000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i01b61b9f737f4bfeb5d1e650b58a2ff0_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjktMTMtMS0xLTk0NDE0_89217467-c402-49ac-b2bc-cfaa8e499b63"
      unitRef="usd">196000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i820113b59fbd45409278436c72703385_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjktMTUtMS0xLTk0NDE0_bf759fda-59e9-440c-a760-5800816ca2ed"
      unitRef="usd">270000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i17a30514b5f04fcaa8af426469cdf39a_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjktMTctMS0xLTk0NDE0_9e5da61c-e43f-456f-9190-5476fde22123"
      unitRef="usd">466000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib31766a1f9ca49ed944d511b368436c8_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjktMTktMS0xLTk0NDE0_483ea208-8778-40e6-a909-aa7893bd8ed1"
      unitRef="usd">222000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i462cdaa6b90e45118710c4ae51e35e3a_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjktMjEtMS0xLTk0NDE0_850bf0cb-9fab-4ed8-ab8a-1bc9ab906187"
      unitRef="usd">368000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3f7a6b941763460e99621c2796d825ab_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMjktMjMtMS0xLTk0NDE0_c730413d-78b3-48f7-96c4-1c0f9aa91111"
      unitRef="usd">590000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifb68c7470877490d9ceaade2f13e2c2e_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzEtMS0xLTEtOTQ0MTQ_e0dafc02-992a-4052-9045-30d051b8d848"
      unitRef="usd">20000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i671e7da6a18b400fbf6ead97234042fc_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzEtMy0xLTEtOTQ0MTQ_d9acd31b-ad86-4b77-9b3a-19b48df19ccb"
      unitRef="usd">42000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5651cfaf52164a8ab6636928219a061e_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzEtNS0xLTEtOTQ0MTQ_c9fc011d-381e-4c8f-b173-a252a4e1f2f2"
      unitRef="usd">62000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0c45c8df98804459883ad5bff7805922_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzEtNy0xLTEtOTQ0MTQ_7c23fed1-a18b-4777-a081-ad809a034b95"
      unitRef="usd">23000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i080623730f624bba8919833c19347c19_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzEtOS0xLTEtOTQ0MTQ_b8c1e136-0637-4dca-8dca-fb45ff9c8e51"
      unitRef="usd">58000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idf02f0982f4a409b968d6265bca89fa6_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzEtMTEtMS0xLTk0NDE0_05d28c62-3c50-41c9-b29a-04ef8e36e59f"
      unitRef="usd">81000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idd09a4e622c048fa8abcdbbf99ea24f5_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzEtMTMtMS0xLTk0NDE0_499ba6f7-7e4c-45de-9559-7882d09d3b11"
      unitRef="usd">60000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0f4560eb1ee848ef935cf4f82c3c219b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzEtMTUtMS0xLTk0NDE0_d0ece9ec-eb92-4ae2-a041-36bc74741684"
      unitRef="usd">139000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i28b8b17a1b1c4ca4a2c3921c1d59b492_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzEtMTctMS0xLTk0NDE0_05424810-deed-4beb-bbaa-5c58d5bc15c0"
      unitRef="usd">199000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i29caa9c297504c4895226b55191e48e9_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzEtMTktMS0xLTk0NDE0_490c3e4f-7e2c-45a8-98ec-8467ecf77aa8"
      unitRef="usd">56000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib6f8d0cdf8b34365ad1b5066369bb0c6_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzEtMjEtMS0xLTk0NDE0_fe7911a9-fda6-4c46-a41b-aa820837e7f6"
      unitRef="usd">183000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i39f38d6401dc4807878d88582b25ad7a_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzEtMjMtMS0xLTk0NDE0_ecacfccc-7d4d-4512-9b52-a1d550d80543"
      unitRef="usd">238000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8a5b415115604e5eb5904c3c92e949f3_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzMtMS0xLTEtOTQ0MTQ_20864897-e025-4671-a64d-a14da71e4cc6"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i75c73a0ad09046059e2cacc3ca286709_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzMtMy0xLTEtOTQ0MTQ_998c6b9e-560c-41fd-8698-79aebc056531"
      unitRef="usd">173000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i30253a8fdb944b15bcfad5941879e748_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzMtNS0xLTEtOTQ0MTQ_de9518ee-8f9a-4147-a778-4b9c49001a30"
      unitRef="usd">173000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i477c1387bccc4478a6df52168a873e5e_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzMtNy0xLTEtOTQ0MTQ_2151a128-b27b-4ae3-890b-505229ee03b6"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if6e598d60eca4ef790eea98e2e3cf9fb_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzMtOS0xLTEtOTQ0MTQ_b8ac3a5d-ba71-4a28-b40f-69f0295b5636"
      unitRef="usd">203000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ide9c58e91b6e49748dcf2aabec8cefe5_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzMtMTEtMS0xLTk0NDE0_2ca3a955-515a-4b6b-993a-32408fec0847"
      unitRef="usd">203000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifaba7e93e3174a09b5fe7fadb95cf5a8_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzMtMTMtMS0xLTk0NDE0_c3e74b54-7849-4c6b-b779-2d6ac9728a9c"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id72e0113997c414097828708b9146825_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzMtMTUtMS0xLTk0NDE0_f59d8893-ec5f-40ef-89e4-4d0705ff8e0c"
      unitRef="usd">540000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i31af4a0627894e13a9092294ef53779d_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzMtMTctMS0xLTk0NDE0_b7a5e771-b89f-439c-8037-a38dc4b86279"
      unitRef="usd">540000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i82914b6cb0b04d3b8dfa0c36fcb1e3e1_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzMtMTktMS0xLTk0NDE0_19841a0b-a2f9-4b77-9ba4-28e18953c132"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i875eaced42e244509d41e272f4b64999_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzMtMjEtMS0xLTk0NDE0_467bfda9-6149-41aa-86a8-66d072c16068"
      unitRef="usd">619000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i13f4e544586d4c689babc9b7bb643038_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzMtMjMtMS0xLTk0NDE0_90c67d02-7892-4f4e-a91a-06613d06081c"
      unitRef="usd">619000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4a567b0578254433ab2843507871f589_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzQtMS0xLTEtOTQ0MTQ_8447fddf-389b-4dcc-ba9e-3df796606feb"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i803f3b4be6844c91ad48b04634b3d57a_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzQtMy0xLTEtOTQ0MTQ_90e06280-5548-4f7c-ba38-a541ff0d2db3"
      unitRef="usd">49000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1bcc18bbe90e47da9b7fffcfbe9b7c7f_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzQtNS0xLTEtOTQ0MTQ_f1ed6ea8-52cd-4320-a644-7965e26bbd11"
      unitRef="usd">49000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i34c4ac2cb8084a4192568712dceb7c7b_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzQtNy0xLTEtOTQ0MTQ_03ac330d-fbd6-4ec7-9302-364d4ac57818"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i48743be2360640e9b25e34524209acf5_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzQtOS0xLTEtOTQ0MTQ_ff511c8e-def4-4cfd-a047-8c2faa287269"
      unitRef="usd">73000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie6df70951a3345f5bef560a3d668c977_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzQtMTEtMS0xLTk0NDE0_4e23c607-5bc5-49f0-900b-120ad47567ec"
      unitRef="usd">73000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i04b63cc78f284d3cb3291a6b392e691a_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzQtMTMtMS0xLTk0NDE0_9a73f8cb-7b09-4dbc-830a-7559e231423c"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ida55387137da4467910d468e15316ed5_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzQtMTUtMS0xLTk0NDE0_55cfeabf-0159-4304-8761-30b9ca580db8"
      unitRef="usd">163000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie22a90598b6444e593ecca7b8a7971cf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzQtMTctMS0xLTk0NDE0_cbaa0485-59c8-400e-9bde-69d6cb6f03cf"
      unitRef="usd">163000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7c97559608224dfe87e9d5af61432405_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzQtMTktMS0xLTk0NDE0_5c1ed925-647d-43e7-a86d-aef9aaf59c14"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie6bbe8c6cf234e73a1885c86ba3a53a6_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzQtMjEtMS0xLTk0NDE0_04c08b7e-379c-4d9d-b435-81a0b3c17b23"
      unitRef="usd">233000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3d352f2ba8364c5eaa02ddd326723d7e_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzQtMjMtMS0xLTk0NDE0_c34d3b53-b638-4290-910d-db9ad7b66250"
      unitRef="usd">233000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifee9f2e555d6447ca4a77928972c53a3_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzYtMS0xLTEtOTQ0MTQ_35ad5db2-a1d2-4fb4-8dba-ae76ffa3e1cb"
      unitRef="usd">332000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i29d4d29ca30c43db9f653c0173a02a88_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzYtMy0xLTEtOTQ0MTQ_048eedef-f94c-4098-bd76-30097f877670"
      unitRef="usd">385000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i907dc799123d4d8a8d59145f2fe460ff_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzYtNS0xLTEtOTQ0MTQ_182eddfc-fb4d-4f9f-8e95-6665c976af15"
      unitRef="usd">717000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i71b8800d43dc425ba37b1e7fbaf13774_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzYtNy0xLTEtOTQ0MTQ_c6bde680-f97c-4fad-9dea-70b3b0595d2e"
      unitRef="usd">365000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib88e6348738c43e789677fefc86824f0_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzYtOS0xLTEtOTQ0MTQ_64bbf057-49a5-41c6-a051-d980aff9361b"
      unitRef="usd">487000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2842b6655db442f9b1d51ae4beb1bfbf_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzYtMTEtMS0xLTk0NDE0_d979ed98-634d-4bf3-bae9-ddfa538c79c2"
      unitRef="usd">852000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if4d05b65c7b54139b25ac70c4ab19df3_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzYtMTMtMS0xLTk0NDE0_6ad6952f-e29e-475c-9388-c5e6886d929a"
      unitRef="usd">958000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i553b3f72bfd042dabe4870ebbc230630_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzYtMTUtMS0xLTk0NDE0_8a1bf4ab-5263-492d-b2b7-b233472366ec"
      unitRef="usd">1294000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i56d699e134f741c0a256a5bbbd4a83fe_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzYtMTctMS0xLTk0NDE0_1a6a4d98-a758-4bf3-985d-ba8860fd0fe4"
      unitRef="usd">2252000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if81ecb7810414c37ac52874e47f9559c_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzYtMTktMS0xLTk0NDE0_2a464fc7-d05e-4c42-8d38-e9b2a771fd30"
      unitRef="usd">997000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie3d729fce8a044979a61be3f06e6bf4a_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzYtMjEtMS0xLTk0NDE0_9e62795c-9a8d-4d68-be48-f1962eb184ef"
      unitRef="usd">1448000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i039289771e0a4a92a82f0e23c7b58113_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzYtMjMtMS0xLTk0NDE0_b84c2020-c8d2-4671-bd74-8db803119e1e"
      unitRef="usd">2445000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4c94024cf7444cc986c90074aa354bdb_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzctMS0xLTEtOTQ0MTQ_7301a9a5-97b7-497c-ab7a-e79bfd595774"
      unitRef="usd">90000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iacc83a958e43414884a750ac18d8715c_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzctMy0xLTEtOTQ0MTQ_b8fd0dbd-35bf-4f12-a09b-937306214956"
      unitRef="usd">327000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie795535b2e254799b2ec04408e04506f_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzctNS0xLTEtOTQ0MTQ_813691e7-8ab9-4197-b6da-59cf2b9545c1"
      unitRef="usd">417000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic7abdbd57cda413bb900bc952b307246_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzctNy0xLTEtOTQ0MTQ_fdb3b54c-05c8-46d0-a453-aae9e7691792"
      unitRef="usd">86000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie81d29f45ec7442a847822087f81a983_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzctOS0xLTEtOTQ0MTQ_49ccc99b-bef2-4e66-aa56-22d8cfeed2f1"
      unitRef="usd">401000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaeb741d79fae4f8c9612915e80120b77_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzctMTEtMS0xLTk0NDE0_7910d83d-644e-485c-b08f-565b3a388e9a"
      unitRef="usd">487000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i91f6e6feded64f13ad8e45634369dff0_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzctMTMtMS0xLTk0NDE0_507f82a3-e184-44a6-9a4b-6f4085b7bf6b"
      unitRef="usd">258000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if25cccf1ea4a4ce9b81f781649b78865_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzctMTUtMS0xLTk0NDE0_5e16c91d-cd37-48cc-aef1-6849f608cf2f"
      unitRef="usd">1089000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i242133cf5e834e02a75bc0fb1d5dbaa2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzctMTctMS0xLTk0NDE0_02d71263-176f-40af-9219-0d03b33641af"
      unitRef="usd">1347000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic0a3898f0f3e4eda824b64c14e338702_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzctMTktMS0xLTk0NDE0_4cb6f05d-77f3-41a8-8299-f3b2f046644d"
      unitRef="usd">244000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i08274445c04f4069980cb990559bb715_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzctMjEtMS0xLTk0NDE0_cdee93ca-3bd7-4bd6-9ee2-47007872d2d4"
      unitRef="usd">1205000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2ffb95f5c9c046ba9c390129a0e69d65_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzctMjMtMS0xLTk0NDE0_64136269-2658-4292-8f7d-0cdcf212c2d7"
      unitRef="usd">1449000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibb00fde3c5fe4302aff44ebc212aecc1_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzgtMS0xLTEtOTQ0MTQ_ce16d030-c148-49ed-a838-6cb7c79332fd"
      unitRef="usd">244000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if513f7a17c0e49989ccf849ee4dc9331_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzgtMy0xLTEtOTQ0MTQ_686e20f0-5c60-4cca-ba66-80cb748ea9be"
      unitRef="usd">321000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i638069bb860a415daddfd8838b2cdd19_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzgtNS0xLTEtOTQ0MTQ_67679d5d-bfa8-46e2-b81b-381f8d8ff960"
      unitRef="usd">564000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9f7703ad94b54db9a9215c0db5b0cd62_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzgtNy0xLTEtOTQ0MTQ_080c1029-f62a-44b8-bb71-8b4c987af7f8"
      unitRef="usd">210000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i783f44f8b2654fc4af2d919e37ce22a7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzgtOS0xLTEtOTQ0MTQ_2edb6a2a-3be5-4644-aa01-1c01cef5175e"
      unitRef="usd">306000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i66a5cfc38a70434b9ceec5c2285168aa_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzgtMTEtMS0xLTk0NDE0_d2021ac0-9b95-4cc4-8c3b-5f4ad48e2122"
      unitRef="usd">518000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1310ca8214184c8b9d2a080cfe0da7c0_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzgtMTMtMS0xLTk0NDE0_4fb2e573-cb3b-4386-a634-7f0b8e63924d"
      unitRef="usd">616000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1abf9ffbfb5d44aeb0a9463ac4398eab_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzgtMTUtMS0xLTk0NDE0_0f8db17c-f66e-4ab2-a7a0-d3ae7797e2eb"
      unitRef="usd">949000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i71b867c3c4ec478abe984d94d0169df7_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzgtMTctMS0xLTk0NDE0_97aec0c1-0f7d-4c02-9bcc-ea707d1077b6"
      unitRef="usd">1565000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i823ae7ab9f7e4d099e7876b9b19ae298_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzgtMTktMS0xLTk0NDE0_b0b14ab0-9ae6-4d0b-bdce-4fe6cf9f2724"
      unitRef="usd">637000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i095b912afc3343538d71712bd5e5af82_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzgtMjEtMS0xLTk0NDE0_b734f57d-d29f-4f6c-98f4-0999525837d3"
      unitRef="usd">950000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1f8a3bf7c42c44aea99cef1412e8dbb0_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzgtMjMtMS0xLTk0NDE0_e8cca3c4-0658-4fd9-93a2-404022c6b580"
      unitRef="usd">1589000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic22e7e95653e4fb0a95e61763a3569b2_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzktMS0xLTEtOTQ0MTQ_c721bf88-e709-4a98-83e8-5016f38a1a3e"
      unitRef="usd">6620000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id51e37617d5248369c24578f16a1cf14_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzktMy0xLTEtOTQ0MTQ_643a53cf-dd91-4165-857f-a8f8b42a6b70"
      unitRef="usd">6343000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i44564486e4b54deba76702deafc0f64b_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzktNS0xLTEtOTQ0MTQ_9831f916-9985-4515-af78-7c656985fbc0"
      unitRef="usd">12963000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id1e17bbb1a904f4f9887423378bb5af6_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzktNy0xLTEtOTQ0MTQ_059c2d3f-57fa-407b-93fa-9dedda4f4cf8"
      unitRef="usd">5670000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i07782e31373f44de9555f3b81cdd9628_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzktOS0xLTEtOTQ0MTQ_2a292a46-9e22-4011-9461-7aa63dd1b855"
      unitRef="usd">5826000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibd79168d00974ebc85c149dd99401528_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzktMTEtMS0xLTk0NDE0_06355fda-a411-444a-adc1-d7b4a296d277"
      unitRef="usd">11496000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if91a5aa8a47941858c207f93c372c557_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzktMTMtMS0xLTk0NDE0_996cd2d9-a4b8-4121-9764-9f0ca220c435"
      unitRef="usd">19119000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i50377394250b4f6eb2cdd388e247c98e_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzktMTUtMS0xLTk0NDE0_9c10ca11-503d-4b85-a4f4-5ad7f48192d8"
      unitRef="usd">20707000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4485c1a08fb843e2a1746a8633829398_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzktMTctMS0xLTk0NDE0_1b78f327-9698-416f-a580-6fd95e2b065c"
      unitRef="usd">39826000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8da429c5485f4cb78dbd9c99fc97e840_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzktMTktMS0xLTk0NDE0_35f673d7-533f-4b03-ba7d-94394dc1b23b"
      unitRef="usd">14611000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i241616d8d1cc4bd1a17072d1fe359907_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzktMjEtMS0xLTk0NDE0_c91d982e-d743-4d1c-9253-6242ccf23ee0"
      unitRef="usd">16103000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3168b97c7cfe40dd968aff24fac21714_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfMzktMjMtMS0xLTk0NDE0_e0566cf8-94a1-4e24-b93f-7ecff4ecfbae"
      unitRef="usd">30714000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic827d96e5107479f8a50ac1552243075_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDEtMS0xLTEtOTQ0MTQ_d19a356e-4b07-44f0-8582-767979823522"
      unitRef="usd">186000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9f280f0335f34739a091905a7605c8fb_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDEtMy0xLTEtOTQ0MTQ_7bef67c6-5de5-4b5e-ab83-8cc835f96ca6"
      unitRef="usd">643000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie50dbb604c9b4e1a89e5a02734c3435e_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDEtNS0xLTEtOTQ0MTQ_7bb54c5a-cddd-4693-ba4e-e2eb3b5a0fdc"
      unitRef="usd">829000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie7e482e96daf4d1aba90f65b4d004d1c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDEtNy0xLTEtOTQ0MTQ_e3253e2b-2593-4ff1-9804-c74cf3e913d6"
      unitRef="usd">190000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0984754f7dc14a15ae031293bbf02033_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDEtOS0xLTEtOTQ0MTQ_a04d425f-bb30-43fe-8a91-16bb64cdbec3"
      unitRef="usd">675000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icb3bab98f9034f8381e05152809cb5ba_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDEtMTEtMS0xLTk0NDE0_8cc89e18-9031-48d8-b49f-28ac4d5ffce9"
      unitRef="usd">864000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia409b352549644d08a3f0a4940dba700_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDEtMTMtMS0xLTk0NDE0_d2797c3b-6dc4-491d-9e83-1facb211c7a6"
      unitRef="usd">521000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3d9ec8e3f10a4277a866ec3be3d50f2e_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDEtMTUtMS0xLTk0NDE0_6a556fa0-0f07-41d3-8d06-4da7b678dd8e"
      unitRef="usd">1965000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i11db00c425ed4fb0885192fe0be29cc9_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDEtMTctMS0xLTk0NDE0_d323a237-43c0-4639-98d6-3b65d8b4ceeb"
      unitRef="usd">2486000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i839b44dbb9c245789d8af1b83cda8eb5_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDEtMTktMS0xLTk0NDE0_54b9d022-1280-469f-b381-206a7a29e4e2"
      unitRef="usd">508000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0efc28dad4a44fa5966707fcb540b4b1_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDEtMjEtMS0xLTk0NDE0_7cb4bc8c-3938-4f2a-8ec3-5fd0178ec0d8"
      unitRef="usd">1996000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1aea48b047e34184a2746ed722f8d736_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDEtMjMtMS0xLTk0NDE0_b3900760-806e-43f6-81eb-9847eb6ec759"
      unitRef="usd">2503000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9588db6b282c4b73afec4971984508f9_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDItMS0xLTEtOTQ0MTQ_7ef5e884-f28e-4e96-ba5a-9eb69f841632"
      unitRef="usd">289000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i097a676b323a42889c16acb4a376e3c0_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDItMy0xLTEtOTQ0MTQ_947356e8-b235-4e71-8aa9-838a6fc234b1"
      unitRef="usd">253000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic40e96203c084d60902d25625a1bc564_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDItNS0xLTEtOTQ0MTQ_f5393dbb-4663-4af0-aeb5-9d81f0c02380"
      unitRef="usd">542000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6427cb6f43ec40cfa361720f0ac45cd2_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDItNy0xLTEtOTQ0MTQ_f67f0c4a-96c0-482d-a833-c86e76b1bb04"
      unitRef="usd">277000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i43885c95db8a44fe80b17b1fef791c59_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDItOS0xLTEtOTQ0MTQ_0aa18390-c18e-4473-9bc9-ed44a52b18e6"
      unitRef="usd">276000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i38960dddb9404fe98542807220cd75b8_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDItMTEtMS0xLTk0NDE0_49ba7ed9-bc0b-43d8-b16a-50a2ef65c834"
      unitRef="usd">553000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8993fa041a484e879c4a6485620bebd7_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDItMTMtMS0xLTk0NDE0_964fac6a-8a22-4b92-9b4e-d765dab8e403"
      unitRef="usd">904000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9ee7156a4b614122a54d9522c59d5c78_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDItMTUtMS0xLTk0NDE0_b9a80c3d-da05-4d62-9e21-035a82817a6a"
      unitRef="usd">929000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i641cb943aa714600b89da7ddd3df0d89_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDItMTctMS0xLTk0NDE0_374bdc9f-e8a2-476a-862e-c5f634ed1b3d"
      unitRef="usd">1834000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia71e4576e6394e3780b1fb370ab8eca7_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDItMTktMS0xLTk0NDE0_c918eee6-53f4-4d28-87cc-2f828c9a2950"
      unitRef="usd">855000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if8df911dbd564fbf849019ee57246892_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDItMjEtMS0xLTk0NDE0_e84722b7-a9c5-446f-a19f-57e59b0bb738"
      unitRef="usd">948000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7b5cb0fe57d04ef598a24dd039eef72c_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDItMjMtMS0xLTk0NDE0_99dc730b-7030-4ce6-88eb-b8d3a26bd726"
      unitRef="usd">1804000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i54a7afab074f405e8ef80dabdfecdf0e_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDMtMS0xLTEtOTQ0MTQ_514d0033-0a37-40c4-9aed-ebd72d661271"
      unitRef="usd">475000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i31118e3777414395bca00605e465fac7_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDMtMy0xLTEtOTQ0MTQ_04355e51-ef11-47a9-bc9a-01cfa113035c"
      unitRef="usd">896000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0c738afeb7f541e7a7cee2e74587d6e2_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDMtNS0xLTEtOTQ0MTQ_88303301-17bd-4151-b03d-64f9420e64d6"
      unitRef="usd">1371000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic630a421623e412e899316999b1d84a3_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDMtNy0xLTEtOTQ0MTQ_81c587f5-1218-4363-80c7-9f2b9ef0b6cf"
      unitRef="usd">467000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i947ae1e75b3d491087466d3c41d239a4_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDMtOS0xLTEtOTQ0MTQ_d4bd8b12-224c-46d1-b253-2285eada76dd"
      unitRef="usd">951000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic7874341a97d4c089a290cd4c52ca3ef_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDMtMTEtMS0xLTk0NDE0_eb3798e3-e40d-4b3e-bbb9-ed3449fe06e7"
      unitRef="usd">1417000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic3a9a7407ef94ca0a066f8f1b41ac915_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDMtMTMtMS0xLTk0NDE0_656ddf5f-36f3-4f23-bad3-3ddab8899168"
      unitRef="usd">1425000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie74c0c26e4194d0ca851b4f339b64aff_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDMtMTUtMS0xLTk0NDE0_cf71bfec-1c9e-4aac-a614-72ce55bc61a4"
      unitRef="usd">2894000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if24d9980d69a415285bcfb8af2e4760a_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDMtMTctMS0xLTk0NDE0_c3597710-219b-468c-a173-73e7919a9cc4"
      unitRef="usd">4320000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie52d61f419f94c0cafc9a9d7cc18a763_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDMtMTktMS0xLTk0NDE0_8797bfc9-38b4-4c92-a321-6d6e2a33c83b"
      unitRef="usd">1363000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0eaeb3befcf640f7b164ca0a1c2686aa_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDMtMjEtMS0xLTk0NDE0_bc442df7-f3f3-41e8-a49a-23a428cc71c3"
      unitRef="usd">2944000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0d6fe701a40b465cacd7765161ea4559_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDMtMjMtMS0xLTk0NDE0_dbe027a4-addc-427a-8842-6460ab4810c5"
      unitRef="usd">4307000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic37bfb89cb3640ad8e236e59f73d6359_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDQtMS0xLTEtOTQ0MTQ_1316c6df-2bef-4489-8426-15cd77731ba1"
      unitRef="usd">7095000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if8fd87789a924ef1962a3681f884ed11_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDQtMy0xLTEtOTQ0MTQ_4c26faf3-a361-4514-ab83-6057d86fd759"
      unitRef="usd">7239000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie736eb61ba964832abed00a756bb99fe_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDQtNS0xLTEtOTQ0MTQ_19e3a2e3-703f-429b-8293-b0cc8a0f59dc"
      unitRef="usd">14334000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2bf14f8f5d2747e58b18f20cc5051555_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDQtNy0xLTEtOTQ0MTQ_ccfc6600-ee8e-427e-90fc-767b24b25e5a"
      unitRef="usd">6137000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i30e83259e5b648859b1c791fc219f795_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDQtOS0xLTEtOTQ0MTQ_585a9e58-4ff5-45a2-96ad-44a7d8768eab"
      unitRef="usd">6777000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i769a6f6f373c4424a78daa11151e8693_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDQtMTEtMS0xLTk0NDE0_cad00cdb-e167-498b-b5f5-510507adab4d"
      unitRef="usd">12913000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifae6a5b5be2d4e27b57c8cb59e7b736d_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDQtMTMtMS0xLTk0NDE0_8dcd63f4-cbfb-4caa-8d25-ae50e316b8e0"
      unitRef="usd">20544000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia4d49c3f485c4a969fc279eae65aea0c_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDQtMTUtMS0xLTk0NDE0_482bc6ab-4b20-4fbf-bd43-09619982d8dc"
      unitRef="usd">23601000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic976522683894b2f851b9eb9a9e99339_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDQtMTctMS0xLTk0NDE0_35d5f30f-7529-4451-b3a3-0a5e49d410d9"
      unitRef="usd">44146000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id6158ef12bd24d40b494575847b10455_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDQtMTktMS0xLTk0NDE0_c449d497-a5a7-4829-8617-002c73da7284"
      unitRef="usd">15974000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6c9b56c797144ae883e07ceee9eb81ad_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDQtMjEtMS0xLTk0NDE0_3f02db33-0958-47c6-b9f3-004d8c587aed"
      unitRef="usd">19047000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i748adeb1c1b74b4a80ea71f1622e0a83_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDQtMjMtMS0xLTk0NDE0_b5cd72ed-7746-4996-b51d-d15459148016"
      unitRef="usd">35021000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i58abc744b88c49d996c9335dc7e4e26a_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDUtMS0xLTEtOTQ0MTQ_62d7479c-12c6-4e6c-b3c8-50921039004e"
      unitRef="usd">227000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia2cdaaadd890437ea5827bcebf07e28c_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDUtMy0xLTEtOTQ0MTQ_0fb3040d-8963-4ab3-8878-aec28e464a2c"
      unitRef="usd">398000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3b6ac35939974a6680f67f6f5cb6cfbd_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDUtNS0xLTEtOTQ0MTQ_d02833c6-175c-43f8-9851-a19bbc7aa5b2"
      unitRef="usd">625000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifecb5cf258f942c68db448dc19d76074_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDUtNy0xLTEtOTQ0MTQ_c5af9965-bb13-415c-9c15-36b9a0e1be20"
      unitRef="usd">139000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id7452b2558944b89aa0c78702511531b_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDUtOS0xLTEtOTQ0MTQ_3326da6e-01d6-483f-81d8-679ce0c6c4e9"
      unitRef="usd">101000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie95d0a9de94f48bc9a2edc6e093ccd9d_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDUtMTEtMS0xLTk0NDE0_88e27a3b-3d34-4f8c-be01-061e4251c79b"
      unitRef="usd">241000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i46b3dbdcc4454d4ab3079f2407d0e808_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDUtMTMtMS0xLTk0NDE0_7f6459fd-52df-4018-b0f9-b576c9e8c5ae"
      unitRef="usd">383000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i997e727369cc4c879b4f65634d5c9167_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDUtMTUtMS0xLTk0NDE0_c6145549-a7c0-41e9-bc38-2f3379141f1e"
      unitRef="usd">925000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ied57d33df852404ea42cbb9249fb4ff7_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDUtMTctMS0xLTk0NDE0_46505535-dd2f-4ccf-ae90-77df5af8fab6"
      unitRef="usd">1307000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3dd1ed9c80f84232aa613ebfc30fce1b_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDUtMTktMS0xLTk0NDE0_8fd366f2-de60-4363-b129-b5c7be339b1c"
      unitRef="usd">192000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2f54658358b74dd2a2602a4b93e49d03_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDUtMjEtMS0xLTk0NDE0_23891760-ec51-40a6-9bef-ec406acf8be5"
      unitRef="usd">-30000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic7a6672a05e34d6090ab13ec171a3c16_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDUtMjMtMS0xLTk0NDE0_4a0ce95f-01d2-4ad0-907c-82739bc720b7"
      unitRef="usd">162000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9dbe9922fd544a0e817961eb18397dfb_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDYtMS0xLTEtOTQ0MTQ_c82bcf4c-0589-41c2-a088-f763e8046002"
      unitRef="usd">7322000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i998bc7df80cd421c86a31d55b20b2f00_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDYtMy0xLTEtOTQ0MTQ_09348014-f70c-4d8e-8fd0-c1faab53a67b"
      unitRef="usd">7637000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDYtNS0xLTEtOTQ0MTQ_fe29e578-1d7e-4575-8cba-2797d8052c68"
      unitRef="usd">14959000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1501c38c01f24f46ab98fa0918a29aea_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDYtNy0xLTEtOTQ0MTQ_116053bf-86d2-4eed-907a-458e9e52f1d6"
      unitRef="usd">6276000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i461edb12a6e0421a95ce0ac6c93adbca_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDYtOS0xLTEtOTQ0MTQ_d9c0f04b-fd33-4b50-89c2-3cc1819bdb99"
      unitRef="usd">6878000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDYtMTEtMS0xLTk0NDE0_f9c5bfdf-0b74-4dcb-aeb9-df4e4cf1e82c"
      unitRef="usd">13154000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie95f6e7a4c9a45b98ee10519480bcc57_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDYtMTMtMS0xLTk0NDE0_f93e346c-568f-48c6-9ae1-fbb2edb1de47"
      unitRef="usd">20927000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i609ee3a20dca4ef2a07a72f3aa7bd472_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDYtMTUtMS0xLTk0NDE0_cf502ab1-0866-4047-b780-1490bbaea063"
      unitRef="usd">24526000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDYtMTctMS0xLTk0NDE0_f6844a61-4e2f-4cd2-b7ec-a18beb90ca57"
      unitRef="usd">45453000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5dcd8e73f06541bf90ce68a9090f463c_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDYtMTktMS0xLTk0NDE0_12ebcefd-df7c-4396-bcf3-91b031b0e765"
      unitRef="usd">16166000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6ddf8513030e4e22ab98fead59aa24a8_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDYtMjEtMS0xLTk0NDE0_5e036e63-5ec8-4d29-8de8-c7c8c83bc505"
      unitRef="usd">19017000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjk1MTZkNWI0MmU0OTRlM2NhODRlZGNlMTI4NjFjMDZlL3RhYmxlcmFuZ2U6OTUxNmQ1YjQyZTQ5NGUzY2E4NGVkY2UxMjg2MWMwNmVfNDYtMjMtMS0xLTk0NDE0_f34b0be5-c01c-4a6d-b900-4b8c88645fab"
      unitRef="usd">35183000000</us-gaap:Revenues>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RleHRyZWdpb246NGRlODU3NTdjYTEyNGIxMTk5MzBjYzBlMDFmZWViMzRfMjc5MA_30d3116c-4cd1-465d-bb9e-7fd19a3a6817"
      unitRef="usd">156000000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RleHRyZWdpb246NGRlODU3NTdjYTEyNGIxMTk5MzBjYzBlMDFmZWViMzRfMjc5Nw_db9586ec-c223-4416-a1eb-522c5e629e41"
      unitRef="usd">191000000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <mrk:SalesDiscounts
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RleHRyZWdpb246NGRlODU3NTdjYTEyNGIxMTk5MzBjYzBlMDFmZWViMzRfMzQ1MQ_960b3c1c-ada2-472c-9eb0-b48c1f01051b"
      unitRef="usd">3300000000</mrk:SalesDiscounts>
    <mrk:SalesDiscounts
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RleHRyZWdpb246NGRlODU3NTdjYTEyNGIxMTk5MzBjYzBlMDFmZWViMzRfMzQ1OA_8d8354a0-fe4f-423c-a90f-48fa5a65fcb9"
      unitRef="usd">3100000000</mrk:SalesDiscounts>
    <mrk:SalesDiscounts
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RleHRyZWdpb246NGRlODU3NTdjYTEyNGIxMTk5MzBjYzBlMDFmZWViMzRfMzUxNw_1904d887-5d92-419a-a0aa-557191e989e8"
      unitRef="usd">9100000000</mrk:SalesDiscounts>
    <mrk:SalesDiscounts
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RleHRyZWdpb246NGRlODU3NTdjYTEyNGIxMTk5MzBjYzBlMDFmZWViMzRfMzUxNw_83a36eec-7753-414a-9245-ab97127536dc"
      unitRef="usd">9100000000</mrk:SalesDiscounts>
    <us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RleHRyZWdpb246NGRlODU3NTdjYTEyNGIxMTk5MzBjYzBlMDFmZWViMzRfNTQ3Ng_1951f1c0-a32e-49df-b3e4-dac44756d43b">&lt;div style="margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consolidated sales by geographic area where derived are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.946%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe, Middle East and Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asia Pacific (other than China and Japan)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Latin America&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock>
    <us-gaap:Revenues
      contextRef="i9dbe9922fd544a0e817961eb18397dfb_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfMi0xLTEtMS05NDQxNA_f8f2f519-74b7-4f27-ac09-8a1b61086e20"
      unitRef="usd">7322000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1501c38c01f24f46ab98fa0918a29aea_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfMi0zLTEtMS05NDQxNA_2498dfba-0e6a-4263-a555-77ddc90a0965"
      unitRef="usd">6276000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie95f6e7a4c9a45b98ee10519480bcc57_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfMi01LTEtMS05NDQxNA_2b7be72c-bf42-4770-b599-1a7c68b434e8"
      unitRef="usd">20927000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5dcd8e73f06541bf90ce68a9090f463c_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfMi03LTEtMS05NDQxNA_51972058-f104-4cd7-b53a-c591de769ecf"
      unitRef="usd">16166000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ide9fd53158404da68f8ed38707c6e730_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfMy0xLTEtMS05NDQxNA_27960502-3333-4289-8956-8a0a91a8278d"
      unitRef="usd">3286000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia5c146f01bfc4a0fb436eac2074cdf40_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfMy0zLTEtMS05NDQxNA_7b394bce-d07a-4ef5-86ff-43c8a2d5237f"
      unitRef="usd">3342000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9eb6d9a053c248a8abc9535a66f119f6_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfMy01LTEtMS05NDQxNA_28220b52-b0ea-4095-b8b8-3ac2b577ecc8"
      unitRef="usd">11228000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i95e954dfb89d4490bc7f62728171c3c7_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfMy03LTEtMS05NDQxNA_1449bc69-ab2d-4449-a6fd-de55251aa2df"
      unitRef="usd">9912000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic896ad83efec4ff7a7a62329387853a7_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfNC0xLTEtMS05NDQxNA_f551a5b6-7fd3-49bc-ab2a-6541622ea7fb"
      unitRef="usd">1442000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0e4b569901524a64b1ef34cb1524a967_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfNC0zLTEtMS05NDQxNA_6e0ae353-437f-4604-a463-22794d08d0cd"
      unitRef="usd">1307000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3fce1d67949c48ccb03f9e12c3e52dae_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfNC01LTEtMS05NDQxNA_b4e26275-1dbb-472c-8c31-bd43bd37de7d"
      unitRef="usd">3957000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i050b473f8c3f4780be91b8883989770d_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfNC03LTEtMS05NDQxNA_4fac8b4a-169b-4490-be8c-4b5f66c8ddf3"
      unitRef="usd">3004000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icab0d5373a6143ba8a8971886fd366eb_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfNS0xLTEtMS05NDQxNA_180dd442-9a08-4e37-a560-71d5735f7946"
      unitRef="usd">673000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i94657ee062ab4c07a5644722ec7e5f4d_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfNS0zLTEtMS05NDQxNA_3703275a-41de-4797-929f-50a200c2657e"
      unitRef="usd">638000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i011ff8ae410c45ee9363ef7b31f62ff6_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfNS01LTEtMS05NDQxNA_1d9eed65-da2c-452e-a4a6-fd5759c97794"
      unitRef="usd">2776000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8ccfec64c8df4db89a86df0ec6e79d66_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfNS03LTEtMS05NDQxNA_bc5f056c-d6b0-45b3-902b-d5c23f009bfa"
      unitRef="usd">1929000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6bf58675420348dea4421700f6d61b1d_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfNi0xLTEtMS05NDQxNA_b2d44e43-e33f-4566-9a24-c9153913c8f6"
      unitRef="usd">854000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i22eef57a3e534bce9a842560378654e4_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfNi0zLTEtMS05NDQxNA_c2b1f295-9fdf-40c2-960c-1730e7c9c898"
      unitRef="usd">613000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7fe1b46c7e9040539c417e8044482c9a_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfNi01LTEtMS05NDQxNA_86e64967-ab6b-4cbf-9366-ee232632ecce"
      unitRef="usd">2792000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0820e5db91674b1b9eb3859fb1471846_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfNi03LTEtMS05NDQxNA_5ab5b970-a216-423e-b77a-1fae61275ffc"
      unitRef="usd">1782000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3e743f7eaf994261a54320837d8cdc38_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfNy0xLTEtMS05NDQxNA_a8f48443-c68a-461f-b733-8cbf602c016c"
      unitRef="usd">684000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic25e83ccb0774f9f8d3a60252008d95d_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfNy0zLTEtMS05NDQxNA_e97ed0ff-4b14-4fa9-aa98-cfbfb1e22ce9"
      unitRef="usd">599000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2c91091b09d34c3eb1b8f917bf6a6e92_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfNy01LTEtMS05NDQxNA_e3309f51-a526-4fe7-a465-ca84ccf555db"
      unitRef="usd">1933000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8b5a7c79bc084682a64cd091d3a8258c_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfNy03LTEtMS05NDQxNA_aca3fc6e-842c-4a13-a2be-ccc29f71f868"
      unitRef="usd">1631000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i97fa5da6b3924d8d99c2fbceb69c59d9_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfOC0xLTEtMS05NDQxNA_4df31dbe-8503-40e8-ba96-ac3887d6f8f3"
      unitRef="usd">698000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iccf7a7e39a1444609739fe18036ae1a6_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfOC0zLTEtMS05NDQxNA_98e69a17-09af-4510-8705-38b64fa7b55a"
      unitRef="usd">379000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i22490ec2cbf04c3994fd5195617c0cd1_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfOC01LTEtMS05NDQxNA_ba57e2b2-d999-4c00-b155-af7b0c1eeed2"
      unitRef="usd">1840000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3d7cf65513ab4159b2feb11639c2f8b8_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfOC03LTEtMS05NDQxNA_0119df20-7cb4-4da4-9c0e-f774b116d9af"
      unitRef="usd">759000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfOS0xLTEtMS05NDQxNA_617cbc2a-1d42-41fb-b023-9402239a2e8a"
      unitRef="usd">14959000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfOS0zLTEtMS05NDQxNA_1e7cfe8f-4131-47cb-ac65-193555db3848"
      unitRef="usd">13154000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfOS01LTEtMS05NDQxNA_220dbd22-992c-49c6-9256-81b646cbcac4"
      unitRef="usd">45453000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjJjMDNlYWIwMWY1MDQ2ZWE5ZTE2Njk1Mzg4MGI2NTVmL3RhYmxlcmFuZ2U6MmMwM2VhYjAxZjUwNDZlYTllMTY2OTUzODgwYjY1NWZfOS03LTEtMS05NDQxNA_906b558d-7f88-4076-958c-da55b032b854"
      unitRef="usd">35183000000</us-gaap:Revenues>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RleHRyZWdpb246NGRlODU3NTdjYTEyNGIxMTk5MzBjYzBlMDFmZWViMzRfNTUwMw_c8000baf-ea03-4e60-bb41-cfeeb95a77ba">&lt;div style="margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of segment profits to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income from Continuing Operations Before Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.531%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment profits:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical segment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Animal Health segment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total segment profits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other profits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unallocated:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(244)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(727)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(597)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(460)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(360)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,623)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,231)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(448)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(358)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,257)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,031)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,312)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,775)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(288)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(487)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other unallocated, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,416)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,628)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,044)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i44564486e4b54deba76702deafc0f64b_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMy0xLTEtMS05NDQxNA_e74c01c1-cb31-407e-8a29-e4385b035469"
      unitRef="usd">9590000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ibd79168d00974ebc85c149dd99401528_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMy0zLTEtMS05NDQxNA_203391c7-9e18-4336-bd59-2a12baa14b22"
      unitRef="usd">8606000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i4485c1a08fb843e2a1746a8633829398_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMy01LTEtMS05NDQxNA_25611ad7-4e65-4ba9-96f4-02b8c28604dd"
      unitRef="usd">28263000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i3168b97c7cfe40dd968aff24fac21714_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMy03LTEtMS05NDQxNA_1bfa8bf9-c22b-442f-86b5-e9368d380954"
      unitRef="usd">22450000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i0c738afeb7f541e7a7cee2e74587d6e2_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfNC0xLTEtMS05NDQxNA_dc036efa-1aef-44cb-bc62-052008819817"
      unitRef="usd">515000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ic7874341a97d4c089a290cd4c52ca3ef_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfNC0zLTEtMS05NDQxNA_24b2367d-460a-4526-8a78-e3b88526d2a4"
      unitRef="usd">505000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if24d9980d69a415285bcfb8af2e4760a_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfNC01LTEtMS05NDQxNA_b3a15056-d305-47fe-8862-8b76c0a42b0e"
      unitRef="usd">1672000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i0d6fe701a40b465cacd7765161ea4559_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfNC03LTEtMS05NDQxNA_75f33c40-3fc8-4afc-b542-1045030d65c0"
      unitRef="usd">1629000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie736eb61ba964832abed00a756bb99fe_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfNS0xLTEtMS05NDQxNA_2b131e49-ecf3-4cce-8009-9fb14fd320d5"
      unitRef="usd">10105000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i769a6f6f373c4424a78daa11151e8693_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfNS0zLTEtMS05NDQxNA_4089f473-e9ef-412b-a18b-ba18e3b73987"
      unitRef="usd">9111000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ic976522683894b2f851b9eb9a9e99339_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfNS01LTEtMS05NDQxNA_9c6e71f0-96b5-44e2-b3e2-47a97289ee3d"
      unitRef="usd">29935000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i748adeb1c1b74b4a80ea71f1622e0a83_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfNS03LTEtMS05NDQxNA_a696640a-0d8e-49e3-92e9-53ef10da3587"
      unitRef="usd">24079000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i3b6ac35939974a6680f67f6f5cb6cfbd_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfNi0xLTEtMS05NDQxNA_c4510ec5-f540-4b76-a353-8569d1b93283"
      unitRef="usd">377000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie95d0a9de94f48bc9a2edc6e093ccd9d_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfNi0zLTEtMS05NDQxNA_42d73dec-5b50-45d7-8f0b-4c332166d929"
      unitRef="usd">141000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ied57d33df852404ea42cbb9249fb4ff7_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfNi01LTEtMS05NDQxNA_20fd93e0-edcc-4899-9f95-d996bafcada5"
      unitRef="usd">831000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ic7a6672a05e34d6090ab13ec171a3c16_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfNi03LTEtMS05NDQxNA_fa8469a9-59ed-4890-8ffd-62ca51b214fb"
      unitRef="usd">29000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i69959f4306b342dbbb1318e7d3cf276a_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfOC0xLTEtMS05NDQxNA_2d7b765d-a984-4662-83f8-9d31a8e0e944"
      unitRef="usd">40000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i59506b8e5aae42f880005525de216ce0_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfOC0zLTEtMS05NDQxNA_aac2a61c-b7e2-4d2b-8c73-f55a9ede64a0"
      unitRef="usd">7000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i1091a13b711442e0848bc698d9a73a45_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfOC01LTEtMS05NDQxNA_764c4dcb-9bd9-4e75-822e-eb95a90db5b3"
      unitRef="usd">62000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="id9e3336b01ef433aa8801b345dea8c4d_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfOC03LTEtMS05NDQxNA_508d61ae-502f-416b-8240-127746f8d82c"
      unitRef="usd">27000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i69959f4306b342dbbb1318e7d3cf276a_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfOS0xLTEtMS05NDQxNA_4c1705af-4a56-4604-a632-d357d5b01bee"
      unitRef="usd">244000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i59506b8e5aae42f880005525de216ce0_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfOS0zLTEtMS05NDQxNA_acbc5eab-22cb-4d12-9c9f-3361b0ef5820"
      unitRef="usd">196000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i1091a13b711442e0848bc698d9a73a45_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfOS01LTEtMS05NDQxNA_4ced9426-e7f6-4026-82ee-61453b211821"
      unitRef="usd">727000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="id9e3336b01ef433aa8801b345dea8c4d_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfOS03LTEtMS05NDQxNA_b11db5e8-8245-47d3-a932-875904d296c7"
      unitRef="usd">597000000</us-gaap:InterestExpense>
    <us-gaap:AdjustmentForAmortization
      contextRef="i69959f4306b342dbbb1318e7d3cf276a_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMTAtMS0xLTEtOTQ0MTQ_93382605-f2ee-4e2a-9dc1-c26384aa12dd"
      unitRef="usd">460000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="i59506b8e5aae42f880005525de216ce0_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMTAtMy0xLTEtOTQ0MTQ_c6387d6b-388c-4660-bacd-677ba27b0ccf"
      unitRef="usd">360000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="i1091a13b711442e0848bc698d9a73a45_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMTAtNS0xLTEtOTQ0MTQ_7967ebcd-e987-4639-bcd1-1f2dc2d83fc5"
      unitRef="usd">1623000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="id9e3336b01ef433aa8801b345dea8c4d_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMTAtNy0xLTEtOTQ0MTQ_0f9d975e-3ee5-4733-b2bc-04df3bd0043c"
      unitRef="usd">1231000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:Depreciation
      contextRef="i69959f4306b342dbbb1318e7d3cf276a_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMTEtMS0xLTEtOTQ0MTQ_ad60f4fe-3210-44a8-a5fa-e627e44abf0c"
      unitRef="usd">448000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i59506b8e5aae42f880005525de216ce0_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMTEtMy0xLTEtOTQ0MTQ_6758dfa1-5242-47c1-a1cc-814c371e6e8c"
      unitRef="usd">358000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i1091a13b711442e0848bc698d9a73a45_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMTEtNS0xLTEtOTQ0MTQ_393c7074-0020-4415-bc4f-48f1257ddbad"
      unitRef="usd">1257000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="id9e3336b01ef433aa8801b345dea8c4d_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMTEtNy0xLTEtOTQ0MTQ_101c5596-609b-4afe-821a-b24cfc616fd6"
      unitRef="usd">1031000000</us-gaap:Depreciation>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i69959f4306b342dbbb1318e7d3cf276a_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMTItMS0xLTEtOTQ0MTQ_89fc9d36-2b8c-4116-bc23-df9b0ae770df"
      unitRef="usd">4277000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i59506b8e5aae42f880005525de216ce0_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMTItMy0xLTEtOTQ0MTQ_95b27f87-ee3e-435f-9fef-2a9f0af80cb9"
      unitRef="usd">2312000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i1091a13b711442e0848bc698d9a73a45_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMTItNS0xLTEtOTQ0MTQ_25daa67f-541c-43dc-81d9-bb977021498b"
      unitRef="usd">9374000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id9e3336b01ef433aa8801b345dea8c4d_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMTItNy0xLTEtOTQ0MTQ_4ccf5b12-877c-462f-a6c0-c1c48783b9de"
      unitRef="usd">8775000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:RestructuringCharges
      contextRef="i69959f4306b342dbbb1318e7d3cf276a_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMTMtMS0xLTEtOTQ0MTQ_cbf60e52-377c-4df7-92d2-bc2858214875"
      unitRef="usd">94000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i59506b8e5aae42f880005525de216ce0_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMTMtMy0xLTEtOTQ0MTQ_ecec2a5b-26e8-44b5-bf7d-bb4c5bdf2c55"
      unitRef="usd">107000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i1091a13b711442e0848bc698d9a73a45_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMTMtNS0xLTEtOTQ0MTQ_5b159c41-3eca-4c45-835f-2be7ee0a887a"
      unitRef="usd">288000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="id9e3336b01ef433aa8801b345dea8c4d_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMTMtNy0xLTEtOTQ0MTQ_8cafb66b-83a6-447c-981a-26595403d643"
      unitRef="usd">487000000</us-gaap:RestructuringCharges>
    <mrk:SegmentReportingUnallocatedOtherExpensesNet
      contextRef="i69959f4306b342dbbb1318e7d3cf276a_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMTQtMS0xLTEtOTQ0MTQ_3071a8ba-c4cd-435d-bf18-47506bb17141"
      unitRef="usd">1416000000</mrk:SegmentReportingUnallocatedOtherExpensesNet>
    <mrk:SegmentReportingUnallocatedOtherExpensesNet
      contextRef="i59506b8e5aae42f880005525de216ce0_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMTQtMy0xLTEtOTQ0MTQ_7c634ffc-dae6-475a-84c8-81fe0a3d1be1"
      unitRef="usd">660000000</mrk:SegmentReportingUnallocatedOtherExpensesNet>
    <mrk:SegmentReportingUnallocatedOtherExpensesNet
      contextRef="i1091a13b711442e0848bc698d9a73a45_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMTQtNS0xLTEtOTQ0MTQ_e65f23bc-e850-4050-9e91-5b46eda8a683"
      unitRef="usd">4628000000</mrk:SegmentReportingUnallocatedOtherExpensesNet>
    <mrk:SegmentReportingUnallocatedOtherExpensesNet
      contextRef="id9e3336b01ef433aa8801b345dea8c4d_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMTQtNy0xLTEtOTQ0MTQ_41ac7255-593f-4d5a-97e2-55b629b2be2f"
      unitRef="usd">2044000000</mrk:SegmentReportingUnallocatedOtherExpensesNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMTUtMS0xLTEtOTQ0MTQ_78182dfd-dc5f-4351-af98-04e1c4d13c66"
      unitRef="usd">3583000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ide122c722e0d4b878b4ca10ea5a4c1b9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMTUtMy0xLTEtOTQ0MTQ_53fbb069-494b-4faa-8ee2-b1fde51d0c0e"
      unitRef="usd">5266000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMTUtNS0xLTEtOTQ0MTQ_e8622375-813c-425a-bddf-fad0db7778d4"
      unitRef="usd">12931000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i4068211e109d4d7da65c6be7b495d094_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF83Ni9mcmFnOjRkZTg1NzU3Y2ExMjRiMTE5OTMwY2MwZTAxZmVlYjM0L3RhYmxlOjQxNDQ2Y2YzMDMyMzRlZjJhZjI0NDYwNDUzN2RmZWJhL3RhYmxlcmFuZ2U6NDE0NDZjZjMwMzIzNGVmMmFmMjQ0NjA0NTM3ZGZlYmFfMTUtNy0xLTEtOTQ0MTQ_f3cb7a8f-1321-48bd-9876-7d64adb9e451"
      unitRef="usd">9970000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>82
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M^^P1?6+FF0:.4D9G$=NRW2,C9QO"@[7P8%A/GHUNM[M"ZY@E<=VNC;O$N&0
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MQ;_@N<): [#<,TZR*EC,($OR\C-^J0K1"!!YS &H"D!J@-,28%<!]KDC.%6
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MTLD7],C7HN(P#J9-M_.MMI=DQ5G=5"]=M1CW\ S4ZF*"QX.B02[V884TX<O
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MS?'S ](8X/E""/VV,/VG_:#%_P%02P,$%     @ DX-C54<$]=D$"0  'Q<
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MQO*7A"3;-4@KTPLEO\GE/'-(XQF\&%9R;&N-D8%>97FLQ!PTL,Q]Z]A(^'3
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M-&;R.%2_&'^5HGC?44U-$SP[N[QHW9SLEZ1@Y['X <_W%X$3H@CYGK1SA8Q
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M%.I5^N)-S1>OY\9[4_+'E4*=M_0"GB\,$CE^H07:F_BO_P-02P,$%     @
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MP(;O^_Y0V^$Q&CQT>OKU7K]M^?]1;>^/R__CY)"=Z*[8D07?@.K+?17%Z.S
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M /?715&;+SB!_7&NE_\'4$L#!!0    ( ).#8U56H&G\:@,  +0'   9
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MXWK>=@T)R?],44$V^6QZ$RC.5^W&Y/;;1Z09K6VV]M%W?_W+Y;.+K^]!X;.
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M\Y,RH?0@"9LAJ??G9PX&5&!!)LUUF*&?^>GU\$OVW^\^'0WY"&+E![0Y*IR
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M'Q;T.D+M!.C_6BF[FS@#^_?6_"]02P,$%     @ DX-C550K7RM3!0  7A
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MZ49<?U:N=WA!:X*+Y="WHX!'ZB6K?44>KE2M[=I ENVN;49WF$48V9ZEF%3
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M# 1R(U3S%CG76&0AJC1L;.H*(4KF4A3<24[PF;-8!<*:X%H*F.8Z'!EJEX4
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M;9B*W_D@\?+/.NGST^!7*O!J6.,?$JKLAG/&<5)N4L!3@WWI_$)'$Y6?J^M
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MW2E+P]DO*WH-43L%DA=*V</&.1C>U_4W4$L#!!0    ( ).#8U6 [EY#?@4
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M.:::T:[9&+FVX]1"&AK.[#*G:1@5"]#]4DJSV["#;KZ>_P-02P,$%     @
MDX-C51L;^XK2#@  KC,  !D   !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL
MQ1O;<MLV]E<PKK<CSRBV>-$M33SCV$GK'2?UQ$G[L+,/D A)2"B"!4@[ZM?O
M.0>\@!)%R6FG^V") HB#<[\!?O6D]%>S$B)CW]9Q8EZ?K+(L?7EQ8>8KL>;F
M7*4B@9F%TFN>P4^]O#"I%CRB1>OXPA\,1A=K+I.3RU<T=J\O7ZD\BV4B[C4S
M^7K-]>:-B-73ZQ/OI!SX*)>K# <N+E^E?"D>1/8YO=?PZZ*"$LFU2(Q4"=-B
M\?KDRGOYQO-Q ;WQFQ1/QGEF2,I,J:_XXS9Z?3) C$0LYAF"X/#U**Y%'",D
MP../ NA)M2<N=)]+Z.^(>"!FQHVX5O'O,LI6KT\F)RP2"Y['V4?U](LH"!HB
MO+F*#7VRI^+=P0F;YR93ZV(Q8+"6B?WFWPI&'+/ +Q80(R[L1H3E#<_XY2NM
MGIC&MP$:/A"IM!J0DPE*Y2'3,"MA77;Y3B8\F4L>L]O$9#H'AF>&]3[Q62S,
MV:N+#/; -R_F!;PW%IZ_!]Z4O5=)MC+L;1*)J+G^ G"K$/1+!-_XG0 ?1'K.
M@D&?^0/?[X 75 0'!"_8 ^]&:/G(414:%/,D8K^(:"F3);M"39&9%(;=2#./
ME<FU8/^YFL'KH$7_;>.*W31LWQ1-ZZ5)^5R\/@';,4(_BI/+'W_P1H.?.D@*
M*Y+"+NB7;Q<+T'&F%NP#F/%M\BA,AE0104 $*/^OU[=$8K82[%HE1L4RXIF(
MV$,&7_0R++]-YFHMVLCK1N 30!6$A$$P=I-URI/-CS],?&_\DV$)8"9KS%;?
MA1GC( >S4D\)FZ$_><FNUBJW;]QKD?%OK/<S>*(S=J>,81_%7"T3^2< D[ 1
M[* )+RU6Z%9( PALSSM[/J2>I,5G3'P#%VE$GV@$/UF  A/X-H]SL *VT&K-
MK)1@UT0 Q$_ "=2U3RLM1,-F&&@\$#Z#+5#M/P"ON^;_,H#>*=*TEG$,7M*<
MD9WAAW?@J477D*"/(N;H;\U*IH:!YP2_F "/YBN>+ 6; R)H1(:=$MM/F8=/
MX1@?>SY]D=+X/]&X':9/#[[>YEJ]B$2BP!62EB0J SWJ^</!&>N-87DO# !L
MSYM.SRI ^[X1@0^*\4)>3P+42XMYS(V1"UD*[NK7ZSM@4::8E3B\$M/>,():
M:W@L4&\XA+:9D9&$Z';>8=;#RJR'G595JA$JGT:Y@;6\X3&X:\$>*&)_K!%Y
MQZ5FO_$X%X75MUEQYW[M3@I-.\-@8"V.T0QBA93':DZR)NH+;'6)+2A58=,1
MFD?4M.XF(0Y'Y_DZCZU_AF@KP3-'7W*K8X:L:X&4/A*EUHN\9-=<ZPUY[LJ(
MB0D1NY-\)F/KRZ]KR/5[6WPC(-6&Z!\@U3'@(6Z$?3K#,6O5)8%;FV_;4]/:
MR'X 6#'B]:TQ'?52DV=W:->WL JW>UK)^:HDV@Z:&M,[Q1/#4KXA0:*WG>=:
M(X&ITJ4 8Y4L7V1"KR&IF64-,_3[_BAHC'@!Z]#P4:7AHTX-=Y@/"-21F0(#
M9S]K]+UO2 L>Q%*+)2G)3&1/0B#S%4C&796M>$8QXD88\#KT-C>58+?CO050
M+?J@LL,+V\RJD\AVL[JW9E1KD6MCTEJ7H^C G6B;.TOBCK41LX\[41MWH@:1
MJX)(V<T=<+2'%[X\3I'WR9U]/G\X9S<JCKD^[J5M8[LRADS#6OUFY[>K+8>5
MI&EPUSPE6[D%N8'XP&O!6F:>>.I$-9L;E.;%<7O3L)RV)R_<-K?AH"MTMFXR
M\4<5C#%!\,=>-3+JC\>3PS"O"EC#:J'7#P<3%@;.P'#H=4&ZFL]UCDP%)5(-
M3&/'&U?@6#"N?O@A@!_YP6%$/ZBDA'K7"G7J8(SHG[*IAZF&#W^3_G@R@>_
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M2D]$,GYM.:/N2 _<7;^R7X;<*9<YM_A1R^^B<JMI-(J@P@5?2W>G-Y]QF\_
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MH=?U;**\G%E)QIG@269K^Q*21ME,%-;3WXL+PV"O*DBN-1L)#^5'*V"\U5)
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MI6$ ^EP(O>H8!>M+SLD_4$L#!!0    ( ).#8U6#$M5V^@0  ,8-   9
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M! @T%($T2+S<P05H38H0QC^=SD%OD@2WYQOMOT3?T9=;Z>'"ZC]5&=9G@WS
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M9_C2X]JOAO8FV#J^J=_:@._]<;K&#RUPM &?+ZT-FQLRT'^Z+?X%4$L#!!0
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M<RSGJBWX[<#(VA79E318LIU8XAL)E%V _]=2FMW &MB_NF9_ U!+ P04
M" "3@V-53+K)G6,%  ! $   &0   'AL+W=O<FMS:&5E=',O<VAE970S-"YX
M;6R]6&%OVS80_2N$5Q0RX,4B1<I2FAA(T@[KT#9!TVT?AGV@9<K2*HDN2<?-
M?OWN2-FUVR1U@'1 8%$2[]T=[_&)EY.U-A]MI90CG]NFLZ>#RKGE\7ALBTJU
MTA[II>K@3:E-*QW<FL78+HV2<V_4-F,6Q^FXE74WF)[X9U=F>J)7KJD[=66(
M7;6M-+?GJM'KTP$=;!Z\KQ>5PP?CZ<E2+M2U<K\OKPS<C;<H\[I5G:UU1XPJ
M3P=G]/B<XWP_X8]:K>W.F& F,ZT_XLWK^>D@QH!4HPJ'"!(N-^I"-0T"01B?
M>LS!UB4:[HXWZ+_XW"&7F;3J0C=_UG-7G0ZR 9FK4JX:]UZO?U5]/@+Q"MU8
M_TO682Y/!J186:?;WA@B:.LN7.7G?AUV#++X'@/6&S ?=W#DHWPIG9R>&+TF
M!F<#&@Y\JMX:@JL[+,JU,_"V!CLWO725,N1"MU#2"M?Z1I'77:%;1:(WVMHA
MB3[(6:/L\&3LP!]:C8L>^SQ@LWNP<_)6=ZZRY%4W5_-]^S'$N0V6;8(]9P\"
M7JOE$4GB$6$Q8P_@)=OD$X^7W(/WZM.J=K?DK[.9=0;X\?==.08(?C<$[IEC
MNY2%.AW "EIE;M1@^OPGFL8O'@B0;P/D#Z%/+RK9+90E=4?.+B]>D]FM+Y7N
M5.?NBO5@-"6+BA0;**)+HCT1BCTBU#T1&D\$:121EI2Z@9ULC\F'RBBU5V("
M!7*JG0$05BEZAJ[:NFE@_P' 2V7J&XF[$.:WRT;?@CWL+=@Y';E8&:.ZXI:<
M%<6J7372 5Y@Y[EL9%<H\MNJN2745Q]^.^7C=O(SP#TC$4N'>$E&,<O\B([$
MA/L1'Z7X[/*[*<X4R)P"L2D::6U=UH4,VC'_![8B:)&S(P+6X)1,&/@$_"@'
MQQ$'_ _P-*)P1U-"&?X]D<>]5$5*(G 69>@[ 6_O#XDV 2LZ)&D&00_)\Y\R
M1MD+0F,>HD9 MO,B2N+O >\%Q3+"TZWUA'\_\Z\ ,DZ2+"0%UTW%]_ET9]U%
MYHL_RO.XKWHJLK[J I_=P1[V#4J2QP&&IV(81DRP'B9ADZ<F3YHA>W(L84K]
MXN."!P+Q!.K$B(BA"O3)'.]S*,G1)208B=2[3^F!1(J8P*AA^F2RQZ6(3B8A
M!9&$R#=O&'L,E2(6@^T.FR(JQ '+\!5,@G2B6;I-D>/.O)=8WU)BPGIFI8+V
ME,A8W%-B@D5Z!_KZO^J?[%9P<'I( M,-\_EF-V2]&J:C-.%/36.:)Q#-!-E$
M4Z@^C%,1:,PIRE,F-DHE:/QCN$P%2.TH$1RI23$&)L1A7&8T\TQF--ZC,H?2
MAR2\M.^2/,L>I8L4OA(41'=CG_#X\4QF')(2C&T3%+D@U\NZ^UF7)<Z[- O9
M01R1!4*]TTZ1G9!1FADEG.<_1E;W2/GM-J*<!R2_90(ED\TVXBQ_<DJ.6 +Z
M0QDRCXYB%!,:3T(]F0!_3!!*\7.7_!A"YO#YBV@<X]$ 5RJB]-"O=,3S)(@K
M;.5]=66L5U<:0WIXL-D6.'^4O"88$\W9CK[FAQR.OOZ$P!<;0/H4$\J?6%QQ
M$:Y,#9UB#=]MHU 0+7&:E+U@%AO!+*2M2 EG4E*I.9YO724=6:N]JH&8ED:W
M>(Q^@RC7$GH:<N37&/J=9C6'6PQ2MMJX^M^PC!#QTM0:FE@XV->06J$M3.GF
MV$T"[6O9D 5TOM8_PV7RQVL/-T?Q1\0ER+Z>UP50J5-E[0+(E[U*Z?#HKEYA
MO-/5M<HL?.]JP7K5N=#@;9]NV^.ST!5^F1YZZ[?2+##*1I5@&A]-Q("8T*^&
M&Z>7OD><:0<=IQ]6T.(K@Q/@?:DATOX&'6S_:3#]#U!+ P04    " "3@V-5
M" "B:-$+   P&@  &0   'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6RU66MO
MVS@6_2L7F6#@ $HLD7IFV@!N.SO-[+3-)FT7V,5^8"0F%BJ)+B4E<7_]GDO)
M<AY.=C[L -:;O+SO>R[]ZM;8;^U2ZX[NZJII7^\MNVYU/)^W^5+7JCTR*]W@
MRY6QM>KP:*_G[<IJ5;A)=347OA_/:U4V>R>OW+LS>_+*]%U5-OK,4MO7M;+K
M-[HRMZ_W@KW-B_/R>MGQB_G)JY6ZUA>Z^[(ZLWB:3U2*LM9-6YJ&K+YZO;<(
MCM_$/-X-^%KJV_;>/;$DE\9\XX?3XO6>SPSI2N<=4U"XW.BWNJJ8$-CX/M+<
MFY;DB??O-]3_YF2'+)>JU6]-]<^RZ):O]](]*O25ZJONW-R^UZ,\$=/+3=6Z
M,]T.8Z-DC_*^[4P]3@8'==D,5W4WZN'>A-1_9H(8)PC']["0X_*=ZM3)*VMN
MR?)H4.,;)ZJ;#>;*AHURT5E\+3&O.[G0UU!Q1^=Z96Q7-M<T^ZPN*]T>O)IW
MH,^CYOE(Z\U 2SQ#*Z,/INF6+?W:%+IX.'\.OB;FQ(:Y-^)%@A=Z=432]TCX
M0KQ 3T["2D=/_FEA_[VX;#L+U_C/+G$':N%N:APNQ^U*Y?KU'N*AU?9&[YW\
M_%,0^[^\P&LX\1J^1/WD0L$(=&5-36?6%'W>M;M8_#-$S!5U2TUO3;U2S?KG
MGU(1)+^TM!K)TJVVFA06,Q5BM#VFSTNK]0-C$DS1Z?I26V>/CUCGI>]L+SX%
M]^YF^U0V<.&J0C2V!_3EZ.*(3IMNY*>BSZ93U?_G]=E2(6)SW7=EKJIC^M0@
M3LSUFOZNUYWM"T7[)#TI UR%YV<1KI$7BM@]1ZF/:^!E48AKZ$62KYDG_037
MV N&[YB0\HO$"_S4$8A\)A@(+_8S6D!0U>0:J>M&-[T^_&/=K)3]H6@6'% 0
MACA\$BFN(J,@2$B$,84B(9DEE(J(9!*0C'Q*H+VGU'1S4]8;8H)BG]4,.B$E
M()FFQ.((&5',G\"I" (*L_0IJ7-]69D?ZXIFXH"D(.: G$;%+T^N("03L!P^
M.^*KRG/X1TN_*5NHMJSFFQO**(LP&9H'.Y[(0DJQ5. %T#3TG4F<4U_"-C$6
M8(ND>!/[$5L%(T./]89X^$>OBOF'PP^'YW1Z2O.ORI8WZHXB<!_(&"*GN&<V
M6?Q@7%$FO%82Q#B+:- OJ$--Y_":S_H[.3Z@11%A#%27X18&8:.((*48B\LX
MQ+N,(C![UNB^-KRPD(0E8_ /GPK2@&!"D>" JP2XAA!;@K@($UC*AXZ^=XK8
MUF V9*6#JS"%J2EF$: 8GR((+U-Z;]I5R5Z]R/L.8:P0K6]L67!1$Q)+9CXX
ME&Y9MKN,,P@=4>3$%> Y"O$4L;!^%D-]^F9=ERV<@==FCX%JP6 6.^4%\!\9
M@&_X2Q!EX-*G=^55F9>%XX\@3P3%$"O+N2]8P#0$ 30>1%@ CGF'8-]X!/2"
MW_24$2@RKY$[-N\#N ,?'\V=NH*S!-)QR-2A/Z<F"!3R1)]U%>!K #V?-C>J
M^0%^\ [1PDX,XT:8/499ZMZQ* &D? O?+^&.X !A$T)O!&OS#RM*IW%,8L7
MHO_2]E+=P5*AXT*Z<','*&(,%@H$UHSP)N8O^ 0#P38WJLW[2MFGX;8H-!)Q
M._^J[??^QM!,'A#4( FV2R0[10 /$8YU>&(*=X.V$<L09)P[Z0SRX#<]L5MN
M]9D.KKA]3MWQM;1#,OP#J.O&EF8:$<+Z?#P7V8$7">D2)\9Y:?1\ECAM46=1
M%-OY=$?OWW&,<(PC(A-V%9@VS9SSL(^%<>Q$E1R\\.F/NK>FS4O-R@-\;$UM
M80EV=O8*< +=0#ZDMX ](\O8BD$*%<*&IW7=-X.<%V6],DVY%0-:YF/S+)!Q
M^)C4B+S,Q^2P,#T?Y[I&.2GT5E\9_S9/H'B/:,#)X)[7<Z3R\:Y4E[I#=OQ=
M-?U-J4@B^"7LGP2<#2+BHI(BOC(.?Y<CD2GY.>/,&<()!,Z1FU\#M4-3DG,4
MIJ<P"TH04Q!NML_J]628#.[D"612II'1)R "2ZL'=9)FX8$;* 7'!!9&%I ^
M(H-S'Q)4QA'G16 R1CK-$&QXPA*[BBZU(]AJ'0:)D6=]G"4'G/ R:";R8E@]
M\E+X=@"N.(=D7@!%"]]+?*Y"P[?0BSD5H?!R:< WQ,6B08ZIZ+U65;<\IC\
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M?C(U >- R5 1V"Z5/ [1IJ"4G"/_F+?8$.*(GW)0+WN>:\*2[2=]MT+* Q)
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MLVE?#=SMJW^NYI_3W,MNO5I?_^G_,L_N\F1>OQGTN.VWS;:C$46K5*@6H)I
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M>RSNZ>$WU$XH4'P9Q5S_@D,S=NY8(-MS0:L6+)^@*DGS#Y_;0/0 DF<<X+4
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MG0='B71^DOO<<#$<$Y^."8+KHT"?C@G]HQ2:3L[P?\9OT<5O,1F_S>N+T+P
MO"29>BGHCL$*J$:M/F;&XK@XK0_>246:E+]T;9^CF)A43 V1#;RY[KRYGO1&
M?@0BF7]&=P.3R$OSCTFRV"198I(L-40V\-)U7C\9G1^YTV_9#3ENE"TVRI88
M94M-L0U=[QT4N#]JPS_-?+'C)MEBHVR)4;:T91O4W%Z1:(RT>X<_%6([?4S'
MI1=[(IJO]ZZW.PK\H _ COIOW.7&'>F/W672'/2]TC?GCK>0[4K" 49;*24W
MW'(GPIJCO*8A:*V/GAZI$+32EP6".6)J@+R_I52\-)1 =Z :_0=02P,$%
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M6HL4JJ1*<FVLB-Y8G2S52-L)-86:OG1O-C\MZ$$55+FL;1S1V[@_Q(;Q3JY
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M<<-Z2P;JCT)I#$KC4)KP^_NC@?9' [<_^FPQZF:;N:/T50J4%D%I#$KC4)I
MT4PM:8\U\%#%*(#:K%!:!*4Q*(U#:0)%,_6B;=; ?5)VSXNP4<?/*IY>A WJ
MH_:(S*"1.90F4#0SW=HE#=PN:71P,;9(ELDJ:US3N"2_R.6J/IWWX+*F5@5
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M<FMS:&5E=',O<VAE970T-BYX;6RM55U/VS 4_2M7&9I &N2CI9M8&@E:(9!
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M-'"[UU53*.G+W_/4E=.2WV%[Q.ZK<Q'L ]\"B6^!U\N5('"Z)>I*34V"I,+
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M94*;B*#?*70EI&]R,>UJB,8&=CLLG=%!>]..L.FPH+G%.OS,DV*>K0JI)BE
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M@N;EX1HC63*5@;R_I%2\G*@'U/]\,/\/4$L#!!0    ( ).#8U7P6HVD?@,
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M.0@7"])6 XD;H.(;9@76\%X:&FN^%&08 ]/P%N,E%\L:7R= PWBB3XCYPSR
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M_J/GXMI!#RUW4O&X"-8CB,,D?Z7?"R$J 1K''. 6 >YQ@'\BP"L"O',9_"+
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MV7G4WQEN,=$7-],^>$=L#JPL!%86]()&UQ2"PERFJ%=DMPFCG? -&4I-#9G
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M1;WRT'NW.([I?^ICJ18JQV%R6@HEJHVF;J]X&@E+!'19)E:.P^2T1$B '-&
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MXS Y+9<2@^>3%PGG6&B&RC&L'(?)J8DH)&@N7CE=NC G0AO5R&)C5"/:#^_
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M.+>>#,>_>Z=!MZ85]I\/WF]=\":81ZK@1O"_6*G7LV <H!*6=,/U@]A]@'U
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M01H#W%\*H1\GI@&I^LW@'U!+ P04    " "3@V-5]#5_GQ0#   9#   &0
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M+>GXI8F^X?.?X)LI62M"B82S:U644<5/="D$2(%^7BL,FDE(Q:\F _, G>8
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M;9GAN\N,[AG[SSS[QY?[SF!!NPNH1J$:@VH<JH503: T.X)M=^'#NPL?VEU
M-0K5&%3C4"V$:@*EV>>T:+N+H&]W\?J4=9-]8PC5*%1C4(T'+WN0_</4(72+
M J79X6J+B\!=7'1/V>O/-Y]OKSY==D8+6EI -0K5&%3C4"V$:@*EV2%LVXW
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MELF!K%%F:"<GLQ)%F7R8ZX$.-#XQAQ2F/75+"$2Q[IPFB')M(!0 B)RX>=<
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M"=3WNS25IX/L M7K;\M_ 5!+ P04    " "3@V-5>?^$]W4"   /!@  &0
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M3M6K&RTVY2GP@]!:Y.7E&M@"I*U@GB^%T,\WMH'FMPVS_P!02P,$%     @
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M+J7!5NN6!8Y;4%8!SU=2FOW&&F@'>/H'4$L#!!0    ( ).#8U7XW9<)!@D
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M8A\0:_UF95YO?P:O>VTX"&:;NBE7^\;R&ZRR8O<[_;Q/Q%$#Z0,WP/L&6&]
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M8%7:1\;$Y(<</#VABX=0&J%HW>*U3K2<,L!:0KTFE!:A-$+1NI]':;UF-3+
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M*71=$8LC&$[4S[/Z39EV/=)AQ8)Z4RR.8#A1K((5:V3:]7B@>&*:M!1%E7S
M4U/5\[2CI*JJZ,G.NWE@YYBW=*,;R@G;<V+<X5,5NMR(Q1$,)\I8LC).&7<]
MTF'%@GI4+(Y@.%&LBA5K9-SU>&#H/!Z5MD=5E3*2IJEJ^7275%6RV\#Y[E/3
M[.-ROWS]\KK9?FP6S=6A"5QL;M?[^SG)_G:V;3X<+H'Y^AM[=I[\_;?FZX51
M_CZ:K^GA[\];_.N7-\N/S??+[<?5>C>[:CX<AII_=1_ZWZX^?GKZA_WFYM79
MX>;SQ\U^O[E^^..G9GG9;.\%AW__8;/9'__A?H#/F^U/#Z?S^O\!4$L#!!0
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MQ*,O@FV*?U2E/Y#;:O)2#Z^++5VPR4@*7L'R9S::_O@#=LV?5?,.219"DD5
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MMA"4+8)BZU:IM778/ZM:@+H\4+80E"V"8NO6J75Z6&M3-&H1#%:OW__Q<*X
MN=CJJ\401+R ]-5BB,*>?\)#D-8F$;U-^DI%DJ&9[+D3/R?HX]_;::!L(2A;
M!,76K43KY@@^IR(04,\'RA:"LD50;-TZM9Z/:+W*:46HXSJ+W>\K@@+D!+TW
M$Z$"A .K_\Y!A7(M?$(16J]$]%[IC_*)09D?Z"LM4+80E"V"8NM6H/5RQ#ZK
M$H Z/E"V$)0M@F+KUJEU?$3_?NZT$CB#UX%NX/>58 BRO($2#$'8M\V^$@Q1
MGM,W$L;1K@G91JMJNTJ!%GR7B<-;\>9JLR5F5FT$Z5V_P==SK+@>XNOHL.&E
MI3_LO[FE^2K)"I2RI;R5>>7)\>:'+2V'$\&WU9Z-)RYDCU>':T9CEI< ^?F2
M<_%Z4MZ@V5@T_0]02P,$%     @ DX-C51[RH'U(!@  9"@  !D   !X;"]W
M;W)K<VAE971S+W-H965T-S N>&ULM5IM;Z0V$/XKUO94W4F7+#;OZ6:E)%!=
MI%X;);WV0]4/A/7NH@.\!6^25OWQ-2^!Q0R^3>-\28!]YK%GQAYF&"\>6?&U
MW%+*T5.6YN7Y;,OY[FP^+^,MS:+RE.UH+GY9LR*+N+@M-O-R5]!H50MEZ9P8
MAC//HB2?+1?ULYMBN6![GB8YO2E0N<^RJ/C[DJ;L\7R&9\\/;I/-EE</YLO%
M+MK0.\J_[&X*<3?O6%9)1O,R83DJZ/I\=H'/0K,6J!&_)?2Q/+A&E2KWC'VM
M;JY7YS.CFA%-:<PKBDC\>Z!7-$TK)C&/OUK263=F)7AX_<S^8ZV\4.8^*ND5
M2W]/5GQ[/O-F:$77T3[EM^SQ$VT5LBN^F*5E_1<]MEACAN)]R5G6"HL99$G>
M_(^>6D,<" @>6("T D06L"8$S%; /'8$JQ6PCAW!;@5JU>>-[K7A@HA'RT7!
M'E%1H05;=5%;OY86]DKR:J'<\4+\F@@YOKRC&^%VCF[ICA4\R3?H1%S'+(^3
M-(EJ7[(U>D;=%&R=\!)QAJ[SF&44W5.Q6"GZ-7JB)7H?4!XE:?E!D'RY"]#[
M=Q_0.Y3DZ'.2IH*J7,RYF',U\CQNYW?9S(],S,]$GUG.MR4*\Q5= ?*!6MY7
MR,^%K3J#D6>#71(EX1W=G2+3^(B(00@PGZOCQ3&DSNM&#__WZ -CF-WJ,6L^
M\^C5<YTWP:M:.'_\).#HFM.L_!/R?,-MP=Q5A#PK=U%,SV<B!):T>*"SY???
M8<?X 3*[3K) )UFHB6S@(*MSD*5B7[8;%K)^(^C4@M7KY&%IVIZYF#\<6G4,
MLHGC#$'!&(2);^(A*ARC?-\U.M! /;M3SU:J=YUS*HS&18RIHA&D9D-@'PQK
M&9*28X@K:3A&.$12;PPA+JR<TRGG'*<<?1)I00EJYXQ&/2&6)>D'@+ O.Q$
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M$LI3&#GFAKF?>I=5%+L]$]DNS]V@,E,WFJ]>=S^_[MR^_!=02P,$%     @
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M@R*K09'5H,AJ4&0U*+(>_Z>L]\ZM_SA^?):=;?JW?#;^67'Q E!+ 0(4 Q0
M   ( ).#8U4'04UB@0   +$    0              "  0    !D;V-0<F]P
M<R]A<' N>&UL4$L! A0#%     @ DX-C5>5)+D;M    *P(  !$
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M970R+GAM;%!+ 0(4 Q0    ( ).#8U4QJ<RG-@0  /L.   8
M  " @5$6  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " "3
M@V-5#*[,QR4'  !O'   &               @(&]&@  >&PO=V]R:W-H965T
M<R]S:&5E=#0N>&UL4$L! A0#%     @ DX-C54L;QAU3 P  80D  !@
M         ("!&"(  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0
M   ( ).#8U7NO12NYP<   DC   8              " @:$E  !X;"]W;W)K
M<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " "3@V-5E:+AU7<"  #<!@
M&               @(&^+0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L!
M A0#%     @ DX-C54<$]=D$"0  'Q<  !@              ("!:S   'AL
M+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( ).#8U43PU]GA@D
M ,4:   8              " @:4Y  !X;"]W;W)K<VAE971S+W-H965T.2YX
M;6Q02P$"% ,4    " "3@V-5)8KUR-T/  "5+P  &0              @(%A
M0P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( ).#8U5N
M25NL9!$  ,<[   9              " @753  !X;"]W;W)K<VAE971S+W-H
M965T,3$N>&UL4$L! A0#%     @ DX-C5;HL2=1I"   C!8  !D
M     ("!$&4  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ).#8U5T8!_6)04  .(4   9              "
M@0JU  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ DX-C
M5:6S(+4'!P  .A(  !D              ("!9KH  'AL+W=O<FMS:&5E=',O
M<VAE970Q."YX;6Q02P$"% ,4    " "3@V-5MP_HT\ #  "6"   &0
M        @(&DP0  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0
M   ( ).#8U6TM%BRB00  *X+   9              " @9O%  !X;"]W;W)K
M<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ DX-C57S1A)6& P  >PD
M !D              ("!6\H  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q0
M2P$"% ,4    " "3@V-55"M?*U,%  !>$   &0              @($8S@
M>&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( ).#8U4KAIB*
M#A$  !8I   9              " @:+3  !X;"]W;W)K<VAE971S+W-H965T
M,C,N>&UL4$L! A0#%     @ DX-C50(5TS+3!P  \A0  !D
M ("!Y^0  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " "3
M@V-5S!S8A6@#  !K!P  &0              @('Q[   >&PO=V]R:W-H965T
M<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( ).#8U6 [EY#?@4  #H1   9
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M970S,"YX;6Q02P$"% ,4    " "3@V-5@Q+5=OH$  #&#0  &0
M    @($:$@$ >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    (
M ).#8U5AL)*G P,  ( &   9              " @4L7 0!X;"]W;W)K<VAE
M971S+W-H965T,S(N>&UL4$L! A0#%     @ DX-C54HKM6V5 P  @0D  !D
M             ("!A1H! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"
M% ,4    " "3@V-53+K)G6,%  ! $   &0              @(%1'@$ >&PO
M=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( ).#8U4( *)HT0L
M # :   9              " @>LC 0!X;"]W;W)K<VAE971S+W-H965T,S4N
M>&UL4$L! A0#%     @ DX-C516'RC"F!@  +3T  !D              ("!
M\R\! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " "3@V-5
MO(=S>,$$  #T&0  &0              @('0-@$ >&PO=V]R:W-H965T<R]S
M:&5E=#,W+GAM;%!+ 0(4 Q0    ( ).#8U5S/?M7&Q$  'P; 0 9
M      " @<@[ 0!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%
M  @ DX-C57)B2D3X#0  E;H  !D              ("!&DT! 'AL+W=O<FMS
M:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " "3@V-5RZ\/S'P.   0K
M&0              @(%)6P$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+
M 0(4 Q0    ( ).#8U5<*'I&[0,  %P5   9              " @?QI 0!X
M;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ DX-C5=2PI8MT
M"   (U@  !D              ("!(&X! 'AL+W=O<FMS:&5E=',O<VAE970T
M,BYX;6Q02P$"% ,4    " "3@V-5^>QXEH\%   Q*@  &0
M@('+=@$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( ).#
M8U5^12?7" L  (!R   9              " @9%\ 0!X;"]W;W)K<VAE971S
M+W-H965T-#0N>&UL4$L! A0#%     @ DX-C50!*=N0Y!   2Q<  !D
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M=#0Y+GAM;%!+ 0(4 Q0    ( ).#8U7P6HVD?@,  "\.   9
M  " @?Z? 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @
MDX-C53529]:A!@  P3<  !D              ("!LZ,! 'AL+W=O<FMS:&5E
M=',O<VAE970U,2YX;6Q02P$"% ,4    " "3@V-5*/^DL7X3  !0  $ &0
M            @(&+J@$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4
M Q0    ( ).#8U5])8<$Z0,   ,/   9              " @4"^ 0!X;"]W
M;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ DX-C53"U+MA' P
M=0H  !D              ("!8,(! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX
M;6Q02P$"% ,4    " "3@V-5*:H2T-8"  !["@  &0              @('>
MQ0$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( ).#8U7T
M-7^?% ,  !D,   9              " @>O( 0!X;"]W;W)K<VAE971S+W-H
M965T-38N>&UL4$L! A0#%     @ DX-C5=10%@\1"0  T'   !D
M     ("!-LP! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ).#8U5:4W4_80(  +,%   9              "
M@:;M 0!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @ DX-C
M55_4W<.H!   YR   !D              ("!/O ! 'AL+W=O<FMS:&5E=',O
M<VAE970V,RYX;6Q02P$"% ,4    " "3@V-5,$$M4A4%  "@&   &0
M        @($=]0$ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0
M   ( ).#8U6C$JU.B (  ,P'   9              " @6GZ 0!X;"]W;W)K
M<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ DX-C5?C=EPD&"0  -D$
M !D              ("!*/T! 'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q0
M2P$"% ,4    " "3@V-59:"(*, "  !5"0  &0              @(%E!@(
M>&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( ).#8U6S@76@
M_B   ,:W 0 9              " @5P) @!X;"]W;W)K<VAE971S+W-H965T
M-C@N>&UL4$L! A0#%     @ DX-C5?ZI=[%-!0  9"0  !D
M ("!D2H" 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"% ,4    " "3
M@V-5'O*@?4@&  !D*   &0              @($5, ( >&PO=V]R:W-H965T
M<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    ( ).#8U7L7MXX1P,  *H4   -
M          "  90V @!X;"]S='EL97,N>&UL4$L! A0#%     @ DX-C59>*
MNQS     $P(   L              ( !!CH" %]R96QS+RYR96QS4$L! A0#
M%     @ DX-C55\\_[YJ!0  /2X   \              ( ![SH" 'AL+W=O
M<FMB;V]K+GAM;%!+ 0(4 Q0    ( ).#8U7;=K!Q,0(  (DI   :
M      "  89  @!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0
M   ( ).#8U6DR,-W^@$  +0H   3              "  >]" @!;0V]N=&5N
B=%]4>7!E<UTN>&UL4$L%!@    !. $X 614  !I% @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>968</ContextCount>
  <ElementCount>344</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>155</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - CONDENSED CONSOLIDATED STATEMENT OF INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENT OF INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEET</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/BasisofPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Spin-Off of Organon &amp; Co.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SpinOffofOrganonCo</Role>
      <ShortName>Spin-Off of Organon &amp; Co.</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Acquisitions, Research Collaborations and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreements</Role>
      <ShortName>Acquisitions, Research Collaborations and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Collaborative Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/CollaborativeArrangements</Role>
      <ShortName>Collaborative Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/Restructuring</Role>
      <ShortName>Restructuring</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Other Intangibles</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/OtherIntangibles</Role>
      <ShortName>Other Intangibles</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/Contingencies</Role>
      <ShortName>Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Pension and Other Postretirement Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans</Role>
      <ShortName>Pension and Other Postretirement Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Other (Income) Expense, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/OtherIncomeExpenseNet</Role>
      <ShortName>Other (Income) Expense, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Taxes on Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/TaxesonIncome</Role>
      <ShortName>Taxes on Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Other Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/OtherComprehensiveIncomeLoss</Role>
      <ShortName>Other Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/BasisofPresentationPolicies</Role>
      <ShortName>Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Spin-Off of Organon &amp; Co. (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SpinOffofOrganonCoTables</Role>
      <ShortName>Spin-Off of Organon &amp; Co. (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/SpinOffofOrganonCo</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Collaborative Arrangements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/CollaborativeArrangementsTables</Role>
      <ShortName>Collaborative Arrangements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/CollaborativeArrangements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Restructuring (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/RestructuringTables</Role>
      <ShortName>Restructuring (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/Restructuring</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/FinancialInstruments</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/Inventories</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/Equity</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Pension and Other Postretirement Benefit Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables</Role>
      <ShortName>Pension and Other Postretirement Benefit Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Other (Income) Expense, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/OtherIncomeExpenseNetTables</Role>
      <ShortName>Other (Income) Expense, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/OtherIntangibles</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/EarningsPerShare</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Other Comprehensive Income (Loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/OtherComprehensiveIncomeLossTables</Role>
      <ShortName>Other Comprehensive Income (Loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/OtherComprehensiveIncomeLoss</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/SegmentReporting</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Spin-Off of Organon &amp; Co. - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails</Role>
      <ShortName>Spin-Off of Organon &amp; Co. - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Spin-Off of Organon &amp; Co. - Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails</Role>
      <ShortName>Spin-Off of Organon &amp; Co. - Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Acquisitions, Research Collaborations and License Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails</Role>
      <ShortName>Acquisitions, Research Collaborations and License Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreements</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Collaborative Arrangements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails</Role>
      <ShortName>Collaborative Arrangements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Collaborative Arrangements - Financial Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails</Role>
      <ShortName>Collaborative Arrangements - Financial Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Restructuring - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/RestructuringNarrativeDetails</Role>
      <ShortName>Restructuring - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Restructuring - Charges Activities by Type of Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails</Role>
      <ShortName>Restructuring - Charges Activities by Type of Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Restructuring - Activities by Program (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/RestructuringActivitiesbyProgramDetails</Role>
      <ShortName>Restructuring - Activities by Program (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Financial Instruments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsNarrativeDetails</Role>
      <ShortName>Financial Instruments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Financial Instruments - Effect of Net Investment Hedges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails</Role>
      <ShortName>Financial Instruments - Effect of Net Investment Hedges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Financial Instruments - Fair Value Hedges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails</Role>
      <ShortName>Financial Instruments - Fair Value Hedges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails</Role>
      <ShortName>Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails</Role>
      <ShortName>Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Financial Instruments - Location and Amount of Pretax (Gains) Losses of Derivatives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails</Role>
      <ShortName>Financial Instruments - Location and Amount of Pretax (Gains) Losses of Derivatives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails</Role>
      <ShortName>Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Financial Instruments - Information on Available-for-sale Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails</Role>
      <ShortName>Financial Instruments - Information on Available-for-sale Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails</Role>
      <ShortName>Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails</Role>
      <ShortName>Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Inventories - Schedule of Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/InventoriesScheduleofInventoriesDetails</Role>
      <ShortName>Inventories - Schedule of Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Inventories - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/InventoriesNarrativeDetails</Role>
      <ShortName>Inventories - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Other Intangibles (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/OtherIntangiblesDetails</Role>
      <ShortName>Other Intangibles (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.merck.com/role/OtherIntangibles</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ContingenciesDetails</Role>
      <ShortName>Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.merck.com/role/Contingencies</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Equity - Rollforward Reconciliations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/EquityRollforwardReconciliationsDetails</Role>
      <ShortName>Equity - Rollforward Reconciliations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Pension and Other Postretirement Benefit Plans - Net Benefit Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails</Role>
      <ShortName>Pension and Other Postretirement Benefit Plans - Net Benefit Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Pension and Other Postretirement Benefit Plans - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails</Role>
      <ShortName>Pension and Other Postretirement Benefit Plans - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails</Role>
      <ShortName>Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.merck.com/role/OtherIncomeExpenseNetTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Other (Income) Expense, Net - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails</Role>
      <ShortName>Other (Income) Expense, Net - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.merck.com/role/OtherIncomeExpenseNetTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Taxes on Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/TaxesonIncomeDetails</Role>
      <ShortName>Taxes on Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.merck.com/role/TaxesonIncome</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Earnings Per Share - Calculations of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails</Role>
      <ShortName>Earnings Per Share - Calculations of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Earnings Per Share - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/EarningsPerShareNarrativeDetails</Role>
      <ShortName>Earnings Per Share - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/OtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.merck.com/role/OtherComprehensiveIncomeLossTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - Segment Reporting - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SegmentReportingNarrativeDetails</Role>
      <ShortName>Segment Reporting - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - Segment Reporting - Sales from Products (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SegmentReportingSalesfromProductsDetails</Role>
      <ShortName>Segment Reporting - Sales from Products (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - Segment Reporting - Consolidated Sales by Geographic Area (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails</Role>
      <ShortName>Segment Reporting - Consolidated Sales by Geographic Area (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="mrk-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>0000070 - Disclosure - Segment Reporting - Reconciliation of Segment Profits to Income before Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails</Role>
      <ShortName>Segment Reporting - Reconciliation of Segment Profits to Income before Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 6 fact(s) appearing in ix:hidden were eligible for transformation: mrk:LossContingencyTrialPeriod, us-gaap:RelatedPartiesAmountInCostOfSales, us-gaap:RevenueFromRelatedParties, us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 -  mrk-20220930.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="mrk-20220930.htm">mrk-20220930.htm</File>
    <File>exhibit311-rule13ax14a15dx.htm</File>
    <File>exhibit312-rule13ax14a15dx.htm</File>
    <File>exhibit321-section1350cert.htm</File>
    <File>exhibit322-section1350cert.htm</File>
    <File>mrk-20220930.xsd</File>
    <File>mrk-20220930_cal.xml</File>
    <File>mrk-20220930_def.xml</File>
    <File>mrk-20220930_lab.xml</File>
    <File>mrk-20220930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="1902">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="41">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>88
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mrk-20220930.htm": {
   "axisCustom": 0,
   "axisStandard": 39,
   "contextCount": 968,
   "dts": {
    "calculationLink": {
     "local": [
      "mrk-20220930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mrk-20220930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "mrk-20220930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mrk-20220930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mrk-20220930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "mrk-20220930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 657,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 23,
    "http://www.merck.com/20220930": 1,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 29
   },
   "keyCustom": 44,
   "keyStandard": 300,
   "memberCustom": 77,
   "memberStandard": 71,
   "nsprefix": "mrk",
   "nsuri": "http://www.merck.com/20220930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "role": "http://www.merck.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrk:AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Acquisitions, Research Collaborations and License Agreements",
     "role": "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreements",
     "shortName": "Acquisitions, Research Collaborations and License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrk:AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Collaborative Arrangements",
     "role": "http://www.merck.com/role/CollaborativeArrangements",
     "shortName": "Collaborative Arrangements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Restructuring",
     "role": "http://www.merck.com/role/Restructuring",
     "shortName": "Restructuring",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Financial Instruments",
     "role": "http://www.merck.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Inventories",
     "role": "http://www.merck.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Other Intangibles",
     "role": "http://www.merck.com/role/OtherIntangibles",
     "shortName": "Other Intangibles",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Contingencies",
     "role": "http://www.merck.com/role/Contingencies",
     "shortName": "Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Equity",
     "role": "http://www.merck.com/role/Equity",
     "shortName": "Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Pension and Other Postretirement Benefit Plans",
     "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans",
     "shortName": "Pension and Other Postretirement Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Other (Income) Expense, Net",
     "role": "http://www.merck.com/role/OtherIncomeExpenseNet",
     "shortName": "Other (Income) Expense, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - CONDENSED CONSOLIDATED STATEMENT OF INCOME",
     "role": "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME",
     "shortName": "CONDENSED CONSOLIDATED STATEMENT OF INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "mrk:CostsExpensesAndOther",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Taxes on Income",
     "role": "http://www.merck.com/role/TaxesonIncome",
     "shortName": "Taxes on Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Earnings Per Share",
     "role": "http://www.merck.com/role/EarningsPerShare",
     "shortName": "Earnings Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Other Comprehensive Income (Loss)",
     "role": "http://www.merck.com/role/OtherComprehensiveIncomeLoss",
     "shortName": "Other Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Segment Reporting",
     "role": "http://www.merck.com/role/SegmentReporting",
     "shortName": "Segment Reporting",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Basis of Presentation (Policies)",
     "role": "http://www.merck.com/role/BasisofPresentationPolicies",
     "shortName": "Basis of Presentation (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Spin-Off of Organon & Co. (Tables)",
     "role": "http://www.merck.com/role/SpinOffofOrganonCoTables",
     "shortName": "Spin-Off of Organon & Co. (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Collaborative Arrangements (Tables)",
     "role": "http://www.merck.com/role/CollaborativeArrangementsTables",
     "shortName": "Collaborative Arrangements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Restructuring (Tables)",
     "role": "http://www.merck.com/role/RestructuringTables",
     "shortName": "Restructuring (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Financial Instruments (Tables)",
     "role": "http://www.merck.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Inventories (Tables)",
     "role": "http://www.merck.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME",
     "role": "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME",
     "shortName": "CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Equity (Tables)",
     "role": "http://www.merck.com/role/EquityTables",
     "shortName": "Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i320809a777744dfdb73841889368aa2c_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Pension and Other Postretirement Benefit Plans (Tables)",
     "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables",
     "shortName": "Pension and Other Postretirement Benefit Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i320809a777744dfdb73841889368aa2c_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Other (Income) Expense, Net (Tables)",
     "role": "http://www.merck.com/role/OtherIncomeExpenseNetTables",
     "shortName": "Other (Income) Expense, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Earnings Per Share (Tables)",
     "role": "http://www.merck.com/role/EarningsPerShareTables",
     "shortName": "Earnings Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Other Comprehensive Income (Loss) (Tables)",
     "role": "http://www.merck.com/role/OtherComprehensiveIncomeLossTables",
     "shortName": "Other Comprehensive Income (Loss) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Segment Reporting (Tables)",
     "role": "http://www.merck.com/role/SegmentReportingTables",
     "shortName": "Segment Reporting (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "ic7ff920b80fa44a2bb7838de95556452_I20210602",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Spin-Off of Organon & Co. - Narrative (Details)",
     "role": "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails",
     "shortName": "Spin-Off of Organon & Co. - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "ic7ff920b80fa44a2bb7838de95556452_I20210602",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i4068211e109d4d7da65c6be7b495d094_D20210101-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Spin-Off of Organon & Co. - Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests (Details)",
     "role": "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails",
     "shortName": "Spin-Off of Organon & Co. - Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i4068211e109d4d7da65c6be7b495d094_D20210101-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Acquisitions, Research Collaborations and License Agreements (Details)",
     "role": "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails",
     "shortName": "Acquisitions, Research Collaborations and License Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentForAmortization",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Collaborative Arrangements - Narrative (Details)",
     "role": "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
     "shortName": "Collaborative Arrangements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": "-1",
      "lang": "en-US",
      "name": "mrk:SupplyCommitmentMinimumNumberOfMarkets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "market",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET",
     "role": "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Collaborative Arrangements - Financial Information (Details)",
     "role": "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
     "shortName": "Collaborative Arrangements - Financial Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "id55d4ae3b325406e91eef2de4b2e7b99_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ReceivablesNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostExpectedCost1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Restructuring - Narrative (Details)",
     "role": "http://www.merck.com/role/RestructuringNarrativeDetails",
     "shortName": "Restructuring - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": "2",
      "lang": "en-US",
      "name": "mrk:EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostIncurredCost",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Restructuring - Charges Activities by Type of Cost (Details)",
     "role": "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails",
     "shortName": "Restructuring - Charges Activities by Type of Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "ic03376b1c2a3499d90e8c3ebcf2e8843_D20220701-20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostIncurredCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "ib9490e02538244c88fb94e67f0f84467_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Restructuring - Activities by Program (Details)",
     "role": "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails",
     "shortName": "Restructuring - Activities by Program (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "ib9490e02538244c88fb94e67f0f84467_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Financial Instruments - Narrative (Details)",
     "role": "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
     "shortName": "Financial Instruments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "ie27e3a1d731a4e8aab46753956e07c5d_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Financial Instruments - Effect of Net Investment Hedges (Details)",
     "role": "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails",
     "shortName": "Financial Instruments - Effect of Net Investment Hedges (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "ie27e3a1d731a4e8aab46753956e07c5d_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "ibdb46049abd240818d8639edc52d2396_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HedgedLiabilityFairValueHedge",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Financial Instruments - Fair Value Hedges (Details)",
     "role": "http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails",
     "shortName": "Financial Instruments - Fair Value Hedges (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "ibdb46049abd240818d8639edc52d2396_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HedgedLiabilityFairValueHedge",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details)",
     "role": "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails",
     "shortName": "Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "iaf409d1f24c84ee6b661d53c0d63d271_I20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details)",
     "role": "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails",
     "shortName": "Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Financial Instruments - Location and Amount of Pretax (Gains) Losses of Derivatives (Details)",
     "role": "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails",
     "shortName": "Financial Instruments - Location and Amount of Pretax (Gains) Losses of Derivatives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i1a250ba5d2eb4f398ca0d688c55ce97b_D20220701-20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical)",
     "role": "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i8487d36b908947f3b19f1402064fea62_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details)",
     "role": "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails",
     "shortName": "Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i8487d36b908947f3b19f1402064fea62_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Financial Instruments - Information on Available-for-sale Investments (Details)",
     "role": "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails",
     "shortName": "Financial Instruments - Information on Available-for-sale Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "ib9490e02538244c88fb94e67f0f84467_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "role": "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
     "shortName": "Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i03d038eb8e67488896fcaf65d65f5a4c_I20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:TradingSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "ib9490e02538244c88fb94e67f0f84467_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details)",
     "role": "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails",
     "shortName": "Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryFinishedGoods",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Inventories - Schedule of Inventories (Details)",
     "role": "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails",
     "shortName": "Inventories - Schedule of Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryFinishedGoods",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Inventories - Narrative (Details)",
     "role": "http://www.merck.com/role/InventoriesNarrativeDetails",
     "shortName": "Inventories - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i5a678e64e2774577a007e2d6f57ae9e6_I20220930",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:InventoryNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Other Intangibles (Details)",
     "role": "http://www.merck.com/role/OtherIntangiblesDetails",
     "shortName": "Other Intangibles (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i0b998b01dd7b4aedbe8d12d9cd13b5db_D20220701-20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i5e7203ee8afa4167bcbca2845a05174c_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LitigationReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Contingencies (Details)",
     "role": "http://www.merck.com/role/ContingenciesDetails",
     "shortName": "Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i5e7203ee8afa4167bcbca2845a05174c_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LitigationReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesIssued",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "ib9490e02538244c88fb94e67f0f84467_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Equity - Rollforward Reconciliations (Details)",
     "role": "http://www.merck.com/role/EquityRollforwardReconciliationsDetails",
     "shortName": "Equity - Rollforward Reconciliations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "ie3dcb6bbb4364846bb3cb11e71d7614c_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Pension and Other Postretirement Benefit Plans - Net Benefit Costs (Details)",
     "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails",
     "shortName": "Pension and Other Postretirement Benefit Plans - Net Benefit Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "ie3dcb6bbb4364846bb3cb11e71d7614c_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS",
     "role": "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Pension and Other Postretirement Benefit Plans - Narrative (Details)",
     "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
     "shortName": "Pension and Other Postretirement Benefit Plans - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details)",
     "role": "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails",
     "shortName": "Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Other (Income) Expense, Net - Narrative (Details)",
     "role": "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails",
     "shortName": "Other (Income) Expense, Net - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Taxes on Income (Details)",
     "role": "http://www.merck.com/role/TaxesonIncomeDetails",
     "shortName": "Taxes on Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperations",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Earnings Per Share - Calculations of Earnings Per Share (Details)",
     "role": "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails",
     "shortName": "Earnings Per Share - Calculations of Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Earnings Per Share - Narrative (Details)",
     "role": "http://www.merck.com/role/EarningsPerShareNarrativeDetails",
     "shortName": "Earnings Per Share - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i0d5f781c87ab40f58ea21a9500d8154a_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - Other Comprehensive Income (Loss) (Details)",
     "role": "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails",
     "shortName": "Other Comprehensive Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - Segment Reporting - Narrative (Details)",
     "role": "http://www.merck.com/role/SegmentReportingNarrativeDetails",
     "shortName": "Segment Reporting - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - Segment Reporting - Sales from Products (Details)",
     "role": "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails",
     "shortName": "Segment Reporting - Sales from Products (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - Segment Reporting - Consolidated Sales by Geographic Area (Details)",
     "role": "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails",
     "shortName": "Segment Reporting - Consolidated Sales by Geographic Area (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "ide9fd53158404da68f8ed38707c6e730_D20220701-20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Parenthetical)",
     "role": "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWSParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000070 - Disclosure - Segment Reporting - Reconciliation of Segment Profits to Income before Taxes (Details)",
     "role": "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails",
     "shortName": "Segment Reporting - Reconciliation of Segment Profits to Income before Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "ie736eb61ba964832abed00a756bb99fe_D20220701-20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Basis of Presentation",
     "role": "http://www.merck.com/role/BasisofPresentation",
     "shortName": "Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Spin-Off of Organon & Co.",
     "role": "http://www.merck.com/role/SpinOffofOrganonCo",
     "shortName": "Spin-Off of Organon & Co.",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20220930.htm",
      "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 155,
   "tag": {
    "country_CN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHINA",
        "terseLabel": "China"
       }
      }
     },
     "localname": "CN",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CO": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "COLOMBIA",
        "terseLabel": "COLOMBIA"
       }
      }
     },
     "localname": "CO",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S.",
        "verboseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails",
      "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r780"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r781"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance",
        "label": "Entities [Table]",
        "terseLabel": "Entities [Table]"
       }
      }
     },
     "localname": "EntitiesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r778"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r778"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r778"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Information [Line Items]",
        "terseLabel": "Entity Information [Line Items]"
       }
      }
     },
     "localname": "EntityInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r789"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r778"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r778"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r778"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r778"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r777"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r779"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "mrk_A0.500Notesdue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.500% Notes due 2024 [Member]",
        "label": "0.500% Notes due 2024 [Member]",
        "terseLabel": "0.500% Notes due 2024"
       }
      }
     },
     "localname": "A0.500Notesdue2024Member",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A1.375Notesdue2036Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.375% Notes due 2036 [Member]",
        "label": "1.375% Notes due 2036 [Member]",
        "terseLabel": "1.375% Notes due 2036"
       }
      }
     },
     "localname": "A1.375Notesdue2036Member",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A1.875Notesdue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.875% Notes due 2026 [Member]",
        "label": "1.875% Notes due 2026 [Member]",
        "terseLabel": "1.875% Notes due 2026"
       }
      }
     },
     "localname": "A1.875Notesdue2026Member",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A2.35NotesDue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.35% Notes Due 2022 [Member]",
        "label": "2.35% Notes Due 2022 [Member]",
        "terseLabel": "2.35% Notes Due 2022"
       }
      }
     },
     "localname": "A2.35NotesDue2022Member",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A2.40NotesDue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.40% Notes Due 2022 [Member]",
        "label": "2.40% Notes Due 2022 [Member]",
        "terseLabel": "2.40% Notes Due 2022"
       }
      }
     },
     "localname": "A2.40NotesDue2022Member",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A2.500Notesdue2034Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.500% Notes due 2034 [Member]",
        "label": "2.500% Notes due 2034 [Member]",
        "terseLabel": "2.500% Notes due 2034"
       }
      }
     },
     "localname": "A2.500Notesdue2034Member",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AcceleratedDepreciationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accelerated Depreciation [Member]",
        "label": "Accelerated Depreciation [Member]",
        "terseLabel": "Accelerated Depreciation"
       }
      }
     },
     "localname": "AcceleratedDepreciationMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to acquisitions, divestitures, research collaborations and license agreements.",
        "label": "Acquisitions Research Collaborations And License Agreements [Text Block]",
        "terseLabel": "Acquisitions, Research Collaborations and License Agreements"
       }
      }
     },
     "localname": "AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrk_AdempasMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adempas",
        "label": "Adempas [Member]",
        "terseLabel": "Adempas"
       }
      }
     },
     "localname": "AdempasMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AllianceRevenueAdempasVerquvoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alliance revenue - Adempas/Verquvo",
        "label": "Alliance revenue - Adempas/Verquvo [Member]",
        "terseLabel": "Alliance revenue - Adempas/Verquvo"
       }
      }
     },
     "localname": "AllianceRevenueAdempasVerquvoMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AllianceRevenueKoselugoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alliance revenue - Koselugo",
        "label": "Alliance revenue - Koselugo [Member]",
        "terseLabel": "Alliance revenue - Koselugo"
       }
      }
     },
     "localname": "AllianceRevenueKoselugoMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AllianceRevenueReblozylMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alliance Revenue - Reblozyl",
        "label": "Alliance Revenue - Reblozyl [Member]",
        "terseLabel": "Alliance Revenue - Reblozyl"
       }
      }
     },
     "localname": "AllianceRevenueReblozylMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AlliancerevenueLynparzaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alliance revenue - Lynparza [Member]",
        "label": "Alliance revenue - Lynparza [Member]",
        "terseLabel": "Alliance revenue - Lynparza"
       }
      }
     },
     "localname": "AlliancerevenueLynparzaMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AnimalHealthsegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Animal Health segment [Member]",
        "label": "Animal Health segment [Member]",
        "terseLabel": "Animal Health",
        "verboseLabel": "Animal Health segment"
       }
      }
     },
     "localname": "AnimalHealthsegmentMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ArtivaBiotherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Artiva Biotherapeutics, Inc.",
        "label": "Artiva Biotherapeutics, Inc. [Member]",
        "terseLabel": "Artiva Biotherapeutics, Inc."
       }
      }
     },
     "localname": "ArtivaBiotherapeuticsIncMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Other Assets and Liabilities Recognized, Net",
        "label": "Asset Acquisition, Other Assets and Liabilities Recognized, Net",
        "terseLabel": "Net assets"
       }
      }
     },
     "localname": "AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_AstraZenecaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AstraZeneca [Member]",
        "label": "AstraZeneca [Member]",
        "terseLabel": "AstraZeneca"
       }
      }
     },
     "localname": "AstraZenecaMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails",
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_BayerAGMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bayer AG [Member]",
        "label": "Bayer AG [Member]",
        "terseLabel": "Bayer AG"
       }
      }
     },
     "localname": "BayerAGMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_BelsomraMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Belsomra [Member]",
        "label": "Belsomra [Member]",
        "terseLabel": "Belsomra"
       }
      }
     },
     "localname": "BelsomraMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_BridionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bridion [Member].",
        "label": "Bridion [Member]",
        "terseLabel": "Bridion"
       }
      }
     },
     "localname": "BridionMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails",
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_BristolMyersSquibbMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bristol Myers Squibb",
        "label": "Bristol Myers Squibb [Member]",
        "terseLabel": "Bristol Myers Squibb"
       }
      }
     },
     "localname": "BristolMyersSquibbMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_COVID19Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19",
        "label": "COVID-19 [Member]",
        "terseLabel": "COVID-19"
       }
      }
     },
     "localname": "COVID19Member",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_CancidasMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cancidas [Member].",
        "label": "Cancidas [Member]",
        "terseLabel": "Cancidas"
       }
      }
     },
     "localname": "CancidasMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cases Company Agreed To Toll Statute Of Limitations[Member]",
        "label": "Cases Company Agreed ToToll Statute Of Limitations [Member]",
        "terseLabel": "Cases Company Agreed To Toll Statute Of Limitations"
       }
      }
     },
     "localname": "CasesCompanyAgreedToTollStatuteOfLimitationsMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ChargesRelatedToProgramDiscontinuation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Charges related to program discontinuation",
        "label": "Charges related to program discontinuation",
        "terseLabel": "Charges related to program discontinuation"
       }
      }
     },
     "localname": "ChargesRelatedToProgramDiscontinuation",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_CollaborativeArrangementNumberOfCollaborationTargets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Number Of Collaboration Targets",
        "label": "Collaborative Arrangement, Number Of Collaboration Targets",
        "terseLabel": "Number of collaboration targets"
       }
      }
     },
     "localname": "CollaborativeArrangementNumberOfCollaborationTargets",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrk_CollaborativeArrangementNumberOfResearchPrograms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Number Of Research Programs",
        "label": "Collaborative Arrangement, Number Of Research Programs",
        "terseLabel": "Number of research programs"
       }
      }
     },
     "localname": "CollaborativeArrangementNumberOfResearchPrograms",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrk_CollaborativeArrangementProfitSharing": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Profit Sharing",
        "label": "Collaborative Arrangement, Profit Sharing",
        "terseLabel": "Alliance revenue - profit sharing"
       }
      }
     },
     "localname": "CollaborativeArrangementProfitSharing",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_CollaborativeArrangementSalesNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Sales, Net",
        "label": "Collaborative Arrangement, Sales, Net",
        "terseLabel": "Net sales by Merck"
       }
      }
     },
     "localname": "CollaborativeArrangementSalesNet",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_CollaborativeArrangementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangements [Abstract]",
        "label": "Collaborative Arrangements [Abstract]",
        "terseLabel": "Collaborative Arrangements [Abstract]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAbstract",
     "nsuri": "http://www.merck.com/20220930",
     "xbrltype": "stringItemType"
    },
    "mrk_CompanionAnimalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Companion Animals [Member]",
        "label": "Companion Animals [Member]",
        "terseLabel": "Companion Animals"
       }
      }
     },
     "localname": "CompanionAnimalsMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Component of Other Income / Expense of Nonoperating [Table]",
        "label": "Component of Other Income / Expense of Nonoperating [Line Items]",
        "terseLabel": "Component of Other Income / Expense of Nonoperating [Line Items]"
       }
      }
     },
     "localname": "ComponentofOtherIncomeExpenseofNonoperatingLineItems",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_ComponentofOtherIncomeExpenseofNonoperatingTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component of Other Income / Expense of Nonoperating [Table]",
        "label": "Component of Other Income / Expense of Nonoperating [Table]",
        "terseLabel": "Component of Other Income / Expense of Nonoperating [Table]"
       }
      }
     },
     "localname": "ComponentofOtherIncomeExpenseofNonoperatingTable",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_ContingentPaymentsCollaborativeArrangement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents payments that may be made in the future contingent upon the achievement of regulatory and/or sales milestones as part of a collaborative arrangement.",
        "label": "Contingent Payments Collaborative Arrangement",
        "terseLabel": "Contingent milestone payments collaborative arrangement"
       }
      }
     },
     "localname": "ContingentPaymentsCollaborativeArrangement",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_CostsExpensesAndOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of cost of sales, operating expenses and nonoperating income or expense.",
        "label": "Costs Expenses And Other",
        "totalLabel": "Total Costs, Expenses and Other"
       }
      }
     },
     "localname": "CostsExpensesAndOther",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_DebtSecuritiesandEquitySecuritiesFVNI": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities and Equity Securities, FV-NI",
        "label": "Debt Securities and Equity Securities, FV-NI",
        "totalLabel": "Total debt and publicly traded equity securities, fair value"
       }
      }
     },
     "localname": "DebtSecuritiesandEquitySecuritiesFVNI",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_DeferredIncomeTaxesAndOtherAssetsCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Income Taxes and Other Assets, Current",
        "label": "Deferred Income Taxes and Other Assets, Current [Member]",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndOtherAssetsCurrentMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Income Taxes And Other Assets, Noncurrent",
        "label": "Deferred Income Taxes And Other Assets, Noncurrent [Member]",
        "terseLabel": "Other Assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndOtherAssetsNoncurrentMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_DevelopmentMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development Milestones [Member]",
        "label": "Development Milestones [Member]",
        "terseLabel": "Development Milestones"
       }
      }
     },
     "localname": "DevelopmentMilestonesMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_DificidMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dificid",
        "label": "Dificid [Member]",
        "terseLabel": "Dificid"
       }
      }
     },
     "localname": "DificidMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_DisposalGroupInclDiscontinuedOperationsDistributionReceived": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group Incl. Discontinued Operations Distribution Received",
        "label": "Disposal Group Incl. Discontinued Operations Distribution Received",
        "terseLabel": "Distribution from Organon &amp; Co."
       }
      }
     },
     "localname": "DisposalGroupInclDiscontinuedOperationsDistributionReceived",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Other Income (Expense), Net",
        "label": "Disposal Group, Including Discontinued Operation, Other Income (Expense), Net",
        "negatedTerseLabel": "Other (income) expense, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operations, Research and Development Expenses",
        "label": "Disposal Group, Including Discontinued Operations, Research and Development Expenses",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operations, Restructuring Costs",
        "label": "Disposal Group, Including Discontinued Operations, Restructuring Costs",
        "terseLabel": "Restructuring costs"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_EisaiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eisai [Member]",
        "label": "Eisai [Member]",
        "terseLabel": "Eisai"
       }
      }
     },
     "localname": "EisaiMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimate of cumulative pre tax costs that will be noncash.",
        "label": "Estimate Of Cumulative Pre Tax Costs That Will Be Noncash",
        "terseLabel": "Estimate of cumulative pre tax costs that will be noncash"
       }
      }
     },
     "localname": "EstimateOfCumulativePreTaxCostsThatWillBeNoncash",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimate of cumulative pre tax costs that will result in cash outlays (primarily from employee separation expense).",
        "label": "Estimate Of Cumulative Pre Tax Costs That Will Result In Cash Outlays",
        "terseLabel": "Estimate of cumulative pre tax costs that will result in cash outlays"
       }
      }
     },
     "localname": "EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrk_EurodominatedNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Euro-dominated Notes [Member]",
        "label": "Euro-dominated Notes [Member]",
        "terseLabel": "Euro-denominated notes"
       }
      }
     },
     "localname": "EurodominatedNotesMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Other",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Other",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_FederalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal.",
        "label": "Federal [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "FederalMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_FemurFractureLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Femur Fracture litigation.",
        "label": "Femur Fracture Litigation [Member]",
        "terseLabel": "Femur Fracture Litigation"
       }
      }
     },
     "localname": "FemurFractureLitigationMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_FirstCommercialSaleMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First Commercial Sale Milestones",
        "label": "First Commercial Sale Milestones [Member]",
        "terseLabel": "First Commercial Sale Milestones"
       }
      }
     },
     "localname": "FirstCommercialSaleMilestonesMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_FosamaxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fosamax [Member].",
        "label": "Fosamax [Member]",
        "terseLabel": "Fosamax"
       }
      }
     },
     "localname": "FosamaxMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_GardasilGardasil9Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gardasil/Gardasil 9 [Member].",
        "label": "Gardasil/Gardasil 9 [Member]",
        "terseLabel": "Gardasil/Gardasil 9"
       }
      }
     },
     "localname": "GardasilGardasil9Member",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails",
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_InternationalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "International [Member]",
        "label": "International [Member]",
        "terseLabel": "Int\u2019l"
       }
      }
     },
     "localname": "InternationalMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_InvanzMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Invanz [Member].",
        "label": "Invanz [Member]",
        "terseLabel": "Invanz"
       }
      }
     },
     "localname": "InvanzMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_InventoriesProducedinPreparationforProductLaunchesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventories Produced in Preparation for Product Launches [Member]",
        "label": "Inventories Produced in Preparation for Product Launches [Member]",
        "terseLabel": "Inventories Produced in Preparation for Product Launches"
       }
      }
     },
     "localname": "InventoriesProducedinPreparationforProductLaunchesMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_InventoryNetAndInventoryNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of current and noncurrent inventories.",
        "label": "Inventory Net And Inventory Noncurrent",
        "totalLabel": "Total current and noncurrent inventories"
       }
      }
     },
     "localname": "InventoryNetAndInventoryNoncurrent",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_InventoryNotExpectedtobeSoldWithinOneYearMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory Not Expected to be Sold Within One Year [Member]",
        "label": "Inventory Not Expected to be Sold Within One Year [Member]",
        "terseLabel": "Inventories Not Expected to be Sold Within One Year"
       }
      }
     },
     "localname": "InventoryNotExpectedtobeSoldWithinOneYearMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_InventoryTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory [Table]",
        "label": "Inventory [Table]",
        "terseLabel": "Inventory [Table]"
       }
      }
     },
     "localname": "InventoryTable",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_IsentressIsentressHDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Isentress/Isentress HD [Member].",
        "label": "Isentress/Isentress HD [Member]",
        "terseLabel": "Isentress/Isentress HD"
       }
      }
     },
     "localname": "IsentressIsentressHDMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_JanumetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janumet [Member].",
        "label": "Janumet [Member]",
        "terseLabel": "Janumet"
       }
      }
     },
     "localname": "JanumetMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_JanuviaAndJanumetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Januvia and Janumet",
        "label": "Januvia and Janumet [Member]",
        "terseLabel": "Januvia and Janumet"
       }
      }
     },
     "localname": "JanuviaAndJanumetMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_JanuviaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Januvia [Member] .",
        "label": "Januvia [Member]",
        "terseLabel": "Januvia"
       }
      }
     },
     "localname": "JanuviaMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails",
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_KeytrudaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Keytruda [Member]",
        "label": "Keytruda [Member]",
        "terseLabel": "Keytruda"
       }
      }
     },
     "localname": "KeytrudaMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_LagevrioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lagevrio",
        "label": "Lagevrio [Member]",
        "terseLabel": "Lagevrio"
       }
      }
     },
     "localname": "LagevrioMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_LegalDefenseCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal Defense Costs [Member]",
        "label": "Legal Defense Costs [Member]",
        "terseLabel": "Legal Defense Costs"
       }
      }
     },
     "localname": "LegalDefenseCostsMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_LenvimaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lenvima [Member]",
        "label": "Lenvima [Member]",
        "terseLabel": "Alliance revenue - Lenvima",
        "verboseLabel": "Lenvima"
       }
      }
     },
     "localname": "LenvimaMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_Licenseoptionpaymentrelatedtocollaborativearrangement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License option payment related to collaborative arrangement",
        "label": "License option payment related to collaborative arrangement",
        "terseLabel": "License option payment related to collaborative arrangement"
       }
      }
     },
     "localname": "Licenseoptionpaymentrelatedtocollaborativearrangement",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_LivestockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Livestock [Member]",
        "label": "Livestock [Member]",
        "terseLabel": "Livestock"
       }
      }
     },
     "localname": "LivestockMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_LongTermDebtCurrentMaturitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Debt, Current Maturities [Member]",
        "label": "Long Term Debt, Current Maturities [Member]",
        "terseLabel": "Loans payable and current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrentMaturitiesMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_LossContingencyClaimsonAppealNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Claims on Appeal, Number",
        "label": "Loss Contingency, Claims on Appeal, Number",
        "terseLabel": "Loss contingency, claims on appeal"
       }
      }
     },
     "localname": "LossContingencyClaimsonAppealNumber",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrk_LossContingencyRecoveryFromThirdPartyBenchTrialPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Recovery From Third Party, Bench Trial Period",
        "label": "Loss Contingency, Recovery From Third Party, Bench Trial Period",
        "terseLabel": "Loss contingency, recovery from third party, bench trial period"
       }
      }
     },
     "localname": "LossContingencyRecoveryFromThirdPartyBenchTrialPeriod",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrk_LossContingencyTrialPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Trial Period",
        "label": "Loss Contingency, Trial Period",
        "terseLabel": "Loss contingency, trial period"
       }
      }
     },
     "localname": "LossContingencyTrialPeriod",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrk_LynparzaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lynparza [Member]",
        "label": "Lynparza [Member]",
        "terseLabel": "Lynparza"
       }
      }
     },
     "localname": "LynparzaMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ManufacturingAndSupplyAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Manufacturing and supply agreements",
        "label": "Manufacturing and supply agreements [Member]",
        "terseLabel": "Manufacturing and supply agreements"
       }
      }
     },
     "localname": "ManufacturingAndSupplyAgreementsMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_MilestonePaymentToBeMadeToACollaborativePartner": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payment to be Made to a Collaborative Partner",
        "label": "Milestone Payment to be Made to a Collaborative Partner",
        "terseLabel": "Milestone payment to be made to a collaborative partner"
       }
      }
     },
     "localname": "MilestonePaymentToBeMadeToACollaborativePartner",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_MilestonePaymentsAccruedSalesBased": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments Accrued Sales Based",
        "label": "Milestone Payments Accrued Sales Based",
        "terseLabel": "Milestone payments accrued but not yet paid"
       }
      }
     },
     "localname": "MilestonePaymentsAccruedSalesBased",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_MilestonePaymentsMadetoCollaborativePartner": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments Made to Collaborative Partner",
        "label": "Milestone Payments Made to Collaborative Partner",
        "terseLabel": "Capitalized milestone payment"
       }
      }
     },
     "localname": "MilestonePaymentsMadetoCollaborativePartner",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_MilestonePaymentsSalesBased": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments Sales-Based",
        "label": "Milestone Payments Sales-Based",
        "terseLabel": "Sales-based milestone payments"
       }
      }
     },
     "localname": "MilestonePaymentsSalesBased",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_MilestonePaymentsToBeMadeToACollaborativePartner": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments to be Made to a Collaborative Partner",
        "label": "Milestone Payments to be Made to a Collaborative Partner",
        "terseLabel": "Milestone payments to be made to a collaborative partner"
       }
      }
     },
     "localname": "MilestonePaymentsToBeMadeToACollaborativePartner",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_NemtabrutinibMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "nemtabrutinib",
        "label": "nemtabrutinib [Member]",
        "terseLabel": "nemtabrutinib"
       }
      }
     },
     "localname": "NemtabrutinibMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/OtherIntangiblesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_NoxafilMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noxafil [Member].",
        "label": "Noxafil [Member]",
        "terseLabel": "Noxafil"
       }
      }
     },
     "localname": "NoxafilMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_OffsettingAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative positions subject to master netting arrangements as if they were presented on a net basis.",
        "label": "Offsetting Assets And Liabilities [Table Text Block]",
        "terseLabel": "Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis"
       }
      }
     },
     "localname": "OffsettingAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrk_OrganonCoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organon &amp; Co.",
        "label": "Organon &amp; Co. [Member]",
        "terseLabel": "Organon &amp; Co."
       }
      }
     },
     "localname": "OrganonCoMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_OrionCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Orion Corporation",
        "label": "Orion Corporation [Member]",
        "terseLabel": "Orion Corporation"
       }
      }
     },
     "localname": "OrionCorporationMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_OrnaTherapeuticsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Orna Therapeutics",
        "label": "Orna Therapeutics [Member]",
        "terseLabel": "Orna Therapeutics"
       }
      }
     },
     "localname": "OrnaTherapeuticsMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_OtherCountriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Countries [Member]",
        "label": "Other Countries [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherCountriesMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_OtherNonoperatingIncomeExpenseOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other nonoperating income and expense items not separately disclosed.",
        "label": "Other Nonoperating Income Expense, Other",
        "negatedLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseOther",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_OtherPharmaceuticalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other pharmaceutical.",
        "label": "Other Pharmaceutical [Member]",
        "terseLabel": "Other pharmaceutical"
       }
      }
     },
     "localname": "OtherPharmaceuticalMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_PandionTherapeuticsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pandion Therapeutics",
        "label": "Pandion Therapeutics [Member]",
        "terseLabel": "Pandion Therapeutics"
       }
      }
     },
     "localname": "PandionTherapeuticsMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_PatentInfringementLawsuitAgainstZydusWorldwideDMCCZydusPharmaceuticalsUSAIncAndCadilaHealthcareLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patent Infringement Lawsuit Against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc. And Cadila Healthcare Ltd.",
        "label": "Patent Infringement Lawsuit Against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc. And Cadila Healthcare Ltd. [Member]",
        "terseLabel": "Patent Infringement Lawsuit Against Zydus"
       }
      }
     },
     "localname": "PatentInfringementLawsuitAgainstZydusWorldwideDMCCZydusPharmaceuticalsUSAIncAndCadilaHealthcareLtdMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_PharmaceuticalsegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmaceutical segment.",
        "label": "Pharmaceutical segment [Member]",
        "terseLabel": "Pharmaceutical",
        "verboseLabel": "Pharmaceutical segment"
       }
      }
     },
     "localname": "PharmaceuticalsegmentMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_Pneumovax23Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pneumovax 23[Member].",
        "label": "Pneumovax 23 [Member]",
        "terseLabel": "Pneumovax 23"
       }
      }
     },
     "localname": "Pneumovax23Member",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_PotentialFutureMilestonePaymentsRegulatory": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Future Milestone Payments Regulatory",
        "label": "Potential Future Milestone Payments Regulatory",
        "terseLabel": "Potential future regulatory milestone payments"
       }
      }
     },
     "localname": "PotentialFutureMilestonePaymentsRegulatory",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_PotentialFutureMilestonePaymentsSalesBased": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Future Milestone Payments Sales-Based",
        "label": "Potential Future Milestone Payments Sales-Based",
        "terseLabel": "Potential future sales-based milestone payments"
       }
      }
     },
     "localname": "PotentialFutureMilestonePaymentsSalesBased",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_PrevymisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prevymis [Member]",
        "label": "Prevymis [Member]",
        "terseLabel": "Prevymis"
       }
      }
     },
     "localname": "PrevymisMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_PrimaxinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primaxin [Member].",
        "label": "Primaxin [Member]",
        "terseLabel": "Primaxin"
       }
      }
     },
     "localname": "PrimaxinMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ProQuadMMRIIVarivaxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ProQuad/M-M-R II/Varivax [Member].",
        "label": "ProQuad MMR II Varivax [Member]",
        "terseLabel": "ProQuad/M-M-R II/Varivax"
       }
      }
     },
     "localname": "ProQuadMMRIIVarivaxMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ProbableContingentPaymentsCollaborativeArrangement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Probable Contingent Payments Collaborative Arrangement",
        "label": "Probable Contingent Payments Collaborative Arrangement",
        "terseLabel": "Probable contingent payments"
       }
      }
     },
     "localname": "ProbableContingentPaymentsCollaborativeArrangement",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_RecognizedAsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recognized as.",
        "label": "Recognized As [Abstract]",
        "terseLabel": "Recognized as:"
       }
      }
     },
     "localname": "RecognizedAsAbstract",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_RegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory Milestones [Member]",
        "label": "Regulatory Milestones [Member]",
        "terseLabel": "Regulatory Milestones"
       }
      }
     },
     "localname": "RegulatoryMilestonesMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_RemicadeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remicade [Member].",
        "label": "Remicade [Member]",
        "terseLabel": "Remicade"
       }
      }
     },
     "localname": "RemicadeMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Additional Funding By Others, Development Costs Subject To Funding",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Additional Funding By Others, Development Costs Subject To Funding",
        "terseLabel": "Additional funding by others, development costs subject to funding"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Additional Funding By Others, Percentage Of Development Costs",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Additional Funding By Others, Percentage Of Development Costs",
        "terseLabel": "Additional funding by others, percentage of development costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrk_ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartner": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Payments to be Made to a Collaborative Partner",
        "label": "Research and Development Payments to be Made to a Collaborative Partner",
        "terseLabel": "Research and development payments to be made to a collaborative partner (up to)"
       }
      }
     },
     "localname": "ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartner",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_RestructuringReserveIncreaseDecreaseNoncashActivity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash activity affecting the restructuring reserve, including accelerated depreciation.",
        "label": "Restructuring Reserve, Increase (Decrease) Noncash Activity",
        "terseLabel": "Non-cash activity"
       }
      }
     },
     "localname": "RestructuringReserveIncreaseDecreaseNoncashActivity",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_RidgebackBiotherapeuticsLPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ridgeback Biotherapeutics LP",
        "label": "Ridgeback Biotherapeutics LP [Member]",
        "terseLabel": "Ridgeback Biotherapeutics LP"
       }
      }
     },
     "localname": "RidgebackBiotherapeuticsLPMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_RotateqMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RotaTeq [Member]",
        "label": "Rotateq [Member]",
        "terseLabel": "RotaTeq"
       }
      }
     },
     "localname": "RotateqMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_RoyaltyRateDeductionPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Rate, Deduction, Percentage",
        "label": "Royalty Rate, Deduction, Percentage",
        "terseLabel": "Royalty rate, deduction"
       }
      }
     },
     "localname": "RoyaltyRateDeductionPercentage",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "mrk_RoyaltyRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Rate, Percentage",
        "label": "Royalty Rate, Percentage",
        "terseLabel": "Royalty rate"
       }
      }
     },
     "localname": "RoyaltyRatePercentage",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrk_SalesBasedMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales-Based Milestones [Member]",
        "label": "Sales-Based Milestones [Member]",
        "terseLabel": "Sales-Based Milestones"
       }
      }
     },
     "localname": "SalesBasedMilestonesMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_SalesDiscounts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Discounts",
        "label": "Sales Discounts",
        "terseLabel": "Sales discounts"
       }
      }
     },
     "localname": "SalesDiscounts",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_SanofiPasteurMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sanofi Pasteur [Member]",
        "label": "Sanofi Pasteur [Member]",
        "terseLabel": "Sanofi Pasteur"
       }
      }
     },
     "localname": "SanofiPasteurMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_SegmentReportingUnallocatedOtherExpensesNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other net expenses not allocated to segments.",
        "label": "Segment Reporting Unallocated Other Expenses Net",
        "negatedLabel": "Other unallocated, net"
       }
      }
     },
     "localname": "SegmentReportingUnallocatedOtherExpensesNet",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.",
        "label": "Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. [Member]",
        "terseLabel": "Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd."
       }
      }
     },
     "localname": "SichuanKelunBiotechBiopharmaceuticalCoLtdMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_SimponiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Simponi [Member].",
        "label": "Simponi [Member]",
        "terseLabel": "Simponi"
       }
      }
     },
     "localname": "SimponiMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_StockholdersEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Stockholders Equity [Table]",
        "label": "Stockholders Equity [Line Items]",
        "terseLabel": "Stockholders Equity [Line Items]"
       }
      }
     },
     "localname": "StockholdersEquityLineItems",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/EquityRollforwardReconciliationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_StockholdersEquityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stockholders Equity [Table]",
        "label": "Stockholders Equity [Table]",
        "terseLabel": "Stockholders Equity [Table]"
       }
      }
     },
     "localname": "StockholdersEquityTable",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/EquityRollforwardReconciliationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_SupplyCommitmentMinimumNumberOfMarkets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supply Commitment, Minimum, Number of Markets",
        "label": "Supply Commitment, Minimum, Number of Markets",
        "terseLabel": "Number of markets (more than)"
       }
      }
     },
     "localname": "SupplyCommitmentMinimumNumberOfMarkets",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrk_SupplyCommitmentRemainingMinimumCoursesCommitted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supply Commitment, Remaining Minimum Courses Committed",
        "label": "Supply Commitment, Remaining Minimum Courses Committed",
        "terseLabel": "Remaining minimum courses committed (in courses)"
       }
      }
     },
     "localname": "SupplyCommitmentRemainingMinimumCoursesCommitted",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrk_TransitionServicesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transition services agreement",
        "label": "Transition services agreement [Member]",
        "terseLabel": "Transition services agreement"
       }
      }
     },
     "localname": "TransitionServicesAgreementMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront and milestone payments made to partner as part of collaborative arrangement.",
        "label": "Upfront And Milestone Payments Made To Collaborative Partner",
        "terseLabel": "Upfront and milestone payments"
       }
      }
     },
     "localname": "UpfrontAndMilestonePaymentsMadeToCollaborativePartner",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront and Milestone Payments to be Made to Collaborative Partner",
        "label": "Upfront and Milestone Payments to be Made to Collaborative Partner",
        "terseLabel": "Upfront and milestone payments to be made"
       }
      }
     },
     "localname": "UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_VaqtaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vaqta [Member]",
        "label": "Vaqta [Member]",
        "terseLabel": "Vaqta"
       }
      }
     },
     "localname": "VaqtaMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_VerquvoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Verquvo",
        "label": "Verquvo [Member]",
        "terseLabel": "Verquvo"
       }
      }
     },
     "localname": "VerquvoMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ZerbaxaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zerbaxa [Member]",
        "label": "Zerbaxa [Member]",
        "terseLabel": "Zerbaxa"
       }
      }
     },
     "localname": "ZerbaxaMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ZetiaantitrustlitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zetia antitrust litigation [Member]",
        "label": "Zetia antitrust litigation [Member]",
        "terseLabel": "Zetia antitrust litigation"
       }
      }
     },
     "localname": "ZetiaantitrustlitigationMember",
     "nsuri": "http://www.merck.com/20220930",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_AsiaPacificMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asia Pacific [Member]",
        "terseLabel": "Asia Pacific (other than China and Japan)"
       }
      }
     },
     "localname": "AsiaPacificMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r162",
      "r215",
      "r228",
      "r229",
      "r230",
      "r231",
      "r233",
      "r235",
      "r239",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r353",
      "r354",
      "r356",
      "r358",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r162",
      "r215",
      "r228",
      "r229",
      "r230",
      "r231",
      "r233",
      "r235",
      "r239",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r353",
      "r354",
      "r356",
      "r358",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r88",
      "r91",
      "r160",
      "r161",
      "r365",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails",
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LatinAmericaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Latin America [Member]",
        "terseLabel": "Latin America"
       }
      }
     },
     "localname": "LatinAmericaMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r335",
      "r337",
      "r338",
      "r339",
      "r364",
      "r385",
      "r495",
      "r501",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r685",
      "r735",
      "r738",
      "r774",
      "r775"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r335",
      "r337",
      "r338",
      "r339",
      "r364",
      "r385",
      "r495",
      "r501",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r685",
      "r735",
      "r738",
      "r774",
      "r775"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r242",
      "r337",
      "r338",
      "r406",
      "r407",
      "r687",
      "r734",
      "r736"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails",
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/ContingenciesDetails",
      "http://www.merck.com/role/OtherIntangiblesDetails",
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r242",
      "r337",
      "r338",
      "r406",
      "r407",
      "r687",
      "r734",
      "r736"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails",
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/ContingenciesDetails",
      "http://www.merck.com/role/OtherIntangiblesDetails",
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r310",
      "r335",
      "r337",
      "r338",
      "r339",
      "r364",
      "r385",
      "r436",
      "r495",
      "r501",
      "r503",
      "r504",
      "r505",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r685",
      "r735",
      "r738",
      "r774",
      "r775"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r310",
      "r335",
      "r337",
      "r338",
      "r339",
      "r364",
      "r385",
      "r436",
      "r495",
      "r501",
      "r503",
      "r504",
      "r505",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r685",
      "r735",
      "r738",
      "r774",
      "r775"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r90",
      "r91",
      "r160",
      "r161",
      "r365",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails",
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r177",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails",
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails",
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r177",
      "r182",
      "r333",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails",
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails",
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r243",
      "r244",
      "r406",
      "r408",
      "r737",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails",
      "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r243",
      "r244",
      "r406",
      "r408",
      "r737",
      "r763",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails",
      "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r177",
      "r182",
      "r333",
      "r496",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails",
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails",
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Roll Forward]"
       }
      }
     },
     "localname": "AOCIAttributableToParentNetOfTaxRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by legal entity of counterparty. A counterparty is the other party that participates in a financial transaction.",
        "label": "Legal Entity of Counterparty, Type [Axis]",
        "terseLabel": "Legal Entity of Counterparty, Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities.",
        "label": "Accounts Payable and Accrued Liabilities [Member]",
        "terseLabel": "Accounts Payable and Accrued Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r69",
      "r652"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Trade accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r248",
      "r249"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable (net of allowance for doubtful accounts of $77 in 2022 and $62 in 2021)"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableSale": {
     "auth_ref": [
      "r268"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease from sale of accounts receivable.",
        "label": "Accounts Receivable, Sale",
        "terseLabel": "Factored accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableSale",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r46",
      "r694",
      "r717"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "auth_ref": [
      "r94",
      "r100",
      "r109",
      "r110",
      "r111",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "terseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r40",
      "r303"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember": {
     "auth_ref": [
      "r100",
      "r109",
      "r110",
      "r111",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, including portion attributable to noncontrolling interest.",
        "label": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]",
        "terseLabel": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest"
       }
      }
     },
     "localname": "AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "auth_ref": [
      "r100",
      "r109",
      "r110",
      "r111",
      "r112",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "terseLabel": "Derivatives"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r56",
      "r97",
      "r99",
      "r100",
      "r719",
      "r743",
      "r744"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r109",
      "r110",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r96",
      "r100",
      "r109",
      "r110",
      "r111",
      "r169",
      "r170",
      "r171",
      "r568",
      "r646",
      "r739",
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss",
        "verboseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EquityRollforwardReconciliationsDetails",
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r92",
      "r100",
      "r109",
      "r110",
      "r111",
      "r568",
      "r634",
      "r635",
      "r636",
      "r637",
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Foreign Currency Translation Adjustment"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Other paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r169",
      "r170",
      "r171",
      "r507",
      "r508",
      "r509",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Other Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EquityRollforwardReconciliationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentForAmortization": {
     "auth_ref": [
      "r146",
      "r297"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.",
        "label": "Amortization",
        "negatedLabel": "Amortization",
        "terseLabel": "Amortization"
       }
      }
     },
     "localname": "AdjustmentForAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income from continuing operations to net cash provided by operating activities of continuing operations:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r60",
      "r250",
      "r267"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r146",
      "r292",
      "r297"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive shares (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EarningsPerShareNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails",
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "auth_ref": [
      "r551",
      "r552",
      "r553",
      "r554"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.",
        "label": "Asset Acquisition, Consideration Transferred",
        "terseLabel": "Consideration transferred, asset acquisition"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferred",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost": {
     "auth_ref": [
      "r551",
      "r552",
      "r553",
      "r554"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction cost incurred as part of consideration transferred in asset acquisition.",
        "label": "Asset Acquisition, Consideration Transferred, Transaction Cost",
        "terseLabel": "Asset acquisition costs"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferredTransactionCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r43",
      "r154",
      "r223",
      "r230",
      "r237",
      "r265",
      "r346",
      "r347",
      "r348",
      "r350",
      "r351",
      "r352",
      "r353",
      "r355",
      "r357",
      "r359",
      "r360",
      "r564",
      "r569",
      "r627",
      "r650",
      "r652",
      "r692",
      "r716"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r33",
      "r68",
      "r154",
      "r265",
      "r346",
      "r347",
      "r348",
      "r350",
      "r351",
      "r352",
      "r353",
      "r355",
      "r357",
      "r359",
      "r360",
      "r564",
      "r569",
      "r627",
      "r650",
      "r652"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current Assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r616"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r256"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Debt securities, unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r257"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Debt securities, unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r254",
      "r274"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Debt securities, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r252",
      "r255",
      "r274",
      "r700"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_TradingSecurities",
       "weight": 1.0
      },
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Debt securities, fair value",
        "verboseLabel": "Investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r581",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/BasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionContingentConsiderationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition, Contingent Consideration [Line Items]",
        "terseLabel": "Business Acquisition, Contingent Consideration [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentConsiderationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r145",
      "r549"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Changes in estimated fair value"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r544",
      "r545",
      "r547"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "periodEndLabel": "Fair value, ending balance",
        "periodStartLabel": "Fair value, beginning balance",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r544",
      "r546"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Current liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Contingent consideration, measurement input, discount rate"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r29",
      "r39",
      "r148"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r142",
      "r148",
      "r150"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $134 and $30 at September\u00a030, 2022 and 2021, respectively, included in Other current assets)",
        "periodStartLabel": "Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $71 and $103 at January 1, 2022 and 2021, respectively, included in Other current assets)"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r142",
      "r632"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net Increase in Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r39"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r142"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInDiscontinuedOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Cash Provided by (Used in) Financing Activities, Discontinued Operations",
        "terseLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r22",
      "r142"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInDiscontinuedOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Cash Provided by (Used in) Investing Activities, Discontinued Operations",
        "terseLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r22",
      "r142"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInDiscontinuedOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations",
        "terseLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": {
     "auth_ref": [
      "r608"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments",
        "negatedTerseLabel": "Derivatives designated as hedging instruments"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1": {
     "auth_ref": [
      "r608"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge",
        "negatedTerseLabel": "Hedged items"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r50",
      "r51",
      "r52",
      "r151",
      "r154",
      "r187",
      "r188",
      "r193",
      "r196",
      "r198",
      "r206",
      "r207",
      "r208",
      "r265",
      "r346",
      "r351",
      "r352",
      "r353",
      "r359",
      "r360",
      "r383",
      "r384",
      "r388",
      "r392",
      "r399",
      "r627",
      "r782"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r555",
      "r556",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborative Arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement.",
        "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r329",
      "r330",
      "r331",
      "r341",
      "r764"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/Contingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Cash dividends declared on common stock (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EquityRollforwardReconciliationsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r169",
      "r170",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock ($0.50\u00a0par value)",
        "verboseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage",
      "http://www.merck.com/role/EquityRollforwardReconciliationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, authorized (shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Common stock, ending balance (in shares)",
        "periodStartLabel": "Common stock, beginning balance (in shares)",
        "terseLabel": "Common stock, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical",
      "http://www.merck.com/role/EquityRollforwardReconciliationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r52",
      "r652"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2022 and 2021"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r105",
      "r107",
      "r108",
      "r120",
      "r707",
      "r729"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive Income Attributable to Merck\u00a0&amp; Co., Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r119",
      "r130",
      "r706",
      "r728"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "terseLabel": "Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r437",
      "r485",
      "r745"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate notes and bonds"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r228",
      "r229",
      "r230",
      "r231",
      "r233",
      "r239",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Corporate, Non-Segment",
        "verboseLabel": "Corporate, Non-Segment"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r125",
      "r687"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": 1.0,
       "parentTag": "mrk_CostsExpensesAndOther",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME",
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of sales",
        "verboseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs, Expenses and Other"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrencySwapMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Swap involving the exchange of principal and interest in one currency for another currency.",
        "label": "Currency Swap [Member]",
        "terseLabel": "Currency Swap"
       }
      }
     },
     "localname": "CurrencySwapMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtCurrent": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of debt and lease obligation, classified as current.",
        "label": "Debt, Current",
        "terseLabel": "Loans payable and current portion of long-term debt"
       }
      }
     },
     "localname": "DebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r44",
      "r46",
      "r48",
      "r153",
      "r162",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r379",
      "r380",
      "r381",
      "r382",
      "r644",
      "r693",
      "r695",
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r361",
      "r379",
      "r380",
      "r642",
      "r644",
      "r645"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Face amount of debt"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r370",
      "r379",
      "r380",
      "r626"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Fair value of loans payable and long-term debt, including current portion"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r73",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r74",
      "r153",
      "r162",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r379",
      "r380",
      "r381",
      "r382",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtLongtermAndShorttermCombinedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the aggregate of total long-term debt, including current maturities and short-term debt.",
        "label": "Debt, Long-Term and Short-Term, Combined Amount",
        "terseLabel": "Debt, carrying amount"
       }
      }
     },
     "localname": "DebtLongtermAndShorttermCombinedAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r146",
      "r155",
      "r524",
      "r529",
      "r530",
      "r531"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r514",
      "r515"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred Income Taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other assets expected to be realized or consumed within one year or normal operating cycle, if longer.",
        "label": "Deferred Income Taxes and Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other assets expected to be realized or consumed after one year or normal operating cycle, if longer.",
        "label": "Deferred Income Taxes and Other Assets, Noncurrent",
        "terseLabel": "Other Assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndOtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": {
     "auth_ref": [
      "r413",
      "r452",
      "r479",
      "r485",
      "r486"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Gain (Loss)",
        "negatedLabel": "Net loss amortization"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": {
     "auth_ref": [
      "r413",
      "r453",
      "r480",
      "r485",
      "r486"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)",
        "terseLabel": "Amortization of unrecognized prior service credit"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement": {
     "auth_ref": [
      "r417"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of (increase) decrease to benefit obligation of defined benefit plan from remeasurement due to settlement. Excludes decrease to benefit obligation for settlement payment.",
        "label": "Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Remeasurement due to Settlement",
        "negatedTerseLabel": "Increase to pension liabilities due to remeasurement"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod": {
     "auth_ref": [
      "r466"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost of providing special or contractual termination benefits payable from defined benefit plan.",
        "label": "Defined Benefit Plan, Cost of Providing Special and Contractual Termination Benefits",
        "terseLabel": "Termination benefits"
       }
      }
     },
     "localname": "DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "auth_ref": [
      "r413",
      "r451",
      "r478",
      "r485",
      "r486"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "negatedLabel": "Expected return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "auth_ref": [
      "r413",
      "r418",
      "r450",
      "r477",
      "r485",
      "r486"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.",
        "label": "Defined Benefit Plan, Interest Cost",
        "terseLabel": "Interest cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanInterestCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "auth_ref": [
      "r448",
      "r475",
      "r485",
      "r486"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "totalLabel": "Net periodic benefit cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments": {
     "auth_ref": [
      "r414",
      "r455",
      "r482"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from event reducing expected years of future service of present employees or eliminating accrual of defined benefits for some or all future services of present employees.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment",
        "negatedLabel": "Curtailments"
       }
      }
     },
     "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1": {
     "auth_ref": [
      "r414",
      "r455",
      "r482"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement",
        "negatedTerseLabel": "Settlements"
       }
      }
     },
     "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "auth_ref": [
      "r416",
      "r449",
      "r476",
      "r485",
      "r486"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Service Cost",
        "terseLabel": "Service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanServiceCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r146",
      "r302"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "negatedLabel": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection": {
     "auth_ref": [
      "r85",
      "r87"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after effects of master netting arrangements, deduction of assets not subject to a master netting arrangement and elected not to be offset, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against an obligation to return collateral.",
        "label": "Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election",
        "totalLabel": "Net amounts, asset"
       }
      }
     },
     "localname": "DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction": {
     "auth_ref": [
      "r82",
      "r83",
      "r87"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset, subject to master netting arrangement or similar agreement and not elected or qualified to offset, deducted from derivative asset.",
        "label": "Derivative Asset, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset",
        "negatedTerseLabel": "Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, asset"
       }
      }
     },
     "localname": "DerivativeAssetNotOffsetPolicyElectionDeduction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration": {
     "auth_ref": [
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes derivative asset.",
        "label": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r81",
      "r86",
      "r91",
      "r626"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "netLabel": "Gross amounts recognized in the consolidated balance sheet, asset",
        "terseLabel": "Derivative assets",
        "verboseLabel": "Fair Value of Derivative, Asset"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAverageRemainingMaturity1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average remaining period until maturity of the derivative contract, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Average Remaining Maturity",
        "terseLabel": "Maximum average period of maturities of contracts in years (less than)"
       }
      }
     },
     "localname": "DerivativeAverageRemainingMaturity1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativeCollateralObligationToReturnCash": {
     "auth_ref": [
      "r84",
      "r87",
      "r89",
      "r604"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets.",
        "label": "Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Cash Not Offset",
        "negatedLabel": "Cash collateral received, asset",
        "terseLabel": "Cash collateral received from counterparties"
       }
      }
     },
     "localname": "DerivativeCollateralObligationToReturnCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeCollateralRightToReclaimCash": {
     "auth_ref": [
      "r84",
      "r87",
      "r89",
      "r604"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of right to receive cash collateral under master netting arrangements that have not been offset against derivative liabilities.",
        "label": "Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Cash Not Offset",
        "negatedLabel": "Cash collateral received, liability"
       }
      }
     },
     "localname": "DerivativeCollateralRightToReclaimCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r583"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "terseLabel": "Amount of gain recognized in Other (income) expense, net on derivatives"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from derivative.",
        "label": "Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "terseLabel": "Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]"
       }
      }
     },
     "localname": "DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r91",
      "r582",
      "r585",
      "r591",
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about derivatives and hedging activities.",
        "label": "Derivative Instruments and Hedging Activities Disclosures [Table]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
     "auth_ref": [
      "r579",
      "r582",
      "r591",
      "r599",
      "r600",
      "r606",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails",
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments, Gain (Loss) [Line Items]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails",
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred": {
     "auth_ref": [
      "r610"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated value of gains (losses), net anticipated to be transferred in the future from accumulated other comprehensive income into earnings.",
        "label": "Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred",
        "terseLabel": "Pretax net unrealized gains on derivatives maturing within next 12 months estimated to be reclassified from AOCI to sales"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": {
     "auth_ref": [
      "r590",
      "r592"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net",
        "negatedTerseLabel": "Amount of Derivative Pretax (Gain) Loss Recognized in Income"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r81",
      "r86",
      "r91",
      "r626"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "netLabel": "Gross amounts recognized in the consolidated balance sheet, liability",
        "terseLabel": "Derivative liabilities",
        "verboseLabel": "Fair Value of Derivative, Liability"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection": {
     "auth_ref": [
      "r85",
      "r87"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after effects of master netting arrangements, deduction of liabilities not subject to a master netting arrangement and elected not to be offset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against the right to receive collateral.",
        "label": "Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election",
        "totalLabel": "Net amounts, liability"
       }
      }
     },
     "localname": "DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction": {
     "auth_ref": [
      "r82",
      "r83",
      "r87"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset, subject to master netting arrangement or similar agreement and not elected or qualified to offset, deducted from derivative liability.",
        "label": "Derivative Liability, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset",
        "negatedTerseLabel": "Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, liability"
       }
      }
     },
     "localname": "DerivativeLiabilityNotOffsetPolicyElectionDeduction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration": {
     "auth_ref": [
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes derivative liability.",
        "label": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r576",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Total swap notional amount",
        "verboseLabel": "U.S Dollar Notional Amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r575",
      "r577",
      "r578",
      "r579",
      "r580",
      "r587",
      "r591",
      "r603",
      "r605",
      "r609",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivatives, Fair Value [Line Items]",
        "terseLabel": "Derivatives, Fair Value [Line Items]"
       }
      }
     },
     "localname": "DerivativesFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Derivatives Designated as Hedging Instruments"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax": {
     "auth_ref": [
      "r7",
      "r8",
      "r20"
     ],
     "calculation": {
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of income (loss) from operations classified as a discontinued operation. Excludes gain (loss) on disposal and provision for gain (loss) until its disposal.",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, before Income Tax",
        "totalLabel": "Income from discontinued operations before taxes"
       }
      }
     },
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share",
        "terseLabel": "Income from Discontinued Operations (in dollars per share)"
       }
      }
     },
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME",
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of expected continuing involvement with a discontinued operation after the disposal date, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Discontinued Operation, Period of Continuing Involvement after Disposal",
        "terseLabel": "Period of continuing involvement after disposal"
       }
      }
     },
     "localname": "DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod": {
     "auth_ref": [
      "r8",
      "r24",
      "r534"
     ],
     "calculation": {
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) attributable to income (loss) from operations classified as a discontinued operation. Excludes tax expense (benefit) for gain (loss) on disposal and for provision for gain (loss) until disposal.",
        "label": "Discontinued Operation, Tax Effect of Income (Loss) from Discontinued Operation During Phase-out Period",
        "terseLabel": "Income tax benefit"
       }
      }
     },
     "localname": "DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]",
        "terseLabel": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Consideration",
        "terseLabel": "Consideration received"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": {
     "auth_ref": [
      "r21",
      "r27"
     ],
     "calculation": {
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Operating Expense",
        "totalLabel": "Operating expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense": {
     "auth_ref": [
      "r21"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Other Expense",
        "terseLabel": "Disposal group, other expense"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": {
     "auth_ref": [
      "r21",
      "r27"
     ],
     "calculation": {
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Revenue",
        "terseLabel": "Sales"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]",
        "terseLabel": "Costs, Expenses and Other"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r28",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Spin-Off of Organon &amp; Co."
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCo"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DividendsCommonStockCash": {
     "auth_ref": [
      "r400"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Common Stock, Cash",
        "negatedLabel": "Cash dividends declared on common stock"
       }
      }
     },
     "localname": "DividendsCommonStockCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EquityRollforwardReconciliationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPayableCurrent": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Dividends Payable, Current",
        "terseLabel": "Dividends payable"
       }
      }
     },
     "localname": "DividendsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Domestic Tax Authority"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DomesticPlanMember": {
     "auth_ref": [
      "r490",
      "r494",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Domestic Plan [Member]",
        "terseLabel": "Domestic Plan"
       }
      }
     },
     "localname": "DomesticPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueFromRelatedPartiesCurrent": {
     "auth_ref": [
      "r31",
      "r53",
      "r158",
      "r349",
      "r351",
      "r352",
      "r358",
      "r359",
      "r360",
      "r648"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).",
        "label": "Due from Related Parties, Current",
        "terseLabel": "Due from related parties, current"
       }
      }
     },
     "localname": "DueFromRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r69",
      "r158",
      "r349",
      "r351",
      "r352",
      "r358",
      "r359",
      "r360",
      "r648"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "terseLabel": "Due to related parties, current"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EMEAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regions of Europe, Middle East and Africa.",
        "label": "EMEA [Member]",
        "terseLabel": "Europe, Middle East and Africa"
       }
      }
     },
     "localname": "EMEAMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r121",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r184",
      "r187",
      "r196",
      "r197",
      "r198",
      "r202",
      "r203",
      "r614",
      "r615",
      "r708",
      "r730"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net Income (in dollars per share)",
        "totalLabel": "Net Income (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME",
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Basic Earnings per Common Share Attributable to Merck &amp; Co., Inc. Common Shareholders:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME",
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r121",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r187",
      "r196",
      "r197",
      "r198",
      "r202",
      "r203",
      "r614",
      "r615",
      "r708",
      "r730"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net Income (in dollars per share)",
        "totalLabel": "Net Income (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME",
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Earnings per Common Share Assuming Dilution Attributable to Merck &amp; Co., Inc. Common Shareholders:",
        "verboseLabel": "Earnings per Common Share Assuming Dilution Attributable to Merck &amp; Co., Inc. Common Shareholders:"
       }
      }
     },
     "localname": "EarningsPerShareDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME",
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r199",
      "r200",
      "r201",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r632"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue from External Customer [Line Items]",
        "terseLabel": "Revenue from External Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r109",
      "r110",
      "r111",
      "r169",
      "r170",
      "r171",
      "r173",
      "r179",
      "r181",
      "r205",
      "r266",
      "r399",
      "r400",
      "r507",
      "r508",
      "r509",
      "r525",
      "r526",
      "r613",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r639",
      "r646",
      "r739",
      "r740",
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EquityRollforwardReconciliationsDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails",
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityFundsMember": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An investment that pools funds from many investors to invest in a combination of underlying investments, primarily equity investments.",
        "label": "Equity Funds [Member]",
        "terseLabel": "Equity Funds"
       }
      }
     },
     "localname": "EquityFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFVNINoncurrent": {
     "auth_ref": [
      "r625"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent.",
        "label": "Equity Securities, FV-NI, Noncurrent",
        "terseLabel": "Equity securities, noncurrent"
       }
      }
     },
     "localname": "EquitySecuritiesFVNINoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r32",
      "r45",
      "r625"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_TradingSecurities",
       "weight": 1.0
      },
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "mrk_DebtSecuritiesandEquitySecuritiesFVNI",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Publicly traded equity securities, fair value",
        "verboseLabel": "Publicly traded equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "auth_ref": [
      "r264"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      },
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "negatedLabel": "Loss (income) from investments in equity securities, net",
        "negatedTerseLabel": "Loss (income) from investments in equity securities, net"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r264",
      "r731"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "negatedTerseLabel": "Unrealized net (gains) losses"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails",
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r260",
      "r714",
      "r760",
      "r761",
      "r762"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Publicly traded equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r261"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "terseLabel": "Equity investments without readily determinable fair values"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount": {
     "auth_ref": [
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from downward price adjustment on investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount",
        "terseLabel": "Unrealized losses recognized on investments in equity securities without readily determinable fair values"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount": {
     "auth_ref": [
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cumulative loss from downward price adjustment on investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount",
        "terseLabel": "Cumulative unrealized losses on investments"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount": {
     "auth_ref": [
      "r263"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain from upward price adjustment on investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount",
        "terseLabel": "Unrealized gains recognized on investments in equity securities without readily determinable fair value"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount": {
     "auth_ref": [
      "r263"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cumulative gain from upward price adjustment on investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount",
        "terseLabel": "Cumulative unrealized gains on investments"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Financial Assets and Liabilities Measured at Fair Value on Recurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r616",
      "r617",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r370",
      "r379",
      "r380",
      "r437",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r485",
      "r617",
      "r658",
      "r659",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r616",
      "r617",
      "r618",
      "r619",
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r370",
      "r437",
      "r439",
      "r444",
      "r485",
      "r617",
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r370",
      "r379",
      "r380",
      "r437",
      "r439",
      "r444",
      "r485",
      "r617",
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r370",
      "r379",
      "r380",
      "r437",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r485",
      "r617",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r620",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Information About the Changes in Liabilities for Contingent Consideration"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r621"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedTerseLabel": "Payments"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r370",
      "r379",
      "r380",
      "r437",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r485",
      "r658",
      "r659",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r622",
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "auth_ref": [
      "r581",
      "r587",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]"
       }
      }
     },
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r258",
      "r259",
      "r261",
      "r262",
      "r263",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r275",
      "r276",
      "r277",
      "r278",
      "r378",
      "r397",
      "r611",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.",
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r296",
      "r688"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Finite-lived intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r628",
      "r629",
      "r630",
      "r631"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "negatedLabel": "Exchange losses"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r91",
      "r437",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign exchange contracts"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignExchangeFutureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A standardized contract, traded on a futures exchange, to buy or sell a certain currency, at a specified future date, at a fixed exercise rate (expressed as an exchange).",
        "label": "Foreign Exchange Future [Member]",
        "terseLabel": "Foreign Exchange Future"
       }
      }
     },
     "localname": "ForeignExchangeFutureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignExchangeOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An option that allows the holder to buy (if call) or sell (if put) an underlying currency at a fixed exercise rate, expressed as an exchange, during a specified period (an American option) or at a specified date (a European option).",
        "label": "Foreign Exchange Option [Member]",
        "terseLabel": "Currency options"
       }
      }
     },
     "localname": "ForeignExchangeOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r437",
      "r745"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt security issued by government not domiciled in United States of America (US).",
        "label": "Debt Security, Government, Non-US [Member]",
        "terseLabel": "Foreign government bonds"
       }
      }
     },
     "localname": "ForeignGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignPlanMember": {
     "auth_ref": [
      "r490",
      "r494",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Foreign Plan [Member]",
        "terseLabel": "International"
       }
      }
     },
     "localname": "ForeignPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r41",
      "r280",
      "r281",
      "r288",
      "r290",
      "r652",
      "r691"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgedLiabilityFairValueHedge": {
     "auth_ref": [
      "r601"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability hedged in fair value hedging relationship.",
        "label": "Hedged Liability, Fair Value Hedge",
        "terseLabel": "Carrying Amount of Hedged Liabilities"
       }
      }
     },
     "localname": "HedgedLiabilityFairValueHedge",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease": {
     "auth_ref": [
      "r602"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.",
        "label": "Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)",
        "verboseLabel": "Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount"
       }
      }
     },
     "localname": "HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r579",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r146",
      "r299"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Intangible asset impairment charges"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r146",
      "r299"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)",
        "terseLabel": "Impairment charge"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherIntangiblesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "In Process Research and Development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherIntangiblesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "auth_ref": [
      "r124",
      "r147",
      "r174",
      "r175",
      "r176",
      "r177",
      "r194",
      "r198",
      "r561"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent",
        "terseLabel": "Net Income from Continuing Operations Attributable to Merck\u00a0&amp; Co., Inc.",
        "totalLabel": "Net Income from Continuing Operations Attributable to Merck\u00a0&amp; Co., Inc."
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME",
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity": {
     "auth_ref": [
      "r559",
      "r562"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Less: Net Income Attributable to Noncontrolling Interests"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r116",
      "r223",
      "r229",
      "r233",
      "r236",
      "r239",
      "r689",
      "r703",
      "r710",
      "r732"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Profits",
        "totalLabel": "Income from Continuing Operations Before Taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r154",
      "r172",
      "r223",
      "r229",
      "r233",
      "r236",
      "r239",
      "r265",
      "r346",
      "r347",
      "r348",
      "r351",
      "r352",
      "r353",
      "r355",
      "r357",
      "r359",
      "r360",
      "r562",
      "r615",
      "r627"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      },
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income from continuing operations",
        "totalLabel": "Net Income from Continuing Operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS",
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r113",
      "r121",
      "r172",
      "r174",
      "r175",
      "r176",
      "r177",
      "r187",
      "r196",
      "r197",
      "r615",
      "r702",
      "r704",
      "r708",
      "r725"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Income from Continuing Operations (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME",
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r113",
      "r121",
      "r172",
      "r174",
      "r175",
      "r176",
      "r177",
      "r187",
      "r196",
      "r197",
      "r198",
      "r615",
      "r708",
      "r725",
      "r728",
      "r730"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Income from Continuing Operations (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME",
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r24",
      "r27",
      "r535",
      "r726"
     ],
     "calculation": {
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Income from discontinued operations, net of taxes"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r20",
      "r24",
      "r559",
      "r562"
     ],
     "calculation": {
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Less: Income of discontinued operations attributable to noncontrolling interests"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r20",
      "r24",
      "r562"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      },
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent",
        "terseLabel": "Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests",
        "totalLabel": "Income from discontinued operations, net of taxes and amounts attributable to noncontrolling interests"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME",
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails",
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "auth_ref": [
      "r188",
      "r196",
      "r197",
      "r573"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "terseLabel": "Income from Discontinued Operations (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME",
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r2",
      "r13",
      "r14",
      "r15",
      "r16",
      "r18",
      "r19",
      "r23",
      "r25",
      "r26",
      "r27",
      "r307",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r305",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails",
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails",
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]",
        "terseLabel": "Income Tax Authority, Name [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority, Name [Domain]",
        "terseLabel": "Income Tax Authority, Name [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r156",
      "r518",
      "r522",
      "r523",
      "r527",
      "r532",
      "r536",
      "r537",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Taxes on Income"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Examination [Line Items]",
        "terseLabel": "Income Tax Examination [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxExaminationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExaminationTable": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A summary of income tax examinations that an enterprise is currently subject to or that have been completed in the current period typically including a description of the examination, the jurisdiction conducting the examination, the tax year(s) under examination, the likelihood of an unfavorable settlement, the range of possible losses, the liability recorded, the Increase or Decrease in the liability from the prior period, and any penalties and interest that have been incurred or accrued.",
        "label": "Income Tax Examination [Table]",
        "terseLabel": "Income Tax Examination [Table]"
       }
      }
     },
     "localname": "IncomeTaxExaminationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r157",
      "r180",
      "r181",
      "r221",
      "r516",
      "r528",
      "r533",
      "r733"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Taxes on Income from Continuing Operations"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r143",
      "r149"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Income taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapital": {
     "auth_ref": [
      "r145"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period of all assets and liabilities used in operating activities.",
        "label": "Increase (Decrease) in Operating Capital",
        "negatedLabel": "Net changes in assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EquityRollforwardReconciliationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r293",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherIntangiblesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Indefinite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Indefinite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherIntangiblesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r293",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherIntangiblesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Other Intangibles"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherIntangibles"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r291",
      "r295"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Other Intangibles, Net",
        "verboseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET",
      "http://www.merck.com/role/OtherIntangiblesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r114",
      "r217",
      "r641",
      "r643",
      "r709"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaid": {
     "auth_ref": [
      "r149"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.",
        "label": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateContractMember": {
     "auth_ref": [
      "r91",
      "r437",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.",
        "label": "Interest Rate Contract [Member]",
        "terseLabel": "Interest Rate Contract"
       }
      }
     },
     "localname": "InterestRateContractMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest rate swap contracts",
        "verboseLabel": "Interest rate swaps"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.",
        "label": "Internal Revenue Service (IRS) [Member]",
        "terseLabel": "Internal Revenue Service (IRS)"
       }
      }
     },
     "localname": "InternalRevenueServiceIRSMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 1.0,
       "parentTag": "mrk_InventoryNetAndInventoryNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Total (approximates current cost)"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLIFOReserve": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 2.0,
       "parentTag": "mrk_InventoryNetAndInventoryNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which inventory stated at last-in first-out (LIFO) is less than (in excess of) inventory stated at other inventory cost methods.",
        "label": "Inventory, LIFO Reserve",
        "negatedLabel": "Decrease to LIFO cost"
       }
      }
     },
     "localname": "InventoryLIFOReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r30",
      "r66",
      "r652"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails_1": {
       "order": 1.0,
       "parentTag": "mrk_InventoryNetAndInventoryNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "verboseLabel": "Inventories (excludes inventories of $2,641 in 2022 and $2,194 in 2021 classified in Other assets - see Note\u00a07)"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET",
      "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNoncurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails_1": {
       "order": 2.0,
       "parentTag": "mrk_InventoryNetAndInventoryNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Noncurrent",
        "terseLabel": "Inventories classified in Other assets",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "InventoryNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical",
      "http://www.merck.com/role/InventoriesNarrativeDetails",
      "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessAndRawMaterials": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate carrying amount as of the balance sheet date of items held by the entity which are partially completed at the time of measurement and unprocessed items that will go through the production process and become part of the final product. Includes supplies used directly or indirectly in the manufacturing or production process. This element may be used when the reporting entity combines work in process and raw materials into an aggregate amount.",
        "label": "Inventory, Work in Process and Raw Materials",
        "terseLabel": "Raw materials and work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessAndRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r127",
      "r216"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "negatedLabel": "Interest income",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LegalCostsPolicyTextBlock": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.",
        "label": "Legal Costs, Policy [Policy Text Block]",
        "terseLabel": "Legal Costs"
       }
      }
     },
     "localname": "LegalCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/BasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LegalEntityTypeOfCounterpartyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature of the other party participating in a financial transaction.",
        "label": "Legal Entity Type of Counterparty [Domain]",
        "terseLabel": "Legal Entity Type of Counterparty [Domain]"
       }
      }
     },
     "localname": "LegalEntityTypeOfCounterpartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r70",
      "r154",
      "r231",
      "r265",
      "r346",
      "r347",
      "r348",
      "r351",
      "r352",
      "r353",
      "r355",
      "r357",
      "r359",
      "r360",
      "r565",
      "r569",
      "r570",
      "r627",
      "r650",
      "r651"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r59",
      "r154",
      "r265",
      "r627",
      "r652",
      "r697",
      "r722"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Liabilities and Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r34",
      "r72",
      "r154",
      "r265",
      "r346",
      "r347",
      "r348",
      "r351",
      "r352",
      "r353",
      "r355",
      "r357",
      "r359",
      "r360",
      "r565",
      "r569",
      "r570",
      "r627",
      "r650",
      "r651",
      "r652"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "verboseLabel": "Payables included in Accrued and other liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET",
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r616"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, Fair Value Disclosure",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r36",
      "r37",
      "r38",
      "r48",
      "r49",
      "r154",
      "r265",
      "r346",
      "r347",
      "r348",
      "r351",
      "r352",
      "r353",
      "r355",
      "r357",
      "r359",
      "r360",
      "r565",
      "r569",
      "r570",
      "r627",
      "r650",
      "r651"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "terseLabel": "Payables included in Other Noncurrent Liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Licensing Agreements"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LitigationReserve": {
     "auth_ref": [
      "r76",
      "r332"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.",
        "label": "Estimated Litigation Liability",
        "terseLabel": "Legal defense costs reserve"
       }
      }
     },
     "localname": "LitigationReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationStatusAxis": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Axis]",
        "terseLabel": "Litigation Status [Axis]"
       }
      }
     },
     "localname": "LitigationStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusDomain": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Domain]",
        "terseLabel": "Litigation Status [Domain]"
       }
      }
     },
     "localname": "LitigationStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Long-Term Debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r74",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r332",
      "r334",
      "r335",
      "r336",
      "r337",
      "r342",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r332",
      "r334",
      "r335",
      "r336",
      "r337",
      "r342",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyClaimsDismissedNumber": {
     "auth_ref": [
      "r334",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of claims dismissed.",
        "label": "Loss Contingency, Claims Dismissed, Number",
        "terseLabel": "Loss contingency, claims dismissed"
       }
      }
     },
     "localname": "LossContingencyClaimsDismissedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyClaimsSettledNumber": {
     "auth_ref": [
      "r334",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of claims settled.",
        "label": "Loss Contingency, Claims Settled, Number",
        "terseLabel": "Loss contingency, claims settled"
       }
      }
     },
     "localname": "LossContingencyClaimsSettledNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r332",
      "r334",
      "r335",
      "r336",
      "r337",
      "r342",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "auth_ref": [
      "r334",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.",
        "label": "Loss Contingency, New Claims Filed, Number",
        "terseLabel": "Loss contingency, new claims filed"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "auth_ref": [
      "r334",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of pending claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Pending Claims, Number",
        "terseLabel": "Loss contingency, pending claims"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MaterialReconcilingItemsMember": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.",
        "label": "Segment Reconciling Items [Member]",
        "terseLabel": "Segment Reconciling Items"
       }
      }
     },
     "localname": "MaterialReconcilingItemsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r80",
      "r154",
      "r265",
      "r346",
      "r351",
      "r352",
      "r353",
      "r359",
      "r360",
      "r627",
      "r696",
      "r721"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling Interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [
      "r400"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedTerseLabel": "Distributions attributable to noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EquityRollforwardReconciliationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInDiscontinuedOperations": {
     "auth_ref": [
      "r142"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in cash associated with the entity's discontinued operations.",
        "label": "Net Cash Provided by (Used in) Discontinued Operations",
        "totalLabel": "Net Cash Flows Provided by Discontinued Operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Discontinued Operations [Abstract]",
        "terseLabel": "Cash Flows from Discontinued Operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInDiscontinuedOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows from Financing Activities of Continuing Operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations": {
     "auth_ref": [
      "r142"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations",
        "totalLabel": "Net Cash Used in Financing Activities of Continuing Operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash Flows from Investing Activities of Continuing Operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations": {
     "auth_ref": [
      "r142"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations",
        "totalLabel": "Net Cash Used in Investing Activities of Continuing Operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows from Operating Activities of Continuing Operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": {
     "auth_ref": [
      "r142",
      "r144",
      "r147"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations",
        "totalLabel": "Net Cash Provided by Operating Activities of Continuing Operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r27",
      "r103",
      "r106",
      "r111",
      "r118",
      "r147",
      "r154",
      "r172",
      "r174",
      "r175",
      "r176",
      "r177",
      "r180",
      "r181",
      "r194",
      "r223",
      "r229",
      "r233",
      "r236",
      "r239",
      "r265",
      "r346",
      "r347",
      "r348",
      "r351",
      "r352",
      "r353",
      "r355",
      "r357",
      "r359",
      "r360",
      "r615",
      "r627",
      "r705",
      "r727"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net Income Attributable to Merck\u00a0&amp; Co., Inc.",
        "totalLabel": "Net Income Attributable to Merck &amp; Co., Inc.",
        "verboseLabel": "Net income attributable to Merck\u00a0&amp; Co., Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME",
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME",
      "http://www.merck.com/role/EquityRollforwardReconciliationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r103",
      "r106",
      "r111",
      "r180",
      "r181",
      "r566",
      "r572"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "verboseLabel": "Net income attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EquityRollforwardReconciliationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r174",
      "r175",
      "r176",
      "r177",
      "r184",
      "r185",
      "r195",
      "r198",
      "r223",
      "r229",
      "r233",
      "r236",
      "r239"
     ],
     "calculation": {
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net income attributable to Merck &amp; Co., Inc., basic"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r186",
      "r189",
      "r190",
      "r191",
      "r192",
      "r195",
      "r198"
     ],
     "calculation": {
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net income attributable to Merck &amp; Co., Inc., diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent": {
     "auth_ref": [
      "r413"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for net periodic benefit cost components, excluding service cost component, of defined benefit plan. Amount includes, but is not limited to, interest cost, expected (return) loss on plan asset, amortization of prior service cost (credit), amortization of (gain) loss, amortization of transition (asset) obligation, settlement (gain) loss, curtailment (gain) loss and certain termination benefits.",
        "label": "Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component",
        "terseLabel": "Net periodic defined benefit plan (credit) cost other than service cost"
       }
      }
     },
     "localname": "NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Standards and Recently Issued Accounting Standards Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/BasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Non-US"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r169",
      "r170",
      "r171",
      "r400",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non- controlling Interests"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EquityRollforwardReconciliationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "verboseLabel": "Derivatives Not Designated as Hedging Instruments"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfInterestRateDerivativesHeld": {
     "auth_ref": [
      "r576",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of interest rate derivative instruments held by the entity at the reporting date.",
        "label": "Number of Interest Rate Derivatives Held",
        "verboseLabel": "Number of interest rate swaps held (in interest rate swaps)"
       }
      }
     },
     "localname": "NumberOfInterestRateDerivativesHeld",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent.",
        "label": "OCI, before Reclassifications, before Tax, Attributable to Parent",
        "terseLabel": "Other comprehensive income (loss) before reclassification adjustments, pretax"
       }
      }
     },
     "localname": "OciBeforeReclassificationsBeforeTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": {
     "auth_ref": [
      "r100",
      "r112"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.",
        "label": "OCI, before Reclassifications, Net of Tax, Attributable to Parent",
        "totalLabel": "Other comprehensive income (loss) before reclassification adjustments, net of taxes"
       }
      }
     },
     "localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OneTimeTerminationBenefitsMember": {
     "auth_ref": [
      "r313",
      "r314",
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A lump sum payment to an involuntarily terminated employee in conjunction with exit or disposal activities.",
        "label": "One-time Termination Benefits [Member]",
        "terseLabel": "Separation Costs"
       }
      }
     },
     "localname": "OneTimeTerminationBenefitsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r228",
      "r229",
      "r230",
      "r231",
      "r233",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments",
        "verboseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r168",
      "r183",
      "r209",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.",
        "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/BasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r95",
      "r97",
      "r562",
      "r567"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent",
        "negatedLabel": "Benefit plan net (loss) gain and prior service (cost) credit, net of amortization"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r562",
      "r563",
      "r567"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Cumulative translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax": {
     "auth_ref": [
      "r98",
      "r109"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) before reclassification adjustment from accumulated other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss) before Reclassifications, Tax",
        "negatedTerseLabel": "Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent",
        "verboseLabel": "Net unrealized gain on derivatives, net of reclassifications"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r93",
      "r97",
      "r584",
      "r589",
      "r607"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Amount of gain (loss) recognized in OCI on derivatives"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": {
     "auth_ref": [
      "r97",
      "r101"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax",
        "terseLabel": "Increase (decrease) in Sales as a result of AOCL reclassifications"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r593"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "negatedLabel": "Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r594"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax",
        "negatedLabel": "Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r104",
      "r107",
      "r109",
      "r110",
      "r112",
      "r119",
      "r399",
      "r633",
      "r638",
      "r639",
      "r706",
      "r728"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss), net of taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EquityRollforwardReconciliationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other Comprehensive (Loss) Income Net of Taxes:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r104",
      "r107",
      "r562",
      "r563",
      "r567"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive income (loss)",
        "totalLabel": "Other comprehensive income (loss), net of taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME",
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails",
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "auth_ref": [
      "r581",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current assets.",
        "label": "Other Current Assets [Member]",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": {
     "auth_ref": [
      "r409",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.",
        "label": "Other Income and Other Expense Disclosure [Text Block]",
        "terseLabel": "Other (Income) Expense, Net"
       }
      }
     },
     "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets classified as other.",
        "label": "Other Intangible Assets [Member]",
        "terseLabel": "Other Intangible Assets"
       }
      }
     },
     "localname": "OtherIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherInventorySupplies": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of other supplies used within the manufacturing or production process expected to be consumed within one year or operating cycle, if longer.",
        "label": "Other Inventory, Supplies, Gross",
        "terseLabel": "Supplies"
       }
      }
     },
     "localname": "OtherInventorySupplies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r71",
      "r652"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other Noncurrent Liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r147"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other Noncurrent Assets"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other Noncurrent Liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": 5.0,
       "parentTag": "mrk_CostsExpensesAndOther",
       "weight": -1.0
      },
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other (income) expense, net",
        "negatedTotalLabel": "Other (income) expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME",
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails",
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).",
        "label": "Other Nonoperating Income (Expense) [Member]",
        "terseLabel": "Other (income) expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails",
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": {
     "auth_ref": [
      "r411",
      "r412",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r460",
      "r461",
      "r463",
      "r466",
      "r470",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.",
        "label": "Other Postretirement Benefits Plan [Member]",
        "terseLabel": "Other Postretirement Benefit Plans"
       }
      }
     },
     "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherRestructuringMember": {
     "auth_ref": [
      "r313",
      "r314",
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and related activities classified as other.",
        "label": "Other Restructuring [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherRestructuringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PatentsMember": {
     "auth_ref": [
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Patents [Member]",
        "terseLabel": "Patents"
       }
      }
     },
     "localname": "PatentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r132",
      "r135"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r138"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Purchases of treasury stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r141",
      "r314"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "negatedLabel": "(Payments) receipts, net"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividendsCommonStock": {
     "auth_ref": [
      "r138"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.",
        "label": "Payments of Ordinary Dividends, Common Stock",
        "negatedLabel": "Dividends paid to stockholders"
       }
      }
     },
     "localname": "PaymentsOfDividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired": {
     "auth_ref": [
      "r135"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with a second acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Business Two, Net of Cash Acquired",
        "negatedTerseLabel": "Acquisition of Pandion Therapeutics, Inc., net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessTwoNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r133"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedTerseLabel": "Other acquisitions, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r135"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "terseLabel": "Amount paid for investment"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r253"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of securities and other investments"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r134",
      "r551",
      "r552",
      "r553"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "negatedLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PendingLitigationMember": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.",
        "label": "Pending Litigation [Member]",
        "terseLabel": "Pending Litigation"
       }
      }
     },
     "localname": "PendingLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r436",
      "r438",
      "r444",
      "r462",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r485",
      "r487",
      "r488",
      "r489",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Pension and Other Postretirement Benefit Plans"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "auth_ref": [
      "r410",
      "r412",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r460",
      "r461",
      "r463",
      "r466",
      "r470",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r489",
      "r490",
      "r497",
      "r498",
      "r499",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.",
        "label": "Pension Plan [Member]",
        "terseLabel": "Pension Plans"
       }
      }
     },
     "localname": "PensionPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r137",
      "r140"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfShortTermDebt": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from (Repayments of) Short-Term Debt",
        "terseLabel": "Net change in short-term borrowings"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r132"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "terseLabel": "Proceeds from sales of securities and other investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfIntangibleAssets": {
     "auth_ref": [
      "r131"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Proceeds from Sale of Intangible Assets",
        "terseLabel": "Revenue related to the sale of the marketing rights"
       }
      }
     },
     "localname": "ProceedsFromSaleOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r136",
      "r506"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r304",
      "r652",
      "r712",
      "r724"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, Plant and Equipment, at cost, net of accumulated depreciation of $17,921 in 2022 and $18,192 in 2021"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PublicUtilitiesInventoryAxis": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of inventory held.",
        "label": "Inventory [Axis]",
        "terseLabel": "Inventory [Axis]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PublicUtilitiesInventoryTypeDomain": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.",
        "label": "Inventory [Domain]",
        "terseLabel": "Inventory [Domain]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r652",
      "r723",
      "r746"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "verboseLabel": "Receivables included in Other current assets"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.",
        "label": "Reclassification from AOCI, Current Period, before Tax, Attributable to Parent",
        "negatedLabel": "Reclassification adjustments, pretax"
       }
      }
     },
     "localname": "ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": {
     "auth_ref": [
      "r100",
      "r112"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.",
        "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent",
        "negatedTotalLabel": "Reclassification adjustments, net of taxes"
       }
      }
     },
     "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodTax": {
     "auth_ref": [
      "r98",
      "r102",
      "r109"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss).",
        "label": "Reclassification from AOCI, Current Period, Tax",
        "terseLabel": "Tax"
       }
      }
     },
     "localname": "ReclassificationFromAociCurrentPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r229",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Reconciliation of Segment Profits to Income before Taxes"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RelatedPartiesAmountInCostOfSales": {
     "auth_ref": [
      "r117"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount included in cost of sales related to transactions with related parties incurred and recorded in the statement of operations for the period.",
        "label": "Related Parties Amount in Cost of Sales",
        "terseLabel": "Related party amount in cost of sales"
       }
      }
     },
     "localname": "RelatedPartiesAmountInCostOfSales",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r463",
      "r647",
      "r648",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt",
        "negatedLabel": "Payments on debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": {
     "auth_ref": [
      "r512",
      "r513"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Earned",
        "terseLabel": "Compensation earned"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": {
     "auth_ref": [
      "r294"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.",
        "label": "Research and Development Asset Acquired Other than Through Business Combination, Written-off",
        "terseLabel": "Charge for the acquisition of Pandion Therapeutics, Inc."
       }
      }
     },
     "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r511",
      "r686",
      "r776"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": 3.0,
       "parentTag": "mrk_CostsExpensesAndOther",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "negatedLabel": "Research and development",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails",
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME",
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r39",
      "r148",
      "r150",
      "r690",
      "r718"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r39",
      "r150"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]",
        "terseLabel": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r312",
      "r314",
      "r317",
      "r327",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/Restructuring"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": {
     "auth_ref": [
      "r313",
      "r316",
      "r323",
      "r326"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs incurred to date for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Cost Incurred to Date",
        "terseLabel": "Cumulative costs since program inception"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostCostIncurredToDate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "auth_ref": [
      "r313",
      "r316",
      "r323",
      "r326"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Expected Cost",
        "terseLabel": "Expected restructuring and related cost"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedCostIncurredCost": {
     "auth_ref": [
      "r313",
      "r316",
      "r323",
      "r326"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.",
        "label": "Restructuring and Related Cost, Incurred Cost",
        "terseLabel": "Total pretax restructuring costs",
        "verboseLabel": "Expense"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostIncurredCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails",
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r146",
      "r311",
      "r320",
      "r323"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": 4.0,
       "parentTag": "mrk_CostsExpensesAndOther",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "negatedLabel": "Restructuring costs",
        "terseLabel": "Restructuring costs"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringChargesMember": {
     "auth_ref": [
      "r320",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about restructuring charges have been included.",
        "label": "Restructuring Charges [Member]",
        "terseLabel": "Restructuring costs"
       }
      }
     },
     "localname": "RestructuringChargesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r313",
      "r314",
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails",
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r314",
      "r321"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Restructuring reserve, ending balance",
        "periodStartLabel": "Restructuring reserve, beginning balance"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Restructuring Reserve [Roll Forward]",
        "terseLabel": "Restructuring Reserve [Roll Forward]"
       }
      }
     },
     "localname": "RestructuringReserveRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r55",
      "r400",
      "r652",
      "r720",
      "r742",
      "r744"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r169",
      "r170",
      "r171",
      "r173",
      "r179",
      "r181",
      "r266",
      "r507",
      "r508",
      "r509",
      "r525",
      "r526",
      "r613",
      "r739",
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EquityRollforwardReconciliationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationAxis": {
     "auth_ref": [
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r463",
      "r466",
      "r471",
      "r472",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r490",
      "r494",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Axis]",
        "terseLabel": "Retirement Plan Sponsor Location [Axis]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationDomain": {
     "auth_ref": [
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r463",
      "r466",
      "r471",
      "r472",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r490",
      "r494",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Domain]",
        "terseLabel": "Retirement Plan Sponsor Location [Domain]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r410",
      "r411",
      "r412",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r460",
      "r461",
      "r463",
      "r466",
      "r470",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r497",
      "r498",
      "r499",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r410",
      "r411",
      "r412",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r460",
      "r461",
      "r463",
      "r466",
      "r470",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r497",
      "r498",
      "r499",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromRelatedParties": {
     "auth_ref": [
      "r122",
      "r349",
      "r351",
      "r352",
      "r358",
      "r359",
      "r360",
      "r747"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.",
        "label": "Revenue from Related Parties",
        "terseLabel": "Revenue from related party"
       }
      }
     },
     "localname": "RevenueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r115",
      "r154",
      "r214",
      "r215",
      "r228",
      "r234",
      "r235",
      "r242",
      "r243",
      "r246",
      "r265",
      "r346",
      "r347",
      "r348",
      "r351",
      "r352",
      "r353",
      "r355",
      "r357",
      "r359",
      "r360",
      "r627",
      "r710"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Sales",
        "totalLabel": "Sales"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME",
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails",
      "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyIncomeNonoperating": {
     "auth_ref": [
      "r128"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.",
        "label": "Royalty Income, Nonoperating",
        "terseLabel": "Royalties"
       }
      }
     },
     "localname": "RoyaltyIncomeNonoperating",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesMember": {
     "auth_ref": [
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.",
        "label": "Sales [Member]",
        "terseLabel": "Sales",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "SalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r100",
      "r638",
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Changes in AOCI by Component"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Information on Investments in Debt and Equity Securities"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable": {
     "auth_ref": [
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information about a contingent payment arrangement including the terms that will result in payment and the accounting treatment that will be followed if such contingency occurs, including the potential impact on earnings per share if the contingency is to be settled in shares of common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]",
        "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r539",
      "r540",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Collaboration Arrangements"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r469",
      "r470",
      "r473",
      "r474",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r582",
      "r591",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "terseLabel": "Location and Amount of Pretax Gains and Losses of Derivatives"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "terseLabel": "Fair Value of Derivatives on a Gross Basis Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "auth_ref": [
      "r2",
      "r13",
      "r14",
      "r15",
      "r16",
      "r18",
      "r19",
      "r23",
      "r25",
      "r26",
      "r27",
      "r307",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations"
       }
      }
     },
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Calculations of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Sales from Products"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r616",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for fair value hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.",
        "label": "Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]",
        "terseLabel": "Amounts Recorded on Balance Sheet Related to Fair Value Hedges"
       }
      }
     },
     "localname": "ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r298",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherIntangiblesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r35",
      "r63",
      "r64",
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.",
        "label": "Schedule of Net Benefit Costs [Table Text Block]",
        "terseLabel": "Net Benefit Costs"
       }
      }
     },
     "localname": "ScheduleOfNetBenefitCostsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.",
        "label": "Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Effect of Net Investment Hedges on OCI and the Consolidated Statement of Income"
       }
      }
     },
     "localname": "ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r590",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.",
        "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]",
        "terseLabel": "Income Statement Effects of Derivatives Not Designated as Hedging Instruments"
       }
      }
     },
     "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "terseLabel": "Other (Income) Expense, Net"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r313",
      "r314",
      "r315",
      "r316",
      "r323",
      "r324",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails",
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r318",
      "r319",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Charges Related to Restructuring Program Activities by Type of Cost"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/RestructuringTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "auth_ref": [
      "r314",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Charges and Spending Relating to Restructuring Activities by Program"
       }
      }
     },
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/RestructuringTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": {
     "auth_ref": [
      "r123",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]",
        "terseLabel": "Consolidated Sales by Geographic Area"
       }
      }
     },
     "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "auth_ref": [
      "r115",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r223",
      "r226",
      "r232",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.",
        "label": "Schedule of Stockholders Equity [Table Text Block]",
        "terseLabel": "Schedule of Equity"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentContinuingOperationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component of an entity expected to operate in the foreseeable future.",
        "label": "Continuing Operations [Member]",
        "terseLabel": "Continuing Operations"
       }
      }
     },
     "localname": "SegmentContinuingOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentDiscontinuedOperationsMember": {
     "auth_ref": [
      "r3",
      "r4",
      "r5",
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of or classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale.",
        "label": "Discontinued Operations [Member]",
        "terseLabel": "Discontinued Operations"
       }
      }
     },
     "localname": "SegmentDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r210",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r228",
      "r229",
      "r230",
      "r231",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r239",
      "r246",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r316",
      "r326",
      "r734"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentOperatingActivitiesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operations of an entity including continuing and discontinued operations.",
        "label": "Operating Activities [Domain]",
        "terseLabel": "Operating Activities [Domain]"
       }
      }
     },
     "localname": "SegmentOperatingActivitiesDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r210",
      "r212",
      "r213",
      "r223",
      "r227",
      "r233",
      "r237",
      "r238",
      "r239",
      "r240",
      "r242",
      "r245",
      "r246",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReporting"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r126"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": 2.0,
       "parentTag": "mrk_CostsExpensesAndOther",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME",
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r145"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r67",
      "r698",
      "r699",
      "r715"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-Term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r12",
      "r210",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r228",
      "r229",
      "r230",
      "r231",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r239",
      "r246",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r306",
      "r316",
      "r326",
      "r734"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r50",
      "r51",
      "r52",
      "r151",
      "r154",
      "r187",
      "r188",
      "r193",
      "r196",
      "r198",
      "r206",
      "r207",
      "r208",
      "r265",
      "r346",
      "r351",
      "r352",
      "r353",
      "r359",
      "r360",
      "r383",
      "r384",
      "r388",
      "r392",
      "r399",
      "r627",
      "r782"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r77",
      "r109",
      "r110",
      "r111",
      "r169",
      "r170",
      "r171",
      "r173",
      "r179",
      "r181",
      "r205",
      "r266",
      "r399",
      "r400",
      "r507",
      "r508",
      "r509",
      "r525",
      "r526",
      "r613",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r639",
      "r646",
      "r739",
      "r740",
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EquityRollforwardReconciliationsDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails",
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOperatingActivitiesSegmentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by continuing and discontinuing operations.",
        "label": "Operating Activities [Axis]",
        "terseLabel": "Operating Activities [Axis]"
       }
      }
     },
     "localname": "StatementOperatingActivitiesSegmentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r52",
      "r57",
      "r58",
      "r154",
      "r251",
      "r265",
      "r627",
      "r652"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Merck\u00a0&amp; Co., Inc. stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Merck\u00a0&amp; Co., Inc. Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityBeforeTreasuryStock": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total amount of stockholders' equity (deficit) items including stock value, paid in capital, retained earnings and including equity attributable to noncontrolling interests and before deducting the carrying value of treasury stock.",
        "label": "Stockholders' Equity before Treasury Stock",
        "totalLabel": "Stockholders' equity before deduction for treasury stock"
       }
      }
     },
     "localname": "StockholdersEquityBeforeTreasuryStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r110",
      "r154",
      "r169",
      "r170",
      "r171",
      "r173",
      "r179",
      "r265",
      "r266",
      "r400",
      "r507",
      "r508",
      "r509",
      "r525",
      "r526",
      "r559",
      "r560",
      "r571",
      "r613",
      "r627",
      "r633",
      "r634",
      "r639",
      "r646",
      "r740",
      "r741"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Equity, ending balance",
        "periodStartLabel": "Equity, beginning balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET",
      "http://www.merck.com/role/EquityRollforwardReconciliationsDetails",
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r152",
      "r384",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r398",
      "r400",
      "r405",
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/Equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteSpinoffTransaction": {
     "auth_ref": [
      "r404"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The change in equity as a result of a spin-off transaction (a regular or reverse spin-off) which is based on the recorded amounts.",
        "label": "Stockholders' Equity Note, Spinoff Transaction",
        "terseLabel": "Spin-off of Organon &amp; Co."
       }
      }
     },
     "localname": "StockholdersEquityNoteSpinoffTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EquityRollforwardReconciliationsDetails",
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Stock conversion ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "negatedTerseLabel": "Share-based compensation plans and other"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EquityRollforwardReconciliationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityOtherShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of increase (decrease) in shares of stock classified as other.",
        "label": "Stockholders' Equity, Other Shares",
        "negatedLabel": "Share-based compensation plans and other (in shares)"
       }
      }
     },
     "localname": "StockholdersEquityOtherShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EquityRollforwardReconciliationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r640",
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails",
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r640",
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails",
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r640",
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails",
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradingSecurities": {
     "auth_ref": [
      "r32",
      "r45",
      "r701"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI",
        "totalLabel": "Investments"
       }
      }
     },
     "localname": "TradingSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r258",
      "r259",
      "r261",
      "r262",
      "r263",
      "r378",
      "r397",
      "r611",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonMember": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockCommonMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EquityRollforwardReconciliationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonShares": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Shares",
        "periodEndLabel": "Treasury stock, ending balance (in shares)",
        "periodStartLabel": "Treasury stock, beginning balance (in shares)",
        "terseLabel": "Treasury stock (in shares)"
       }
      }
     },
     "localname": "TreasuryStockCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical",
      "http://www.merck.com/role/EquityRollforwardReconciliationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockCommonValue": {
     "auth_ref": [
      "r79",
      "r402",
      "r403"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Value",
        "terseLabel": "Less treasury stock, at cost: 1,043,697,097 shares in 2022 and 1,049,499,023 shares in 2021"
       }
      }
     },
     "localname": "TreasuryStockCommonValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r52",
      "r399",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "terseLabel": "Treasury stock shares purchased (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EquityRollforwardReconciliationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r399",
      "r400",
      "r402"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Treasury stock shares purchased"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EquityRollforwardReconciliationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails",
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r313",
      "r314",
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r159",
      "r437",
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. government and agency securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "auth_ref": [
      "r521"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "terseLabel": "Tax benefit recognized related to settlement"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from acquisitions.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Acquisition",
        "terseLabel": "Tax benefit resulting from acquisition"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r163",
      "r164",
      "r165",
      "r166",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r163",
      "r164",
      "r165",
      "r166",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r198"
     ],
     "calculation": {
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "terseLabel": "Common shares issuable (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r186",
      "r198"
     ],
     "calculation": {
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Average common shares outstanding assuming dilution (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r184",
      "r198"
     ],
     "calculation": {
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Average common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 12
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL34724391-108580"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868656-224227"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(2))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.13)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "https://asc.fasb.org/topic&trid=2134417"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "https://asc.fasb.org/topic&trid=2122394"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8475-108599"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/subtopic&trid=2122178"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721491-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144471"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(c))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "https://asc.fasb.org/topic&trid=2175745"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149975-122751"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "60",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6406278&loc=d3e26268-112671"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "610",
   "URI": "https://asc.fasb.org/topic&trid=49130413"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(21))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721501-107759"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "720",
   "URI": "https://asc.fasb.org/topic&trid=2122503"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "c",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6829253&loc=SL6831962-166255"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613673-111683"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.E)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120398118&loc=d3e355146-122828"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721503-107759"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4EE",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109999712-113959"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4EE",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109999712-113959"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121549185&loc=d3e80845-113994"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(5))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.1(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r777": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r778": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r779": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r780": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r781": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r782": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r783": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r784": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r785": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r786": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r787": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r788": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r789": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)(i)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)(ii)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226016-175313"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226038-175313"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>89
<FILENAME>0000310158-22-000034-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000310158-22-000034-xbrl.zip
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MVZV)D$A/$@BJ?]551[\9>%P5,YW-))%YP2?U&SM3\XK,RTPO)'KG4QV8A#_
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M2D!C$/M>RPZE5>7%400?*5SLX.@O4D,#W2O@/Q-Q9[ZB^=7G0OSGYT+6M%%
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MC67U:./6-R4H^H\'JI:Y1FL"5VMC PS#A>#WK? O6?[[Y-71-0<$?Y*TH4!
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MP1Q+ Q8#)!C&6_1OS<1,52</KJK 36*)V3"#>(@BJ(04KS"FJ.&9D[$6^9L
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M""FH)BJ(L8V(MLG4?U0!H92:@FIA5O54( L$WS))2I;!3[F@'7 PUZ_9T<0
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MEL1%V)$<RR11MX'EEJH]+5<1K/KE0MBW*>QE -E #'5'1BPFB;H-+$=72P[
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M,5V=U<P@;1"V)1H(BA:<"OPT)MI W3V?E=)H@92-4'12J)%+R<(MI4&Y?=J
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M6\SXZXJ1J\R8&R /FC: G$1&@Z:?VEK.$&SOR=8;[8^*'C[6.E$&G(J@C.G
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M]7R0'.NM<L[)B6VRN-A\OK@#BA> EGA ]H(E)E& ^2CE:I< [-55SB8$R37
MVZ0&]0'6B5746%$G/VJJ1YG+=@F"W(!=&2MI'36U&:Y.V-8J6@AJ6R5E.1H=
MI09A4Y7S:W\]O]SPFQ0G2>-2JE$5U#L!&&<90#,(Z&M9]&AX_*U!9T+LU77.
M-EOHU"R3JJ_QFCAD2IR(L)A/*!K&S9 =,>1&[+I_! .Q8DJ)0"!S:7UJG#+,
M%V*/4H9P"YV3DF*;_5F$4-5+[:E#FKZ[-*_0"DR/+1;'+STX$V*O+G2VV9G5
M1V#BEJ5.8D13C]:3U-$[&2/>#-D10V[$KC$AH+V:(44A&-6TEAG!=JU<O,]'
M!TFTWD+GI*38ICQ'6JM3[M<9JP)TY)P&=/+<:NX^CE^><R;$7EWH;,(0+T4X
M-2;M ."-JYL)*@DR9HN;(3MBR(W8U3X[]7=KW!.5 B.<T'DTB9ZA%DCM(+G6
M6^B<E!2;Y'.]JSI9MR@5'*MDHF;45:JT*L>?G7,FQ%Y=Z&PS.V?45J*H4.U@
MS452&6/4TK'4@7XS9$<,N1&[^JW<.8JWUL;4YK@&6R)R(<9BTZ??LW-^ "G^
MI[SY\,W#/4_J+.G<P@/&FIY9DT$=RM%;M9370)TB=/S1("<"[-5ESB8$X83#
MD#E/40.#A$;C#"U*./04QZ_0.1%!;L"NZYRL1"F-Z<T-2IL!*VIV#)7(%1$.
MDFF]5<XY.;%)+G<RPGL%PDI3Y3@2=\3P,.I4(-)!.'$)P%Y=Y6Q"D$)0M/<9
M&2M "=8\6A8'=<T:&C=!]D.0&[#K+@=&:MJ;H3;(=55<BN&,844SCT]SD/>>
M9KU5SCDYL4DBM[6J-;!HC 1EB/I4/,E5K=34:SH()RX!V*NKG&T(TD=G]EPA
M$+(E*:U+4]4!0C7\)LA^"'(#=JD<RFZ*E!-DL(IBK1"" P:WQG:0'.NM<L[)
MB6TJ<^K PF%.D@ 867I6KY&Z=PTX_LZ>$P'VZBIG$X*D^E33@-F3@' 1*I&\
MU!4J4\[U)LA^"'(#=G7/&D,J8%.4 Y@Q=>.4$$1J QUZBA3K:_^I/>IS2*F;
M$W]6^;]\%E?,J HW<JA3^Q.!8$MBF09A;G9S8C^ O;K*V80@CC,"KDV+EP;(
M/!_8C <2>8*6^CGJ<DY"D!NP$["&,K7,:&A#(%?5J7'4N!6M"0OT4Z18;Y5S
M5$YL,Q6$\B@<T-RF]I^1*B!-7TT8E(6IWIS8#V"OKG(V(8BX(N2!'.(09-QS
MX=R<4BY)3S VYT0$N0&[RN5S=._APT>'R%7&C&!;KU [CXASU"#<*N>HG-@F
MBUN:F45V 0%S5LJ!E#NP(E$__M"<$SGQJZN<30A2H.1:+::NJ>"I"#:U%*L(
M>:A(N0FR'X+<@%UW.4DJ,46*ZN!#J*S%/9;!:R5,Y10IUEOE')43VY0=4%GY
MVV8) E)GIF3*G%IC5<Q'&2-U"2=^=96S"4%*A'*+9CPITE78*J=<6)+/V+C?
M!-D106[ KJY932F&5VOA4*<LCP!PM9*+N%D^2(IUT^KC7[W_K3_^,4QO?IPD
MHQLMUT#):,EAZATV"P)VAV%<ZU'X<3GP7EW];$*67FD&!:K4DT!N0\:(051)
MBXV1C[(@\7)DN<&[LEJ!F*H,!FTPE(5+GH'NT*;)1B\'2</>2NC\_-@DZXM4
M9V@0TY?W!F$@409G]HJVYN$?OTSAI."]NA+:A"R]2[.P2H()*BB;NS4KA5KN
M)'*399]DN<&[%M9.$)E0R9 )C)1'D43)PM.0&0@?)%5[*Z'S\V.3S' 6#8[0
MT#8 Q#4)0Z]B4)E<]"#\N!QXKZZ$MMD\E)4Z6C5P R119X(99(^45[4HWF39
M)UEN\$[P4JGB*,J!/A'+[$C8E36S>&$Z2#KW5D+GY\<V]4#<E'.1&>E6J*W2
MP(RYZ&C>).CX-7(G!>_5E= F9,E!4C70H-@*&X39/&:079R&:KK)LD^RW.!=
MU="E.#JWWJI#K(BW><\XH][:.FLY2&KW+E2^1C)WM.P5)T!'*T"ULQ5H2)&[
M9)L^]P!PW0.6KJX3-L$N0.L U/VI$,%5L&,JPZ?*3M'A"*/2]H#=&TO+#V;/
MJ*I9>+5L!!,AE%J15-?Z[X/D(>]C^QJ9QX1(Q6NNN&I-QM2;K455RC8&]T('
M@.L>L'3U8WN;_6,#.7<:*3&N#@IJEH$G;ADFMF[LWECZ;W0=<)8F0@+(D*F1
M3;T77*VN-=;M*$FS^]B^1IJLI8I8&4I+"M']J=R_$GD!-*8C[%S9 Y:N?FQO
M@MT9:<^#6A*%$E0ODA&Z4*^5"E>F&[LWEGYPN< 0*&QM0BI@[?09.MB8PQB=
MX"@9GOO8OD9.IT#NN0\:V0QTY.GZ$I:1PVMC3G@ N.X!2U<_MC?!;IVAMC(:
M6CBD=3M$$E$@Q$K&CPF>&[LWEGY(;IL*3@!YRPEGP!TD3ULX6BL%:L)V@(3+
M?UV8\<7#-_[N_5O[MY_8W;VP.OCLS<-K>?4/+J_>__;$G-BH&[I0BE1KBPHS
MMI?$F5,3[*G9C)5N3NP'L%<7(-OLIFEIJ/8$Q@J>A=B;I((5;)7"^DV0_1#D
M!NS3,B4'*LY]2, ,]E0X16\*(Z7Y;SM ?NI6.>?EQ#;U!DR #0*'99#<Q"=:
M"U?52&6*GYL3^P'LU57.)@0QK2K*%)PJ!%7*GMJJ9DALVO3X<RQ.1) ;L&N9
M$B36VDH#[C"E#4F-), PU;I@.LKLBEOEG),3FZ0EZV W\AIY,J$@"O7N5M7K
M:"G*$<HS+N/$KZYRMAGHDH>F9%":C]7<1M0RE_"D7MB,;X+LAR W8%>A266=
MZD;U8U\;#Y+(2M6&D.OQUPS<*N?(G-AF%H6'%1HR0 !"&O>."6.&J9 4--^<
MV ]@KZYRMID_(2Y F@"]KLF.4A"Z#RPE:&#M-T'V0Y ;L*L&H1$-[5JH&"A6
M"3=@S$S0$L51U@F<7G[\949^_O;UU_)FON-W7_FOH?20U-@DF9L8I6/76JI
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M;+?;'[G^QZ5<PYYWW!^O9.L4UJ730](Z>?%I[X_\G'_"]]^2]NN=CWL'OY_
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M\MO^07/(J_W<\6,&3_"]%DI?_VSW%VEP^*W:.ZF;DJ(6'7*K##V .J>=T0C
M*G8!?0;]7B9&W8LJ DFZJ';SVF)]G12_;4=V7#;Z"N#&TS0&Y"\7^CI3Y^4Y
MG,ZQR'#[,KX][XYK?>VC@^I)_K;ZC3*Z<7G"Z+A3UVX]R[5;'QJ8Q\_[&6KC
M\)?9 NE7(YL']A)7'Q^0DC=4)$N,U0AX/]@#01ND'4O(<2Z)(U9YI@N0KCZ0
MRJ4%4H M6W7A36)EO0<@'=@,A!E6!IGN7?O7"B0977-@> KX"_<87%$L )]3
M&(&+]<QMX6+ !?.8O:W>#OH?1L=7AS> ZL;ZR4),G5[=NZ N<))+?5!XR1N>
MKSY,?KLZ[8<GW/Q\5R=F?GMY\@W/>G5FIS=>(8!((7K%V+^FZ1O5DV?U\/=[
M\9>GMY&BN;0#4AM&ZY])2"9J0Y/;I?C>*2%9;4C6?)LA*C:T>H#+\@TJ]1RZ
M%RVJXZ>QCAN#9Z#';_N#BVO\/O5)M8;[RY.6V@74?OWJT^')%MSG!3DZV8+[
MO+@X^F/G8_ODSQ.X!V]OM\31P<O3UHF?[*](C@[:G=;VVP]'V_^<MK9?X*/M
M/]\='NS05G[.@[>X]:G;;?]Q>-$FUQ0"=RP2Y6A$*E"). $3T#!JD.<BBNBQ
MTDFN;?YU/?K.MT;<SS?BNETF_P0S6K;"=]<K[M;T'*[<G/'?KMO3;+(&\UQ.
M79W5HWT==UQ)0:Q6"SWV;V+/JS5Y#\YNZG'\_7P(=QX.5[?[XHQ8S<5?!ZV)
MC:W$5="!HT %1YP2CHSF&C&,\]YC2BZW-_E1]\5'N'@\S)/,KSWE[6!MYWH[
MOX#:G4#M:A3_J ?QV7@,"[C=$]SP%+A98Q0FG*&0B$:<18,T@!W2)GF<*.;.
M\SN VVUVZ>?KS4S?\1OF@K_7.CL[Z;H-HWJ;"!AGKU]O\)P/QSY'>--QW_AK
M&J?V!_6]NA?YYA\Z<&NX;=6#5^MG(O2^,ZP9;,_V?,=VLY&<>Y?EDX<CVPMV
M$(95+EW?"=?7@:L(>V)_N=Y]6-W! 7UC></E<$ /CV.W>S6KU1.8J]H1/&Z+
M^'TWZ[=[7X=Q>/5K/7;7;2S,<4OAX;EE'LCKT/=IZGR, 5ZJ.US.@-5[[=31
M-SS&1$**"(8V(.YS#)^&H0S4R\0TB53&K[P^WVO)O?@:>'!\51(]:\SPV YB
MO9WBQV7'AG4H5_]\5&-472U]>*5:OML?UA7VW*6!DHOK[?E1'RXV5A]&UG-6
M,'UZ5=W\>;T7#*>=]SIC61[?<>U;^4XL*>X$L2)X'KQTPD2)"=-:. E2_F8W
M7Y5@1M9 ^WT'K*3A_UO;;3^_)I*G?H\Z(FV_OM7>EW?Y5NIA%%#HU]4$\P6!
MN@$?@VOA1Z<#;]F;9 $2<]L\#P./. D866P$DMYCK))F0I&U3;HNF%AG1JR#
M+EQIPM4<WTH5)NIRSZLOK=X@C/[,SA9\T^";#U^SJ3-A(;+O6(B7[WWY)F V
M5,-^MQ.J*U"X/)['<?K@S=;=C43N\I%X'K.S_IC>/!W$',WR/EX.U:6-\-6W
M+A\/?_F*=? HYZ/IK]P<O?GUSWSM6N.DXY%3C6V@C',KG%<I>&N5BIRHA-^H
MM:OO' ^^6%IO(W*#:-\AFT"8GMKN!WLQ7/OU6Q$$";EZ7;JA\AO?_F%O\29W
M[U]^PXWN>)7&5@]";\52#FH]A37@6<;OWFAXGQ>8L=*S#4783VUGLPV.;[>3
M>Z?+F@W)E^:RU&PPVGR1<4(WN+I=D?&YNJIFY@";:[NWZ]U@?P/$YD:FLVB0
M^[#O=[T'[.^MEP?5[HU>O5L5G/]1%]L;WRRE!WNS[U7+_I==F&>IC@?9"OB/
M'Z__!*]M/M]M;[6?[6[]50'_WWO9VCK8W6O_ZU<[N2PW[YN]1:+*PXWI7:NA
M/^3\WO%9[C:_[(:YO#N=_B$>3ROV*F_!WQ+L=T?QM"(;RXV&CT-;&*#A9_]R
MW2OU=$S)"QBNR/3^  P;1+Y[S/_E)5 ^_RG1]1W+_-]__F5N!@%?[.6-)/A4
M^WOJN*C/NIXM\=V>[Y_&HO0K,^E%Z1_Q_)O;*7W>QQO$8S@MYS 6"%@Q$2@0
M\'CGG](;(>!WV[6YZ>7^<8RCHNXK,]V\J/OCG7]QRQ7?#H^KY]W^AV+?K\[$
MBT56_#++#<PR(W7O;WBF4;^Z0<^+$V^EIU^6'8T'R."XRW8&+=L9BZ\J"NS>
MENW9MS4 YEH:1/TVK+8[0W\^'.8@TER!8ZMGNQ?#3AV4^@4W,[".H_/S.2_C
M\+P[JD_9.XOC1WI00!V+=T'368@(*QO$"[!!S JB+KZZ$$+7-E_DM*+.J([I
MK=$1_M"]^CV#:[<_/,]) -;UST=5RP[>Q5'ULC-\5RCHZDB!P 4UYX^:O*#F
M,NC+V",W&L#<U(CY]Z#O8\@@62!Q=:98D!6&Q+(EL-3BJ0&!['F^@!U<5,^M
M'_4'P^H@%P!NV8MJ*Z5<4_WY^0A Z<K<+=BT.I._TMBT6'3M>RDA)2=D"7)"
M*%G;W#OX]\[+KQ-"JH*&JX&&>78+&BZ"\5IR0I9"7_C:YE_QK>V.K=:ZOT2A
MABLTN04,%P(,MPH:+H/"J+7-O)5Q94(7(%R=>9TE$"[ZJ:L&KR5@9QFTD.&U
MS5>]<<'&F!N0[=ONN)K<SO^>=T877W>IS/LHK\;EXRZ):0'C%1(#00L8KRH8
MRP+&RZ"%;&USY^-QQW7*5M JS>DLD75QMJD;$<\BA(T(H5S;W(>AM:.?CH"9
M:_>( EBSE17QW0#MJ6*TMZJ&.E&Z=2F*U>9B9HM;K7;F?))^7][_MH-1M5NA
MKY(Z=GOC<MUPYK1@W'(.V-HUTC355W6QAB*3[G$]=;)Q0V[@3XZ&_,%HF.M*
MD<X^ J.N--S:>?GLOR][--C3L]^J9WL;Z]5N^]E&M=7>KO9?_;Z_N[V[]7)W
M9_]&V%B4=WFVU][>:>_O;,-+M/?W_MK=WCJ 7_8/X)_63ON@VGN>WVROM;/P
MK_+D5<^>A\XHAO7J/W,+#KA'M^[)'#_Z>#;*[5'&;04J>YH;G@Q_N0&>&GOR
MNW037]1>RP#L&W@,[G>M3BWXAL3-%V8V&YS*G[KJ]X\)=KOR^>59%^)9V>V>
M9QE\7OI6+J\)G/@IC]<L:WC?[JT.@,/'J@7G'0^KG=S2JB:'^X#8L6X&P_#Z
M'=K:W2^\?/&&IPU_N<OH/!IQGVI.\OWF(TLQV;F74%,O? MWQ4H-'&D")%9T
M;(I0-2)4/\!69_V[MP.P+ *Z?$+O8TSI=MV1%KY>2;V%/BE(C;TZKI9AU_$_
M'^[]OW[O0;[E0KWXC5WSSH=AHF4>HX*88+G%07'LA:5>2J8<%YAZ[<5E2TCU
M34O(+[WSD+QJG7<^1&^M/7OZ,KZ/O?,XO%V3/#GG)GGMCCGUI\][>Z>O+HY.
M0K>U_58<O=[]N'?P@K>VMSC<F^T=M"Z.7N_P]O8AAL^?_F(OCP]//W;W3MY1
MN#]OOWX%Y_UYW#YY<7%X\OMQ:]NS0_K/2?NT];'UZ>VG]NNC=U??@7N=']%7
M<N_@Z+C]Z2W)S7@/3W=H>_O/3NN/G0_M3^'DZ'6+'G[:^;2WW2+PS*G5R<UY
M=W*37M'>AG?=>B,3B=83BH2G'G&2 K)>*<2,D<PIPD1T:YN$KQMAIOKK74_5
MFH3%ZHXZ\KT%ZE[/,[D"%@ L #@!@"$22KVB-.+ G5;:<6\)CE98[HDS-0"2
M*P D!0#G H"?)@!0>1.)L!X930CBS$2D>90H2B>9T,Z'0   V3H1TPU&"P 6
M "P >*^FX 4 9PR 9 ( #7.1P%PA0P-#G#N!@/=Y1& 2DT\N.LG7-KE8YSF.
MH@!@ < "@#< ((">IH1$X':!!Q6L%%ZZ"#:P$0$;?LD 26& \P1 -@& . @7
MJ R(V@0FL(#9<9QK9#"5-H:DB,H]D,0ZT4L#@'=V6:;ZOQ5Q63[K#T?#]6KG
MXUFN;3Y.]=D;'<?!;?SA]QJ:VSC*RPW*#>YP@Y_=?;@.1M0X=',1%9=>*6Y.
MR!M>M^?P^>7IW5[^6GZUU#RC<5=['O>]]$>_'X9;O; ?!^\[/@[W^]U0F$=3
MS*/];,KYGA0GBDB%2,0<<0+VES:$(JZQ(IJPH)@#YK%N6%.NISD85S]$S4>O
MSHT[CHLZST2=IUS)6#)!P(80S!)09Q*09DP@X6ABUF(;(\GJS'/MZZ+.JZK.
MC;M!BSK/1)TG':.$<,H=%B@IFA!G0B(MM$; N )+*21I=;TS)%C1YQ76Y\:]
M>D6?9Z+/DWX^*JRCSD@$%#N"%DN/-*@P8A2$V*D$AI1:VS3K*B>X+XPZ_ZPG
M;\G,_W&H8>S"']^N5V]C+PYLMW;<V7#:Z76&HT&=5_M33H%KAF3U8*IQI\#E
M;/PQG@M JJUO9N+2NUH@JS'(VI]R$ C#%><\(&R=1]Q[BQS1#,6\*VN<UIJ
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M,=,M(0H.K 0.S-YC4G!@ 7!@TE,BB)36BH"P%A;QP"Q8! DC1:C146&+&>
MF)"+@0,KFJG62+'$6SB![Y=IO-R -WL_2 YV*Q#6,(1=3'DVHO<J$D60P,D@
M'JU&5GJ"$LPLQTYS1MG:)B<-Q'DL3#F"1E(-'R%@+&K>2X&)QF%BTO%AHY-$
M\X2DH1B83@2+QQ*+3- X1.&8\K[!X) "%4L.%8OM5"F@\2"@,>DF28I:KKQ
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MC3[H'YMN^WM>U\G"P1]_F$%[<!#?],, )J)\:32 00X&NV'@^NW<,A,L^ X
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MNJ!O=S)Z@T%))S4'B;&7-KCU[.6;]\_!OG7<C)-:^Y\_>H9R/L:FO1+7-!W
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MO)RI+'_ZQ>1HD^D)#+*<E=P%U883TYF.?6R6-Z]GO@P\Y &#]:IW>. VO5/
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MQ!!@A*E@CR."%-9YG\HK2W'K_8MUSTIZ;#";^N=4=?B;&-^Z>\ #>&#X[5K
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M]J#5[:7[@*AT<_^:<O).VK" _5S ?G+!N4+ZX^N%S-ES3<%TL;0?V8[P77B
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M,^'9E-B:P4EY@*S9';K^[M!--<DY9ZPO@K<2G(>HG=!2$LFC*@KP-Z_JSK?
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M!'+L*GT&ONG#Z\QV9SOUN=2,^3[31F$2CQ?QZHZ9ZF7IZ5S*["<X!HQ=4B(
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MEY+>^S/*M0W2^N0],LJ!<JT=10XSA< 4DA$S3AT#7))XQ4<6BTK0'WAJT4#
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M)BPYQA-)VA.<S[N4T9%1&A?V4S7\NFI^G79062=B( DC$@/HP(9:9!VE*+I
M)(DV1@'BE?!U4H=_:&._QV"U=[$#'QYM%D?Q-/9LIRJ4%$[:I^VR6B)8[G,C
M+YN>0EIBQYVE23JNHM.14!R,8=Q$FK1>VA2O=^//:B\ ?W:N[$1=::\!HF6
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M*"!GQ1A7NG#'HC_T/O;[:0B$YX_;0%TCW"D7&F4M8D+^PI+N70$3.N+*$PO
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M1=@FH[$!OF<,?(D8ZHT.QJK('?9:$X^M")8(%SA?O U% WP/!'PS32(9-28
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MY#5%FBN*.-,2&8(]THHYJYB75HI<3&J-O(6-=W_55CIEH"8XX;0 *UT&QWC
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M=IEMT/LT_&"/YK0['=!S2')(+SW,>R%/>N%2_$F'4T^O L ]T693GMD5O7E
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MO@U]&_JN#GV+%TH[:7(R4)![#3Z+E$N,I.DZ:/KMUT/91:>K$)F#B<BX#L@
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M$+?HY,\<(RG/DFE>VQIP6YCG@C.=70!-ZP22;VS)!G -X!K ?36 :WEO=P:
M2_5KN+=&QL!RB:968$>&$1WC'JP#\%DYM['EGEBWJMJC#00;"#X\$!0ZV:QD
M$MI+T,EY(Z6&(#!R4('[5@'HZ^#;8@6@$&AA@O!,)<P,3 3F N&;D*EDJPU
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M$A!X:?-]Z]2S2JR56"NQ+C6Q5C?!71+O1(I(5H%1+QRQ-@D"V4CBA4R$4R4
M%\T:[=<V!']FY6J$OMH4DG\.G3](^&_L?-DX?:R=XT/<@V'C?_#%TX<X=/V/
MG6X[%G69QSX=#X:=?#)ZJ=.-J8M@DBW++A2PC/X,L;P@=G/0='O#4C/4][ZD
M9\UP/S4O>X<XDI.FGP).Z:#I# <(P5.8#1H$MFMPB0:#QKM!!S_0'7^O/,X
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MF5/G@X3.-EN.!F.2I0PNZI@NE4-"8-NE-"(4JW'ZA&35-%<#R4YP"49X,$8
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M*[1.<\F\VV<*72/SYO;A3'EO\C#UJ_]F?J$YE2YD(4?E#=%"<0+,2F(2%\2
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M4N513 ;2^4;V.Q$_]+RJ=#]4Z5"=>SG19(;)%&@YQ^&](Y"])<ZA:NXA:&^
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MW,G)=8-4+K"V\0O[]6SOM3-]D[SUF=;]VJ3V>H,G<(,93B[,S!XK=ZQA4?'
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MLM,2/-H<[,2 *PO6<Q$<>,U<=DKPK$34C#H7*SLM)SM]VQY[MW?WWN#8WWP
M&QQSTI/$O$/C31CBG+-$)Y#&@ 2I1:6G2D]+\&CSM!.)&B5K#-8X@)BSE4Q'
M$;B!S S25J6G9:6GD\OTA&+%<IN*0>?QA_&&6.43T3)[QEFR7H1*3Y6>EN#1
MYJ"G)'20D7(;E (3C.,I4N%,--9E5*HJ/2TI/>U,:$^&!05"22*\!0* 9I[/
M3!,MD@L\2FKH4AIW"\I!?0RI5P@-_+/;?.SAH+IM_43?Z\;KTU#Y?--P)>T^
M9G)R3%*;P#J?&$1/#<?_3(; C/6@5 W++2,Y=::2EJC*J90F)#;%3$#3$I8+
M:.B!C2P#94+IA7'3#_CAKE2G6=-3GSR>@PB9,QN8%\ 8VD4@A%69(J =]W>0
MA%AQ.P]N)]-\A,O.YY+FPR4E$ T0C]HB,=X+BGJCY#ZO;5S7:J8B]O$C-KC,
MC(Z114;!,MP+P:.YRXI"Z06KB3%+BN3)Q!CJI*?)>*($Z)(88XB#;$F65BOF
M@?L%AGXJGI<6STG&[#4OW:44@.-6>RMP-SCO>71@JP1^6-Q.II(P:4(LS>-5
MCI& X9%X%VEQ.AK&/;76L"J!5QFQ'%#<AB14=JGTZ;0B@'(T:4Y%B-E5!]UR
M(GDR^<*+[*UGCA@4P02<R<0PZ8E%P6Q "9-YE<!/ ,]"!Y4$2F!J.*2$ZZY!
M:DU#"M;Q> ?)5!6W<_FN)M,2DA#>>U8.MT1!($E4G;U(1.)Z>3!::,VK"%YE
MR'H=++72*"8C!%/\5Y2+*)5(4D8OJPA>5BA/A/ E#TJQF(G+E!)@+!.?M2/2
M(JQ#\%IE667PZ@-:I!08+K^RS('0S HN701FE&$NL"J#'QJX4\'MR+-FJ#*G
M&#@!ZBFQADLB'?#L<Z10VF$ODPQ^0A5%_GOL#SIAU.0YIMBDMK%[,SC;_C>*
M;\^:5O28>4A+ RB1@A4Y@$W:)B>DESI $E98.JLW[E4[X^=\\]N7G<YE):)[
M?$ABK^VN5ZY2"6D>0CJ9"FAKC?:;2LA'65@"G$5B.$_$"HT*1N!&1;6VP9Y1
MPY8HU69!F8 5OJ?!,9V#T5Z! @F:29]\9LFHE"(/(L/BX%MM@)LB=S*D30TN
MFJ6(7 .) %!!G/* .H46@?&<='#+F"97L;O@4T.":1>4L<D*<-;X$*RC1FF1
MDTMTYD!8Q>[=87<RB,URC(PY2KQ5:+YGE+\6!3%QPEH.F1L35OF 4,7NJ=R-
M0'/IA@R2@@ $L> J:D=9DMS.GD96U>8[!O!4800JM-,R$]2=78F!:6),CL1[
M+4$DC3+95K5YU>%KJ/0YHX*<I(8,X*/SVCC!F0XY1S.K]^UJ^%:$SH/0R2AU
M,#P@D0)!+BW!KN01G,"(X%12H0SC+*]MX"\5GRN+3^NB-:AI268C).D==RJ"
MX8DR[RE7M\-G58T7XI":C%)GZP-70I.H2^4S5(N(=Y")T=0#6 DLY*H;/P'P
M(F!-\M;P<L1",\N<TT(*K7CY<^;SG!6\=PG>B;ATM!I)ED7</!D(:)>(3]$0
MX$&Y& R$M+BX= 7OTH*7B\A%EAP@)HA9.FVR#T$8A*SSP5;-^!Y!.AF#EB$F
M*2@GIA3. J\,<5PEPGV2AEEJ**/+IAK?]'#UM:V$EJSUSVTZO,^0!#-SI[Z5
M8Z(H0Y!&>.&"!.FRYSIJRECV41MMTJPNMKV^*Y-T76Y;]:_=G*-V7TZ%I57T
MDH*W!)"+"*C("8H001*%8).A'I=O0?ZU>1%R3ZEOMVNR5BGA1Y2@/:52&2J4
M+@>1O,ZJ' %6T3@CQ,S)*E=00D7]/*B?#&E+8YF0-!*F$RHF"143;T,F5F6K
M;%94)KNVH2KB*^+G[(I@J(HZ*BTY QF,C<JEJ#SC@:(N;!:D!%1'PDV98#)
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MM9<$$%:8[%DNL>"P'FY<Q\!WEH$=Z%HV)::82S*KX+E'YP;/E(5 N>ZB5OO
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M"$YRLIQ(1PT)2C,26%3,2.&\,IU"T"'!M?);;0S2^B*2T-**$*1GV!7)&5'
M..CZAM\V"&P&[2U+J5CM2:+%$"E9Q+(U0R+V?G>,J5V.T>Y@X"N!@>""<ER
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M&:P"EA/A6W79+V!=WP]&\?57QR3PVKO7+X5-SAGA28DJ$!SF0+SFA8@H@K?
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M0;82[7DBDCE+;'+PI\3F"RP6JLV]!TSI+0C?\NE<$R0_1Q?27?0:_0(1X!H
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M6^3P"U T$O3#87J.[(V_-P802)JJ47?4<2EUO(LOC:>AP!&0P+(C,@KXS>E
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M/WGN6S>TO /!.PR"N_)5=R!XXR"XV8_5!6IXSHHX$%$XN06K@(,F2N9H7-*
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M/D_[U5'_Z/$/].]7WP.'?W^*<[6?OAO :[^_/GKU%WOV^&3P[/'W?;C?^6:
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MG:O_JR;-0F=Y5($$,\KJ9R>+9)L7-2/F47\<0<_IW5_[\YOJ1U_ E#FXX!O
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M<S*;K!!"C1,V"<1 FJ]RHVG!U=$%/\1X##;SGRS[-6"?_V:_Z\WP!/.TOPC
M-D2S3HWK_1J;(MO)EB2>=QE8^?1I;0G8A',6#2"1UA*L#17#IL'?RE>:P"<F
MPV9L,Q";GA3+A4W@J08>8SBE6@CM%QIBNM)3KZYIT@=J?(-]7>$ZI>FL@[T=
MA^WOF!65L<H;7DPU:[H)9Z11G#6)E%A!.Q_Z=+!R+/4J\/J;?G[;'-)\Y8M6
M.(_:OCH+[EY?_LJ5-E8_R#XM0C78OF?8;A-<J5WXF@+]O$D4;"H3UN.,:_T5
M%KW9UAOH8&A[F*>XJH+\/\]0P23KA-IZ34:=^M?UF@M@:O+)KBQX;TG*/EJV
M/\)#:KJ<WZFRX;^!NV\WOVF_K/*'*-3&Z&^XWC'O=SCF_7E[\,_SQP>]Y_&D
MZ83[:(0*<YM*,W^5_#H8S8Y/UM]$IGCZ_%=,=SGV9YB5,)=%O_SR"-.W:UNQ
M=G),S7ZH_L['BP#_-]5R7P;\FP*797.6171HD17!*;.]FMDT3Z1)_44K2DP_
MKG^ SA]/P*P;5U=\)?+>_?P._CWMA_Q-XV:J35K[H\&\K5=9.#@J(E?_JU_0
M RYE30]J14[]6!/<KNV+VZYIL,1:M^)GDZ:-3&-V-)K0BF\XKF;CUZ?_<(TP
M[F3S3+4\N$T(:3TN.>08?>_[C V"GY_6]K2-T^4'O^UT^4\?27C+!.I*2;9+
M27A72O)UE9)\L#1DHY3$B>ARBCIPZ:5WV<K(,PL\%A:UT>D+;55Y<='@)M"N
M!:3:YF/;<+SZJ0;2YZE=U=U;_3/84;(VSYK.:Q:7$0 ZOWF+8'&M'@\3#/QX
M>N'Z-G+)+KM?@]_-*[5FIOD,(.6UTI(4UU8(%9F)19;"@I<V9V.\MU;JV,S(
MH]2NUV(_.?JQ<RM?V4OX[,5OXNG;E\$)%[5F!'@.$Y-")K#)E"B?>+*I."6P
M=\<%SN0M$MD@MC8!\D>DL676[&KA[SH=+AP;%]%5DR"Y5@N,)%CPVGF\9GA=
M5-B[?H.FJJDN=[4B:[[B#W,=^J2&^>V"_RYGOV?#'J;WHWW'U6H>Y:D_;FST
MIOXYUV:&:&ZN%5IO<"I@65.&>X7;_IC#N-[7KM[VP\\VJGZ.>;[H]&1E9<N+
M-XFN3*Q?>G.M_<4Y7WK3.:Q<=3\OHK!+X&R#@,HJ&EV@Z=X!S]>383M/!]BD
MV9X_<!Y-ZOT[^\'T)**Q\!S=)A%]03A>YZ!74W1\^\<CU!&'>=5*6;J'6F_0
M?_L^'N&/V(>C^41S=2QF'+9#>RXP79Y@8S3XWK+D\9N#7E6RYRS5&BN-%K^:
M![QPAK6)Q.]3Q!>I(1>92VO/<EI]*@O/435I6E,&4Y>K/P?;TLW5_X7%L&;%
MK&1GKETAP)I[_SG',9_#N?.N,5N6M0H;(=\//EKCOD6<6P+;8E5W@'Q70<NM
M(LLV[<R)IL7+VD<9WYNL]B!8O<0F*1ST7F%M+'8(QJULC-&T\C96V39C6YHR
MCV6G[EIML6@0N+VV.:0M%[4:1D7KODT!1Y!K263>HAA)Q<^3^U?OCK=J/TL6
MHU+:SJH3."AL1MQ&<>\ )3R92YBK":[FK&HJ_%Q3P)[+=;OA4'W".S2^Y<O]
M&UADO1S3M-&3&5D7?T>RF_>?:8%FW?O2W+TI&%KVJFG:EZZF8]1/U'2,!2LO
M>F5^R#9HB!6+AQ9OU+Y(9VV@:%T,3I<$=7#1ML &_#R#?Q?#C'%ILR'JT>F"
M_5IL0IN+C@K.ZM</KJGI"\HE%Y%)GJ2BWHK"DW8),P=42;IMOJL%)?-?KI,R
M /38*/L_(EY\Y1K_TQ<_8 +)2RM9BM9;DE0H1'(GB5->@MY/K0TL)E/DO0=<
M;*O\H*,MXI8H06O4K(+102^,T<$YK9]90M]%;#+OB_<6%(G>I/E6,SP0=!-0
M/^Y"L>FS-=-B31(M%?_&Y;AH)O5[[89=6?SW-96[ZOWSME";DFPN;O!K/PWR
M$".(%[R]ZBC8+"8[7-61JG[2& %+O>32I;6=G3"'[*WOM]C25"TN>F/54&CS
MK-6ANHI26.TTB2<Y-2U_*B+.6R*LP-X\*]</+U4(X$L+F2'N0F6+D/1[S$T!
M(#_=2=1L7WBCH6 \^;GJO\"+M3*62ZJMUXJL1X,9IB#5%(@3U,"'QTW0?)!K
M\Z?F7FUH/RT[9K0VR^\9\&<<VU#_W#;J/5P)H6/$X-^_/W]8VW0VO=5 2"XS
M4-:[6*T=&B+:\;CI.@WG5[W[ASV\V.+S[3*7-<.U$\UDM15-G6^SC+3,%<]Z
MI[8JL+GHPAO2*H9M*['6Q[I:_3W/ EE<!Q@GYB:/Y$W-^%UDI\PF37OOX12E
MP#S%91XM;WJ1U'+;_AO@O44P&W11V.":" ''5NV\1=,R-,7;/&6\6YT;!C<Y
MZ/77JR7'^<R?U]A[H]J=KUUB]:L-HK1["?M5>[K,+3NX4O/.I-FE"CFU!]AH
MGL7CA[/2]'=!R["9FCC_SM)>.\F#>2?ZV1"LU3(;8%NT&F@Z&^2-_-[#]OA
M@Z_EG&UFS]KI-Z=='1MS0L4:O4D-@?6G*P"\1E=KN3QX//7=.J)DAA".=;[
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MN4JB&&N2LP\\^TQJ^DQCXF\TYI/33I-_TYD,[[8/O/QTHT6>NO7L;87JF^>
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M!?+RIT85\FYW/'1MPQ$UX%,E7"5<)5PE7"5<)5PE7"6\RA)>P+)TI;$BY=I
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MDE7(IWCB^1)/*!]B6115\R%6CM$^MQA-Q&1064Z82IG1DD=B93($\\0'T,)
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M20DE.-_8EINTE@:\3\=PR9X@KB1K-@4"8\9"@\^3HWS1#O9"IU\J+=1,SAH
MK!)>)PDOHNS>@Y.XJ==2]]!%]M#7<VY?3Z5 %(% B)!56B4)LF0)LTF9D'4C
M%Z%$55<CJ/KH(59)K$IXW25\]39Q/[F\5^P4DW[O=;]89+]H9_,R&8.RU!.&
MD#>-B(98KQA!C5J&;%S[TG9/U>UBU5P@2X#9C;V/53.[!=+:*;RN<6 P26*>
M- *2)>*2BB0&5%2"\)3JC6VA5JD6WJ,'7-4>5HC2EN#5K93V+2FM[; U0D9-
M.1#G(!)P'HFAAA)AE5>:4JX\V]CFYLX91JN7QSO"'KW$;]LNV[DRCMQKNO7V
M+O2[SI\:-;R^7;N7M0U U?!ZE7"5<)5PE7"5<)5PE7"5\"I+^'XS]:YI%_I\
M1ID^Z.]=4*5?CC7I:FDN8&GN'CP_W7]!/Q5K<__@MSSVW]X: Q&C%\09*0A8
MXPEFZY-P$:@,"96B:6.;S<<U*P)7 8'?MF%O1>"W0.#KBPA$%,YR )*<<P3R
M[P0C%\1(ZSVS-,6T:@A<4FK>&OIZ=KK#$23R! R_K;MG;3W3U?=?)5PE7"5<
M)5PE7"5<)5PEO,H2ON>3F1>MS=UNKS_HGGZ>&),[T9<*8?'G0?_X@JI]E?7Y
MGU'N035"%S)"?YIQ WFYN_/RK4B.15".R* % <T<P:05L=Y0;IW1RKB-;3Y_
M[K_F*SXT*)?N JJ@?"A0OIX!Y<'+MZ" :>.!9'IE&936$PLEFS@X[APR9V5:
M'5#>-@'(]0=YM9#3_LFS<NMA_Z@;.@5A:W.2\T<\PIXOV3^=U_'D-!Z[..@(
MNMDI>+M+JL^5HFE+9SU8;;'S#E'D11ZD54I&R"A QU C3TXXP;T1;U_>C,YF
MN@2-CC:\' [/2KGR>N)\>=2UVW)J<P.2:1X(8LK4A=P1*X0F@EE%@V<NB;BQ
M+3:EUDOR:]\8*W=0.KXM7B_CM(>$ZW??; H6$/TJT=2\[K4LCIK/HW[9\T=G
M16"O^H,RBIN%XBJE+9'2NJU(N49(LFC1QLNL@VE)K!&4 (^1*168!+FQS3:U
M,972*J6MU',OXN,Q@9K(K9") @IC>?#&);#>H96(E=+6F-(^7Z0TH)*')"TQ
MV9HDX#0C"-*3J)E!*U+*BELI][C)EE;QL7):Y;3[5].B RDB4DTQKWF-P7H5
M@H!,<L9253EM?3EMKY70Z$%9"#81HTJA%L5X5M-,((Q"?H<RE3>TC6W)-M72
MJIU53JN<=O]^?VL]Y10-5<% 8-[99+P)5@MN??[U:E*[\6'>RFX/SFXMOYJ6
M,C@A)#%2<P)2&H*<)I)?#-3S4(JME^X#TM*[5U>]#UZK[O ;NL.%EE1QFV<\
M2(C!. Z6&2XY5<ZEQ*Z N[BV!=?8-SZ^7P7N$H';\AXE%H)ER E7: D(%8G1
MV=3B(J$#CZ7 ?O$>98NL:B55*UFIYUY$*[DE356M9*W(K>U'DBXDXQ+QRJML
M<V7]Q%*AB(TJ&>,!P/AL<^E-#K >:DDEMJ= ;(MD6;GH04BNDE7 6#FRY5"B
M-8Q*0=6]1_HJ8]TRWW'$6-;&D$I"@@2>,F/%3%9)(9&1,<8U4Q9+><;J]:Z4
MM;Z493(;(;6. 05NA>$TN>@HD]$IS6WU>J\QG[7\0L8++H5$PJ5A!&S6P%S6
MPPF5>;/R-&G*W,:VD)M&+:LMY3?GM-N>,IX9&/_:P%:9XF;22G_%WAD./H\F
MBC6)I?PNAXIO+*+'Z$F3!FU$II0+!A1W695+S(5((_7"Q##B1<8%JXFE#TQT
M+^<22R4MYQLH+8ZSK+@%(PAZP8CT'*/PSONFVN\R$DMO02=+U]V6@M=5([:;
MZVX+/_YZTM2\[K8LCJJZVPI26BLT$"V"-SXK:Q8PVZ+.$&LE$!F0)G#"4X%+
M2BRME%8I[<$H#9(+ 1QH1&"H;$A!<O0<0 @C4J6T-::T5D! )B=!6R#:1U&Z
MGPB29U@2::."0)%CH$UB*1>5TRJGK2VGA<22\"S_0R5D8G/!*^Z]R.06K9.5
MT]:8T]J)I88):CGG1#CE"$!BQ$GT^<^D (6DGI<@I]A4=KZM4^6TU<#V4^6T
M15(XLJ*FE%$!57 0A<'H> 3'E0K>&'8-J=44CO5AMY9?S7/EHC.>R*8*:0Q
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M<TEL[=!9$WTF4GE.(EC&YL>#](:G =XEF.<%O$V!MVZL\ZB9,XXAQ7U$/.B
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M@+3N\=$A2$>\1XD9AKCT"5D*^D&. 9>Y,KR""=DAMY[F+"#= ) NP&E10/H
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MT:,@:$(\>88LJ (H!(PI-]$SSL':+WC=4+PVEI6@X'4A>*W;ZS&Z1%G@2,0
M6CP."1EA,9)6\%Q)3<J0O7,/2JE8 +O"@&TL2*  =B& K9O=@% K%9%(&)"M
M/#&&C(\)*4IB/J_DG0; ZC6/ YBD))R4_*,S60E7O +)0TJC+6UH-CNI:P/C
ML]HDOQ*A%#\F_,+U<W#]_FQJB$@,2Z X(YL21IQ@CTPP GFFO#,\):XJ8VK6
MQ?K(U++<I-@/:^\]DV87_GWB_/NH)V(*[S;)NW4G%J6"2LH<8IA$!"0+#"RQ
M1<IJ;!/VDCD+O"N:*Q]5*+=0;J'<M3C6]#/J+<<@&N/ENK.2696L$19%8&+$
M.5/(.J\0H<9A"H9-JO(>/Q.JJ21+A9X+/1=Z7F6W<Z'EI=-RW26MP82AT1ID
MI 9:5CHAC;5$-'K& F5<^HJ6,6ZN6,WC,7+ETOYU9%TW7J9O&7>J?78"P/%5
M5IUI/R9/1)G%GIOKS'9\-AQUTOGXK4XOQ-[H.3(5]38*7[%-Y\]N0V_/;D.W
M]8^RVV06R%CO],YL10,5IB2GW*5 9>2&FV#SYB*FUFKB5))BP@_PG1A>9IAZ
M&92)A@45,6<>VYB3$3AO!7:!"5EET1D+]=F?U8Q<;</.0M(&Z7L-ZVTC]/,>
M Z5USP(T+"="&D1XVD4,+=L+P+27?WZVG=ZP>G.</OENR95:L5.=4.Q_S0<9
M0V<0_:A[WNKG,XL P\]'U97!\*AS"M\?YR"O[O3]QJT$:!UNM_Z<IRVC(SMJ
MV4&\\LBJ!=5;$9YS4IVLA ]!\UH1[M1/U<M!/.T/,L]/CF$^:WT]ZG3C+8^\
M8^.KQUKO@7=&\%20&2V8'0L_8NN_9W8 7VUU[>?MV?75NI[0Z0H#G-C!YTZO
M(B3Y<_QST3S^?RZ^Z;4B5J>V,^Y['N<>?*YU E\^&N;AAU%Y'T]'\<3%P1AK
M##]K91.J&O,LJUM?[;#UCU6H9/$?Z,A&2_YN_)]WYQ\_A--<!?/PX+?CPX,_
MS]O'W2]['_XZ:O]Q2 XOOGP[_ #//W@#;?NKDS6"PY._4OOX3_I)$> 6DP)B
M.,=^<$R1YC@B(7@@AGO/H]O:D3><O&S!\NOF6<US/L]4+ZP>0IGJVZ?Z\.)3
MU)HFEPA2-M>(-I0@0V-$FG!M*,^A WYK1ZC;I_H9,.[P%"@:U(#N^78M?]V,
MN,T$.);[CD=.-;99$>16@+V><ITBI2(G*N%/N0K*#UF3Y%QZU_0HHJ=$.M6:
M\CL3VMSYEQO\NG,K'4\HC]-M5=UW1L7YV@FCHZG#Z<H7)QHG_OX5ZT"[/!O=
M_I4K7.]C7JB/Q.RH154+U:;LRL^CP7=U]7-$#N3W%V03-/BY[7ZUY\.M7Z]/
M#LQ,;1SK0_ 8'1TO"<![?U"MPN<@TN-@K)2V^R-XS*C?^KV?E\P0Y!B\JJP#
MFT7]ZT[/]GS'=EOO1_#&6#GYY:QGST('KO]S(?KC':>O]<NE:ES/&]D<;!;7
M*75CIPC;OE5[OV9.-: KU$5&=@P<V&^[G:$')?%L$ _@_K]U^_[+8\N&\XEL
M.-[[=GC\[Y.]D[_ 4/_KI'T SSH.1_L?_A3[!X<7AQ>OOH(Q?G1X\?F\+AOV
M+EYW]DX.X>_7G8\?#@D\^[Q-7XF/!U]$^[A]O'?P\N+C'Z^/]W?_G?8._B3[
M;S]1)WD"(PQ))13B+G"48\P0CI9KI;Q, =?M,^,U=8D&;AWF4F#K8*DY2Z35
M)D6MMEH1!.YI9L'!&0 0QAL6#V@'X^&?L9FOK>L;[:.?/G$]U>Z#;->D-):L
MK7%&W-;(?FL!B4W-E\E@9&MGXM\"[FI]!<VG=:OR!?J/R^&6348"L9F,4-.&
M7X+J';3Z]\OF[E^V]E+_0O2)@:Q]\><G3)+6'G-0N*1!W .XK)(!*4PMDPJ4
M(P[KUVS/AEG_WTK'GF^6'QAN4&;Y'K.\O_OFD\""4,$D,B97 #&)(<UX0@"P
M7/^#*HUQ)?ENFN:IP3TZZ@S"I;>AGZX;U]?5\&?W6!P/M+;+XKB7G-VCGR)G
MC(,UC5Q.M\H5L\CHE)!C8 X3'QP8P; ZR/:L$78?$GB@J5WF^5[S_/;B4](V
M@8+BD0B4(AZ,05HXCBB++D6@"*^ ZPG?GJVA_9T%4F<P'%USOOV8";9;]]<C
M!C%UX6O5<\<I["I#J'-R"LW*STWCBA6M: ?0HL_#ASRLT[N!Y7*??M#C[K"?
MGY%]W^/!L7^#B>>Z\4H;LTO\BA=\+M]W?GRG-[*]SYU\4PM?'56W[@PJW[ _
M F4R%R#X>M3Q1V.]"SK[W2_]Y_;[[<ON_V1T[C XMPT%F4[5L/K86>_[0(P?
MES]G)\V]7$K60X?'+HM\_3_0V_PR7Q[W9WF!C#.V6-XK\/W/O3QGP"C3A!Y
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MSONA:# ^Y" ]P[2QCK"QBY5B65RL*\CL;V9<K(JG*(Q@".R<7.!12.2"ERB
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M<2 :J+ORB%L]\QZ)O:R4W1@:Q;864T!6]WS>&<%#_4\A^N*T/^SD 7\^B%U
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MP5GVQR?9[]/>N:4I(X>4%=W.?E!69E+T+>IK[K*>VN!S")E2;P5PM),L,:3
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MUK4S.A>'7SW[S-62L6ZD=:%G@Y&]&0LVIC99&&E=!SGU<-)Y0V=.$+E[GR"
MZX*8U;*UB0.Z@HDFG;NB<YD2[4L3*L0FVE(-=$Z&.Y%ZG3'&1!4PA^,3M7 F
MG0=+9P^N>(QD01*01\J)L#LL BU9M)/.G=&YG 0#/G*K^C2*([5L6S#"7$Q2
M!8U]-$*W<GR2YFG* =,9.OL<7&XE= #?I1*4'H;CV5R3F1*],SJ7*=&IL_66
MK2FQCJ"06(.].N-LSVKF@J\81XN9 QQ',.F\2;J,RB",OD^6@(78N= E<'8U
MH TSZ7)7=*ZG1!='I<31-3&JWPE-#'$48Z75WDOS+*-0WAU@6^Q)Y\TL5B0O
M4#-;<.!UQ6O%X'NT(WX;-^II/^F\'9T+R];:[(D2FU8(#+1@#8L/)O4@DJ-^
MK]+Q"= ^Q6QGH^AE2O1739Z<__SBR:'D1/O9*/HWLD< JV_HA7($UP,VBMPM
MIQ@4WSS3+G<BJ%_^<2TGNF5O*W0QQ5<8[2[%L&_.2*F]QI3UOWY\$C;.[)KU
M7WO+IFNU%H$@L7H@]MPA."RV>$CL>YEL[HC-M93H!KXW20:S%P.2K4$;L\'2
ML!272FKU^&0V'3E<-%MB"=0Q(S%(Z@P]^=!92<U9'9&)YH[07&9$EY +]G$D
MC5:WS=B]$:II5&:V"#+F,;;1$6BR>;!L^FC1MY1:5#9#R*Q?5@I=4HSC='J#
MO*Y7ATWUTY]:-3^WB_/)[.V8729*,TO,:+N)5-I(]RH&1R$@@KHF8CG&XHX5
M4/3.?S;!/5APV6<>,W-[ZAY4R%DM7Y>K1>J^E;I) ^D)[C; 7291@X6&/2NS
M,.:EY)X-I>P&N+H^3.@+3W /']S,+2*-YA<B@)XHM\B,C9+S0?&=X'[HX-+R
M+"W:FGQ!,*%Z,N L&L$.QD,."73A:J!)[N&3"SY1Q9Z2"QE<<"(L.?@$M7!E
MZC-3;&>$+L[3&$JTB<#4QM4 A62(F<V(*A0(')/XXY/-4U$FG'L+IX71Q=9;
MZ8' 9R2(7O1?$L>F_A%/.'<%YUK?:0_JJR(;$I=U^U2SA$6L"<YV55*A&,;A
MS(3S@.',+E;?F%MJ((V06[-2;744'/G9=GIW<"YV3B1U/KRM!ETJ!@JJ0]K8
MF\B!! M@@%%W[^>@P,.E4VD,6%FM6-TI.25,E%U*L0-@B;))%N?T2+="[5H[
MZBSHR77#MM)H95,,4D"3,E%;N20\8TD? ;F90G&ZAZJ$=^">I+2>;09R5%O#
M-LG]P.2NY667;F4,2C: (U.ICYU7.ACJM4/1[[&32>[ADYNR2.[6^AX0R'JQ
MC*GT2LZ3]+))7=,D=SOD+BOY(^>0 QEJ12UE\&PDHQA/W38(GBNU?21WUZVL
M/P!W_^!2]!\OE[=WJ]4D\QKS&O,:\QKS&G?_&CNJ97IV_O0#%3+=JF+H^.0_
M^:+RY>F3W]]\<?1>:IK>;C>G687TF\W?&4I M7I U&<4F]E1=$(UN%IG.O4N
M7(3[#S]_MG3NL=<BZ,BT NKA]]@,91M,UL<1BG.UH]7G.\ZCKL.E,]98+,68
MH63 [%#_PJF/J0S5.]BDV.%5Q_[L^?>FGC\SU[\YT;TMNFL9))XL2S(QL*++
MXHRTD/6/%B/&RB'ZXQ-W+\QSZ@.&U[> *74*)53P#24BD\NC^72"8NV$=R_@
M76:8I-$\WJ(W5I -4"'#%+K)D5T6)1L<'9_X>_K%A/=@X>WL.RJ:&"6#+Y8M
M,@9/7%-#&V?[^-WQN=A<:^?*39K1N]X,N*J;:TABI)=(DEL"R<<G. L-#YA.
MO0".J>8=6QYCD3C9B!Y"]>K$]BY;*GN86^MFZ"XS39SG&)-%@\0C/RRS4IO(
MI Y-Y;8'QC%M\)Z+<VL]7'C)^NS$=T+5ZJ!F54X8,+3 !:C*MFJ6)KP;.K57
M%8<*\'?VP9_^;+_A!#4"-=/$Q4%O-1+S*/ O%0@Y%!FS(>X1A4GOP=(;B@7R
MF7QA"U*#>DOJRRJE3CU=CKA!]O6D=YOTWO\EO15)N V/MH/2Z]D:0DRF@<5$
M#!QR'O2BG?0>+KVQ=4XMYUZ"0"B.1D3#2O6*::6XR?2(2>\VZ?WZE_06KE*C
M,INL1P/<BA$H8"ARX.1J$M2]-]Q+L[;B@.E52SG6SCD7AY!KE0B!:F^Q10KE
M.L]STOOAZ2V_I+<GS]QZ45/9D@'(XR@HL>$FWC-EQT6.3^(]\!OWZ)WT[BV]
M-<?1UMZ2[Z/AJQ.Q!5)']:JRNKMA2UG:D]Y-Z?UN83G;Y'3[]::EHN8SQF#8
ME6I\#&/G52L*^K"<D]UXLM.D=V_IQ<;@&C<(#:#EB#6'/K"E)JUCG_3N![W?
M+J-6Z-1D;FBZV&Y I!C&V@UGMH%"$S=JI/R]. ^,#IC>5 E7R3?8DSX#2-:F
M&GL0I^Q2F_3N"[V+J%41B#R*D3&,J6W))X.^-5/88]5]EV,;$T_O.=@GOW='
M55)W)B/\KQ?G?WO.]??WS7WSU8?,!O_BB_?[XK>\+[__!U^<_L _;9"C_C&,
M'J*0HBW>5:MR4$L;7=,20H>$DCO-'/4=Z?.?UW+42\H6NV63U10VX$H>W;^S
M261S;12#6LW')W'S61ES,-C>TAG!<2N1()<"'?-JI&;%[H*/XYAITKDS.A>9
M<J[4ILZI&$JA&*@]&NH]&6N#+SE+\WX$+L(<%W^X=";U<?-(TZ@YP)C9EZ&0
M),_Z(.0RZ=P=G<L\\^8DD\=LG*#HWDG18,K!,&4@L-!CX#&0>I_&]DTZMTMG
M<38VD4!U9&7T*KGE)"F*[[GXM,G C$GG[>A<[)TM2V'O];X3>:53K&'TP72
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MJ'7LDMVA,'!THYD34/,UAS&>P4XZ=T7GLIJF48HQ%6O(5V> FQAI:<SS(D<
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M>)LIJBZ/C"CX_]E[WQ[+CB.]\ZL(M8O%#- IYY^(C @)*,!K&_ L/.OUKFW
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M$F](Y^5HB =,ZUH3.,U%YUA@SMQ3CDY&Q7O.J_*\IU$R!\YWME4,\9S58;!
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ME0FN4MH@#^,EUX%8%'JU/D[DO!F<5[MPY%4G:U"2@9Y 5@S5F?."DP, PF/
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M]KH?48LE8Z]I)4"# (C;V&'US;NW#IQW"^?4:8O%Z#P0@F/])M-[IR =,.S
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MGH45A\Y;T7GM)24S!$=-/L9(T&6?VD*D/>ZUV;I)<_C3,]=[6C]ZZ'QG.BF
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MAU,V;RN5-A:WMM(='1RU]4"9U$9O^);)[T?9WDO9_L-'S16EE>Y]S%17IIH
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MB',J(-EL+_/K;4\<^8#U/ $^ GP$^%X%N%:?A%IEM(#<1>NL?:57:I9+*4>
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M[UZ"MB\ +"I6_%21*.4[%JM@\Z:6%@K:YWOILNF?;-%D4XSGY..)-D[K4DM
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MD1]Q3*2)8@=3:GQ#C]PPU$WB4R^('-O!'?/=%,%6 *@ \( !4!7A>PP :"\
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M&*Y-+2<@ 8EHZ-HN\;S8-,/84]&1/@CO4G0D@*6(7$N/# [":X2N'@51H-L
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M9A2J:H1] .#%6);)P1/B00S8:YNZ VBL$^JYNAG:8L?9#AS<N+('YMV/3RD
M5@"L /@>(Y(T]L'N#9G-'<,#XRFVO#BT212!6VVJM)]> /!2UP?+8!&S+#T,
M,7,@I)X>6MAOR8P\QP/CF%#GV0O''3CNKO)^%  K %8 O'L !M -+-/D8-LR
MA_F,>"[U(NY'3N@R(W14ZE8? '@QY!P:7N2Z =/]. ATQ_ !@-V ZHRX;F38
M5A2X ,"V.S"#@P%@$;+^J2)1RN$G2RY?M#-[6XN322W;-W_NP-!8Y&QX(DW2
MA" 9W\7OQKS @U$7[XL\3JK?\[+\I<A''_G%B&=5^2D_RS-!!E)Q]@E&\C+-
MZ=?'R? I_^W#Y.\_V3BR'._MKQ_2=Z\^VV\_L2]_?7H]>?OKFV_GG[ZZY]]?
M?OGK^\OT_-4OH[___",Y__XA?OOI\]7YU7]I &P0D5CG!).#N&?H4>28.OAQ
M/ I=XOL1>:9Q0(4Q4+PJ:@[+#FO<LN6(%!=))KC+:[52DC&@\W/'%3KR@7'6
M$@5JM&*.)[0\UDJY_-I8,$6I5;G6BMH]#5$\\7E2@=#0-0;])J/YB&LQL*H&
M' H,7 ,/:PTW \MJ+SE -]<^D6^\O.>QWSA2+2DU4H(>2=/\JGS>(9:0_=7,
M$0I>$"#1(9H$)AAT2L8E?][^\C-+RG%*)L^33+Q:W/1S\ZP&YH"UEG:ED/7D
MUS]?):P:HLX],:3>;7;4FC<W7Y^(KQ9P5G[G62>6X5S[M7%B7OO=38_U3US+
MW>JI-W_GVM>_4XVU=V.UUQO/+7O!&^[:WH_A>Y>-VVY.X3ISH@#>O.C3K#X-
M"\ZU<[AN6&JO0>FQ_XV*GUY\Y..*CR)>:+8QN';.R^MX;8;-(R7/6_AD$^H\
M*G9?7[<+6AS]H"69!F]*49%?7Q=O)H"Q9<)&__@ S?9=3?A:&3E0PIF[P(\#
MI8UBJITPU;;GMGJ>4;9F1.[CO%?X?!V>NA-%UF$V]0+U@@U>L*,R1R+XYY_X
M;I_E]?V0%"-">2V&TP9U[G+>]4"W5 YT5\3!EBB!A\U*'<8CXGN^83%.8FK$
MGK-Y_R(9=&M#Q-.PVS3J)H-N\CH1>7O]K2H("&F2D6+R!IR9\FV>X2B+',S[
M[.(-JGQ>5D]AHP7>^^H_UE_67]_/7YW#V#ZD?W_YU_#O+V^,MZ_^NGK[ZO/W
MM]:'T=]__FNXN-'R]M5KN.;O+W]_.;\Z__[F^]M?_QB=CWX9G7_YC_'VRZGQ
M]A.,]]>_T[]&OV"'],5<3^X[U#"IJ=,(4XT,G^L!L4*=.W: .RVNXX78(=T-
M[WSVIG\%+A2\'2B\1<P/32]@AA'Z#H]HX%+3"1D+0P?[,@<;ISTJ>'L<\+:8
M26D9MAV:U-=#;@:Z8]N>'C$WU"UB6A$AIA-9UK,7P< S#K!KC8*W X4WL-P
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MWR&>%QBQYX.[YM+(HW'$^A7]42"V/H@E2P$>BNW5.'7UV'4,W8E\3P?@LO7
M]4(&=K-M!3;V6O-[%,=6^UJ[#O=B_4P2,AXZL1-$%/M",#">0;(I92'K5SQ&
M"?PF K\4<K&8;\/:Z6[D@L"[S->#V(ATA]JV97H>"ZT0.X+<.>"B!+[' L]<
MG]DVBP/7<@R'$\>B411:3AA'3AS[_0J1*('?1."7#A89,0MM;N@ Z51W@A!W
M;T(7.S1Z$8DI8<1]]B*X>^-T)?#]%7CJ@QWO6\1PN>TPSP@-$IDVIZ9O$IN:
M7K^"%DK@-Q'XQ;A$3 +'"TFHNR%G*/ &:/B8Z9Y%B6M&ENG$$88]>R3O!Y^9
M\CDC:9I3K*Z]73VM6\Y/JF?T\!E/Z>Q8"]Y:(@!?!=>NT\1>&+IA[-B&%]G@
MBT419M@$',QQ&EN^1[8(KET"W3'C3>I:I4:W4*/OEH]\@9\<^9[+=!(&CNYX
MF.YMQX$>,MLD 3=XZ&#C(-7'_("%U0U=D-. NX1PQXH#[ SANI;+N&5ZE!M;
M!,:4L.Y"6!>C6H10BW@FU2,?-_B9%>D!]6T]=ET"5C#W'&(\>Z&"V <LJR!]
M)C'MR#=-Q[&X$6 DVPL#%A+?)HZ[14Q+R>HN9'4Q(.5[#G48C?0P8J'N<-_5
M \OBNFBN$QHL<B/[V0M/G:0Z8&%E(;=MVXL,DX,M;!,"JM4$@Q@T*PF .[:(
M1REAW86P+@:37"-@GDFX[AH69NAZH%@MQ]!-R_<=+PY88-%G+ZP^:=:G5/NY
M<[OYMS'/RNW\[G5K;/4/<8[VZWA+VK^6I%=(LPG2+!\U<JCI&RX!D"&NAV47
M')UXMJ4SV_69"YHBXAS3Z9;;I"_UCGE$A>^4@-ZGLZT$] X"NN1CTXBZG$2Z
M98'Q[C#3TD,:QCK8<69D\-@-+#ST'"Z7WU4">A ">@\>MA+0.PCHHF/M4,Y"
MQ_)T[L>@00VL661QKGNFX]J199J!93Y[X:\PUI6 'H2 WH-7K03T#@*ZZ$Q'
MILDBEP?H0F,9(6;K) 03-_#=T'"8%7H4JPB&/1'0I[1_?3K*823?1>K2$]N\
MWJL3?<J^U#)N]TM>S"Z"PII-ZBU_.D6<$2[UNT__@;'_Y[\AMA#P#%>/T09P
MN$7TD&%W(,NS X<0T\*"\N!GWP%L5(B]Q[*Z<W]:R>K.9'4R+ZL41-)G7J3;
M04 QU\30@6N9[OE^1"P_,BB-G[VPE:P>JJSNW+6^05;5D?#="?+;!:7KAY[/
M(Y!<'@8^"+(=ZO"7J9NQQ:C% CNFKBP,N-S$18GR08CRSIUP)<H/(\H+.MF(
M0Q;Z+M=MSM%9MVT]LB*J@Z,>VQ$S#,>F*,K6BI-3>Q'EI[3O_8J/"^#S[=WU
MIQ$0W+F[/DMWA3 ;(<SK)0^=,,^(G1@0!M2 [C@DT(D;$YU[EL_ASR@V &$<
M)^A'.%#%ZWOOH2OQO(MX+A@ GN\&+":F[EH.%HVCIDY,2O7 =*CMF]SC 8BG
M[2KQ/%#QW+E3/B^>RGC?G>PN^N%V:%/?\!W=,"Q4K:8+?K@3ZTX0FY;K,Q81
M)HQWMR=[;4IZ>^^'*^F]-^E=T+RP)M1U0T_WC##"]AI<#RR3@/_MT)AZIA<S
M#Z77N)/KK7;*MY+!#[SDI*!#C60,Y.62I_GX"38*W:L;WJ[!:<9>35>@R])1
MV+0K;'JSY+0'84Q#9GLZ]F77'=/TP+*P;)W%8600[OL&B\%I'U@K2B:J"/]!
MB//.W78ES@\GS@NF1NA&EA\'OLZYS77'=F,]C'FL6R2,#1('!HW"9R^L@6TN
MGT=5XGP0XKQS-U^)\X.)\Z+?#R!,B.?'NNN8H)UMAN$Z%NI1%()FMDPG#")L
M*&/[=SE&IL2YQ^*\<[]?B?/#B?."=G8HC=W(Q QY'_/BK%@G'C5T:E(G\ ,[
M"AE_]B(8^/YR Q>U!W__@8"JJ&E5%S!RF&UYMUZ;!PY+]Q$#F)+_;$B*"UXJ
MP-D(<,Z7O'L:Q9[!74NW!>"PV-=#BUGHX@=N /9#X+M@/Z@SZ <JI??AVBLI
MO;.4+I@%G')J$3?2+8\'NN-$KA[%/@,KWZ%NQ&*+NJ(KK=K;.U QO0^778GI
M7<5TT1D'R]T-J6/J-J=$=ZCCZ@$&V*R(^QQ[Y04^>?;""E0"S8&*Z7VXXDI,
M[RRF"]HTH"2./"SL9A,/M"D8OF%@$E"N8 TYALT\QW[V BS??HCI4]IKEPT+
MZVGS@(&6<;73_@!>]JCX^OPCO\!(WP<^QC,WV<5,$P>Q,$T(L'S+5:/5'2+4
M?Y:\<MOP31)$1*<.9;A)!Z9^;(+E[Z.W%IF^Z9B8#^28=ZD]I:+Z/1;LG3GF
M&PNVDMW-9'?!NO"I9SMQ3'5&N(<22_3 H8$>F#&X #8S(PZRZZFC[8<JN3OS
MU95*WJ-8+_KVW'-CRXZHS@-L(VK /R$/3=V-'(\S$A /^P8[ \^ZBW>O!+O'
M@KTS[UX)]CX%>W'+W234MUQ7=T,[UAT&^CK$GBJN&WE6&%D1MV),B#/N5(BY
M!UON45XP7NCR83""2BOS-&%:*V3-]^#\/S>7OMQ_X\%@+7G>L K_KDFS$O56
M$6BOH/?#_NC3;VVP@3*P+=<,&7&(P7S'H"ZQJ.?9?N2XAD4#ZFY17?\>&\PJ
M!;(K!?)Y*5CC!V9@L9CIC+HQ!FM,G<1AH!L.-\$J,&U@C&<O[($;+)= VC-<
M/=#.T4[&NVB8*DQ7F+[K)DW<M"PP!L%I9TX4^$'D4&(:G+C$H684;M&006'Z
MX\#T!:? M>,H,KQ0=T(GTIV8$#W@X!1$9LRX:S*#&OS9"W=@><L!>(7I"M,5
MIO<%TP'08Q^L\Y#9W &))E9L>7%H$Y!OTS2M+7IX*$Q_%)B^%,$-/,NRL?DF
MF.2Z8[E$CQB+@4.9P2+?]P/F/'MA6H-P194%!>H*U!6H]P74 <@#RS0YF.#,
M83XCGDN]B/N1$[K,")TM^KXH4'\<H+Y@J,<VC7P2Q+II6Z;N!!'3P\#W=)]Y
M#F%1R!W7Q/.OH;^\W_Y(,5W$_W^J2)1R^,F2RQ?MS-[6(Q ]^N)_X<-V'B-2
M7"29&(XWCXQ89#F))_*C)&,\ \ET!70_L/A;*/[OAP3$A/):S%PKY?Z8-B[R
M.*E*C10<,& T+I*2,RV/NPM*D)]2@_]*&#')&"F8/)LWT$BI7?$TQ9\E%T(Y
MT"YX!B*=BF(^A(V2+"DK%/%+WK:4+366%)Q6Z41+,EH7!;POFFC5D+?O/-%.
M,Y1>[3=.TFJXX5@'<K $!H;C%-_+S[<=+WY77%.E2-)BC2G]DA?P)6!6!F^#
MU2077-Q?M#N4,#UX!US!M"H7]])APF,MEQ@)%R"HE0C=(_*5%P/MG!?TJ\9R
M&&*65UJ[P2GN+?B(P&2:@Y0=$<2%,,:T9O">)%NF+<R%E[1((OB>1/DE'UP_
M]XY"W:SAB7)4756GW^$A,/Z\2' )<&AGL'0DF_S/_P$=X_]<7O]X$#,YWVI(
M*H!Y6N.[X.]A#034AH([](*GN*NK(>I<)I5X#=!ZC84= #4*2>F&1C%HFXPB
MU>#3DL\\\T3[R,>D0/*VPRHU)'$%_^$4QO!!$B5I4DU0(VFC'/1K+HZRXA#$
MBD\?W$B07 FYMM-B<%H[)>"#./F&<RM+#HL#LIN"R+?,5<Z.!5XBR%L(12I^
MG0A)N67%3[0WF8:PB6\>-.P\,X!B[E3N+)%GQ EI2&8JR2,MD33910(PV@X?
MZ3"N8:6)("T%]!=\3;J"]&4WXFZW'L?0#+D\Z92)@.7'",,R WL6R0#&8/3P
MIGE,&R4E!>J2C.=U"5\5XUQP7W/K'/FG$-$^>&8!JV%2,!UX%Q@3AE_'I%O,
MHH 5XH=%VL7D]E;(X#T=7,5@A,Z0M)'/&<H(/* (Q@50^B+/V5622BS)Q5L6
MF5M+ -.20FH$>8X$[@-H*!&+4C!\)7))$(;EC>H2)E *%&K&I0D-@0;P[/+!
MTV"-$&*%E($T KO@=S&\3[LD:<VU$2=E74A] L].$R* *,&IPD.IL+<OI+8"
ME&*-T3V8F= \NS7#@'O;L25H@2\P"9I%\MFU>-YNV.;%_T;%3R^N9<=FR1U+
M'K48YZ5 KN>"9(#N/U\EK!JV/L_,C8U%:4QO(1%8CW5U_2TS@Y;,L"?.UC7;
MTO0%XL_\BT,6[HT7.=RQ H,PRW8<XD;4CQDEQ/>Y8_JQ\5\_?-;>-"S::8S!
M%M&C@I.O.HEAEL])>D4FY;.?YA<45G.!^(MTNWX!;T(5<U^0(3D0K*I<RL-S
M\$9X@5<]>X$>IW1@K!/MO#/7.J/E%<A+70KK!(7H%%!G4B9"M'^11@38'N#H
M2KTJK@&3J$XK<<G4[UWF\_46,K">W8K5]TY4?T.B3NEXK7CW5[V F?2.5GD$
M8(F1[-;\)ED&=@Q%L$8K%95OE*.3!,LLO8*\*%$K@4L#T IJGJ?P(5S_ 9]5
M:><GVBL"5AS87FA#9^A%G G+__4W3FMAL;Z+XX3"BY&-WH-%EB Q!M(T*BY1
M!Z&> /U#A.F%BD(, G1+'',JGO&*4S["T9L#,8$3<*\TH=;*&M/GF/9OGH'"
M'&IGX*T4Y'N"/L;5,)<7%;R"V: .>PM.@7B0;31/6M-VZ!T_OFR4L#93AVF%
M1"Y/QNZU(?02YG*E 1@16-H1#'LB_#\8:0)L1, ,:*V/.7>KL>W1M0 3("9H
MC32<\I%S6/:*2T2T.P<UQ[FBP8IV!49BI&72 6!9P0?2L$=#I'4SX)LDDV$[
M^.L 3$_ !G /*RD6L^C O\$/8=(C,.1CH0R >E_R1 AZ0W\AV&!RC?!J@CZ>
M!AJB1$H)?P\6#<7_$IPF>+<V^O#V5'=,U__IC] QT*<J:US69EE A8^$F@%"
M\&_@]TJ3%JR[J!$"\;X4( 5-.W)1<&D[7B4@_><YPR#% /Q">J(=-7\>(Q0D
MX*070HM)5Y)H/UBN(9D"J)KBDZ7UB]^VRWI/"R*>^#RI@$1TC26ZK<ST/MAF
M-H B5PY]->V?&IRU!NWCI !7)!.K#L\;BG650OD);AB3B5@Y6/EFH;0K@H$)
MQMMGQGE=P+*V#^UN7V B@(NI_HDXL@Q'[X(T:PW<&8%<"^X1?-*OY?TWGU1%
MS<A>E_-H# A0  Y^KT<D.FY H+,90403_?TKW11Q&C*>""<>HQ^70GK! A=1
M$(&58R"U $Y!["&\1B^2\BOX>N"DP5BE_+T7L11+HS :$=>M"L1=N7X(S[4P
M-:))RQXGVF?4?X(S+,/TIM(O!P._-7$B^#:8&CELRE^)B*RV:"),@CDUL@!E
M4\"1QL90AF_+)B!$LDD7M># I"FP7]T,$7CR*B]2<+X9GP>PP] 9I_4%C&G!
MG&3:.R3S)\$B(EQ?:D?O) 03+4I #=-A!H.\D!$C04 @"><RJ*-E,+XDN\1(
MP05IU"U-22F@@V= ';@4E4I2T#H%-0] H!WE\.]QPY@BO"<<7L$* "YD47]T
M.@.^9. +@4T(UF+#!X,5^FP$6B,9IR* =5&0T5STLU%LDB.JV9DW( 8\0TH9
M513V+ 8IX+5<1!(QB)%109%9]N[4H'C E,TEH05$PJK7X[C(,1PZ15)!?[CO
M!W-!N;4Z$"&V0(NR$95^0>'A:;JY"+58'4 &#D(M G B2$TY^CAQ7=4"7;J
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M]4A';@5:H1Y9>MT0GI!I?)R )AG!.YN&>=C^%[ZU0'>__J!;Q[KT#D"FA/T
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MK!3':P1Q]0ZI$+^D;,+B\#B1374US*5,LJ1$R[N331S5U*X>%PGFRDS*BH]
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MY#*$ZOH9";LTI3U&3*!_R4=SHL14G^--M<0&.[E+-68_WZ$Q>^.T_!;@196
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MQ *J)GYJ)PVV#E*$)LH-&4E>Z5?2.U6+ P"JJ=K2":J<3\H857H608V<H#2
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M7NH#;]6Z[7T7!U='7O0C[^R[3K:*]>WC9"ZCF7#)5ODGU,L;Q_>=,MF]/U&
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M&K2CMX&Y_%O[K-'L]U?^W&RT5OZV[K&=0:/5[>[_L:U&]WSUS\G'OB5(2&@
MO/'T_ONG\Y\R1V*+,2 8,!*@ E#[-!JK7SV)?ZM^QM->_G&.S,"9_-R>_V"M
MM#25!+04?:*3W#=9#9;"9(,L71&B*TD4X?=*V'6RL%,(FH; NXT NS7D\'%+
M9.#.DW3ZDI!K(>1D4?!*)IU4F<[WKS$MKW*);[94.GZS>]9^%E].MW$VV-[+
MU%H=G6TW^NUUX=F3]NFS;&138*Y6H0MRVM*$6?7O%S#32%^K7Z!U\"ET)D7?
M$*!OJ]GNLQ-'S$ \>B'5()P6?=GKS^&CF(&=I^)6[#-A.3 3,-)6[DOQ1LE7
M#WP>G>89._DSY/<NJ"U8_W%TS&4]^-L#+9P4HM4/>"#;T'1J%RV9"I/:1[?Q
M#+;]EJ@U3.'6?\U3E48E/*"+J,RSA(O_F"YO*>$./JMI%"5<^FYD?5:@'0!)
MMUO=)COYR[+1'1QP+,Z]%Z8+8KR,Q/P+M;<JX<)_E8-A2KCRIRI+A=K,SM*Z
M4+NXEMW>2KCRFZ@M7=$M"&2=9X/FD:C6K=.3SH;\'@78P<@34V^Y/XO8S&I6
M7QPTP2F!SY.KDUC$5FBR7,E8(A8QU!&X.W).?@UGKK=:U!0'#;KM,U"TQOQ>
M_"6.U"RO?'[;^)K*Z>U#-!ZF\'A3%T!!]K#>]7<9#6LL]SYN!16I 6*5>Q\E
M))"SSK%HA6L<KL\,[Q??ZWHL7/[WH")O Y=E0>CA=3#;[7R8YQEENHSNC@+M
M82MG1X'6O8&$+DI0\=A$=*]_UCT2$=TJ@=?F1O6W+@-FG)V#D3YRL>SG2(WT
MHD+_Z%)CGI-KYB6]OMQ-.KFSRCTL;^YA3S*\?A?#OS8WL1U[*)LS9^._16!]
MO>>*;22/XI!"\I'(=5&6N:7)=LBE/A92+\HZ/V*O#:Q2^2*,[X5?[:.V;E$6
MNJO&4!I-^9 ++9$J%@FZLW:1HK"XK'^"B/+$Y$CD[*8)!(6*)O]BV1;W%B5<
M>:GS5B\=TYT)*MDNX^H?5X**N_ATRG )-[!!CEAQ%W^+)<1JR&H)E_^'Z["/
MUGPN[/HG6 X/V7O99J<^]'W7L*B]A4S)82>7WPKO=,)A.*W6.2SY^\)_GK[N
MA?()%T5_W#V)ZZ V^B/*0F'6:0,#V=#]=,AU7@CO'E&X\ O=1%TIREK+XO8H
MH4=?C6:/9M\=C;PH@X.TK'F_@_Y9EYW<6R/7#UY-3+$PL6?MKBQ\EK#"E&$:
M578JKRVRBE2<A6Y1*5AH':DX*]W2(55TA:XXB]W2W53\8%:!EGM$Q:N[>/9*
M$^UZZ8R4=3W&5J>J5'DJSZ4;G3?;>NKAD:C/8':508,NC4;WJVVY(QN4NHTS
M\0_*_+:,8A2:41=FI25S*/UQWCV66K$R)**OS%TZE/2=6M\!2T-GP=D?EA?Z
M[ _9:KGP>-N*"R@.#<3W B HV <<Q% Z*+:* D4YP.M*#_ J.NAP'$'OO/4+
M.XGG3_T7?=D<'(M[M5N&Z#F>POO4*22&J1W+28"FWEL^C$-1*H[%-J:N3?-'
MX#\S:[-DW ,W.>ZW^D4!X1><!&"X $/+8'<!:.'N%'TG@!P^._DRO/M8!M+K
M]'N]$BRSWVP71E>X!AJ?>.Y#,&5W"\?TW%GAE03T?30'/78RLSQX#O*HG#C0
M@>!Y$]HSEP9X#3U@1CA"B=B3FJI1 MCVNH/51)0R7+H':\?[&.R3(&?O01?^
MZK)/L&3V47 OT!EZ)3B,P7F_S4Y\%WT-'LZ/*0RBWR6'<Y4 DCBKZTB4KWYA
MD.#K% 3&"+91BC;P[6:_61C(18/N;@6 #P<ULO>"9D&70TRTSKOM+9>Y,DQ%
MTUO>TBRAG(>I-[^VV5%GU>RH%;.C8,V-IESWML.C.KU&I]E9^?.N4Y[:O<9Y
M]QEF4O4:W=[J6Q\='K44\MUSGX'B3H?JZ/G9'1QW"!HA3M>+Q68V-MY_^I2M
MW2+@182@G+-Z2T./4Q!3.);AR^UF2_* -.*!32D_M_>5=U#^W(*A _+*PI&Y
M%]=_7+T'&5H4=:3 K?VP@63!*I5Q69] [MY[EGO83K\GWQIWC5-V\IDO<#)L
MZXC\RX/"6#FE20G:?1A144H:XA: [&0X]RP[C=4%AGT9>MH?AD<5'NE4/A<[
MN1/S0 [:!J7FO(S-&R["@#O"#7UV!UQ@AA\4,863T _DOC:O0RY U9Z6;:U>
M2=:=&4"FE]]_9/G%Q:G/PL>AXK:%14-Z.V=EW(EJC,M.W@LCHO,U.RD*2NEL
MPPCZ:WA34=:<R3N,EIZCUA54F)^D="?FAR-#<]?3X@NUG&+BA!0HATZUG\D:
MQ:@ 8R=?W'O-=-:!OS"YH:LK@=C)M1&X:BO%[Z-;P%YGS6+V.GN"Q5Z">OFD
M<?E!C+P0E7[ X&89,+AJRG.PDN@DNRNI69@00[$.4 K.7;47*90&^5OHB+):
M( FKKR0\?_?V%T4YA'PS9$O/;J&PZ#/WC&EYV.=KJQ(N"MZD1&Z)\#UNK8',
MWEZ49-F1MW@')E^8[B [F25%*!^-N6(9%(-<F;1N P6M0*QR15:4WX'.9+I4
M>P=7_%=<B7>ZBL!*+A&+4XIWXXAPYAJN@2Y#573,AF9H%WXL_1^M5C^6>#D*
MQL&+6LI:4+1<PP)PYHZFPASEXD"@OA7^'(<^N;"PNX5C+ *$-A70EP#,K7ZO
MRTX,6_B>>T]--=>''!YO$'74N9CXG,^N+0R*TE\Z6.HJ_+>*9RT?>'%31HN'
MBE6^YLI\S40*2,F5CN+P[0LWG$Q+0!:#=A\X]$2,^=SZP1V4@Y2^>R0(<?8\
M&]F)MC(HN6+.Y]H?-XSJ) S95_:@JL/DCNP*EL,MA]V%\[DML 84I/L'"RZ<
M%$;M*$W*>QG2KM?37:>UW$:AW7Z9/@KYZ__[?YRUV_UW#/YW)PS7,7&RD6"9
MQ-9'4.31/;Y0JXC\+9[\?OFO+]=?+^N=\ZX6PZMS^C;GDX<\JZ'Y[_ >*\KS
M_)O'<5K-\U9T6D_)IMY<1"9*G3M8?%Y<3#C:7(F2D^4'R_,#R4$_BX!C(K=E
ML"BE6Q+F%KSG8$1X<WL]%W:*_MC);S=?BDR%6RO^6Q8Z+Q6.%USES0!4K78)
MIN<'R5U;4D6I%<8'UPT<-Q#^SX^AQR%WLQMC;.^%,1Y>[:6#8L^NAZ]]_2\"
M#IR9XE[8[ER8#"PLSJCW") 11P@W*@3*'U9UD/-B+.?$#'<VLAPZ+?9@!=,"
MF7;M(E34TB(J/%Y1>5 0/.8^F[D.UDQZ?+[ [)ZWKE<F[*X0;$7;Z0,AV+7#
M/KP?,@-^HUJLJ6N;U1FM2($Y[!F!Z4U9 ]59;=*_\D!G)5N#M4>:9U,?1@,,
M<I_A,/H1\7/#K8]# 'MU>NG3>Z9I IN?WO">6S8U' 21"D*6H3^"A=2U['(F
MO(EPC 7[!B<\#(.IZUE_5=K_(:*UY3(?KQSF"7_N.H W@4MX=7'[";XS! #5
M9&//G=&WR.7'H,\%4PO8Q7P.NY,:'6!C(JVM76.?A6=\9W#57'APQPRY"B(6
M7@V2@<,_"Q^V@.G?W(%SLN8\@+_]<#2S@@ OIY=8#MXM7Z*6AHM0V#]&_R*;
M<GO,W#&^N?,<F+Z9@VY/#U[7%-8R__LGJS_J"FP.P,UVI]OEO9$Q&)L&YX.!
MZ+8&X^;_:S4[/ZWW([;:^Z?BI>:N^1ZM3]:?H05H0*8!N^!SI!'L ^R&GK%F
MSF9YVZX.VHU!9_7/N_9';;4:_=;Y3H]=_UOOF1;;WDLSURV=O\_33?1L>S9/
MN'/R!AD7O,D&=N:O;LFZT79?LGWJV6-BA+87MQ#K-&LD![;889/)",.Q ".J
MQ>JT"!:M%"P>:UG,C>\3SP6]KJZ6:QA"C,<[=RM>'1AY7B&0#YL+[D^)_UO.
MO?"I%;R?196]0:+)#LHK-@3)F^?;?W+?%&HKU,9;[5J[TT[73^T=!OCKEK!8
ME^'WI/5D&5V%Z*\#T<]JW7Z_H'B^M3@:T__*(W'^Z7K?R;$E#8Z5>DD[5]G(
MI:SB85BK6>OU.VM1[/F8XJ-Z7*E!VZ]USKO/#MDG:H7*H&V75S'\ZJ(WP!2C
M@)P]])=M\9%E4X4:Z8SBS] *%AM0\%[ M3E^'@YJ[;/&>MS<%^)LB-2'@\3?
M-C XGPR,#3C<"Z/>05ECI]58+W->&/L."HR_+5OY*V=[)5R:_?0A_SOT VN\
M2+F-N\^0@[[A0"XRU^=866T*DXT6S)T+S"I#E[Z!);K$F]TQ4((#WX;X@[K$
M=7SVP'WVIM5M#-A(>K[2WGL'LX-G<.?45T[\-B:+S+D'+Z-,D3=GC>:F][:8
M)\8V-@V!1?B!YSH3X246K,(1F'A<@V<9=FC*6(-@%KS3"/ YSQ*,B8&]97!(
M5^\^][+6+N+$%X)]<0,A2;VK@S%8(B,<7R ;=(A\>8 1(XO:Y8+XIDQO\O"<
M-M@3,>E1O$%4 [0)#?GT-ZW&F5ROQAZX$( C_,"%F^=\00MC%#Z$6V!/J:1)
M/XN(W4Y;NV_3CT+%Q)U3E&J#ISZ&PT\&E/H6+H&7CX2,Z.%6G 5FY[<&[WQX
MNC7#>)V,O."S,.1/=\C3$XF7.D*8?DU"0?PPA _OP"4"-MW3HGQZQP;/5!88
M/&4N'-,*0D_ @X$MPD[QTCFW"&3^%."."23"DWI?@/U(0WQXX!K?V1S>@*D,
M?H,-X0(,8(8V42\N!/#=E,TLX")@ 0CRV[_SV?S=>[T"%1IG7F@CG*8\H 0(
M$$S(/>Z%#'3R'VPA."QA)(!9.[17'#7(EOR[["1QX+B&KW#O11C(U?_FCGPV
ME.R%.L'7DH?"8"=RYU.@.4'O%7XJQK\ES\1K?3ZC(X%]X!Z0]UGNXRD=)1%(
MH2_39J4/>2MAU&FT=Y9%W49W8UG48%_A9]M]@!.%Y=*J<.D[K5K2%@"3F2&%
MZ>5SC0@6B*_< .M()D5(O%/X!*S$0!*.0_D^MVE!OC!"+[:N*',SZ9>OZ;0N
M>+$['OLB0':D'ZN)<),G-587^F3&<[Z6,:?GI1AS6B)>H-2.;7C!H-'?F1>T
M&ZTM>0%HG"C&2!X93UOY$C\@=0R?:5K8#W(4ZLP<I18GDWFNO0EWY*_P!D<V
MV4M(CCF</5 [RZA][5W4/K@DG-L::)IS:"T)7FN#DEX'O)Y)ST^";3VB%BB8
M ]OQ,(M1R;<= $WPS&%S#OS'$_%:@<E-72^0BP5]SG,?L'/!6OU$KW))$$N=
MPX1].2[H!09L8]6.5G/.$M'ILMXG/7QP+EF)#&Q]^@@I$LC7$USY@?8UHR)R
M VA)VA9(S90"-08\=CU"Z(DG),U)4HNIT7)@6T$861^&:L-!3_,L:2?X6#"?
M\P9)4'H9\G5X9NU&)SHS/ WXXHPE#*V\Q0+"1UDBDJ7H5!%ZA%:JU4]*LZY1
M=J+4RNU%3:6[PN'[J=U['FKZ2FEYF%K&-+(%75## WB!)/L5.R0VL9SSN J*
M^( Y, /%V ":N3::HNB+B&%>)!GFG6:3"# 291] K0-5Z2H^)&G2K-DK*G[$
MZQ#H)N@!R/])4J2-C <X&S)% 93 8H!/S9*<.&.^1 <=PRF"JQ7@)9@U.K,"
M/[HC%U(2N,A)"<!CW)]\%SE>7+4YM2ZIN((=%@$7T#Z79^\(V/(SA??+0A$E
MCA:*8!0(]J:7)<Y>PH<F4W@?XZ[+I->0= FXJ6;NMB6"_>)RS\1[WUO8]MN%
M59C"L$E3XNS/D&/W3E14U,KQTC?-1O\<!9P4Z:@'Y'DII##5"P8R@Q>I!TKY
M^: M9TQ!UAU,B7ZBOUYXD6,W](#[KEQE<G[4$1CC .ED8^%V+1=$;UJ-=D\C
M(+#U1J?W-T:E[6S&41F01<O FSV3_$1:%[4 @J!M21V+<!L5,LND(TX.+5WS
MYF;*"8AO[S;W\/9D(]>5[VXE=MUIG V>O.VCP!B</:F*!")@Y1 H5T4L *:4
MJR&<(]M[TVHF]8WTT\!4 YZ6($T25$I'ES)IA<8>O57Z!U'O<D!* 028;8&\
MDT>"LG2$CD83V,(]TCE>(+4 IPYG\1TD'HAAQ^=2JM78R,;7)+]#A@)+0TL+
MCD'\D,[*&I,ELV QW(,4L]$.F;A@G)!T3MR>ULRT)1'O [XDOD4PP_VG@&*&
MG@Y]K!0$Y%R%SRN4MGRL!ZT ]!8*P$R5*,\'+1G@O0QY'@.&+^GM[$T_(7_!
M- 4+"#4L3&Q82!$A^8$OY1@-&FKWY0%'UZF @,\PI HT8$?%%%KV9(\"#QS(
M G6R.4<Y%AFM\5,I$5='"B)/XD0X EOO F>:8^!"(%[-77*X9[>'6&=Z_,$A
M=S\]7&K/\%C]FAQ)MVDY2[^XY2P7Z/#$4M>AM"IP[Y> BC,L9MJPF*4<>!PK
M.[!.:PR;!MV:Q[N>@^J-\S$C$X%BJQ2)X=)2B9XP$L!LA(82X=^_0W.BK!GD
M&.IF$H[YWJ?U/J>('LC=(K"2=85MF7I56H)\<+T9:S7Q[^;YN]_A1>BJ<&-U
M1ZVJ5U.L\B[E*VOMX"N3@BI1\J843FZJX"*P8@>.-@%WLFM!</J:GRNVC5Y
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M3R4>N")S.^]!3R#90<D1%32#I$I0?BTQ-[)-C#H;+LPJ J/0Q_'T:(S95.]
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M9.U=6W/;N))^GU^!]<-63M4HOL6Y[22G9-F>>$>VM98G<W9>IB 2E+ A"04
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M4=<G,$$R!'*!)>;P1-!YJ.BP4(;5*:BU;(CK-5]"?,UD,_W.W,BBNAA]N)2
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M4M/M7CDB"\ ;P[1 J-R,8>6Q2&:!ZC<\Q.VSZW74%E3DE@34P2XQ7"!2H+)
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MD+SO86G9CXY[I>6K\31,TSJ0T=LD-,4A17)9;V"B8"0*2AL#O6&-5NWCO)T
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M.<B@-*;6:=LF^#;<T__/H5LKG?;'.A)3/J\2N3B%-[+622>L V\UK]="UGZ
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M4('<?I*RA!B$#.J QO9Q_O8JJ9]P2O^;'%&>G4_'TWJ^/M1V=I>"0V%XP"2
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M^!@=(+,<?=8I&3X0RMX /J0-Q2?!V.W5WAMCKV#?' 2%+IB=5R0?&Q5%1RR
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M&FZJSC67%2]>KW_%L,"__^G_ U!+ P04    " "3@V-5?>6KD'F4   L4@8
M%    &UR:RTR,#(R,#DS,%]D968N>&UL[+U;EQLYDB;X/K\B-_=U48G[I4_7
MS)&4F=4ZHTII)57W[+SP& "#Q$D&J2(9RE3]^C60P;B2$4XZG''3F1ZE+E'N
M'^PS!\P,=OGW__'GR>2'KSA?C&?3O_XH_L)__ &G:9;'TT]__?$?'W]E_L?_
M\=__VW_[]_^+L?_U\OV;'WZ>I=,3G"Y_>#5'6&+^X8_Q\O,/_Y5Q\?L/93X[
M^>&_9O/?QU^!L?^^^A^]FGWY-A]_^KS\07(IK__K_-^$C^AE*<P"(--6*Q9-
M,@S!9M1&9K3I__GT;\[YXB/]1#8Y,!TS,-"0&2;A5)%>F2Q6#YV,I[__6_TE
MP@)_H,5-%ZL__O7'S\OEEW_[Z:<__OCC+W_&^>0OL_FGGR3GZJ?-3_]X]N-_
MWOCY/]3JIT4(X:?5OY[_Z&*\[0?IL>*G__7W-Q_29SP!-IXNEC!-%R^@U^?E
M^?_P,AKST_H?Z4<7XW];K/[W;V8)EBMZ[ES"#SM_HOZ);7Z,U;]B0C(E_O+G
M(O_XW__;#S^L)0?S-)]-\#V6'\Y^^X_WKV\B'4^7/^7QR4]G/_,33":$>/6$
MY;<O^-<?%^.3+Q/<_-WG.9:=Z#=+KJ!,A?-_UZ?]U!O39P(R3Z>1=&9,&EL5
MO"'&;4_OC_G\62QC@=/)LB'BF\]NBG=V N.6 K[QZ 9H5P]B)W@2<=X2ZI7G
M7L*Y 7D=87WD":G/[W])LY.?5MA>S6@3?@>?\&Y<)_/?6=U,>5!\]?Z+_^VE
M=Q/)X^FX[AMOZ(]G#ZBO.@ %_KG$:<;\XP_C_-<?QT;[S&544G'4.00?)=J"
MA>N4"X(<73RFXMD@FLS2E:=.ZKXV.R=B A$GJ[\=91R/?IDNQ\MOKZ=E-C^!
MLV7@ZR6>+$;"89$"$_,A>Z:S"PR$%(R;[$&9DITN-ZE<;%1C@>DOGV9??Z*W
M_%3E6'^S$NB:S%O?O9;P82O:')T?Z6='7/H0A)-,BI"9EE*Q$)5E,:LL2:I.
M!]UK#9??=A7UA6:\F&_PGWTB!WY#]>!OSMQRUD!T:UX(_(\_S.89YW_]D;>@
M\/\]A?D2YY-O[_'+;+X<"6E##BL#1BB"!('%HC.C[T(K;A%R-$W8O/;B)T-L
M'X'>Y%BTX/@=SL>S_,LT_TQV[DB5'#U7D26=$M-><@9299:5]@ V"EIE$X:O
MO/;)\'NX,&^R*YMLPG,@ZZ(N\DSCLE$NV"0)CA:,MI#"P"C)("DEN--8T+?9
MD*^]^<EPW$ND-VE6?6A>+_/7\01_.ZW"&#DO/0?K&!9'&XIPI'(Q1V;1VZBE
M"=ZI!C;#Q1L?/:V]1'B33MV?SO?X:;Q8DI8M?X,3'%D4P>O@6>!9DWH%L@.*
ML0RR!:U5BMJZ!I1>?>L3H;6'*&]2:_I3^WJ:9G/:-%:+_+"D0^+5['2ZG'][
M-<LXRL&JXFG[D+:0YB4,S&MNF4&5C*/#Q(5^AV\'$$^$^':"OJD'MK\>?(0_
M7V<Z2\9EO YZG>T]PD7CA(D,#5GZVD19+09D!0H8TE&OTQ;O?6\-V/'Z)\)]
M"^'>9-WU9_U%SG-<+,[^4Y<K1M;+@CPA4S[2EN1%861+1):]-XK3N4-K;L#X
MEE<_$;;["O4FT[X9TZ_HMV_G'V=_3$>!0RZ2''E>D)0O9\,B<'+N"P=TUBK1
MTW7>\>*GQ?*! KW)<6C&\>IP>3M_-Y]]'4\3CJ33/EFI69#>D.[QP((OGEEA
MHQ5)9BUE.Z*OO?UIL=U'M%NB);U"8E> O9LMEC#YW^,O*VO"&NE5AL!0B;I6
M NA]SHP\!>"V!&YZQDQVO_MI\7VX6+>PW2LX5O>9%W.$%1"P]%IM-1.ID'^?
MN2(@!9F7T7MN"@^VWQ=]^6V/GM&#1;>%PUXAL'J?/'GW>3;=./8^DE>/H%@,
MD;8/C(YP@&:@G(\IBA0A]>+Q^AL?/9>]1+B%SUZQK@^83N>T0B'CQ_%R@B-T
M4480R(1U!"8%R[SPY,^!DAJ,T9#[[;O7W_CH^>PEPBU\]@IV?9Q#3;_Y\.TD
MSB8C0$[[>C#,V4SFG%)DSAGK&0$D)TT;:WI^G%=>]^B9/%QX6VCL%=C:Z-0O
M?Z;/,/V$ZT!;<38(PA)2 MHG4+"8"K"LDB%+O13M^MTR;'OKHR>UMRBW<-L@
M6/7J=#['Z7)]VU&5CLSRT\4H>_+  "5+5A,P:3@YV996&94,PMAD= NS=_O;
M'SW7S42[A?,&H:K7TR7.(2W'7_%G6,(9SA&7(FD= [.1U_NN[%C4AC2RJ!22
MLS%"O^_ZMK<_$<X;B'8+YPV"5O4.;/Z*7.Y/L_FWD46KC(3$DBLU_222T1=C
M82F4F+(5)=@6H>@K+WTB#!\NR"W$-HA4?3B!R>3EZ8*6MUB,N!>1G#+%,@;'
MM#-DPVL!S&5ABW262&IQ17SEI4^$V,,%N26]HT$XZI<3G'^B8^-O\]D?R\^O
M9B=?8/IME),DX\!&1OYU==(LLNB%8YES'Y5*D?,6>8-;7_Y$B.XOV"V$]XI(
MG2G@9YQ,-G <-R \1/*^36*:"SHL:K& !9MDXM$;VR^W\N8[GPB]!XMQ"ZN]
M8E1G5N#LY*3>4L_2[Q\^PQP7;T^7M92B>G@CI"W&!17) J1?=+:!!>Z025EL
M*$Y"=KR%F7T+AB?">C,Q;]&"7I&M%R<XS36U[-<)?!I)TD87M&%&TTJUD'6Y
MVK.(&(0J]6JSWXWPE=<]>FX/%]X6&GL%M#8)@K^.%PDF_Q_"_%?ZF\6H%$"1
M7&0)P#*=O&$! %ATMH@<8M&\WQ>\X\6/GMH6 MU"<J]PUU5,ZWS?-2HRY17/
M(3".BE2O:*15DN=N7$@\RQ"LZY>GM_/53XSH0X6ZA>H6T2_"-8?)ZVG&/_\G
M?ALE,@!3R+0R7LT%GPH+V@$S=%K$Q#'%GK<.6U_[Z"GN+\PM]/8*=)T%7BXV
METW:?M+")/"188RT1%VW%T=GB 1MI<TN*=TOR+7KS8^>Y"8BW<)S_^#6&!<?
M(4YPY(10 %H2DD).>XID[2OIF)*HI Q<<R?Z?[Z;US5D]%+M\7$^UH-$MJU(
MZ8=U(>F_I<EL@?FO/R[GIWCQE[/I$O]<_C+!>@#\]<<%?CJY$>OM3OCI@GT"
M^#):I0[5![V:P&+QMJRL_A=_CA<C+;51O-32^YHW5E/& #$S*:)Q/$EN\#8%
M*+"(*W[.WK36 IPL%YN_N5"'.\$T5(];RL"WJ,MAW,Z&D''#LK8-L,MX?EYM
MA)T0C:X5HS=B_R::EOO\KDKZ"](;TS4;1-;'T0(3R&3D43)R!6,U-RR+GM?8
M+2$F!U_*6S?_A\S^E;X$]TC^/B(>@O2+&,_?5[;/B-Q^8Y..S!;+:]*H81YK
M&77TJ*5/*?+;[K$.XOPZB.,9=JV8N4YT+[$VK$X_F?\^>L'_8CC_;;;$13Y%
MDKX^P^2M$2&C9CQ;6YOL1(*3-#/1(D834<5K.40W>DS<]OQ'RV(SH37\8%>8
MQ%^\,Y<PV3-,H+PJ)B$+TM1DM$@6;,'"I'' "PICK]]@;2=RQ_,?-Y$MA-:P
MVGR%25Y5+G6N7!"MT&14 G<U'(N*_#YR]U726H:H2]"Y"Y$[GO^XB6PAM(;U
MY&?*I2XKE]HHEQ&0N240HA2H2W,,9!+,6*]"YCQGWXG('<]_W$2V$-K.2O)_
M_^F:3,B]__V@WDOOUK8B3//;Y6><UVJ+.2['\Y5=^!*G](;ENPE,UZ[AXBJR
M3AV:]GU#WSY.O59TK=N3\]KZ%-$4K;23P@>K><J!RT)_"WZT[\OZ&;(_5WE@
MOO3<G\>+&D$YG>-%@$<&'S!DQTS ZKYGP\#6O$%2,=(QKN"ZQ=/;N.T$K'?X
M)GW&?#K!M^4WW,CV%0E\+=N/1-U+^O'?1V2;I!!,9LEBS:VB[Y8.1T._<R28
M9"W7MZ5 '!3,Z0;M^#M:>XVY$? 9@)6&OL%-F#=%LKB0R5D$+"H?/"<[R?.:
MQ14TL*"C958*G: DY^1MUW;]5*@#P*%#R/>A/JUY>2A1Y_?GYT%=4^WBM@JQ
MF*A#K&%XQ7,U+#)GL;8=42XH8X0!+6[+N#Q$Q;8C.7:\^0C,SYHS,$!4ZB:J
MC<G9 == 8>E=F.XG.-V"MSM5H8?0CZD4:%!&37LL.(?D_Y7 0@9-;HG-2JG$
M(=QV__SPE>&.6/4Q=6$?60^@ V<^Q7H?O+(U;L*LQ8C 162R%$N+1O))BT?"
MI[**Z#BDVW*Y#]&%NS =W[)MP]YL0-$/8,7>X61NA:Q1.<A&L^BM9+IXSCPY
ML"Q(3E\.ET:5VU)'#]&6 V ^$04:FJ"=VTV[B-"'+^/IVU)FY>W\$TQGTU>S
MWV!>>Z9]Q9]Q">/)(4&@#@_M&_?9%_>U4$\$J"W 3.8ND$^:HN%:!7)F:G='
MH7'4X?G]/N[:GNX$SR]E7\*D#D[X\!EQ^6*:7^2\D@A,+MG&+[_1'[[,%C#Y
MVWQV^F5!CYB<UM3U^C/DSHRGIYC?DE&^R@%:7+AL0=I8D#8N,JEK,6DI+.JH
MF8O&UAH6D[-MO"D<<7G]$X5FZ??/LPE]8(M?_GDZ7GZK@=QUD<"728UO3,_&
MAKRO;Q8CZ43,$!(S1=(G'%1FT1I/'S,*EZQR%EH[<_MB//X&^U#U^6;*TH!L
M#V $_(QQ^7I*1\PZ/1H2OCBI?2Q'@OLB@DN,FUA3X.EW0>K G!'@E;#HY6TU
M!8<%?K=C^:YMN[2M"7L#>!U71'&[).B#6(SSV1]&Q1:2@,U,>$DNF-2U74R]
MF<0H-?EGSH;F6G<@UN]:N5,KC\%^PP2#2[AO(ES7BKPMK];_0@MY/?TZFWQ=
M4?"B+'&^6>Y(D\.60&?&+=!6KJ'4K1Q92A%\-+&HYH'^GI"_Z_ M.GPT76B8
M8G'ACWY%@OXKR?\]3NI\N7<PKTG9(^$U!OJ26+*U4**0Y1&4SRR0XRB+%Z;$
MUCOL3C#?U6]W.+$%?PV'!UP NXQF;6V\GM8[VK?E TP((/GI(*65+"<O:-D6
MV"KGQ5ORWT'+'&/[NZ@[0'U7M-V*UI+/AB,-SC?B;5_!IJ613B*H8C33JJ:6
M&ZY9H*^!R1R"]3[+:*#UB7L+GN]JMO,X;<5BPV$)E[!]G&U')H)(WF9DUCE7
M.P37X6C!L237P3WZ!%I?E.U&\UV[;M&N%@PV',EP@"NTBO;_\N<7G"YP1,O'
MD,@)<M'2IBNB8P"N#I:0LA8N:Q-:W\H="/6[5C9P@P_FON%LB>.)=YV$8TV,
M4+0A[UZ1AR1$8,%A8@42#\9S8V3KS,HC+>U8"76/Y4-XB!IUWPE]J^;G^ DF
M9_,):OZ)4P)L3H)!IF]>"T^6MD7!2E)(;I\2&>,M7T2']O%77WA?R7H/4A]F
M;7AI/$-UC>(LEZ +C@ZY?%T;Q-Q'MEYO\=]H"--#=H-R65MX.LRL>%^'"]&F
M&G$UPS79J$S24K28RG4/27;#4;B'R!K7D9YG:9QEV7" (+7,C!2&3L,@ XM6
M"J84ZFP+:J6O[=1;B]6N/?8^NO,<(MM9&\$TO,U>S)>C][6A_4K;DLOH=1#D
MY"5#BS'(@M*.>5I@2B([!9V2U.BIEZQ*^M/%%W;EA=_/T9OGZ.&,-+S8.P=Q
MIIU=8.R3#-]%0=I_VG>?HCV$?YV^'I)KN =?AU-4'9V<)%,%D6GE(PM)>V9*
M!!4U:I=N:Y'W8 C<<82VYV\?@37F[>\DJ9/3DTT/ 1E %5N8<G7"7BR6A0B>
M98&.S@B>(;?8FZ^\]'CG:B^QSUK(K/&A^G?X\S*08NN\>6 FF\BTIE\BDCKJ
MZ+0142+OENAY%WF77_H(R3M89H/4 )U'Q;]]G,-T4>>"D/3JQJ)J4QTOD<E8
MK?(@2:_J_$,T!#.X:/#6:> ];VJOP_EN1=VTHEJS.$BFR59H9WY%%W"#E1_>
M NR^:A ;T=A-/7IP<+R=Z QD0NTS(F="*$^;;:2O0TM@*G)M@#X45UKGSMV#
M@MQ9EW@?^K&/Z!O'559@5G+]@/.OXX2+%Y_FN-J'SXY/U*% R((.35YS X",
M7VV1@9:^),%M3-<R/+9&6NY\T7V4C#4C93:41!OWU?L[3$_IN%N>SNFLI,/U
MP^F7+Y-OYP 79PAML!J=$ Q0Z=J2W;'HR8+*0GI(TN; ?0?.N[WMJ1 _@&P;
M.X*O:FX9SK_4==?!D^O(<!:E"!>8"X*L(NX$\Y$,-Y<*_<=&86P+?W#;N[\;
MG-O#=KUY:IAVNO+)\,OI/'V&!9YK\W6(%U'L.T&VC.]U!7;\Z%]_#F?'(J!U
MF+ SV!"4\-8H9L$(LJALG7MK#+-!<ANR5*+--<']:LDM(<9[4I)]Y#[P/9[0
M& T'8$4B0>%\-9/+,4%"B!Z4=-=5X&'=XPTH^%LN^?:1VDX+LEV/@1?IGZ?C
MM<V[>(\+I)=]?C6;$/6SL_,0IOD-F<+32R):'-Y^H-_[^G8F:+C::TT+BDA>
MUI"R3EYGG0%C;8?C:L62]:!'_5[=+WJPF8EZ"<.;\^2T)'E)/@(C1SC4 8N%
MQ2"0*>,"&;N!?.?6@<S;\/2/E*QE2];@S_@5)[,OJ_JR^;P&I]??=QURE)8?
M9^]P7J>R_#J;KU)(%W7D)(E_Q<8O,)]B'M6R,UY ,Z]R_>K)[/=%.F9\,%QD
M^O)+ZQJ)I@LXOH/63-=NQF'NB]C&CGR/A5SX-[^>K@9COORV_@?Z0=HYEO!I
MU<3O_*&K]I^CK)3-*9A:$\+K>*?$(!7-L"AC7-0>3)>0P+%Q/P'=??!T-S81
MAUCK]?5].(W_!^L3SGYNY!3WV@G+,&&I52ID=$-RM? =N*?C6,8N4<[[P/Y=
MQ8]#>^.!"O_X0H*=UH#3W\<37"QG4WP'W]:10LCX<7;)L/N*-58YK;%C'[VP
MAK.@JW-8Y1RBY8P,1\P9 #2Z#GIZT,N?B*(-+_C&$QO6S0X^U=9V9SBO(+ST
MB8R*B=J8Q!GX2/HL(+ 8;61)AI L2".QRWB<[F]\(CHQD(@;QF%76^3L&TR6
MW][#$B\.[Y$HY/;7?&$NM6,:0RT,*I&)Q*WQLNADNJ1";WWX$Z&WO^ &J*O?
M:-K'V6JM<WP]_4K;T>KO1D6D9(NWS$*]);+2L(!DA$4=LPI)AQQ:]W"X#<\3
MT(/F8F]8"+^Z/KQ^&'V<O<3U@?1BZXF4?"93I00&,NL:3"287AE62#J<[)HL
MKE<H;[^DW?.]3T 5!A=WPSKV;5CO@IJ=S205Q5Q(GJ!"S7@LBI6B,19 E;,Z
M0#.>IV*T%';#8O'=+E-7A3919:&Y889'P309L@PR&3)0;,"HN;?7^U#MX?(^
MK\WD>$3<U* P3+![TPM!."EDC))%L)G1,1B8-R0289/1TL34ODG K8">@,:T
M%_R6"%ROZ/(M+O*%,F_591DRV$12D!SHE.2U^SF=C00]6O1HBNLT1/!@ $]
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MBK>TS[M.E<:/8PS\7F+?.09^'YDU=&ENCC0OED#;6L!$QS+3A4LZIA,9X[:
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M?2"C94D'EXMV.HL6F4S;WW[<Z'XC6K80W4.F1QB'>M5$^@SS3[AXD<@O7U6
MQV\U%716Z@'7*/+?Z1U-;P/V7]7U*:@Y6:.T=@A:2ZL]=RI82&BY<Q'=:/_7
M'>'6P 5.-DB]\C.^)M"!)$LD2R:B4:F0^POIB=T:7/'^:U(HHA5,0*J3@B22
MGV9K>[?"53 Y"-$ZM?MQAV3VT9=#0S+[D#) BYI]#'G):_IP%+56JU[J!LG
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M'(V^.G&PK#OX*61WUW;%MQ32"BMMS :"+.0XD8E""ID1>+9"1I1)IM9M%AZ
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MXCF"4O3-T]X=ZEA6QD5MJ&%:FUP#8)TJP?U$^K)-:QOQUL'VNH:X">"ZF<\
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M>VK'XE;U:$1!UPJH#1@M"SDKLITB1@M*% :N6O6^E.RU2#JSUNV6CJ\>3SA
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M>-J4@Q&T,R?Z+H/68)P/H2 Y?LVO(!\%=/R-L+UV/$A*;\9 !R?[(;CUSKU
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MG_[@U=7\\V1Y573!D+%@R$-,6M7NMNC!>[(&6-%T_*$V++=.IFVZ@!] (X_
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M"KCQH<9CBRRMN_,?"/E\E?&87#Y41=<^T/=N,L>/7T?C22FW)@]<Y,!=EC(
M=Z8.KU!DG9(+!+QP$Z.4)CO3/92W&=OY*E<7=AYJD7\FX6+.T+/""W N#:TB
M)_#,U2Y\+A7N,/D.:6/MP\7=KK66"6,L*BZ93F#I$",I&0F1Z0!:\VR9\1)#
MZZ8\N^ [5KWH<:]N>A'T7*I*KW.'EA_!=<^\V2)CB"F7N#6TJ5A?YSX&VL/0
M(_@ZM\@)LJ)B^\W_$4"GRN+LIP;;$CL/IJ/#Y<L]3.MJJ &@.N5P;@1TXL3-
MPXG;V*^^A=2/IA(B2.ZS")"DJ-TT0R(/2PC(+F7CO6?)MZX@/*(J#,W&/)(F
M["+L#AIP:VM<STX@:_AUF'W^]7+RK[]C_H1+&WF5U15<YB$S!]RG!"K4?D#"
M"TB&<>4X(_.U=6>3'2$>WZUH0.QVNZ4Y*QW23F[!O3LV:C%(^%7^WU?+P9HK
MM#H+$@&2EQ#K8&K+#7BAR('.Q1/6I))L/>5Y-X1GID*M.>F[#2W\X\M%A/ !
M2F=<T(Q4''G-6=6%@PO2@TG57^;&<=51<QY!=F8:TXJ##OD< VSY=7]6S43R
M9,BS4!-/HC80.*'E6.OP<Z0=L^-1]3BX,].7ADQL3<EHEPJ^RE[_#;_64-'X
MT\=PB;,JL0_32;Y*\P/RP0<_^M"D\/W6<"\S/)6<D&G+D5G%A7)98RED2MA8
ME"KR8O!;FM1U7+_FS;A,IE_NM1*+# 4K)4+1,E?3.]7^W1:PH*EY/4;KYDVM
M!^ Z_)9ST4FDEIRCS\G1I^&=!%7[I;FH"D@N)$:.(JO633K6[SY9=4H[QA]>
M-NXAU@ZF,7TH"3'/%ETLZ>MY7]Z,YV'\:10O\=5LAO/9!>VUG!Q'"3Q(2P>J
M)=,KU?(J^B8)LX^N^2WUTZC.4"4:4]&C"C)]QGQ5D3TBC)^^K_YP-?5$)),B
M)XQA415:!#A1R'#W):M05!;8NH'''C"/=;O078EZ4_3L+A9^NIJ1X&;K2N1E
M&,RB949'#M&Q.L_7UC("%B D$7E)1O+4.EOU44"GNECHK@W;[A<.9J5?#??*
MLQ@"IF]OB&=QGW X45M*;_>7<G?J=;8RV$#^7?:)-%Q'".@=6!>$+@*ML<UW
MA_Z4#[TWZ,SX+L)MR'2=R/;A<Z M+>'5?)3"Y>J@6;GX!I6QF;8QQ6AM2@D'
M,5LD6"([;D4V]E[![L89QH^\XF06Z3Z"G[276D/GI,)Z-1Y]"9=_QW Y_WP7
M5 DY^=K#4HMJ^B)9PG1 T4)%<LEY3J#2 "JWON"E$ME&8HVGA+Z>C&>3RU%>
M6!H+\W:QWV!&(6AI8 PWH)QR$&0NP*.3Z +2H@==X3XQ)73SV\_=&FLD]X;!
M\<V(UHT^!F!J.!MZ&X[CCX9NP=&CE!\@X.[;P'4OPT@;$.US41(LE7P&5RS]
MX(1CQ@2#N<]&<*+!T,?B?!>Y]BBD7[?U65N9JY-(VNB(& Y"IYI0+#0!1 ZL
M.)_)GG"Y>9+I%BC''17=AJ?[-0(-A-PAI/QZ,J5CC;R-=Y/QQSMV2!*&N^PD
MI&AJ2R?EP5DO@/%D1>%%"-OZ"F$KF#/@OXV@&^_TJYNW]]-5[_GEK ,GO<-4
MP*0Z#[WZF+&.O^+2V12T3'E8HN\3N_RF=_\(QM[!,F_89^ 6GMFK<5XA6JO[
M$% -;;VM0(YO[!W.T4/"&PFXSPZP 1PK)KI()Q&/M,4I[SV$1'ZHT$SD(+W2
M=E Y]?-B_1%K[TBD[R+7QC&W_P>_SZ=7.:P.GAR%3]86T%(G4-+7H3:)%LA\
MX<K%:M0.B,W<?>IQC^I&8IXTD5'KH-KEY2B,$TZ7V0=OOX^_ANF_U\"DCX7^
MGR&94.@,JA/H;=3@C<L%3932R0'D/?J2E\YE.PDV_A#?XOC;Z,L:2&'*DC51
MBWZ-!L6XJ,U3,Z#DY!08^L]]MWHCE7<>^M*IVU]"#2-AMW5HE0/T&\;+R;^_
M7ZYG,5A6O),&+ HZ'GQTX"6Y<,RC-4IB0#>$ND=?\M*I;"?!AI9O!?:W,,UA
M-KI<_]>O(*$NOJ!@('.-P-=*_.J%@TR%,T-Z%^.0ZZ<MCW_I=+:06L/658M;
ML>GD_[T*^1__^.W-F_\*T]&W\.=:NTQ6R@<-Z&NR\*(O=;$>LHS&%V>+2T-.
MR:TO>.EDMI%<PZY/%=1ODWK]_<\5D#I@,;* 4 (= ,IJ1GN_2X"D;DR4;+D:
M<H-XYZ$OG;;])=2PM=)"?\9X]65"6B/D"@Q326A-MC+M!Z'J#6T#@39U78HU
MKA1$/>B+N__@ET[989)JV("H@OFO\,_YVK9BDGE6QTKZ16\2EPU$D6OXT8H2
MN8Q\T W]K4>^=*KVE4[#UCP5QD_342:IK3]RS-EJ07:2JF-:,$KR5NB@#58J
MP06*/,C2O//0ET[4_A)JV/]F>8SBM^]?1M>338)P2F8$D:O2>$L;LBH&2DZ1
M/FT;"S>#K([;3WWI9!T@HPW>]T&1E9]KV[A17N=-67(?B^+ 4EV0= 6<Y!&X
MYE:C0H?W.Y9N9.O.0U\Z6?M+: -7A^4)3D=?PI^C]4?NT,H<LX3"=:SQ6/J^
ML5:HT[=/F RSP@WZM&X_]:6S=8",-M!U4+CDW>3/4$9KY]X)FRS# L)K5UN2
M(?F$+((5G'$R<6),:@!;=Q[ZTLG:7T(;N#HH_O%F_"V,_[WN^B!C5$'6SM.6
M3D\;/<2D!8A8&"\AHT8[@*K;SWSI3.TMGPU$'13?>!W&M!F']=%I:W.%*!P9
M.K0458N/8@P1"I:80W&\W!_@LY&JNT]]Z60=(*,-=!T4O_@?G,;PY]J#2"%H
MFXH ;4RJ8^XRQ& R&3I:*,O1JCAD#[SST)=.UOX2VL#500&,>\'I5QF_? VS
M_\+I/Z^^3:X3ZUWM#NB!\R)KZ^H,7@@Z7@-S,7*ABABR-0YXU4OGM;4T-[!]
M4-QC!>@Z;N8"-TA[>/"+&:@6R.O(0+A"PB0UWF]GNYG7VP]]\0SN+:$-7!T4
M_G@;/N&WZ6ARO:$''[3AY--K@I)2!L<4:1%C/">KC?5#R+K[U)?.U@$RVD#7
M02&0-S,<SZ<XFUW_Y.\_W\2GI<JH("=3FV 6#3Y&!I%A+L)HG<T0ZK:_X:73
MV$AV&VZ^#PJ3_(27L\F7Z?J8%EH:0RXDI)@-K2Y%\(E[R-E(%YT060RA\>Y3
M7SIU!\AH UT'14H^CFH[IM&Z!YLHM!19P#H?H0[J ^^U!(:).X:!I4&!DCL/
M?>ED[2^A#5P=%";Y#;^,$CF-ZRPS23Z)#PBVWIBK1.:09Q9!BY"C"#$9RP>0
M=?>I+YVM V2T@:Z#(B7_&<97WT;7=T)*&Z6#KIG?@?9D'2"XE(#6*6BIC+M!
M&^&=A[YTLO:7T :N#@J65"1?\+J:UF9,,06P(9&WH:2"H!2'7&+@/"1;"AO(
MU?5#SX&K_22T@:N#(B6+5G]W:]K7!ZD5*"578(PKH'AV$+2MN6&D5CYDD3 .
MX&WK"UXZAVTDMX'/@Z(I;T??<%:G::RQ.$4."+W<B1AKKT8-SOL"Q;(<:WZ?
M2T,RS.\]]J5S=XB4-C!V4$2D]MD,XRJ\14."M>,?38A*, 72L^IV+-H:2 >E
M).:5TR[?']J].<2\\>DOG;\&,MM X][!DKK(ZX8Q?\/)IVGX^KEN",LF\TXK
M7LL),2&2<F4%OD[JEF3>8A)!%MZB9GLK@!^AI*^-]!LFQ2Y +5=V&]):[P>
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MQ>L%*\N/9EF;+42LXU2PG(.80PZ03C6@-K039XAH*6*%E%<T5@\9IO::[U0
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MSOA\8;C]Z,'9JJQ<66^_KZTIPA?J[?+AKBE@-M-9DA&1Y8#R3!ES@6OS$Q$
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MZA\O\)J5JK1.9;9\NKXIE)+?5M]6BX6UBA[6ZI/^,+^;UT>2FWR'A*<PT50
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M]U#8MDTS30C/$IP!87D(X90!EA$!>$X19QE56>I76?#8+%-CH\_LR;K;;3Q
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MEQOE#KP* _/L$ O@3:P70!B(3?M(,"J%7@#1<]Z\9*A^9/F6%4LS?/E9%38
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M1VA/>1D2;WTI>X8:N2'E9:6/.U$:W'.5I^@X"F.6$T2BA <PPR&'*(P#F),
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M\DH=E=U+/75]AMM._6ZY>M(]$(1Z\%?QH%_))L>9<,S3-"$P3U.=KIH@B%'
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M-,D(9S@Q[CCD),'4R*Y1HLKB>&S5:+<VAD<J[M-Q>0,_.,@#LUR+KU( ;#4
MK0I ZP#NEV!/"]"H,33ZYCOXP6=AI!U\_]L.'O5LJ&W\4ZT (&7UHPZ0.KNS
M]^3 O0KAGJV]VW-'V]I?I79W:W_=@]SL[*_K)?O7M^5<W5'^\M^;8OT\2\(H
MS1@/H*2QVL>G40HI34-(0YE$(:)Q)*1-/OOQ$%8+R C)[/=ZC)[R/*#LJ/#G
M_\BC,/LK$)4J=O;S";3-3.3K,!QX?>@*]_^"6KS!"^^<1\23J7MB@%&MV?,*
M'AJL/5<Z!O9H0_>6J4>5A5[,[I:+LN!-59Y[M6R44E059O6/A-67E.N9Q(3Q
MD"I[- TCB/(TA42F"&91)!DE/,74J/O0E7),S3ZMU !DIT==^-HRUL=Q3LSX
M902D!R:A&N2."CJ+NZ,$Z&AQ SIZ5,6P/<;[7(>DK\ ?1RG&C0"Z#JJC4* K
M'V>_?_^E7!>/9"T^R5U1^\\K75=7/[B\_T;6_RCF\R^BW,S7[Q9WI/SV:;.>
MD^=REL1Y@-(DUNW9 HA(Q"!F@:)*1G&2D%P&TJAR]G5B3(TI6TVJW<JN3\#3
M2ID0Y$?3+V"M] %_*(7 JM)(M[=D2B>PK)4RWW)>,7^7=_WCS,K K+J=D$^R
MV[U2Z5%5]*XT 5H5H'4!M3+*9@9:'?!IQ DQ=P2,,S$C>0.\?#'@U9,.6%H5
M\^>ZL*9H@Y-+\42:]5/4V3L_>7(67#\+/1Z#*QX^FMO@>@"ZO@,/3W.MDK(J
MOC=-375;BLI=\2LI%KJPY_MMA0[* BQ$',%$1Z,AC"2D3(20DX!(1/,01Y9E
M4DR&G=KZMI,:=,2^ 5KPMK+M-;52C*;";$?@'^"!ERIOV#I43+&!REO)%*-!
M1ZZ98@/$<=$4J[OMZ(J+8O;+8EVLG]_I8 5M_G\7;\B:W.E>.8OUC @:Y#BF
M4*8R@TC1E [HSV >Y;G$84#CQ(B@+@TT-4JJ904=874S* (:<<T8Z"*Z_9SC
M$[.A#6)'N(Q)Q12+$S12"O;SP_+[7]0C:@91/^R(X^*#1Z$*4_5:<C"^WG[W
M_AOY[S5I$YHEDR%!.4SSA&K/I8 XEAC21)*0X2#/A7'?],YSI_:Q5Z*9;\>Z
M"%W>\#KJ/? '6TGED+_3U=U\;^F(P4B;14,LK/9Q)S3NV9AUKQYMIW5"Q.[6
MZ=2O[=GD+2E6OY'Y1GP01)=YT]/YCV+][>^+)2W%ZKL^!WNW>-JL2UU0:<&*
M>5'-MOJ;8K)B\:"KZ"HSAU#UF_5S539CEJ.0LB2)8(Y8JNLLQ) $<083$H=Y
M( ,9)]EL(1YT]/>]&3L-(:?1JX[K5_U(VN%>]THV\R]^D!F\3)LO-B'C\*]6
M#U3ZW8".AN /I2+HZ@AJ)<&^EC=@JV=5VEMMZ+:JWH IS+#YXO#2,SW2*O."
M,VZU<@TY'3U+X"##CK:6#@E:=U$>=!S[U?WKYNEI_GRW?'PLJG("7X3.<5##
M?%!_/FX>[]374XJROD M;[,T0&&LBYV0(%(KMVXS1.,LAD%.LQ"C1.:94;$3
ME\&GMNO8R@L>:X$!JR56_VU$KEI=-/]JV.#":5HN+\=#@CWP4EN+#G:R:RIM
MH6_$!XW\8*O @&B;+XU#HC[2LN<9?:NES!6^GF7*^I&C+4&NRG:7%^=GN-3J
M+H6ZX=OM@K\1W\5\^:0'; -[[Y>O11W<>WLROCV)PB2(L%H]<"8@RA"%-$L2
MR.,H25@H0Q88)WM<)<GT%I5:F2H.GN_4V47"KY> BFT\/#D(?V_CXU]MGM2O
M+=:<Z^;S\@(TVBP-O!KM35!'DUWB2#U!'[83=&4"R7438U/H?*0)&JTB^K 3
M95E*W0.XO377KWG^B,79/<"P7\7=QP/=0D2V>[EV.U:(LMG6\4\'.[:C_=W^
M]NY>_%B_5B#]:Q;+,.)8;:L8)PE$#,=J80PXC$E.69"B'$5&!=B&%')J:^:[
MA5RN'NMPKENZW*R!VA:#NV\Z#ZS406$=W8&ZM&FP_*#)8"^:UBXN99#Y[U](
MIS*K(SI7NW/7J@C41!]YTXY=< <>N*9X.M :@TIEC\$R0\Z(I]":040<-1!G
M2) /PW8&'<MMP?DBUD27 FT;53;'N)*C($0BAB'/=#&\2$(BU$\!(R1/U:I!
MI%&!HOYAID;ZK92@%=..O,]@:4:_UR,T^";E )P!*@#W@^")L\X,,BKK]"MZ
MR!L7KK9WM'3LVFW^=/NZ(AE'=8]N3C/UZ5,"<:*/U G+@B@D(2;&%3%[QIG:
MM]_=S>UD-=]2]T%ZV9/A":B!*> T1@X10WU@F7L7/($VDN_ %3PKGX !)#T[
M_KZ[1]O/&ZC0W:V;7.Y8[Z'N__!%/"U7>FO7V1*^WV8(,&4F<90*R%.L#"64
M48AS7=.1<$Y0Q%,:)#:&DLF@4Z/.MEW)5FC0W3V[)VD838"9=>4;UJ&/)Z]'
MU+Y*A 5$ONI&F PY;B4)"Q".:DO8W.N8059\+[A8\.JT;;FHJEGH_+19EO(X
MTKS#6$0@2JG>KZGM&Q8X3W-*PE@$;?2C&1&=&\HA@'%@^JGR9WDK+N""S4GC
MT&&5['5-&LL$L7-(F_'-5>B-9,RU(MZ 6DA027E3Y2-[S/BZ@(2O'*]SPXR;
MU75!V:,\KDO7N]%$%<+5[1RXUU2PM;-Y&F F),015_L\'*60)"*!08(D"U,>
M9F997#:#3LURJ3MDOBHJ27]J\[9OP$)8-JDS0MR,.GSC.#"-U!#N-11M.HZ^
M:D3^:0!'D0U(GAC&:,A1V<8&A$/FL;K7H074<JU,H8+,WV[6FY4X*M+WE:A_
M>$U*'?Z)L40I4NR3"0Y1(E.8IZ& 6.)(_7N(XH@:MX<R'G9J3+25',A*=%!J
M42'5LEY5J=5B)BZ[J8;!=V"&VD%;2WVJ,&LE.*PD'P1:BYY6@T \5K\K3U#;
M-<.R1JRO49;YP\9KHF6MX%Z#+?N[[?G^X_('D<6\,70$BY(\3B3D$<$014D$
M22@R*"5.TER***21*:7O/7EJK-T(9TX9^SA=)EQG[0?FU$8N!]?_/@+FO.B,
MQ$C4=XB(I]I/)]7NX:_]ZT>CJ)-B=EGH] 5NV]OWQ;IXJ*;SJYK53=ET^(FS
M.,PCA&".,P:1S!-(:2!ARE!"!,,T8%9]34X/,S4*VDD):C$MNRA= -5LSWH]
M5 /SE0-*UGO2?A \[4+/##+JOK-?T<.=YH6KW2B@XR]K5Q*:8T2E@ RS'"(6
M,;6-C!"D68S3B$C$F+#Y^H]&F-J'WW7:@E=_"GY.@KHB^Q-9@>\ZRLPP4^,\
MIEF2<\0%@XE(8HC2,(0YSR+(4)1SF6 D")]]%RNZ' 75[DC#X=J4M:_^W/.,
M7XNF&95>A=# ++KWROEWZIU5W1-W'C]_5-H\J]XA8YZ_\(KC /70IY7X)A9E
M535.._MTL;B/8OU)WI,?G_69Y7+1;45POZP;$<QB(F+.<PDSF2&(=&XVCED
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M&6R5_72=.%,CSZ.HB^6FLI(Z"H&>1AMNF_8K9]3T%&:L>1K\S&78*7))Z_2
MK+_\SVN$&3M1U -P)S)*?3S5E9RK,3Z3U?KY?D46)6';"@RAI#)!*()9ILQ0
MA"6!5-FF,,YDDI-41CFVBK/N&6MZM%I_EY6LH".L8[&+\R";DJ$7Z 9G.D?4
M'"CL(A[>^.G\2".3ST65CYGE\BW.97.(CKW[A:QT,=^R0U<Z*H\5ZUF*,,MD
MGD-!=+'=/)%J)RLBF*2(,%TW/P\L[;9+0TZ/1&J)@6A$MBZ1<PEC4_+PB=S@
M'-* UDH+7G4-I4;@\X?1+D5R#-'Q5R7GTH!CE\DQ!.!$G1S3.^T]9)]7R_^U
M(?S#AR_OWOU&5L5W\J/M3!RA+*!$PHPB!!'-L6(6R6 82XXS)B1+L:F/[.PH
M4R.31M"_?( ?X!?P[MU?&FG-'4'G ;WL+/,"T\#,T<@(E) *']"(Z> Q.P^4
MN<_,"V C><W.O5I;Z,Z';5HYT2YBTN-&.W_O:(ZTB^)W76F7+W8L"G"4\Z"V
MC\N'1?%OP3^*]:^*C_7YQIN-N%]^%>OUO I0+\-9AEF$<]V40B*N-G/ZI#F/
M8RAXFL@P2=1_F4,#-5=YC#Z#\=NJ=42TK 3@.B]F)MR@,(]4&^!D#ID^U/U<
M=;LHV/97=\MR#5[=52F$/]T K5U[1*PTU.>].QT]%@^X$F-?501<Q1BWG,"5
M8!W5%;CV>6YT>D?*;[_\]T;1\UP_[G9]1U:K9V7+_J:;HLP4-Z)09C&43*>%
M)&K[BK,\43^E0<8PQC*U"@SN'VYJ)J>6%HB=N':,> %:,][S!]C [%9AU9'T
M!A#%8XVPH)+6'U.9H>*)CRX,-BKKF"E^R"V&=SE&!3.VW*BG[NI"=BJ-!B0/
M4YHAR%!,(&*80!(B#"..PTA*&<6Q59>VOL&FQAZMK+J5=R,L>-66 YC/EW_H
M&M]5!AE?;NA:;N: M+>H2_Z49;H&K'X=J^/\/Z51\_?0,A.A=X;,:,@7[@.3
MT!;RG9QMEO[M'N*U:=4D]WLO&VN"EJ^XY+ZAQHU.-E#Z*$;9Y)[K6FK?+YOL
MAU-5*&<HQ2PD6$+&0V7?4)S '!$*)9=YCG0).<'MZJ(8C>NP^1O:N]9MIUUN
M!:V89UF=S1>N96C-9L*,A_RA.W*;;;5E:R0&)PO5^F^T;021YU[;_6.^2+MM
M(QC.==PVN_G*OG7:,EL_Z_B&Y:(RS_2I>$I8G@=(,1'C""*1I)"FRH3":90)
MG@12Q&Z]ZTZ--C7+J981[(2\KH7=28#-^,8;; /SC#5B[MWL^I#PW='NY%@O
MT]6N3^VSG>UZ;[(ONO.5B059%<N_+\HGP0I9"-Y$%.JP)$&DH@NLK!=$(PYS
MQA"41%$'EHHZTMRT",_94:9&$ZV@ED&<_4CV\X(W? ;F W-HK$KS7%3]BE(]
MYY\]6NF>B^IU2_E<OMC-+M MJ2N_3*>^DMX@J5U1L7AHSF%3'.1"" EY@)5Y
MP)6-@#$FD 6AC+(<T2RUZLEE,NC4/O^J=_=O=>_NKM@W8"NXG<%@A+R9W> ;
MSX'IH@OE5LK+@0/61H0-+)YL":,A1S4I;$ XM"RL[K4W,-ZKC<U#W;2;E.)>
M/:!9%3$-XCP-<TAQEJOM2!Y"$A .J<PD34+"D\PH3;MOD*GQRTY.H 5UL#+.
MPGG9R/ !TL"D88V/E:EQ"8 K+(VSCQ[-T+BD7-?.N'BM?63A)RE+L5XKQJB+
M6-\N^/N"T&)>^36J9KJ[GL5Q))) 1!*F@7:19@&#!!,,L90H)82(7*2FP88V
M T^-#MXMY'+UV"0P+< ;H6.:UCI/Z?.RKK!1@J\;^D_!UMK;]X&4^MCA8ZTN
MN%VM=.G'VAE(2E!(73?P&?PA5NH!2D[U"UW!80%(%1+RFI2%H9_5>D;[V6?(
M>1J8D79B-UT"@!(<="2WZ11]'<;F@9)#83U2[*02<#,GJZH02=V:N"I+LOLZ
MGK9?1[G[.A[KKV/1S!;I^SJ>]K\.?8)*]=?A*2C3!?^>.$VKQXT6NNFB9#>:
MT^E^]X9N;]7+1.;_6Y#56_4OY8P*P:* Q+JF6 912&-(">60\%@2Q%&4$&+;
MT.U@C*DM-]N.9;6<0 L**DGM.[H=PMF_ '@":6"N=\#'J:7;&02N:NEV^,S1
M6[J=4>I42[=SESHZMY8K43PL='ACXT^1,8T3+G(8QKII&XM"2',9ZN[R"0W#
M&.'$*D+H:(2I?=A5[9RZMBN96SJHCM S]$9=@\G0KJ=:MKHA_  >IW.J^W(O
M'3U_7%_2.?6.'$=G+[3?/NYU.GM7]2M7AL'):E)5ZGZ=K?_+CR>Q*'6 SPRE
M&<4LCB"/40218!B24'WS-(I2+HA(<9A:I&+XD,DA(F>,=(RZ+,:KHFE&(VIY
MJZY"YAN7J^?K\H9Q%/A':^'8:=-85>VOM3E3F.^FJ5W25O)KE/JI2NT8<9+,
M=YQC3M9(N]!Q)LUJ7^D+Y9Z]YM5#C+;_] 5&=T_J[9GV*^ OY;IX5&O )WE7
MYWL7W\7GE;@G/W3F5GG_C:S_4<SGKX4NFTC*;S.9<R:83*&@6&U@.4ITF=L4
MQF&2AC*E2";&3E3;P:=F +?R:S\1VVJ@W3Q@37X W3ZOU)TWUN /I0:@HBI>
MJQ0Q)U/K^;F\P@V)^L KVA;P3Q+LA-=>YZIW724_T H K0%X+<#'P0$W7ZV&
M!'ZDU<GYC??DXG2%L&?IL7[D:$N-J[+=I<7Y&6Y>$9WTH)[R>;7\7G#!7S__
MO13\W:)9OA8/MTP)4'E:M[V+*0M8%!(,@RC.(8ID#K%,))1)%(<\DPE/C#RB
M[B),;5FI$A#?SI=_E'49[:WH8">[_@#O:NM _V)7]-C.#^,P7V:.FF%G8>!E
M1A];5I/0B@_H,WBE-0#%XJ?3\S%$LVIW$#WYA!P$&-5IY [0H5?IBB?9&]U?
M"QU&732>3YIGA$L6P)PF$422JY]B'$*1Y@2S.(Z3T"A!XNC)4^.U1CAS6VP?
MI\N6K;/V _-)(Y=#_:)]!,Q-36<D1K(C#Q'Q9!Z>5+O']MN_?C3#[J287:OM
M] 4._FU!U[LT+[+@=1K'[I_>_O;QW2Q%H: I0A 'R@Q#+$LA3G(,%1W15)E?
M.8N"V7JY)G,#[[7)B%;$M!UWP,@//0;@2O0J2_1I0^<%FS\#Q?-Z\1=U2M(N
ME_0&2!UF_+VW%(3C9!AXJ'U#/+0;6N/Z=3\1M\GR^MJ!].UO\.,[WVA:N))]
MHSJ6O]@'NG;N8!ND^GR^1L\9S[%KH]:>]];J1L=:<>8>8K4K+)4)6_]E%N(T
M8Z%,($4BA$C$'.*(2QC'(4MC&84\#VUVUZZ"3,T6W1.NJ6O2T^'3[Z28;:''
M@'IR)Y![FG@L"'<EEKX*PKF*,6Y!N"O!.BH(=^WS7#L\<EV)KEB+]_K;?J>6
MXL5#0>>B#OQ\_?R!_'.YNM,-&]X7"_%N+1[+6<Q)&":"0I9*Q9<R)C#G:03S
M,!928$YR;E20^!HAIL:5.QU@I038:=%&I_^NA0>5]):U#9QFR8Q A\9^8/+T
M!;M#@T1WW+PU07008>1&A^X@'3<SO.)9;N3X>E.J)Y7EW?*1%HN6>[6G4VU9
M]EBXC8Y_;NNLD9S*1!($:1H*B&+"81[E',9!D*$T3TF82QN*=!=E:D39B 7F
MK9QV5'C%G)@1XCA(#TR+K1*@H\4-V.FQ;T+>;).FG@<HCW<]H)[X\@I!1F7-
MZP$[Y$X/3[3WJ^IJB]M1V+.N;_Q=K)YU*]K[;\6J;M/S6OWJV_VJ(/.Z*O9,
MZIA@%F&82B'U08_4I6UR&!",@CR+:<B-#WJ<))@:7VHE -MI<:,WXI4>]<'W
M6FL"GK0J-X!J9<!::P.>*G7,G85N\W79%3OX+ S,I=4$W'4GH%4!:!U I43=
M ^P&5'J 2I&FSOO0$V#NO1U\(D;RY@XU(58.WJO [''XNCUW- ?P56IW'<+7
M/>C*6DNOG[<__JU0*]^*?7M^+[XKU'2M0+7/"'$B..1)@" *20XQ"3F4B 61
M6HQP;%<%WVS8J:T[NR)!8"ML=7#R\?8WIP*-ANB;6>G^,1UX%;D&3O?"2T;H
M^"Z]U#_HRQ1?,@+B;/DEL[L="\.*N?KMPZ]BH1X\OUWP6_Y8+ H=/Z7C4)L$
MAIF".PN3%$,6$ 91RBFD09A#)@5E69++/+,J 6<V[-1(J9'Z!CS4<E=?$-F3
MW+)JK!GZ9J3D'].!26D+YZ\=./>%!HW4'DO+6J'DJ\:LV:#C%INU N*HZJS=
MW6[DM&^EM;4_9AE/<9HA I,L5!92D*<0YPG6J?P!1REE,@]LR.CT,%,CGX-]
MQZ[ D*4A= 94,XZY'JIQM\LF*%E32#\(GBCCS""C4D2_HH>4<.'JH0]!ND7/
M[K[I']\M;A]UQX]/\I*[,9QAC' 2B@1&691")'67VYPF,)$\EB&2(HP'.C&Y
M2NZID52M0*E[!XDFK8E;1V*./?>^3V9&F]%)'>/L51U4EU6*ZQ>A5GV7#=5[
M O02!S]>YFOT4Z+KI)[HD9*7J7 _?_(SO&-KN^^DF.L5\^UR]97,Q7[,:J?9
M^Z\KM=#^?;$29*[[=>IE][60RRIC=)9E:AU#.8(L"SE$<4Y@G@>1^@EE84PS
M93)+A\;#7H0SHK;QR]Y4X=G=S('-5GPP5_+W]$L:<"+-%J7QYN5%$A%NP%9!
MJ(2%6D7U;SNU0*47V"G6=-FCE6ZZXH#'1GL^L?;5D<^+3..V[O,)XU&//Z\/
M=^Y1VHY2E8+1'7E6XIM0B\9W4=>%:9(% Y;%&2$YE#%79)US[<.( QBE1/"$
M9B3/K8YZC$>>VK:A^T77M9+V1*\^:NLVI(:30"C->< 3R!(2J$D0(:1AEL*
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ME#$JH!22>UGB%T>:VKI3"9MLI4WVX@94/^E$]O)Z$@VO@5>,LU#UJ1C3B5E
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M<+$J* 6-/6X)I3ZP'-50ZO60*QS@=LN8VD#=&AW<$%&D& *)%'+'/7- &2Y
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M-/O*\TH-.*^$[WS+SFL?W+LEV^I)JYH>OO(?>KT]I4)E6C F"8 YM"YND2'
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ML;"FH,H+5S!9 0P9 S37$AA22)2AG&*"0ZBA:["IT8.5%20M:9.MN(&YM)T
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MW2 ,%'1_#<^K6]%+@>](+3):?MS=<KVY72C[.[UR1^BV>>RDH#*360Z4=<
M1AD!S!6,$EFF<I'B3.B@4VH^@TZ-)0Y##D[H*@C;B'U%W0"O&?!CC]BX#NX
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MRIY-?MQ9%*W>6!?(E)M/=F)=@$]:Y^ZSWCRM%A\7[G?UR949-E@QQ"G@)L4
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M;,_F&O2N2,[H0&7PC(JFN5XI#:)#[?;<A:Z;KJA"?@S!*\LB5:< D51,$8(
M$ED(4$HDP#B6(,$T2L,(I2AVRCKHF&MN5%(Z[4=9^\I_.6-KQQT#(38R<[2
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M3A]D&3'V;K'<Z=]]U9P@-W>[[69+"T*X%?^WVQ0!9O=4(4H15H"H4%-H$H>
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MG_[VE_UO]#^F-,3?_O+_4$L#!!0    ( ).#8U41)>"=[<8  ++4"  4
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M0K=.,NU#7[^'ET,!Y[&*&QXVW\[FFQO%*K&[1:RCP"TMLFSKG&\+RE<N"[?
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M4 \V5E< [CFC/#B, ;PK$107"6*2&92(,GE)/\O68T":,K 3YMV?%_.GQL
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MGR^^?9O\N&9H<<F1\4:AY1P"2@6J4%00'>WYF0L7DC#9,[<#7G9[6]\79KL
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MRBD?"<MC#CZ!+H+TX&6&:#0YY 6Y349:$UHWOMN7QC][)<F!8+M;5]VEY@>
M[-<8ES>S#=Z&A"_.ZPX\XLP5[FT"IF.=HDK?>:'(+=,\.,D-.M&\$O(!6O[L
MA]EMD-I$DT- Y*;H'I=<K?(>Y\L?1L64.M K W<BUN:L!AS/GK;"*)2.RAK?
M0>WN0;3^V8].&B'Z%$@8!N+O<_01Y^-9_E!>K?_/JA?*]]GD^TIE+PJ]_4H\
M(\5"2D%E8*;.]U6AU"T'(:487-2QR.;]G8\D^<^>"VN&_Y/A8@#+8./BVD:.
M>XR+$7<*/:U:2"963XJ\*R]=!H_2BN*X+K&U97^0F#]['-D&NFUT.0A0;E*_
M]JC>36LOO0^ECF1<C 3S00@C("?'24PF@&=1@#->LJ!$CK%]C_,GB.IWKNSS
M 6E+W0X K*^WK;C+ 4TCE;B7Z\EO6 ]]66WI(1V([+UQ+HNH0VLOX1%Z^IWM
M^EP@VDRCPT#GE]EV3KCGR9F,8*RUH+(P$+.WD(0T.C/RUYO/8'J8FGXGL#XC
M9+;0YA!PN7N8N>J@=-F-<D3B0I\HP+31T.; HX40; 340EB,26G?>H[ @:3V
M.T3UV2#Z!#AX)ET%UBJKJMPN\/>XG)4OX0]<!-+@RG&Z[BU2SZ&6L_>S:?T[
M>OYD%:(2_;A8+EIV*>B<R"ZZ'IQ6LCUU42@I&F,+ R$Q@O).0ZQ7=J0(G)/Y
M)YVV[IAUXBX*>]B*RU!XA$;%['0"[;DF,V$=U'XCM$GZ$HHS/)D>MXM+*I]7
M;X-]<':$M3]$@T/S:][/EEMYN[,Y;^S!-U+V"D4.#E)QY,X5ZR$PJR!X90(J
M;I1N/D.D#>G]'ASVAN83Z7IH$'_JA(@VR0_EE]DL+S[/)GG$(V.<)$NLJGHA
MD MP6DM $0IW3A&[G<)Z/W)[-\RGA]<QIX%'Z/IYP?H7G-)WDU4@=3Z>CJN@
M:U.MJ^#$ZJ2=L0(R8[7]3Y;@-7TGBBM9*53:-L^L-*.^=_O]G$#?$@D]ESWO
MP?7B$X&""/U:]U7RTR:S;U4/5_-)1H$)%W3,P(5'4#KR&IRK.M5-J!RM37<[
MZ6RMF&Y'4;^E'WUBND?-/B\\+^<7EQ>Q5AO92":;N>8>4 96I[IZ<%E;<@Q3
M""D+)I5MC^$[5/1;LO',<'N,!I\/5K<.-!MQ)H,/!L&D>D50RWJVGPIM-ARC
M$4(RN4L3JV/IZ+=.XQGA]7@M[H]8OT;L%,_6#7K[.,JY:B%\Y1\5GU.)TD(R
M)H *RH%CA7X,@F7C%.K2_'S\<'+[K?!X9J[Q4;H^W![/EF'278'HS>R6MP^=
M)KQ>;4$?Z_VZ#Q?+=>7@2RRS^>7@ER_ACY$4QC#,H8X -76*GH+:$P>XYUI:
MCLG;DQ2/MF&G=^_ZE!F_06!BJ,N#^'A3"J;EAW*@5$9*<:&"$) <UHG@40#9
M# >>I,.C<HGEUBVL.V*E=^>]WV5Q8BP,((.X YOUJ/E#/6JN \Y-5#*!B+4=
MC(\!G/3T1;/DN?$4J;3.A.]#7^^>_,G VYG6!F"D]^%ML^#ARP,%#R-RW8AQ
M$R&R2((NKOJ.6 MTB]3>&1%+GZC=A8?>G?A!(KNY]I^9/;[-__4@G74S[9&C
MF"GEC"!,*:!<O=3# J?=*(K:X#0ZWKH'9#/B^ZWY?AYX/T;?S<Q\R^K"%^F_
M+L;K?G37*?U7M)I#G%T*(DSSK^-4 _.;?F.'%PH>][[C:_X:\MNH?._EQ6(\
MQ<7BU>P\CJ?K]3;-+Q8+7&X0>XU[$5A!&S*)M29'K/7@:JL=U*GXDE/*KG78
MLQ^%[08E7KUW4V<O?VS\M.ZJX@6Y^#$[D-Q(6H,4!H3B!& @@^#)_[<1&TMD
M7QK[K0_I$&$/#SKL0'D]-Y&[G$;Z87[9N'/5$,TI[K7E ;0A.2DB&+RT!7)T
MAF?+LMZM;O2)?G';WMWSM-A.-3UK*/9AP&9SB.UEU[12R!LN#*%V_@05F(,0
M3*% T6 *SGMK6_2.?Y" _CK+':_3^P Y4L ]'^R^^O"?[UYS?]D'3ZB0F7$)
MD*&J)]*U39$BMU*S*++3(B7^A*-U[Z&]:_M8!<U:2*MG-?_Z8TKR^D>XI#Q;
M=(&)!%:CI:T6!<24%6B9.;H2LM9R!SW??FI_XR':*_H(>0VQP7%6.E-<:$'Z
MD$ IV@V#*)Q^5-%X)7W9+9?;58/C[J9JG\I;.%KLSZ93<9$%5>$,1#3U?KF,
MX$I)H+-WB0F3D]NI[<J?M%/Q7CH_J%/Q/@KHO5/Q-'SYBO/P#2^6XW3=+UX5
M<JL$!ZL< Q63A, D[:,\1VNXC(AFA^UG^].?0]_BO50X:RK/WA&QNHDQ_W:9
M]KKD($J!1G(D5TJ00&QT:Q_<,#*Y$I--0>^$B&U/[W%NU0D0<;0\>T;$YW'Z
M>A&F_P,G%].7X]D2TU?ZY]O7,#\/:07S,'DU^W69K\%N0Y16@<S5%V.8("K4
MP%0249BBI=AE",R>K^VGA.@T&.I2 SV#Z\5\.?X>*E,;5O/=-%UR(@M%_AYI
M=[91K9N@1K0>,&8?O NH<9=X]_&W]%-F<QKH-)1OWTBI6>C_C5,*"Z\&#;*$
M.N0 /(@ BE.,'XS/%!04CCX%QO0N>]*]!_=3N7(B/!PEQ0$<R7^ASWTH+^;S
M.G%RU3QS-9^-!2*:'"QD=4QH1G*P<HBTL3*TJ'(2NG67AJV$]%O(>I)@NITB
M!H"F#?)K<NK];!IN?K,QINO:D4\LQ.(4;:6YWEYC!7SB!DHNQAH5DLJ\,<[V
M)+'?PY\&H)B=3D,# ."ZHJ .;[L[LTVS6-"4U>S;.E%)(?BL)%C.><F<X@;7
MNF+H06+Z!56G$)AUH8\! &NC=N4[OM@JK[^-EU_7\PAG#WWZDG?%;:%]@I%[
M(2F@X%K6"FH/A85B!&>1J]:=G%O2WV^*^Y3P[4WKO6>MMN;=4@Y,VA  2\A5
ME+5KM8K$D(C*<"&<+3M$"$?D,3OS]4Z!JD:2'80UK'6<9ZMX:F/DQ,L?U6%9
M^2BEE)@S,Q"2J0RI>DE$..!%\V T)B9;WR-]DJA^[_^<-)IHJZ#A(JZR<QG"
M.PJP4ZS=C63$.AN1@1>T0#7)*Y1LBHRM';PGB>K7T6L,@MT@=J!&^N[W<--:
MY;?Q!!?+&2W0*]MLC=.,9T K:1UZGVD=)@M62#2XFJ3I=]CU'GG%(&%RJ")G
M[:7:,S@^X=G%I/[_'_>X$(8E&Z,&GBH7UD<@BVW!9;2QU$H<W 4;#[^A7U^[
M.V@TDFG?9WEU/L;+L,!\CXO:WIWVZ 2HLJ'XUBMPH9!T"/BL!K[A;K_0[<=V
M#[ZA7W^Y.V0TDFG/R'@[GB](-.?U6LPX3"I3]]@ABE'H&A#&3 %AU 6BL*96
MV=E(0436;)>N;#N\JE_/MSNLM)9RWT5I->!<.6:B9!ZBXX1O44?N2 _1KSJU
MY.B]TY&)G1+C3Q6=7;VPW]OE)ZM:/$S 0T#%)9C)W DMM((B&3GL5A'C*DO@
M5@1E:GL&WPP7O9>7'::LN^H^0'(]*_RW\71\?G%^2;B/A&8K(B0MZV -YH&D
MP(&S)(LS9+WL3M?NGE#YK9?VK/1#5#9K(;^^%1_^V""\&&+2U)L6M%&!*DRL
M;UYS4X)A$FOHWD+QFR_ML72PA>(/EM\ ,ESW[HE6RV>B)$=(!G"<OBA%85#@
MT@"CS4_JE J6UHVKM]'1;XN.DV9.CU;# *%TZ64S:8UCY& 'YA.M"E>KTU@M
M4@H^>V4\^<(=@VD(:='C-?P$9 X0=\_1ZL<PS77UW#^8*IQ63 H>?' 4<B=1
MC6B((*-U(1BK1=CEYMR#+Q@6% [1W*RU& =@0#Y?Q 7^UP5)\,WW>OYY=5[@
MM)0Y&4NQ='"T,0<2#"L%4L10&->TT[;>CAX@I=\F.B?=D5HH8YB8NBJ^S4E)
M83BP'&FY):2%5Z*!D%70,G(A=.M!:0\2TW.SAQ:J?AH^!\A]> "ZM*Q,9.2"
M*3#(:XMN"N^<YQ9$B:R60D976M=2;25D<, Y1,F/0^< B0\ -ELL]*_7DU*3
M8"6Y&$#[=2^, M%S!%FO<5CNI6I>%?H8/?T.73[IKM9,+0. V/89+1LE9?4$
MI/9\^C+[B/,RFY^_G<U7$P=JKZC:C'VEXS=A/L4\BD8C*T&!DYF#(F;!%4&V
MW_EZ8,Z,;]Z"ORD#PVC"=3RN9D-1<N_E#P<S?C/6^NW%M XF>/EC_3_H@ZFB
MXHR,S<9#UW-BLI0F)Z]!9,]J+)X@I*( B]3:1N6"OA-E/%!4<5JZ^RW5:([[
MP:O^3[@L[LJ#'+#_@_4)EY\;6<F<LMP )BR@:@\$%Y(%B3$PEYP2<9?+X'W0
MWF^]RK-9'DTAT/,2^8]OI @2R/2FE.=C^+&^!10RWKDQ46]13&O!AHN.&\W
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M9Y_G?_P5O]3-8E<,[=JO/7/DT&V<=DT!@I U&<4,!.NYB[7[FK7>1?(H0;T
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M?\SQ<KGY_6MUO5HLJ[NTO=2$-(E"00Z.!T9V@E,LZ.JBD<)#(D<LB]@ZKSR
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M)JZ;FP8P#\&VD?9Z N0^AG:/R2HF+;E*$$T.Q)+Q@-XE"@($>NT+>M8Z832
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M,>2J1&,02LD*5-(>?'5IM+$!Z<P7$5KGZYJ.FQD-G(TA<>R(F4/TTX6/N7?
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M?[Y^@Y=S\L!75VO"3&+>E=J^80.H.K+6"UL7@A0=C+82 S\ 8H=^?]KWV2?
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M'&<!&(;:>VVX->XGOLJ]'YU<VZ<J:-%"6A.K^?_!^>6W&>X(3]':3$1 ":(
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MFL^@Y1% _$:LN-S4HI60$9VE3U+%FC50M3<>P2C+3?"I)-F^S?L>">/S&=O
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MUY'&@M/:0T 5I3%TPN36ON[I5 \[D>-<&#ZS=D\UP>=#=#U<O+*>>ZDA)%]
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MI XPV/N"4018)X*@C?0&A,!RL9J\J9LO+Z=Y,P.Y-@:L[2)F%()$ <;P=3Z
M0D29"_#H)+J )*1.LP+H%7?."_K;[5FQ_^T#@^-,GD<CZ8\./[M.O!0)Z?1!
M15F'?B:?P15+?SCAF#'!8.X'04,Z':UT^BQ$CA#P"'S21SG'K:V4-M8]C1R$
M3O7V3FAB"#FPXGRFT]+EYA.5]I R)L@<H^.'%_L-!#X"W+R9+\C\D@__;C[[
M=.^43<)PEYV$%$VD4U9Y<-8+8#Q947@1PLK&R-E+S#!'5F_8:2/T@8^F;1KU
M_>(3+JZG"==F6#GI':8")GFL.V$%'=). 9?.IJ!ERMW&:[UP+#WU[F$;/<[I
MUIPL^7$@9WDQRUL.=A\5*R:Z2-:21ULG]WL/(9%G+S03.<BZ-JY3R7 W^#PF
M8+@SZG2=/@;(B0(>.'K^/_ACM;C*86L9<Q0^60KYM=041DK/()9$ F&^<.5B
M]?8ZA,SWGSJXOD]5T;R)O(;.DUQ>3L,LX0*O<7:%O_V8D?S^W#$B?2STOPS)
MA$*F4D;P-FKPQN6")DKI9 ?%/_N2X?R+]CAH)\V!8?$;SJZG7W>$%Z8L'9BU
M_+4N\V%<0& YUYGOY&D;^K^' >^3,+CWT&%<AG[4?KRT1O+U?]S@]2/&R_F?
M/RZWC'#+BG?2@*U3_I6/#KRDF(IYM$9)#.BZJ/W9EPS3;]GOUW^Z- >&Q=_"
M(H?E]'+W_W[+ NKB"PH&,M?D;ZV%KR$UR%0X,X3Q&+O<H.QY_#!MB_U H84$
MA[Y*6\S_\RKDWW__^.NO_PR+Z77XOD.RR4KYH %]G;* FD,HUD.6T?CB;'&I
MBU>P]P7#= CV X0V4AP8"A_G]:;YWUO";8@VLH!0 AURRFI&YYM+@ 1M)DJV
M7'6Y0+OWT&$:[/I1^?'2&OJ+G^'5USDA5,@M\4PEH37%,&2W0L4HF:M !Y<N
MQ1I7"J+N]*4_?/ P_6<]?>$G26U@E?\S_'NU\UN99)ZYPL&O6T)<-A!%KOE/
M*TKD,O).%^-W'CE,-U<_:CY64@,K^*?%-).\=\8(<[9:D ^J>$5FE!2!DB,2
MK%2""Q2YDT=_[Z$#-3WUH^7CQ36T[5[@]8^OT]U-F O"*9D11*X(]99.'54,
ME)PBV2 ;"S>=7+2[3^VFZ5>2LCM!8 .K^N?:H#_-NYHL*WFN"[)8JOQ+5\!)
M'H%K;C4J=/AP0LV3FK[WT&Z*?B4YN>/%-?@G/?T:OD]WQLBAE3EF"87K6"\D
MR YAW7A -HI8,,P*U^F3OOO4;II^)6FX$P0VL*K?S;^',MUEBIRPR3(L(+QV
MM>L;P646P0K../F/,2;50=/W'MI-T:\DT7:\N ;6\Z^SZS#[<[>]1,:H@JS3
MU"QY%S9ZB$D+$+$P7D)&C;:#FN\^LYN67TD.[6AA#:SD-V%&YTW8>1:V+@F)
MPI$329PKPB/$&"(4+#&'XGAY.-G[237??VHW1;^2'-D) AM8U?\7%S%\WX6%
M*01M4Q&@C4F@.&:(P63R(;50EJ-5L8O=OO?0;HI^)9FQX\4UKGNRBXQ?OX7E
M/W'Q[ZOK^4USA*O3Y3UP7F0=Y);!"T'>1V N1BY4$5W,>8=7=</$*TF?M1;M
MT$C9T'^3_'6!&Z1C*M3K'A4M4""9@=@("9/4^'#2TM.8N/O0;MI_)5FUX\4U
M=(%$^(S7B^G\YLP*/FC#P5M-E*>4P3%%@&6,YV2UL;Z+HN\_M5MES"O)K)T@
ML*&=]BIV$O[RYA_^_O/MY8Y4&17D9.KVFZ+!Q\@@,LQ%&*VSZ:+V_6_H!H%7
MDG)K),BA,^IXN9Q_7>R\&*&E,3E;2#$;$D:*X!/WD+.1+CHALN@"@?M/[:;V
M5Y* .T%@0\_CF=85;-/=OD=1B'-9P#H?H6Y' >^U!(:).X:!I4X)N'L/[:;H
M5Y)_.UY<0]<WX-=I"GFW R]+"C-]0+"U-$<E\C0]LPA:A!Q%B,E8WD'1]Y_:
M3=.O) %W@L &5O5_A-G5]?3F(E=IHW30M0LDT+&C P27$I!8!$F&<=?)>-][
M:#=%OY(<W/'B&H&>O^)-U[K-F&(*8$.B %))!4$I#KG$P'E(MA364<\W#^VF
MYU>2@CM>7 /K>3WC^?[,BIV?805*R148XPHHGAT$;6O1+2'8ARP2Q@XZW_N"
M;OI_)9FY-F(<.B:?7N.RSJ;=D>X4Q91$JQ,QUEVV&ISW!8IE.=:B:Y>ZM"T]
M>&PWO;^2[-LI(AOZFF7^]5N85;&OAY7L<DC1A*@$4R ]JY'D>N2)=%!*8EXY
M[?+#[91/7[<\^?1NNG\EN;<& ARXF?5F -;?</YY$;Y]J79KW;W)G%:\-F]C
M0B0<9P6^KK"4%'5@$D$6_J#0[:AFUKT$#+M&[)P-T6UT,#20-I*XR\+NXR)!
MT%%'46S-22E=),10EY]Q7[F@(%>Y%D#:1\!P7;*-%#MO+>4!H;(>,KSX,?G'
MITF2PCGI$+@@CT@5DR@4\A9DS)HAIB2?'::ZQ/0_/\^O_]?VB1MH;/]RBXS;
M]PT(@S9*FY\DP:%O .K*@ME:W#=^<8PAF'I,,A43*",X1%4*:$??0T'',O,=
M_(PG'CU<0W1;7;>0W BF]#QSA/YVLW$^,A2L5JH4+<D'HQB9 J1L@4@V=9FK
MT;KUJ*<N= V["?+L@VY;:VH$Z-N612PGW*//R1D(WDE0F;Y%1Y\-2"XD1HXB
MJ]8CH7;O'L58TX9:?;3V[@@1CP :%!&2_Y67=4U?';#_OI"U#;//4_J.+I9+
M7"TGV24N(DK@0=+7I*T!GVIIA27#[:2/KOFNQ9>I&L6 U/[@U%@MKV)+Q>VD
M-LSK70_QQZT3<;' T&YK1>=7M=]B<1R7?6^U2#)X;I4!AH0CE80!9PE6(7FG
MLA%H0^OMD_UOM=C9Y/H1O?V^]B$OWUPM5W-244V!_3:??:ZYR[SYHC:^0U(4
M._A@P85"DK!UYX_T=9$,"US9E/!AI77#!1?'4#RN@_4H1.W?==&["H?.&>W-
MCZA KH.4$9CUO,Y*S\2$5"!X(+:L5:RT&,1X6O+Q#.LM^D= ISSD(>H8&E-[
M _ 4$N-)*0BY7L-Y8\$C14@VB:BUE,YYW0)3KRD/>9!B.^4A#Y'R./*0D6F5
M0Q!0HF&@3"%/U5/,$F22HBB5**#YB^<A#U+:XSSD(1(\6N?7N(CS1G'?V]_?
M7NPF"J*LM1H*$H^R#I>)X(2RH!/S=5U5D*+U1K/;MX\Q3WD,%DZ4ZPCLP)MW
MDX2&R"H(LA;4*J(# KI8%Y:C3P$IW'S.]SW,#KQY-]STQG[LP($2'('._^/#
MQ.MH.:OS1)WB=2==AA YA\2TXUPX)%^IF<[_X\-PHQK[T?F!$AS8-;Q83L.'
MD.HPBUVM3K ),Y/ .=9[E!C (0;PRGAMO?"^VU:]%US"1R\>;DYC6QR<+M6!
M(?%;W8%Q0<$4"6(W"Z$('SGYP+Y$DH.U#)RT'*R2EAE3-$\MAK@_?O-P,QO;
M@^)$N8ZA(O;-VL9-<5?4Q6(T1:0,TDE/ALYQ<)$'$,E$3N&V2K'+*NFGGCW<
MZ,:VFF\BNQ%<"[V=K::K'_^:9KQSM;%-Q3R5B;ESZQ%85"0LL+:F7F*R$#PW
MQ&@1R%%GFSKE& Z))HXE=BR+U,Z6XSJO>D> XYMKV:S6W< "0J"(3#D;P4LE
M( F6M% Z:=TIG?KJ;K[/I.I]U^&'R/U5W%)^Q#2?I>GE=/W8^:XJY<-B7J8K
M$N&O,_I5C$BRQC_"=WQZ2_U1MY9'O[K]+68;*?1]J\D)7K6 '9BJ*[Y*\;6E
M,$*0U@F)1BO3^BSJ_U:S>QF4E(:EG#C(5&?C%*QC"HV#8(/C(65GHFW-_N%D
MCO3^\A#L[+^_[$=9H]MINKY)T;HXI, 6DJ?(5Q5>&_X2 QN%<#X[B=TV5?:W
M$_<,UY4]*?SEG;B'2']T^-E&7%GJ8$O)8)@FCT,6!8ZAJ*.2D_58$BLM^B1>
MS4[<@W3:92?N(0(>@?>^;T5K"NBS+1&RKL&T=QI")!^5:VDDY\JIA\LC3C[8
M7L].W(-TW'$G[B$"'\7UYOX%K8;B$($4-F.J>Z9#X72D2TZQ<^*12<[DPX[N
MD['SFK;BGH*>-D(?!7Y^)RX6TW!Y$^?025ZEM)LTE5$7F5(= $[\*)' .5YW
M-Y!X1.%H;.LK\^<I&NXJM1<D-13_"(ZQF^*CGZZ6TQDNESOKNC[D32)36C?#
MFA)$S>-Q\#$)*!HE(GJ-#T=^GAZE/4?06)*B_7K2[74S!J!M:-\M.!<A<RLC
M2&(!5)*AWE]D$$$9BTZ7(#NUKQ^>_1C2G>Y!L4]WB!TAY:%W0=P;S;*\=T)'
M)P//3 -F3P(AKB#Z+ %UU%ZB<KK;KI?]KQA%GN<8I<W;2W!0'V<],G<]K>/O
M&"Y77^ZS(9/SUAH/,?,ZO,46B$QXL!BR25(%[KM,/-K[@E$T;IT(@S;2&X6C
MVZF3S5H21"2&L@O5WXH)0F8<L"B5@P_%A)Y.DM,;DYL[O8-Y*JTU-0*'97--
M]-M\N;[ZIE""&+LBWK9Y" HM?EI?(6W^N_5%TMOOJT4@W4YG8?%CS31%FQ0E
MK(BT=9Q0AP7@<C5)CNF@*,@,3I(]5G38^Q0E)))TR)ES%UL'^CVR,XK3LR'V
MYN,$PBB^B3I-K8I[P^P-'[EP2:Z%A6R\!,6R 1^4 *FSCM8E'TWK'LU]M(SB
M$.\3C0U4, HH;>A^^_T;SI8XB1B"Y&H]"(/(=U+6-!P#<G:\D)IIYT-S!-TC
M8> CNW_@'"_PP_'B-WB9X>?:3-X$,1?YOZXVR/]EOKCX6L7TYUH^$^OKW%;R
M6@IS%I2,9$\Y\^0P<\Z5]*[DUMC92\S @_'Z1E$;)8P"3S\CO3MMJH0F.02.
M+E,T%#"#LHR\7PJ*H"Y1#$0\9M?I>O< "-U]_\!SC/I&S=&B'@50/I(VB(0O
M%[/\,U[CY?Q;E=;.CG)1IP8H!\+J>O^8(_AZ"2DR8R@*\91:7_@^2] PC0IG
M@U([98P%6ZO%55I=+>K\E2]A\1F7$Q9MO=(.=3(Y?2'HZF8)5YD*6;AZ6\E:
M>]-/T3%,X\,YD72:Z <%T'H?R0,1_6,6+M>_@7G=Z+']*I;O<#7QUNL4#8),
M@8$**D#PA4-D,I$KJ 3%"!URIP>\LA-\FH\1[QT^?0J^(:+VUIEO?U#_B&&)
M__M__']02P$"% ,4    " "3@V-5[DBM>+L'  !)(0  '@
M@ $     97AH:6)I=#,Q,2UR=6QE,3-A>#$T83$U9'@N:'1M4$L! A0#%
M  @ DX-C5;.6']C)!P  KB   !X              ( !]P<  &5X:&EB:70S
M,3(M<G5L93$S87@Q-&$Q-61X+FAT;5!+ 0(4 Q0    ( ).#8U4*H[FW7P0
M %\/   >              "  ?P/  !E>&AI8FET,S(Q+7-E8W1I;VXQ,S4P
M8V5R="YH=&U02P$"% ,4    " "3@V-5,F%7F&4$  "I#@  '@
M    @ &7%   97AH:6)I=#,R,BUS96-T:6]N,3,U,&-E<G0N:'1M4$L! A0#
M%     @ DX-C54'PL(%Y/P0 L4,Y !               ( !.!D  &UR:RTR
M,#(R,#DS,"YH=&U02P$"% ,4    " "3@V-5Z0$/08T6  #*^@  $
M        @ '?6 0 ;7)K+3(P,C(P.3,P+GAS9%!+ 0(4 Q0    ( ).#8U4E
MG9 M(BD  -^@ 0 4              "  9IO! !M<FLM,C R,C Y,S!?8V%L
M+GAM;%!+ 0(4 Q0    ( ).#8U5]Y:N0>90  "Q2!@ 4              "
M >Z8! !M<FLM,C R,C Y,S!?9&5F+GAM;%!+ 0(4 Q0    ( ).#8U793IV]
MC#@! &6R#  4              "  9DM!0!M<FLM,C R,C Y,S!?;&%B+GAM
M;%!+ 0(4 Q0    ( ).#8U41)>"=[<8  ++4"  4              "  5=F
L!@!M<FLM,C R,C Y,S!?<')E+GAM;%!+!08     "@ * +0"  !V+0<    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
